

# **APPROVED DRUG PRODUCTS**

**WITH**

**THERAPEUTIC  
EQUIVALENCE  
EVALUATIONS**

**36<sup>th</sup> EDITION**

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER  
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION  
OFFICE OF MEDICAL PRODUCTS AND TOBACCO  
CENTER FOR DRUG EVALUATION AND RESEARCH  
OFFICE OF GENERIC DRUGS  
OFFICE OF GENERIC DRUG POLICY**

**2016**

# **APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS**

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2015.

## **36<sup>th</sup> EDITION**



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION  
OFFICE OF MEDICAL PRODUCTS AND TOBACCO  
CENTER FOR DRUG EVALUATION AND RESEARCH  
OFFICE OF GENERIC DRUGS  
OFFICE OF GENERIC DRUG POLICY

**2016**

**FOOD AND DRUG ADMINISTRATION  
 CENTER FOR DRUG EVALUATION AND RESEARCH  
 APPROVED DRUG PRODUCTS  
 with  
 Therapeutic Equivalence Evaluations**

**CONTENTS**

	<i>PAGE</i>
PREFACE TO THIRTY SIXTH EDITION.....	iv
1 INTRODUCTION.....	vi
1.1 Content and Exclusion .....	vi
1.2 Therapeutic Equivalence-Related Terms .....	vi
1.3 Further Guidance on Bioequivalence .....	ix
1.4 Reference Listed Drug .....	ix
1.5 General Policies and Legal Status .....	x
1.6 Practitioner/User Responsibilities .....	x
1.7 Therapeutic Equivalence Evaluations Codes .....	xii
1.8 Description of Certain Special Situations .....	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity .....	xxii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product .....	xxii
1.11 Discontinued Section .....	xxiii
1.12 Changes to the Orange Book.....	xxiii
1.13 Availability of the Edition .....	xxiv
2 HOW TO USE THE DRUG PRODUCTS LISTS .....	2-1
2.1 Key Sections for Using the Drug Product Lists .....	2-1
2.2 Drug Product Illustration .....	2-3
2.3 Therapeutic Equivalence Evaluations Illustration .....	2-4
<b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List .....	3-1
OTC Drug Product List .....	4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research List .....	5-1
Discontinued Drug Product List .....	6-1
Orphan Products Designations and Approvals List .....	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	8-1
<b>APPENDICES</b>	
A. Product Name Index .....	A-1
B. Product Name Index Listed by Applicant .....	B-1
C. Uniform Terms .....	C-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM .....</b>	<b>AD1</b>
A. Patent and Exclusivity Lists .....	ADA1
B. Patent and Exclusivity Terms .....	ADB1

**FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH  
APPROVED DRUG PRODUCTS**

**with  
Therapeutic Equivalence Evaluations**

**PREFACE TO THIRTY SIXTH EDITION**

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

**Background of the Publication.** To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis

for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the FD&C Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Legal & Regulatory Support, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7620 Standish Place, Rockville, MD 20855-2773. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

# 1. INTRODUCTION

## 1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.<sup>1</sup> This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as described in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided in Appendix C.

An *Addendum* contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the List. Tentative approval lists are available on FDA's website at [Drug Approval Reports](#). When the tentative approval becomes a full approval through a subsequent action letter to the applicant, the Agency will list the drug product and the final approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

## 1.2 Therapeutic Equivalence-Related Terms

---

<sup>1</sup> Newly approved products are added to parts 1, 2, or 3, of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

**Pharmaceutical Equivalents.** Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are identical in strength or concentration (e.g., chlordiazepoxide hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

**Pharmaceutical Alternatives.** Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

**Therapeutic Equivalents.** Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an applicant's drug product are considered to have the same code as the applicant. Therapeutic equivalence determinations are not made for unapproved, off-label uses.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the

full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

**Strength.** Strength refers to the amount of drug substance (active ingredient) contained in, delivered, or deliverable from a drug product. Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the List, but rather intends to apply the criteria prospectively to drug products added to the List.

The strength of drug products in the List is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, but is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the List include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

**Bioavailability.** This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

**Bioequivalent Drug Products.** This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j) (8) (B) of the FD&C Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.



### 1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.<sup>2</sup>

### 1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence (reference standard) and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different drugs.

However, in some instances when a listed drug is not designated as the reference listed drug and/or not shown to be bioequivalent to the reference listed drug, such listed drug may be shielded from generic competition. An applicant wishing to market a generic version of a listed drug that is not designated as the reference listed drug may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and CFR 10.30). If the citizen petition is approved, the listed drug will be designated as an additional reference listed drug, in which case an ANDA citing the designated reference listed drug may be submitted. Section 1.7, *Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements)* explains the character coding system (e.g., **AB**, **AB1**, **AB2**, **AB3**...) for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other have both been designated as reference listed drugs. The first situation is when the *in vivo* determination of bioequivalence is self-evident and a waiver of any *in vivo* bioequivalence may be granted. The second situation is when the bioequivalence of two listed products may be determined through *in vitro* methodology.

Reference listed drugs are identified by the symbol "+" in the Prescription and Over-the-Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Office of Bioequivalence at this time. The Prescription and OTC Drug Product Lists

---

<sup>2</sup> We note that prior editions of the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See FDA Drugs guidance Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>; FDA Drugs guidance (Product-Specific Recommendations for Generic Drug Development) Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm>; see generally 21 CFR part 320.

identify reference drugs for approved drug products. It is recommended that an applicant planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, submit a controlled correspondence to the Office of Generic Drugs to confirm the appropriate reference listed drug.

## **1.5 General Policies and Legal Status**

The List contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the FD&C Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

## **1.6 Practitioner/User Responsibilities**

### ***Professional care and judgment should be exercised in using the List.***

Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. For example, there may also be allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

**Multisource and single-source drug products.** FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an applicant's drug product are considered to have the same code as the applicant. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

**Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product.** There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In many instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the

marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established name of the active ingredient, if no trade name exists) appears on the List. If a corporate relationship exists between an applicant and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the applicant to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name (i.e., non-proprietary name) appears on the List.

***Every product on the List is subject at all times to regulatory action.***

From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

## **1.7 Therapeutic Equivalence Evaluations Codes**

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

**A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:**

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

**B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,**

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active

ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX,** or **B\***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

## "A" CODES

### **Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.**

"A" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP,** or **AT,** depending on the dosage form, as described below); or
- (2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency may use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical alternatives and thus not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

## **AA Products in conventional dosage forms not presenting bioequivalence problems**

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

### **AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements**

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength*) generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products that are not identified as bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

### **AN Solutions and powders for aerosolization**

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

### **AO Injectable oil solutions**

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

#### **AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions**

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

The strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.<sup>3</sup> In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as xmg/mL. The amount of dry powder or freeze dried powder in a container has always been identified as the strength, expressed as xmg/vial.

With the finalization of the 1984 Amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end, the Orange Book now displays the

---

<sup>3</sup> The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.



strength of all new approvals of parenteral solutions. Previously, we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/mL. If this drug product had a 20 mL and 60 mL container approved, we would now display two product strengths for this product, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1Gm / 20mL (50mg/mL) and 3Gm / 60mL (50mg/mL).

## **AT Topical products**

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

## **"B" CODES**

### **Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.**

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

### **B\* Drug products requiring further FDA investigation and review to determine therapeutic equivalence**

The code **B\*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through

further Agency investigation and/or review of data and information submitted by the applicant. The **B\*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

### **BC Extended-release dosage forms (capsules, injectables and tablets)**

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

### **BD Active ingredients and dosage forms with documented bioequivalence problems**

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

### **BE Delayed-release oral dosage forms**

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

### **BN Products in aerosol-nebulizer drug delivery systems**

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

## **BP Active ingredients and dosage forms with potential bioequivalence problems**

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

## **BR Suppositories or enemas that deliver drugs for systemic absorption**

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

## **BS Products having drug standard deficiencies**

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

## **BT Topical products with bioequivalence issues**

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

## **BX Drug products for which the data are insufficient to determine therapeutic equivalence**

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically

inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

## 1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

**Amino Acid and Protein Hydrolysate Injections.** These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

**Gaviscon®.** Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

**Levothyroxine Sodium.** Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), and Unithroid (Jerome Stevens NDA 021210), tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187), tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be

therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHROID	LLOYD	0.025MG	AB4	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

**Patent Certification(s) and Reference Listed Drug based upon a suitability petition.** An ANDA that refers to a reference listed drug approved pursuant to a suitability petition must demonstrate that the proposed product can be expected to have the same therapeutic effect as the reference listed drug, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition. This concept also applies to an ANDA applicant that cites a reference listed drug that was based upon an NDA that is still covered by patent(s) and/or exclusivity, e.g. a second RLD selected for use in conducting bioequivalence studies.

**Waived exclusivity.** If an NDA submitted under section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will not accept for review and/or will delay the approval of a 505(b)(2) application or an ANDA under section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications that might otherwise be blocked by such NDA. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be accepted for review and/or

approved, as applicable, pursuant to the NDA holder's exclusivity being waived. An NDA for which the holder has waived its exclusivity as to all 505(b) (2) and ANDA applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

### 1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

### 1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a

change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and CFR 10.30).

### **1.11 Discontinued Section**

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has already been made that the products were not withdrawn for safety or effectiveness reasons have **“\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*”** following the product strength. Those drug products are only reflective of determinations made since 1995. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions for the same drug product. FR notices no longer applicable are removed from the Annual Edition (i.e., there is a currently marketed reference listed drug and no applicable patent or exclusivity). The Orange Book [FR Safety or Effectiveness Determinations List](#), available on FDA's website, lists products that have current and removed notices. The list is updated quarterly. Notices issued during the year are added to the [Electronic Orange Book Query](#) on FDA's website in the month they become effective.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports indicate the product is no longer marketed or as a result of other Agency administrative actions. Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

### **1.12 Changes to the Orange Book**

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book staff of any changes or corrections, including any change in a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that 21 CFR 314.81(b)(3)(iv) requires an applicant to submit a notice to the Agency within fifteen working days of the withdrawal from sale of a drug product. In addition, a request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1, 2 or 3 of the List (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already included in the List, but rather intends to apply the change prospectively to drug products added to the List.

We can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov). Send Changes by mail to:

FDA/CDER Orange Book Staff  
Office of Generic Drugs  
7620 Standish Place  
Rockville, MD 20855-2773

### **1.13 Availability of the Edition**

Commencing with the 25<sup>th</sup> edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, [Electronic Orange Book Query](#), by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Printing Office, 866-512-1800.



## 2. HOW TO USE THE DRUG PRODUCT LISTS

### 2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

**Illustrations.** The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

**Drug Product Lists.** The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

**Product Name Index** (*Prescription and OTC Drug Product Lists*). This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

**Product Name Index Listed by Applicant** (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (\*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

**Uniform Terms.** To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

## 2.2 DRUG PRODUCT ILLUSTRATION

### SINGLE INGREDIENT

ACTIVE INGREDIENT	→	<u>MEPERIDINE HYDROCHLORIDE</u>					
DOSAGE FORM; ROUTE OF ADMINISTRATION	→	INJECTABLE; INJECTION					
TRADE OR GENERIC NAMES	→	<u>HEXANON</u>					
REFERENCE LISTED DRUG	→	<u>AP</u> + PAGE PHARMA	<u>25MG/ML</u>	<u>N013111</u>	<u>001</u>	AUG 22, 1983	
		<u>AP</u> +	<u>50MG/ML</u>	<u>N013111</u>	<u>002</u>	AUG 22, 1983	
		<u>AP</u> +	<u>75MG/ML</u>	<u>N013111</u>	<u>003</u>	AUG 22, 1983	
		<u>AP</u> +	<u>100MG/ML</u>	<u>N013111</u>	<u>004</u>	JAN 04, 1989	
		<u>MEPERIDINE HCL</u>					
THERAPEUTIC EQUIVALENCE (TE)	→	<u>AP</u> GREENBERG PHARM	<u>25MG/ML</u>	<u>A064890</u>	001	FEB 29, 1987	
CODE FOR MULTISOURCE PRODUCT	→	<u>AP</u>	<u>50MG/ML</u>	<u>A064890</u>	002	FEB 29, 1987	
		<u>AP</u>	<u>75MG/ML</u>	<u>A064890</u>	003	FEB 29, 1987	
		<u>AP</u>	<u>100MG/ML</u>	<u>A064890</u>	004	MAR 08, 1992	
SINGLE SOURCE PRODUCT (NO TE CODE)		<u>AP</u> TIMOKIM LLC	10MG/ML	A099225	001	DEC 12, 1995	
		<u>AP</u> JOHNSON MED	<u>25MG/ML</u>	<u>A099226</u>	<u>001</u>	NOV 27, 1993	
		<u>AP</u> KENDRA PHARM	150MG/ML	A079444	001	OCT 31, 1999	
APPLICANT	→						
AVAILABLE STRENGTH(S) OF A PRODUCT	→						
APPLICATION NUMBER AND PRODUCT NUMBER	→						
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY	→						
APPROVAL DATE	→						


### MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY		
ACTIVE INGREDIENT	→	<u>HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE</u>
PRODUCT INFORMATION	→	TABLET; ORAL HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL REINWALD INC 25MG; 15MG; 0.1MG A069808 001 JAN 18, 1982

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

### 2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

## PRESCRIPTION DRUG PRODUCT LIST

ABACAVIR SULFATE

SOLUTION;ORAL

ZIAGEN

+ VIIIV HLTHCARE

EQ 20MG BASE/ML

N020978 001 Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATEAB APOTEX INCEQ 300MG BASEA201570 001 Dec 17, 2012AB AUROBINDO PHARMA LTDEQ 300MG BASEA077844 001 Dec 17, 2012AB HETERO LABS LTD IIIEQ 300MG BASEA091560 001 Sep 13, 2013AB MYLAN PHARMS INCEQ 300MG BASEA091294 001 Jun 18, 2012ZIAGENAB + VIIIV HLTHCAREEQ 300MG BASEN020977 001 Dec 17, 1998ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

+ VIIIV HLTHCARE

EQ 600MG BASE;EQ 50MG BASE;300MG

N205551 001 Aug 22, 2014

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

EPZICOM

+ VIIIV HLTHCARE

EQ 600MG BASE;300MG

N021652 001 Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINEAB LUPIN LTDEQ 300MG BASE;150MG;300MGA202912 001 Dec 05, 2013TRIZIVIRAB + VIIIV HLTHCAREEQ 300MG BASE;150MG;300MGN021205 001 Nov 14, 2000ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

+ JANSSEN BIOTECH

250MG

N202379 001 Apr 28, 2011

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUMAB BARR LABS DIV TEVA333MGA200143 001 Nov 18, 2013AB GLENMARK GENERICS333MGA202229 001 Jul 16, 2013AB MYLAN PHARMS INC333MGA200142 001 Mar 11, 2014CAMPRALAB + FOREST LABS333MGN021431 001 Jul 29, 2004ACARBOSE

TABLET;ORAL

ACARBOSEAB EMCURE PHARMS LTD25MGA202271 001 Feb 07, 2012AB50MGA202271 002 Feb 07, 2012AB100MGA202271 003 Feb 07, 2012AB IMPAX LABS25MGA078441 001 May 14, 2009AB50MGA078441 002 May 14, 2009AB100MGA078441 003 May 14, 2009AB MYLAN25MGA091053 001 Jan 06, 2011AB50MGA091053 002 Jan 06, 2011AB100MGA091053 003 Jan 06, 2011AB ROXANE25MGA078470 001 May 07, 2008AB50MGA078470 002 May 07, 2008AB100MGA078470 003 May 07, 2008AB STRIDES PHARMA25MGA090912 001 Jul 27, 2011AB50MGA090912 002 Jul 27, 2011AB100MGA090912 003 Jul 27, 2011AB VIRTUS PHARM25MGA091343 001 Oct 17, 2013AB50MGA091343 002 Oct 17, 2013AB100MGA091343 003 Oct 17, 2013AB WATSON LABS25MGA077532 001 May 07, 2008AB50MGA077532 002 May 07, 2008AB100MGA077532 003 May 07, 2008PRECOSEAB + BAYER HLTHCARE25MGN020482 004 May 29, 1997AB50MGN020482 001 Sep 06, 1995AB100MGN020482 002 Sep 06, 1995

## PRESCRIPTION DRUG PRODUCT LIST

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

<b>AB</b>	AMNEAL PHARM	<b>EQ 200MG BASE</b>	<b>A075047 001</b>	Dec 30, 1999
<b>AB</b>		<b>EQ 400MG BASE</b>	<b>A075047 002</b>	Dec 30, 1999
<b>AB</b>	MYLAN	<b>EQ 200MG BASE</b>	<b>A074288 001</b>	Apr 24, 1995
<b>AB</b>		<b>EQ 400MG BASE</b>	<b>A074288 002</b>	Apr 24, 1995
<b>SECTRAL</b>				
<b>AB</b>	PROMIUS PHARMA	<b>EQ 200MG BASE</b>	<b>N018917 001</b>	Dec 28, 1984
<b>AB</b>	+	<b>EQ 400MG BASE</b>	<b>N018917 003</b>	Dec 28, 1984

ACETAMINOPHEN

SOLUTION; IV (INFUSION)

ACETAMINOPHEN

	FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767 001	Oct 28, 2015
	OFIRMEV			
	+ MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450 001	Nov 02, 2010

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

<b>AA</b>	LARKEN LABS INC	<b>325MG; 50MG</b>	<b>A203484 002</b>	Dec 04, 2015
<b>AA</b>	TEDOR PHARMA INC	<b>325MG; 50MG</b>	<b>A205120 001</b>	Oct 30, 2015
<b>BUTAPAP</b>				
<b>AA</b>	+ MIKART	<b>325MG; 50MG</b>	<b>A089987 001</b>	Oct 26, 1992
	ALLZITAL			
	LARKEN LABS INC	325MG; 25MG	A203484 001	Dec 04, 2015
	BUTALBITAL AND ACETAMINOPHEN			
	+ NEXGEN PHARMA	300MG; 50MG	A090956 001	Aug 23, 2011

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	+ MIKART	325MG; 50MG; 40MG	A089007 001	Mar 17, 1986
	+ NEXGEN PHARMA	300MG; 50MG; 40MG	A040885 001	Nov 16, 2009

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	+ MIKART	325MG/15ML; 50MG/15ML; 40MG/15ML	A040387 001	Jan 31, 2003
--	----------	----------------------------------	-------------	--------------

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<b>AA</b>	HIKMA PHARMS LLC	<b>325MG; 50MG; 40MG</b>	<b>A089718 001</b>	Jun 12, 1995
<b>AA</b>	LANNETT HOLDINGS INC	<b>325MG; 50MG; 40MG</b>	<b>A200243 001</b>	Sep 13, 2012
<b>AA</b>	MALLINCKRODT	<b>325MG; 50MG; 40MG</b>	<b>A087804 001</b>	Jan 24, 1985
<b>AA</b>	MIKART	<b>325MG; 50MG; 40MG</b>	<b>A089175 001</b>	Jan 21, 1987
<b>AA</b>	+ VINTAGE PHARMS	<b>325MG; 50MG; 40MG</b>	<b>A040511 001</b>	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

<b>AB</b>	HIKMA INTL PHARMS	<b>325MG; 50MG; 40MG; 30MG</b>	<b>A075618 001</b>	Mar 23, 2001
<b>AB</b>	NEXGEN PHARMA INC	<b>325MG; 50MG; 40MG; 30MG</b>	<b>A076560 001</b>	Jun 10, 2004
<b>AB</b>	VINTAGE PHARMS	<b>325MG; 50MG; 40MG; 30MG</b>	<b>A075929 001</b>	Apr 22, 2002
<b>FIORICET W/ CODEINE</b>				
<b>AB</b>	+ ACTAVIS LABS UT INC	<b>325MG; 50MG; 40MG; 30MG</b>	<b>N020232 001</b>	Jul 30, 1992
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE			
	NEXGEN PHARMA INC	300MG; 50MG; 40MG; 30MG	A076560 002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

TREZIX

	WRASER PHARMS LLC	320.5MG; 30MG; 16MG	A204785 001	Nov 26, 2014
--	-------------------	---------------------	-------------	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<b>AA</b>	HI TECH PHARMA	<b>120MG/5ML; 12MG/5ML</b>	<b>A040119 001</b>	Apr 26, 1996
<b>AA</b>	MIKART	<b>120MG/5ML; 12MG/5ML</b>	<b>A089450 001</b>	Oct 27, 1992
<b>AA</b>	+ PHARM ASSOC	<b>120MG/5ML; 12MG/5ML</b>	<b>A087508 001</b>	
<b>AA</b>	VINTAGE PHARMS	<b>120MG/5ML; 12MG/5ML</b>	<b>A091238 001</b>	Nov 10, 2011
<b>AA</b>	WOCKHARDT	<b>120MG/5ML; 12MG/5ML</b>	<b>A087006 001</b>	
SUSPENSION; ORAL				
CAPITAL AND CODEINE				
	+ VALEANT PHARMS LLC	120MG/5ML; 12MG/5ML	A086024 001	

## PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG;30MG</u>	<u>A040779 001</u>	May 29, 2008
<u>AA</u>	AUROLIFE PHARMA LLC	<u>300MG;15MG</u>	<u>A202800 001</u>	Apr 15, 2013
<u>AA</u>		<u>300MG;30MG</u>	<u>A202800 002</u>	Apr 15, 2013
<u>AA</u>		<u>300MG;60MG</u>	<u>A202800 003</u>	Apr 15, 2013
<u>AA</u>	+ MALLINCKRODT INC	<u>300MG;15MG</u>	<u>A040419 001</u>	May 31, 2001
<u>AA</u>		<u>300MG;30MG</u>	<u>A040419 002</u>	May 31, 2001
<u>AA</u>		<u>300MG;60MG</u>	<u>A040419 003</u>	May 31, 2001
<u>AA</u>	SUN PHARM INDS LTD	<u>300MG;30MG</u>	<u>A085868 001</u>	
<u>AA</u>		<u>300MG;60MG</u>	<u>A087083 001</u>	
<u>AA</u>	TEVA	<u>300MG;15MG</u>	<u>A088627 001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628 001</u>	Mar 06, 1985
<u>AA</u>	+	<u>300MG;60MG</u>	<u>A088629 001</u>	Mar 06, 1985
<u>AA</u>	VINTAGE	<u>300MG;15MG</u>	<u>A089990 001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805 001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828 001</u>	Sep 30, 1988
	<u>TYLENOL W/ CODEINE NO. 3</u>			
<u>AA</u>	+ JANSSEN PHARMS	<u>300MG;30MG</u>	<u>A085055 003</u>	
	<u>TYLENOL W/ CODEINE NO. 4</u>			
<u>AA</u>	JANSSEN PHARMS	<u>300MG;60MG</u>	<u>A085055 004</u>	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	+ MIKART	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040482 001</u>	Sep 25, 2003
<u>AA</u>	PHARM ASSOC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040838 001</u>	May 10, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040894 001</u>	Jul 19, 2011
<u>AA</u>	VISTAPHARM	<u>325MG/15ML;7.5MG/15ML</u>	<u>A200343 001</u>	Jan 25, 2012
	+ MIKART	300MG/15ML;10MG/15ML	A040881 001	Feb 25, 2010
	+ PHARM ASSOC	325MG/15ML;10MG/15ML	A040834 001	Apr 18, 2008

TABLET; ORAL

ANEXSIA 5/325

<u>AA</u>	MALLINCKRODT	<u>325MG;5MG</u>	<u>A040409 001</u>	Oct 20, 2000
	<u>ANEXSIA 7.5/325</u>			
<u>AA</u>	MALLINCKRODT	<u>325MG;7.5MG</u>	<u>A040405 001</u>	Sep 08, 2000

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	AMNEAL PHARMS NY	<u>325MG;5MG</u>	<u>A040736 001</u>	Aug 25, 2006
<u>AA</u>		<u>325MG;10MG</u>	<u>A040746 001</u>	Aug 25, 2006
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG;5MG</u>	<u>A201013 001</u>	Apr 11, 2012
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A201013 002</u>	Apr 11, 2012
<u>AA</u>		<u>325MG;10MG</u>	<u>A201013 003</u>	Apr 11, 2012
<u>AA</u>	MALLINCKRODT	<u>325MG;10MG</u>	<u>A040400 001</u>	Jul 26, 2000
<u>AA</u>	+ MIKART	<u>300MG;5MG</u>	<u>A040658 001</u>	Jan 19, 2006
<u>AA</u>	+	<u>300MG;7.5MG</u>	<u>A040556 002</u>	Mar 24, 2006
<u>AA</u>	+	<u>300MG;10MG</u>	<u>A040556 001</u>	Jun 23, 2004
<u>AA</u>	+	<u>325MG;2.5MG</u>	<u>A040846 001</u>	Jun 09, 2010
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040432 001</u>	Jan 22, 2003
<u>AA</u>	SUN PHARM INDS INC	<u>325MG;5MG</u>	<u>A090118 001</u>	Dec 23, 2008
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A090118 002</u>	Dec 23, 2008
<u>AA</u>		<u>325MG;10MG</u>	<u>A090118 003</u>	Dec 23, 2008
<u>AA</u>	TRIS PHARMA INC	<u>325MG;5MG</u>	<u>A202214 001</u>	Mar 27, 2013
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A202214 002</u>	Mar 27, 2013
<u>AA</u>		<u>325MG;10MG</u>	<u>A202214 003</u>	Mar 27, 2013
<u>AA</u>	VINTAGE PHARMS	<u>300MG;5MG</u>	<u>A090415 001</u>	Jan 24, 2011
<u>AA</u>		<u>300MG;7.5MG</u>	<u>A090415 002</u>	Jan 24, 2011
<u>AA</u>		<u>300MG;10MG</u>	<u>A090415 003</u>	Jan 24, 2011
<u>AA</u>		<u>325MG;5MG</u>	<u>A040655 001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040656 001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG;10MG</u>	<u>A040355 001</u>	May 31, 2000
	<u>NORCO</u>			
<u>AA</u>	ACTAVIS LABS FL INC	<u>325MG;2.5MG</u>	<u>A040148 004</u>	Jul 07, 2014
<u>AA</u>		<u>325MG;5MG</u>	<u>A040148 005</u>	Jul 07, 2014
<u>AA</u>	+	<u>325MG;7.5MG</u>	<u>A040148 003</u>	Sep 12, 2000
<u>AA</u>	+	<u>325MG;10MG</u>	<u>A040148 001</u>	Feb 14, 1997
<u>AA</u>	+ WATSON LABS	<u>325MG;5MG</u>	<u>A040099 001</u>	Jun 25, 1997

## PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

<b>AA</b>	VINTAGE PHARMS	<u>325MG/5ML; 5MG/5ML</u>	<b>A203573 001</b>	Dec 18, 2014
-----------	----------------	---------------------------	--------------------	--------------

ROXICET

<b>AA</b>	+ ROXANE	<u>325MG/5ML; 5MG/5ML</u>	<b>A089351 001</b>	Dec 03, 1986
-----------	----------	---------------------------	--------------------	--------------

TABLET; ORAL

OXYCET

<b>AA</b>	MALLINCKRODT	<u>325MG; 5MG</u>	<b>A087463 001</b>	Dec 07, 1983
-----------	--------------	-------------------	--------------------	--------------

OXYCODONE AND ACETAMINOPHEN

<b>AA</b>	ACTAVIS ELIZABETH	<u>325MG; 2.5MG</u>	<b>A201447 001</b>	Apr 12, 2013
-----------	-------------------	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 5MG</u>	<b>A201447 002</b>	Apr 12, 2013
-----------	--	-------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 7.5MG</u>	<b>A201447 003</b>	Apr 12, 2013
-----------	--	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A201447 004</b>	Apr 12, 2013
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	ALVOGEN INC	<u>325MG; 7.5MG</u>	<b>A202677 001</b>	Jul 26, 2012
-----------	-------------	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A202677 002</b>	Jul 26, 2012
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<b>A040777 001</b>	Nov 27, 2007
-----------	------------------	-------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A040778 001</b>	Nov 27, 2007
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	AUROLIFE PHARMA LLC	<u>325MG; 2.5MG</u>	<b>A201972 001</b>	Jul 15, 2013
-----------	---------------------	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 5MG</u>	<b>A201972 002</b>	Jul 15, 2013
-----------	--	-------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 7.5MG</u>	<b>A201972 003</b>	Jul 15, 2013
-----------	--	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A201972 004</b>	Jul 15, 2013
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	COASTAL PHARMS	<u>325MG; 2.5MG</u>	<b>A090177 001</b>	Oct 20, 2008
-----------	----------------	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 5MG</u>	<b>A090177 002</b>	Oct 20, 2008
-----------	--	-------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 7.5MG</u>	<b>A090177 003</b>	Oct 20, 2008
-----------	--	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A090177 004</b>	Oct 20, 2008
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<b>A040545 001</b>	Jun 30, 2004
-----------	--------------	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A040545 002</b>	Jun 30, 2004
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	RHODES PHARMS	<u>325MG; 5MG</u>	<b>A201278 001</b>	Aug 28, 2014
-----------	---------------	-------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 7.5MG</u>	<b>A201278 002</b>	Aug 28, 2014
-----------	--	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A201278 003</b>	Aug 28, 2014
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	SUN PHARM INDS INC	<u>325MG; 2.5MG</u>	<b>A090535 001</b>	Dec 26, 2013
-----------	--------------------	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 5MG</u>	<b>A090535 002</b>	Dec 26, 2013
-----------	--	-------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 7.5MG</u>	<b>A090535 003</b>	Dec 26, 2013
-----------	--	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A090535 004</b>	Dec 26, 2013
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	VINTAGE PHARMS	<u>325MG; 2.5MG</u>	<b>A090733 001</b>	Jul 11, 2013
-----------	----------------	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 5MG</u>	<b>A040105 001</b>	Jul 30, 1996
-----------	--	-------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 7.5MG</u>	<b>A090734 001</b>	Jul 11, 2013
-----------	--	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A090734 002</b>	Jul 11, 2013
-----------	--	--------------------	--------------------	--------------

<b>AA</b>	WATSON LABS	<u>325MG; 5MG</u>	<b>A040171 001</b>	Oct 30, 1997
-----------	-------------	-------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 7.5MG</u>	<b>A040535 001</b>	Sep 05, 2003
-----------	--	---------------------	--------------------	--------------

<b>AA</b>		<u>325MG; 10MG</u>	<b>A040535 002</b>	Sep 05, 2003
-----------	--	--------------------	--------------------	--------------

PERCOCET

<b>AA</b>	+ VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<b>A040330 001</b>	Jun 25, 1999
-----------	----------------------	---------------------	--------------------	--------------

<b>AA</b>	+	<u>325MG; 5MG</u>	<b>A040330 002</b>	Jun 25, 1999
-----------	---	-------------------	--------------------	--------------

<b>AA</b>	+	<u>325MG; 7.5MG</u>	<b>A040434 001</b>	Nov 23, 2001
-----------	---	---------------------	--------------------	--------------

<b>AA</b>	+	<u>325MG; 10MG</u>	<b>A040434 002</b>	Nov 23, 2001
-----------	---	--------------------	--------------------	--------------

ROXICET

<b>AA</b>	ROXANE	<u>325MG; 5MG</u>	<b>A087003 001</b>	
-----------	--------	-------------------	--------------------	--

OXYCODONE AND ACETAMINOPHEN

	+ MIKART	<u>300MG; 2.5MG</u>	A040608 001	Dec 30, 2005
--	----------	---------------------	-------------	--------------

	+	<u>300MG; 5MG</u>	A040608 002	Dec 30, 2005
--	---	-------------------	-------------	--------------

	+	<u>300MG; 7.5MG</u>	A040608 003	Dec 30, 2005
--	---	---------------------	-------------	--------------

	+	<u>300MG; 10MG</u>	A040608 004	Dec 30, 2005
--	---	--------------------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

	+ MALLINCKRODT INC	<u>325MG; 7.5MG</u>	N204031 001	Mar 11, 2014
--	--------------------	---------------------	-------------	--------------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<b>AB</b>	ALLIED PHARMA INC	<u>325MG; 37.5MG</u>	<b>A202076 001</b>	Mar 30, 2012
-----------	-------------------	----------------------	--------------------	--------------

<b>AB</b>	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<b>A090485 001</b>	Dec 09, 2009
-----------	---------------	----------------------	--------------------	--------------

<b>AB</b>	APOTEX INC	<u>325MG; 37.5MG</u>	<b>A078778 001</b>	Apr 07, 2014
-----------	------------	----------------------	--------------------	--------------

<b>AB</b>	MICRO LABS LTD INDIA	<u>325MG; 37.5MG</u>	<b>A201952 001</b>	Dec 14, 2012
-----------	----------------------	----------------------	--------------------	--------------

<b>AB</b>	MYLAN	<u>325MG; 37.5MG</u>	<b>A077858 001</b>	Sep 26, 2008
-----------	-------	----------------------	--------------------	--------------

<b>AB</b>	PAR PHARM	<u>325MG; 37.5MG</u>	<b>A076475 001</b>	Apr 21, 2005
-----------	-----------	----------------------	--------------------	--------------

<b>AB</b>	SUN PHARM INDS INC	<u>325MG; 37.5MG</u>	<b>A077184 001</b>	Dec 16, 2005
-----------	--------------------	----------------------	--------------------	--------------

<b>AB</b>	ZYDUS PHARMS USA INC	<u>325MG; 37.5MG</u>	<b>A090460 001</b>	Sep 06, 2012
-----------	----------------------	----------------------	--------------------	--------------

ULTRACET

<b>AB</b>	+ JANSSEN PHARMS	<u>325MG; 37.5MG</u>	<b>N021123 001</b>	Aug 15, 2001
-----------	------------------	----------------------	--------------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<b>AB</b>	HERITAGE PHARMS INC	<b>500MG</b>	<b>A090779 001</b>	Jul 14, 2011
<b>AB</b>	ZYDUS PHARMS USA INC	<b>500MG</b>	<b>A040904 001</b>	Dec 10, 2008

DIAMOX

<b>AB</b>	+ TEVA BRANDED PHARM	<b>500MG</b>	<b>N012945 001</b>	
-----------	----------------------	--------------	--------------------	--

TABLET; ORAL

ACETAZOLAMIDE

<b>AB</b>	LANNETT	<b>250MG</b>	<b>A084840 001</b>	
<b>AB</b>	MUTUAL PHARM	<b>125MG</b>	<b>A089752 001</b>	Jun 22, 1988
<b>AB</b>	TARO	<b>125MG</b>	<b>A040195 001</b>	May 28, 1997
<b>AB</b>	+	<b>250MG</b>	<b>A040195 002</b>	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<b>AP</b>	EUROHLTH INTL SARL	<b>EQ 500MG BASE/VIAL</b>	<b>A040089 001</b>	Feb 28, 1995
<b>AP</b>	SAGENT AGILA	<b>EQ 500MG BASE/VIAL</b>	<b>A200880 001</b>	May 09, 2012
<b>AP</b>	+ X GEN PHARMS	<b>EQ 500MG BASE/VIAL</b>	<b>A040784 001</b>	Dec 10, 2008

ACETAZOLAMIDE SODIUM

<b>AP</b>	EMCURE PHARMS LTD	<b>EQ 500MG BASE/VIAL</b>	<b>A202693 001</b>	Dec 19, 2014
-----------	-------------------	---------------------------	--------------------	--------------

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

<b>AT</b>	B BRAUN	<b>250MG/100ML</b>	<b>N018161 001</b>	
<b>AT</b>	BAXTER HLTHCARE	<b>250MG/100ML</b>	<b>N018523 001</b>	Feb 19, 1982
<b>AT</b>	HOSPIRA	<b>250MG/100ML</b>	<b>N017656 001</b>	

SOLUTION/DROPS; OTIC

ACETIC ACID

<b>AT</b>	TARO	<b>2%</b>	<b>A088638 001</b>	Sep 06, 1984
<b>AT</b>	VINTAGE	<b>2%</b>	<b>A040607 001</b>	Feb 24, 2005
<b>AT</b>	+ WOCKHARDT	<b>2%</b>	<b>A040166 001</b>	Jul 26, 1996

VOSOL

<b>AT</b>	HI TECH PHARMA	<b>2%</b>	<b>N012179 001</b>	
-----------	----------------	-----------	--------------------	--

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

+	BAUSCH AND LOMB	<b>2%;0.79%</b>	<b>A040063 001</b>	Feb 25, 1994
---	-----------------	-----------------	--------------------	--------------

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

<b>AT</b>	ACTAVIS MID ATLANTIC	<b>2%;1%</b>	<b>A087143 001</b>	Jan 13, 1982
-----------	----------------------	--------------	--------------------	--------------

HYDROCORTISONE AND ACETIC ACID

<b>AT</b>	TARO	<b>2%;1%</b>	<b>A088759 001</b>	Mar 04, 1985
<b>AT</b>	VINTAGE	<b>2%;1%</b>	<b>A040609 001</b>	Feb 06, 2006

VOSOL HC

<b>AT</b>	+ HI TECH PHARMA	<b>2%;1%</b>	<b>N012770 001</b>	
-----------	------------------	--------------	--------------------	--

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

+	MISSION PHARMA	<b>250MG</b>	<b>N018749 001</b>	May 31, 1983
---	----------------	--------------	--------------------	--------------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+	BAUSCH AND LOMB	<b>20MG/VIAL</b>	<b>N020213 001</b>	Sep 22, 1993
---	-----------------	------------------	--------------------	--------------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

<b>AP</b>	+ CUMBERLAND PHARMS	<b>6GM/30ML (200MG/ML)</b>	<b>N021539 001</b>	Jan 23, 2004
-----------	---------------------	----------------------------	--------------------	--------------

ACETYLCYSTEINE

<b>AP</b>	AKORN INC	<b>6GM/30ML (200MG/ML)</b>	<b>A203173 001</b>	Mar 24, 2015
<b>AP</b>	INNOPHARMA LICENSING	<b>6GM/30ML (200MG/ML)</b>	<b>A200644 001</b>	Nov 07, 2012
<b>AP</b>	MYLAN INSTITUTIONAL	<b>6GM/30ML (200MG/ML)</b>	<b>A203624 001</b>	Jun 19, 2015

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

<b>AN</b>	ALVOGEN INC	<b>10%</b>	<b>A204674 001</b>	Feb 11, 2014
<b>AN</b>		<b>20%</b>	<b>A203853 001</b>	Jun 21, 2012
<b>AN</b>	HOSPIRA	<b>10%</b>	<b>A073664 001</b>	Aug 30, 1994
<b>AN</b>		<b>20%</b>	<b>A074037 001</b>	Aug 30, 1994

## PRESCRIPTION DRUG PRODUCT LIST

ACETYL CYSTEINE

SOLUTION; INHALATION, ORAL

ACETYL CYSTEINE

<b>AN</b>	+	LUITPOLD	<b>10%</b>	<b>A072489 001</b>	Jul 28, 1995
<b>AN</b>	+		<b>20%</b>	<b>A072547 001</b>	Jul 28, 1995

ACITRETIN

CAPSULE; ORAL

ACITRETIN

<b>AB</b>		BARR LABS INC	<b>10MG</b>	<b>A091455 001</b>	Apr 04, 2013
<b>AB</b>			<b>25MG</b>	<b>A091455 002</b>	Apr 04, 2013
<b>AB</b>		MYLAN PHARMS INC	<b>10MG</b>	<b>A202148 001</b>	Sep 10, 2015
<b>AB</b>			<b>17.5MG</b>	<b>A203707 001</b>	Sep 10, 2015
<b>AB</b>			<b>22.5MG</b>	<b>A203707 002</b>	Sep 10, 2015
<b>AB</b>			<b>25MG</b>	<b>A202148 002</b>	Sep 10, 2015
<b>AB</b>		SIGMAPHARM LABS LLC	<b>10MG</b>	<b>A204633 001</b>	May 22, 2015
<b>AB</b>			<b>17.5MG</b>	<b>A204633 002</b>	May 22, 2015
<b>AB</b>			<b>22.5MG</b>	<b>A204633 003</b>	May 22, 2015
<b>AB</b>			<b>25MG</b>	<b>A204633 004</b>	May 22, 2015
<b>AB</b>		TEVA PHARMS USA	<b>17.5MG</b>	<b>A202897 001</b>	Apr 04, 2013
<b>AB</b>			<b>22.5MG</b>	<b>A202897 002</b>	Apr 04, 2013
<b>AB</b>		WATSON LABS INC	<b>10MG</b>	<b>A202552 001</b>	Dec 23, 2015
<b>AB</b>			<b>17.5MG</b>	<b>A202552 002</b>	Dec 23, 2015
<b>AB</b>			<b>22.5MG</b>	<b>A202552 003</b>	Dec 23, 2015
<b>AB</b>			<b>25MG</b>	<b>A202552 004</b>	Dec 23, 2015

SORIATANE

<b>AB</b>		STIEFEL LABS INC	<b>10MG</b>	<b>N019821 001</b>	Oct 28, 1996
<b>AB</b>			<b>17.5MG</b>	<b>N019821 003</b>	Aug 06, 2009
<b>AB</b>			<b>22.5MG</b>	<b>N019821 004</b>	Aug 06, 2009
<b>AB</b>	+		<b>25MG</b>	<b>N019821 002</b>	Oct 28, 1996

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+ ASTRAZENECA PHARMS 0.4MG/INH

N202450 001 Jul 23, 2012

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ AUXILIUM PHARMS LLC 8MG; 60MG

N019806 001 Mar 25, 1994

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

<b>AB</b>		APOTEX INC	<b>200MG</b>	<b>A075677 001</b>	Sep 28, 2005
<b>AB</b>		CADILA PHARMS LTD	<b>200MG</b>	<b>A201445 001</b>	Mar 06, 2014
<b>AB</b>		DAVA PHARMS INC	<b>200MG</b>	<b>A074833 001</b>	Apr 22, 1997
<b>AB</b>		MYLAN	<b>200MG</b>	<b>A074727 001</b>	Apr 22, 1997
<b>AB</b>		RANBAXY	<b>200MG</b>	<b>A074975 001</b>	Sep 30, 1998
<b>AB</b>		STASON	<b>200MG</b>	<b>A075090 001</b>	Jan 26, 1999
<b>AB</b>		TEVA	<b>200MG</b>	<b>A074578 001</b>	Apr 22, 1997

ZOVIRAX

<b>AB</b>	+	DELCOR ASSET	<b>200MG</b>	<b>N018828 001</b>	Jan 25, 1985
-----------	---	--------------	--------------	--------------------	--------------

CREAM; TOPICAL

ZOVIRAX

	+	VIB	<b>5%</b>	<b>N021478 001</b>	Dec 30, 2002
--	---	-----	-----------	--------------------	--------------

OINTMENT; TOPICAL

ACYCLOVIR

<b>AB</b>		AMNEAL PHARMS	<b>5%</b>	<b>A204605 001</b>	Jun 18, 2014
<b>AB</b>		MYLAN PHARMS INC	<b>5%</b>	<b>A202459 001</b>	Apr 03, 2013

ZOVIRAX

<b>AB</b>	+	VALEANT BERMUDA	<b>5%</b>	<b>N018604 001</b>	Mar 29, 1982
-----------	---	-----------------	-----------	--------------------	--------------

SUSPENSION; ORAL

ACYCLOVIR

<b>AB</b>		ACTAVIS MID ATLANTIC	<b>200MG/5ML</b>	<b>A074738 001</b>	Apr 28, 1997
<b>AB</b>		HI TECH PHARMA	<b>200MG/5ML</b>	<b>A077026 001</b>	Jun 07, 2005

ZOVIRAX

<b>AB</b>	+	DELCOR ASSET	<b>200MG/5ML</b>	<b>N019909 001</b>	Dec 22, 1989
-----------	---	--------------	------------------	--------------------	--------------

TABLET; BUCCAL

SITAVIG

+ INNOCUTIS HOLDINGS 50MG

N203791 001 Apr 12, 2013

TABLET; ORAL

ACYCLOVIR

<b>AB</b>		APOTEX INC	<b>400MG</b>	<b>A077309 001</b>	Sep 29, 2005
-----------	--	------------	--------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

<u>AB</u>		<u>800MG</u>	<u>A077309 002</u>	Sep 29, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>400MG</u>	<u>A202168 001</u>	Nov 15, 2013
<u>AB</u>		<u>800MG</u>	<u>A202168 002</u>	Nov 15, 2013
<u>AB</u>	CARLSBAD	<u>400MG</u>	<u>A075382 001</u>	Apr 30, 1999
<u>AB</u>		<u>800MG</u>	<u>A075382 002</u>	Apr 30, 1999
<u>AB</u>	DAVA PHARMS INC	<u>400MG</u>	<u>A074946 001</u>	Nov 19, 1997
<u>AB</u>		<u>800MG</u>	<u>A074946 002</u>	Nov 19, 1997
<u>AB</u>	HETERO LABS LTD V	<u>400MG</u>	<u>A203834 001</u>	Oct 29, 2013
<u>AB</u>		<u>800MG</u>	<u>A203834 002</u>	Oct 29, 2013
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075211 001</u>	Sep 28, 1998
<u>AB</u>		<u>800MG</u>	<u>A075211 002</u>	Sep 28, 1998
<u>AB</u>	SUN PHARM INDS LTD	<u>400MG</u>	<u>A074980 001</u>	Sep 30, 1998
<u>AB</u>		<u>800MG</u>	<u>A074980 002</u>	Sep 30, 1998
<u>AB</u>	TEVA	<u>400MG</u>	<u>A074556 002</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074556 003</u>	Apr 22, 1997
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A204314 001</u>	Aug 19, 2014
<u>AB</u>		<u>800MG</u>	<u>A204314 002</u>	Aug 19, 2014
<u>ZOVIRAX</u>				
<u>AB</u>	DELCOR ASSET	<u>400MG</u>	<u>N020089 001</u>	Apr 30, 1991
<u>AB</u>	+	<u>800MG</u>	<u>N020089 002</u>	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/ML</u>	<u>A203701 001</u>	Oct 11, 2013
<u>AP</u>	BEDFORD	<u>EQ 500MG BASE/VIAL</u>	<u>A074596 002</u>	Apr 22, 1997
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074930 001</u>	May 13, 1998
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A075015 001</u>	Apr 30, 1998
	ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE			
	+ HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885 001	Dec 19, 1997
		EQ 1GM BASE/VIAL	A074885 002	Dec 19, 1997
	ACYCLOVIR SODIUM			
	+ BEDFORD	EQ 1GM BASE/VIAL	A074596 001	Apr 22, 1997

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

	+ VALEANT BERMUDA	5%;1%	N022436 001	Jul 31, 2009
--	-------------------	-------	-------------	--------------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A090824 001</u>	Jun 30, 2010
<u>DIFFERIN</u>				
<u>AB</u>	+ GALDERMA LABS LP	<u>0.1%</u>	<u>N020748 001</u>	May 26, 2000

GEL; TOPICAL

ADAPALENE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.3%</u>	<u>A201000 001</u>	Oct 27, 2014
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A091314 001</u>	Jul 01, 2010
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.1%</u>	<u>A090962 001</u>	Jun 02, 2010
<u>AB</u>	TOLMAR	<u>0.3%</u>	<u>A200298 001</u>	Jun 14, 2012
<u>DIFFERIN</u>				
<u>AB</u>	+ GALDERMA LABS LP	<u>0.1%</u>	<u>N020380 001</u>	May 31, 1996
<u>AB</u>	+	<u>0.3%</u>	<u>N021753 001</u>	Jun 19, 2007

LOTION; TOPICAL

DIFFERIN

	+ GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010
--	--------------------	------	-------------	--------------

SOLUTION; TOPICAL

ADAPALENE

	+ CALL INC	0.1%	A204593 001	Jan 05, 2016
--	------------	------	-------------	--------------

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.1%;2.5%</u>	<u>A203790 001</u>	Sep 30, 2015
<u>EPIDUO</u>				
<u>AB</u>	+ GALDERMA LABS LP	<u>0.1%;2.5%</u>	<u>N022320 001</u>	Dec 08, 2008
	EPIDUO FORTE			
	+ GALDERMA LABS	0.3%;2.5%	N207917 001	Jul 15, 2015

## PRESCRIPTION DRUG PRODUCT LIST

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

<b>AB</b>	SIGMAPHARM LABS LLC	<b>10MG</b>	<b>A202051 001</b>	Aug 29, 2013
-----------	---------------------	-------------	--------------------	--------------

HEPSERA

<b>AB</b>	+ GILEAD	<b>10MG</b>	<b>N021449 001</b>	Sep 20, 2002
-----------	----------	-------------	--------------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

<b>AP</b>	+ ASTELLAS	<b>3MG/ML</b>	<b>N019937 002</b>	Oct 30, 1989
-----------	------------	---------------	--------------------	--------------

ADENOSINE

<b>AP</b>	AKORN	<b>3MG/ML</b>	<b>A078076 001</b>	Oct 31, 2008
-----------	-------	---------------	--------------------	--------------

<b>AP</b>	BEDFORD	<b>3MG/ML</b>	<b>A076404 001</b>	Jun 16, 2004
-----------	---------	---------------	--------------------	--------------

<b>AP</b>	EUROHLTH INTL SARL	<b>3MG/ML</b>	<b>A076500 001</b>	Jun 16, 2004
-----------	--------------------	---------------	--------------------	--------------

<b>AP</b>	FRESENIUS KABI USA	<b>3MG/ML</b>	<b>A077133 001</b>	Apr 27, 2005
-----------	--------------------	---------------	--------------------	--------------

<b>AP</b>	GLAND PHARMA LTD	<b>3MG/ML</b>	<b>A077283 001</b>	Jun 14, 2007
-----------	------------------	---------------	--------------------	--------------

<b>AP</b>	LUITPOLD	<b>3MG/ML</b>	<b>A090010 001</b>	Apr 28, 2009
-----------	----------	---------------	--------------------	--------------

<b>AP</b>	MYLAN LABS LTD	<b>3MG/ML</b>	<b>A078640 001</b>	Mar 21, 2014
-----------	----------------	---------------	--------------------	--------------

<b>AP</b>		<b>3MG/ML</b>	<b>A078686 001</b>	May 13, 2009
-----------	--	---------------	--------------------	--------------

SOLUTION; IV (INFUSION)

ADENOSCAN

<b>AP</b>	+ ASTELLAS	<b>60MG/20ML (3MG/ML)</b>	<b>N020059 001</b>	May 18, 1995
-----------	------------	---------------------------	--------------------	--------------

<b>AP</b>	+	<b>90MG/30ML (3MG/ML)</b>	<b>N020059 002</b>	May 18, 1995
-----------	---	---------------------------	--------------------	--------------

ADENOSINE

<b>AP</b>	AKORN	<b>60MG/20ML (3MG/ML)</b>	<b>A090450 001</b>	Oct 02, 2014
-----------	-------	---------------------------	--------------------	--------------

<b>AP</b>		<b>90MG/30ML (3MG/ML)</b>	<b>A090450 002</b>	Oct 02, 2014
-----------	--	---------------------------	--------------------	--------------

<b>AP</b>	EMCURE PHARMS LTD	<b>60MG/20ML (3MG/ML)</b>	<b>A202313 001</b>	Sep 15, 2014
-----------	-------------------	---------------------------	--------------------	--------------

<b>AP</b>		<b>90MG/30ML (3MG/ML)</b>	<b>A202313 002</b>	Sep 15, 2014
-----------	--	---------------------------	--------------------	--------------

<b>AP</b>	HOSPIRA INC	<b>60MG/20ML (3MG/ML)</b>	<b>A203883 001</b>	Mar 24, 2014
-----------	-------------	---------------------------	--------------------	--------------

<b>AP</b>		<b>90MG/30ML (3MG/ML)</b>	<b>A203883 002</b>	Mar 24, 2014
-----------	--	---------------------------	--------------------	--------------

<b>AP</b>	SAGENT STRIDES	<b>60MG/20ML (3MG/ML)</b>	<b>A090212 001</b>	Mar 28, 2014
-----------	----------------	---------------------------	--------------------	--------------

<b>AP</b>		<b>90MG/30ML (3MG/ML)</b>	<b>A090212 002</b>	Mar 28, 2014
-----------	--	---------------------------	--------------------	--------------

<b>AP</b>	TEVA PHARMS USA	<b>60MG/20ML (3MG/ML)</b>	<b>A077425 001</b>	Aug 29, 2013
-----------	-----------------	---------------------------	--------------------	--------------

<b>AP</b>		<b>90MG/30ML (3MG/ML)</b>	<b>A077425 002</b>	Aug 29, 2013
-----------	--	---------------------------	--------------------	--------------

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292 001	Jul 12, 2013
--	----------------------	--------------	-------------	--------------

		EQ 30MG BASE	N201292 002	Jul 12, 2013
--	--	--------------	-------------	--------------

+		EQ 40MG BASE	N201292 003	Jul 12, 2013
---	--	--------------	-------------	--------------

ALBENDAZOLE

TABLET; ORAL

ALBENZA

+	AMEDRA PHARMS LLC	200MG	N020666 001	Jun 11, 1996
---	-------------------	-------	-------------	--------------

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+	GE HEALTHCARE	10MG/ML	N020899 001	Dec 31, 1997
---	---------------	---------	-------------	--------------

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

	ISO TEX	100uCi/10ML (10uCi/ML)	N017836 003	Jun 08, 2004
--	---------	------------------------	-------------	--------------

		500uCi/0.5ML	N017836 001	
--	--	--------------	-------------	--

+		1,000uCi/ML	N017836 002	
---	--	-------------	-------------	--

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

+	ISO TEX	0.5mCi/VIAL	N017837 001	
---	---------	-------------	-------------	--

+		1mCi/VIAL	N017837 002	
---	--	-----------	-------------	--

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

<b>BX</b>	+ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457 001	Oct 29, 2004
-----------	----------------------	--------------------	-------------	--------------

PROVENTIL-HFA

<b>BX</b>	+ 3M	EQ 0.09MG BASE/INH	N020503 001	Aug 15, 1996
-----------	------	--------------------	-------------	--------------

VENTOLIN HFA

<b>BX</b>	+ GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983 001	Apr 19, 2001
-----------	-------------------	--------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ALBUTEROL SULFATE

POWDER, METERED; INHALATION

PROAIR RESPICLICK

+ TEVA BRANDED PHARM

EQ 0.090MG BASE/INH

N205636 001 Mar 31, 2015

SOLUTION; INHALATION

ACCUNETAN + MYLAN SPECLTEQ 0.021% BASEN020949 002 Apr 30, 2001AN +EQ 0.042% BASEN020949 001 Apr 30, 2001ALBUTEROL SULFATEAN + BAUSCH AND LOMBEQ 0.5% BASEA075050 001 Jun 18, 1998AN HI TECH PHARMAEQ 0.083% BASEA075063 001 Feb 09, 1999ANEQ 0.5% BASEA074543 001 Jan 15, 1998AN LANDELA PHARMEQ 0.083% BASEA077569 001 Apr 04, 2006AN + MYLAN SPECLTEQ 0.083% BASEA072652 001 Feb 21, 1992AN NEPHRONEQ 0.021% BASEA076355 002 Mar 31, 2010ANEQ 0.042% BASEA076355 001 Jun 28, 2004ANEQ 0.083% BASEA074880 001 Sep 17, 1997ANEQ 0.5% BASEA075664 001 Jun 26, 2001AN RITEDOSE CORPEQ 0.083% BASEA077839 001 Dec 16, 2008ANEQ 0.083% BASEA075343 001 Nov 09, 1999AN WATSON LABSEQ 0.021% BASEA077772 001 Sep 25, 2007ANEQ 0.042% BASEA077772 002 Sep 25, 2007AN WATSON LABS INCEQ 0.083% BASEA076370 001 Nov 24, 2003

SYRUP; ORAL

ALBUTEROL SULFATEAA AMNEAL PHARMSEQ 2MG BASE/5MLA079241 001 May 12, 2010AA G AND W LABS INCEQ 2MG BASE/5MLA074454 001 Sep 25, 1995AA HI TECH PHARMAEQ 2MG BASE/5MLA074749 001 Jan 30, 1998AA + TEVAEQ 2MG BASE/5MLA073419 001 Mar 30, 1992AA VINTAGEEQ 2MG BASE/5MLA078105 001 Dec 27, 2006AA VISTAPHARMEQ 2MG BASE/5MLA077788 001 Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATEAB MUTUAL PHARMEQ 2MG BASEA072637 002 Dec 05, 1989ABEQ 4MG BASEA072637 001 Dec 05, 1989AB MYLANEQ 2MG BASEA072894 002 Jan 17, 1991AB +EQ 4MG BASEA072894 001 Jan 17, 1991

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATEAB MYLANEQ 4MG BASEA078092 002 Jan 29, 2007ABEQ 8MG BASEA078092 001 Jan 29, 2007VOSPIRE ERAB DAVA PHARMS INCEQ 4MG BASEA076130 002 Sep 26, 2002AB +EQ 8MG BASEA076130 003 Sep 26, 2002ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDEAN CIPLA LTDEQ 0.083% BASE; 0.017%A077559 001 Dec 31, 2007AN NEPHRONEQ 0.083% BASE; 0.017%A076749 001 Dec 31, 2007AN RITEDOSE CORPEQ 0.083% BASE; 0.017%A202496 001 Oct 01, 2012AN TEVA PHARMSEQ 0.083% BASE; 0.017%A076724 001 Dec 31, 2007AN WATSON LABSEQ 0.083% BASE; 0.017%A077063 001 Dec 31, 2007DUONERAN + MYLAN SPECLTEQ 0.083% BASE; 0.017%N020950 001 Mar 21, 2001

SPRAY, METERED; INHALATION

COMBIVENT RESPIMAT

+ BOEHRINGER INGELHEIM

EQ 0.1MG BASE/INH; 0.02MG/INH

N021747 001 Oct 07, 2011

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+ ALLERGAN

0.25%

N022134 001 Jul 28, 2010

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATEAB + FOUGERA PHARMS0.05%A076973 001 Jul 12, 2005AB GLENMARK GENERICS0.05%A079061 001 Jun 23, 2009AB TARO0.05%A076587 001 Sep 15, 2005

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATEAB + FOUGERA PHARMS0.05%A076884 001 Jul 18, 2005AB GLENMARK GENERICS0.05%A079227 001 Jul 30, 2009

## PRESCRIPTION DRUG PRODUCT LIST

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	TARO	<u>0.05%</u>	<u>A076730</u>	<u>001</u>	Jul 29, 2004
-----------	------	--------------	----------------	------------	--------------

ALECTINIB HYDROCHLORIDE

CAPSULE; ORAL

ALECENSA

+ HOFFMANN-LA ROCHE

EQ 150MG BASE

N208434 001 Dec 11, 2015

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

<u>AA</u>	ROXANE	<u>EQ 70MG BASE/75ML</u>	<u>A090520</u>	<u>001</u>	Feb 25, 2013
-----------	--------	--------------------------	----------------	------------	--------------

FOSAMAX

<u>AA</u>	+ MERCK	<u>EQ 70MG BASE/75ML</u>	<u>N021575</u>	<u>001</u>	Sep 17, 2003
-----------	---------	--------------------------	----------------	------------	--------------

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE</u>	<u>A077982</u>	<u>001</u>	Aug 04, 2008
-----------	--------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077982</u>	<u>002</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A077982</u>	<u>003</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A077982</u>	<u>004</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A090124</u>	<u>001</u>	Aug 04, 2008
-----------	------------------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090124</u>	<u>002</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090124</u>	<u>003</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 5MG BASE</u>	<u>A090258</u>	<u>001</u>	Sep 24, 2009
-----------	------------------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090258</u>	<u>002</u>	Sep 24, 2009
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090258</u>	<u>003</u>	Sep 24, 2009
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090258</u>	<u>004</u>	Sep 24, 2009
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	CADISTA PHARMS	<u>EQ 5MG BASE</u>	<u>A090557</u>	<u>001</u>	Feb 18, 2010
-----------	----------------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090557</u>	<u>002</u>	Feb 18, 2010
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090557</u>	<u>003</u>	Feb 18, 2010
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090557</u>	<u>004</u>	Feb 18, 2010
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A076768</u>	<u>001</u>	Aug 04, 2008
-----------	-----------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076768</u>	<u>002</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076768</u>	<u>003</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076768</u>	<u>004</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076768</u>	<u>005</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	<u>A079109</u>	<u>001</u>	Aug 04, 2008
-----------	--------------------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079109</u>	<u>002</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A079049</u>	<u>001</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A079049</u>	<u>002</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076584</u>	<u>001</u>	Aug 04, 2008
-----------	-------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076584</u>	<u>002</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076584</u>	<u>003</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076584</u>	<u>004</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A090022</u>	<u>001</u>	Sep 10, 2008
-----------	-------------------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022</u>	<u>002</u>	Sep 10, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022</u>	<u>003</u>	Sep 10, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022</u>	<u>004</u>	Sep 10, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A075710</u>	<u>001</u>	Feb 06, 2008
-----------	-------------	--------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075710</u>	<u>002</u>	Feb 06, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075710</u>	<u>003</u>	Feb 06, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075710</u>	<u>004</u>	Feb 06, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075710</u>	<u>005</u>	Feb 06, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>	WATSON LABS	<u>EQ 35MG BASE</u>	<u>A076984</u>	<u>001</u>	Aug 04, 2008
-----------	-------------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984</u>	<u>002</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984</u>	<u>003</u>	Aug 04, 2008
-----------	--	---------------------	----------------	------------	--------------

FOSAMAX

<u>AB</u>	+ MERCK AND CO INC	<u>EQ 70MG BASE</u>	<u>N020560</u>	<u>005</u>	Oct 20, 2000
-----------	--------------------	---------------------	----------------	------------	--------------

TABLET, EFFERVESCENT; ORAL

BINOSTO

+ MISSION PHARMA

EQ 70MG BASE

N202344 001 Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

EQ 70MG BASE; 2,800 IU

N021762 001 Apr 07, 2005

+

EQ 70MG BASE; 5,600 IU

N021762 002 Apr 26, 2007

## PRESCRIPTION DRUG PRODUCT LIST

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

<b>AP</b>	+ AKORN	<b>EQ 0.5MG BASE/ML</b>	<b>N019353 001</b>	Dec 29, 1986
-----------	---------	-------------------------	--------------------	--------------

ALFENTANIL

<b>AP</b>	HOSPIRA	<b>EQ 0.5MG BASE/ML</b>	<b>A075221 001</b>	Oct 28, 1999
-----------	---------	-------------------------	--------------------	--------------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

<b>AB</b>	APOTEX INC	<b>10MG</b>	<b>A079013 001</b>	Jul 18, 2011
-----------	------------	-------------	--------------------	--------------

<b>AB</b>	AUROBINDO PHARMA LTD	<b>10MG</b>	<b>A079060 001</b>	Aug 30, 2012
-----------	----------------------	-------------	--------------------	--------------

<b>AB</b>	INVAGEN PHARMS	<b>10MG</b>	<b>A090284 001</b>	Jan 17, 2012
-----------	----------------	-------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>10MG</b>	<b>A079014 001</b>	Jul 18, 2011
-----------	-------	-------------	--------------------	--------------

<b>AB</b>	SUN PHARMA GLOBAL	<b>10MG</b>	<b>A079057 001</b>	Jul 18, 2011
-----------	-------------------	-------------	--------------------	--------------

<b>AB</b>	TEVA PHARMS	<b>10MG</b>	<b>A079056 001</b>	Jul 18, 2011
-----------	-------------	-------------	--------------------	--------------

<b>AB</b>	TORRENT PHARMS	<b>10MG</b>	<b>A079054 001</b>	Jul 18, 2011
-----------	----------------	-------------	--------------------	--------------

UROXATRAL

<b>AB</b>	+ CONCORDIA PHARMS INC	<b>10MG</b>	<b>N021287 001</b>	Jun 12, 2003
-----------	------------------------	-------------	--------------------	--------------

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

	NOVARTIS	EQ 150MG BASE	N021985 001	Mar 05, 2007
--	----------	---------------	-------------	--------------

+		EQ 300MG BASE	N021985 002	Mar 05, 2007
---	--	---------------	-------------	--------------

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

	NOVARTIS	EQ 150MG BASE; 12.5MG	N022107 001	Jan 18, 2008
--	----------	-----------------------	-------------	--------------

		EQ 150MG BASE; 25MG	N022107 002	Jan 18, 2008
--	--	---------------------	-------------	--------------

+		EQ 300MG BASE; 12.5MG	N022107 003	Jan 18, 2008
---	--	-----------------------	-------------	--------------

+		EQ 300MG BASE; 25MG	N022107 004	Jan 18, 2008
---	--	---------------------	-------------	--------------

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+	EISAI INC	EQ 0.1% BASE	N020886 001	Feb 02, 1999
---	-----------	--------------	-------------	--------------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<b>AB</b>	ACCORD HLTHCARE	<b>100MG</b>	<b>A203154 001</b>	May 06, 2013
-----------	-----------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A203154 002</b>	May 06, 2013
-----------	--	--------------	--------------------	--------------

<b>AB</b>	APOTEX INC	<b>100MG</b>	<b>A077353 001</b>	Sep 08, 2005
-----------	------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A077353 002</b>	Sep 08, 2005
-----------	--	--------------	--------------------	--------------

<b>AB</b>	IPCA LABS LTD	<b>100MG</b>	<b>A090637 001</b>	Mar 16, 2011
-----------	---------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A090637 002</b>	Mar 16, 2011
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MUTUAL PHARM	<b>100MG</b>	<b>A071449 001</b>	Jan 09, 1987
-----------	--------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A071450 001</b>	Jan 09, 1987
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>100MG</b>	<b>A018659 001</b>	Oct 24, 1986
-----------	-------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A018659 002</b>	Oct 24, 1986
-----------	--	--------------	--------------------	--------------

<b>AB</b>	NORTHSTAR HLTHCARE	<b>100MG</b>	<b>A078253 001</b>	Sep 11, 2007
-----------	--------------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A078253 002</b>	Sep 11, 2007
-----------	--	--------------	--------------------	--------------

<b>AB</b>	SUN PHARM INDS INC	<b>100MG</b>	<b>A078390 001</b>	Aug 30, 2007
-----------	--------------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A078390 002</b>	Aug 30, 2007
-----------	--	--------------	--------------------	--------------

<b>AB</b>	VINTAGE PHARMS	<b>100MG</b>	<b>A075798 001</b>	Jun 27, 2003
-----------	----------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A075798 002</b>	Jun 27, 2003
-----------	--	--------------	--------------------	--------------

<b>AB</b>	WATSON LABS	<b>100MG</b>	<b>N018832 002</b>	Sep 28, 1984
-----------	-------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>N018877 001</b>	Sep 28, 1984
-----------	--	--------------	--------------------	--------------

LOPURIN

<b>AB</b>	DR REDDYS LA	<b>100MG</b>	<b>A071586 001</b>	Apr 02, 1987
-----------	--------------	--------------	--------------------	--------------

<b>AB</b>		<b>300MG</b>	<b>A071587 001</b>	Apr 02, 1987
-----------	--	--------------	--------------------	--------------

ZYLOPRIM

<b>AB</b>	PROMETHEUS LABS	<b>100MG</b>	<b>N016084 001</b>	
-----------	-----------------	--------------	--------------------	--

<b>AB</b>	+	<b>300MG</b>	<b>N016084 002</b>	
-----------	---	--------------	--------------------	--

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

<b>AP</b>	EUROHLTH INTL SARR	<b>EQ 500MG BASE/VIAL</b>	<b>A076870 001</b>	Aug 26, 2004
-----------	--------------------	---------------------------	--------------------	--------------

ALOPRIM

<b>AP</b>	+ MYLAN INSTITUTIONAL	<b>EQ 500MG BASE/VIAL</b>	<b>N020298 001</b>	May 17, 1996
-----------	-----------------------	---------------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

<b>AB</b>	MYLAN PHARMS INC	<b>EQ 6.25MG BASE</b>	<b>A205171 001</b>	Nov 09, 2015
<b>AB</b>		<b>EQ 12.5MG BASE</b>	<b>A205171 002</b>	Nov 09, 2015
<b>AB</b>	TEVA PHARMS USA	<b>EQ 6.25MG BASE</b>	<b>A078027 001</b>	Jul 07, 2015
<b>AB</b>		<b>EQ 12.5MG BASE</b>	<b>A078027 002</b>	Jul 07, 2015
<b>AXERT</b>				
<b>AB</b>	JANSSEN PHARMS	<b>EQ 6.25MG BASE</b>	<b>N021001 001</b>	May 07, 2001
<b>AB</b>	+	<b>EQ 12.5MG BASE</b>	<b>N021001 002</b>	May 07, 2001

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271 001	Jan 25, 2013
		EQ 12.5MG BASE	N022271 002	Jan 25, 2013
+		EQ 25MG BASE	N022271 003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

	TAKEDA PHARMS USA	EQ 12.5MG BASE; 500MG	N203414 001	Jan 25, 2013
+		EQ 12.5MG BASE; 1GM	N203414 002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

	TAKEDA PHARMS USA	EQ 12.5MG BASE; EQ 15MG BASE	N022426 004	Jan 25, 2013
		EQ 12.5MG BASE; EQ 30MG BASE	N022426 005	Jan 25, 2013
		EQ 12.5MG BASE; EQ 45MG BASE	N022426 006	Jan 25, 2013
		EQ 25MG BASE; EQ 15MG BASE	N022426 001	Jan 25, 2013
		EQ 25MG BASE; EQ 30MG BASE	N022426 002	Jan 25, 2013
+		EQ 25MG BASE; EQ 45MG BASE	N022426 003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

<b>AB</b>	ROXANE	<b>EQ 0.5MG BASE</b>	<b>A200652 001</b>	May 04, 2015
<b>AB</b>		<b>EQ 1MG BASE</b>	<b>A200652 002</b>	May 04, 2015
<b>LOTROXEX</b>				
<b>AB</b>	PROMETHEUS LABS	<b>EQ 0.5MG BASE</b>	<b>N021107 002</b>	Dec 23, 2003
<b>AB</b>	+	<b>EQ 1MG BASE</b>	<b>N021107 001</b>	Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163 001	May 18, 2000
---	--------	---	-------------	--------------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559 001	Jun 16, 2003
---	--------	--	-------------	--------------

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

+	ROXANE	1MG/ML	A074312 001	Oct 31, 1993
---	--------	--------	-------------	--------------

TABLET; ORAL

ALPRAZOLAM

<b>AB</b>	ACTAVIS ELIZABETH	<b>0.25MG</b>	<b>A074342 001</b>	Oct 31, 1993
<b>AB</b>		<b>0.5MG</b>	<b>A074342 002</b>	Oct 31, 1993
<b>AB</b>		<b>1MG</b>	<b>A074342 003</b>	Oct 31, 1993
<b>AB</b>		<b>2MG</b>	<b>A074342 004</b>	Oct 31, 1993
<b>AB</b>	APOTEX INC	<b>0.25MG</b>	<b>A077741 001</b>	Jan 19, 2007
<b>AB</b>		<b>0.5MG</b>	<b>A077741 002</b>	Jan 19, 2007
<b>AB</b>		<b>1MG</b>	<b>A077741 003</b>	Jan 19, 2007
<b>AB</b>		<b>2MG</b>	<b>A077741 004</b>	Jan 19, 2007
<b>AB</b>	AUROBINDO PHARMA LTD	<b>0.25MG</b>	<b>A203346 001</b>	Jul 31, 2015
<b>AB</b>		<b>0.5MG</b>	<b>A203346 002</b>	Jul 31, 2015
<b>AB</b>		<b>1MG</b>	<b>A203346 003</b>	Jul 31, 2015



## PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>		<u>2MG</u>	<u>A203346</u>	<u>004</u>	Jul 31, 2015
<u>AB</u>	DAVA INTL INC	<u>0.25MG</u>	<u>A074174</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074174</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074174</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074174</u>	<u>004</u>	Oct 19, 1993
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215</u>	<u>003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215</u>	<u>004</u>	Jan 27, 1994
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A074046</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074046</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074046</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074046</u>	<u>004</u>	May 07, 1997
<u>AB</u>	NATCO PHARMA LTD	<u>0.25MG</u>	<u>A200739</u>	<u>001</u>	Apr 15, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A200739</u>	<u>002</u>	Apr 15, 2015
<u>AB</u>		<u>1MG</u>	<u>A200739</u>	<u>003</u>	Apr 15, 2015
<u>AB</u>		<u>2MG</u>	<u>A200739</u>	<u>004</u>	Apr 15, 2015
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112</u>	<u>001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112</u>	<u>002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112</u>	<u>003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.25MG</u>	<u>A090082</u>	<u>001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082</u>	<u>002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082</u>	<u>003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082</u>	<u>004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078491</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491</u>	<u>004</u>	Dec 12, 2008
<u>AB</u>	VINTAGE PHARMS	<u>0.25MG</u>	<u>A090248</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090248</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090248</u>	<u>004</u>	Sep 17, 2010
<u>XANAX</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>		<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>		<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007
<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A077198</u>	<u>001</u>	May 13, 2010
<u>AB</u>		<u>1MG</u>	<u>A077198</u>	<u>002</u>	May 13, 2010
<u>AB</u>		<u>2MG</u>	<u>A077198</u>	<u>003</u>	May 13, 2010
<u>AB</u>		<u>3MG</u>	<u>A077198</u>	<u>004</u>	May 13, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A078469</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A078469</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A078469</u>	<u>004</u>	Sep 29, 2011
<u>AB</u>	ANI PHARMS INC	<u>0.5MG</u>	<u>A077725</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725</u>	<u>002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725</u>	<u>004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>		<u>1MG</u>	<u>A078449</u>	<u>004</u>	Dec 23, 2015
<u>AB</u>		<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008
<u>AB</u>	AUROBINDO PHARMA USA	<u>0.5MG</u>	<u>A090871</u>	<u>001</u>	Jun 07, 2011
<u>AB</u>		<u>1MG</u>	<u>A090871</u>	<u>002</u>	Jun 07, 2011
<u>AB</u>		<u>2MG</u>	<u>A090871</u>	<u>003</u>	Jun 07, 2011
<u>AB</u>		<u>3MG</u>	<u>A090871</u>	<u>004</u>	Jun 07, 2011
<u>AB</u>	COREPHARMA	<u>0.5MG</u>	<u>A077996</u>	<u>001</u>	Jan 31, 2007

## PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

<u>AB</u>		<u>1MG</u>	<u>A077996 002</u>	Jan 31, 2007
<u>AB</u>		<u>2MG</u>	<u>A077996 003</u>	Jan 31, 2007
<u>AB</u>		<u>3MG</u>	<u>A077996 004</u>	Jan 31, 2007
<u>AB</u>	HERITAGE PHARMS INC	<u>0.5MG</u>	<u>A078489 001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489 002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489 003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489 004</u>	Oct 17, 2008
<u>AB</u>	IMPAX LABS	<u>0.5MG</u>	<u>A077968 004</u>	May 24, 2007
<u>AB</u>		<u>1MG</u>	<u>A077968 003</u>	May 24, 2007
<u>AB</u>		<u>2MG</u>	<u>A077968 002</u>	May 24, 2007
<u>AB</u>		<u>3MG</u>	<u>A077968 001</u>	May 24, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077391 002</u>	Jan 26, 2006
<u>AB</u>		<u>1MG</u>	<u>A077391 003</u>	Jan 26, 2006
<u>AB</u>		<u>2MG</u>	<u>A077391 004</u>	Jan 26, 2006
<u>AB</u>		<u>3MG</u>	<u>A077391 001</u>	Jan 26, 2006

XANAX XR

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434 001</u>	Jan 17, 2003
<u>AB</u>		<u>1MG</u>	<u>N021434 002</u>	Jan 17, 2003
<u>AB</u>		<u>2MG</u>	<u>N021434 003</u>	Jan 17, 2003
<u>AB</u>	+	<u>3MG</u>	<u>N021434 004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561 001</u>	Mar 16, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078561 002</u>	Mar 16, 2010
<u>AB</u>		<u>1MG</u>	<u>A078561 003</u>	Mar 16, 2010
<u>AB</u>		<u>2MG</u>	<u>A078561 004</u>	Mar 16, 2010
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A078088 001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088 002</u>	Jan 09, 2009
<u>AB</u>	+	<u>1MG</u>	<u>A078088 003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088 004</u>	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

<u>AP</u>	EUROHLTH INTL SARL	<u>0.5MG/ML</u>	<u>A074815 001</u>	Jan 20, 1998
<u>AP</u>	TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196 001</u>	Apr 30, 1999

CAVERJECT

<u>AP</u>	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379 001</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.02MG/VIAL</u>	<u>N020379 002</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020379 004</u>	May 19, 1997

EDEX

<u>AP</u>	AUXILIUM PHARMS LLC	<u>0.01MG/VIAL</u>	<u>N020649 002</u>	Jun 12, 1997
<u>AP</u>		<u>0.02MG/VIAL</u>	<u>N020649 003</u>	Jun 12, 1997
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020649 004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484 001</u>	
		CAVERJECT			
		PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379 003	Jun 27, 1996
		CAVERJECT IMPULSE			
		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212 001	Jun 11, 2002
			0.02MG/VIAL	N021212 002	Jun 11, 2002
		EDEX			
		+	AUXILIUM PHARMS LLC	N020649 005	Jul 30, 1998
		+		N020649 006	Jul 30, 1998
		+		N020649 007	Jul 30, 1998

SUPPOSITORY;URETHRAL

## MUSE

	MEDA PHARMS	0.125MG	N020700 001	Nov 19, 1996
		0.25MG	N020700 002	Nov 19, 1996
		0.5MG	N020700 003	Nov 19, 1996
	+	1MG	N020700 004	Nov 19, 1996

ALTRETAMINE

CAPSULE;ORAL

## HEXALEN

	+	EISAI INC	50MG	N019926 001	Dec 26, 1990
--	---	-----------	------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+ CUBIST PHARMS

12MG

N021775 001 May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDEAB BANNER LIFE SCIENCES100MGA078720 001 May 29, 2008AB + SANDOZ100MGA071293 001 Feb 18, 1987AB USL PHARMA100MGA070589 001 Aug 05, 1986

SYRUP; ORAL

AMANTADINE HYDROCHLORIDEAA + CAROLINA MEDCL50MG/5MLA075819 001 Sep 11, 2002AA + HI TECH PHARMA50MG/5MLA074170 001 Oct 28, 1994AA + MIKART50MG/5MLA074028 001 Jun 28, 1993AA + PHARM ASSOC50MG/5MLA074509 001 Jul 17, 1995AA + WOCKHARDT50MG/5MLA075060 001 Dec 24, 1998

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

+ USL PHARMA

100MG

A076186 001 Dec 16, 2002

AMBRISENTAN

TABLET; ORAL

LETAIRIS

GILEAD

5MG

N022081 001 Jun 15, 2007

+

10MG

N022081 002 Jun 15, 2007

AMCINONIDE

CREAM; TOPICAL

AMCINONIDEAB + FOUGERA PHARMS0.1%A076065 001 May 15, 2003AB TARO PHARM INDS0.1%A076229 001 May 31, 2002

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS

0.1%

A076329 001 Nov 06, 2002

OINTMENT; TOPICAL

AMCINONIDEAB + FOUGERA PHARMS0.1%A076096 001 Nov 19, 2002AB TARO PHARM INDS0.1%A076367 001 Mar 19, 2003AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINEAP SUN PHARMA GLOBAL500MG/VIALA077126 001 Mar 14, 2008ETHYOLAP + CLINIGEN HLTHCARE500MG/VIALN020221 001 Dec 08, 1995AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATEAP EMCURE PHARMS LTDEQ 250MG BASE/MLA204040 001 Dec 12, 2013AP + EUROHLTH INTL SARLEQ 50MG BASE/MLA063313 001 Apr 11, 1994AP +EQ 250MG BASE/MLA063315 001 Apr 11, 1994AP FRESENIUS KABI USAEQ 50MG BASE/MLA205605 001 Dec 09, 2015APEQ 250MG BASE/MLA205604 001 Dec 09, 2015AP TEVA PHARMS USAEQ 250MG BASE/MLA064045 002 Sep 28, 1993AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDEAB + PAR PHARM5MGA070346 001 Jan 22, 1986AB SIGMAPHARM LABS LLC5MGA079133 001 Jan 30, 2009AB ZYDUS PHARMS USA INC5MGA204180 001 Aug 07, 2015MIDAMORAB PADDOCK LLC5MGN018200 001AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEAB BARREQ 5MG ANHYDROUS; 50MGA071111 001 May 10, 1988AB + MYLANEQ 5MG ANHYDROUS; 50MGA073209 001 Oct 31, 1991

## PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS

## INJECTABLE; INJECTION

## AMINO ACIDS

B BRAUN	15% (150GM/1000ML)	A091112 001	Apr 13, 2012
	15% (300GM/2000ML)	A091112 002	Apr 13, 2012
AMINOSYN 10%			
HOSPIRA	10% (10GM/100ML)	N017673 003	
AMINOSYN 10% (PH6)			
HOSPIRA	10% (10GM/100ML)	N017673 008	Nov 18, 1985
AMINOSYN 3.5%			
HOSPIRA	3.5% (3.5GM/100ML)	N017789 004	
AMINOSYN 5%			
HOSPIRA	5% (5GM/100ML)	N017673 001	
AMINOSYN 7%			
HOSPIRA	7% (7GM/100ML)	N017673 002	
AMINOSYN 7% (PH6)			
HOSPIRA	7% (7GM/100ML)	N017673 006	Nov 18, 1985
AMINOSYN 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N017673 004	
AMINOSYN 8.5% (PH6)			
HOSPIRA	8.5% (8.5GM/100ML)	N017673 007	Nov 18, 1985
AMINOSYN II 10%			
HOSPIRA	10% (10GM/100ML)	N019438 005	Apr 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER			
HOSPIRA	10% (10GM/100ML)	N020015 001	Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER			
HOSPIRA	15% (15GM/100ML)	N020041 001	Dec 19, 1991
AMINOSYN II 7%			
HOSPIRA	7% (7GM/100ML)	N019438 003	Apr 03, 1986
AMINOSYN II 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N019438 004	Apr 03, 1986
AMINOSYN-HBC 7%			
HOSPIRA	7% (7GM/100ML)	N019374 001	Jul 12, 1985
AMINOSYN-HF 8%			
HOSPIRA	8% (8GM/100ML)	A020345 001	Apr 04, 1996
AMINOSYN-PF 10%			
HOSPIRA	10% (10GM/100ML)	N019492 002	Oct 17, 1986
AMINOSYN-PF 7%			
HOSPIRA	7% (7GM/100ML)	N019398 001	Sep 06, 1985
AMINOSYN-RF 5.2%			
HOSPIRA	5.2% (5.2GM/100ML)	N018429 001	
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER			
BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996
FREAMINE HBC 6.9%			
B BRAUN	6.9% (6.9GM/100ML)	N016822 006	May 17, 1983
FREAMINE III 10%			
B BRAUN	10% (10GM/100ML)	N016822 005	
FREAMINE III 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N016822 004	
HEPATAMINE 8%			
B BRAUN	8% (8GM/100ML)	N018676 001	Aug 03, 1982
NEPHRAMINE 5.4%			
B BRAUN	5.4% (5.4GM/100ML)	N017766 001	
PREMASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10GM/100ML)	A075880 002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	6% (6GM/100ML)	A075880 001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	20% (20GM/100ML)	N020849 001	Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10MG/100ML)	N018931 003	Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931 001	Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931 002	Aug 23, 1984
TROPHAMINE			
+ B BRAUN	6% (6GM/100ML)	N019018 001	Jul 20, 1984
TROPHAMINE 10%			
+ B BRAUN	10% (10GM/100ML)	N019018 003	Sep 07, 1988

## PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE

B BRAUN

3%; 26MG/100ML; 3GM/100ML; 54MG/100ML; 41MG  
/100ML; 150MG/100ML; 200MG/100ML; 120MG/10  
0ML

N018582 001 May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML;  
261MG/100ML; 217MG/100ML; 112MG/100ML

N020678 002 Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML;  
261MG/100ML; 217MG/100ML; 112MG/100ML

N020678 005 Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 2  
61MG/100ML; 217MG/100ML; 112MG/100ML

N020678 001 Mar 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML;  
261MG/100ML; 297MG/100ML; 77MG/100ML

N020678 009 Mar 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML;  
261MG/100ML; 297MG/100ML; 77MG/100ML

N020678 011 Mar 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML;  
261MG/100ML; 297MG/100ML; 77MG/100ML

N020678 012 Mar 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

4.25%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 2  
61MG/100ML; 297MG/100ML; 77MG/100ML

N020678 008 Mar 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261  
MG/100ML; 340MG/100ML; 59MG/100ML

N020678 016 Mar 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261  
MG/100ML; 340MG/100ML; 59MG/100ML

N020678 017 Mar 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261  
MG/100ML; 340MG/100ML; 59MG/100ML

N020678 018 Mar 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

5%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261  
MG/100ML; 340MG/100ML; 59MG/100ML

N020678 019 Mar 26, 1997

CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261  
MG/100ML; 340MG/100ML; 59MG/100ML

N020678 021 Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; IV (INFUSION)

KABIVEN IN PLASTIC CONTAINER

FRESENIUS KABI USA

3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML;  
174MG/100ML; 239MG/100ML  
; 147MG/100ML; 3.9GM/100ML (1026ML)

N200656 004 Aug 25, 2014

3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML;  
174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9  
GM/100ML (1540ML)

N200656 005 Aug 25, 2014

3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML;  
174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9  
GM/100ML (2053ML)

N200656 006 Aug 25, 2014

+

3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML;  
174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9  
GM/100ML (2566ML)

N200656 007 Aug 25, 2014

PERIKABIVEN IN PLASTIC CONTAINER

FRESENIUS KABI USA

2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML;  
124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5  
GM/100ML (1440ML)

N200656 001 Aug 25, 2014

2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML;  
124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5  
GM/100ML (1920ML)

N200656 002 Aug 25, 2014

2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML;  
124MG/100ML; 170MG/100ML  
; 105MG/100ML; 3.5GM/100ML (2400ML)

N200656 003 Aug 25, 2014

**PRESCRIPTION DRUG PRODUCT LIST**AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;10GM/100ML	N020734 002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;25GM/100ML	N020734 005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;5GM/100ML	N020734 001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;10GM/100ML	N020734 008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;20GM/100ML	N020734 010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;25GM/100ML	N020734 011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;5GM/100ML	N020734 007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;10GM/100ML	N020734 014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;15GM/100ML	N020734 015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;20GM/100ML	N020734 016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;25GM/100ML	N020734 017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;35GM/100ML	N020734 018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

## INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML ;440MG/100ML;690MG/100ML	N016822 007	Jul 01, 1988
--	---	-------------	--------------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N017789 003	
----------------------------	--	-------------	--

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;20 0MG/100ML;120MG/100ML	N016822 003	
--	--	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML; 410MG/100ML	N019437 004	Apr 03, 1986
AMINOSYN II 8.5% W/ ELECTROLYTES HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML ;410MG/100ML	N019437 005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
AMINOSYN 8.5% W/ ELECTROLYTES HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100M L	N017673 005	

AMINOCAPROIC ACID

## INJECTABLE; INJECTION

AMINOCAPROIC ACID

<b>AP</b> LUITPOLD	<b>250MG/ML</b>	<b>A071192 001</b>	Dec 01, 1987
<u>AMINOCAPROIC ACID IN PLASTIC CONTAINER</u>			
<b>AP</b> + HOSPIRA	<b>250MG/ML</b>	<b>A070010 001</b>	Mar 09, 1987
SYRUP; ORAL			
<u>AMICAR</u>			
<b>AA</b> + CLOVER PHARMS	<b>1.25GM/5ML</b>	<b>N015230 002</b>	
<u>AMINOCAPROIC ACID</u>			
<b>AA</b> VERSAPHARM INC	<b>1.25GM/5ML</b>	<b>A074759 001</b>	Sep 02, 1998

## PRESCRIPTION DRUG PRODUCT LIST

AMINOCAPROIC ACID

TABLET; ORAL

AMICAR

<b>AB</b>	CLOVER PHARMS	<b>500MG</b>	<b>N015197 001</b>	
-----------	---------------	--------------	--------------------	--

AMINOCAPROIC

<b>AB</b>	VERSAPHARM INC	<b>500MG</b>	<b>A075602 001</b>	May 24, 2001
	AMICAR			
	+ CLOVER PHARMS	1GM	N015197 002	Jun 24, 2004

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

LEVULAN

	+ DUSA	20%	N020965 001	Dec 03, 1999
--	--------	-----	-------------	--------------

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

<b>AP</b>	+ HOSPIRA	<b>25MG/ML</b>	<b>A087242 001</b>	Oct 26, 1983
-----------	-----------	----------------	--------------------	--------------

<b>AP</b>	LUITPOLD	<b>25MG/ML</b>	<b>A087600 001</b>	
-----------	----------	----------------	--------------------	--

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

	+ JACOBUS	4GM/PACKET	A074346 001	Jun 30, 1994
--	-----------	------------	-------------	--------------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

<b>AP</b>	+ AKORN	<b>50MG/ML</b>	<b>A076232 001</b>	Jul 05, 2006
-----------	---------	----------------	--------------------	--------------

<b>AP</b>	+ FRESENIUS KABI USA	<b>50MG/ML</b>	<b>A075761 001</b>	Oct 15, 2002
-----------	----------------------	----------------	--------------------	--------------

<b>AP</b>	+ GLAND PHARMA LTD	<b>50MG/ML</b>	<b>A077161 001</b>	Apr 20, 2005
-----------	--------------------	----------------	--------------------	--------------

<b>AP</b>	HIKMA FARMACEUTICA	<b>50MG/ML</b>	<b>A077234 001</b>	Feb 25, 2008
-----------	--------------------	----------------	--------------------	--------------

<b>AP</b>	+ HOSPIRA	<b>50MG/ML</b>	<b>A075955 001</b>	Oct 18, 2002
-----------	-----------	----------------	--------------------	--------------

<b>AP</b>	HOSPIRA INC	<b>50MG/ML</b>	<b>A203884 001</b>	Nov 25, 2013
-----------	-------------	----------------	--------------------	--------------

<b>AP</b>		<b>50MG/ML</b>	<b>A203885 001</b>	Nov 25, 2013
-----------	--	----------------	--------------------	--------------

<b>AP</b>	+ MYLAN INSTITUTIONAL	<b>50MG/ML</b>	<b>A076217 001</b>	Oct 15, 2002
-----------	-----------------------	----------------	--------------------	--------------

<b>AP</b>	WOCKHARDT	<b>50MG/ML</b>	<b>A077610 001</b>	Oct 30, 2008
-----------	-----------	----------------	--------------------	--------------

<b>AP</b>		<b>50MG/ML</b>	<b>A077834 001</b>	Oct 30, 2008
-----------	--	----------------	--------------------	--------------

NEXTERONE

<b>AP</b>	BAXTER HLTHCARE	<b>50MG/ML</b>	<b>N022325 001</b>	Dec 24, 2008
-----------	-----------------	----------------	--------------------	--------------

	+	150MG/100ML (1.5MG/ML)	N022325 002	Nov 16, 2010
--	---	------------------------	-------------	--------------

	+	360MG/200ML (1.8MG/ML)	N022325 003	Nov 16, 2010
--	---	------------------------	-------------	--------------

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

<b>AB</b>	APOTEX CORP	<b>200MG</b>	<b>A078578 001</b>	Nov 06, 2008
-----------	-------------	--------------	--------------------	--------------

<b>AB</b>	MURTY PHARMS	<b>200MG</b>	<b>A077069 001</b>	Apr 08, 2005
-----------	--------------	--------------	--------------------	--------------

<b>AB</b>		<b>400MG</b>	<b>A077069 002</b>	Apr 08, 2005
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>200MG</b>	<b>A075188 001</b>	Feb 24, 1999
-----------	-------	--------------	--------------------	--------------

<b>AB</b>	SANDOZ	<b>200MG</b>	<b>A075315 001</b>	Dec 23, 1998
-----------	--------	--------------	--------------------	--------------

<b>AB</b>		<b>400MG</b>	<b>A075315 002</b>	Jun 30, 2000
-----------	--	--------------	--------------------	--------------

<b>AB</b>	SWAN PHARMS LLC	<b>200MG</b>	<b>A075389 001</b>	Jan 25, 2001
-----------	-----------------	--------------	--------------------	--------------

<b>AB</b>	TARO	<b>100MG</b>	<b>A075424 002</b>	Dec 18, 2002
-----------	------	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A075424 001</b>	Mar 30, 2001
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>400MG</b>	<b>A076362 001</b>	Nov 29, 2002
-----------	--	--------------	--------------------	--------------

<b>AB</b>	TEVA PHARMS	<b>200MG</b>	<b>A074739 001</b>	Nov 30, 1998
-----------	-------------	--------------	--------------------	--------------

<b>AB</b>	ZYDUS PHARMS USA INC	<b>200MG</b>	<b>A079029 001</b>	Sep 16, 2008
-----------	----------------------	--------------	--------------------	--------------

CORDARONE

<b>AB</b>	+ WYETH PHARMS INC	<b>200MG</b>	<b>N018972 001</b>	Dec 24, 1985
-----------	--------------------	--------------	--------------------	--------------

PACERONE

<b>AB</b>	UPSHER SMITH	<b>100MG</b>	<b>A075135 002</b>	Apr 12, 2005
-----------	--------------	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A075135 001</b>	Apr 30, 1998
-----------	--	--------------	--------------------	--------------

AMIODARONE HYDROCHLORIDE

TARO

		300MG	A076362 002	Dec 02, 2003
--	--	-------	-------------	--------------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<b>AB</b>	ACCORD HLTHCARE	<b>10MG</b>	<b>A202446 001</b>	Jun 04, 2014
-----------	-----------------	-------------	--------------------	--------------

<b>AB</b>		<b>25MG</b>	<b>A202446 002</b>	Jun 04, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>50MG</b>	<b>A202446 003</b>	Jun 04, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>75MG</b>	<b>A202446 004</b>	Jun 04, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>100MG</b>	<b>A202446 005</b>	Jun 04, 2014
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>150MG</b>	<b>A202446 006</b>	Jun 04, 2014
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MUTUAL PHARM	<b>10MG</b>	<b>A089399 002</b>	Jul 14, 1987
-----------	--------------	-------------	--------------------	--------------

<b>AB</b>		<b>25MG</b>	<b>A089399 001</b>	Jul 14, 1987
-----------	--	-------------	--------------------	--------------

**PRESCRIPTION DRUG PRODUCT LIST**

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A089399 003</u>	Jul 14, 1987
<u>AB</u>		<u>75MG</u>	<u>A089399 004</u>	Jul 14, 1987
<u>AB</u>		<u>100MG</u>	<u>A089399 005</u>	Jul 14, 1987
<u>AB</u>		<u>150MG</u>	<u>A089399 006</u>	Jul 14, 1987
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A086009 002</u>	
<u>AB</u>		<u>25MG</u>	<u>A086009 003</u>	
<u>AB</u>		<u>50MG</u>	<u>A086009 001</u>	
<u>AB</u>		<u>75MG</u>	<u>A086009 004</u>	
<u>AB</u>		<u>100MG</u>	<u>A086009 005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009 006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969 001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085966 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968 001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971 001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967 001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970 001</u>	
<u>AB</u>	SUN PHARM INDS INC	<u>10MG</u>	<u>A040816 002</u>	Jun 27, 2008
<u>AB</u>		<u>25MG</u>	<u>A040816 001</u>	Jun 27, 2008
<u>AB</u>		<u>50MG</u>	<u>A040816 003</u>	Jun 27, 2008
<u>AB</u>		<u>75MG</u>	<u>A040816 004</u>	Jun 27, 2008
<u>AB</u>		<u>100MG</u>	<u>A040816 005</u>	Jun 27, 2008
<u>AB</u>		<u>150MG</u>	<u>A040816 006</u>	Jun 27, 2008
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218 001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218 002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218 003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218 004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218 005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218 006</u>	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986
	+	EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443 002	Nov 10, 1988
		10MG;4MG	A071443 003	Nov 10, 1988
	+	25MG;2MG	A071443 004	Nov 10, 1988
	+	25MG;4MG	A071443 005	Nov 10, 1988
	+	50MG;4MG	A071443 001	Nov 10, 1988

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A202553 001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202553 002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202553 003</u>	Apr 29, 2013
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925 001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925 002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925 003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477 001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477 002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477 003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719 001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719 002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719 003</u>	May 23, 2007
<u>AB</u>	ASCENT PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A206367 001</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206367 002</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206367 003</u>	Dec 10, 2015
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021 001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021 002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021 003</u>	Jul 17, 2007
<u>AB</u>	CHINA RESOURCES	<u>EQ 5MG BASE</u>	<u>A090752 001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752 002</u>	Apr 15, 2011
<u>AB</u>	CIPLA LTD	<u>EQ 2.5MG BASE</u>	<u>A077073 001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073 002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073 003</u>	Sep 26, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692 001</u>	Jul 20, 2007



## PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692 002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692 003</u>	Jul 20, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552 001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552 002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552 003</u>	Apr 08, 2009
<u>AB</u>	HIKMA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077771 001</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077771 002</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077771 003</u>	Apr 12, 2011
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955 001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955 002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955 003</u>	Aug 28, 2007
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043 001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043 002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043 003</u>	Jul 12, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201380 001</u>	Apr 13, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201380 002</u>	Apr 13, 2012
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418 001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418 002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418 003</u>	Oct 03, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A078224 001</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078224 002</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078224 003</u>	Feb 27, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453 001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453 002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453 003</u>	Jul 02, 2009
<u>AB</u>	ROXANE	<u>EQ 2.5MG BASE</u>	<u>A077262 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262 003</u>	Jul 09, 2007
<u>AB</u>	SOVEREIGN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A204900 001</u>	Jul 23, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204900 002</u>	Jul 23, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204900 003</u>	Jul 23, 2015
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 2.5MG BASE</u>	<u>A078231 001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078231 002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231 003</u>	Nov 30, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A077974 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974 003</u>	Jul 09, 2007
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846 001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846 002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846 003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573 001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573 002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573 003</u>	Sep 22, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A203245 001</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203245 002</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245 003</u>	Oct 21, 2013
<u>AB</u>	UPSHER SMITH	<u>EQ 2.5MG BASE</u>	<u>A077759 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759 003</u>	Jul 09, 2007
<u>AB</u>	VINTAGE	<u>EQ 2.5MG BASE</u>	<u>A078414 001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414 003</u>	Apr 07, 2010
<u>AB</u>	VIVIMED LABS	<u>EQ 2.5MG BASE</u>	<u>A077516 001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516 002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516 003</u>	Jul 11, 2007
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077671 001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671 002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671 003</u>	Jul 19, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500 001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500 002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500 003</u>	Sep 06, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226 003</u>	Jul 09, 2007
<u>NORVASC</u>				
<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787 001</u>	Jul 31, 1992
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N019787 002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787 003</u>	Jul 31, 1992

## PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A203874 001</u>	Mar 07, 2014
AB		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A203874 002</u>	Mar 07, 2014
AB		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A203874 003</u>	Mar 07, 2014
AB		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A203874 004</u>	Mar 07, 2014
AB		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A203874 005</u>	Mar 07, 2014
AB		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A203874 006</u>	Mar 07, 2014
AB		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A203874 007</u>	Mar 07, 2014
AB		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A203874 008</u>	Mar 07, 2014
AB		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A203874 009</u>	Mar 07, 2014
AB		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A203874 010</u>	Mar 07, 2014
AB		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A203874 011</u>	Mar 07, 2014
AB	MYLAN PHARMS INC	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A200465 001</u>	Nov 29, 2013
AB		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A200465 002</u>	Nov 29, 2013
AB		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A200465 003</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465 004</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465 005</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465 006</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465 007</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465 008</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465 009</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465 010</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465 011</u>	Nov 29, 2013

CADUET

AB	PFIZER	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540 009</u>	Jul 29, 2004
AB		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540 010</u>	Jul 29, 2004
AB		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540 011</u>	Jul 29, 2004
AB		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540 001</u>	Jan 30, 2004
AB		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540 002</u>	Jan 30, 2004
AB		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540 003</u>	Jan 30, 2004
AB		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540 004</u>	Jan 30, 2004
AB		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540 005</u>	Jan 30, 2004
AB		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540 006</u>	Jan 30, 2004
AB		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540 007</u>	Jan 30, 2004
AB	+	<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540 008</u>	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A091431 001</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;10MG</u>	<u>A091431 002</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;20MG</u>	<u>A091431 003</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;40MG</u>	<u>A091431 004</u>	Dec 30, 2013
AB		<u>EQ 10MG BASE;20MG</u>	<u>A091431 005</u>	Dec 30, 2013
AB		<u>EQ 10MG BASE;40MG</u>	<u>A091431 006</u>	Dec 30, 2013
AB	AUROBINDO PHARMA LTD	<u>EQ 2.5MG BASE;10MG</u>	<u>A202239 001</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;10MG</u>	<u>A202239 002</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;20MG</u>	<u>A202239 003</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;40MG</u>	<u>A202239 004</u>	Sep 05, 2012
AB		<u>EQ 10MG BASE;20MG</u>	<u>A202239 005</u>	Sep 05, 2012
AB		<u>EQ 10MG BASE;40MG</u>	<u>A202239 006</u>	Sep 05, 2012
AB	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183 001</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077183 002</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A077183 003</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A090149 001</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A077183 004</u>	Apr 15, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A090149 002</u>	Jul 05, 2011
AB	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466 001</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A078466 002</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A078466 003</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A078466 005</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A078466 004</u>	Feb 05, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A078466 006</u>	Jul 05, 2011
AB	MYLAN	<u>EQ 2.5MG BASE;10MG</u>	<u>A077375 001</u>	May 21, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077375 002</u>	May 21, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A077375 003</u>	May 21, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A079047 001</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A077375 004</u>	May 21, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A079047 002</u>	Jul 05, 2011
AB	PAR PHARM	<u>EQ 2.5MG BASE;10MG</u>	<u>A078381 001</u>	Jul 29, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A078381 002</u>	Jul 29, 2010

## PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078381 003</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078381 005</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078381 004</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078381 006</u>	Jul 29, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077179 001</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077179 002</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077179 003</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A077179 005</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077179 004</u>	May 18, 2007
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A077179 006</u>	Jul 05, 2011
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890 001</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077890 002</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077890 003</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077890 004</u>	Oct 14, 2010
<u>AB</u>	WATSON LABS INC	<u>EQ 5MG BASE;40MG</u>	<u>A090364 001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090364 002</u>	Jul 05, 2011

LOTREL

<u>AB</u>	NOVARTIS	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364 002</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>N020364 003</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>N020364 004</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>N020364 007</u>	Apr 11, 2006
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>N020364 005</u>	Jun 20, 2002
<u>AB</u>	+	<u>EQ 10MG BASE;40MG</u>	<u>N020364 006</u>	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

TRIBENZOR

	DAIICHI SANKYO	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>N200175 001</u>	Jul 23, 2010
		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>N200175 002</u>	Jul 23, 2010
		<u>EQ 5MG BASE;25MG;40MG</u>	<u>N200175 003</u>	Jul 23, 2010
		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>N200175 004</u>	Jul 23, 2010
	+	<u>EQ 10MG BASE;25MG;40MG</u>	<u>N200175 005</u>	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	LUPIN LTD	<u>5MG;12.5MG;160MG</u>	<u>A200797 001</u>	Jun 03, 2015
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A200797 002</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A200797 003</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A200797 004</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A200797 005</u>	Jun 03, 2015
<u>AB</u>	PAR PHARM	<u>5MG;12.5MG;160MG</u>	<u>A201087 001</u>	Jun 01, 2015
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A201087 002</u>	Jun 01, 2015
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A201087 003</u>	Jun 01, 2015
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A201087 004</u>	Jun 01, 2015
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A201087 005</u>	Jun 01, 2015
<u>AB</u>	TEVA PHARMS	<u>5MG;12.5MG;160MG</u>	<u>A200435 001</u>	Sep 25, 2012
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A200435 002</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A200435 005</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A200435 003</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A200435 004</u>	Sep 25, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>5MG;12.5MG;160MG</u>	<u>A201593 001</u>	Jun 03, 2015
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A201593 002</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A201593 003</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A201593 004</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A201593 005</u>	Jun 03, 2015

EXFORGE HCT

<u>AB</u>	NOVARTIS	<u>5MG;12.5MG;160MG</u>	<u>N022314 001</u>	Apr 30, 2009
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>N022314 002</u>	Apr 30, 2009
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>N022314 003</u>	Apr 30, 2009
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>N022314 004</u>	Apr 30, 2009
<u>AB</u>	+	<u>10MG;25MG;320MG</u>	<u>N022314 005</u>	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AZOR

	DAIICHI SANKYO	<u>EQ 5MG BASE;20MG</u>	<u>N022100 001</u>	Sep 26, 2007
		<u>EQ 5MG BASE;40MG</u>	<u>N022100 002</u>	Sep 26, 2007
		<u>EQ 10MG BASE;20MG</u>	<u>N022100 003</u>	Sep 26, 2007
	+	<u>EQ 10MG BASE;40MG</u>	<u>N022100 004</u>	Sep 26, 2007

## PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003 001	Jan 21, 2015
		EQ 5MG BASE;7MG	N205003 002	Jan 21, 2015
+		EQ 10MG BASE;14MG	N205003 003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

<b>AB</b>	LUPIN LTD	<u>EQ 5MG BASE;40MG</u>	<u>A201586 001</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 5MG BASE;80MG</u>	<u>A201586 003</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 10MG BASE;40MG</u>	<u>A201586 002</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 10MG BASE;80MG</u>	<u>A201586 004</u>	Jan 08, 2014
<b>AB</b>	MYLAN PHARMS INC	<u>EQ 5MG BASE;40MG</u>	<u>A202516 001</u>	Aug 26, 2014
<b>AB</b>		<u>EQ 5MG BASE;80MG</u>	<u>A202516 003</u>	Aug 26, 2014
<b>AB</b>		<u>EQ 10MG BASE;40MG</u>	<u>A202516 002</u>	Aug 26, 2014
<b>AB</b>		<u>EQ 10MG BASE;80MG</u>	<u>A202516 004</u>	Aug 26, 2014
<b>AB</b>	TORRENT PHARMS LTD	<u>EQ 5MG BASE;40MG</u>	<u>A202517 001</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 5MG BASE;80MG</u>	<u>A202517 003</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 10MG BASE;40MG</u>	<u>A202517 002</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 10MG BASE;80MG</u>	<u>A202517 004</u>	Jan 08, 2014
<b><u>TWYNSTA</u></b>				
<b>AB</b>	BOEHRINGER INGELHEIM	<u>EQ 5MG BASE;40MG</u>	<u>N022401 001</u>	Oct 16, 2009
<b>AB</b>		<u>EQ 5MG BASE;80MG</u>	<u>N022401 003</u>	Oct 16, 2009
<b>AB</b>		<u>EQ 10MG BASE;40MG</u>	<u>N022401 002</u>	Oct 16, 2009
<b>AB</b>	+	<u>EQ 10MG BASE;80MG</u>	<u>N022401 004</u>	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<b>AB</b>	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE;160MG</u>	<u>A202713 001</u>	Apr 03, 2015
<b>AB</b>		<u>EQ 5MG BASE;320MG</u>	<u>A202713 003</u>	Apr 03, 2015
<b>AB</b>		<u>EQ 10MG BASE;160MG</u>	<u>A202713 002</u>	Apr 03, 2015
<b>AB</b>		<u>EQ 10MG BASE;320MG</u>	<u>A202713 004</u>	Apr 03, 2015
<b>AB</b>	LUPIN	<u>EQ 5MG BASE;160MG</u>	<u>A090245 001</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 5MG BASE;320MG</u>	<u>A090245 003</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;160MG</u>	<u>A090245 002</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;320MG</u>	<u>A090245 004</u>	Mar 30, 2015
<b>AB</b>	MYLAN PHARMS INC	<u>EQ 5MG BASE;160MG</u>	<u>A090483 001</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 5MG BASE;320MG</u>	<u>A090483 003</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;160MG</u>	<u>A090483 002</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;320MG</u>	<u>A090483 004</u>	Mar 30, 2015
<b>AB</b>	NOVEL LABS INC	<u>EQ 5MG BASE;160MG</u>	<u>A202829 001</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 5MG BASE;320MG</u>	<u>A202829 003</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;160MG</u>	<u>A202829 002</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;320MG</u>	<u>A202829 004</u>	Mar 30, 2015
<b>AB</b>	PAR PHARM INC	<u>EQ 5MG BASE;160MG</u>	<u>A090011 001</u>	Mar 28, 2013
<b>AB</b>		<u>EQ 5MG BASE;320MG</u>	<u>A090144 001</u>	Mar 28, 2013
<b>AB</b>		<u>EQ 10MG BASE;160MG</u>	<u>A090011 002</u>	Mar 28, 2013
<b>AB</b>		<u>EQ 10MG BASE;320MG</u>	<u>A090011 004</u>	Mar 28, 2013
<b>AB</b>	TEVA PHARMS USA	<u>EQ 5MG BASE;160MG</u>	<u>A091235 001</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 5MG BASE;320MG</u>	<u>A091235 003</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;160MG</u>	<u>A091235 002</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;320MG</u>	<u>A091235 004</u>	Mar 30, 2015
<b>AB</b>	TORRENT PHARMS LTD	<u>EQ 5MG BASE;160MG</u>	<u>A202377 001</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 5MG BASE;320MG</u>	<u>A202377 002</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;160MG</u>	<u>A202377 003</u>	Mar 30, 2015
<b>AB</b>		<u>EQ 10MG BASE;320MG</u>	<u>A202377 004</u>	Mar 30, 2015
<b><u>EXFORGE</u></b>				
<b>AB</b>	NOVARTIS	<u>EQ 5MG BASE;160MG</u>	<u>N021990 002</u>	Jun 20, 2007
<b>AB</b>		<u>EQ 5MG BASE;320MG</u>	<u>N021990 004</u>	Jun 20, 2007
<b>AB</b>	+	<u>EQ 10MG BASE;160MG</u>	<u>N021990 003</u>	Jun 20, 2007
<b>AB</b>	+	<u>EQ 10MG BASE;320MG</u>	<u>N021990 005</u>	Jun 20, 2007

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<b>AP</b>	3D IMAGING DRUG	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203779 001</u>	Oct 19, 2015
<b>AP</b>	BIOMEDCL RES FDN	<u>48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)</u>	<u>A204352 001</u>	May 01, 2015
<b>AP</b>	BRIGHAM WOMENS HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203783 001</u>	Oct 30, 2014
<b>AP</b>	CARDINAL HEALTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700 001</u>	Feb 25, 2013
<b>AP</b>	+	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>N022119 001</u>	Aug 23, 2007

## PRESCRIPTION DRUG PRODUCT LIST

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	GLOBAL ISOTOPES LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204465</u>	<u>001</u>	Oct 23, 2014
<u>AP</u>	IBA MOLECULAR N AM	<u>18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)</u>	<u>A204667</u>	<u>001</u>	Apr 22, 2015
<u>AP</u>	JOHNS HOPKINS UNIV	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204514</u>	<u>001</u>	Aug 19, 2014
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938</u>	<u>001</u>	Dec 09, 2013
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321</u>	<u>001</u>	Feb 25, 2013
<u>AP</u>	MIPS CRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204535</u>	<u>001</u>	Nov 20, 2014
<u>AP</u>	PETNET	<u>30mCi-300mCi (3.75-37.5mCi/ML)</u>	<u>A204510</u>	<u>001</u>	Nov 02, 2015
<u>AP</u>	SPECTRON MRC LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204455</u>	<u>001</u>	Apr 23, 2015
<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812</u>	<u>001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204496</u>	<u>001</u>	Mar 28, 2014
<u>AP</u>	UNIV TX MD ANDERSON	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203933</u>	<u>001</u>	Jun 27, 2014
<u>AP</u>	WA UNIV SCH MED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204506</u>	<u>001</u>	Feb 07, 2014
	ESSENTIAL ISOTOPES	3.75-260mCi/ML	A205687	001	Dec 17, 2015
	HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543	001	Dec 14, 2012
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366	001	Sep 19, 2014
	WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356	001	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER  
+ HOSPIRA

A088366 001 Jun 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075774</u>	<u>001</u>	May 01, 2002
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A075883</u>	<u>001</u>	Apr 10, 2003
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A076829</u>	<u>001</u>	Feb 07, 2006

LAC-HYDRIN

<u>AB</u>	+ RANBAXY	<u>EQ 12% BASE</u>	<u>N020508</u>	<u>001</u>	Aug 29, 1996
-----------	-----------	--------------------	----------------	------------	--------------

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075570</u>	<u>001</u>	Jun 23, 2004
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A076216</u>	<u>001</u>	May 28, 2004
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A075575</u>	<u>001</u>	Jun 11, 2002

LAC-HYDRIN

<u>AB</u>	+ RANBAXY	<u>EQ 12% BASE</u>	<u>N019155</u>	<u>001</u>	Apr 24, 1985
-----------	-----------	--------------------	----------------	------------	--------------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

WATSON LABS

25MG

A072688 001 Aug 28, 1992

50MG

A072689 001 Aug 28, 1992

100MG

A072690 001 Aug 28, 1992

+

150MG

A072691 001 Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AM ANTIBIOTICS	<u>250MG</u>	<u>A062058</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062058</u>	<u>002</u>	
<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065271</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>500MG</u>	<u>A065271</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A062884</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>		<u>500MG</u>	<u>A062881</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	HIKMA PHARMS	<u>250MG</u>	<u>A065291</u>	<u>001</u>	Feb 05, 2007
<u>AB</u>		<u>500MG</u>	<u>A065291</u>	<u>002</u>	Feb 05, 2007
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A064076</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>		<u>500MG</u>	<u>A064076</u>	<u>002</u>	Sep 30, 1994
<u>AB</u>	SUN PHARM INDS LTD	<u>250MG</u>	<u>A065016</u>	<u>001</u>	Apr 08, 1999
<u>AB</u>		<u>500MG</u>	<u>A065016</u>	<u>002</u>	Apr 08, 1999
<u>AB</u>	TEVA	<u>250MG</u>	<u>A061926</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A061926</u>	<u>003</u>	
	<u>AMOXIL</u>				
<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A062216</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062216</u>	<u>004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
-----------	-----------	------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

<u>AB</u>		<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>125MG/5ML</u>	<u>A204030</u>	<u>001</u>	Sep 15, 2014
<u>AB</u>		<u>250MG/5ML</u>	<u>A204030</u>	<u>002</u>	Sep 15, 2014
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>125MG/5ML</u>	<u>A061931</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	+	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>	WOCKHARDT	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
-----------	------	----------------	----------------	------------	--------------

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>N050760</u>	<u>001</u>	Apr 15, 1999
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	
<u>AB</u>		<u>400MG/5ML</u>	<u>N050760</u>	<u>002</u>	Apr 15, 1999

LAROTID

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET;ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>500MG</u>	<u>A065059</u>	<u>001</u>	Nov 24, 2000
<u>AB</u>		<u>875MG</u>	<u>A065059</u>	<u>002</u>	Nov 24, 2000
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	+	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>N050754</u>	<u>002</u>	Jul 10, 1998
<u>AB</u>		<u>875MG</u>	<u>N050754</u>	<u>001</u>	Jul 10, 1998

TABLET, CHEWABLE;ORAL

AMOXICILLIN

<u>AB</u>	SUN PHARM INDS LTD	<u>125MG</u>	<u>A065021</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>250MG</u>	<u>A065021</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>125MG</u>	<u>N050542</u>	<u>002</u>	
<u>AB</u>		<u>250MG</u>	<u>N050542</u>	<u>001</u>	

TABLET, EXTENDED RELEASE;ORAL

## MOXATAG

+	PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008
---	-------------------	-------	---------	-----	--------------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

<u>AB</u>	SANDOZ INC	<u>500MG,N/A,N/A:N/A,500MG,N/A:N/A,N/A,30MG</u>	<u>A202588</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	TEVA PHARMS USA	<u>500MG,N/A,N/A:N/A,500MG,N/A:N/A,N/A,30MG</u>	<u>A200218</u>	<u>001</u>	Aug 30, 2013

PREVPAC

<u>AB</u>	+	TAKEDA PHARMS USA	<u>500MG,N/A,N/A:N/A,500MG,N/A:N/A,N/A,30MG</u>	<u>N050757</u>	<u>001</u>	Dec 02, 1997
-----------	---	-------------------	---	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	GASTROENTERO	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 20M	N050824	001	Feb 08, 2011
---	--------------	---	---------	-----	--------------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	SANDOZ INC	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065132</u>	<u>001</u>	Mar 19, 2003
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065132</u>	<u>002</u>	Mar 19, 2003
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065207</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	TEVA	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
<u>AB</u>	+	<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
<u>AB</u>	+	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT	<u>250MG/5ML; EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>	WOCKHARDT EU OPERATN	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065420</u>	<u>001</u>	Dec 02, 2013

AUGMENTIN '125'

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML; EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984	
	<u>AUGMENTIN '200'</u>					
<u>AB</u>	DR REDDYS LABS INC	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>N050725</u>	<u>001</u>	May 31, 1996	
	<u>AUGMENTIN '250'</u>					
<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>250MG/5ML; EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984
	<u>AUGMENTIN '400'</u>					
<u>AB</u>	DR REDDYS LABS INC	<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>N050725</u>	<u>002</u>	May 31, 1996	
	<u>AUGMENTIN ES-600</u>					
<u>AB</u>	DR REDDYS LABS INC	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>N050755</u>	<u>001</u>	Jun 22, 2001	

SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A201090</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A201090</u>	<u>002</u>	Dec 20, 2011
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A201091</u>	<u>001</u>	Dec 20, 2011

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG; EQ 125MG BASE</u>	<u>A091569</u>	<u>001</u>	Jan 20, 2012	
<u>AB</u>		<u>500MG; EQ 125MG BASE</u>	<u>A091569</u>	<u>002</u>	Jan 20, 2012	
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A091568</u>	<u>001</u>	Jan 20, 2012	
<u>AB</u>	SANDOZ	<u>250MG; EQ 125MG BASE</u>	<u>A065189</u>	<u>001</u>	Aug 23, 2005	
<u>AB</u>		<u>500MG; EQ 125MG BASE</u>	<u>A065064</u>	<u>001</u>	Mar 15, 2002	
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A065063</u>	<u>001</u>	Mar 14, 2002	
<u>AB</u>	SANDOZ INC	<u>500MG; EQ 125MG BASE</u>	<u>A065117</u>	<u>001</u>	Nov 27, 2002	
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A065093</u>	<u>001</u>	Nov 21, 2002	
<u>AB</u>	SUN PHARM INDS LTD	<u>875MG; EQ 125MG BASE</u>	<u>A065102</u>	<u>001</u>	Sep 17, 2002	
<u>AB</u>	TEVA	<u>500MG; EQ 125MG BASE</u>	<u>A065101</u>	<u>001</u>	Oct 30, 2002	
<u>AB</u>	TEVA PHARMS USA	<u>875MG; EQ 125MG BASE</u>	<u>A065096</u>	<u>001</u>	Oct 29, 2002	
	<u>AUGMENTIN '250'</u>					
<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>250MG; EQ 125MG BASE</u>	<u>N050564</u>	<u>001</u>	Aug 06, 1984
	<u>AUGMENTIN '500'</u>					
<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>500MG; EQ 125MG BASE</u>	<u>N050564</u>	<u>002</u>	Aug 06, 1984
	<u>AUGMENTIN '875'</u>					
<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>875MG; EQ 125MG BASE</u>	<u>N050720</u>	<u>001</u>	Feb 13, 1996

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	SANDOZ	<u>200MG; EQ 28.5MG BASE</u>	<u>A065065</u>	<u>001</u>	Apr 18, 2002
<u>AB</u>		<u>400MG; EQ 57MG BASE</u>	<u>A065065</u>	<u>002</u>	Apr 18, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>200MG; EQ 28.5MG BASE</u>	<u>A065161</u>	<u>001</u>	Dec 03, 2003
<u>AB</u>		<u>400MG; EQ 57MG BASE</u>	<u>A065161</u>	<u>002</u>	Dec 03, 2003
<u>AB</u>	TEVA	<u>200MG; EQ 28.5MG BASE</u>	<u>A065205</u>	<u>001</u>	Feb 09, 2005
<u>AB</u>	+	<u>400MG; EQ 57MG BASE</u>	<u>A065205</u>	<u>002</u>	Feb 09, 2005
	<u>AUGMENTIN '125'</u>				
<u>AB</u>	DR REDDYS LABS INC	<u>125MG; EQ 31.25MG BASE</u>	<u>N050597</u>	<u>001</u>	Jul 22, 1985
	<u>AUGMENTIN '200'</u>				
<u>AB</u>	DR REDDYS LABS INC	<u>200MG; EQ 28.5MG BASE</u>	<u>N050726</u>	<u>001</u>	May 31, 1996
	<u>AUGMENTIN '250'</u>				
<u>AB</u>	DR REDDYS LABS INC	<u>250MG; EQ 62.5MG BASE</u>	<u>N050597</u>	<u>002</u>	Jul 22, 1985

## PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE; ORAL

AUGMENTIN '400'

<b>AB</b>	DR REDDYS LABS INC	<b>400MG;EQ 57MG BASE</b>	<b>N050726 002</b>	May 31, 1996
-----------	--------------------	---------------------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<b>AB</b>	SANDOZ	<b>1GM;EQ 62.5MG BASE</b>	<b>A090227 001</b>	Apr 21, 2010
-----------	--------	---------------------------	--------------------	--------------

AUGMENTIN XR

<b>AB</b>	+ DR REDDYS LABS INC	<b>1GM;EQ 62.5MG BASE</b>	<b>N050785 001</b>	Sep 25, 2002
-----------	----------------------	---------------------------	--------------------	--------------

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE; ORAL

DYANAVEL XR

	+ TRIS PHARMA INC	EQ 2.5MG BASE/ML	N208147 001	Oct 19, 2015
--	-------------------	------------------	-------------	--------------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

<b>AB</b>	SHIRE	<b>2.5MG;2.5MG;2.5MG;2.5MG</b>	<b>N021303 001</b>	Oct 11, 2001
-----------	-------	--------------------------------	--------------------	--------------

ADDERALL XR 15

<b>AB</b>	SHIRE	<b>3.75MG;3.75MG;3.75MG;3.75MG</b>	<b>N021303 006</b>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

ADDERALL XR 20

<b>AB</b>	SHIRE	<b>5MG;5MG;5MG;5MG</b>	<b>N021303 002</b>	Oct 11, 2001
-----------	-------	------------------------	--------------------	--------------

ADDERALL XR 25

<b>AB</b>	SHIRE	<b>6.25MG;6.25MG;6.25MG;6.25MG</b>	<b>N021303 004</b>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

ADDERALL XR 30

<b>AB</b>	+ SHIRE	<b>7.5MG;7.5MG;7.5MG;7.5MG</b>	<b>N021303 003</b>	Oct 11, 2001
-----------	---------	--------------------------------	--------------------	--------------

ADDERALL XR 5

<b>AB</b>	SHIRE	<b>1.25MG;1.25MG;1.25MG;1.25MG</b>	<b>N021303 005</b>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

<b>AB</b>	TEVA	<b>1.25MG;1.25MG;1.25MG;1.25MG</b>	<b>A077488 001</b>	Apr 29, 2013
-----------	------	------------------------------------	--------------------	--------------

<b>AB</b>		<b>2.5MG;2.5MG;2.5MG;2.5MG</b>	<b>A077488 002</b>	Apr 29, 2013
-----------	--	--------------------------------	--------------------	--------------

<b>AB</b>		<b>3.75MG;3.75MG;3.75MG;3.75MG</b>	<b>A077488 003</b>	Apr 29, 2013
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>5MG;5MG;5MG;5MG</b>	<b>A077488 004</b>	Apr 29, 2013
-----------	--	------------------------	--------------------	--------------

<b>AB</b>		<b>6.25MG;6.25MG;6.25MG;6.25MG</b>	<b>A077488 005</b>	Apr 29, 2013
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>7.5MG;7.5MG;7.5MG;7.5MG</b>	<b>A077488 006</b>	Apr 29, 2013
-----------	--	--------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<b>AB</b>	ACTAVIS ELIZABETH	<b>1.25MG;1.25MG;1.25MG;1.25MG</b>	<b>A077302 001</b>	Jun 22, 2012
-----------	-------------------	------------------------------------	--------------------	--------------

<b>AB</b>		<b>2.5MG;2.5MG;2.5MG;2.5MG</b>	<b>A077302 002</b>	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

<b>AB</b>		<b>3.75MG;3.75MG;3.75MG;3.75MG</b>	<b>A077302 003</b>	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>5MG;5MG;5MG;5MG</b>	<b>A077302 004</b>	Jun 22, 2012
-----------	--	------------------------	--------------------	--------------

<b>AB</b>		<b>6.25MG;6.25MG;6.25MG;6.25MG</b>	<b>A077302 005</b>	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>7.5MG;7.5MG;7.5MG;7.5MG</b>	<b>A077302 006</b>	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<b>AB</b>	BARR LABS INC	<b>1.25MG;1.25MG;1.25MG;1.25MG</b>	<b>A076536 001</b>	Feb 12, 2013
-----------	---------------	------------------------------------	--------------------	--------------

<b>AB</b>		<b>2.5MG;2.5MG;2.5MG;2.5MG</b>	<b>A076536 002</b>	Feb 12, 2013
-----------	--	--------------------------------	--------------------	--------------

<b>AB</b>		<b>3.75MG;3.75MG;3.75MG;3.75MG</b>	<b>A076536 003</b>	Feb 12, 2013
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>5MG;5MG;5MG;5MG</b>	<b>A076536 004</b>	Feb 12, 2013
-----------	--	------------------------	--------------------	--------------

<b>AB</b>		<b>6.25MG;6.25MG;6.25MG;6.25MG</b>	<b>A076536 005</b>	Feb 12, 2013
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>7.5MG;7.5MG;7.5MG;7.5MG</b>	<b>A076536 006</b>	Feb 12, 2013
-----------	--	--------------------------------	--------------------	--------------

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<b>AB</b>	ACTAVIS ELIZABETH	<b>1.25MG;1.25MG;1.25MG;1.25MG</b>	<b>A040456 001</b>	May 06, 2003
-----------	-------------------	------------------------------------	--------------------	--------------

<b>AB</b>		<b>2.5MG;2.5MG;2.5MG;2.5MG</b>	<b>A040456 002</b>	May 06, 2003
-----------	--	--------------------------------	--------------------	--------------

<b>AB</b>		<b>5MG;5MG;5MG;5MG</b>	<b>A040456 003</b>	May 06, 2003
-----------	--	------------------------	--------------------	--------------

<b>AB</b>		<b>7.5MG;7.5MG;7.5MG;7.5MG</b>	<b>A040456 004</b>	May 06, 2003
-----------	--	--------------------------------	--------------------	--------------

<b>AB</b>	AUROLIFE PHARMA LLC	<b>1.25MG;1.25MG;1.25MG;1.25MG</b>	<b>A202424 001</b>	Nov 27, 2013
-----------	---------------------	------------------------------------	--------------------	--------------

<b>AB</b>		<b>1.875MG;1.875MG;1.875MG;1.875MG</b>	<b>A202424 002</b>	Nov 27, 2013
-----------	--	--	--------------------	--------------

<b>AB</b>		<b>2.5MG;2.5MG;2.5MG;2.5MG</b>	<b>A202424 003</b>	Nov 27, 2013
-----------	--	--------------------------------	--------------------	--------------

<b>AB</b>		<b>3.125MG;3.125MG;3.125MG;3.125MG</b>	<b>A202424 004</b>	Nov 27, 2013
-----------	--	--	--------------------	--------------

<b>AB</b>		<b>3.75MG;3.75MG;3.75MG;3.75MG</b>	<b>A202424 005</b>	Nov 27, 2013
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>5MG;5MG;5MG;5MG</b>	<b>A202424 006</b>	Nov 27, 2013
-----------	--	------------------------	--------------------	--------------

<b>AB</b>		<b>7.5MG;7.5MG;7.5MG;7.5MG</b>	<b>A202424 007</b>	Nov 27, 2013
-----------	--	--------------------------------	--------------------	--------------

<b>AB</b>	BARR	<b>1.25MG;1.25MG;1.25MG;1.25MG</b>	<b>A040422 001</b>	Feb 11, 2002
-----------	------	------------------------------------	--------------------	--------------

<b>AB</b>		<b>1.875MG;1.875MG;1.875MG;1.875MG</b>	<b>A040422 005</b>	Mar 19, 2003
-----------	--	--	--------------------	--------------

<b>AB</b>		<b>2.5MG;2.5MG;2.5MG;2.5MG</b>	<b>A040422 002</b>	Feb 11, 2002
-----------	--	--------------------------------	--------------------	--------------

<b>AB</b>		<b>3.125MG;3.125MG;3.125MG;3.125MG</b>	<b>A040422 006</b>	Mar 19, 2003
-----------	--	--	--------------------	--------------

<b>AB</b>		<b>3.75MG;3.75MG;3.75MG;3.75MG</b>	<b>A040422 007</b>	Mar 19, 2003
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>5MG;5MG;5MG;5MG</b>	<b>A040422 003</b>	Feb 11, 2002
-----------	--	------------------------	--------------------	--------------

<b>AB</b>	+ COREPHARMA	<b>7.5MG;7.5MG;7.5MG;7.5MG</b>	<b>A040422 004</b>	Feb 11, 2002
-----------	--------------	--------------------------------	--------------------	--------------

<b>AB</b>		<b>1.25MG;1.25MG;1.25MG;1.25MG</b>	<b>A040444 001</b>	Jun 19, 2002
-----------	--	------------------------------------	--------------------	--------------

<b>AB</b>		<b>1.875MG;1.875MG;1.875MG;1.875MG</b>	<b>A040444 005</b>	Nov 03, 2014
-----------	--	--	--------------------	--------------

<b>AB</b>		<b>2.5MG;2.5MG;2.5MG;2.5MG</b>	<b>A040444 002</b>	Jun 19, 2002
-----------	--	--------------------------------	--------------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040444 006</u>	Nov 03, 2014
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040444 007</u>	Nov 03, 2014
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040444 003</u>	Jun 19, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040444 004</u>	Jun 19, 2002
<u>AB</u>	MALLINCKRODT INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040440 001</u>	Oct 07, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040440 002</u>	Oct 07, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040440 003</u>	Oct 07, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040440 004</u>	Oct 07, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040440 005</u>	Oct 07, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040440 006</u>	Oct 07, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040440 007</u>	Oct 07, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A206721 001</u>	Nov 10, 2015
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A206721 002</u>	Nov 10, 2015
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A206721 003</u>	Nov 10, 2015
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A206721 004</u>	Nov 10, 2015
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A206721 005</u>	Nov 10, 2015
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A206721 006</u>	Nov 10, 2015
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A206721 007</u>	Nov 10, 2015
<u>AB</u>	SANDOZ	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040439 004</u>	Sep 27, 2002
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040439 001</u>	Jun 14, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040439 002</u>	Jun 14, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040439 003</u>	Jun 14, 2002
<u>AB</u>	SUN PHARM INDS	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040480 001</u>	Sep 09, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040480 002</u>	Sep 09, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040480 003</u>	Sep 09, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040480 004</u>	Sep 09, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040480 005</u>	Sep 09, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040480 006</u>	Sep 09, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040480 007</u>	Sep 09, 2003

AMPHETAMINE SULFATE

TABLET; ORAL

EVEKEO

ARBOR PHARMS LLC  
+5MG  
10MGA200166 001 Aug 09, 2012  
A200166 002 Aug 09, 2012AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

+ X GEN PHARMS 50MG/VIAL

A063206 001 Apr 29, 1992

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+ SIGMA TAU 5MG/ML

N050724 001 Nov 20, 1995

AMPHOTEC

+ ALKOPHARMA USA 50MG/VIAL

N050729 001 Nov 22, 1996

+ 100MG/VIAL

N050729 002 Nov 22, 1996

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+ ASTELLAS 50MG/VIAL

N050740 001 Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 500MG BASE/VIAL</u>	<u>A090884 001</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090884 002</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090884 003</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090889 001</u>	Apr 03, 2013
<u>AP</u>	ANTIBIOTICE	<u>EQ 250MG BASE/VIAL</u>	<u>A090354 001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354 002</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090354 003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354 004</u>	Dec 28, 2009
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 125MG BASE/VIAL</u>	<u>A065499 001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A065499 002</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065499 003</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065499 004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499 005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493 001</u>	Aug 17, 2010
<u>AP</u>	HANFORD GC	<u>EQ 250MG BASE/VIAL</u>	<u>A063145 001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063146 001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062772 001</u>	Apr 15, 1993

## PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP		<u>EQ 2GM BASE/VIAL</u>	<u>A063140 001</u>	Apr 15, 1993
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A063142 001</u>	Apr 15, 1993
AP	HOSPIRA INC	<u>EQ 250MG BASE/VIAL</u>	<u>A202864 001</u>	Sep 04, 2015
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A202864 002</u>	Sep 04, 2015
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A202864 003</u>	Sep 04, 2015
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A202864 004</u>	Sep 04, 2015
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A202865 001</u>	Sep 04, 2015
AP	ISTITUTO BIO ITA SPA	<u>EQ 10GM BASE/VIAL</u>	<u>A201404 001</u>	Dec 20, 2013
AP		<u>EQ 125MG BASE/VIAL</u>	<u>A062797 001</u>	Jul 12, 1993
AP		<u>EQ 250MG BASE/VIAL</u>	<u>A062719 001</u>	May 12, 1987
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A062719 003</u>	May 12, 1987
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A062719 002</u>	May 12, 1987
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A062797 002</u>	Jul 12, 1993
AP	MYLAN LABS LTD	<u>EQ 10GM BASE/VIAL</u>	<u>A202198 001</u>	Apr 07, 2014
AP	SAGENT PHARMS	<u>EQ 125MG BASE/VIAL</u>	<u>A090583 001</u>	Nov 27, 2015
AP		<u>EQ 250MG BASE/VIAL</u>	<u>A090583 002</u>	Nov 27, 2015
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A090583 003</u>	Nov 27, 2015
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A090583 004</u>	Nov 27, 2015
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A090583 005</u>	Nov 27, 2015
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A090581 001</u>	Oct 20, 2015
AP	+ SANDOZ	<u>EQ 125MG BASE/VIAL</u>	<u>A061395 001</u>	
AP	+	<u>EQ 250MG BASE/VIAL</u>	<u>A061395 002</u>	
AP	+	<u>EQ 500MG BASE/VIAL</u>	<u>A061395 003</u>	
AP	+	<u>EQ 1GM BASE/VIAL</u>	<u>A061395 004</u>	
AP	+	<u>EQ 2GM BASE/VIAL</u>	<u>A061395 005</u>	
AP	+	<u>EQ 10GM BASE/VIAL</u>	<u>A061395 006</u>	
AP	STRIDES ARCOLAB LTD	<u>EQ 250MG BASE/VIAL</u>	<u>A201025 001</u>	Apr 09, 2014
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A201025 002</u>	Apr 09, 2014
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A201025 003</u>	Apr 09, 2014
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A201025 004</u>	Apr 09, 2014

POWDER; INTRAVENOUS

AMPICILLIN SODIUM

AP	+ SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062738 001</u>	Feb 19, 1987
AP	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062738 002</u>	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406 001</u>	Dec 22, 2009
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406 002</u>	Dec 22, 2009
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403 001</u>	Dec 23, 2009
AP	ANTIBIOTICS SA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201406 001</u>	Dec 07, 2015
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201406 002</u>	Dec 07, 2015
AP	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340 001</u>	Sep 20, 2010
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349 001</u>	Sep 20, 2010
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340 002</u>	Sep 20, 2010
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349 002</u>	Sep 20, 2010
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339 001</u>	Sep 20, 2010
AP	HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176 001</u>	Nov 30, 2005
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176 002</u>	Nov 30, 2005
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188 001</u>	Nov 25, 2005
AP	HIKMA MAPLE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074 001</u>	Mar 19, 2002
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074 002</u>	Mar 19, 2002
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076 001</u>	Mar 19, 2002
AP	HOSPIRA INC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090375 001</u>	Dec 21, 2011
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090653 001</u>	Dec 21, 2011
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090375 002</u>	Dec 21, 2011
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090653 002</u>	Dec 21, 2011
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090646 001</u>	Dec 21, 2011
AP	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222 001</u>	Nov 29, 2005
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222 002</u>	Nov 29, 2005
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314 001</u>	Nov 27, 2006
AP	MUSTAFA NEVZAT ILAC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316 001</u>	Jun 29, 2007
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316 002</u>	Jun 29, 2007
AP	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201024 001</u>	Apr 07, 2014
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201024 002</u>	Apr 07, 2014
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A202197 001</u>	Apr 07, 2014
AP	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090579 001</u>	Jan 08, 2016
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090579 002</u>	Jan 08, 2016
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090578 001</u>	Jan 11, 2016

## PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241 001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310 001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241 002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310 002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240 001</u>	Jul 25, 2006
<u>UNASYN</u>				
<u>AP</u>	+ PFIZER	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901 002</u>	Feb 27, 1992
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901 001</u>	Nov 23, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608 002</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608 001</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608 005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062883 001</u>	Feb 25, 1988
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A062882 001</u>	Feb 25, 1988
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064082 001</u>	Aug 29, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A064082 002</u>	Aug 29, 1995
FOR SUSPENSION; ORAL				
AMPICILLIN TRIHYDRATE				
	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982 001	Feb 10, 1989
	+	EQ 250MG BASE/5ML	A062982 002	Feb 10, 1989

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

<u>AB</u>	SHIRE LLC	<u>EQ 0.5MG BASE</u>	<u>N020333 001</u>	Mar 14, 1997
<u>ANAGRELIDE HYDROCHLORIDE</u>				
<u>AB</u>	BARR	<u>EQ 0.5MG BASE</u>	<u>A076530 001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076530 002</u>	Apr 18, 2005
<u>AB</u>	IMPAX LABS	<u>EQ 0.5MG BASE</u>	<u>A076910 001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076910 002</u>	Apr 18, 2005
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 0.5MG BASE</u>	<u>A076468 001</u>	Apr 18, 2005
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>A076468 002</u>	Apr 18, 2005
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A076811 001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076811 002</u>	Apr 18, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 0.5MG BASE</u>	<u>A077613 001</u>	Jun 27, 2006
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077613 002</u>	Jun 27, 2006

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

<u>AB</u>	ACCORD HLTHCARE	<u>1MG</u>	<u>A090568 001</u>	Jun 28, 2010
<u>AB</u>	APOTEX INC	<u>1MG</u>	<u>A200654 001</u>	May 11, 2012
<u>AB</u>	CIPLA LTD	<u>1MG</u>	<u>A091164 001</u>	Jun 28, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A090732 001</u>	Jun 28, 2010
<u>AB</u>	FRESENIUS KABI ONCOL	<u>1MG</u>	<u>A090088 001</u>	Jun 28, 2010
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A091051 001</u>	Jun 28, 2010
<u>AB</u>	NATCO PHARMA LTD	<u>1MG</u>	<u>A079220 001</u>	Jun 28, 2010
<u>AB</u>	ROXANE	<u>1MG</u>	<u>A078485 001</u>	Jun 28, 2010
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A079007 001</u>	Jun 28, 2010
<u>AB</u>	SANTOS BIOTECH	<u>1MG</u>	<u>A078944 001</u>	Jun 28, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>1MG</u>	<u>A091177 001</u>	Jul 15, 2011
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A078058 001</u>	Jun 28, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1MG</u>	<u>A078921 001</u>	Jun 28, 2010
<u>ARIMIDEX</u>				
<u>AB</u>	+ ASTRAZENECA	<u>1MG</u>	<u>N020541 001</u>	Dec 27, 1995

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+	VICURON	50MG/VIAL	N021632 001	Feb 17, 2006
+		100MG/VIAL	N021632 002	Nov 14, 2006

APIXABAN

TABLET; ORAL

ELIQUIS

	BRISTOL MYERS SQUIBB	2.5MG	N202155 001	Dec 28, 2012
+		5MG	N202155 002	Dec 28, 2012

## PRESCRIPTION DRUG PRODUCT LIST

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+ US WORLDMEDS

30MG/3ML (10MG/ML)

N021264 002 Apr 20, 2004

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDEAT AKORN INCEQ 0.5% BASEA077764 001 Mar 12, 2009IOPIDINEAT + ALCONEQ 0.5% BASEN020258 001 Jul 30, 1993

+

EQ 1% BASE

N019779 001 Dec 31, 1987

APREMILAST

TABLET; ORAL

OTEZLA

CELGENE CORP

10MG

N205437 001 Mar 21, 2014

20MG

N205437 002 Mar 21, 2014

+

30MG

N205437 003 Mar 21, 2014

APREPITANT

CAPSULE; ORAL

APREPITANTAB SANDOZ40MGA090999 001 Sep 24, 2012AB80MGA090999 002 Sep 24, 2012AB125MGA090999 003 Sep 24, 2012EMENDAB MERCK40MGN021549 003 Jun 30, 2006AB80MGN021549 001 Mar 26, 2003AB +125MGN021549 002 Mar 26, 2003

FOR SUSPENSION; ORAL

EMEND

+ MSD MERCK CO

125MG/KIT

N207865 001 Dec 17, 2015

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+ SUNOVION

EQ 0.015MG BASE/2ML

N021912 001 Oct 06, 2006

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBANAP FRESENIUS KABI USA250MG/2.5ML (100MG/ML)N201811 001 Mar 23, 2015AP HIKMA PHARM CO LTD250MG/2.5ML (100MG/ML)N203049 001 Jan 05, 2012AP MYLAN INSTITUTIONAL250MG/2.5ML (100MG/ML)A202626 001 Jun 30, 2014AP PAR STERILE PRODUCTS250MG/2.5ML (100MG/ML)A091665 001 Jun 30, 2014AP + PFIZER250MG/2.5ML (100MG/ML)N020883 001 Jun 30, 2000

INJECTABLE; IV (INFUSION)

ARGATROBAN IN 0.9% SODIUM CHLORIDE

TEVA PHARMS USA

250MG/250ML (1MG/ML)

N206769 001 Dec 15, 2014

ARGATROBAN IN SODIUM CHLORIDE

+ EAGLE PHARMS

50MG/50ML (1MG/ML)

N022434 001 Jun 29, 2011

+ SANDOZ

125MG/125ML (1MG/ML)

N022485 001 May 09, 2011

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+ PHARMACIA AND UPJOHN

10GM/100ML

N016931 001

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

OTSUKA PHARM CO LTD

300MG/VIAL

N202971 001 Feb 28, 2013

300MG

N202971 003 Sep 29, 2014

+

400MG/VIAL

N202971 002 Feb 28, 2013

400MG

N202971 004 Sep 29, 2014

INJECTABLE; INTRAMUSCULAR

ABILIFY

+ OTSUKA

9.75MG/1.3ML (7.5MG/ML)

N021866 001 Sep 20, 2006

SOLUTION; ORAL

ARIPIPRAZOLEAA AMNEAL PHARMS1MG/MLA203906 001 Aug 14, 2015AA APOTEX INC1MG/MLA204094 001 Sep 30, 2015AA SILARX PHARMS INC1MG/MLA204171 001 Aug 14, 2015

## PRESCRIPTION DRUG PRODUCT LIST

ARIPIPIRAZOLE

TABLET; ORAL

ABILIFY

<u>AB</u>	OTSUKA	<u>2MG</u>	<u>N021436</u>	<u>006</u>	Nov 15, 2002
<u>AB</u>	+	<u>5MG</u>	<u>N021436</u>	<u>005</u>	Nov 15, 2002
<u>AB</u>	+	<u>10MG</u>	<u>N021436</u>	<u>001</u>	Nov 15, 2002
<u>AB</u>		<u>15MG</u>	<u>N021436</u>	<u>002</u>	Nov 15, 2002
<u>AB</u>		<u>20MG</u>	<u>N021436</u>	<u>003</u>	Nov 15, 2002
<u>AB</u>		<u>30MG</u>	<u>N021436</u>	<u>004</u>	Nov 15, 2002

ARIPIPIRAZOLE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>2MG</u>	<u>A202101</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A202101</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A202101</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A202101</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A202101</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A202101</u>	<u>006</u>	Apr 28, 2015
<u>AB</u>	APOTEX INC	<u>2MG</u>	<u>A078583</u>	<u>001</u>	Jul 24, 2015
<u>AB</u>		<u>5MG</u>	<u>A078583</u>	<u>002</u>	Jul 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A078583</u>	<u>003</u>	Jul 24, 2015
<u>AB</u>		<u>15MG</u>	<u>A078583</u>	<u>004</u>	Jul 24, 2015
<u>AB</u>		<u>20MG</u>	<u>A078583</u>	<u>005</u>	Jul 24, 2015
<u>AB</u>		<u>30MG</u>	<u>A078583</u>	<u>006</u>	Jul 24, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2MG</u>	<u>A203908</u>	<u>001</u>	Oct 08, 2015
<u>AB</u>		<u>5MG</u>	<u>A203908</u>	<u>002</u>	Oct 08, 2015
<u>AB</u>		<u>10MG</u>	<u>A203908</u>	<u>003</u>	Oct 08, 2015
<u>AB</u>		<u>15MG</u>	<u>A203908</u>	<u>004</u>	Oct 08, 2015
<u>AB</u>		<u>20MG</u>	<u>A203908</u>	<u>005</u>	Oct 08, 2015
<u>AB</u>		<u>30MG</u>	<u>A203908</u>	<u>006</u>	Oct 08, 2015
<u>AB</u>	HETERO LABS LTD V	<u>2MG</u>	<u>A205064</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A205064</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A205064</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A205064</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A205064</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A205064</u>	<u>006</u>	Apr 28, 2015
<u>AB</u>	TEVA PHARMS USA	<u>2MG</u>	<u>A078607</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A078607</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A078608</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A078708</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A078708</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A078708</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>	TORRENT PHARMS LTD	<u>2MG</u>	<u>A201519</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A201519</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A201519</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A201519</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A201519</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A201519</u>	<u>006</u>	Apr 28, 2015

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

<u>AB</u>	+	OTSUKA	<u>10MG</u>	<u>N021729</u>	<u>002</u>	Jun 07, 2006
<u>AB</u>			<u>15MG</u>	<u>N021729</u>	<u>003</u>	Jun 07, 2006

ARIPIPIRAZOLE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A202102</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A202102</u>	<u>002</u>	Apr 28, 2015

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
	+	882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015

ARMODAFINIL

TABLET; ORAL

NUVIGIL

	CEPHALON	50MG	N021875	001	Jun 15, 2007
		150MG	N021875	003	Jun 15, 2007
		200MG	N021875	005	Mar 26, 2009
	+	250MG	N021875	004	Jun 15, 2007

## PRESCRIPTION DRUG PRODUCT LIST

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

+ CEPHALON

1MG/ML

N021248 001 Sep 25, 2000

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+ NOVARTIS

20MG; 120MG

N022268 001 Apr 07, 2009

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE**AP** HOSPIRA**4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)****A079138 001** Jun 18, 2010SEPTOCAINE**AP** + DEPROCO**4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)****N020971 001** Apr 03, 2000

ORABLOC

PIERREL

4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)

N022466 001 Feb 26, 2010

+

4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)

N022466 002 Feb 26, 2010

SEPTOCAINE

+ DEPROCO

4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)

N022010 001 Mar 30, 2006

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SANDOZ

80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021265 001 Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SANDOZ

80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021646 001 Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ HOSPIRA

80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG BASE/VIAL; 0.7MG/VIAL; 7MG/VIAL

N018920 001 Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

+ HOSPIRA

20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML

N008809 006 Sep 09, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ HOSPIRA

200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL

N021625 001 Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ HOSPIRA

200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5ML

N021643 001 Feb 18, 2004

## PRESCRIPTION DRUG PRODUCT LIST

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+ SALIX PHARMS

4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM

N021881 001 Aug 02, 2006

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

FOREST LABS LLC

EQ 5MG BASE

N022117 001 Aug 13, 2009

+

EQ 10MG BASE

N022117 002 Aug 13, 2009

ASPIRIN

CAPSULE, EXTENDED RELEASE; ORAL

DURLAZA

+ NEW HAVEN PHARMS

162.5MG

N200671 001 Sep 04, 2015

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL**AA** + ACTAVIS LABS UT INC**325MG; 50MG; 40MG****N017534 005** Apr 16, 1986LANORINAL**AA** LANNETT**325MG; 50MG; 40MG****A086996 002** Oct 11, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE**AA** + HIKMA INTL PHARMS**325MG; 50MG; 40MG****A086162 002** Feb 16, 1984ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE**AB** COASTAL PHARMS**325MG; 50MG; 40MG; 30MG****A203335 001** Oct 30, 2015BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE**AB** NEXGEN PHARMA INC**325MG; 50MG; 40MG; 30MG****A075231 001** Nov 30, 2001**AB** STEVENS J**325MG; 50MG; 40MG; 30MG****A074951 001** Aug 31, 1998FIORINAL W/CODEINE**AB** + ACTAVIS LABS UT INC**325MG; 50MG; 40MG; 30MG****N019429 003** Oct 26, 1990ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ SUN PHARM INDS

356.4MG; 30MG; 16MG

N011483 004 Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ

385MG; 30MG; 25MG

A074654 001 Dec 31, 1996

+

770MG; 60MG; 50MG

A074654 002 Dec 31, 1996

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN**AB** HERITAGE PHARMS INC**325MG; 200MG****A089594 001** Mar 31, 1989**AB** MIRROR PHARMS**325MG; 200MG****A040832 001** Jan 07, 2010**AB** PROSAM LABS**325MG; 200MG****A040252 001** Dec 10, 1997**AB** SANDOZ**325MG; 200MG****A040116 001** Apr 25, 1996SOMA COMPOUND**AB** + MEDA PHARMS**325MG; 200MG****N012365 005** Jul 11, 1983ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE**AB** SANDOZ**325MG; 200MG; 16MG****A040118 001** Apr 16, 1996SOMA COMPOUND W/ CODEINE**AB** + MEDA PHARMS**325MG; 200MG; 16MG****N012366 002** Jul 11, 1983ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOLX**AB** + BOEHRINGER INGELHEIM**25MG; 200MG****N020884 001** Nov 22, 1999ASPIRIN AND DIPYRIDAMOLE**AB** BARR**25MG; 200MG****A078804 001** Aug 14, 2009

## PRESCRIPTION DRUG PRODUCT LIST

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

+ STEVENS J

325MG; 400MG

A081145 001 Jan 31, 1995

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRINAA ACTAVIS LABS FL INC325MG; 4.8355MGA090084 001 Mar 22, 2011AA COASTAL PHARMS325MG; 4.8355MGA091670 001 Mar 16, 2011PERCODANAA + ENDO PHARMS325MG; 4.8355MGN007337 007 Aug 05, 2005ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATEAB TEVA PHARMS USAEQ 150MG BASEA091673 002 Apr 22, 2014ABEQ 200MG BASEA091673 003 Apr 22, 2014ABEQ 300MG BASEA091673 004 Apr 22, 2014REYATAZAB BRISTOL MYERS SQUIBBEQ 150MG BASEN021567 002 Jun 20, 2003ABEQ 200MG BASEN021567 003 Jun 20, 2003AB +EQ 300MG BASEN021567 004 Oct 16, 2006

ATAZANAVIR SULFATE

TEVA PHARMS USA

EQ 100MG BASE

A091673 001 Apr 22, 2014

POWDER; ORAL

REYATAZ

+ BRISTOL MYERS SQUIBB

EQ 50MG BASE/PACKET

N206352 001 Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET; ORAL

EVOTAZ

+ BRISTOL MYERS SQUIBB

EQ 300MG BASE; 150MG

N206353 001 Jan 29, 2015

ATENOLOL

TABLET; ORAL

ATENOLOLAB ALVOGEN IPCO SARL25MGA073646 001 Jul 31, 1992AB50MGA072303 001 Jul 15, 1988AB100MGA072304 001 Jul 15, 1988AB AUROBINDO PHARMA25MGA078512 001 Oct 31, 2007AB50MGA078512 002 Oct 31, 2007AB100MGA078512 003 Oct 31, 2007AB DAVA PHARMS INC50MGA073542 001 Dec 19, 1991AB100MGA073543 001 Dec 19, 1991AB IPCA LABS LTD25MGA077877 001 Dec 27, 2006AB50MGA077877 002 Dec 27, 2006AB100MGA077877 003 Dec 27, 2006AB MYLAN25MGA073457 002 Apr 26, 1999AB50MGA073457 003 Jan 24, 1992AB100MGA073457 001 Jan 24, 1992AB NORTHSTAR HLTHCARE25MGA078254 001 Sep 25, 2009AB50MGA078254 002 Sep 25, 2009AB100MGA078254 003 Sep 25, 2009AB SANDOZ25MGA074052 001 May 01, 1992AB50MGA073025 001 Sep 17, 1991AB100MGA073026 001 Sep 17, 1991AB SUN PHARM INDS25MGA074499 001 Jul 30, 1997AB50MGA073475 001 Mar 30, 1993AB100MGA073476 001 Mar 30, 1993AB SUN PHARM INDS INC25MGA078210 001 Jul 10, 2007AB50MGA078210 002 Jul 10, 2007AB100MGA078210 003 Jul 10, 2007AB TEVA25MGA074056 003 Jul 19, 2004AB50MGA074056 001 Jan 18, 1995AB100MGA074056 002 Jan 18, 1995AB UNIQUE PHARM LABS25MGA077443 001 Sep 13, 2006AB50MGA077443 002 Sep 13, 2006AB100MGA077443 003 Sep 13, 2006AB ZYDUS PHARMS USA25MGA076900 001 Jan 28, 2005AB50MGA076900 002 Jan 28, 2005AB100MGA076900 003 Jan 28, 2005TENORMINAB ALVOGEN IPCO SARL25MGN018240 004 Apr 09, 1990



## PRESCRIPTION DRUG PRODUCT LIST

ATENOLOL

TABLET; ORAL

TENORMIN

<u>AB</u>		<u>50MG</u>	<u>N018240</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018240</u>	<u>002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	ALVOGEN IPCO SARL	<u>50MG;25MG</u>	<u>A072301</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>100MG;25MG</u>	<u>A072302</u>	<u>001</u>	May 31, 1990
<u>AB</u>	MUTUAL PHARM	<u>50MG;25MG</u>	<u>A073581</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>		<u>100MG;25MG</u>	<u>A073582</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>	MYLAN	<u>50MG;25MG</u>	<u>A074203</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG;25MG</u>	<u>A074203</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>50MG;25MG</u>	<u>A073665</u>	<u>001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG;25MG</u>	<u>A073665</u>	<u>002</u>	Jul 02, 1992

TENORETIC 100

<u>AB</u>	+	ALVOGEN IPCO SARL	<u>100MG;25MG</u>	<u>N018760</u>	<u>001</u>	Jun 08, 1984
-----------	---	-------------------	-------------------	----------------	------------	--------------

TENORETIC 50

<u>AB</u>		ALVOGEN IPCO SARL	<u>50MG;25MG</u>	<u>N018760</u>	<u>002</u>	Jun 08, 1984
-----------	--	-------------------	------------------	----------------	------------	--------------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY

		10MG	N021411	002	Nov 26, 2002
		18MG	N021411	003	Nov 26, 2002
		25MG	N021411	004	Nov 26, 2002
		40MG	N021411	005	Nov 26, 2002
	+	60MG	N021411	006	Nov 26, 2002
		80MG	N021411	007	Feb 14, 2005
		100MG	N021411	008	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A090548</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090548</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090548</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090548</u>	<u>004</u>	May 29, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A091650</u>	<u>001</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091650</u>	<u>002</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091650</u>	<u>003</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202357</u>	<u>001</u>	Jul 17, 2012
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 10MG BASE</u>	<u>A091624</u>	<u>001</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091624</u>	<u>002</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091624</u>	<u>003</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091624</u>	<u>004</u>	Apr 05, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A091226</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091226</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091226</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091226</u>	<u>004</u>	May 29, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A077575</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077575</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077575</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077575</u>	<u>004</u>	May 29, 2012
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 10MG BASE</u>	<u>A076477</u>	<u>001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076477</u>	<u>002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076477</u>	<u>003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A076477</u>	<u>004</u>	Nov 30, 2011

LIPITOR

<u>AB</u>	PFIZER	<u>EQ 10MG BASE</u>	<u>N020702</u>	<u>001</u>	Dec 17, 1996
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020702</u>	<u>002</u>	Dec 17, 1996
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>N020702</u>	<u>003</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 80MG BASE</u>	<u>N020702</u>	<u>004</u>	Apr 07, 2000

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

<u>AB</u>	AMNEAL PHARMS	<u>750MG/5ML</u>	<u>A202960</u>	<u>001</u>	Mar 18, 2014
-----------	---------------	------------------	----------------	------------	--------------

MEPRON

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>750MG/5ML</u>	<u>N020500</u>	<u>001</u>	Feb 08, 1995
-----------	---	---------------------	------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<b>AB</b>	GLENMARK GENERICS	<b>62.5MG;25MG</b>	<b>A091211 002</b>	Apr 06, 2015
<b>AB</b>		<b>250MG;100MG</b>	<b>A091211 001</b>	Jan 12, 2011
<b>AB</b>	MYLAN PHARMS INC	<b>62.5MG;25MG</b>	<b>A202362 001</b>	May 27, 2014
<b>AB</b>		<b>250MG;100MG</b>	<b>A202362 002</b>	May 27, 2014
<b>MALARONE</b>				
<b>AB</b>	+ GLAXOSMITHKLINE	<b>250MG;100MG</b>	<b>N021078 001</b>	Jul 14, 2000
<b>MALARONE PEDIATRIC</b>				
<b>AB</b>	GLAXOSMITHKLINE	<b>62.5MG;25MG</b>	<b>N021078 002</b>	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

<b>AP</b>	AUROBINDO PHARMA LTD	<b>10MG/ML</b>	<b>A206011 001</b>	Apr 08, 2015
<b>AP</b>	+ EUROHLTH INTL SARL	<b>10MG/ML</b>	<b>A074901 001</b>	Jul 18, 1997
<b>AP</b>	HOSPIRA INC	<b>10MG/ML</b>	<b>A090761 001</b>	Oct 18, 2012
<b>AP</b>	SAGENT PHARMS	<b>10MG/ML</b>	<b>A091489 001</b>	Feb 17, 2012
<b>ATRACURIUM BESYLATE PRESERVATIVE FREE</b>				
<b>AP</b>	AUROBINDO PHARMA LTD	<b>10MG/ML</b>	<b>A206010 001</b>	Apr 08, 2015
<b>AP</b>	+ EUROHLTH INTL SARL	<b>10MG/ML</b>	<b>A074900 001</b>	Jul 18, 1997
<b>AP</b>	HOSPIRA INC	<b>10MG/ML</b>	<b>A090782 001</b>	Oct 18, 2012
<b>AP</b>	SAGENT PHARMS	<b>10MG/ML</b>	<b>A091488 001</b>	Feb 17, 2012

ATROPINE

INJECTABLE; INJECTION

ATROPEN

	+ MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106 004	Sep 17, 2004
	+	EQ 0.5MG SULFATE/0.7ML	N017106 003	Jun 19, 2003
	+	EQ 1MG SULFATE/0.7ML	N017106 002	Jun 19, 2003
	+	EQ 2MG SULFATE/0.7ML	N017106 001	

ATROPINE SULFATE

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

	+ HOSPIRA	0.05MG/ML	N021146 002	Jul 09, 2001
	+	0.1MG/ML	N021146 001	Jul 09, 2001

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

	+ AKORN	1%	N206289 001	Jul 18, 2014
--	---------	----	-------------	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

	+ SEBELA IRELAND LTD	0.025MG;1MG	N017744 002	
--	----------------------	-------------	-------------	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

<b>AA</b>	+ ROXANE	<b>0.025MG/5ML;2.5MG/5ML</b>	<b>A087708 001</b>	May 03, 1982
-----------	----------	------------------------------	--------------------	--------------

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

<b>AA</b>	LANNETT	<b>0.025MG;2.5MG</b>	<b>A085372 001</b>	
<b>AA</b>	MYLAN	<b>0.025MG;2.5MG</b>	<b>A085762 001</b>	
<b>AA</b>	PAR PHARM	<b>0.025MG;2.5MG</b>	<b>A040357 001</b>	May 02, 2000
<b>LOMOTIL</b>				
<b>AA</b>	+ GD SEARLE LLC	<b>0.025MG;2.5MG</b>	<b>N012462 001</b>	
<b>LONOX</b>				
<b>AA</b>	SANDOZ	<b>0.025MG;2.5MG</b>	<b>A085311 002</b>	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

	+ MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019678 001	Nov 06, 1991
--	-----------------------	-------------------	-------------	--------------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

	+ MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML	N021983 001	Sep 28, 2006
--	------------------	-----------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

AURANOFIN

CAPSULE; ORAL

RIDAURA

+ PROMETHEUS LABS

3MG

N018689 001 May 24, 1985

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

50MG

N202276 001 Apr 27, 2012

100MG

N202276 002 Apr 27, 2012

+

200MG

N202276 003 Apr 27, 2012

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+ CEREXA INC

EQ 0.5GM BASE; 2GM/VIAL

N206494 001 Feb 25, 2015

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

1MG

N202324 001 Jan 27, 2012

+

5MG

N202324 002 Jan 27, 2012

AZACITIDINE

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINEAP DR REDDYS LABS LTD100MG/VIALA201537 001 Sep 16, 2013VIDAZAAP + CELGENE100MG/VIALN050794 001 May 19, 2004AZATHIOPRINE

TABLET; ORAL

AZASANAB AAIPHARMA LLC25MGA075252 002 Feb 03, 2003AB50MGA075252 001 Jun 07, 1999AB75MGA075252 003 Feb 03, 2003AB100MGA075252 004 Feb 03, 2003AZATHIOPRINEAB AMNEAL PHARMS LLC50MGA074069 001 Feb 16, 1996AB

MYLAN

50MGA075568 001 Dec 13, 1999AB

ZYDUS PHARMS USA

25MGA077621 002 Sep 05, 2008AB50MGA077621 001 Mar 15, 2007AB75MGA077621 003 Sep 05, 2008AB100MGA077621 004 Sep 05, 2008IMURANAB + PROMETHEUS LABS50MGN016324 001AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+ EUROHLTH INTL SARL

EQ 100MG BASE/VIAL

A074419 001 Mar 31, 1995

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+ BAYER HLTHCARE

15%

N207071 001 Jul 29, 2015

CREAM; TOPICAL

AZELEX

+ ALLERGAN

20%

N020428 001 Sep 13, 1995

GEL; TOPICAL

FINACEA

+ BAYER HLTHCARE

15%

N021470 001 Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDEAT ALCON PHARMA0.05%A202305 001 May 31, 2012AT

APOTEX INC

0.05%A078621 001 Aug 03, 2009AT

SUN PHARMA GLOBAL

0.05%A078738 001 Jun 21, 2010OPTIVARAT + MEDA PHARMS0.05%N021127 001 May 22, 2000

SPRAY, METERED; NASAL

ASTELINAB + MEDA PHARMSEQ 0.125MG BASE/SPRAYN020114 001 Nov 01, 1996ASTEPROAB + MEDA PHARMSEQ 0.1876MG BASE/SPRAYN022203 002 Aug 31, 2009

## PRESCRIPTION DRUG PRODUCT LIST

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

<b>AB</b>	APOTEX INC	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A077954</u>	<u>001</u>	Apr 30, 2009
<b>AB</b>		<u>EQ 0.1876MG BASE/SPRAY</u>	<u>A201846</u>	<u>001</u>	Aug 31, 2012
<b>AB</b>	BRECKENRIDGE PHARMS	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A090176</u>	<u>001</u>	Jul 28, 2015
<b>AB</b>	PERRIGO ISRAEL	<u>EQ 0.1876MG BASE/SPRAY</u>	<u>A202743</u>	<u>001</u>	May 08, 2014
<b>AB</b>	ROXANE	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A091444</u>	<u>001</u>	Oct 24, 2014
<b>AB</b>	SUN PHARMA GLOBAL	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A090423</u>	<u>001</u>	May 23, 2012

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

DYMISTA

+ MEDA PHARMS

EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY

N202236 001 May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

ARBOR PHARMS IRELAND

EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011

+

EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

ARBOR PHARMS IRELAND

EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011

+

EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

<b>AB</b>	LUPIN LTD	<u>EQ 100MG BASE/5ML</u>	<u>A065488</u>	<u>001</u>	May 15, 2015
<b>AB</b>		<u>EQ 200MG BASE/5ML</u>	<u>A065488</u>	<u>002</u>	May 15, 2015
<b>AB</b>	PLIVA	<u>EQ 100MG BASE/5ML</u>	<u>A065246</u>	<u>002</u>	Jul 05, 2006
<b>AB</b>		<u>EQ 200MG BASE/5ML</u>	<u>A065246</u>	<u>001</u>	Jul 05, 2006
<b>AB</b>	TEVA PHARMS	<u>EQ 100MG BASE/5ML</u>	<u>A065419</u>	<u>001</u>	Jun 24, 2008
<b>AB</b>		<u>EQ 200MG BASE/5ML</u>	<u>A065419</u>	<u>002</u>	Jun 24, 2008

ZITHROMAX

<b>AB</b>	PFIZER	<u>EQ 100MG BASE/5ML</u>	<u>N050710</u>	<u>001</u>	Oct 19, 1995
<b>AB</b>	+	<u>EQ 200MG BASE/5ML</u>	<u>N050710</u>	<u>002</u>	Oct 19, 1995
	+	EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

+ PF PRISM CV

EQ 2GM BASE/BOT

N050797 001 Jun 10, 2005

INJECTABLE;INJECTION

AZITHROMYCIN

<b>AP</b>	AUROBINDO PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A203294</u>	<u>001</u>	Jun 19, 2015
<b>AP</b>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A065179</u>	<u>001</u>	Dec 13, 2005
<b>AP</b>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065501</u>	<u>001</u>	Nov 09, 2009
<b>AP</b>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A065500</u>	<u>001</u>	Jun 26, 2009
<b>AP</b>		<u>EQ 500MG BASE/VIAL</u>	<u>A065511</u>	<u>001</u>	Jun 26, 2009
<b>AP</b>	SAGENT STRIDES	<u>EQ 500MG BASE/VIAL</u>	<u>A065506</u>	<u>001</u>	Mar 24, 2009
<b>AP</b>	SUN PHARM INDS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A090923</u>	<u>001</u>	Apr 02, 2013

ZITHROMAX

<b>AP</b>	+	PFIZER	<u>EQ 500MG BASE/VIAL</u>	<u>N050733</u>	<u>001</u>	Jan 30, 1997
-----------	---	--------	---------------------------	----------------	------------	--------------

SOLUTION/DROPS;OPHTHALMIC

AZASITE

+ OAK PHARMS INC

1%

N050810 001 Apr 27, 2007

TABLET;ORAL

AZITHROMYCIN

<b>AB</b>	APOTEX CORP	<u>EQ 250MG BASE</u>	<u>A065507</u>	<u>001</u>	Jul 13, 2011
<b>AB</b>		<u>EQ 500MG BASE</u>	<u>A065509</u>	<u>001</u>	Jul 13, 2011
<b>AB</b>		<u>EQ 600MG BASE</u>	<u>A065508</u>	<u>001</u>	Jul 13, 2011
<b>AB</b>	LUPIN LTD	<u>EQ 250MG BASE</u>	<u>A065398</u>	<u>001</u>	May 15, 2015
<b>AB</b>		<u>EQ 500MG BASE</u>	<u>A065399</u>	<u>001</u>	May 15, 2015
<b>AB</b>		<u>EQ 600MG BASE</u>	<u>A065400</u>	<u>001</u>	May 15, 2015
<b>AB</b>	MYLAN	<u>EQ 250MG BASE</u>	<u>A065365</u>	<u>001</u>	May 30, 2007
<b>AB</b>		<u>EQ 500MG BASE</u>	<u>A065366</u>	<u>001</u>	May 30, 2007
<b>AB</b>		<u>EQ 600MG BASE</u>	<u>A065360</u>	<u>001</u>	Jan 08, 2007
<b>AB</b>	PLIVA	<u>EQ 250MG BASE</u>	<u>A065225</u>	<u>001</u>	Nov 14, 2005
<b>AB</b>		<u>EQ 500MG BASE</u>	<u>A065223</u>	<u>001</u>	Nov 14, 2005
<b>AB</b>		<u>EQ 600MG BASE</u>	<u>A065218</u>	<u>001</u>	Nov 14, 2005
<b>AB</b>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211</u>	<u>001</u>	Nov 14, 2005
<b>AB</b>		<u>EQ 500MG BASE</u>	<u>A065212</u>	<u>001</u>	Nov 14, 2005
<b>AB</b>		<u>EQ 600MG BASE</u>	<u>A065209</u>	<u>001</u>	Nov 14, 2005

## PRESCRIPTION DRUG PRODUCT LIST

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065153 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065193 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065150 001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302 003</u>	Feb 11, 2008

ZITHROMAX

<u>AB</u>	PFIZER	<u>EQ 250MG BASE</u>	<u>N050711 001</u>	Jul 18, 1996
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050784 001</u>	May 24, 2002
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N050730 001</u>	Jun 12, 1996

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+ GILEAD

75MG/VIAL

N050814 001 Feb 22, 2010

INJECTABLE; INJECTION

AZACTAM

<u>AP</u>	+	BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580 002</u>	Dec 31, 1986
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050580 003</u>	Dec 31, 1986

AZTREONAM

<u>AP</u>		EUROHLTH INTL SARL	<u>1GM/VIAL</u>	<u>A065286 001</u>	Mar 23, 2011
<u>AP</u>			<u>2GM/VIAL</u>	<u>A065286 002</u>	Mar 23, 2011
<u>AP</u>		FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439 002</u>	Jun 18, 2010
<u>AP</u>			<u>2GM/VIAL</u>	<u>A065439 003</u>	Jun 18, 2010

AZACTAM IN PLASTIC CONTAINER

+ BRISTOL MYERS SQUIBB

20MG/ML

N050632 002 May 24, 1989

+

40MG/ML

N050632 001 May 24, 1989

AZTREONAM

FRESENIUS KABI USA

500MG/VIAL

A065439 001 Jun 18, 2010

BACITRACIN

INJECTABLE; INJECTION

BACIIM

<u>AP</u>		X GEN PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A064153 001</u>	May 09, 1997
-----------	--	--------------	--------------------------	--------------------	--------------

BACITRACIN

<u>AP</u>		FRESENIUS KABI USA	<u>50,000 UNITS/VIAL</u>	<u>A065116 001</u>	Dec 03, 2002
<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>50,000 UNITS/VIAL</u>	<u>A060733 002</u>	
<u>AP</u>		SAGENT STRIDES	<u>50,000 UNITS/VIAL</u>	<u>A090211 001</u>	May 11, 2010
<u>AP</u>		XELLIA PHARMS APS	<u>50,000 UNITS/VIAL</u>	<u>A203177 001</u>	Aug 25, 2014
		PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733 001	

OINTMENT; OPHTHALMIC

BACITRACIN

+ PERRIGO CO TENNESSEE

500 UNITS/GM

A061212 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

<u>AT</u>		AKORN	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065213 001</u>	Jul 25, 2012
<u>AT</u>	+	BAUSCH AND LOMB	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064068 001</u>	Oct 30, 1995

OINTMENT; TOPICAL

CORTISPORIN

+ MONARCH PHARMS

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

N050168 002 May 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

<u>AT</u>		AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065088 001</u>	Feb 06, 2004
<u>AT</u>	+	BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064064 001</u>	Oct 30, 1995
<u>AT</u>		PERRIGO CO TENNESSEE	<u>400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM</u>	<u>A060764 002</u>	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

<u>AT</u>		AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028 001</u>	Jan 30, 1995
<u>AT</u>	+	BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046 001</u>	Jan 26, 1995
<u>AT</u>		PERRIGO CO TENNESSEE	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022 001</u>	Feb 27, 2002

## PRESCRIPTION DRUG PRODUCT LIST

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+ PERRIGO CO TENNESSEE 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM A062166 002

BACLOFEN

INJECTABLE;INTRATHECAL

GABLOFENAP MALLINCKRODT INC 0.05MG/ML N022462 001 Nov 19, 2010AP 0.5MG/ML N022462 002 Nov 19, 2010AP 2MG/ML N022462 003 Nov 19, 2010LIORESALAP + MEDTRONIC NEURO 0.05MG/ML N020075 003 Nov 07, 1996AP + 0.5MG/ML N020075 001 Jun 17, 1992AP + 2MG/ML N020075 002 Jun 17, 1992

GABLOFEN

MALLINCKRODT INC 1MG/ML N022462 004 Jun 22, 2012

TABLET;ORAL

BACLOFENAB CARACO 10MG A077984 001 Aug 14, 2006AB IMPAX LABS 10MG A078146 001 Oct 26, 2007AB 20MG A077971 002 Oct 26, 2007AB IVAX SUB TEVA PHARMS 10MG A072234 001 Jul 21, 1988AB + 20MG A072235 001 Jul 21, 1988AB LANNETT 10MG A078220 001 Jul 06, 2007AB 20MG A077241 001 Dec 20, 2005AB MYLAN 10MG A077181 001 Jul 29, 2005AB 20MG A077121 002 Jul 29, 2005AB MYLAN PHARMS INC 10MG A090334 001 Feb 18, 2010AB 20MG A090334 002 Feb 18, 2010AB NORTHSTAR HLTHCARE 10MG A078504 001 Sep 18, 2009AB 20MG A078401 001 Sep 18, 2009AB PROSAM LABS 10MG A077089 001 Oct 31, 2007AB 20MG A077088 001 Oct 31, 2007AB SUN PHARM INDS INC 20MG A077862 002 Aug 14, 2006AB USL PHARMA 10MG A074584 001 Aug 19, 1996AB 20MG A074584 002 Aug 19, 1996AB VINTAGE PHARMS 10MG A077156 001 Aug 30, 2005AB 20MG A077068 001 Aug 30, 2005AB WATSON LABS 10MG A072824 001 Sep 18, 1991AB 20MG A072825 001 Sep 18, 1991BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUMAB APOTEX INC 750MG A077883 001 Dec 28, 2007AB MYLAN 750MG A077807 001 Dec 28, 2007AB ROXANE 750MG A077806 001 Dec 28, 2007COLAZALAB + VALEANT PHARMS INTL 750MG N020610 001 Jul 18, 2000

TABLET;ORAL

BALSALAZIDE DISODIUMAB PAR PHARM INC 1.1GM A206336 001 Sep 08, 2015GIAZOAB + VALEANT PHARMS INTL 1.1GM N022205 001 Feb 03, 2012BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET;ORAL

DUAVEE

+ WYETH PHARMS PFIZER EQ 20MG BASE;0.45MG N022247 001 Oct 03, 2013

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR 40

+ TEVA BRANDED PHARM 0.04MG/INH N020911 002 Sep 15, 2000

QVAR 80

+ TEVA BRANDED PHARM 0.08MG/INH N020911 001 Sep 15, 2000

AEROSOL, METERED;NASAL

QNASL

TEVA BRANDED PHARM 0.04MG/ACTUATION N202813 002 Dec 17, 2014

+ 0.08MG/ACTUATION N202813 001 Mar 23, 2012

## PRESCRIPTION DRUG PRODUCT LIST

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

BECONASE AQ

+ GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY

N019389 001 Jul 27, 1987

BEDAQUILINE FUMARATE

TABLET;ORAL

SIRTURO

+ JANSSEN THERAP EQ 100MG BASE

N204384 001 Dec 28, 2012

BELINOSTAT

POWDER;IV (INFUSION)

BELEODAQ

+ SPECTRUM PHARMS 500MG/VIAL

N206256 001 Jul 03, 2014

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG</u>	<u>A076267 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076267 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076267 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076267 004</u>	Feb 11, 2004
<u>AB</u>	AMNEAL PHARMS LLC	<u>5MG</u>	<u>A076820 001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820 002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820 003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820 004</u>	Feb 03, 2006
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077128 001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128 002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128 003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128 004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212 001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212 002</u>	May 22, 2008
<u>AB</u>		<u>40MG</u>	<u>A078212 003</u>	May 22, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076333 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076333 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076333 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076333 004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076430 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076430 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076430 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076430 004</u>	Feb 11, 2004
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A076118 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118 004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A076402 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402 004</u>	Feb 11, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A076344 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344 004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211 004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848 001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848 002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848 003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848 004</u>	May 23, 2008
	<u>LOTENSIN</u>			
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG</u>	<u>N019851 001</u>	Jun 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019851 002</u>	Jun 25, 1991
<u>AB</u>		<u>20MG</u>	<u>N019851 003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851 004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG;6.25MG</u>	<u>A076342 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG;12.5MG</u>	<u>A076342 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076342 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG;25MG</u>	<u>A076342 004</u>	Feb 11, 2004

## PRESCRIPTION DRUG PRODUCT LIST

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG; 6.25MG</u>	<u>A078794 001</u>	Aug 21, 2014
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A078794 002</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A078794 003</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 25MG</u>	<u>A078794 004</u>	Aug 21, 2014
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG; 6.25MG</u>	<u>A076348 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076348 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076348 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076348 004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688 004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631 004</u>	Feb 11, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG; 6.25MG</u>	<u>A077483 001</u>	Sep 08, 2005
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A077483 002</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A077483 003</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 25MG</u>	<u>A077483 004</u>	Sep 08, 2005
<u>LOTENSIN HCT</u>				
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG; 6.25MG</u>	<u>N020033 001</u>	May 19, 1992
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>N020033 002</u>	May 19, 1992
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>N020033 004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033 003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

+ CEPHALON

25MG/VIAL

N022249 002 May 01, 2009

+

100MG/VIAL

N022249 001 Mar 20, 2008

SOLUTION; IV (INFUSION)

BENDEKA

EAGLE PHARMS

100MG/4ML (25MG/ML)

N208194 001 Dec 07, 2015

TREANDA

+ CEPHALON

45MG/0.5ML (90MG/ML)

N022249 003 Sep 13, 2013

+

180MG/2ML (90MG/ML)

N022249 004 Sep 13, 2013

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

<u>AB</u>	KING PHARMS	<u>5MG; 40MG</u>	<u>N018647 001</u>	May 25, 1983
<u>AB</u>	+	<u>5MG; 80MG</u>	<u>N018647 002</u>	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	IMPAX LABS	<u>5MG; 40MG</u>	<u>A077833 001</u>	Mar 30, 2007
<u>AB</u>		<u>5MG; 80MG</u>	<u>A077833 002</u>	Mar 30, 2007
<u>AB</u>	MYLAN	<u>5MG; 40MG</u>	<u>A078688 001</u>	Feb 15, 2008
<u>AB</u>		<u>5MG; 80MG</u>	<u>A078688 002</u>	Feb 15, 2008

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	APOTEX INC	<u>100MG</u>	<u>A091310 001</u>	Jan 16, 2015
<u>AA</u>		<u>200MG</u>	<u>A091310 002</u>	Jan 16, 2015
<u>AA</u>	BANNER LIFE SCIENCES	<u>100MG</u>	<u>A081297 001</u>	Jan 29, 1993
<u>AA</u>		<u>200MG</u>	<u>A081297 002</u>	Oct 30, 2007
<u>AA</u>	CSPC NBP PHARM CO	<u>200MG</u>	<u>A202765 001</u>	Jul 31, 2015
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040851 001</u>	Nov 09, 2009
<u>AA</u>		<u>150MG</u>	<u>A040851 002</u>	Nov 09, 2009
<u>AA</u>		<u>200MG</u>	<u>A040851 003</u>	Nov 09, 2009
<u>AA</u>	ORIT LABS LLC	<u>100MG</u>	<u>A040682 001</u>	Jul 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040682 002</u>	Jul 30, 2007
<u>AA</u>	STRIDES PHARMA	<u>100MG</u>	<u>A091133 001</u>	Jul 30, 2015
<u>AA</u>		<u>200MG</u>	<u>A091133 002</u>	Jul 30, 2015
<u>AA</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A040587 001</u>	Mar 19, 2008
<u>AA</u>		<u>200MG</u>	<u>A040587 002</u>	Mar 19, 2008
<u>AA</u>	+	<u>100MG</u>	<u>A040627 001</u>	Mar 30, 2007
<u>AA</u>	+	<u>200MG</u>	<u>A040749 001</u>	Jul 25, 2007
<u>AA</u>	+	<u>150MG</u>	<u>A201209 001</u>	Sep 24, 2014
<u>AA</u>	ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597 001</u>	Jun 08, 2007
<u>AA</u>		<u>200MG</u>	<u>A040597 002</u>	Jun 08, 2007



## PRESCRIPTION DRUG PRODUCT LIST

BENZONATATE

CAPSULE; ORAL

TESSALON

<b>AA</b>	PFIZER	<b>100MG</b>	<b>N011210</b>	<b>001</b>	
-----------	--------	--------------	----------------	------------	--

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

<b>AB</b>	+ DOW PHARM	<b>2.5%;EQ 1.2% BASE</b>	<b>N050819</b>	<b>001</b>	Oct 23, 2008
-----------	-------------	--------------------------	----------------	------------	--------------

BENZACLIN

<b>AB</b>	+ VALEANT BERMUDA	<b>5%;EQ 1% BASE</b>	<b>N050756</b>	<b>001</b>	Dec 21, 2000
-----------	-------------------	----------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

<b>AB</b>	ACTAVIS LABS UT INC	<b>2.5%;EQ 1.2% BASE</b>	<b>A205128</b>	<b>001</b>	Jun 19, 2015
-----------	---------------------	--------------------------	----------------	------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<b>5%;EQ 1% BASE</b>	<b>A065443</b>	<b>001</b>	Aug 11, 2009
-----------	------------------	----------------------	----------------	------------	--------------

<b>AB</b>	PERRIGO ISRAEL	<b>5%;EQ 1% BASE</b>	<b>A202440</b>	<b>001</b>	Sep 21, 2015
-----------	----------------	----------------------	----------------	------------	--------------

<b>AB</b>		<b>5%;1.2%</b>	<b>A090979</b>	<b>001</b>	Jun 26, 2012
-----------	--	----------------	----------------	------------	--------------

DUAC

<b>AB</b>	+ STIEFEL	<b>5%;1.2%</b>	<b>N050741</b>	<b>001</b>	Aug 26, 2002
-----------	-----------	----------------	----------------	------------	--------------

ONEXTON

	+ DOW PHARM	<b>3.75%;EQ 1.2% BASE</b>	<b>N050819</b>	<b>002</b>	Nov 24, 2014
--	-------------	---------------------------	----------------	------------	--------------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

<b>AB</b>	+ VALEANT INTL	<b>5%;3%</b>	<b>N050557</b>	<b>001</b>	Oct 26, 1984
-----------	----------------	--------------	----------------	------------	--------------

ERYTHROMYCIN AND BENZOYL PEROXIDE

<b>AB</b>	LYNE	<b>5%;3%</b>	<b>A065385</b>	<b>001</b>	Sep 18, 2015
-----------	------	--------------	----------------	------------	--------------

<b>AB</b>	TOLMAR	<b>5%;3%</b>	<b>A065112</b>	<b>001</b>	Mar 29, 2004
-----------	--------	--------------	----------------	------------	--------------

BENZAMYCIN PAK

	+ VALEANT LUXEMBOURG	<b>5%;3%</b>	<b>N050769</b>	<b>001</b>	Nov 27, 2000
--	----------------------	--------------	----------------	------------	--------------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

<b>AA</b>	EMCURE PHARMS LTD	<b>50MG</b>	<b>A202061</b>	<b>001</b>	Jan 27, 2012
-----------	-------------------	-------------	----------------	------------	--------------

<b>AA</b>	EPIC PHARMA LLC	<b>50MG</b>	<b>A090346</b>	<b>001</b>	Dec 15, 2015
-----------	-----------------	-------------	----------------	------------	--------------

<b>AA</b>	IMPAX LABS	<b>50MG</b>	<b>A040845</b>	<b>001</b>	Nov 18, 2008
-----------	------------	-------------	----------------	------------	--------------

<b>AA</b>	+ KVK TECH	<b>50MG</b>	<b>A090968</b>	<b>001</b>	Jul 20, 2010
-----------	------------	-------------	----------------	------------	--------------

<b>AA</b>	MALLINCKRODT INC	<b>50MG</b>	<b>A040773</b>	<b>001</b>	Apr 25, 2007
-----------	------------------	-------------	----------------	------------	--------------

<b>AA</b>	MIKART	<b>25MG</b>	<b>A090473</b>	<b>001</b>	Sep 15, 2010
-----------	--------	-------------	----------------	------------	--------------

<b>AA</b>		<b>50MG</b>	<b>A090473</b>	<b>002</b>	Sep 15, 2010
-----------	--	-------------	----------------	------------	--------------

<b>AA</b>	PADDOCK	<b>50MG</b>	<b>A040578</b>	<b>001</b>	Apr 17, 2006
-----------	---------	-------------	----------------	------------	--------------

<b>AA</b>	TEDOR PHARM	<b>25MG</b>	<b>A040747</b>	<b>002</b>	Nov 20, 2015
-----------	-------------	-------------	----------------	------------	--------------

<b>AA</b>		<b>50MG</b>	<b>A040747</b>	<b>001</b>	Mar 30, 2007
-----------	--	-------------	----------------	------------	--------------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<b>AP</b>	FRESENIUS KABI USA	<b>1MG/ML</b>	<b>A090233</b>	<b>001</b>	Jul 28, 2009
-----------	--------------------	---------------	----------------	------------	--------------

<b>AP</b>	HIKMA FARMACEUTICA	<b>1MG/ML</b>	<b>A090287</b>	<b>001</b>	Aug 31, 2009
-----------	--------------------	---------------	----------------	------------	--------------

<b>AP</b>	LUITPOLD	<b>1MG/ML</b>	<b>A091152</b>	<b>001</b>	Mar 29, 2010
-----------	----------	---------------	----------------	------------	--------------

<b>AP</b>	NAVINTA LLC	<b>1MG/ML</b>	<b>A091525</b>	<b>001</b>	Feb 05, 2013
-----------	-------------	---------------	----------------	------------	--------------

COGENTIN

<b>AP</b>	+ OAK PHARMS AKORN	<b>1MG/ML</b>	<b>N012015</b>	<b>001</b>	
-----------	--------------------	---------------	----------------	------------	--

TABLET; ORAL

BENZTROPINE MESYLATE

<b>AA</b>	COREPHARMA	<b>0.5MG</b>	<b>A072264</b>	<b>001</b>	Feb 27, 1989
-----------	------------	--------------	----------------	------------	--------------

<b>AA</b>		<b>1MG</b>	<b>A072265</b>	<b>001</b>	Feb 27, 1989
-----------	--	------------	----------------	------------	--------------

<b>AA</b>		<b>2MG</b>	<b>A072266</b>	<b>001</b>	Feb 27, 1989
-----------	--	------------	----------------	------------	--------------

<b>AA</b>	INVAGEN PHARMS	<b>0.5MG</b>	<b>A090294</b>	<b>001</b>	Mar 29, 2010
-----------	----------------	--------------	----------------	------------	--------------

<b>AA</b>		<b>1MG</b>	<b>A090294</b>	<b>002</b>	Mar 29, 2010
-----------	--	------------	----------------	------------	--------------

<b>AA</b>		<b>2MG</b>	<b>A090294</b>	<b>003</b>	Mar 29, 2010
-----------	--	------------	----------------	------------	--------------

<b>AA</b>	LEADING PHARMA LLC	<b>0.5MG</b>	<b>A090168</b>	<b>001</b>	Nov 28, 2012
-----------	--------------------	--------------	----------------	------------	--------------

<b>AA</b>		<b>1MG</b>	<b>A090168</b>	<b>002</b>	Nov 28, 2012
-----------	--	------------	----------------	------------	--------------

<b>AA</b>		<b>2MG</b>	<b>A090168</b>	<b>003</b>	Nov 28, 2012
-----------	--	------------	----------------	------------	--------------

<b>AA</b>	NUVO PHARM INC	<b>0.5MG</b>	<b>A204713</b>	<b>001</b>	Apr 14, 2015
-----------	----------------	--------------	----------------	------------	--------------

<b>AA</b>		<b>1MG</b>	<b>A204713</b>	<b>002</b>	Apr 14, 2015
-----------	--	------------	----------------	------------	--------------

<b>AA</b>		<b>2MG</b>	<b>A204713</b>	<b>003</b>	Apr 14, 2015
-----------	--	------------	----------------	------------	--------------

<b>AA</b>	PLIVA	<b>0.5MG</b>	<b>A089058</b>	<b>001</b>	Aug 10, 1988
-----------	-------	--------------	----------------	------------	--------------

<b>AA</b>		<b>1MG</b>	<b>A089059</b>	<b>001</b>	Aug 10, 1988
-----------	--	------------	----------------	------------	--------------

<b>AA</b>		<b>2MG</b>	<b>A089060</b>	<b>001</b>	Aug 10, 1988
-----------	--	------------	----------------	------------	--------------

<b>AA</b>	+ USL PHARMA	<b>0.5MG</b>	<b>A040103</b>	<b>001</b>	Dec 12, 1996
-----------	--------------	--------------	----------------	------------	--------------

<b>AA</b>		<b>1MG</b>	<b>A040103</b>	<b>002</b>	Dec 12, 1996
-----------	--	------------	----------------	------------	--------------

<b>AA</b>		<b>2MG</b>	<b>A040103</b>	<b>003</b>	Dec 12, 1996
-----------	--	------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>	VINTAGE	<u>0.5MG</u>	<u>A040738</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>		<u>1MG</u>	<u>A040742</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>		<u>2MG</u>	<u>A040715</u>	<u>003</u>	Aug 27, 2007

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+ SHIONOGI INC

5%

N022129 001 Apr 09, 2009

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ ALLERQUEST

60UMOLAR

N050114 001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+ BAUSCH AND LOMB INC

1.5%

N022288 001 Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

+ ABBVIE

25MG/ML

N020032 001 Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+ BAUSCH AND LOMB

EQ 0.6% BASE

N022308 001 May 28, 2009

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

+ RARE DIS THERAP

1GM/SCOOPFUL

N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

<u>AB</u>	LUITPOLD	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>A090747</u>	<u>001</u>	Jul 31, 2009
<u>AB</u>	+ MERCK SHARP DOHME	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>N014602</u>	<u>001</u>	

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070885</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>	+ FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>N019137</u>	<u>001</u>	Jun 26, 1984
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A073552</u>	<u>001</u>	Apr 30, 1992

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A076215</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.05% BASE</u>	<u>A078930</u>	<u>001</u>	Sep 23, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>EQ 0.05% BASE</u>	<u>A076592</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076543</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	TOLMAR	<u>EQ 0.05% BASE</u>	<u>A076603</u>	<u>001</u>	Jan 23, 2004

DIPROLENE AF

<u>AB</u>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE</u>	<u>N019555</u>	<u>001</u>	Apr 27, 1987
-----------	---------------------	----------------------	----------------	------------	--------------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	+ FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A075276</u>	<u>001</u>	May 13, 2003
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076508</u>	<u>001</u>	Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070281</u>	<u>001</u>	Jul 31, 1985
<u>AB</u>	+ FOUGERA	<u>EQ 0.05% BASE</u>	<u>A070275</u>	<u>001</u>	Aug 12, 1985
<u>AB</u>	G AND W LABS INC	<u>EQ 0.05% BASE</u>	<u>A071467</u>	<u>001</u>	Aug 10, 1987
<u>AB</u>	PERRIGO NEW YORK	<u>EQ 0.05% BASE</u>	<u>A072538</u>	<u>001</u>	Jan 31, 1990

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A077111</u>	<u>001</u>	May 21, 2007
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A077477</u>	<u>001</u>	May 21, 2007

DIPROLENE

<u>AB</u>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE</u>	<u>N019716</u>	<u>001</u>	Aug 01, 1988
-----------	---------------------	----------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<b>A071012 001</b>	Feb 03, 1987
<b>AB</b>	+ FOUGERA	<u>EQ 0.05% BASE</u>	<b>N019141 001</b>	Sep 04, 1984
<b>AB</b>	TARO	<u>EQ 0.05% BASE</u>	<b>A074271 001</b>	Sep 15, 1994

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<b>A074304 001</b>	Aug 31, 1995
<b>AB</b>	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<b>A075373 001</b>	Jun 22, 1999
<b>AB</b>	TARO	<u>EQ 0.05% BASE</u>	<b>A076753 001</b>	Oct 12, 2004

DIPROLENE

<b>AB</b>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE</u>	<b>N018741 001</b>	Jul 27, 1983
-----------	---------------------	----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

ENSTILAR

	+ LEO PHARMA AS	0.064%; 0.005%	N207589 001	Oct 16, 2015
--	-----------------	----------------	-------------	--------------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

<b>AB</b>	PERRIGO ISRAEL	<u>0.064%; 0.005%</u>	<b>A200174 001</b>	Dec 12, 2014
<b>AB</b>	TOLMAR	<u>0.064%; 0.005%</u>	<b>A201615 001</b>	Jan 14, 2013

TACLONEX

<b>AB</b>	+ LEO PHARMA AS	<u>0.064%; 0.005%</u>	<b>N021852 001</b>	Jan 09, 2006
-----------	-----------------	-----------------------	--------------------	--------------

SUSPENSION; TOPICAL

TACLONEX

	+ LEO PHARMA AS	0.064%; 0.005%	N022185 001	May 09, 2008
--	-----------------	----------------	-------------	--------------

	+	0.064%; 0.005%	N022185 002	Oct 29, 2015
--	---	----------------	-------------	--------------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE; 1%</u>	<b>A076002 001</b>	Aug 02, 2002
<b>AB</b>	FOUGERA PHARMS	<u>EQ 0.05% BASE; 1%</u>	<b>A075502 001</b>	Jun 05, 2001
<b>AB</b>	GLENMARK PHARMS LTD	<u>EQ 0.05% BASE; 1%</u>	<b>A202894 001</b>	Oct 30, 2015
<b>AB</b>	TARO	<u>EQ 0.05% BASE; 1%</u>	<b>A075673 001</b>	May 29, 2001

LOTRISONE

<b>AB</b>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE; 1%</u>	<b>N018827 001</b>	Jul 10, 1984
-----------	---------------------	--------------------------	--------------------	--------------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<b>AB</b>	FOUGERA PHARMS	<u>EQ 0.05% BASE; 1%</u>	<b>A076516 001</b>	Jun 16, 2005
<b>AB</b>	TARO	<u>EQ 0.05% BASE; 1%</u>	<b>A076493 001</b>	Jul 28, 2004

LOTRISONE

<b>AB</b>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE; 1%</u>	<b>N020010 001</b>	Dec 08, 2000
-----------	---------------------	--------------------------	--------------------	--------------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

<b>AB</b>	PERRIGO	<u>0.12%</u>	<b>A078337 001</b>	Nov 26, 2012
-----------	---------	--------------	--------------------	--------------

LUXIQ

<b>AB</b>	+ DELCOR ASSET	<u>0.12%</u>	<b>N020934 001</b>	Feb 28, 1999
-----------	----------------	--------------	--------------------	--------------

CREAM; TOPICAL

BETA-VAL

<b>AB</b>	G AND W LABS INC	<u>EQ 0.1% BASE</u>	<b>N018642 001</b>	Mar 24, 1983
-----------	------------------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

<b>AB</b>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<b>N018861 001</b>	Aug 31, 1983
-----------	-----------	---------------------	--------------------	--------------

DERMABET

<b>AB</b>	TARO	<u>EQ 0.1% BASE</u>	<b>A072041 001</b>	Jan 06, 1988
-----------	------	---------------------	--------------------	--------------

VALNAC

<b>AB</b>	ACTAVIS MID ATLANTIC	<u>EQ 0.1% BASE</u>	<b>A070050 001</b>	Oct 10, 1984
-----------	----------------------	---------------------	--------------------	--------------

LOTION; TOPICAL

BETA-VAL

<b>AB</b>	G AND W LABS INC	<u>EQ 0.1% BASE</u>	<b>A070072 001</b>	Jun 27, 1985
-----------	------------------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

<b>AB</b>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<b>N018866 001</b>	Aug 31, 1983
<b>AB</b>	STI PHARMA LLC	<u>EQ 0.1% BASE</u>	<b>A070052 001</b>	Jul 31, 1985

OINTMENT; TOPICAL

BETA-VAL

<b>AB</b>	G AND W LABS INC	<u>EQ 0.1% BASE</u>	<b>A070069 001</b>	Dec 19, 1985
-----------	------------------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<u>EQ 0.1% BASE</u>	<b>A070051 001</b>	Oct 10, 1984
<b>AB</b>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<b>N018865 001</b>	Aug 31, 1983

## PRESCRIPTION DRUG PRODUCT LIST

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

<u>AT</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A075386 001</u>	Jun 30, 2000
<u>AT</u>	IGI LABS INC	<u>EQ 0.5% BASE</u>	<u>A075630 001</u>	Apr 12, 2001
<u>AT</u>	WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078694 001</u>	Nov 16, 2009

BETOPTIC

<u>AT</u>	+ ALCON	<u>EQ 0.5% BASE</u>	<u>N019270 001</u>	Aug 30, 1985
-----------	---------	---------------------	--------------------	--------------

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC S

+ ALCON

EQ 0.25% BASE

N019845 001 Dec 29, 1989

TABLET;ORAL

BETAXOLOL HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>10MG</u>	<u>A075541 001</u>	Oct 22, 1999
<u>AB</u>	+	<u>20MG</u>	<u>A075541 002</u>	Oct 22, 1999
<u>AB</u>	KVK TECH	<u>10MG</u>	<u>A078962 001</u>	Jun 27, 2008
<u>AB</u>		<u>20MG</u>	<u>A078962 002</u>	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

<u>AA</u>	AMNEAL PHARM	<u>5MG</u>	<u>A040855 001</u>	Nov 21, 2007
<u>AA</u>		<u>10MG</u>	<u>A040855 002</u>	Nov 21, 2007
<u>AA</u>		<u>25MG</u>	<u>A040855 003</u>	Nov 21, 2007
<u>AA</u>		<u>50MG</u>	<u>A040855 004</u>	Nov 21, 2007
<u>AA</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A091256 001</u>	May 04, 2010
<u>AA</u>		<u>10MG</u>	<u>A091256 002</u>	May 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A091256 003</u>	May 04, 2010
<u>AA</u>		<u>50MG</u>	<u>A091256 004</u>	May 04, 2010
<u>AA</u>	IMPAX LABS	<u>5MG</u>	<u>A040739 001</u>	Nov 01, 2006
<u>AA</u>		<u>10MG</u>	<u>A040741 001</u>	Nov 01, 2006
<u>AA</u>		<u>25MG</u>	<u>A040740 001</u>	Nov 01, 2006
<u>AA</u>		<u>50MG</u>	<u>A040721 004</u>	Nov 01, 2006
<u>AA</u>	LANNETT	<u>10MG</u>	<u>A040704 001</u>	Mar 27, 2008
<u>AA</u>		<u>25MG</u>	<u>A040678 003</u>	Mar 27, 2008
<u>AA</u>	LANNETT HOLDINGS INC	<u>5MG</u>	<u>A040703 001</u>	Mar 27, 2008
<u>AA</u>		<u>50MG</u>	<u>A040677 001</u>	Mar 27, 2008
<u>AA</u>	PHARMAX	<u>5MG</u>	<u>A040725 001</u>	Oct 26, 2007
<u>AA</u>		<u>10MG</u>	<u>A040726 001</u>	Oct 26, 2007
<u>AA</u>		<u>25MG</u>	<u>A040727 001</u>	Oct 26, 2007
<u>AA</u>		<u>50MG</u>	<u>A040728 001</u>	Oct 26, 2007
<u>AA</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A040897 001</u>	Apr 22, 2009
<u>AA</u>		<u>10MG</u>	<u>A040897 002</u>	Apr 22, 2009
<u>AA</u>		<u>25MG</u>	<u>A040897 003</u>	Apr 22, 2009
<u>AA</u>		<u>50MG</u>	<u>A040897 004</u>	Apr 22, 2009
<u>AA</u>	UPSHER SMITH	<u>5MG</u>	<u>A040633 001</u>	Jun 01, 2005
<u>AA</u>		<u>10MG</u>	<u>A040634 001</u>	Jun 01, 2005
<u>AA</u>		<u>25MG</u>	<u>A040635 001</u>	Jun 01, 2005
<u>AA</u>		<u>50MG</u>	<u>A040636 001</u>	Jun 01, 2005
<u>AA</u>	WOCKHARDT	<u>5MG</u>	<u>A040532 001</u>	Sep 29, 2003
<u>AA</u>		<u>10MG</u>	<u>A040533 001</u>	Sep 29, 2003
<u>AA</u>		<u>25MG</u>	<u>A040534 001</u>	Sep 29, 2003
<u>AA</u>		<u>50MG</u>	<u>A040518 001</u>	Sep 29, 2003

DUVOID

<u>AA</u>	WELLSPRING PHARM	<u>10MG</u>	<u>A086262 001</u>	
<u>AA</u>		<u>25MG</u>	<u>A086263 001</u>	
<u>AA</u>		<u>50MG</u>	<u>A085882 003</u>	

URECHOLINE

<u>AA</u>	+ ODYSSEY PHARMS	<u>5MG</u>	<u>A089095 001</u>	Dec 19, 1985
<u>AA</u>	+	<u>10MG</u>	<u>A088440 001</u>	May 29, 1984
<u>AA</u>	+	<u>25MG</u>	<u>A088441 001</u>	May 29, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A089096 001</u>	Dec 19, 1985

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

<u>AB</u>	BIONPHARMA INC	<u>75MG</u>	<u>A203174 001</u>	Aug 12, 2014
-----------	----------------	-------------	--------------------	--------------

TARGETIN

<u>AB</u>	+ VALEANT LUXEMBOURG	<u>75MG</u>	<u>N021055 001</u>	Dec 29, 1999
-----------	----------------------	-------------	--------------------	--------------

GEL;TOPICAL

TARGETIN

+ VALEANT LUXEMBOURG

1%

N021056 001 Jun 28, 2000

## PRESCRIPTION DRUG PRODUCT LIST

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

<u>AB</u>	ACCORD HLTHCARE	<u>50MG</u>	<u>A078917 001</u>	Jul 06, 2009
<u>AB</u>	ACTAVIS TOTOWA	<u>50MG</u>	<u>A078634 001</u>	Aug 28, 2009
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A200274 001</u>	May 21, 2015
<u>AB</u>	FRESENIUS KABI ONCOL	<u>50MG</u>	<u>A079045 001</u>	May 13, 2010
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A079185 001</u>	Jul 06, 2009
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A078575 001</u>	Jul 06, 2009
<u>AB</u>	STASON PHARMS	<u>50MG</u>	<u>A091011 001</u>	Jun 10, 2015
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A079110 001</u>	Jul 06, 2009
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076932 001</u>	Jul 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A079089 001</u>	Jul 06, 2009

CASODEX

<u>AB</u>	+ ASTRAZENECA	<u>50MG</u>	<u>N020498 001</u>	Oct 04, 1995
-----------	---------------	-------------	--------------------	--------------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

<u>AT</u>	ALCON RES LTD	<u>0.03%</u>	<u>A202565 001</u>	May 05, 2015
<u>AT</u>	APOTEX INC	<u>0.03%</u>	<u>A090449 001</u>	Jul 20, 2015
<u>AT</u>	+ LUPIN LTD	<u>0.03%</u>	<u>A203991 001</u>	Feb 20, 2015
	LUMIGAN			
	+ ALLERGAN	0.01%	N022184 001	Aug 31, 2010

SOLUTION/DROPS; TOPICAL

BIMATOPROST

<u>AT</u>	APOTEX INC	<u>0.03%</u>	<u>A201894 001</u>	Dec 01, 2014
-----------	------------	--------------	--------------------	--------------

LATISSE

<u>AT</u>	+ ALLERGAN	<u>0.03%</u>	<u>N022369 001</u>	Dec 24, 2008
-----------	------------	--------------	--------------------	--------------

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

	+ NOVEL LABS INC	5MG; N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM ; N/A, 5.6GM	A202217 001	Aug 20, 2014
--	------------------	--	-------------	--------------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

	+ FOREST LABS LLC	140MG; 125MG; 125MG	N050786 001	Sep 28, 2006
--	-------------------	---------------------	-------------	--------------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077910 001</u>	Dec 27, 2006
<u>AB</u>		<u>10MG</u>	<u>A077910 002</u>	Dec 27, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075831 001</u>	Dec 14, 2005
<u>AB</u>		<u>10MG</u>	<u>A075831 002</u>	Dec 14, 2005
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A075643 001</u>	Nov 16, 2000
<u>AB</u>		<u>10MG</u>	<u>A075643 002</u>	Nov 16, 2000
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A075644 001</u>	Jun 26, 2001
<u>AB</u>		<u>10MG</u>	<u>A075644 002</u>	Jun 26, 2001
<u>AB</u>	UNICHEM PHARMS (USA)	<u>5MG</u>	<u>A078635 001</u>	Aug 18, 2009
<u>AB</u>		<u>10MG</u>	<u>A078635 002</u>	Aug 18, 2009

ZEBETA

<u>AB</u>	TEVA WOMENS	<u>5MG</u>	<u>N019982 002</u>	Jul 31, 1992
<u>AB</u>	+	<u>10MG</u>	<u>N019982 001</u>	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>2.5MG; 6.25MG</u>	<u>A075768 001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075768 002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075768 003</u>	Sep 25, 2000
<u>AB</u>	SANDOZ	<u>2.5MG; 6.25MG</u>	<u>A075579 001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075579 002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075579 003</u>	Sep 25, 2000
<u>AB</u>	UNICHEM	<u>2.5MG; 6.25MG</u>	<u>A079106 001</u>	Jul 28, 2010
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A079106 002</u>	Jul 28, 2010
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A079106 003</u>	Jul 28, 2010

ZIAC

<u>AB</u>	TEVA WOMENS	<u>2.5MG; 6.25MG</u>	<u>N020186 003</u>	Mar 26, 1993
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>N020186 001</u>	Mar 26, 1993
<u>AB</u>	+	<u>10MG; 6.25MG</u>	<u>N020186 002</u>	Mar 26, 1993

## PRESCRIPTION DRUG PRODUCT LIST

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

<b>AP</b>	+	THE MEDICINES CO	<b>250MG/VIAL</b>	<b>N020873 001</b>	Dec 15, 2000
-----------	---	------------------	-------------------	--------------------	--------------

BIVALIRUDIN

<b>AP</b>		HOSPIRA INC	<b>250MG/VIAL</b>	<b>A090811 001</b>	Jul 14, 2015
-----------	--	-------------	-------------------	--------------------	--------------

<b>AP</b>			<b>250MG/VIAL</b>	<b>A090816 001</b>	Jul 14, 2015
-----------	--	--	-------------------	--------------------	--------------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<b>AP</b>		EUROHLTH INTL SARL	<b>EQ 15 UNITS BASE/VIAL</b>	<b>A065042 002</b>	Oct 17, 2001
-----------	--	--------------------	------------------------------	--------------------	--------------

<b>AP</b>			<b>EQ 30 UNITS BASE/VIAL</b>	<b>A065042 001</b>	Oct 17, 2001
-----------	--	--	------------------------------	--------------------	--------------

<b>AP</b>	+	FRESENIUS KABI USA	<b>EQ 15 UNITS BASE/VIAL</b>	<b>A065185 001</b>	Jan 28, 2008
-----------	---	--------------------	------------------------------	--------------------	--------------

<b>AP</b>	+		<b>EQ 30 UNITS BASE/VIAL</b>	<b>A065185 002</b>	Jan 28, 2008
-----------	---	--	------------------------------	--------------------	--------------

<b>AP</b>		HOSPIRA	<b>EQ 15 UNITS BASE/VIAL</b>	<b>A065031 001</b>	Mar 10, 2000
-----------	--	---------	------------------------------	--------------------	--------------

<b>AP</b>			<b>EQ 30 UNITS BASE/VIAL</b>	<b>A065031 002</b>	Mar 10, 2000
-----------	--	--	------------------------------	--------------------	--------------

<b>AP</b>		TEVA PHARMS USA	<b>EQ 15 UNITS BASE/VIAL</b>	<b>A065033 001</b>	Jun 27, 2000
-----------	--	-----------------	------------------------------	--------------------	--------------

<b>AP</b>			<b>EQ 30 UNITS BASE/VIAL</b>	<b>A065033 002</b>	Jun 27, 2000
-----------	--	--	------------------------------	--------------------	--------------

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

	+	MERCK SHARP DOHME	200MG	N202258 001	May 13, 2011
--	---	-------------------	-------	-------------	--------------

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

	+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602 001	May 13, 2003
--	---	-------------------	------------	-------------	--------------

BOSENTAN

TABLET; ORAL

TRACLEER

		ACTELION PHARMS LTD	62.5MG	N021290 001	Nov 20, 2001
--	--	---------------------	--------	-------------	--------------

	+		125MG	N021290 002	Nov 20, 2001
--	---	--	-------	-------------	--------------

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

	+	WYETH PHARMS INC	EQ 100MG BASE	N203341 001	Sep 04, 2012
--	---	------------------	---------------	-------------	--------------

			EQ 500MG BASE	N203341 002	Sep 04, 2012
--	--	--	---------------	-------------	--------------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	B BRAUN	100MG/100ML	N019121 001	Apr 29, 1986
--	---	---------	-------------	-------------	--------------

	+		200MG/100ML	N019121 002	Apr 29, 1986
--	---	--	-------------	-------------	--------------

	+		400MG/100ML	N019121 003	Apr 29, 1986
--	---	--	-------------	-------------	--------------

BREXPIRAZOLE

TABLET; ORAL

REXULTI

		OTSUKA PHARM CO LTD	0.25MG	N205422 001	Jul 10, 2015
--	--	---------------------	--------	-------------	--------------

			0.5MG	N205422 002	Jul 10, 2015
--	--	--	-------	-------------	--------------

			1MG	N205422 003	Jul 10, 2015
--	--	--	-----	-------------	--------------

			2MG	N205422 004	Jul 10, 2015
--	--	--	-----	-------------	--------------

			3MG	N205422 005	Jul 10, 2015
--	--	--	-----	-------------	--------------

	+		4MG	N205422 006	Jul 10, 2015
--	---	--	-----	-------------	--------------

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

	+	GALDERMA LABS LP	EQ 0.33% BASE	N204708 001	Aug 23, 2013
--	---	------------------	---------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

<b>AT</b>	+	ALLERGAN	<b>0.15%</b>	<b>N021262 001</b>	Mar 16, 2001
-----------	---	----------	--------------	--------------------	--------------

BRIMONIDINE TARTRATE

<b>AT</b>		AKORN	<b>0.2%</b>	<b>A076439 001</b>	Mar 14, 2006
-----------	--	-------	-------------	--------------------	--------------

<b>AT</b>		ALCON PHARMS LTD	<b>0.2%</b>	<b>A076254 001</b>	Sep 16, 2003
-----------	--	------------------	-------------	--------------------	--------------

<b>AT</b>	+	BAUSCH AND LOMB	<b>0.2%</b>	<b>A076260 001</b>	May 28, 2003
-----------	---	-----------------	-------------	--------------------	--------------

<b>AT</b>		INDOCO REMEDIES	<b>0.2%</b>	<b>A091691 001</b>	Nov 18, 2014
-----------	--	-----------------	-------------	--------------------	--------------

<b>AT</b>		SANDOZ	<b>0.2%</b>	<b>A078075 001</b>	Jan 30, 2008
-----------	--	--------	-------------	--------------------	--------------

OOLIANA

<b>AT</b>		ALCON PHARMS LTD	<b>0.15%</b>	<b>N021764 001</b>	May 22, 2006
-----------	--	------------------	--------------	--------------------	--------------

ALPHAGAN P

	+	ALLERGAN	0.1%	N021770 001	Aug 19, 2005
--	---	----------	------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

SIMBRINZA

+ ALCON RES LTD 0.2%;1%

N204251 001 Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COMBIGAN

+ ALLERGAN 0.2%;EQ 0.5% BASE

N021398 001 Oct 30, 2007

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

AZOPT

+ ALCON PHARMS LTD 1%

N020816 001 Apr 01, 1998

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUMAT1 APOTEX INC EQ 0.09% ACIDA202435 001 Jun 19, 2014AT1 + COASTAL PHARMS EQ 0.09% ACIDA201211 001 May 11, 2011AT1 LUITPOLD EQ 0.09% ACIDA202030 001 Jan 09, 2013AT1 PADDOCK LLC EQ 0.09% ACIDA201941 001 Feb 10, 2015AT2 APOTEX INC EQ 0.09% ACIDA202620 001 Jun 23, 2014AT2 HI-TECH PHARMACAL EQ 0.09% ACIDA203395 001 Jan 22, 2014

PROLENSA

+ BAUSCH AND LOMB EQ 0.07% ACID

N203168 001 Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATEAB MYLAN EQ 5MG BASEA077226 001 Apr 04, 2005AB ZYDUS PHARMS USA INC EQ 5MG BASEA078899 001 Jul 30, 2008PARLODELAB + US PHARMS HOLDINGS I EQ 5MG BASEN017962 002 Mar 01, 1982

TABLET;ORAL

BROMOCRIPTINE MESYLATEAB LEK PHARMS EQ 2.5MG BASEA074631 001 Jan 13, 1998AB MYLAN EQ 2.5MG BASEA076962 001 Sep 24, 2004AB PADDOCK LLC EQ 2.5MG BASEA077646 001 Oct 01, 2008PARLODELAB + US PHARMS HOLDINGS I EQ 2.5MG BASEN017962 001

CYCLOSET

+ VEROSCIENCE EQ 0.8MG BASE

N020866 001 May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DMAA + WOCKHARDT 2MG/5ML;10MG/5ML;30MG/5MLA088811 001 Jun 07, 1985BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDEAA PADDOCK LLC 2MG/5ML;10MG/5ML;30MG/5MLA205292 001 Jul 15, 2014AA VINTAGE PHARMS 2MG/5ML;10MG/5ML;30MG/5MLA202940 001 Jul 21, 2014BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

+ VALEANT PHARMS INTL 2MG/ACTUATION

N205613 001 Oct 07, 2014

CAPSULE;ORAL

BUDESONIDEAB BARR LABS DIV TEVA 3MGA090379 001 Apr 02, 2014AB MYLAN 3MGA090410 001 May 16, 2011ENTOCORT ECAB + ASTRAZENECA 3MGN021324 001 Oct 02, 2001

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

ASTRAZENECA 0.08MG/INH

N021949 001 Jul 12, 2006

+ 0.16MG/INH

N021949 002 Jul 12, 2006

SPRAY, METERED;NASAL

BUDESONIDE

APOTEX INC 0.032MG/INH

A078949 001 May 12, 2014

SUSPENSION;INHALATION

BUDESONIDEAN SANDOZ INC 0.25MG/2MLA201966 003 Sep 27, 2013AN 0.5MG/2MLA201966 002 Sep 27, 2013AN 1MG/2MLA201966 001 Sep 27, 2013AN TEVA PHARMS 0.25MG/2MLA077519 001 Nov 18, 2008

## PRESCRIPTION DRUG PRODUCT LIST

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

<u>AN</u>		<u>0.5MG/2ML</u>	<u>A077519 002</u>	Nov 18, 2008
<u>AN</u>	WATSON LABS INC	<u>0.25MG/2ML</u>	<u>A078404 001</u>	Jul 31, 2012
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A078404 002</u>	Jul 31, 2012

PULMICORT RESPULES

<u>AN</u>	ASTRAZENECA PHARMS	<u>0.25MG/2ML</u>	<u>N020929 001</u>	Aug 08, 2000
<u>AN</u>		<u>0.5MG/2ML</u>	<u>N020929 002</u>	Aug 08, 2000
<u>AN</u>	+	<u>1MG/2ML</u>	<u>N020929 003</u>	Aug 08, 2000

TABLET, EXTENDED RELEASE; ORAL

UCERIS

+	VALEANT PHARMS INTL	9MG	N203634 001	Jan 14, 2013
---	---------------------	-----	-------------	--------------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+	ASTRAZENECA	0.08MG/INH; 0.0045MG/INH	N021929 001	Jul 21, 2006
+		0.16MG/INH; 0.0045MG/INH	N021929 002	Jul 21, 2006

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>	+	BEDFORD	<u>0.25MG/ML</u>	<u>A074441 001</u>	Jan 27, 1995
<u>AP</u>		EUROHLTH INTL SARL	<u>0.25MG/ML</u>	<u>A079196 001</u>	Apr 30, 2008
<u>AP</u>		HOSPIRA	<u>0.25MG/ML</u>	<u>A074332 001</u>	Oct 31, 1994

TABLET; ORAL

BUMETANIDE

<u>AB</u>		IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A074225 001</u>	Apr 24, 1995
<u>AB</u>			<u>1MG</u>	<u>A074225 002</u>	Apr 24, 1995
<u>AB</u>			<u>2MG</u>	<u>A074225 003</u>	Apr 24, 1995
<u>AB</u>		SANDOZ	<u>0.5MG</u>	<u>A074700 001</u>	Nov 21, 1996
<u>AB</u>			<u>1MG</u>	<u>A074700 002</u>	Nov 21, 1996
<u>AB</u>	+		<u>2MG</u>	<u>A074700 003</u>	Nov 21, 1996

BUMEX

<u>AB</u>		VALIDUS PHARMS INC	<u>0.5MG</u>	<u>N018225 002</u>	Feb 28, 1983
<u>AB</u>			<u>1MG</u>	<u>N018225 001</u>	Feb 28, 1983
<u>AB</u>			<u>2MG</u>	<u>N018225 003</u>	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+	PACIRA PHARMS INC	266MG/20ML (13.3MG/ML)	N022496 002	Oct 28, 2011
---	-------------------	------------------------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA	<u>0.25%</u>	<u>A070583 001</u>	Feb 17, 1987
<u>AP</u>			<u>0.25%</u>	<u>A070586 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.25%</u>	<u>A070590 001</u>	Feb 17, 1987
<u>AP</u>			<u>0.25%</u>	<u>N018053 002</u>	
<u>AP</u>			<u>0.5%</u>	<u>A070584 001</u>	Feb 17, 1986
<u>AP</u>			<u>0.5%</u>	<u>A070597 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.5%</u>	<u>A070609 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.5%</u>	<u>N018053 001</u>	
<u>AP</u>			<u>0.75%</u>	<u>A070585 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.75%</u>	<u>N018053 003</u>	
<u>AP</u>		SAGENT AGILA	<u>0.25%</u>	<u>A091503 001</u>	Oct 18, 2011
<u>AP</u>			<u>0.5%</u>	<u>A091503 002</u>	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A203895 001</u>	Nov 05, 2013
<u>AP</u>			<u>0.5%</u>	<u>A203895 002</u>	Nov 05, 2013
<u>AP</u>			<u>0.75%</u>	<u>A203895 003</u>	Nov 05, 2013
<u>AP</u>		SAGENT AGILA	<u>0.25%</u>	<u>A091487 002</u>	Oct 18, 2011
<u>AP</u>			<u>0.5%</u>	<u>A091487 001</u>	Oct 18, 2011
<u>AP</u>			<u>0.75%</u>	<u>A091487 003</u>	Oct 18, 2011

MARCAINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964 001</u>	
<u>AP</u>	+		<u>0.5%</u>	<u>N016964 006</u>	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964 012</u>	
<u>AP</u>	+		<u>0.5%</u>	<u>N016964 005</u>	
<u>AP</u>	+		<u>0.75%</u>	<u>N016964 009</u>	



**PRESCRIPTION DRUG PRODUCT LIST**

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.25%</u>	<u>A070552 001</u>	May 21, 1986
<u>AP</u>		<u>0.25%</u>	<u>N018304 001</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070553 001</u>	May 21, 1986
<u>AP</u>		<u>0.5%</u>	<u>N018304 002</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070554 001</u>	May 21, 1986
<u>AP</u>		<u>0.75%</u>	<u>N018304 003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.75%</u>	<u>A071810 001</u>	Dec 11, 1987
	<u>MARCAINE</u>			
<u>AP</u>	+ HOSPIRA	<u>0.75%</u>	<u>N018692 001</u>	May 04, 1984
	<u>SENSORCAINE</u>			
<u>AP</u>	FRESENIUS KABI USA	<u>0.75%</u>	<u>A071202 001</u>	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	+ HOSPIRA	<u>0.5%;0.005MG/ML</u>	<u>A071168 001</u>	Jun 16, 1988
<u>AP</u>		<u>0.5%;0.005MG/ML</u>	<u>A071170 001</u>	Jun 16, 1988
		0.25%;0.005MG/ML	A071165 001	Jun 16, 1988
		0.25%;0.005MG/ML	A071167 001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	SEPTODONT	<u>0.5%;0.0091MG/ML</u>	<u>A077250 001</u>	Sep 27, 2006
	<u>BUPIVACAINE HYDROCHLORIDE W/ EPINEPHRINE</u>			
<u>AP</u>	+ HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N022046 001</u>	Jul 13, 1983
	<u>MARCAINE HYDROCHLORIDE W/ EPINEPHRINE</u>			
<u>AP</u>	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964 004</u>	
<u>AP</u>	+ HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N016964 008</u>	
	<u>MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE</u>			
<u>AP</u>	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964 013</u>	
<u>AP</u>	+ HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N016964 007</u>	
<u>AP</u>	+ HOSPIRA	<u>0.75%;0.0091MG/ML</u>	<u>N016964 010</u>	
	<u>SENSORCAINE</u>			
<u>AP</u>	FRESENIUS KABI USA	<u>0.25%;0.0091MG/ML</u>	<u>A070966 001</u>	Oct 13, 1987
<u>AP</u>		<u>0.25%;0.0091MG/ML</u>	<u>A070967 001</u>	Oct 13, 1987
<u>AP</u>		<u>0.5%;0.0091MG/ML</u>	<u>A070968 001</u>	Oct 13, 1987
<u>AP</u>		<u>0.5%;0.0091MG/ML</u>	<u>N018304 004</u>	Sep 02, 1983
<u>AP</u>		<u>0.75%;0.0091MG/ML</u>	<u>N018304 005</u>	Sep 02, 1983

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

	PURDUE PHARMA LP	5MCG/HR	N021306 001	Jun 30, 2010
		7.5MCG/HR	N021306 005	Jun 30, 2014
		10MCG/HR	N021306 002	Jun 30, 2010
		15MCG/HR	N021306 004	Jul 25, 2013
		20MCG/HR	N021306 003	Jun 30, 2010

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

	ENDO PHARMS INC	EQ 0.075MG BASE	N207932 001	Oct 23, 2015
		EQ 0.15MG BASE	N207932 002	Oct 23, 2015
		EQ 0.3MG BASE	N207932 003	Oct 23, 2015
		EQ 0.45MG BASE	N207932 004	Oct 23, 2015
		EQ 0.6MG BASE	N207932 005	Oct 23, 2015
		EQ 0.75MG BASE	N207932 006	Oct 23, 2015
		EQ 0.9MG BASE	N207932 007	Oct 23, 2015

INJECTABLE; INJECTION

BUPRENEX

<u>AP</u>	+ INDIVIOR INC	<u>EQ 0.3MG BASE/ML</u>	<u>N018401 001</u>	
	<u>BUPRENORPHINE HYDROCHLORIDE</u>			
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 0.3MG BASE/ML</u>	<u>A076931 001</u>	Mar 02, 2005
<u>AP</u>	HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	<u>A074137 001</u>	Jun 03, 1996
<u>AP</u>	LUITPOLD	<u>EQ 0.3MG BASE/ML</u>	<u>A078331 001</u>	Mar 27, 2007
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 0.3MG BASE/ML</u>	<u>A206586 001</u>	Jul 28, 2015

## PRESCRIPTION DRUG PRODUCT LIST

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090819 001</u>	Feb 19, 2015
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090819 002</u>	Feb 19, 2015
<u>AB</u>	BARR	<u>EQ 2MG BASE</u>	<u>A090360 001</u>	May 07, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090360 002</u>	May 07, 2010
<u>AB</u>	ETHYPHARM	<u>EQ 2MG BASE</u>	<u>A090622 001</u>	Sep 24, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090622 002</u>	Sep 24, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A201066 001</u>	Mar 06, 2015
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201066 002</u>	Mar 06, 2015
<u>AB</u>	ROXANE	<u>EQ 2MG BASE</u>	<u>A078633 001</u>	Oct 08, 2009
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>A078633 002</u>	Oct 08, 2009
<u>AB</u>	SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A090279 001</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090279 002</u>	Jun 10, 2015

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL

BUNAVAIL

	BIODELIVERY SCI INTL	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637 001	Jun 06, 2014
		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637 002	Jun 06, 2014
	+	EQ 6.3MG BASE;EQ 1MG BASE	N205637 003	Jun 06, 2014

FILM;BUCCAL, SUBLINGUAL

SUBOXONE

	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010
		EQ 4MG BASE;EQ 1MG BASE	N022410 003	Aug 10, 2012
		EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010
	+	EQ 12MG BASE;EQ 3MG BASE	N022410 004	Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A091422 001</u>	Feb 22, 2013
<u>AB</u>	+	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A091422 002</u>	Feb 22, 2013
<u>AB</u>	AMNEAL PHARMS	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203136 002</u>	Feb 22, 2013
<u>AB</u>	ETHYPHARM USA CORP	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A204431 001</u>	Oct 16, 2015
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A204431 002</u>	Oct 16, 2015
<u>AB</u>	ROXANE	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203326 001</u>	Jun 27, 2014
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203326 002</u>	Jun 27, 2014
<u>AB</u>	TEVA PHARMS USA	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A091149 001</u>	Sep 08, 2014
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A091149 002</u>	Sep 08, 2014

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203136 001</u>	Feb 22, 2013
	ZUBSOLV			
	OREXO AB	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242 001	Jul 03, 2013
		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242 005	Jun 04, 2015
	+	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242 002	Jul 03, 2013
		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242 003	Dec 11, 2014
		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242 004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

	VALEANT PHARMS NORTH	174MG	N022108 001	Apr 23, 2008
		348MG	N022108 002	Apr 23, 2008
	+	522MG	N022108 003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A076143 001</u>	Jan 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A076143 002</u>	Jan 17, 2006
<u>AB</u>	MYLAN	<u>75MG</u>	<u>A075491 001</u>	Apr 17, 2000
<u>AB</u>		<u>100MG</u>	<u>A075491 002</u>	Apr 17, 2000
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A075584 001</u>	Feb 07, 2000
<u>AB</u>		<u>100MG</u>	<u>A075584 002</u>	Feb 07, 2000
	<u>WELLBUTRIN</u>			
<u>AB</u>	GLAXOSMITHKLINE	<u>75MG</u>	<u>N018644 002</u>	Dec 30, 1985
<u>AB</u>	+	<u>100MG</u>	<u>N018644 003</u>	Dec 30, 1985

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>100MG</u>	<u>A079095 001</u>	Mar 24, 2009
<u>AB1</u>		<u>150MG</u>	<u>A079095 002</u>	Mar 24, 2009
<u>AB1</u>		<u>200MG</u>	<u>A079095 003</u>	Mar 24, 2009
<u>AB1</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091459 001</u>	Jun 09, 2011
<u>AB1</u>		<u>150MG</u>	<u>A091459 002</u>	Jun 09, 2011

## PRESCRIPTION DRUG PRODUCT LIST

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>		<u>200MG</u>	<u>A091459 003</u>	Jun 09, 2011
<u>AB1</u>	IMPAX LABS	<u>100MG</u>	<u>A075913 001</u>	Jan 28, 2004
<u>AB1</u>		<u>150MG</u>	<u>A075913 002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A076711 001</u>	Dec 03, 2004
<u>AB1</u>	JUBILANT GENERICS	<u>100MG</u>	<u>A202774 001</u>	Oct 11, 2013
<u>AB1</u>		<u>150MG</u>	<u>A202774 002</u>	Oct 11, 2013
<u>AB1</u>		<u>200MG</u>	<u>A202774 003</u>	Oct 11, 2013
<u>AB1</u>	MYLAN	<u>100MG</u>	<u>A090325 001</u>	Apr 08, 2010
<u>AB1</u>		<u>150MG</u>	<u>A090325 002</u>	Apr 08, 2010
<u>AB1</u>		<u>200MG</u>	<u>A090325 003</u>	Apr 08, 2010
<u>AB1</u>	PRINSTON INC	<u>100MG</u>	<u>A202304 001</u>	May 26, 2015
<u>AB1</u>		<u>150MG</u>	<u>A202304 002</u>	May 26, 2015
<u>AB1</u>		<u>200MG</u>	<u>A202304 003</u>	May 26, 2015
<u>AB1</u>	SANDOZ	<u>100MG</u>	<u>A075932 001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932 002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932 003</u>	Jun 22, 2005
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A078866 001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866 002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866 003</u>	Apr 06, 2010
<u>AB1</u>	TORRENT PHARMS LTD	<u>100MG</u>	<u>A203969 001</u>	Oct 31, 2014
<u>AB1</u>		<u>150MG</u>	<u>A203969 002</u>	Oct 31, 2014
<u>AB1</u>		<u>200MG</u>	<u>A203969 003</u>	Oct 31, 2014
<u>AB1</u>	WATSON LABS INC	<u>100MG</u>	<u>A077455 001</u>	Jul 19, 2010
<u>AB1</u>		<u>150MG</u>	<u>A077455 002</u>	Mar 12, 2008
<u>AB1</u>		<u>200MG</u>	<u>A077455 003</u>	Jul 19, 2010

WELLBUTRIN SR

<u>AB1</u>	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358 002</u>	Oct 04, 1996
<u>AB1</u>		<u>150MG</u>	<u>N020358 003</u>	Oct 04, 1996
<u>AB1</u>	+	<u>200MG</u>	<u>N020358 004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A079094 001</u>	Mar 24, 2009
<u>AB2</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A091520 001</u>	Jun 09, 2011
<u>AB2</u>	IMPAX LABS	<u>150MG</u>	<u>A075914 001</u>	May 27, 2004
<u>AB2</u>	JUBILANT GENERICS	<u>150MG</u>	<u>A202775 001</u>	Oct 11, 2013
<u>AB2</u>	MYLAN	<u>150MG</u>	<u>A090941 001</u>	May 03, 2010
<u>AB2</u>	SANDOZ INC	<u>150MG</u>	<u>A077475 001</u>	Mar 12, 2008

ZYBAN

<u>AB2</u>	+	<u>GLAXOSMITHKLINE</u>	<u>150MG</u>	<u>N020711 003</u>	May 14, 1997
------------	---	------------------------	--------------	--------------------	--------------

BUPROPION HYDROCHLORIDE

<u>AB3</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A077715 001</u>	Nov 26, 2008
<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284 001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284 002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415 001</u>	Nov 26, 2008
<u>AB3</u>	MYLAN	<u>150MG</u>	<u>A090942 001</u>	Jul 14, 2010
<u>AB3</u>		<u>300MG</u>	<u>A090942 002</u>	Jul 14, 2010
<u>AB3</u>	SUN PHARMA GLOBAL	<u>150MG</u>	<u>A200695 001</u>	Dec 18, 2014
<u>AB3</u>	WATSON LABS INC	<u>150MG</u>	<u>A077285 001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285 002</u>	Aug 15, 2008
<u>AB3</u>	WOCKHARDT LTD	<u>150MG</u>	<u>A202189 001</u>	Nov 21, 2012
<u>AB3</u>	ZYDUS PHARMS USA INC	<u>300MG</u>	<u>A201567 001</u>	Jan 17, 2014

WELLBUTRIN XL

<u>AB3</u>	VALEANT INTL	<u>150MG</u>	<u>N021515 001</u>	Aug 28, 2003	
<u>AB3</u>	+	<u>300MG</u>	<u>N021515 002</u>	Aug 28, 2003	
	FORFIVO XL				
	+	EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

	+	TAKEDA PHARMS USA	90MG;8MG	N200063 001	Sep 10, 2014
--	---	-------------------	----------	-------------	--------------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A202557 001</u>	Dec 30, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202557 002</u>	Dec 30, 2014
<u>AB</u>		<u>10MG</u>	<u>A202557 003</u>	Dec 30, 2014
<u>AB</u>		<u>15MG</u>	<u>A202557 004</u>	Dec 30, 2014
<u>AB</u>		<u>30MG</u>	<u>A202557 005</u>	Dec 30, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078246 001</u>	Feb 27, 2009

## PRESCRIPTION DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A078246 002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246 003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246 004</u>	Feb 27, 2009
<u>AB</u>	EMCURE PHARMS USA	<u>5MG</u>	<u>A204582 001</u>	Sep 18, 2015
<u>AB</u>		<u>10MG</u>	<u>A204582 002</u>	Sep 18, 2015
<u>AB</u>		<u>15MG</u>	<u>A204582 003</u>	Sep 18, 2015
<u>AB</u>		<u>30MG</u>	<u>A204582 004</u>	Sep 18, 2015
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075272 001</u>	Mar 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075467 001</u>	Feb 28, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467 002</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A075272 002</u>	Mar 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075467 003</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075272 003</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A075467 004</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A076008 001</u>	Jun 28, 2001
<u>AB</u>	ORION CORP ORION	<u>5MG</u>	<u>A202087 001</u>	Dec 16, 2015
<u>AB</u>		<u>10MG</u>	<u>A202087 002</u>	Dec 16, 2015
<u>AB</u>		<u>15MG</u>	<u>A202087 003</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A202087 004</u>	Dec 16, 2015
<u>AB</u>	PROSAM LABS	<u>30MG</u>	<u>A078302 001</u>	Dec 17, 2007
<u>AB</u>	STRIDES ARCOLAB LTD	<u>5MG</u>	<u>A202330 001</u>	Aug 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A202330 002</u>	Aug 25, 2014
<u>AB</u>		<u>15MG</u>	<u>A202330 003</u>	Aug 25, 2014
<u>AB</u>		<u>30MG</u>	<u>A202330 004</u>	Aug 25, 2014
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022 001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022 002</u>	Feb 28, 2002
<u>AB</u>	+	<u>15MG</u>	<u>A075022 003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022 004</u>	Mar 25, 2004
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074253 001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253 002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253 003</u>	Mar 13, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078888 001</u>	Feb 07, 2014
<u>AB</u>		<u>10MG</u>	<u>A078888 002</u>	Feb 07, 2014
<u>AB</u>		<u>15MG</u>	<u>A078888 003</u>	Feb 07, 2014
<u>AB</u>		<u>30MG</u>	<u>A078888 004</u>	Feb 07, 2014

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

<u>AP</u>	PHARMAFORCE	<u>6MG/ML</u>	<u>A202259 001</u>	Dec 22, 2015
-----------	-------------	---------------	--------------------	--------------

BUSULEFEX

<u>AP</u>	+	OTSUKA PHARM	<u>6MG/ML</u>	<u>N020954 001</u>	Feb 04, 1999
-----------	---	--------------	---------------	--------------------	--------------

TABLET; ORAL

## MYLERAN

+ ASPEN GLOBAL

2MG

N009386 001

BUTABARBITAL SODIUM

TABLET; ORAL

## BUTISOL SODIUM

+ MEDA PHARMS

30MG

N000793 004

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

## MENTAX

+ MYLAN

1%

N020524 001 Oct 18, 1996

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

## GYNAZOLE-1

+ PERRIGO ISRAEL

2%

A200923 001 May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A075046 001</u>	Aug 12, 1998
-----------	---------	---------------	--------------------	--------------

<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400 001</u>	May 01, 2009
-----------	--------------------	---------------	--------------------	--------------

<u>AP</u>		<u>2MG/ML</u>	<u>A078400 002</u>	May 01, 2009
-----------	--	---------------	--------------------	--------------

BUTORPHANOL TARTRATE PRESERVATIVE FREE

<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075045 001</u>	Aug 12, 1998
-----------	---------	---------------	--------------------	--------------

<u>AP</u>		<u>2MG/ML</u>	<u>A075045 002</u>	Aug 12, 1998
-----------	--	---------------	--------------------	--------------

<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074626 001</u>	Jan 23, 1997
-----------	---------	---------------	--------------------	--------------

<u>AP</u>		<u>2MG/ML</u>	<u>A074626 002</u>	Jan 23, 1997
-----------	--	---------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

BUTORPHANOL TARTRATE

SPRAY, METERED;NASAL

BUTORPHANOL TARTRATE

<b>AB</b>	+	MYLAN	<u>1MG/SPRAY</u>	<u>A075759</u>	<u>001</u>	Aug 08, 2001
<b>AB</b>		NOVEX	<u>1MG/SPRAY</u>	<u>A075499</u>	<u>001</u>	Dec 04, 2002
<b>AB</b>		ROXANE	<u>1MG/SPRAY</u>	<u>A075824</u>	<u>001</u>	Mar 12, 2002

CABAZITAXEL

SOLUTION;IV (INFUSION)

JEVTANA KIT

	+	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010
--	---	-------------------	----------------------	---------	-----	--------------

CABERGOLINE

TABLET;ORAL

CABERGOLINE

<b>AB</b>		ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A078035</u>	<u>001</u>	Apr 21, 2008
<b>AB</b>		APOTEX CORP	<u>0.5MG</u>	<u>A201503</u>	<u>001</u>	Mar 08, 2013
<b>AB</b>		IMPAX LABS INC	<u>0.5MG</u>	<u>A077843</u>	<u>001</u>	Jul 03, 2007
<b>AB</b>		IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A077750</u>	<u>001</u>	Mar 07, 2007
<b>AB</b>		MYLAN PHARMS INC	<u>0.5MG</u>	<u>A202947</u>	<u>001</u>	Dec 02, 2013
<b>AB</b>	+	PAR PHARM	<u>0.5MG</u>	<u>A076310</u>	<u>001</u>	Dec 29, 2005

CABOZANTINIB S-MALATE

CAPSULE;ORAL

COMETRIQ

		EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012
	+		EQ 80MG BASE	N203756	002	Nov 29, 2012

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAF CIT

<b>AP</b>	+	EUROHLTH INTL SARL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>001</u>	Sep 21, 1999
-----------	---	--------------------	---	----------------	------------	--------------

CAFFEINE CITRATE

<b>AP</b>		AUROBINDO PHARMA LTD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A205013</u>	<u>001</u>	Sep 22, 2015
<b>AP</b>		EXELA PHARMA SCIENCE	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077233</u>	<u>001</u>	Sep 21, 2006
<b>AP</b>		FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077997</u>	<u>001</u>	Jul 20, 2007
<b>AP</b>		LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077906</u>	<u>001</u>	May 15, 2007
<b>AP</b>		SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090827</u>	<u>001</u>	Aug 29, 2012
<b>AP</b>		SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090077</u>	<u>001</u>	Sep 30, 2009

SOLUTION;ORAL

CAF CIT

<b>AA</b>	+	EUROHLTH INTL SARL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>002</u>	Apr 12, 2000
-----------	---	--------------------	---	----------------	------------	--------------

CAFFEINE CITRATE

<b>AA</b>		EXELA PHARMA SCS LLC	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077304</u>	<u>001</u>	Sep 21, 2006
<b>AA</b>		FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A078002</u>	<u>001</u>	Jan 31, 2008
<b>AA</b>		LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090064</u>	<u>001</u>	Nov 20, 2009
<b>AA</b>		SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A091102</u>	<u>001</u>	Aug 29, 2012
<b>AA</b>		SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090357</u>	<u>001</u>	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

	+	CREALTA PHARMS LLC	100MG;2MG	A086557	001	Oct 04, 1983
--	---	--------------------	-----------	---------	-----	--------------

TABLET;ORAL

CAFERGOT

<b>AA</b>	+	SANDOZ	<u>100MG;1MG</u>	<u>A084294</u>	<u>001</u>	
-----------	---	--------	------------------	----------------	------------	--

ERGOTAMINE TARTRATE AND CAFFEINE

<b>AA</b>		HIKMA INTL PHARMS	<u>100MG;1MG</u>	<u>A040510</u>	<u>001</u>	Sep 17, 2004
<b>AA</b>		MIKART	<u>100MG;1MG</u>	<u>A040590</u>	<u>001</u>	Sep 16, 2005

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

	+	STIEFEL LABS INC	0.005%	N022563	001	Oct 06, 2010
--	---	------------------	--------	---------	-----	--------------

CREAM;TOPICAL

CALCIPOTRIENE

<b>AB</b>		GLENMARK PHARMS LTD	<u>0.005%</u>	<u>A205772</u>	<u>001</u>	Jun 09, 2015
<b>AB</b>		TOLMAR	<u>0.005%</u>	<u>A200935</u>	<u>001</u>	May 30, 2012

DOVONEX

<b>AB</b>	+	LEO PHARMA AS	<u>0.005%</u>	<u>N020554</u>	<u>001</u>	Jul 22, 1996
-----------	---	---------------	---------------	----------------	------------	--------------

OINTMENT;TOPICAL

CALCIPOTRIENE

	+	GLENMARK GENERICS	0.005%	A090633	001	Mar 24, 2010
--	---	-------------------	--------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

<u>AT</u>	FOUGERA PHARMS	<u>0.005%</u>	<u>A078305</u>	<u>001</u>	May 06, 2008
<u>AT</u>	G AND W LABS INC	<u>0.005%</u>	<u>A078468</u>	<u>001</u>	Mar 24, 2011
<u>AT</u>	HI TECH PHARMA	<u>0.005%</u>	<u>A077579</u>	<u>001</u>	Nov 19, 2009
<u>AT</u>	+ TOLMAR	<u>0.005%</u>	<u>A077029</u>	<u>001</u>	Nov 20, 2009

CALCITONIN SALMON

INJECTABLE; INJECTION

MIACALCIN

+ MYLAN IRELAND LTD 200 IU/ML N017808 002 Mar 29, 1991

SPRAY, METERED; NASAL

CALCITONIN-SALMON

<u>AB</u>	APOTEX INC	<u>200 IU/SPRAY</u>	<u>A076396</u>	<u>001</u>	Nov 17, 2008
<u>AB</u>	PAR PHARM	<u>200 IU/SPRAY</u>	<u>A076979</u>	<u>001</u>	Jun 08, 2009
<u>AB</u>	+ MYLAN IRELAND LTD	<u>200 IU/SPRAY</u>	<u>N020313</u>	<u>002</u>	Aug 17, 1995

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL

FORTICAL

+ UPSHER SMITH 200 IU/SPRAY N021406 001 Aug 12, 2005

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

<u>AB</u>	BANNER LIFE SCIENCES	<u>0.25MCG</u>	<u>A091174</u>	<u>001</u>	May 24, 2013
<u>AB</u>		<u>0.5MCG</u>	<u>A091174</u>	<u>002</u>	May 24, 2013
<u>AB</u>	ROXANE	<u>0.25MCG</u>	<u>A076917</u>	<u>001</u>	Mar 27, 2006
<u>AB</u>	STRIDES PHARMA	<u>0.25MCG</u>	<u>A091356</u>	<u>001</u>	Dec 12, 2014
<u>AB</u>		<u>0.5MCG</u>	<u>A091356</u>	<u>002</u>	Dec 12, 2014
<u>AB</u>	TEVA	<u>0.25MCG</u>	<u>A075765</u>	<u>001</u>	Oct 12, 2001
<u>AB</u>		<u>0.5MCG</u>	<u>A075765</u>	<u>002</u>	Oct 12, 2001

ROCALTROL

<u>AB</u>	VALIDUS PHARMS	<u>0.25MCG</u>	<u>N018044</u>	<u>001</u>	
<u>AB</u>	+	<u>0.5MCG</u>	<u>N018044</u>	<u>002</u>	

INJECTABLE; INJECTION

CALCITRIOL

<u>AP</u>	AKORN	<u>0.001MG/ML</u>	<u>A078066</u>	<u>001</u>	Jan 29, 2008
<u>AP</u>	ROCKWELL MEDCL	<u>0.001MG/ML</u>	<u>A076206</u>	<u>001</u>	Sep 17, 2003

OINTMENT; TOPICAL

VECTICAL

+ GALDERMA LABS LP 3MCG/GM N022087 001 Jan 23, 2009

SOLUTION; ORAL

CALCITRIOL

<u>AA</u>	ROXANE	<u>1MCG/ML</u>	<u>A076242</u>	<u>001</u>	Jul 18, 2003
-----------	--------	----------------	----------------	------------	--------------

ROCALTROL

<u>AA</u>	+ VALIDUS PHARMS	<u>1MCG/ML</u>	<u>N021068</u>	<u>001</u>	Nov 20, 1998
-----------	------------------	----------------	----------------	------------	--------------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

<u>AB</u>	AMNEAL PHARMS	<u>EQ 169MG CALCIUM</u>	<u>A201658</u>	<u>001</u>	Oct 06, 2014
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 169MG CALCIUM</u>	<u>A202315</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>	INVAGEN PHARMS	<u>EQ 169MG CALCIUM</u>	<u>A203135</u>	<u>001</u>	Feb 07, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 169MG CALCIUM</u>	<u>A202127</u>	<u>001</u>	Jul 09, 2015
<u>AB</u>	NOSTRUM LABS INC	<u>EQ 169MG CALCIUM</u>	<u>A203179</u>	<u>001</u>	Oct 26, 2015
<u>AB</u>	PADDOCK LLC	<u>EQ 169MG CALCIUM</u>	<u>A091312</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>	ROXANE	<u>EQ 169MG CALCIUM</u>	<u>A077728</u>	<u>001</u>	Feb 26, 2008

PHOSLO GELCAPS

<u>AB</u>	+ FRESENIUS MEDCL	<u>EQ 169MG CALCIUM</u>	<u>N021160</u>	<u>003</u>	Apr 02, 2001
-----------	-------------------	-------------------------	----------------	------------	--------------

SOLUTION; ORAL

PHOSLYRA

+ FRESENIUS MEDCL EQ 169MG CALCIUM/5ML N022581 001 Apr 18, 2011

TABLET; ORAL

CALCIUM ACETATE

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 169MG CALCIUM</u>	<u>A202885</u>	<u>001</u>	Jan 22, 2015
<u>AB</u>	INVAGEN PHARMS	<u>EQ 169MG CALCIUM</u>	<u>A202420</u>	<u>001</u>	Feb 05, 2013
<u>AB</u>	PADDOCK LLC	<u>EQ 169MG CALCIUM</u>	<u>A091561</u>	<u>001</u>	Apr 13, 2011

ELIPHOS

<u>AB</u>	+ CYPRESS PHARM	<u>EQ 169MG CALCIUM</u>	<u>A078502</u>	<u>001</u>	Nov 25, 2008
-----------	-----------------	-------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA 100MG/ML N021117 001 Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUMBICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

**BSS PLUS**

**AT** + ALCON **0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML** **N018469 001**

**ENDOSOL EXTRA**

**AT** + AKORN **0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML** **N020079 001** Nov 27, 1991

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML) N021703 010 Oct 10, 2008

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML) N021703 011 Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML) N021703 013 Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 006 Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 002 Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 003 Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 015 Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 004 Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 014 Oct 10, 2008

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 001 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

+ B BRAUN 510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML N018807 001 Aug 26, 1983

+ B BRAUN 510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML N018807 003 Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

+ B BRAUN 510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML N018807 002 Aug 26, 1983

+ B BRAUN 510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML N018807 004 Aug 26, 1983

## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE  
SOLUTION; INTRAPERITONEAL

<u>DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N018379 002
AT		<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N018883 001 Nov 30, 1984
<u>DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N018883 004 Nov 30, 1984
<u>DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N020171 001 Aug 19, 1992
<u>DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N018379 003
AT		<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N018883 002 Nov 30, 1984
<u>DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N018883 005 Nov 30, 1984
<u>DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N020171 002 Aug 19, 1992
<u>DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N018379 007 Jun 24, 1988
<u>DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u>	N018379 001
AT		<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u>	N018883 003 Nov 30, 1984
<u>DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u>	N018883 006 Nov 30, 1984
<u>DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u>	N020171 003 Aug 19, 1992
<u>DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N018379 004 Jul 07, 1982
<u>DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N018379 005 Jul 07, 1982
<u>DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N018379 008 Jun 24, 1988
<u>DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>			
AT	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u>	N018379 006 Jul 07, 1982
<u>DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N017512 001
<u>DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N017512 003
<u>DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u>	N017512 002
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N020183 001 Dec 04, 1992
<u>DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N017512 007 Jul 09, 1984
<u>DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N017512 008 Jul 09, 1984
<u>DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	N017512 010 Nov 18, 1985
<u>DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u>	N017512 009 Jul 09, 1984
<u>DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	N017512 004
AT		<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;</u>	N020163 001 Dec 04, 1992



## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE  
SOLUTION; INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

538MG/100ML; 448MG/100ML

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

**AT** BAXTER HLTHCARE 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5 **N017512 005**  
38MG/100ML; 448MG/100ML

**AT** 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5 **N020163 002** Dec 04, 1992  
38MG/100ML; 448MG/100ML

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

**AT** BAXTER HLTHCARE 25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5 **N017512 011** Nov 18, 1985  
38MG/100ML; 448MG/100ML

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

**AT** BAXTER HLTHCARE 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; **N017512 006**  
538MG/100ML; 448MG/100ML

**AT** 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; **N020163 003** Dec 04, 1992  
538MG/100ML; 448MG/100ML

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 007 Jan 29, 1986

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 005 Nov 02, 1983

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML N018460 009 Jan 29, 1986

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 002 Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 003 Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 004 Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+ LUKARE MEDICAL LLC 0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML N020577 001 Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

**AP** HOSPIRA 33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/1 **N018254 001**  
00ML

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

**AP** B BRAUN 33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/1 **N020000 001** Apr 17, 1992  
00ML

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

**AP** HOSPIRA 20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/1 **N017608 001**  
00ML; 310MG/100ML

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

**AP** B BRAUN 20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/1 **N019634 003** Feb 24, 1988  
00ML; 310MG/100ML

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

**AP** BAXTER HLTHCARE 20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/1 **N016679 001**  
00ML; 310MG/100ML

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

**AP** BAXTER HLTHCARE 20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/ **N019367 006** Apr 05, 1985  
100ML; 310MG/100ML

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

**AP** BAXTER HLTHCARE 20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/ **N019367 004** Apr 05, 1985  
100ML; 310MG/100ML

**AP** 20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/ **N019367 005** Apr 05, 1985  
100ML; 310MG/100ML

**AP** HOSPIRA 20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/ **N019685 002** Oct 17, 1988  
100ML; 310MG/100ML

**AP** 20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/ **N019685 008** Oct 17, 1988  
100ML; 310MG/100ML

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

**AP** BAXTER HLTHCARE 20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/ **N019367 007** Apr 05, 1985  
100ML; 310MG/100ML

**PRESCRIPTION DRUG PRODUCT LIST**CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 008</u>	Apr 05, 1985
-----------	-----------------	---	--------------------	--------------

<b>AP</b>	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 004</u>	Oct 17, 1988
-----------	---------	---	--------------------	--------------

## DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100ML	N019634 001	Feb 24, 1988
--	---------	---	-------------	--------------

## POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	N019367 002	Apr 05, 1985
--	-----------------	--	-------------	--------------

		20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019367 003	Apr 05, 1985
--	--	--	-------------	--------------

## POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	N019367 001	Apr 05, 1985
--	-----------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

## TPN ELECTROLYTES IN PLASTIC CONTAINER

	+ HOSPIRA	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	N018895 001	Jul 20, 1984
--	-----------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT

<b>AT</b>	AKORN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A075503 001</u>	Sep 27, 2006
-----------	-------	---	--------------------	--------------

<b>AT</b>	B BRAUN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A091387 001</u>	Feb 03, 2010
-----------	---------	---	--------------------	--------------

BSS

<b>AT</b>	+ ALCON	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>N020742 001</u>	Dec 10, 1997
-----------	---------	---	--------------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

## PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026 002	Jan 13, 2015
--	-------------------	--	-------------	--------------

## PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML	N207026 001	Jan 13, 2015
--	-------------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>A075323 001</u>	Apr 21, 2000
-----------	-----------------	--	--------------------	--------------

PLEGISOL IN PLASTIC CONTAINER

<b>AT</b>	+ HOSPIRA	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>N018608 001</u>	Feb 26, 1982
-----------	-----------	--	--------------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020002 001</u>	Apr 17, 1992
-----------	---------	--	--------------------	--------------

<b>AP</b>	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N016693 001</u>	
-----------	-----------------	--	--------------------	--

<b>AP</b>	HOSPIRA	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018251 001</u>	
-----------	---------	--	--------------------	--

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

<b>AT</b>	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018156 001</u>	
-----------	---------	--	--------------------	--

<b>AT</b>	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018495 001</u>	Feb 19, 1982
-----------	-----------------	--	--------------------	--------------

<b>AT</b>	HOSPIRA	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N017635 001</u>	
-----------	---------	--	--------------------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019632 001</u>	Feb 29, 1988
-----------	---------	---	--------------------	--------------

<b>AP</b>	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016682 001</u>	
-----------	-----------------	---	--------------------	--

<b>AP</b>	HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017641 001</u>	
-----------	---------	---	--------------------	--

## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AT</b>	+	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018681 001</u>	Dec 27, 1982
<b>AT</b>		BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018494 001</u>	Feb 19, 1982
<b>AT</b>	+		<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018921 001</u>	Apr 03, 1984
<b>AT</b>	+	HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019416 001</u>	Jan 17, 1986

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

	+	ONY	35MG/ML	N020521 001	Jul 01, 1998
--	---	-----	---------	-------------	--------------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

		JANSSEN PHARMS	100MG	N204042 001	Mar 29, 2013
	+		300MG	N204042 002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

INVOKAMET

		JANSSEN PHARMS	50MG; 500MG	N204353 001	Aug 08, 2014
			50MG; 1GM	N204353 002	Aug 08, 2014
			150MG; 500MG	N204353 003	Aug 08, 2014
	+		150MG; 1GM	N204353 004	Aug 08, 2014

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

<b>AB</b>		ASTRAZENECA	<u>4MG</u>	<u>N020838 001</u>	Jun 04, 1998
<b>AB</b>			<u>8MG</u>	<u>N020838 002</u>	Jun 04, 1998
<b>AB</b>			<u>16MG</u>	<u>N020838 003</u>	Jun 04, 1998
<b>AB</b>	+		<u>32MG</u>	<u>N020838 004</u>	Jun 04, 1998

CANDESARTAN CILEXETIL

<b>AB</b>		APOTEX INC	<u>4MG</u>	<u>A202079 001</u>	Jan 10, 2014
<b>AB</b>			<u>8MG</u>	<u>A202079 002</u>	Jan 10, 2014
<b>AB</b>			<u>16MG</u>	<u>A202079 003</u>	Jan 10, 2014
<b>AB</b>			<u>32MG</u>	<u>A202079 004</u>	Jan 10, 2014
<b>AB</b>		SANDOZ	<u>4MG</u>	<u>A078702 001</u>	May 03, 2013
<b>AB</b>			<u>8MG</u>	<u>A078702 002</u>	May 03, 2013
<b>AB</b>			<u>16MG</u>	<u>A078702 003</u>	May 03, 2013
<b>AB</b>			<u>32MG</u>	<u>A078702 004</u>	May 03, 2013

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

<b>AB</b>		ASTRAZENECA	<u>16MG; 12.5MG</u>	<u>N021093 001</u>	Sep 05, 2000
<b>AB</b>			<u>32MG; 12.5MG</u>	<u>N021093 002</u>	Sep 05, 2000
<b>AB</b>	+		<u>32MG; 25MG</u>	<u>N021093 003</u>	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<b>AB</b>		APOTEX INC	<u>16MG; 12.5MG</u>	<u>A202884 001</u>	Dec 04, 2012
<b>AB</b>			<u>32MG; 12.5MG</u>	<u>A202884 002</u>	Dec 04, 2012
<b>AB</b>			<u>32MG; 25MG</u>	<u>A202884 003</u>	Jun 03, 2013
<b>AB</b>		DR REDDYS LABS LTD	<u>16MG; 12.5MG</u>	<u>A202965 001</u>	Jun 03, 2013
<b>AB</b>			<u>32MG; 12.5MG</u>	<u>A202965 002</u>	Jun 03, 2013
<b>AB</b>			<u>32MG; 25MG</u>	<u>A202965 003</u>	Jun 03, 2013
<b>AB</b>		MACLEODS PHARMS LTD	<u>16MG; 12.5MG</u>	<u>A204100 001</u>	Feb 27, 2015
<b>AB</b>			<u>32MG; 12.5MG</u>	<u>A204100 002</u>	Feb 27, 2015
<b>AB</b>			<u>32MG; 25MG</u>	<u>A204100 003</u>	Feb 27, 2015
<b>AB</b>		MYLAN LABS	<u>16MG; 12.5MG</u>	<u>A090704 001</u>	Dec 04, 2012
<b>AB</b>			<u>32MG; 12.5MG</u>	<u>A090704 002</u>	Dec 04, 2012
<b>AB</b>			<u>32MG; 25MG</u>	<u>A090704 003</u>	Dec 04, 2012

CANGRELOR

POWDER; IV (INFUSION)

KENGREAL

	+	THE MEDICINES CO	50MG/VIAL	N204958 001	Jun 22, 2015
--	---	------------------	-----------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>	ACCORD HLTHCARE	<u>150MG</u>	<u>A202593 001</u>	Apr 23, 2015
<u>AB</u>		<u>500MG</u>	<u>A202593 002</u>	Apr 23, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>150MG</u>	<u>A090943 001</u>	Aug 08, 2014
<u>AB</u>		<u>500MG</u>	<u>A090943 002</u>	Aug 08, 2014
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A091649 001</u>	Sep 16, 2013
<u>AB</u>		<u>500MG</u>	<u>A091649 002</u>	Sep 16, 2013

XELODA

<u>AB</u>	HOFFMANN LA ROCHE	<u>150MG</u>	<u>N020896 001</u>	Apr 30, 1998
<u>AB</u>	+	<u>500MG</u>	<u>N020896 002</u>	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

+ AKORN

EQ 1GM BASE/VIAL

N050095 001

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+ ACORDA

8%

N022395 001 Nov 16, 2009

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A074737 001</u>	Oct 28, 1998
<u>AB</u>		<u>25MG</u>	<u>A074737 002</u>	Oct 28, 1998
<u>AB</u>		<u>50MG</u>	<u>A074737 003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A074737 004</u>	Oct 28, 1998
<u>AB</u>	HIKMA PHARMS LLC	<u>12.5MG</u>	<u>A074505 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074505 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505 004</u>	Feb 13, 1996
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A074434 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074434 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074434 003</u>	Feb 13, 1996
<u>AB</u>	+	<u>100MG</u>	<u>A074434 004</u>	Feb 13, 1996
<u>AB</u>	SANDOZ	<u>12.5MG</u>	<u>A074363 001</u>	Nov 09, 1995
<u>AB</u>		<u>25MG</u>	<u>A074363 002</u>	Nov 09, 1995
<u>AB</u>		<u>50MG</u>	<u>A074363 003</u>	Nov 09, 1995
<u>AB</u>		<u>100MG</u>	<u>A074363 004</u>	Nov 09, 1995
<u>AB</u>	STASON	<u>12.5MG</u>	<u>A074677 004</u>	May 30, 1997
<u>AB</u>		<u>25MG</u>	<u>A074677 002</u>	May 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A074677 001</u>	May 30, 1997
<u>AB</u>		<u>100MG</u>	<u>A074677 003</u>	May 30, 1997
<u>AB</u>	TEVA	<u>12.5MG</u>	<u>A074322 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074322 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074322 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074322 004</u>	Feb 13, 1996
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	<u>A074386 001</u>	May 23, 1996
<u>AB</u>		<u>25MG</u>	<u>A074386 002</u>	May 23, 1996
<u>AB</u>		<u>50MG</u>	<u>A074386 003</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386 004</u>	May 23, 1996
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>	<u>A074532 001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532 002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532 003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532 004</u>	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	G AND W LABS INC	<u>25MG; 15MG</u>	<u>A074827 001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG; 25MG</u>	<u>A074827 002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 15MG</u>	<u>A074827 004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 25MG</u>	<u>A074827 003</u>	Dec 29, 1997
<u>AB</u>	MYLAN	<u>25MG; 15MG</u>	<u>A074896 001</u>	Dec 29, 1997
<u>AB</u>	+	<u>25MG; 25MG</u>	<u>A074896 002</u>	Dec 29, 1997
<u>AB</u>	+	<u>50MG; 15MG</u>	<u>A074896 004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 25MG</u>	<u>A074896 003</u>	Dec 29, 1997

## PRESCRIPTION DRUG PRODUCT LIST

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+ ALCON

0.01%

N016968 001

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A078986 001</u>	Nov 25, 2011
<u>AB</u>		<u>200MG</u>	<u>A078986 002</u>	Nov 25, 2011
<u>AB</u>		<u>300MG</u>	<u>A078986 003</u>	Nov 25, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A076697 001</u>	May 20, 2011
<u>AB</u>		<u>200MG</u>	<u>A076697 002</u>	May 20, 2011
<u>AB</u>		<u>300MG</u>	<u>A076697 003</u>	May 20, 2011
<u>AB</u>	TARO	<u>100MG</u>	<u>A201106 001</u>	Jun 21, 2013
<u>AB</u>		<u>200MG</u>	<u>A201106 002</u>	Jun 21, 2013
<u>AB</u>		<u>300MG</u>	<u>A201106 003</u>	Jun 21, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A078592 001</u>	Sep 20, 2012
<u>AB</u>		<u>200MG</u>	<u>A078592 002</u>	Sep 20, 2012
<u>AB</u>		<u>300MG</u>	<u>A078592 003</u>	Sep 20, 2012

CARBATROL

<u>AB</u>	SHIRE	<u>100MG</u>	<u>N020712 003</u>	Sep 30, 1997
<u>AB</u>		<u>200MG</u>	<u>N020712 001</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020712 002</u>	Sep 30, 1997
	EQUETRO			
	VALIDUS PHARMS INC	100MG	N021710 001	Dec 10, 2004
		200MG	N021710 002	Dec 10, 2004
	+	300MG	N021710 003	Dec 10, 2004

SUSPENSION; ORAL

CARBAMAZEPINE

<u>AB</u>	WOCKHARDT	<u>100MG/5ML</u>	<u>A075714 001</u>	Jun 05, 2002
<u>AB</u>	+	<u>100MG/5ML</u>	<u>N018927 001</u>	Dec 18, 1987
	TERIL			
<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A076729 001</u>	Sep 20, 2004

TABLET; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948 001</u>	Feb 27, 2002
<u>AB</u>	TARO	<u>200MG</u>	<u>A074649 001</u>	Oct 03, 1996
<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272 002</u>	Dec 07, 2005

EPITOL

<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541 001</u>	Sep 17, 1986
-----------	------	--------------	--------------------	--------------

TEGRETOL

<u>AB</u>	+	<u>200MG</u>	<u>N016608 001</u>	
	CARBAMAZEPINE			
	TORRENT PHARMS	100MG	A077272 001	Dec 07, 2005
		300MG	A077272 003	Dec 07, 2005
		400MG	A077272 004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO PHARM INDS	<u>100MG</u>	<u>A075687 001</u>	Oct 24, 2000
<u>AB</u>	TORRENT PHARMS	<u>100MG</u>	<u>A075712 001</u>	Jul 05, 2001

EPITOL

<u>AB</u>	TEVA	<u>100MG</u>	<u>A073524 001</u>	Jul 29, 1992
-----------	------	--------------	--------------------	--------------

TEGRETOL

<u>AB</u>	+	<u>100MG</u>	<u>N018281 001</u>	
	CARBAMAZEPINE			
	+	<u>200MG</u>	<u>A075687 002</u>	Jul 29, 2002
	TARO PHARM INDS			

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO	<u>100MG</u>	<u>A078115 001</u>	Mar 31, 2009
<u>AB</u>		<u>200MG</u>	<u>A078115 002</u>	Mar 31, 2009
<u>AB</u>		<u>400MG</u>	<u>A078115 003</u>	Mar 31, 2009

TEGRETOL-XR

<u>AB</u>	NOVARTIS	<u>100MG</u>	<u>N020234 001</u>	Mar 25, 1996
<u>AB</u>		<u>200MG</u>	<u>N020234 002</u>	Mar 25, 1996
<u>AB</u>	+	<u>400MG</u>	<u>N020234 003</u>	Mar 25, 1996

## PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA

TABLET; ORAL

CARBIDOPA

<u>AB</u>	ALVOGEN MALTA	<u>25MG</u>	<u>A204291 001</u>	Jan 08, 2016
<u>AB</u>	AMERIGEN PHARMS LTD	<u>25MG</u>	<u>A203261 001</u>	Mar 10, 2014

LODOSYN

<u>AB</u>	+ ATON	<u>25MG</u>	<u>N017830 001</u>	
-----------	--------	-------------	--------------------	--

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

<u>AB</u>	SUN PHARMA GLOBAL	<u>25MG;200MG;100MG</u>	<u>A079085 001</u>	May 10, 2012
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A079085 002</u>	May 10, 2012
<u>AB</u>	WOCKHARDT LTD	<u>12.5MG;200MG;50MG</u>	<u>A090786 001</u>	Nov 20, 2012
<u>AB</u>		<u>18.75MG;200MG;75MG</u>	<u>A090833 001</u>	Nov 20, 2012
<u>AB</u>		<u>25MG;200MG;100MG</u>	<u>A090833 002</u>	Nov 20, 2012
<u>AB</u>		<u>31.25MG;200MG;125MG</u>	<u>A090833 003</u>	Nov 20, 2012
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A090833 004</u>	Nov 20, 2012
<u>AB</u>		<u>50MG;200MG;200MG</u>	<u>A090833 005</u>	Nov 20, 2012

STALEVO 100

<u>AB</u>	ORION PHARMA	<u>25MG;200MG;100MG</u>	<u>N021485 002</u>	Jun 11, 2003
-----------	--------------	-------------------------	--------------------	--------------

STALEVO 125

<u>AB</u>	ORION PHARMA	<u>31.25MG;200MG;125MG</u>	<u>N021485 006</u>	Aug 29, 2008
-----------	--------------	----------------------------	--------------------	--------------

STALEVO 150

<u>AB</u>	ORION PHARMA	<u>37.5MG;200MG;150MG</u>	<u>N021485 003</u>	Jun 11, 2003
-----------	--------------	---------------------------	--------------------	--------------

STALEVO 200

<u>AB</u>	+ ORION PHARMA	<u>50MG;200MG;200MG</u>	<u>N021485 004</u>	Aug 02, 2007
-----------	----------------	-------------------------	--------------------	--------------

STALEVO 50

<u>AB</u>	+ ORION PHARMA	<u>12.5MG;200MG;50MG</u>	<u>N021485 001</u>	Jun 11, 2003
-----------	----------------	--------------------------	--------------------	--------------

STALEVO 75

<u>AB</u>	ORION PHARMA	<u>18.75MG;200MG;75MG</u>	<u>N021485 005</u>	Aug 29, 2008
-----------	--------------	---------------------------	--------------------	--------------

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

	IMPAX LABS INC	23.75MG;95MG	N203312 001	Jan 07, 2015
		36.25MG;145MG	N203312 002	Jan 07, 2015
		48.75MG;195MG	N203312 003	Jan 07, 2015
	+	61.25MG;245MG	N203312 004	Jan 07, 2015

SUSPENSION; ENTERAL

DUOPA

	+ ABBVIE INC	4.63MG/ML;20MG/ML	N203952 001	Jan 09, 2015
--	--------------	-------------------	-------------	--------------

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260 001</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;100MG</u>	<u>A074260 002</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;250MG</u>	<u>A074260 003</u>	Sep 03, 1993
<u>AB</u>	APOTEX INC	<u>10MG;100MG</u>	<u>A077120 001</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A077120 002</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A077120 003</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A090324 001</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A090324 002</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A090324 003</u>	Sep 28, 2009
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536 001</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078536 002</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078536 003</u>	Oct 28, 2008
<u>AB</u>	TEVA	<u>10MG;100MG</u>	<u>A073618 001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;100MG</u>	<u>A073589 001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;250MG</u>	<u>A073607 001</u>	Aug 28, 1992

SINEMET

<u>AB</u>	MERCK SHARP DOHME	<u>10MG;100MG</u>	<u>N017555 001</u>	
-----------	-------------------	-------------------	--------------------	--

<u>AB</u>		<u>25MG;100MG</u>	<u>N017555 003</u>	
-----------	--	-------------------	--------------------	--

<u>AB</u>	+	<u>25MG;250MG</u>	<u>N017555 002</u>	
-----------	---	-------------------	--------------------	--

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACCORD HLTHCARE	<u>25MG;100MG</u>	<u>A202323 001</u>	Feb 08, 2013
<u>AB</u>		<u>50MG;200MG</u>	<u>A202323 002</u>	Feb 08, 2013
<u>AB</u>	APOTEX	<u>25MG;100MG</u>	<u>A076212 001</u>	Jun 16, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076212 002</u>	Jun 16, 2004
<u>AB</u>	IMPAX LABS	<u>25MG;100MG</u>	<u>A076521 001</u>	May 14, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076521 002</u>	May 14, 2004
<u>AB</u>	MYLAN	<u>25MG;100MG</u>	<u>A075091 002</u>	Apr 21, 2000
<u>AB</u>		<u>50MG;200MG</u>	<u>A075091 001</u>	Sep 30, 1999

## PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828 001</u>	Aug 23, 2007
<u>AB</u>		<u>50MG;200MG</u>	<u>A077828 002</u>	Aug 23, 2007

SINEMET CR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG;100MG</u>	<u>N019856 002</u>	Dec 24, 1992
<u>AB</u>	+	<u>50MG;200MG</u>	<u>N019856 001</u>	May 30, 1991

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A078893 001</u>	Sep 18, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078893 002</u>	Sep 18, 2008
<u>AB</u>	+	<u>25MG;250MG</u>	<u>A078893 003</u>	Sep 18, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG;100MG</u>	<u>A078690 001</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A078690 002</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A078690 003</u>	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	CYPRESS PHARM	<u>4MG/5ML</u>	<u>A090418 001</u>	May 04, 2010
<u>AA</u>	+	<u>4MG/5ML</u>	<u>A040458 001</u>	Apr 25, 2003
<u>AA</u>	VINTAGE PHARMS	<u>4MG/5ML</u>	<u>A040814 001</u>	Feb 26, 2008

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

+ TRIS PHARMA INC 4MG/5ML

N022556 001 Mar 28, 2013

TABLET;ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	CYPRESS PHARM	<u>4MG</u>	<u>A090417 001</u>	Aug 23, 2010
<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435 001</u>	Apr 15, 2010
<u>AA</u>	+	<u>4MG</u>	<u>A040442 001</u>	Mar 19, 2003
<u>AA</u>	MISSION PHARMACAL CO	<u>4MG</u>	<u>A090756 001</u>	May 27, 2011
<u>AA</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040639 002</u>	May 30, 2008

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/5ML (10MG/ML)</u>	<u>A078732 001</u>	Feb 06, 2012
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078732 002</u>	Feb 06, 2012
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078732 003</u>	Feb 06, 2012
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078732 004</u>	Feb 06, 2012
<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475 001</u>	Jul 29, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475 002</u>	Jul 29, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475 003</u>	Jul 29, 2009
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091268 002</u>	Jul 28, 2010
<u>AP</u>	CIPLA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A077861 001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861 002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861 003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861 004</u>	Jan 18, 2007
<u>AP</u>	EBEWE PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078280 001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280 002</u>	May 08, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280 003</u>	May 08, 2008
<u>AP</u>	EUROHLTH INTL SARL	<u>50MG/5ML (10MG/ML)</u>	<u>A077244 001</u>	Oct 15, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244 002</u>	Oct 15, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244 003</u>	Oct 15, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244 004</u>	Jan 20, 2006
<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/5ML (10MG/ML)</u>	<u>A077432 001</u>	Sep 29, 2006
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077432 002</u>	Sep 29, 2006
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077432 003</u>	Sep 29, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>450MG/45ML (10MG/ML)</u>	<u>A077247 003</u>	Oct 21, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266 003</u>	Feb 15, 2006
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266 004</u>	Feb 15, 2006
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517 001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517 002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517 003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059 001</u>	Nov 23, 2004
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077998 001</u>	Apr 24, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077998 002</u>	Apr 24, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077998 003</u>	Apr 24, 2007
<u>AP</u>	MYLAN LABS LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A091063 001</u>	Nov 09, 2011
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A091063 002</u>	Nov 09, 2011
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A091063 003</u>	Nov 09, 2011
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091063 004</u>	Nov 09, 2011

## PRESCRIPTION DRUG PRODUCT LIST

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	+	PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077269 001</u>	Oct 14, 2004
<u>AP</u>	+		<u>150MG/15ML (10MG/ML)</u>	<u>A077269 002</u>	Oct 14, 2004
<u>AP</u>	+		<u>450MG/45ML (10MG/ML)</u>	<u>A077269 003</u>	Oct 14, 2004
<u>AP</u>	+		<u>600MG/60ML (10MG/ML)</u>	<u>A077269 004</u>	Dec 28, 2007
<u>AP</u>		PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631 001</u>	Dec 02, 2008
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A078631 002</u>	Dec 02, 2008
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A078631 003</u>	Dec 02, 2008
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A078631 004</u>	Dec 02, 2008
<u>AP</u>		SAGENT PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A077096 001</u>	Jun 14, 2005
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A077096 002</u>	Jun 14, 2005
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077096 003</u>	Jun 14, 2005
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A077096 004</u>	Jun 03, 2013
<u>AP</u>		SUN PHARMA GLOBAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077926 001</u>	Sep 19, 2008
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A077926 002</u>	Sep 19, 2008
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077926 003</u>	Sep 19, 2008
<u>AP</u>	+	TEVA PHARMS USA	<u>50MG/5ML (10MG/ML)</u>	<u>A077139 001</u>	Sep 21, 2005
<u>AP</u>	+		<u>150MG/15ML (10MG/ML)</u>	<u>A077139 002</u>	Sep 21, 2005
<u>AP</u>	+		<u>450MG/45ML (10MG/ML)</u>	<u>A077139 003</u>	Sep 21, 2005
<u>AP</u>	+		<u>600MG/60ML (10MG/ML)</u>	<u>A077139 004</u>	Sep 21, 2005
	+	MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478 001	Nov 23, 2011

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N017989 001

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS 60MG/VIAL N202714 001 Jul 20, 2012

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+ ORPHAN EUROPE 200MG N022562 001 Mar 18, 2010

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

FOREST RES INST INC	EQ 1.5MG BASE	N204370 001	Sep 17, 2015
	EQ 3MG BASE	N204370 002	Sep 17, 2015
	EQ 4.5MG BASE	N204370 003	Sep 17, 2015
+	EQ 6MG BASE	N204370 004	Sep 17, 2015

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	ACCELRX LABS	<u>350MG</u>	<u>A040576 001</u>	Jun 07, 2005
<u>AA</u>	AUROBINDO PHARMA	<u>350MG</u>	<u>A040792 001</u>	Aug 06, 2009
<u>AA</u>	INDICUS PHARMA	<u>350MG</u>	<u>A205126 002</u>	Jul 08, 2015
<u>AA</u>	MIRROR PHARMS	<u>350MG</u>	<u>A040823 001</u>	Oct 22, 2008
<u>AA</u>	NATCO PHARMA LTD	<u>350MG</u>	<u>A090988 001</u>	Oct 28, 2014
<u>AA</u>	ORIENT PHARMA CO LTD	<u>350MG</u>	<u>A205085 001</u>	Oct 28, 2014
<u>AA</u>	SCIEGEN PHARMS INC	<u>350MG</u>	<u>A203374 001</u>	Jan 27, 2014
<u>AA</u>	SHASUN PHARMS LTD	<u>350MG</u>	<u>A205513 002</u>	Nov 12, 2015
<u>AA</u>	SUN PHARM INDS	<u>350MG</u>	<u>A089346 001</u>	Oct 17, 1991
<u>AA</u>	SUN PHARM INDS LTD	<u>350MG</u>	<u>A040755 001</u>	Feb 27, 2007
<u>AA</u>	VINTAGE PHARMS	<u>350MG</u>	<u>A040245 001</u>	Sep 08, 1997
<u>AA</u>	WATSON LABS	<u>350MG</u>	<u>A087499 001</u>	Apr 20, 1982

SOMA

<u>AA</u>	MEDA PHARMS	<u>350MG</u>	<u>N011792 001</u>	
-----------	-------------	--------------	--------------------	--

CARISOPRODOL

<u>AB</u>	INDICUS PHARMA	<u>250MG</u>	<u>A205126 001</u>	Jul 08, 2015
<u>AB</u>	SHASUN PHARMS LTD	<u>250MG</u>	<u>A205513 001</u>	Nov 12, 2015

SOMA

<u>AB</u>	+	MEDA PHARMS	<u>250MG</u>	<u>N011792 004</u>	Sep 13, 2007
-----------	---	-------------	--------------	--------------------	--------------





## PRESCRIPTION DRUG PRODUCT LIST

CARVEDILOL

TABLET;ORAL

CARVEDILOL

<u>AB</u>		<u>12.5MG</u>	<u>A076373</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614</u>	<u>003</u>	Sep 05, 2007

COREG

<u>AB</u>	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297</u>	<u>004</u>	May 29, 1997
<u>AB</u>		<u>6.25MG</u>	<u>N020297</u>	<u>003</u>	Sep 14, 1995
<u>AB</u>	+	<u>12.5MG</u>	<u>N020297</u>	<u>002</u>	Sep 14, 1995
<u>AB</u>		<u>25MG</u>	<u>N020297</u>	<u>001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

COREG CR

	SB PHARMO	10MG	N022012	001	Oct 20, 2006
		20MG	N022012	002	Oct 20, 2006
	+	40MG	N022012	003	Oct 20, 2006
		80MG	N022012	004	Oct 20, 2006

CASPOFUNGIN ACETATE

INJECTABLE;IV (INFUSION)

CANCIDAS

	+ MERCK	50MG/VIAL	N021227	001	Jan 26, 2001
	+	70MG/VIAL	N021227	002	Jan 26, 2001

CEFACTOR

CAPSULE;ORAL

CEFACTOR

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350</u>	<u>001</u>	Apr 03, 2007
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065350</u>	<u>002</u>	Apr 03, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146</u>	<u>001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146</u>	<u>002</u>	Jan 22, 2004

FOR SUSPENSION;ORAL

CEFACTOR

<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065412</u>	<u>001</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 187MG BASE/5ML</u>	<u>A065412</u>	<u>002</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065412</u>	<u>003</u>	Feb 17, 2012
<u>AB</u>	+	<u>EQ 375MG BASE/5ML</u>	<u>A065412</u>	<u>004</u>	Feb 17, 2012

TABLET, EXTENDED RELEASE;ORAL

CEFACTOR

	TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
	+	EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>	HIKMA	<u>EQ 500MG BASE</u>	<u>A065311</u>	<u>001</u>	Feb 07, 2006
<u>AB</u>	LUPIN	<u>EQ 500MG BASE</u>	<u>A065392</u>	<u>001</u>	May 29, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE</u>	<u>A065309</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>	SANDOZ	<u>EQ 500MG BASE</u>	<u>A062291</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065282</u>	<u>001</u>	Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO	<u>EQ 250MG BASE/5ML</u>	<u>A065349</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065349</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A091036</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A091036</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>	LUPIN	<u>EQ 250MG BASE/5ML</u>	<u>A065396</u>	<u>001</u>	Feb 21, 2008
<u>AB</u>	+	<u>EQ 500MG BASE/5ML</u>	<u>A065396</u>	<u>002</u>	Feb 21, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE/5ML</u>	<u>A065307</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065307</u>	<u>003</u>	Oct 16, 2006
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 250MG BASE/5ML</u>	<u>A065115</u>	<u>002</u>	Mar 26, 2003
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065115</u>	<u>003</u>	Mar 26, 2003
		EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003

TABLET;ORAL

CEFADROXIL

<u>AB</u>	HIKMA	<u>EQ 1GM BASE</u>	<u>A065260</u>	<u>001</u>	Mar 30, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE</u>	<u>A065301</u>	<u>001</u>	Sep 18, 2006
	+	EQ 1GM BASE	A062774	001	Apr 08, 1987

## PRESCRIPTION DRUG PRODUCT LIST

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065303 001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065303 002</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065306 001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 20GM BASE/VIAL</u>	<u>A065306 002</u>	Aug 18, 2014
<u>AP</u>	FACTA FARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A063214 001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A063207 001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063209 001</u>	Dec 27, 1991
<u>AP</u>	+	<u>EQ 20GM BASE/VIAL</u>	<u>A063209 002</u>	Apr 30, 1999
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 500MG BASE/VIAL</u>	<u>A065047 001</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065047 002</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065143 001</u>	Oct 18, 2004
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A065226 001</u>	Apr 21, 2005
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065226 002</u>	Apr 21, 2005
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065244 001</u>	Aug 12, 2005
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A065247 001</u>	Aug 12, 2005
<u>AP</u>	QILU PHARM CO LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A203661 001</u>	Dec 28, 2015
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A062831 001</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062831 002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345 001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831 003</u>	Sep 25, 1992

KEFZOL

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A061773 002</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A061773 003</u>	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A061773 004</u>	
	ANCEF IN PLASTIC CONTAINER			
	+	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001 Mar 28, 1991
	+		EQ 20MG BASE/ML	A063002 002 Mar 28, 1991
	CEFAZOLIN AND DEXTROSE			
	+	B BRAUN	EQ 1GM BASE/VIAL	N050779 002 Jul 27, 2000
			EQ 2GM BASE/VIAL	N050779 003 Jan 13, 2012
	CEFAZOLIN SODIUM			
	+	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141 001 Nov 29, 2006
	+		EQ 300GM BASE/VIAL	A065141 002 Nov 29, 2006
	SOLUTION; INTRAVENOUS			
	CEFAZOLIN IN PLASTIC CONTAINER			
		BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131 001 Aug 07, 2015

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434 001</u>	Jan 07, 2008	
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264 001</u>	May 19, 2006	
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418 001</u>	Jul 18, 2007	
<u>AB</u>	+	SANDOZ	<u>300MG</u>	<u>A065330 001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368 001</u>	May 09, 2007	

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473 001</u>	Dec 14, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065473 002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259 001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259 002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429 001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429 002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337 001</u>	Apr 06, 2007
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065337 002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332 001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332 002</u>	May 04, 2007

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

	VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001
	+	400MG	N021222 002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441 001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441 002</u>	Mar 20, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>A065369 001</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065369 002</u>	Jun 18, 2007

## PRESCRIPTION DRUG PRODUCT LIST

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202268 001</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065369 003</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202268 002</u>	Jul 30, 2012
<u>MAXIPIIME</u>				
<u>AP</u>	+ HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>N050679 001</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N050679 002</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050679 003</u>	Jan 18, 1996
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER				
	B BRAUN	EQ 1GM BASE/VIAL	N050821 001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821 002	May 06, 2010
CEFEPIME IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817 001	Aug 05, 2008
	+	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817 002	Aug 05, 2008

CEFIXIME

CAPSULE; ORAL

SUPRAX

+ LUPIN LTD

400MG

N203195 001 Jun 01, 2012

FOR SUSPENSION; ORAL

CEFIXIME

<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG/5ML</u>	<u>A204835 001</u>	Apr 14, 2015
<u>AB</u>		<u>200MG/5ML</u>	<u>A204835 002</u>	Apr 14, 2015
<u>SUPRAX</u>				
<u>AB</u>	LUPIN PHARMS	<u>100MG/5ML</u>	<u>A065129 001</u>	Feb 23, 2004
<u>AB</u>		<u>200MG/5ML</u>	<u>A065355 001</u>	Apr 10, 2007
	+ LUPIN LTD	500MG/5ML	N202091 001	Feb 20, 2013
TABLET; ORAL				
SUPRAX				
	+ LUPIN PHARMS	400MG	A065130 001	Feb 12, 2004
TABLET, CHEWABLE; ORAL				
SUPRAX				
	LUPIN LTD	100MG	A065380 001	Oct 25, 2010
		150MG	A065380 002	Oct 25, 2010
	+	200MG	A065380 003	Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

<u>AP</u>	HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065072 001</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065072 002</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065072 003</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065071 001</u>	Nov 20, 2002
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065197 001</u>	Aug 29, 2006

CEFOTAXIME SODIUM

<u>AP</u>	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>A065290 001</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065290 002</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065293 001</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065290 003</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065293 002</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065292 001</u>	Aug 10, 2006
<u>AP</u>	LUPIN	<u>EQ 500MG BASE/VIAL</u>	<u>A065124 001</u>	Sep 24, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065124 002</u>	Sep 24, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065124 003</u>	Sep 24, 2003
<u>AP</u>	WOCKHARDT	<u>EQ 500MG BASE/VIAL</u>	<u>A065197 002</u>	Jun 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065197 003</u>	Jun 20, 2008

CLAFORAN

<u>AP</u>	+ SANOFI AVENTIS US	<u>EQ 500MG BASE/VIAL</u>	<u>N050547 001</u>	
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062659 001</u>	Jan 13, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N050547 002</u>	
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062659 002</u>	Jan 13, 1987
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050547 003</u>	
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>N050547 004</u>	Dec 29, 1983
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	+ SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596 002	May 20, 1985
	+	EQ 40MG BASE/ML	N050596 004	May 20, 1985

## PRESCRIPTION DRUG PRODUCT LIST

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

<u>AP</u>	+	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A065374 001</u>	Aug 09, 2007
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A065374 002</u>	Aug 09, 2007
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL</u>	<u>A065375 001</u>	Aug 09, 2007
<u>AP</u>		WEST-WARD PHARM CORP	<u>EQ 1GM BASE/VIAL</u>	<u>A091031 001</u>	Oct 26, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091031 002</u>	Oct 26, 2011
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A091030 001</u>	Oct 26, 2011
		CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER			
	+	B BRAUN	EQ 1GM BASE/VIAL	A065430 001	Aug 09, 2007
	+		EQ 2GM BASE/VIAL	A065430 002	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

<u>AP</u>	+	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065414 001</u>	Jun 12, 2009
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A065414 002</u>	Jun 12, 2009
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL</u>	<u>A065415 001</u>	May 19, 2010
<u>AP</u>		ANTIBIOTICOS BRASIL	<u>EQ 1GM BASE/VIAL</u>	<u>A065467 001</u>	Aug 31, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065467 002</u>	Aug 31, 2011
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065464 001</u>	Aug 31, 2011
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065238 001</u>	Mar 12, 2010
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065238 002</u>	Mar 12, 2010
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065239 001</u>	Mar 02, 2010
<u>AP</u>		HIKMA MAPLE	<u>EQ 1GM BASE/VIAL</u>	<u>A065051 001</u>	Sep 11, 2000
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065051 002</u>	Sep 11, 2000
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065050 001</u>	Sep 11, 2000
<u>AP</u>		HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065313 001</u>	Jan 23, 2006
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065313 002</u>	Jan 23, 2006
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065312 001</u>	Feb 13, 2006

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>		B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>A065214 001</u>	Mar 10, 2006
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065214 002</u>	Mar 10, 2006
		MEFOXIN IN PLASTIC CONTAINER			
	+	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182 001	Jan 25, 1993
	+		EQ 40MG BASE/ML	A063182 002	Jan 25, 1993
		POWDER; IV (INFUSION)			
		CEFOXITIN IN PLASTIC CONTAINER			
		SAMSON MEDCL	EQ 100GM BASE	A200938 001	Nov 16, 2015

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/5ML</u>	<u>A065409 001</u>	Jun 08, 2007
<u>AB</u>			<u>EQ 100MG BASE/5ML</u>	<u>A065409 002</u>	Jun 08, 2007
<u>AB</u>		SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031 001</u>	Jan 14, 2009
<u>AB</u>	+		<u>EQ 100MG BASE/5ML</u>	<u>A090031 002</u>	Jan 14, 2009
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 50MG BASE/5ML</u>	<u>A065082 001</u>	May 31, 2002
<u>AB</u>			<u>EQ 100MG BASE/5ML</u>	<u>A065082 002</u>	May 31, 2002

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370 001</u>	Jun 11, 2007
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A065370 002</u>	Jun 11, 2007
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388 001</u>	Nov 14, 2007
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A065388 002</u>	Nov 14, 2007
<u>AB</u>		SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462 001</u>	May 28, 2008
<u>AB</u>	+		<u>EQ 200MG BASE</u>	<u>A065462 002</u>	May 28, 2008
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 100MG BASE</u>	<u>A065083 001</u>	Aug 20, 2003
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A065083 002</u>	Aug 20, 2003

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>		APOTEX INC	<u>125MG/5ML</u>	<u>A065351 001</u>	Feb 29, 2012
<u>AB</u>			<u>250MG/5ML</u>	<u>A065351 002</u>	Feb 29, 2012
<u>AB</u>		AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381 001</u>	Jan 30, 2007
<u>AB</u>			<u>250MG/5ML</u>	<u>A065381 002</u>	Jan 30, 2007
<u>AB</u>		LUPIN	<u>125MG/5ML</u>	<u>A065261 001</u>	Dec 19, 2005
<u>AB</u>	+		<u>250MG/5ML</u>	<u>A065261 002</u>	Dec 19, 2005
<u>AB</u>		ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284 002</u>	Dec 30, 2005
<u>AB</u>			<u>250MG/5ML</u>	<u>A065284 001</u>	Dec 30, 2005
<u>AB</u>		SANDOZ	<u>125MG/5ML</u>	<u>A065257 001</u>	Dec 08, 2005
<u>AB</u>			<u>250MG/5ML</u>	<u>A065257 002</u>	Dec 08, 2005

## PRESCRIPTION DRUG PRODUCT LIST

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065236</u>	<u>002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>	+	<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428</u>	<u>002</u>	Jun 14, 2007

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)

TEFLARO

CEREXA

+

400MG/VIAL

600MG/VIAL

N200327 001 Oct 29, 2010

N200327 002 Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>500MG/VIAL</u>	<u>A062640</u>	<u>001</u>	Nov 20, 1985
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062640</u>	<u>002</u>	Nov 20, 1985
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062640</u>	<u>003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640</u>	<u>004</u>	Feb 03, 1992
<u>AP</u>	WOCKHARDT	<u>1GM/VIAL</u>	<u>A065196</u>	<u>001</u>	Oct 15, 2008

FORTAZ

<u>AP</u>	+	IGI LABS INC	<u>500MG/VIAL</u>	<u>N050578</u>	<u>001</u>	Jul 19, 1985
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>N050578</u>	<u>002</u>	Jul 19, 1985
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050578</u>	<u>003</u>	Jul 19, 1985
<u>AP</u>	+		<u>6GM/VIAL</u>	<u>N050578</u>	<u>004</u>	Jul 19, 1985

TAZICEF

<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A062662</u>	<u>001</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062662</u>	<u>002</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032</u>	<u>001</u>	Oct 31, 1993
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662</u>	<u>003</u>	Mar 06, 1986
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032</u>	<u>002</u>	Oct 31, 1993
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662</u>	<u>004</u>	Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

B BRAUN

+

EQ 1GM BASE

EQ 2GM BASE

N050823 001 Jun 13, 2011

N050823 002 Jun 13, 2011

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+

+

EQ 20MG BASE/ML

EQ 40MG BASE/ML

N050634 002 Apr 28, 1989

N050634 003 Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+

PERNIX THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995

FOR SUSPENSION; ORAL

CEDAX

+

PERNIX THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995

+

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; IV (INFUSION)

ZERBAXA

+

CUBIST PHARMS LLC

EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL

N206829 001 Dec 19, 2014

## PRESCRIPTION DRUG PRODUCT LIST

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065329 001</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065329 002</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065329 003</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065328 001</u>	Jul 24, 2008
<u>AP</u>	BEDFORD	<u>EQ 10GM BASE/VIAL</u>	<u>A065475 001</u>	Aug 18, 2008
<u>AP</u>	FACTA FARMA	<u>EQ 10GM BASE/VIAL</u>	<u>A065269 001</u>	Feb 28, 2007
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065231 001</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202563 001</u>	Aug 20, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065231 002</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202563 002</u>	Aug 20, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065232 001</u>	Aug 02, 2005
<u>AP</u>	LUPIN	<u>EQ 10GM BASE/VIAL</u>	<u>A065263 001</u>	Sep 12, 2006
<u>AP</u>	+ SANDOZ	<u>EQ 10GM BASE/VIAL</u>	<u>A065168 001</u>	May 17, 2005
<u>AP</u>	+ SANDOZ INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065204 001</u>	May 03, 2005
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A065204 002</u>	May 03, 2005
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065180 001</u>	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N050796 001</u>	Apr 20, 2005
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050796 002</u>	Apr 20, 2005

ROCEPHIN

<u>AP</u>	+ HOFFMANN LA ROCHE	<u>EQ 500MG BASE/VIAL</u>	<u>A063239 002</u>	Aug 13, 1993
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A063239 003</u>	Aug 13, 1993

## CEFTRIAXONE

SAMSON MEDCL EQ 100GM BASE/VIAL A090057 001 Apr 25, 2014

## CEFTRIAXONE IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224 001	Aug 23, 2005
	+	EQ 40MG BASE/ML	A065224 002	Aug 23, 2005

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

<u>AP</u>	AKORN INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065305 001</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065305 002</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065305 003</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065305 004</u>	Jan 11, 2008
<u>AP</u>	BEDFORD	<u>EQ 250MG BASE/VIAL</u>	<u>A065465 001</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065465 002</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065465 003</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065465 004</u>	Aug 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342 001</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065342 002</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065342 003</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065342 004</u>	Jan 10, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065230 001</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065230 002</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065230 003</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065230 004</u>	Aug 02, 2005
<u>AP</u>	LUPIN	<u>EQ 250MG BASE/VIAL</u>	<u>A065125 001</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065125 002</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065125 003</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065125 004</u>	Sep 30, 2003
<u>AP</u>	+ SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A065169 001</u>	May 09, 2005
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A065169 002</u>	May 09, 2005
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065169 003</u>	May 09, 2005
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A065169 004</u>	May 09, 2005
<u>AP</u>	WOCKHARDT	<u>EQ 250MG BASE/VIAL</u>	<u>A065391 001</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065391 002</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065391 003</u>	Apr 12, 2007

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE/5ML</u>	<u>N050672 001</u>	Jun 30, 1994
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>N050672 002</u>	Apr 29, 1997

CEFUROXIME AXETIL

<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 125MG BASE/5ML</u>	<u>A065323 001</u>	Feb 05, 2008
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065323 002</u>	Feb 05, 2008

TABLET; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE</u>	<u>N050605 001</u>	Dec 28, 1987
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N050605 002</u>	Dec 28, 1987
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050605 003</u>	Dec 28, 1987

## PRESCRIPTION DRUG PRODUCT LIST

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A065496 001</u>	Jun 07, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065496 002</u>	Jun 07, 2010
<u>AB</u>	ANI PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065190 001</u>	Oct 18, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065190 002</u>	Oct 18, 2004
<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A065069 001</u>	Oct 02, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065069 002</u>	Oct 02, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308 001</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065308 002</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065308 003</u>	Mar 29, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065135 001</u>	Jul 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065135 002</u>	Jul 25, 2003
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359 001</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065359 002</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065359 003</u>	Feb 15, 2008
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 125MG BASE</u>	<u>A065118 001</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065118 002</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065118 003</u>	Apr 25, 2003
<u>AB</u>	WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166 001</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065166 002</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065166 003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 750MG BASE/VIAL</u>	<u>N050780 001</u>	Feb 21, 2001
<u>AP</u>	+	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780 002</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>	FACTA FARMA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125 002</u>	May 30, 1997
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124 001</u>	May 30, 1997
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048 002</u>	Jan 09, 2004
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046 001</u>	Jan 09, 2004
<u>AP</u>	HOSPIRA INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483 002</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503 001</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484 001</u>	Oct 15, 2008

ZINACEF

<u>AP</u>	+ CONCORDIA PHARMS INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558 003</u>	Oct 19, 1983
<u>AP</u>	+	<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558 004</u>	Oct 23, 1986

ZINACEF IN PLASTIC CONTAINER

	+ CONCORDIA PHARMS INC	<u>EQ 30MG BASE/ML</u>	<u>N050643 002</u>	Apr 28, 1989
--	------------------------	------------------------	--------------------	--------------

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

<u>AB</u>	FACTA FARMA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125 001</u>	May 30, 1997
<u>AB</u>	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048 001</u>	Jan 09, 2004

ZINACEF

<u>AB</u>	+ CONCORDIA PHARMS INC	<u>EQ 750MG BASE/VIAL</u>	<u>N050558 002</u>	Oct 19, 1983
-----------	------------------------	---------------------------	--------------------	--------------

CEFUROXIME SODIUM

<u>AP</u>	HOSPIRA INC	<u>EQ 750MG BASE/VIAL</u>	<u>A065483 001</u>	Oct 15, 2008
-----------	-------------	---------------------------	--------------------	--------------

CELECOXIB

CAPSULE; ORAL

CELEBREX

<u>AB</u>	GD SEARLE	<u>50MG</u>	<u>N020998 004</u>	Dec 15, 2006
<u>AB</u>		<u>100MG</u>	<u>N020998 001</u>	Dec 31, 1998
<u>AB</u>		<u>200MG</u>	<u>N020998 002</u>	Dec 31, 1998
<u>AB</u>	+	<u>400MG</u>	<u>N020998 003</u>	Aug 29, 2002

CELECOXIB

<u>AB</u>	ALEMBIC PHARMS LTD	<u>50MG</u>	<u>A204519 001</u>	Aug 21, 2015
<u>AB</u>		<u>100MG</u>	<u>A204519 002</u>	Aug 21, 2015
<u>AB</u>		<u>200MG</u>	<u>A204519 003</u>	Aug 21, 2015
<u>AB</u>		<u>400MG</u>	<u>A204519 004</u>	Aug 21, 2015
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A204197 001</u>	Jun 02, 2015
<u>AB</u>		<u>100MG</u>	<u>A204197 002</u>	Jun 02, 2015
<u>AB</u>		<u>200MG</u>	<u>A204197 003</u>	Jun 02, 2015
<u>AB</u>	CIPLA LTD	<u>50MG</u>	<u>A207446 001</u>	Sep 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207446 002</u>	Sep 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207446 003</u>	Sep 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207446 004</u>	Sep 23, 2015
<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A202240 001</u>	Oct 29, 2014
<u>AB</u>		<u>100MG</u>	<u>A202240 002</u>	Jun 09, 2015
<u>AB</u>		<u>200MG</u>	<u>A202240 003</u>	Jun 09, 2015



## PRESCRIPTION DRUG PRODUCT LIST

CELECOXIB

CAPSULE; ORAL

CELECOXIB

<u>AB</u>		<u>400MG</u>	<u>A202240 004</u>	Jun 09, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A078857 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A078857 002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A078857 003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A078857 004</u>	Feb 11, 2015
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076898 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A076898 002</u>	May 30, 2014
<u>AB</u>		<u>200MG</u>	<u>A076898 003</u>	May 30, 2014
<u>AB</u>		<u>400MG</u>	<u>A076898 004</u>	May 30, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>50MG</u>	<u>A207677 001</u>	Dec 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207677 002</u>	Dec 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207677 003</u>	Dec 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207677 004</u>	Dec 23, 2015
<u>AB</u>	WATSON LABS INC	<u>50MG</u>	<u>A200562 001</u>	Feb 11, 2015
<u>AB</u>		<u>100MG</u>	<u>A200562 002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A200562 003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A200562 004</u>	Feb 11, 2015

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A090836 001</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090836 002</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090836 004</u>	Mar 29, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253 001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253 002</u>	Nov 16, 2005
<u>AB</u>	BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713 001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713 002</u>	Jul 15, 1988
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215 001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215 002</u>	Jan 24, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229 001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229 002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248 001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248 002</u>	Jun 28, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 250MG BASE</u>	<u>A062791 001</u>	Jun 11, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062791 002</u>	Jun 11, 1987
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 250MG BASE</u>	<u>A065007 001</u>	Sep 16, 1999
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065007 002</u>	Sep 16, 1999
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702 001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702 002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152 001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152 002</u>	Feb 24, 2005

KEFLEX

<u>AB</u>	SHIONOGI INC	<u>EQ 250MG BASE</u>	<u>N050405 002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050405 003</u>	
<u>AB</u>	+	<u>EQ 750MG BASE</u>	<u>N050405 005</u>	May 12, 2006

CEPHALEXIN

ALKEM LABS LTD  
FOR SUSPENSION; ORAL

EQ 333MG BASE

A090836 003 Mar 29, 2013

CEPHALEXIN

<u>AB</u>	LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234 001</u>	Aug 17, 2005
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065234 002</u>	Aug 17, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326 001</u>	Jul 10, 2006
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065326 002</u>	Jul 10, 2006
<u>AB</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703 001</u>	Feb 13, 1987
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>A062703 002</u>	Feb 13, 1987

TABLET; ORAL

CEPHALEXIN

TEVA

EQ 250MG BASE

A063023 001 Jan 12, 1989

+

EQ 500MG BASE

A063024 001 Jan 12, 1989

CERITINIB

CAPSULE; ORAL

ZYKADIA

+ NOVARTIS PHARMS CORP

150MG

N205755 001 Apr 29, 2014

## PRESCRIPTION DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

<b>AA</b>	AMNEAL PHARMS	<b>5MG/5ML</b>	<b>A090766 001</b>	Oct 07, 2009
<b>AA</b>	BIO PHARM INC	<b>5MG/5ML</b>	<b>A078870 001</b>	Apr 27, 2009
<b>AA</b>	BRECKENRIDGE PHARM	<b>5MG/5ML</b>	<b>A078488 001</b>	Oct 06, 2008
<b>AA</b>	PERRIGO R AND D	<b>5MG/5ML</b>	<b>A078398 001</b>	Jun 17, 2008
<b>AA</b>	SILARX	<b>5MG/5ML</b>	<b>A078876 001</b>	May 11, 2012
<b>AA</b>	SUN PHARM INDS INC	<b>5MG/5ML</b>	<b>A090191 001</b>	Nov 12, 2009
<b>AA</b>	TARO	<b>5MG/5ML</b>	<b>A076601 001</b>	Jun 20, 2008
<b>AA</b>	TEVA PHARMS	<b>5MG/5ML</b>	<b>A077279 001</b>	May 27, 2008
<b>AA</b>	VINTAGE	<b>5MG/5ML</b>	<b>A078496 001</b>	Sep 25, 2009
<b>AA</b>	WOCKHARDT	<b>5MG/5ML</b>	<b>A078757 001</b>	Aug 28, 2009
<b>ZYRTEC</b>				
<b>AA</b>	+ J AND J CONSUMER INC	<b>5MG/5ML</b>	<b>N020346 001</b>	Sep 27, 1996

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+ EMD SERONO INC EQ 0.25MG BASE/ML N021197 001 Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE

<b>AB</b>	APOTEX INC	<b>30MG</b>	<b>A091260 001</b>	Aug 25, 2011
<b>CEVIMELINE HYDROCHLORIDE</b>				
<b>AB</b>	PACK PHARMS LLC	<b>30MG</b>	<b>A203775 001</b>	Jun 04, 2014
<b>AB</b>	ROXANE	<b>30MG</b>	<b>A091591 001</b>	Jul 08, 2013
<b>EVOXAC</b>				
<b>AB</b>	+ DAIICHI SANKYO	<b>30MG</b>	<b>N020989 002</b>	Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

+ NEXGEN PHARMA 250MG A091019 001 Oct 22, 2009

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+ ASPEN GLOBAL INC 2MG N010669 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

+ FRESENIUS KABI USA EQ 1GM BASE/VIAL A062365 001 Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

<b>AB</b>	BARR	<b>5MG</b>	<b>A084768 001</b>	
<b>AB</b>		<b>10MG</b>	<b>A083116 001</b>	
<b>AB</b>		<b>25MG</b>	<b>A084769 001</b>	
<b>AB</b>	USL PHARMA	<b>10MG</b>	<b>A084623 001</b>	
<b>LIBRIUM</b>				
<b>AB</b>	VALEANT PHARM INTL	<b>5MG</b>	<b>A085461 001</b>	
<b>AB</b>		<b>10MG</b>	<b>A085472 001</b>	
<b>AB</b>	+	<b>25MG</b>	<b>A085475 001</b>	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

<b>AT</b>	HI TECH PHARMA	<b>0.12%</b>	<b>A074356 001</b>	May 07, 1996
<b>AT</b>	LYNE	<b>0.12%</b>	<b>A074291 001</b>	Dec 28, 1995
<b>AT</b>	TEVA	<b>0.12%</b>	<b>A074522 001</b>	Dec 15, 1995
<b>AT</b>	WOCKHARDT	<b>0.12%</b>	<b>A075006 001</b>	Mar 03, 2004
<b>AT</b>	XTTRIUM	<b>0.12%</b>	<b>A077789 001</b>	Jun 18, 2009
<b>PAROEX</b>				
<b>AT</b>	SUNSTAR AMERICAS	<b>0.12%</b>	<b>A076434 001</b>	Nov 29, 2005
<b>PERIDEX</b>				
<b>AT</b>	+ 3M	<b>0.12%</b>	<b>N019028 001</b>	Aug 13, 1986
<b>PERIOGARD</b>				
<b>AT</b>	COLGATE	<b>0.12%</b>	<b>A073695 001</b>	Jan 14, 1994
TABLET; DENTAL				
PERIOCHIP				
	+ DEXCEL PHARMA	2.5MG	N020774 001	May 15, 1998

## PRESCRIPTION DRUG PRODUCT LIST

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

<b>AP</b>	EUROHLTH INTL SARL	<u>2%</u>	<u>A040273 001</u>	Sep 09, 1998
<b>AP</b>		<u>3%</u>	<u>A040273 002</u>	Sep 09, 1998
<b>AP</b>	HOSPIRA	<u>2%</u>	<u>A087447 001</u>	Apr 16, 1982
<b>AP</b>		<u>3%</u>	<u>A087446 001</u>	Apr 16, 1982

NESACAINE

<b>AP</b>	FRESENIUS KABI USA	<u>2%</u>	<u>N009435 002</u>	
<u>NESACAINE-MPF</u>				
<b>AP</b>	+ FRESENIUS KABI USA	<u>2%</u>	<u>N009435 006</u>	May 02, 1996
<b>AP</b>	+ NESACAINE	<u>3%</u>	<u>N009435 007</u>	May 02, 1996
	+ FRESENIUS KABI USA	<u>1%</u>	N009435 001	

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

<b>AA</b>	+ SANOFI AVENTIS US	<u>EQ 300MG BASE</u>	<u>N006002 001</u>	
<u>CHLOROQUINE PHOSPHATE</u>				
<b>AA</b>	+ HIKMA PHARMS LLC	<u>EQ 150MG BASE</u>	<u>A083082 001</u>	
<b>AA</b>		<u>EQ 300MG BASE</u>	<u>A083082 002</u>	Sep 17, 1999
<b>AA</b>	IMPAX LABS	<u>EQ 150MG BASE</u>	<u>A080880 001</u>	
<b>AA</b>		<u>EQ 300MG BASE</u>	<u>A040516 001</u>	Aug 29, 2003
<b>AA</b>	IPCA LABS LTD	<u>EQ 150MG BASE</u>	<u>A090610 001</u>	Dec 03, 2009
<b>AA</b>		<u>EQ 300MG BASE</u>	<u>A090249 001</u>	Dec 03, 2009
<b>AA</b>	NATCO PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A091621 001</u>	Jan 21, 2011
<b>AA</b>		<u>EQ 300MG BASE</u>	<u>A090612 001</u>	Jan 21, 2011

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+ SALIX PHARMS

250MG/5ML

N011870 001

TABLET; ORAL

CHLOROTHIAZIDE

+ MYLAN

250MG

A084388 001

500MG

A084217 001

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

<b>AP</b>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090896 001</u>	Oct 16, 2009
<b>AP</b>	LUITPOLD	<u>EQ 500MG BASE/VIAL</u>	<u>A202561 001</u>	Apr 22, 2013
<b>AP</b>	MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<u>A202493 001</u>	Jun 18, 2014
<b>AP</b>	SAGENT PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A202462 001</u>	May 29, 2015
<b>AP</b>	SUN PHARMA GLOBAL	<u>EQ 500MG BASE/VIAL</u>	<u>A091546 001</u>	Jul 26, 2011
<u>DIURIL</u>				
<b>AP</b>	+ OAK PHARMS AKORN	<u>EQ 500MG BASE/VIAL</u>	<u>N011145 005</u>	

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

SPRIASO LLC

8MG; 54.3MG

N206323 001 Jun 22, 2015

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

<b>AA</b>	TRIS PHARMA INC	<u>4MG/5ML; 5MG/5ML</u>	<u>A206438 001</u>	Jan 27, 2015
<u>VITUZ</u>				
<b>AA</b>	+ CYPRESS PHARM	<u>4MG/5ML; 5MG/5ML</u>	<u>N204307 001</u>	Feb 20, 2013

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<b>AA</b>	TRIS PHARMA INC	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>A203838 001</u>	Nov 26, 2014
<u>HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
<b>AA</b>	PADDOCK LLC	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>A204627 001</u>	Apr 29, 2014
<u>HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
<b>AA</b>	COASTAL PHARMS	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>A205657 001</u>	Aug 03, 2015
<u>ZUTRIPRO</u>				
<b>AA</b>	+ CYPRESS PHARM	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>N022439 001</u>	Jun 08, 2011

## PRESCRIPTION DRUG PRODUCT LIST

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

+ VERNALIS R AND D LTD EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML N207768 001 Apr 30, 2015

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

ECR PHARMA EQ 4MG MALEATE;EQ 5MG BITARTRATE A077273 002 Sep 24, 2007

+ EQ 8MG MALEATE;EQ 10MG BITARTRATE A077273 001 Sep 24, 2007

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX**AB** TRIS PHARMA INC EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **A091632 001** Oct 01, 2010HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX**AB** NEOS THERAP INC EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **A091671 001** Jun 29, 2012TUSSIONEX PENNKINETIC**AB** + UCB INC EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **N019111 001** Dec 31, 1987CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+ EUROHLTH INTL SARL 25MG/ML A083329 001

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

BP USL PHARMA 10MG A083386 001

BP 25MG A084112 001

BP 50MG A084113 001

BP 100MG A084114 001

BP 200MG A084115 001

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE**AB** ANI PHARMS INC 100MG **A088921 001** Apr 12, 1985**AB** 250MG **A088922 001** Apr 12, 1985**AB** MYLAN 100MG **A088549 002** Jun 01, 1984**AB** 250MG **A088549 001** Jun 01, 1984DIABINESE**AB** PFIZER 100MG **N011641 003****AB** + 250MG **N011641 006**CHLOROTHALIDONE

TABLET;ORAL

CHLOROTHALIDONE**AB** + MYLAN 50MG **A086831 001****AB** SUN PHARM INDS 50MG **A089286 001** Jul 21, 1986

MYLAN 25MG A086831 002

CHLOROTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLORPRES

MYLAN 15MG;0.1MG A071325 003 Feb 09, 1987

15MG;0.2MG A071325 002 Feb 09, 1987

+ 15MG;0.3MG A071325 001 Feb 09, 1987

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE**AA** BARR 500MG **A089895 001** May 04, 1988**AA** WATSON LABS 500MG **A089859 001** May 04, 1988

MIKART 375MG A040861 001 Jun 01, 2010

750MG A040861 002 Jun 01, 2010

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE**AB** PAR PHARM EQ 4GM RESIN/PACKET **A077204 001** Aug 26, 2005**AB** EQ 4GM RESIN/SCOOPFUL **A077204 002** Aug 26, 2005**AB** + SANDOZ EQ 4GM RESIN/PACKET **A074557 001** Aug 15, 1996**AB** EQ 4GM RESIN/SCOOPFUL **A074557 002** Aug 15, 1996CHOLESTYRAMINE LIGHT**AB** PAR PHARM EQ 4GM RESIN/PACKET **A077203 001** Aug 26, 2005**AB** EQ 4GM RESIN/SCOOPFUL **A077203 002** Aug 26, 2005

## PRESCRIPTION DRUG PRODUCT LIST

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

<b>AB</b>	+	SANDOZ	<b>EQ 4GM RESIN/PACKET</b>	<b>A074558 001</b>	Aug 15, 1996
<b>AB</b>			<b>EQ 4GM RESIN/SCOOPFUL</b>	<b>A074558 002</b>	Aug 15, 1996

PREVALITE

<b>AB</b>		UPSHER SMITH	<b>EQ 4GM RESIN/PACKET</b>	<b>A073263 001</b>	Feb 22, 1996
<b>AB</b>			<b>EQ 4GM RESIN/SCOOPFUL</b>	<b>A073263 002</b>	Oct 30, 1997

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

		RTRX	50MG	N205750 001	Mar 17, 2015
	+		250MG	N205750 002	Mar 17, 2015

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

<b>AP</b>		GLOBAL ISOTOPES LLC	<b>4-33.1mCi/ML</b>	<b>A206319 001</b>	Nov 13, 2015
<b>AP</b>	+	MCPRF	<b>4-33.1mCi/ML</b>	<b>N203155 001</b>	Sep 12, 2012
<b>AP</b>		UNIV TX MD ANDERSON	<b>4-33.1mCi/ML</b>	<b>A205690 001</b>	Oct 29, 2015

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

<b>AB</b>		ACTAVIS ELIZABETH	<b>EQ 45MG FENOFIBRIC ACID</b>	<b>A200920 001</b>	Oct 07, 2015
<b>AB</b>			<b>EQ 135MG FENOFIBRIC ACID</b>	<b>A200920 002</b>	Oct 07, 2015
<b>AB</b>		ANCHEN PHARMS	<b>EQ 45MG FENOFIBRIC ACID</b>	<b>A201573 002</b>	Jul 18, 2013
<b>AB</b>			<b>EQ 135MG FENOFIBRIC ACID</b>	<b>A201573 001</b>	Jul 18, 2013
<b>AB</b>		LUPIN LTD	<b>EQ 45MG FENOFIBRIC ACID</b>	<b>A200750 001</b>	Dec 04, 2013
<b>AB</b>			<b>EQ 135MG FENOFIBRIC ACID</b>	<b>A200750 002</b>	Dec 04, 2013
<b>AB</b>		MYLAN PHARMS INC	<b>EQ 45MG FENOFIBRIC ACID</b>	<b>A200913 001</b>	Mar 25, 2013
<b>AB</b>			<b>EQ 135MG FENOFIBRIC ACID</b>	<b>A200913 002</b>	Mar 25, 2013
<b>TRILIPIX</b>					
<b>AB</b>		ABBVIE	<b>EQ 45MG FENOFIBRIC ACID</b>	<b>N022224 001</b>	Dec 15, 2008
<b>AB</b>	+		<b>EQ 135MG FENOFIBRIC ACID</b>	<b>N022224 002</b>	Dec 15, 2008

CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

OVIDREL

	+	EMD SERONO	EQ 0.25MG /0.5ML	N021149 002	Oct 06, 2003
--	---	------------	------------------	-------------	--------------

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961 001	Jun 26, 1986
--	---	---------	------------------------	-------------	--------------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

		TAKEDA GMBH	0.08MG/INH	N021658 002	Jan 10, 2008
	+		0.16MG/INH	N021658 003	Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

	+	TAKEDA GMBH	0.037MG/INH	N202129 001	Jan 20, 2012
--	---	-------------	-------------	-------------	--------------

SPRAY, METERED; NASAL

OMNARIS

	+	TAKEDA GMBH	0.05MG/INH	N022004 001	Oct 20, 2006
--	---	-------------	------------	-------------	--------------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

<b>AB</b>		FOUGERA PHARMS	<b>0.77%</b>	<b>A076435 001</b>	Dec 29, 2004
<b>AB</b>		G AND W LABS INC	<b>0.77%</b>	<b>A078463 001</b>	Dec 20, 2010
<b>AB</b>		GLENMARK PHARMS	<b>0.77%</b>	<b>A090273 001</b>	Nov 10, 2009
<b>AB</b>		PERRIGO	<b>0.77%</b>	<b>A077364 001</b>	Mar 03, 2006
<b>AB</b>		TARO	<b>0.77%</b>	<b>A076790 001</b>	Apr 12, 2005

LOPROX

<b>AB</b>	+	MEDIMETRIKS PHARMS	<b>0.77%</b>	<b>N018748 001</b>	Dec 30, 1982
-----------	---	--------------------	--------------	--------------------	--------------

GEL; TOPICAL

CICLOPIROX

<b>AB</b>		FOUGERA PHARMS	<b>0.77%</b>	<b>A077896 001</b>	Jun 10, 2008
<b>AB</b>		GLENMARK GENERICS	<b>0.77%</b>	<b>A091595 001</b>	Feb 29, 2012
<b>AB</b>		PADDOCK LLC	<b>0.77%</b>	<b>A078266 001</b>	Jan 07, 2009

## PRESCRIPTION DRUG PRODUCT LIST

CICLOPIROX

GEL; TOPICAL

LOPROX

**AB** + CNTY LINE PHARMS **0.77%** **N020519 001** Jul 21, 1997  
SHAMPOO; TOPICAL

CICLOPIROX

**AT** ACTAVIS MID ATLANTIC **1%** **A090490 001** Nov 24, 2009  
**AT** FOUGERA PHARMS **1%** **A090146 001** May 25, 2010  
**AT** PERRIGO **1%** **A078594 001** Feb 16, 2010  
**AT** TARO **1%** **A090269 001** Feb 23, 2011

LOPROX

**AT** + MEDICIS **1%** **N021159 001** Feb 28, 2003  
SOLUTION; TOPICAL

CICLOPIROX

**AT** ACTAVIS MID ATLANTIC **8%** **A078046 001** Sep 18, 2007  
**AT** APOTEX INC **8%** **A078172 001** Sep 18, 2007  
**AT** CIPLA LTD **8%** **A078124 001** Sep 18, 2007  
**AT** G AND W LABS **8%** **A078233 001** Sep 18, 2007  
**AT** HI TECH PHARMA **8%** **A078270 001** Sep 18, 2007  
**AT** PERRIGO NEW YORK **8%** **A077623 001** Sep 18, 2007  
**AT** TARO PHARM INDS **8%** **A078144 001** Sep 18, 2007  
**AT** TOLMAR **8%** **A077687 001** Sep 18, 2007  
**AT** VERSAPHARM **8%** **A078975 001** Feb 17, 2010

PENLAC

**AT** + VALEANT BERMUDA **8%** **N021022 001** Dec 17, 1999  
SUSPENSION; TOPICAL

CICLOPIROX

**AB** FOUGERA PHARMS **0.77%** **A076422 001** Aug 06, 2004  
**AB** PERRIGO NEW YORK **0.77%** **A077676 001** Dec 15, 2006  
**AB** TARO **0.77%** **A077092 001** Aug 10, 2005

LOPROX

**AB** + MEDIMETRIKS PHARMS **0.77%** **N019824 001** Dec 30, 1988

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

**AP** EMCURE PHARMS LTD **EQ 75MG BASE/ML** **A202501 001** Jul 26, 2012  
**AP** + MYLAN INSTITUTIONAL **EQ 75MG BASE/ML** **A201276 001** Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAMUSCULAR

PRIMAXIN

MERC

EQ 500MG BASE/VIAL; 500MG/VIAL

N050630 001 Dec 14, 1990

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

**AP** ACS DOBFAR **EQ 250MG BASE/VIAL; 250MG/VIAL** **A090577 001** Dec 21, 2011  
**AP** **EQ 500MG BASE/VIAL; 500MG/VIAL** **A090577 002** Dec 21, 2011  
**AP** HOSPIRA INC **EQ 250MG BASE/VIAL; 250MG/VIAL** **A090825 001** Nov 16, 2011  
**AP** **EQ 500MG BASE/VIAL; 500MG/VIAL** **A090825 002** Nov 16, 2011  
**AP** **EQ 500MG BASE/VIAL; 500MG/VIAL** **A091007 001** Nov 16, 2011

PRIMAXIN

**AP** + MERCK **EQ 250MG BASE/VIAL; 250MG/VIAL** **N050587 001** Nov 26, 1985  
**AP** + **EQ 500MG BASE/VIAL; 500MG/VIAL** **N050587 002** Nov 26, 1985

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

**AB** APOTEX INC **50MG** **A077030 001** Dec 10, 2004  
**AB** **100MG** **A077030 002** Dec 10, 2004  
**AB** BIOKEY **50MG** **A077722 001** Sep 24, 2012  
**AB** **100MG** **A077831 001** Sep 24, 2012  
**AB** BRECKENRIDGE PHARM **50MG** **A077708 001** Sep 28, 2009  
**AB** **100MG** **A077708 002** Sep 28, 2009  
**AB** MYLAN **50MG** **A077323 002** Apr 20, 2006  
**AB** **100MG** **A077323 001** Apr 20, 2006  
**AB** MYLAN PHARMS INC **50MG** **A077019 001** Nov 23, 2004  
**AB** **100MG** **A077019 002** Nov 23, 2004  
**AB** PLIVA HRVATSKA DOO **50MG** **A077898 001** Oct 29, 2007  
**AB** **100MG** **A077898 002** Oct 29, 2007  
**AB** ROXANE **50MG** **A077024 001** May 17, 2005  
**AB** **100MG** **A077024 002** May 17, 2005  
**AB** SANDOZ **50MG** **A077310 001** Nov 08, 2005  
**AB** **100MG** **A077021 001** Nov 23, 2004  
**AB** TEVA **50MG** **A077027 001** Nov 24, 2004

## PRESCRIPTION DRUG PRODUCT LIST

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>		<u>100MG</u>	<u>A077027 002</u>	Nov 24, 2004
	<u>PLETAL</u>			
<u>AB</u>	+ OTSUKA	<u>50MG</u>	<u>N020863 001</u>	Jan 15, 1999
<u>AB</u>	+	<u>100MG</u>	<u>N020863 002</u>	Jan 15, 1999

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A074890 001</u>	Dec 18, 1998
<u>AB</u>		<u>300MG</u>	<u>A074890 002</u>	Dec 18, 1998
<u>AB</u>		<u>400MG</u>	<u>A074890 003</u>	Dec 18, 1998
<u>AB</u>		<u>800MG</u>	<u>A074890 004</u>	Dec 18, 1998
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246 001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246 002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246 003</u>	May 17, 1994
<u>AB</u>	+	<u>800MG</u>	<u>A074246 004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>800MG</u>	<u>A074566 001</u>	Feb 27, 1997
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151 001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151 002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151 003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463 001</u>	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

<u>AP</u>	DAVA PHARMS INC	<u>EQ 300MG BASE/2ML</u>	<u>A074428 001</u>	Apr 25, 1996
	SOLUTION; ORAL			
	<u>CIMETIDINE HYDROCHLORIDE</u>			
<u>AA</u>	ANI PHARMS INC	<u>EQ 300MG BASE/5ML</u>	<u>A074610 001</u>	Sep 26, 1996
<u>AA</u>	+ HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664 001</u>	Oct 28, 1997
<u>AA</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553 001</u>	Jan 27, 1997
<u>AA</u>	WOCKHARDT	<u>EQ 300MG BASE/5ML</u>	<u>A074757 001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

+

EQ 30MG BASE  
EQ 60MG BASE  
EQ 90MG BASEN021688 001 Mar 08, 2004  
N021688 002 Mar 08, 2004  
N021688 003 Mar 08, 2004CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

<u>AB</u>	BAYER HLTHCARE	<u>250MG/5ML</u>	<u>N020780 001</u>	Sep 26, 1997
<u>AB</u>	+	<u>500MG/5ML</u>	<u>N020780 002</u>	Sep 26, 1997
	<u>CIPROFLOXACIN</u>			
<u>AB</u>	LUPIN LTD	<u>250MG/5ML</u>	<u>A200563 001</u>	Mar 05, 2014
<u>AB</u>		<u>500MG/5ML</u>	<u>A200563 002</u>	Mar 05, 2014

INJECTABLE; INJECTION

CIPRO

<u>AP</u>	+ BAYER HLTHCARE	<u>400MG/40ML (10MG/ML)</u>	<u>N019847 001</u>	Dec 26, 1990
<u>AP</u>	+	<u>200MG/20ML (10MG/ML)</u>	<u>N019847 002</u>	Dec 26, 1990
	<u>CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ BAYER HLTHCARE	<u>200MG/100ML</u>	<u>N019857 001</u>	Dec 26, 1990
<u>AP</u>	+	<u>400MG/200ML</u>	<u>N019857 002</u>	Dec 26, 1990

CIPROFLOXACIN

<u>AP</u>	CLARIS PHARMASERVICE	<u>200MG/20ML (10MG/ML)</u>	<u>A078062 001</u>	Apr 29, 2008
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A078062 002</u>	Apr 29, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717 001</u>	Dec 22, 2009
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A076717 002</u>	Dec 22, 2009
<u>AP</u>	HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245 001</u>	Aug 28, 2006
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A077245 002</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252 001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078252 002</u>	Mar 18, 2008
<u>AP</u>	CLARIS PHARMASERVICE	<u>200MG/100ML</u>	<u>A078024 001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078024 002</u>	Mar 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431 001</u>	Nov 18, 2009
<u>AP</u>	HOSPIRA	<u>200MG/100ML</u>	<u>A077753 001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077753 002</u>	Mar 18, 2008

## PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN

INJECTABLE, SUSPENSION;OTIC

OTIPRIO

+ OTONOMY INC

6% (60MG/ML)

N207986 001 Dec 10, 2015

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC

CILOXAN

+ ALCON PHARMS LTD

EQ 0.3% BASE

N020369 001 Mar 30, 1998

SOLUTION/DROPS;OPHTHALMIC

CILOXANAT + ALCON PHARMS LTDEQ 0.3% BASEN019992 001 Dec 31, 1990CIPROFLOXACIN HYDROCHLORIDEAT AKORN INCEQ 0.3% BASEA076555 001 Dec 11, 2008AT FDC LTDEQ 0.3% BASEA077568 001 Jun 30, 2008AT IGI LABS INCEQ 0.3% BASEA076754 001 Jun 09, 2004AT PHARMAFORCEEQ 0.3% BASEA078598 001 Jan 16, 2008AT RISING PHARMS INCEQ 0.3% BASEA077689 001 Dec 13, 2006AT WATSON LABS INCEQ 0.3% BASEA076673 001 Jan 21, 2005

SOLUTION/DROPS;OTIC

CETRALAX

+ WRASER PHARMS

EQ 0.2% BASE

N021918 001 May 01, 2009

TABLET;ORAL

CIPROAB BAYER HLTHCAREEQ 100MG BASEN019537 001 Apr 08, 1996ABEQ 250MG BASEN019537 002 Oct 22, 1987AB +EQ 500MG BASEN019537 003 Oct 22, 1987ABEQ 750MG BASEN019537 004 Oct 22, 1987CIPROFLOXACIN HYDROCHLORIDEAB APOTEXEQ 250MG BASEA076896 001 Nov 04, 2004ABEQ 500MG BASEA076896 002 Nov 04, 2004ABEQ 750MG BASEA076896 003 Nov 04, 2004AB AUROBINDO PHARMAEQ 250MG BASEA077859 001 Apr 26, 2007ABEQ 500MG BASEA077859 002 Apr 26, 2007ABEQ 750MG BASEA077859 003 Apr 26, 2007AB CARLSBADEQ 250MG BASEA076126 002 Jun 09, 2004ABEQ 500MG BASEA076126 003 Jun 09, 2004ABEQ 750MG BASEA076126 004 Jun 09, 2004AB DR REDDYS LABS LTDEQ 100MG BASEA075593 002 Jun 09, 2004ABEQ 250MG BASEA075593 003 Jun 09, 2004ABEQ 500MG BASEA075593 004 Jun 09, 2004ABEQ 750MG BASEA075593 001 Jun 09, 2004AB HIKMAEQ 250MG BASEA076558 002 Jun 09, 2004ABEQ 500MG BASEA076558 003 Jun 09, 2004ABEQ 750MG BASEA076558 004 Jun 09, 2004AB IVAX SUB TEVA PHARMSEQ 250MG BASEA076089 002 Jun 09, 2004ABEQ 500MG BASEA076089 003 Jun 09, 2004ABEQ 750MG BASEA076089 004 Jun 09, 2004AB MYLANEQ 100MG BASEA075817 001 Jun 25, 2007ABEQ 250MG BASEA075685 002 Jun 09, 2004ABEQ 250MG BASEA075817 002 Jun 09, 2004ABEQ 500MG BASEA075685 003 Jun 09, 2004ABEQ 500MG BASEA075817 003 Jun 09, 2004ABEQ 750MG BASEA075685 001 Jun 09, 2004ABEQ 750MG BASEA075817 004 Jun 09, 2004AB SUN PHARM INDS LTDEQ 250MG BASEA075747 001 Jun 09, 2004ABEQ 500MG BASEA075747 002 Jun 09, 2004ABEQ 750MG BASEA075747 003 Jun 09, 2004AB TAROEQ 100MG BASEA076912 001 Feb 18, 2005ABEQ 250MG BASEA076912 002 Oct 06, 2004ABEQ 500MG BASEA076912 003 Oct 06, 2004ABEQ 750MG BASEA076912 004 Oct 06, 2004AB UNIQUE PHARM LABSEQ 250MG BASEA076639 001 Sep 10, 2004ABEQ 500MG BASEA076639 002 Sep 10, 2004ABEQ 750MG BASEA076639 003 Sep 10, 2004AB WATSON LABSEQ 100MG BASEA076794 001 Feb 10, 2005ABEQ 250MG BASEA076794 002 Jun 09, 2004ABEQ 500MG BASEA076794 003 Jun 09, 2004ABEQ 750MG BASEA076794 004 Jun 09, 2004



## PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

+ ALCON PHARMS LTD EQ 0.2% BASE;1% N020805 001 Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

<u>AB</u>	ACTAVIS LABS FL INC	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A077417 001</u>	Nov 30, 2010
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077809 001</u>	Nov 30, 2010
<u>AB</u>	ANCHEN PHARMS	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078166 002</u>	Nov 27, 2007
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078166 001</u>	Nov 27, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077701 001</u>	Mar 26, 2007
<u>AB</u>	+ MYLAN PHARMS INC	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078183 001</u>	Mar 22, 2007
<u>AB</u>	+	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078183 002</u>	Mar 22, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

+ ALCON PHARMS LTD 0.3%;0.1% N021537 001 Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A203183 001</u>	Feb 26, 2015
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200159 001</u>	Feb 03, 2012
<u>CISATRACURIUM BESYLATE PRESERVATIVE FREE</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A203182 001</u>	Feb 26, 2015
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A203182 002</u>	Feb 26, 2015
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200154 001</u>	Feb 03, 2012
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A200154 002</u>	Feb 03, 2012
<u>NIMBEX</u>				
<u>AP</u>	+ ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551 001</u>	Dec 15, 1995
<u>NIMBEX PRESERVATIVE FREE</u>				
<u>AP</u>	+ ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551 003</u>	Dec 15, 1995
<u>AP</u>	+	<u>EQ 10MG BASE/ML</u>	<u>N020551 002</u>	Dec 15, 1995

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

<u>AP</u>	ACCORD HLTHCARE	<u>1MG/ML</u>	<u>A206774 001</u>	Aug 18, 2015
<u>AP</u>	EUROHLTH INTL SARL	<u>1MG/ML</u>	<u>A075036 001</u>	Nov 07, 2000
<u>AP</u>	+ FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A074735 001</u>	Jul 16, 1999
<u>AP</u>	HQ SPCLT PHARMA	<u>1MG/ML</u>	<u>N018057 004</u>	Nov 08, 1988
<u>AP</u>	MYLAN LABS LTD	<u>1MG/ML</u>	<u>A091062 001</u>	Apr 18, 2012
<u>AP</u>	PHARMACHEMIE BV	<u>1MG/ML</u>	<u>A074656 001</u>	May 16, 2000

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC EQ 10MG BASE A077668 001 Feb 28, 2007

EQ 20MG BASE A077668 002 Feb 28, 2007

+ EQ 40MG BASE A077668 003 Feb 28, 2007

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/5ML</u>	<u>A077812 001</u>	Aug 28, 2006
<u>AA</u>	HETERO LABS LTD III	<u>EQ 10MG BASE/5ML</u>	<u>A201450 001</u>	Dec 15, 2015
<u>AA</u>	+ ROXANE	<u>EQ 10MG BASE/5ML</u>	<u>A077043 001</u>	Dec 13, 2004
<u>AA</u>	SILARX	<u>EQ 10MG BASE/5ML</u>	<u>A077629 001</u>	Jun 15, 2006

TABLET;ORAL

CELEXA

<u>AB</u>	FOREST LABS	<u>EQ 10MG BASE</u>	<u>N020822 001</u>	Apr 27, 2000
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020822 002</u>	Jul 17, 1998
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020822 003</u>	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 10MG BASE</u>	<u>A077289 001</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077289 002</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077289 003</u>	Nov 30, 2006
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A077046 001</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077046 002</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077046 003</u>	Nov 24, 2004
<u>AB</u>	AUROBINDO	<u>EQ 10MG BASE</u>	<u>A077031 001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077031 002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077031 003</u>	Oct 28, 2004
<u>AB</u>	CIPLA LTD	<u>EQ 10MG BASE</u>	<u>A077044 001</u>	Nov 05, 2004

## PRESCRIPTION DRUG PRODUCT LIST

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044 003</u>	Nov 05, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A077038 001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077038 002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077038 003</u>	Oct 28, 2004
<u>AB</u>	EPIC PHARMA	<u>EQ 10MG BASE</u>	<u>A077045 003</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077045 002</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077045 001</u>	Apr 29, 2005
<u>AB</u>	G AND W LABS INC	<u>EQ 10MG BASE</u>	<u>A077048 001</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077048 002</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077048 003</u>	Nov 16, 2004
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A077654 001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077654 002</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077654 003</u>	Feb 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A077534 001</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077534 002</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077534 003</u>	Oct 03, 2006
<u>AB</u>	JUBILANT GENERICS	<u>EQ 10MG BASE</u>	<u>A205407 001</u>	Dec 23, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205407 002</u>	Dec 23, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205407 003</u>	Dec 23, 2015
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A077039 001</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077042 001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077039 002</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077042 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077039 003</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077042 003</u>	Nov 05, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A077037 001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077037 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077037 003</u>	Nov 05, 2004
<u>AB</u>	PLIVA	<u>EQ 10MG BASE</u>	<u>A077232 001</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077232 002</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077232 003</u>	Oct 31, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 10MG BASE</u>	<u>A077032 001</u>	Nov 12, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077032 002</u>	Nov 12, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077032 003</u>	Nov 12, 2004
<u>AB</u>	TORRENT PHARMS	<u>EQ 10MG BASE</u>	<u>A078216 001</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078216 002</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078216 003</u>	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

+ UNITED GUARDIAN 6.602GM/100ML; 198MG/100ML; 3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+ FERRING PHARMS AS 12GM/PACKET; 3.5GM/PACKET; 10MG/PACKET N202535 001 Jul 16, 2012

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+ EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

<u>AP</u>	EUROHLTH INTL SARL	<u>1MG/ML</u>	<u>A075405 001</u>	Feb 28, 2000
<u>AP</u>	+ FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076571 001</u>	Apr 22, 2004
<u>AP</u>	MYLAN LABS LTD	<u>1MG/ML</u>	<u>A200510 001</u>	Oct 06, 2011

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

<u>AB</u>	ABBVIE	<u>125MG/5ML</u>	<u>N050698 001</u>	Dec 23, 1993
<u>AB</u>	+	<u>250MG/5ML</u>	<u>N050698 002</u>	Dec 23, 1993

CLARITHROMYCIN

<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065283 002</u>	Sep 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065283 003</u>	Sep 04, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>125MG/5ML</u>	<u>A065382 001</u>	Aug 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065382 002</u>	Aug 30, 2007

## PRESCRIPTION DRUG PRODUCT LIST

CLARITHROMYCIN

TABLET; ORAL

BIAXIN

<u>AB</u>	+	ABBVIE	<u>250MG</u>	<u>N050662</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>	+		<u>500MG</u>	<u>N050662</u>	<u>002</u>	Oct 31, 1991

CLARITHROMYCIN

<u>AB</u>		ALLIED PHARMA INC	<u>250MG</u>	<u>A202710</u>	<u>001</u>	Jun 10, 2013
<u>AB</u>			<u>500MG</u>	<u>A202710</u>	<u>002</u>	Jun 10, 2013
<u>AB</u>		APOTEX CORP	<u>250MG</u>	<u>A065384</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>			<u>500MG</u>	<u>A065384</u>	<u>002</u>	Aug 20, 2007
<u>AB</u>		AUROBINDO	<u>250MG</u>	<u>A065489</u>	<u>001</u>	Jul 25, 2012
<u>AB</u>			<u>500MG</u>	<u>A065489</u>	<u>002</u>	Jul 25, 2012
<u>AB</u>		HEC PHARM USA INC	<u>250MG</u>	<u>A203584</u>	<u>001</u>	Sep 28, 2015
<u>AB</u>			<u>500MG</u>	<u>A203584</u>	<u>002</u>	Sep 28, 2015
<u>AB</u>		MYLAN	<u>250MG</u>	<u>A065195</u>	<u>001</u>	Mar 11, 2005
<u>AB</u>			<u>500MG</u>	<u>A065195</u>	<u>002</u>	Mar 11, 2005
<u>AB</u>		ROXANE	<u>250MG</u>	<u>A065178</u>	<u>002</u>	May 25, 2004
<u>AB</u>			<u>500MG</u>	<u>A065178</u>	<u>001</u>	May 25, 2004
<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A065144</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>			<u>500MG</u>	<u>A065136</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>		SUN PHARM INDS LTD	<u>250MG</u>	<u>A065174</u>	<u>001</u>	Sep 24, 2004
<u>AB</u>			<u>500MG</u>	<u>A065174</u>	<u>002</u>	Sep 24, 2004
<u>AB</u>		TEVA	<u>250MG</u>	<u>A065155</u>	<u>001</u>	May 31, 2005
<u>AB</u>			<u>500MG</u>	<u>A065155</u>	<u>002</u>	May 31, 2005
<u>AB</u>		WOCKHARDT	<u>250MG</u>	<u>A065266</u>	<u>001</u>	May 31, 2006
<u>AB</u>			<u>500MG</u>	<u>A065266</u>	<u>002</u>	May 31, 2006

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

<u>AB</u>		ACTAVIS LABS FL INC	<u>500MG</u>	<u>A065145</u>	<u>001</u>	Jun 24, 2004
<u>AB</u>		LUPIN LTD	<u>500MG</u>	<u>A202532</u>	<u>001</u>	Sep 15, 2015
<u>AB</u>	+	TEVA	<u>500MG</u>	<u>A065154</u>	<u>001</u>	May 18, 2005

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

<u>AA</u>	+	TEVA	<u>EQ 0.5MG BASE/5ML</u>	<u>A073399</u>	<u>001</u>	Jun 30, 1994
<u>AA</u>		WOCKHARDT	<u>EQ 0.5MG BASE/5ML</u>	<u>A074863</u>	<u>001</u>	Mar 13, 1998

TABLET; ORAL

CLEMASTINE FUMARATE

<u>AB</u>		SANDOZ	<u>2.68MG</u>	<u>A073459</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	+	TEVA	<u>2.68MG</u>	<u>A073283</u>	<u>001</u>	Jan 31, 1992

CLEVIDIPINE

EMULSION; INTRAVENOUS

## CLEVIPREX

+	THE MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008
+		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

<u>AB</u>		PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162</u>	<u>001</u>	
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>N050162</u>	<u>002</u>	
<u>AB</u>	+		<u>EQ 300MG BASE</u>	<u>N050162</u>	<u>003</u>	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065442</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>		COREPHARMA	<u>EQ 150MG BASE</u>	<u>A065194</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065194</u>	<u>002</u>	Mar 22, 2004
<u>AB</u>		G AND W LABS INC	<u>EQ 150MG BASE</u>	<u>A063029</u>	<u>001</u>	Sep 20, 1989
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A063029</u>	<u>002</u>	Aug 05, 2005
<u>AB</u>		LANNETT	<u>EQ 75MG BASE</u>	<u>A065242</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A065242</u>	<u>002</u>	Aug 12, 2005
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065243</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A091225</u>	<u>001</u>	May 31, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A091225</u>	<u>002</u>	May 31, 2011
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A091225</u>	<u>003</u>	May 31, 2011
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001
<u>AB</u>		WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A063083</u>	<u>002</u>	Mar 18, 2003
<u>AB</u>		ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217</u>	<u>001</u>	Jan 31, 2005
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A065217</u>	<u>002</u>	Jan 31, 2005

## PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE**AB** + PHARMACIA AND UPJOHN **EQ 300MG BASE** **A065217 003** Jan 31, 2005CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN**AA** + PHARMACIA AND UPJOHN **EQ 75MG BASE/5ML** **A062644 001** Apr 07, 1986CLINDAMYCIN PALMITATE HYDROCHLORIDE**AA** AMNEAL PHARMS **EQ 75MG BASE/5ML** **A203513 001** Mar 13, 2014**AA** AUROBINDO PHARMA LTD **EQ 75MG BASE/5ML** **A202409 001** Apr 30, 2013**AA** LYNE **EQ 75MG BASE/5ML** **A201821 001** Aug 28, 2012**AA** PADDOCK LABS **EQ 75MG BASE/5ML** **A090902 001** Jul 07, 2010CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE**AT** PERRIGO UK FINCO **1%** **A090785 001** Mar 31, 2010EVOCLIN**AT** + DELCOR ASSET **1%** **N050801 001** Oct 22, 2004

CREAM;VAGINAL

CLEOCIN**AB** + PHARMACIA AND UPJOHN **EQ 2% BASE** **N050680 002** Mar 02, 1998CLINDAMYCIN PHOSPHATE**AB** FOUGERA PHARMS **EQ 2% BASE** **A065139 001** Dec 27, 2004

CLINDESSE

+ ELAN PHARMA INTL LTD **EQ 2% BASE** **N050793 001** Nov 30, 2004

GEL;TOPICAL

CLEOCIN T**AB** + PHARMACIA AND UPJOHN **EQ 1% BASE** **N050615 001** Jan 07, 1987CLINDAMYCIN PHOSPHATE**AB** FOUGERA PHARMS **EQ 1% BASE** **A064160 001** Jan 28, 2000

CLINDAGEL

**BT** + PRECISION DERMAT **EQ 1% BASE** **N050782 001** Nov 27, 2000

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE**AP** PHARMACIA AND UPJOHN **EQ 150MG BASE/ML** **A062803 001** Oct 16, 1987**AP** + **EQ 150MG BASE/ML** **N050441 001**CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER**AP** + PHARMACIA AND UPJOHN **EQ 6MG BASE/ML** **N050639 001** Aug 30, 1989**AP** + **EQ 12MG BASE/ML** **N050639 002** Aug 30, 1989**AP** + **EQ 18MG BASE/ML** **N050639 003** Apr 10, 1991CLINDAMYCIN PHOSPHATE**AP** ALVOGEN INC **EQ 150MG BASE/ML** **A062800 001** Jul 24, 1987**AP** **EQ 150MG BASE/ML** **A062801 001** Jul 24, 1987**AP** **EQ 150MG BASE/ML** **A062943 001** Sep 29, 1988**AP** BEDFORD **EQ 150MG BASE/ML** **A065206 001** Sep 24, 2004**AP** FRESENIUS KABI USA **EQ 150MG BASE/ML** **A065346 001** Mar 29, 2007**AP** **EQ 150MG BASE/ML** **A065347 001** May 09, 2007**AP** HIKMA MAPLE **EQ 150MG BASE/ML** **A062889 001** Apr 25, 1988**AP** SAGENT PHARMS **EQ 150MG BASE/ML** **A090108 001** Sep 30, 2011**AP** SAGENT STRIDES **EQ 150MG BASE/ML** **A090109 001** Sep 30, 2011CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER**AP** AKORN INC **EQ 6MG BASE/ML** **A203048 001** Apr 04, 2013**AP** **EQ 12MG BASE/ML** **A203048 002** Apr 04, 2013**AP** **EQ 18MG BASE/ML** **A203048 003** Apr 04, 2013**AP** SANDOZ INC **EQ 6MG BASE/ML** **A201692 001** May 31, 2012**AP** **EQ 12MG BASE/ML** **A201692 002** May 31, 2012**AP** **EQ 18MG BASE/ML** **A201692 003** May 31, 2012

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

+ ABRAXIS PHARM **EQ 900MG BASE/100ML** **N050635 001** Dec 22, 1989

LOTION;TOPICAL

CLEOCIN T**AB** + PHARMACIA AND UPJOHN **EQ 1% BASE** **N050600 001** May 31, 1989CLINDAMYCIN PHOSPHATE**AB** FOUGERA PHARMS **EQ 1% BASE** **A065067 001** Jan 31, 2002

SOLUTION;TOPICAL

CLEOCIN T**AT** + PHARMACIA AND UPJOHN **EQ 1% BASE** **N050537 001**CLINDA-DERM**AT** PADDOCK LLC **EQ 1% BASE** **A063329 001** Sep 30, 1992

## PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

<b>AT</b>	FOUGERA	<b>EQ 1% BASE</b>	<b>A064159 001</b>	Jun 05, 1997
<b>AT</b>	FOUGERA PHARMS	<b>EQ 1% BASE</b>	<b>A065254 001</b>	Feb 14, 2006
<b>AT</b>	G AND W LABS INC	<b>EQ 1% BASE</b>	<b>A062811 001</b>	Sep 01, 1988
<b>AT</b>	PERRIGO NEW YORK	<b>EQ 1% BASE</b>	<b>A064050 001</b>	Nov 30, 1995
<b>AT</b>	TARO PHARM INDS	<b>EQ 1% BASE</b>	<b>A065184 001</b>	Mar 31, 2004
<b>AT</b>	VINTAGE PHARMS	<b>EQ 1% BASE</b>	<b>A203343 001</b>	May 29, 2015
<b>AT</b>	WOCKHARDT	<b>EQ 1% BASE</b>	<b>A063304 001</b>	Jul 15, 1997

SUPPOSITORY; VAGINAL

CLEOCIN

	+ PHARMACIA AND UPJOHN	100MG	N050767 001	Aug 13, 1999
--	------------------------	-------	-------------	--------------

SWAB; TOPICAL

CLEOCIN

<b>AT</b>	PHARMACIA AND UPJOHN	<b>EQ 1% BASE</b>	<b>N050537 002</b>	Feb 22, 1994
-----------	----------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<b>AT</b>	PERRIGO NEW YORK	<b>EQ 1% BASE</b>	<b>A065049 001</b>	May 25, 2000
-----------	------------------	-------------------	--------------------	--------------

<b>AT</b>	VERSAPHARM	<b>EQ 1% BASE</b>	<b>A065513 001</b>	Jun 17, 2010
-----------	------------	-------------------	--------------------	--------------

CLINDETS

<b>AT</b>	PERRIGO	<b>EQ 1% BASE</b>	<b>A064136 001</b>	Sep 30, 1996
-----------	---------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>1.2%;0.025%</b>	<b>A202564 001</b>	Jun 12, 2015
-----------	----------------------	--------------------	--------------------	--------------

ZIANA

<b>AB</b>	+ MEDICIS	<b>1.2%;0.025%</b>	<b>N050802 001</b>	Nov 07, 2006
-----------	-----------	--------------------	--------------------	--------------

VELTIN

<b>BX</b>	+ STIEFEL GSK	1.2%;0.025%	N050803 001	Jul 16, 2010
-----------	---------------	-------------	-------------	--------------

CLOBAZAM

SUSPENSION; ORAL

ONFI

	+ LUNDBECK LLC	2.5MG/ML	N203993 001	Dec 14, 2012
--	----------------	----------	-------------	--------------

TABLET; ORAL

ONFI

	LUNDBECK LLC	10MG	N202067 002	Oct 21, 2011
--	--------------	------	-------------	--------------

		20MG	N202067 003	Oct 21, 2011
--	--	------	-------------	--------------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

<b>AB1</b>	PERRIGO ISRAEL	<b>0.05%</b>	<b>A077763 001</b>	Mar 10, 2008
------------	----------------	--------------	--------------------	--------------

OLUX

<b>AB1</b>	+ DELCOR ASSET	<b>0.05%</b>	<b>N021142 001</b>	May 26, 2000
------------	----------------	--------------	--------------------	--------------

CLOBETASOL PROPIONATE

<b>AB2</b>	PERRIGO ISRAEL	<b>0.05%</b>	<b>A201402 001</b>	Aug 14, 2012
------------	----------------	--------------	--------------------	--------------

OLUX E

<b>AB2</b>	+ DELCOR ASSET	<b>0.05%</b>	<b>N022013 001</b>	Jan 12, 2007
------------	----------------	--------------	--------------------	--------------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

<b>AB1</b>	FOUGERA	<b>0.05%</b>	<b>A074392 001</b>	Sep 30, 1996
------------	---------	--------------	--------------------	--------------

<b>AB1</b>	G AND W LABS INC	<b>0.05%</b>	<b>A074139 001</b>	Aug 03, 1994
------------	------------------	--------------	--------------------	--------------

<b>AB1</b>	TARO	<b>0.05%</b>	<b>A074249 001</b>	Jul 08, 1996
------------	------	--------------	--------------------	--------------

CORMAX

<b>AB1</b>	+ HI TECH PHARMA	<b>0.05%</b>	<b>A074220 001</b>	May 16, 1997
------------	------------------	--------------	--------------------	--------------

CLOBETASOL PROPIONATE (EMOLLIENT)

<b>AB2</b>	+ FOUGERA PHARMS	<b>0.05%</b>	<b>A075430 001</b>	May 26, 1999
------------	------------------	--------------	--------------------	--------------

<b>AB2</b>	TARO	<b>0.05%</b>	<b>A075633 001</b>	May 17, 2000
------------	------	--------------	--------------------	--------------

EMBELINE E

<b>AB2</b>	HI TECH PHARMA	<b>0.05%</b>	<b>A075325 001</b>	Dec 24, 1998
------------	----------------	--------------	--------------------	--------------

GEL; TOPICAL

CLOBETASOL PROPIONATE

<b>AB</b>	+ FOUGERA PHARMS	<b>0.05%</b>	<b>A075368 001</b>	Feb 15, 2000
-----------	------------------	--------------	--------------------	--------------

<b>AB</b>	PERRIGO	<b>0.05%</b>	<b>A075027 001</b>	Oct 31, 1997
-----------	---------	--------------	--------------------	--------------

<b>AB</b>	TARO	<b>0.05%</b>	<b>A075279 001</b>	May 28, 1999
-----------	------	--------------	--------------------	--------------

EMBELINE

<b>AB</b>	HI TECH PHARMA	<b>0.05%</b>	<b>A076141 001</b>	Apr 12, 2002
-----------	----------------	--------------	--------------------	--------------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>0.05%</b>	<b>A078223 001</b>	Dec 04, 2008
-----------	----------------------	--------------	--------------------	--------------

<b>AB</b>	TARO	<b>0.05%</b>	<b>A200302 001</b>	Jul 02, 2012
-----------	------	--------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

LOTION; TOPICAL

CLOBEX

**AB** + GALDERMA LABS LP **0.05%** **N021535 001** Jul 24, 2003  
 OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

**AB** FOUGERA PHARMS **0.05%** **A074407 001** Feb 23, 1996  
**AB** G AND W LABS INC **0.05%** **A074089 001** Feb 16, 1994  
**AB** TARO **0.05%** **A074248 001** Jul 12, 1996

EMBELINE

**AB** HI TECH PHARMA **0.05%** **A074221 001** Mar 31, 1995

TEMOVATE

**AB** + FOUGERA PHARMS **0.05%** **N019323 001** Dec 27, 1985  
 SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

**AB** ACTAVIS MID ATLANTIC **0.05%** **A078854 001** Jun 07, 2011  
**AB** PERRIGO ISRAEL **0.05%** **A090974 001** Aug 09, 2012

CLOBEX

**AB** + GALDERMA LABS **0.05%** **N021644 001** Feb 05, 2004  
 SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

**AT** FOUGERA PHARMS **0.05%** **A075391 001** Feb 08, 1999  
**AT** G AND W LABS INC **0.05%** **A074331 001** Dec 15, 1995  
**AT** NOVEL LABS INC **0.05%** **A206075 001** Nov 23, 2015  
**AT** TARO **0.05%** **A075224 001** Nov 16, 1998  
**AT** **0.05%** **A075363 001** Dec 29, 2000  
**AT** TOLMAR **0.05%** **A076977 001** Aug 05, 2005  
**AT** WOCKHARDT **0.05%** **A075205 001** Nov 13, 1998

EMBELINE

**AT** + HI TECH PHARMA **0.05%** **A074222 001** Dec 06, 1995  
 SPRAY; TOPICAL

CLOBETASOL PROPIONATE

**AT** PADDOCK LLC **0.05%** **A090898 001** Jun 16, 2011

CLOBEX

**AT** + GALDERMA LABS LP **0.05%** **N021835 001** Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+ PROMIUS PHARMA LLC 0.1%

N017765 001

CLOFARABINE

INJECTABLE; IV (INFUSION)

CLOLAR

+ GENZYME 20MG/20ML (1MG/ML)

N021673 001 Dec 28, 2004

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

+ NOVARTIS 50MG

N019500 002 Dec 15, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID

**AB** + SANOFI AVENTIS US **50MG** **N016131 002**

CLOMIPHENE CITRATE

**AB** PAR PHARM **50MG** **A075528 001** Aug 30, 1999

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

**AB** MALLINCKRODT LLC **25MG** **N019906 001** Dec 29, 1989

**AB** + **50MG** **N019906 002** Dec 29, 1989

**AB** **75MG** **N019906 003** Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

**AB** MYLAN **25MG** **A074947 001** Apr 30, 1998

**AB** **50MG** **A074947 002** Apr 30, 1998

**AB** **75MG** **A074947 003** Apr 30, 1998

**AB** SANDOZ **25MG** **A074364 001** Mar 29, 1996

**AB** **50MG** **A074364 002** Mar 29, 1996

**AB** **75MG** **A074364 003** Mar 29, 1996

**AB** TARO **25MG** **A074694 001** Dec 31, 1996

**AB** **50MG** **A074694 002** Dec 31, 1996

**AB** **75MG** **A074694 003** Dec 31, 1996

**AB** TEVA **25MG** **A074958 001** Aug 26, 1997

**PRESCRIPTION DRUG PRODUCT LIST**CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A074958 002</u>	Aug 26, 1997
<u>AB</u>		<u>75MG</u>	<u>A074958 003</u>	Aug 26, 1997

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A077147 001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147 002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147 003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869 001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869 002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869 003</u>	Oct 31, 1996
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A075150 001</u>	Oct 05, 1998
<u>AB</u>		<u>1MG</u>	<u>A075150 002</u>	Oct 05, 1998
<u>AB</u>		<u>2MG</u>	<u>A075150 003</u>	Oct 05, 1998
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A074940 001</u>	Oct 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074940 002</u>	Oct 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074940 003</u>	Oct 30, 1997
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979 001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979 002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979 003</u>	Aug 29, 1997
<u>AB</u>	SUN PHARM INDS INC	<u>0.5MG</u>	<u>A075423 001</u>	Apr 27, 2001
<u>AB</u>		<u>1MG</u>	<u>A075423 002</u>	Apr 27, 2001
<u>AB</u>		<u>2MG</u>	<u>A075423 003</u>	Apr 27, 2001
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569 001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569 002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569 003</u>	Sep 10, 1996
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077856 001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856 002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856 003</u>	Jun 28, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964 001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964 002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964 003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	ROCHE	<u>0.5MG</u>	<u>N017533 001</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N017533 002</u>	
<u>AB</u>		<u>2MG</u>	<u>N017533 003</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194 001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194 002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194 003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194 004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194 005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171 001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171 002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171 003</u>	Aug 03, 2005
<u>AB</u>	+	<u>1MG</u>	<u>A077171 004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171 005</u>	Aug 03, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A078654 001</u>	Aug 27, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A078654 002</u>	Aug 27, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078654 003</u>	Aug 27, 2014
<u>AB</u>		<u>1MG</u>	<u>A078654 004</u>	Aug 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A078654 005</u>	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891 001</u>	Oct 10, 1984
-----------	----------------------	-------------------	--------------------	--------------

CATAPRES-TTS-2

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891 002</u>	Oct 10, 1984
-----------	----------------------	-------------------	--------------------	--------------

CATAPRES-TTS-3

<u>AB</u>	+	<u>BOEHRINGER INGELHEIM</u>	<u>0.3MG/24HR</u>	<u>N018891 003</u>	Oct 10, 1984
-----------	---	-----------------------------	-------------------	--------------------	--------------

CLONIDINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>0.1MG/24HR</u>	<u>A090873 001</u>	May 06, 2014
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A090873 002</u>	May 06, 2014
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A090873 003</u>	May 06, 2014
<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157 001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157 002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157 003</u>	Aug 18, 2009

## PRESCRIPTION DRUG PRODUCT LIST

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

<u>AB</u>	BARR	<u>0.1MG/24HR</u>	<u>A079090 001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090 002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090 003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166 001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166 002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166 003</u>	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	EXELA PHARMA SCS LLC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167 001</u>	Oct 29, 2013
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167 002</u>	Oct 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673 001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673 002</u>	Jul 08, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300 001</u>	Jan 26, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300 002</u>	Jan 26, 2011
<u>AP</u>	LUITPOLD	<u>1MG/10ML (0.1MG/ML)</u>	<u>A091104 001</u>	Oct 08, 2009
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A091104 002</u>	Oct 08, 2009
<u>AP</u>	ZYDUS PHARMS USA INC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A202601 001</u>	Feb 20, 2014
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A202601 002</u>	Feb 20, 2014

DURACLON

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020615 001</u>	Oct 02, 1996
<u>AP</u>	+	<u>5MG/10ML (0.5MG/ML)</u>	<u>N020615 002</u>	Apr 27, 1999

TABLET; ORAL

CATAPRES

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407 001</u>	
<u>AB</u>		<u>0.2MG</u>	<u>N017407 002</u>	
<u>AB</u>	+	<u>0.3MG</u>	<u>N017407 003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974 001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975 001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976 001</u>	Dec 16, 1986
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368 001</u>	Dec 06, 2011
<u>AB</u>		<u>0.2MG</u>	<u>A091368 002</u>	Dec 06, 2011
<u>AB</u>		<u>0.3MG</u>	<u>A091368 003</u>	Dec 06, 2011
<u>AB</u>	CARLSBAD	<u>0.1MG</u>	<u>A202297 001</u>	Jun 13, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202297 002</u>	Jun 13, 2013
<u>AB</u>		<u>0.3MG</u>	<u>A202297 003</u>	Jun 13, 2013
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099 001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099 002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099 003</u>	Aug 27, 2009
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317 002</u>	Jul 09, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070317 003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317 001</u>	Jun 09, 1987
<u>AB</u>	SUN PHARM INDS	<u>0.1MG</u>	<u>A070925 001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924 001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923 001</u>	Sep 04, 1987
<u>AB</u>	SUN PHARM INDS INC	<u>0.1MG</u>	<u>A090329 001</u>	Jul 03, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A090329 002</u>	Jul 03, 2014
<u>AB</u>		<u>0.3MG</u>	<u>A090329 003</u>	Jul 03, 2014
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895 001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895 002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895 003</u>	Aug 26, 2009
<u>AB</u>	VINTAGE	<u>0.1MG</u>	<u>A077901 001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901 002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901 003</u>	Mar 09, 2007

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB1</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A203320 001</u>	May 15, 2015
<u>AB1</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984 001</u>	Sep 30, 2013
<u>AB1</u>	+	<u>0.1MG</u>	<u>N022331 003</u>	Sep 28, 2010
<u>AB2</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A202792 001</u>	May 15, 2015



## PRESCRIPTION DRUG PRODUCT LIST

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 75MG BASE</u>	<u>A202925 001</u>	Mar 27, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202925 002</u>	Mar 27, 2013
<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 75MG BASE</u>	<u>A090307 001</u>	May 28, 2013
<u>AB</u>	AMNEAL PHARMS	<u>EQ 75MG BASE</u>	<u>A203751 001</u>	Apr 11, 2014
<u>AB</u>	APOTEX INC	<u>EQ 75MG BASE</u>	<u>A076274 001</u>	May 17, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076274 002</u>	Mar 04, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A090540 001</u>	May 17, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 75MG BASE</u>	<u>A076273 001</u>	Jan 14, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 300MG BASE</u>	<u>A091023 001</u>	May 17, 2012
<u>AB</u>	GATE PHARMS	<u>EQ 300MG BASE</u>	<u>A091216 001</u>	May 17, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A202928 001</u>	Feb 10, 2014
<u>AB</u>	MUTUAL PHARM	<u>EQ 75MG BASE</u>	<u>A078133 001</u>	Jun 10, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A077665 001</u>	May 17, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077665 002</u>	May 17, 2012
<u>AB</u>	ROXANE	<u>EQ 75MG BASE</u>	<u>A078004 001</u>	May 17, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A204165 001</u>	Sep 15, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204165 002</u>	Sep 15, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 75MG BASE</u>	<u>A090494 001</u>	May 17, 2012
<u>AB</u>	TEVA	<u>EQ 75MG BASE</u>	<u>A076999 001</u>	May 17, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 300MG BASE</u>	<u>A090625 001</u>	May 17, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844 001</u>	May 17, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 75MG BASE</u>	<u>A202266 001</u>	Aug 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202266 002</u>	Nov 20, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 75MG BASE</u>	<u>A201686 001</u>	Oct 10, 2012

PLAVIX

<u>AB</u>	SANOFI AVENTIS US	<u>EQ 75MG BASE</u>	<u>N020839 001</u>	Nov 17, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020839 002</u>	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	MYLAN	<u>3.75MG</u>	<u>A071858 002</u>	Jul 17, 1987
<u>AB</u>		<u>7.5MG</u>	<u>A071858 003</u>	Jul 17, 1987
<u>AB</u>		<u>15MG</u>	<u>A071858 001</u>	Jul 17, 1987
<u>AB</u>	SUN PHARM INDS LTD	<u>3.75MG</u>	<u>A076911 001</u>	Sep 29, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A076911 002</u>	Sep 29, 2004
<u>AB</u>		<u>15MG</u>	<u>A076911 003</u>	Sep 29, 2004
<u>AB</u>	TARO	<u>3.75MG</u>	<u>A075731 003</u>	Apr 27, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A075731 002</u>	Apr 27, 2000
<u>AB</u>		<u>15MG</u>	<u>A075731 001</u>	Apr 27, 2000

GEN-XENE

<u>AB</u>	ALRA	<u>3.75MG</u>	<u>A071787 001</u>	Apr 26, 1988
<u>AB</u>		<u>7.5MG</u>	<u>A071788 001</u>	Apr 26, 1988
<u>AB</u>		<u>15MG</u>	<u>A071789 001</u>	Apr 26, 1988

TRANXENE

<u>AB</u>	RECORDATI RARE	<u>3.75MG</u>	<u>N017105 006</u>	
<u>AB</u>		<u>7.5MG</u>	<u>N017105 007</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017105 008</u>	

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>1%</u>	<u>A078338 001</u>	Sep 02, 2008
<u>AB</u>	GLENMARK PHARMS	<u>1%</u>	<u>A090219 001</u>	Aug 03, 2010
<u>AB</u>	+	<u>1%</u>	<u>A072640 001</u>	Aug 31, 1993

SOLUTION; TOPICAL

CLOTRIMAZOLE

<u>AT</u>	+	TARO	<u>1%</u>	<u>A074580 001</u>	Jul 29, 1996
<u>AT</u>		TEVA	<u>1%</u>	<u>A073306 001</u>	Feb 28, 1995

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

<u>AB</u>	PADDOCK LLC	<u>10MG</u>	<u>A076763 001</u>	Oct 28, 2005	
<u>AB</u>	+	ROXANE	<u>10MG</u>	<u>A076387 001</u>	Jul 29, 2004

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+	JAZZ PHARMS III	<u>50MG/ML</u>	<u>N203479 001</u>	Feb 06, 2013
---	-----------------	----------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CLOZAPINE

TABLET;ORAL

CLOZAPINE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A202873 001</u>	Nov 25, 2015
<u>AB</u>		<u>100MG</u>	<u>A202873 002</u>	Nov 25, 2015
<u>AB</u>	ACTAVIS LABS FL INC	<u>25MG</u>	<u>A203807 001</u>	Sep 17, 2015
<u>AB</u>		<u>100MG</u>	<u>A203807 002</u>	Sep 17, 2015
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A074949 003</u>	Jul 31, 2003
<u>AB</u>		<u>25MG</u>	<u>A074949 001</u>	Nov 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074949 004</u>	Apr 25, 2005
<u>AB</u>		<u>50MG</u>	<u>A076809 003</u>	Dec 16, 2005
<u>AB</u>		<u>100MG</u>	<u>A074949 002</u>	Nov 26, 1997
<u>AB</u>		<u>100MG</u>	<u>A076809 002</u>	Dec 16, 2005
<u>AB</u>		<u>200MG</u>	<u>A076809 001</u>	Dec 16, 2005
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075417 003</u>	Apr 15, 2010
<u>AB</u>		<u>25MG</u>	<u>A075417 001</u>	May 27, 1999
<u>AB</u>		<u>50MG</u>	<u>A075417 004</u>	Apr 15, 2010
<u>AB</u>		<u>100MG</u>	<u>A075417 002</u>	May 27, 1999
<u>AB</u>		<u>200MG</u>	<u>A075417 005</u>	Apr 15, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A075713 001</u>	Nov 15, 2002
<u>AB</u>		<u>50MG</u>	<u>A075713 003</u>	Aug 19, 2005
<u>AB</u>		<u>100MG</u>	<u>A075713 002</u>	Nov 15, 2002

CLOZARIL

<u>AB</u>	HERITAGE LIFE	<u>25MG</u>	<u>N019758 001</u>	Sep 26, 1989
<u>AB</u>	+	<u>100MG</u>	<u>N019758 002</u>	Sep 26, 1989

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

<u>AB</u>	BARR LABS INC	<u>25MG</u>	<u>A090308 001</u>	Nov 25, 2015
<u>AB</u>		<u>100MG</u>	<u>A090308 002</u>	Nov 25, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A201824 002</u>	Sep 15, 2015
<u>AB</u>		<u>100MG</u>	<u>A201824 003</u>	Sep 15, 2015
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A203039 001</u>	Nov 25, 2015
<u>AB</u>		<u>200MG</u>	<u>A203039 002</u>	Nov 25, 2015

FAZACLO ODT

<u>AB</u>	JAZZ PHARMS III	<u>25MG</u>	<u>N021590 001</u>	Feb 10, 2004
<u>AB</u>	+	<u>100MG</u>	<u>N021590 002</u>	Feb 10, 2004
<u>AB</u>		<u>150MG</u>	<u>N021590 005</u>	Jul 09, 2010
<u>AB</u>		<u>200MG</u>	<u>N021590 006</u>	Jul 09, 2010
		12.5MG	N021590 004	May 30, 2007

COBICISTAT

TABLET;ORAL

TYBOST

+	GILEAD SCIENCES INC	150MG	N203094 001	Sep 24, 2014
---	---------------------	-------	-------------	--------------

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

+	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395 001	Jan 29, 2015
---	---------------	---------------------	-------------	--------------

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

GENVOYA

+	GILEAD SCIENCES INC	150MG;150MG;200MG;EQ 10MG BASE	N207561 001	Nov 05, 2015
---	---------------------	--------------------------------	-------------	--------------

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

+	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100 001	Aug 27, 2012
---	---------------------	-------------------------	-------------	--------------

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

+	GENENTECH INC	EQ 20MG BASE	N206192 001	Nov 10, 2015
---	---------------	--------------	-------------	--------------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<u>AA</u>	VINTAGE	<u>10MG/5ML;5MG/5ML;6.25MG/5ML</u>	<u>A040660 001</u>	Dec 07, 2006
<u>AA</u>	+	<u>ACTAVIS MID ATLANTIC</u>	<u>10MG/5ML;5MG/5ML;6.25MG/5ML</u>	<u>A088764 001</u>
				Oct 31, 1984
<u>AA</u>		<u>HI-TECH PHARMA CO</u>	<u>10MG/5ML;5MG/5ML;6.25MG/5ML</u>	<u>A040674 001</u>
				Dec 23, 2014
<u>AA</u>		<u>AMNEAL PHARMS</u>	<u>10MG/5ML;5MG/5ML;6.25MG/5ML</u>	<u>A200963 001</u>
				Aug 26, 2015

## PRESCRIPTION DRUG PRODUCT LIST

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

<b>AA</b>	+	ACTAVIS MID ATLANTIC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A088763 001</u>	Oct 31, 1984
<b>AA</b>		AMNEAL PHARMS	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A200894 001</u>	Apr 24, 2013
<b>AA</b>		HI TECH PHARMA	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A040151 001</u>	Aug 26, 1997
<b>AA</b>		SUN PHARM INDS INC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A090180 001</u>	Mar 17, 2010
<b>AA</b>		TRIS PHARMA INC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A200386 001</u>	Jun 29, 2012
<b>AA</b>		WOCKHARDT	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A088875 001</u>	Dec 17, 1984
<u>PROMETHAZINE WITH CODEINE</u>					
<b>AA</b>		VINTAGE	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A040650 001</u>	Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIAICIN-C

+	STI PHARMA LLC	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A088704 001	Mar 22, 1985
---	----------------	--------------------------------	-------------	--------------

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE

<b>AB</b>		LANNETT HOLDINGS INC	<u>15MG</u>	<u>A203046 001</u>	Jun 13, 2014
<b>AB</b>			<u>30MG</u>	<u>A203046 002</u>	Jun 13, 2014
<b>AB</b>			<u>60MG</u>	<u>A203046 003</u>	Jun 13, 2014
<b>AB</b>		ROXANE	<u>15MG</u>	<u>N022402 001</u>	Jul 16, 2009
<b>AB</b>			<u>30MG</u>	<u>N022402 002</u>	Jul 16, 2009
<b>AB</b>	+		<u>60MG</u>	<u>N022402 003</u>	Jul 16, 2009

COLCHICINE

CAPSULE; ORAL

MITIGARE

	HIKMA INTL PHARMS	0.6MG	N204820 001	Sep 26, 2014
--	-------------------	-------	-------------	--------------

TABLET; ORAL

COLCRYS

+	TAKEDA PHARMS USA	0.6MG	N022352 001	Jul 29, 2009
---	-------------------	-------	-------------	--------------

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

<b>AB</b>	+	WATSON LABS	<u>0.5MG; 500MG</u>	<u>A084279 001</u>	
<u>PROBENECID AND COLCHICINE</u>					
<b>AB</b>		MIRROR PHARMS	<u>0.5MG; 500MG</u>	<u>A040618 001</u>	May 13, 2008

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

	DAIICHI SANKYO	1.875GM/PACKET	N022362 001	Oct 02, 2009
--	----------------	----------------	-------------	--------------

+		3.75GM/PACKET	N022362 002	Oct 02, 2009
---	--	---------------	-------------	--------------

TABLET; ORAL

WELCHOL

+	DAIICHI SANKYO	625MG	N021176 001	May 26, 2000
---	----------------	-------	-------------	--------------

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

<b>AB</b>		PHARMACIA AND UPJOHN	<u>5GM/SCOOPFUL</u>	<u>N017563 003</u>	Sep 22, 1995
<b>AB</b>	+		<u>5GM/PACKET</u>	<u>N017563 004</u>	Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

<b>AB</b>		IMPAX LABS	<u>5GM/SCOOPFUL</u>	<u>A077277 001</u>	May 02, 2006
<b>AB</b>			<u>5GM/PACKET</u>	<u>A077277 002</u>	May 02, 2006
FLAVORED COLESTID					
		PHARMACIA AND UPJOHN	5GM/PACKET	N017563 001	
			5GM/SCOOPFUL	N017563 002	

TABLET; ORAL

COLESTID

<b>AB</b>	+	PHARMACIA AND UPJOHN	<u>1GM</u>	<u>N020222 001</u>	Jul 19, 1994
<u>COLESTIPOL HYDROCHLORIDE</u>					
<b>AB</b>		IMPAX LABS	<u>1GM</u>	<u>A077510 001</u>	Oct 24, 2006

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

<b>AP</b>		EMCURE PHARMS LTD	<u>EQ 150MG BASE/VIAL</u>	<u>A202359 001</u>	Sep 28, 2012
<b>AP</b>		FRESENIUS KABI USA	<u>EQ 150MG BASE/VIAL</u>	<u>A065364 001</u>	Apr 17, 2008
<b>AP</b>		PADDOCK LLC	<u>EQ 150MG BASE/VIAL</u>	<u>A065177 001</u>	Mar 19, 2004
<b>AP</b>		SAGENT PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A201365 001</u>	Feb 19, 2014
<b>AP</b>		X GEN PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A064216 001</u>	Feb 26, 1999

## PRESCRIPTION DRUG PRODUCT LIST

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM**AP** XELLIA PHARMS APS **EQ 150MG BASE/VIAL** **A205356 001** May 29, 2015COLY-MYCIN M**AP** + PAR STERILE PRODUCTS **EQ 150MG BASE/VIAL** **N050108 002**COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+ PAR STERILE PRODUCTS EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG  
BASE/ML; 0.5MG/ML N050356 001CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+ CUMBERLAND PHARMS 20MG/100ML (0.2MG/ML) N021697 002 Oct 08, 2008

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+ TEVA WOMENS 309MG/COPPER N018680 001 Nov 15, 1984

CORTICORELIN OVINE TRIFLUATATE

INJECTABLE; INJECTION

ACTHREL

+ FERRING EQ 0.1MG BASE/VIAL N020162 001 May 23, 1996

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

+ MALLINCKRODT ARD 80 UNITS/ML N008372 008

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

+ HIKMA INTL PHARMS 25MG A080776 002

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN**AP** + AMPHASTAR PHARMS INC **0.25MG/VIAL** **N016750 001**COSYNTROPIN**AP** MYLAN INSTITUTIONAL **0.25MG/VIAL** **A090574 001** Dec 17, 2009**AP** SANDOZ **0.25MG/VIAL** **A202147 001** Jun 29, 2012CRIZOTINIB

CAPSULE; ORAL

XALKORI

PF PRISM CV 200MG N202570 001 Aug 26, 2011

+ 250MG N202570 002 Aug 26, 2011

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

FULYZAQ

+ SALIX PHARMS 125MG N202292 001 Dec 31, 2012

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM**AA** MICRO LABS LTD INDIA **100MG/5ML** **A202745 001** Apr 04, 2013**AA** PACK PHARMS LLC **100MG/5ML** **A202583 001** Oct 27, 2011GASTROCROM**AA** + MEDA PHARMS **100MG/5ML** **N020479 001** Feb 29, 1996

SOLUTION; INHALATION

CROMOLYN SODIUM**AN** BAUSCH AND LOMB **10MG/ML** **A075585 001** Dec 21, 2000**AN** MYLAN SPECLT **10MG/ML** **A074209 001** Apr 26, 1994**AN** + TEVA PHARMS **10MG/ML** **A075271 001** Jan 18, 2000**AN** WOCKHARDT **10MG/ML** **A075346 001** Oct 25, 1999

SOLUTION/DROPS; OPHTHALMIC

CROLOM**AT** BAUSCH AND LOMB **4%** **A074443 001** Jan 30, 1995CROMOLYN SODIUM**AT** + AKORN **4%** **A074706 001** Apr 29, 1998**AT** ALCON **4%** **A075282 001** Jun 16, 1999

## PRESCRIPTION DRUG PRODUCT LIST

CROTAMITON

CREAM; TOPICAL

EURAX

+ RANBAXY

10%

N006927 001

LOTION; TOPICAL

CROTAN**AT** SUMMERS**10%****A087204 001**EURAX**AT** + RANBAXY**10%****N009112 003**CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.4MG COPPER/ML

N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN**AP** GAVIS PHARMS LLC**1MG/ML****A206503 001** Dec 11, 2015**AP** + LUITPOLD**1MG/ML****A080737 001**VIBISON**AP** + FRESENIUS KABI USA**1MG/ML****A080557 003**

SPRAY, METERED; NASAL

NASCOBAL

+ PAR PHARM

0.5MG/SPRAY

N021642 001 Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX**AB** IVAX INTL**15MG****N021777 001** Feb 01, 2007**AB** +**30MG****N021777 002** Feb 01, 2007CYCLOBENZAPRINE HYDROCHLORIDE**AB** TWI PHARMS INC**15MG****A091281 001** Jan 31, 2013**AB****30MG****A091281 002** Jan 31, 2013

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE**AB** ACTAVIS LABS FL INC**5MG****A071611 002** Feb 03, 2006**AB****7.5MG****A071611 003** Feb 03, 2006**AB****10MG****A071611 001** May 03, 1989**AB**

AUROBINDO PHARMA

**5MG****A078643 001** Sep 26, 2008**AB****10MG****A078643 002** Sep 26, 2008**AB**

INVAGEN PHARMS

**5MG****A090478 001** Jul 23, 2010**AB****10MG****A090478 002** Jul 23, 2010**AB**

JUBILANT CADISTA

**5MG****A077563 001** Apr 19, 2006**AB****10MG****A077563 002** Apr 19, 2006**AB**

KVK TECH

**5MG****A078048 001** Feb 28, 2011**AB****10MG****A078048 002** Feb 28, 2011**AB**

MYLAN PHARMS INC

**5MG****A073144 002** Feb 03, 2006**AB****7.5MG****A073144 003** Mar 25, 2013**AB** +**10MG****A073144 001** May 30, 1991**AB**

ORIT LABS LLC

**5MG****A078218 002** Jun 19, 2015**AB****10MG****A078218 001** Apr 18, 2008**AB**

PLIVA

**10MG****A074421 001** Sep 29, 1995**AB**

PROSAM LABS

**10MG****A077209 001** Oct 04, 2005**AB**

SUN PHARM INDS

**5MG****A073541 002** Apr 06, 2006**AB****10MG****A073541 001** May 23, 1995**AB**

SUN PHARM INDS LTD

**5MG****A078722 001** May 12, 2008**AB****7.5MG****A078722 002** May 12, 2008**AB****10MG****A078722 003** May 12, 2008**AB**

VINTAGE PHARMS

**5MG****A077797 001** Feb 28, 2007**AB****10MG****A077797 002** Feb 28, 2007CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE**AT** AKORN**1%****A040164 001** Jan 13, 1997CYCLOGYL**AT** + ALCON**0.5%****A084109 001****AT** +**1%****A084110 001**CYCLOPENTOLATE HYDROCHLORIDE**AT** AKORN INC**0.5%****A205937 001** Dec 09, 2015PENTOLAIR**AT** BAUSCH AND LOMB**1%****A040075 001** Apr 29, 1994

## PRESCRIPTION DRUG PRODUCT LIST

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOGYL

+ ALCON LABS INC 2% A084108 001

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOMYDRIL

+ ALCON 0.2%;1% A084300 001

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

ROXANE 25MG N203856 001 Sep 16, 2013

+ 50MG N203856 002 Sep 16, 2013

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>A040745 001</u>	May 21, 2008
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>A040745 002</u>	May 21, 2008
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>A040745 003</u>	May 21, 2008
<u>AP</u>		JIANGSU HENGRUI MED	<u>500MG/VIAL</u>	<u>A204555 001</u>	Oct 31, 2014
<u>AP</u>			<u>1GM/VIAL</u>	<u>A204555 002</u>	Oct 31, 2014
<u>AP</u>			<u>2GM/VIAL</u>	<u>A204555 003</u>	Oct 31, 2014

CYTOXAN (LYOPHILIZED)

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>N012142 003</u>	
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>N012142 004</u>	Aug 30, 1982
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N012142 005</u>	Aug 30, 1982

TABLET;ORAL

CYCLOPHOSPHAMIDE

ROXANE 25MG A040032 001 Aug 17, 1999

+ 50MG A040032 002 Aug 17, 1999

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

+ PURDUE GMP 250MG A060593 001

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

<u>AB1</u>		IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A065110 003</u>	Mar 29, 2005
<u>AB1</u>			<u>50MG</u>	<u>A065110 001</u>	Mar 29, 2005
<u>AB1</u>			<u>100MG</u>	<u>A065110 002</u>	Mar 29, 2005
<u>AB1</u>		SANDOZ	<u>25MG</u>	<u>A065017 002</u>	Jan 13, 2000
<u>AB1</u>			<u>100MG</u>	<u>A065017 001</u>	Jan 13, 2000
<u>AB1</u>		WATSON LABS INC	<u>25MG</u>	<u>A065044 002</u>	Dec 20, 2000
<u>AB1</u>			<u>100MG</u>	<u>A065044 001</u>	Dec 20, 2000

GENGRAF

<u>AB1</u>		ABBVIE	<u>25MG</u>	<u>A065003 001</u>	May 12, 2000
<u>AB1</u>			<u>50MG</u>	<u>A065003 002</u>	May 12, 2000
<u>AB1</u>			<u>100MG</u>	<u>A065003 003</u>	May 12, 2000

NEORAL

<u>AB1</u>		NOVARTIS	<u>25MG</u>	<u>N050715 001</u>	Jul 14, 1995
<u>AB1</u>	+		<u>100MG</u>	<u>N050715 002</u>	Jul 14, 1995

CYCLOSPORINE

<u>AB2</u>		APOTEX	<u>25MG</u>	<u>A065040 001</u>	May 09, 2002
<u>AB2</u>			<u>100MG</u>	<u>A065040 002</u>	May 09, 2002

SANDIMMUNE

<u>AB2</u>		NOVARTIS	<u>25MG</u>	<u>N050625 001</u>	Mar 02, 1990
<u>AB2</u>	+		<u>100MG</u>	<u>N050625 002</u>	Mar 02, 1990
BX			50MG	N050625 003	Nov 23, 1992

EMULSION;OPHTHALMIC

RESTASIS

+ ALLERGAN 0.05% N050790 001 Dec 23, 2002

INJECTABLE;INJECTION

CYCLOSPORINE

<u>AP</u>		EUROHLTH INTL SARL	<u>50MG/ML</u>	<u>A065004 001</u>	Oct 29, 1999
<u>AP</u>		LUITPOLD	<u>50MG/ML</u>	<u>A065151 001</u>	Oct 07, 2003

SANDIMMUNE

<u>AP</u>	+	NOVARTIS	<u>50MG/ML</u>	<u>N050573 001</u>	Nov 14, 1983
-----------	---	----------	----------------	--------------------	--------------

SOLUTION;ORAL

CYCLOSPORINE

<u>AB1</u>		ABBVIE	<u>100MG/ML</u>	<u>A065025 001</u>	Mar 03, 2000
<u>AB1</u>		IVAX SUB TEVA PHARMS	<u>100MG/ML</u>	<u>A065078 001</u>	Mar 25, 2005

## PRESCRIPTION DRUG PRODUCT LIST

CYCLOSPORINE

SOLUTION;ORAL

CYCLOSPORINEAB1 WATSON LABS 100MG/ML A065054 001 Dec 18, 2001NEORALAB1 + NOVARTIS 100MG/ML N050716 001 Jul 14, 1995CYCLOSPORINEAB2 WOCKHARDT 100MG/ML A065133 001 Sep 17, 2004SANDIMMUNEAB2 + NOVARTIS 100MG/ML N050574 001 Nov 14, 1983CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDEAA + LYNE 2MG/5ML A040668 001 Jun 28, 2006AA PHARM ASSOC 2MG/5ML A091295 001 Mar 28, 2013

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDEAA COREPHARMA 4MG A040537 001 Sep 30, 2003AA + IVAX SUB TEVA PHARMS 4MG A087056 001AA MIRROR PHARMS LLC 4MG A205087 001 Sep 23, 2015AA PAR PHARM 4MG A087129 001AA STASON PHARMS 4MG A040644 001 May 30, 2006CYSTEAMINE BITARTRATE

CAPSULE;ORAL

CYSTAGON

MYLAN EQ 50MG BASE N020392 001 Aug 15, 1994

+ EQ 150MG BASE N020392 002 Aug 15, 1994

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

RAPTOR INC EQ 25MG BASE N203389 001 Apr 30, 2013

+ EQ 75MG BASE N203389 002 Apr 30, 2013

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTARAN

+ SIGMA TAU EQ 0.44% BASE N200740 001 Oct 02, 2012

CYTARABINE

INJECTABLE;INJECTION

CYTARABINEAP EUROHLTH INTL SARL 100MG/VIAL A071471 001 Aug 02, 1989AP 500MG/VIAL A071472 001 Aug 02, 1989AP 1GM/VIAL A074245 001 Aug 31, 1994AP 2GM/VIAL A074245 002 Aug 31, 1994AP + FRESENIUS KABI USA 100MG/ML A076512 001 Jan 15, 2004AP + HOSPIRA 20MG/ML A071868 001 Jun 04, 1990AP + 20MG/ML A072168 001 Aug 31, 1990AP + 20MG/ML A072945 001 Feb 28, 1994AP 100MG/ML A075383 001 Nov 22, 1999AP MYLAN LABS LTD 20MG/ML A200914 001 Dec 13, 2011AP 20MG/ML A200915 001 Dec 13, 2011AP 20MG/ML A200916 001 Dec 13, 2011AP 100MG/ML A201784 001 Jan 30, 2012CYTOSAR-UAP TEVA PHARMS USA 100MG/VIAL A075206 001 Dec 30, 1998AP + 500MG/VIAL A075206 002 Dec 30, 1998AP + 1GM/VIAL A075206 004 Dec 30, 1998AP + 2GM/VIAL A075206 003 Dec 30, 1998

INJECTABLE, LIPOSOMAL;INJECTION

DEPOCYT

+ PACIRA PHARMS INC 10MG/ML N021041 001 Apr 01, 1999

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

PRADAXA

BOEHRINGER INGELHEIM EQ 75MG BASE N022512 001 Oct 19, 2010

+ EQ 110MG BASE N022512 003 Nov 20, 2015

+ EQ 150MG BASE N022512 002 Oct 19, 2010

## PRESCRIPTION DRUG PRODUCT LIST

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806 001	May 29, 2013
+	EQ 75MG BASE	N202806 002	May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

<b>AP</b>	EUROHLTH INTL SARL	<b>200MG/VIAL</b>	<b>A075812 001</b>	Jun 15, 2001
<b>AP</b>		<b>500MG/VIAL</b>	<b>A075812 002</b>	Oct 31, 2002
<b>AP</b>	FRESENIUS KABI USA	<b>100MG/VIAL</b>	<b>A075371 001</b>	Aug 27, 1999
<b>AP</b>		<b>200MG/VIAL</b>	<b>A075371 002</b>	Aug 27, 1999
<b>AP</b>	HOSPIRA	<b>200MG/VIAL</b>	<b>A075940 001</b>	Oct 18, 2001
<b>AP</b>	TEVA PHARMS USA	<b>200MG/VIAL</b>	<b>A075259 002</b>	Aug 27, 1998
<b>AP</b>	+	<b>500MG/VIAL</b>	<b>A075259 001</b>	Sep 22, 2000
<b>DTIC-DOME</b>				
<b>AP</b>	+	BAYER HLTHCARE	<b>100MG/VIAL</b>	<b>N017575 001</b>
<b>AP</b>	+		<b>200MG/VIAL</b>	<b>N017575 002</b>

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843 001	Jul 24, 2015
+	EQ 60MG BASE	N206843 002	Jul 24, 2015

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

<b>AP</b>	+	RECORDATI RARE	<b>0.5MG/VIAL</b>	<b>N050682 001</b>
-----------	---	----------------	-------------------	--------------------

DACTINOMYCIN

<b>AP</b>	EUROHLTH INTL SARL	<b>0.5MG/VIAL</b>	<b>A090304 001</b>	Mar 16, 2010
<b>AP</b>	LUITPOLD	<b>0.5MG/VIAL</b>	<b>A202562 001</b>	Aug 23, 2013

DALBAVANCIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

DALVANCE

+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883 001	May 23, 2014
---	---------------------	--------------------	-------------	--------------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

+	ACORDA	10MG	N022250 001	Jan 22, 2010
---	--------	------	-------------	--------------

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+	KING PHARMS	350MG/VIAL; 150MG/VIAL	N050748 001	Sep 21, 1999
---	-------------	------------------------	-------------	--------------

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287 001	Dec 22, 1994
	5,000IU/0.2ML (25,000IU/ML)	N020287 003	Mar 18, 1996
	7,500IU/0.3ML (25,000IU/ML)	N020287 005	Apr 04, 2002
	10,000IU/ML (10,000IU/ML)	N020287 004	Jan 30, 1998
	12,500IU/0.5ML (25,000IU/ML)	N020287 009	May 01, 2007
	15,000IU/0.6ML (25,000IU/ML)	N020287 010	May 01, 2007
	18,000IU/0.72ML (25,000IU/ML)	N020287 011	May 01, 2007
+	95,000IU/3.8ML (25,000IU/ML)	N020287 006	Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOL

<b>AB</b>	BARR	<b>50MG</b>	<b>A074582 003</b>	May 29, 1998
<b>AB</b>		<b>100MG</b>	<b>A074582 002</b>	May 29, 1998
<b>AB</b>	+	<b>200MG</b>	<b>A074582 001</b>	Aug 09, 1996
<b>AB</b>	LANNETT	<b>50MG</b>	<b>A078214 001</b>	Apr 19, 2007
<b>AB</b>		<b>100MG</b>	<b>A078214 002</b>	Apr 19, 2007
<b>AB</b>		<b>200MG</b>	<b>A077246 001</b>	Sep 28, 2005



## PRESCRIPTION DRUG PRODUCT LIST

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIU

<u>AB</u>	PAR STERILE PRODUCTS	<u>25MG</u>	<u>N017443</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>N017443</u>	<u>003</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N017443</u>	<u>002</u>	

DANTROLENE SODIUM

<u>AB</u>	ELITE LABS INC	<u>25MG</u>	<u>A076686</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>		<u>50MG</u>	<u>A076686</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>100MG</u>	<u>A076686</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A076856</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>50MG</u>	<u>A076856</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>100MG</u>	<u>A076856</u>	<u>003</u>	Mar 01, 2005

FOR SUSPENSION; INTRAVENOUS

RYANODEX

	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014
--	--------------	------------	---------	-----	--------------

INJECTABLE; INJECTION

DANTRIU

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>20MG/VIAL</u>	<u>N018264</u>	<u>001</u>
-----------	---	----------------------	------------------	----------------	------------

REVONTO

<u>AP</u>		US WORLDMEDS	<u>20MG/VIAL</u>	<u>A078378</u>	<u>001</u>	Jul 24, 2007
-----------	--	--------------	------------------	----------------	------------	--------------

DAPAGLIFLOZIN PROPANEDIOL

TABLET; ORAL

FARXIGA

	ASTRAZENECA AB	EQ 5MG BASE	N202293	001	Jan 08, 2014
+		EQ 10MG BASE	N202293	002	Jan 08, 2014

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

XIGDUO XR

	ASTRAZENECA AB	EQ 5MG BASE; 500MG	N205649	001	Oct 29, 2014
		EQ 5MG BASE; 1GM	N205649	002	Oct 29, 2014
		EQ 10MG BASE; 500MG	N205649	003	Oct 29, 2014
+		EQ 10MG BASE; 1GM	N205649	004	Oct 29, 2014

DAPSONE

GEL; TOPICAL

ACZONE

+	ALLERGAN	5%	N021794	001	Jul 07, 2005
---	----------	----	---------	-----	--------------

TABLET; ORAL

DAPSONE

<u>AB</u>	FERA PHARMS LLC	<u>25MG</u>	<u>A205429</u>	<u>001</u>	Jan 07, 2016
<u>AB</u>		<u>100MG</u>	<u>A205429</u>	<u>002</u>	Jan 07, 2016
<u>AB</u>	JACOBUS	<u>25MG</u>	<u>A086841</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>A086842</u>	<u>001</u>	

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

CUBICIN

<u>AP</u>	+	CUBIST	<u>500MG/VIAL</u>	<u>N021572</u>	<u>002</u>	Sep 12, 2003
-----------	---	--------	-------------------	----------------	------------	--------------

DAPTOMYCIN

<u>AP</u>		HOSPIRA INC	<u>500MG/VIAL</u>	<u>A202857</u>	<u>001</u>	Sep 12, 2014
-----------	--	-------------	-------------------	----------------	------------	--------------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

<u>AB</u>	ANCHEN PHARMS	<u>EQ 7.5MG BASE</u>	<u>A091190</u>	<u>001</u>	Mar 13, 2015
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A091190</u>	<u>002</u>	Mar 13, 2015

ENABLEX

<u>AB</u>	WARNER CHILCOTT LLC	<u>EQ 7.5MG BASE</u>	<u>N021513</u>	<u>001</u>	Dec 22, 2004
<u>AB</u>	+	<u>EQ 15MG BASE</u>	<u>N021513</u>	<u>002</u>	Dec 22, 2004

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011
---	---------------	------------------	---------	-----	--------------

TABLET; ORAL

PREZISTA

	JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008
		EQ 150MG BASE	N021976	005	Dec 18, 2008
		EQ 600MG BASE	N021976	002	Feb 25, 2008
+		EQ 800MG BASE	N021976	006	Nov 09, 2012

## PRESCRIPTION DRUG PRODUCT LIST

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET;ORAL

VIEKIRA PAK (COPACKAGED)

+ ABBVIE INC

EQ 250MG BASE,N/A,N/A,N/A;  
N/A,12.5MG,75MG,50MG

N206619 001 Dec 19, 2014

DASATINIB

TABLET;ORAL

SPRYCEL

BRISTOL MYERS SQUIBB 20MG

50MG

70MG

80MG

+

100MG

140MG

N021986 001 Jun 28, 2006

N021986 002 Jun 28, 2006

N021986 003 Jun 28, 2006

N021986 005 Oct 28, 2010

N021986 004 May 30, 2008

N021986 006 Oct 28, 2010

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL;INJECTION

DAUNOXOME

+ GALEN (UK)

EQ 2MG BASE/ML

N050704 002 Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

CERUBIDINEAP + EUROHLTH INTL SARLEQ 20MG BASE/VIALA064103 001 Feb 03, 1995DAUNORUBICIN HYDROCHLORIDEAP + EUROHLTH INTL SARLEQ 5MG BASE/MLN050731 001 Jan 30, 1998AP FRESENIUS KABI USAEQ 20MG BASE/VIALA065000 001 May 25, 1999AP TEVA PHARMS USAEQ 5MG BASE/MLA065035 001 Jan 24, 2000

FRESENIUS KABI USA

EQ 5MG BASE/VIAL

A065034 001 Nov 20, 2001

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGENAP + OTSUKA PHARM CO LTD50MG/VIALN021790 001 May 02, 2006DECITABINEAP DR REDDYS LABS LTD50MG/VIALA203131 001 Jul 11, 2013AP SANDOZ INC50MG/VIALA202969 001 Aug 28, 2014

POWDER;INTRAVENOUS

DECITABINE

+ SUN PHARMA GLOBAL

50MG/VIAL

N205582 001 Jan 28, 2014

DEFERASIROX

TABLET;ORAL

JADENU

NOVARTIS PHARMS CORP 90MG

180MG

N206910 001 Mar 30, 2015

N206910 002 Mar 30, 2015

+

360MG

N206910 003 Mar 30, 2015

TABLET, FOR SUSPENSION;ORAL

EXJADE

NOVARTIS 125MG

250MG

N021882 001 Nov 02, 2005

N021882 002 Nov 02, 2005

+

500MG

N021882 003 Nov 02, 2005

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

+ AOPHARMA INC

100MG/ML

N208030 001 Sep 09, 2015

TABLET;ORAL

FERRIPROX

+ AOPHARMA INC

500MG

N021825 001 Oct 14, 2011

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATEAP EUROHLTH INTL SARL500MG/VIALA078086 001 May 30, 2007AP2GM/VIALA078086 002 May 30, 2007AP FRESENIUS KABI USA500MG/VIALA078718 001 Sep 15, 2009AP2GM/VIALA078718 002 Sep 15, 2009AP HOSPIRA500MG/VIALA076019 001 Mar 17, 2004AP2GM/VIALA076019 002 Mar 17, 2004DESFERALAP + NOVARTIS500MG/VIALN016267 001AP +2GM/VIALN016267 002 May 25, 2000

**PRESCRIPTION DRUG PRODUCT LIST**DEGARELIX ACETATEPOWDER; SUBCUTANEOUS  
FIRMAGON

FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
+	EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAVIRDINE MESYLATETABLET; ORAL  
RESCRIPTOR

VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
+	200MG	N020705	002	Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

<b>AB</b>	AMNEAL PHARM	<b>150MG</b>	<b>A065425</b>	<b>001</b>	Feb 27, 2008
<b>AB</b>	+	<b>300MG</b>	<b>A065425</b>	<b>002</b>	Feb 27, 2008
<b>AB</b>	BARR	<b>150MG</b>	<b>A065171</b>	<b>001</b>	Dec 13, 2004
<b>AB</b>		<b>300MG</b>	<b>A065171</b>	<b>002</b>	Dec 13, 2004
<b>AB</b>	EPIC PHARMA LLC	<b>150MG</b>	<b>A065447</b>	<b>001</b>	Aug 18, 2015
<b>AB</b>		<b>300MG</b>	<b>A065447</b>	<b>002</b>	Aug 18, 2015
<b>AB</b>	IMPAX LABS	<b>150MG</b>	<b>A065094</b>	<b>001</b>	Mar 22, 2004
<b>AB</b>		<b>300MG</b>	<b>A065094</b>	<b>002</b>	Mar 22, 2004
<b>AB</b>	VERSAPHARM	<b>150MG</b>	<b>A065389</b>	<b>001</b>	Dec 01, 2008
<b>AB</b>		<b>300MG</b>	<b>A065389</b>	<b>002</b>	Dec 01, 2008

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS  
KYBELLA

+	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015
---	-------------------	--------------------	---------	-----	--------------

DESFLURANELIQUID; INHALATION  
SUPRANE

+	BAXTER HLTHCARE	99.9%	N020118	001	Sep 18, 1992
---	-----------------	-------	---------	-----	--------------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<b>AB</b>	ACTAVIS TOTOWA	<b>10MG</b>	<b>A074430</b>	<b>001</b>	Feb 09, 1996
<b>AB</b>		<b>25MG</b>	<b>A071601</b>	<b>001</b>	Jun 05, 1987
<b>AB</b>		<b>50MG</b>	<b>A071588</b>	<b>001</b>	Jun 05, 1987
<b>AB</b>		<b>75MG</b>	<b>A071602</b>	<b>001</b>	Oct 05, 1987
<b>AB</b>		<b>100MG</b>	<b>A071766</b>	<b>001</b>	Oct 05, 1987
<b>AB</b>		<b>150MG</b>	<b>A074430</b>	<b>002</b>	Feb 09, 1996
<b>AB</b>	SANDOZ	<b>10MG</b>	<b>A072099</b>	<b>001</b>	May 24, 1988
<b>AB</b>		<b>25MG</b>	<b>A072100</b>	<b>001</b>	May 24, 1988
<b>AB</b>		<b>50MG</b>	<b>A072101</b>	<b>001</b>	May 24, 1988
<b>AB</b>		<b>75MG</b>	<b>A072102</b>	<b>001</b>	Jun 20, 1988
<b>AB</b>		<b>100MG</b>	<b>A072103</b>	<b>001</b>	Jun 20, 1988
<b>AB</b>		<b>150MG</b>	<b>A072104</b>	<b>001</b>	Jun 20, 1988

NORPRAMIN

<b>AB</b>	SANOFI AVENTIS US	<b>10MG</b>	<b>N014399</b>	<b>007</b>	Feb 11, 1982
<b>AB</b>		<b>25MG</b>	<b>N014399</b>	<b>001</b>	
<b>AB</b>		<b>50MG</b>	<b>N014399</b>	<b>003</b>	
<b>AB</b>		<b>75MG</b>	<b>N014399</b>	<b>004</b>	
<b>AB</b>	+	<b>100MG</b>	<b>N014399</b>	<b>005</b>	
<b>AB</b>		<b>150MG</b>	<b>N014399</b>	<b>006</b>	

DESIPRAMINE HYDROCHLORIDE  
ANI PHARMS INC

25MG	A071803	002	Dec 08, 1987
50MG	A071803	003	Dec 08, 1987
75MG	A071803	004	Dec 08, 1987
150MG	A071803	005	May 29, 1997

DESIRUDIN RECOMBINANTINJECTABLE; SUBCUTANEOUS  
IPRIVASK

+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003
---	----------------------	-----------	---------	-----	--------------

DESLORATADINE

SOLUTION; ORAL

CLARINEX

<b>AA</b>	+	MERCK SHARP DOHME	<b>0.5MG/ML</b>	<b>N021300</b>	<b>001</b>	Sep 01, 2004
-----------	---	-------------------	-----------------	----------------	------------	--------------

DESLORATADINE

<b>AA</b>	TARO PHARM INDS	<b>0.5MG/ML</b>	<b>A202592</b>	<b>001</b>	Jun 30, 2015
-----------	-----------------	-----------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DESLORATADINE

TABLET; ORAL

CLARINEX

<u>AB</u>	+ MERCK SHARP DOHME	<u>5MG</u>	<u>N021165</u>	<u>001</u>	Dec 21, 2001
-----------	---------------------	------------	----------------	------------	--------------

DESLORATADINE

<u>AB</u>	BELCHER PHARMS	<u>5MG</u>	<u>A078355</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078365</u>	<u>001</u>	Mar 08, 2011
<u>AB</u>	LUPIN PHARMS	<u>5MG</u>	<u>A078352</u>	<u>001</u>	Oct 25, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A078351</u>	<u>001</u>	Feb 10, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A078357</u>	<u>001</u>	Feb 19, 2010
<u>AB</u>	PERRIGO R AND D	<u>5MG</u>	<u>A078361</u>	<u>001</u>	Dec 22, 2011
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A078364</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A078359</u>	<u>001</u>	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

<u>AB</u>	MERCK SHARP DOHME	<u>2.5MG</u>	<u>N021312</u>	<u>002</u>	Jul 14, 2005
<u>AB</u>	+	<u>5MG</u>	<u>N021312</u>	<u>001</u>	Jun 26, 2002

DESLORATADINE

<u>AB</u>	REDDYS	<u>2.5MG</u>	<u>A078367</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>		<u>5MG</u>	<u>A078367</u>	<u>002</u>	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

<u>AB</u>	+ MERCK SHARP DOHME	<u>5MG;240MG</u>	<u>N021605</u>	<u>001</u>	Mar 03, 2005
	<u>DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;240MG</u>	<u>A078366</u>	<u>001</u>	Apr 26, 2011
	CLARINEX-D 12 HOUR				
	+ MERCK SHARP DOHME	2.5MG;120MG	N021313	001	Feb 01, 2006

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

<u>AP</u>	+ FERRING PHARMS INC	<u>0.004MG/ML</u>	<u>N018938</u>	<u>001</u>	Mar 30, 1984
	<u>DESMOPRESSIN ACETATE</u>				
<u>AP</u>	HOSPIRA	<u>0.004MG/ML</u>	<u>A075220</u>	<u>001</u>	Aug 28, 2000
<u>AP</u>	SUN PHARM INDS LTD	<u>0.004MG/ML</u>	<u>A091280</u>	<u>001</u>	Jan 25, 2013
<u>AP</u>	TEVA PHARMS USA	<u>0.004MG/ML</u>	<u>A074888</u>	<u>001</u>	Oct 15, 1997

SOLUTION; NASAL

DDAVP

<u>AB</u>	+ FERRING PHARMS INC	<u>0.01%</u>	<u>N017922</u>	<u>001</u>	
	<u>DESMOPRESSIN ACETATE</u>				
<u>AB</u>	SUN PHARM INDS	<u>0.01%</u>	<u>A077212</u>	<u>001</u>	Apr 12, 2012

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

<u>AB</u>	+ FERRING PHARMS INC	<u>0.01MG/SPRAY</u>	<u>N017922</u>	<u>003</u>	Aug 07, 1996
	<u>DESMOPRESSIN ACETATE</u>				
<u>AB</u>	+ BAUSCH AND LOMB	<u>0.01MG/SPRAY</u>	<u>A074830</u>	<u>001</u>	Jan 25, 1999
	<u>DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)</u>				
<u>AB</u>	APOTEX INC	<u>0.01MG/SPRAY</u>	<u>A076703</u>	<u>001</u>	Jan 27, 2005
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.01MG/SPRAY</u>	<u>A078271</u>	<u>001</u>	Dec 23, 2013

MINIRIN

<u>AB</u>	+ FERRING	<u>0.01MG/SPRAY</u>	<u>N021333</u>	<u>001</u>	Sep 16, 2002
	STIMATE (NEEDS NO REFRIGERATION)				
	+ CSL BEHRING	1.5MG/SPRAY	N020355	002	Oct 24, 2007

TABLET; ORAL

DDAVP

<u>AB</u>	FERRING PHARMS INC	<u>0.1MG</u>	<u>N019955</u>	<u>001</u>	Sep 06, 1995
<u>AB</u>	+	<u>0.2MG</u>	<u>N019955</u>	<u>002</u>	Sep 06, 1995
	<u>DESMOPRESSIN ACETATE</u>				
<u>AB</u>	ACTAVIS LABS FL INC	<u>0.1MG</u>	<u>A076470</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>		<u>0.2MG</u>	<u>A076470</u>	<u>002</u>	Jul 01, 2005
<u>AB</u>	APOTEX INC	<u>0.1MG</u>	<u>A077414</u>	<u>001</u>	Mar 07, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077414</u>	<u>002</u>	Mar 07, 2006
<u>AB</u>	GLENMARK PHARMS LTD	<u>0.1MG</u>	<u>A201831</u>	<u>001</u>	May 28, 2015
<u>AB</u>		<u>0.2MG</u>	<u>A201831</u>	<u>002</u>	May 28, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>0.1MG</u>	<u>A200653</u>	<u>001</u>	Jun 27, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A200653</u>	<u>002</u>	Jun 27, 2014
<u>AB</u>	TEVA PHARMS	<u>0.1MG</u>	<u>A077122</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077122</u>	<u>002</u>	Jan 25, 2006
	FERRING	0.1MG	N021795	001	May 08, 2008
	+	0.2MG	N021795	002	May 08, 2008

## PRESCRIPTION DRUG PRODUCT LIST

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

<u>BEKYREE</u>				
<b>AB</b>	LUPIN LTD	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A202226 001</u>	Aug 12, 2015
<u>CYCLESSA</u>				
<b>AB</b>	+ ASPEN GLOBAL INC	<u>0.125MG; 0.15MG; 0.1MG; 0.025MG; 0.025MG; 0.025MG</u>	<u>N021090 001</u>	Dec 20, 2000
<u>DESOGEN</u>				
<b>AB</b>	ORGANON USA INC	<u>0.15MG; 0.03MG</u>	<u>N020071 002</u>	Dec 10, 1992
<u>DESOGESTREL AND ETHINYL ESTRADIOL</u>				
<b>AB</b>	DURAMED PHARMS BARR	<u>0.15MG; 0.03MG</u>	<u>A075256 002</u>	Aug 12, 1999
<b>AB</b>	JAI PHARMA LTD	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A202296 001</u>	Aug 30, 2013
<b>AB</b>		<u>0.15MG; 0.03MG</u>	<u>A202085 001</u>	May 20, 2015
<b>AB</b>	NOVAST LABS LTD	<u>0.15MG; 0.03MG</u>	<u>A091234 001</u>	Jul 12, 2013
<b>AB</b>	WATSON LABS	<u>0.15MG, N/A; 0.02MG, 0.01MG; 0.02MG, 0.01MG</u>	<u>A076916 001</u>	Dec 29, 2008
<b>AB</b>		<u>0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG</u>	<u>A077182 001</u>	Jan 24, 2006
<b>AB</b>		<u>0.15MG; 0.03MG</u>	<u>A076915 001</u>	Jul 29, 2005
<u>EMOQUETTE</u>				
<b>AB</b>	VINTAGE PHARMS LLC	<u>0.15MG; 0.03MG</u>	<u>A076675 001</u>	Feb 25, 2011
<u>ENSKYCE</u>				
<b>AB</b>	LUPIN LTD	<u>0.15MG; 0.03MG</u>	<u>A201887 001</u>	Mar 07, 2013
<u>ISIBLOOM</u>				
<b>AB</b>	SANDOZ INC	<u>0.15MG; 0.03MG</u>	<u>A202789 001</u>	Aug 12, 2015
<u>KARIVA</u>				
<b>AB</b>	+ BARR	<u>0.15MG, N/A; 0.02MG, 0.01MG; 0.02MG, 0.01MG</u>	<u>A075863 001</u>	Apr 05, 2002
<u>KIMIDESS</u>				
<b>AB</b>	VINTAGE PHARMS	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A076681 001</u>	Apr 30, 2015
<u>ORTHO-CEPT</u>				
<b>AB</b>	+ JANSSEN PHARMS	<u>0.15MG; 0.03MG</u>	<u>N020301 002</u>	Dec 14, 1992
<u>PIMTREA</u>				
<b>AB</b>	NOVAST LABS LTD	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A091247 001</u>	Aug 01, 2013
<u>VELIVET</u>				
<b>AB</b>	DURAMED PHARMS BARR	<u>0.125MG; 0.15MG; 0.1MG; 0.025MG; 0.025MG; 0.025MG</u>	<u>A076455 001</u>	Feb 24, 2004
<u>VIORELE</u>				
<b>AB</b>	GLENMARK GENERICS	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A091346 001</u>	Apr 02, 2012
<u>DESONIDE</u>				
AEROSOL, FOAM; TOPICAL				
VERDESO				
	+ AQUA PHARMS	0.05%	<u>N021978 001</u>	Sep 19, 2006
CREAM; TOPICAL				
<u>DESONIDE</u>				
<b>AB</b>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010 001</u>	
<b>AB</b>	TARO	<u>0.05%</u>	<u>A073548 001</u>	Jun 30, 1992
<b>AB</b>	TEVA PHARMS	<u>0.05%</u>	<u>A074027 001</u>	Sep 28, 1992
<u>DESOWEN</u>				
<b>AB</b>	GALDERMA LABS LP	<u>0.05%</u>	<u>N019048 001</u>	Dec 14, 1984
GEL; TOPICAL				
DESONATE				
	+ BAYER HLHCARE	0.05%	<u>N021844 001</u>	Oct 20, 2006
LOTION; TOPICAL				
<u>DESONIDE</u>				
<b>AB</b>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075860 001</u>	Mar 19, 2002
<b>AB</b>	TARO	<u>0.05%</u>	<u>A202161 001</u>	Oct 31, 2014
<u>DESOWEN</u>				
<b>AB</b>	+ GALDERMA LABS LP	<u>0.05%</u>	<u>A072354 001</u>	Jan 24, 1992
OINTMENT; TOPICAL				
<u>DESONIDE</u>				
<b>AB</b>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075751 001</u>	Mar 12, 2001
<b>AB</b>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426 001</u>	
<b>AB</b>	TARO	<u>0.05%</u>	<u>A074254 001</u>	Aug 03, 1994
<u>DESOWEN</u>				
<b>AB</b>	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425 001</u>	Jun 15, 1988
<u>DESOXIMETASONE</u>				
CREAM; TOPICAL				
<u>DESOXIMETASONE</u>				
<b>AB</b>	ACTAVIS MID ATLANTIC	<u>0.25%</u>	<u>A205082 001</u>	Sep 04, 2015
<b>AB</b>	FOUGERA PHARMS	<u>0.25%</u>	<u>A078369 001</u>	Jun 29, 2010
<b>AB</b>	PERRIGO NEW YORK	<u>0.25%</u>	<u>A076510 001</u>	Jul 01, 2003
<b>AB</b>	VERSAPHARM INC	<u>0.25%</u>	<u>A203234 001</u>	Jun 12, 2015

## PRESCRIPTION DRUG PRODUCT LIST

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

<b>AB</b>	+	TARO	<u>0.25%</u>	<u>A073193</u>	<u>001</u>	Nov 30, 1990
		+	0.05%	A073210	001	Nov 30, 1990

GEL; TOPICAL

DESOXIMETASONE

<b>AB</b>		PERRIGO NEW YORK	<u>0.05%</u>	<u>A077552</u>	<u>001</u>	Jan 09, 2006
-----------	--	------------------	--------------	----------------	------------	--------------

<b>AB</b>		VERSAPHARM	<u>0.05%</u>	<u>A090727</u>	<u>001</u>	Mar 10, 2011
-----------	--	------------	--------------	----------------	------------	--------------

TOPICORT

<b>AB</b>	+	TARO	<u>0.05%</u>	<u>A074904</u>	<u>001</u>	Jul 14, 1998
-----------	---	------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

<b>AB</b>		FOUGERA PHARMS	<u>0.25%</u>	<u>A078657</u>	<u>001</u>	Sep 28, 2012
-----------	--	----------------	--------------	----------------	------------	--------------

<b>AB</b>		GLENMARK GENERICS	<u>0.25%</u>	<u>A202838</u>	<u>001</u>	Sep 20, 2013
-----------	--	-------------------	--------------	----------------	------------	--------------

<b>AB</b>		PERRIGO NEW YORK	<u>0.25%</u>	<u>A077770</u>	<u>001</u>	Apr 20, 2015
-----------	--	------------------	--------------	----------------	------------	--------------

<b>AB</b>		VERSAPHARM INC	<u>0.25%</u>	<u>A201005</u>	<u>001</u>	Apr 24, 2014
-----------	--	----------------	--------------	----------------	------------	--------------

TOPICORT

<b>AB</b>	+	TARO	<u>0.25%</u>	<u>A074286</u>	<u>001</u>	Jun 07, 1996
-----------	---	------	--------------	----------------	------------	--------------

		+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985
--	--	---	-------------------	-------	---------	-----	--------------

SPRAY; TOPICAL

TOPICORT

		+	TARO	0.25%	N204141	001	Apr 11, 2013
--	--	---	------	-------	---------	-----	--------------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

BC	+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
----	---	--------------------	------	---------	-----	--------------

BC	+		100MG	N204150	002	Mar 04, 2013
----	---	--	-------	---------	-----	--------------

KHEDEZLA

BC		OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
----	--	---------------------	------	---------	-----	--------------

BC			100MG	N204683	002	Jul 10, 2013
----	--	--	-------	---------	-----	--------------

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

	+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014
--	---	-------------------	--------------	---------	-----	--------------

	+		EQ 100MG BASE	N205583	002	Jan 28, 2014
--	---	--	---------------	---------	-----	--------------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

<b>AB</b>		ALEMBIC PHARMS LTD	<u>EQ 50MG BASE</u>	<u>A204003</u>	<u>001</u>	Jun 29, 2015
-----------	--	--------------------	---------------------	----------------	------------	--------------

<b>AB</b>			<u>EQ 100MG BASE</u>	<u>A204003</u>	<u>002</u>	Jun 29, 2015
-----------	--	--	----------------------	----------------	------------	--------------

<b>AB</b>		LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204172</u>	<u>001</u>	Jun 29, 2015
-----------	--	-----------	---------------------	----------------	------------	--------------

<b>AB</b>			<u>EQ 100MG BASE</u>	<u>A204172</u>	<u>002</u>	Jun 29, 2015
-----------	--	--	----------------------	----------------	------------	--------------

<b>AB</b>		MYLAN PHARMS INC	<u>EQ 50MG BASE</u>	<u>A204095</u>	<u>001</u>	Jun 29, 2015
-----------	--	------------------	---------------------	----------------	------------	--------------

<b>AB</b>			<u>EQ 100MG BASE</u>	<u>A204095</u>	<u>002</u>	Jun 29, 2015
-----------	--	--	----------------------	----------------	------------	--------------

<b>AB</b>		SANDOZ INC	<u>EQ 50MG BASE</u>	<u>A204028</u>	<u>001</u>	Jun 29, 2015
-----------	--	------------	---------------------	----------------	------------	--------------

<b>AB</b>			<u>EQ 100MG BASE</u>	<u>A204028</u>	<u>002</u>	Jun 29, 2015
-----------	--	--	----------------------	----------------	------------	--------------

PRISTIQ

<b>AB</b>	+	WYETH PHARMS INC	<u>EQ 50MG BASE</u>	<u>N021992</u>	<u>001</u>	Feb 29, 2008
-----------	---	------------------	---------------------	----------------	------------	--------------

<b>AB</b>	+		<u>EQ 100MG BASE</u>	<u>N021992</u>	<u>002</u>	Feb 29, 2008
-----------	---	--	----------------------	----------------	------------	--------------

			EQ 25MG BASE	N021992	003	Aug 20, 2014
--	--	--	--------------	---------	-----	--------------

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

	+	ROXANE	1MG/ML	A088252	001	Sep 01, 1983
--	---	--------	--------	---------	-----	--------------

ELIXIR; ORAL

DEXAMETHASONE

<b>AA</b>		LYNE	<u>0.5MG/5ML</u>	<u>A090891</u>	<u>001</u>	Jul 12, 2011
-----------	--	------	------------------	----------------	------------	--------------

<b>AA</b>	+	STI PHARMA LLC	<u>0.5MG/5ML</u>	<u>A084754</u>	<u>001</u>	
-----------	---	----------------	------------------	----------------	------------	--

<b>AA</b>		VINTAGE PHARMS	<u>0.5MG/5ML</u>	<u>A091188</u>	<u>001</u>	May 11, 2011
-----------	--	----------------	------------------	----------------	------------	--------------

<b>AA</b>		WOCKHARDT EU OPERATN	<u>0.5MG/5ML</u>	<u>A088254</u>	<u>001</u>	Jul 27, 1983
-----------	--	----------------------	------------------	----------------	------------	--------------

IMPLANT; INTRAVITREAL

OZURDEX

	+	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009
--	---	----------	-------	---------	-----	--------------

SOLUTION; ORAL

DEXAMETHASONE

	+	ROXANE	0.5MG/5ML	A088248	001	Sep 01, 1983
--	---	--------	-----------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

MAXIDEX

	+	ALCON	0.1%	N013422	001	
--	---	-------	------	---------	-----	--

## PRESCRIPTION DRUG PRODUCT LIST

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

<b>AB</b>	ECR	<u>1.5MG</u>	<u>A040700 001</u>	Aug 15, 2008
<b>AB</b>	ROXANE	<u>1.5MG</u>	<u>A084610 001</u>	
BP	PAR PHARM	0.5MG	A088148 001	Apr 28, 1983
BP		0.75MG	A088160 001	Apr 28, 1983
BP		1.5MG	A088237 001	Apr 28, 1983
BP		4MG	A088238 001	Apr 28, 1983
BP	+	6MG	A088481 001	Nov 28, 1983
BP	ROXANE	0.5MG	A084611 001	
BP		0.75MG	A084613 001	
BP		1MG	A088306 001	Sep 15, 1983
BP		2MG	A087916 001	Aug 26, 1982
BP		4MG	A084612 001	
BP	+	6MG	A088316 001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

<b>AP</b>	AUROBINDO PHARMA LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A206781 001</u>	Dec 01, 2015
<b>AP</b>	BD RX	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A203129 001</u>	Sep 30, 2015
<b>AP</b>	+	<u>EUROHLTH INTL SARL</u>	<u>EQ 10MG PHOSPHATE/ML</u>	Sep 07, 1982
<b>AP</b>	FRESENIUS KABI USA	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916 001</u>	
<b>AP</b>	+	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491 001</u>	Apr 11, 2003
<b>AP</b>	+	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572 001</u>	Apr 22, 2005
<b>AP</b>	+	<u>LUITPOLD</u>	<u>EQ 4MG PHOSPHATE/ML</u>	Jul 21, 1982
<b>AP</b>	MYLAN LABS LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803 001</u>	Aug 29, 2008
<b>AP</b>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802 001</u>	Aug 29, 2008

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

<b>AT</b>	+	ALCON PHARMS LTD	<u>EQ 0.1% PHOSPHATE</u>	<u>A088771 001</u>	Jan 16, 1985
<b>AT</b>		BAUSCH AND LOMB	<u>EQ 0.1% PHOSPHATE</u>	<u>A040069 001</u>	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

<b>AT</b>	+	ALCON LABS INC	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050065 002</u>	
-----------	---	----------------	--	--------------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

<b>AT</b>		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064063 001</u>	Jul 25, 1994
<b>AT</b>		PERRIGO CO TENNESSEE	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A062938 001</u>	Jul 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN

<b>AT</b>		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064135 001</u>	Sep 13, 1995
-----------	--	-----------------	--	--------------------	--------------

MAXITROL

<b>AT</b>		ALCON	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062341 001</u>	May 22, 1984
<b>AT</b>	+	ALCON LABS INC	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050023 002</u>	

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBRADEX

	+	ALCON	0.1%;0.3%	N050616 001	Sep 28, 1988
--	---	-------	-----------	-------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

<b>AB</b>	+	ALCON	<u>0.1%;0.3%</u>	<u>N050592 001</u>	Aug 18, 1988
-----------	---	-------	------------------	--------------------	--------------

TOBRAMYCIN AND DEXAMETHASONE

<b>AB</b>		BAUSCH AND LOMB	<u>0.1%;0.3%</u>	<u>A064134 001</u>	Oct 27, 1999
-----------	--	-----------------	------------------	--------------------	--------------

TOBRADEX ST

	+	ALCON PHARMS LTD	0.05%;0.3%	N050818 001	Feb 13, 2009
--	---	------------------	------------	-------------	--------------

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

	+	WOCKHARDT	2MG/5ML	A088251 001	Mar 23, 1984
--	---	-----------	---------	-------------	--------------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXILANT

		TAKEDA PHARMS USA	30MG	N022287 001	Jan 30, 2009
	+		60MG	N022287 002	Jan 30, 2009

## PRESCRIPTION DRUG PRODUCT LIST

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202585 001</u>	Nov 24, 2014
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A201072 001</u>	Sep 18, 2015
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202881 001</u>	Aug 18, 2014
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A203972 001</u>	Aug 18, 2014
<u>AP</u>	SUN PHARM INDS INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202126 001</u>	Aug 20, 2015

PRECEDEX

<u>AP</u>	+ HOSPIRA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>N021038 001</u>	Dec 17, 1999
		EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038 004	Nov 14, 2014
	+	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038 002	Mar 13, 2013
	+	EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038 003	Mar 13, 2013
SOLUTION; IV (INFUSION)				
<u>DEXMEDETOMIDINE HYDROCHLORIDE</u>				
	+ HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628 002	Oct 21, 2015
		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628 001	Oct 21, 2015

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	INTELLIPHARMACEUTICS	<u>15MG</u>	<u>A078992 003</u>	Nov 18, 2013
<u>AB</u>		<u>30MG</u>	<u>A078992 004</u>	Nov 18, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A204266 001</u>	Aug 25, 2015
<u>AB</u>		<u>10MG</u>	<u>A204266 002</u>	Aug 25, 2015
<u>AB</u>		<u>15MG</u>	<u>A204266 003</u>	Aug 25, 2015
<u>AB</u>		<u>20MG</u>	<u>A204266 004</u>	Dec 21, 2015
<u>AB</u>		<u>30MG</u>	<u>A202580 001</u>	Aug 28, 2013
<u>AB</u>		<u>40MG</u>	<u>A204266 007</u>	Aug 25, 2015
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A078908 001</u>	Nov 19, 2013
<u>AB</u>		<u>10MG</u>	<u>A078908 002</u>	Nov 19, 2013
<u>AB</u>		<u>15MG</u>	<u>A078908 004</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A078908 003</u>	Nov 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202731 003</u>	May 19, 2014
<u>AB</u>		<u>40MG</u>	<u>A202731 002</u>	Nov 19, 2013
<u>AB</u>	WATSON LABS INC	<u>5MG</u>	<u>A079108 001</u>	Aug 05, 2015
<u>AB</u>		<u>10MG</u>	<u>A079108 002</u>	Aug 05, 2015
<u>AB</u>		<u>15MG</u>	<u>A079108 003</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A079108 004</u>	Dec 21, 2015
<u>AB</u>		<u>30MG</u>	<u>A079108 005</u>	Nov 21, 2013
<u>FOCALIN XR</u>				
<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N021802 001</u>	May 26, 2005
<u>AB</u>		<u>10MG</u>	<u>N021802 002</u>	May 26, 2005
<u>AB</u>		<u>15MG</u>	<u>N021802 004</u>	Aug 01, 2006
<u>AB</u>		<u>20MG</u>	<u>N021802 003</u>	May 26, 2005
<u>AB</u>		<u>30MG</u>	<u>N021802 005</u>	Oct 23, 2009
<u>AB</u>	+	<u>40MG</u>	<u>N021802 006</u>	Aug 11, 2010
		25MG	N021802 008	Apr 21, 2011
		35MG	N021802 007	Apr 21, 2011

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI INC	<u>2.5MG</u>	<u>A206931 001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A206931 002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A206931 003</u>	Dec 04, 2015
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204534 001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A204534 002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A204534 003</u>	Dec 04, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A201231 001</u>	Sep 24, 2015
<u>AB</u>		<u>5MG</u>	<u>A201231 002</u>	Sep 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A201231 003</u>	Sep 24, 2015
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A077107 003</u>	Jan 29, 2007
<u>AB</u>		<u>5MG</u>	<u>A077107 001</u>	Jan 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077107 002</u>	Jan 29, 2007

FOCALIN

<u>AB</u>	NOVARTIS	<u>2.5MG</u>	<u>N021278 001</u>	Nov 13, 2001
<u>AB</u>		<u>5MG</u>	<u>N021278 002</u>	Nov 13, 2001
<u>AB</u>	+	<u>10MG</u>	<u>N021278 003</u>	Nov 13, 2001



## PRESCRIPTION DRUG PRODUCT LIST

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 250MG BASE/VIAL</u>	<u>A076068 001</u>	Sep 28, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068 002</u>	Sep 28, 2004
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752 001</u>	Oct 19, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752 002</u>	Oct 19, 2011
<u>ZINECARD</u>				
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212 001</u>	May 26, 1995
<u>AP</u>	+ TOTECT	<u>EQ 500MG BASE/VIAL</u>	<u>N020212 002</u>	May 26, 1995
	+ BIOCDEX INC	EQ 500MG BASE/VIAL	N022025 001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>	AMEDRA PHARMS	<u>5MG</u>	<u>N017078 001</u>	
<u>AB</u>		<u>10MG</u>	<u>N017078 002</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017078 003</u>	
<u>DEXTROAMPHETAMINE SULFATE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901 001</u>	Nov 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A203901 002</u>	Nov 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A203901 003</u>	Nov 30, 2012
<u>AB</u>	BARR	<u>5MG</u>	<u>A076137 001</u>	Jan 18, 2002
<u>AB</u>		<u>10MG</u>	<u>A076137 002</u>	Jan 18, 2002
<u>AB</u>		<u>15MG</u>	<u>A076137 003</u>	Jan 18, 2002
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A076353 001</u>	May 06, 2003
<u>AB</u>		<u>10MG</u>	<u>A076353 002</u>	May 06, 2003
<u>AB</u>		<u>15MG</u>	<u>A076353 003</u>	May 06, 2003

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	+ OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776 001</u>	Jan 29, 2008
<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644 001</u>	May 29, 2013

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893 001</u>	Jul 31, 2013
<u>AA</u>		<u>10MG</u>	<u>A202893 002</u>	Jul 31, 2013
<u>AA</u>	AVANTHI INC	<u>5MG</u>	<u>A203548 001</u>	Nov 23, 2015
<u>AA</u>		<u>10MG</u>	<u>A203548 002</u>	Nov 23, 2015
<u>AA</u>	BARR	<u>5MG</u>	<u>A040361 001</u>	Jan 31, 2001
<u>AA</u>	+	<u>10MG</u>	<u>A040361 002</u>	Jan 31, 2001
<u>AA</u>	COREPHARMA	<u>5MG</u>	<u>A090652 001</u>	Mar 07, 2014
<u>AA</u>		<u>10MG</u>	<u>A090652 002</u>	Mar 07, 2014
<u>AA</u>	MALLINCKRODT	<u>5MG</u>	<u>A040436 001</u>	Jan 29, 2002
<u>AA</u>		<u>10MG</u>	<u>A040436 002</u>	Jan 29, 2002
<u>AA</u>	MIKART	<u>5MG</u>	<u>A090533 002</u>	Oct 25, 2011
<u>AA</u>		<u>10MG</u>	<u>A090533 004</u>	Oct 25, 2011
		2.5MG	A090533 001	Oct 25, 2011
		7.5MG	A090533 003	Oct 25, 2011
		15MG	A090533 005	Oct 25, 2011
		20MG	A090533 006	Oct 25, 2011
		30MG	A090533 007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

<u>AA</u>	G AND W LABS INC	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088762 001</u>	Oct 31, 1984
<u>PROMETHAZINE DM</u>				
<u>AA</u>	+ VINTAGE	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040649 001</u>	Feb 14, 2006
<u>PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE</u>				
<u>AA</u>	HI TECH PHARMA	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040027 001</u>	Jul 31, 1996
<u>PROMETHAZINE W/ DEXTROMETHORPHAN</u>				
<u>AA</u>	WOCKHARDT	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088864 001</u>	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

## NUDEXTA

	+ AVANIR PHARMS	20MG; 10MG	N021879 001	Oct 29, 2010
--	-----------------	------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>10GM/100ML</u>	<u>N019626</u>	<u>004</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694</u>	<u>001</u>	
<u>AP</u>	+	HOSPIRA	<u>10GM/100ML</u>	<u>N018080</u>	<u>001</u>	

DEXTROSE 20% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N017521</u>	<u>004</u>	
<u>AP</u>	+	HOSPIRA	<u>20GM/100ML</u>	<u>N018564</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>30GM/100ML</u>	<u>N017521</u>	<u>003</u>	
<u>AP</u>	+	HOSPIRA	<u>30GM/100ML</u>	<u>N019345</u>	<u>001</u>	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>40GM/100ML</u>	<u>N017521</u>	<u>002</u>	
<u>AP</u>	+	HOSPIRA	<u>40GM/100ML</u>	<u>N018562</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>50MG/ML</u>	<u>N016730</u>	<u>002</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N016730</u>	<u>001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019626</u>	<u>002</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N016673</u>	<u>003</u>	Oct 30, 1985
<u>AP</u>	+		<u>50MG/ML</u>	<u>N020179</u>	<u>002</u>	Dec 07, 1992
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N016673</u>	<u>001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N020179</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>	+	HOSPIRA	<u>50MG/ML</u>	<u>N016367</u>	<u>002</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>N019222</u>	<u>001</u>	Jul 13, 1984
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019466</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019479</u>	<u>001</u>	Sep 17, 1985

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N017521</u>	<u>001</u>	
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N020047</u>	<u>001</u>	Jul 02, 1991
<u>AP</u>	+	HOSPIRA	<u>50GM/100ML</u>	<u>N018563</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>60GM/100ML</u>	<u>N017521</u>	<u>005</u>	Mar 26, 1982
-----------	---	-----------------	-------------------	----------------	------------	--------------

DEXTROSE 70% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>70GM/100ML</u>	<u>N017521</u>	<u>006</u>	Mar 26, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N020047</u>	<u>003</u>	Jul 02, 1991
<u>AP</u>	+	HOSPIRA	<u>70GM/100ML</u>	<u>N018561</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N019893</u>	<u>001</u>	Dec 26, 1989

DEXTROSE 25%

+	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998
---	---------	----------	---------	-----	--------------

DEXTROSE 50%

	HOSPIRA	500MG/ML	N019445	003	Sep 03, 2014
--	---------	----------	---------	-----	--------------

DEXTROSE 50% IN PLASTIC CONTAINER

	HOSPIRA	500MG/ML	N019445	001	Jun 03, 1986
--	---------	----------	---------	-----	--------------

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/100ML	N017385	001	
--	-----------------	---	---------	-----	--

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017610	001	
--	---------	---	---------	-----	--

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019873	001	Jun 10, 1993
--	---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML	N019515	001	May 08, 1986
--	---------	---	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML	N017484 001	
-----------------	---	-------------	--

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML	N019513 001	May 08, 1986
---------	---	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N019844 001	Jun 10, 1993
---------	---	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017609 001	
---------	--	-------------	--

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 150MG/100ML</b>	<b>N017634 001</b>	
-----------	-----------------	-------------------------------	--------------------	--

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 224MG/100ML</b>	<b>N017634 003</b>	
-----------	-----------------	-------------------------------	--------------------	--

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 300MG/100ML</b>	<b>N017634 002</b>	
-----------	-----------------	-------------------------------	--------------------	--

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<b>5GM/100ML; 150MG/100ML</b>	<b>N019699 004</b>	Sep 29, 1989
-----------	---------	-------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<b>5GM/100ML; 300MG/100ML</b>	<b>N019699 006</b>	Sep 29, 1989
-----------	---------	-------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

<b>AP</b>	HOSPIRA	<b>5GM/100ML; 224MG/100ML</b>	<b>N018371 003</b>	
-----------	---------	-------------------------------	--------------------	--

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 75MG/100ML	N017634 004	
-----------------	-----------------------	-------------	--

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 149MG/100ML	N018371 001	
---------	------------------------	-------------	--

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 298MG/100ML	N018371 002	
---------	------------------------	-------------	--

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML	N019870 001	Jun 10, 1993
---------	--	-------------	--------------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 75MG/100ML; 200MG/100ML</b>	<b>N018037 006</b>	Apr 13, 1982
-----------	-----------------	---	--------------------	--------------

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 150MG/100ML; 200MG/100ML</b>	<b>N018037 007</b>	Apr 13, 1982
-----------	-----------------	--	--------------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 224MG/100ML; 200MG/100ML</b>	<b>N018037 004</b>	
-----------	-----------------	--	--------------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 150MG/100ML; 200MG/100ML</b>	<b>N018037 008</b>	Apr 13, 1982
-----------	-----------------	--	--------------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 300MG/100ML; 200MG/100ML</b>	<b>N018037 001</b>	
-----------	-----------------	--	--------------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 224MG/100ML; 200MG/100ML</b>	<b>N018037 005</b>	Apr 13, 1982
-----------	-----------------	--	--------------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 300MG/100ML; 200MG/100ML</b>	<b>N018037 009</b>	Apr 13, 1982
-----------	-----------------	--	--------------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 75MG/100ML; 200MG/100ML</b>	<b>N018037 002</b>	
-----------	-----------------	---	--------------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 150MG/100ML; 200MG/100ML</b>	<b>N018037 003</b>	
-----------	-----------------	--	--------------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 75MG/100ML; 330MG/100ML</b>	<b>N018629 005</b>	Mar 23, 1982
-----------	-----------------	---	--------------------	--------------

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 150MG/100ML; 330MG/100ML</b>	<b>N018629 002</b>	Mar 23, 1982
-----------	-----------------	--	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 003 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;330MG/100ML	N018629 004 Mar 23, 1982
AP		5GM/100ML;300MG/100ML;330MG/100ML	N018629 006 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 007 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;330MG/100ML	N018629 008 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 001 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 010
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N019630 008 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N019630 014 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N019630 020 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;75MG/100ML;900MG/100ML	N019630 026 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N019630 010 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630 016 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630 022 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630 028 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630 012 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630 018 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630 024 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML;300MG/100ML;900MG/100ML	N019630 030 Feb 17, 1988
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 005 Apr 28, 1982
AP		5GM/100ML;150MG/100ML;450MG/100ML	N018008 006 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 005 Mar 28, 1988
AP		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 009 Jul 05, 1983
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308 004 Apr 05, 1985
AP		5GM/100ML;150MG/100ML;900MG/100ML	N019308 002 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 002 Mar 24, 1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 004 Mar 24, 1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 006 Mar 28, 1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 006 Mar 24, 1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 007 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;149MG/100ML;450MG/100ML	N018362 010 Jul 05, 1983
AP		5GM/100ML;298MG/100ML;450MG/100ML	N018362 007 Mar 28, 1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 005 Apr 05, 1985
AP		5GM/100ML;300MG/100ML;900MG/100ML	N019308 003 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N019691 005 Mar 24, 1988
AP		5GM/100ML;298MG/100ML;900MG/100ML	N019691 008 Mar 24, 1988
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 008 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 002
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308 006 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 007 Mar 24, 1988
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 009 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N018362 003

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEO IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308 007</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691 009</u>	Mar 24, 1988

POTASSIUM CHLORIDE 5MEO IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008 004</u>	
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362 008</u>	Mar 28, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362 004</u>	Mar 28, 1988

POTASSIUM CHLORIDE 5MEO IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308 001</u>	Apr 05, 1985
<u>AP</u>	HOSPIRA	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691 001</u>	Mar 24, 1988
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691 003</u>	Mar 24, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML;200MG/100ML N019630 031 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML;450MG/100ML N019630 037 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML;900MG/100ML N019630 043 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;110MG/100ML N019630 001 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;200MG/100ML N019630 007 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;330MG/100ML N019630 013 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;450MG/100ML N019630 019 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML;900MG/100ML N019630 025 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;75MG/100ML;200MG/100ML N019630 032 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;75MG/100ML;450MG/100ML N019630 038 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;75MG/100ML;900MG/100ML N019630 044 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML;75MG/100ML;300MG/100ML N019630 049 May 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;75MG/100ML;110MG/100ML N019630 002 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;110MG/100ML;200MG/100ML N019630 033 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;110MG/100ML;450MG/100ML N019630 039 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;110MG/100ML;900MG/100ML N019630 045 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML;110MG/100ML;300MG/100ML N019630 050 May 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;110MG/100ML N019630 003 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;200MG/100ML N019630 009 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;330MG/100ML N019630 015 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;450MG/100ML N019630 021 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;110MG/100ML;900MG/100ML N019630 027 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;150MG/100ML;200MG/100ML N019630 034 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;150MG/100ML;450MG/100ML N019630 040 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;150MG/100ML;900MG/100ML N019630 046 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML;150MG/100ML;300MG/100ML N019630 051 May 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;150MG/100ML;110MG/100ML N019630 004 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;220MG/100ML;200MG/100ML N019630 035 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;220MG/100ML;450MG/100ML N019630 041 Feb 17, 1988

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML	N019630	047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML	N019630	052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML	N019630	005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N019630	011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N019630	017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N019630	023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML	N019630	029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML	N019630	036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML	N019630	042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML	N019630	048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML	N019630	053	May 07, 1992
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML	N019630	006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983
	5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986
	5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876	007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001	
	5GM/100ML;298MG/100ML;225MG/100ML	N018365	009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876	008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;149MG/100ML;300MG/100ML	N018876	002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876	003	Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876	004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988
	5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	005	Mar 28, 1988
	5GM/100ML;149MG/100ML;300MG/100ML	N018876	009	Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
<b>AP</b>	B BRAUN	<u>10GM/100ML;900MG/100ML</u>	<b>N019631</b>	<b>015</b> Feb 24, 1988
<b>AP</b>	BAXTER HLTHCARE	<u>10GM/100ML;900MG/100ML</u>	<b>N016696</b>	<b>001</b>
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
<b>AP</b>	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>	<b>N019631</b>	<b>004</b> Feb 24, 1988
<b>AP</b>	BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>	<b>N016697</b>	<b>001</b>
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>				
<b>AP</b>	B BRAUN	<u>5GM/100ML;200MG/100ML</u>	<b>N019631</b>	<b>007</b> Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>				
<b>AP</b>	B BRAUN	<u>5GM/100ML;330MG/100ML</u>	<b>N019631</b>	<b>008</b> Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
<b>AP</b>	B BRAUN	<u>5GM/100ML;450MG/100ML</u>	<b>N019631</b>	<b>009</b> Feb 24, 1988
<b>AP</b>	HOSPIRA	<u>5GM/100ML;450MG/100ML</u>	<b>N017607</b>	<b>001</b>

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;900MG/100ML</u>	<u>N019631 010</u>	Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;900MG/100ML</u>	<u>N017585 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;200MG/100ML</u>	<u>N016689 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;330MG/100ML</u>	<u>N016687 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;450MG/100ML</u>	<u>N016683 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;900MG/100ML</u>	<u>N016678 001</u>	
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML	N019631 011	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;200MG/100ML	N019631 012	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;330MG/100ML	N019631 013	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;450MG/100ML	N019631 014	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;110MG/100ML	N019631 001	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;200MG/100ML	N019631 002	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;330MG/100ML	N019631 003	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;900MG/100ML	N019631 005	Feb 24, 1988
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;300MG/100ML	N019631 016	Jan 19, 1990
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML	N019631 006	Feb 24, 1988
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;225MG/100ML	N017606 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;300MG/100ML	N017799 001	

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

## CYSTOGRAFIN

BRACCO

30%

N010040 018

## CYSTOGRAFIN DILUTE

BRACCO

18%

N010040 022 Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76RAP + LIEBEL-FLARSHEIM 66%;10% N019292 001 Sep 29, 1989RENOGRAFIN-76AP + BRACCO 66%;10% N010040 001

SOLUTION; ORAL, RECTAL

GASTROGRAFINAA + BRACCO 66%;10% N011245 003MD-GASTROVIEWAA LIEBEL-FLARSHEIM 66%;10% A087388 001DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

## SINOGRAFIN

+ BRACCO

52.7%;26.8%

N011324 002

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAMAA LANNETT HOLDINGS INC 5MG/ML A204433 001 Apr 14, 2014DIAZEPAM INTENSOLAA + ROXANE 5MG/ML A071415 001 Apr 03, 1987

GEL; RECTAL

## DIASTAT

VALEANT PHARMS NORTH 2.5MG/0.5ML (5MG/ML)

N020648 001 Jul 29, 1997

## DIASTAT ACUDIAL

VALEANT PHARMS NORTH 10MG/2ML (5MG/ML)

N020648 007 Sep 15, 2005

+ 20MG/4ML (5MG/ML)

N020648 006 Sep 15, 2005

## PRESCRIPTION DRUG PRODUCT LIST

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A071583</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>		<u>5MG/ML</u>	<u>A072079</u>	<u>001</u>	Dec 20, 1988

SOLUTION; ORAL

DIAZEPAM

+ ROXANE

5MG/5ML

A070928 001 Apr 03, 1987

TABLET; ORAL

DIAZEPAM

<u>AB</u>	BARR	<u>2MG</u>	<u>A070152</u>	<u>001</u>	Nov 01, 1985
<u>AB</u>		<u>10MG</u>	<u>A070154</u>	<u>001</u>	Nov 01, 1985
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2MG</u>	<u>A071307</u>	<u>001</u>	Dec 10, 1986
<u>AB</u>		<u>5MG</u>	<u>A071321</u>	<u>001</u>	Dec 10, 1986
<u>AB</u>		<u>10MG</u>	<u>A071322</u>	<u>001</u>	Dec 10, 1986
<u>AB</u>	MYLAN	<u>2MG</u>	<u>A070325</u>	<u>002</u>	Sep 04, 1985
<u>AB</u>		<u>5MG</u>	<u>A070325</u>	<u>003</u>	Sep 04, 1985
<u>AB</u>		<u>10MG</u>	<u>A070325</u>	<u>001</u>	Sep 04, 1985
<u>AB</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A077749</u>	<u>001</u>	Mar 31, 2006
<u>AB</u>		<u>5MG</u>	<u>A077749</u>	<u>002</u>	Mar 31, 2006
<u>AB</u>		<u>10MG</u>	<u>A077749</u>	<u>003</u>	Mar 31, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A071134</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>		<u>5MG</u>	<u>A071135</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>		<u>10MG</u>	<u>A071136</u>	<u>001</u>	Feb 03, 1987

VALIUM

<u>AB</u>	ROCHE	<u>2MG</u>	<u>N013263</u>	<u>002</u>	
<u>AB</u>		<u>5MG</u>	<u>N013263</u>	<u>004</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N013263</u>	<u>006</u>	

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

+ TEVA BRANDED PHARM

50MG/ML

N017453 001

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

TARO

50MG

N011366 002 Aug 07, 2015

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

IROKO PHARMS LLC

18MG

N204592 001 Oct 18, 2013

+

35MG

N204592 002 Oct 18, 2013

DICLOFENAC EPOLAMINE

PATCH; TOPICAL

FLECTOR

+ INST BIOCHEM

1.3%

N021234 001 Jan 31, 2007

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+ DEPOMED INC

25MG

N022202 001 Jun 16, 2009

FOR SOLUTION; ORAL

CAMBIA

+ DEPOMED INC

50MG

N022165 001 Jun 17, 2009

TABLET; ORAL

CATAFLAM

<u>AB</u>	+ NOVARTIS	<u>50MG</u>	<u>N020142</u>	<u>002</u>	Nov 24, 1993
-----------	------------	-------------	----------------	------------	--------------

DICLOFENAC POTASSIUM

<u>AB</u>	APOTEX	<u>50MG</u>	<u>A076561</u>	<u>001</u>	Mar 18, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075463</u>	<u>001</u>	Jul 26, 1999
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A075229</u>	<u>001</u>	Nov 20, 1998
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075219</u>	<u>001</u>	Aug 06, 1998

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>3%</u>	<u>A206493</u>	<u>001</u>	Dec 02, 2015
-----------	----------------------	-----------	----------------	------------	--------------

DICLOFENAC SODIUM

<u>AB</u>	TOLMAR	<u>3%</u>	<u>A200936</u>	<u>001</u>	Oct 28, 2013
-----------	--------	-----------	----------------	------------	--------------

SOLARAZE

<u>AB</u>	+ FOUGERA PHARMS	<u>3%</u>	<u>N021005</u>	<u>001</u>	Oct 16, 2000
-----------	------------------	-----------	----------------	------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

DICLOFENAC SODIUM

GEL; TOPICAL

VOLTAREN

+ GLAXOSMITHKLINE CONS 1%

N022122 001 Oct 17, 2007

SOLUTION; INTRAVENOUS

DYLOJECT

+ JAVELIN PHARMS INC 37.5MG/ML (37.5MG/ML)

N022396 001 Dec 23, 2014

SOLUTION; TOPICAL

DICLOFENAC SODIUM

<b>AT</b>	APOTEX INC	<u>1.5%</u>	<b><u>A202027</u></b>	<b><u>001</u></b>	May 27, 2014
<b>AT</b>	IGI LABS INC	<u>1.5%</u>	<b><u>A202769</u></b>	<b><u>001</u></b>	Jul 08, 2015
<b>AT</b>	LUPIN LTD	<u>1.5%</u>	<b><u>A204132</u></b>	<b><u>001</u></b>	Aug 20, 2015
<b>AT</b>	NOVEL LABS INC	<u>1.5%</u>	<b><u>A205878</u></b>	<b><u>001</u></b>	Dec 09, 2015
<b>AT</b>	PADDOCK LLC	<u>1.5%</u>	<b><u>A202393</u></b>	<b><u>001</u></b>	Nov 24, 2014
<b>AT</b>	TARO	<u>1.5%</u>	<b><u>A203818</u></b>	<b><u>001</u></b>	Nov 26, 2014
<b>AT</b>	WATSON LABS INC	<u>1.5%</u>	<b><u>A202852</u></b>	<b><u>001</u></b>	Nov 24, 2014

PENNSAID

<b>AT</b>	+ NUVO RES INC	<u>1.5%</u>	<b><u>N020947</u></b>	<b><u>001</u></b>	Nov 04, 2009
	+ HORIZON PHARMA	2%	N204623	001	Jan 16, 2014

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

<b>AT</b>	AKORN	<u>0.1%</u>	<b><u>A077845</u></b>	<b><u>001</u></b>	Apr 17, 2008
<b>AT</b>	ALCON PHARMS LTD	<u>0.1%</u>	<b><u>A078031</u></b>	<b><u>001</u></b>	Feb 06, 2008
<b>AT</b>	ALTAIRE PHARMS INC	<u>0.1%</u>	<b><u>A203383</u></b>	<b><u>001</u></b>	Nov 16, 2015
<b>AT</b>	BAUSCH AND LOMB	<u>0.1%</u>	<b><u>A078792</u></b>	<b><u>001</u></b>	Dec 28, 2007
<b>AT</b>	NEXUS PHARMS	<u>0.1%</u>	<b><u>A078553</u></b>	<b><u>001</u></b>	Dec 28, 2007

VOLTAREN

<b>AT</b>	+ NOVARTIS	<u>0.1%</u>	<b><u>N020037</u></b>	<b><u>001</u></b>	Mar 28, 1991
-----------	------------	-------------	-----------------------	-------------------	--------------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

<b>AB</b>	ACTAVIS ELIZABETH	<u>50MG</u>	<b><u>A074514</u></b>	<b><u>001</u></b>	Mar 26, 1996
<b>AB</b>		<u>75MG</u>	<b><u>A074514</u></b>	<b><u>002</u></b>	Mar 26, 1996
<b>AB</b>	CARLSBAD	<u>25MG</u>	<b><u>A075185</u></b>	<b><u>002</u></b>	Nov 13, 1998
<b>AB</b>		<u>50MG</u>	<b><u>A075185</u></b>	<b><u>003</u></b>	Nov 13, 1998
<b>AB</b>		<u>75MG</u>	<b><u>A075185</u></b>	<b><u>001</u></b>	Nov 13, 1998
<b>AB</b>	MYLAN PHARMS INC	<u>50MG</u>	<b><u>A075281</u></b>	<b><u>002</u></b>	Feb 12, 2002
<b>AB</b>		<u>75MG</u>	<b><u>A075281</u></b>	<b><u>003</u></b>	Feb 12, 2002
<b>AB</b>	+ SANDOZ	<u>25MG</u>	<b><u>A074376</u></b>	<b><u>001</u></b>	Sep 28, 1995
<b>AB</b>	+	<u>50MG</u>	<b><u>A074376</u></b>	<b><u>002</u></b>	Sep 28, 1995
<b>AB</b>	+	<u>75MG</u>	<b><u>A074394</u></b>	<b><u>001</u></b>	Nov 30, 1995
<b>AB</b>	UNIQUE PHARM LABS	<u>25MG</u>	<b><u>A090066</u></b>	<b><u>001</u></b>	Dec 01, 2010
<b>AB</b>		<u>50MG</u>	<b><u>A090066</u></b>	<b><u>002</u></b>	Dec 01, 2010
<b>AB</b>		<u>75MG</u>	<b><u>A077863</u></b>	<b><u>003</u></b>	Jun 08, 2007

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

<b>AB</b>	ACTAVIS ELIZABETH	<u>100MG</u>	<b><u>A075910</u></b>	<b><u>001</u></b>	Jan 07, 2002
<b>AB</b>	DEXCEL LTD	<u>100MG</u>	<b><u>A076201</u></b>	<b><u>001</u></b>	Nov 06, 2002
<b>AB</b>	MYLAN	<u>100MG</u>	<b><u>A076152</u></b>	<b><u>001</u></b>	Dec 13, 2001
<b>AB</b>	VPNA	<u>100MG</u>	<b><u>A075492</u></b>	<b><u>001</u></b>	Feb 11, 2000

VOLTAREN-XR

<b>AB</b>	+ NOVARTIS	<u>100MG</u>	<b><u>N020254</u></b>	<b><u>001</u></b>	Mar 08, 1996
-----------	------------	--------------	-----------------------	-------------------	--------------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

<b>AB</b>	GD SEARLE LLC	<u>50MG; 0.2MG</u>	<b><u>N020607</u></b>	<b><u>001</u></b>	Dec 24, 1997
<b>AB</b>	+	<u>75MG; 0.2MG</u>	<b><u>N020607</u></b>	<b><u>002</u></b>	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

<b>AB</b>	ACTAVIS LABS FL INC	<u>50MG; 0.2MG</u>	<b><u>A201089</u></b>	<b><u>001</u></b>	Jul 09, 2012
<b>AB</b>		<u>75MG; 0.2MG</u>	<b><u>A201089</u></b>	<b><u>002</u></b>	Jul 09, 2012
<b>AB</b>	EAGLE PHARMS	<u>50MG; 0.2MG</u>	<b><u>A200540</u></b>	<b><u>001</u></b>	Mar 14, 2014
<b>AB</b>		<u>75MG; 0.2MG</u>	<b><u>A200540</u></b>	<b><u>002</u></b>	Mar 14, 2014
<b>AB</b>	SANDOZ	<u>50MG; 0.2MG</u>	<b><u>A200158</u></b>	<b><u>001</u></b>	May 09, 2013
<b>AB</b>		<u>75MG; 0.2MG</u>	<b><u>A200158</u></b>	<b><u>002</u></b>	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

<b>AB</b>	SANDOZ	<u>EQ 250MG BASE</u>	<b><u>A061454</u></b>	<b><u>001</u></b>	
<b>AB</b>	+	<u>EQ 500MG BASE</u>	<b><u>A061454</u></b>	<b><u>003</u></b>	
<b>AB</b>	TEVA	<u>EQ 250MG BASE</u>	<b><u>A062286</u></b>	<b><u>001</u></b>	Jun 03, 1982
<b>AB</b>		<u>EQ 500MG BASE</u>	<b><u>A062286</u></b>	<b><u>002</u></b>	Jun 03, 1982
	SANDOZ	<u>EQ 125MG BASE</u>	A061454	002	

## PRESCRIPTION DRUG PRODUCT LIST

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

<b>AB</b>	+	FOREST LABS INC	<b>10MG</b>	<b>N007409 003</b>	Oct 15, 1984
<b><u>DICYCLOMINE HYDROCHLORIDE</u></b>					
<b>AB</b>		LANNETT	<b>10MG</b>	<b>A084285 001</b>	
<b>AB</b>		MYLAN	<b>10MG</b>	<b>A040319 001</b>	Sep 07, 1999
<b>AB</b>		WATSON LABS	<b>10MG</b>	<b>A085082 001</b>	Jun 19, 1986

INJECTABLE; INJECTION

BENTYL

<b>AP</b>	+	FOREST LABS INC	<b>10MG/ML</b>	<b>N008370 001</b>	Oct 15, 1984
<b><u>BENTYL PRESERVATIVE FREE</u></b>					
<b>AP</b>	+	FOREST LABS INC	<b>10MG/ML</b>	<b>N008370 002</b>	Oct 15, 1984
<b><u>DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)</u></b>					
<b>AP</b>		EUROHLTH INTL SARL	<b>10MG/ML</b>	<b>A040465 001</b>	Jun 30, 2003

SYRUP; ORAL

BENTYL

<b>AA</b>	+	APTALIS PHARMA US	<b>10MG/5ML</b>	<b>N007961 002</b>	Oct 15, 1984
<b><u>DICYCLOMINE HYDROCHLORIDE</u></b>					
<b>AA</b>		MIKART	<b>10MG/5ML</b>	<b>A040169 001</b>	Mar 24, 2005

TABLET; ORAL

BENTYL

<b>AB</b>	+	FOREST LABS INC	<b>20MG</b>	<b>N007409 001</b>	Oct 15, 1984
<b><u>DICYCLOMINE HYDROCHLORIDE</u></b>					
<b>AB</b>		LANNETT	<b>20MG</b>	<b>A040230 001</b>	Feb 26, 1999
<b>AB</b>		MYLAN	<b>20MG</b>	<b>A040317 001</b>	Sep 07, 1999
<b>AB</b>		WATSON LABS	<b>20MG</b>	<b>A085223 001</b>	Jul 30, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

<b>AB</b>		AUROBINDO PHARMA	<b>125MG</b>	<b>A090094 001</b>	Sep 24, 2008
<b>AB</b>			<b>200MG</b>	<b>A090094 002</b>	Sep 24, 2008
<b>AB</b>			<b>250MG</b>	<b>A090094 003</b>	Sep 24, 2008
<b>AB</b>			<b>400MG</b>	<b>A090094 004</b>	Sep 24, 2008
<b>AB</b>		BARR	<b>200MG</b>	<b>A077167 001</b>	Dec 03, 2004
<b>AB</b>			<b>250MG</b>	<b>A077167 002</b>	Dec 03, 2004
<b>AB</b>			<b>400MG</b>	<b>A077167 003</b>	Dec 03, 2004
<b>AB</b>		MYLAN PHARMS INC	<b>125MG</b>	<b>A090788 001</b>	Apr 08, 2010
<b>AB</b>			<b>200MG</b>	<b>A090788 002</b>	Apr 08, 2010
<b>AB</b>			<b>250MG</b>	<b>A090788 003</b>	Apr 08, 2010
<b>AB</b>			<b>400MG</b>	<b>A090788 004</b>	Apr 08, 2010

VIDEX EC

<b>AB</b>		BRISTOL MYERS SQUIBB	<b>125MG</b>	<b>N021183 001</b>	Oct 31, 2000
<b>AB</b>			<b>200MG</b>	<b>N021183 002</b>	Oct 31, 2000
<b>AB</b>			<b>250MG</b>	<b>N021183 003</b>	Oct 31, 2000
<b>AB</b>	+		<b>400MG</b>	<b>N021183 004</b>	Oct 31, 2000

FOR SOLUTION; ORAL

DIDANOSINE

<b>AA</b>		AUROBINDO PHARMA	<b>10MG/ML</b>	<b>A078112 001</b>	Mar 08, 2007
-----------	--	------------------	----------------	--------------------	--------------

VIDEX

<b>AA</b>	+	BRISTOL MYERS SQUIBB	<b>10MG/ML</b>	<b>N020156 001</b>	Oct 09, 1991
-----------	---	----------------------	----------------	--------------------	--------------

TABLET, FOR SUSPENSION; ORAL

DIDANOSINE

		AUROBINDO	100MG	A077275 001	Aug 14, 2012
			150MG	A077275 002	Aug 14, 2012
	+		200MG	A077275 003	Aug 14, 2012

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

NATAZIA

	+	BAYER HLTHCARE	2MG; 3MG; N/A; 1MG; 2MG; 2MG; 3MG; N/A	N022252 001	May 06, 2010
--	---	----------------	--	-------------	--------------

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

<b>AA</b>		AVANTHI INC	<b>25MG</b>	<b>A201212 001</b>	Dec 22, 2010
<b>AA</b>		COREPHARMA	<b>25MG</b>	<b>A040828 001</b>	Nov 05, 2008
<b>AA</b>		LANNETT HOLDINGS INC	<b>25MG</b>	<b>A200177 001</b>	Jul 18, 2011

TENUATE

<b>AA</b>	+	ACTAVIS LABS UT INC	<b>25MG</b>	<b>N011722 002</b>	
-----------	---	---------------------	-------------	--------------------	--

## PRESCRIPTION DRUG PRODUCT LIST

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE**AB** LANNETT HOLDINGS INC **75MG** **A091680 001** Oct 24, 2011TENUATE DOSPAN**AB** + ACTAVIS LABS UT INC **75MG** **N012546 001**DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX + FOUGERA PHARMS 0.05% A076263 001 Dec 20, 2002

BX + TARO 0.05% A075508 001 Apr 24, 2000

OINTMENT;TOPICAL

DIFLORASONE DIACETATE**AB** FOUGERA PHARMS **0.05%** **A075374 001** Apr 27, 1999**AB** + TARO **0.05%** **A075331 001** May 14, 1999**AB** VERSAPHARM INC **0.05%** **A206572 001** Jul 24, 2015DIFLUNISAL

TABLET;ORAL

DIFLUNISAL**AB** HERITAGE PHARMA **500MG** **A202845 001** Mar 08, 2012**AB** + TEVA **500MG** **A073673 001** Jul 31, 1992DIFLUPREDNATE

EMULSION;OPHTHALMIC

DUREZOL

+ ALCON PHARMS LTD 0.05% N022212 001 Jun 23, 2008

DIGOXIN

ELIXIR;ORAL

DIGOXIN

+ ROXANE 0.05MG/ML N021648 001 Aug 26, 2004

INJECTABLE;INJECTION

DIGOXIN**AP** EUROHLTH INTL SARL **0.25MG/ML** **A083391 001****AP** SANDOZ **0.25MG/ML** **A040481 001** Aug 21, 2003LANOXIN**AP** + COVIS INJECTABLES **0.25MG/ML** **N009330 002**

LANOXIN PEDIATRIC

+ COVIS INJECTABLES 0.1MG/ML N009330 004

TABLET;ORAL

DIGOXIN**AB** HIKMA INTL PHARMS **0.125MG** **A077002 002** Oct 30, 2007**AB** **0.25MG** **A077002 001** Oct 30, 2007**AB** IMPAX LABS **0.125MG** **A078556 001** Jul 20, 2009**AB** **0.25MG** **A078556 002** Jul 20, 2009**AB** MYLAN PHARMS INC **0.125MG** **A040282 001** Dec 23, 1999**AB** **0.25MG** **A040282 002** Dec 23, 1999**AB** STEVENS J **0.125MG** **A076268 001** Jul 26, 2002**AB** **0.25MG** **A076268 002** Jul 26, 2002**AB** SUN PHARM INDS INC **0.125MG** **A076363 001** Jan 31, 2003**AB** **0.25MG** **A076363 002** Jan 31, 2003LANOXIN**AB** CONCORDIA PHARMS INC **0.125MG** **N020405 002** Sep 30, 1997**AB** + **0.25MG** **N020405 004** Sep 30, 1997

0.0625MG N020405 001 Sep 30, 1997

0.1875MG N020405 003 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

D.H.E. 45**AP** + VALEANT **1MG/ML** **N005929 001**DIHYDROERGOTAMINE MESYLATE**AP** BEDFORD LABS **1MG/ML** **A040453 001** Jun 09, 2003**AP** PADDOCK LLC **1MG/ML** **A040475 001** Apr 28, 2003

SPRAY, METERED;NASAL

MIGRANAL

+ VALEANT 0.5MG/INH N020148 001 Dec 08, 1997

**PRESCRIPTION DRUG PRODUCT LIST**

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB2</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A074852</u>	<u>001</u>	Oct 10, 1997
<u>AB2</u>		<u>180MG</u>	<u>A074852</u>	<u>002</u>	Oct 10, 1997
<u>AB2</u>		<u>240MG</u>	<u>A074852</u>	<u>003</u>	Oct 10, 1997
<u>AB2</u>	APOTEX	<u>120MG</u>	<u>A074943</u>	<u>003</u>	Dec 19, 2000
<u>AB2</u>		<u>180MG</u>	<u>A074943</u>	<u>002</u>	Dec 19, 2000
<u>AB2</u>		<u>240MG</u>	<u>A074943</u>	<u>001</u>	Aug 06, 1998
<u>AB2</u>	MYLAN	<u>120MG</u>	<u>A075124</u>	<u>002</u>	Mar 18, 1998
<u>AB2</u>		<u>180MG</u>	<u>A075124</u>	<u>003</u>	Mar 18, 1998
<u>AB2</u>	+	<u>240MG</u>	<u>A075124</u>	<u>001</u>	Mar 18, 1998

CARDIZEM CD

<u>AB3</u>	VALEANT INTL	<u>120MG</u>	<u>N020062</u>	<u>001</u>	Aug 10, 1992
<u>AB3</u>		<u>180MG</u>	<u>N020062</u>	<u>002</u>	Dec 27, 1991
<u>AB3</u>		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u>		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991
<u>AB3</u>	+	<u>360MG</u>	<u>N020062</u>	<u>005</u>	Aug 24, 1999

CARTIA XT

<u>AB3</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>		<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>		<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>		<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>	PAR PHARM	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>		<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>		<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>		<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>		<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>	VALEANT INTL	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999
<u>AB4</u>	SANDOZ	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010

DILTIZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395</u>	<u>001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395</u>	<u>002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395</u>	<u>003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395</u>	<u>004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395</u>	<u>005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	VALEANT PHARMS NORTH	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995
<u>AB4</u>		<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u>	+	<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998

DILTIAZEM HYDROCHLORIDE

BC	+	MYLAN	120MG	A074910	003	May 02, 1997
			60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

## PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998
<u>AP</u>	+ BEDFORD	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>	EUROHLTH INTL SARL	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651</u>	<u>001</u>	Aug 09, 2012
<u>AP</u>	HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>	INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001
	+ HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002
	+ TEVA PHARMS USA	10MG/ML	A074894	002	Apr 19, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	VALEANT INTL	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u>	+	<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>30MG</u>	<u>A072838</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A072838</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072838</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	VALEANT INTL	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u>	+	<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>		<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>		<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>		<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>		<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>		<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

	+ FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004
--	----------------------	---------	---------	-----	--------------

DIMERCAPROL

INJECTABLE; INJECTION

BAL

	+ AKORN	10%	N005939	001	
--	---------	-----	---------	-----	--

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

	BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013
	+	240MG	N204063	002	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

<u>AT</u>	MYLAN INSTITUTIONAL	<u>50%</u>	<u>A076185</u>	<u>001</u>	Nov 29, 2002
<u>AT</u>	+	<u>50%</u>	<u>N017788</u>	<u>001</u>	

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

	+ PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992
--	------------------------	-----------	---------	-----	--------------

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

	+ FERRING CONTROLLED	10MG	N020411	001	Mar 30, 1995
--	----------------------	------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DINOPROSTONE

SUPPOSITORY; VAGINAL

PROSTIN E2

+ PHARMACIA AND UPJOHN 20MG

N017810 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+ BARR 50MG

A080738 001

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+ PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDEAP APP PHARMS 50MG/ML A040466 001 May 28, 2002AP + EUROHLTH INTL SARL 50MG/ML A080817 002AP HOSPIRA 50MG/ML A040140 001 Nov 20, 1998AP MYLAN INSTITUTIONAL 50MG/ML A040498 001 Jul 12, 2005DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREEAP BD RX 50MG/ML A091526 001 Mar 26, 2013DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLEAP + BEDFORD 5MG/ML A074939 001 Apr 13, 1998AP EUROHLTH INTL SARL 5MG/ML A074521 001 Oct 18, 1996AP FRESENIUS KABI USA 5MG/ML A074956 001 Sep 30, 1998

TABLET; ORAL

DIPYRIDAMOLEAB BARR 25MG A087184 001 Oct 03, 1990AB 50MG A087716 001 Oct 03, 1990AB 75MG A087717 001 Oct 03, 1990AB IMPAX LABS 25MG A040782 001 Jul 18, 2007AB 50MG A040782 002 Jul 18, 2007AB 75MG A040782 003 Jul 18, 2007AB LANNETT 25MG A040898 001 Apr 23, 2008AB 50MG A040898 002 Apr 23, 2008AB 75MG A040898 003 Apr 23, 2008AB MURTY PHARMS 25MG A040733 001 Feb 13, 2007AB 50MG A040733 002 Feb 13, 2007AB 75MG A040733 003 Feb 13, 2007AB PUREPAC PHARM 25MG A089425 001 Jul 12, 1990AB ZYDUS PHARMS USA INC 25MG A040874 001 Jan 28, 2008AB 50MG A040874 002 Jan 28, 2008AB 75MG A040874 003 Jan 28, 2008PERSANTINEAB BOEHRINGER INGELHEIM 25MG N012836 003 Dec 22, 1986AB 50MG N012836 004 Feb 06, 1987AB + 75MG N012836 005 Feb 06, 1987DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATEAB TEVA EQ 100MG BASE A070101 001 Feb 22, 1985AB EQ 150MG BASE A070102 001 Feb 22, 1985AB WATSON LABS EQ 100MG BASE A070173 001 May 31, 1985AB EQ 150MG BASE A070174 001 May 31, 1985NORPACEAB GD SEARLE LLC EQ 100MG BASE N017447 001AB + EQ 150MG BASE N017447 002

CAPSULE, EXTENDED RELEASE; ORAL

NORPACE CRAB + GD SEARLE LLC EQ 150MG BASE N018655 002 Jul 20, 1982

EQ 100MG BASE

N018655 001 Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSEAB ODYSSEY PHARMS 250MG A088482 001 Dec 08, 1983AB + 500MG A088483 001 Dec 08, 1983DISULFIRAMAB MYLAN PHARMS INC 250MG A203916 001 Mar 04, 2015AB 500MG A203916 002 Mar 04, 2015AB ROXANE 250MG A202652 001 Feb 05, 2014

## PRESCRIPTION DRUG PRODUCT LIST

DISULFIRAM

TABLET; ORAL

DISULFIRAM

<u>AB</u>		<u>500MG</u>	<u>A202652</u>	<u>002</u>	Feb 05, 2014
<u>AB</u>	SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A091619</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>		<u>500MG</u>	<u>A091619</u>	<u>002</u>	Mar 28, 2011
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A091563</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>500MG</u>	<u>A091563</u>	<u>002</u>	Dec 31, 2012

DISULFIRAM

<u>AB</u>	ALVOGEN PINE BROOK	<u>250MG</u>	<u>A091681</u>	<u>001</u>	Aug 08, 2013
-----------	--------------------	--------------	----------------	------------	--------------

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+ ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989
-----------	----------	-------------------------------	----------------	------------	--------------

DIVALPROEX SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090407</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

<u>AB</u>	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723</u>	<u>003</u>	Oct 26, 1984
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>N018723</u>	<u>001</u>	Mar 10, 1983
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N018723</u>	<u>002</u>	Mar 10, 1983

DIVALPROEX SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080</u>	<u>001</u>	Feb 25, 2011
<u>AB</u>	ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411</u>	<u>001</u>	Nov 03, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554</u>	<u>001</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090554</u>	<u>002</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090554</u>	<u>003</u>	Apr 21, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078755</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078755</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078790</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078790</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090062</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090062</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090062</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077615</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077615</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A076941</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A076941</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163</u>	<u>001</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A079163</u>	<u>002</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A079163</u>	<u>003</u>	Apr 05, 2011
<u>AB</u>	UPSHER SMITH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	VINTAGE	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210</u>	<u>001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210</u>	<u>002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210</u>	<u>003</u>	Nov 30, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296</u>	<u>001</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077296</u>	<u>002</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077296</u>	<u>003</u>	Jul 31, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100</u>	<u>003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

<u>AB</u>	ABBVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168</u>	<u>002</u>	May 31, 2002
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168</u>	<u>001</u>	Aug 04, 2000

## PRESCRIPTION DRUG PRODUCT LIST

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A203730 001</u>	May 29, 2015
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A203730 002</u>	May 29, 2015
<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445 001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445 002</u>	Aug 04, 2009
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A202419 001</u>	Jun 02, 2014
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A202419 002</u>	Jun 02, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161 001</u>	Mar 15, 2012
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791 001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791 002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567 001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567 002</u>	Jan 29, 2009
<u>AB</u>	REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070 001</u>	Mar 12, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705 002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705 001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239 001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239 002</u>	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 12.5MG BASE/ML</u>	<u>A074277 001</u>	Oct 31, 1994
<u>AP</u>	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086 001</u>	Nov 29, 1993
<u>AP</u>	+	<u>EQ 12.5MG BASE/ML</u>	<u>A074292 001</u>	Feb 16, 1995

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020255 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020255 004</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020255 005</u>	Oct 19, 1993
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020201 002</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020201 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020201 006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195 003</u>	Apr 20, 2012	
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N201195 004</u>	Apr 20, 2012	
<u>AP</u>	+	<u>160MG/8ML (20MG/ML)</u>	<u>N201195 005</u>	Apr 20, 2012	
<u>AP</u>	ACTAVIS INC	<u>20MG/ML (20MG/ML)</u>	<u>N203551 001</u>	Apr 12, 2013	
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N203551 002</u>	Apr 12, 2013	
<u>AP</u>	DR REDDYS LABS LTD	<u>20MG/ML (20MG/ML)</u>	<u>A204193 001</u>	Nov 05, 2014	
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A204193 002</u>	Nov 05, 2014	
<u>AP</u>	+	HOSPIRA INC	<u>20MG/2ML (10MG/ML)</u>	<u>N022234 001</u>	Mar 08, 2011
<u>AP</u>	+		<u>80MG/8ML (10MG/ML)</u>	<u>N022234 002</u>	Mar 08, 2011
<u>AP</u>	+		<u>160MG/16ML (10MG/ML)</u>	<u>N022234 003</u>	Mar 08, 2011
<u>AP</u>	SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525 001</u>	Jun 29, 2011	
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>N201525 002</u>	Jun 29, 2011	
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>N201525 003</u>	Jun 29, 2011	
<u>AP</u>	TEVA PHARMS USA	<u>20MG/ML (20MG/ML)</u>	<u>A203877 001</u>	Sep 16, 2015	
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A203877 002</u>	Sep 16, 2015	

TAXOTERE

<u>AP</u>	+	SANOFI AVENTIS US	<u>20MG/ML (20MG/ML)</u>	<u>N020449 003</u>	Aug 03, 2010
<u>AP</u>	+		<u>80MG/4ML (20MG/ML)</u>	<u>N020449 004</u>	Aug 02, 2010
<u>AP</u>	+		<u>160MG/8ML (20MG/ML)</u>	<u>N020449 005</u>	Apr 13, 2012

## DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534 001	May 03, 2011
+		80MG/VIAL	N022534 002	May 03, 2011

## DOCETAXEL

ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011
	80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011
ACTAVIS INC	140MG/7ML (20MG/ML)	N203551 003	Apr 12, 2013
PFIZER LABS	20MG/2ML (10MG/ML)	N202356 001	Mar 13, 2014
	80MG/8ML (10MG/ML)	N202356 002	Mar 13, 2014
	130MG/13ML (10MG/ML)	N202356 003	Mar 13, 2014
	200MG/20ML (10MG/ML)	N202356 004	Mar 13, 2014

SOLUTION; IV (INFUSION)

## DOCETAXEL

TEIKOKU PHARMA	20MG/ML (20MG/ML)	N205934 001	Dec 22, 2015
	80MG/4ML (20MG/ML)	N205934 002	Dec 22, 2015



## PRESCRIPTION DRUG PRODUCT LIST

DOCETAXEL

SOLUTION; IV (INFUSION)

DOCETAXEL

160MG/8ML (20MG/ML)

N205934 003 Dec 22, 2015

DOFETILIDE

CAPSULE; ORAL

TIKOSYN

PFIZER

0.125MG

N020931 001 Oct 01, 1999

0.25MG

N020931 002 Oct 01, 1999

+

0.5MG

N020931 003 Oct 01, 1999

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+ SANOFI AVENTIS US

12.5MG/0.625ML (20MG/ML)

N020624 002 Sep 11, 1997

+

100MG/5ML (20MG/ML)

N020624 001 Sep 11, 1997

+

500MG/25ML (20MG/ML)

N020624 003 Dec 11, 2001

TABLET; ORAL

ANZEMET

SANOFI AVENTIS US

50MG

N020623 001 Sep 11, 1997

+

100MG

N020623 002 Sep 11, 1997

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

+ VIVV HLTHCARE

EQ 50MG BASE

N204790 001 Aug 12, 2013

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPTAB EISAI INC5MGN020690 002 Nov 25, 1996AB +10MGN020690 001 Nov 25, 1996AB +23MGN022568 001 Jul 23, 2010DONEPEZIL HYDROCHLORIDEAB ACTAVIS ELIZABETH23MGA202415 001 Dec 17, 2015AB ALEMBIC PHARMS LTD5MGA201724 001 Feb 25, 2013AB 10MGA201724 002 Feb 25, 2013AB APOTEX5MGA078841 001 Jun 02, 2011AB 10MGA078841 002 Jun 02, 2011AB AUROBINDO5MGA090056 001 May 31, 2011AB 10MGA090056 002 May 31, 2011AB CIPLA LTD5MGA077518 001 May 31, 2011AB 10MGA077518 002 May 31, 2011AB CSPC OUYI PHARM CO5MGA202114 001 Jul 05, 2013AB 10MGA202114 002 Jul 05, 2013AB DR REDDYS LABS LTD5MGA201001 001 May 31, 2011AB 10MGA201001 002 May 31, 2011AB 23MGA202723 001 Jul 24, 2013AB HETERO LABS LTD V5MGA203034 001 Jan 30, 2015AB 10MGA203034 002 Jan 30, 2015AB HIKMA PHARMS5MGA090247 001 May 31, 2011AB 10MGA090247 002 May 31, 2011AB INDICUS PHARMA5MGA201634 001 Jun 13, 2012AB 10MGA201634 002 Jun 13, 2012AB JUBILANT GENERICS5MGA090768 001 May 31, 2011AB 10MGA090768 002 May 31, 2011AB LUPIN LTD23MGA202782 001 Oct 30, 2015AB MACLEODS PHARMS LTD5MGA201146 001 Aug 17, 2012AB 10MGA201146 002 Aug 17, 2012AB 23MGA202631 001 Jan 22, 2014AB MYLAN PHARMS INC5MGA090521 001 May 31, 2011AB 10MGA090521 002 May 31, 2011AB 23MGA202656 001 Oct 22, 2015AB PAR PHARM23MGA202542 001 Jul 24, 2013AB PLIVA HRVATSKA DOO5MGA090425 001 May 31, 2011AB 10MGA090425 002 May 31, 2011AB PRINSTON INC5MGA200292 001 May 31, 2011AB 10MGA200292 002 May 31, 2011AB ROXANE5MGA078662 001 May 31, 2011AB 10MGA078662 002 May 31, 2011AB SANDOZ5MGA090290 001 May 31, 2011AB 10MGA090290 002 May 31, 2011AB SCIEGEN PHARMS INC5MGA203907 001 Oct 29, 2014

## PRESCRIPTION DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A203907 002</u>	Oct 29, 2014
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090493 001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090493 002</u>	May 31, 2011
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A076786 001</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A076786 002</u>	Nov 26, 2010
<u>AB</u>		<u>23MG</u>	<u>A204293 001</u>	Jun 05, 2015
<u>AB</u>	TEVA	<u>5MG</u>	<u>A077344 001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077344 002</u>	May 31, 2011
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A090686 001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090686 002</u>	May 31, 2011
<u>AB</u>	TWI PHARMS INC	<u>23MG</u>	<u>A203104 001</u>	Oct 29, 2014
<u>AB</u>	VIVIMED LABS	<u>5MG</u>	<u>A090551 001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090551 002</u>	May 31, 2011
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A091267 001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A091267 002</u>	May 31, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090100 001</u>	Oct 24, 2012
<u>AB</u>		<u>10MG</u>	<u>A090100 002</u>	Oct 24, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N021720 001</u>	Oct 18, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N021720 002</u>	Oct 18, 2004
	<u>DONEPEZIL HYDROCHLORIDE</u>			
<u>AB</u>	BARR	<u>5MG</u>	<u>A078388 002</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A078388 001</u>	Nov 26, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787 001</u>	Dec 14, 2012
<u>AB</u>		<u>10MG</u>	<u>A201787 002</u>	Dec 14, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A091198 001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A091198 002</u>	May 10, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090175 001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A090175 002</u>	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

	FOREST LABS LLC	10MG; 14MG	N206439 001	Dec 23, 2014
	+	10MG; 28MG	N206439 002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>40MG/ML</u>	<u>N018132 001</u>	
<u>AP</u>	+		<u>80MG/100ML</u>	<u>N018132 002</u>	Feb 04, 1982
<u>AP</u>	+		<u>80MG/ML</u>	<u>N018132 004</u>	Jul 09, 1982
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018132 003</u>	Feb 04, 1982
<u>AP</u>	+	LUITPOLD	<u>40MG/ML</u>	<u>A070799 001</u>	Feb 11, 1987
<u>AP</u>	+		<u>80MG/ML</u>	<u>A070820 001</u>	Feb 11, 1987
<u>AP</u>	+		<u>160MG/ML</u>	<u>A070826 001</u>	Feb 11, 1987

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+	B BRAUN	<u>80MG/100ML</u>	<u>N019099 002</u>	Oct 15, 1986
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019099 004</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>160MG/100ML</u>	<u>N019099 003</u>	Oct 15, 1986
-----------	---	---------	--------------------	--------------------	--------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>80MG/100ML</u>	<u>N019615 001</u>	Mar 27, 1987
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N019615 002</u>	Mar 27, 1987
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019615 003</u>	Mar 27, 1987
<u>AP</u>	+	HOSPIRA	<u>80MG/100ML</u>	<u>N018826 001</u>	Sep 30, 1983
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018826 002</u>	Sep 30, 1983
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N018826 003</u>	Sep 30, 1983
		DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER			
		+ B BRAUN	40MG/100ML	N019099 001	Oct 15, 1986
		DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER			
		+ BAXTER HLTHCARE	640MG/100ML	N019615 004	Mar 27, 1987

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

	SHIONOGI INC	250MG/VIAL	N022106 002	Oct 05, 2010
	+	500MG/VIAL	N022106 001	Oct 12, 2007

## PRESCRIPTION DRUG PRODUCT LIST

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

<u>AT</u>	ALCON PHARMS LTD	<u>EQ 2% BASE</u>	<u>A078981 001</u>	Apr 13, 2009
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE</u>	<u>A090143 001</u>	Jun 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>EQ 2% BASE</u>	<u>A077846 001</u>	Oct 28, 2008
<u>AT</u>	LUITPOLD	<u>EQ 2% BASE</u>	<u>A079186 001</u>	Nov 18, 2009
<u>AT</u>	SANDOZ	<u>EQ 2% BASE</u>	<u>A078748 001</u>	Nov 06, 2008
<u>AT</u>	TEVA PHARMS	<u>EQ 2% BASE</u>	<u>A078756 001</u>	Dec 04, 2008
<u>AT</u>	WATSON LABS INC	<u>EQ 2% BASE</u>	<u>A202053 001</u>	Sep 11, 2014
<u>AT</u>	ZACH SYSTEMS	<u>EQ 2% BASE</u>	<u>A091034 001</u>	Dec 04, 2013

TRUSOPT

<u>AT</u>	+ MERCK	<u>EQ 2% BASE</u>	<u>N020408 001</u>	Dec 09, 1994
-----------	---------	-------------------	--------------------	--------------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

<u>AT</u>	+ OAK PHARMS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N020869 001</u>	Apr 07, 1998
-----------	------------------	--------------------------------	--------------------	--------------

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

<u>AT</u>	AKORN INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A203058 001</u>	Sep 22, 2014
<u>AT</u>	ALCON RES	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090604 001</u>	Nov 18, 2009
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090037 001</u>	Jul 14, 2009
<u>AT</u>	HI TECH PHARMA	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A077847 001</u>	Oct 28, 2008
<u>AT</u>	LANNETT HOLDINGS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A201998 001</u>	Dec 17, 2014
<u>AT</u>	SANDOZ	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078749 001</u>	Nov 06, 2008
<u>AT</u>	TEVA PHARMS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078704 001</u>	Sep 28, 2009
<u>AT</u>	WATSON LABS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A202054 001</u>	Sep 03, 2014
<u>AT</u>	ZACH SYSTEMS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A091180 001</u>	Dec 04, 2013

COSOPT PF

	+ OAK PHARMS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N202667 001</u>	Feb 01, 2012
--	------------------	--------------------------------	--------------------	--------------

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

<u>AP</u>	+ EUROHLTH INTL SARL	<u>20MG/ML</u>	<u>N014879 001</u>	
-----------	----------------------	----------------	--------------------	--

DOXAPRAM HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>20MG/ML</u>	<u>A076266 001</u>	Jan 10, 2003
-----------	---------	----------------	--------------------	--------------

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

<u>AB</u>	+ PFIZER	<u>EQ 1MG BASE</u>	<u>N019668 001</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N019668 002</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N019668 003</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N019668 004</u>	Nov 02, 1990

DOXAZOSIN MESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 1MG BASE</u>	<u>A202824 001</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202824 002</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202824 003</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202824 004</u>	Jun 11, 2014
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075580 001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075580 002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075580 003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075580 004</u>	Oct 18, 2000
<u>AB</u>	DAVA PHARMS INC	<u>EQ 1MG BASE</u>	<u>A076161 001</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A076161 002</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076161 003</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076161 004</u>	Jun 10, 2004
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075509 001</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075509 002</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075509 003</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075509 004</u>	Oct 19, 2000
<u>AB</u>	PLIVA	<u>EQ 1MG BASE</u>	<u>A075750 001</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075750 002</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075750 003</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075750 004</u>	Jun 08, 2001
<u>AB</u>	TEVA	<u>EQ 1MG BASE</u>	<u>A075536 001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075536 002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075536 003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075536 004</u>	Oct 18, 2000

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

	PFIZER	<u>EQ 4MG BASE</u>	<u>N021269 001</u>	Feb 22, 2005
	+	<u>EQ 8MG BASE</u>	<u>N021269 002</u>	Feb 22, 2005

## PRESCRIPTION DRUG PRODUCT LIST

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791 002</u>	May 13, 1986
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A070791 003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791 001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791 004</u>	May 13, 1986
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A070791 005</u>	May 13, 1986
	+ PAR PHARM	EQ 150MG BASE	A071669 001	Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721 001</u>	Dec 29, 1998
<u>AA</u>	+	<u>EQ 10MG BASE/ML</u>	<u>A071609 001</u>	Nov 09, 1987
<u>AA</u>	WOCKHARDT	<u>EQ 10MG BASE/ML</u>	<u>A071918 001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

+ DELCOR ASSET CORP

5%

N020126 001 Apr 01, 1994

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951 001</u>	Jul 26, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201951 002</u>	Jul 26, 2013

SILENOR

<u>AB</u>	PERNIX THERAPS LLC	<u>EQ 3MG BASE</u>	<u>N022036 001</u>	Mar 17, 2010
<u>AB</u>	+	<u>EQ 6MG BASE</u>	<u>N022036 002</u>	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	ROXANE	<u>0.5MCG</u>	<u>A091433 001</u>	Sep 23, 2011
<u>AB</u>		<u>1MCG</u>	<u>A091433 002</u>	Jan 14, 2014
<u>AB</u>		<u>2.5MCG</u>	<u>A091433 003</u>	Jan 14, 2014

HECTOROL

<u>AB</u>	GENZYME CORP	<u>0.5MCG</u>	<u>N020862 002</u>	Apr 23, 2004
<u>AB</u>		<u>1MCG</u>	<u>N020862 003</u>	Jul 13, 2009
<u>AB</u>	+	<u>2.5MCG</u>	<u>N020862 001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	AKORN INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A203929 001</u>	May 07, 2015
<u>AP</u>	HIKMA PHARMS LLC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101 001</u>	Aug 30, 2013
<u>AP</u>	SANDOZ INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091333 001</u>	May 05, 2014
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A200926 001</u>	Feb 04, 2014

HECTOROL

<u>AP</u>	+	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027 001</u>	Apr 06, 2000
	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027 002	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	+	<u>2MG/ML</u>	<u>A203622 001</u>	Jun 27, 2014
<u>AP</u>	+	<u>200MG/100ML</u>	<u>A203622 002</u>	Jun 27, 2014
<u>AP</u>	ALVOGEN INC	<u>2MG/ML</u>	<u>A065515 001</u>	Nov 08, 2012
<u>AP</u>	EUROHLTH INTL SARL	<u>2MG/ML</u>	<u>A062975 001</u>	Mar 17, 1989
<u>AP</u>	+	<u>10MG/VIAL</u>	<u>A062921 001</u>	Mar 17, 1989
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A062921 002</u>	Mar 17, 1989
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A062921 003</u>	Mar 17, 1989
<u>AP</u>		<u>200MG/100ML</u>	<u>A064097 001</u>	Sep 13, 1994
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277 001</u>	Oct 26, 1995
<u>AP</u>	MYLAN LABS LTD	<u>2MG/ML</u>	<u>A200901 001</u>	Feb 14, 2012
<u>AP</u>		<u>10MG/VIAL</u>	<u>A200170 001</u>	Oct 28, 2011
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200170 002</u>	Oct 28, 2011
<u>AP</u>	PHARMACHEMIE BV	<u>2MG/ML</u>	<u>A063336 001</u>	Feb 28, 1995
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097 001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097 002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097 003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336 004</u>	Feb 28, 1995
<u>AP</u>	PHARMACIA AND UPJOHN	<u>2MG/ML</u>	<u>N050629 001</u>	Dec 23, 1987
<u>AP</u>		<u>200MG/100ML</u>	<u>N050629 002</u>	May 03, 1988
<u>AP</u>	SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495 001</u>	Mar 18, 2013
<u>AP</u>	SANDOZ INC	<u>2MG/ML</u>	<u>A200146 001</u>	Jul 18, 2012
<u>AP</u>	SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418 001</u>	Feb 15, 2012
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A064140 001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140 002</u>	Jul 28, 1995
	PHARMACIA AND UPJOHN	150MG/75ML	N050629 003	Mar 28, 2011

## PRESCRIPTION DRUG PRODUCT LIST

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	JANSSEN RES AND DEV	<u>20MG/10ML (2MG/ML)</u>	<u>N050718 001</u>	Nov 17, 1995
<u>AB</u>		<u>50MG/25ML (2MG/ML)</u>	<u>N050718 002</u>	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

<u>AB</u>	+ SUN PHARMA GLOBAL	<u>20MG/10ML (2MG/ML)</u>	<u>A203263 001</u>	Feb 04, 2013
<u>AB</u>	+	<u>50MG/25ML (2MG/ML)</u>	<u>A203263 002</u>	Feb 04, 2013

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	IMPAX LABS INC	<u>EQ 150MG BASE</u>	<u>A200065 001</u>	Feb 17, 2011
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204234 001</u>	Mar 05, 2014
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204234 002</u>	Mar 05, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204234 003</u>	Mar 05, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A202778 001</u>	Jun 08, 2012
<u>AB</u>	NOVEL LABS INC	<u>EQ 50MG BASE</u>	<u>A204446 001</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204446 002</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204446 003</u>	May 28, 2015
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055 001</u>	Dec 01, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055 002</u>	Dec 01, 2000
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>A065055 003</u>	Jul 15, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065053 001</u>	Nov 22, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053 003</u>	Sep 10, 2003
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065053 002</u>	Nov 22, 2000

MONODOX

<u>AB</u>	AQUA PHARMS	<u>EQ 50MG BASE</u>	<u>N050641 002</u>	Feb 10, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N050641 003</u>	Oct 18, 2006
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050641 001</u>	Dec 29, 1989

ORACEA

+ GALDERMA LABS LP  
FOR SUSPENSION; ORAL

40MG

N050805 001 May 26, 2006

DOXYCYCLINE

<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 25MG BASE/5ML</u>	<u>A065454 001</u>	Jul 16, 2008
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678 001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+ PFIZER	<u>EQ 25MG BASE/5ML</u>	<u>N050006 001</u>	
-----------	----------	-------------------------	--------------------	--

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 50MG BASE</u>	<u>A091605 001</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091605 002</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091605 003</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091605 004</u>	Dec 20, 2011
<u>AB</u>	LANNETT	<u>EQ 50MG BASE</u>	<u>A065285 001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285 003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285 002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285 004</u>	Jul 30, 2008
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A065377 001</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065377 002</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065377 003</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065427 001</u>	Jun 07, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065070 001</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065070 003</u>	Dec 30, 2002
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065070 002</u>	Dec 15, 2000
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>A065070 004</u>	Jul 14, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065356 001</u>	May 31, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356 002</u>	May 31, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356 003</u>	May 31, 2006

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+ PFIZER

EQ 50MG BASE/5ML

N050480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 50MG BASE</u>	<u>A062031 002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031 001</u>	
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 50MG BASE</u>	<u>A062500 001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500 002</u>	Sep 11, 1984
<u>AB</u>	HIKMA INTL PHARMS	<u>EQ 50MG BASE</u>	<u>A062396 002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396 001</u>	May 07, 1984

## PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A062675 001</u>	Jul 10, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062676 001</u>	Jul 10, 1986
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A062337 001</u>	Mar 29, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062337 002</u>	Mar 29, 1982

VIBRAMYCIN

<u>AB</u>	+ PFIZER	<u>EQ 100MG BASE</u>	<u>N050007 002</u>	
	DOXYCYCLINE HYCLATE			
	+ HIKMA INTL PHARMS	EQ 20MG BASE	A065103 001	May 13, 2005
	CAPSULE, DELAYED RELEASE; ORAL			
	DOXYCYCLINE HYCLATE			
	MEDICIS	EQ 75MG BASE	A065281 001	Dec 21, 2005
	+	EQ 100MG BASE	A065281 002	Dec 21, 2005
	INJECTABLE; INJECTION			

DOXY 100

<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 100MG BASE/VIAL</u>	<u>A062475 001</u>	Dec 09, 1983
	<u>DOXYCYCLINE</u>			
<u>AP</u>	+ EUROHLTH INTL SARL	<u>EQ 100MG BASE/VIAL</u>	<u>A062569 001</u>	Mar 09, 1988
<u>AP</u>	MYLAN LABS LTD	<u>EQ 100MG BASE/VIAL</u>	<u>A091406 001</u>	Aug 21, 2012
	DOXY 200			
	+ FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A062475 002	Dec 09, 1983
	SYSTEM, EXTENDED RELEASE; PERIODONTAL			
	ATRIDOX			
	+ TOLMAR	50MG	N050751 001	Sep 03, 1998

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 100MG BASE</u>	<u>A062421 001</u>	Feb 02, 1983
<u>AB</u>	BLU CARIBE INC	<u>EQ 100MG BASE</u>	<u>A062269 002</u>	Nov 08, 1982
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 100MG BASE</u>	<u>A062505 001</u>	Sep 11, 1984
<u>AB</u>	COREPHARMA	<u>EQ 20MG BASE</u>	<u>A065182 001</u>	May 13, 2005
<u>AB</u>	+ HIKMA INTL PHARMS	<u>EQ 100MG BASE</u>	<u>A065095 001</u>	Jul 02, 2003
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163 001</u>	May 13, 2005
<u>AB</u>	+ LANNETT	<u>EQ 20MG BASE</u>	<u>A065277 001</u>	Nov 10, 2005
<u>AB</u>	LARKEN LABS	<u>EQ 20MG BASE</u>	<u>A065287 001</u>	Feb 28, 2006
<u>AB</u>	MUTUAL PHARM	<u>EQ 100MG BASE</u>	<u>A062677 001</u>	Jul 10, 1986
<u>AB</u>	MUTUAL PHARMA	<u>EQ 20MG BASE</u>	<u>A065134 001</u>	May 13, 2005
<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A062432 001</u>	Feb 15, 1983
<u>AB</u>	VINTAGE PHARMS	<u>EQ 100MG BASE</u>	<u>A062538 001</u>	Apr 07, 1986

ACTICLATE

AQUA PHARMS LLC

+

TABLET, DELAYED RELEASE; ORAL

DORYX

<u>AB</u>	MAYNE PHARMA	<u>EQ 75MG BASE</u>	<u>N050795 001</u>	May 06, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050795 002</u>	May 06, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>N050795 003</u>	Jun 20, 2008

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 75MG BASE</u>	<u>A090134 001</u>	Dec 14, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090134 002</u>	Dec 14, 2011
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 75MG BASE</u>	<u>A200856 001</u>	Apr 30, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200856 002</u>	Apr 30, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A200856 003</u>	Apr 30, 2013
<u>AB</u>	IMPAX LABS INC	<u>EQ 75MG BASE</u>	<u>A090505 001</u>	Dec 28, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090505 002</u>	Dec 28, 2010
<u>AB</u>	MYLAN	<u>EQ 75MG BASE</u>	<u>A090431 001</u>	Dec 28, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090431 002</u>	Dec 28, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A091052 001</u>	Feb 08, 2012

DORYX

MAYNE PHARMA

+

DOXTERIC

MAYNE PHARMA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

+ DUCHESNAY

10MG; 10MG N021876 001 Apr 08, 2013

## PRESCRIPTION DRUG PRODUCT LIST

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>	AKORN INC	<u>2.5MG</u>	<u>A079217 001</u>	Jun 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A079217 002</u>	Jun 20, 2014
<u>AB</u>		<u>10MG</u>	<u>A079217 003</u>	Jun 20, 2014
<u>AB</u>	SVC PHARMA	<u>2.5MG</u>	<u>A078292 001</u>	Jun 27, 2008
<u>AB</u>		<u>5MG</u>	<u>A078292 002</u>	Jun 27, 2008
<u>AB</u>		<u>10MG</u>	<u>A078292 003</u>	Jun 27, 2008

MARINOL

<u>AB</u>	ABBVIE	<u>2.5MG</u>	<u>N018651 001</u>	May 31, 1985
<u>AB</u>	+	<u>5MG</u>	<u>N018651 002</u>	May 31, 1985
<u>AB</u>		<u>10MG</u>	<u>N018651 003</u>	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

## MULTAQ

+	SANOFI AVENTIS US	EQ 400MG BASE	N022425 001	Jul 01, 2009
---	-------------------	---------------	-------------	--------------

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

<u>AP</u>	HOSPIRA	<u>2.5MG/ML</u>	<u>A071981 001</u>	Feb 29, 1988
<u>AP</u>	LUITPOLD	<u>2.5MG/ML</u>	<u>A072123 001</u>	Oct 24, 1988

INAPSINE

<u>AP</u>	+	AKORN INC	<u>2.5MG/ML</u>	<u>N016796 001</u>
-----------	---	-----------	-----------------	--------------------

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

## ANGELIQ

	BAYER HLTHCARE	0.25MG; 0.5MG	N021355 001	Feb 29, 2012
+		0.5MG; 1MG	N021355 002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u>	BARR	<u>3MG; 0.02MG</u>	<u>A078515 001</u>	Mar 30, 2009
<u>AB</u>	GLENMARK PHARMS LTD	<u>3MG; 0.02MG</u>	<u>A204296 001</u>	Aug 17, 2015
<u>AB</u>	JAI PHARMA LTD	<u>3MG; 0.02MG</u>	<u>A202594 001</u>	Oct 22, 2015
<u>AB</u>	WATSON LABS	<u>3MG; 0.02MG</u>	<u>A078833 001</u>	Nov 28, 2011
<u>AB</u>	SANDOZ	<u>3MG; 0.02MG</u>	<u>A079221 001</u>	Mar 28, 2011
<u>AB</u>	LUPIN LTD	<u>3MG; 0.02MG</u>	<u>A201661 001</u>	May 27, 2014
<u>AB</u>	+	BAYER HLTHCARE	<u>3MG; 0.02MG</u>	<u>N021676 001</u>

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u>	BARR	<u>3MG; 0.03MG</u>	<u>A077527 001</u>	May 09, 2008
<u>AB</u>	JAI PHARMA LTD	<u>3MG; 0.03MG</u>	<u>A202131 001</u>	May 04, 2015
<u>AB</u>	LUPIN LTD	<u>3MG; 0.03MG</u>	<u>A201663 001</u>	Dec 18, 2012
<u>AB</u>	WATSON LABS	<u>3MG; 0.03MG</u>	<u>A090081 001</u>	Sep 07, 2010
<u>AB</u>	SANDOZ	<u>3MG; 0.03MG</u>	<u>A090114 001</u>	Mar 28, 2011
<u>AB</u>	NOVAST LABS LTD	<u>3MG; 0.03MG</u>	<u>A202015 001</u>	Nov 19, 2014
<u>AB</u>	+	BAYER HLTHCARE	<u>3MG; 0.03MG</u>	<u>N021098 001</u>

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

## BEYAZ

	BAYER HLTHCARE	3MG, N/A; 0.02MG, N/A; 0.451MG, 0.451MG	N022532 001	Sep 24, 2010
	SAFYRAL			
+	BAYER HLTHCARE	3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG	N022574 001	Dec 16, 2010

DROXIDOPA

CAPSULE; ORAL

## NORTHERA

	LUNDBECK NA LTD	100MG	N203202 001	Feb 18, 2014
		200MG	N203202 002	Feb 18, 2014
+		300MG	N203202 003	Feb 18, 2014

## PRESCRIPTION DRUG PRODUCT LIST

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

<u>AB</u>	LILLY	<u>EQ 20MG BASE</u>	<u>N021427 001</u>	Aug 03, 2004
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N021427 002</u>	Aug 03, 2004
<u>AB</u>	+	<u>EQ 60MG BASE</u>	<u>N021427 004</u>	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 20MG BASE</u>	<u>A090776 001</u>	Dec 17, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090776 002</u>	Dec 17, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090776 003</u>	Dec 17, 2013
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A202949 001</u>	Jun 09, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202949 002</u>	Jun 09, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202949 003</u>	Jun 09, 2014
<u>AB</u>	ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A203197 001</u>	Aug 26, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203197 002</u>	Aug 26, 2015
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A203197 003</u>	Aug 26, 2015
<u>AB</u>	ANCHEN PHARMS	<u>EQ 20MG BASE</u>	<u>A090780 001</u>	Oct 28, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090780 002</u>	Oct 28, 2015
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090780 003</u>	Oct 28, 2015
<u>AB</u>	APOTEX INC	<u>EQ 20MG BASE</u>	<u>A202045 001</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202045 002</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202045 003</u>	Jun 11, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A090778 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090778 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090778 003</u>	Dec 11, 2013
<u>AB</u>	BRECKENRIDGE PHARM	<u>EQ 20MG BASE</u>	<u>A203088 001</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203088 002</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A203088 003</u>	Jun 11, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A090723 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090723 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090723 003</u>	Dec 11, 2013
<u>AB</u>	INVENTIA HLTHCARE	<u>EQ 20MG BASE</u>	<u>A202336 001</u>	Oct 28, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202336 002</u>	Oct 28, 2015
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202336 003</u>	Oct 28, 2015
<u>AB</u>	LUPIN LTD	<u>EQ 20MG BASE</u>	<u>A090694 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090694 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090694 004</u>	Dec 11, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE</u>	<u>A090745 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090745 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090745 003</u>	Dec 11, 2013
<u>AB</u>	TEVA PHARMS USA	<u>EQ 20MG BASE</u>	<u>A090783 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090783 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090783 003</u>	Dec 11, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A090774 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090774 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090774 003</u>	Dec 11, 2013
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 20MG BASE</u>	<u>A090728 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090739 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090728 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090739 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090728 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090739 003</u>	Jan 08, 2014
	LUPIN LTD	EQ 40MG BASE	A090694 003	Dec 11, 2013

DUTASTERIDE

CAPSULE;ORAL

AVODART

<u>AB</u>	+	GLAXOSMITHKLINE	<u>0.5MG</u>	<u>N021319 001</u>	Nov 20, 2001
-----------	---	-----------------	--------------	--------------------	--------------

DUTASTERIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A202808 001</u>	Nov 20, 2015
<u>AB</u>	AMNEAL PHARMS	<u>0.5MG</u>	<u>A203118 001</u>	Nov 20, 2015
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A204292 001</u>	Nov 24, 2015
<u>AB</u>	BANNER PHARMACAPS	<u>0.5MG</u>	<u>A200899 001</u>	Nov 20, 2015
<u>AB</u>	BARR	<u>0.5MG</u>	<u>A090095 001</u>	Dec 21, 2010
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.5MG</u>	<u>A204705 001</u>	Nov 20, 2015
<u>AB</u>	RISING PHARMS INC	<u>0.5MG</u>	<u>A202530 001</u>	Nov 20, 2015
<u>AB</u>	ROXANE	<u>0.5MG</u>	<u>A202204 001</u>	Nov 23, 2015
<u>AB</u>	SANDOZ INC	<u>0.5MG</u>	<u>A202660 001</u>	Nov 20, 2015
<u>AB</u>	STRIDES ARCOLAB LTD	<u>0.5MG</u>	<u>A204262 001</u>	Nov 20, 2015
<u>AB</u>	VINTAGE PHARMS LLC	<u>0.5MG</u>	<u>A202421 001</u>	Nov 20, 2015



## PRESCRIPTION DRUG PRODUCT LIST

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

<b>AB</b>	ACTAVIS LABS FL INC	<b>0.5MG; 0.4MG</b>	<b>A202975 001</b>	Nov 20, 2015
<b>AB</b>	ANCHEN PHARMS	<b>0.5MG; 0.4MG</b>	<b>A202509 001</b>	Feb 26, 2014

JALYN

<b>AB</b>	+ GLAXOSMITHKLINE	<b>0.5MG; 0.4MG</b>	<b>N022460 001</b>	Jun 14, 2010
-----------	-------------------	---------------------	--------------------	--------------

DYPHYLLINE

TABLET; ORAL

LUFYLLIN

MEDA PHARMS

200MG

A084566 001

+

400MG

A084566 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

+ WYETH PHARMS INC

0.125%

N011963 001

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL

ECOZA

+ VELDANA MEDICAL SA

1%

N205175 001 Oct 24, 2013

CREAM; TOPICAL

ECONAZOLE NITRATE

<b>AB</b>	FOUGERA PHARMS	<b>1%</b>	<b>A076075 001</b>	Nov 26, 2002
-----------	----------------	-----------	--------------------	--------------

<b>AB</b>	IGI LABS INC	<b>1%</b>	<b>A076574 001</b>	Dec 17, 2004
-----------	--------------	-----------	--------------------	--------------

<b>AB</b>	+ PERRIGO NEW YORK	<b>1%</b>	<b>A076479 001</b>	Jun 23, 2004
-----------	--------------------	-----------	--------------------	--------------

<b>AB</b>	TARO	<b>1%</b>	<b>A076005 001</b>	Nov 26, 2002
-----------	------	-----------	--------------------	--------------

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+ MEDICIS

200MG/ML

N008922 001

EDOXYBAN TOSYLATE

TABLET; ORAL

SAVAYSA

DAIICHI SANKYO

EQ 15MG BASE

N206316 001 Jan 08, 2015

EQ 30MG BASE

N206316 002 Jan 08, 2015

+

EQ 60MG BASE

N206316 003 Jan 08, 2015

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

+ MYLAN INSTITUTIONAL

10MG/ML

A088873 001 Aug 06, 1985

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

50MG

N020972 001 Sep 17, 1998

+

200MG

N020972 003 Sep 17, 1998

TABLET; ORAL

SUSTIVA

+ BRISTOL MYERS SQUIBB

600MG

N021360 002 Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+ GILEAD

600MG; 200MG; 300MG

N021937 001 Jul 12, 2006

EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

+ DOW PHARM

10%

N203567 001 Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ SKINMEDICA

13.9%

N021145 001 Jul 27, 2000

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAK

PFIZER IRELAND

EQ 20MG BASE

N021016 001 Dec 26, 2002

+

EQ 40MG BASE

N021016 002 Dec 26, 2002

## PRESCRIPTION DRUG PRODUCT LIST

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

+ GENZYME CORP

EQ 84MG BASE

N205494 001 Aug 19, 2014

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA

+ NOVARTIS PHARMS CORP

EQ 25MG ACID/PACKET

N207027 001 Aug 24, 2015

TABLET; ORAL

PROMACTA

NOVARTIS PHARMS CORP

EQ 12.5MG ACID

N022291 004 Oct 20, 2011

EQ 25MG ACID

N022291 001 Nov 20, 2008

EQ 50MG ACID

N022291 002 Nov 20, 2008

+ EQ 75MG ACID

N022291 003 Sep 08, 2009

+ EQ 100MG ACID

N022291 005 Nov 16, 2012

ELUXADOLINE

TABLET; ORAL

VIBERZI

FOREST TOSARA LTD

75MG

N206940 001 May 27, 2015

+ 100MG

N206940 002 May 27, 2015

ELVITEGRAVIR

TABLET; ORAL

VITEKTA

GILEAD SCIENCES INC

85MG

N203093 001 Sep 24, 2014

+ 150MG

N203093 002 Sep 24, 2014

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

EMADINE

+ ALCON

0.05%

N020706 001 Dec 29, 1997

EMPAGLIFLOZIN

TABLET; ORAL

JARDIANCE

BOEHRINGER INGELHEIM

10MG

N204629 001 Aug 01, 2014

+ 25MG

N204629 002 Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL

GLYXAMBI

BOEHRINGER INGELHEIM

10MG; 5MG

N206073 001 Jan 30, 2015

+ 25MG; 5MG

N206073 002 Jan 30, 2015

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SYNJARDY

BOEHRINGER INGELHEIM

5MG; 500MG

N206111 001 Aug 26, 2015

5MG; 1GM

N206111 002 Aug 26, 2015

12.5MG; 500MG

N206111 003 Aug 26, 2015

+ 12.5MG; 1GM

N206111 004 Aug 26, 2015

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

+ GILEAD

200MG

N021500 001 Jul 02, 2003

SOLUTION; ORAL

EMTRIVA

+ GILEAD

10MG/ML

N021896 001 Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+ GILEAD SCIENCES INC

200MG; EQ 25MG BASE; 300MG

N202123 001 Aug 10, 2011

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

+ GILEAD

200MG; 300MG

N021752 001 Aug 02, 2004

## PRESCRIPTION DRUG PRODUCT LIST

ENALAPRIL MALEATE

FOR SOLUTION; ORAL

EPANED KIT

+ SILVERGATE PHARMS

1MG/ML

N204308 001 Aug 13, 2013

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>	APOTEX	<u>2.5MG</u>	<u>A075178 002</u>	Mar 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075178 001</u>	Mar 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075178 003</u>	Mar 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075178 004</u>	Mar 23, 2001
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A075480 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075480 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075480 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075480 004</u>	Aug 22, 2000
<u>AB</u>	SANDOZ INC	<u>2.5MG</u>	<u>A075496 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075496 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075459 001</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075459 002</u>	Aug 22, 2000
<u>AB</u>	TARO	<u>2.5MG</u>	<u>A075657 001</u>	Jan 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075657 002</u>	Jan 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075657 003</u>	Jan 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075657 004</u>	Jan 23, 2001
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A075479 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075479 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075479 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075479 004</u>	Aug 22, 2000
<u>AB</u>	WOCKHARDT USA	<u>2.5MG</u>	<u>A075483 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075483 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075483 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075483 004</u>	Aug 22, 2000
<u>VASOTEC</u>				
<u>AB</u>	VALEANT PHARMS NORTH	<u>2.5MG</u>	<u>N018998 005</u>	Jul 26, 1988
<u>AB</u>		<u>5MG</u>	<u>N018998 001</u>	Dec 24, 1985
<u>AB</u>		<u>10MG</u>	<u>N018998 002</u>	Dec 24, 1985
<u>AB</u>	+	<u>20MG</u>	<u>N018998 003</u>	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG;12.5MG</u>	<u>A076486 001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486 002</u>	Oct 27, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909 001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909 002</u>	Oct 15, 2001
<u>AB</u>	G AND W LABS INC	<u>5MG;12.5MG</u>	<u>A075727 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727 002</u>	Sep 18, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624 002</u>	Sep 18, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788 002</u>	Sep 18, 2001
<u>VASERETIC</u>				
<u>AB</u>	VALEANT INTL	<u>5MG;12.5MG</u>	<u>N019221 003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221 001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	+	BEDFORD	<u>1.25MG/ML</u>	<u>A075634 001</u>	Aug 22, 2000
<u>AP</u>		HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687 001</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>1.25MG/ML</u>	<u>A075458 001</u>	Aug 22, 2000
<u>AP</u>		TEVA PHARMS USA	<u>1.25MG/ML</u>	<u>A075578 001</u>	Aug 22, 2000

ENFLURANE

LIQUID; INHALATION

ENFLURANE

<u>AN</u>	PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074396 001</u>	Jul 29, 1994
<u>ETHRANE</u>				
<u>AN</u>	+	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017087 001</u>

PRESCRIPTION DRUG PRODUCT LIST

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+ ROCHE 90MG/VIAL

N021481 001 Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB SANDOZ INC 300MG/3ML (100MG/ML)

A078660 001 Nov 28, 2011

LOVENOX

AB SANOFI AVENTIS US 300MG/3ML (100MG/ML)

N020164 009 Jan 23, 2003

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP AMPHASTAR PHARM 30MG/0.3ML (100MG/ML)

A076684 001 Sep 19, 2011

AP 40MG/0.4ML (100MG/ML)

A076684 002 Sep 19, 2011

AP 60MG/0.6ML (100MG/ML)

A076684 003 Sep 19, 2011

AP 80MG/0.8ML (100MG/ML)

A076684 004 Sep 19, 2011

AP 100MG/ML (100MG/ML)

A076684 005 Sep 19, 2011

AP 120MG/0.8ML (150MG/ML)

A076684 006 Sep 19, 2011

AP 150MG/ML (150MG/ML)

A076684 007 Sep 19, 2011

AP SANDOZ 30MG/0.3ML (100MG/ML)

A077857 002 Jul 23, 2010

AP 40MG/0.4ML (100MG/ML)

A077857 003 Jul 23, 2010

AP 60MG/0.6ML (100MG/ML)

A077857 004 Jul 23, 2010

AP 80MG/0.8ML (100MG/ML)

A077857 005 Jul 23, 2010

AP 100MG/ML (100MG/ML)

A077857 001 Jul 23, 2010

AP 120MG/0.8ML (150MG/ML)

A077857 006 Jul 23, 2010

AP 150MG/ML (150MG/ML)

A077857 007 Jul 23, 2010

AP TEVA 30MG/0.3ML (100MG/ML)

A076726 001 Jun 23, 2014

AP 40MG/0.4ML (100MG/ML)

A076726 002 Jun 23, 2014

AP 60MG/0.6ML (100MG/ML)

A076726 003 Jun 23, 2014

AP 80MG/0.8ML (100MG/ML)

A076726 004 Jun 23, 2014

AP 100MG/ML (100MG/ML)

A076726 005 Jun 23, 2014

AP 120MG/0.8ML (150MG/ML)

A076726 006 Jun 23, 2014

AP 150MG/ML (150MG/ML)

A076726 007 Jun 23, 2014

LOVENOX (PRESERVATIVE FREE)

AP SANOFI AVENTIS US 30MG/0.3ML (100MG/ML)

N020164 001 Mar 29, 1993

AP 40MG/0.4ML (100MG/ML)

N020164 002 Jan 30, 1998

AP 60MG/0.6ML (100MG/ML)

N020164 003 Mar 27, 1998

AP 80MG/0.8ML (100MG/ML)

N020164 004 Mar 27, 1998

AP + 100MG/ML (100MG/ML)

N020164 005 Mar 27, 1998

AP 120MG/0.8ML (150MG/ML)

N020164 007 Jun 02, 2000

AP 150MG/ML (150MG/ML)

N020164 008 Jun 02, 2000

ENTACAPONE

TABLET; ORAL

COMTAN

AB + ORION PHARMA 200MG

N020796 001 Oct 19, 1999

ENTACAPONE

AB AUROBINDO PHARMA LTD 200MG

A203437 001 Jun 19, 2015

AB MYLAN PHARMS INC 200MG

A202394 001 May 13, 2013

AB SUN PHARMA GLOBAL 200MG

A090690 001 Jul 16, 2012

AB WOCKHARDT LTD 200MG

A078941 001 Aug 16, 2012

ENTECAVIR

SOLUTION; ORAL

BARACLUE

+ BRISTOL MYERS SQUIBB 0.05MG/ML

N021798 001 Mar 29, 2005

TABLET; ORAL

BARACLUE

AB BRISTOL MYERS SQUIBB 0.5MG

N021797 001 Mar 29, 2005

AB + 1MG

N021797 002 Mar 29, 2005

ENTECAVIR

AB AMNEAL PHARMS 0.5MG

A206652 001 Nov 12, 2015

AB 1MG

A206652 002 Nov 12, 2015

AB AUROBINDO PHARMA LTD 0.5MG

A206217 001 Aug 26, 2015

AB 1MG

A206217 002 Aug 26, 2015

AB HETERO LABS LTD V 0.5MG

A205740 001 Aug 21, 2015

AB 1MG

A205740 002 Aug 21, 2015

AB TEVA PHARMS USA 0.5MG

A202122 001 Aug 26, 2014

AB 1MG

A202122 002 Aug 26, 2014

## PRESCRIPTION DRUG PRODUCT LIST

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+ ASTELLAS

40MG

N203415 001 Aug 31, 2012

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTATAT + ALLERGAN0.05%N021565 001 Oct 16, 2003EPINASTINE HYDROCHLORIDEAT APOTEX0.05%A090919 001 Oct 31, 2011AT BRECKENRIDGE PHARM0.05%A090870 001 Mar 14, 2011AT GAVIS PHARMS LLC0.05%A090951 001 Oct 31, 2011AT SUN PHARM INDS0.05%A091626 001 Oct 31, 2011EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N204200 001 Dec 07, 2012

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

ADRENACLICK

BX + AMEDRA PHARMS

EQ 0.15MG/DELIVERY

N020800 003 Nov 25, 2009

BX +

EQ 0.3MG/DELIVERY

N020800 004 Nov 25, 2009

AUVI-Q

BX + SANOFI AVENTIS US

EQ 0.15MG/DELIVERY

N201739 002 Aug 10, 2012

BX

EQ 0.3MG/DELIVERY

N201739 001 Aug 10, 2012

EPIPEN

BX + MYLAN SPECLT

0.3MG/DELIVERY

N019430 001 Dec 22, 1987

EPIPEN JR.

BX + MYLAN SPECLT

0.15MG/DELIVERY

N019430 002 Dec 22, 1987

TWINJECT 0.15

BX + AMEDRA PHARMS

EQ 0.15MG/DELIVERY

N020800 002 May 28, 2004

TWINJECT 0.3

BX + AMEDRA PHARMS

EQ 0.3MG/DELIVERY

N020800 001 May 30, 2003

ADRENALIN

+ PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML)

N204640 001 Dec 18, 2013

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+ DEPROCO

EQ 0.02MG BASE/ML; 2%

A088389 001 Jan 22, 1985

LIGNOSPAN STANDARD

+ DEPROCO

EQ 0.01MG BASE/ML; 2%

A088390 001 Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILLOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTALAP + DENTSPLY PHARM0.005MG/ML; 4%N021383 001PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATEAP SEPTODONT INC0.005MG/ML; 4%A078959 001 Aug 30, 2011EPINEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION), INTRAOCULAR

EPINEPHRINE

BELCHER PHARMS LLC

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINEAP EASTMAN KODAK0.01MG/ML; 2%A040057 002 Feb 26, 1993AP0.02MG/ML; 2%A040057 001 Feb 26, 1993AP HOSPIRA0.005MG/ML; 0.5%A089635 001 Jun 21, 1988AP0.005MG/ML; 1.5%A088571 001 Sep 13, 1985AP0.005MG/ML; 1.5%A089645 001 Jun 21, 1988AP0.005MG/ML; 2%A089651 001 Jun 21, 1988AP0.01MG/ML; 1%A089644 001 Jun 21, 1988AP0.01MG/ML; 2%A078772 001 May 12, 2008AP0.01MG/ML; 2%A089646 001 Jun 21, 1988AP0.02MG/ML; 2%A078772 002 May 12, 2008OCTOCAINEAP + SEPTODONT0.01MG/ML; 2%A084048 001AP +0.02MG/ML; 2%A084048 002XYLOCAINE W/ EPINEPHRINEAP + FRESENIUS KABI USA0.005MG/ML; 0.5%N006488 012AP +0.005MG/ML; 1%N006488 018 Nov 13, 1986

## PRESCRIPTION DRUG PRODUCT LIST

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE W/ EPINEPHRINE

<u>AP</u>	+		<u>0.005MG/ML;1.5%</u>	<u>N006488 017</u>	
<u>AP</u>	+		<u>0.005MG/ML;2%</u>	<u>N006488 019</u>	Nov 13, 1986
<u>AP</u>	+		<u>0.01MG/ML;1%</u>	<u>N006488 004</u>	
<u>AP</u>	+		<u>0.02MG/ML;2%</u>	<u>N006488 005</u>	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

<u>AP</u>	+	PFIZER INC	<u>200MG/100ML (2MG/ML)</u>	<u>N050778 001</u>	Sep 15, 1999
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>N050778 002</u>	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>		ACTAVIS TOTOWA	<u>10MG/5ML (2MG/ML)</u>	<u>A065445 001</u>	Sep 18, 2008
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A065445 002</u>	Sep 18, 2008
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065445 003</u>	Sep 18, 2008
<u>AP</u>		AKORN INC	<u>50MG/25ML (2MG/ML)</u>	<u>A090163 001</u>	Jun 24, 2009
<u>AP</u>		CIPLA LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A065361 001</u>	Oct 22, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065361 002</u>	Oct 22, 2007
<u>AP</u>		EUROHLTH INTL SARL	<u>50MG/25ML (2MG/ML)</u>	<u>A065289 001</u>	Jun 27, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065289 002</u>	Jun 27, 2007
<u>AP</u>		FRESENIUS KABI ONCOL	<u>200MG/100ML (2MG/ML)</u>	<u>A065411 001</u>	Aug 20, 2007
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A065411 002</u>	Aug 20, 2007
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/5ML (2MG/ML)</u>	<u>A065408 001</u>	Oct 15, 2007
<u>AP</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A065408 002</u>	Oct 15, 2007
<u>AP</u>			<u>150MG/75ML (2MG/ML)</u>	<u>A065408 003</u>	Oct 15, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065408 004</u>	Oct 15, 2007
<u>AP</u>		HISUN PHARM HANGZHOU	<u>50MG/25ML (2MG/ML)</u>	<u>A090075 001</u>	Mar 25, 2010
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A090075 002</u>	Mar 25, 2010
<u>AP</u>		HOSPIRA	<u>10MG/5ML (2MG/ML)</u>	<u>A065343 001</u>	Apr 19, 2007
<u>AP</u>			<u>150MG/75ML (2MG/ML)</u>	<u>A065343 003</u>	Apr 19, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065343 004</u>	Apr 19, 2007
<u>AP</u>		MYLAN LABS LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A091599 001</u>	Mar 12, 2012
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A091599 002</u>	Mar 12, 2012
<u>AP</u>		TEVA PHARMS USA	<u>50MG/25ML (2MG/ML)</u>	<u>A065331 001</u>	Aug 09, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065331 002</u>	Aug 09, 2007

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>		APOTEX	<u>25MG</u>	<u>A078482 001</u>	Jul 30, 2008
<u>AB</u>			<u>50MG</u>	<u>A078482 002</u>	Jul 30, 2008
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A078510 001</u>	Aug 01, 2008
<u>AB</u>			<u>50MG</u>	<u>A078510 002</u>	Aug 01, 2008
		<u>INSPIRA</u>			
<u>AB</u>		GD SEARLE LLC	<u>25MG</u>	<u>N021437 001</u>	Sep 27, 2002
<u>AB</u>	+		<u>50MG</u>	<u>N021437 002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>		TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396 001</u>	Apr 23, 2008
<u>AP</u>			<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396 002</u>	Apr 23, 2008
		<u>FIOLAN</u>			
<u>AP</u>	+	GLAXOSMITHKLINE LLC	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444 001</u>	Sep 20, 1995
<u>AP</u>	+		<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444 002</u>	Sep 20, 1995
		<u>VELETRI</u>			
		ACTELION PHARMS LTD	<u>EQ 0.5MG BASE/VIAL</u>	<u>N022260 002</u>	Jun 28, 2012
	+		<u>EQ 1.5MG BASE/VIAL</u>	<u>N022260 001</u>	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

<u>AB</u>		MYLAN PHARMS INC	<u>EQ 400MG BASE</u>	<u>A202012 001</u>	Nov 16, 2011
<u>AB</u>			<u>EQ 600MG BASE</u>	<u>A202012 002</u>	Nov 16, 2011
		<u>TEVETEN</u>			
<u>AB</u>		ABBVIE	<u>EQ 400MG BASE</u>	<u>N020738 005</u>	Dec 22, 1997
<u>AB</u>	+		<u>EQ 600MG BASE</u>	<u>N020738 006</u>	May 27, 1999

## PRESCRIPTION DRUG PRODUCT LIST

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>2MG/ML</u>	<u>A206127 001</u>	Dec 08, 2015
<u>AP</u>		<u>75MG/100ML</u>	<u>A206127 002</u>	Dec 08, 2015
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A090854 001</u>	Jun 12, 2015
<u>AP</u>		<u>75MG/100ML</u>	<u>A091555 001</u>	Jun 05, 2015

INTEGRILIN

<u>AP</u>	+ SCHERING	<u>2MG/ML</u>	<u>N020718 001</u>	May 18, 1998
<u>AP</u>	+	<u>75MG/100ML</u>	<u>N020718 002</u>	May 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

<u>AA</u>	+ SANOFI AVENTIS US	<u>50,000 IU</u>	<u>N003444 001</u>	
-----------	---------------------	------------------	--------------------	--

ERGOCALCIFEROL

<u>AA</u>	ORIT LABS LLC	<u>50,000 IU</u>	<u>A040833 001</u>	May 20, 2009
<u>AA</u>	SIGMAPHARM LABS LLC	<u>50,000 IU</u>	<u>A091004 001</u>	Jul 14, 2010
<u>AA</u>	STRIDES PHARMA	<u>50,000 IU</u>	<u>A090455 001</u>	Aug 03, 2010
<u>AA</u>	SUN PHARM INDS INC	<u>50,000 IU</u>	<u>A040865 001</u>	Dec 29, 2009

VITAMIN D

<u>AA</u>	BANNER LIFE SCIENCES	<u>50,000 IU</u>	<u>A080704 001</u>	
-----------	----------------------	------------------	--------------------	--

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

<u>AB</u>	MUTUAL PHARM	<u>1MG</u>	<u>A081113 001</u>	Oct 31, 1991
-----------	--------------	------------	--------------------	--------------

HYDERGINE

<u>AB</u>	+ NOVARTIS	<u>1MG</u>	<u>N017993 001</u>	
-----------	------------	------------	--------------------	--

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

	+ ROSEDALE THERAPEUTIC	2MG	A087693 001	Feb 24, 1983
--	------------------------	-----	-------------	--------------

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

	+ EISAI INC	1MG/2ML (0.5MG/ML)	N201532 001	Nov 15, 2010
--	-------------	--------------------	-------------	--------------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

TARCEVA

	OSI PHARMS	EQ 25MG BASE	N021743 001	Nov 18, 2004
		EQ 100MG BASE	N021743 002	Nov 18, 2004
	+	EQ 150MG BASE	N021743 003	Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

INVANZ

	+ MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337 001	Nov 21, 2001
--	---------------------	------------------	-------------	--------------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

<u>AB</u>	+ MAYNE PHARMA	<u>250MG</u>	<u>N050536 001</u>	
-----------	----------------	--------------	--------------------	--

ERYTHROMYCIN

<u>AB</u>	ARBOR PHARMS LLC	<u>250MG</u>	<u>A062746 001</u>	Dec 22, 1986
-----------	------------------	--------------	--------------------	--------------

GEL; TOPICAL

ERYGEL

<u>AT</u>	+ DELCOR ASSET CORP	<u>2%</u>	<u>N050617 001</u>	Oct 21, 1987
-----------	---------------------	-----------	--------------------	--------------

ERYTHROMYCIN

<u>AT</u>	FOUGERA PHARMS	<u>2%</u>	<u>A064184 001</u>	Sep 30, 1997
<u>AT</u>	PERRIGO	<u>2%</u>	<u>A063211 001</u>	Jan 29, 1993

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A064030 001</u>	Jul 18, 1996
<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A064067 001</u>	Jul 29, 1994
<u>AT</u>	+ PERRIGO CO TENNESSEE	<u>0.5%</u>	<u>A062447 001</u>	Sep 26, 1983

OINTMENT; TOPICAL

AKNE-MYCIN

	+ DOW PHARM	2%	N050584 001	Jan 10, 1985
--	-------------	----	-------------	--------------

SOLUTION; TOPICAL

C-SOLVE-2

<u>AT</u>	FOUGERA PHARMS	<u>2%</u>	<u>A062468 001</u>	Jul 03, 1985
-----------	----------------	-----------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ERYTHROMYCIN

SOLUTION; TOPICAL

ERYTHRO-STATIN**AT** HI TECH PHARMA **2%** **A064101 001** Oct 22, 1996ERYTHROMYCIN**AT** FOUGERA PHARMS **2%** **A064187 001** Sep 30, 1997**AT** + PERRIGO NEW YORK **2%** **A063038 001** Jan 11, 1991**AT** WOCKHARDT **2%** **A062825 001** Oct 23, 1987

SWAB; TOPICAL

ERYTHROMYCIN**AT** + PERRIGO **2%** **A064126 001** Jul 03, 1996**AT** VERSAPHARM **2%** **A090215 001** May 12, 2010

TABLET; ORAL

## ERYTHROMYCIN

ARBOR PHARMS LLC 250MG A061621 001

+ 500MG A061621 002

TABLET, COATED PARTICLES; ORAL

## PCE

ARBOR PHARMS LLC 333MG N050611 001 Sep 09, 1986

+ 500MG N050611 002 Aug 22, 1990

TABLET, DELAYED RELEASE; ORAL

## ERY-TAB

ARBOR PHARMS LLC 250MG A062298 001

333MG A062298 003 Mar 29, 1982

+ 500MG A062298 002

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.**AB** ARBOR PHARMS LLC **EQ 200MG BASE/5ML** **N050207 001**ERYPED**AB** ARBOR PHARMS LLC **EQ 200MG BASE/5ML** **N050207 003** Mar 30, 1987+ **EQ 400MG BASE/5ML** N050207 002

TABLET; ORAL

## E.E.S. 400

BX + ARBOR PHARMS LLC EQ 400MG BASE A061905 002 Aug 12, 1982

## ERYTHROMYCIN ETHYLSUCCINATE

BX + ARBOR PHARMS LLC EQ 400MG BASE A061904 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

## ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+ BARR EQ 200MG BASE/5ML; EQ 600MG BASE/5ML A062759 001 May 20, 1988

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN**AP** HOSPIRA **EQ 500MG BASE/VIAL** **A062638 001** Oct 31, 1986**AP** + **EQ 500MG BASE/VIAL** **N050609 001** Sep 24, 1986

+ EQ 1GM BASE/VIAL A062638 002 Oct 31, 1986

ERYTHROMYCIN STEARATE

TABLET; ORAL

## ERYTHROCIN STEARATE

+ ARBOR PHARMS LLC EQ 250MG BASE A060359 001

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE**AA** AMNEAL PHARMS **EQ 5MG BASE/5ML** **A202227 001** Mar 14, 2012**AA** ANTRIM PHARMS LLC **EQ 5MG BASE/5ML** **A203967 001** May 26, 2015**AA** AUROBINDO PHARMA LTD **EQ 5MG BASE/5ML** **A079062 001** Apr 02, 2012**AA** HETERO LABS LTD III **EQ 5MG BASE/5ML** **A202221 001** Jun 12, 2012**AA** SILARX PHARMS INC **EQ 5MG BASE/5ML** **A090477 001** Jun 12, 2013**AA** TARO **EQ 5MG BASE/5ML** **A079121 001** May 03, 2012LEXAPRO**AA** + FOREST LABS **EQ 5MG BASE/5ML** **N021365 001** Nov 27, 2002

TABLET; ORAL

ESCITALOPRAM OXALATE**AB** ACCORD HLTHCARE **EQ 5MG BASE** **A202389 001** Sep 11, 2012**AB** **EQ 10MG BASE** **A202389 002** Sep 11, 2012**AB** **EQ 20MG BASE** **A202389 003** Sep 11, 2012**AB** APOTEX INC **EQ 5MG BASE** **A078777 001** Sep 11, 2012**AB** **EQ 10MG BASE** **A078777 002** Sep 11, 2012**AB** **EQ 20MG BASE** **A078777 003** Sep 11, 2012



## PRESCRIPTION DRUG PRODUCT LIST

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

<b>AB</b>	AUROBINDO PHARMA LTD	<b>EQ 5MG BASE</b>	<b>A090432 001</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A090432 002</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A090432 003</b>	Sep 11, 2012
<b>AB</b>	HIKMA PHARMS	<b>EQ 5MG BASE</b>	<b>A078766 001</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A078766 002</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A078766 003</b>	Sep 11, 2012
<b>AB</b>	INVAGEN PHARMS	<b>EQ 5MG BASE</b>	<b>A078604 001</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A078604 002</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A078604 003</b>	Sep 11, 2012
<b>AB</b>	JUBILANT GENERICS	<b>EQ 5MG BASE</b>	<b>A202280 001</b>	Sep 12, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A202280 002</b>	Sep 12, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A202280 003</b>	Sep 12, 2012
<b>AB</b>	LUPIN LTD	<b>EQ 5MG BASE</b>	<b>A078169 001</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A078169 002</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A078169 003</b>	Sep 11, 2012
<b>AB</b>	MACLEODS PHARMS LTD	<b>EQ 5MG BASE</b>	<b>A202210 001</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A202210 002</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A202210 003</b>	Sep 11, 2012
<b>AB</b>	MYLAN PHARMS INC	<b>EQ 5MG BASE</b>	<b>A077550 001</b>	May 14, 2015
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A077550 002</b>	May 14, 2015
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077550 003</b>	May 14, 2015
<b>AB</b>	PRINSTON INC	<b>EQ 5MG BASE</b>	<b>A078032 001</b>	Aug 28, 2015
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A078032 002</b>	Aug 28, 2015
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A078032 003</b>	Aug 28, 2015
<b>AB</b>	STI PHARMA LLC	<b>EQ 5MG BASE</b>	<b>A077512 001</b>	Sep 12, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A077512 002</b>	Sep 12, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077512 003</b>	Sep 12, 2012
<b>AB</b>	TEVA PHARMS USA	<b>EQ 5MG BASE</b>	<b>A076765 001</b>	Mar 14, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A076765 002</b>	Mar 14, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A076765 003</b>	Mar 14, 2012
<b>AB</b>	TORRENT PHARMS LTD	<b>EQ 5MG BASE</b>	<b>A090939 001</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A090939 002</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A090939 003</b>	Sep 11, 2012
<b>AB</b>	ZYDUS PHARMS USA INC	<b>EQ 5MG BASE</b>	<b>A077734 001</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A077734 002</b>	Sep 11, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077734 003</b>	Sep 11, 2012

LEXAPRO

<b>AB</b>	FOREST LABS	<b>EQ 5MG BASE</b>	<b>N021323 001</b>	Aug 14, 2002
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>N021323 002</b>	Aug 14, 2002
<b>AB</b>	+	<b>EQ 20MG BASE</b>	<b>N021323 003</b>	Aug 14, 2002

ESLICARBAZEPINE ACETATE

TABLET; ORAL

APTIOM

	SUNOVION PHARMS INC	200MG	N022416 001	Nov 08, 2013
		400MG	N022416 002	Nov 08, 2013
		600MG	N022416 003	Nov 08, 2013
	+	800MG	N022416 004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<b>AP</b>	+	BAXTER HLTHCARE	<b>10MG/ML</b>	<b>N019386 006</b>	Feb 25, 2003
<b>AP</b>		AUROBINDO PHARMA LTD	<b>10MG/ML</b>	<b>A205520 001</b>	Jul 23, 2015
<b>AP</b>		EUROHLTH INTL SARL	<b>10MG/ML</b>	<b>A076323 001</b>	Aug 10, 2004
<b>AP</b>		FRESENIUS KABI USA	<b>10MG/ML</b>	<b>A076573 001</b>	May 02, 2005
<b>AP</b>		LUITPOLD	<b>10MG/ML</b>	<b>A201126 001</b>	Feb 20, 2015
<b>AP</b>		MYLAN INSTITUTIONAL	<b>10MG/ML</b>	<b>A076474 001</b>	May 02, 2005
		BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER			
		+	BAXTER HLTHCARE	2GM/100ML	N019386 005
		BREVIBLOC IN PLASTIC CONTAINER			
		+	BAXTER HLTHCARE	1GM/100ML	N019386 004

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

<b>AB</b>	DR REDDYS LABS LTD	<b>EQ 20MG BASE</b>	<b>A078279 001</b>	Sep 25, 2015
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A078279 002</b>	Sep 25, 2015
<b>AB</b>	HETERO LABS LTD III	<b>EQ 20MG BASE</b>	<b>A202784 001</b>	Sep 21, 2015
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A202784 002</b>	Sep 21, 2015

## PRESCRIPTION DRUG PRODUCT LIST

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

<b>AB</b>	IVAX SUB TEVA PHARMS	<b>EQ 20MG BASE</b>	<b>A078003 001</b>	Jan 26, 2015
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A078003 002</b>	Jan 26, 2015
<b>AB</b>	MYLAN PHARMS INC	<b>EQ 20MG BASE</b>	<b>A078936 001</b>	Aug 02, 2015
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A078936 002</b>	Aug 03, 2015
<b>AB</b>	TORRENT PHARMS LTD	<b>EQ 20MG BASE</b>	<b>A203636 001</b>	Oct 19, 2015
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A203636 002</b>	Oct 19, 2015

NEXIUM

<b>AB</b>	ASTRAZENECA PHARMS	<b>EQ 20MG BASE</b>	<b>N021153 001</b>	Feb 20, 2001
<b>AB</b>	+	<b>EQ 40MG BASE</b>	<b>N021153 002</b>	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE;ORAL

NEXIUM

	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011
		EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011
		EQ 10MG BASE/PACKET	N022101 001	Feb 27, 2008
		EQ 20MG BASE/PACKET	N021957 001	Oct 20, 2006
	+	EQ 40MG BASE/PACKET	N021957 002	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

<b>AB</b>	DR REDDYS LABS LTD	<b>EQ 20MG BASE;375MG</b>	<b>A202461 001</b>	Sep 27, 2013
<b>AB</b>		<b>EQ 20MG BASE;500MG</b>	<b>A202461 002</b>	Sep 27, 2013

VIMOVO

<b>AB</b>	HORIZON PHARMA	<b>EQ 20MG BASE;375MG</b>	<b>N022511 002</b>	Apr 30, 2010
<b>AB</b>	+	<b>EQ 20MG BASE;500MG</b>	<b>N022511 001</b>	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

<b>AP</b>	ACCORD HLTHCARE	<b>EQ 40MG BASE/VIAL</b>	<b>A205379 001</b>	Sep 25, 2015
<b>AP</b>	SUN PHARMA GLOBAL	<b>EQ 20MG BASE/VIAL</b>	<b>A200882 001</b>	Mar 18, 2013
<b>AP</b>		<b>EQ 40MG BASE/VIAL</b>	<b>A200882 002</b>	Mar 18, 2013

NEXIUM IV

<b>AP</b>	+	ASTRAZENECA PHARMS	<b>EQ 20MG BASE/VIAL</b>	<b>N021689 001</b>	Mar 31, 2005
<b>AP</b>	+		<b>EQ 40MG BASE/VIAL</b>	<b>N021689 002</b>	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

	HANMI PHARM CO LTD	24.65MG	N202342 001	Aug 06, 2013
	+	49.3MG	N202342 002	Aug 06, 2013

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

<b>AB</b>	PAR PHARM	<b>1MG</b>	<b>A074826 001</b>	Jul 03, 1997
<b>AB</b>		<b>2MG</b>	<b>A074826 002</b>	Jul 03, 1997
<b>AB</b>	TEVA	<b>1MG</b>	<b>A074921 001</b>	Jul 10, 1997
<b>AB</b>	+	<b>2MG</b>	<b>A074921 002</b>	Jul 10, 1997
<b>AB</b>	WATSON LABS	<b>1MG</b>	<b>A074818 001</b>	Aug 19, 1997
<b>AB</b>		<b>2MG</b>	<b>A074818 002</b>	Aug 19, 1997

ESTRADIOL

CREAM; VAGINAL

ESTRACE

	+	WARNER CHILCOTT US	0.01%	A086069 001	Jan 31, 1984
--	---	--------------------	-------	-------------	--------------

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

<b>AB</b>	BAYER HLTHCARE	<b>0.0375MG/24HR</b>	<b>N020375 005</b>	May 27, 2003
<b>AB</b>		<b>0.06MG/24HR</b>	<b>N020375 006</b>	May 27, 2003

ESTRADIOL

<b>AB</b>	MYLAN TECHNOLOGIES	<b>0.0375MG/24HR</b>	<b>A075182 004</b>	Jul 20, 2006
<b>AB</b>		<b>0.06MG/24HR</b>	<b>A075182 005</b>	Jul 20, 2006
<b>AB1</b>		<b>0.025MG/24HR</b>	<b>A201675 001</b>	Dec 19, 2014
<b>AB1</b>		<b>0.0375MG/24HR</b>	<b>A201675 002</b>	Dec 19, 2014
<b>AB1</b>		<b>0.05MG/24HR</b>	<b>A201675 003</b>	Dec 19, 2014
<b>AB1</b>		<b>0.075MG/24HR</b>	<b>A201675 004</b>	Dec 19, 2014
<b>AB1</b>		<b>0.1MG/24HR</b>	<b>A201675 005</b>	Dec 19, 2014

VIVELLE

<b>AB1</b>	NOVARTIS	<b>0.05MG/24HR</b>	<b>N020323 002</b>	Oct 28, 1994
<b>AB1</b>		<b>0.1MG/24HR</b>	<b>N020323 004</b>	Oct 28, 1994

## PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

VIVELLE-DOT

<u>AB1</u>	NOVARTIS	<u>0.025MG/24HR</u>	<u>N020538</u>	<u>009</u>	May 03, 2002
<u>AB1</u>		<u>0.0375MG/24HR</u>	<u>N020538</u>	<u>005</u>	Jan 08, 1999
<u>AB1</u>		<u>0.05MG/24HR</u>	<u>N020538</u>	<u>006</u>	Jan 08, 1999
<u>AB1</u>		<u>0.075MG/24HR</u>	<u>N020538</u>	<u>007</u>	Jan 08, 1999
<u>AB1</u>	+	<u>0.1MG/24HR</u>	<u>N020538</u>	<u>008</u>	Jan 08, 1999

CLIMARA

<u>AB2</u>	BAYER HLHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
<u>AB2</u>	+	<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
<u>AB2</u>		<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000

## ALORA

BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002
BX		0.05MG/24HR	N020655	001	Dec 20, 1996
BX		0.075MG/24HR	N020655	002	Dec 20, 1996
BX		0.1MG/24HR	N020655	003	Dec 20, 1996

## ESTRADERM

BX	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
BX	+	0.1MG/24HR	N019081	003	Sep 10, 1986
	MENOSTAR				
	+ BAYER HLHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004
	MINIVELLE				
	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014
		0.0375MG/24HR	N203752	001	Oct 29, 2012
		0.05MG/24HR	N203752	003	Oct 29, 2012
		0.075MG/24HR	N203752	002	Oct 29, 2012
	+	0.1MG/24HR	N203752	004	Oct 29, 2012

GEL;TRANSDERMAL

## DIVIGEL

	VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007
		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007
	+	0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007

GEL, METERED;TRANSDERMAL

## ELESTRIN

	+ MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006
--	---------------	---------------------------	---------	-----	--------------

## ESTROGEL

	+ ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004
--	---------------------	---------------------------	---------	-----	--------------

INSERT, EXTENDED RELEASE;VAGINAL

## ESTRING

	+ PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996
--	------------------------	---------------	---------	-----	--------------

SPRAY;TRANSDERMAL

## EVAMIST

	+ ELAN PHARMA INTL LTD	1.53MG/SPRAY	N022014	001	Jul 27, 2007
--	------------------------	--------------	---------	-----	--------------

TABLET;ORAL

ESTRADIOL

<u>AB</u>	BARR LABS INC	<u>0.5MG</u>	<u>A040197</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>		<u>1MG</u>	<u>A040197</u>	<u>002</u>	Oct 22, 1997
<u>AB</u>	+	<u>2MG</u>	<u>A040197</u>	<u>003</u>	Oct 22, 1997
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A040326</u>	<u>001</u>	Apr 21, 1999
<u>AB</u>		<u>1MG</u>	<u>A040326</u>	<u>002</u>	Apr 21, 1999
<u>AB</u>		<u>2MG</u>	<u>A040326</u>	<u>003</u>	Apr 21, 1999
<u>AB</u>	USL PHARMA	<u>0.5MG</u>	<u>A040297</u>	<u>001</u>	Apr 17, 2002
<u>AB</u>		<u>1MG</u>	<u>A040297</u>	<u>002</u>	Apr 17, 2002
<u>AB</u>		<u>2MG</u>	<u>A040297</u>	<u>003</u>	Apr 17, 2002
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A040114</u>	<u>003</u>	Mar 14, 1996
<u>AB</u>		<u>1MG</u>	<u>A040114</u>	<u>001</u>	Mar 14, 1996
<u>AB</u>		<u>2MG</u>	<u>A040114</u>	<u>002</u>	Mar 14, 1996

TABLET;VAGINAL

## VAGIFEM

	+ NOVO NORDISK INC	10MCG	N020908	002	Nov 25, 2009
--	--------------------	-------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367 001	Mar 20, 2003
+	EQ 0.1MG BASE/24HR	N021367 002	Mar 20, 2003

TABLET;ORAL

FEMTRACE

WARNER CHILCOTT LLC	0.45MG	N021633 001	Aug 20, 2004
	0.9MG	N021633 002	Aug 20, 2004
+	1.8MG	N021633 003	Aug 20, 2004

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

+ PHARMACIA AND UPJOHN	5MG/ML	A085470 003	
------------------------	--------	-------------	--

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL

ESTRASORB

+ MEDICIS	0.25%	N021371 001	Oct 09, 2003
-----------	-------	-------------	--------------

ESTRADIOL VALERATE

INJECTABLE;INJECTION

DELESTROGEN

<u>AO</u>	+	PAR STERILE PRODUCTS	<u>20MG/ML</u>	<u>N009402 004</u>	
<u>AO</u>	+		<u>40MG/ML</u>	<u>N009402 003</u>	

ESTRADIOL VALERATE

<u>AO</u>		LUITPOLD	<u>20MG/ML</u>	<u>A090920 001</u>	Jan 19, 2010
<u>AO</u>			<u>40MG/ML</u>	<u>A090920 002</u>	Jan 19, 2010

DELESTROGEN

+ PAR STERILE PRODUCTS	10MG/ML	N009402 002	
------------------------	---------	-------------	--

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

+ BAYER HLHCARE	0.045MG/24HR;0.015MG/24HR	N021258 001	Nov 21, 2003
-----------------	---------------------------	-------------	--------------

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870 001	Aug 07, 1998
+	0.05MG/24HR;0.25MG/24HR	N020870 002	Aug 07, 1998

TABLET;ORAL

ACTIVELLA

<u>AB</u>		AMNEAL PHARMS LLC	<u>0.5MG;0.1MG</u>	<u>N020907 002</u>	Dec 28, 2006
<u>AB</u>	+		<u>1MG;0.5MG</u>	<u>N020907 001</u>	Nov 18, 1998

ESTRADIOL AND NORETHINDRONE ACETATE

<u>AB</u>		BARR	<u>1MG;0.5MG</u>	<u>A079193 001</u>	May 11, 2010
<u>AB</u>		BRECKENRIDGE PHARM	<u>0.5MG;0.1MG</u>	<u>A078324 002</u>	Jun 09, 2011
<u>AB</u>			<u>1MG;0.5MG</u>	<u>A078324 001</u>	Apr 17, 2008
<u>AB</u>		TEVA PHARMS USA	<u>0.5MG;0.1MG</u>	<u>A200747 001</u>	Mar 08, 2012

ESTRADIOL; NORGESTIMATE

TABLET;ORAL

ESTRADIOL AND NORGESTIMATE

+ BARR	1MG,1MG;1MG,1MG;N/A,0.09MG	A076812 001	Apr 29, 2005
--------	----------------------------	-------------	--------------

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL

EMCYT

+ PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045 001	
------------------------	--------------------	-------------	--

ESTROGENS, CONJUGATED

CREAM;TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC	0.625MG/GM	N020216 001	
--------------------	------------	-------------	--

INJECTABLE;INJECTION

PREMARIN

+ WYETH PHARMS INC	25MG/VIAL	N010402 001	
--------------------	-----------	-------------	--

TABLET;ORAL

PREMARIN

WYETH PHARMS INC	0.3MG	N004782 003	
	0.45MG	N004782 006	Jul 16, 2003
+	0.625MG	N004782 004	
+	0.9MG	N004782 005	Jan 26, 1984
+	1.25MG	N004782 001	

## PRESCRIPTION DRUG PRODUCT LIST

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

TEVA BRANDED PHARM	0.3MG	N020992 001	Jun 21, 2002
	0.45MG	N020992 005	Feb 05, 2004
	0.625MG	N020992 002	Mar 24, 1999
	0.9MG	N020992 003	Mar 24, 1999
+	1.25MG	N020992 004	Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

TEVA WOMENS	0.3MG	N021443 001	Dec 20, 2004
	0.45MG	N021443 002	Dec 20, 2004
	0.625MG	N021443 003	May 10, 2004
	0.9MG	N021443 005	Apr 27, 2007
+	1.25MG	N021443 004	May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+ WYETH PHARMS INC	0.625MG; 0.625MG; 0.625MG; 0.625MG; N/A, 5MG	N020527 002	Nov 17, 1995
PREMPRO			
+ WYETH PHARMS INC	0.3MG; 1.5MG	N020527 005	Jun 04, 2003
+	0.45MG; 1.5MG	N020527 004	Mar 12, 2003
+	0.625MG; 0.625MG; 2.5MG; 2.5MG	N020527 001	Nov 17, 1995
+	0.625MG; 0.625MG; 5MG; 5MG	N020527 003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS	0.3MG	A084951 001	
	0.625MG	A084948 001	
	1.25MG	A084950 001	
+	2.5MG	A084949 001	

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

<u>AB</u>	BARR	<u>0.75MG</u>	<u>A040135 001</u>	Nov 27, 1996
<u>AB</u>		<u>1.5MG</u>	<u>A040135 002</u>	Nov 27, 1996
<u>AB</u>		<u>3MG</u>	<u>A040135 003</u>	Nov 27, 1996
<u>AB</u>	MYLAN	<u>0.75MG</u>	<u>A040359 001</u>	Aug 26, 1999
<u>AB</u>		<u>1.5MG</u>	<u>A040359 002</u>	Aug 26, 1999
<u>AB</u>	WATSON LABS	<u>0.75MG</u>	<u>A081213 001</u>	Sep 23, 1993
<u>AB</u>		<u>1.5MG</u>	<u>A081214 001</u>	Sep 23, 1993
<u>AB</u>		<u>3MG</u>	<u>A081215 001</u>	Sep 23, 1993
<u>AB</u>	<u>OGEN .625</u>			
	PHARMACIA AND UPJOHN	<u>0.75MG</u>	<u>A083220 001</u>	
<u>AB</u>	<u>OGEN 1.25</u>			
	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>A083220 002</u>	
<u>AB</u>	<u>OGEN 2.5</u>			
	PHARMACIA AND UPJOHN	<u>3MG</u>	<u>A083220 003</u>	
<u>AB</u>	OGEN 5			
	PHARMACIA AND UPJOHN	6MG	A083220 004	

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A091024 001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091024 002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091024 003</u>	Apr 15, 2014
<u>AB</u>	GLENMARK GENERICS	<u>1MG</u>	<u>A091166 001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091166 002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091166 003</u>	Apr 15, 2014
<u>AB</u>	LUPIN LTD	<u>1MG</u>	<u>A091124 001</u>	Sep 13, 2011
<u>AB</u>		<u>2MG</u>	<u>A091124 002</u>	Sep 13, 2011
<u>AB</u>		<u>3MG</u>	<u>A091124 003</u>	Sep 13, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>1MG</u>	<u>A202929 001</u>	Jan 30, 2015
<u>AB</u>		<u>2MG</u>	<u>A202929 002</u>	Jan 30, 2015
<u>AB</u>		<u>3MG</u>	<u>A202929 003</u>	Jan 30, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A091151 001</u>	Mar 26, 2013
<u>AB</u>		<u>2MG</u>	<u>A091151 002</u>	Mar 26, 2013
<u>AB</u>		<u>3MG</u>	<u>A091151 003</u>	Mar 26, 2013
<u>AB</u>	ORCHID HLTHCARE	<u>1MG</u>	<u>A091113 001</u>	Jun 10, 2014

## PRESCRIPTION DRUG PRODUCT LIST

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

<u>AB</u>		<u>2MG</u>	<u>A091113 002</u>	Jun 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A091113 003</u>	Jun 10, 2014
<u>AB</u>	ROXANE	<u>1MG</u>	<u>A091153 001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091153 002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091153 003</u>	Apr 15, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>1MG</u>	<u>A091103 001</u>	Apr 03, 2013
<u>AB</u>		<u>2MG</u>	<u>A091103 002</u>	Apr 03, 2013
<u>AB</u>		<u>3MG</u>	<u>A091103 003</u>	Apr 03, 2013
<u>AB</u>	TEVA	<u>1MG</u>	<u>A091169 001</u>	May 23, 2011
<u>AB</u>		<u>2MG</u>	<u>A091169 002</u>	May 23, 2011
<u>AB</u>		<u>3MG</u>	<u>A091169 003</u>	May 23, 2011

LUNESTA

<u>AB</u>	SUNOVION PHARMS INC	<u>1MG</u>	<u>N021476 001</u>	Dec 15, 2004
<u>AB</u>		<u>2MG</u>	<u>N021476 002</u>	Dec 15, 2004
<u>AB</u>	+	<u>3MG</u>	<u>N021476 003</u>	Dec 15, 2004

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRIN

<u>AP</u>	+	ATON	<u>EQ 50MG BASE/VIAL</u>	<u>N016093 001</u>
-----------	---	------	--------------------------	--------------------

ETHACRYNATE SODIUM

<u>AP</u>		PAR STERILE PRODUCTS	<u>EQ 50MG BASE/VIAL</u>	<u>A205473 001</u>	Jul 29, 2015
-----------	--	----------------------	--------------------------	--------------------	--------------

ETHACRYNIC ACID

TABLET; ORAL

EDECRIN+

ATON

25MG

N016092 001

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

<u>AB</u>	BARR	<u>400MG</u>	<u>A076057 001</u>	Nov 26, 2001
<u>AB</u>	LUPIN	<u>100MG</u>	<u>A078939 001</u>	Jun 17, 2009
<u>AB</u>		<u>400MG</u>	<u>A078939 002</u>	Jun 17, 2009
<u>AB</u>	VERSAPHARM INC	<u>100MG</u>	<u>A075095 001</u>	Nov 30, 1999
<u>AB</u>		<u>400MG</u>	<u>A075095 002</u>	Nov 30, 1999

MYAMBUTOL

<u>AB</u>	STI PHARMA LLC	<u>100MG</u>	<u>N016320 001</u>
<u>AB</u>	+	<u>400MG</u>	<u>N016320 003</u>

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+

QOL MEDCL

50MG/ML

N019357 001

Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR

<u>AB</u>	BARR	<u>0.035MG;1MG</u>	<u>A076785 001</u>	May 23, 2005	
<u>AB</u>		<u>0.035MG;1MG</u>	<u>A072721 001</u>	Dec 30, 1991	
<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>A072721 001</u>	Dec 30, 1991	
	ZOVIA 1/50E-28				
	+	WATSON LABS	<u>0.05MG;1MG</u>	<u>A072723 001</u>	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+

ORGANON USA INC

0.015MG/24HR;0.12MG/24HR

N021187 001

Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

ASHLYNA

<u>AB</u>	GLENMARK GENERICS	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A203163 001</u>	Feb 23, 2015
-----------	-------------------	---------------------------------	--------------------	--------------

DAYSEE

<u>AB</u>	LUPIN LTD	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A091467 001</u>	Apr 10, 2013
-----------	-----------	---------------------------------	--------------------	--------------

INTROVALE

<u>AB</u>	SANDOZ	<u>0.03MG;0.15MG</u>	<u>A079064 001</u>	Sep 27, 2010
-----------	--------	----------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	GLENMARK GENERICS	<u>0.02MG;0.09MG</u>	<u>A202791 001</u>	Apr 09, 2015
<u>AB</u>	GLENMARK PHARMS LTD	<u>0.03MG;0.15MG</u>	<u>A203164 001</u>	Jun 12, 2015
<u>AB</u>	HAUPT PHARMA	<u>0.03MG;0.15MG</u>	<u>A203871 001</u>	Nov 13, 2015
<u>AB</u>		<u>0.03MG,0.01MG;0.15MG,NA</u>	<u>A203872 001</u>	Dec 22, 2015
<u>AB</u>	JAI PHARMA LTD	<u>0.03MG;0.15MG</u>	<u>A200490 001</u>	Apr 21, 2015

## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	LUPIN LTD	<u>0.02MG;0.01MG;0.1MG,N/A</u>	<u>A091674 001</u>	Oct 26, 2011
<u>AB</u>		<u>0.03MG;0.15MG</u>	<u>A091440 001</u>	Oct 23, 2012
<u>AB</u>	+ WATSON LABS	<u>0.02MG;0.09MG</u>	<u>A079218 001</u>	Jun 06, 2011
<u>AB</u>		<u>0.02MG,0.01MG;0.1MG,N/A</u>	<u>A200407 001</u>	Oct 25, 2011

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

<u>AB</u>	JAI PHARMA LTD	<u>0.02MG,0.01MG;0.1MG,N/A</u>	<u>A200493 001</u>	Jun 17, 2015
<u>AB</u>		<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A200492 001</u>	May 27, 2015
<u>AB</u>	WATSON LABS	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A078834 001</u>	May 31, 2011

LOSEASONIQUE

<u>AB</u>	TEVA BRANDED PHARM	<u>0.01MG;0.02MG;0.1MG</u>	<u>N022262 001</u>	Oct 24, 2008
-----------	--------------------	----------------------------	--------------------	--------------

QUASENSE

<u>AB</u>	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A077101 001</u>	Sep 06, 2006
-----------	-------------	----------------------	--------------------	--------------

SEASONALE

<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.03MG;0.15MG</u>	<u>N021544 001</u>	Sep 05, 2003
-----------	----------------------	----------------------	--------------------	--------------

SEASONIQUE

<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.03MG,0.01MG;0.03MG,0.01MG;0.15MG,N/A</u>	<u>N021840 001</u>	May 25, 2006
-----------	----------------------	---	--------------------	--------------

SETLAKIN

<u>AB</u>	NOVAST LABS LTD	<u>0.03MG;0.15MG</u>	<u>A090716 001</u>	Sep 15, 2014
-----------	-----------------	----------------------	--------------------	--------------

QUARTETTE

	+ TEVA BRANDED PHARM	0.02MG;0.15MG	N204061 001	Mar 28, 2013
--	----------------------	---------------	-------------	--------------

TABLET; ORAL-28

ALTAVERA

<u>AB</u>	SANDOZ	<u>0.03MG;0.15MG</u>	<u>A079102 001</u>	Aug 03, 2010
-----------	--------	----------------------	--------------------	--------------

ELIFEMME

<u>AB</u>	SANDOZ INC	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A202507 001</u>	Dec 04, 2015
-----------	------------	--	--------------------	--------------

ENPRESSE-28

<u>AB</u>	DURAMED PHARMS BARR	<u>0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.125MG</u>	<u>A075809 002</u>	Jul 16, 2001
-----------	---------------------	--	--------------------	--------------

KURVELO

<u>AB</u>	LUPIN LTD	<u>0.03MG;0.15MG</u>	<u>A091408 001</u>	Oct 17, 2012
-----------	-----------	----------------------	--------------------	--------------

LEVONEST

<u>AB</u>	NOVAST LABS LTD	<u>0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.125MG</u>	<u>A090719 001</u>	Dec 29, 2010
-----------	-----------------	--	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	HAUPT PHARMA	<u>0.03MG;0.15MG</u>	<u>A201095 001</u>	Dec 08, 2014
-----------	--------------	----------------------	--------------------	--------------

<u>AB</u>	JAI PHARMA LTD	<u>0.03MG;0.15MG</u>	<u>A091663 001</u>	Dec 21, 2012
-----------	----------------	----------------------	--------------------	--------------

<u>AB</u>	LUPIN LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A200248 001</u>	Nov 19, 2015
-----------	-----------	--	--------------------	--------------

LEVORA 0.15/30-28

<u>AB</u>	+ WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A073594 001</u>	Dec 13, 1993
-----------	---------------	----------------------	--------------------	--------------

MARLISSA

<u>AB</u>	GLENMARK GENERICS	<u>0.03MG;0.15MG</u>	<u>A091452 001</u>	Feb 29, 2012
-----------	-------------------	----------------------	--------------------	--------------

MYZILRA

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A077502 001</u>	Nov 23, 2011
-----------	--------------------	--	--------------------	--------------

PORTIA-28

<u>AB</u>	BARR	<u>0.03MG;0.15MG</u>	<u>A075866 002</u>	May 23, 2002
-----------	------	----------------------	--------------------	--------------

TRIVORA-28

<u>AB</u>	+ WATSON LABS	<u>0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.125MG</u>	<u>A074538 002</u>	Dec 18, 1997
-----------	---------------	--	--------------------	--------------

AVIANE-28

<u>AB1</u>	DURAMED PHARMS BARR	<u>0.02MG;0.1MG</u>	<u>A075796 001</u>	Apr 30, 2001
------------	---------------------	---------------------	--------------------	--------------

FALMINA

<u>AB1</u>	NOVAST LABS LTD	<u>0.02MG;0.1MG</u>	<u>A090721 001</u>	Mar 28, 2012
------------	-----------------	---------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB1</u>	HAUPT PHARMA	<u>0.02MG;0.1MG</u>	<u>A201108 001</u>	Feb 05, 2014
------------	--------------	---------------------	--------------------	--------------

<u>AB1</u>	JAI PHARMA LTD	<u>0.02MG;0.1MG</u>	<u>A200245 001</u>	Oct 09, 2013
------------	----------------	---------------------	--------------------	--------------

<u>AB1</u>	LUPIN LTD	<u>0.02MG;0.1MG</u>	<u>A091425 001</u>	Jan 18, 2013
------------	-----------	---------------------	--------------------	--------------

<u>AB1</u>	+ WATSON LABS	<u>0.02MG;0.1MG</u>	<u>A076625 001</u>	Nov 18, 2004
------------	---------------	---------------------	--------------------	--------------

ORSYTHIA

<u>AB1</u>	VINTAGE PHARMS LLC	<u>0.02MG;0.1MG</u>	<u>A077099 001</u>	May 11, 2011
------------	--------------------	---------------------	--------------------	--------------

VIENVA

<u>AB1</u>	SANDOZ INC	<u>0.02MG;0.1MG</u>	<u>A201088 001</u>	May 21, 2015
------------	------------	---------------------	--------------------	--------------

LESSINA-28

<u>AB2</u>	BARR	<u>0.02MG;0.1MG</u>	<u>A075803 002</u>	Mar 20, 2002
------------	------	---------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB2</u>	JAI PHARMA LTD	<u>0.02MG;0.1MG</u>	<u>A202247 001</u>	Dec 08, 2014
------------	----------------	---------------------	--------------------	--------------

<u>AB2</u>	+ WATSON LABS	<u>0.02MG;0.1MG</u>	<u>A077681 001</u>	May 31, 2006
------------	---------------	---------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

XULANE

<b>AB</b>	+ MYLAN TECHNOLOGIES	<u>0.035MG/24HR;0.15MG/24HR</u>	<u>A200910 001</u>	Apr 16, 2014
-----------	----------------------	---------------------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+35 21-DAY

<b>AB</b>	ACTAVIS LABS UT INC	<u>0.035MG;1MG</u>	<u>N017565 001</u>	
-----------	---------------------	--------------------	--------------------	--

NORTREL 1/35-21

<b>AB</b>	BARR	<u>0.035MG;1MG</u>	<u>A072693 001</u>	Feb 28, 1992
-----------	------	--------------------	--------------------	--------------

NORTREL 7/7/7

	BARR	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A075478 001</u>	Aug 30, 2002
--	------	---	--------------------	--------------

TABLET; ORAL-28

ALYACEN 1/35

<b>AB</b>	GLENMARK GENERICS	<u>0.035MG;1MG</u>	<u>A091634 001</u>	Jan 19, 2012
-----------	-------------------	--------------------	--------------------	--------------

ALYACEN 7/7/7

<b>AB</b>	GLENMARK GENERICS	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A091636 001</u>	Jan 19, 2012
-----------	-------------------	---	--------------------	--------------

ARANELLE

<b>AB</b>	BARR	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG</u>	<u>A076783 001</u>	Sep 29, 2004
-----------	------	--	--------------------	--------------

BALZIVA-28

<b>AB</b>	BARR	<u>0.035MG;0.4MG</u>	<u>A076238 001</u>	Apr 22, 2004
-----------	------	----------------------	--------------------	--------------

BREVICON 28-DAY

<b>AB</b>	ACTAVIS LABS UT INC	<u>0.035MG;0.5MG</u>	<u>N017743 001</u>	
-----------	---------------------	----------------------	--------------------	--

BRIELLYN

<b>AB</b>	GLENMARK GENERICS	<u>0.035MG;0.4MG</u>	<u>A090538 001</u>	Mar 22, 2011
-----------	-------------------	----------------------	--------------------	--------------

CYCLAFEM 0.5/35

<b>AB</b>	VINTAGE PHARMS	<u>0.035MG;0.5MG</u>	<u>A203413 001</u>	Dec 16, 2015
-----------	----------------	----------------------	--------------------	--------------

CYCLAFEM 1/35

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.035MG;1MG</u>	<u>A076337 001</u>	Nov 12, 2010
-----------	--------------------	--------------------	--------------------	--------------

CYCLAFEM 7/7/7

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A076338 001</u>	Nov 16, 2010
-----------	--------------------	---	--------------------	--------------

DASETTA 1/35

<b>AB</b>	NOVAST LABS LTD	<u>0.035MG;1MG</u>	<u>A090948 001</u>	Dec 22, 2011
-----------	-----------------	--------------------	--------------------	--------------

DASETTA 7/7/7

<b>AB</b>	NOVAST LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A090946 001</u>	Dec 22, 2011
-----------	-----------------	---	--------------------	--------------

GILDAGIA

<b>AB</b>	VINTAGE PHARMS	<u>0.035MG;0.4MG</u>	<u>A078376 001</u>	Nov 06, 2012
-----------	----------------	----------------------	--------------------	--------------

MODICON 28

<b>AB</b>	+ JANSSEN PHARMS	<u>0.035MG;0.5MG</u>	<u>N017735 001</u>	
-----------	------------------	----------------------	--------------------	--

NORETHINDRONE AND ETHINYL ESTRADIOL

<b>AB</b>	+ JAI PHARMA LTD	<u>0.035MG;0.4MG</u>	<u>A200897 001</u>	May 11, 2015
-----------	------------------	----------------------	--------------------	--------------

<b>AB</b>		<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A200486 001</u>	Dec 28, 2015
-----------	--	---	--------------------	--------------

<b>AB</b>		<u>0.035MG;0.5MG</u>	<u>A200488 001</u>	Oct 21, 2015
-----------	--	----------------------	--------------------	--------------

<b>AB</b>		<u>0.035MG;1MG</u>	<u>A200489 001</u>	Oct 21, 2015
-----------	--	--------------------	--------------------	--------------

<b>AB</b>	WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078323 001</u>	Feb 04, 2010
-----------	-------------	----------------------	--------------------	--------------

<b>AB</b>		<u>0.035MG;0.5MG</u>	<u>A070686 001</u>	Jan 29, 1987
-----------	--	----------------------	--------------------	--------------

<b>AB</b>		<u>0.035MG;1MG</u>	<u>A070687 001</u>	Jan 29, 1987
-----------	--	--------------------	--------------------	--------------

NORINYL 1+35 28-DAY

<b>AB</b>	ACTAVIS LABS UT INC	<u>0.035MG;1MG</u>	<u>N017565 002</u>	
-----------	---------------------	--------------------	--------------------	--

NORTREL 0.5/35-28

<b>AB</b>	BARR	<u>0.035MG;0.5MG</u>	<u>A072695 001</u>	Feb 28, 1992
-----------	------	----------------------	--------------------	--------------

NORTREL 1/35-28

<b>AB</b>	BARR	<u>0.035MG;1MG</u>	<u>A072696 001</u>	Feb 28, 1992
-----------	------	--------------------	--------------------	--------------

NORTREL 7/7/7

<b>AB</b>	BARR	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A075478 002</u>	Aug 30, 2002
-----------	------	---	--------------------	--------------

ORTHO-NOVUM 1/35-28

<b>AB</b>	+ JANSSEN PHARMS	<u>0.035MG;1MG</u>	<u>N017919 002</u>	
-----------	------------------	--------------------	--------------------	--

ORTHO-NOVUM 7/7/7-28

<b>AB</b>	+ JANSSEN PHARMS	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>N018985 002</u>	Apr 04, 1984
-----------	------------------	---	--------------------	--------------

PHILITH

<b>AB</b>	NOVAST LABS LTD	<u>0.035MG;0.4MG</u>	<u>A090947 001</u>	Dec 22, 2011
-----------	-----------------	----------------------	--------------------	--------------

PIRMELLA 1/35

<b>AB</b>	LUPIN LTD	<u>0.035MG;1MG</u>	<u>A201512 001</u>	Apr 24, 2013
-----------	-----------	--------------------	--------------------	--------------

PIRMELLA 7/7/7

<b>AB</b>	LUPIN LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A201510 001</u>	Apr 24, 2013
-----------	-----------	---	--------------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

TRI-NORINYL 28-DAY

<b>AB</b>	+ ACTAVIS LABS UT INC	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG</u>	<u>N018977 002</u>	Apr 13, 1984
-----------	-----------------------	--	--------------------	--------------

VYFEMLA

<b>AB</b>	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886 001</u>	Sep 26, 2013
-----------	-----------	----------------------	--------------------	--------------

WERA

<b>AB</b>	NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204 001</u>	Mar 27, 2012
-----------	-----------------	----------------------	--------------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL

	+ JAI PHARMA LTD	0.05MG;1MG	A203006 001	Aug 05, 2013
--	------------------	------------	-------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

	WATSON LABS	0.035MG;0.035MG;0.5MG;1MG	A071044 001	Apr 01, 1988
--	-------------	---------------------------	-------------	--------------

TABLET, CHEWABLE; ORAL

FEMCON FE

<b>AB</b>	+ WARNER CHILCOTT LLC	<u>0.035MG;0.4MG</u>	<u>N021490 001</u>	Nov 14, 2003
-----------	-----------------------	----------------------	--------------------	--------------

KAITLIB FE

<b>AB</b>	LUPIN LTD	<u>0.025MG;0.8MG</u>	<u>A203448 001</u>	Dec 17, 2015
-----------	-----------	----------------------	--------------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

<b>AB</b>	AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892 001</u>	Sep 26, 2011
-----------	---------------	----------------------	--------------------	--------------

<b>AB</b>	BARR	<u>0.035MG;0.4MG</u>	<u>A078965 001</u>	Aug 05, 2010
-----------	------	----------------------	--------------------	--------------

<b>AB</b>	JAI PHARMA LTD	<u>0.025MG;0.8MG</u>	<u>A203371 001</u>	Apr 23, 2014
-----------	----------------	----------------------	--------------------	--------------

<b>AB</b>		<u>0.035MG;0.4MG</u>	<u>A202086 001</u>	Apr 01, 2015
-----------	--	----------------------	--------------------	--------------

<b>AB</b>	+ WARNER CHILCOTT	<u>0.025MG;0.8MG</u>	<u>N022573 001</u>	Dec 22, 2010
-----------	-------------------	----------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

BLISOVI 24 FE

<b>AB</b>	LUPIN LTD	<u>0.02MG;1MG</u>	<u>A091398 001</u>	Oct 28, 2015
-----------	-----------	-------------------	--------------------	--------------

FEMHRT

<b>AB</b>	WARNER CHILCOTT LLC	<u>0.0025MG;0.5MG</u>	<u>N021065 001</u>	Jan 14, 2005
-----------	---------------------	-----------------------	--------------------	--------------

FYAVOLV

<b>AB</b>	LUPIN LTD	<u>0.005MG;1MG</u>	<u>A204213 002</u>	Dec 10, 2015
-----------	-----------	--------------------	--------------------	--------------

<b>AB</b>		<u>0.0025MG;0.5MG</u>	<u>A204213 001</u>	Dec 10, 2015
-----------	--	-----------------------	--------------------	--------------

GILDESS 24 FE

<b>AB</b>	VINTAGE PHARMS	<u>0.02MG;1MG</u>	<u>A090293 001</u>	Dec 01, 2014
-----------	----------------	-------------------	--------------------	--------------

LARIN 24 FE

<b>AB</b>	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A202994 001</u>	Feb 18, 2015
-----------	-----------------	-------------------	--------------------	--------------

LOESTRIN 24 FE

<b>AB</b>	WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N021871 001</u>	Feb 17, 2006
-----------	-----------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

<b>AB</b>	+ BARR LABS INC	<u>0.005MG;1MG</u>	<u>A076221 001</u>	Nov 06, 2009
-----------	-----------------	--------------------	--------------------	--------------

<b>AB</b>	GLENMARK GENERICS	<u>0.0025MG;0.5MG</u>	<u>A203038 001</u>	Apr 02, 2015
-----------	-------------------	-----------------------	--------------------	--------------

<b>AB</b>		<u>0.005MG;1MG</u>	<u>A203038 002</u>	Apr 02, 2015
-----------	--	--------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

<b>AB</b>	+ AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A078267 001</u>	Sep 01, 2009
-----------	-----------------	-------------------	--------------------	--------------

<b>AB</b>	BARR LABS INC	<u>0.02MG;1MG</u>	<u>A090938 001</u>	Dec 01, 2014
-----------	---------------	-------------------	--------------------	--------------

<b>AB</b>	JAI PHARMA LTD	<u>0.02MG;1MG</u>	<u>A202742 001</u>	Oct 30, 2014
-----------	----------------	-------------------	--------------------	--------------

LO LOESTRIN FE

	+ WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010
--	-----------------------	-----------------------	-------------	--------------

TABLET; ORAL-21

GILDESS 1.5/30

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075 002</u>	Jul 24, 2012
-----------	--------------------	---------------------	--------------------	--------------

GILDESS 1/20

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077 002</u>	Jul 24, 2012
-----------	--------------------	-------------------	--------------------	--------------

JUNEL 1.5/30

<b>AB</b>	BARR	<u>0.03MG;1.5MG</u>	<u>A076381 001</u>	May 30, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL 1/20

<b>AB</b>	BARR	<u>0.02MG;1MG</u>	<u>A076380 001</u>	May 30, 2003
-----------	------	-------------------	--------------------	--------------

LARIN 1.5/30

<b>AB</b>	NOVAST LABS LTD	<u>0.03MG;1.5MG</u>	<u>A202996 001</u>	Mar 20, 2014
-----------	-----------------	---------------------	--------------------	--------------

LARIN 1/20

<b>AB</b>	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A202995 001</u>	Dec 04, 2013
-----------	-----------------	-------------------	--------------------	--------------

LOESTRIN 21 1.5/30

<b>AB</b>	WARNER CHILCOTT LLC	<u>0.03MG;1.5MG</u>	<u>N017875 001</u>	
-----------	---------------------	---------------------	--------------------	--

LOESTRIN 21 1/20

<b>AB</b>	WARNER CHILCOTT LLC	<u>0.02MG;1MG</u>	<u>N017876 001</u>	
-----------	---------------------	-------------------	--------------------	--

MICROGESTIN 1.5/30

<b>AB</b>	WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548 002</u>	Jul 30, 2003
-----------	-------------	---------------------	--------------------	--------------

MICROGESTIN 1/20

<b>AB</b>	WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647 002</u>	Jul 30, 2003
-----------	-------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

<b>AB</b>	JAI PHARMA LTD	<u>0.02MG;1MG</u>	<u>A202771 001</u>	Nov 06, 2013
-----------	----------------	-------------------	--------------------	--------------

<b>AB</b>		<u>0.03MG;1.5MG</u>	<u>A202770 001</u>	Feb 19, 2015
-----------	--	---------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET; ORAL-21						
	TRI-LEGEST 21						
	BARR	0.02MG; 0.035MG; 0.03MG; 1MG; 1MG; 1MG		A076405	001	Oct 26, 2007	
	TABLET; ORAL-28						
	<u>BLISOVI FE 1.5/30</u>						
AB	LUPIN LTD	0.03MG; 1.5MG		A201585	001	Nov 18, 2015	
	<u>BLISOVI FE 1/20</u>						
AB	LUPIN LTD	0.02MG; 1MG		A201584	001	Nov 18, 2015	
	<u>ESTROSTEP FE</u>						
AB	+ WARNER CHILCOTT LLC	0.02MG; 0.035MG; 0.03MG; 1MG; 1MG; 1MG		N020130	002	Oct 09, 1996	
	<u>GILDESS FE 1.5/30</u>						
AB	VINTAGE PHARMS LLC	0.03MG; 1.5MG		A077075	001	Apr 28, 2005	
	<u>GILDESS FE 1/20</u>						
AB	VINTAGE PHARMS LLC	0.02MG; 1MG		A077077	001	May 20, 2005	
	<u>JUNEL FE 1.5/30</u>						
AB	BARR	0.03MG; 1.5MG		A076064	001	Sep 18, 2003	
	<u>JUNEL FE 1/20</u>						
AB	BARR	0.02MG; 1MG		A076081	001	Sep 18, 2003	
	<u>LARIN FE 1.5/30</u>						
AB	NOVAST LABS LTD	0.03MG; 1.5MG		A091453	001	Aug 23, 2013	
	<u>LARIN FE 1/20</u>						
AB	NOVAST LABS LTD	0.02MG; 1MG		A091454	001	Aug 26, 2013	
	<u>LOESTRIN FE 1.5/30</u>						
AB	+ WARNER CHILCOTT LLC	0.03MG; 1.5MG		N017355	001		
	<u>LOESTRIN FE 1/20</u>						
AB	WARNER CHILCOTT	0.02MG; 1MG		N017354	001		
	<u>MICROGESTIN FE 1.5/30</u>						
AB	WATSON LABS	0.03MG; 1.5MG		A075548	001	Feb 05, 2001	
	<u>MICROGESTIN FE 1/20</u>						
AB	WATSON LABS	0.02MG; 1MG		A075647	001	Feb 05, 2001	
	<u>NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL</u>						
AB	JAI PHARMA LTD	0.02MG; 1MG		A202772	001	Nov 14, 2013	
AB		0.03MG; 1.5MG		A202741	001	Feb 20, 2015	
AB	WATSON LABS	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG		A076629	001	Mar 18, 2010	
	<u>TRI-LEGEST FE</u>						
AB	BARR	0.02MG; 0.035MG; 0.03MG; 1MG; 1MG; 1MG		A076105	001	Oct 26, 2007	
	TABLET, CHEWABLE; ORAL						
	MINASTRIN 24 FE						
	+ WARNER CHILCOTT LLC	0.02MG; 1MG		N203667	001	May 08, 2013	
	TABLET, CHEWABLE, TABLET; ORAL						
	LO MINASTRIN FE						
	+ WARNER CHILCOTT	0.01MG, 0.01MG, N/A; 1MG, N/A, N/A		N204654	001	Jul 24, 2013	
	<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>						
	TABLET; ORAL						
	<u>NORGESTIMATE AND ETHINYL ESTRADIOL</u>						
AB	GLENMARK GENERICS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG		A200494	001	Jun 17, 2011	
	TABLET; ORAL-28						
	<u>ESTARYLLA</u>						
AB	SANDOZ	0.035MG; 0.25MG		A090794	001	Jan 30, 2013	
	<u>MONO-LINYAH</u>						
AB	NOVAST LABS LTD	0.035MG; 0.25MG		A090523	001	May 23, 2012	
	<u>NORGESTIMATE AND ETHINYL ESTRADIOL</u>						
AB	GLENMARK GENERICS	0.035MG; 0.25MG		A200538	001	Apr 05, 2012	
AB	HAUPT PHARMA	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG		A203870	001	Nov 12, 2015	
		0.035MG; 0.25MG		A203865	001	Oct 27, 2015	
AB	JAI PHARMA LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG		A202132	001	Sep 09, 2015	
AB	LUPIN PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG		A200541	001	Jun 25, 2012	
AB	OC PHARMA	0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG; 0.25MG		A200383	001	Apr 07, 2015	
AB		0.035MG; 0.25MG		A200384	001	Apr 07, 2015	
	<u>ORTHO CYCLEN-28</u>						
AB	+ JANSSEN PHARMS	0.035MG; 0.25MG		N019653	002	Dec 29, 1989	
	<u>ORTHO TRI-CYCLEN</u>						
AB	+ JANSSEN PHARMS	0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG; 0.25MG		N019697	001	Jul 03, 1992	
	<u>ORTHO TRI-CYCLEN LO</u>						
AB	+ JANSSEN PHARMS	0.025MG; 0.025MG; 0.025MG; 0.18MG; 0.215MG; 0.25MG		N021241	001	Aug 22, 2002	

## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

PREVIFEM

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.035MG;0.25MG</u>	<u>A076334</u>	<u>001</u>	Jan 09, 2004
-----------	--------------------	-----------------------	----------------	------------	--------------

SPRINTEC

<b>AB</b>	BARR	<u>0.035MG;0.25MG</u>	<u>A075804</u>	<u>001</u>	Sep 25, 2002
-----------	------	-----------------------	----------------	------------	--------------

TRI LO SPRINTEC

<b>AB</b>	BARR LABS INC	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	<u>A076784</u>	<u>001</u>	Jun 29, 2009
-----------	---------------	--	----------------	------------	--------------

TRI-ESTARYLLA

<b>AB</b>	SANDOZ	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A090793</u>	<u>001</u>	Jan 30, 2013
-----------	--------	--	----------------	------------	--------------

TRI-LINYAH

<b>AB</b>	NOVAST LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A090524</u>	<u>001</u>	May 30, 2012
-----------	-----------------	--	----------------	------------	--------------

TRI-LO-ESTARYLLA

<b>AB</b>	SANDOZ INC	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	<u>A091232</u>	<u>001</u>	Jun 29, 2015
-----------	------------	--	----------------	------------	--------------

TRI-PREVIFEM

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	<u>A076335</u>	<u>001</u>	Mar 26, 2004
-----------	--------------------	--	----------------	------------	--------------

TRI-SPRINTEC

<b>AB</b>	BARR	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	<u>A075808</u>	<u>001</u>	Dec 29, 2003
-----------	------	--	----------------	------------	--------------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSSELLE

<b>AB</b>	DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840</u>	<u>001</u>	Nov 30, 2001
-----------	---------------------	---------------------	----------------	------------	--------------

TABLET; ORAL-28

CRYSSELLE

<b>AB</b>	DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840</u>	<u>002</u>	Nov 30, 2001
-----------	---------------------	---------------------	----------------	------------	--------------

ELINEST

<b>AB</b>	NOVAST LABS LTD	<u>0.03MG;0.3MG</u>	<u>A091105</u>	<u>001</u>	Mar 28, 2012
-----------	-----------------	---------------------	----------------	------------	--------------

LO/OVRAL-28

<b>AB</b>	WYETH PHARMS	<u>0.03MG;0.3MG</u>	<u>N017802</u>	<u>001</u>	
-----------	--------------	---------------------	----------------	------------	--

LOW-OGESTREL-28

<b>AB</b>	WATSON LABS	<u>0.03MG;0.3MG</u>	<u>A075288</u>	<u>002</u>	Jul 28, 1999
-----------	-------------	---------------------	----------------	------------	--------------

OGESTREL 0.5/50-28

+	WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999
---	-------------	--------------	---------	-----	--------------

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+	GUERBET	99%	N009190	001	
---	---------	-----	---------	-----	--

ETHIONAMIDE

TABLET; ORAL

TRECATOR

+	WYETH PHARMS INC	250MG	N013026	002	
---	------------------	-------	---------	-----	--

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

<b>AB</b>	BANNER LIFE SCIENCES	<u>250MG</u>	<u>A040430</u>	<u>001</u>	Oct 28, 2002
-----------	----------------------	--------------	----------------	------------	--------------

<b>AB</b>	HERITAGE PHARMS INC	<u>250MG</u>	<u>A200892</u>	<u>001</u>	Sep 25, 2012
-----------	---------------------	--------------	----------------	------------	--------------

<b>AB</b>	VERSAPHARM	<u>250MG</u>	<u>A040686</u>	<u>001</u>	May 28, 2008
-----------	------------	--------------	----------------	------------	--------------

ZARONTIN

<b>AB</b>	+ PARKE DAVIS	<u>250MG</u>	<u>N012380</u>	<u>001</u>	
-----------	---------------	--------------	----------------	------------	--

SYRUP; ORAL

ETHOSUXIMIDE

<b>AA</b>	MIKART	<u>250MG/5ML</u>	<u>A040506</u>	<u>001</u>	Dec 22, 2003
-----------	--------	------------------	----------------	------------	--------------

<b>AA</b>	PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253</u>	<u>001</u>	Nov 22, 2000
-----------	-------------	------------------	----------------	------------	--------------

<b>AA</b>	TEVA PHARMS	<u>250MG/5ML</u>	<u>A081306</u>	<u>001</u>	Jul 30, 1993
-----------	-------------	------------------	----------------	------------	--------------

ZARONTIN

<b>AA</b>	+ PARKE DAVIS	<u>250MG/5ML</u>	<u>A080258</u>	<u>001</u>	
-----------	---------------	------------------	----------------	------------	--

ETHOTOIN

TABLET; ORAL

PEGANONE

+	RECORDATI RARE	250MG	N010841	001	
---	----------------	-------	---------	-----	--

## PRESCRIPTION DRUG PRODUCT LIST

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

<u>AB</u>	PROCTER AND GAMBLE	<u>200MG</u>	<u>N017831</u>	<u>001</u>	
<u>AB</u>	+	<u>400MG</u>	<u>N017831</u>	<u>002</u>	

ETIDRONATE DISODIUM

<u>AB</u>	MYLAN	<u>200MG</u>	<u>A075800</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>400MG</u>	<u>A075800</u>	<u>002</u>	Jan 24, 2003

ETODOLAC

CAPSULE; ORAL

ETODOLAC

<u>AB</u>	ANI PHARMS INC	<u>200MG</u>	<u>A075126</u>	<u>001</u>	Sep 16, 1999
<u>AB</u>		<u>300MG</u>	<u>A075126</u>	<u>002</u>	Sep 16, 1999
<u>AB</u>	APOTEX	<u>200MG</u>	<u>A075419</u>	<u>001</u>	Jul 28, 2000
<u>AB</u>		<u>300MG</u>	<u>A075419</u>	<u>002</u>	Jul 28, 2000
<u>AB</u>	TARO	<u>200MG</u>	<u>A075078</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	+	<u>300MG</u>	<u>A075078</u>	<u>002</u>	Apr 30, 1998

TABLET; ORAL

ETODOLAC

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A076004</u>	<u>001</u>	Dec 03, 2002
<u>AB</u>		<u>500MG</u>	<u>A076004</u>	<u>002</u>	Dec 03, 2002
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075104</u>	<u>001</u>	Feb 06, 1998
<u>AB</u>		<u>500MG</u>	<u>A075104</u>	<u>002</u>	Nov 20, 1998
<u>AB</u>	SANDOZ	<u>400MG</u>	<u>A074903</u>	<u>001</u>	Apr 11, 1997
<u>AB</u>		<u>500MG</u>	<u>A074903</u>	<u>002</u>	Apr 19, 1999
<u>AB</u>	TARO PHARM INDS	<u>400MG</u>	<u>A075074</u>	<u>001</u>	Mar 11, 1998
<u>AB</u>	+	<u>500MG</u>	<u>A075074</u>	<u>002</u>	Apr 25, 2000
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075009</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>500MG</u>	<u>A075009</u>	<u>002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>		<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>		<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	+	<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A091134</u>	<u>001</u>	Jan 23, 2014
<u>AB</u>		<u>500MG</u>	<u>A091134</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>		<u>600MG</u>	<u>A091134</u>	<u>003</u>	Jan 23, 2014

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982
-----------	---	---------	---------------	----------------	------------	--------------

ETOMIDATE

<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996
<u>AP</u>	EMCURE PHARMS LTD	<u>2MG/ML</u>	<u>A204618</u>	<u>001</u>	Aug 13, 2014
<u>AP</u>	LUITPOLD	<u>2MG/ML</u>	<u>A078867</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>	MYLAN LABS LTD	<u>2MG/ML</u>	<u>A078289</u>	<u>001</u>	Jan 02, 2009
<u>AP</u>	PAR STERILE PRODUCTS	<u>2MG/ML</u>	<u>A091297</u>	<u>001</u>	Jun 20, 2012
<u>AP</u>	ZYDUS PHARMS USA INC	<u>2MG/ML</u>	<u>A202360</u>	<u>001</u>	Jul 18, 2014

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011
---	-----------------	--------------	---------	-----	--------------

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

+	MYLAN	50MG	A075635	001	Sep 19, 2001
---	-------	------	---------	-----	--------------

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>	ACCORD HLTHCARE	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996	
<u>AP</u>	EUROHLTH INTL SARL	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995	
<u>AP</u>	+	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>	TEVA PHARMS USA	<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996	

## PRESCRIPTION DRUG PRODUCT LIST

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+ BRISTOL MYERS SQUIBB EQ 100MG BASE/VIAL N020457 001 May 17, 1996

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSSEN R AND D 25MG N022187 003 Mar 26, 2012

100MG N022187 001 Jan 18, 2008

+ 200MG N022187 002 Dec 22, 2010

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS 2.5MG N022334 003 Jul 09, 2010

5MG N022334 001 Mar 30, 2009

+ 7.5MG N022334 004 Mar 30, 2012

+ 10MG N022334 002 Mar 30, 2009

ZORTRESS

NOVARTIS 0.25MG N021560 001 Apr 20, 2010

0.5MG N021560 002 Apr 20, 2010

+ 0.75MG N021560 003 Apr 20, 2010

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

NOVARTIS PHARM 2MG N203985 001 Aug 29, 2012

3MG N203985 002 Aug 29, 2012

+ 5MG N203985 003 Aug 29, 2012

EXEMESTANE

TABLET; ORAL

AROMASIN**AB** + PHARMACIA AND UPJOHN **25MG** **N020753 001** Oct 21, 1999EXEMESTANE**AB** ALVOGEN INC **25MG** **A200898 001** Jul 28, 2014**AB** ROXANE **25MG** **A077431 001** Apr 01, 2011EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+ ASTRAZENECA AB 2MG/VIAL N022200 001 Jan 27, 2012

INJECTABLE; SUBCUTANEOUS

BYETTA

+ ASTRAZENECA AB 300MCG/1.2ML (250MCG/ML) N021773 001 Apr 28, 2005

+ 600MCG/2.4ML (250MCG/ML) N021773 002 Apr 28, 2005

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSD INTL GMBH 10MG N021445 001 Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL 10MG; 10MG N021687 001 Jul 23, 2004

10MG; 20MG N021687 002 Jul 23, 2004

+ 10MG; 40MG N021687 003 Jul 23, 2004

10MG; 80MG N021687 004 Jul 23, 2004

EZOAGABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE 50MG N022345 001 Jun 10, 2011

200MG N022345 002 Jun 10, 2011

+ 300MG N022345 003 Jun 10, 2011

400MG N022345 004 Jun 10, 2011

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR**AB** APOTEX **125MG** **A091480 001** Jul 22, 2011**AB** **250MG** **A091480 002** Jul 22, 2011**AB** **500MG** **A091480 003** Jul 22, 2011**AB** AUROBINDO PHARMA LTD **125MG** **A091114 001** Mar 21, 2011**AB** **250MG** **A091114 002** Mar 21, 2011**AB** **500MG** **A091114 003** Mar 21, 2011

## PRESCRIPTION DRUG PRODUCT LIST

## FAMCICLOVIR

TABLET; ORAL

**FAMCICLOVIR**

<b>AB</b>	CIPLA LTD	<b>125MG</b>	<b>A078278 001</b>	Mar 21, 2011
<b>AB</b>		<b>250MG</b>	<b>A078278 002</b>	Mar 21, 2011
<b>AB</b>		<b>500MG</b>	<b>A078278 003</b>	Mar 21, 2011
<b>AB</b>	HETERO LABS LTD V	<b>125MG</b>	<b>A202438 001</b>	Sep 10, 2014
<b>AB</b>		<b>250MG</b>	<b>A202438 002</b>	Sep 10, 2014
<b>AB</b>		<b>500MG</b>	<b>A202438 003</b>	Sep 10, 2014
<b>AB</b>	MACLEODS PHARMS LTD	<b>125MG</b>	<b>A201022 001</b>	Jan 12, 2012
<b>AB</b>		<b>250MG</b>	<b>A201022 002</b>	Jan 12, 2012
<b>AB</b>		<b>500MG</b>	<b>A201022 003</b>	Jan 12, 2012
<b>AB</b>	MYLAN	<b>125MG</b>	<b>A201333 001</b>	Mar 24, 2011
<b>AB</b>		<b>250MG</b>	<b>A201333 002</b>	Mar 24, 2011
<b>AB</b>		<b>500MG</b>	<b>A201333 003</b>	Mar 24, 2011
<b>AB</b>	ROXANE	<b>125MG</b>	<b>A090128 001</b>	Mar 21, 2011
<b>AB</b>		<b>250MG</b>	<b>A090128 002</b>	Mar 21, 2011
<b>AB</b>		<b>500MG</b>	<b>A090128 003</b>	Mar 21, 2011
<b>AB</b>	TEVA PHARMS	<b>125MG</b>	<b>A077487 001</b>	Aug 24, 2007
<b>AB</b>		<b>250MG</b>	<b>A077487 002</b>	Aug 24, 2007
<b>AB</b>		<b>500MG</b>	<b>A077487 003</b>	Aug 24, 2007

**FAMVIR**

<b>AB</b>	NOVARTIS	<b>125MG</b>	<b>N020363 003</b>	Dec 11, 1995
<b>AB</b>		<b>250MG</b>	<b>N020363 001</b>	Apr 26, 1996
<b>AB</b>	+	<b>500MG</b>	<b>N020363 002</b>	Jun 29, 1994

## FAMOTIDINE

FOR SUSPENSION; ORAL

**FAMOTIDINE**

<b>AB</b>	HI-TECH PHARMA CO	<b>40MG/5ML</b>	<b>A201995 001</b>	May 30, 2014
<b>AB</b>	LUPIN LTD	<b>40MG/5ML</b>	<b>A090440 001</b>	Jun 29, 2010
<b>AB</b>	NAVINTA LLC	<b>40MG/5ML</b>	<b>A091020 001</b>	May 27, 2010

**PEPCID**

<b>AB</b>	+	<b>40MG/5ML</b>	<b>N019527 001</b>	Feb 02, 1987
-----------	---	-----------------	--------------------	--------------

INJECTABLE; INJECTION

**FAMOTIDINE**

<b>AP</b>	BEDFORD	<b>10MG/ML</b>	<b>A075651 001</b>	Apr 16, 2001
<b>AP</b>		<b>10MG/ML</b>	<b>A075684 001</b>	Apr 16, 2001
<b>AP</b>	+	<b>10MG/ML</b>	<b>A075488 001</b>	Apr 16, 2001
<b>AP</b>	FRESENIUS KABI USA	<b>10MG/ML</b>	<b>A075709 001</b>	Apr 16, 2001
<b>AP</b>	MYLAN LABS LTD	<b>10MG/ML</b>	<b>A078641 001</b>	Jun 25, 2008

**FAMOTIDINE PRESERVATIVE FREE**

<b>AP</b>	BEDFORD	<b>10MG/ML</b>	<b>A075622 001</b>	Apr 16, 2001
<b>AP</b>	BEDFORD LABS	<b>10MG/ML</b>	<b>A075825 001</b>	Apr 17, 2001
<b>AP</b>	+	<b>10MG/ML</b>	<b>A075486 001</b>	Apr 16, 2001
<b>AP</b>	FRESENIUS KABI USA	<b>10MG/ML</b>	<b>A075813 001</b>	Apr 16, 2001
<b>AP</b>	MYLAN LABS LTD	<b>10MG/ML</b>	<b>A078642 001</b>	Jun 25, 2008

**FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER**

<b>AP</b>	+	<b>0.4MG/ML</b>	<b>A075591 001</b>	May 10, 2001
-----------	---	-----------------	--------------------	--------------

SUSPENSION; ORAL

**FAMOTIDINE**

<b>AB</b>	NOVEL LABS INC	<b>40MG/5ML</b>	<b>A201695 001</b>	Dec 17, 2012
-----------	----------------	-----------------	--------------------	--------------

TABLET; ORAL

**FAMOTIDINE**

<b>AB</b>	ALEMBIC PHARMS LTD	<b>20MG</b>	<b>A078916 001</b>	May 22, 2009
<b>AB</b>		<b>40MG</b>	<b>A078916 002</b>	May 22, 2009
<b>AB</b>	APOTEX	<b>20MG</b>	<b>A075611 001</b>	Jul 23, 2001
<b>AB</b>		<b>40MG</b>	<b>A075611 002</b>	Jul 23, 2001
<b>AB</b>	AUROBINDO PHARMA LTD	<b>20MG</b>	<b>A206530 001</b>	Dec 22, 2015
<b>AB</b>		<b>40MG</b>	<b>A206530 002</b>	Dec 22, 2015
<b>AB</b>	CARLSBAD	<b>20MG</b>	<b>A075805 001</b>	Apr 16, 2001
<b>AB</b>		<b>40MG</b>	<b>A075805 002</b>	Apr 16, 2001
<b>AB</b>	DR REDDYS LABS LTD	<b>20MG</b>	<b>A075718 001</b>	Apr 16, 2001
<b>AB</b>		<b>40MG</b>	<b>A075718 002</b>	Apr 16, 2001
<b>AB</b>	IVAX SUB TEVA PHARMS	<b>20MG</b>	<b>A075511 001</b>	Apr 16, 2001
<b>AB</b>		<b>40MG</b>	<b>A075511 002</b>	Apr 16, 2001
<b>AB</b>	MYLAN	<b>20MG</b>	<b>A075704 001</b>	Apr 16, 2001
<b>AB</b>		<b>40MG</b>	<b>A075704 002</b>	Apr 16, 2001
<b>AB</b>	PERRIGO	<b>20MG</b>	<b>A077352 002</b>	Jul 27, 2005
<b>AB</b>		<b>40MG</b>	<b>A077352 001</b>	Jul 27, 2005
<b>AB</b>	TEVA	<b>20MG</b>	<b>A075311 001</b>	Apr 16, 2001
<b>AB</b>		<b>40MG</b>	<b>A075311 002</b>	Apr 16, 2001
<b>AB</b>	WOCKHARDT	<b>20MG</b>	<b>A075786 001</b>	Apr 16, 2001

## PRESCRIPTION DRUG PRODUCT LIST

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001
-----------	--	-------------	----------------	------------	--------------

PEPCID

<u>AB</u>	VALEANT PHARMS NORTH	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
-----------	----------------------	-------------	----------------	------------	--------------

<u>AB</u>	+	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986
-----------	---	-------------	----------------	------------	--------------

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+ HORIZON PHARMA

26.6MG; 800MG

N022519 001 Apr 23, 2011

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA

40MG

N021856 001 Feb 13, 2009

+

80MG

N021856 002 Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>600MG/5ML</u>	<u>A202385</u>	<u>001</u>	Dec 16, 2011
-----------	---------------	------------------	----------------	------------	--------------

FELBATOL

<u>AB</u>	+	MEDA PHARMS	<u>600MG/5ML</u>	<u>N020189</u>	<u>003</u>	Jul 29, 1993
-----------	---	-------------	------------------	----------------	------------	--------------

TABLET; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>400MG</u>	<u>A201680</u>	<u>001</u>	Sep 13, 2011
-----------	---------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>600MG</u>	<u>A201680</u>	<u>002</u>	Sep 13, 2011
-----------	--	--------------	----------------	------------	--------------

<u>AB</u>	COREPHARMA	<u>400MG</u>	<u>A202284</u>	<u>001</u>	Nov 04, 2015
-----------	------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>600MG</u>	<u>A202284</u>	<u>002</u>	Nov 04, 2015
-----------	--	--------------	----------------	------------	--------------

<u>AB</u>	MYLAN PHARMS INC	<u>400MG</u>	<u>A204595</u>	<u>001</u>	Jan 11, 2016
-----------	------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>600MG</u>	<u>A204595</u>	<u>002</u>	Jan 11, 2016
-----------	--	--------------	----------------	------------	--------------

FELBATOL

<u>AB</u>	MEDA PHARMS	<u>400MG</u>	<u>N020189</u>	<u>001</u>	Jul 29, 1993
-----------	-------------	--------------	----------------	------------	--------------

<u>AB</u>	+		<u>N020189</u>	<u>002</u>	Jul 29, 1993
-----------	---	--	----------------	------------	--------------

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A203417</u>	<u>001</u>	Jan 17, 2013
-----------	----------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A203417</u>	<u>002</u>	Jan 17, 2013
-----------	--	------------	----------------	------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A203417</u>	<u>003</u>	Jan 17, 2013
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A090365</u>	<u>001</u>	Dec 17, 2010
-----------	-------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A090365</u>	<u>002</u>	Dec 17, 2010
-----------	--	------------	----------------	------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A090365</u>	<u>003</u>	Dec 17, 2010
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	HERITAGE PHARMS INC	<u>2.5MG</u>	<u>A201964</u>	<u>001</u>	Nov 08, 2013
-----------	---------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A201964</u>	<u>002</u>	Nov 08, 2013
-----------	--	------------	----------------	------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A201964</u>	<u>003</u>	Nov 08, 2013
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A075896</u>	<u>001</u>	Nov 02, 2004
-----------	--------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A075896</u>	<u>002</u>	Nov 02, 2004
-----------	--	------------	----------------	------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A075896</u>	<u>003</u>	Nov 02, 2004
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078855</u>	<u>001</u>	Apr 17, 2008
-----------	-------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A078855</u>	<u>002</u>	Apr 17, 2008
-----------	--	------------	----------------	------------	--------------

<u>AB</u>	+		<u>A078855</u>	<u>003</u>	Apr 17, 2008
-----------	---	--	----------------	------------	--------------

<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A203032</u>	<u>001</u>	May 21, 2015
-----------	-----------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A203032</u>	<u>002</u>	May 21, 2015
-----------	--	------------	----------------	------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A203032</u>	<u>003</u>	May 21, 2015
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091200</u>	<u>001</u>	Dec 13, 2013
-----------	--------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A091200</u>	<u>002</u>	Dec 13, 2013
-----------	--	------------	----------------	------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A091200</u>	<u>003</u>	Dec 13, 2013
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A202170</u>	<u>001</u>	Nov 28, 2011
-----------	--------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A202170</u>	<u>002</u>	Nov 28, 2011
-----------	--	------------	----------------	------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A202170</u>	<u>003</u>	Nov 28, 2011
-----------	--	-------------	----------------	------------	--------------

<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A200815</u>	<u>001</u>	Oct 28, 2011
-----------	--------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A200815</u>	<u>002</u>	Oct 28, 2011
-----------	--	------------	----------------	------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A200815</u>	<u>003</u>	Oct 28, 2011
-----------	--	-------------	----------------	------------	--------------

FENOIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

<u>AB</u>	LUPIN ATLANTIS	<u>43MG</u>	<u>N021695</u>	<u>001</u>	Nov 30, 2004
-----------	----------------	-------------	----------------	------------	--------------

<u>AB</u>	+		<u>N021695</u>	<u>003</u>	Nov 30, 2004
-----------	---	--	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE

<u>AB</u>	SUN PHARM INDS LTD	<u>43MG</u>	<u>A201748</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>130MG</u>	<u>A201748</u>	<u>002</u>	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

<u>AB</u>	APOTEX INC	<u>43MG</u>	<u>A202252</u>	<u>001</u>	Jul 26, 2013
<u>AB</u>		<u>130MG</u>	<u>A202252</u>	<u>002</u>	Jul 26, 2013
<u>AB</u>	DR REDDYS LABS SA	<u>43MG</u>	<u>A090859</u>	<u>001</u>	Mar 01, 2012
<u>AB</u>		<u>130MG</u>	<u>A090859</u>	<u>002</u>	Mar 01, 2012
<u>AB</u>	IMPAX LABS	<u>67MG</u>	<u>A075868</u>	<u>001</u>	Oct 27, 2003
<u>AB</u>		<u>134MG</u>	<u>A075868</u>	<u>002</u>	Oct 27, 2003
<u>AB</u>		<u>200MG</u>	<u>A075868</u>	<u>003</u>	Oct 27, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>43MG</u>	<u>A202579</u>	<u>001</u>	Jan 10, 2013
<u>AB</u>		<u>67MG</u>	<u>A202676</u>	<u>001</u>	Oct 23, 2012
<u>AB</u>		<u>130MG</u>	<u>A202579</u>	<u>002</u>	Jan 10, 2013
<u>AB</u>		<u>134MG</u>	<u>A202676</u>	<u>002</u>	Oct 23, 2012
<u>AB</u>		<u>200MG</u>	<u>A202676</u>	<u>003</u>	Oct 23, 2012
<u>AB</u>	TEVA	<u>67MG</u>	<u>A075753</u>	<u>001</u>	Sep 03, 2002
<u>AB</u>		<u>134MG</u>	<u>A075753</u>	<u>002</u>	Apr 09, 2002
<u>AB</u>	+	<u>200MG</u>	<u>A075753</u>	<u>003</u>	Apr 09, 2002
	ANTARA (MICRONIZED)				
	LUPIN ATLANTIS	30MG	N021695	004	Oct 18, 2013
		90MG	N021695	005	Oct 18, 2013
	LIPOFEN				
	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
	+	150MG	N021612	003	Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>160MG</u>	<u>A076509</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	LUPIN LTD	<u>48MG</u>	<u>A090856</u>	<u>001</u>	Dec 23, 2011
<u>AB</u>		<u>54MG</u>	<u>A204019</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>		<u>145MG</u>	<u>A090856</u>	<u>002</u>	Dec 23, 2011
<u>AB</u>		<u>160MG</u>	<u>A204019</u>	<u>002</u>	Aug 17, 2015
<u>AB</u>	MYLAN	<u>54MG</u>	<u>A076520</u>	<u>001</u>	Oct 25, 2007
<u>AB</u>		<u>160MG</u>	<u>A076520</u>	<u>003</u>	Oct 25, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>48MG</u>	<u>A202856</u>	<u>001</u>	Dec 07, 2012
<u>AB</u>		<u>145MG</u>	<u>A202856</u>	<u>002</u>	Dec 07, 2012
<u>AB</u>	SUN PHARM INDS LTD	<u>54MG</u>	<u>A076635</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>		<u>160MG</u>	<u>A076635</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>	TEVA	<u>54MG</u>	<u>A076433</u>	<u>001</u>	May 13, 2005
<u>AB</u>	+	<u>160MG</u>	<u>A076433</u>	<u>002</u>	May 13, 2005
<u>AB</u>	VALEANT PHARMS NORTH	<u>48MG</u>	<u>A090715</u>	<u>001</u>	Apr 05, 2012
<u>AB</u>		<u>145MG</u>	<u>A090715</u>	<u>002</u>	Apr 05, 2012

TRICOR

<u>AB</u>	ABBVIE	<u>48MG</u>	<u>N021656</u>	<u>001</u>	Nov 05, 2004	
<u>AB</u>	+	<u>145MG</u>	<u>N021656</u>	<u>002</u>	Nov 05, 2004	
	TRIGLIDE					
BX	+	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005
	FENOFIBRATE					
	SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005	
	FENOGLIDE					
	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	
	+	120MG	N022118	002	Aug 10, 2007	

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

	TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009
	+	105MG	N022418	002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

<u>AP</u>	+	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922</u>	<u>001</u>	Sep 23, 1997
		<u>FENOLDOPAM MESYLATE</u>				
<u>AP</u>		EUROHLTH INTL SARL	<u>EQ 10MG BASE/ML</u>	<u>A076582</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>		SANDOZ	<u>EQ 10MG BASE/ML</u>	<u>A077155</u>	<u>001</u>	Feb 15, 2005



## PRESCRIPTION DRUG PRODUCT LIST

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+ XSPIRE

EQ 200MG BASE

N017604 003

EQ 400MG BASE

N017604 004 Jul 21, 2009

TABLET; ORAL

FENOPROFEN CALCIUM

+ MYLAN PHARMS INC

EQ 600MG BASE

A072267 001 Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100AB JANSSEN PHARMS100MCG/HRN019813 001 Aug 07, 1990DURAGESIC-12AB JANSSEN PHARMS12.5MCG/HRN019813 005 Feb 04, 2005DURAGESIC-25AB + JANSSEN PHARMS25MCG/HRN019813 004 Aug 07, 1990DURAGESIC-50AB JANSSEN PHARMS50MCG/HRN019813 003 Aug 07, 1990DURAGESIC-75AB JANSSEN PHARMS75MCG/HRN019813 002 Aug 07, 1990FENTANYL-100AB ACTAVIS LABS UT INC100MCG/HRA076709 004 Aug 20, 2007AB AVEVA100MCG/HRA077449 004 Oct 20, 2008AB LAVIPHARM LABS100MCG/HRA077051 004 Aug 04, 2006AB MALLINCKRODT INC100MCG/HRA077154 004 Feb 09, 2011AB MYLAN TECHNOLOGIES100MCG/HRA076258 004 Jan 28, 2005AB PAR PHARM INC100MCG/HRA077062 004 Aug 20, 2007FENTANYL-12AB MALLINCKRODT INC12.5MCG/HRA077154 005 Jun 11, 2015AB MYLAN TECHNOLOGIES12.5MCG/HRA076258 005 Jan 23, 2007FENTANYL-25AB ACTAVIS LABS UT INC25MCG/HRA076709 001 Aug 20, 2007AB AVEVA25MCG/HRA077449 001 Oct 20, 2008AB LAVIPHARM LABS25MCG/HRA077051 001 Aug 04, 2006AB MALLINCKRODT INC25MCG/HRA077154 001 Feb 09, 2011AB MYLAN TECHNOLOGIES25MCG/HRA076258 001 Jan 28, 2005AB PAR PHARM INC25MCG/HRA077062 001 Aug 20, 2007FENTANYL-50AB ACTAVIS LABS UT INC50MCG/HRA076709 002 Aug 20, 2007AB AVEVA50MCG/HRA077449 002 Oct 20, 2008AB LAVIPHARM LABS50MCG/HRA077051 002 Aug 04, 2006AB MALLINCKRODT INC50MCG/HRA077154 002 Feb 09, 2011AB MYLAN TECHNOLOGIES50MCG/HRA076258 002 Jan 28, 2005AB PAR PHARM INC50MCG/HRA077062 002 Aug 20, 2007FENTANYL-75AB ACTAVIS LABS UT INC75MCG/HRA076709 003 Aug 20, 2007AB AVEVA75MCG/HRA077449 003 Oct 20, 2008AB LAVIPHARM LABS75MCG/HRA077051 003 Aug 04, 2006AB MALLINCKRODT INC75MCG/HRA077154 003 Feb 09, 2011AB MYLAN TECHNOLOGIES75MCG/HRA076258 003 Jan 28, 2005AB PAR PHARM INC75MCG/HRA077062 003 Aug 20, 2007

FENTANYL-37

MYLAN TECHNOLOGIES

37.5MCG/HR

A076258 006 Dec 29, 2014

FENTANYL-62

MYLAN TECHNOLOGIES

62.5MCG/HR

A076258 007 Dec 29, 2014

FENTANYL-87

MYLAN TECHNOLOGIES

87.5MCG/HR

A076258 008 Dec 29, 2014

SPRAY; SUBLINGUAL

SUBSYS

INSYS THERAP

0.1MG

N202788 001 Jan 04, 2012

0.2MG

N202788 002 Jan 04, 2012

+

0.4MG

N202788 003 Jan 04, 2012

0.6MG

N202788 004 Jan 04, 2012

0.8MG

N202788 005 Jan 04, 2012

1.2MG

N202788 006 Aug 30, 2012

1.6MG

N202788 007 Aug 30, 2012

## PRESCRIPTION DRUG PRODUCT LIST

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

<b>AP</b>	HOSPIRA	<b>EQ 0.05MG BASE/ML</b>	<b>N019115 001</b>	Jan 12, 1985
-----------	---------	--------------------------	--------------------	--------------

FENTANYL CITRATE PRESERVATIVE FREE

<b>AP</b>	+	EUROHLTH INTL SARL	<b>EQ 0.05MG BASE/ML</b>	<b>N019101 001</b>	Jul 11, 1984
-----------	---	--------------------	--------------------------	--------------------	--------------

<b>AP</b>		HOSPIRA	<b>EQ 0.05MG BASE/ML</b>	<b>A072786 001</b>	Sep 24, 1991
-----------	--	---------	--------------------------	--------------------	--------------

SUBLIMAZE PRESERVATIVE FREE

<b>AP</b>	+	AKORN	<b>EQ 0.05MG BASE/ML</b>	<b>N016619 001</b>	
-----------	---	-------	--------------------------	--------------------	--

SPRAY, METERED; NASAL

LAZANDA

DEPOMED INC

EQ 0.1MG BASE

N022569 001 Jun 30, 2011

EQ 0.3MG BASE

N022569 003 Dec 21, 2015

+

EQ 0.4MG BASE

N022569 002 Jun 30, 2011

TABLET; BUCCAL, SUBLINGUAL

FENTORA

CEPHALON

EQ 0.1MG BASE

N021947 001 Sep 25, 2006

EQ 0.2MG BASE

N021947 002 Sep 25, 2006

+

EQ 0.4MG BASE

N021947 003 Sep 25, 2006

EQ 0.6MG BASE

N021947 004 Sep 25, 2006

EQ 0.8MG BASE

N021947 005 Sep 25, 2006

TABLET; SUBLINGUAL

ABSTRAL

SENTYNL THERAPS INC

EQ 0.1MG BASE

N022510 001 Jan 07, 2011

EQ 0.2MG BASE

N022510 002 Jan 07, 2011

EQ 0.3MG BASE

N022510 003 Jan 07, 2011

+

EQ 0.4MG BASE

N022510 004 Jan 07, 2011

EQ 0.6MG BASE

N022510 005 Jan 07, 2011

EQ 0.8MG BASE

N022510 006 Jan 07, 2011

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

<b>AB</b>		CEPHALON	<b>EQ 0.2MG BASE</b>	<b>N020747 001</b>	Nov 04, 1998
-----------	--	----------	----------------------	--------------------	--------------

<b>AB</b>	+		<b>EQ 0.4MG BASE</b>	<b>N020747 002</b>	Nov 04, 1998
-----------	---	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 0.6MG BASE</b>	<b>N020747 003</b>	Nov 04, 1998
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 0.8MG BASE</b>	<b>N020747 004</b>	Nov 04, 1998
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 1.2MG BASE</b>	<b>N020747 005</b>	Nov 04, 1998
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 1.6MG BASE</b>	<b>N020747 006</b>	Nov 04, 1998
-----------	--	--	----------------------	--------------------	--------------

FENTANYL CITRATE

<b>AB</b>		MALLINCKRODT	<b>EQ 0.2MG BASE</b>	<b>A078907 001</b>	Oct 30, 2009
-----------	--	--------------	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 0.4MG BASE</b>	<b>A078907 002</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 0.6MG BASE</b>	<b>A078907 003</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 0.8MG BASE</b>	<b>A078907 004</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 1.2MG BASE</b>	<b>A078907 005</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 1.6MG BASE</b>	<b>A078907 006</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>		PAR PHARM	<b>EQ 0.2MG BASE</b>	<b>A077312 001</b>	Oct 30, 2009
-----------	--	-----------	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 0.4MG BASE</b>	<b>A077312 002</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 0.6MG BASE</b>	<b>A077312 003</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 0.8MG BASE</b>	<b>A077312 004</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 1.2MG BASE</b>	<b>A077312 005</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>			<b>EQ 1.6MG BASE</b>	<b>A077312 006</b>	Oct 30, 2009
-----------	--	--	----------------------	--------------------	--------------

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

+ THE MEDICINES CO

EQ 40MCG BASE/ACTIVATION

N021338 001 May 22, 2006

FERRIC CARBOXYMALTOSE

INJECTABLE; INTRAVENOUS

INJECTAFER

+ LUITPOLD

750MG IRON/15ML (50MG IRON/ML)

N203565 001 Jul 25, 2013

FERRIC CITRATE

TABLET; ORAL

AURYXIA

+ KERYX BIOPHARMS

EQ 210MG IRON

N205874 001 Sep 05, 2014

FERRIC HEXACYANOFERRATE (II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+ HEYL CHEMISCH

500MG

N021626 001 Oct 02, 2003

## PRESCRIPTION DRUG PRODUCT LIST

FERRIC PYROPHOSPHATE CITRATE

SOLUTION; IV (INFUSION)

TRIFERIC

+ ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317 001	Jan 23, 2015
	272MG IRON/50ML (5.44MG IRON/ML)	N206317 002	Sep 04, 2015

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

+ AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180 001	Jun 30, 2009
-------------------	--------------------------------------	-------------	--------------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

<b>AB</b>	ALKEM LABS LTD	<b>4MG</b>	<b>A204827 001</b>	Dec 10, 2015
-----------	----------------	------------	--------------------	--------------

<b>AB</b>		<b>8MG</b>	<b>A204827 002</b>	Dec 10, 2015
-----------	--	------------	--------------------	--------------

TOVIAZ

<b>AB</b>	PFIZER	<b>4MG</b>	<b>N022030 001</b>	Oct 31, 2008
-----------	--------	------------	--------------------	--------------

<b>AB</b>	+	<b>8MG</b>	<b>N022030 002</b>	Oct 31, 2008
-----------	---	------------	--------------------	--------------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

<b>AB</b>	+ SANOFI AVENTIS US	<b>30MG/5ML</b>	<b>N021963 001</b>	Oct 16, 2006
-----------	---------------------	-----------------	--------------------	--------------

FEXOFENADINE HYDROCHLORIDE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>30MG/5ML</b>	<b>A201311 001</b>	Jul 25, 2012
-----------	----------------------	-----------------	--------------------	--------------

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

<b>AB</b>	BARR	<b>30MG</b>	<b>A076191 001</b>	Aug 31, 2005
-----------	------	-------------	--------------------	--------------

<b>AB</b>		<b>60MG</b>	<b>A076191 002</b>	Aug 31, 2005
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>180MG</b>	<b>A076191 003</b>	Aug 31, 2005
-----------	--	--------------	--------------------	--------------

<b>AB</b>	DR REDDYS LABS LTD	<b>30MG</b>	<b>A076502 001</b>	Apr 11, 2006
-----------	--------------------	-------------	--------------------	--------------

<b>AB</b>		<b>60MG</b>	<b>A076502 002</b>	Apr 11, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>180MG</b>	<b>A076502 003</b>	Apr 11, 2006
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>30MG</b>	<b>A077081 002</b>	Apr 11, 2008
-----------	-------	-------------	--------------------	--------------

<b>AB</b>		<b>60MG</b>	<b>A077081 003</b>	Apr 11, 2008
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>180MG</b>	<b>A077081 001</b>	Apr 16, 2007
-----------	--	--------------	--------------------	--------------

<b>AB</b>	TEVA	<b>30MG</b>	<b>A076447 001</b>	Sep 01, 2005
-----------	------	-------------	--------------------	--------------

<b>AB</b>		<b>60MG</b>	<b>A076447 002</b>	Sep 01, 2005
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>180MG</b>	<b>A076447 003</b>	Sep 01, 2005
-----------	--	--------------	--------------------	--------------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<b>AB</b>	BARR	<b>60MG; 120MG</b>	<b>A076236 001</b>	Apr 14, 2005
-----------	------	--------------------	--------------------	--------------

<b>AB</b>	IMPAX PHARMS	<b>60MG; 120MG</b>	<b>A076298 001</b>	Nov 12, 2010
-----------	--------------	--------------------	--------------------	--------------

FIDAXOMICIN

TABLET; ORAL

DIFICID

+ CUBIST PHARMS LLC	200MG	N201699 001	May 27, 2011
---------------------	-------	-------------	--------------

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

+ ALCON RES LTD	0.3%	N206307 001	Dec 17, 2014
-----------------	------	-------------	--------------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

<b>AB</b>	ACCORD HLTHCARE	<b>5MG</b>	<b>A090121 001</b>	Feb 23, 2010
-----------	-----------------	------------	--------------------	--------------

<b>AB</b>	ACCORD HLTHCARE INC	<b>1MG</b>	<b>A091643 001</b>	Nov 05, 2013
-----------	---------------------	------------	--------------------	--------------

<b>AB</b>	ACTAVIS TOTOWA	<b>1MG</b>	<b>A078371 001</b>	Nov 05, 2013
-----------	----------------	------------	--------------------	--------------

<b>AB</b>		<b>5MG</b>	<b>A077914 001</b>	Mar 28, 2007
-----------	--	------------	--------------------	--------------

<b>AB</b>	AUROBINDO PHARMA	<b>5MG</b>	<b>A078341 001</b>	Oct 30, 2007
-----------	------------------	------------	--------------------	--------------

<b>AB</b>	AUROBINDO PHARMA LTD	<b>1MG</b>	<b>A203687 001</b>	Nov 05, 2013
-----------	----------------------	------------	--------------------	--------------

<b>AB</b>	CIPLA LTD	<b>1MG</b>	<b>A077335 001</b>	Nov 20, 2014
-----------	-----------	------------	--------------------	--------------

<b>AB</b>	DR REDDYS LABS INC	<b>1MG</b>	<b>A076436 001</b>	Jul 28, 2006
-----------	--------------------	------------	--------------------	--------------

<b>AB</b>	DR REDDYS LABS LTD	<b>5MG</b>	<b>A076437 001</b>	Feb 28, 2007
-----------	--------------------	------------	--------------------	--------------

<b>AB</b>	GEDEON RICHTER USA	<b>5MG</b>	<b>A077251 001</b>	Dec 22, 2006
-----------	--------------------	------------	--------------------	--------------

<b>AB</b>	HETERO LABS LTD III	<b>1MG</b>	<b>A090060 001</b>	Jul 01, 2013
-----------	---------------------	------------	--------------------	--------------

<b>AB</b>		<b>5MG</b>	<b>A090061 001</b>	Jun 07, 2010
-----------	--	------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>5MG</b>	<b>A077578 001</b>	Dec 18, 2006
-----------	-------	------------	--------------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<b>1MG</b>	<b>A078161 001</b>	Nov 05, 2013
-----------	------------------	------------	--------------------	--------------

<b>AB</b>	SUN PHARMA GLOBAL	<b>1MG</b>	<b>A090508 001</b>	Jul 01, 2013
-----------	-------------------	------------	--------------------	--------------

<b>AB</b>		<b>5MG</b>	<b>A090507 001</b>	Aug 16, 2011
-----------	--	------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

FINASTERIDE

TABLET; ORAL

FINASTERIDE

<u>AB</u>	TEVA	<u>1MG</u>	<u>A076905</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009
<u>PROPECIA</u>					
<u>AB</u>	+ MERCK	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997
<u>PROSCAR</u>					
<u>AB</u>	+ MERCK	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992

FINGOLIMOD

CAPSULE; ORAL

GILENYA

+ NOVARTIS

0.5MG

N022527 001 Sep 21, 2010

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>100MG</u>	<u>A076835</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	IMPAX PHARMS	<u>100MG</u>	<u>A076234</u>	<u>001</u>	Aug 28, 2003
<u>AB</u>	+ PADDOCK LLC	<u>100MG</u>	<u>A076831</u>	<u>001</u>	Dec 16, 2004

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A075442</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>		<u>100MG</u>	<u>A075442</u>	<u>002</u>	Jul 31, 2001
<u>AB</u>		<u>150MG</u>	<u>A075442</u>	<u>003</u>	Jul 31, 2001
<u>AB</u>	ANI PHARMS INC	<u>50MG</u>	<u>A075882</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>		<u>100MG</u>	<u>A075882</u>	<u>002</u>	Oct 28, 2002
<u>AB</u>		<u>150MG</u>	<u>A075882</u>	<u>003</u>	Oct 28, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A202821</u>	<u>001</u>	Jul 08, 2015
<u>AB</u>		<u>100MG</u>	<u>A202821</u>	<u>002</u>	Jul 08, 2015
<u>AB</u>		<u>150MG</u>	<u>A202821</u>	<u>003</u>	Jul 08, 2015
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A076278</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>		<u>100MG</u>	<u>A076278</u>	<u>002</u>	Jan 14, 2003
<u>AB</u>	+	<u>150MG</u>	<u>A076278</u>	<u>003</u>	Jan 14, 2003
<u>AB</u>	SUN PHARM INDS LTD	<u>50MG</u>	<u>A076421</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>100MG</u>	<u>A076421</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>		<u>150MG</u>	<u>A076421</u>	<u>003</u>	Mar 28, 2003

FLIBANSERIN

TABLET; ORAL

ADDYI

+ SPROUT PHARMS

100MG

N022526 001 Aug 18, 2015

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+ PIRAMAL IMAGING

30ML (1.4-135mCi/ML)

N204677 001 Mar 19, 2014

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+ AVID RADIOPHARMS INC

10ML (13.5-51mCi/ML)

N202008 001 Apr 06, 2012

+

10-30ML (13.5-51mCi/ML)

N202008 002 Apr 06, 2012

+

10-50ML (13.5-51mCi/ML)

N202008 003 Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

<u>AP</u>	+ EUROHLTH INTL SARL	<u>500MG/VIAL</u>	<u>A075387</u>	<u>001</u>	Apr 16, 2000
<u>AP</u>	FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A075837</u>	<u>001</u>	Feb 22, 2001

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

<u>AB</u>	PFIZER	<u>50MG/5ML</u>	<u>N020090</u>	<u>001</u>	Dec 23, 1993
<u>AB</u>	+	<u>200MG/5ML</u>	<u>N020090</u>	<u>002</u>	Dec 23, 1993
<u>FLUCONAZOLE</u>					
<u>AB</u>	AUROBINDO PHARM	<u>50MG/5ML</u>	<u>A079150</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>		<u>200MG/5ML</u>	<u>A079150</u>	<u>002</u>	Sep 18, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG/5ML</u>	<u>A077523</u>	<u>001</u>	Sep 12, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A077523</u>	<u>002</u>	Sep 12, 2007
<u>AB</u>	ROXANE	<u>50MG/5ML</u>	<u>A076246</u>	<u>001</u>	Jul 29, 2004

## PRESCRIPTION DRUG PRODUCT LIST

## FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

<u>AB</u>		<u>200MG/5ML</u>	<u>A076246</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>50MG/5ML</u>	<u>A076332</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>200MG/5ML</u>	<u>A076332</u>	<u>002</u>	Jul 29, 2004

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>003</u>	Sep 29, 1992
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>005</u>	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>001</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>006</u>	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>002</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>004</u>	Jan 29, 1990

FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML (2MG/ML)</u>	<u>A079104</u>	<u>001</u>	Jul 30, 2009
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A079104</u>	<u>002</u>	Jul 30, 2009

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	CLARIS PHARMASERVICE	<u>200MG/100ML (2MG/ML)</u>	<u>A077988</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077988</u>	<u>002</u>	May 26, 2010
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078764</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078764</u>	<u>002</u>	Jan 30, 2012
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076304</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076304</u>	<u>002</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

<u>AP</u>	BEDFORD	<u>200MG/100ML (2MG/ML)</u>	<u>A076087</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076087</u>	<u>003</u>	Jul 29, 2004
<u>AP</u>	CLARIS PHARMASERVICE	<u>200MG/100ML (2MG/ML)</u>	<u>A077947</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077947</u>	<u>002</u>	May 26, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>200MG/100ML (2MG/ML)</u>	<u>A076145</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076145</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A076736</u>	<u>001</u>	Aug 23, 2005
<u>AP</u>	TEVA PHARMS USA	<u>200MG/100ML (2MG/ML)</u>	<u>A076653</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076653</u>	<u>002</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML (2MG/ML)</u>	<u>A076766</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076766</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	BEDFORD LABS	<u>200MG/100ML (2MG/ML)</u>	<u>A078107</u>	<u>001</u>	Jul 30, 2008
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078107</u>	<u>002</u>	Jul 30, 2008
<u>AP</u>	CLARIS PHARMASERVICE	<u>200MG/100ML (2MG/ML)</u>	<u>A077909</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077909</u>	<u>002</u>	May 26, 2010
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078698</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078698</u>	<u>002</u>	Jan 30, 2012
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076303</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076303</u>	<u>002</u>	Jul 29, 2004

## FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

BEDFORD 100MG/50ML (2MG/ML) A076087 002 Sep 26, 2008

## FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

CLARIS PHARMASERVICE 100MG/50ML (2MG/ML) A077909 003 Apr 20, 2015

TABLET; ORAL

DIFLUCAN

<u>AB</u>	PFIZER	<u>50MG</u>	<u>N019949</u>	<u>001</u>	Jan 29, 1990
<u>AB</u>		<u>100MG</u>	<u>N019949</u>	<u>002</u>	Jan 29, 1990
<u>AB</u>		<u>150MG</u>	<u>N019949</u>	<u>004</u>	Jun 30, 1994
<u>AB</u>	+	<u>200MG</u>	<u>N019949</u>	<u>003</u>	Jan 29, 1990

FLUCONAZOLE

<u>AB</u>	APOTEX	<u>50MG</u>	<u>A076665</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076665</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076665</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076665</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>50MG</u>	<u>A077731</u>	<u>001</u>	Oct 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077731</u>	<u>002</u>	Oct 07, 2008
<u>AB</u>		<u>150MG</u>	<u>A077731</u>	<u>003</u>	Oct 07, 2008
<u>AB</u>		<u>200MG</u>	<u>A077731</u>	<u>004</u>	Oct 07, 2008
<u>AB</u>	DR REDDYS LABS INC	<u>50MG</u>	<u>A076658</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076658</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076658</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076658</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	GLENMARK GENERICS	<u>50MG</u>	<u>A077253</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>		<u>100MG</u>	<u>A077253</u>	<u>002</u>	Jan 25, 2006

## PRESCRIPTION DRUG PRODUCT LIST

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

<u>AB</u>		<u>150MG</u>	<u>A077253 003</u>	Jan 25, 2006
<u>AB</u>		<u>200MG</u>	<u>A077253 004</u>	Jan 25, 2006
<u>AB</u>	HARRIS PHARM	<u>50MG</u>	<u>A078423 001</u>	Mar 07, 2011
<u>AB</u>		<u>100MG</u>	<u>A078423 002</u>	Mar 07, 2011
<u>AB</u>		<u>150MG</u>	<u>A078423 003</u>	Mar 07, 2011
<u>AB</u>		<u>200MG</u>	<u>A078423 004</u>	Mar 07, 2011
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A076077 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076077 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076077 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076077 004</u>	Jul 29, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A076351 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076351 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076351 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076351 004</u>	Jul 29, 2004
<u>AB</u>	TARO	<u>50MG</u>	<u>A076507 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076507 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076507 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076507 004</u>	Jul 29, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074681 001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A074681 002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A074681 003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A074681 004</u>	Jul 29, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957 001</u>	Sep 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076957 002</u>	Sep 28, 2005
<u>AB</u>		<u>200MG</u>	<u>A076957 003</u>	Sep 28, 2005

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

<u>AB</u>	VALEANT	<u>250MG</u>	<u>N017001 001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N017001 002</u>	

FLUCYTOSINE

<u>AB</u>	SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A201566 001</u>	Jun 28, 2011
<u>AB</u>		<u>500MG</u>	<u>A201566 002</u>	Jun 28, 2011

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610 001</u>	Feb 11, 2009	
<u>AP</u>	+	<u>FRESENIUS KABI USA</u>	<u>50MG/2ML (25MG/ML)</u>	<u>A078393 001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078544 001</u>	Oct 15, 2007	
<u>AP</u>	+	HOSPIRA	<u>50MG/VIAL</u>	<u>A077790 001</u>	Apr 06, 2007
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>50MG/2ML (25MG/ML)</u>	<u>A090724 001</u>	Sep 27, 2010	
<u>AP</u>	MYLAN LABS LTD	<u>50MG/2ML (25MG/ML)</u>	<u>A200647 001</u>	Dec 21, 2011	
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200648 001</u>	Oct 16, 2012	
<u>AP</u>	+	SANDOZ	<u>50MG/2ML (25MG/ML)</u>	<u>N022137 001</u>	Sep 21, 2007
<u>AP</u>	TEVA PHARMS USA	<u>50MG/VIAL</u>	<u>A076349 001</u>	Aug 28, 2003	
<u>AP</u>		<u>50MG/2ML (25MG/ML)</u>	<u>A076661 001</u>	Apr 28, 2004	

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	3D IMAGING DRUG	<u>20-300mCi/ML</u>	<u>A203778 001</u>	Oct 30, 2015	
<u>AP</u>	BIOMEDCL RES FDN	<u>20-300mCi/ML</u>	<u>A203710 001</u>	May 01, 2015	
<u>AP</u>		<u>20-300mCi/ML</u>	<u>A203837 001</u>	May 01, 2015	
<u>AP</u>	BRIGHAM WOMENS	<u>20-300mCi/ML</u>	<u>A203816 001</u>	Oct 30, 2014	
<u>AP</u>	CARDINAL HEALTH 414	<u>20-300mCi/ML</u>	<u>A203603 001</u>	Nov 13, 2015	
<u>AP</u>	CHILDRENS HOSP MI	<u>20-300mCi/ML</u>	<u>A204385 001</u>	Oct 29, 2014	
<u>AP</u>	CPDC	<u>20-300mCi/ML</u>	<u>A204525 001</u>	Oct 29, 2014	
<u>AP</u>	ESSENTIAL ISOTOPES	<u>20-300mCi/ML</u>	<u>A203946 001</u>	Feb 05, 2014	
<u>AP</u>	+	FEINSTEIN	<u>20-200mCi/ML</u>	<u>N021870 001</u>	Aug 19, 2005
<u>AP</u>	+		<u>20-400mCi/ML</u>	<u>N021870 002</u>	Nov 21, 2008
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>20-300mCi/ML</u>	<u>A204463 001</u>	Oct 21, 2014	
<u>AP</u>	+	HOUSTON CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203665 001</u>	Feb 14, 2013
<u>AP</u>	IBA MOLECULAR N AM	<u>20-300mCi/ML</u>	<u>A203591 001</u>	Aug 31, 2015	
<u>AP</u>	KETTERING MEDCTR	<u>4-40mCi/ML</u>	<u>A204759 001</u>	Oct 27, 2015	
<u>AP</u>	LANTHEUS MEDICAL	<u>20-200mCi/ML</u>	<u>A203664 001</u>	Feb 04, 2014	
<u>AP</u>	MA GENERAL HOSP	<u>20-300mCi/ML</u>	<u>A204333 001</u>	Sep 25, 2014	
<u>AP</u>	MCPRF	<u>20-240mCi/ML</u>	<u>A203612 001</u>	Aug 05, 2013	
<u>AP</u>	METHODIST HOSP RES	<u>20-300mCi/ML</u>	<u>A203904 001</u>	Apr 23, 2015	
<u>AP</u>	MIDWEST MEDCL	<u>20-200mCi/ML</u>	<u>A203736 001</u>	Nov 19, 2015	

## PRESCRIPTION DRUG PRODUCT LIST

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	MIPS CRF	<u>20-300mCi/ML</u>	<u>A204472</u>	<u>001</u>	Sep 11, 2015
<u>AP</u>	NCM USA BRONX LLC	<u>20-300mCi/ML</u>	<u>A204512</u>	<u>001</u>	Jan 07, 2015
<u>AP</u>	PETNET	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
<u>AP</u>	SHERTECH LABS LLC	<u>20-300mCi/ML</u>	<u>A204264</u>	<u>001</u>	Dec 18, 2014
<u>AP</u>	TRIAD ISOTOPES INC	<u>20-300mCi/ML</u>	<u>A203920</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	TRUSTEES UNIV PA	<u>20-200mCi/ML</u>	<u>A203801</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	+ UCLA BIOMEDICAL	<u>4-40mCi/ML</u>	<u>A203811</u>	<u>001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>20-300mCi/ML</u>	<u>A203902</u>	<u>001</u>	May 09, 2014
<u>AP</u>	UIHC PET IMAGING	<u>20-300mCi/ML</u>	<u>A203990</u>	<u>001</u>	Aug 06, 2014
<u>AP</u>	UNIV MICHIGAN	<u>20-300mCi/ML</u>	<u>A204531</u>	<u>001</u>	Jul 17, 2015
<u>AP</u>	UNIV TX MD ANDERSON	<u>20-300mCi/ML</u>	<u>A203246</u>	<u>002</u>	Jan 13, 2014
<u>AP</u>	UNIV UTAH CYCLOTRON	<u>20-300mCi/ML</u>	<u>A204498</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	WI MEDCL CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203709</u>	<u>001</u>	Oct 23, 2013
<u>AP</u>	WUSM CYCLOTRON	<u>20-300mCi/ML</u>	<u>A203935</u>	<u>001</u>	Feb 05, 2014
	HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015
	QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015
	UNIV NORTH DAKOTA	4-500mCi/ML	A203994	001	Feb 04, 2015
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	HIKMA PHARMS	<u>0.1MG</u>	<u>A091302</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	+ IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	BEDFORD LABS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	EUROHLTH INTL SARL	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	MYLAN LABS LTD	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	+ SAGENT PHARMS	<u>1MG/10ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ MEDA PHARMS INC

0.078MG/INH

N021247 001 Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	HI TECH PHARMA CO	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
	+ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	G AND W LABS	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A089525</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982
	<u>SYNALAR</u>				
<u>AT</u>	+ MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>005</u>	

IMPLANT; INTRAVITREAL

ILUVIEN

+ ALIMERA SCIENCES INC

0.19MG

N201923 001 Sep 26, 2014

## PRESCRIPTION DRUG PRODUCT LIST

FLUOCINOLONE ACETONIDE

IMPLANT; INTRAVITREAL

RETISERT

+ BAUSCH AND LOMB

0.59MG

N021737 001 Apr 08, 2005

OIL; TOPICAL

DERMA-SMOOTH/FS**AT** + HILL DERMAC0.01%**N019452 001** Feb 03, 1988**AT** +0.01%**N019452 002** Nov 09, 2005FLUOCINOLONE ACETONIDE**AT** IDENTI PHARMS INC0.01%**A201759 001** Oct 17, 2011**AT**0.01%**A201764 001** Oct 17, 2011**AT** PERRIGO ISRAEL0.01%**A202847 001** Aug 09, 2013**AT**0.01%**A202848 001** Aug 09, 2013**AT** VERSAPHARM INC0.01%**A091514 001** Jun 25, 2015

OIL/DROPS; OTIC

DERMOTIC**AT** + HILL DERMAC0.01%**N019452 003** Nov 09, 2005FLUOCINOLONE ACETONIDE**AT** IDENTI PHARMS INC0.01%**A091306 001** Oct 17, 2011

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE**AT** FOUGERA0.025%**A088168 001** Dec 16, 1982**AT** G AND W LABS0.025%**A089524 001** Jul 26, 1988**AT** TARO0.025%**A040041 001** Sep 15, 1994SYNALAR**AT** + MEDIMETRIKS PHARMS0.025%**N013960 001**

SHAMPOO; TOPICAL

CAPEX

+ GALDERMA LABS LP

0.01%

N020001 001 Aug 27, 1990

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE**AT** FOUGERA0.01%**A088167 001** Dec 16, 1982**AT** GAVIS PHARMS LLC0.01%**A206422 001** Sep 02, 2015**AT** TARO0.01%**A089124 001** Sep 11, 1985SYNALAR**AT** + MEDIMETRIKS PHARMS0.01%**N015296 001**FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+ GALDERMA LABS LP

0.01%; 4%; 0.05%

N021112 001 Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

+ MEDIMETRIKS PHARMS

0.025%; EQ 3.5MG BASE/GM

A060700 001

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE**AB** FOUGERA PHARMS INC0.1%**A200735 001** Jul 14, 2014**AB** GLENMARK GENERICS0.1%**A091282 001** Jul 14, 2014**AB** PERRIGO ISRAEL0.1%**A090256 001** Jan 14, 2014**AB** TARO0.1%**A200734 001** Jul 14, 2014VANOS**AB** + MEDICIS0.1%**N021758 001** Feb 11, 2005FLUOCINONIDE**AB1** FOUGERA0.05%**A073030 001** Oct 17, 1994**AB1** G AND W LABS INC0.05%**A073085 001** Feb 14, 1992**AB1** + TARO0.05%**N019117 001** Jun 26, 1984**AB1** TEVA0.05%**A072488 001** Feb 06, 1989FLUOCINONIDE EMULSIFIED BASE**AB2** FOUGERA PHARMS0.05%**A076586 001** Jun 23, 2004**AB2** + TARO0.05%**A072494 001** Jan 19, 1989**AB2** TEVA0.05%**A072490 001** Feb 07, 1989

GEL; TOPICAL

FLUOCINONIDE**AB** FOUGERA0.05%**A072933 001** Dec 30, 1994**AB** G AND W LABS INC0.05%**A072537 001** Feb 07, 1989**AB** + TARO0.05%**A074935 001** Jul 29, 1997

OINTMENT; TOPICAL

FLUOCINONIDE**AB** FOUGERA PHARMS0.05%**A074905 001** Aug 26, 1997**AB** + TARO0.05%**A075008 001** Jun 30, 1999



## PRESCRIPTION DRUG PRODUCT LIST

FLUOCINONIDE

OINTMENT; TOPICAL

FLUOCINONIDE

<b>AB</b>	TEVA	<u>0.05%</u>	<u>A073481</u>	<u>001</u>	Dec 27, 1991
-----------	------	--------------	----------------	------------	--------------

SOLUTION; TOPICAL

FLUOCINONIDE

<b>AT</b>	FOUGERA	<u>0.05%</u>	<u>A072934</u>	<u>001</u>	Feb 27, 1995
-----------	---------	--------------	----------------	------------	--------------

<b>AT</b>	G AND W LABS INC	<u>0.05%</u>	<u>A071535</u>	<u>001</u>	Dec 02, 1988
-----------	------------------	--------------	----------------	------------	--------------

<b>AT</b>	+ TARO	<u>0.05%</u>	<u>A074799</u>	<u>001</u>	Dec 31, 1996
-----------	--------	--------------	----------------	------------	--------------

<b>AT</b>	TEVA	<u>0.05%</u>	<u>A072511</u>	<u>001</u>	Feb 07, 1989
-----------	------	--------------	----------------	------------	--------------

LIDEX

<b>AT</b>	CNTY LINE PHARMS	<u>0.05%</u>	<u>N018849</u>	<u>001</u>	Apr 06, 1984
-----------	------------------	--------------	----------------	------------	--------------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

<b>AP</b>	AKORN	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N022186</u>	<u>001</u>	Aug 08, 2008
-----------	-------	---	----------------	------------	--------------

FLUORESCITE

<b>AP</b>	+ ALCON PHARMS LTD	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N021980</u>	<u>001</u>	Mar 28, 2006
-----------	--------------------	---	----------------	------------	--------------

AK-FLUOR 25%

	+ AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008
--	---------	--------------------------------------	---------	-----	--------------

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	N017760	001	Sep 04, 1985
--	------------	------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	N016851	002	Jul 28, 1982
--	------------	------	---------	-----	--------------

FML FORTE

	ALLERGAN	0.25%	N019216	001	Apr 23, 1986
--	----------	-------	---------	-----	--------------

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

	+ ALCON	0.1%	N019079	001	Feb 11, 1986
--	---------	------	---------	-----	--------------

FLUOROURACIL

CREAM; TOPICAL

CARAC

<b>AB</b>	+ VALEANT PHARMS NORTH	<u>0.5%</u>	<u>N020985</u>	<u>001</u>	Oct 27, 2000
-----------	------------------------	-------------	----------------	------------	--------------

EFUDEX

<b>AB</b>	+ VALEANT PHARM INTL	<u>5%</u>	<u>N016831</u>	<u>003</u>	
-----------	----------------------	-----------	----------------	------------	--

FLUOROURACIL

<b>AB</b>	SPEAR PHARMS	<u>5%</u>	<u>A077524</u>	<u>001</u>	Apr 11, 2008
-----------	--------------	-----------	----------------	------------	--------------

<b>AB</b>	SPEAR PHARMS INC	<u>0.5%</u>	<u>A203122</u>	<u>001</u>	Apr 20, 2015
-----------	------------------	-------------	----------------	------------	--------------

<b>AB</b>	TARO	<u>5%</u>	<u>A090368</u>	<u>001</u>	Mar 05, 2010
-----------	------	-----------	----------------	------------	--------------

FLUOROPLEX

	+ AQUA PHARMS	1%	N016988	001	
--	---------------	----	---------	-----	--

TOLAK

	+ HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015
--	-----------------------	----	---------	-----	--------------

INJECTABLE; INJECTION

FLUOROURACIL

<b>AP</b>	+ ACCORD HLTHCARE	<u>500MG/10ML (50MG/ML)</u>	<u>A040743</u>	<u>002</u>	Apr 26, 2007
-----------	-------------------	-----------------------------	----------------	------------	--------------

<b>AP</b>	+	<u>1GM/20ML (50MG/ML)</u>	<u>A040743</u>	<u>001</u>	Apr 26, 2007
-----------	---	---------------------------	----------------	------------	--------------

<b>AP</b>	+	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040798</u>	<u>002</u>	Apr 26, 2007
-----------	---	-----------------------------	----------------	------------	--------------

<b>AP</b>	+	<u>5GM/100ML (50MG/ML)</u>	<u>A040798</u>	<u>001</u>	Apr 26, 2007
-----------	---	----------------------------	----------------	------------	--------------

<b>AP</b>	+ FRESENIUS KABI USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040279</u>	<u>002</u>	Sep 30, 1998
-----------	----------------------	-----------------------------	----------------	------------	--------------

<b>AP</b>	+	<u>1GM/20ML (50MG/ML)</u>	<u>A040279</u>	<u>001</u>	Sep 30, 1998
-----------	---	---------------------------	----------------	------------	--------------

<b>AP</b>	+	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040278</u>	<u>001</u>	Sep 30, 1998
-----------	---	-----------------------------	----------------	------------	--------------

<b>AP</b>	+	<u>5GM/100ML (50MG/ML)</u>	<u>A040278</u>	<u>002</u>	Sep 30, 1998
-----------	---	----------------------------	----------------	------------	--------------

<b>AP</b>	MYLAN LABS LTD	<u>500MG/10ML (50MG/ML)</u>	<u>A202668</u>	<u>001</u>	Jul 17, 2012
-----------	----------------	-----------------------------	----------------	------------	--------------

<b>AP</b>		<u>1GM/20ML (50MG/ML)</u>	<u>A202668</u>	<u>002</u>	Jul 17, 2012
-----------	--	---------------------------	----------------	------------	--------------

<b>AP</b>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A202669</u>	<u>001</u>	Jul 17, 2012
-----------	--	-----------------------------	----------------	------------	--------------

<b>AP</b>		<u>5GM/100ML (50MG/ML)</u>	<u>A202669</u>	<u>002</u>	Jul 17, 2012
-----------	--	----------------------------	----------------	------------	--------------

<b>AP</b>	SANDOZ	<u>2.5GM/50ML (50MG/ML)</u>	<u>A091299</u>	<u>001</u>	May 02, 2011
-----------	--------	-----------------------------	----------------	------------	--------------

<b>AP</b>		<u>5GM/100ML (50MG/ML)</u>	<u>A091299</u>	<u>002</u>	May 02, 2011
-----------	--	----------------------------	----------------	------------	--------------

<b>AP</b>	+ TEVA PHARMS USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040333</u>	<u>001</u>	Jan 27, 2000
-----------	-------------------	-----------------------------	----------------	------------	--------------

<b>AP</b>	+	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040334</u>	<u>001</u>	Feb 25, 2000
-----------	---	-----------------------------	----------------	------------	--------------

<b>AP</b>	+	<u>5GM/100ML (50MG/ML)</u>	<u>A040334</u>	<u>002</u>	Feb 25, 2000
-----------	---	----------------------------	----------------	------------	--------------

SOLUTION; TOPICAL

EFUDEX

<b>AT</b>	+ VALEANT PHARM INTL	<u>2%</u>	<u>N016831</u>	<u>001</u>	
-----------	----------------------	-----------	----------------	------------	--

<b>AT</b>	+	<u>5%</u>	<u>N016831</u>	<u>002</u>	
-----------	---	-----------	----------------	------------	--

## PRESCRIPTION DRUG PRODUCT LIST

FLUOROURACIL

SOLUTION;TOPICAL

FLUOROURACIL

<u>AT</u>	TARO	<u>2%</u>	<u>A076526</u>	<u>001</u>	Nov 05, 2003
<u>AT</u>		<u>5%</u>	<u>A076526</u>	<u>002</u>	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A090223</u>	<u>003</u>	Mar 19, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 40MG BASE</u>	<u>A075465</u>	<u>003</u>	Aug 02, 2001
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 40MG BASE</u>	<u>A201336</u>	<u>003</u>	Oct 01, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245</u>	<u>003</u>	Sep 28, 2004
<u>AB</u>	MYLAN	<u>EQ 40MG BASE</u>	<u>A075207</u>	<u>003</u>	May 25, 2007
<u>AB</u>	PAR PHARM	<u>EQ 40MG BASE</u>	<u>A076922</u>	<u>003</u>	Dec 16, 2004
<u>AB</u>	SANDOZ	<u>EQ 40MG BASE</u>	<u>A075049</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 40MG BASE</u>	<u>A204597</u>	<u>003</u>	Mar 16, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 40MG BASE</u>	<u>A076990</u>	<u>001</u>	Dec 13, 2004
<u>AB</u>	TEVA	<u>EQ 40MG BASE</u>	<u>A075452</u>	<u>003</u>	Jan 29, 2002

PROZAC

<u>AB</u>	+ ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936</u>	<u>003</u>	Jun 15, 1999
-----------	--------------------	---------------------	----------------	------------	--------------

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223</u>	<u>001</u>	Mar 19, 2009
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A090223</u>	<u>002</u>	Mar 19, 2009
<u>AB1</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619</u>	<u>001</u>	Jan 31, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078619</u>	<u>002</u>	Jan 31, 2008
<u>AB1</u>	BARR	<u>EQ 10MG BASE</u>	<u>A074803</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A074803</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A075465</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075465</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	HERITAGE PHARMS INC	<u>EQ 10MG BASE</u>	<u>A201336</u>	<u>001</u>	Oct 01, 2012
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A201336</u>	<u>002</u>	Oct 01, 2012
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245</u>	<u>002</u>	Jan 31, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075245</u>	<u>001</u>	Jan 31, 2002
<u>AB1</u>	LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075464</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	MALLINCKRODT	<u>EQ 10MG BASE</u>	<u>A075658</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075207</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075207</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075577</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075577</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075049</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A204597</u>	<u>001</u>	Mar 16, 2015
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A204597</u>	<u>002</u>	Mar 16, 2015
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A076001</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001</u>	<u>002</u>	Jan 29, 2002

PROZAC

<u>AB1</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>006</u>	Dec 23, 1992
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>001</u>	Dec 29, 1987

FLUOXETINE HYDROCHLORIDE

<u>AB2</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078045</u>	<u>001</u>	Nov 17, 2008
	+	<u>EQ 20MG BASE</u>	<u>A078045</u>	<u>002</u>	Nov 17, 2008

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 90MG BASE</u>	<u>A076237</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572</u>	<u>001</u>	Mar 22, 2010

PROZAC WEEKLY

<u>AB</u>	+ LILLY	<u>EQ 90MG BASE</u>	<u>N021235</u>	<u>001</u>	Feb 26, 2001
-----------	---------	---------------------	----------------	------------	--------------

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A079209</u>	<u>001</u>	Mar 20, 2009
<u>AA</u>	LANNETT	<u>EQ 20MG BASE/5ML</u>	<u>A076458</u>	<u>001</u>	May 14, 2004
<u>AA</u>	MALLINCKRODT	<u>EQ 20MG BASE/5ML</u>	<u>A075920</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>	+ PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015</u>	<u>001</u>	Jan 30, 2002
<u>AA</u>	SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849</u>	<u>001</u>	Feb 09, 2007
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506</u>	<u>001</u>	Aug 02, 2001
<u>AA</u>	WOCKHARDT	<u>EQ 20MG BASE/5ML</u>	<u>A075514</u>	<u>001</u>	Aug 29, 2002

## PRESCRIPTION DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006 001</u>	Jan 30, 2002
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755 001</u>	Aug 02, 2001
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872 001</u>	Jan 29, 2002
<u>SARAFEM</u>				
<u>AB1</u>	WARNER CHILCOTT LLC	<u>EQ 10MG BASE</u>	<u>N021860 001</u>	May 19, 2006
<u>AB1</u>		<u>EQ 15MG BASE</u>	<u>N021860 002</u>	May 19, 2006
<u>AB1</u>	+	<u>EQ 20MG BASE</u>	<u>N021860 003</u>	May 19, 2006
<u>SELFEMRA</u>				
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A200151 001</u>	Feb 03, 2014
<u>AB1</u>		<u>EQ 15MG BASE</u>	<u>A200151 002</u>	Feb 03, 2014
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A200151 003</u>	Feb 03, 2014
FLUOXETINE HYDROCHLORIDE				
	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133 001	Oct 06, 2011
	+	EQ 20MG BASE	A075755 002	Aug 02, 2001

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742 001</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742 002</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742 003</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742 004</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742 005</u>	Nov 02, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901 005</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901 001</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901 003</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901 002</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901 004</u>	Nov 16, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A202074 001</u>	Mar 25, 2013
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528 001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528 002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528 003</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077528 004</u>	Jun 19, 2012
<u>SYMBYAX</u>				
<u>AB</u>	LILLY	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>N021520 001</u>	Apr 09, 2007
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>N021520 002</u>	Dec 24, 2003
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>N021520 004</u>	Dec 24, 2003
<u>AB</u>	+	<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>N021520 003</u>	Dec 24, 2003
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>N021520 005</u>	Dec 24, 2003

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

+ USL PHARMA

10MG

A088342 001 Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

<u>AO</u>	EUROHLTH INTL SARL	<u>25MG/ML</u>	<u>A074531 001</u>	Aug 30, 1996
<u>AO</u>	+	<u>25MG/ML</u>	<u>A071413 001</u>	Jul 14, 1987
<u>AO</u>	PAR STERILE PRODUCTS	<u>25MG/ML</u>	<u>A203732 001</u>	Jul 03, 2014

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC

5MG/ML

A074725 001 Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC

2.5MG/5ML

A040146 001 Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

+ FRESENIUS KABI USA

2.5MG/ML

A089556 001 Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>1MG</u>	<u>A089740 001</u>	Aug 25, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089741 001</u>	Aug 25, 1988
<u>AB</u>		<u>5MG</u>	<u>A089742 001</u>	Aug 25, 1988
<u>AB</u>		<u>10MG</u>	<u>A089743 001</u>	Aug 25, 1988
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A089804 002</u>	Aug 12, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089804 003</u>	Aug 12, 1988
<u>AB</u>		<u>5MG</u>	<u>A089804 004</u>	Aug 12, 1988

## PRESCRIPTION DRUG PRODUCT LIST

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<b>AB</b>	+		<b>10MG</b>	<b>A089804 001</b>	Aug 12, 1988
<b>AB</b>		SANDOZ	<b>1MG</b>	<b>A089583 001</b>	Oct 16, 1987
<b>AB</b>			<b>2.5MG</b>	<b>A089584 001</b>	Oct 16, 1987
<b>AB</b>			<b>5MG</b>	<b>A089585 001</b>	Oct 16, 1987
<b>AB</b>			<b>10MG</b>	<b>A089586 001</b>	Oct 16, 1987

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+ AQUA PHARMS

0.025%

N012806 003

+

0.05%

N012806 002

LOTION; TOPICAL

CORDRAN

+ AQUA PHARMS

0.05%

N013790 001

OINTMENT; TOPICAL

CORDRAN

+ AQUA PHARMS

0.05%

N012806 001

TAPE; TOPICAL

CORDRAN

+ ACTAVIS LABS UT INC

0.004MG/SQ CM

N016455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

MYLAN PHARMS INC

15MG

A070345 002 Nov 27, 1985

+

30MG

A070345 001 Nov 27, 1985

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

<b>AB</b>		MYLAN	<b>50MG</b>	<b>A074358 001</b>	Jun 20, 1994
<b>AB</b>	+		<b>100MG</b>	<b>A074358 002</b>	Jun 20, 1994
<b>AB</b>		SUN PHARM INDS INC	<b>50MG</b>	<b>A075058 001</b>	Apr 27, 2001
<b>AB</b>			<b>100MG</b>	<b>A075058 002</b>	Apr 27, 2001
<b>AB</b>		TEVA	<b>100MG</b>	<b>A074431 001</b>	May 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

<b>AT</b>		BAUSCH AND LOMB	<b>0.03%</b>	<b>A074447 001</b>	Jan 04, 1995
				<b>N019404 001</b>	Dec 31, 1986

OCUFEN

<b>AT</b>	+	ALLERGAN	<b>0.03%</b>	<b>N019404 001</b>	Dec 31, 1986
-----------	---	----------	--------------	--------------------	--------------

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

<b>AB</b>		ACTAVIS LABS FL INC	<b>125MG</b>	<b>A075820 001</b>	Sep 18, 2001
<b>AB</b>	+	IVAX SUB TEVA PHARMS	<b>125MG</b>	<b>A075780 001</b>	Sep 19, 2001
<b>AB</b>		MYLAN	<b>125MG</b>	<b>A076224 001</b>	May 09, 2003
<b>AB</b>		PAR PHARM	<b>125MG</b>	<b>A075298 001</b>	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+ GE HEALTHCARE

40.5mCi/10ML (4.05mCi/ML)

N203137 001 Oct 25, 2013

+

121.5mCi/30ML (4.05mCi/ML)

N203137 002 Oct 25, 2013

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

GLAXOSMITHKLINE

0.1MG/INH

N205625 001 Aug 20, 2014

+

0.2MG/INH

N205625 002 Aug 20, 2014

SPRAY, METERED; NASAL

VERAMYST

+ GLAXOSMITHKLINE

0.0275MG/INH

N022051 001 Apr 27, 2007

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

+ GLAXO GRP LTD

0.1MG/INH;EQ 0.025MG BASE/INH

N204275 001 May 10, 2013

0.2MG/INH;EQ 0.025MG BASE/INH

N204275 002 Apr 30, 2015

## PRESCRIPTION DRUG PRODUCT LIST

FLUTICASONE PROPIONATE

## AEROSOL, METERED; INHALATION

## FLOVENT HFA

+	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
+		0.11MG/INH	N021433	002	May 14, 2004
+		0.22MG/INH	N021433	001	May 14, 2004

## CREAM; TOPICAL

FLUTICASONE PROPIONATE

<b>AB</b>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076451</u>	<u>001</u>	May 14, 2004
<b>AB</b>	G AND W LABS	<u>0.05%</u>	<u>A077055</u>	<u>001</u>	Jun 30, 2006
<b>AB</b>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>A076793</u>	<u>001</u>	May 14, 2004
<b>AB</b>	TOLMAR	<u>0.05%</u>	<u>A076633</u>	<u>001</u>	May 14, 2004

## LOTION; TOPICAL

CUTIVATE

<b>AB</b>	+ FOUGERA PHARMS	<u>0.05%</u>	<u>N021152</u>	<u>001</u>	Mar 31, 2005
-----------	------------------	--------------	----------------	------------	--------------

FLUTICASONE PROPIONATE

<b>AB</b>	GLENMARK GENERICS	<u>0.05%</u>	<u>A090759</u>	<u>001</u>	May 02, 2011
<b>AB</b>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A091553</u>	<u>001</u>	Jul 30, 2013

## OINTMENT; TOPICAL

CUTIVATE

<b>AB</b>	+ FOUGERA PHARMS	<u>0.005%</u>	<u>N019957</u>	<u>001</u>	Dec 14, 1990
-----------	------------------	---------------	----------------	------------	--------------

FLUTICASONE PROPIONATE

<b>AB</b>	FOUGERA PHARMS	<u>0.005%</u>	<u>A076300</u>	<u>001</u>	May 14, 2004
<b>AB</b>	G AND W LABS	<u>0.005%</u>	<u>A077168</u>	<u>001</u>	Mar 03, 2006
<b>AB</b>	PERRIGO NEW YORK	<u>0.005%</u>	<u>A076668</u>	<u>001</u>	May 14, 2004

## POWDER; INHALATION

## FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000
---	---------------	-----------	---------	-----	--------------

## FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000
---	---------------	------------	---------	-----	--------------

## FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000
---	---------------	------------	---------	-----	--------------

## SPRAY, METERED; NASAL

FLONASE

<b>AB</b>	+ GLAXOSMITHKLINE	<u>0.05MG/SPRAY</u>	<u>N020121</u>	<u>001</u>	Oct 19, 1994
-----------	-------------------	---------------------	----------------	------------	--------------

FLUTICASONE PROPIONATE

<b>AB</b>	APOTEX INC	<u>0.05MG/SPRAY</u>	<u>A077538</u>	<u>001</u>	Sep 12, 2007
<b>AB</b>	HI TECH PHARMA	<u>0.05MG/SPRAY</u>	<u>A077570</u>	<u>001</u>	Jan 16, 2008
<b>AB</b>	ROXANE	<u>0.05MG/SPRAY</u>	<u>A076504</u>	<u>001</u>	Feb 22, 2006
<b>AB</b>	WOCKHARDT	<u>0.05MG/SPRAY</u>	<u>A078492</u>	<u>001</u>	Jan 09, 2012

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

## AEROSOL, METERED; INHALATION

## ADVAIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

## POWDER; INHALATION

## ADVAIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000
---	---------------	------------------------------	---------	-----	--------------

## ADVAIR DISKUS 250/50

+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000
---	---------------	-------------------------------	---------	-----	--------------

## ADVAIR DISKUS 500/50

+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000
---	---------------	------------------------------	---------	-----	--------------

FLUVASTATIN SODIUM

## CAPSULE; ORAL

FLUVASTATIN SODIUM

<b>AB</b>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090595</u>	<u>001</u>	Apr 11, 2012
<b>AB</b>		<u>EQ 40MG BASE</u>	<u>A090595</u>	<u>002</u>	Apr 11, 2012
<b>AB</b>	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078407</u>	<u>001</u>	Jun 12, 2012
<b>AB</b>		<u>EQ 40MG BASE</u>	<u>A078407</u>	<u>002</u>	Jun 12, 2012

LESCOL

<b>AB</b>	NOVARTIS	<u>EQ 20MG BASE</u>	<u>N020261</u>	<u>001</u>	Dec 31, 1993
<b>AB</b>	+	<u>EQ 40MG BASE</u>	<u>N020261</u>	<u>002</u>	Dec 31, 1993

## TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

<b>AB</b>	MYLAN PHARMS INC	<u>80MG</u>	<u>A202458</u>	<u>001</u>	Sep 11, 2015
-----------	------------------	-------------	----------------	------------	--------------

LESCOL XL

<b>AB</b>	+ NOVARTIS	<u>80MG</u>	<u>N021192</u>	<u>001</u>	Oct 06, 2000
-----------	------------	-------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091482</u>	<u>001</u>	Apr 23, 2013
<u>AB</u>		<u>150MG</u>	<u>A091482</u>	<u>002</u>	Nov 18, 2013
<u>AB</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091476</u>	<u>001</u>	Mar 13, 2013
<u>AB</u>		<u>150MG</u>	<u>A091476</u>	<u>002</u>	Mar 13, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>100MG</u>	<u>A203240</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>150MG</u>	<u>A203240</u>	<u>002</u>	Oct 31, 2014

LUVOX CR

<u>AB</u>	JAZZ PHARMS	<u>100MG</u>	<u>N022033</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>	+	<u>150MG</u>	<u>N022033</u>	<u>002</u>	Feb 28, 2008

TABLET;ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	ANI PHARMS INC	<u>25MG</u>	<u>A075897</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>		<u>50MG</u>	<u>A075897</u>	<u>002</u>	Jan 25, 2001
<u>AB</u>		<u>100MG</u>	<u>A075897</u>	<u>003</u>	Jan 25, 2001
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001
<u>AB</u>		<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001
<u>AB</u>		<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075889</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075889</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>		<u>100MG</u>	<u>A075889</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	+	<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	TEVA	<u>25MG</u>	<u>A075893</u>	<u>001</u>	Sep 10, 2002
<u>AB</u>		<u>50MG</u>	<u>A075893</u>	<u>002</u>	Sep 10, 2002
<u>AB</u>		<u>100MG</u>	<u>A075893</u>	<u>003</u>	Sep 10, 2002

LUVOX

<u>AB</u>	ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
<u>AB</u>		<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

+ FRESENIUS KABI USA

5MG/ML

A089202 001 Feb 18, 1986

TABLET;ORAL

FOLIC ACID

<u>AA</u>	AIPING PHARM INC	<u>1MG</u>	<u>A091145</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>	+	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>	CADILA PHARMS LTD	<u>1MG</u>	<u>A202437</u>	<u>001</u>	Jan 27, 2014
<u>AA</u>	CONTRACT PHARMACAL	<u>1MG</u>	<u>A085061</u>	<u>001</u>	
<u>AA</u>	HIKMA PHARMS LLC	<u>1MG</u>	<u>A080600</u>	<u>001</u>	
<u>AA</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>	LEADING PHARMA LLC	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>	NUVO PHARM INC	<u>1MG</u>	<u>A204418</u>	<u>001</u>	Jul 28, 2015
<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040756</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>	+	<u>1MG</u>	<u>A080680</u>	<u>001</u>	

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

FOLLISTIM AQ

+ ORGANON USA INC

75 IU/0.5ML

N021273 001 Aug 26, 2005

+ 150 IU/0.5ML

N021273 002 Aug 26, 2005

+ 300 IU/0.36ML

N021211 001 Mar 23, 2004

+ 600 IU/0.72ML

N021211 002 Mar 23, 2004

+ 900 IU/1.08ML

N021211 004 Feb 11, 2005

GONAL-F

+ EMD SERONO

450 IU/VIAL

N020378 005 Mar 26, 2004

1,050 IU/VIAL

N020378 004 Feb 28, 2001

GONAL-F RFF

+ EMD SERONO

75 IU/VIAL

N021765 002 Mar 25, 2004

GONAL-F RFF REDI-JECT

+ EMD SERONO

300 IU/0.5ML

N021684 001 May 25, 2004

+ 450 IU/0.75ML

N021684 002 May 25, 2004

+ 900 IU/1.5ML

N021684 003 May 25, 2004

## PRESCRIPTION DRUG PRODUCT LIST

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

<b>AP</b>	<b>+</b>	<b>PALADIN LABS</b>	<b><u>1.5GM/1.5ML (1GM/ML)</u></b>	<b><u>N020696 001</u></b>	<b>Dec 04, 1997</b>
-----------	----------	---------------------	------------------------------------	---------------------------	---------------------

FOMEPIZOLE

<b>AP</b>		<b>LUITPOLD</b>	<b><u>1.5GM/1.5ML (1GM/ML)</u></b>	<b><u>A078368 001</u></b>	<b>Dec 14, 2007</b>
-----------	--	-----------------	------------------------------------	---------------------------	---------------------

<b>AP</b>		<b>MYLAN INSTITUTIONAL</b>	<b><u>1.5GM/1.5ML (1GM/ML)</u></b>	<b><u>A078639 001</u></b>	<b>Mar 03, 2008</b>
-----------	--	----------------------------	------------------------------------	---------------------------	---------------------

<b>AP</b>		<b>NAVINTA LLC</b>	<b><u>1.5GM/1.5ML (1GM/ML)</u></b>	<b><u>A078537 001</u></b>	<b>Mar 06, 2008</b>
-----------	--	--------------------	------------------------------------	---------------------------	---------------------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIKTRA

<b>AP</b>	<b>+</b>	<b>MYLAN IRELAND LTD</b>	<b><u>2.5MG/0.5ML</u></b>	<b><u>N021345 001</u></b>	<b>Dec 07, 2001</b>
-----------	----------	--------------------------	---------------------------	---------------------------	---------------------

<b>AP</b>	<b>+</b>		<b><u>5MG/0.4ML</u></b>	<b><u>N021345 002</u></b>	<b>May 28, 2004</b>
-----------	----------	--	-------------------------	---------------------------	---------------------

<b>AP</b>	<b>+</b>		<b><u>7.5MG/0.6ML</u></b>	<b><u>N021345 003</u></b>	<b>May 28, 2004</b>
-----------	----------	--	---------------------------	---------------------------	---------------------

<b>AP</b>	<b>+</b>		<b><u>10MG/0.8ML</u></b>	<b><u>N021345 004</u></b>	<b>May 28, 2004</b>
-----------	----------	--	--------------------------	---------------------------	---------------------

FONDAPARINUX SODIUM

<b>AP</b>		<b>DR REDDYS LABS LTD</b>	<b><u>2.5MG/0.5ML</u></b>	<b><u>A091316 001</u></b>	<b>Jul 11, 2011</b>
-----------	--	---------------------------	---------------------------	---------------------------	---------------------

<b>AP</b>			<b><u>5MG/0.4ML</u></b>	<b><u>A091316 002</u></b>	<b>Jul 11, 2011</b>
-----------	--	--	-------------------------	---------------------------	---------------------

<b>AP</b>			<b><u>7.5MG/0.6ML</u></b>	<b><u>A091316 003</u></b>	<b>Jul 11, 2011</b>
-----------	--	--	---------------------------	---------------------------	---------------------

<b>AP</b>			<b><u>10MG/0.8ML</u></b>	<b><u>A091316 004</u></b>	<b>Jul 11, 2011</b>
-----------	--	--	--------------------------	---------------------------	---------------------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

<b>+</b>	<b>NOVARTIS</b>	<b>0.012MG/INH</b>	<b>N020831 001</b>	<b>Feb 16, 2001</b>
----------	-----------------	--------------------	--------------------	---------------------

SOLUTION; INHALATION

PERFORMIST

<b>+</b>	<b>MYLAN SPECLT</b>	<b>0.02MG/2ML</b>	<b>N022007 001</b>	<b>May 11, 2007</b>
----------	---------------------	-------------------	--------------------	---------------------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

<b>+</b>	<b>MERCK SHARP DOHME</b>	<b>0.005MG/INH;0.1MG/INH</b>	<b>N022518 001</b>	<b>Jun 22, 2010</b>
----------	--------------------------	------------------------------	--------------------	---------------------

<b>+</b>		<b>0.005MG/INH;0.2MG/INH</b>	<b>N022518 002</b>	<b>Jun 22, 2010</b>
----------	--	------------------------------	--------------------	---------------------

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

<b>+</b>	<b>VIIIV HLTHCARE</b>	<b>EQ 50MG BASE/ML</b>	<b>N022116 001</b>	<b>Jun 14, 2007</b>
----------	-----------------------	------------------------	--------------------	---------------------

TABLET; ORAL

LEXIVA

<b>+</b>	<b>VIIIV HLTHCARE</b>	<b>EQ 700MG BASE</b>	<b>N021548 001</b>	<b>Oct 20, 2003</b>
----------	-----------------------	----------------------	--------------------	---------------------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

<b>+</b>	<b>MERCK AND CO INC</b>	<b>EQ 150MG BASE/VIAL</b>	<b>N022023 002</b>	<b>Nov 12, 2010</b>
----------	-------------------------	---------------------------	--------------------	---------------------

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

<b>AP</b>		<b>HOSPIRA</b>	<b><u>2.4GM/100ML</u></b>	<b><u>A077174 001</u></b>	<b>May 31, 2005</b>
-----------	--	----------------	---------------------------	---------------------------	---------------------

FOSCAVIR

<b>AP</b>	<b>+</b>	<b>CLINIGEN HLTHCARE</b>	<b><u>2.4GM/100ML</u></b>	<b><u>N020068 001</u></b>	<b>Sep 27, 1991</b>
-----------	----------	--------------------------	---------------------------	---------------------------	---------------------

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

<b>+</b>	<b>ZAMBON SPA</b>	<b>EQ 3GM BASE/PACKET</b>	<b>N050717 001</b>	<b>Dec 19, 1996</b>
----------	-------------------	---------------------------	--------------------	---------------------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<b>AB</b>		<b>ACTAVIS LABS FL INC</b>	<b><u>10MG</u></b>	<b><u>A076620 001</u></b>	<b>Oct 15, 2004</b>
-----------	--	----------------------------	--------------------	---------------------------	---------------------

<b>AB</b>			<b><u>20MG</u></b>	<b><u>A076620 002</u></b>	<b>Oct 15, 2004</b>
-----------	--	--	--------------------	---------------------------	---------------------

<b>AB</b>			<b><u>40MG</u></b>	<b><u>A076620 003</u></b>	<b>Oct 15, 2004</b>
-----------	--	--	--------------------	---------------------------	---------------------

<b>AB</b>		<b>APOTEX INC</b>	<b><u>10MG</u></b>	<b><u>A076906 001</u></b>	<b>May 17, 2005</b>
-----------	--	-------------------	--------------------	---------------------------	---------------------

<b>AB</b>			<b><u>20MG</u></b>	<b><u>A076906 002</u></b>	<b>May 17, 2005</b>
-----------	--	--	--------------------	---------------------------	---------------------

<b>AB</b>			<b><u>40MG</u></b>	<b><u>A076906 003</u></b>	<b>May 17, 2005</b>
-----------	--	--	--------------------	---------------------------	---------------------

<b>AB</b>		<b>AUROBINDO PHARMA LTD</b>	<b><u>10MG</u></b>	<b><u>A091163 001</u></b>	<b>Mar 30, 2011</b>
-----------	--	-----------------------------	--------------------	---------------------------	---------------------

<b>AB</b>			<b><u>20MG</u></b>	<b><u>A091163 002</u></b>	<b>Mar 30, 2011</b>
-----------	--	--	--------------------	---------------------------	---------------------

<b>AB</b>			<b><u>40MG</u></b>	<b><u>A091163 003</u></b>	<b>Mar 30, 2011</b>
-----------	--	--	--------------------	---------------------------	---------------------

<b>AB</b>		<b>INVAGEN PHARMS</b>	<b><u>10MG</u></b>	<b><u>A077222 001</u></b>	<b>Apr 20, 2005</b>
-----------	--	-----------------------	--------------------	---------------------------	---------------------

<b>AB</b>			<b><u>20MG</u></b>	<b><u>A077222 002</u></b>	<b>Apr 20, 2005</b>
-----------	--	--	--------------------	---------------------------	---------------------

<b>AB</b>			<b><u>40MG</u></b>	<b><u>A077222 003</u></b>	<b>Apr 20, 2005</b>
-----------	--	--	--------------------	---------------------------	---------------------

## PRESCRIPTION DRUG PRODUCT LIST

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076483 001</u>	Apr 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A076483 002</u>	Apr 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A076483 003</u>	Apr 23, 2004
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076139 001</u>	Nov 25, 2003
<u>AB</u>		<u>20MG</u>	<u>A076139 002</u>	Nov 25, 2003
<u>AB</u>	+	<u>40MG</u>	<u>A076139 003</u>	Nov 25, 2003

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>10MG;12.5MG</u>	<u>A076608 001</u>	Dec 03, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076608 002</u>	Dec 03, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245 001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079245 002</u>	Jul 09, 2009
<u>AB</u>	EMCURE PHARMS INDIA	<u>10MG;12.5MG</u>	<u>A079025 001</u>	Sep 17, 2010
<u>AB</u>	+	<u>20MG;12.5MG</u>	<u>A079025 002</u>	Sep 17, 2010
<u>AB</u>	INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228 001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A090228 002</u>	Jul 09, 2009
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961 001</u>	Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961 002</u>	Sep 28, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>10MG;12.5MG</u>	<u>A076739 001</u>	Dec 17, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076739 002</u>	Dec 17, 2004

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

<u>AP</u>	PARKE DAVIS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>N020450 001</u>	Aug 05, 1996
-----------	-------------	--------------------------------	--------------------	--------------

FOSPHENYTOIN SODIUM

<u>AP</u>	AMNEAL PHARMS CO	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078476 001</u>	Mar 18, 2008
<u>AP</u>	BEDFORD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481 001</u>	Aug 06, 2007
<u>AP</u>	+	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052 001</u>	Aug 06, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765 001</u>	Dec 02, 2009
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989 001</u>	Aug 06, 2007
<u>AP</u>	HIKMA MAPLE	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989 001</u>	Aug 06, 2007
<u>AP</u>	HOSPIRA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078158 001</u>	Aug 06, 2007
<u>AP</u>	LUITPOLD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277 001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A090099 001</u>	May 13, 2010
<u>AP</u>	MYLAN LABS LTD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736 001</u>	Jun 08, 2010
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417 001</u>	Mar 18, 2008
<u>AP</u>	WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137 001</u>	Aug 06, 2007

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

<u>AB</u>	+	ENDO PHARMS	<u>EQ 2.5MG BASE</u>	<u>N021006 001</u>	Nov 08, 2001
-----------	---	-------------	----------------------	--------------------	--------------

FROVATRIPTAN SUCCINATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A202931 001</u>	Aug 28, 2014
-----------	------------------	----------------------	--------------------	--------------

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

## FASLODEX

+	ASTRAZENECA	50MG/ML	N021344 001	Apr 25, 2002
---	-------------	---------	-------------	--------------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	CLARIS LIFESCIENCES	<u>10MG/ML</u>	<u>A202747 001</u>	Jan 27, 2014	
<u>AP</u>	EMCURE PHARMS LTD	<u>10MG/ML</u>	<u>A203428 001</u>	Aug 26, 2014	
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902 001</u>	May 22, 1984	
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A075241 001</u>	May 28, 1999	
<u>AP</u>		<u>10MG/ML</u>	<u>N018667 001</u>	May 28, 1982	
<u>AP</u>	+	LUITPOLD	<u>10MG/ML</u>	<u>N018579 001</u>	Nov 30, 1983
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941 001</u>	Mar 22, 2007	

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	+	ROXANE	<u>10MG/ML</u>	<u>A070434 001</u>	Apr 22, 1987
<u>AA</u>		WOCKHARDT	<u>10MG/ML</u>	<u>A070655 001</u>	Oct 02, 1987
		ROXANE	40MG/5ML	A070433 001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	IPCA LABS LTD	<u>20MG</u>	<u>A078010 001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010 002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010 003</u>	Sep 18, 2006



## PRESCRIPTION DRUG PRODUCT LIST

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>N018413</u>	<u>001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413</u>	<u>002</u>	Nov 30, 1983
<u>AB</u>	LEADING PHARMA LLC	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>	MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>	ROXANE	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>		<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984
<u>AB</u>	SUN PHARM INDS INC	<u>20MG</u>	<u>A091258</u>	<u>001</u>	Apr 01, 2014
<u>AB</u>		<u>40MG</u>	<u>A091258</u>	<u>002</u>	Apr 01, 2014
<u>AB</u>		<u>80MG</u>	<u>A091258</u>	<u>003</u>	Apr 01, 2014
<u>AB</u>	VINTAGE PHARMS	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>		<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004

LASIX

<u>AB</u>	SANOVI AVENTIS US	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>	ALKEM	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	AUROBINDO PHARM	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	HIKMA	<u>100MG</u>	<u>A078150</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078150</u>	<u>002</u>	Sep 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078150</u>	<u>003</u>	Sep 25, 2007
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>	MARKSANS PHARMA	<u>100MG</u>	<u>A090007</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>		<u>300MG</u>	<u>A090007</u>	<u>002</u>	Jul 21, 2011
<u>AB</u>		<u>400MG</u>	<u>A090007</u>	<u>003</u>	Jul 21, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A090158</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>300MG</u>	<u>A090158</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>400MG</u>	<u>A090158</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A076606</u>	<u>001</u>	Oct 07, 2005
<u>AB</u>		<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A076606</u>	<u>002</u>	Oct 07, 2005
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A076606</u>	<u>003</u>	Oct 07, 2005
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TARO	<u>100MG</u>	<u>A077261</u>	<u>001</u>	Aug 02, 2013
<u>AB</u>		<u>300MG</u>	<u>A077261</u>	<u>002</u>	Aug 02, 2013
<u>AB</u>		<u>400MG</u>	<u>A077261</u>	<u>003</u>	Aug 02, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435</u>	<u>001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435</u>	<u>002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435</u>	<u>003</u>	Oct 08, 2004

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>		<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993

## PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN

CAPSULE; ORAL

NEURONTIN

**AB** + **400MG** **N020235 003** Dec 30, 1993  
SOLUTION; ORAL

GABAPENTIN

**AA** ACELLA PHARMS LLC **250MG/5ML** **A076403 001** May 01, 2012  
**AA** AMNEAL PHARMS **250MG/5ML** **A202024 001** Mar 23, 2012  
**AA** HI TECH PHARMA **250MG/5ML** **A078974 001** Feb 18, 2011  
**AA** TARO **250MG/5ML** **A076672 001** Jul 03, 2013

NEURONTIN

**AA** + PARKE DAVIS **250MG/5ML** **N021129 001** Mar 02, 2000  
TABLET; ORAL

GABAPENTIN

**AB** ACI HEALTHCARE LTD **600MG** **A203244 002** Jul 12, 2013  
**AB** **800MG** **A203244 001** Jul 12, 2013  
**AB** ACTAVIS ELIZABETH **600MG** **A075694 001** Oct 21, 2004  
**AB** **800MG** **A075694 002** Oct 21, 2004  
**AB** ALKEM LABS LTD **600MG** **A206402 001** Dec 23, 2015  
**AB** **800MG** **A206402 002** Dec 23, 2015  
**AB** APOTEX INC **100MG** **A077894 001** Oct 10, 2006  
**AB** **300MG** **A077894 002** Oct 10, 2006  
**AB** **400MG** **A077894 003** Oct 10, 2006  
**AB** **600MG** **A077661 004** Sep 13, 2006  
**AB** **800MG** **A077661 005** Sep 13, 2006  
**AB** AUROBINDO PHARMA LTD **600MG** **A200651 001** Oct 06, 2011  
**AB** **800MG** **A200651 002** Oct 06, 2011  
**AB** GLENMARK GENERICS **600MG** **A077662 001** Aug 18, 2006  
**AB** **800MG** **A077662 002** Aug 18, 2006  
**AB** INVAGEN PHARMS **600MG** **A202764 001** Oct 16, 2012  
**AB** **800MG** **A202764 002** Oct 16, 2012  
**AB** IVAX SUB TEVA PHARMS **100MG** **A076017 001** Apr 28, 2004  
**AB** **300MG** **A076017 002** Apr 28, 2004  
**AB** **400MG** **A076017 003** Apr 28, 2004  
**AB** **600MG** **A076017 004** Apr 29, 2005  
**AB** **800MG** **A076017 005** Apr 29, 2005  
**AB** MYLAN PHARMS INC **600MG** **A090335 001** Jun 01, 2010  
**AB** **800MG** **A090335 002** Jun 01, 2010  
**AB** SUN PHARM INDS LTD **600MG** **A077525 001** Aug 24, 2006  
**AB** **800MG** **A077525 002** Aug 24, 2006  
**AB** ZYDUS PHARMS USA INC **600MG** **A078926 001** Feb 11, 2011  
**AB** **800MG** **A078926 002** Feb 11, 2011

NEURONTIN

**AB** PFIZER PHARMS **600MG** **N020882 001** Oct 09, 1998  
**AB** + **800MG** **N020882 002** Oct 09, 1998  
GRALISE  
BX + DEPOMED INC 300MG N022544 001 Jan 28, 2011  
BX + 600MG N022544 002 Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

XENOPORT INC 300MG N022399 002 Dec 13, 2011  
+ 600MG N022399 001 Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+ BRACCO 2.645GM/5ML (529MG/ML) N021357 001 Nov 23, 2004  
+ 5.29GM/10ML (529MG/ML) N021357 002 Nov 23, 2004  
+ 7.935GM/15ML (529MG/ML) N021357 003 Nov 23, 2004  
+ 10.58GM/20ML (529MG/ML) N021357 004 Nov 23, 2004

MULTIHANCE MULTIPACK

+ BRACCO 26.45GM/50ML (529MG/ML) N021358 001 Nov 23, 2004  
+ 52.9GM/100ML (529MG/ML) N021358 002 Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+ BAYER HLTHCARE 1.20944GM/2ML (604.72MG/ML) N201277 006 Dec 18, 2013  
+ 4.5354GM/7.5ML (604.72MG/ML) N201277 001 Mar 14, 2011  
+ 6.0472GM/10ML (604.72MG/ML) N201277 002 Mar 14, 2011  
+ 9.0708GM/15ML (604.72MG/ML) N201277 003 Mar 14, 2011  
+ 18.1416GM/30ML (604.72MG/ML) N201277 004 Mar 14, 2011

## PRESCRIPTION DRUG PRODUCT LIST

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+

39.3068GM/65ML (604.72MG/ML)

N201277 005 Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+ GE HEALTHCARE

287MG/ML

N020123 001 Jan 08, 1993

+

28.7GM/100ML (287MG/ML)

N022066 002 Sep 05, 2007

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS

ABLAVAR

LANTHEUS MEDCL

2440MG/10ML (244MG/ML)

N021711 001 Dec 22, 2008

+

3660MG/15ML (244MG/ML)

N021711 002 Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

MAGNEVIST

+ BAYER HLTHCARE

469.01MG/ML

N019596 001 Jun 02, 1988

+

469.01MG/ML

N021037 001 Mar 10, 2000

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+ GUERBET

37.69GM/100ML (376.9MG/ML)

N204781 001 Mar 20, 2013

+

3.769GM/10ML (376.9MG/ML)

N204781 002 Mar 20, 2013

+

5.6535GM/15ML (376.9MG/ML)

N204781 003 Mar 20, 2013

+

7.538GM/20ML (376.9MG/ML)

N204781 004 Mar 20, 2013

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+ BRACCO

279.3MG/ML

N020131 001 Nov 16, 1992

PROHANCE MULTIPACK

+ BRACCO

279.3MG/ML

N021489 001 Oct 09, 2003

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+ LIEBEL-FLARSHEIM

1654.5MG/5ML (330.9MG/ML)

N020937 001 Dec 08, 1999

+

3309MG/10ML (330.9MG/ML)

N020937 002 Dec 08, 1999

+

4963.5MG/15ML (330.9MG/ML)

N020937 003 Dec 08, 1999

+

6618MG/20ML (330.9MG/ML)

N020937 004 Dec 08, 1999

+

16.545GM/50ML (330.9MG/ML)

N020975 001 Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+ LIEBEL-FLARSHEIM

3309MG/10ML (330.9MG/ML)

N020976 002 Dec 08, 1999

+

4963.5MG/15ML (330.9MG/ML)

N020976 003 Dec 08, 1999

+

6618MG/20ML (330.9MG/ML)

N020976 004 Dec 08, 1999

+

9927MG/30ML (330.9MG/ML)

N020976 001 Dec 08, 1999

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+ BAYER HLTHCARE

1.8143GM/10ML (181.43MG/ML)

N022090 001 Jul 03, 2008

2.72145GM/15ML (181.43MG/ML)

N022090 002 Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE**AB** BARR**EQ 8MG BASE****A078189 001** Sep 15, 2008**AB****EQ 16MG BASE****A078189 002** Sep 15, 2008**AB****EQ 24MG BASE****A078189 003** Sep 15, 2008**AB** IMPAX LABS**EQ 8MG BASE****A078484 001** May 27, 2009**AB****EQ 16MG BASE****A078484 002** May 27, 2009**AB****EQ 24MG BASE****A078484 003** May 27, 2009**AB** MYLAN**EQ 8MG BASE****A090900 001** Jan 24, 2011**AB****EQ 16MG BASE****A090900 002** Jan 24, 2011**AB****EQ 24MG BASE****A090900 003** Jan 24, 2011**AB** SUN PHARMA GLOBAL**EQ 8MG BASE****A090178 001** Feb 02, 2011**AB****EQ 16MG BASE****A090178 002** Feb 02, 2011**AB****EQ 24MG BASE****A090178 003** Feb 02, 2011**AB** WATSON LABS**EQ 8MG BASE****A079028 001** Dec 15, 2008**AB****EQ 16MG BASE****A079028 002** Dec 15, 2008**AB****EQ 24MG BASE****A079028 003** Dec 15, 2008

## PRESCRIPTION DRUG PRODUCT LIST

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

RAZADYNE ER

<u>AB</u>	+	JANSSEN PHARMS	<u>EQ 8MG BASE</u>	<u>N021615 001</u>	Apr 01, 2005
<u>AB</u>			<u>EQ 16MG BASE</u>	<u>N021615 002</u>	Apr 01, 2005
<u>AB</u>			<u>EQ 24MG BASE</u>	<u>N021615 003</u>	Apr 01, 2005

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

<u>AA</u>		ROXANE	<u>4MG/ML</u>	<u>A078185 001</u>	Jan 30, 2009
-----------	--	--------	---------------	--------------------	--------------

RAZADYNE

<u>AA</u>	+	JANSSEN PHARMS	<u>4MG/ML</u>	<u>N021224 001</u>	Jun 22, 2001
-----------	---	----------------	---------------	--------------------	--------------

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>		APOTEX INC	<u>EQ 4MG BASE</u>	<u>A077781 001</u>	Sep 27, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077781 002</u>	Sep 27, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077781 003</u>	Sep 27, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A090957 001</u>	Mar 29, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090957 002</u>	Mar 29, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A090957 003</u>	Mar 29, 2011
<u>AB</u>		BARR	<u>EQ 4MG BASE</u>	<u>A077605 001</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077605 002</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077605 003</u>	Aug 28, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593 001</u>	Sep 11, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077593 002</u>	Sep 11, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077593 003</u>	Sep 11, 2008
<u>AB</u>		MYLAN	<u>EQ 4MG BASE</u>	<u>A077590 001</u>	May 29, 2009
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A077603 001</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077590 002</u>	May 29, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077603 002</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077590 003</u>	May 29, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077603 003</u>	Aug 28, 2008
<u>AB</u>		ROXANE	<u>EQ 4MG BASE</u>	<u>A077608 001</u>	Feb 11, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077608 002</u>	Feb 11, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077608 003</u>	Feb 11, 2009
<u>AB</u>		SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589 001</u>	Jun 22, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077589 002</u>	Jun 22, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077589 003</u>	Jun 22, 2009
<u>AB</u>		TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587 001</u>	Jul 09, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077587 002</u>	Jul 09, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077587 003</u>	Jul 09, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 4MG BASE</u>	<u>A078898 001</u>	Feb 17, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A078898 002</u>	Feb 17, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A078898 003</u>	Feb 17, 2011

RAZADYNE

<u>AB</u>	+	JANSSEN PHARMS	<u>EQ 4MG BASE</u>	<u>N021169 001</u>	Feb 28, 2001
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>N021169 002</u>	Feb 28, 2001
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>N021169 003</u>	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS		LANTHEUS MEDCL	2mCi/ML	N017478 001	
BS		MALLINKRODT NUCLEAR	2mCi/ML	N018058 001	

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

+	BAUSCH AND LOMB	0.15%	N022211 001	Sep 15, 2009
---	-----------------	-------	-------------	--------------

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

CYTOVENE

<u>AP</u>	+	ROCHE PALO	<u>EQ 500MG BASE/VIAL</u>	<u>N019661 001</u>	Jun 23, 1989
-----------	---	------------	---------------------------	--------------------	--------------

GANCICLOVIR

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090658 001</u>	Jun 21, 2010
<u>AP</u>		LUITPOLD	<u>EQ 500MG BASE/VIAL</u>	<u>A202624 001</u>	Sep 18, 2013

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057 001	Jul 29, 1999
---	-----------------	----------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

<u>AT</u>	HI-TECH PHARMA CO	<u>0.5%</u>	<u>A203189</u>	<u>001</u>	Sep 03, 2014
<u>AT</u>	LUPIN LTD	<u>0.5%</u>	<u>A202653</u>	<u>001</u>	Aug 28, 2013
<u>ZYMAXID</u>					
<u>AT</u>	+ ALLERGAN	<u>0.5%</u>	<u>N022548</u>	<u>001</u>	May 18, 2010
	ZYMAR				
	+ ALLERGAN	0.3%	N021493	001	Mar 28, 2003

GEFITINIB

TABLET;ORAL

IRESSA

	+ ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015
--	----------------------	-------	---------	-----	--------------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 200MG BASE/VIAL</u>	<u>A091594</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091594</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091594</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 200MG BASE/VIAL</u>	<u>A079160</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A079160</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>	CIPLA LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A078759</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078759</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A091365</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091365</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202997</u>	<u>001</u>	May 07, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A202063</u>	<u>001</u>	Sep 11, 2012
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202063</u>	<u>002</u>	Sep 11, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 200MG BASE/VIAL</u>	<u>A090799</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090799</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090799</u>	<u>003</u>	May 16, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2GM BASE/VIAL</u>	<u>A090242</u>	<u>003</u>	May 16, 2011
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A204520</u>	<u>001</u>	Jan 05, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A204520</u>	<u>002</u>	Jan 05, 2016
<u>AP</u>	HAMELN RDS GMBH	<u>EQ 200MG BASE/VIAL</u>	<u>A090663</u>	<u>001</u>	Sep 10, 2012
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090663</u>	<u>002</u>	Sep 10, 2012
<u>AP</u>	HOSPIRA	<u>EQ 200MG BASE/VIAL</u>	<u>A078339</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078339</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>	+ HOSPIRA INC	<u>EQ 2GM BASE/VIAL</u>	<u>A079183</u>	<u>001</u>	Nov 15, 2010
<u>AP</u>	JIANGSU HANSON PHARM	<u>EQ 200MG BASE/VIAL</u>	<u>A202485</u>	<u>001</u>	May 07, 2013
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202485</u>	<u>002</u>	May 07, 2013
<u>AP</u>	LUITPOLD	<u>EQ 200MG BASE/VIAL</u>	<u>A202031</u>	<u>001</u>	May 07, 2013
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202031</u>	<u>002</u>	May 07, 2013
<u>AP</u>	MYLAN LABS LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A200145</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A200145</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200145</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A091597</u>	<u>001</u>	May 07, 2013
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091597</u>	<u>002</u>	May 07, 2013
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 200MG BASE/VIAL</u>	<u>A078433</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078433</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>	TEVA PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A077983</u>	<u>002</u>	Jan 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A077983</u>	<u>001</u>	Jan 25, 2011

GEMZAR

<u>AP</u>	+ LILLY	<u>EQ 200MG BASE/VIAL</u>	<u>N020509</u>	<u>001</u>	May 15, 1996
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>N020509</u>	<u>002</u>	May 15, 1996
<u>GEMCITABINE HYDROCHLORIDE</u>					
	+ HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011
		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011
		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034</u>	<u>001</u>	Jul 20, 1998
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A202726</u>	<u>001</u>	Sep 16, 2015
<u>AB</u>	BLU CARIBE	<u>600MG</u>	<u>A078012</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>	DAVA PHARMS INC	<u>600MG</u>	<u>A074270</u>	<u>001</u>	Sep 27, 1993
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078599</u>	<u>001</u>	Aug 16, 2010
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207</u>	<u>001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>	NORTHSTAR HLTHCARE	<u>600MG</u>	<u>A079072</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A079239</u>	<u>001</u>	Dec 29, 2008

## PRESCRIPTION DRUG PRODUCT LIST

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZILAB + TEVA 600MG A074256 001 Oct 31, 1993LOPIDAB + PFIZER PHARMS 600MG N018422 003 Nov 20, 1986GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVEAB + LG LIFE SCIENCES EQ 320MG BASE N021158 001 Apr 04, 2003GEMIFLOXACIN MESYLATEAB ORCHID HLTHCARE EQ 320MG BASE A090466 001 Jun 15, 2015GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATEAT + FOUGERA EQ 0.1% BASE A062531 001 Jul 05, 1984AT PERRIGO NEW YORK EQ 0.1% BASE A062307 001AT TARO EQ 0.1% BASE A062427 001 May 26, 1983

INJECTABLE; INJECTION

GENTAMICIN SULFATEAP FRESENIUS KABI USA EQ 10MG BASE/ML A062366 002 Feb 06, 1986AP + EQ 40MG BASE/ML A062366 001 Aug 04, 1983AP HOSPIRA EQ 10MG BASE/ML A062420 001 Aug 15, 1983AP EQ 10MG BASE/ML A062612 004 Feb 20, 1986AP EQ 40MG BASE/ML A062420 002 Aug 15, 1983GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP BAXTER HLTHCARE EQ 1.2MG BASE/ML A062373 007 Sep 07, 1982AP EQ 1.6MG BASE/ML A062373 008 Sep 07, 1982AP EQ 80MG BASE/100ML A062373 002 Sep 07, 1982AP EQ 100MG BASE/100ML A062373 005 Sep 07, 1982AP HOSPIRA EQ 1.2MG BASE/ML A062414 001 Aug 15, 1983AP EQ 1.6MG BASE/ML A062414 003 Aug 15, 1983AP EQ 80MG BASE/100ML A062414 008 Aug 15, 1983AP EQ 100MG BASE/100ML A062414 010 Aug 15, 1983AP + BAXTER HLTHCARE EQ 2MG BASE/ML A062373 009 Sep 07, 1982AP + EQ 120MG BASE/100ML A062373 006 Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATEAT + AKORN EQ 0.3% BASE A064093 001 Aug 31, 1995AT PERRIGO CO TENNESSEE EQ 0.3% BASE A065024 001 Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATEAT FOUGERA EQ 0.1% BASE A062533 001 Oct 05, 1984AT + PERRIGO NEW YORK EQ 0.1% BASE A062351 001 Feb 18, 1982AT TARO EQ 0.1% BASE A062477 001 Dec 23, 1983

SOLUTION/DROPS; OPHTHALMIC

GENOPTICAT ALLERGAN EQ 0.3% BASE A062452 001 Oct 10, 1984GENTAKAT AKORN EQ 0.3% BASE A064163 001 Oct 12, 2001GENTAMICIN SULFATEAT AKORN EQ 0.3% BASE A062635 001 Jan 08, 1987AT ALCON RES LTD EQ 0.3% BASE A062196 001AT + BAUSCH AND LOMB EQ 0.3% BASE A064048 001 May 11, 1994AT PERRIGO CO TENNESSEE EQ 0.3% BASE A065121 001 Jan 30, 2004GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

AP + ALLERGAN EQ 0.3% BASE; 0.6% N050612 001 Dec 01, 1989

SUSPENSION/DROPS; OPHTHALMIC

PRED-G

AP + ALLERGAN EQ 0.3% BASE; 1% N050586 001 Jun 10, 1988GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

COPAXONEAP + TEVA PHARMS USA 20MG/ML N020622 002 Feb 12, 2002GLATOPIAAP SANDOZ INC 20MG/ML A090218 001 Apr 16, 2015

COPAXONE

AP + TEVA PHARMS USA 40MG/ML N020622 003 Jan 28, 2014

## PRESCRIPTION DRUG PRODUCT LIST

GLIMEPIRIDE

TABLET; ORAL

AMARYL

<u>AB</u>	+ SANOFI AVENTIS US	<u>1MG</u>	<u>N020496</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>		<u>2MG</u>	<u>N020496</u>	<u>002</u>	Nov 30, 1995
<u>AB</u>		<u>4MG</u>	<u>N020496</u>	<u>003</u>	Nov 30, 1995

GLIMEPIRIDE

<u>AB</u>	ACCORD HLTHCARE	<u>1MG</u>	<u>A078181</u>	<u>001</u>	Aug 23, 2007
<u>AB</u>		<u>2MG</u>	<u>A078181</u>	<u>002</u>	Aug 23, 2007
<u>AB</u>		<u>4MG</u>	<u>A078181</u>	<u>003</u>	Aug 23, 2007
<u>AB</u>	ACTAVIS LABS FL INC	<u>1MG</u>	<u>A076995</u>	<u>001</u>	Apr 27, 2010
<u>AB</u>		<u>2MG</u>	<u>A076995</u>	<u>002</u>	Apr 27, 2010
<u>AB</u>		<u>4MG</u>	<u>A076995</u>	<u>003</u>	Apr 27, 2010
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1MG</u>	<u>A202759</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>		<u>2MG</u>	<u>A202759</u>	<u>002</u>	Jun 29, 2012
<u>AB</u>		<u>4MG</u>	<u>A202759</u>	<u>003</u>	Jun 29, 2012
<u>AB</u>	CARLSBAD	<u>1MG</u>	<u>A077911</u>	<u>001</u>	Sep 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A077911</u>	<u>002</u>	Sep 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A077911</u>	<u>003</u>	Sep 22, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A077091</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077091</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077091</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	INDOCO REMEDIES	<u>1MG</u>	<u>A202112</u>	<u>001</u>	Apr 17, 2013
<u>AB</u>		<u>2MG</u>	<u>A202112</u>	<u>002</u>	Apr 17, 2013
<u>AB</u>		<u>4MG</u>	<u>A202112</u>	<u>003</u>	Apr 17, 2013
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A077295</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A077295</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A077295</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	MICRO LABS LTD INDIA	<u>1MG</u>	<u>A091220</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>		<u>2MG</u>	<u>A091220</u>	<u>002</u>	Jun 29, 2012
<u>AB</u>		<u>4MG</u>	<u>A091220</u>	<u>004</u>	Jun 29, 2012
<u>AB</u>		<u>8MG</u>	<u>A091220</u>	<u>006</u>	Jun 29, 2012
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A077624</u>	<u>001</u>	Nov 28, 2005
<u>AB</u>		<u>2MG</u>	<u>A077624</u>	<u>002</u>	Nov 28, 2005
<u>AB</u>		<u>4MG</u>	<u>A077624</u>	<u>003</u>	Nov 28, 2005
<u>AB</u>	TEVA	<u>1MG</u>	<u>A076802</u>	<u>001</u>	Oct 06, 2005
<u>AB</u>		<u>2MG</u>	<u>A076802</u>	<u>002</u>	Oct 06, 2005
<u>AB</u>		<u>4MG</u>	<u>A076802</u>	<u>003</u>	Oct 06, 2005
<u>AB</u>	VINTAGE	<u>1MG</u>	<u>A077370</u>	<u>001</u>	Dec 23, 2005
<u>AB</u>		<u>2MG</u>	<u>A077370</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>		<u>4MG</u>	<u>A077370</u>	<u>003</u>	Dec 23, 2005
<u>AB</u>		<u>8MG</u>	<u>A077370</u>	<u>004</u>	Dec 23, 2005
	MICRO LABS LTD INDIA	3MG	A091220	003	Jun 29, 2012
		6MG	A091220	005	Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

<u>AB</u>	+ TAKEDA PHARMS USA	<u>2MG; 30MG</u>	<u>N021925</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>		<u>4MG; 30MG</u>	<u>N021925</u>	<u>002</u>	Jul 28, 2006

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

<u>AB</u>	SANDOZ	<u>2MG; 30MG</u>	<u>A201049</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>		<u>4MG; 30MG</u>	<u>A201049</u>	<u>002</u>	Jan 04, 2013

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A074550</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>10MG</u>	<u>A074550</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>	ANI PHARMS INC	<u>5MG</u>	<u>A074497</u>	<u>001</u>	Aug 31, 1995
<u>AB</u>		<u>10MG</u>	<u>A074497</u>	<u>002</u>	Aug 31, 1995
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A075795</u>	<u>001</u>	Jun 13, 2001
<u>AB</u>		<u>10MG</u>	<u>A075795</u>	<u>002</u>	Jun 13, 2001
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A074226</u>	<u>001</u>	May 10, 1994
<u>AB</u>		<u>5MG</u>	<u>A074438</u>	<u>001</u>	Jun 20, 1995
<u>AB</u>		<u>10MG</u>	<u>A074226</u>	<u>002</u>	May 10, 1994
<u>AB</u>		<u>10MG</u>	<u>A074438</u>	<u>002</u>	Jun 20, 1995
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A074305</u>	<u>001</u>	Apr 07, 1995
<u>AB</u>		<u>10MG</u>	<u>A074305</u>	<u>002</u>	Apr 07, 1995
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A077820</u>	<u>001</u>	Jul 11, 2006
<u>AB</u>		<u>10MG</u>	<u>A077820</u>	<u>002</u>	Jul 11, 2006
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074223</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>		<u>10MG</u>	<u>A074223</u>	<u>002</u>	Feb 27, 1995

## PRESCRIPTION DRUG PRODUCT LIST

GLIPIZIDE

TABLET; ORAL

GLUCOTROL

<b>AB</b>	PFIZER	<b>5MG</b>	<b>N017783 001</b>	May 08, 1984
<b>AB</b>	+	<b>10MG</b>	<b>N017783 002</b>	May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

<b>AB</b>	MYLAN PHARMS INC	<b>2.5MG</b>	<b>A202298 001</b>	May 19, 2015
<b>AB</b>		<b>5MG</b>	<b>A202298 002</b>	May 19, 2015
<b>AB</b>		<b>10MG</b>	<b>A202298 003</b>	May 19, 2015
<b>AB</b>	PAR PHARM	<b>5MG</b>	<b>A076159 002</b>	Sep 20, 2013
<b>AB</b>		<b>10MG</b>	<b>A076159 001</b>	Sep 20, 2013
<b>AB</b>	WATSON LABS	<b>2.5MG</b>	<b>A076467 003</b>	Mar 27, 2006
<b>AB</b>		<b>5MG</b>	<b>A076467 001</b>	Sep 08, 2003
<b>AB</b>		<b>10MG</b>	<b>A076467 002</b>	Nov 07, 2003

GLUCOTROL XL

<b>AB</b>	PFIZER	<b>2.5MG</b>	<b>N020329 003</b>	Aug 10, 1999
<b>AB</b>		<b>5MG</b>	<b>N020329 001</b>	Apr 26, 1994
<b>AB</b>	+	<b>10MG</b>	<b>N020329 002</b>	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

<b>AB</b>	COREPHARMA	<b>2.5MG; 250MG</b>	<b>A077507 001</b>	Oct 27, 2005
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A077507 002</b>	Oct 27, 2005
<b>AB</b>		<b>5MG; 500MG</b>	<b>A077507 003</b>	Oct 27, 2005
<b>AB</b>	HERITAGE PHARMS INC	<b>2.5MG; 250MG</b>	<b>A078728 001</b>	Jun 23, 2010
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A078728 002</b>	Jun 23, 2010
<b>AB</b>		<b>5MG; 500MG</b>	<b>A078728 003</b>	Jun 23, 2010
<b>AB</b>	MYLAN	<b>2.5MG; 250MG</b>	<b>A078083 001</b>	Apr 12, 2007
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A078083 002</b>	Apr 12, 2007
<b>AB</b>		<b>5MG; 500MG</b>	<b>A078083 003</b>	Apr 12, 2007
<b>AB</b>	SUN PHARM INDS INC	<b>2.5MG; 250MG</b>	<b>A077620 001</b>	Jan 11, 2008
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A077620 002</b>	Jan 11, 2008
<b>AB</b>		<b>5MG; 500MG</b>	<b>A077620 003</b>	Jan 11, 2008
<b>AB</b>	TEVA PHARMS	<b>2.5MG; 250MG</b>	<b>A077270 001</b>	Oct 28, 2005
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A077270 002</b>	Oct 28, 2005
<b>AB</b>	+	<b>5MG; 500MG</b>	<b>A077270 003</b>	Oct 28, 2005
<b>AB</b>	ZYDUS PHARMS USA INC	<b>2.5MG; 250MG</b>	<b>A078905 001</b>	Jan 31, 2011
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A078905 002</b>	Jan 31, 2011
<b>AB</b>		<b>5MG; 500MG</b>	<b>A078905 003</b>	Jan 31, 2011

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849 001	May 08, 2015
---	--------------------	------------------	-------------	--------------

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918 001	Jun 22, 1998
---	--------------	------------------	-------------	--------------

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+	LILLY	1MG/VIAL	N020928 001	Sep 11, 1998
---	-------	----------	-------------	--------------

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+	EMMAUS MEDCL	5GM/PACKET	N021667 001	Jun 10, 2004
---	--------------	------------	-------------	--------------

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

<b>AB</b>	DAVA PHARMS INC	<b>1.5MG</b>	<b>A074591 001</b>	Dec 22, 1997
<b>AB</b>		<b>3MG</b>	<b>A074591 002</b>	Dec 22, 1997
<b>AB</b>		<b>4.5MG</b>	<b>A074591 003</b>	Dec 22, 1997
<b>AB</b>		<b>6MG</b>	<b>A074591 004</b>	Dec 22, 1997
<b>AB</b>	HIKMA	<b>1.5MG</b>	<b>A075890 001</b>	Jul 31, 2003
<b>AB</b>		<b>3MG</b>	<b>A075890 002</b>	Jul 31, 2003
<b>AB</b>		<b>6MG</b>	<b>A075890 003</b>	Jul 31, 2003
<b>AB</b>	MYLAN	<b>1.5MG</b>	<b>A074792 001</b>	Jun 26, 1998
<b>AB</b>		<b>3MG</b>	<b>A074792 002</b>	Jun 26, 1998
<b>AB</b>		<b>6MG</b>	<b>A074792 003</b>	Aug 17, 1999



## PRESCRIPTION DRUG PRODUCT LIST

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

<b>AB</b>	TEVA	<b>1.5MG</b>	<b>A074686 001</b>	Apr 20, 1999
<b>AB</b>		<b>3MG</b>	<b>A074686 002</b>	Apr 20, 1999
<b>AB</b>		<b>4.5MG</b>	<b>A074686 003</b>	Apr 20, 1999
<b>AB</b>		<b>6MG</b>	<b>A074686 004</b>	Apr 20, 1999

GLYNASE

<b>AB</b>	PHARMACIA AND UPJOHN	<b>1.5MG</b>	<b>N020051 001</b>	Mar 04, 1992
<b>AB</b>		<b>3MG</b>	<b>N020051 002</b>	Mar 04, 1992
<b>AB</b>	+	<b>6MG</b>	<b>N020051 004</b>	Sep 24, 1993

GLYBURIDE

<b>AB1</b>	AUROBINDO PHARMA	<b>1.25MG</b>	<b>A077537 001</b>	Oct 18, 2007
<b>AB1</b>		<b>2.5MG</b>	<b>A077537 002</b>	Oct 18, 2007
<b>AB1</b>		<b>5MG</b>	<b>A077537 003</b>	Oct 18, 2007
<b>AB1</b>	COREPHARMA	<b>1.25MG</b>	<b>A076257 001</b>	Jun 27, 2002
<b>AB1</b>		<b>2.5MG</b>	<b>A076257 002</b>	Jun 27, 2002
<b>AB1</b>		<b>5MG</b>	<b>A076257 003</b>	Jun 27, 2002
<b>AB1</b>	HERITAGE PHARMS INC	<b>1.25MG</b>	<b>A090937 001</b>	Feb 28, 2011
<b>AB1</b>		<b>2.5MG</b>	<b>A090937 002</b>	Feb 28, 2011
<b>AB1</b>		<b>5MG</b>	<b>A090937 003</b>	Feb 28, 2011
<b>AB1</b>	TEVA	<b>1.25MG</b>	<b>A074388 001</b>	Aug 29, 1995
<b>AB1</b>		<b>2.5MG</b>	<b>A074388 002</b>	Aug 29, 1995
<b>AB1</b>	+	<b>5MG</b>	<b>A074388 003</b>	Aug 29, 1995

DIABETA

<b>AB2</b>	SANOFI AVENTIS US	<b>1.25MG</b>	<b>N017532 001</b>	May 01, 1984
<b>AB2</b>		<b>2.5MG</b>	<b>N017532 002</b>	May 01, 1984
<b>AB2</b>	+	<b>5MG</b>	<b>N017532 003</b>	May 01, 1984

GLYBURIDE

<b>AB2</b>	COREPHARMA	<b>1.25MG</b>	<b>A206079 001</b>	Sep 30, 2015
<b>AB2</b>		<b>2.5MG</b>	<b>A206079 002</b>	Sep 30, 2015
<b>AB2</b>		<b>5MG</b>	<b>A206079 003</b>	Sep 30, 2015

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

<b>AB</b>	+	BRISTOL MYERS SQUIBB	<b>2.5MG; 500MG</b>	<b>N021178 002</b>	Jul 31, 2000
<b>AB</b>			<b>5MG; 500MG</b>	<b>N021178 003</b>	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

<b>AB</b>	ACTAVIS ELIZABETH	<b>1.25MG; 250MG</b>	<b>A076716 001</b>	Jun 28, 2005
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A076716 002</b>	Jun 28, 2005
<b>AB</b>		<b>5MG; 500MG</b>	<b>A076716 003</b>	Jun 28, 2005
<b>AB</b>	AUROBINDO PHARMA	<b>1.25MG; 250MG</b>	<b>A077870 001</b>	Nov 14, 2007
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A077870 002</b>	Nov 14, 2007
<b>AB</b>		<b>5MG; 500MG</b>	<b>A077870 003</b>	Nov 14, 2007
<b>AB</b>	COREPHARMA	<b>1.25MG; 250MG</b>	<b>A076731 001</b>	Nov 19, 2004
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A076731 002</b>	Nov 19, 2004
<b>AB</b>		<b>5MG; 500MG</b>	<b>A076731 003</b>	Nov 19, 2004
<b>AB</b>	HERITAGE PHARMS INC	<b>1.25MG; 250MG</b>	<b>A079009 001</b>	Jun 03, 2009
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A079009 002</b>	Jun 03, 2009
<b>AB</b>		<b>5MG; 500MG</b>	<b>A079009 003</b>	Jun 03, 2009
<b>AB</b>	IVAX SUB TEVA PHARMS	<b>1.25MG; 250MG</b>	<b>A076345 001</b>	Feb 18, 2004
<b>AB</b>		<b>2.5MG; 500MG</b>	<b>A076345 002</b>	Feb 18, 2004
<b>AB</b>		<b>5MG; 500MG</b>	<b>A076345 003</b>	Feb 18, 2004

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

	+	HORIZON THERAPS INC	<b>1.1GM/ML</b>	<b>N203284 001</b>	Feb 01, 2013
--	---	---------------------	-----------------	--------------------	--------------

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<b>1.5GM/100ML</b>	<b>N017865 001</b>	
<b>AT</b>	B BRAUN	<b>1.5GM/100ML</b>	<b>N016784 001</b>	
<b>AT</b>	HOSPIRA	<b>1.5GM/100ML</b>	<b>N018315 001</b>	

## PRESCRIPTION DRUG PRODUCT LIST

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

<u>AP</u>	HIKMA FARMACEUTICA	<u>0.2MG/ML</u>	<u>A090963</u>	<u>001</u>	Sep 21, 2011
<u>AP</u>	LUITPOLD	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u>	Jul 23, 1986

ROBINUL

<u>AP</u>	+ EUROHLTH INTL SARL	<u>0.2MG/ML</u>	<u>N017558</u>	<u>001</u>	
	POWDER; INHALATION				
	SEEBRI				
	+ NOVARTIS PHARMS CORP	15.6MCG/INH	N207923	001	Oct 29, 2015
	SOLUTION; ORAL				
	CUVPOSA				
	+ MERZ PHARMS	1MG/5ML	N022571	001	Jul 28, 2010

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>1MG</u>	<u>A202675</u>	<u>001</u>	Apr 15, 2013
<u>AA</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>2MG</u>	<u>A040847</u>	<u>002</u>	Mar 21, 2008
<u>AA</u>	LEADING PHARMA LLC	<u>1MG</u>	<u>A090195</u>	<u>001</u>	Sep 21, 2012
<u>AA</u>		<u>2MG</u>	<u>A090195</u>	<u>002</u>	Sep 21, 2012
<u>AA</u>	NEXGEN PHARMA	<u>1.5MG</u>	<u>A091522</u>	<u>001</u>	Mar 12, 2012
<u>AA</u>	PAR PHARM	<u>1MG</u>	<u>A040653</u>	<u>001</u>	Aug 31, 2006
<u>AA</u>		<u>2MG</u>	<u>A040653</u>	<u>002</u>	Aug 31, 2006
<u>AA</u>	STASON PHARMS	<u>1MG</u>	<u>A091182</u>	<u>001</u>	Feb 03, 2014
<u>AA</u>		<u>2MG</u>	<u>A091182</u>	<u>002</u>	Feb 03, 2014
<u>AA</u>	SUN PHARM INDS LTD	<u>1MG</u>	<u>A040844</u>	<u>001</u>	Aug 18, 2009
<u>AA</u>		<u>2MG</u>	<u>A040844</u>	<u>002</u>	Aug 18, 2009
<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040821</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>		<u>2MG</u>	<u>A040821</u>	<u>002</u>	Dec 29, 2008
<u>AA</u>	VINTAGE PHARMS	<u>1MG</u>	<u>A090020</u>	<u>001</u>	Oct 19, 2011
<u>AA</u>		<u>2MG</u>	<u>A090020</u>	<u>002</u>	Oct 19, 2011

ROBINUL

<u>AA</u>	+ SHIONOGI INC	<u>1MG</u>	<u>N012827</u>	<u>001</u>	
-----------	----------------	------------	----------------	------------	--

ROBINUL FORTE

<u>AA</u>	+ SHIONOGI INC	<u>2MG</u>	<u>N012827</u>	<u>002</u>	
-----------	----------------	------------	----------------	------------	--

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

	+ NOVARTIS PHARMS CORP	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015
--	------------------------	--------------------------	---------	-----	--------------

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

<u>AP</u>	+ FERRING	<u>10,000 UNITS/VIAL</u>	<u>N017016</u>	<u>007</u>	
-----------	-----------	--------------------------	----------------	------------	--

<u>AP</u>	+ FRESENIUS KABI USA	<u>10,000 UNITS/VIAL</u>	<u>N017067</u>	<u>002</u>	
-----------	----------------------	--------------------------	----------------	------------	--

PREGNYL

<u>AP</u>	+ ORGANON USA INC	<u>10,000 UNITS/VIAL</u>	<u>N017692</u>	<u>001</u>	
-----------	-------------------	--------------------------	----------------	------------	--

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

	+ ASTRAZENECA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
--	---------------	---------------	---------	-----	--------------

		EQ 10.8MG BASE	N020578	001	Jan 11, 1996
--	--	----------------	---------	-----	--------------

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	+ BAUSCH AND LOMB	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A064047</u>	<u>001</u>	Jan 31, 1996
-----------	-------------------	---	----------------	------------	--------------

<u>AT</u>	LUITPOLD	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A065187</u>	<u>001</u>	Oct 28, 2005
-----------	----------	---	----------------	------------	--------------

NEOSPORIN

<u>AT</u>	+ MONARCH PHARMS	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A060582</u>	<u>001</u>	
-----------	------------------	---	----------------	------------	--

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

	+ PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008
--	------------------	------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119 001</u>	Sep 10, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078 001</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078 002</u>	Sep 14, 2009
<u>AP</u>	BANNER LIFE SCIENCES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880 001</u>	Jun 30, 2008
<u>AP</u>	BEDFORD LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913 001</u>	Jun 26, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187 001</u>	Jun 30, 2008
<u>AP</u>	CIPLA LTD	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258 002</u>	Jun 30, 2008
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177 001</u>	Dec 31, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090 001</u>	Jun 30, 2008
<u>AP</u>	LUITPOLD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091274 001</u>	Sep 22, 2010
<u>AP</u>	SAGENT AGILA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137 002</u>	Apr 09, 2010
<u>AP</u>	SAGENT STRIDES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136 001</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136 002</u>	Apr 09, 2010
<u>AP</u>	SANDOZ	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534 001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531 001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531 002</u>	Apr 30, 2009
<u>AP</u>	SANDOZ INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835 002</u>	Jun 30, 2008
<u>AP</u>	+ TEVA PHARMS USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963 001</u>	Jan 03, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297 001</u>	Jun 30, 2008
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566 001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565 001</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	BANNER LIFE SCIENCES	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863 002</u>	Jun 30, 2008
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096 001</u>	Jun 30, 2008

GRANISTERON HYDROCHLORIDE

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629 001</u>	Dec 23, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629 002</u>	Dec 23, 2009

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843 001</u>	Feb 27, 2008
<u>AB</u>	CIPLA LTD	<u>EQ 1MG BASE</u>	<u>A078037 001</u>	Feb 27, 2008
<u>AB</u>	COREPHARMA	<u>EQ 1MG BASE</u>	<u>A078260 001</u>	Dec 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846 001</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725 001</u>	Jan 30, 2008
<u>AB</u>	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969 001</u>	Jun 22, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678 001</u>	Feb 13, 2008
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A077842 001</u>	Dec 31, 2007
<u>AB</u>	TARO	<u>EQ 1MG BASE</u>	<u>A090817 001</u>	May 28, 2010
<u>AB</u>	+ TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078080 001</u>	Dec 31, 2007

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

<u>AB</u>	+ ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394 001</u>	Jul 06, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>125MG/5ML</u>	<u>A065354 001</u>	Sep 10, 2007
<u>AB</u>	PERRIGO CO TENNESSEE	<u>125MG/5ML</u>	<u>A065200 001</u>	Mar 02, 2005
<u>AB</u>	VINTAGE PHARMS	<u>125MG/5ML</u>	<u>A065438 001</u>	Oct 08, 2010

TABLET; ORAL

GRISEOFULVIN

<u>AB</u>	+ SANDOZ INC	<u>500MG</u>	<u>A091592 002</u>	Aug 07, 2013
<u>AB</u>	SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482 001</u>	Oct 22, 2012
	SANDOZ INC	<u>250MG</u>	<u>A091592 001</u>	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRIS-PEG

<u>AB</u>	VALEANT PHARMS INC	<u>125MG</u>	<u>N050475 001</u>	
<u>AB</u>		<u>250MG</u>	<u>N050475 002</u>	
<u>AB</u>	RICONPHARMA LLC	<u>125MG</u>	<u>A204371 001</u>	Jan 09, 2014
<u>AB</u>		<u>250MG</u>	<u>A204371 002</u>	Jan 09, 2014

## PRESCRIPTION DRUG PRODUCT LIST

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZED

<b>AB</b>	SIGMAPHARM LABS LLC	<b>125MG</b>	<b>A202545 001</b>	Oct 22, 2012
<b>AB</b>		<b>250MG</b>	<b>A202545 002</b>	Oct 22, 2012

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

FLOWTUSS

MISSION PHARMACAL CO 200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015

OBREDON

+ SOVEREIGN PHARMS 200MG/5ML; 2.5MG/5ML N205474 001 Nov 14, 2014

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+ MIKART INC 200MG/5ML; 2.5MG/5ML; 30MG/5ML N022279 001 May 14, 2015

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

ANI PHARMS INC EQ 4MG BASE A074149 001 Apr 07, 1995

+ EQ 8MG BASE A074149 002 Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

<b>AB</b>	AMNEAL PHARM	<b>EQ 1MG BASE</b>	<b>A075109 001</b>	Nov 25, 1998
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A075109 002</b>	Nov 25, 1998
<b>AB</b>	EPIC PHARMA LLC	<b>EQ 1MG BASE</b>	<b>A074673 001</b>	Feb 28, 1997
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A074673 002</b>	Feb 28, 1997
<b>AB</b>	MYLAN	<b>EQ 1MG BASE</b>	<b>A074796 001</b>	Jan 27, 1997
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A074796 002</b>	Jan 27, 1997
<b>AB</b>	WATSON LABS	<b>EQ 1MG BASE</b>	<b>A074145 001</b>	Oct 17, 1995
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A074145 002</b>	Oct 17, 1995

TENEX

<b>AB</b>	PROMIUS PHARMA	<b>EQ 1MG BASE</b>	<b>N019032 001</b>	Oct 27, 1986
<b>AB</b>	+	<b>EQ 2MG BASE</b>	<b>N019032 002</b>	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

<b>AB</b>	ACTAVIS ELIZABETH	<b>EQ 1MG BASE</b>	<b>A200881 001</b>	Oct 05, 2012
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A200881 002</b>	Oct 05, 2012
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>A200881 003</b>	Oct 05, 2012
<b>AB</b>		<b>EQ 4MG BASE</b>	<b>A200881 004</b>	Oct 05, 2012
<b>AB</b>	IMPAX LABS INC	<b>EQ 1MG BASE</b>	<b>A202238 001</b>	Oct 20, 2015
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A202238 002</b>	Oct 20, 2015
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>A202238 003</b>	Oct 20, 2015
<b>AB</b>		<b>EQ 4MG BASE</b>	<b>A202238 004</b>	Oct 20, 2015
<b>AB</b>	MYLAN PHARMS INC	<b>EQ 1MG BASE</b>	<b>A202578 001</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A202578 002</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>A202578 003</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 4MG BASE</b>	<b>A202578 004</b>	Jun 02, 2015
<b>AB</b>	SANDOZ INC	<b>EQ 1MG BASE</b>	<b>A202568 001</b>	Jun 03, 2015
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A202568 002</b>	Jun 03, 2015
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>A202568 003</b>	Jun 03, 2015
<b>AB</b>		<b>EQ 4MG BASE</b>	<b>A202568 004</b>	Jun 03, 2015
<b>AB</b>	TEVA PHARMS USA	<b>EQ 1MG BASE</b>	<b>A201382 001</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A201382 002</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>A201382 003</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 4MG BASE</b>	<b>A201382 004</b>	Jun 02, 2015
<b>AB</b>	TWI PHARMS INC	<b>EQ 1MG BASE</b>	<b>A201408 001</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A201408 002</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>A201408 003</b>	Jun 02, 2015
<b>AB</b>		<b>EQ 4MG BASE</b>	<b>A201408 004</b>	Jun 02, 2015

INTUNIV

<b>AB</b>	SHIRE	<b>EQ 1MG BASE</b>	<b>N022037 001</b>	Sep 02, 2009
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>N022037 002</b>	Sep 02, 2009
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>N022037 003</b>	Sep 02, 2009
<b>AB</b>	+	<b>EQ 4MG BASE</b>	<b>N022037 004</b>	Sep 02, 2009

## PRESCRIPTION DRUG PRODUCT LIST

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE  
MERCK SHARP DOHME

125MG

N001546 001

HALCINONIDE

CREAM; TOPICAL

HALOG

+ RANBAXY

0.1%

N017556 001

OINTMENT; TOPICAL

HALOG

+ RANBAXY

0.1%

N017824 001

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE**AB** FOUGERA PHARMS**0.05%****A077001 001** Dec 16, 2004**AB** G AND W LABS**0.05%****A078162 001** Apr 24, 2007**AB** PERRIGO ISRAEL**0.05%****A077123 001** Dec 16, 2004**AB** TARO**0.05%****A077227 001** Aug 04, 2005ULTRAVATE**AB** + RANBAXY**0.05%****N019967 001** Dec 27, 1990

LOTION; TOPICAL

ULTRAVATE

+ FERNDALE LABS INC

0.05%

N208183 001 Nov 06, 2015

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE**AB** G AND W LABS**0.05%****A077721 001** Sep 07, 2006**AB** PERRIGO**0.05%****A076872 001** Dec 16, 2004**AB** TARO**0.05%****A076994 001** Dec 16, 2004ULTRAVATE**AB** + RANBAXY**0.05%****N019968 001** Dec 17, 1990HALOPERIDOL

TABLET; ORAL

HALOPERIDOL**AB** MYLAN**0.5MG****A070278 006** Jun 10, 1986**AB****1MG****A070278 004** Jun 10, 1986**AB****2MG****A070278 001** Jun 10, 1986**AB****5MG****A070278 005** Jun 10, 1986**AB****10MG****A070278 002** Jul 16, 2009**AB****20MG****A070278 003** Jul 16, 2009**AB** SANDOZ**0.5MG****A071206 001** Nov 17, 1986**AB****1MG****A071207 001** Nov 17, 1986**AB** +**2MG****A071208 001** Nov 17, 1986**AB****5MG****A071209 001** Nov 17, 1986**AB****10MG****A071210 001** Mar 11, 1988**AB****20MG****A071211 001** Mar 11, 1988**AB** ZYDUS PHARMS USA**5MG****A077580 003** Nov 29, 2007**AB****10MG****A077580 004** Nov 29, 2007**AB****20MG****A077580 005** Nov 29, 2007HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL**AO** + JANSSEN PHARMS**EQ 50MG BASE/ML****N018701 001** Jan 14, 1986**AO** +**EQ 100MG BASE/ML****N018701 002** Jan 31, 1997HALOPERIDOL DECANOATE**AO** EUROHLTH INTL SARL**EQ 50MG BASE/ML****A074811 001** Jan 30, 1998**AO****EQ 100MG BASE/ML****A075305 001** Sep 28, 1998**AO** FRESENIUS KABI USA**EQ 50MG BASE/ML****A074893 001** Dec 19, 1997**AO****EQ 100MG BASE/ML****A074893 002** Dec 19, 1997**AO** MYLAN LABS LTD**EQ 50MG BASE/ML****A075440 001** Feb 28, 2000**AO****EQ 100MG BASE/ML****A075440 002** Feb 28, 2000**AO** TEVA PHARMS USA**EQ 50MG BASE/ML****A075393 001** May 11, 1999**AO****EQ 100MG BASE/ML****A075393 002** May 11, 1999HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL**AA** PHARM ASSOC**EQ 2MG BASE/ML****A073037 001** Feb 26, 1993**AA** SILARX**EQ 2MG BASE/ML****A073364 001** Sep 28, 1993**AA** + TEVA PHARMS**EQ 2MG BASE/ML****A071617 001** Dec 01, 1988

## PRESCRIPTION DRUG PRODUCT LIST

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+	JANSSEN PHARMS	<u>EQ 5MG BASE/ML</u>	<u>N015923</u>	<u>001</u>	
<u>HALOPERIDOL</u>						
<u>AP</u>		EUROHLTH INTL SARL	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>		MYLAN LABS LTD	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>		SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A200742</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A076035</u>	<u>001</u>	Aug 29, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	+	EUROHLTH INTL SARL	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>	
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>	
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>	
<u>AP</u>	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>	
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>	
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>	
<u>AP</u>	+		<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>	
<u>AP</u>		HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090808</u>	<u>002</u>	Jun 30, 2010
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090808</u>	<u>003</u>	Jun 30, 2010
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A090809</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091659</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091682</u>	<u>002</u>	Jun 08, 2011
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A201002</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202957</u>	<u>001</u>	Jun 12, 2014
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A202733</u>	<u>001</u>	Jun 12, 2014
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A202957</u>	<u>002</u>	Jun 12, 2014
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A203198</u>	<u>001</u>	Jun 12, 2014
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A203198</u>	<u>002</u>	Jun 12, 2014
<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>		BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>001</u>	Apr 28, 1982
<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	+	B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>010</u>	Jun 23, 1989
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
<u>AP</u>		HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>003</u>	Mar 27, 1985
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>		BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>002</u>	Apr 28, 1982
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>		HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>011</u>	Jun 23, 1989
<u>HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
<u>AP</u>	+	B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805</u>	<u>001</u>	Jan 25, 1989
<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>						
<u>AP</u>	+	B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952</u>	<u>004</u>	Jul 20, 1992
<u>AP</u>	+		<u>10,000 UNITS/100ML</u>	<u>N019952</u>	<u>005</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339</u>	<u>004</u>	Mar 27, 1985
<u>AP</u>			<u>5,000 UNITS/100ML</u>	<u>N019805</u>	<u>002</u>	Jan 25, 1989
<u>AP</u>			<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>002</u>	Mar 27, 1985
<u>HEPARIN SODIUM IN PLASTIC CONTAINER</u>						
<u>AP</u>	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>013</u>	Dec 05, 1985
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017029</u>	<u>014</u>	Dec 05, 1985
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>015</u>	Dec 05, 1985
<u>AP</u>	+		<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>016</u>	Dec 05, 1985
<u>HEPARIN SODIUM PRESERVATIVE FREE</u>						
<u>AP</u>	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>010</u>	Apr 28, 1986
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090810</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202732</u>	<u>001</u>	Jun 12, 2014
<u>HEPARIN SODIUM</u>						
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
	+	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983
	+	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
	+		5,000 UNITS/ML	N201370	002	Jul 21, 2011

## PRESCRIPTION DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

+

10,000 UNITS/ML

N201370 003 Jul 21, 2011

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5,000 UNITS/100ML

N019339 001 Mar 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

5,000 UNITS/100ML

N018916 006 Jan 31, 1984

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

5,000 UNITS/100ML

N018916 007 Jan 31, 1984

10,000 UNITS/100ML

N018916 008 Jan 31, 1984

HEPARIN SODIUM PRESERVATIVE FREE

+ FRESENIUS KABI USA

10,000 UNITS/ML

N017029 019 Nov 22, 2010

+ HOSPIRA

10,000 UNITS/ML

A089522 001 May 04, 1987

+ PFIZER

1,000 UNITS/ML

N201370 004 Jul 21, 2011

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

+ SANOFI AVENTIS US

3%

N006882 001

SPONGE; TOPICAL

PRE-OP**AT** + DAVIS AND GECK**480MG****N017433 001**PRE-OP II**AT** DAVIS AND GECK**480MG****N017433 002**HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+ PHOTOCURE ASA

100MG/VIAL

N022555 001 May 28, 2010

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+ ENDO PHARM

50MG

N022058 001 May 03, 2007

VANTAS

+ ENDO PHARM

50MG

N021732 001 Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE**AA** ACTAVIS MID ATLANTIC**1.5MG/5ML; 5MG/5ML****A088017 001** Jul 05, 1983**AA** + HI TECH PHARMA**1.5MG/5ML; 5MG/5ML****A040613 001** Feb 08, 2008**AA** WOCKHARDT**1.5MG/5ML; 5MG/5ML****A088008 001** Mar 03, 1983

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE**AA** NOVEL LABS INC**1.5MG; 5MG****A091528 001** Apr 20, 2011TUSSIGON**AA** + KING PHARMS**1.5MG; 5MG****A088508 001** Jul 30, 1985HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

+ AMPHASTAR PHARM

150 UNITS/ML

N021665 001 Oct 26, 2004

VITRASE

+ BAUSCH AND LOMB

200 UNITS/VIAL

N021640 002 Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

+ HALOZYME THERAP

150 UNITS/ML

N021859 001 Dec 02, 2005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE**AP** + AKORN**20MG/ML****A040730 001** Apr 21, 2009**AP** FRESENIUS KABI USA**20MG/ML****A040388 001** Mar 13, 2001**AP** LUITPOLD**20MG/ML****A040136 001** Jun 30, 1997**AP** NAVINTA LLC**20MG/ML****A202938 001** Mar 28, 2013**AP** X-GEN PHARMS INC**20MG/ML****A203110 001** Jun 29, 2015

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE**AA** ACTAVIS GRP PTC**10MG****A091679 001** Mar 04, 2013**AA****25MG****A091679 002** Mar 04, 2013**AA****50MG****A091679 003** Mar 04, 2013**AA****100MG****A091679 004** Mar 04, 2013

## PRESCRIPTION DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>	ALKEM LABS LTD	<u>10MG</u>	<u>A200737</u>	<u>001</u>	Dec 07, 2012
<u>AA</u>		<u>25MG</u>	<u>A200737</u>	<u>002</u>	Dec 07, 2012
<u>AA</u>		<u>50MG</u>	<u>A200737</u>	<u>003</u>	Dec 07, 2012
<u>AA</u>		<u>100MG</u>	<u>A200737</u>	<u>004</u>	Dec 07, 2012
<u>AA</u>	CADILA PHARMS LTD	<u>25MG</u>	<u>A203845</u>	<u>001</u>	Sep 18, 2014
<u>AA</u>		<u>50MG</u>	<u>A203845</u>	<u>002</u>	Sep 18, 2014
<u>AA</u>		<u>100MG</u>	<u>A203845</u>	<u>003</u>	Sep 18, 2014
<u>AA</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>		<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>		<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>		<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A086242</u>	<u>001</u>	Feb 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>		<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>		<u>100MG</u>	<u>A086242</u>	<u>004</u>	Feb 04, 2010
<u>AA</u>	HETERO LABS LTD III	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>		<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>		<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>		<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>		<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>		<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>		<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>	MYLAN	<u>10MG</u>	<u>A090413</u>	<u>001</u>	Dec 08, 2010
<u>AA</u>		<u>25MG</u>	<u>A090413</u>	<u>002</u>	Dec 08, 2010
<u>AA</u>		<u>50MG</u>	<u>A090413</u>	<u>003</u>	Dec 08, 2010
<u>AA</u>		<u>100MG</u>	<u>A090413</u>	<u>004</u>	Dec 08, 2010
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	+ PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	+	<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	STRIDES PHARMA	<u>25MG</u>	<u>A200770</u>	<u>001</u>	May 03, 2013
<u>AA</u>		<u>50MG</u>	<u>A200770</u>	<u>002</u>	May 03, 2013
<u>AA</u>		<u>100MG</u>	<u>A200770</u>	<u>003</u>	May 03, 2013

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

	PAR PHARM	25MG; 25MG	A088957	001	Oct 21, 1985
	+	50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

	+ ARBOR PHARMS LLC	37.5MG; 20MG	N020727	001	Jun 23, 2005
--	--------------------	--------------	---------	-----	--------------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG</u>	<u>A200645</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A078389</u>	<u>001</u>	May 16, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	LANNETT HOLDINGS INC	<u>12.5MG</u>	<u>A091662</u>	<u>001</u>	Jan 27, 2012
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A090651</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>	UNICHEM	<u>12.5MG</u>	<u>A090510</u>	<u>001</u>	Jan 19, 2010
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002

MICROZIDE

<u>AB</u>	+ ACTAVIS LABS UT INC	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996
-----------	-----------------------	---------------	----------------	------------	--------------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ACCORD HLTHCARE	<u>12.5MG</u>	<u>A202556</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A202556</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A202556</u>	<u>003</u>	Sep 24, 2012



## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707 001</u>	Feb 27, 2007
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A040774 001</u>	Oct 03, 2007
<u>AB</u>		<u>50MG</u>	<u>A040774 002</u>	Oct 03, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780 001</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040780 002</u>	Jul 20, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A087059 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A087068 001</u>	
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182 002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085182 001</u>	
<u>AB</u>	HIKMA PHARMS LLC	<u>50MG</u>	<u>A084878 001</u>	
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807 001</u>	Jul 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040807 002</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040807 003</u>	Jul 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177 001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A083177 002</u>	
<u>AB</u>	JUBILANT CADISTA	<u>25MG</u>	<u>A040809 001</u>	Sep 04, 2007
<u>AB</u>		<u>50MG</u>	<u>A040809 002</u>	Sep 04, 2007
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A084325 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084324 001</u>	
<u>AB</u>	LEADING PHARMA LLC	<u>25MG</u>	<u>A040702 001</u>	Mar 16, 2007
<u>AB</u>		<u>50MG</u>	<u>A040702 002</u>	Mar 16, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A040770 001</u>	Jan 23, 2007
<u>AB</u>		<u>25MG</u>	<u>A040735 002</u>	Jan 23, 2007
<u>AB</u>		<u>50MG</u>	<u>A040735 003</u>	Jan 23, 2007
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A203018 001</u>	Jul 23, 2014
<u>AB</u>		<u>50MG</u>	<u>A203018 002</u>	Jul 23, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040857 001</u>	May 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040810 001</u>	Mar 27, 2007
<u>AB</u>		<u>50MG</u>	<u>A040810 002</u>	Mar 27, 2007
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A040907 001</u>	Aug 15, 2008
<u>AB</u>		<u>50MG</u>	<u>A040907 002</u>	Aug 15, 2008
<u>AB</u>	VINTAGE PHARMS	<u>25MG</u>	<u>A040412 001</u>	Mar 29, 2002
<u>AB</u>		<u>50MG</u>	<u>A040412 002</u>	Mar 29, 2002
	<u>ORETIC</u>			
<u>AB</u>	ABBVIE	<u>50MG</u>	<u>N011971 002</u>	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

<u>AB</u>	+	SANOFI AVENTIS US	<u>12.5MG; 150MG</u>	<u>N020758 002</u>	Sep 30, 1997
<u>AB</u>	+		<u>12.5MG; 300MG</u>	<u>N020758 003</u>	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC LTD	<u>12.5MG; 150MG</u>	<u>A091370 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A091370 002</u>	Oct 15, 2012
<u>AB</u>	APOTEX INC	<u>12.5MG; 150MG</u>	<u>A201505 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A201505 002</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG; 150MG</u>	<u>A203630 001</u>	Feb 22, 2013
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203630 002</u>	Feb 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>12.5MG; 150MG</u>	<u>A203500 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203500 002</u>	Sep 27, 2012
<u>AB</u>	LUPIN LTD	<u>12.5MG; 150MG</u>	<u>A201524 001</u>	Feb 27, 2013
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A201524 002</u>	Feb 27, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG; 150MG</u>	<u>A202414 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A202414 002</u>	Sep 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG; 150MG</u>	<u>A077969 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A077969 002</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>12.5MG; 150MG</u>	<u>A203072 001</u>	May 09, 2014
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203072 002</u>	May 09, 2014
<u>AB</u>	ROXANE	<u>12.5MG; 150MG</u>	<u>A090351 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A090351 002</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>12.5MG; 150MG</u>	<u>A077446 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A077446 002</u>	Sep 27, 2012
<u>AB</u>	TEVA	<u>12.5MG; 150MG</u>	<u>A077369 001</u>	Mar 30, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A077369 002</u>	Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>12.5MG; 150MG</u>	<u>A091539 001</u>	Oct 22, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A091539 002</u>	Oct 22, 2012

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>12.5MG;10MG</u>	<u>A076674 001</u>	Oct 05, 2004
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076674 002</u>	Oct 05, 2004
<u>AB</u>		<u>25MG;20MG</u>	<u>A076674 003</u>	Oct 05, 2004
<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606 001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606 002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606 003</u>	Mar 14, 2006
<u>AB</u>	HIKMA INTL PHARMS	<u>12.5MG;10MG</u>	<u>A076265 001</u>	Jul 08, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076265 002</u>	Jul 08, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076265 003</u>	Jul 08, 2002
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG;10MG</u>	<u>A075776 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A075776 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A075776 003</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912 001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912 002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912 003</u>	Sep 27, 2006
<u>AB</u>	MYLAN	<u>12.5MG;10MG</u>	<u>A076113 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076113 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076113 003</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230 003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262 003</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>12.5MG;10MG</u>	<u>A076007 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007 003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194 003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194 001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194 002</u>	Jul 01, 2002
	<u>ZESTORETIC</u>			
<u>AB</u>	ALVOGEN IPCO SARL	<u>12.5MG;10MG</u>	<u>N019888 003</u>	Nov 18, 1993
<u>AB</u>	+	<u>12.5MG;20MG</u>	<u>N019888 001</u>	Sep 20, 1990
<u>AB</u>	+	<u>25MG;20MG</u>	<u>N019888 002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>12.5MG;50MG</u>	<u>N020387 001</u>	Apr 28, 1995
<u>AB</u>		<u>12.5MG;100MG</u>	<u>N020387 003</u>	Oct 20, 2005
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N020387 002</u>	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617 001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091617 002</u>	Feb 17, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A091617 003</u>	Feb 17, 2012
<u>AB</u>	APOTEX	<u>12.5MG;50MG</u>	<u>A090150 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090150 002</u>	Aug 11, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090150 003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091629 002</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091629 003</u>	Jan 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>12.5MG;50MG</u>	<u>A201845 001</u>	Sep 18, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201845 002</u>	Sep 18, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A201845 003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>12.5MG;50MG</u>	<u>A201682 001</u>	Mar 01, 2013
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201682 002</u>	Mar 01, 2013
<u>AB</u>		<u>25MG;100MG</u>	<u>A201682 003</u>	Mar 01, 2013
<u>AB</u>	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A078245 002</u>	May 21, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078245 003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;50MG</u>	<u>A202289 001</u>	Aug 09, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A202289 002</u>	Aug 09, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A202289 003</u>	Aug 09, 2012
<u>AB</u>	MYLAN	<u>12.5MG;50MG</u>	<u>A091652 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091652 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091652 003</u>	Oct 06, 2010
<u>AB</u>	ROXANE	<u>12.5MG;50MG</u>	<u>A077732 002</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077732 001</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077732 003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948 001</u>	Oct 06, 2010

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077948 003</u>	Aug 19, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077948 002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157 001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077157 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077157 003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>12.5MG;50MG</u>	<u>A090528 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090528 003</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090528 002</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385 001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078385 002</u>	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

## METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN	15MG;250MG	A070265 002	Jan 23, 1986
+	25MG;250MG	A070265 001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

## DUTOPROL

CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006
	12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006
+	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

<u>AB</u>	US PHARMS HOLDINGS I	<u>25MG;50MG</u>	<u>N018303 001</u>	Dec 31, 1984
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N018303 002</u>	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG;50MG</u>	<u>A202870 001</u>	Nov 06, 2013
<u>AB</u>		<u>25MG;100MG</u>	<u>A202870 002</u>	Nov 06, 2013
<u>AB</u>		<u>50MG;100MG</u>	<u>A202870 003</u>	Nov 06, 2013
<u>AB</u>	MYLAN	<u>25MG;50MG</u>	<u>A076792 001</u>	Aug 20, 2004
<u>AB</u>		<u>25MG;100MG</u>	<u>A076792 002</u>	Aug 20, 2004
<u>AB</u>		<u>50MG;100MG</u>	<u>A076792 003</u>	Aug 20, 2004
<u>AB</u>	SUN PHARM INDS	<u>25MG;50MG</u>	<u>A090654 001</u>	Jan 19, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A090654 002</u>	Jan 19, 2012
<u>AB</u>		<u>50MG;100MG</u>	<u>A090654 003</u>	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GLENMARK PHARMS	<u>12.5MG;7.5MG</u>	<u>A090718 001</u>	Mar 17, 2010
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A090718 002</u>	Mar 17, 2010
<u>AB</u>		<u>25MG;15MG</u>	<u>A090718 003</u>	Mar 17, 2010
<u>AB</u>	TEVA	<u>12.5MG;7.5MG</u>	<u>A076980 001</u>	Mar 07, 2007
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A076980 003</u>	Mar 07, 2007
<u>AB</u>		<u>25MG;15MG</u>	<u>A076980 002</u>	Mar 07, 2007

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>12.5MG;7.5MG</u>	<u>A202150 001</u>	Mar 07, 2014
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A202150 002</u>	Mar 07, 2014
<u>AB</u>		<u>25MG;15MG</u>	<u>A202150 003</u>	Mar 07, 2014

UNIRETIC

<u>AB</u>	UCB INC	<u>12.5MG;7.5MG</u>	<u>N020729 001</u>	Jun 27, 1997
<u>AB</u>		<u>12.5MG;15MG</u>	<u>N020729 003</u>	Feb 14, 2002
<u>AB</u>	+	<u>25MG;15MG</u>	<u>N020729 002</u>	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

## BENICAR HCT

DAIICHI SANKYO	12.5MG;20MG	N021532 002	Jun 05, 2003
	12.5MG;40MG	N021532 003	Jun 05, 2003
+	25MG;40MG	N021532 005	Jun 05, 2003

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ANI PHARMS INC	<u>25MG;40MG</u>	<u>A072042 001</u>	Mar 14, 1988
<u>AB</u>		<u>25MG;80MG</u>	<u>A072043 001</u>	Mar 14, 1988
<u>AB</u>	+	<u>25MG;40MG</u>	<u>A070947 002</u>	Mar 04, 1987
<u>AB</u>	+	<u>25MG;80MG</u>	<u>A070947 001</u>	Apr 01, 1987

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>	PFIZER PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>N020125 001</u>	Dec 28, 1999
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>N020125 002</u>	Dec 28, 1999
<u>AB</u>	+	<u>25MG;EQ 20MG BASE</u>	<u>N020125 003</u>	Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX CORP	<u>12.5MG;EQ 10MG BASE</u>	<u>A091524 001</u>	Mar 12, 2013
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A091524 002</u>	Mar 12, 2013
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A091524 003</u>	Mar 12, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450 001</u>	Aug 24, 2007
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A078450 002</u>	Aug 24, 2007
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078450 003</u>	Aug 24, 2007
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG;10MG</u>	<u>A201356 001</u>	Apr 20, 2011
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A201356 002</u>	Apr 20, 2011
<u>AB</u>		<u>25MG;20MG</u>	<u>A201356 003</u>	Apr 20, 2011
<u>AB</u>	MYLAN	<u>12.5MG;EQ 10MG BASE</u>	<u>A077093 001</u>	Mar 28, 2005
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A077093 002</u>	Mar 28, 2005
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A077093 003</u>	Mar 28, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>12.5MG;EQ 10MG BASE</u>	<u>A078211 001</u>	Mar 04, 2009
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A078211 002</u>	Mar 04, 2009
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078211 003</u>	Mar 04, 2009

QUINARETIC

<u>AB</u>	GAVIS PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374 001</u>	Mar 31, 2004
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A076374 002</u>	Mar 31, 2004
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A076374 003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

<u>AB</u>	GD SEARLE LLC	<u>25MG;25MG</u>	<u>N012616 004</u>	Dec 30, 1982
<u>AB</u>		<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>		
<u>AB</u>	MUTUAL PHARM	<u>25MG;25MG</u>	<u>A089534 001</u>	Jul 02, 1987
<u>AB</u>	MYLAN	<u>25MG;25MG</u>	<u>A086513 001</u>	
	ALDACTAZIDE			
	+ GD SEARLE LLC	<u>50MG;50MG</u>	<u>N012616 005</u>	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

<u>AB</u>	BOEHRINGER INGELHEIM	<u>12.5MG;40MG</u>	<u>N021162 001</u>	Nov 17, 2000
<u>AB</u>		<u>12.5MG;80MG</u>	<u>N021162 002</u>	Nov 17, 2000
<u>AB</u>	+	<u>25MG;80MG</u>	<u>N021162 003</u>	Apr 19, 2004
	<u>TELMISARTAN AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;40MG</u>	<u>A203010 001</u>	Feb 25, 2014
<u>AB</u>		<u>12.5MG;80MG</u>	<u>A203010 002</u>	Feb 25, 2014
<u>AB</u>		<u>25MG;80MG</u>	<u>A203010 003</u>	Feb 25, 2014
<u>AB</u>	LUPIN LTD	<u>12.5MG;40MG</u>	<u>A091351 001</u>	Aug 07, 2014
<u>AB</u>		<u>12.5MG;80MG</u>	<u>A091351 002</u>	Aug 07, 2014
<u>AB</u>		<u>25MG;80MG</u>	<u>A091351 003</u>	Aug 07, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;40MG</u>	<u>A204169 001</u>	Nov 02, 2015
<u>AB</u>		<u>12.5MG;80MG</u>	<u>A204169 002</u>	Nov 02, 2015
<u>AB</u>		<u>25MG;80MG</u>	<u>A204169 003</u>	Nov 02, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;40MG</u>	<u>A091648 001</u>	Feb 25, 2014
<u>AB</u>		<u>12.5MG;80MG</u>	<u>A091648 002</u>	Feb 25, 2014
<u>AB</u>		<u>25MG;80MG</u>	<u>A091648 003</u>	Feb 25, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>12.5MG;40MG</u>	<u>A201192 001</u>	Feb 25, 2014
<u>AB</u>		<u>12.5MG;80MG</u>	<u>A201192 002</u>	Feb 25, 2014
<u>AB</u>		<u>25MG;80MG</u>	<u>A201192 003</u>	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG;37.5MG</u>	<u>N016042 003</u>	Mar 03, 1994
		<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>		DURAMED PHARMS BARR	<u>25MG;37.5MG</u>	<u>A075052 001</u>	Jun 18, 1999
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>25MG;50MG</u>	<u>A074259 001</u>	Mar 30, 1995
<u>AB</u>		LANNETT HOLDINGS INC	<u>25MG;37.5MG</u>	<u>A201407 001</u>	Dec 09, 2011
<u>AB</u>		MYLAN	<u>25MG;37.5MG</u>	<u>A074701 001</u>	Jun 07, 1996
<u>AB</u>		SANDOZ	<u>25MG;37.5MG</u>	<u>A074821 001</u>	Jun 05, 1997
<u>AB</u>	+		<u>25MG;50MG</u>	<u>A073191 001</u>	Jul 31, 1991

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDEAB + MYLAN PHARMS INC 50MG; 75MG N019129 001 Oct 22, 1984MAXZIDE-25AB MYLAN PHARMS INC 25MG; 37.5MG N019129 003 May 13, 1988TRIAMTERENE AND HYDROCHLOROTHIAZIDEAB ANI PHARMS INC 50MG; 75MG A073467 001 Jan 31, 1996AB APOTEX INC 25MG; 37.5MG A071251 002 May 05, 1998AB 50MG; 75MG A071251 001 Apr 17, 1988AB PLIVA 25MG; 37.5MG A074026 001 Apr 26, 1996AB SANDOZ 25MG; 37.5MG A073281 001 Apr 30, 1992AB 50MG; 75MG A072011 001 Jun 17, 1988AB WATSON LABS 25MG; 37.5MG A073449 001 Sep 23, 1993AB 50MG; 75MG A071851 001 Nov 30, 1988HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCTAB NOVARTIS 12.5MG; 80MG N020818 001 Mar 06, 1998AB 12.5MG; 160MG N020818 002 Mar 06, 1998AB 12.5MG; 320MG N020818 004 Apr 28, 2006AB 25MG; 160MG N020818 003 Jan 17, 2002AB + 25MG; 320MG N020818 005 Apr 28, 2006VALSARTAN AND HYDROCHLOROTHIAZIDEAB ALEMBIC LTD 12.5MG; 80MG A201662 001 Mar 21, 2013AB 12.5MG; 160MG A201662 002 Mar 21, 2013AB 12.5MG; 320MG A201662 003 Mar 21, 2013AB 25MG; 160MG A201662 004 Mar 21, 2013AB 25MG; 320MG A201662 005 Mar 21, 2013AB APOTEX INC 12.5MG; 80MG A203026 001 Mar 21, 2013AB 12.5MG; 160MG A203026 002 Mar 21, 2013AB 12.5MG; 320MG A203026 003 Mar 21, 2013AB 25MG; 160MG A203026 004 Mar 21, 2013AB 25MG; 320MG A203026 005 Mar 21, 2013AB AUROBINDO PHARMA LTD 12.5MG; 80MG A202519 001 Mar 21, 2013AB 12.5MG; 160MG A202519 002 Mar 21, 2013AB 12.5MG; 320MG A202519 003 Mar 21, 2013AB 25MG; 160MG A202519 004 Mar 21, 2013AB 25MG; 320MG A202519 005 Mar 21, 2013AB LUPIN LTD 12.5MG; 80MG A078946 003 Mar 21, 2013AB 12.5MG; 160MG A078946 004 Mar 21, 2013AB 12.5MG; 320MG A078946 001 Mar 21, 2013AB 25MG; 160MG A078946 005 Mar 21, 2013AB 25MG; 320MG A078946 002 Mar 21, 2013AB MACLEODS PHARMS LTD 12.5MG; 80MG A203145 001 Apr 19, 2013AB 12.5MG; 160MG A203145 002 Apr 19, 2013AB 12.5MG; 320MG A203145 003 Apr 19, 2013AB 25MG; 160MG A203145 004 Apr 19, 2013AB 25MG; 320MG A203145 005 Apr 19, 2013AB MYLAN PHARMS INC 12.5MG; 80MG A078020 001 Sep 21, 2012AB 12.5MG; 160MG A078020 002 Sep 21, 2012AB 12.5MG; 320MG A078020 004 Sep 21, 2012AB 25MG; 160MG A078020 003 Sep 21, 2012AB 25MG; 320MG A078020 005 Sep 21, 2012AB WATSON LABS INC 12.5MG; 80MG A091519 001 Mar 21, 2013AB 12.5MG; 160MG A091519 002 Mar 21, 2013AB 12.5MG; 320MG A091519 003 Mar 21, 2013AB 25MG; 160MG A091519 004 Mar 21, 2013AB 25MG; 320MG A091519 005 Mar 21, 2013HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+ PERNIX IRELAND PAIN 10MG N202880 001 Oct 25, 2013

15MG N202880 002 Oct 25, 2013

20MG N202880 003 Oct 25, 2013

30MG N202880 004 Oct 25, 2013

40MG N202880 005 Oct 25, 2013

50MG N202880 006 Oct 25, 2013

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA

+ PURDUE PHARMA LP 20MG N206627 001 Nov 20, 2014

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

30MG	N206627	002	Nov 20, 2014
40MG	N206627	003	Nov 20, 2014
60MG	N206627	004	Nov 20, 2014
80MG	N206627	005	Nov 20, 2014
100MG	N206627	006	Nov 20, 2014
120MG	N206627	007	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG;200MG</u>	<u>A077454</u>	<u>001</u>	Jun 23, 2010
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076604</u>	<u>001</u>	Dec 31, 2003
<u>AB</u>	AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642</u>	<u>002</u>	Mar 18, 2004
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076642</u>	<u>001</u>	Oct 12, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>2.5MG;200MG</u>	<u>A091633</u>	<u>001</u>	May 28, 2013
<u>AB</u>		<u>5MG;200MG</u>	<u>A091633</u>	<u>002</u>	May 28, 2013
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A091633</u>	<u>003</u>	May 28, 2013
<u>AB</u>		<u>10MG;200MG</u>	<u>A091633</u>	<u>004</u>	May 28, 2013
<u>AB</u>	TEVA	<u>7.5MG;200MG</u>	<u>A076023</u>	<u>001</u>	Apr 11, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727</u>	<u>001</u>	Nov 06, 2006
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A077723</u>	<u>001</u>	Nov 06, 2006
<u>AB</u>		<u>10MG;200MG</u>	<u>A077723</u>	<u>002</u>	Nov 06, 2006

REPREXAIN

<u>AB</u>	AMNEAL PHARMS NY	<u>2.5MG;200MG</u>	<u>A076642</u>	<u>003</u>	Oct 19, 2007
<u>AB</u>		<u>10MG;200MG</u>	<u>A076642</u>	<u>004</u>	Oct 19, 2007

VICOPROFEN

<u>AB</u>	+ ABBVIE	<u>7.5MG;200MG</u>	<u>N020716</u>	<u>001</u>	Sep 23, 1997
-----------	----------	--------------------	----------------	------------	--------------

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<u>AA</u>	COASTAL PHARMS	<u>5MG/5ML; 60MG/5ML</u>	<u>A205658</u>	<u>001</u>	Nov 17, 2015
<u>AA</u>	PADDOCK LLC	<u>5MG/5ML; 60MG/5ML</u>	<u>A204658</u>	<u>001</u>	Apr 29, 2014
<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML; 60MG/5ML</u>	<u>A203839</u>	<u>001</u>	Oct 28, 2014
<u>REZIRA</u>					
<u>AA</u>	+ CYPRESS PHARM	<u>5MG/5ML; 60MG/5ML</u>	<u>N022442</u>	<u>001</u>	Jun 08, 2011

HYDROCORTISONE

CREAM;TOPICAL

ALA-CORT

<u>AT</u>	CROWN LABS	<u>2.5%</u>	<u>A080706</u>	<u>007</u>	Jan 05, 2016
<u>AT</u>		<u>1%</u>	<u>A080706</u>	<u>006</u>	

ANUSOL HC

<u>AT</u>	SALIX PHARMS	<u>2.5%</u>	<u>A088250</u>	<u>001</u>	Jun 06, 1984
-----------	--------------	-------------	----------------	------------	--------------

HYDROCORTISONE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795</u>	<u>001</u>	May 03, 1983
<u>AT</u>		<u>2.5%</u>	<u>A089682</u>	<u>001</u>	Mar 10, 1988
<u>AT</u>	+ FOUGERA	<u>1%</u>	<u>A080693</u>	<u>003</u>	
<u>AT</u>	+	<u>2.5%</u>	<u>A089414</u>	<u>001</u>	Dec 16, 1986
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025</u>	<u>001</u>	
<u>AT</u>	RISING PHARMS INC	<u>2.5%</u>	<u>A040879</u>	<u>001</u>	Aug 20, 2010
<u>AT</u>	TARO	<u>2.5%</u>	<u>A088799</u>	<u>001</u>	Nov 09, 1984
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040503</u>	<u>001</u>	Mar 12, 2004

SYNACORT

<u>AT</u>	MEDICIS	<u>1%</u>	<u>A087458</u>	<u>001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A087457</u>	<u>001</u>	

ENEMA;RECTAL

COLOCORT

<u>AB</u>	PADDOCK LLC	<u>100MG/60ML</u>	<u>A075172</u>	<u>001</u>	Dec 03, 1999
-----------	-------------	-------------------	----------------	------------	--------------

CORTENEMA

<u>AB</u>	+ ANI PHARMS	<u>100MG/60ML</u>	<u>N016199</u>	<u>001</u>	
-----------	--------------	-------------------	----------------	------------	--

HYDROCORTISONE

<u>AB</u>	TEVA PHARMS	<u>100MG/60ML</u>	<u>A074171</u>	<u>001</u>	May 27, 1994
-----------	-------------	-------------------	----------------	------------	--------------

LOTION;TOPICAL

HYDROCORTISONE

<u>AT</u>	+ FOUGERA PHARMS	<u>2.5%</u>	<u>A040351</u>	<u>001</u>	Jul 25, 2000
<u>AT</u>	TARO	<u>2.5%</u>	<u>A040247</u>	<u>001</u>	Jul 23, 1999
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040417</u>	<u>001</u>	Jul 30, 2003

NUTRACORT

<u>AT</u>	DOW PHARM	<u>2.5%</u>	<u>A087644</u>	<u>001</u>	Aug 24, 1982
-----------	-----------	-------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE

LOTION; TOPICAL

STIE-CORT

<b>AT</b>	PERRIGO	<b>2.5%</b>	<b>A089074 001</b>	Nov 26, 1985
	ALA-SCALP			
	CROWN LABS	2%	A083231 001	

OINTMENT; TOPICAL

HYDROCORTISONE

<b>AT</b>	ACTAVIS MID ATLANTIC	<b>1%</b>	<b>A087796 001</b>	Oct 13, 1982
<b>AT</b>	+ FOUGERA	<b>2.5%</b>	<b>A081203 001</b>	May 28, 1993
<b>AT</b>	+ FOUGERA PHARMS	<b>1%</b>	<b>A080692 001</b>	
<b>AT</b>	PERRIGO NEW YORK	<b>2.5%</b>	<b>A085027 001</b>	
<b>AT</b>	TARO	<b>1%</b>	<b>A086257 001</b>	

HYDROCORTISONE IN ABSORBASE

<b>AT</b>	CAROLINA MEDCL	<b>1%</b>	<b>A088138 001</b>	Sep 06, 1985
	SOLUTION; TOPICAL			
	TEXACORT			
	+ MISSION PHARMA	2.5%	A081271 001	Apr 17, 1992
	TABLET; ORAL			

CORTEF

<b>AB</b>	PHARMACIA AND UPJOHN	<b>5MG</b>	<b>N008697 003</b>	
<b>AB</b>		<b>10MG</b>	<b>N008697 001</b>	
<b>AB</b>	+	<b>20MG</b>	<b>N008697 002</b>	

HYDROCORTISONE

<b>AB</b>	AMEDRA PHARMS	<b>5MG</b>	<b>A040646 001</b>	Mar 30, 2007
<b>AB</b>		<b>10MG</b>	<b>A040646 002</b>	Mar 30, 2007
<b>AB</b>		<b>20MG</b>	<b>A040646 003</b>	Mar 30, 2007
<b>AB</b>	HIKMA INTL PHARMS	<b>5MG</b>	<b>A083365 002</b>	Feb 23, 2015
<b>AB</b>		<b>10MG</b>	<b>A083365 003</b>	Feb 23, 2015
<b>AB</b>		<b>20MG</b>	<b>A083365 001</b>	
<b>AB</b>	VINTAGE	<b>5MG</b>	<b>A040761 001</b>	Jul 16, 2007
<b>AB</b>		<b>10MG</b>	<b>A040761 002</b>	Jul 16, 2007
<b>AB</b>		<b>20MG</b>	<b>A040761 003</b>	Jul 16, 2007

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+ MEDA PHARMS

10%

N017351 001 Feb 10, 1982

CREAM; TOPICAL

HYDROCORTISONE ACETATE

+ FERNDALE LABS

2.5%

A040259 001 Jul 29, 1999

MICORT-HC

+ SEBELA IRELAND LTD

2%

A040398 001 Mar 29, 2002

2.5%

A040396 001 Feb 27, 2001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+ MONARCH PHARMS

0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX	MEDA PHARMS	1%;1%	A086457 001	
----	-------------	-------	-------------	--

PROCTOFOAM HC

BX	MEDA PHARMS	1%;1%	A086195 001	
----	-------------	-------	-------------	--

CREAM; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD

0.5%;1%

A083778 001

1%;1%

A085368 001

LOTION; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD

1%;1%

A085980 001

2.5%;1%

A085979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

U-CORT

TARO

1%;10%

A089472 001 Jun 13, 1988

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE**AB1** TARO PHARM INDS **0.1%** **A076654 001** Aug 03, 2005LOCOID**AB1** + PRECISION DERMAT **0.1%** **N018514 001** Mar 31, 1982HYDROCORTISONE BUTYRATE**AB2** GLENMARK GENERICS **0.1%** **A202145 001** Sep 27, 2013LOCOID LIPOCREAM**AB2** + PRECISION DERMAT **0.1%** **N020769 001** Sep 08, 1997

LOTION; TOPICAL

LOCOID

+ PRECISION DERMAT 0.1% N022076 001 May 18, 2007

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE**AB** TARO **0.1%** **A076842 001** Dec 27, 2004LOCOID**AB** + PRECISION DERMAT **0.1%** **N018652 001** Oct 29, 1982

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE**AT** TARO PHARM INDS **0.1%** **A076364 001** Jan 14, 2004LOCOID**AT** + PRECISION DERMAT **0.1%** **N019116 001** Feb 25, 1987HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

+ FOUGERA PHARMS 0.1% N020453 001 Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT**AP** HOSPIRA **EQ 100MG BASE/VIAL** **A040666 001** Apr 06, 2006SOLU-CORTEF**AP** + PHARMACIA AND UPJOHN **EQ 100MG BASE/VIAL** **N009866 001****AP** + **EQ 250MG BASE/VIAL** **N009866 002****AP** + **EQ 500MG BASE/VIAL** **N009866 003****AP** + **EQ 1GM BASE/VIAL** **N009866 004**HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE**AB** PERRIGO NEW YORK **0.2%** **A075666 001** May 24, 2000**AB** + TARO **0.2%** **A075042 001** Aug 25, 1998

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

+ TARO 0.2% A075043 001 Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN**AT** + MONARCH PHARMS **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **N050479 001**NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE**AT** ALCON PHARMS LTD **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A062423 001** Aug 25, 1983**AT** BAUSCH AND LOMB **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A064053 001** Dec 29, 1995**AT** LUITPOLD **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A065216 001** Oct 31, 2005

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

+ ALCON PHARMS LTD 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062874 001 May 11, 1988

SUSPENSION/DROPS; OTIC

CORTISPORIN**AT** + CITRON PHARMA LLC **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **N060613 001**NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE**AT** ALCON PHARMS LTD **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A062488 001** Nov 06, 1985**AT** LUITPOLD **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A065219 001** May 01, 2006OTICAIR**AT** BAUSCH AND LOMB **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A064065 001** Aug 28, 1996PEDIOTIC**AT** MONARCH PHARMS **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** **A062822 001** Sep 29, 1987



## PRESCRIPTION DRUG PRODUCT LIST

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

<b>AB</b>	+	SHIRE LLC	<b>50MG</b>	<b>N011949</b>	<b>001</b>	
-----------	---	-----------	-------------	----------------	------------	--

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

<b>AP</b>	+	PURDUE PHARM PRODS	<b>1MG/ML</b>	<b>N019034</b>	<b>003</b>	Apr 30, 2009
-----------	---	--------------------	---------------	----------------	------------	--------------

<b>AP</b>	+		<b>2MG/ML</b>	<b>N019034</b>	<b>004</b>	Apr 30, 2009
-----------	---	--	---------------	----------------	------------	--------------

<b>AP</b>	+		<b>4MG/ML</b>	<b>N019034</b>	<b>005</b>	Apr 30, 2009
-----------	---	--	---------------	----------------	------------	--------------

DILAUDID-HP

<b>AP</b>	+	PURDUE PHARM PRODS	<b>10MG/ML</b>	<b>N019034</b>	<b>001</b>	Jan 11, 1984
-----------	---	--------------------	----------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

<b>AP</b>		AKORN	<b>10MG/ML</b>	<b>A078228</b>	<b>001</b>	Apr 14, 2010
-----------	--	-------	----------------	----------------	------------	--------------

<b>AP</b>			<b>10MG/ML</b>	<b>A078261</b>	<b>001</b>	Apr 14, 2010
-----------	--	--	----------------	----------------	------------	--------------

<b>AP</b>		BARR	<b>10MG/ML</b>	<b>A076444</b>	<b>001</b>	Apr 25, 2003
-----------	--	------	----------------	----------------	------------	--------------

<b>AP</b>		HOSPIRA	<b>10MG/ML</b>	<b>A074598</b>	<b>001</b>	Jun 19, 1997
-----------	--	---------	----------------	----------------	------------	--------------

<b>AP</b>		HOSPIRA INC	<b>1MG/ML</b>	<b>N200403</b>	<b>001</b>	Dec 01, 2011
-----------	--	-------------	---------------	----------------	------------	--------------

<b>AP</b>			<b>2MG/ML</b>	<b>N200403</b>	<b>002</b>	Dec 01, 2011
-----------	--	--	---------------	----------------	------------	--------------

<b>AP</b>			<b>4MG/ML</b>	<b>N200403</b>	<b>003</b>	Dec 01, 2011
-----------	--	--	---------------	----------------	------------	--------------

<b>AP</b>			<b>10MG/ML</b>	<b>A078591</b>	<b>001</b>	Jun 17, 2008
-----------	--	--	----------------	----------------	------------	--------------

SOLUTION; ORAL

DILAUDID

<b>AA</b>	+	PURDUE PHARM PRODS	<b>5MG/5ML</b>	<b>N019891</b>	<b>001</b>	Dec 07, 1992
-----------	---	--------------------	----------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

<b>AA</b>		ROXANE	<b>5MG/5ML</b>	<b>A074653</b>	<b>001</b>	Jul 29, 1998
-----------	--	--------	----------------	----------------	------------	--------------

TABLET; ORAL

DILAUDID

<b>AB</b>		PURDUE PHARM PRODS	<b>2MG</b>	<b>N019892</b>	<b>003</b>	Nov 09, 2007
-----------	--	--------------------	------------	----------------	------------	--------------

<b>AB</b>			<b>4MG</b>	<b>N019892</b>	<b>002</b>	Nov 09, 2007
-----------	--	--	------------	----------------	------------	--------------

<b>AB</b>	+		<b>8MG</b>	<b>N019892</b>	<b>001</b>	Dec 07, 1992
-----------	---	--	------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

<b>AB</b>		ELITE LABS	<b>8MG</b>	<b>A076723</b>	<b>001</b>	Oct 18, 2005
-----------	--	------------	------------	----------------	------------	--------------

<b>AB</b>		LANNETT	<b>2MG</b>	<b>A078439</b>	<b>001</b>	Dec 09, 2009
-----------	--	---------	------------	----------------	------------	--------------

<b>AB</b>			<b>4MG</b>	<b>A078439</b>	<b>002</b>	Dec 09, 2009
-----------	--	--	------------	----------------	------------	--------------

<b>AB</b>			<b>8MG</b>	<b>A077471</b>	<b>001</b>	Dec 09, 2009
-----------	--	--	------------	----------------	------------	--------------

<b>AB</b>		MALLINCKRODT	<b>8MG</b>	<b>A076855</b>	<b>001</b>	Dec 23, 2004
-----------	--	--------------	------------	----------------	------------	--------------

<b>AB</b>		MALLINCKRODT INC	<b>2MG</b>	<b>A078273</b>	<b>001</b>	Sep 19, 2007
-----------	--	------------------	------------	----------------	------------	--------------

<b>AB</b>			<b>4MG</b>	<b>A078273</b>	<b>002</b>	Sep 19, 2007
-----------	--	--	------------	----------------	------------	--------------

<b>AB</b>		ROXANE	<b>4MG</b>	<b>A074597</b>	<b>003</b>	May 29, 2009
-----------	--	--------	------------	----------------	------------	--------------

<b>AB</b>			<b>8MG</b>	<b>A074597</b>	<b>001</b>	Jul 29, 1998
-----------	--	--	------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

EXALGO

<b>AB</b>		MALLINCKRODT INC	<b>8MG</b>	<b>N021217</b>	<b>001</b>	Mar 01, 2010
-----------	--	------------------	------------	----------------	------------	--------------

<b>AB</b>			<b>12MG</b>	<b>N021217</b>	<b>002</b>	Mar 01, 2010
-----------	--	--	-------------	----------------	------------	--------------

<b>AB</b>			<b>16MG</b>	<b>N021217</b>	<b>003</b>	Mar 01, 2010
-----------	--	--	-------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

<b>AB</b>		ACTAVIS LABS FL INC	<b>8MG</b>	<b>A202144</b>	<b>001</b>	May 12, 2014
-----------	--	---------------------	------------	----------------	------------	--------------

<b>AB</b>			<b>12MG</b>	<b>A202144</b>	<b>002</b>	May 12, 2014
-----------	--	--	-------------	----------------	------------	--------------

<b>AB</b>			<b>16MG</b>	<b>A202144</b>	<b>003</b>	May 12, 2014
-----------	--	--	-------------	----------------	------------	--------------

<b>AB</b>		PADDOCK LLC	<b>8MG</b>	<b>A204278</b>	<b>001</b>	Apr 06, 2015
-----------	--	-------------	------------	----------------	------------	--------------

<b>AB</b>			<b>12MG</b>	<b>A204278</b>	<b>002</b>	Apr 06, 2015
-----------	--	--	-------------	----------------	------------	--------------

<b>AB</b>			<b>16MG</b>	<b>A204278</b>	<b>003</b>	Apr 06, 2015
-----------	--	--	-------------	----------------	------------	--------------

EXALGO

+	MALLINCKRODT INC	<b>32MG</b>	<b>N021217</b>	<b>004</b>	Aug 24, 2012
---	------------------	-------------	----------------	------------	--------------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

+	SERB SAS	<b>5GM/VIAL (5GM/KIT)</b>	<b>N022041</b>	<b>001</b>	Apr 08, 2011
---	----------	---------------------------	----------------	------------	--------------

HYDROXOCOBALAMIN

+	WATSON LABS	<b>1MG/ML</b>	<b>A085998</b>	<b>001</b>	
---	-------------	---------------	----------------	------------	--

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+	AKORN	<b>1%;0.25%</b>	<b>N019261</b>	<b>001</b>	Jan 30, 1992
---	-------	-----------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

<b>AB</b>	HIKMA PHARMS LLC	<b>200MG</b>	<b>A040760 001</b>	Aug 15, 2007
<b>AB</b>	IPCA LABS LTD	<b>200MG</b>	<b>A040766 001</b>	Jun 14, 2007
<b>AB</b>	MYLAN	<b>200MG</b>	<b>A040274 001</b>	May 29, 1998
<b>AB</b>	SANDOZ	<b>200MG</b>	<b>A040104 001</b>	Nov 30, 1995
<b>AB</b>	TEVA PHARMS	<b>200MG</b>	<b>A040081 001</b>	Sep 30, 1994
<b>AB</b>	ZYDUS PHARMS USA INC	<b>200MG</b>	<b>A040657 001</b>	Sep 21, 2007

PLAQUENIL

<b>AB</b>	+ CONCORDIA PHARMS INC	<b>200MG</b>	<b>N009768 001</b>	
-----------	------------------------	--------------	--------------------	--

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

+ MCGUFF

250MG/ML

A200271 001 Aug 24, 2015

SOLUTION; INTRAMUSCULAR

MAKENA

+ LUMARA HEALTH INC

1250MG/5ML (250MG/ML)

N021945 001 Feb 03, 2011

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+ ATON

5MG

N018771 001

HYDROXYUREA

CAPSULE; ORAL

HYDREA

<b>AB</b>	+ BRISTOL MYERS SQUIBB	<b>500MG</b>	<b>N016295 001</b>	
-----------	------------------------	--------------	--------------------	--

HYDROXYUREA

<b>AB</b>	BARR	<b>500MG</b>	<b>A075143 001</b>	Oct 16, 1998
<b>AB</b>	PAR PHARM	<b>500MG</b>	<b>A075340 001</b>	Feb 24, 1999
	DROXIA			
	BRISTOL MYERS SQUIBB	200MG	N016295 002	Feb 25, 1998
		300MG	N016295 003	Feb 25, 1998
		400MG	N016295 004	Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

<b>AP</b>	+ FRESENIUS KABI USA	<b>25MG/ML</b>	<b>A087329 001</b>	
<b>AP</b>	+ FRESENIUS KABI USA	<b>50MG/ML</b>	<b>A087329 002</b>	
<b>AP</b>	LUITPOLD	<b>25MG/ML</b>	<b>A087408 001</b>	
<b>AP</b>	LUITPOLD	<b>50MG/ML</b>	<b>A087408 002</b>	

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

<b>AA</b>	+ HI TECH PHARMA	<b>10MG/5ML</b>	<b>A040010 001</b>	Oct 28, 1994
<b>AA</b>	SILARX PHARMS INC	<b>10MG/5ML</b>	<b>A201674 001</b>	Aug 21, 2013
<b>AA</b>	+ VINTAGE PHARMS	<b>10MG/5ML</b>	<b>A040391 001</b>	Apr 10, 2002
<b>AA</b>	+ WOCKHARDT	<b>10MG/5ML</b>	<b>A087294 001</b>	Apr 12, 1982

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<b>AB</b>	AMNEAL PHARM	<b>10MG</b>	<b>A040808 001</b>	Sep 24, 2008
<b>AB</b>		<b>25MG</b>	<b>A040808 002</b>	Sep 24, 2008
<b>AB</b>		<b>50MG</b>	<b>A040808 003</b>	Sep 24, 2008
<b>AB</b>	ELITE LABS INC	<b>10MG</b>	<b>A040600 001</b>	Dec 28, 2004
<b>AB</b>		<b>25MG</b>	<b>A040602 001</b>	Dec 28, 2004
<b>AB</b>		<b>50MG</b>	<b>A040604 001</b>	Dec 28, 2004
<b>AB</b>	HERITAGE PHARMA	<b>10MG</b>	<b>A204279 001</b>	Aug 20, 2014
<b>AB</b>		<b>25MG</b>	<b>A204279 002</b>	Aug 20, 2014
<b>AB</b>		<b>50MG</b>	<b>A204279 003</b>	Aug 20, 2014
<b>AB</b>	HERITAGE PHARMS INC	<b>10MG</b>	<b>A040804 001</b>	Jun 30, 2008
<b>AB</b>		<b>25MG</b>	<b>A040804 002</b>	Jun 30, 2008
<b>AB</b>		<b>50MG</b>	<b>A040804 003</b>	Jun 30, 2008
<b>AB</b>	HETERO LABS LTD III	<b>10MG</b>	<b>A040805 001</b>	May 29, 2008
<b>AB</b>		<b>25MG</b>	<b>A040805 002</b>	May 29, 2008
<b>AB</b>		<b>50MG</b>	<b>A040805 003</b>	May 29, 2008
<b>AB</b>	INVAGEN PHARMS	<b>10MG</b>	<b>A040812 001</b>	Mar 12, 2008
<b>AB</b>		<b>25MG</b>	<b>A040812 002</b>	Mar 12, 2008
<b>AB</b>		<b>50MG</b>	<b>A040812 003</b>	Mar 12, 2008
<b>AB</b>	KVK TECH	<b>10MG</b>	<b>A040786 001</b>	Mar 20, 2007
<b>AB</b>		<b>25MG</b>	<b>A040787 001</b>	Mar 20, 2007
<b>AB</b>		<b>50MG</b>	<b>A040788 001</b>	Mar 20, 2007
<b>AB</b>	MYLAN	<b>10MG</b>	<b>A091176 001</b>	Jun 07, 2010

## PRESCRIPTION DRUG PRODUCT LIST

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>		<u>25MG</u>	<u>A091176 002</u>	Jun 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A091176 003</u>	Jun 07, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A040840 002</u>	Mar 31, 2008
<u>AB</u>		<u>25MG</u>	<u>A040840 003</u>	Mar 31, 2008
<u>AB</u>		<u>50MG</u>	<u>A040840 001</u>	Mar 31, 2008
<u>AB</u>	+ PLIVA	<u>10MG</u>	<u>A088617 001</u>	Jan 10, 1986
<u>AB</u>	+	<u>25MG</u>	<u>A088618 001</u>	Jan 10, 1986
<u>AB</u>	+	<u>50MG</u>	<u>A088619 001</u>	Jan 10, 1986
<u>AB</u>	SUN PHARM INDS INC	<u>10MG</u>	<u>A040899 001</u>	Jun 10, 2008
<u>AB</u>		<u>25MG</u>	<u>A040899 002</u>	Jun 10, 2008
<u>AB</u>		<u>50MG</u>	<u>A040899 003</u>	Jun 10, 2008
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040579 001</u>	May 27, 2005
<u>AB</u>		<u>25MG</u>	<u>A040574 001</u>	May 27, 2005
<u>AB</u>		<u>50MG</u>	<u>A040580 001</u>	May 27, 2005

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>	BARR	<u>EQ 25MG HCL</u>	<u>A088496 001</u>	Jun 15, 1984
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A088487 001</u>	Jun 15, 1984
<u>AB</u>	HERITAGE PHARMA	<u>EQ 25MG HYDROCHLORIDE</u>	<u>A201507 001</u>	Jun 03, 2013
<u>AB</u>		<u>EQ 50MG HYDROCHLORIDE</u>	<u>A201507 002</u>	Jun 03, 2013
<u>AB</u>	SANDOZ	<u>EQ 25MG HCL</u>	<u>A087479 001</u>	
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A086183 001</u>	
<u>AB</u>	WATSON LABS	<u>EQ 25MG HCL</u>	<u>A040156 001</u>	Jul 15, 1996
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A040156 002</u>	Jul 15, 1996
<u>VISTARIL</u>				
<u>AB</u>	PFIZER	<u>EQ 25MG HCL</u>	<u>N011459 002</u>	
<u>AB</u>	+	<u>EQ 50MG HCL</u>	<u>N011459 004</u>	
	HYDROXYZINE PAMOATE			
	BARR	<u>EQ 100MG HCL</u>	<u>A088488 001</u>	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

<u>AP</u>	+ ROCHE	<u>EQ 3MG BASE/3ML</u>	<u>N021858 001</u>	Jan 06, 2006
<u>IBANDRONATE SODIUM</u>				
<u>AP</u>	APOTEX INC	<u>EQ 3MG BASE/3ML</u>	<u>A204222 001</u>	Oct 16, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 3MG BASE/3ML</u>	<u>A205332 001</u>	Aug 19, 2015
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A203987 001</u>	Sep 02, 2014
<u>AP</u>	MYLAN LABS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A202671 001</u>	Sep 02, 2014
<u>AP</u>	SAGENT PHARMS	<u>EQ 3MG BASE/3ML</u>	<u>A202235 001</u>	Sep 02, 2014
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A090853 001</u>	Feb 14, 2014

TABLET; ORAL

BONIVA

<u>AB</u>	+ HOFFMANN LA ROCHE	<u>EQ 150MG BASE</u>	<u>N021455 002</u>	Mar 24, 2005
<u>IBANDRONATE SODIUM</u>				
<u>AB</u>	APOTEX INC	<u>EQ 150MG BASE</u>	<u>A078948 001</u>	Mar 19, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A078997 001</u>	Apr 30, 2012
<u>AB</u>	MUTUAL PHARM CO INC	<u>EQ 150MG BASE</u>	<u>A078996 001</u>	Aug 15, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078995 001</u>	Mar 19, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 150MG BASE</u>	<u>A078998 001</u>	Mar 19, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 150MG BASE</u>	<u>A079003 001</u>	Mar 20, 2012

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

	+ PHARMACYCLICS INC	140MG	<u>N205552 001</u>	Nov 13, 2013
--	---------------------	-------	--------------------	--------------

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

	+ CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	<u>N022348 002</u>	Jun 11, 2009
--	---------------------	----------------------	--------------------	--------------

SUSPENSION; ORAL

IBUPROFEN

<u>AB</u>	+ ACTAVIS MID ATLANTIC	<u>100MG/5ML</u>	<u>A074978 001</u>	Mar 25, 1998
<u>AB</u>	PERRIGO R AND D	<u>100MG/5ML</u>	<u>A076925 001</u>	Sep 23, 2004

TABLET; ORAL

IBU-TAB

<u>AB</u>	ALRA	<u>400MG</u>	<u>A071058 001</u>	Aug 11, 1988
<u>AB</u>		<u>600MG</u>	<u>A071059 001</u>	Aug 11, 1988

## PRESCRIPTION DRUG PRODUCT LIST

IBUPROFEN

TABLET; ORAL

IBUPROFEN

<u>AB</u>	AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>400MG</u>	<u>A078558</u>	<u>001</u>	Jun 18, 2007
<u>AB</u>		<u>600MG</u>	<u>A071335</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>600MG</u>	<u>A078558</u>	<u>002</u>	Jun 18, 2007
<u>AB</u>		<u>800MG</u>	<u>A071935</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>800MG</u>	<u>A078558</u>	<u>003</u>	Jun 18, 2007
<u>AB</u>	CONTRACT PHARMACAL	<u>400MG</u>	<u>A071267</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>		<u>600MG</u>	<u>A071268</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>		<u>800MG</u>	<u>A072300</u>	<u>001</u>	Jul 01, 1988
<u>AB</u>	DR REDDYS LA	<u>400MG</u>	<u>A075682</u>	<u>001</u>	Nov 14, 2001
<u>AB</u>		<u>600MG</u>	<u>A075682</u>	<u>002</u>	Nov 14, 2001
<u>AB</u>	+	<u>800MG</u>	<u>A075682</u>	<u>003</u>	Nov 14, 2001
<u>AB</u>	DR REDDYS LABS INC	<u>400MG</u>	<u>A076112</u>	<u>001</u>	Oct 31, 2001
<u>AB</u>		<u>600MG</u>	<u>A076112</u>	<u>002</u>	Oct 31, 2001
<u>AB</u>		<u>800MG</u>	<u>A076112</u>	<u>003</u>	Oct 31, 2001
<u>AB</u>	GRANULES INDIA LTD	<u>400MG</u>	<u>A091625</u>	<u>001</u>	Sep 15, 2015
<u>AB</u>		<u>600MG</u>	<u>A091625</u>	<u>002</u>	Sep 15, 2015
<u>AB</u>		<u>800MG</u>	<u>A091625</u>	<u>003</u>	Sep 15, 2015
<u>AB</u>	MARKSANS PHARMA	<u>400MG</u>	<u>A090796</u>	<u>001</u>	Dec 21, 2010
<u>AB</u>		<u>600MG</u>	<u>A090796</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>		<u>800MG</u>	<u>A090796</u>	<u>003</u>	Dec 21, 2010
<u>AB</u>	PERRIGO R AND D	<u>400MG</u>	<u>A077114</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>		<u>600MG</u>	<u>A077114</u>	<u>002</u>	Jul 18, 2005
<u>AB</u>		<u>800MG</u>	<u>A077114</u>	<u>003</u>	Jul 18, 2005
<u>AB</u>	SHASUN USA	<u>400MG</u>	<u>A078329</u>	<u>001</u>	Feb 05, 2009
<u>AB</u>		<u>600MG</u>	<u>A078329</u>	<u>002</u>	Feb 05, 2009
<u>AB</u>		<u>800MG</u>	<u>A078329</u>	<u>003</u>	Feb 05, 2009
<u>AB</u>	VINTAGE PHARMS	<u>400MG</u>	<u>A071644</u>	<u>001</u>	Feb 01, 1988

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ RECORDATI RARE EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N021903 001 Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

<u>AB</u>	ACTAVIS ELIZABETH	<u>400MG; 5MG</u>	<u>A078769</u>	<u>001</u>	Jan 04, 2008
<u>AB</u>	+	<u>400MG; 5MG</u>	<u>A078316</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	WATSON LABS	<u>400MG; 5MG</u>	<u>A078394</u>	<u>001</u>	Nov 26, 2007

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERTAP + PHARMACIA AND UPJOHN 0.1MG/ML N020491 001 Dec 28, 1995IBUTILIDE FUMARATE

<u>AP</u>	LUITPOLD	<u>0.1MG/ML</u>	<u>A090240</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>	MYLAN INSTITUTIONAL	<u>0.1MG/ML</u>	<u>A090643</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		<u>0.1MG/ML</u>	<u>A090924</u>	<u>001</u>	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

+ SHIRE ORPHAN THERAP EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N022150 001 Aug 25, 2011

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAL

+ BAXTER HLTHCARE 7.5GM/100ML N021321 001 Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMS 1GM N202057 001 Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFSAP + PHARMACIA AND UPJOHN 1MG/ML N050734 001 Feb 17, 1997IDARUBICIN HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL SARL	<u>1MG/ML</u>	<u>A065275</u>	<u>001</u>	Dec 14, 2006
<u>AP</u>		<u>1MG/ML</u>	<u>A065288</u>	<u>001</u>	May 15, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A065440</u>	<u>001</u>	Aug 04, 2009

## PRESCRIPTION DRUG PRODUCT LIST

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

<b>AP</b>	MYLAN LABS LTD	<b>1MG/ML</b>	<b>A200144</b>	<b>001</b>	Oct 11, 2012
-----------	----------------	---------------	----------------	------------	--------------

IDARUBICIN HYDROCHLORIDE PFS

<b>AP</b>	TEVA PHARMS USA	<b>1MG/ML</b>	<b>A065036</b>	<b>001</b>	May 01, 2002
-----------	-----------------	---------------	----------------	------------	--------------

IDELALISIB

TABLET; ORAL

ZYDELIG

	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014
+		150MG	N205858	002	Jul 23, 2014

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID

<b>AT</b>	+ ALCON	<b>0.1%</b>	<b>N014169</b>	<b>001</b>	
-----------	---------	-------------	----------------	------------	--

HERPLEX

<b>AT</b>	+ ALLERGAN	<b>0.1%</b>	<b>N013935</b>	<b>002</b>	
-----------	------------	-------------	----------------	------------	--

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

<b>AP</b>	BAXTER HLTHCARE	<b>1GM/VIAL</b>	<b>N019763</b>	<b>001</b>	Dec 30, 1988
-----------	-----------------	-----------------	----------------	------------	--------------

<b>AP</b>		<b>3GM/VIAL</b>	<b>N019763</b>	<b>002</b>	Dec 30, 1988
-----------	--	-----------------	----------------	------------	--------------

IFOSFAMIDE

<b>AP</b>	EUROHLTH INTL SARL	<b>1GM/20ML (50MG/ML)</b>	<b>A076619</b>	<b>001</b>	Jun 29, 2011
-----------	--------------------	---------------------------	----------------	------------	--------------

<b>AP</b>		<b>3GM/60ML (50MG/ML)</b>	<b>A076619</b>	<b>002</b>	Jun 29, 2011
-----------	--	---------------------------	----------------	------------	--------------

<b>AP</b>	+ FRESENIUS KABI USA	<b>1GM/VIAL</b>	<b>A076078</b>	<b>001</b>	May 28, 2002
-----------	----------------------	-----------------	----------------	------------	--------------

<b>AP</b>		<b>1GM/20ML (50MG/ML)</b>	<b>A090181</b>	<b>001</b>	Sep 22, 2009
-----------	--	---------------------------	----------------	------------	--------------

<b>AP</b>	+	<b>3GM/VIAL</b>	<b>A076078</b>	<b>002</b>	May 28, 2002
-----------	---	-----------------	----------------	------------	--------------

<b>AP</b>		<b>3GM/60ML (50MG/ML)</b>	<b>A090181</b>	<b>002</b>	Sep 22, 2009
-----------	--	---------------------------	----------------	------------	--------------

<b>AP</b>	MYLAN LABS LTD	<b>1GM/20ML (50MG/ML)</b>	<b>A201689</b>	<b>001</b>	Nov 26, 2012
-----------	----------------	---------------------------	----------------	------------	--------------

<b>AP</b>		<b>3GM/60ML (50MG/ML)</b>	<b>A201689</b>	<b>002</b>	Nov 26, 2012
-----------	--	---------------------------	----------------	------------	--------------

<b>AP</b>	+ TEVA PHARMS USA	<b>1GM/20ML (50MG/ML)</b>	<b>A076657</b>	<b>001</b>	Apr 04, 2007
-----------	-------------------	---------------------------	----------------	------------	--------------

<b>AP</b>	+	<b>3GM/60ML (50MG/ML)</b>	<b>A076657</b>	<b>002</b>	Apr 04, 2007
-----------	---	---------------------------	----------------	------------	--------------

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+	TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	001	Feb 26, 2002
---	-----------------	--	---------	-----	--------------

+		3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	002	Feb 26, 2002
---	--	--	---------	-----	--------------

ILOPERIDONE

TABLET; ORAL

FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009
---	------------------	-----	---------	-----	--------------

		2MG	N022192	002	May 06, 2009
--	--	-----	---------	-----	--------------

		4MG	N022192	003	May 06, 2009
--	--	-----	---------	-----	--------------

		6MG	N022192	004	May 06, 2009
--	--	-----	---------	-----	--------------

		8MG	N022192	005	May 06, 2009
--	--	-----	---------	-----	--------------

		10MG	N022192	006	May 06, 2009
--	--	------	---------	-----	--------------

		12MG	N022192	007	May 06, 2009
--	--	------	---------	-----	--------------

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+	ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
---	---------------------	---------------------	---------	-----	--------------

+		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009
---	--	---------------------	---------	-----	--------------

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

<b>AB</b>	NOVARTIS	<b>EQ 100MG BASE</b>	<b>N021588</b>	<b>001</b>	Apr 18, 2003
-----------	----------	----------------------	----------------	------------	--------------

<b>AB</b>	+	<b>EQ 400MG BASE</b>	<b>N021588</b>	<b>002</b>	Apr 18, 2003
-----------	---	----------------------	----------------	------------	--------------

IMATINIB MESYLATE

<b>AB</b>	SUN PHARMA GLOBAL	<b>EQ 100MG BASE</b>	<b>A078340</b>	<b>001</b>	Dec 03, 2015
-----------	-------------------	----------------------	----------------	------------	--------------

<b>AB</b>		<b>EQ 400MG BASE</b>	<b>A078340</b>	<b>002</b>	Dec 03, 2015
-----------	--	----------------------	----------------	------------	--------------

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

	GENZYME	200 UNITS/VIAL	N020367	001	May 23, 1994
--	---------	----------------	---------	-----	--------------

+		400 UNITS/VIAL	N020367	002	Sep 22, 1999
---	--	----------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>	LEADING PHARMA LLC	<u>10MG</u>	<u>A040903</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A040903</u>	<u>002</u>	Oct 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A040903</u>	<u>003</u>	Oct 24, 2012
<u>AB</u>	LUPIN LTD	<u>10MG</u>	<u>A090443</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>		<u>25MG</u>	<u>A090442</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>		<u>50MG</u>	<u>A090441</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A081048</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>25MG</u>	<u>A081049</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>50MG</u>	<u>A081050</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A088292</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		<u>10MG</u>	<u>A089422</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A088262</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		<u>50MG</u>	<u>A088276</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A084936</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A083745</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084937</u>	<u>001</u>	
<u>TOFRANIL</u>					
<u>AB</u>	MALLINCKRODT INC	<u>10MG</u>	<u>A087844</u>	<u>001</u>	May 22, 1984
<u>AB</u>		<u>25MG</u>	<u>A087845</u>	<u>001</u>	May 22, 1984
<u>AB</u>	+	<u>50MG</u>	<u>A087846</u>	<u>001</u>	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>	LUPIN LTD	<u>EQ 75MG HCL</u>	<u>A090444</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A090444</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A090444</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A090444</u>	<u>004</u>	Apr 16, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG HCL</u>	<u>A202338</u>	<u>001</u>	Jun 28, 2013
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A202338</u>	<u>002</u>	Jun 28, 2013
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A202338</u>	<u>003</u>	Jun 28, 2013
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A202338</u>	<u>004</u>	Jun 28, 2013
<u>AB</u>	ROXANE	<u>EQ 75MG HCL</u>	<u>A091099</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A091099</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A091099</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A091099</u>	<u>004</u>	Apr 16, 2010

TOFRANIL-PM

<u>AB</u>	+	MALLINCKRODT INC	<u>EQ 75MG HCL</u>	<u>N017090</u>	<u>001</u>
<u>AB</u>			<u>EQ 100MG HCL</u>	<u>N017090</u>	<u>004</u>
<u>AB</u>			<u>EQ 125MG HCL</u>	<u>N017090</u>	<u>003</u>
<u>AB</u>			<u>EQ 150MG HCL</u>	<u>N017090</u>	<u>002</u>

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+	MEDICIS	<u>5%</u>	<u>N020723</u>	<u>001</u>	Feb 27, 1997
-----------	---	---------	-----------	----------------	------------	--------------

IMIQUIMOD

<u>AB</u>	APOTEX INC	<u>5%</u>	<u>A091308</u>	<u>001</u>	Apr 06, 2012	
<u>AB</u>	FOUGERA PHARMS	<u>5%</u>	<u>A078548</u>	<u>001</u>	Feb 25, 2010	
<u>AB</u>	G AND W LABS INC	<u>5%</u>	<u>A200481</u>	<u>001</u>	Apr 18, 2011	
<u>AB</u>	GLENMARK GENERICS	<u>5%</u>	<u>A201994</u>	<u>001</u>	Mar 06, 2012	
<u>AB</u>	PERRIGO ISRAEL	<u>5%</u>	<u>A078837</u>	<u>001</u>	Sep 07, 2010	
<u>AB</u>	STRIDES PHARMA	<u>5%</u>	<u>A202002</u>	<u>001</u>	Jun 24, 2014	
<u>AB</u>	TARO	<u>5%</u>	<u>A200173</u>	<u>001</u>	Apr 15, 2011	
<u>AB</u>	TOLMAR	<u>5%</u>	<u>A091044</u>	<u>001</u>	Feb 28, 2011	
<u>ZYCLARA</u>						
	+	MEDICIS	2.5%	N022483	002	Jul 15, 2011
	+		3.75%	N022483	001	Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A075513	001	May 09, 2000
--	---	--------------------	----------------	---------	-----	--------------

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

	+	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011
--	---	----------	---------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<b>AB</b>	ACTAVIS ELIZABETH	<b>1.25MG</b>	<b>A074722 001</b>	Jun 17, 1996
<b>AB</b>		<b>2.5MG</b>	<b>A074722 002</b>	Jun 17, 1996
<b>AB</b>	ANI PHARMS INC	<b>1.25MG</b>	<b>A074299 002</b>	Apr 29, 1996
<b>AB</b>		<b>2.5MG</b>	<b>A074299 001</b>	Jul 27, 1995
<b>AB</b>	MYLAN	<b>1.25MG</b>	<b>A074461 002</b>	Mar 26, 1997
<b>AB</b>	+	<b>2.5MG</b>	<b>A074461 001</b>	Mar 27, 1996
<b>AB</b>	MYLAN PHARMS INC	<b>1.25MG</b>	<b>A075105 001</b>	Jul 23, 1998
<b>AB</b>		<b>2.5MG</b>	<b>A075105 002</b>	Jul 23, 1998

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

	MERCK SHARP DOHME	EQ 200MG BASE	N020685 003	Mar 13, 1996
	+	EQ 400MG BASE	N020685 001	Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

	+	GE HEALTHCARE	2mCi/0.2ML	N019862 001	Dec 29, 1992
		INDIUM IN 111 CHLORIDE			
	+	MALLINCKRODT	5mCi/0.5ML	N019841 001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE

	+	GE HEALTHCARE	1mCi/ML	N019044 001	Dec 24, 1985
--	---	---------------	---------	-------------	--------------

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

	+	GE HEALTHCARE	1mCi/ML	N017707 001	Feb 18, 1982
--	---	---------------	---------	-------------	--------------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

	+	MALLINCKRODT	3mCi/ML	N020314 001	Jun 02, 1994
--	---	--------------	---------	-------------	--------------

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

<b>AP</b>	+	AKORN	<b>25MG/VIAL</b>	<b>N011525 001</b>	
<b>AP</b>		PULSION MEDCL	<b>25MG/VIAL</b>	<b>A040811 001</b>	Nov 21, 2007

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

<b>AB</b>	GLENMARK GENERICS	<b>25MG</b>	<b>A091276 001</b>	Dec 22, 2010
<b>AB</b>		<b>50MG</b>	<b>A091276 002</b>	Dec 22, 2010
<b>AB</b>	HERITAGE PHARMS INC	<b>25MG</b>	<b>N018851 001</b>	May 18, 1984
<b>AB</b>		<b>50MG</b>	<b>N018851 002</b>	May 18, 1984
<b>AB</b>	HETERO LABS LTD III	<b>25MG</b>	<b>A091240 001</b>	Apr 12, 2011
<b>AB</b>		<b>50MG</b>	<b>A091240 002</b>	Apr 12, 2011
<b>AB</b>	IVAX SUB TEVA PHARMS	<b>25MG</b>	<b>A070719 001</b>	Feb 12, 1986
<b>AB</b>		<b>50MG</b>	<b>A070756 001</b>	Feb 12, 1986
<b>AB</b>	MYLAN	<b>25MG</b>	<b>N018858 001</b>	Apr 20, 1984
<b>AB</b>	+	<b>50MG</b>	<b>A070624 001</b>	Sep 04, 1985
<b>AB</b>	SANDOZ	<b>25MG</b>	<b>A070673 001</b>	Apr 29, 1987
<b>AB</b>		<b>50MG</b>	<b>A070674 001</b>	Apr 29, 1987
<b>AB</b>	SUN PHARM INDS INC	<b>25MG</b>	<b>A091401 001</b>	Mar 28, 2013
<b>AB</b>		<b>50MG</b>	<b>A091401 002</b>	Mar 28, 2013
<b>AB</b>	ZYDUS PHARMS USA INC	<b>25MG</b>	<b>A090403 001</b>	Nov 15, 2010
<b>AB</b>		<b>50MG</b>	<b>A090403 002</b>	Nov 15, 2010
	TIVORBEX			
	IROKO PHARMS LLC	20MG	N204768 001	Feb 24, 2014
	+	40MG	N204768 002	Feb 24, 2014

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

<b>AB</b>	AMNEAL PHARMS	<b>75MG</b>	<b>A091549 001</b>	Dec 01, 2010
<b>AB</b>	AVANTHI INC	<b>75MG</b>	<b>A079175 001</b>	Mar 06, 2009
<b>AB</b>	HETERO LABS LTD III	<b>75MG</b>	<b>A201807 001</b>	Sep 28, 2012
<b>AB</b>	JUBILANT GENERICS	<b>75MG</b>	<b>A202706 001</b>	Oct 05, 2015
<b>AB</b>	MYLAN PHARMS INC	<b>75MG</b>	<b>A202139 001</b>	Mar 20, 2014

## PRESCRIPTION DRUG PRODUCT LIST

INDOMETHACIN

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

<b>AB</b>	PADDOCK LLC	<b>75MG</b>	<b>A200529 001</b>	Nov 30, 2010
<b>AB</b>	+ SANDOZ	<b>75MG</b>	<b>A074464 001</b>	May 28, 1998
<b>AB</b>	WATSON LABS INC	<b>75MG</b>	<b>A202572 001</b>	Dec 09, 2013

INJECTABLE;INJECTION

## INDOMETHACIN

+ FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N022536 001	Mar 17, 2010
----------------------	------------------	-------------	--------------

SUPPOSITORY;RECTAL

## INDOMETHACIN

+ G AND W LABS	50MG	A073314 001	Aug 31, 1992
----------------	------	-------------	--------------

SUSPENSION;ORAL

## INDOCIN

+ IROKO PHARMS	25MG/5ML	N018332 001	Oct 10, 1985
----------------	----------	-------------	--------------

INDOMETHACIN SODIUM

INJECTABLE;INJECTION

INDOCIN

<b>AP</b>	+ RECORDATI RARE	<b>EQ 1MG BASE/VIAL</b>	<b>N018878 001</b>	Jan 30, 1985
-----------	------------------	-------------------------	--------------------	--------------

INDOMETHACIN SODIUM

<b>AP</b>	EUROHLTH INTL SARL	<b>EQ 1MG BASE/VIAL</b>	<b>A078713 001</b>	Jul 16, 2008
-----------	--------------------	-------------------------	--------------------	--------------

INGENOL MEBUTATE

GEL;TOPICAL

## PICATO

+ LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012
-----------------	--------	-------------	--------------

+	0.05%	N202833 002	Jan 23, 2012
---	-------	-------------	--------------

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

## NOVOLOG MIX 70/30

+ NOVO NORDISK INC	700 UNITS/10ML;300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)	N021172 001	Nov 01, 2001
--------------------	--	-------------	--------------

## NOVOLOG MIX 70/30 FLEXPEN

+ NOVO NORDISK INC	210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172 004	May 03, 2002
--------------------	---	-------------	--------------

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

## NOVOLOG

+ NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N020986 001	Jun 07, 2000
--------------------	--------------------------------	-------------	--------------

## NOVOLOG FLEXPEN

+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 003	Jan 19, 2001
--------------------	------------------------------	-------------	--------------

## NOVOLOG FLEXTOUCH

+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 005	Oct 31, 2013
--------------------	------------------------------	-------------	--------------

## NOVOLOG PENFILL

+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 002	Jun 07, 2000
--------------------	------------------------------	-------------	--------------

INSULIN ASPART; INSULIN DEGLUDEC

SOLUTION;SUBCUTANEOUS

## RYZODEG 70/30

+ NOVO NORDISK INC	90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)	N203313 001	Sep 25, 2015
--------------------	--	-------------	--------------

INSULIN DEGLUDEC

SOLUTION;SUBCUTANEOUS

## TRESIBA

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N203314 001	Sep 25, 2015
------------------	------------------------------	-------------	--------------

+	600 UNITS/3ML (200 UNITS/ML)	N203314 002	Sep 25, 2015
---	------------------------------	-------------	--------------

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

## LEVEMIR

+ NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N021536 001	Jun 16, 2005
--------------------	--------------------------------	-------------	--------------

## LEVEMIR FLEXPEN

+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 002	Jun 16, 2005
--------------------	------------------------------	-------------	--------------

## LEVEMIR FLEXTOUCH

+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 005	Oct 31, 2013
--------------------	------------------------------	-------------	--------------

INSULIN GLARGINE

SOLUTION;SUBCUTANEOUS

## BASAGLAR

ELI LILLY AND CO	300 UNITS/3ML (100 UNITS/ML)	N205692 001	Dec 16, 2015
------------------	------------------------------	-------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+ SANOFI AVENTIS US 100 UNITS/ML N021081 001 Apr 20, 2000

LANTUS SOLOSTAR

+ SANOFI AVENTIS US 300 UNITS/3ML (100 UNITS/ML) N021081 002 Apr 27, 2007

SOLUTION; SUBCUTANEOUS

TOUJEO SOLOSTAR

+ SANOFI US SERVICES 300 UNITS/ML (300 UNITS/ML) N206538 001 Feb 25, 2015

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

APIDRA

+ SANOFI AVENTIS US 1000 UNITS/10ML (100 UNITS/ML) N021629 001 Apr 16, 2004

+ 300 UNITS/3ML (100 UNITS/ML) N021629 002 Dec 20, 2005

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

SANOFI AVENTIS US 300 UNITS/3ML N021629 003 Feb 24, 2009

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY 50 UNITS/ML; 50 UNITS/ML N021018 001 Dec 22, 1999

HUMALOG MIX 50/50 KWIKPEN

+ LILLY 50 UNITS/ML; 50 UNITS/ML N021018 002 Sep 06, 2007

HUMALOG MIX 75/25

+ LILLY 75 UNITS/ML; 25 UNITS/ML N021017 001 Dec 22, 1999

HUMALOG MIX 75/25 KWIKPEN

+ LILLY 75 UNITS/ML; 25 UNITS/ML N021017 002 Sep 06, 2007

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY 100 UNITS/ML N020563 001 Jun 14, 1996

HUMALOG KWIKPEN

+ LILLY 100 UNITS/ML N020563 003 Sep 06, 2007

SOLUTION; SUBCUTANEOUS

HUMALOG KWIKPEN

+ ELI LILLY AND CO 200 UNITS/ML N205747 001 May 26, 2015

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY 500 UNITS/ML N018780 004 Mar 31, 1994

POWDER; INHALATION

AFREZZA

SANOFI AVENTIS 4 UNITS/INH N022472 001 Jun 27, 2014

+ 8 UNITS/INH N022472 002 Jun 27, 2014

12 UNITS/INH N022472 003 Apr 17, 2015

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS

ADREVIEW

+ GE HEALTHCARE 10mCi/5ML (2mCi/ML) N022290 001 Sep 19, 2008

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

+ BRACCO 52% N009321 003

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

+ GE HEALTHCARE 55% N020351 001 Mar 22, 1996

55% N020808 001 Aug 29, 1997

VISIPAQUE 320

+ GE HEALTHCARE 65.2% N020351 002 Mar 22, 1996

65.2% N020808 002 Aug 29, 1997

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+ GE HLTHCARE INC 5mCi/2.5ML (2mCi/ML) N022454 001 Jan 14, 2011

## PRESCRIPTION DRUG PRODUCT LIST

IOHEXOL

FOR SOLUTION;ORAL

ORALTAG

INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015
INJECTABLE;INJECTION				
OMNIPAQUE 140				
+ GE HEALTHCARE	30.2%	N018956	005	Nov 30, 1988
SOLUTION;INJECTION, ORAL				
OMNIPAQUE 350				
+ GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985
	75.5%	N020608	003	Oct 24, 1995
SOLUTION;INJECTION, ORAL, RECTAL				
OMNIPAQUE 180				
+ GE HEALTHCARE	38.8%	N018956	001	Dec 26, 1985
OMNIPAQUE 240				
+ GE HEALTHCARE	51.8%	N018956	002	Dec 26, 1985
	51.8%	N020608	001	Oct 24, 1995
OMNIPAQUE 300				
+ GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985
	64.7%	N020608	002	Oct 24, 1995

IOPAMIDOL

INJECTABLE;INJECTION

**ISOVUE-300**

<b><u>AP</u></b> + BRACCO	<b><u>61%</u></b>	<b><u>N018735</u></b>	<b><u>002</u></b>	Dec 31, 1985
<b><u>ISOVUE-370</u></b>				
<b><u>AP</u></b> + BRACCO	<b><u>76%</u></b>	<b><u>N018735</u></b>	<b><u>003</u></b>	Dec 31, 1985
<b><u>SCANLUX-300</u></b>				
<b><u>AP</u></b> MYLAN INSTITUTIONAL	<b><u>61%</u></b>	<b><u>A090394</u></b>	<b><u>001</u></b>	Jun 18, 2010
<b><u>SCANLUX-370</u></b>				
<b><u>AP</u></b> MYLAN INSTITUTIONAL	<b><u>76%</u></b>	<b><u>A090394</u></b>	<b><u>002</u></b>	Jun 18, 2010
ISOVUE-200				
+ BRACCO	41%	N018735	006	Jul 07, 1987
ISOVUE-250				
+ BRACCO	51%	N018735	007	Jul 06, 1992
+ BRACCO	51%	N020327	002	Oct 12, 1994
ISOVUE-300				
+ BRACCO	61%	N020327	003	Oct 12, 1994
ISOVUE-370				
+ BRACCO	76%	N020327	004	Oct 12, 1994
ISOVUE-M 200				
+ BRACCO	41%	N018735	001	Dec 31, 1985
ISOVUE-M 300				
+ BRACCO	61%	N018735	004	Dec 31, 1985

IOPROMIDE

INJECTABLE;INJECTION

ULTRAVIST (PHARMACY BULK)

+ BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004
+ BAYER HLTHCARE	62.3%	N021425	001	Sep 20, 2002
+ BAYER HLTHCARE	76.9%	N021425	002	Sep 20, 2002
ULTRAVIST 150				
+ BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995
ULTRAVIST 240				
+ BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995
ULTRAVIST 300				
+ BAYER HLTHCARE	62.3%	N020220	002	May 10, 1995
ULTRAVIST 300 IN PLASTIC CONTAINER				
+ BAYER HLTHCARE	62.3%	N020220	005	Nov 18, 2008
ULTRAVIST 370				
+ BAYER HLTHCARE	76.9%	N020220	001	May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION

CONRAY

+ LIEBEL-FLARSHEIM	60%	N013295	001	
CONRAY 30				
+ LIEBEL-FLARSHEIM	30%	N016983	001	
CONRAY 43				
+ LIEBEL-FLARSHEIM	43%	N013295	002	
SOLUTION;INTRAVESICAL				
CYSTO-CONRAY II				
LIEBEL-FLARSHEIM	17.2%	N017057	002	

## PRESCRIPTION DRUG PRODUCT LIST

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

ISOTEX

250-300uCi/ML

N017279 001

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+ LIEBEL-FLARSHEIM

51%

N019710 002 Dec 30, 1988

OPTIRAY 300

+ LIEBEL-FLARSHEIM

64%

N019710 004 Jan 22, 1992

+

64%

N020923 004 May 13, 1999

OPTIRAY 320

+ LIEBEL-FLARSHEIM

68%

N019710 001 Dec 30, 1988

+

68%

N020923 002 May 29, 1998

OPTIRAY 350

+ LIEBEL-FLARSHEIM

74%

N019710 005 Jan 22, 1992

+

74%

N020923 003 May 28, 1998

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET

62%

N020316 001 Dec 21, 1995

OXILAN-350

GUERBET

73%

N020316 002 Dec 21, 1995

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+ BOEHRINGER INGELHEIM

0.021MG/INH

N021527 001 Nov 27, 2004

SOLUTION; INHALATION

IPRATROPIUM BROMIDEAN BAUSCH AND LOMB0.02%A075835 001 Oct 15, 2001AN LANDELA PHARM0.02%A077072 001 Jul 19, 2005AN + MYLAN SPECLT0.02%A074755 001 Jan 10, 1997AN NEPHRON0.02%A075562 001 Sep 27, 2001AN RITEDOSE CORP0.02%A075693 001 Jan 26, 2001AN WATSON LABS0.02%A076291 001 May 09, 2005

SPRAY, METERED; NASAL

ATROVENTAB + BOEHRINGER INGELHEIM0.021MG/SPRAYN020393 001 Oct 20, 1995AB +0.042MG/SPRAYN020394 001 Oct 20, 1995IPRATROPIUM BROMIDEAB BAUSCH AND LOMB0.021MG/SPRAYA076025 001 Mar 31, 2003AB0.042MG/SPRAYA076103 001 Mar 31, 2003AB MYLAN SPECLT0.021MG/SPRAYA075552 001 Mar 31, 2003AB0.042MG/SPRAYA075553 001 Mar 31, 2003AB ROXANE0.021MG/SPRAYA076664 001 Nov 05, 2003AB0.042MG/SPRAYA076598 001 Nov 05, 2003IRBESARTAN

TABLET; ORAL

AVAPROAB SANOFI AVENTIS US75MGN020757 001 Sep 30, 1997AB150MGN020757 002 Sep 30, 1997AB +300MGN020757 003 Sep 30, 1997IRBESARTANAB AJANTA PHARMA LTD75MGA203685 001 Dec 10, 2015AB150MGA203685 002 Dec 10, 2015AB300MGA203685 003 Dec 10, 2015AB ALEMBIC PHARMS LTD75MGA091236 001 Oct 15, 2012AB150MGA091236 002 Oct 15, 2012AB300MGA091236 003 Oct 15, 2012AB APOTEX INC75MGA200832 001 Oct 15, 2012AB150MGA200832 002 Oct 15, 2012AB300MGA200832 003 Oct 15, 2012AB AUROBINDO PHARMA LTD75MGA203081 001 Sep 27, 2012AB150MGA203081 002 Sep 27, 2012AB300MGA203081 003 Sep 27, 2012AB CIPLA LTD75MGA077205 001 Nov 14, 2012AB150MGA077205 002 Nov 14, 2012AB300MGA077205 003 Nov 14, 2012AB DR REDDYS LABS LTD75MGA203161 001 Sep 27, 2012AB150MGA203161 002 Sep 27, 2012

## PRESCRIPTION DRUG PRODUCT LIST

IRBESARTAN

TABLET; ORAL

IRBESARTAN

<u>AB</u>		<u>300MG</u>	<u>A203161 003</u>	Sep 27, 2012
<u>AB</u>	HETERO LABS LTD V	<u>75MG</u>	<u>A202910 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A202910 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A202910 003</u>	Sep 27, 2012
<u>AB</u>	JUBILANT GENERICS	<u>75MG</u>	<u>A203534 001</u>	Feb 23, 2015
<u>AB</u>		<u>150MG</u>	<u>A203534 002</u>	Feb 23, 2015
<u>AB</u>		<u>300MG</u>	<u>A203534 003</u>	Feb 23, 2015
<u>AB</u>	LUPIN LTD	<u>75MG</u>	<u>A201531 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A201531 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A201531 003</u>	Oct 15, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254 001</u>	Oct 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A202254 002</u>	Oct 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A202254 003</u>	Oct 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>75MG</u>	<u>A200461 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A200461 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A200461 003</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>75MG</u>	<u>A203071 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203071 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203071 003</u>	Sep 27, 2012
<u>AB</u>	ROXANE	<u>75MG</u>	<u>A090201 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A090201 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A090201 003</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466 003</u>	Sep 27, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>75MG</u>	<u>A204774 001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A204774 002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A204774 003</u>	Dec 07, 2015
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159 001</u>	Mar 30, 2012
<u>AB</u>		<u>150MG</u>	<u>A077159 002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159 003</u>	Mar 30, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>75MG</u>	<u>A203020 001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A203020 002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A203020 003</u>	Dec 07, 2015
<u>AB</u>	WATSON LABS INC	<u>75MG</u>	<u>A090720 001</u>	Oct 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090720 002</u>	Oct 12, 2012
<u>AB</u>		<u>300MG</u>	<u>A090720 003</u>	Oct 12, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213 003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	+	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571 001</u>	Jun 14, 1996
<u>AP</u>	+		<u>100MG/5ML (20MG/ML)</u>	<u>N020571 002</u>	Jun 14, 1996

IRINOTECAN HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068 001</u>	Nov 21, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A079068 002</u>	Nov 21, 2008
<u>AP</u>		ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078589 002</u>	Feb 27, 2008
<u>AP</u>			<u>500MG/25ML (20MG/ML)</u>	<u>A078589 003</u>	Nov 18, 2015
<u>AP</u>		AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726 001</u>	Sep 16, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090726 002</u>	Sep 16, 2009
<u>AP</u>		BEDFORD LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A078753 001</u>	Dec 24, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078753 002</u>	Dec 24, 2008
<u>AP</u>		CIPLA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A077219 001</u>	Feb 20, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077219 002</u>	Feb 20, 2008
<u>AP</u>		DR REDDYS LABS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A078953 001</u>	Apr 15, 2010
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078953 002</u>	Apr 15, 2010
<u>AP</u>		EBEWE PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090137 001</u>	Nov 12, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090137 002</u>	Nov 12, 2009
<u>AP</u>		EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771 001</u>	Feb 14, 2012
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A200771 002</u>	Feb 14, 2012
<u>AP</u>		FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078188 002</u>	Feb 27, 2008
<u>AP</u>		FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077776 002</u>	Feb 27, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032 001</u>	Dec 20, 2010
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A091032 002</u>	Dec 20, 2010

## PRESCRIPTION DRUG PRODUCT LIST

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016 001</u>	Jan 28, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090016 002</u>	Jan 28, 2009
<u>AP</u>	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915 001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077915 002</u>	Feb 27, 2008
<u>AP</u>	+	<u>500MG/25ML (20MG/ML)</u>	<u>A078796 001</u>	Feb 27, 2008
<u>AP</u>	JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675 002</u>	Dec 16, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090675 001</u>	Dec 16, 2011
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>40MG/2ML (20MG/ML)</u>	<u>A090393 002</u>	May 13, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090393 003</u>	May 13, 2011
<u>AP</u>	PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122 001</u>	Oct 31, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078122 002</u>	Oct 31, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805 001</u>	Apr 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078805 002</u>	Apr 21, 2008
<u>AP</u>	TEVA PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A090101 002</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090101 003</u>	Feb 27, 2008
<u>AP</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A090101 001</u>	Nov 26, 2008
	CAMPTOSAR			
	+ PFIZER INC	300MG/15ML (20MG/ML)	N020571 003	Aug 05, 2010
	INJECTABLE, LIPOSOMAL; IV (INFUSION)			
	ONIVYDE			
	+ MERRIMACK PHARMS	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793 001	Oct 22, 2015

IRON DEXTRAN

INJECTABLE; INJECTION

## DEXFERRUM

BP	LUITPOLD	EQ 50MG IRON/ML	N040024 001	Feb 23, 1996
	INFED			
BP	+ ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441 001	
	PROFERDEX			
BP	NEW RIVER	EQ 50MG IRON/ML	N017807 001	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

## VENOFER

	LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135 002	Mar 20, 2005
	+	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135 001	Nov 06, 2000
		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135 004	Feb 09, 2007

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

## CRESEMBA

	+ ASTELLAS	186MG	N207500 001	Mar 06, 2015
	POWDER; IV (INFUSION)			
	CRESEMBA			
	+ ASTELLAS	372MG	N207501 001	Mar 06, 2015

ISOCARBOXAZID

TABLET; ORAL

## MARPLAN

	+ VALIDUS PHARMS INC	10MG	N011961 001	
--	----------------------	------	-------------	--

ISOFLURANE

LIQUID; INHALATION

FORANE

<u>AN</u>	+ BAXTER HLTHCARE	<u>99.9%</u>	<u>N017624 001</u>	
	<u>ISOFLURANE</u>			
<u>AN</u>	HALOCARBON PRODS	<u>99.9%</u>	<u>A075225 001</u>	Oct 20, 1999
<u>AN</u>	HOSPIRA	<u>99.9%</u>	<u>A074097 001</u>	Jan 25, 1993
<u>AN</u>	PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074416 001</u>	Sep 30, 1994
<u>AN</u>	PIRAMAL ENT	<u>99.9%</u>	<u>A074502 001</u>	Jun 27, 1995

ISONIAZID

INJECTABLE; INJECTION

## ISONIAZID

	+ SANDOZ	100MG/ML	A040648 001	Jul 05, 2005
	SYRUP; ORAL			
	ISONIAZID			
	+ CAROLINA MEDCL	50MG/5ML	A088235 001	Nov 10, 1983
	TABLET; ORAL			
	<u>ISONIAZID</u>			
<u>AA</u>	BARR	<u>100MG</u>	<u>A080936 001</u>	
<u>AA</u>		<u>300MG</u>	<u>A080937 002</u>	

## PRESCRIPTION DRUG PRODUCT LIST

ISONIAZID

TABLET; ORAL

ISONIAZID

<b>AA</b>	+	SANDOZ	<b>100MG</b>	<b>N008678 002</b>	
<b>AA</b>	+		<b>300MG</b>	<b>N008678 003</b>	
<b>AA</b>		THEPHARMANETWORK LLC	<b>100MG</b>	<b>A202610 001</b>	Oct 29, 2014
<b>AA</b>			<b>300MG</b>	<b>A202610 002</b>	Oct 29, 2014

LANIAZID

<b>AA</b>		LANNETT	<b>300MG</b>	<b>A089776 001</b>	Jun 13, 1988
-----------	--	---------	--------------	--------------------	--------------

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+	SANOFI AVENTIS US	50MG; 300MG; 120MG	N050705 001	May 31, 1994
---	-------------------	--------------------	-------------	--------------

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

+	SANOFI AVENTIS US	150MG; 300MG	A061884 001	
---	-------------------	--------------	-------------	--

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISUPREL

+	HOSPIRA	0.2MG/ML	N010515 001	
---	---------	----------	-------------	--

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+	AUXILIUM PHARMS LLC	40MG	N019790 001	Sep 02, 1988
---	---------------------	------	-------------	--------------

TABLET; ORAL

ISORDIL

<b>AB</b>		VALEANT PHARMS NORTH	<b>5MG</b>	<b>N012093 007</b>	Jul 29, 1988
-----------	--	----------------------	------------	--------------------	--------------

ISOSORBIDE DINITRATE

<b>AB</b>		HIKMA INTL PHARMS	<b>5MG</b>	<b>A086067 001</b>	Oct 29, 1987
<b>AB</b>			<b>10MG</b>	<b>A086066 001</b>	Oct 29, 1987
<b>AB</b>			<b>20MG</b>	<b>A088088 001</b>	Nov 02, 1987
<b>AB</b>			<b>30MG</b>	<b>A040591 001</b>	Jan 10, 2007
<b>AB</b>		PAR PHARM	<b>5MG</b>	<b>A086923 001</b>	Mar 12, 1987
<b>AB</b>			<b>10MG</b>	<b>A086925 001</b>	Mar 12, 1987
<b>AB</b>			<b>20MG</b>	<b>A087537 001</b>	Oct 02, 1987
<b>AB</b>	+		<b>30MG</b>	<b>A087946 001</b>	Jan 12, 1988
<b>AB</b>		SANDOZ	<b>5MG</b>	<b>A086221 001</b>	Jan 07, 1988
<b>AB</b>			<b>10MG</b>	<b>A086223 001</b>	Jan 07, 1988
<b>AB</b>			<b>20MG</b>	<b>A089367 001</b>	Apr 07, 1988

ISORDIL

+	VALEANT PHARMS NORTH	40MG	N012093 001	Jul 29, 1988
---	----------------------	------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

<b>AB</b>		COREPHARMA	<b>40MG</b>	<b>A040723 001</b>	Mar 17, 2008
<b>AB</b>	+	SUN PHARM INDS INC	<b>40MG</b>	<b>A040009 001</b>	Dec 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

<b>AB</b>		ACTAVIS ELIZABETH	<b>10MG</b>	<b>A075037 002</b>	Oct 30, 1998
<b>AB</b>			<b>20MG</b>	<b>A075037 001</b>	Oct 30, 1998
<b>AB</b>		ANI PHARMS INC	<b>20MG</b>	<b>A075147 001</b>	Nov 27, 1998
<b>AB</b>		HIKMA PHARMS LLC	<b>20MG</b>	<b>A075361 001</b>	Oct 05, 2000

MONOKET

<b>AB</b>		KREMERS URBAN PHARMS	<b>10MG</b>	<b>N020215 002</b>	Jun 30, 1993
<b>AB</b>	+		<b>20MG</b>	<b>N020215 001</b>	Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

<b>AB</b>		DEXCEL LTD	<b>60MG</b>	<b>A075522 001</b>	Apr 17, 2000
<b>AB</b>		HIKMA PHARMS	<b>30MG</b>	<b>A076813 002</b>	Mar 30, 2006
<b>AB</b>			<b>60MG</b>	<b>A076813 001</b>	Jan 07, 2005
<b>AB</b>		KREMERS URBAN PHARMS	<b>30MG</b>	<b>A075155 002</b>	Jan 13, 2000
<b>AB</b>			<b>60MG</b>	<b>A075155 001</b>	Oct 30, 1998
<b>AB</b>	+		<b>120MG</b>	<b>A075155 003</b>	Aug 04, 2000
<b>AB</b>		NESHER PHARMS	<b>30MG</b>	<b>A075395 001</b>	Mar 16, 2000
<b>AB</b>			<b>60MG</b>	<b>A075395 002</b>	Mar 16, 2000
<b>AB</b>			<b>120MG</b>	<b>A075395 003</b>	Mar 16, 2000
<b>AB</b>		TORRENT PHARMS	<b>30MG</b>	<b>A200270 001</b>	Jun 03, 2011
<b>AB</b>			<b>60MG</b>	<b>A200495 001</b>	Jun 03, 2011
<b>AB</b>			<b>120MG</b>	<b>A200495 002</b>	Jun 03, 2011

## PRESCRIPTION DRUG PRODUCT LIST

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	VINTAGE PHARMS	<u>30MG</u>	<u>A090598 001</u>	Aug 11, 2010
<u>AB</u>		<u>60MG</u>	<u>A090598 002</u>	Aug 11, 2010
<u>AB</u>		<u>120MG</u>	<u>A090598 003</u>	Aug 11, 2010

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

+ MYLAN INSTITUTIONAL 1%

A090874 001 Jul 20, 2010

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A075945 001</u>	Nov 08, 2002
<u>AB</u>		<u>20MG</u>	<u>A075945 002</u>	Nov 08, 2002
<u>AB</u>		<u>40MG</u>	<u>A075945 003</u>	Nov 08, 2002

CLARAVIS

<u>AB</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A076356 001</u>	Apr 11, 2003
<u>AB</u>		<u>20MG</u>	<u>A076135 002</u>	Apr 11, 2003
<u>AB</u>		<u>30MG</u>	<u>A076135 003</u>	May 11, 2006
<u>AB</u>	+	<u>40MG</u>	<u>A076135 001</u>	Apr 11, 2003

MYORISAN

<u>AB</u>	DOUGLAS PHARMS	<u>10MG</u>	<u>A076485 001</u>	Jan 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A076485 002</u>	Jan 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A076485 004</u>	Aug 25, 2015
<u>AB</u>		<u>40MG</u>	<u>A076485 003</u>	Jan 19, 2012

SOTRET

<u>AB</u>	SUN PHARM INDS LTD	<u>10MG</u>	<u>A076041 001</u>	Dec 24, 2002
<u>AB</u>		<u>20MG</u>	<u>A076041 002</u>	Dec 24, 2002
<u>AB</u>		<u>30MG</u>	<u>A076503 001</u>	Jun 20, 2003
<u>AB</u>		<u>40MG</u>	<u>A076041 003</u>	Dec 24, 2002

ZENATANE

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A202099 001</u>	Mar 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202099 002</u>	Mar 25, 2013
<u>AB</u>		<u>30MG</u>	<u>A202099 004</u>	Feb 23, 2015
<u>AB</u>		<u>40MG</u>	<u>A202099 003</u>	Mar 25, 2013

## ABSORICA

BX	RANBAXY	10MG	N021951 001	May 25, 2012
BX		20MG	N021951 002	May 25, 2012
BX		30MG	N021951 003	May 25, 2012
BX	+	40MG	N021951 004	May 25, 2012
		25MG	N021951 005	Aug 15, 2014
		35MG	N021951 006	Aug 15, 2014

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

<u>AB</u>	ELITE LABS INC	<u>2.5MG</u>	<u>A077169 001</u>	Apr 24, 2006
<u>AB</u>		<u>5MG</u>	<u>A077169 002</u>	Apr 24, 2006
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A077317 001</u>	Jan 05, 2006
<u>AB</u>	+	<u>5MG</u>	<u>A077317 002</u>	Jan 05, 2006

TABLET, EXTENDED RELEASE;ORAL

ISRADIPINE

MYLAN PHARMS INC 5MG

A201067 001 Nov 27, 2015

10MG

A201067 002 Nov 27, 2015

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A200463 001</u>	Jul 20, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A076104 001</u>	May 28, 2004

SPORANOX

<u>AB</u>	+	JANSSEN PHARMS	<u>100MG</u>	<u>N020083 001</u>	Sep 11, 1992
-----------	---	----------------	--------------	--------------------	--------------

SOLUTION; ORAL

ITRACONAZOLE

<u>AA</u>	AMNEAL PHARMS	<u>10MG/ML</u>	<u>A205573 001</u>	Oct 30, 2015
-----------	---------------	----------------	--------------------	--------------

SPORANOX

<u>AA</u>	+	JANSSEN PHARMS	<u>10MG/ML</u>	<u>N020657 001</u>	Feb 21, 1997
-----------	---	----------------	----------------	--------------------	--------------

TABLET; ORAL

ONMEL

+ MERZ PHARMS 200MG

N022484 001 Apr 29, 2010

## PRESCRIPTION DRUG PRODUCT LIST

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

AMGEN INC

EQ 5MG BASE

N206143 001 Apr 15, 2015

+

EQ 7.5MG BASE

N206143 002 Apr 15, 2015

IVACAFTOR

GRANULE; ORAL

KALYDECO

VERTEX PHARMS INC

50MG/PACKET

N207925 001 Mar 17, 2015

+

75MG/PACKET

N207925 002 Mar 17, 2015

TABLET; ORAL

KALYDECO

+ VERTEX PHARMS

150MG

N203188 001 Jan 31, 2012

IVACAFTOR; LUMACAFOTOR

TABLET; ORAL

ORKAMBI

+ VERTEX PHARMS INC

125MG; 200MG

N206038 001 Jul 02, 2015

IVERMECTIN

CREAM; TOPICAL

SOOLANTRA

+ GALDERMA LABS LP

1%

N206255 001 Dec 19, 2014

LOTION; TOPICAL

SKLICE

+ SANOFI PASTEUR INC

0.5%

N202736 001 Feb 07, 2012

TABLET; ORAL

IVERMECTIN**AB** EDENBRIDGE PHARMS**3MG****A204154 001** Oct 24, 2014STROMEKTOL**AB** + MERCK SHARP DOHME**3MG****N050742 002** Oct 08, 1998IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+ R-PHARM US LLC

15MG/VIAL

N022065 001 Oct 16, 2007

+

45MG/VIAL

N022065 002 Oct 16, 2007

IXAZOMIB CITRATE

CAPSULE; ORAL

NINLARO

MILLENNIUM PHARMS

EQ 2.3MG BASE

N208462 001 Nov 20, 2015

EQ 3MG BASE

N208462 002 Nov 20, 2015

+

EQ 4MG BASE

N208462 003 Nov 20, 2015

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

FRESENIUS KABI USA

EQ 500MG BASE/2ML

A065111 001 Dec 17, 2002

+

EQ 1GM BASE/3ML

A065111 002 Dec 17, 2002

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR**AP** + PAR STERILE PRODUCTS**EQ 10MG BASE/ML****N016812 001****AP** +**EQ 50MG BASE/ML****N016812 002****AP** +**EQ 100MG BASE/ML****N016812 003**KETAMINE HYDROCHLORIDE**AP** EUROHLTH INTL SARL**EQ 50MG BASE/ML****A074524 001** Mar 22, 1996**AP****EQ 100MG BASE/ML****A074524 002** Mar 22, 1996**AP**

HOSPIRA

**EQ 50MG BASE/ML****A074549 001** Jun 27, 1996**AP****EQ 100MG BASE/ML****A074549 002** Jun 27, 1996**AP**

MYLAN INSTITUTIONAL

**EQ 10MG BASE/ML****A076092 001** Sep 30, 2008**AP****EQ 50MG BASE/ML****A076092 002** Dec 28, 2001**AP****EQ 100MG BASE/ML****A076092 003** Oct 25, 2002KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA**AT** + DELCOR ASSET CORP**2%****N021738 001** Jun 12, 2007KETOCONAZOLE**AT** PERRIGO ISRAEL**2%****A091550 001** Aug 25, 2011

CREAM; TOPICAL

KETOCONAZOLE**AB** FOUGERA PHARMS**2%****A076294 001** Apr 28, 2004



## PRESCRIPTION DRUG PRODUCT LIST

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE**AB** + TEVA **2%** **A075581 001** Apr 25, 2000KETOZOLE**AB** TARO **2%** **A075638 001** Dec 18, 2002

GEL; TOPICAL

XOLEGEL

+ AQUA PHARMS

**2%**

N021946 001 Jul 28, 2006

SHAMPOO; TOPICAL

KETOCONAZOLE**AB** PERRIGO NEW YORK **2%** **A076419 001** Jan 07, 2004**AB** TOLMAR **2%** **A076942 001** Apr 11, 2005NIZORAL**AB** + JANSSEN PHARMS **2%** **N019927 001** Aug 31, 1990

TABLET; ORAL

KETOCONAZOLE**AB** MYLAN **200MG** **A075597 001** Dec 23, 1999**AB** TARO **200MG** **A075319 001** Jun 15, 1999**AB** + TEVA **200MG** **A075273 001** Jun 15, 1999KETOPROFEN

CAPSULE; ORAL

KETOPROFEN**AB** DORADO PHARMA **50MG** **A074014 002** Jan 29, 1993**AB** **75MG** **A074014 003** Jan 29, 1993**AB** MYLAN **50MG** **A074035 002** Dec 31, 1996**AB** **75MG** **A074035 003** Dec 31, 1996**AB** TEVA **50MG** **A073516 001** Dec 22, 1992**AB** + **75MG** **A073517 001** Dec 22, 1992

DORADO PHARMA 25MG

A074014 001 Jan 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN**AB** ACTAVIS LABS FL INC **100MG** **A075270 002** Mar 24, 1999**AB** **150MG** **A075270 003** Mar 24, 1999**AB** **200MG** **A075270 001** Mar 24, 1999**AB** MYLAN **100MG** **A075679 003** Feb 20, 2002**AB** **150MG** **A075679 002** Feb 20, 2002**AB** + **200MG** **A075679 001** Feb 20, 2002KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE**AP** AMPHASTAR PHARM **15MG/ML** **A076209 001** Jul 21, 2004**AP** **30MG/ML** **A076209 002** Jul 21, 2004**AP** BD RX **15MG/ML** **A203242 001** Oct 07, 2015**AP** **30MG/ML** **A203242 002** Oct 07, 2015**AP** FRESENIUS KABI USA **15MG/ML** **A075784 001** Jan 11, 2002**AP** **30MG/ML** **A075784 002** Jan 11, 2002**AP** + HOSPIRA **15MG/ML** **A074802 001** Jun 05, 1997**AP** **15MG/ML** **A074993 001** Jan 27, 1999**AP** + **30MG/ML** **A074802 002** Jun 05, 1997**AP** **30MG/ML** **A074993 002** Jan 27, 1999**AP** MYLAN LABS LTD **15MG/ML** **A078299 001** Jul 16, 2007**AP** **15MG/ML** **A201155 001** Aug 04, 2014**AP** **30MG/ML** **A078299 002** Jul 16, 2007**AP** **30MG/ML** **A201155 002** Aug 04, 2014**AP** SAGENT PHARMS **15MG/ML** **A091065 001** Nov 27, 2013**AP** **30MG/ML** **A091065 002** Nov 27, 2013**AP** SANDOZ **30MG/ML** **A076271 002** Oct 06, 2004**AP** WOCKHARDT **15MG/ML** **A077942 001** Mar 27, 2007**AP** **30MG/ML** **A077942 002** Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR**AT** + ALLERGAN **0.5%** **N019700 001** Nov 09, 1992ACULAR LS**AT** + ALLERGAN **0.4%** **N021528 001** May 30, 2003ACUVAIL**AT** + ALLERGAN **0.45%** **N022427 001** Jul 22, 2009KETOROLAC TROMETHAMINE**AT** AKORN **0.4%** **A078399 001** Nov 05, 2009**AT** **0.5%** **A078434 001** Nov 05, 2009**AT** ALCON PHARMS LTD **0.4%** **A078721 001** Nov 05, 2009

## PRESCRIPTION DRUG PRODUCT LIST

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

<u>AT</u>		<u>0.5%</u>	<u>A076583 001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109 001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017 001</u>	Nov 05, 2009
	SPRAY, METERED;NASAL			
	SPRIX			
	+ EGALET US INC	15.75MG/SPRAY	N022382 001	May 14, 2010

TABLET;ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	+ MYLAN	<u>10MG</u>	<u>A074761 001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284 001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754 001</u>	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

	+ OMEROS	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML	N205388 001	May 30, 2014
--	----------	-------------------------------------	-------------	--------------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075431 001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524 001</u>	Nov 29, 1999
<u>AP</u>	EUROHLTH INTL SARL	<u>5MG/ML</u>	<u>A075303 001</u>	May 28, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699 001</u>	Apr 03, 2012
<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A075239 001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075240 001</u>	Nov 29, 1999

LABETALOL HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>5MG/ML</u>	<u>A079134 001</u>	Feb 03, 2010
-----------	----------------	---------------	--------------------	--------------

TABLET;ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787 003</u>	Aug 03, 1998
<u>AB</u>	MUTUAL PHARM	<u>100MG</u>	<u>A075215 001</u>	Jul 29, 1999
<u>AB</u>		<u>200MG</u>	<u>A075215 002</u>	Jul 29, 1999
<u>AB</u>		<u>300MG</u>	<u>A075215 003</u>	Jul 29, 1999
<u>AB</u>	PAR FORM	<u>100MG</u>	<u>A200908 001</u>	Jul 10, 2012
<u>AB</u>		<u>200MG</u>	<u>A200908 002</u>	Jul 10, 2012
<u>AB</u>		<u>300MG</u>	<u>A200908 003</u>	Jul 10, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113 001</u>	Aug 04, 1998
<u>AB</u>		<u>200MG</u>	<u>A075113 002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113 003</u>	Aug 04, 1998
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133 003</u>	Aug 03, 1998

TRANDATE

<u>AB</u>	CNTY LINE PHARMS	<u>100MG</u>	<u>N018716 001</u>	May 24, 1985
<u>AB</u>		<u>200MG</u>	<u>N018716 002</u>	Aug 01, 1984
<u>AB</u>		<u>300MG</u>	<u>N018716 003</u>	Aug 01, 1984

LACOSAMIDE

SOLUTION;INTRAVENOUS

VIMPAT

	+ UCB INC	200MG/20ML (10MG/ML)	N022254 001	Oct 28, 2008
--	-----------	----------------------	-------------	--------------

SOLUTION;ORAL

VIMPAT

	+ UCB INC	10MG/ML	N022255 001	Apr 20, 2010
--	-----------	---------	-------------	--------------

TABLET;ORAL

VIMPAT

	UCB INC	50MG	N022253 001	Oct 28, 2008
		100MG	N022253 002	Oct 28, 2008
		150MG	N022253 003	Oct 28, 2008
		200MG	N022253 004	Oct 28, 2008

## PRESCRIPTION DRUG PRODUCT LIST

LACTULOSE

FOR SOLUTION;ORAL

LACTULOSE

+ CUMBERLAND PHARMS 10GM/PACKET  
 + 20GM/PACKET

A074712 001 Dec 10, 1997  
 A074712 002 Dec 10, 1997

SOLUTION;ORAL

CONSTILAC

**AA** ALRA 10GM/15ML **A071054** **001** Jul 26, 1988

CONSTULOSE

**AA** + ACTAVIS MID ATLANTIC 10GM/15ML **A070288** **001** Aug 15, 1988

LACTULOSE

**AA** ANI PHARMS 10GM/15ML **A078430** **001** Nov 28, 2007  
**AA** FRESENIUS KABI 10GM/15ML **A090503** **001** Jan 25, 2012  
**AA** HI TECH PHARMA 10GM/15ML **A074076** **001** Jul 03, 1995  
**AA** MORTON GROVE 10GM/15ML **A074602** **001** Nov 14, 1996  
**AA** PHARM ASSOC 10GM/15ML **A074623** **001** Jul 30, 1996  
**AA** ROXANE 10GM/15ML **A073591** **001** May 29, 1992  
**AA** VINTAGE PHARMS 10GM/15ML **A075993** **001** Jul 26, 2001  
**AA** VISTAPHARM 10GM/15ML **A074138** **001** Sep 30, 1992

SOLUTION;ORAL, RECTAL

CHOLAC

**AA** ALRA 10GM/15ML **A071331** **001** Jul 26, 1988

ENULOSE

**AA** + ACTAVIS MID ATLANTIC 10GM/15ML **A071548** **001** Aug 15, 1988

GENERLAC

**AA** MORTON GROVE PHARMS 10GM/15ML **A074603** **001** Oct 31, 1996

LACTULOSE

**AA** ANI PHARMS 10GM/15ML **A090426** **001** Nov 21, 2008  
**AA** BIO-PHARM INC 10GM/15ML **A203762** **001** Mar 27, 2015  
**AA** FRESENIUS KABI 10GM/15ML **A090502** **001** Jan 25, 2012  
**AA** HI TECH PHARMA 10GM/15ML **A074077** **001** Jul 03, 1995

LAMIVUDINE

SOLUTION;ORAL

EPIVIR

**AA** + VIIV HLTHCARE 10MG/ML **N020596** **001** Nov 17, 1995

LAMIVUDINE

**AA** SILARX PHARMS INC 10MG/ML **A203564** **001** Oct 31, 2014  
 EPIVIR-HBV  
 + GLAXOSMITHKLINE 5MG/ML N021004 001 Dec 08, 1998

TABLET;ORAL

EPIVIR

**AB** VIIV HLTHCARE 150MG **N020564** **001** Nov 17, 1995

**AB** + 300MG **N020564** **003** Jun 24, 2002

EPIVIR-HBV

**AB** + GLAXOSMITHKLINE 100MG **N021003** **001** Dec 08, 1998

LAMIVUDINE

**AB** APOTEX 150MG **A091606** **001** Dec 02, 2011  
**AB** 300MG **A091606** **002** Dec 02, 2011  
**AB** APOTEX INC 100MG **A202941** **001** Jan 02, 2014  
**AB** AUROBINDO PHARMA LTD 150MG **A202032** **001** Nov 17, 2011  
**AB** 300MG **A202032** **002** Nov 17, 2011  
**AB** HETERO LABS LTD V 100MG **A203260** **001** Jan 02, 2014  
**AB** 150MG **A203277** **001** Jan 06, 2014  
**AB** 300MG **A203277** **002** Jan 06, 2014  
**AB** LUPIN LTD 150MG **A205217** **001** Dec 18, 2014  
**AB** 300MG **A205217** **002** Dec 18, 2014  
**AB** MYLAN PHARMS INC 100MG **A204002** **001** Dec 31, 2014

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

**AB** + VIIV HLTHCARE 150MG;300MG **N020857** **001** Sep 26, 1997

LAMIVUDINE AND ZIDOVUDINE

**AB** AUROBINDO PHARMA LTD 150MG;300MG **A202418** **001** May 15, 2012  
**AB** HETERO LABS LTD III 150MG;300MG **A079124** **001** Sep 17, 2015  
**AB** HETERO LABS LTD V 150MG;300MG **A203259** **001** Feb 03, 2014  
**AB** LUPIN LTD 150MG;300MG **A090246** **001** May 15, 2012  
**AB** MYLAN PHARMS INC 150MG;300MG **A204005** **001** Aug 28, 2014  
**AB** STRIDES PHARMA 150MG;300MG **A079128** **001** May 13, 2015  
**AB** TEVA PHARMS 150MG;300MG **A079081** **001** May 25, 2011

## PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N020241</u>	<u>005</u>	Dec 27, 1994
<u>AB</u>		<u>100MG</u>	<u>N020241</u>	<u>001</u>	Dec 27, 1994
<u>AB</u>		<u>150MG</u>	<u>N020241</u>	<u>002</u>	Dec 27, 1994
<u>AB</u>		<u>200MG</u>	<u>N020241</u>	<u>003</u>	Dec 27, 1994

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090607</u>	<u>001</u>	Jan 13, 2011
<u>AB</u>		<u>100MG</u>	<u>A090607</u>	<u>002</u>	Jan 13, 2011
<u>AB</u>		<u>150MG</u>	<u>A090607</u>	<u>003</u>	Jan 13, 2011
<u>AB</u>		<u>200MG</u>	<u>A090607</u>	<u>004</u>	Jan 13, 2011
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A200694</u>	<u>001</u>	Jun 14, 2013
<u>AB</u>		<u>100MG</u>	<u>A200694</u>	<u>002</u>	Jun 14, 2013
<u>AB</u>		<u>150MG</u>	<u>A200694</u>	<u>003</u>	Jun 14, 2013
<u>AB</u>		<u>200MG</u>	<u>A200694</u>	<u>004</u>	Jun 14, 2013
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A078625</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078625</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A079132</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A077783</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A077783</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A077783</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A077783</u>	<u>004</u>	Nov 01, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A090169</u>	<u>001</u>	May 12, 2012
<u>AB</u>		<u>100MG</u>	<u>A090169</u>	<u>002</u>	May 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090169</u>	<u>003</u>	May 12, 2012
<u>AB</u>		<u>200MG</u>	<u>A090169</u>	<u>004</u>	May 12, 2012
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u>	Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u>	Jun 01, 2010
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078525</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388</u>	<u>001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388</u>	<u>002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388</u>	<u>003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388</u>	<u>004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170</u>	<u>003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170</u>	<u>004</u>	Oct 06, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
		50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

## PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, CHEWABLE;ORAL

LAMICTAL CD

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764 004</u>	Sep 08, 2000
<u>AB</u>		<u>5MG</u>	<u>N020764 001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764 002</u>	Aug 24, 1998

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201168 001</u>	Jun 12, 2014
<u>AB</u>		<u>25MG</u>	<u>A201168 002</u>	Jun 12, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401 002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401 003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701 001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701 002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A079099 001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099 002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200220 001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220 002</u>	Feb 28, 2011
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076630 001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076630 002</u>	Jan 22, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204 001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204 002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420 001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420 002</u>	Jun 21, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928 001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928 003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009 003</u>	Jan 22, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115 001</u>	May 29, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022115 002</u>	May 29, 2009
<u>AB</u>		<u>100MG</u>	<u>N022115 003</u>	May 29, 2009
<u>AB</u>		<u>200MG</u>	<u>N022115 004</u>	May 29, 2009
<u>AB</u>		<u>250MG</u>	<u>N022115 006</u>	Jun 21, 2011
<u>AB</u>		<u>300MG</u>	<u>N022115 005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672 003</u>	Oct 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A200672 004</u>	Oct 17, 2013
<u>AB</u>		<u>25MG</u>	<u>A200672 001</u>	Oct 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A200672 002</u>	Oct 17, 2013
<u>AB</u>		<u>250MG</u>	<u>A203733 001</u>	Nov 13, 2013
<u>AB</u>		<u>300MG</u>	<u>A200672 005</u>	Oct 17, 2013
<u>AB</u>	ANCHEN PHARMS	<u>25MG</u>	<u>A201374 001</u>	Dec 26, 2012
<u>AB</u>		<u>50MG</u>	<u>A201374 002</u>	Dec 26, 2012
<u>AB</u>		<u>100MG</u>	<u>A201374 003</u>	Dec 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A201374 004</u>	Dec 26, 2012
<u>AB</u>		<u>250MG</u>	<u>A201374 005</u>	Dec 26, 2012
<u>AB</u>		<u>300MG</u>	<u>A201374 006</u>	Dec 26, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383 001</u>	Jun 19, 2013
<u>AB</u>		<u>50MG</u>	<u>A202383 002</u>	Jun 19, 2013
<u>AB</u>		<u>100MG</u>	<u>A202383 003</u>	Jun 19, 2013
<u>AB</u>		<u>200MG</u>	<u>A202383 004</u>	Jun 19, 2013
<u>AB</u>		<u>300MG</u>	<u>A202383 005</u>	Jun 19, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A201791 001</u>	Jan 18, 2013
<u>AB</u>		<u>50MG</u>	<u>A201791 002</u>	Jan 18, 2013
<u>AB</u>		<u>100MG</u>	<u>A201791 003</u>	Jan 18, 2013
<u>AB</u>		<u>200MG</u>	<u>A201791 004</u>	Jan 18, 2013
<u>AB</u>		<u>250MG</u>	<u>A201791 005</u>	Jan 18, 2013
<u>AB</u>		<u>300MG</u>	<u>A201791 006</u>	Jan 18, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>25MG</u>	<u>A203370 001</u>	Dec 23, 2013
<u>AB</u>		<u>50MG</u>	<u>A203370 002</u>	Dec 23, 2013
<u>AB</u>		<u>100MG</u>	<u>A203370 003</u>	Dec 23, 2013
<u>AB</u>		<u>200MG</u>	<u>A203370 004</u>	Dec 23, 2013
<u>AB</u>	WILSHIRE PHARMS INC	<u>25MG</u>	<u>A202887 001</u>	Jun 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A202887 002</u>	Jun 17, 2013
<u>AB</u>		<u>100MG</u>	<u>A202887 003</u>	Jun 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A202887 004</u>	Jun 17, 2013
<u>AB</u>	WOCKHARDT LTD	<u>25MG</u>	<u>A202498 001</u>	Jan 04, 2013
<u>AB</u>		<u>50MG</u>	<u>A202498 002</u>	Jan 04, 2013
<u>AB</u>		<u>100MG</u>	<u>A202498 003</u>	Jan 04, 2013
<u>AB</u>		<u>200MG</u>	<u>A202498 004</u>	Jan 04, 2013

## PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

<b>AB</b>		<b>300MG</b>	<b>A202498 005</b>	Jan 04, 2013
-----------	--	--------------	--------------------	--------------

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<b>AB</b>	GLAXOSMITHKLINE LLC	<b>25MG</b>	<b>N022251 001</b>	May 08, 2009
-----------	---------------------	-------------	--------------------	--------------

<b>AB</b>	+	<b>50MG</b>	<b>N022251 002</b>	May 08, 2009
-----------	---	-------------	--------------------	--------------

<b>AB</b>		<b>100MG</b>	<b>N022251 003</b>	May 08, 2009
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>N022251 004</b>	May 08, 2009
-----------	--	--------------	--------------------	--------------

LAMOTRIGINE

<b>AB</b>	IMPAX LABS INC	<b>25MG</b>	<b>A200828 001</b>	Jul 15, 2013
-----------	----------------	-------------	--------------------	--------------

<b>AB</b>		<b>50MG</b>	<b>A200828 002</b>	Jul 15, 2013
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>100MG</b>	<b>A200828 003</b>	Jul 15, 2013
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A200828 004</b>	Jul 15, 2013
-----------	--	--------------	--------------------	--------------

<b>AB</b>	PAR PHARM	<b>25MG</b>	<b>A204158 001</b>	Oct 27, 2015
-----------	-----------	-------------	--------------------	--------------

<b>AB</b>		<b>50MG</b>	<b>A204158 002</b>	Oct 27, 2015
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>100MG</b>	<b>A204158 003</b>	Oct 27, 2015
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A204158 004</b>	Oct 27, 2015
-----------	--	--------------	--------------------	--------------

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074 001	Aug 30, 2007
---	--------------	---	-------------	--------------

+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074 002	Aug 30, 2007
---	--	---	-------------	--------------

+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074 003	Aug 30, 2007
---	--	---	-------------	--------------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<b>AB</b>	DR REDDYS LABS LTD	<b>15MG</b>	<b>A091269 001</b>	Oct 15, 2010
-----------	--------------------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A091269 002</b>	Oct 15, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<b>15MG</b>	<b>A090763 001</b>	Nov 10, 2009
-----------	------------------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A090763 002</b>	Nov 10, 2009
-----------	--	-------------	--------------------	--------------

<b>AB</b>	NATCO PHARMA LTD	<b>15MG</b>	<b>A201921 001</b>	Dec 18, 2012
-----------	------------------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A201921 002</b>	Dec 18, 2012
-----------	--	-------------	--------------------	--------------

<b>AB</b>	SANDOZ	<b>15MG</b>	<b>A090331 001</b>	Apr 23, 2010
-----------	--------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A090331 002</b>	Apr 23, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>	SUN PHARMA GLOBAL	<b>15MG</b>	<b>A202637 001</b>	Sep 13, 2013
-----------	-------------------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A091509 001</b>	Sep 13, 2013
-----------	--	-------------	--------------------	--------------

<b>AB</b>	TEVA PHARMS	<b>15MG</b>	<b>A077255 001</b>	Nov 10, 2009
-----------	-------------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A077255 002</b>	Nov 10, 2009
-----------	--	-------------	--------------------	--------------

<b>AB</b>	WOCKHARDT USA	<b>15MG</b>	<b>A202176 001</b>	Sep 14, 2012
-----------	---------------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A202176 002</b>	Sep 14, 2012
-----------	--	-------------	--------------------	--------------

<b>AB</b>	ZYDUS HLTHCARE	<b>15MG</b>	<b>A202366 001</b>	Aug 19, 2013
-----------	----------------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A202366 002</b>	Aug 19, 2013
-----------	--	-------------	--------------------	--------------

LANSOPRAZOLE

<b>AB</b>	KRKA TOVARNA ZDRAVIL	<b>15MG</b>	<b>A091212 001</b>	Sep 16, 2013
-----------	----------------------	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A091212 002</b>	Sep 16, 2013
-----------	--	-------------	--------------------	--------------

PREVACID

<b>AB</b>	TAKEDA PHARMS USA	<b>15MG</b>	<b>N020406 001</b>	May 10, 1995
-----------	-------------------	-------------	--------------------	--------------

<b>AB</b>	+	<b>30MG</b>	<b>N020406 002</b>	May 10, 1995
-----------	---	-------------	--------------------	--------------

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL

PREVACID

+	TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002
---	-------------------	------	-------------	--------------

+		30MG	N021428 002	Aug 30, 2002
---	--	------	-------------	--------------

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

+	SHIRE DEV LLC	EQ 750MG BASE	N204734 001	Sep 24, 2014
---	---------------	---------------	-------------	--------------

+		EQ 1GM BASE	N204734 002	Sep 24, 2014
---	--	-------------	-------------	--------------

TABLET, CHEWABLE;ORAL

FOSRENOL

+	SHIRE LLC	EQ 500MG BASE	N021468 002	Oct 26, 2004
---	-----------	---------------	-------------	--------------

+		EQ 750MG BASE	N021468 003	Nov 23, 2005
---	--	---------------	-------------	--------------

+		EQ 1GM BASE	N021468 004	Nov 23, 2005
---	--	-------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+ NOVARTIS PHARMS CORP EQ 250MG BASE

N022059 001 Mar 13, 2007

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

<b>AT</b>	AKORN	<b>0.005%</b>	<b>A090887 001</b>	Jul 19, 2011
<b>AT</b>	ALCON RES	<b>0.005%</b>	<b>A091449 001</b>	Mar 22, 2011
<b>AT</b>	BAUSCH AND LOMB	<b>0.005%</b>	<b>A201006 001</b>	Mar 22, 2011
<b>AT</b>	DR REDDYS LABS LTD	<b>0.005%</b>	<b>A202077 001</b>	Feb 11, 2013
<b>AT</b>	LUITPOLD	<b>0.005%</b>	<b>A200925 001</b>	Mar 22, 2011
<b>AT</b>	MYLAN	<b>0.005%</b>	<b>A201786 001</b>	Mar 22, 2011

XALATAN

<b>AT</b>	+ PHARMACIA AND UPJOHN	<b>0.005%</b>	<b>N020597 001</b>	Jun 05, 1996
-----------	------------------------	---------------	--------------------	--------------

LEDIPASVIR; SOFOSBUVIR

TABLET; ORAL

HARVONI

+ GILEAD SCIENCES INC 90MG; 400MG

N205834 001 Oct 10, 2014

LEFLUNOMIDE

TABLET; ORAL

ARAVA

<b>AB</b>	SANOFI AVENTIS US	<b>10MG</b>	<b>N020905 001</b>	Sep 10, 1998
<b>AB</b>	+	<b>20MG</b>	<b>N020905 002</b>	Sep 10, 1998

LEFLUNOMIDE

<b>AB</b>	ALEMBIC PHARMS LTD	<b>10MG</b>	<b>A091369 001</b>	Nov 21, 2011
<b>AB</b>		<b>20MG</b>	<b>A091369 002</b>	Nov 21, 2011
<b>AB</b>	APOTEX INC	<b>10MG</b>	<b>A077090 001</b>	Sep 13, 2005
<b>AB</b>		<b>20MG</b>	<b>A077090 002</b>	Sep 13, 2005
<b>AB</b>	BARR	<b>10MG</b>	<b>A077083 001</b>	Sep 13, 2005
<b>AB</b>		<b>20MG</b>	<b>A077083 002</b>	Sep 13, 2005
<b>AB</b>	HERITAGE PHARMS INC	<b>10MG</b>	<b>A077086 001</b>	Sep 13, 2005
<b>AB</b>		<b>20MG</b>	<b>A077086 002</b>	Sep 13, 2005
<b>AB</b>	TEVA PHARMS	<b>10MG</b>	<b>A077084 001</b>	Sep 13, 2005
<b>AB</b>		<b>20MG</b>	<b>A077084 002</b>	Sep 13, 2005

ARAVA

+ SANOFI AVENTIS US 100MG

N020905 003 Sep 10, 1998

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE 2.5MG

N021880 005 Dec 21, 2011

5MG

N021880 001 Dec 27, 2005

10MG

N021880 002 Dec 27, 2005

15MG

N021880 003 Jun 29, 2006

20MG

N021880 006 Jun 05, 2013

+ 25MG

N021880 004 Jun 29, 2006

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

EISAI INC EQ 4MG BASE

N206947 001 Feb 13, 2015

+ EQ 10MG BASE

N206947 002 Feb 13, 2015

LESINURAD

TABLET; ORAL

ZURAMPIC

+ ARDEA BIOSCIENCES 200MG

N207988 001 Dec 22, 2015

LETROZOLE

TABLET; ORAL

FEMARA

<b>AB</b>	+	NOVARTIS PHARMS	<b>2.5MG</b>	<b>N020726 001</b>	Jul 25, 1997
-----------	---	-----------------	--------------	--------------------	--------------

LETROZOLE

<b>AB</b>	ACCORD HLTHCARE	<b>2.5MG</b>	<b>A090934 001</b>	Jun 03, 2011
<b>AB</b>	APOTEX INC	<b>2.5MG</b>	<b>A091303 001</b>	Apr 19, 2012
<b>AB</b>	DR REDDYS LABS LTD	<b>2.5MG</b>	<b>A091191 001</b>	Jun 03, 2011
<b>AB</b>	FRESENIUS KABI ONCOL	<b>2.5MG</b>	<b>A090491 001</b>	Jun 03, 2011
<b>AB</b>	INDICUS PHARMA	<b>2.5MG</b>	<b>A201804 001</b>	Jun 03, 2011
<b>AB</b>	JIANGSU HENGRUI MED	<b>2.5MG</b>	<b>A202716 001</b>	May 16, 2013
<b>AB</b>	KUDCO IRELAND	<b>2.5MG</b>	<b>A091098 001</b>	Jun 03, 2011
<b>AB</b>	LANNETT HOLDINGS INC	<b>2.5MG</b>	<b>A202048 001</b>	Oct 29, 2014
<b>AB</b>	MYLAN	<b>2.5MG</b>	<b>A078190 001</b>	Dec 24, 2008

## PRESCRIPTION DRUG PRODUCT LIST

LETROZOLE

TABLET; ORAL

LETROZOLE

<b>AB</b>	NATCO PHARMA LTD	<u>2.5MG</u>	<u>A200161 001</u>	Jun 03, 2011
<b>AB</b>	ROXANE	<u>2.5MG</u>	<u>A090838 001</u>	Jun 03, 2011
<b>AB</b>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091466 001</u>	Jun 03, 2011
<b>AB</b>	TEVA PHARMS	<u>2.5MG</u>	<u>A090289 001</u>	Jun 03, 2011
<b>AB</b>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A090789 001</u>	Jun 03, 2011

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<b>AP</b>	+	EUROHLTH INTL SARL	<u>EQ 50MG BASE/VIAL</u>	<u>A089384 001</u>	Sep 14, 1987
<b>AP</b>	+		<u>EQ 100MG BASE/VIAL</u>	<u>A089717 001</u>	Mar 28, 1988
<b>AP</b>		TEVA PHARMS USA	<u>EQ 100MG BASE/VIAL</u>	<u>A081277 001</u>	Sep 28, 1993
<b>AP</b>			<u>EQ 350MG BASE/VIAL</u>	<u>A040174 001</u>	Jun 12, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

<b>AP</b>	+	EUROHLTH INTL SARL	<u>EQ 200MG BASE/VIAL</u>	<u>A040056 001</u>	May 23, 1995
<b>AP</b>	+		<u>EQ 350MG BASE/VIAL</u>	<u>A040335 001</u>	Apr 20, 2000
<b>AP</b>		FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A040258 001</u>	Feb 26, 1999
<b>AP</b>		SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A200753 001</u>	Sep 06, 2012
<b>AP</b>			<u>EQ 100MG BASE/VIAL</u>	<u>A200753 002</u>	Sep 06, 2012
<b>AP</b>			<u>EQ 200MG BASE/VIAL</u>	<u>A200753 003</u>	Sep 06, 2012
<b>AP</b>			<u>EQ 350MG BASE/VIAL</u>	<u>A200855 001</u>	Sep 06, 2012
	+	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A040347 001	Apr 25, 2000
	+	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286 001	Feb 26, 1999

TABLET; ORAL

LEUCOVORIN CALCIUM

<b>AB</b>		BARR	<u>EQ 5MG BASE</u>	<u>A071198 001</u>	Sep 24, 1987
<b>AB</b>			<u>EQ 25MG BASE</u>	<u>A071199 001</u>	Sep 24, 1987
<b>AB</b>		ROXANE	<u>EQ 5MG BASE</u>	<u>A072733 001</u>	Feb 22, 1993
<b>AB</b>			<u>EQ 15MG BASE</u>	<u>A072735 001</u>	Feb 22, 1993
<b>AB</b>	+		<u>EQ 25MG BASE</u>	<u>A072736 001</u>	Feb 22, 1993
			EQ 10MG BASE	A072734 001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<b>AP</b>	+	SANDOZ	<u>1MG/0.2ML</u>	<u>A074728 001</u>	Aug 04, 1998
<b>AP</b>		SUN PHARMA GLOBAL	<u>1MG/0.2ML</u>	<u>A078885 001</u>	Mar 09, 2009
<b>AP</b>		TEVA PHARMS USA	<u>1MG/0.2ML</u>	<u>A075471 001</u>	Oct 25, 2000

LUPRON DEPOT

	+	ABBVIE ENDOCRINE INC	3.75MG	N020011 002	Oct 26, 1995
	+		7.5MG/VIAL	N019732 001	Jan 26, 1989
	+		11.25MG/VIAL	N020708 001	Mar 07, 1997
	+		22.5MG/VIAL	N020517 001	Dec 22, 1995
	+		30MG/VIAL	N020517 002	May 30, 1997
	+		45MG/VIAL	N020517 003	Jun 17, 2011

LUPRON DEPOT-PED

	+	ABBVIE ENDOCRINE INC	7.5MG/VIAL	N020263 002	Apr 16, 1993
	+		11.25MG/VIAL	N020263 005	Jan 21, 1994
	+		11.25MG/VIAL	N020263 007	Aug 15, 2011
	+		15MG/VIAL	N020263 006	Jan 21, 1994
	+		30MG/VIAL	N020263 008	Aug 15, 2011

INJECTABLE; SUBCUTANEOUS

ELIGARD

	+	TOLMAR THERAP	7.5MG/VIAL	N021343 001	Jan 23, 2002
	+		22.5MG/VIAL	N021379 001	Jul 24, 2002
	+		30MG/VIAL	N021488 001	Feb 13, 2003
	+		45MG/VIAL	N021731 001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

		ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696 001	Dec 14, 2012
	+		11.25MG/VIAL, N/A; N/A, 5MG	N203696 002	Dec 14, 2012

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<b>AN</b>		CIPLA LTD	<u>EQ 0.021% BASE</u>	<u>A078171 002</u>	Dec 13, 2013
<b>AN</b>			<u>EQ 0.042% BASE</u>	<u>A078171 003</u>	Dec 13, 2013
<b>AN</b>			<u>EQ 0.0103% BASE</u>	<u>A078171 001</u>	Dec 13, 2013
<b>AN</b>		MYLAN SPECLT	<u>EQ 0.0103% BASE</u>	<u>A077800 001</u>	Mar 15, 2013



## PRESCRIPTION DRUG PRODUCT LIST

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077800 002</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077800 003</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.25% BASE</u>	<u>A078309 001</u>	Mar 20, 2009
<u>AN</u>	TEVA PARENTERAL	<u>EQ 0.25% BASE</u>	<u>A200875 001</u>	Sep 11, 2014
<u>AN</u>	TEVA PHARMS USA	<u>EQ 0.0103% BASE</u>	<u>A090297 001</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A090297 002</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A090297 003</u>	Apr 26, 2013
<u>AN</u>	WATSON LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756 003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756 001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756 002</u>	Apr 09, 2008

XOPENEX

<u>AN</u>	+ OAK PHARMS INC	<u>EQ 0.0103% BASE</u>	<u>N020837 003</u>	Jan 30, 2002
<u>AN</u>	+	<u>EQ 0.021% BASE</u>	<u>N020837 001</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.042% BASE</u>	<u>N020837 002</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.25% BASE</u>	<u>N020837 004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+ SUNOVION

EQ 0.045MG BASE/INH

N021730 001 Mar 11, 2005

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

<u>AP</u>	+ UCB INC	<u>500MG/5ML (100MG/ML)</u>	<u>N021872 001</u>	Jul 31, 2006
-----------	-----------	-----------------------------	--------------------	--------------

LEVETIRACETAM

<u>AP</u>	FRESENIUS KABI USA	<u>500MG/5ML (100MG/ML)</u>	<u>A090813 001</u>	May 26, 2010
<u>AP</u>		<u>500MG/5ML (100MG/ML)</u>	<u>A090876 001</u>	Aug 13, 2015
<u>AP</u>	HIKMA FARMACEUTICA	<u>500MG/5ML (100MG/ML)</u>	<u>A090981 001</u>	Oct 13, 2011
<u>AP</u>	HOSPIRA INC	<u>500MG/5ML (100MG/ML)</u>	<u>A202869 001</u>	Apr 06, 2012
<u>AP</u>	LUITPOLD	<u>500MG/5ML (100MG/ML)</u>	<u>A202143 001</u>	Jan 31, 2012
<u>AP</u>	SAGENT PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091627 001</u>	Jun 26, 2013
<u>AP</u>	SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754 001</u>	Jun 16, 2010
<u>AP</u>	X GEN PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091485 001</u>	Aug 05, 2011

LEVETIRACETAM IN SODIUM CHLORIDE

+ HQ SPECIALITY PHARMA

500MG/100ML (5MG/ML)

N202543 001 Nov 09, 2011

+

1000MG/100ML (10MG/ML)

N202543 002 Nov 09, 2011

+

1500MG/100ML (15MG/ML)

N202543 003 Nov 09, 2011

SOLUTION; ORAL

KEPPRA

<u>AA</u>	+ UCB INC	<u>100MG/ML</u>	<u>N021505 001</u>	Jul 15, 2003
-----------	-----------	-----------------	--------------------	--------------

LEVETIRACETAM

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976 001</u>	Jan 15, 2009
<u>AA</u>	AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992 001</u>	Oct 27, 2009
<u>AA</u>	AUROBINDO PHARM	<u>100MG/ML</u>	<u>A079063 001</u>	Jan 15, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>100MG/ML</u>	<u>A079120 001</u>	Jan 16, 2009
<u>AA</u>	HETERO LABS LTD III	<u>100MG/ML</u>	<u>A203052 001</u>	Feb 28, 2013
<u>AA</u>	HI-TECH PHARMACAL	<u>100MG/ML</u>	<u>A090601 001</u>	Feb 28, 2012
<u>AA</u>	LUPIN LTD	<u>100MG/ML</u>	<u>A090893 001</u>	Oct 17, 2011
<u>AA</u>	ORIT LABS LLC	<u>100MG/ML</u>	<u>A203067 001</u>	May 09, 2013
<u>AA</u>	PHARM ASSOC	<u>100MG/ML</u>	<u>A201157 001</u>	Jun 04, 2015
<u>AA</u>	ROXANE	<u>100MG/ML</u>	<u>A078582 001</u>	Jan 15, 2009
<u>AA</u>	SILARX	<u>100MG/ML</u>	<u>A090263 001</u>	Apr 03, 2009
<u>AA</u>	TARO	<u>100MG/ML</u>	<u>A078774 001</u>	Feb 10, 2009
<u>AA</u>	TOLMAR	<u>100MG/ML</u>	<u>A079107 001</u>	Jan 15, 2009
<u>AA</u>	TRIS PHARMA INC	<u>100MG/ML</u>	<u>A090461 001</u>	Sep 30, 2010
<u>AA</u>	VINTAGE PHARMS	<u>100MG/ML</u>	<u>A090079 001</u>	Apr 11, 2012
<u>AA</u>	WOCKHARDT	<u>100MG/ML</u>	<u>A090028 001</u>	Mar 03, 2010

TABLET; ORAL

KEPPRA

<u>AB</u>	UCB INC	<u>250MG</u>	<u>N021035 001</u>	Nov 30, 1999
<u>AB</u>		<u>500MG</u>	<u>N021035 002</u>	Nov 30, 1999
<u>AB</u>		<u>750MG</u>	<u>N021035 003</u>	Nov 30, 1999
<u>AB</u>	+	<u>1GM</u>	<u>N021035 004</u>	Jan 06, 2006

LEVETIRACETAM

<u>AB</u>	ACCORD HLTHCARE	<u>250MG</u>	<u>A090843 001</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A090843 002</u>	Feb 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A090843 003</u>	Feb 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A090843 004</u>	Feb 14, 2011
<u>AB</u>	AJANTA PHARMA	<u>250MG</u>	<u>A201293 001</u>	Jun 14, 2011

## PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>500MG</u>	<u>A201293 002</u>	Jun 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A201293 003</u>	Jun 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A201293 004</u>	Jun 14, 2011
<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A078869 001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869 002</u>	Mar 13, 2009
<u>AB</u>		<u>750MG</u>	<u>A078869 003</u>	Mar 13, 2009
<u>AB</u>		<u>1GM</u>	<u>A078869 004</u>	Mar 13, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>250MG</u>	<u>A078993 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078993 004</u>	Jan 15, 2009
<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090511 001</u>	Aug 18, 2011
<u>AB</u>		<u>500MG</u>	<u>A090511 002</u>	Aug 18, 2011
<u>AB</u>		<u>750MG</u>	<u>A090511 003</u>	Aug 18, 2011
<u>AB</u>		<u>1GM</u>	<u>A090511 004</u>	Aug 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>250MG</u>	<u>A076920 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078904 001</u>	Jan 15, 2009
<u>AB</u>	HETERO LABS LTD III	<u>250MG</u>	<u>A090515 001</u>	Oct 08, 2010
<u>AB</u>		<u>500MG</u>	<u>A090515 002</u>	Oct 08, 2010
<u>AB</u>		<u>750MG</u>	<u>A090515 003</u>	Oct 08, 2010
<u>AB</u>		<u>1GM</u>	<u>A090515 004</u>	Oct 08, 2010
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078234 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234 003</u>	Jan 15, 2009
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A090906 001</u>	Nov 05, 2010
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078154 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090025 001</u>	Jan 15, 2009
<u>AB</u>	METHAPHARM	<u>250MG</u>	<u>A090767 001</u>	Jul 28, 2010
<u>AB</u>		<u>500MG</u>	<u>A090767 002</u>	Jul 28, 2010
<u>AB</u>		<u>750MG</u>	<u>A090767 003</u>	Jul 28, 2010
<u>AB</u>		<u>1GM</u>	<u>A090767 004</u>	Jul 28, 2010
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076919 001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919 002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919 003</u>	Nov 04, 2008
<u>AB</u>		<u>1GM</u>	<u>A090261 001</u>	Dec 08, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A078526 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090484 001</u>	Aug 05, 2010
<u>AB</u>	PRINSTON INC	<u>250MG</u>	<u>A078106 001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106 002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106 003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106 004</u>	Feb 10, 2009
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A078042 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078042 004</u>	Jan 15, 2009
<u>AB</u>	SECAN PHARMS	<u>250MG</u>	<u>A205102 001</u>	Dec 16, 2015
<u>AB</u>		<u>750MG</u>	<u>A205102 002</u>	Dec 16, 2015
<u>AB</u>		<u>1GM</u>	<u>A205102 003</u>	Dec 16, 2015
<u>AB</u>	TARO	<u>250MG</u>	<u>A078960 004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960 003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960 002</u>	Feb 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A078960 001</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A078101 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078101 004</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858 004</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A077319 001</u>	Mar 20, 2009
<u>AB</u>		<u>250MG</u>	<u>A091491 001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A077319 002</u>	Mar 20, 2009

## PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>500MG</u>	<u>A091491</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A091491</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>		<u>1GM</u>	<u>A091491</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A079042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918</u>	<u>001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918</u>	<u>002</u>	Apr 29, 2009

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015
		500MG	N207958	002	Jul 31, 2015
		750MG	N207958	003	Jul 31, 2015
		1GM	N207958	004	Jul 31, 2015

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	UCB INC	<u>500MG</u>	<u>N022285</u>	<u>001</u>	Sep 12, 2008
<u>AB</u>	+	<u>750MG</u>	<u>N022285</u>	<u>002</u>	Feb 12, 2009

LEVETIRACETAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A091557</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091557</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A091093</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360</u>	<u>001</u>	Oct 04, 2011
<u>AB</u>		<u>750MG</u>	<u>A091360</u>	<u>002</u>	Oct 04, 2011
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	DEXCEL PHARMA	<u>500MG</u>	<u>A202167</u>	<u>001</u>	Sep 04, 2015
<u>AB</u>		<u>750MG</u>	<u>A202167</u>	<u>002</u>	Sep 04, 2015
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MUTUAL PHARM CO INC	<u>500MG</u>	<u>A091285</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091285</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200475</u>	<u>001</u>	Dec 19, 2011
<u>AB</u>		<u>750MG</u>	<u>A200475</u>	<u>002</u>	Dec 19, 2011
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A091291</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091291</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	PHARMADAX INC	<u>500MG</u>	<u>A201464</u>	<u>001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464</u>	<u>002</u>	May 25, 2012
<u>AB</u>	PRINSTON INC	<u>500MG</u>	<u>A203468</u>	<u>001</u>	May 21, 2015
<u>AB</u>		<u>750MG</u>	<u>A203468</u>	<u>002</u>	May 21, 2015
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>500MG</u>	<u>A203059</u>	<u>001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059</u>	<u>002</u>	Sep 09, 2013
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A091430</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091430</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG</u>	<u>A091338</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>750MG</u>	<u>A091338</u>	<u>002</u>	May 29, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>500MG</u>	<u>A202533</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A202533</u>	<u>002</u>	Jul 20, 2012
	APOTEX INC	1GM	A202958	001	Feb 25, 2015
	MYLAN PHARMS INC	1GM	A200475	003	Dec 07, 2015

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+	ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+		<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	ALCON RES LTD	<u>0.5%</u>	<u>A074850</u>	<u>001</u>	Oct 28, 1996
<u>AT</u>	BAUSCH AND LOMB	<u>0.25%</u>	<u>A074307</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>		<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>	FALCON PHARMS	<u>0.25%</u>	<u>A074851</u>	<u>001</u>	Oct 28, 1996

## PRESCRIPTION DRUG PRODUCT LIST

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITORAP + SIGMA TAU 200MG/ML N020182 001 Dec 16, 1992LEVOCARNITINEAP EUROHLTH INTL SARL 200MG/ML A075567 001 Mar 29, 2001AP LUITPOLD 200MG/ML A075861 001 Jun 22, 2001

SOLUTION; ORAL

CARNITORAA + SIGMA TAU 1GM/10ML N019257 001 Apr 10, 1986CARNITOR SFAA SIGMA TAU 1GM/10ML N019257 002 Mar 28, 2007LEVOCARNITINEAA HI TECH PHARMA 1GM/10ML A077399 001 Oct 25, 2007AA LYNE 1GM/10ML A076851 001 Aug 10, 2004

TABLET; ORAL

CARNITORAB + SIGMA TAU 330MG N018948 001 Dec 27, 1985LEVOCARNITINEAB COREPHARMA 330MG A076858 001 Sep 20, 2004LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDEAA APOTEX INC 2.5MG/5ML A202915 001 Aug 21, 2014AA L PERRIGO CO 2.5MG/5ML A091263 001 Nov 07, 2011AA TARO PHARM INDS 2.5MG/5ML A202673 001 Jul 26, 2013KYZALAA + UCB INC 2.5MG/5ML N022157 001 Jan 28, 2008

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDEAB APOTEX INC 5MG A203027 001 Feb 13, 2015AB DR REDDYS LABS LTD 5MG A090392 001 Feb 24, 2011AB GLENMARK GENERICS 5MG A090385 001 Feb 24, 2011AB HETERO LABS LTD III 5MG A091264 001 Jun 29, 2012AB MACLEODS PHARMS LTD 5MG A205564 001 Jan 11, 2016AB MICRO LABS LTD INDIA 5MG A202046 001 Sep 17, 2013AB SCIEGEN PHARMS INC 5MG A203646 001 Sep 09, 2014AB SUN PHARM INDS LTD 5MG A201653 001 Jun 26, 2015AB SUN PHARMA GLOBAL 5MG A090362 001 Jan 31, 2013AB SYNTHON PHARMS 5MG A090229 001 Nov 26, 2010AB TEVA PHARMS 5MG A090199 001 Aug 22, 2011KYZALAB + UCB INC 5MG N022064 001 May 25, 2007LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUINAP + JANSSEN PHARMS EQ 500MG/20ML (EQ 25MG/ML) N020635 001 Dec 20, 1996AP + EQ 750MG/30ML (EQ 25MG/ML) N020635 004 Dec 20, 1996LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERAP + JANSSEN PHARMS EQ 250MG/50ML (EQ 5MG/ML) N020635 002 Dec 20, 1996AP + EQ 500MG/100ML (EQ 5MG/ML) N020635 003 Dec 20, 1996AP + EQ 750MG/150ML (EQ 5MG/ML) N020635 005 Dec 20, 1996LEVOFLOXACINAP AUROBINDO PHARMA LTD EQ 500MG/20ML (EQ 25MG/ML) A202328 001 Jan 24, 2013AP EQ 750MG/30ML (EQ 25MG/ML) A202328 002 Jan 24, 2013AP CLARIS PHARMASERVICE EQ 500MG/20ML (EQ 25MG/ML) A091436 001 Jun 05, 2013AP EMCURE PHARMS LTD EQ 500MG/20ML (EQ 25MG/ML) A202590 001 Jan 24, 2013AP EQ 750MG/30ML (EQ 25MG/ML) A202590 002 Jan 24, 2013AP HOSPIRA INC EQ 500MG/20ML (EQ 25MG/ML) A078577 001 Aug 12, 2015AP EQ 750MG/30ML (EQ 25MG/ML) A078577 002 Aug 12, 2015AP SAGENT PHARMS EQ 500MG/20ML (EQ 25MG/ML) A200560 001 Jun 20, 2011AP EQ 750MG/30ML (EQ 25MG/ML) A200560 002 Jun 20, 2011LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINERAP ACS DOBFAR INFO SA EQ 250MG/50ML (EQ 5MG/ML) A090343 001 Jul 07, 2011AP EQ 500MG/100ML (EQ 5MG/ML) A090343 002 Jul 07, 2011AP EQ 750MG/150ML (EQ 5MG/ML) A090343 003 Jul 07, 2011AP CLARIS PHARMASERVICE EQ 250MG/50ML (EQ 5MG/ML) A091397 001 Aug 08, 2013AP EQ 500MG/100ML (EQ 5MG/ML) A091397 002 Aug 08, 2013AP EQ 750MG/150ML (EQ 5MG/ML) A091397 003 Aug 08, 2013AP FRESENIUS KABI USA EQ 250MG/50ML (EQ 5MG/ML) A200674 001 Jun 19, 2013AP EQ 500MG/100ML (EQ 5MG/ML) A200674 002 Jun 19, 2013

## PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A200674 003</u>	Jun 19, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375 001</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375 002</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375 003</u>	Sep 16, 2011
<u>AP</u>	HOSPIRA INC	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A078579 001</u>	Sep 03, 2015
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A078579 002</u>	Sep 03, 2015
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A078579 003</u>	Sep 03, 2015

SOLUTION; ORAL

LEVAQUIN

<u>AA</u>	+ JANSSEN PHARMS	<u>250MG/10ML</u>	<u>N021721 001</u>	Oct 21, 2004
-----------	------------------	-------------------	--------------------	--------------

LEVOFLOXACIN

<u>AA</u>	HI TECH PHARMA	<u>250MG/10ML</u>	<u>A091678 001</u>	Jun 20, 2011
-----------	----------------	-------------------	--------------------	--------------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A090268 001</u>	Dec 20, 2010
<u>AT</u>	+ NEXUS PHARMS	<u>0.5%</u>	<u>A077700 001</u>	Dec 20, 2010
<u>AT</u>	WATSON LABS INC	<u>0.5%</u>	<u>A076826 001</u>	Feb 10, 2011

TABLET; ORAL

LEVAQUIN

<u>AB</u>	JANSSEN PHARMS	<u>250MG</u>	<u>N020634 001</u>	Dec 20, 1996
<u>AB</u>		<u>500MG</u>	<u>N020634 002</u>	Dec 20, 1996
<u>AB</u>	+	<u>750MG</u>	<u>N020634 003</u>	Sep 08, 2000

LEVOFLOXACIN

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A090787 001</u>	Sep 29, 2011
<u>AB</u>		<u>500MG</u>	<u>A090787 002</u>	Sep 29, 2011
<u>AB</u>		<u>750MG</u>	<u>A090787 003</u>	Sep 29, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A201043 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A201043 003</u>	Jun 20, 2011
<u>AB</u>	CIPLA LTD	<u>250MG</u>	<u>A076890 001</u>	Mar 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A076890 002</u>	Mar 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A076890 003</u>	Mar 30, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A076710 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076710 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076710 003</u>	Jun 20, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A200250 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A200250 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A200250 003</u>	Jun 20, 2011
<u>AB</u>	HETERO LABS LTD V	<u>250MG</u>	<u>A202801 001</u>	Jan 08, 2015
<u>AB</u>		<u>500MG</u>	<u>A202801 002</u>	Jan 08, 2015
<u>AB</u>		<u>750MG</u>	<u>A202801 003</u>	Jan 08, 2015
<u>AB</u>	JUBILANT GENERICS	<u>250MG</u>	<u>A203613 001</u>	Jun 19, 2015
<u>AB</u>		<u>500MG</u>	<u>A203613 002</u>	Jun 19, 2015
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078424 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A078424 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A078424 003</u>	Jun 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839 001</u>	Mar 22, 2012
<u>AB</u>		<u>500MG</u>	<u>A200839 002</u>	Mar 22, 2012
<u>AB</u>		<u>750MG</u>	<u>A200839 003</u>	Mar 22, 2012
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076276 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076276 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077097 001</u>	Jun 20, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A202200 001</u>	Jan 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202200 002</u>	Jan 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A202200 003</u>	Jan 30, 2012
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077438 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A077438 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077438 003</u>	Jun 20, 2011
<u>AB</u>	TEVA	<u>250MG</u>	<u>A076361 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076361 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076361 003</u>	Jun 20, 2011
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A090722 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090722 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090722 003</u>	Jun 20, 2011
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A090367 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090367 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090367 003</u>	Jun 20, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A077652 001</u>	Sep 07, 2012
<u>AB</u>		<u>500MG</u>	<u>A077652 002</u>	Sep 07, 2012

## PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

<b>AB</b>		<b>750MG</b>		<b>A077652 003</b>	Sep 07, 2012
-----------	--	--------------	--	--------------------	--------------

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

+ SPECTRUM PHARMS

EQ 50MG BASE/VIAL

N020140 001 Mar 07, 2008

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

<b>AP</b>	MYLAN TEORANTA	<b>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</b>		<b>A203576 001</b>	Oct 20, 2015
-----------	----------------	---	--	--------------------	--------------

<b>AP</b>		<b>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</b>		<b>A203576 002</b>	Oct 20, 2015
-----------	--	---	--	--------------------	--------------

<b>AP</b>	SANDOZ INC	<b>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</b>		<b>A203563 001</b>	Mar 09, 2015
-----------	------------	---	--	--------------------	--------------

<b>AP</b>	+	<b>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</b>		<b>A203563 002</b>	Mar 09, 2015
-----------	---	---	--	--------------------	--------------

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

FOREST LABS INC

EQ 20MG BASE

N204168 001 Jul 25, 2013

EQ 40MG BASE

N204168 002 Jul 25, 2013

EQ 80MG BASE

N204168 003 Jul 25, 2013

+

EQ 120MG BASE

N204168 004 Jul 25, 2013

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

+ DEPROCO

0.05MG/ML; 2%

A088388 001 Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

LILETTA

MEDICINES360

52MG

N206229 001 Feb 26, 2015

MIRENA

+ BAYER HLTHCARE

52MG

N021225 001 Dec 06, 2000

SKYLA

+ BAYER HLTHCARE

13.5MG

N203159 001 Jan 09, 2013

TABLET; ORAL

LEVONORGESTREL

<b>AB</b>	NOVEL LABS INC	<b>1.5MG</b>		<b>A202508 001</b>	Feb 22, 2013
-----------	----------------	--------------	--	--------------------	--------------

<b>AB</b>	PERRIGO R AND D	<b>0.75MG</b>		<b>A090740 001</b>	Dec 30, 2010
-----------	-----------------	---------------	--	--------------------	--------------

<b>AB</b>	+	<b>WATSON LABS</b>	<b>0.75MG</b>	<b>A078665 001</b>	Aug 28, 2009
-----------	---	--------------------	---------------	--------------------	--------------

<b>AB</b>	WATSON LABS INC	<b>1.5MG</b>		<b>A200670 001</b>	Jul 12, 2012
-----------	-----------------	--------------	--	--------------------	--------------

PLAN B

<b>AB</b>	+	TEVA BRANDED PHARM	<b>0.75MG</b>	<b>N021045 002</b>	Aug 24, 2006
-----------	---	--------------------	---------------	--------------------	--------------

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

+ SENTYNL THERAPS INC

2MG

A074278 001 Mar 31, 2000

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

INST BIOCHIMIQUE

0.013MG

N022121 001 Aug 01, 2007

INSTITUT BIOCHIMIQUE

0.025MG

N021924 002 Oct 13, 2006

0.05MG

N021924 003 Oct 13, 2006

0.075MG

N021924 004 Oct 13, 2006

0.088MG

N021924 010 Oct 02, 2009

0.1MG

N021924 005 Oct 13, 2006

0.112MG

N021924 008 Oct 02, 2009

0.125MG

N021924 006 Oct 13, 2006

0.137MG

N021924 009 Oct 02, 2009

+

0.15MG

N021924 007 Oct 13, 2006

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

<b>AP</b>	+	FRESENIUS KABI USA	<b>200MCG/VIAL</b>	<b>N202231 002</b>	Jun 24, 2011
-----------	---	--------------------	--------------------	--------------------	--------------

<b>AP</b>		PAR STERILE PRODUCTS	<b>200MCG/VIAL</b>	<b>A205366 001</b>	Dec 07, 2015
-----------	--	----------------------	--------------------	--------------------	--------------

+	FRESENIUS KABI USA	100MCG/VIAL	N202231 001	Jun 24, 2011
---	--------------------	-------------	-------------	--------------

+		500MCG/VIAL	N202231 003	Jun 24, 2011
---	--	-------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

## TABLET;ORAL

SYNTHROID

-->	ABBVIE	--> <u>AB1,AB2</u>	<u>0.025MG</u>	N021402 001	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.05MG</u>	N021402 002	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.075MG</u>	N021402 003	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.088MG</u>	N021402 004	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.1MG</u>	N021402 005	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.112MG</u>	N021402 006	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.125MG</u>	N021402 007	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.137MG</u>	N021402 008	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.15MG</u>	N021402 009	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.175MG</u>	N021402 010	Jul 24, 2002
-->		--> <u>AB1,AB2</u>	<u>0.2MG</u>	N021402 012	Jul 24, 2002
-->	+	--> <u>AB1,AB2</u>	<u>0.3MG</u>	N021402 011	Jul 24, 2002

LEVO-T

-->	ALARA PHARM	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021342 001	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021342 002	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021342 003	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021342 004	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021342 005	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021342 006	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021342 007	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021342 012	Dec 08, 2003
-->		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021342 008	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021342 009	Mar 01, 2002
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021342 010	Mar 01, 2002
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021342 011	Mar 01, 2002

UNITHROID

-->	STEVENS J	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021210 001	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021210 002	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021210 003	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021210 004	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021210 005	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021210 006	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021210 007	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021210 012	Feb 08, 2008
-->		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021210 008	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021210 009	Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021210 010	Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021210 011	Aug 21, 2000

LEVOTHYROXINE SODIUM

-->	MYLAN	-->	<u>0.025MG</u>	A076187 001	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.05MG</u>	A076187 002	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.075MG</u>	A076187 003	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.088MG</u>	A076187 004	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.1MG</u>	A076187 005	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>			
-->		-->	<u>0.112MG</u>	A076187 006	Jun 05, 2002

## PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

	<u>AB3, AB4</u>	<u>0.112MG</u>				
-->	-->	<u>0.125MG</u>	A076187	007	Jun 05, 2002	
	<u>AB1, AB2, AB3, AB4</u>					
-->	-->	<u>0.137MG</u>	A076187	012	Dec 13, 2006	
	<u>AB1, AB2, AB3, AB4</u>					
-->	-->	<u>0.15MG</u>	A076187	008	Jun 05, 2002	
	<u>AB1, AB2, AB3, AB4</u>					
-->	-->	<u>0.175MG</u>	A076187	009	Jun 05, 2002	
	<u>AB1, AB2, AB3, AB4</u>					
-->	-->	<u>0.2MG</u>	A076187	010	Jun 05, 2002	
	<u>AB1, AB2, AB3, AB4</u>					
-->	-->	<u>0.3MG</u>	A076187	011	Jun 05, 2002	
	<u>AB1, AB2, AB3, AB4</u>					

LEVOXYL

-->	KING PHARMS R AND D	--> <u>AB1, AB3</u>	<u>0.025MG</u>	N021301	001	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.05MG</u>	N021301	002	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.075MG</u>	N021301	003	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.088MG</u>	N021301	004	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.1MG</u>	N021301	005	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.112MG</u>	N021301	006	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.125MG</u>	N021301	007	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.137MG</u>	N021301	008	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.15MG</u>	N021301	009	May 25, 2001
-->		--> <u>AB1, AB3</u>	<u>0.175MG</u>	N021301	010	May 25, 2001
-->	+	--> <u>AB1, AB3</u>	<u>0.2MG</u>	N021301	011	May 25, 2001

LEVOTHROID

<u>AB4</u>	LLOYD	<u>0.025MG</u>	<u>N021116</u>	<u>001</u>	Oct 24, 2002
<u>AB4</u>		<u>0.05MG</u>	<u>N021116</u>	<u>002</u>	Oct 24, 2002
<u>AB4</u>		<u>0.075MG</u>	<u>N021116</u>	<u>003</u>	Oct 24, 2002
<u>AB4</u>		<u>0.088MG</u>	<u>N021116</u>	<u>010</u>	Oct 24, 2002
<u>AB4</u>		<u>0.1MG</u>	<u>N021116</u>	<u>004</u>	Oct 24, 2002
<u>AB4</u>		<u>0.112MG</u>	<u>N021116</u>	<u>011</u>	Oct 24, 2002
<u>AB4</u>		<u>0.125MG</u>	<u>N021116</u>	<u>005</u>	Oct 24, 2002
<u>AB4</u>		<u>0.137MG</u>	<u>N021116</u>	<u>012</u>	Dec 07, 2004
<u>AB4</u>		<u>0.15MG</u>	<u>N021116</u>	<u>006</u>	Oct 24, 2002
<u>AB4</u>		<u>0.175MG</u>	<u>N021116</u>	<u>007</u>	Oct 24, 2002
<u>AB4</u>		<u>0.2MG</u>	<u>N021116</u>	<u>008</u>	Oct 24, 2002
<u>AB4</u>	+	<u>0.3MG</u>	<u>N021116</u>	<u>009</u>	Oct 24, 2002

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u>	AMNEAL PHARMS	<u>5%</u>	<u>A206297</u>	<u>001</u>	Aug 07, 2015
<u>AT</u>	+	<u>5%</u>	<u>A080198</u>	<u>001</u>	
<u>AT</u>	NOVOCOL INC	<u>5%</u>	<u>A040911</u>	<u>001</u>	May 23, 2011
<u>AT</u>	TARO	<u>5%</u>	<u>A086724</u>	<u>001</u>	

PATCH; TOPICAL

LIDOCAINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>5%</u>	<u>A200675</u>	<u>001</u>	Aug 23, 2012
<u>AB</u>	MYLAN TECHNOLOGIES	<u>5%</u>	<u>A202346</u>	<u>001</u>	Aug 07, 2015

LIDODERM

<u>AB</u>	+	<u>5%</u>	<u>N020612</u>	<u>001</u>	Mar 19, 1999
-----------	---	-----------	----------------	------------	--------------

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

+ AKORN

3.5%

N022221 001 Oct 07, 2008

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>		<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>		<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>20%</u>	<u>A083158</u>	<u>003</u>	
<u>AP</u>	INTL MEDICATION	<u>1%</u>	<u>A083173</u>	<u>001</u>	
<u>AP</u>		<u>2%</u>	<u>A083173</u>	<u>002</u>	
<u>AP</u>	LUITPOLD	<u>1%</u>	<u>A080850</u>	<u>001</u>	
<u>AP</u>		<u>1%</u>	<u>A091564</u>	<u>001</u>	Aug 14, 2015
<u>AP</u>	MYLAN LABS LTD	<u>0.5%</u>	<u>A091056</u>	<u>001</u>	Dec 08, 2010



## PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

AP		<u>0.5%</u>	<u>A091058 001</u>	Sep 30, 2010
AP		<u>1%</u>	<u>A091056 002</u>	Dec 08, 2010
AP		<u>1%</u>	<u>A091058 002</u>	Sep 30, 2010
AP		<u>2%</u>	<u>A202242 001</u>	Apr 11, 2014
<u>LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>200MG/100ML</u>	<u>N019830 002</u>	Apr 08, 1992
AP	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461 002</u>	
<u>LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>400MG/100ML</u>	<u>N019830 003</u>	Apr 08, 1992
AP	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461 003</u>	
<u>LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
AP	HOSPIRA	<u>400MG/100ML</u>	<u>N018388 002</u>	
<u>LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	<u>800MG/100ML</u>	<u>N019830 004</u>	Apr 08, 1992
AP	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461 004</u>	Feb 22, 1982
<u>LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
AP	HOSPIRA	<u>800MG/100ML</u>	<u>N018388 003</u>	Nov 05, 1982
<u>LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER</u>				
AP	FRESENIUS KABI USA	<u>1%</u>	<u>A088586 001</u>	Jul 24, 1985
AP	HOSPIRA	<u>0.5%</u>	<u>A088325 001</u>	Jul 31, 1984
AP		<u>1%</u>	<u>A088299 001</u>	Jul 31, 1984
AP		<u>2%</u>	<u>A088327 001</u>	Jul 31, 1984
<u>LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE</u>				
AP	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A203040 001</u>	Mar 14, 2013
AP		<u>1%</u>	<u>A203082 001</u>	Mar 14, 2013
AP		<u>2%</u>	<u>A203040 002</u>	Mar 14, 2013
AP		<u>2%</u>	<u>A203082 002</u>	Mar 14, 2013
AP	FRESENIUS KABI USA	<u>1%</u>	<u>A080404 002</u>	
AP		<u>2%</u>	<u>A080404 003</u>	
AP		<u>2%</u>	<u>N017584 001</u>	
AP		<u>4%</u>	<u>N017584 002</u>	
AP	HOSPIRA	<u>1%</u>	<u>A080408 001</u>	
AP		<u>1.5%</u>	<u>A080408 002</u>	
AP		<u>4%</u>	<u>A088295 001</u>	May 17, 1984
AP	INTL MEDICATION	<u>20%</u>	<u>N017702 001</u>	
AP	MYLAN LABS LTD	<u>2%</u>	<u>A090665 001</u>	Sep 27, 2010
<u>LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER</u>				
AP	HOSPIRA	<u>1%</u>	<u>A040302 001</u>	Sep 28, 1998
AP		<u>2%</u>	<u>A040302 002</u>	Sep 28, 1998
<u>XYLOCAINE</u>				
AP	+ FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488 008</u>	
AP	+	<u>1%</u>	<u>N006488 007</u>	
AP	+	<u>1.5%</u>	<u>N006488 010</u>	
AP	+	<u>2%</u>	<u>N006488 002</u>	
<u>XYLOCAINE 4% PRESERVATIVE FREE</u>				
AP	+ FRESENIUS KABI USA	<u>4%</u>	<u>N010417 001</u>	
<u>XYLOCAINE PRESERVATIVE FREE</u>				
AP	+ FRESENIUS KABI USA	<u>1%</u>	<u>N016801 005</u>	Jan 19, 1988
AP	+	<u>2%</u>	<u>N016801 001</u>	
AP	+	<u>4%</u>	<u>N016801 002</u>	
AP	+	<u>20%</u>	<u>N016801 004</u>	
INJECTABLE; SPINAL				
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%				
	+ HOSPIRA	<u>5%</u>	<u>A083914 001</u>	
JELLY; TOPICAL				
<u>GLYDO</u>				
AT	SAGENT PHARMS	<u>2%</u>	<u>A201094 001</u>	Apr 28, 2014
<u>LIDOCAINE HYDROCHLORIDE</u>				
AT	AKORN	<u>2%</u>	<u>A040433 001</u>	Feb 12, 2003
AT	INTL MEDICATION	<u>2%</u>	<u>A086283 001</u>	
AT	WATSON LABS INC	<u>2%</u>	<u>A040837 001</u>	Mar 23, 2011
<u>XYLOCAINE</u>				
AT	+ OAK PHARMS	<u>2%</u>	<u>N008816 001</u>	
SOLUTION; ORAL				
<u>LIDOCAINE HYDROCHLORIDE</u>				
AT	HI TECH PHARMA	<u>2%</u>	<u>A040014 001</u>	Jul 10, 1995
AT	WOCKHARDT	<u>2%</u>	<u>A087872 001</u>	Nov 18, 1982
<u>LIDOCAINE HYDROCHLORIDE VISCOUS</u>				
AT	VINTAGE	<u>2%</u>	<u>A040708 001</u>	Feb 27, 2007

## PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

SOLUTION; ORAL

LIDOCAINE VISCOUS**AT** ROXANE **2%** **A088802 001** Apr 26, 1985XYLOCAINE VISCOUS**AT** + FRESENIUS KABI USA **2%** **N009470 001**

SOLUTION; TOPICAL

LARYNG-O-JET KIT**AT** INTL MEDICATION **4%** **A086364 001**LIDOCAINE HYDROCHLORIDE**AT** IGI LABS INC **4%** **A204494 001** Mar 12, 2014**AT** ROXANE **4%** **A088803 001** Apr 03, 1985**AT** VINTAGE **4%** **A040710 001** Feb 27, 2007**AT** WOCKHARDT **4%** **A087881 001** Nov 18, 1982LTA II KIT**AT** HOSPIRA **4%** **A080409 001**XYLOCAINE 4% PRESERVATIVE FREE**AT** + FRESENIUS KABI USA **4%** **N010417 002**

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS 0.5MG N022114 001 Aug 16, 2007

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA**AB** + ACTAVIS LABS UT INC **2.5%; 2.5%** **N019941 001** Dec 30, 1992LIDOCAINE AND PRILOCAINE**AB** FOUGERA PHARMS **2.5%; 2.5%** **A076453 001** Aug 18, 2003**AB** HI TECH PHARMA **2.5%; 2.5%** **A076290 001** Sep 25, 2003**AB** TOLMAR **2.5%; 2.5%** **A076320 001** Aug 27, 2003

GEL; PERIODONTAL

ORAQIX

+ DENTSPLY PHARM 2.5%; 2.5% N021451 001 Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+ GALDERMA LABS LP 7%; 7% N021717 001 Jun 29, 2006

PATCH; TOPICAL

SYNERA

+ GALEN SPECIALTY 70MG; 70MG N021623 001 Jun 23, 2005

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS LLC 145MCG N202811 001 Aug 30, 2012

+ 290MCG N202811 002 Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+ BOEHRINGER INGELHEIM 5MG N201280 001 May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

BOEHRINGER INGELHEIM 2.5MG; 500MG N201281 001 Jan 30, 2012

2.5MG; 850MG N201281 002 Jan 30, 2012

+ 2.5MG; 1GM N201281 003 Jan 30, 2012

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN**AP** + PHARMACIA AND UPJOHN **EQ 300MG BASE/ML** **N050317 001**LINCOMYCIN**AP** X-GEN PHARMS INC **EQ 300MG BASE/ML** **A201746 001** Jun 04, 2015LINDANE

LOTION; TOPICAL

LINDANE**AT** OLTA PHARMS **1%** **A087313 001****AT** + WOCKHARDT **1%** **A088190 001** Aug 16, 1984

SHAMPOO; TOPICAL

LINDANE**AT** OLTA PHARMS **1%** **A087266 001****AT** + WOCKHARDT **1%** **A088191 001** Sep 18, 1984

## PRESCRIPTION DRUG PRODUCT LIST

LINEZOLID

FOR SUSPENSION;ORAL

LINEZOLID

<b>AB</b>	ROXANE	<u>100MG/5ML</u>	<u>A200068</u>	<u>001</u>	Jun 03, 2015
-----------	--------	------------------	----------------	------------	--------------

ZYVOX

<b>AB</b>	+ PHARMACIA AND UPJOHN	<u>100MG/5ML</u>	<u>N021132</u>	<u>001</u>	Apr 18, 2000
-----------	------------------------	------------------	----------------	------------	--------------

LINEZOLID

<b>AP</b>	HOSPIRA INC	<u>600MG/300ML (2MG/ML)</u>	<u>A205442</u>	<u>001</u>	Jul 07, 2015
-----------	-------------	-----------------------------	----------------	------------	--------------

<b>AP</b>	SANDOZ INC	<u>200MG/100ML (2MG/ML)</u>	<u>A200904</u>	<u>001</u>	Jul 16, 2015
-----------	------------	-----------------------------	----------------	------------	--------------

<b>AP</b>		<u>600MG/300ML (2MG/ML)</u>	<u>A200904</u>	<u>002</u>	Jul 16, 2015
-----------	--	-----------------------------	----------------	------------	--------------

<b>AP</b>	TEVA PHARMS	<u>600MG/300ML (2MG/ML)</u>	<u>A200222</u>	<u>001</u>	Jun 27, 2012
-----------	-------------	-----------------------------	----------------	------------	--------------

ZYVOX

<b>AP</b>	PHARMACIA AND UPJOHN	<u>200MG/100ML (2MG/ML)</u>	<u>N021131</u>	<u>001</u>	Apr 18, 2000
-----------	----------------------	-----------------------------	----------------	------------	--------------

<b>AP</b>	+ PHARMACIA AND UPJOHN	<u>600MG/300ML (2MG/ML)</u>	<u>N021131</u>	<u>003</u>	Apr 18, 2000
-----------	------------------------	-----------------------------	----------------	------------	--------------

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015
---------------	----------------------	---------	-----	--------------

ZYVOX

PHARMACIA AND UPJOHN	400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000
----------------------	----------------------	---------	-----	--------------

TABLET;ORAL

LINEZOLID

<b>AB</b>	ALEMBIC PHARMS LTD	<u>600MG</u>	<u>A205233</u>	<u>001</u>	Dec 21, 2015
-----------	--------------------	--------------	----------------	------------	--------------

<b>AB</b>	ALKEM LABS LTD	<u>600MG</u>	<u>A205517</u>	<u>001</u>	Dec 21, 2015
-----------	----------------	--------------	----------------	------------	--------------

<b>AB</b>	AMNEAL PHARMS	<u>600MG</u>	<u>A204536</u>	<u>001</u>	Dec 21, 2015
-----------	---------------	--------------	----------------	------------	--------------

<b>AB</b>	GLENMARK PHARMS LTD	<u>600MG</u>	<u>A078987</u>	<u>001</u>	Dec 21, 2015
-----------	---------------------	--------------	----------------	------------	--------------

<b>AB</b>	HETERO LABS LTD V	<u>600MG</u>	<u>A204239</u>	<u>001</u>	Dec 21, 2015
-----------	-------------------	--------------	----------------	------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<u>600MG</u>	<u>A078845</u>	<u>001</u>	Dec 21, 2015
-----------	------------------	--------------	----------------	------------	--------------

<b>AB</b>	TEVA PHARMS USA	<u>600MG</u>	<u>A078061</u>	<u>001</u>	May 18, 2015
-----------	-----------------	--------------	----------------	------------	--------------

ZYVOX

<b>AB</b>	+ PHARMACIA AND UPJOHN	<u>600MG</u>	<u>N021130</u>	<u>002</u>	Apr 18, 2000
-----------	------------------------	--------------	----------------	------------	--------------

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

LIOTHYRONINE SODIUM

<b>AP</b>	X GEN PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>A076923</u>	<u>001</u>	Aug 17, 2005
-----------	--------------	--------------------------	----------------	------------	--------------

TRIOSTAT

<b>AP</b>	+ PAR STERILE PRODUCTS	<u>EQ 0.01MG BASE/ML</u>	<u>N020105</u>	<u>001</u>	Dec 31, 1991
-----------	------------------------	--------------------------	----------------	------------	--------------

TABLET;ORAL

CYTOMEL

<b>AB</b>	KING PHARMS R AND D	<u>EQ 0.005MG BASE</u>	<u>N010379</u>	<u>001</u>	
-----------	---------------------	------------------------	----------------	------------	--

<b>AB</b>		<u>EQ 0.025MG BASE</u>	<u>N010379</u>	<u>002</u>	
-----------	--	------------------------	----------------	------------	--

<b>AB</b>	+ PHARMACIA AND UPJOHN	<u>EQ 0.05MG BASE</u>	<u>N010379</u>	<u>003</u>	
-----------	------------------------	-----------------------	----------------	------------	--

LIOTHYRONINE SODIUM

<b>AB</b>	COASTAL PHARMS	<u>EQ 0.005MG BASE</u>	<u>A090097</u>	<u>001</u>	Mar 20, 2009
-----------	----------------	------------------------	----------------	------------	--------------

<b>AB</b>		<u>EQ 0.025MG BASE</u>	<u>A090097</u>	<u>002</u>	Mar 20, 2009
-----------	--	------------------------	----------------	------------	--------------

<b>AB</b>		<u>EQ 0.05MG BASE</u>	<u>A090097</u>	<u>003</u>	Mar 20, 2009
-----------	--	-----------------------	----------------	------------	--------------

<b>AB</b>	MYLAN	<u>EQ 0.005MG BASE</u>	<u>A090326</u>	<u>001</u>	Jul 14, 2009
-----------	-------	------------------------	----------------	------------	--------------

<b>AB</b>		<u>EQ 0.025MG BASE</u>	<u>A090326</u>	<u>002</u>	Jul 14, 2009
-----------	--	------------------------	----------------	------------	--------------

<b>AB</b>		<u>EQ 0.05MG BASE</u>	<u>A090326</u>	<u>003</u>	Jul 14, 2009
-----------	--	-----------------------	----------------	------------	--------------

<b>AB</b>	SIGMAPHARM LABS LLC	<u>EQ 0.005MG BASE</u>	<u>A200295</u>	<u>001</u>	Nov 29, 2012
-----------	---------------------	------------------------	----------------	------------	--------------

<b>AB</b>		<u>EQ 0.025MG BASE</u>	<u>A200295</u>	<u>002</u>	Nov 29, 2012
-----------	--	------------------------	----------------	------------	--------------

<b>AB</b>		<u>EQ 0.05MG BASE</u>	<u>A200295</u>	<u>003</u>	Nov 29, 2012
-----------	--	-----------------------	----------------	------------	--------------

LIOTRIX (T4;T3)

TABLET;ORAL

THYROLAR-0.25

FOREST LABS	0.0031MG;0.0125MG	N016807	001	
-------------	-------------------	---------	-----	--

THYROLAR-0.5

FOREST LABS	0.0063MG;0.025MG	N016807	005	
-------------	------------------	---------	-----	--

THYROLAR-1

FOREST LABS	0.0125MG;0.05MG	N016807	004	
-------------	-----------------	---------	-----	--

THYROLAR-2

FOREST LABS	0.025MG;0.1MG	N016807	002	
-------------	---------------	---------	-----	--

THYROLAR-3

+ FOREST LABS	0.0375MG;0.15MG	N016807	003	
---------------	-----------------	---------	-----	--

LIRAGLUTIDE RECOMBINANT

SOLUTION;SUBCUTANEOUS

SAXENDA

+ NOVO NORDISK INC	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014
--------------------	-------------------	---------	-----	--------------

VICTOZA

+ NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010
--------------------	-------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

SHIRE DEVELOPMENT

10MG

N021977 007 Oct 30, 2014

20MG

N021977 004 Dec 10, 2007

30MG

N021977 001 Feb 23, 2007

40MG

N021977 005 Dec 10, 2007

50MG

N021977 002 Feb 23, 2007

60MG

N021977 006 Dec 10, 2007

+

70MG

N021977 003 Feb 23, 2007

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG</u>	<u>A202554 001</u>	Jul 30, 2013
<u>AB</u>		<u>5MG</u>	<u>A202554 002</u>	Jul 30, 2013
<u>AB</u>		<u>10MG</u>	<u>A202554 003</u>	Jul 30, 2013
<u>AB</u>		<u>20MG</u>	<u>A202554 004</u>	Jul 30, 2013
<u>AB</u>		<u>30MG</u>	<u>A202554 005</u>	Jul 30, 2013
<u>AB</u>		<u>40MG</u>	<u>A202554 006</u>	Jul 30, 2013
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A076102 001</u>	Sep 30, 2002
<u>AB</u>		<u>5MG</u>	<u>A076102 002</u>	Sep 30, 2002
<u>AB</u>		<u>10MG</u>	<u>A076102 003</u>	Sep 30, 2002
<u>AB</u>		<u>20MG</u>	<u>A076102 004</u>	Sep 30, 2002
<u>AB</u>		<u>30MG</u>	<u>A076102 005</u>	Sep 30, 2002
<u>AB</u>		<u>40MG</u>	<u>A076102 006</u>	Sep 30, 2002
<u>AB</u>	AUROBINDO	<u>2.5MG</u>	<u>A077622 001</u>	Feb 22, 2006
<u>AB</u>		<u>5MG</u>	<u>A077622 002</u>	Feb 22, 2006
<u>AB</u>		<u>10MG</u>	<u>A077622 003</u>	Feb 22, 2006
<u>AB</u>		<u>20MG</u>	<u>A077622 004</u>	Feb 22, 2006
<u>AB</u>		<u>30MG</u>	<u>A077622 005</u>	Feb 22, 2006
<u>AB</u>		<u>40MG</u>	<u>A077622 006</u>	Feb 22, 2006
<u>AB</u>	HIKMA INTL PHARMS	<u>2.5MG</u>	<u>A076063 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076063 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076063 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076063 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076063 006</u>	Jun 27, 2003
<u>AB</u>		<u>40MG</u>	<u>A076063 005</u>	Jul 01, 2002
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203508 001</u>	Oct 29, 2013
<u>AB</u>		<u>5MG</u>	<u>A203508 002</u>	Oct 29, 2013
<u>AB</u>		<u>10MG</u>	<u>A203508 003</u>	Oct 29, 2013
<u>AB</u>		<u>20MG</u>	<u>A203508 004</u>	Oct 29, 2013
<u>AB</u>		<u>30MG</u>	<u>A203508 005</u>	Oct 29, 2013
<u>AB</u>		<u>40MG</u>	<u>A203508 006</u>	Oct 29, 2013
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2.5MG</u>	<u>A075752 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075752 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075752 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075752 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075752 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075752 006</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321 001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321 002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321 003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321 004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321 005</u>	Sep 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077321 006</u>	Sep 09, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076071 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076071 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076071 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076071 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076071 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076071 006</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>2.5MG</u>	<u>A076180 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076180 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076180 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164 001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164 002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164 003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075994 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994 005</u>	Jul 01, 2002

## PRESCRIPTION DRUG PRODUCT LIST

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>		<u>40MG</u>	<u>A075994 006</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A075944 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944 006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944 005</u>	Jul 01, 2002
<u>AB</u>	VINTAGE	<u>2.5MG</u>	<u>A075743 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743 006</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059 006</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402 001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402 002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402 003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402 004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402 005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402 006</u>	Apr 19, 2007

PRINIVIL

<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558 001</u>	Dec 29, 1987
<u>AB</u>		<u>10MG</u>	<u>N019558 002</u>	Dec 29, 1987
<u>AB</u>		<u>20MG</u>	<u>N019558 003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558 004</u>	Oct 25, 1988

ZESTRIL

<u>AB</u>	ALVOGEN IPCO SARL	<u>2.5MG</u>	<u>N019777 005</u>	Apr 29, 1993
<u>AB</u>		<u>5MG</u>	<u>N019777 001</u>	May 19, 1988
<u>AB</u>		<u>10MG</u>	<u>N019777 002</u>	May 19, 1988
<u>AB</u>		<u>20MG</u>	<u>N019777 003</u>	May 19, 1988
<u>AB</u>		<u>30MG</u>	<u>N019777 006</u>	Jan 20, 1999
<u>AB</u>	+	<u>40MG</u>	<u>N019777 004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC LTD	<u>150MG</u>	<u>A079159 001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159 002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159 003</u>	Jan 12, 2009
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A079139 001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139 002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139 003</u>	Feb 03, 2009
<u>AB</u>	HETERO LABS LTD III	<u>150MG</u>	<u>A090702 001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702 002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702 003</u>	Sep 25, 2009
<u>AB</u>	HIKMA INTL PHARMS	<u>150MG</u>	<u>A076243 002</u>	Feb 24, 2003
<u>AB</u>		<u>300MG</u>	<u>A076243 001</u>	Jun 27, 2002
<u>AB</u>	ROXANE	<u>150MG</u>	<u>N017812 002</u>	Jan 28, 1987
<u>AB</u>		<u>300MG</u>	<u>N017812 001</u>	
<u>AB</u>	+	<u>600MG</u>	<u>N017812 003</u>	Jan 28, 1987

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	<u>300MG</u>	<u>N018558 001</u>	Jan 29, 1982
<u>AB</u>	SUN PHARM INDS INC	<u>300MG</u>	<u>A091027 001</u>	Jun 24, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>300MG</u>	<u>A204445 001</u>	Jun 10, 2015
<u>AB</u>	GLENMARK GENERICS	<u>450MG</u>	<u>A091616 001</u>	Feb 14, 2011
<u>AB</u>	GLENMARK PHARMS INC	<u>300MG</u>	<u>A091544 001</u>	Dec 27, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>300MG</u>	<u>A202288 001</u>	Jun 29, 2012
<u>AB</u>		<u>450MG</u>	<u>A202219 001</u>	Aug 08, 2012
<u>AB</u>	ROXANE	<u>300MG</u>	<u>A076832 001</u>	Oct 28, 2004
<u>AB</u>	+	<u>450MG</u>	<u>A076691 001</u>	Jan 05, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>300MG</u>	<u>A204779 001</u>	Jul 27, 2015

## PRESCRIPTION DRUG PRODUCT LIST

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL

LITHOBID**AB** + ANI PHARMS INC **300MG** **N018027 001**LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE**AA** + ROXANE **EQ 300MG CARBONATE/5ML** **N018421 001****AA** WOCKHARDT **EQ 300MG CARBONATE/5ML** **A070755 001** May 21, 1986LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

+ ALCON

EQ 0.1% BASE

N020191 001 Sep 23, 1993

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

AEGERION

EQ 5MG BASE

N203858 001 Dec 21, 2012

EQ 10MG BASE

N203858 002 Dec 21, 2012

+

EQ 20MG BASE

N203858 003 Dec 21, 2012

EQ 30MG BASE

N203858 004 Apr 23, 2015

EQ 40MG BASE

N203858 005 Apr 23, 2015

EQ 60MG BASE

N203858 006 Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

CORDEN PHARMA

5MG

N017588 004 Dec 19, 2014

10MG

N017588 001

40MG

N017588 002

+

100MG

N017588 003

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM**AB** + J AND J CONSUMER INC **2MG** **N017694 001**LOPERAMIDE HYDROCHLORIDE**AB** MYLAN **2MG** **A072741 001** Sep 18, 1991**AB** TEVA **2MG** **A073192 001** Apr 30, 1992LOPINAVIR; RITONAVIR

SOLUTION;ORAL

KALETRA

+ ABBVIE

80MG/ML;20MG/ML

N021251 001 Sep 15, 2000

TABLET;ORAL

KALETRA

+ ABBVIE

100MG;25MG

N021906 002 Nov 09, 2007

+

200MG;50MG

N021906 001 Oct 28, 2005

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM**AA** AMNEAL PHARMS **2MG/ML** **A091383 001** Dec 23, 2009**AA** HI-TECH PHARMA CO **2MG/ML** **A200169 001** Jan 30, 2012**AA** LUPIN LTD **2MG/ML** **A091407 001** Feb 19, 2013**AA** PADDOCK LLC **2MG/ML** **A079244 001** Apr 28, 2009**AA** PHARM ASSOC **2MG/ML** **A090260 001** Jun 15, 2010LORAZEPAM INTENSOL**AA** + ROXANE **2MG/ML** **A072755 001** Jun 28, 1991

INJECTABLE; INJECTION

ATIVAN**AP** + EUROHLTH INTL SARL **2MG/ML** **N018140 001****AP** + **4MG/ML** **N018140 002**LORAZEPAM**AP** AKORN **2MG/ML** **A075025 001** Jul 23, 1998**AP** HOSPIRA **2MG/ML** **A074243 001** Apr 12, 1994**AP** **2MG/ML** **A074282 001** May 27, 1994**AP** **4MG/ML** **A074243 002** Apr 12, 1994**AP** **4MG/ML** **A074282 002** May 27, 1994**AP** INTL MEDICATION SYS **2MG/ML** **A076150 001** Nov 15, 2004LORAZEPAM PRESERVATIVE FREE**AP** BEDFORD LABS **2MG/ML** **A077074 001** Jul 13, 2005**AP** **4MG/ML** **A077074 002** Jul 13, 2005

## PRESCRIPTION DRUG PRODUCT LIST

LORAZEPAM

TABLET; ORAL

ATIVAN

<u>AB</u>	VALEANT INTL	<u>0.5MG</u>	<u>N017794</u>	<u>001</u>	
<u>AB</u>		<u>1MG</u>	<u>N017794</u>	<u>002</u>	
<u>AB</u>	+	<u>2MG</u>	<u>N017794</u>	<u>003</u>	

LORAZEPAM

<u>AB</u>	AMNEAL PHARMS	<u>0.5MG</u>	<u>A078826</u>	<u>001</u>	Jun 23, 2010
<u>AB</u>		<u>1MG</u>	<u>A078826</u>	<u>002</u>	Jun 23, 2010
<u>AB</u>		<u>2MG</u>	<u>A078826</u>	<u>003</u>	Jun 23, 2010
<u>AB</u>	ANI PHARMS INC	<u>0.5MG</u>	<u>A077396</u>	<u>001</u>	Dec 13, 2006
<u>AB</u>		<u>1MG</u>	<u>A077396</u>	<u>002</u>	Dec 13, 2006
<u>AB</u>		<u>2MG</u>	<u>A077396</u>	<u>003</u>	Dec 13, 2006
<u>AB</u>	LEADING PHARMA LLC	<u>0.5MG</u>	<u>A078203</u>	<u>001</u>	Jul 30, 2007
<u>AB</u>		<u>1MG</u>	<u>A078203</u>	<u>002</u>	Jul 30, 2007
<u>AB</u>		<u>2MG</u>	<u>A078203</u>	<u>003</u>	Jul 30, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A071589</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>0.5MG</u>	<u>A077657</u>	<u>001</u>	Mar 16, 2006
<u>AB</u>		<u>1MG</u>	<u>A071590</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>1MG</u>	<u>A077657</u>	<u>002</u>	Mar 16, 2006
<u>AB</u>		<u>2MG</u>	<u>A071591</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>2MG</u>	<u>A077657</u>	<u>003</u>	Mar 16, 2006
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071403</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>		<u>1MG</u>	<u>A071404</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>		<u>2MG</u>	<u>A071141</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A076045</u>	<u>001</u>	Aug 29, 2001
<u>AB</u>		<u>1MG</u>	<u>A076045</u>	<u>002</u>	Aug 29, 2001
<u>AB</u>		<u>2MG</u>	<u>A076045</u>	<u>003</u>	Aug 29, 2001
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077754</u>	<u>001</u>	May 10, 2006
<u>AB</u>		<u>1MG</u>	<u>A077754</u>	<u>002</u>	May 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077754</u>	<u>003</u>	May 10, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A072927</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928</u>	<u>001</u>	Oct 31, 1991

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

## BELVIQ

	+	EISAI INC	10MG	<u>N022529</u>	<u>001</u>	Jun 27, 2012
--	---	-----------	------	----------------	------------	--------------

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG</u>	<u>N020386</u>	<u>001</u>	Apr 14, 1995
<u>AB</u>		<u>50MG</u>	<u>N020386</u>	<u>002</u>	Apr 14, 1995
<u>AB</u>	+	<u>100MG</u>	<u>N020386</u>	<u>003</u>	Oct 13, 1998

LOSARTAN POTASSIUM

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	APOTEX CORP	<u>25MG</u>	<u>A090790</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090790</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090790</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A201170</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>		<u>50MG</u>	<u>A201170</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>		<u>100MG</u>	<u>A201170</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>	HETERO LABS LTD V	<u>25MG</u>	<u>A203835</u>	<u>001</u>	Aug 12, 2015
<u>AB</u>		<u>50MG</u>	<u>A203835</u>	<u>002</u>	Aug 12, 2015
<u>AB</u>		<u>100MG</u>	<u>A203835</u>	<u>003</u>	Aug 12, 2015
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A200290</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>		<u>50MG</u>	<u>A200290</u>	<u>002</u>	Aug 30, 2013
<u>AB</u>		<u>100MG</u>	<u>A200290</u>	<u>003</u>	Aug 30, 2013
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230</u>	<u>001</u>	May 30, 2012
<u>AB</u>		<u>50MG</u>	<u>A202230</u>	<u>002</u>	May 30, 2012
<u>AB</u>		<u>100MG</u>	<u>A202230</u>	<u>003</u>	May 30, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>25MG</u>	<u>A091541</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A091541</u>	<u>002</u>	Sep 24, 2012

## PRESCRIPTION DRUG PRODUCT LIST

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

<u>AB</u>		<u>100MG</u>	<u>A091541</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091590</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091590</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091590</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A091497</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091497</u>	<u>002</u>	Jun 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091497</u>	<u>003</u>	Jun 06, 2011
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A077459</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077459</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077459</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077424</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077424</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076958</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A076958</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A076958</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A090467</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090467</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090467</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A203030</u>	<u>001</u>	Oct 14, 2015
<u>AB</u>		<u>50MG</u>	<u>A203030</u>	<u>002</u>	Oct 14, 2015
<u>AB</u>		<u>100MG</u>	<u>A203030</u>	<u>003</u>	Oct 14, 2015
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A090544</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	VIVIMED LABS	<u>25MG</u>	<u>A090382</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090382</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A091129</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091129</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091129</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078243</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078243</u>	<u>003</u>	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB INC 0.5%

N202872 001 Sep 28, 2012

OINTMENT; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB 0.5%

N200738 001 Apr 15, 2011

SUSPENSION/DROPS; OPHTHALMIC

ALREX

+ BAUSCH AND LOMB 0.2%

N020803 001 Mar 09, 1998

LOTEMAX

+ BAUSCH AND LOMB 0.5%

N020583 001 Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

ZYLET

+ BAUSCH AND LOMB 0.5%; 0.3%

N050804 001 Dec 14, 2004

LOVASTATIN

TABLET; ORAL

LOVASTATIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075828</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075828</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075828</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077748</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>20MG</u>	<u>A077748</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>40MG</u>	<u>A077748</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>	CARLSBAD	<u>10MG</u>	<u>A075991</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A075991</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	+	<u>40MG</u>	<u>A075991</u>	<u>003</u>	Jun 05, 2002
<u>AB</u>	LUPIN	<u>10MG</u>	<u>A078296</u>	<u>001</u>	Mar 14, 2008
<u>AB</u>		<u>20MG</u>	<u>A078296</u>	<u>002</u>	Nov 01, 2007
<u>AB</u>		<u>40MG</u>	<u>A078296</u>	<u>003</u>	Nov 01, 2007
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A077520</u>	<u>001</u>	Apr 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077520</u>	<u>002</u>	Apr 14, 2006
<u>AB</u>		<u>40MG</u>	<u>A077520</u>	<u>003</u>	Apr 14, 2006



## PRESCRIPTION DRUG PRODUCT LIST

LOVASTATIN

TABLET; ORAL

LOVASTATIN

<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075451 001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075935 001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075451 002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075935 002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075451 003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075935 003</u>	Dec 17, 2001
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075300 001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075636 001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075300 002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075636 002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075300 003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075636 003</u>	Dec 17, 2001
<u>AB</u>	TEVA	<u>10MG</u>	<u>A075551 003</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075551 002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075551 001</u>	Dec 17, 2001

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

	COVIS PHARMA SARL	20MG	N021316 002	Jun 26, 2002
		40MG	N021316 003	Jun 26, 2002
+		60MG	N021316 004	Jun 26, 2002

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	ABBVIE	20MG; 500MG	N021249 001	Dec 17, 2001
+		20MG; 750MG	N021249 002	Dec 17, 2001
+		20MG; 1GM	N021249 003	Dec 17, 2001
+		40MG; 1GM	N021249 004	Apr 27, 2006

LOXAPINE

POWDER; INHALATION

ADASUVE

+	TEVA PHARMS USA INC	10MG	N022549 001	Dec 21, 2012
---	---------------------	------	-------------	--------------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

<u>AB</u>	ELITE LABS INC	<u>EQ 5MG BASE</u>	<u>A076868 001</u>	Aug 04, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076868 002</u>	Aug 04, 2005
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076868 003</u>	Aug 04, 2005
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076868 004</u>	Aug 04, 2005
<u>AB</u>	LANNETT HOLDINGS INC	<u>EQ 5MG BASE</u>	<u>A090695 001</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090695 002</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A090695 003</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090695 004</u>	Sep 26, 2011
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076762 001</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076762 002</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076762 003</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076762 004</u>	Nov 01, 2004
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A072205 001</u>	Jun 15, 1988
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A072206 001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A072062 001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

	SUCAMPO PHARMA LLC	8MCG	N021908 002	Apr 29, 2008
+		24MCG	N021908 001	Jan 31, 2006

LULICONAZOLE

CREAM; TOPICAL

LUZU

+	MEDICIS	1%	N204153 001	Nov 14, 2013
---	---------	----	-------------	--------------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011
+		40MG	N200603 001	Oct 28, 2010
		60MG	N200603 005	Jul 12, 2013
		80MG	N200603 002	Oct 28, 2010

## PRESCRIPTION DRUG PRODUCT LIST

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

120MG

N200603 004 Apr 26, 2012

MACITENTAN

TABLET; ORAL

OPSUMIT

+ ACTELION PHARMS LTD

10MG

N204410 001 Oct 18, 2013

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+ MYLAN INSTITUTIONAL

EQ 85MG BASE/GM

N016763 001

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE**AT** PAR FORM**5%****A201511 001** Feb 12, 2013SULFAMYLON**AT** + MYLAN INSTITUTIONAL**5%****N019832 003** Jun 05, 1998MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+ B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML

N019696 001 Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER**AP** BAXTER HLTHCARE**30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML****N017378 001**PLASMA-LYTE A IN PLASTIC CONTAINER**AP** BAXTER HLTHCARE**30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML****N017378 002** Nov 22, 1982

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML

N019711 001 Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N017586 001

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML

N019024 001 Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N017637 002 Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+ DIALYSIS SUPS

0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML

N021910 001 Jul 26, 2006

NORMOCARB HF 35

+ DIALYSIS SUPS

0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML

N021910 002 Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ HOSPIRA

1GM/100ML

N020488 001 Jul 11, 1995

+

2GM/100ML

N020488 002 Jul 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA

2GM/50ML (40MG/ML)

N020309 003 Jan 26, 2007

+

4GM/100ML (40MG/ML)

N020309 001 Jun 24, 1994

+

4GM/50ML (80MG/ML)

N020309 002 Jun 24, 1994

20GM/500ML (40MG/ML)

N020309 004 Jan 18, 1995

40GM/1000ML (40MG/ML)

N020309 005 Jan 18, 1995

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE**AP** EXELA PHARMA SCS LLC**5GM/10ML (500MG/ML)****A206039 001** Dec 18, 2014**AP** + FRESENIUS KABI USA**5GM/10ML (500MG/ML)****N019316 001** Sep 08, 1986**AP** + HOSPIRA**5GM/10ML (500MG/ML)****A075151 001** Apr 25, 2000

HOSPIRA INC

10GM/20ML (500MG/ML)

A202411 001 May 14, 2015

## PRESCRIPTION DRUG PRODUCT LIST

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+ FRESENIUS KABI USA 1GM/2ML (500MG/ML)

N019316 002 Sep 08, 1986

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SUPREP BOWEL PREP KIT

+ BRAINTREE LABS 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT

N022372 001 Aug 05, 2010

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

TIS-U-SOL

<b>AT</b>	BAXTER HLTHCARE	<u>20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML</u>	<b>N018508 001</b>	Feb 19, 1982
-----------	-----------------	--	--------------------	--------------

TIS-U-SOL IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML</u>	<b>N018336 001</b>	
-----------	-----------------	--	--------------------	--

MALATHION

LOTION;TOPICAL

MALATHION

<b>AT</b>	SUVEN LIFE	<u>0.5%</u>	<b>A091559 001</b>	May 23, 2012
-----------	------------	-------------	--------------------	--------------

OVIDE

<b>AT</b>	+ TARO PHARMS NORTH	<u>0.5%</u>	<b>N018613 001</b>	Aug 02, 1982
-----------	---------------------	-------------	--------------------	--------------

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA

EQ 0.1MG MANGANESE/ML

N018962 001 Jun 26, 1986

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<u>10GM/100ML</u>	<b>N020006 002</b>	Jul 26, 1993
-----------	---------	-------------------	--------------------	--------------

<b>AP</b>	HOSPIRA	<u>10GM/100ML</u>	<b>N019603 002</b>	Jan 08, 1987
-----------	---------	-------------------	--------------------	--------------

MANNITOL 15% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<u>15GM/100ML</u>	<b>N020006 003</b>	Jul 26, 1993
-----------	---------	-------------------	--------------------	--------------

<b>AP</b>	HOSPIRA	<u>15GM/100ML</u>	<b>N019603 003</b>	Jan 08, 1990
-----------	---------	-------------------	--------------------	--------------

MANNITOL 20% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<u>20GM/100ML</u>	<b>N020006 004</b>	Jul 26, 1993
-----------	---------	-------------------	--------------------	--------------

<b>AP</b>	HOSPIRA	<u>20GM/100ML</u>	<b>N019603 004</b>	Jan 08, 1990
-----------	---------	-------------------	--------------------	--------------

MANNITOL 25%

<b>AP</b>	FRESENIUS KABI USA	<u>12.5GM/50ML</u>	<b>A080677 001</b>	
-----------	--------------------	--------------------	--------------------	--

<b>AP</b>	HOSPIRA	<u>12.5GM/50ML</u>	<b>N016269 006</b>	Aug 25, 1994
-----------	---------	--------------------	--------------------	--------------

<b>AP</b>	INTL MEDICATION	<u>12.5GM/50ML</u>	<b>A083051 001</b>	
-----------	-----------------	--------------------	--------------------	--

<b>AP</b>	LUITPOLD	<u>12.5GM/50ML</u>	<b>A087409 001</b>	Jan 21, 1982
-----------	----------	--------------------	--------------------	--------------

MANNITOL 5% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<u>5GM/100ML</u>	<b>N020006 001</b>	Jul 26, 1993
-----------	---------	------------------	--------------------	--------------

<b>AP</b>	HOSPIRA	<u>5GM/100ML</u>	<b>N019603 001</b>	Jan 08, 1987
-----------	---------	------------------	--------------------	--------------

OSMITROL 10% IN WATER

<b>AP</b>	BAXTER HLTHCARE	<u>10GM/100ML</u>	<b>N013684 002</b>	
-----------	-----------------	-------------------	--------------------	--

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>10GM/100ML</u>	<b>N013684 006</b>	
-----------	-----------------	-------------------	--------------------	--

OSMITROL 15% IN WATER

<b>AP</b>	BAXTER HLTHCARE	<u>15GM/100ML</u>	<b>N013684 004</b>	
-----------	-----------------	-------------------	--------------------	--

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>15GM/100ML</u>	<b>N013684 008</b>	
-----------	-----------------	-------------------	--------------------	--

OSMITROL 20% IN WATER

<b>AP</b>	BAXTER HLTHCARE	<u>20GM/100ML</u>	<b>N013684 003</b>	
-----------	-----------------	-------------------	--------------------	--

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>20GM/100ML</u>	<b>N013684 007</b>	
-----------	-----------------	-------------------	--------------------	--

OSMITROL 5% IN WATER

<b>AP</b>	BAXTER HLTHCARE	<u>5GM/100ML</u>	<b>N013684 001</b>	
-----------	-----------------	------------------	--------------------	--

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>5GM/100ML</u>	<b>N013684 005</b>	
-----------	-----------------	------------------	--------------------	--

SOLUTION;IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N016772 002

## PRESCRIPTION DRUG PRODUCT LIST

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA 540MG/100ML; 2.7GM/100ML

N018316 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

MYLAN 25MG

A072285 002 Oct 03, 1988

+ 50MG

A072285 001 Oct 03, 1988

75MG

A072285 003 Oct 03, 1988

MARAVIROC

TABLET; ORAL

SELZENTRY

VIIV HLTHCARE 150MG

N022128 001 Aug 06, 2007

+ 300MG

N022128 002 Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

+ AMEDRA PHARMS LLC 100MG

A073580 001 Jan 04, 1995

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA 2.5MG

A204054 001 Mar 19, 2013

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+ IPSEN INC 40MG/4ML (10MG/ML)

N021839 001 Aug 30, 2005

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+ ACTELION PHARMS LTD EQ 0.016% BASE

N202317 001 Aug 23, 2013

INJECTABLE; INJECTION

MUSTARGEN

+ RECORDATI RARE 10MG/VIAL

N006695 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

**MECLIZINE HYDROCHLORIDE**

<b><u>AA</u></b>	AMNEAL PHARMS	<b><u>12.5MG</u></b>	<b><u>A201451 001</u></b>	Feb 23, 2011
<b><u>AA</u></b>		<b><u>25MG</u></b>	<b><u>A201451 002</u></b>	Feb 23, 2011
<b><u>AA</u></b>	EPIC PHARMA LLC	<b><u>12.5MG</u></b>	<b><u>A200294 001</u></b>	Apr 13, 2012
<b><u>AA</u></b>		<b><u>25MG</u></b>	<b><u>A200294 002</u></b>	Apr 13, 2012
<b><u>AA</u></b>	JUBILANT CADISTA	<b><u>12.5MG</u></b>	<b><u>A040659 001</u></b>	Jun 04, 2010
<b><u>AA</u></b>		<b><u>25MG</u></b>	<b><u>A040659 002</u></b>	Jun 04, 2010
<b><u>AA</u></b>	MYLAN PHARMS INC	<b><u>12.5MG</u></b>	<b><u>A202640 001</u></b>	Sep 17, 2012
<b><u>AA</u></b>		<b><u>25MG</u></b>	<b><u>A202640 002</u></b>	Sep 17, 2012
<b><u>AA</u></b>	PAR PHARM	<b><u>12.5MG</u></b>	<b><u>A087127 001</u></b>	
<b><u>AA</u></b>		<b><u>25MG</u></b>	<b><u>A087128 001</u></b>	
<b><u>AA</u></b>	SANDOZ	<b><u>12.5MG</u></b>	<b><u>A084843 002</u></b>	May 22, 1989
<b><u>AA</u></b>		<b><u>25MG</u></b>	<b><u>A084092 003</u></b>	May 22, 1989

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

MYLAN EQ 50MG BASE

A071081 002 Sep 03, 1986

+ EQ 100MG BASE

A071081 001 Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

**DEPO-PROVERA****AB** + PHARMACIA AND UPJOHN **150MG/ML** **N020246 001** Oct 29, 1992**MEDROXYPROGESTERONE ACETATE****AB** SANDOZ **150MG/ML** **A078711 001** May 20, 2009**AB** TEVA PHARMS USA **150MG/ML** **A076553 001** Jul 28, 2004

DEPO-PROVERA

+ PHARMACIA AND UPJOHN 400MG/ML

N012541 003

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+ PHARMACIA AND UPJOHN 104MG/0.65ML

N021583 001 Dec 17, 2004

## PRESCRIPTION DRUG PRODUCT LIST

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

<u>AB</u>	BARR	<u>2.5MG</u>	<u>A040159</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>		<u>5MG</u>	<u>A040159</u>	<u>002</u>	Aug 09, 1996
<u>AB</u>		<u>10MG</u>	<u>A040159</u>	<u>003</u>	Aug 09, 1996
<u>PROVERA</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839</u>	<u>001</u>	
<u>AB</u>		<u>5MG</u>	<u>N011839</u>	<u>003</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N011839</u>	<u>004</u>	

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090359</u>	<u>001</u>	Feb 05, 2013
<u>AB</u>	LUPIN LTD	<u>250MG</u>	<u>A091322</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	MICRO LABS LTD	<u>250MG</u>	<u>A090562</u>	<u>001</u>	Nov 19, 2010
<u>AB</u>	VINTAGE PHARMS LLC	<u>250MG</u>	<u>A091608</u>	<u>001</u>	Jun 02, 2014
<u>PONSTEL</u>					
<u>AB</u>	+	<u>250MG</u>	<u>N015034</u>	<u>003</u>	

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004
<u>AB</u>	+	<u>250MG</u>	<u>A076175</u>	<u>001</u>	Feb 20, 2002

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>40MG/ML</u>	<u>N020264</u>	<u>001</u>	Sep 10, 1993
-----------	---	----------------------	----------------	----------------	------------	--------------

MEGACE ES

<u>AB</u>	+	PAR PHARM	<u>125MG/ML</u>	<u>N021778</u>	<u>001</u>	Jul 05, 2005
-----------	---	-----------	-----------------	----------------	------------	--------------

MEGESTROL ACETATE

<u>AB</u>	PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>	ROXANE	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>	TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
<u>AB</u>	TWI PHARMS INC	<u>125MG/ML</u>	<u>A203139</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>	WOCKHARDT	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>	BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>		<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	+	<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	ROXANE	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995

MELOXICAM

CAPSULE; ORAL

VIVLODEX

	IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015
	+	10MG	N207233	002	Oct 22, 2015

SUSPENSION; ORAL

MOBIC

	+	BOEHRINGER INGELHEIM	7.5MG/5ML	N021530	001	Jun 01, 2004
--	---	----------------------	-----------	---------	-----	--------------

TABLET; ORAL

MELOXICAM

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>		<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>	BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARLSBAD	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>	CIPLA LTD	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006

## PRESCRIPTION DRUG PRODUCT LIST

MELOXICAM

TABLET; ORAL

MELOXICAM

<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES PHARMA	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A077937</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077937</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006
<u>MOBIC</u>					
<u>AB</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

ALKERAN

+ GLAXOSMITHKLINE 2MG

N014691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 50MG BASE/VIAL</u>	<u>N020207</u>	<u>001</u>	Nov 18, 1992
<u>MELPHALAN HYDROCHLORIDE</u>						
<u>AP</u>		EUROHLTH INTL SARL	<u>EQ 50MG BASE/VIAL</u>	<u>A090303</u>	<u>001</u>	Oct 28, 2010
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A090270</u>	<u>001</u>	Jun 09, 2009

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

FOREST LABS LLC 7MG

N022525 001 Jun 21, 2010

14MG

N022525 002 Jun 21, 2010

21MG

N022525 003 Jun 21, 2010

28MG

N022525 004 Jun 21, 2010

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

<u>AA</u>		BIO-PHARM INC	<u>2MG/ML</u>	<u>A205446</u>	<u>001</u>	Dec 07, 2015
<u>AA</u>		MACLEODS PHARMS LTD	<u>2MG/ML</u>	<u>A202790</u>	<u>001</u>	Oct 13, 2015
<u>AA</u>		SILARX PHARMS INC	<u>2MG/ML</u>	<u>A204033</u>	<u>001</u>	Oct 13, 2015
<u>NAMENDA</u>						
<u>AA</u>	+	FOREST LABS LLC	<u>2MG/ML</u>	<u>N021627</u>	<u>001</u>	Apr 18, 2005

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>		AJANTA PHARMA LTD	<u>5MG</u>	<u>A206528</u>	<u>001</u>	Nov 30, 2015
<u>AB</u>			<u>10MG</u>	<u>A206528</u>	<u>002</u>	Nov 30, 2015
<u>AB</u>		ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A200891</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A200891</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		AMNEAL PHARMS	<u>5MG</u>	<u>A090041</u>	<u>001</u>	Apr 10, 2015
<u>AB</u>			<u>10MG</u>	<u>A090041</u>	<u>002</u>	Apr 10, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203175</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A203175</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A090048</u>	<u>001</u>	Apr 14, 2010
<u>AB</u>			<u>10MG</u>	<u>A090048</u>	<u>002</u>	Apr 14, 2010
<u>AB</u>		JUBILANT GENERICS	<u>5MG</u>	<u>A091585</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A091585</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		LUPIN LTD	<u>5MG</u>	<u>A090051</u>	<u>001</u>	Apr 10, 2015
<u>AB</u>			<u>10MG</u>	<u>A090051</u>	<u>002</u>	Apr 10, 2015
<u>AB</u>		MACLEODS PHARMS LTD	<u>5MG</u>	<u>A202840</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>			<u>10MG</u>	<u>A202840</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A079225</u>	<u>001</u>	Jan 30, 2015
<u>AB</u>			<u>10MG</u>	<u>A079225</u>	<u>002</u>	Jan 30, 2015
<u>AB</u>		PURACAP PHARM LLC	<u>5MG</u>	<u>A206855</u>	<u>001</u>	Nov 17, 2015
<u>AB</u>			<u>10MG</u>	<u>A206855</u>	<u>002</u>	Nov 17, 2015
<u>AB</u>		SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090058</u>	<u>001</u>	May 05, 2010

## PRESCRIPTION DRUG PRODUCT LIST

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A090058</u>	<u>002</u>	May 05, 2010
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A090052</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090052</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>5MG</u>	<u>A200155</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200155</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	UNICHEM LABS LTD	<u>5MG</u>	<u>A200022</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200022</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	UPSHER SMITH	<u>5MG</u>	<u>A090043</u>	<u>001</u>	Jul 31, 2015
<u>AB</u>		<u>10MG</u>	<u>A090043</u>	<u>002</u>	Jul 31, 2015
<u>AB</u>	WOCKHARDT LTD	<u>5MG</u>	<u>A090073</u>	<u>001</u>	Sep 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A090073</u>	<u>002</u>	Sep 04, 2015
<u>NAMENDA</u>					
<u>AB</u>	FOREST LABS LLC	<u>5MG</u>	<u>N021487</u>	<u>001</u>	Oct 16, 2003
<u>AB</u>	+	<u>10MG</u>	<u>N021487</u>	<u>002</u>	Oct 16, 2003

MENOTROPINS (FSH; LH)

INJECTABLE; SUBCUTANEOUS

MENOPUR

+ FERRING

75 IU/VIAL; 75 IU/VIAL

N021663 001 Oct 29, 2004

MEPENZOLATE BROMIDE

TABLET; ORAL

CANTIL

+ SANOFI AVENTIS US

25MG

N010679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

<u>AP</u>	+	HOSPIRA	<u>25MG/ML</u>	<u>N021171</u>	<u>001</u>
<u>AP</u>	+		<u>50MG/ML</u>	<u>N021171</u>	<u>002</u>
<u>AP</u>	+		<u>75MG/ML</u>	<u>N021171</u>	<u>003</u>
<u>AP</u>	+		<u>100MG/ML</u>	<u>N021171</u>	<u>004</u>

MEPERIDINE HYDROCHLORIDE

<u>AP</u>		EUROHLTH INTL SARL	<u>25MG/ML</u>	<u>A080445</u>	<u>001</u>
<u>AP</u>			<u>50MG/ML</u>	<u>A080445</u>	<u>002</u>
<u>AP</u>			<u>75MG/ML</u>	<u>A080445</u>	<u>003</u>
<u>AP</u>			<u>100MG/ML</u>	<u>A080445</u>	<u>004</u>
<u>AP</u>		HIKMA MAPLE	<u>25MG/ML</u>	<u>A080455</u>	<u>007</u>
<u>AP</u>			<u>50MG/ML</u>	<u>A080455</u>	<u>008</u>
<u>AP</u>			<u>75MG/ML</u>	<u>A080455</u>	<u>009</u>
<u>AP</u>			<u>100MG/ML</u>	<u>A080455</u>	<u>010</u>

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		HIKMA MAPLE	<u>10MG/ML</u>	<u>A081002</u>	<u>001</u>	Jul 30, 1993
<u>AP</u>	+	HOSPIRA	<u>10MG/ML</u>	<u>A088432</u>	<u>001</u>	Aug 16, 1984

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

+ ROXANE

50MG/5ML

A088744 001 Jan 30, 1985

TABLET; ORAL

DEMEROL

<u>AA</u>	+	SANOFI AVENTIS US	<u>50MG</u>	<u>N005010</u>	<u>001</u>
<u>AA</u>	+		<u>100MG</u>	<u>N005010</u>	<u>004</u>

MEPERIDINE HYDROCHLORIDE

<u>AA</u>		BARR	<u>50MG</u>	<u>A088639</u>	<u>001</u>	Jul 02, 1984
<u>AA</u>			<u>100MG</u>	<u>A088640</u>	<u>001</u>	Sep 19, 1984
<u>AA</u>		EPIC PHARMA	<u>50MG</u>	<u>A040331</u>	<u>001</u>	May 28, 1999
<u>AA</u>			<u>100MG</u>	<u>A040331</u>	<u>002</u>	May 28, 1999
<u>AA</u>		MALLINCKRODT	<u>50MG</u>	<u>A040352</u>	<u>001</u>	Jun 13, 2000
<u>AA</u>			<u>100MG</u>	<u>A040352</u>	<u>002</u>	Jun 13, 2000
<u>AA</u>		MIKART	<u>50MG</u>	<u>A040893</u>	<u>001</u>	Jun 24, 2009
<u>AA</u>			<u>100MG</u>	<u>A040893</u>	<u>003</u>	Jun 24, 2009
<u>AA</u>		ROXANE	<u>50MG</u>	<u>A040110</u>	<u>001</u>	Mar 12, 1997
<u>AA</u>			<u>100MG</u>	<u>A040110</u>	<u>002</u>	Mar 12, 1997
<u>AA</u>		SUN PHARM INDS INC	<u>50MG</u>	<u>A040446</u>	<u>001</u>	Aug 08, 2002
<u>AA</u>			<u>100MG</u>	<u>A040446</u>	<u>002</u>	Aug 08, 2002
<u>AA</u>		VINTAGE PHARMS	<u>50MG</u>	<u>A040191</u>	<u>001</u>	Dec 17, 1998
<u>AA</u>			<u>100MG</u>	<u>A040191</u>	<u>002</u>	Dec 17, 1998
<u>AA</u>		MIKART	75MG	A040893	002	Jun 24, 2009
			150MG	A040893	004	Jun 24, 2009

## PRESCRIPTION DRUG PRODUCT LIST

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+	HOSPIRA	<u>1%</u>	<u>N012250</u>	<u>001</u>	
<u>AP</u>	+		<u>1.5%</u>	<u>N012250</u>	<u>005</u>	
<u>AP</u>	+		<u>2%</u>	<u>N012250</u>	<u>002</u>	

ISOCAINE HYDROCHLORIDE

<u>AP</u>	+	NOVOCOL	<u>3%</u>	<u>A080925</u>	<u>001</u>	
-----------	---	---------	-----------	----------------	------------	--

MEPIVACAINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA INC	<u>3%</u>	<u>A040806</u>	<u>001</u>	Apr 28, 2008
-----------	--	-------------	-----------	----------------	------------	--------------

POLOCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089407</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089410</u>	<u>001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089406</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>1.5%</u>	<u>A089408</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089409</u>	<u>001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	+	DEPROCO	<u>3%</u>	<u>A088387</u>	<u>001</u>	Oct 10, 1984
-----------	---	---------	-----------	----------------	------------	--------------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>		ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>			<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>		INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>			<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008
<u>AA</u>	+	WATSON LABS	<u>200MG</u>	<u>A083304</u>	<u>001</u>	
<u>AA</u>	+		<u>400MG</u>	<u>A083308</u>	<u>001</u>	

MERCAPTOPYRINE

SUSPENSION; ORAL

PURIXAN

	+	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014
--	---	---------------	---------	---------	-----	--------------

TABLET; ORAL

MERCAPTOPYRINE

<u>AB</u>		MYLAN	<u>50MG</u>	<u>A040594</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>		PROMETHEUS LABS	<u>50MG</u>	<u>A040461</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>	+	ROXANE	<u>50MG</u>	<u>A040528</u>	<u>001</u>	Feb 13, 2004

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>		ACS DOBFAR	<u>500MG/VIAL</u>	<u>A091404</u>	<u>001</u>	Oct 26, 2011
<u>AP</u>			<u>1GM/VIAL</u>	<u>A091404</u>	<u>002</u>	Oct 26, 2011
<u>AP</u>		DAEWOONG PHARM CO	<u>500MG/VIAL</u>	<u>A204854</u>	<u>001</u>	Dec 18, 2015
<u>AP</u>			<u>1GM/VIAL</u>	<u>A204854</u>	<u>002</u>	Dec 18, 2015
<u>AP</u>		HOSPIRA INC	<u>500MG/VIAL</u>	<u>A090940</u>	<u>001</u>	Jun 22, 2010
<u>AP</u>			<u>1GM/VIAL</u>	<u>A090940</u>	<u>002</u>	Jun 22, 2010
<u>AP</u>		SANDOZ	<u>500MG/VIAL</u>	<u>A091201</u>	<u>001</u>	Mar 29, 2011
<u>AP</u>			<u>1GM/VIAL</u>	<u>A091201</u>	<u>002</u>	Mar 29, 2011

MERREM

<u>AP</u>	+	ASTRAZENECA	<u>500MG/VIAL</u>	<u>N050706</u>	<u>003</u>	Jun 21, 1996
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>N050706</u>	<u>001</u>	Jun 21, 1996

POWDER; IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

		B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015
			1GM/VIAL	N202106	002	Apr 30, 2015

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

	+	WARNER CHILCOTT LLC	400MG	N204412	001	Feb 01, 2013
--	---	---------------------	-------	---------	-----	--------------

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

	+	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008
--	---	---------------------	-------	---------	-----	--------------

PENTASA

		SHIRE	250MG	N020049	001	May 10, 1993
--	--	-------	-------	---------	-----	--------------

	+		500MG	N020049	002	Jul 08, 2004
--	---	--	-------	---------	-----	--------------

ENEMA; RECTAL

MESALAMINE

<u>AB</u>		G AND W LABS INC	<u>4GM/60ML</u>	<u>A076841</u>	<u>001</u>	Sep 30, 2004
<u>AB</u>		PERRIGO ISRAEL	<u>4GM/60ML</u>	<u>A076751</u>	<u>001</u>	Sep 17, 2004



## PRESCRIPTION DRUG PRODUCT LIST

MESALAMINE

ENEMA; RECTAL

ROWASA**AB** + MEDA PHARMS **4GM/60ML** **N019618 001** Dec 24, 1987SFROWASA**AB** MEDA PHARMS **4GM/60ML** **N019618 002** Jun 20, 2008  
SUPPOSITORY; RECTALCANASA**AB** + FOREST LABS LLC **1GM** **N021252 002** Nov 05, 2004MESALAMINE**AB** MYLAN PHARMS INC **1GM** **A204354 001** Nov 24, 2015

TABLET, DELAYED RELEASE; ORAL

ASACOL HD

+ WARNER CHILCOTT LLC 800MG N021830 001 May 29, 2008

LIALDA

+ SHIRE 1.2GM N022000 001 Jan 16, 2007

MESNA

INJECTABLE; INTRAVENOUS

MESNA**AP** EUROHLTH INTL SARL **100MG/ML** **A075739 001** Jan 09, 2004**AP** FRESENIUS KABI USA **100MG/ML** **A075811 001** Apr 26, 2001**AP** MYLAN INSTITUTIONAL **100MG/ML** **A076488 001** Mar 08, 2012**AP** MYLAN LABS LTD **100MG/ML** **A203364 001** Jul 18, 2014**AP** SAGENT PHARMS **100MG/ML** **A090913 001** Apr 13, 2010**AP** TEVA PHARMS USA **100MG/ML** **A075764 001** Apr 27, 2001MESNEX**AP** + BAXTER HLTHCARE **100MG/ML** **N019884 001** Dec 30, 1988

TABLET; ORAL

MESNEX

+ BAXTER HLTHCARE 400MG N020855 001 Mar 21, 2002

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC 0.05MG; 1MG N016659 001

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

+ SILARX 10MG/5ML A073632 001 Jul 22, 1992

TABLET; ORAL

METAPROTERENOL SULFATE

PAR PHARM 10MG A072024 001 Jun 28, 1988

+ 20MG A072025 001 Jun 28, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

+ FRESENIUS KABI USA EQ 10MG BASE/ML A080722 001

METAXALONE

TABLET; ORAL

METAXALONE**AB** AMNEAL PHARMS **800MG** **A203399 001** Jun 21, 2013**AB** SANDOZ **800MG** **A040445 001** Mar 31, 2010SKELAXIN**AB** + KING PHARMS **800MG** **N013217 003** Aug 30, 2002

METAXALONE

COREPHARMA 400MG A040486 001 Feb 27, 2015

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ SUN PHARM INDS LTD 500MG/5ML N021591 001 Sep 11, 2003

TABLET; ORAL

GLUCOPHAGE**AB** BRISTOL MYERS SQUIBB **500MG** **N020357 001** Mar 03, 1995**AB** **850MG** **N020357 002** Mar 03, 1995**AB** + **1GM** **N020357 005** Nov 05, 1998METFORMIN HYDROCHLORIDE**AB** ALKEM **500MG** **A091184 001** Nov 01, 2010**AB** **850MG** **A091184 002** Nov 01, 2010**AB** **1GM** **A091184 003** Nov 01, 2010**AB** AMNEAL PHARMS NY **500MG** **A077880 001** Jun 05, 2006

## PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>850MG</u>	<u>A077880</u>	<u>002</u>	Jun 05, 2006
<u>AB</u>		<u>1GM</u>	<u>A077880</u>	<u>003</u>	Jun 05, 2006
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A075984</u>	<u>001</u>	Apr 23, 2002
<u>AB</u>		<u>500MG</u>	<u>A090666</u>	<u>001</u>	Dec 07, 2011
<u>AB</u>		<u>850MG</u>	<u>A075984</u>	<u>002</u>	Apr 23, 2002
<u>AB</u>		<u>850MG</u>	<u>A090666</u>	<u>002</u>	Dec 07, 2011
<u>AB</u>		<u>1GM</u>	<u>A075984</u>	<u>003</u>	Apr 23, 2002
<u>AB</u>		<u>1GM</u>	<u>A090666</u>	<u>003</u>	Dec 07, 2011
<u>AB</u>	ATLAS PHARMS LLC	<u>500MG</u>	<u>A076033</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A076033</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A076033</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A077095</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>		<u>850MG</u>	<u>A077095</u>	<u>002</u>	Jan 14, 2005
<u>AB</u>		<u>1GM</u>	<u>A077095</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>	CHARTWELL LIFE SCI	<u>500MG</u>	<u>A075972</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075972</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075972</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>A077787</u>	<u>001</u>	Aug 23, 2006
<u>AB</u>		<u>850MG</u>	<u>A077787</u>	<u>002</u>	Aug 23, 2006
<u>AB</u>		<u>1GM</u>	<u>A077787</u>	<u>003</u>	Aug 23, 2006
<u>AB</u>	GLENMARK GENERICS	<u>500MG</u>	<u>A078170</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>850MG</u>	<u>A078170</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>1GM</u>	<u>A078170</u>	<u>003</u>	May 23, 2008
<u>AB</u>	GRANULES INDIA	<u>500MG</u>	<u>A090564</u>	<u>001</u>	Apr 22, 2010
<u>AB</u>		<u>850MG</u>	<u>A090564</u>	<u>002</u>	Apr 22, 2010
<u>AB</u>		<u>1GM</u>	<u>A090564</u>	<u>003</u>	Apr 22, 2010
<u>AB</u>	INDICUS PHARMA	<u>500MG</u>	<u>A079148</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>850MG</u>	<u>A079148</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>1GM</u>	<u>A079148</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090888</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>850MG</u>	<u>A090888</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>1GM</u>	<u>A090888</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	MUTUAL PHARMA	<u>500MG</u>	<u>A076038</u>	<u>001</u>	Feb 21, 2002
<u>AB</u>		<u>850MG</u>	<u>A076038</u>	<u>002</u>	Feb 21, 2002
<u>AB</u>		<u>1GM</u>	<u>A076038</u>	<u>003</u>	Feb 21, 2002
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A075973</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075976</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075976</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075973</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075976</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A075969</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075969</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075969</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	PROVIDENT PHARM	<u>500MG</u>	<u>A077853</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>		<u>850MG</u>	<u>A077853</u>	<u>002</u>	Jul 28, 2006
<u>AB</u>		<u>1GM</u>	<u>A077853</u>	<u>003</u>	Jul 28, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075965</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075985</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075985</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075985</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A203769</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>850MG</u>	<u>A203769</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>1GM</u>	<u>A203769</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>	SUN PHARM INDS INC	<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075978</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075978</u>	<u>003</u>	Nov 05, 2002
<u>AB</u>	TORRENT PHARMS	<u>500MG</u>	<u>A077711</u>	<u>001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711</u>	<u>002</u>	Jan 24, 2007
<u>AB</u>		<u>1GM</u>	<u>A077711</u>	<u>003</u>	Jan 24, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A075961</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075961</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075961</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	ZYDUS HLTHCARE	<u>500MG</u>	<u>A203686</u>	<u>001</u>	Aug 28, 2014

## PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>850MG</u>	<u>A203686</u>	<u>002</u>	Aug 28, 2014
<u>AB</u>		<u>1GM</u>	<u>A203686</u>	<u>003</u>	Aug 28, 2014
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>750MG</u>	<u>N021202</u>	<u>004</u>	Apr 11, 2003
-----------	---	----------------------	--------------	----------------	------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>		AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>		APOTEX	<u>750MG</u>	<u>A076706</u>	<u>002</u>	Dec 29, 2005
<u>AB</u>		AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>		BARR	<u>750MG</u>	<u>A076863</u>	<u>001</u>	Oct 14, 2004
<u>AB</u>		CSPC OUYI PHARM CO	<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>		IMPAX LABS	<u>750MG</u>	<u>A076985</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		MYLAN	<u>750MG</u>	<u>A077113</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>		SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>		TEVA	<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>		ZYDUS PHARMS USA	<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005

GLUCOPHAGE XR

<u>AB1</u>		BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202</u>	<u>001</u>	Oct 13, 2000
------------	--	----------------------	--------------	----------------	------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB1</u>		ACTAVIS LABS FL INC	<u>500MG</u>	<u>A076172</u>	<u>001</u>	Jun 16, 2004
<u>AB1</u>		AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB1</u>		APOTEX	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>		AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118</u>	<u>001</u>	Jul 20, 2012
<u>AB1</u>		CSPC OUYI PHARM CO	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB1</u>		IMPAX LABS	<u>500MG</u>	<u>A076249</u>	<u>001</u>	Jul 30, 2004
<u>AB1</u>		INVENTIA HLTHCARE	<u>500MG</u>	<u>A201991</u>	<u>001</u>	Jan 18, 2012
<u>AB1</u>		MYLAN	<u>500MG</u>	<u>A076650</u>	<u>001</u>	Sep 13, 2005
<u>AB1</u>		NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB1</u>		SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>		SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB1</u>		TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB1</u>		TORRENT PHARM	<u>500MG</u>	<u>A090014</u>	<u>001</u>	Dec 30, 2009
<u>AB1</u>		ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005

FORTAMET

<u>AB2</u>		ANDRX LABS LLC	<u>500MG</u>	<u>N021574</u>	<u>001</u>	Apr 27, 2004
<u>AB2</u>	+		<u>1GM</u>	<u>N021574</u>	<u>002</u>	Apr 27, 2004

METFORMIN HYDROCHLORIDE

<u>AB2</u>		LUPIN LTD	<u>500MG</u>	<u>A090692</u>	<u>001</u>	Jun 29, 2011
<u>AB2</u>			<u>1GM</u>	<u>A090692</u>	<u>002</u>	Jun 29, 2011
<u>AB2</u>		MYLAN PHARMS INC	<u>500MG</u>	<u>A200690</u>	<u>001</u>	Aug 01, 2012
<u>AB2</u>			<u>1GM</u>	<u>A200690</u>	<u>002</u>	Aug 01, 2012
<u>AB3</u>		LUPIN LTD	<u>500MG</u>	<u>A091664</u>	<u>001</u>	Jul 19, 2013
<u>AB3</u>			<u>1GM</u>	<u>A091664</u>	<u>002</u>	Jul 19, 2013

GLUMETZA

		SANTARUS INC	500MG	N021748	001	Jun 03, 2005
	+		1GM	N021748	002	Jun 03, 2005

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

<u>AB</u>		TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>001</u>	Aug 29, 2005
<u>AB</u>	+		<u>850MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>001</u>	Nov 05, 2015
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>002</u>	Nov 05, 2015
<u>AB</u>		MYLAN	<u>500MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>001</u>	Feb 25, 2011
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>002</u>	Feb 25, 2011
<u>AB</u>		SANDOZ	<u>500MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>001</u>	Apr 16, 2013
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>002</u>	Apr 16, 2013
<u>AB</u>		TEVA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>001</u>	Mar 10, 2014
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>002</u>	Mar 10, 2014

## PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	TORRENT PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A202001 001</u>	Feb 13, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A202001 002</u>	Feb 13, 2013

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024 001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024 002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

<u>AB</u>	NOVO NORDISK INC	<u>500MG;1MG</u>	<u>N022386 001</u>	Jun 23, 2008
<u>AB</u>	+	<u>500MG;2MG</u>	<u>N022386 002</u>	Jun 23, 2008

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	LUPIN LTD	<u>500MG;1MG</u>	<u>A200624 001</u>	Jul 15, 2015
<u>AB</u>		<u>500MG;2MG</u>	<u>A200624 002</u>	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

	TEVA	500MG;EQ 2MG BASE	A077337 001	May 07, 2014
		500MG;EQ 4MG BASE	A077337 002	May 07, 2014
+		1GM;EQ 4MG BASE	A077337 004	May 07, 2014
		1GM;EQ 2MG BASE	A077337 003	May 07, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010
		1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010
+		1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007
+		1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012
		1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012
+		1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+	METHAPHARM	100MG/VIAL	N019193 001	Oct 31, 1986
---	------------	------------	-------------	--------------

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	ROXANE	<u>10MG/ML</u>	<u>A040180 001</u>	Apr 30, 1998
<u>AA</u>	VISTAPHARM	<u>10MG/ML</u>	<u>A040088 001</u>	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

<u>AA</u>	ROXANE	<u>10MG/ML</u>	<u>A089897 001</u>	Sep 06, 1988
-----------	--------	----------------	--------------------	--------------

METHADOSE

<u>AA</u>	+	MALLINCKRODT	<u>10MG/ML</u>	<u>N017116 002</u>
-----------	---	--------------	----------------	--------------------

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

+	MYLAN INSTITUTIONAL	10MG/ML	N021624 001	
---	---------------------	---------	-------------	--

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

	MALLINCKRODT	50GM/BOT	N006383 002	
		100GM/BOT	N006383 003	
		500GM/BOT	N006383 004	

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	+	ROXANE	<u>5MG/5ML</u>	<u>A087393 001</u>
<u>AA</u>	+		<u>10MG/5ML</u>	<u>A087997 001</u>
<u>AA</u>		VISTAPHARM	<u>5MG/5ML</u>	<u>A090707 001</u>
<u>AA</u>			<u>10MG/5ML</u>	<u>A090707 002</u>

## PRESCRIPTION DRUG PRODUCT LIST

METHADONE HYDROCHLORIDE

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

<u>AA</u>	+	ROXANE	<u>5MG</u>	<u>N006134</u>	<u>002</u>	
<u>AA</u>	+		<u>10MG</u>	<u>N006134</u>	<u>010</u>	

METHADONE HYDROCHLORIDE

<u>AA</u>		AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A203502</u>	<u>001</u>	Aug 31, 2015
<u>AA</u>			<u>10MG</u>	<u>A203502</u>	<u>002</u>	Aug 31, 2015
<u>AA</u>		COREPHARMA	<u>5MG</u>	<u>A090065</u>	<u>001</u>	Aug 18, 2015
<u>AA</u>			<u>10MG</u>	<u>A090065</u>	<u>002</u>	Aug 18, 2015
<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040517</u>	<u>001</u>	Apr 27, 2004
<u>AA</u>			<u>10MG</u>	<u>A040517</u>	<u>002</u>	Apr 27, 2004
<u>AA</u>		SANDOZ	<u>10MG</u>	<u>A040241</u>	<u>002</u>	May 29, 1998
<u>AA</u>		THE PHARMANETWORK	<u>10MG</u>	<u>A090635</u>	<u>001</u>	Nov 25, 2009
<u>METHADOSE</u>						
<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040050</u>	<u>001</u>	Apr 15, 1993
<u>AA</u>			<u>10MG</u>	<u>A040050</u>	<u>002</u>	Apr 15, 1993

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>		MALLINCKRODT INC	<u>40MG</u>	<u>A077142</u>	<u>001</u>	Jul 12, 2005
<u>AA</u>	+	ROXANE	<u>40MG</u>	<u>N017058</u>	<u>001</u>	
<u>AA</u>		SANDOZ	<u>40MG</u>	<u>A075082</u>	<u>001</u>	Mar 25, 1998

METHADOSE

<u>AA</u>		MALLINCKRODT	<u>40MG</u>	<u>A074184</u>	<u>001</u>	Apr 29, 1993
-----------	--	--------------	-------------	----------------	------------	--------------

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

<u>AA</u>	+	RECORDATI RARE	<u>5MG</u>	<u>N005378</u>	<u>002</u>	
-----------	---	----------------	------------	----------------	------------	--

METHAMPHETAMINE HYDROCHLORIDE

<u>AA</u>		COASTAL PHARMS	<u>5MG</u>	<u>A091189</u>	<u>001</u>	Apr 21, 2010
<u>AA</u>		ROXANE	<u>5MG</u>	<u>A203846</u>	<u>001</u>	Nov 17, 2015

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

<u>AB</u>		ANI PHARMS INC	<u>25MG</u>	<u>A040001</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>			<u>50MG</u>	<u>A040001</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>		MIKART	<u>25MG</u>	<u>A040062</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>	+		<u>50MG</u>	<u>A040062</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A040036</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>			<u>50MG</u>	<u>A040036</u>	<u>002</u>	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

<u>AB</u>	+	SANOFI AVENTIS US	<u>1GM</u>	<u>N017681</u>	<u>001</u>	
-----------	---	-------------------	------------	----------------	------------	--

METHENAMINE HIPPURATE

<u>AB</u>		COREPHARMA	<u>1GM</u>	<u>A076411</u>	<u>001</u>	Jun 20, 2003
-----------	--	------------	------------	----------------	------------	--------------

UREX

<u>AB</u>		CNTY LINE PHARMS	<u>1GM</u>	<u>N016151</u>	<u>001</u>	
-----------	--	------------------	------------	----------------	------------	--

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

<u>AB</u>		CEDAR PHARMS	<u>5MG</u>	<u>A040547</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>			<u>10MG</u>	<u>A040547</u>	<u>002</u>	Feb 18, 2005
<u>AB</u>		HERITAGE PHARMA	<u>5MG</u>	<u>A040734</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>			<u>10MG</u>	<u>A040734</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A040350</u>	<u>001</u>	Mar 29, 2000
<u>AB</u>	+		<u>10MG</u>	<u>A040350</u>	<u>002</u>	Mar 29, 2000
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A040411</u>	<u>001</u>	Mar 27, 2001
<u>AB</u>			<u>10MG</u>	<u>A040411</u>	<u>002</u>	Mar 27, 2001
<u>AB</u>		SUN PHARM INDS INC	<u>5MG</u>	<u>A040870</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>			<u>10MG</u>	<u>A040870</u>	<u>002</u>	Sep 25, 2007
<u>AB</u>		VINTAGE PHARMS	<u>5MG</u>	<u>A202068</u>	<u>001</u>	Mar 07, 2012
<u>AB</u>			<u>10MG</u>	<u>A202068</u>	<u>002</u>	Mar 07, 2012

TAPAZOLE

<u>AB</u>		KING PHARMS	<u>5MG</u>	<u>A040320</u>	<u>001</u>	Mar 31, 2000
<u>AB</u>			<u>10MG</u>	<u>A040320</u>	<u>002</u>	Mar 31, 2000

## PRESCRIPTION DRUG PRODUCT LIST

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1GM/10ML (100MG/ML)</u>	<u>A204404 001</u>	Dec 05, 2014
-----------	---------------------	----------------------------	--------------------	--------------

ROBAXIN

<u>AP</u>	+ EUROHLTH INTL SARL	<u>1GM/10ML (100MG/ML)</u>	<u>N011790 001</u>	
-----------	----------------------	----------------------------	--------------------	--

TABLET;ORAL

METHOCARBAMOL

<u>AA</u>	AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958 001</u>	Oct 21, 2011
-----------	------------------	--------------	--------------------	--------------

<u>AA</u>		<u>750MG</u>	<u>A200958 002</u>	Oct 21, 2011
-----------	--	--------------	--------------------	--------------

<u>AA</u>	HETERO LABS LTD III	<u>500MG</u>	<u>A090200 001</u>	Nov 06, 2009
-----------	---------------------	--------------	--------------------	--------------

<u>AA</u>		<u>750MG</u>	<u>A090200 002</u>	Nov 06, 2009
-----------	--	--------------	--------------------	--------------

<u>AA</u>	HIKMA INTL PHARMS	<u>500MG</u>	<u>A085159 001</u>	
-----------	-------------------	--------------	--------------------	--

<u>AA</u>		<u>750MG</u>	<u>A085123 001</u>	
-----------	--	--------------	--------------------	--

<u>AA</u>	LANNETT HOLDINGS INC	<u>500MG</u>	<u>A084756 002</u>	Mar 31, 2003
-----------	----------------------	--------------	--------------------	--------------

<u>AA</u>		<u>750MG</u>	<u>A084756 001</u>	
-----------	--	--------------	--------------------	--

<u>AA</u>	PRINSTON INC	<u>500MG</u>	<u>A086989 001</u>	
-----------	--------------	--------------	--------------------	--

<u>AA</u>		<u>750MG</u>	<u>A086988 001</u>	
-----------	--	--------------	--------------------	--

<u>AA</u>	SANDOZ	<u>500MG</u>	<u>A084616 001</u>	
-----------	--------	--------------	--------------------	--

<u>AA</u>		<u>750MG</u>	<u>A084615 001</u>	
-----------	--	--------------	--------------------	--

<u>AA</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A040489 001</u>	Jan 29, 2003
-----------	----------------	--------------	--------------------	--------------

<u>AA</u>		<u>750MG</u>	<u>A040489 002</u>	Jan 29, 2003
-----------	--	--------------	--------------------	--------------

<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A084277 001</u>	
-----------	-------------	--------------	--------------------	--

<u>AA</u>		<u>750MG</u>	<u>A084276 002</u>	
-----------	--	--------------	--------------------	--

ROBAXIN

<u>AA</u>	+ AUXILIUM PHARMS LLC	<u>500MG</u>	<u>N011011 004</u>	
-----------	-----------------------	--------------	--------------------	--

ROBAXIN-750

<u>AA</u>	+ AUXILIUM PHARMS LLC	<u>750MG</u>	<u>N011011 006</u>	
-----------	-----------------------	--------------	--------------------	--

METHOHEXITAL SODIUM

INJECTABLE;INJECTION

BREVITAL SODIUM

	+ PAR STERILE PRODUCTS	200MG/VIAL	N011559 004	Dec 21, 2012
--	------------------------	------------	-------------	--------------

		500MG/VIAL	N011559 001	
--	--	------------	-------------	--

		2.5GM/VIAL	N011559 002	
--	--	------------	-------------	--

METHOTREXATE

SOLUTION;SUBCUTANEOUS

OTREXUP

	ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824 005	Nov 07, 2014
--	--------------------	---------------------------	-------------	--------------

		10MG/0.4ML (10MG/0.4ML)	N204824 001	Oct 11, 2013
--	--	-------------------------	-------------	--------------

		15MG/0.4ML (15MG/0.4ML)	N204824 002	Oct 11, 2013
--	--	-------------------------	-------------	--------------

		20MG/0.4ML (20MG/0.4ML)	N204824 003	Oct 11, 2013
--	--	-------------------------	-------------	--------------

		25MG/0.4ML (25MG/0.4ML)	N204824 004	Oct 11, 2013
--	--	-------------------------	-------------	--------------

+

RASUVO

	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776 001	Jul 10, 2014
--	------------------	-----------------------------	-------------	--------------

		10MG/0.20ML (10MG/0.20ML)	N205776 002	Jul 10, 2014
--	--	---------------------------	-------------	--------------

		12.5MG/0.25ML (12.5MG/0.25ML)	N205776 003	Jul 10, 2014
--	--	-------------------------------	-------------	--------------

		15MG/0.30ML (15MG/0.30ML)	N205776 004	Jul 10, 2014
--	--	---------------------------	-------------	--------------

		17.5MG/0.35ML (17.5MG/0.35ML)	N205776 005	Jul 10, 2014
--	--	-------------------------------	-------------	--------------

		20MG/0.4ML (20MG/0.4ML)	N205776 006	Jul 10, 2014
--	--	-------------------------	-------------	--------------

		22.5MG/0.45ML (22.5MG/0.45ML)	N205776 007	Jul 10, 2014
--	--	-------------------------------	-------------	--------------

		25MG/0.5ML (25MG/0.5ML)	N205776 008	Jul 10, 2014
--	--	-------------------------	-------------	--------------

		27.5MG/0.55ML (27.5MG/0.55ML)	N205776 009	Jul 10, 2014
--	--	-------------------------------	-------------	--------------

		30MG/0.6ML (30MG/0.6ML)	N205776 010	Jul 10, 2014
--	--	-------------------------	-------------	--------------

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 25MG BASE/ML</u>	<u>A040265 001</u>	Feb 26, 1999
-----------	--------------------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040266 001</u>	Feb 26, 1999
-----------	--	-------------------------	--------------------	--------------

<u>AP</u>	PHARMACHEMIE BV	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A200171 001</u>	Feb 27, 2012
-----------	-----------------	--	--------------------	--------------

METHOTREXATE SODIUM

<u>AP</u>	+ EUROHLTH INTL SARL	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341 001</u>	Sep 16, 1986
-----------	----------------------	--	--------------------	--------------

<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263 001</u>	Feb 26, 1999
-----------	----------------------	---	--------------------	--------------

<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040263 002</u>	Feb 26, 1999
-----------	--	---	--------------------	--------------

<u>AP</u>	+ HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719 010</u>	Dec 15, 2004
-----------	-----------	---	--------------------	--------------

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+ ACCORD HLTHCARE	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767 001</u>	Apr 30, 2007
-----------	-------------------	---	--------------------	--------------

<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768 001</u>	Apr 30, 2007
-----------	--	---	--------------------	--------------

<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716 001</u>	Apr 30, 2007
-----------	--	---	--------------------	--------------

<u>AP</u>	EBEWE PHARMA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039 001</u>	Mar 31, 2009
-----------	--------------	---	--------------------	--------------

<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039 002</u>	Mar 31, 2009
-----------	--	---	--------------------	--------------

<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029 001</u>	Mar 31, 2009
-----------	--	---	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+	EUROHLTH INTL SARL	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340 001</u>	Sep 16, 1986
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343 001</u>	Sep 16, 1986
<u>AP</u>	+	HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719 012</u>	Apr 13, 2005
<u>AP</u>		MYLAN LABS LTD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A201529 001</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A201529 002</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 200MG BASE/8ML (EQ 25MG BASE/ML)</u>	<u>A201529 003</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529 004</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530 001</u>	Mar 29, 2012
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040850 001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 250MG/10ML (EQ 25MG BASE/ML)</u>	<u>A040853 001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843 001</u>	Jan 11, 2010

METHOTREXATE SODIUM

+ EUROHLTH INTL SARL EQ 200MG BASE/8ML (EQ 25MG BASE/ML)

A089342 001 Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

+ EUROHLTH INTL SARL EQ 1GM BASE/VIAL

A040632 001 Aug 12, 2005

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>		BARR	<u>EQ 2.5MG BASE</u>	<u>A081099 001</u>	Oct 15, 1990
<u>AB</u>	+	DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085 002</u>	
<u>AB</u>		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235 001</u>	May 15, 1992
<u>AB</u>		ORION CORP ORION	<u>EQ 2.5MG BASE</u>	<u>A201749 001</u>	May 21, 2015
<u>AB</u>		ROXANE	<u>EQ 2.5MG BASE</u>	<u>A040054 001</u>	Aug 01, 1994
		TREXALL			
		BARR	EQ 5MG BASE	A040385 001	Mar 21, 2001
			EQ 7.5MG BASE	A040385 002	Mar 21, 2001
			EQ 10MG BASE	A040385 003	Mar 21, 2001
	+		EQ 15MG BASE	A040385 004	Mar 21, 2001

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

<u>AB</u>		ACTAVIS INC	<u>10MG</u>	<u>A202603 001</u>	Jun 09, 2015
<u>AB</u>		STRIDES PHARMA	<u>10MG</u>	<u>A202687 001</u>	Jun 05, 2014

OXSORALEN-ULTRA

<u>AB</u>	+	DOW PHARM	<u>10MG</u>	<u>N019600 001</u>	Oct 30, 1986
		8-MOP			
	+	VALEANT PHARM INTL	10MG	N009048 001	
		INJECTABLE; INJECTION			
		UVADEX			
	+	THERAKOS	0.02MG/ML	N020969 001	Feb 25, 1999
		LOTION; TOPICAL			
		OXSORALEN			
	+	VALEANT PHARM INTL	1%	N009048 002	

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

<u>AA</u>		BAYSHORE PHARMS LLC	<u>2.5MG</u>	<u>A200602 001</u>	Sep 24, 2012
<u>AA</u>			<u>5MG</u>	<u>A200602 002</u>	Sep 24, 2012
<u>AA</u>		BRECKENRIDGE PHARM	<u>2.5MG</u>	<u>A040642 001</u>	Dec 06, 2011
<u>AA</u>			<u>5MG</u>	<u>A040642 002</u>	Dec 06, 2011
<u>AA</u>	+	VINTAGE PHARMS	<u>2.5MG</u>	<u>A040624 001</u>	Dec 28, 2006
<u>AA</u>	+		<u>5MG</u>	<u>A040624 002</u>	Dec 28, 2006

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

PARKE DAVIS

150MG

N010596 007

+

300MG

N010596 008

METHYLCLOTHIAZIDE

TABLET; ORAL

METHYLCLOTHIAZIDE

+ MYLAN PHARMS INC

5MG

A087672 001 Aug 17, 1982

METHYLDOPA

TABLET; ORAL

METHYLDOPA

<u>AB</u>		ACCORD HLTHCARE	<u>250MG</u>	<u>A070084 001</u>	Oct 15, 1985
<u>AB</u>			<u>500MG</u>	<u>A070085 001</u>	Oct 15, 1985
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>A070098 001</u>	Feb 20, 1986
<u>AB</u>			<u>500MG</u>	<u>A070343 001</u>	Feb 20, 1986

## PRESCRIPTION DRUG PRODUCT LIST

METHYLDOPA

TABLET; ORAL

METHYLDOPA

<b>AB</b>	MYLAN	<b>250MG</b>	<b>A070076 002</b>	Apr 18, 1985
<b>AB</b>	+	<b>500MG</b>	<b>A070076 001</b>	Apr 18, 1985
<b>AB</b>	WATSON LABS	<b>500MG</b>	<b>A070625 001</b>	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

<b>AP</b>	+	LUITPOLD	<b>50MG/ML</b>	<b>A071279 001</b>	Oct 02, 1987
-----------	---	----------	----------------	--------------------	--------------

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

<b>AP</b>	+	EDISON THERAPS LLC	<b>0.2MG/ML</b>	<b>N006035 004</b>	
<b>AP</b>		ERGOJECT	<b>0.2MG/ML</b>	<b>A040889 001</b>	Sep 13, 2010
<b>AP</b>		LUITPOLD	<b>0.2MG/ML</b>	<b>A090193 001</b>	Nov 24, 2008

TABLET; ORAL

METHERGINE

<b>AB</b>	+	EDISON THERAPS LLC	<b>0.2MG</b>	<b>N006035 003</b>	
<b>AB</b>		NOVEL LABS INC	<b>0.2MG</b>	<b>A091577 001</b>	May 02, 2011

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

RELISTOR

	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964 002	Sep 27, 2010
+		12MG/0.6ML (12MG/0.6ML)	N021964 001	Apr 24, 2008
+		12MG/0.6ML (12MG/0.6ML)	N021964 003	Sep 27, 2010

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514 001	Apr 06, 2006
		15MG/9HR (1.6MG/HR)	N021514 002	Apr 06, 2006
		20MG/9HR (2.2MG/HR)	N021514 003	Apr 06, 2006
+		30MG/9HR (3.3MG/HR)	N021514 004	Apr 06, 2006

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

<b>AB1</b>	BARR LABS INC	<b>10MG</b>	<b>A079031 004</b>	Oct 15, 2014
<b>AB1</b>		<b>20MG</b>	<b>A079031 001</b>	Jul 13, 2012
<b>AB1</b>		<b>30MG</b>	<b>A079031 002</b>	Jul 13, 2012
<b>AB1</b>		<b>40MG</b>	<b>A079031 003</b>	Jul 13, 2012
<b>AB1</b>	WATSON LABS INC	<b>20MG</b>	<b>A078458 001</b>	Dec 01, 2011
<b>AB1</b>		<b>30MG</b>	<b>A078458 002</b>	Dec 01, 2011
<b>AB1</b>		<b>40MG</b>	<b>A078458 003</b>	Dec 01, 2011

RITALIN LA

<b>AB1</b>	NOVARTIS	<b>10MG</b>	<b>N021284 004</b>	Apr 10, 2004
<b>AB1</b>		<b>20MG</b>	<b>N021284 001</b>	Jun 05, 2002
<b>AB1</b>		<b>30MG</b>	<b>N021284 002</b>	Jun 05, 2002
<b>AB1</b>		<b>40MG</b>	<b>N021284 003</b>	Jun 05, 2002

METADATE CD

<b>AB2</b>	UCB INC	<b>10MG</b>	<b>N021259 003</b>	May 27, 2003
<b>AB2</b>		<b>20MG</b>	<b>N021259 001</b>	Apr 03, 2001
<b>AB2</b>		<b>30MG</b>	<b>N021259 002</b>	Jun 19, 2003
<b>AB2</b>		<b>40MG</b>	<b>N021259 004</b>	Feb 19, 2006
<b>AB2</b>		<b>50MG</b>	<b>N021259 005</b>	Feb 19, 2006
<b>AB2</b>	+	<b>60MG</b>	<b>N021259 006</b>	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

<b>AB2</b>	MALLINCKRODT INC	<b>10MG</b>	<b>A203583 001</b>	Sep 29, 2015
<b>AB2</b>		<b>20MG</b>	<b>A203583 002</b>	Sep 29, 2015
<b>AB2</b>		<b>30MG</b>	<b>A203583 003</b>	Sep 29, 2015
<b>AB2</b>		<b>40MG</b>	<b>A203583 004</b>	Sep 29, 2015
<b>AB2</b>		<b>50MG</b>	<b>A203583 005</b>	Sep 29, 2015
<b>AB2</b>		<b>60MG</b>	<b>A203583 006</b>	Sep 29, 2015
<b>AB2</b>	TEVA PHARMS	<b>10MG</b>	<b>A077707 001</b>	Jul 19, 2012
<b>AB2</b>		<b>20MG</b>	<b>A077707 002</b>	Jul 19, 2012
<b>AB2</b>		<b>30MG</b>	<b>A077707 003</b>	Jul 19, 2012
<b>AB2</b>		<b>40MG</b>	<b>A078873 001</b>	Jul 19, 2012
<b>AB2</b>		<b>50MG</b>	<b>A078873 002</b>	Jul 19, 2012
<b>AB2</b>		<b>60MG</b>	<b>A078873 003</b>	Jul 19, 2012



## PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

APTENSIO XR

RHODES PHARMS

10MG

N205831 001 Apr 17, 2015

15MG

N205831 002 Apr 17, 2015

20MG

N205831 003 Apr 17, 2015

30MG

N205831 004 Apr 17, 2015

40MG

N205831 005 Apr 17, 2015

50MG

N205831 006 Apr 17, 2015

60MG

N205831 007 Apr 17, 2015

+

RITALIN LA

+ NOVARTIS

60MG

N021284 005 Oct 27, 2014

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

+ NEXTWAVE PHARMS

5MG/ML

N202100 001 Sep 27, 2012

SOLUTION;ORAL

METHYLINAA + MALLINCKRODT5MG/5MLN021419 001 Dec 19, 2002AA +10MG/5MLN021419 002 Dec 19, 2002METHYLPHENIDATE HYDROCHLORIDEAA NOVEL LABS INC5MG/5MLA204602 001 Aug 14, 2015AA10MG/5MLA204602 002 Aug 14, 2015AA SUN PHARM INDS INC5MG/5MLA201466 001 Nov 12, 2013AA10MG/5MLA201466 002 Nov 12, 2013AA TRIS PHARMA INC5MG/5MLA091601 001 Jul 23, 2010AA10MG/5MLA091601 002 Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDEAB ACTAVIS LABS FL INC5MGA040220 001 Aug 29, 1997AB10MGA040220 002 Aug 29, 1997AB20MGA040220 003 Aug 29, 1997AB ASCENT PHARMS INC5MGA207416 001 Sep 22, 2015AB10MGA207416 002 Sep 22, 2015AB20MGA207416 003 Sep 22, 2015AB COREPHARMA5MGA091159 001 Mar 12, 2014AB10MGA091159 002 Mar 12, 2014AB20MGA091159 003 Mar 12, 2014AB MALLINCKRODT5MGA040300 001 Nov 27, 1998AB10MGA040300 002 Nov 27, 1998AB20MGA040300 003 Nov 27, 1998AB NOVEL LABS INC5MGA207884 001 Nov 13, 2015AB10MGA207884 002 Nov 13, 2015AB20MGA207884 003 Nov 13, 2015AB SUN PHARM INDS INC5MGA090710 001 Mar 15, 2012AB10MGA090710 002 Mar 15, 2012AB20MGA090710 003 Mar 15, 2012AB UCB INC5MGA086429 001AB10MGA085799 001AB20MGA086428 001AB VINTAGE PHARMS5MGA202892 001 Sep 23, 2014AB10MGA202892 002 Sep 23, 2014AB20MGA202892 003 Sep 23, 2014RITALINAB NOVARTIS5MGN010187 003AB10MGN010187 006AB +20MGN010187 010

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

NOVEL LABS INC

2.5MG

A204115 001 Feb 25, 2015

5MG

A204115 002 Feb 25, 2015

+

10MG

A204115 003 Feb 25, 2015

TABLET, EXTENDED RELEASE;ORAL

METADATE ERAB + UCB INC20MGA089601 001 Jun 01, 1988METHYLIN ERAB MALLINCKRODT INC10MGA075629 001 May 09, 2000AB20MGA075629 002 May 09, 2000METHYLPHENIDATE HYDROCHLORIDEAB ABHAI10MGA207488 001 Jun 09, 2015AB20MGA207488 002 Jun 09, 2015RITALIN-SRAB NOVARTIS20MGN018029 001 Mar 30, 1982

## PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

BX	KREMERS URBAN PHARMS	18MG	A091695	001	Jul 09, 2013
BX		27MG	A091695	002	Jul 09, 2013
BX		36MG	A091695	003	Sep 23, 2013
BX		54MG	A091695	004	Sep 23, 2013
BX	MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012
BX		36MG	A202608	002	Dec 28, 2012
BX		54MG	A202608	003	Dec 28, 2012

## CONCERTA

JANSSEN PHARMS

18MG

N021121 001 Aug 01, 2000

27MG

N021121 004 Apr 01, 2002

36MG

N021121 002 Aug 01, 2000

+

54MG

N021121 003 Dec 08, 2000

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER

PFIZER INC

20MG

N207960 001 Dec 04, 2015

30MG

N207960 002 Dec 04, 2015

+

40MG

N207960 003 Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

<b>AB</b>	PHARMACIA AND UPJOHN	<b>2MG</b>	<b>N011153</b>	<b>002</b>	
<b>AB</b>		<b>4MG</b>	<b>N011153</b>	<b>001</b>	
<b>AB</b>		<b>8MG</b>	<b>N011153</b>	<b>004</b>	
<b>AB</b>		<b>16MG</b>	<b>N011153</b>	<b>003</b>	
<b>AB</b>	+	<b>32MG</b>	<b>N011153</b>	<b>006</b>	

METHYLPREDNISOLONE

<b>AB</b>	DURAMED PHARMS BARR	<b>4MG</b>	<b>A088497</b>	<b>001</b>	Feb 21, 1984
<b>AB</b>	JUBILANT CADISTA	<b>4MG</b>	<b>A040189</b>	<b>001</b>	Oct 31, 1997
<b>AB</b>		<b>8MG</b>	<b>A040189</b>	<b>002</b>	Oct 31, 1997
<b>AB</b>		<b>16MG</b>	<b>A040189</b>	<b>003</b>	Jul 20, 2007
<b>AB</b>		<b>32MG</b>	<b>A040189</b>	<b>004</b>	Jul 20, 2007
<b>AB</b>	SANDOZ	<b>4MG</b>	<b>A040194</b>	<b>001</b>	Oct 31, 1997
<b>AB</b>	VINTAGE PHARMS	<b>4MG</b>	<b>A040183</b>	<b>001</b>	Dec 22, 1998
<b>AB</b>	WATSON LABS	<b>4MG</b>	<b>A040232</b>	<b>001</b>	Oct 16, 1997

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

<b>AB</b>	+	PHARMACIA AND UPJOHN	<b>40MG/ML</b>	<b>N011757</b>	<b>001</b>
<b>AB</b>	+		<b>80MG/ML</b>	<b>N011757</b>	<b>004</b>

METHYLPREDNISOLONE ACETATE

<b>AB</b>	SANDOZ	<b>40MG/ML</b>	<b>A040719</b>	<b>001</b>	Jan 29, 2009
<b>AB</b>		<b>40MG/ML</b>	<b>A040794</b>	<b>001</b>	Mar 05, 2009
<b>AB</b>		<b>80MG/ML</b>	<b>A040719</b>	<b>002</b>	Jan 29, 2009
<b>AB</b>		<b>80MG/ML</b>	<b>A040794</b>	<b>002</b>	Mar 05, 2009
<b>AB</b>	TEVA PHARMS USA	<b>40MG/ML</b>	<b>A040557</b>	<b>001</b>	Feb 23, 2005
<b>AB</b>		<b>40MG/ML</b>	<b>A040620</b>	<b>001</b>	Oct 27, 2006
<b>AB</b>		<b>80MG/ML</b>	<b>A040557</b>	<b>002</b>	Feb 23, 2005
<b>AB</b>		<b>80MG/ML</b>	<b>A040620</b>	<b>002</b>	Oct 27, 2006

## DEPO-MEDROL

+ PHARMACIA AND UPJOHN

20MG/ML

N011757 002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-METHAPRED

<b>AP</b>	HOSPIRA	<b>EQ 40MG BASE/VIAL</b>	<b>A040664</b>	<b>001</b>	Dec 20, 2005
<b>AP</b>		<b>EQ 125MG BASE/VIAL</b>	<b>A040665</b>	<b>001</b>	Dec 20, 2005
<b>AP</b>	HOSPIRA INC	<b>EQ 40MG BASE/VIAL</b>	<b>A040793</b>	<b>001</b>	Nov 25, 2008
<b>AP</b>		<b>EQ 125MG BASE/VIAL</b>	<b>A040827</b>	<b>001</b>	Nov 25, 2008

METHYLPREDNISOLONE SODIUM SUCCINATE

<b>AP</b>	AUROBINDO PHARMA LTD	<b>EQ 40MG BASE/VIAL</b>	<b>A207667</b>	<b>001</b>	Dec 15, 2015
<b>AP</b>		<b>EQ 125MG BASE/VIAL</b>	<b>A207667</b>	<b>002</b>	Dec 15, 2015
<b>AP</b>		<b>EQ 500MG BASE/VIAL</b>	<b>A207667</b>	<b>003</b>	Dec 15, 2015
<b>AP</b>		<b>EQ 2GM BASE/VIAL</b>	<b>A207667</b>	<b>004</b>	Dec 15, 2015
<b>AP</b>	FRESENIUS KABI USA	<b>EQ 40MG BASE/VIAL</b>	<b>A040583</b>	<b>001</b>	Jul 30, 2004
<b>AP</b>		<b>EQ 125MG BASE/VIAL</b>	<b>A040583</b>	<b>002</b>	Jul 30, 2004
<b>AP</b>		<b>EQ 1GM BASE/VIAL</b>	<b>A040612</b>	<b>001</b>	Aug 12, 2004
<b>AP</b>	MUSTAFA NEVSAT	<b>EQ 40MG BASE/VIAL</b>	<b>A040888</b>	<b>001</b>	Jul 18, 2011
<b>AP</b>		<b>EQ 125MG BASE/VIAL</b>	<b>A040888</b>	<b>002</b>	Jul 18, 2011
<b>AP</b>		<b>EQ 500MG BASE/VIAL</b>	<b>A040888</b>	<b>003</b>	Jul 18, 2011

## PRESCRIPTION DRUG PRODUCT LIST

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040888 004</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A040888 005</u>	Jul 18, 2011
<u>SOLU-MEDROL</u>				
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856 003</u>	
<u>AP</u>	+	<u>EQ 125MG BASE/VIAL</u>	<u>N011856 004</u>	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N011856 005</u>	
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N011856 006</u>	
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N011856 007</u>	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

<u>AB</u>	IMPAX LABS INC	<u>10MG</u>	<u>A204851 001</u>	Sep 21, 2015
<u>TESTRED</u>				
<u>AB</u>	+ VALEANT PHARM INTL	<u>10MG</u>	<u>A083976 001</u>	
TABLET; ORAL				
ANDROID 10				
BP	VALEANT PHARM INTL	10MG	A086450 001	
ANDROID 25				
BP	VALEANT PHARM INTL	25MG	A087147 001	
METHYLTESTOSTERONE				
BP	IMPAX LABS	10MG	A080767 002	
BP		25MG	A084310 001	

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

<u>AT</u>	ALCON RES LTD	<u>0.3%</u>	<u>A075720 001</u>	Aug 06, 2001
<u>OPTIPRANOLOL</u>				
<u>AT</u>	+ BAUSCH AND LOMB	<u>0.3%</u>	<u>N019907 001</u>	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 5MG BASE/ML</u>	<u>A204756 001</u>	Dec 20, 2013
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>				
<u>AP</u>	BD RX	<u>EQ 5MG BASE/ML</u>	<u>A091392 001</u>	Apr 19, 2013
<u>AP</u>	+ HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A073118 001</u>	Jan 17, 1991
<u>AP</u>	TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A073135 001</u>	Nov 27, 1991

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A071402 001</u>	Jun 25, 1993
<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A072744 001</u>	May 28, 1991
<u>AA</u>	SILARX	<u>EQ 5MG BASE/5ML</u>	<u>A073680 001</u>	Oct 27, 1992
<u>AA</u>	VISTAPHARM	<u>EQ 5MG BASE/5ML</u>	<u>A075051 001</u>	Jan 26, 2001
<u>AA</u>	+ WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A074703 001</u>	Oct 31, 1997

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>	IPCA LABS LTD	<u>EQ 5MG BASE</u>	<u>A078807 001</u>	Jun 12, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078807 002</u>	Jun 12, 2008
<u>AB</u>	MUTUAL PHARM	<u>EQ 5MG BASE</u>	<u>A071536 002</u>	Jan 16, 1997
<u>AB</u>	NORTHSTAR HLTHCARE	<u>EQ 5MG BASE</u>	<u>A078374 001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078374 002</u>	Nov 30, 2007
<u>AB</u>	PAR PHARM INC	<u>EQ 10MG BASE</u>	<u>A070581 001</u>	Oct 17, 1985
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A072801 001</u>	Jun 15, 1993
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A070184 001</u>	Jul 29, 1985
<u>AB</u>	VINTAGE PHARMS	<u>EQ 5MG BASE</u>	<u>A077878 001</u>	Aug 28, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077878 002</u>	Aug 28, 2006
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072750 001</u>	Dec 28, 1995
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A071250 001</u>	Feb 03, 1988

REGLAN

<u>AB</u>	ANI PHARMS	<u>EQ 5MG BASE</u>	<u>N017854 002</u>	May 05, 1987
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N017854 001</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>	NOVEL LABS INC	<u>EQ 5MG BASE</u>	<u>A202191 001</u>	Aug 15, 2014
<u>METZOZOLV ODT</u>				
<u>AB</u>	+ SALIX PHARMS	<u>EQ 5MG BASE</u>	<u>N022246 001</u>	Sep 04, 2009
METOCLOPRAMIDE HYDROCHLORIDE				
	NOVEL LABS INC	EQ 10MG BASE	A202191 002	Aug 15, 2014

## PRESCRIPTION DRUG PRODUCT LIST

METOLAZONE

TABLET; ORAL

METOLAZONE

<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076698 001</u>	Dec 23, 2003
<u>AB</u>		<u>5MG</u>	<u>A076698 002</u>	Oct 19, 2004
<u>AB</u>		<u>10MG</u>	<u>A076698 003</u>	Oct 19, 2004
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076732 001</u>	Dec 19, 2003
<u>AB</u>		<u>5MG</u>	<u>A076466 001</u>	Dec 19, 2003
<u>AB</u>		<u>10MG</u>	<u>A076466 002</u>	Dec 19, 2003

ZAROXOLYN

<u>AB</u>	UCB INC	<u>2.5MG</u>	<u>N017386 001</u>	
<u>AB</u>	+	<u>5MG</u>	<u>N017386 002</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017386 003</u>	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 25MG TARTRATE</u>	<u>A077118 001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076862 001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A077298 001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A077298 002</u>	Apr 15, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG TARTRATE</u>	<u>A090617 001</u>	Aug 01, 2012
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090617 002</u>	Aug 01, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG TARTRATE</u>	<u>A202033 001</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A202033 002</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A202033 003</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A202033 004</u>	Dec 15, 2011
<u>AB</u>	REDDYS	<u>EQ 100MG TARTRATE</u>	<u>A078889 001</u>	Aug 15, 2012
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A078889 002</u>	Aug 15, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615 001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615 002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615 003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615 004</u>	Jul 22, 2010

TOPROL-XL

<u>AB</u>	ASTRAZENECA PHARMS	<u>EQ 25MG TARTRATE</u>	<u>N019962 004</u>	Feb 05, 2001
<u>AB</u>	+	<u>EQ 50MG TARTRATE</u>	<u>N019962 001</u>	Jan 10, 1992
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>N019962 002</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 200MG TARTRATE</u>	<u>N019962 003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

<u>AP</u>	+	NOVARTIS	<u>1MG/ML</u>	<u>N018704 001</u>	Mar 30, 1984
-----------	---	----------	---------------	--------------------	--------------

METOPROLOL TARTRATE

<u>AP</u>	BEDFORD LABS	<u>1MG/ML</u>	<u>A076495 001</u>	Jul 07, 2003
<u>AP</u>	CLARIS PHARMASERVICE	<u>1MG/ML</u>	<u>A078950 001</u>	Apr 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045 001</u>	Oct 25, 2010
<u>AP</u>	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A204205 001</u>	Aug 27, 2014
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761 001</u>	May 30, 2007
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074133 001</u>	Dec 21, 1993
<u>AP</u>		<u>1MG/ML</u>	<u>A075160 001</u>	Jul 06, 1998
<u>AP</u>		<u>1MG/ML</u>	<u>A078085 001</u>	Apr 29, 2008
<u>AP</u>	LUITPOLD	<u>1MG/ML</u>	<u>A090386 001</u>	Sep 30, 2009
<u>AP</u>		<u>1MG/ML</u>	<u>A091307 001</u>	Dec 29, 2010
<u>AP</u>	SAGENT STRIDES	<u>1MG/ML</u>	<u>A090317 001</u>	Apr 19, 2010
<u>AP</u>	SANDOZ	<u>1MG/ML</u>	<u>A077360 001</u>	Oct 02, 2007

TABLET; ORAL

LOPRESSOR

<u>AB</u>	US PHARMS HOLDINGS I	<u>50MG</u>	<u>N017963 001</u>	
<u>AB</u>		<u>100MG</u>	<u>N017963 002</u>	

METOPROLOL TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871 001</u>	May 28, 2013
<u>AB</u>		<u>50MG</u>	<u>A202871 002</u>	May 28, 2013
<u>AB</u>		<u>100MG</u>	<u>A202871 003</u>	May 28, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A077739 001</u>	Sep 11, 2007
<u>AB</u>		<u>50MG</u>	<u>A077739 002</u>	Sep 11, 2007
<u>AB</u>		<u>100MG</u>	<u>A077739 003</u>	Sep 11, 2007
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A078459 001</u>	Jun 17, 2008
<u>AB</u>		<u>50MG</u>	<u>A078459 002</u>	Jun 17, 2008
<u>AB</u>		<u>100MG</u>	<u>A078459 003</u>	Jun 17, 2008
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A073654 002</u>	Jul 15, 2009
<u>AB</u>		<u>50MG</u>	<u>A073653 001</u>	Dec 21, 1993
<u>AB</u>		<u>100MG</u>	<u>A073654 001</u>	Dec 21, 1993

## PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076704 001</u>	Jan 16, 2004
<u>AB</u>		<u>50MG</u>	<u>A076704 002</u>	Jan 16, 2004
<u>AB</u>	+	<u>100MG</u>	<u>A076704 003</u>	Jan 16, 2004
<u>AB</u>	RUBICON RES PVT LTD	<u>25MG</u>	<u>A200981 001</u>	Oct 28, 2014
<u>AB</u>		<u>50MG</u>	<u>A200981 002</u>	Oct 28, 2014
<u>AB</u>		<u>100MG</u>	<u>A200981 003</u>	Oct 28, 2014
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A073288 001</u>	Mar 25, 1994
<u>AB</u>		<u>100MG</u>	<u>A073289 001</u>	Mar 25, 1994
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A076670 001</u>	Jan 15, 2004
<u>AB</u>		<u>50MG</u>	<u>A074644 001</u>	Dec 10, 1996
<u>AB</u>		<u>100MG</u>	<u>A074644 002</u>	Dec 10, 1996
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074141 001</u>	Jan 31, 1995
<u>AB</u>		<u>100MG</u>	<u>A074141 002</u>	Jan 31, 1995
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A074217 001</u>	May 27, 1994
<u>AB</u>		<u>100MG</u>	<u>A074217 002</u>	May 27, 1994
	MYLAN	37.5MG	A076704 004	Mar 18, 2015
		75MG	A076704 005	Mar 18, 2015

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334 001</u>	May 03, 1995
<u>AB</u>		ALEMBIC LTD	<u>375MG</u>	<u>A079065 001</u>	Jun 23, 2009
<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522 001</u>	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531 001</u>	Sep 20, 1995
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408 001</u>	May 28, 2004
<u>AB</u>		G AND W LABS	<u>0.75%</u>	<u>A077549 001</u>	Dec 19, 2007
		NORITATE			
		+ VALEANT PHARMS NORTH	1%	N020743 001	Sep 26, 1997

GEL; TOPICAL

METROGEL

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N019737 001</u>	Nov 22, 1988
<u>AB</u>	+		<u>1%</u>	<u>N021789 001</u>	Jun 30, 2005
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077018 001</u>	Jun 06, 2006
<u>AB</u>		G AND W LABS INC	<u>0.75%</u>	<u>A078178 001</u>	Jan 19, 2011
<u>AB</u>		TARO	<u>0.75%</u>	<u>A077819 001</u>	Jul 18, 2006
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077547 001</u>	Jul 13, 2006
<u>AB</u>			<u>1%</u>	<u>A090903 001</u>	Jul 22, 2011

GEL; VAGINAL

METROGEL-VAGINAL

<u>AB</u>	+	MEDICIS	<u>0.75%</u>	<u>N020208 001</u>	Aug 17, 1992
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077264 001</u>	Oct 31, 2006
		VANDAZOLE			
BX		TEVA PHARMS	0.75%	N021806 001	May 20, 2005
		NUVESSA			
		+ ACTAVIS LABS UT INC	1.3%	N205223 001	Mar 24, 2014

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657 001</u>	
<u>AP</u>	+	B BRAUN	<u>500MG/100ML</u>	<u>N018900 001</u>	Sep 29, 1983
<u>AP</u>		CLARIS PHARMASERVICE	<u>500MG/100ML</u>	<u>A078084 001</u>	Mar 31, 2008
<u>AP</u>	+	HOSPIRA	<u>500MG/100ML</u>	<u>N018890 002</u>	Nov 18, 1983

LOTION; TOPICAL

METROLOTION

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020901 001</u>	Nov 24, 1998
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077197 001</u>	May 24, 2006

TABLET; ORAL

FLAGYL

<u>AB</u>		GD SEARLE LLC	<u>250MG</u>	<u>N012623 001</u>	
<u>AB</u>	+		<u>500MG</u>	<u>N012623 003</u>	

## PRESCRIPTION DRUG PRODUCT LIST

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>250MG</u>	<u>A079067</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A079067</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>	APPCO PHARMA LLC	<u>250MG</u>	<u>A205245</u>	<u>001</u>	Sep 23, 2015
<u>AB</u>		<u>500MG</u>	<u>A205245</u>	<u>002</u>	Sep 23, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A203974</u>	<u>001</u>	May 29, 2015
<u>AB</u>		<u>500MG</u>	<u>A203974</u>	<u>002</u>	May 29, 2015
<u>AB</u>	MUTUAL PHARM	<u>250MG</u>	<u>A070772</u>	<u>001</u>	Jul 16, 1986
<u>AB</u>		<u>500MG</u>	<u>A070773</u>	<u>001</u>	Jul 16, 1986
<u>AB</u>	PLIVA	<u>500MG</u>	<u>A070033</u>	<u>001</u>	Dec 06, 1984
<u>AB</u>	TEVA PHARMS USA	<u>250MG</u>	<u>A070027</u>	<u>001</u>	Nov 06, 1984
<u>AB</u>	UNICHEM LABS LTD	<u>250MG</u>	<u>A203458</u>	<u>001</u>	Jan 22, 2014
<u>AB</u>		<u>500MG</u>	<u>A203458</u>	<u>002</u>	Jan 22, 2014
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A070035</u>	<u>001</u>	Dec 20, 1984
<u>AB</u>	WATSON LABS INC	<u>500MG</u>	<u>A070044</u>	<u>001</u>	Feb 08, 1985

TABLET, EXTENDED RELEASE;ORAL

FLAGYL ER

<u>AB</u>	+ GD SEARLE LLC	<u>750MG</u>	<u>N020868</u>	<u>001</u>	Nov 26, 1997
-----------	-----------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>	ALEMBIC LTD	<u>750MG</u>	<u>A090222</u>	<u>001</u>	May 05, 2010
-----------	-------------	--------------	----------------	------------	--------------

METYRAPONE

CAPSULE;ORAL

METOPIRONE

	+ HRA PHARMA	250MG	N012911	002	Aug 09, 1996
--	--------------	-------	---------	-----	--------------

METYROSINE

CAPSULE;ORAL

DEMSEER

	+ ATON PHARMA VPNA	250MG	N017871	001	
--	--------------------	-------	---------	-----	--

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

	TEVA	150MG	A074377	001	May 16, 1995
		200MG	A074377	002	May 16, 1995
	+	250MG	A074377	003	May 16, 1995

MICAFUNGIN SODIUM

INJECTABLE;IV (INFUSION)

MYCAMINE

	+ ASTELLAS	50MG/VIAL	N021506	002	Mar 16, 2005
	+	100MG/VIAL	N021506	003	Jun 27, 2006

MICONAZOLE

TABLET;BUCCAL

ORAVIG

	+ DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010
--	--------------------	------	---------	-----	--------------

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG</u>	<u>A073508</u>	<u>001</u>	Nov 19, 1993
-----------	----------------------	--------------	----------------	------------	--------------

MONISTAT 3

<u>AB</u>	+ MEDTECH PRODUCTS	<u>200MG</u>	<u>N018888</u>	<u>001</u>	Aug 15, 1984
-----------	--------------------	--------------	----------------	------------	--------------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

	+ DELCOR ASSET	0.25%;81.35%;15%	N021026	001	Feb 16, 2006
--	----------------	------------------	---------	-----	--------------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 1MG BASE/ML</u>	<u>A075494</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075481</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075494</u>	<u>002</u>	Jun 30, 2000
<u>AP</u>	BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075247</u>	<u>002</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075247</u>	<u>001</u>	Jun 23, 2000
<u>AP</u>	BEDFORD LABS	<u>EQ 1MG BASE/ML</u>	<u>A075421</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075421</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 1MG BASE/ML</u>	<u>A075243</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075243</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075154</u>	<u>002</u>	Jun 20, 2000

## PRESCRIPTION DRUG PRODUCT LIST

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075154 001</u>	Jun 20, 2000
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A090696 001</u>	Feb 29, 2012
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090850 001</u>	Jan 25, 2012
<u>AP</u>	HIKMA MAPLE	<u>EQ 1MG BASE/ML</u>	<u>A075324 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075324 002</u>	Jun 20, 2000
<u>AP</u>	+ HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075293 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075856 001</u>	Jun 13, 2002
<u>AP</u>	+	<u>EQ 5MG BASE/ML</u>	<u>A075293 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075856 002</u>	Jun 13, 2002

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	BD RX	<u>EQ 1MG BASE/ML</u>	<u>A203460 001</u>	Aug 22, 2014
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A203460 002</u>	Aug 22, 2014
<u>AP</u>	+ HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075857 001</u>	Jul 22, 2002
<u>AP</u>	+	<u>EQ 5MG BASE/ML</u>	<u>A075857 002</u>	Jul 22, 2002
<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090315 001</u>	Nov 29, 2010
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090315 002</u>	Nov 29, 2010

MIDAZALAM HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090316 001</u>	May 04, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090316 002</u>	May 04, 2011

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958 001</u>	Sep 04, 2003
<u>AA</u>	PADDOCK LLC	<u>EQ 2MG BASE/ML</u>	<u>A076379 001</u>	May 02, 2005
<u>AA</u>	+ ROXANE	<u>EQ 2MG BASE/ML</u>	<u>A075873 001</u>	Apr 30, 2002
<u>AA</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A076058 001</u>	Mar 15, 2002

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A077746 001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746 002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746 003</u>	Sep 12, 2006
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449 001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449 002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449 003</u>	Dec 16, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A076577 001</u>	Sep 10, 2003
<u>AB</u>	+	<u>5MG</u>	<u>A076577 002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577 003</u>	Sep 10, 2003
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076514 001</u>	Sep 11, 2003
<u>AB</u>		<u>5MG</u>	<u>A076514 002</u>	Sep 11, 2003
<u>AB</u>		<u>10MG</u>	<u>A076514 003</u>	Jul 02, 2004
<u>ORVATEN</u>				
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076725 001</u>	Nov 03, 2004
<u>AB</u>		<u>5MG</u>	<u>A076725 002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725 003</u>	Nov 03, 2004

MIFEPRISTONE

TABLET; ORAL

KORLYM

	+ CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012
	MIFEPREX			
	+ DANCO LABS LLC	200MG	N020687 001	Sep 28, 2000

MIGLITOL

TABLET; ORAL

GLYSET

<u>AB</u>	PHARMACIA AND UPJOHN	<u>25MG</u>	<u>N020682 001</u>	Dec 18, 1996
<u>AB</u>		<u>50MG</u>	<u>N020682 002</u>	Dec 18, 1996
<u>AB</u>	+	<u>100MG</u>	<u>N020682 003</u>	Dec 18, 1996

MIGLITOL

<u>AB</u>	ORIENT PHARMA CO LTD	<u>25MG</u>	<u>A203965 001</u>	Feb 24, 2015
<u>AB</u>		<u>50MG</u>	<u>A203965 002</u>	Feb 24, 2015
<u>AB</u>		<u>100MG</u>	<u>A203965 003</u>	Feb 24, 2015

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

	+ ACTELION PHARMS LTD	100MG	N021348 001	Jul 31, 2003
--	-----------------------	-------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009
		25MG	N022256	002	Jan 14, 2009
+		50MG	N022256	003	Jan 14, 2009
		100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

<u>AP</u>	BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075660</u>	<u>001</u>	May 28, 2002
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 1MG BASE/ML</u>	<u>A075530</u>	<u>001</u>	May 28, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075936</u>	<u>001</u>	May 28, 2002
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A077190</u>	<u>001</u>	Oct 31, 2006
<u>AP</u>	+ HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML</u>	<u>A077966</u>	<u>001</u>	Dec 03, 2010
<u>AP</u>	HOSPIRA INC	<u>EQ 1MG BASE/ML</u>	<u>A203280</u>	<u>001</u>	Sep 03, 2014
<u>AP</u>	INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076013</u>	<u>001</u>	Aug 02, 2002

MILRINONE LACTATE IN DEXTROSE 5%

<u>AP</u>	APOTEX INC	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151</u>	<u>002</u>	Jul 20, 2005
-----------	------------	--	----------------	------------	--------------

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A076414</u>	<u>001</u>	Aug 18, 2004
<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>001</u>	May 28, 2002
<u>AP</u>	+	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>002</u>	May 28, 2002
<u>AP</u>	BEDFORD LABS	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>001</u>	May 21, 2008
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>002</u>	May 21, 2008
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>001</u>	May 28, 2002
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>002</u>	May 28, 2002

MILRINONE LACTATE IN PLASTIC CONTAINER

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u>	<u>001</u>	Jan 21, 2010
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u>	<u>002</u>	Jan 21, 2010

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

+	KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014
---	----------------	------	---------	-----	--------------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

<u>AB</u>	CNTY LINE PHARMS	<u>EQ 75MG BASE</u>	<u>A063067</u>	<u>002</u>	Sep 15, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063067</u>	<u>001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	PRECISION DERMAT	<u>EQ 50MG BASE</u>	<u>N050649</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050649</u>	<u>002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470</u>	<u>001</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065470</u>	<u>002</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065470</u>	<u>003</u>	Mar 11, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005</u>	<u>001</u>	Mar 23, 1999
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065005</u>	<u>003</u>	Apr 18, 2001
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065005</u>	<u>002</u>	Mar 23, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 50MG BASE</u>	<u>A090867</u>	<u>001</u>	May 13, 2013
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090867</u>	<u>002</u>	May 13, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090867</u>	<u>003</u>	May 13, 2013
<u>AB</u>	TEVA	<u>EQ 50MG BASE</u>	<u>A063011</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009</u>	<u>002</u>	Aug 12, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A063009</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>	TORRENT PHARMA INC	<u>EQ 50MG BASE</u>	<u>A065062</u>	<u>001</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065062</u>	<u>002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062</u>	<u>003</u>	Nov 30, 2000
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A063181</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063065</u>	<u>002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065</u>	<u>001</u>	Dec 30, 1991

INJECTABLE; INJECTION

MINOCIN

+	REMPEX PHARMS INC	EQ 100MG BASE/VIAL	N050444	001	
---	-------------------	--------------------	---------	-----	--

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001
---	-----------	-------------	---------	-----	--------------

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436</u>	<u>001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436</u>	<u>002</u>	Dec 26, 2007



## PRESCRIPTION DRUG PRODUCT LIST

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436 003</u>	Dec 26, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065131 001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131 002</u>	Apr 16, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A065131 003</u>	Apr 16, 2003
<u>AB</u>	TORRENT PHARMA INC	<u>EQ 50MG BASE</u>	<u>A065156 001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156 002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156 003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261 001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261 003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261 005</u>	Nov 19, 2012
<u>AB</u>	BARR LABS INC	<u>EQ 45MG BASE</u>	<u>A065485 001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A065485 004</u>	May 18, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A065485 002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A065485 005</u>	May 18, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A065485 003</u>	Mar 17, 2009
<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG BASE</u>	<u>A090024 001</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090024 002</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090024 003</u>	Feb 03, 2009
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424 004</u>	Nov 30, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 45MG BASE</u>	<u>A090911 001</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A203443 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090911 002</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203443 003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090911 003</u>	Jul 20, 2010
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422 001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422 002</u>	Aug 13, 2009
<u>AB</u>	+	<u>EQ 135MG BASE</u>	<u>A090422 003</u>	Aug 13, 2009
<u>AB</u>	SIDMAK LABS INDIA	<u>EQ 45MG BASE</u>	<u>A204394 001</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204394 004</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204394 005</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204394 007</u>	Dec 30, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 45MG BASE</u>	<u>A091118 001</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091118 004</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091118 005</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A091118 006</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091118 008</u>	Sep 25, 2014
<u>SOLODYN</u>				
<u>AB</u>	MEDICIS	<u>EQ 65MG BASE</u>	<u>N050808 004</u>	Jul 23, 2009
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>N050808 007</u>	Aug 27, 2010
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>N050808 006</u>	Aug 27, 2010
<u>AB</u>	+	<u>EQ 115MG BASE</u>	<u>N050808 005</u>	Jul 23, 2009
		EQ 55MG BASE	N050808 008	Aug 27, 2010

MINOXIDIL

TABLET; ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708 001</u>	Dec 14, 1995
<u>AB</u>		<u>10MG</u>	<u>A072709 001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826 001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839 001</u>	Nov 14, 1988
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344 001</u>	Mar 03, 1987
<u>AB</u>	+	<u>10MG</u>	<u>A071345 001</u>	Mar 03, 1987

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+ GENZYME CORP 200MG/ML (200MG/ML) N203568 001 Jan 29, 2013

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

APGDI 25MG N202611 001 Jun 28, 2012

+ 50MG N202611 002 Jun 28, 2012

## PRESCRIPTION DRUG PRODUCT LIST

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>15MG</u>	<u>A076336 001</u>	Jun 20, 2003
<u>AB</u>		<u>30MG</u>	<u>A076336 002</u>	Jun 20, 2003
<u>AB</u>		<u>45MG</u>	<u>A076336 003</u>	Jun 20, 2003
<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666 001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666 002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666 003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921 001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921 002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921 003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921 004</u>	Oct 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122 003</u>	Jun 19, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A076176 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076176 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076176 003</u>	Jun 19, 2003
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A076219 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219 003</u>	Jun 19, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A076541 004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541 001</u>	Apr 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076541 002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541 003</u>	Apr 22, 2004
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119 001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119 002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119 003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076312 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076312 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076312 003</u>	Jun 19, 2003

REMERON

<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N020415 001</u>	Jun 14, 1996
<u>AB</u>		<u>30MG</u>	<u>N020415 002</u>	Jun 14, 1996
<u>AB</u>		<u>45MG</u>	<u>N020415 003</u>	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>15MG</u>	<u>A076307 001</u>	Dec 17, 2003
<u>AB</u>		<u>30MG</u>	<u>A076307 002</u>	Dec 17, 2003
<u>AB</u>		<u>45MG</u>	<u>A076307 003</u>	Feb 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376 002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376 003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376 004</u>	Feb 28, 2006
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076901 001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901 002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901 003</u>	Jun 28, 2005

REMERON SOLTAB

<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N021208 001</u>	Jan 12, 2001
<u>AB</u>		<u>30MG</u>	<u>N021208 002</u>	Jan 12, 2001
<u>AB</u>		<u>45MG</u>	<u>N021208 003</u>	Jan 12, 2001

MISOPROSTOL

TABLET; ORAL

CYTOTEK

<u>AB</u>	GD SEARLE LLC	<u>0.1MG</u>	<u>N019268 003</u>	Sep 21, 1990
<u>AB</u>	+	<u>0.2MG</u>	<u>N019268 001</u>	Dec 27, 1988

MISOPROSTOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.1MG</u>	<u>A076095 001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095 002</u>	Jul 10, 2002
<u>AB</u>	NOVEL LABS INC	<u>0.1MG</u>	<u>A091667 001</u>	Jul 25, 2012
<u>AB</u>		<u>0.2MG</u>	<u>A091667 002</u>	Jul 25, 2012

MITOMYCIN

FOR SOLUTION; TOPICAL

## MITOSOL

+ MOBIUS THERAP

0.2MG/VIAL

N022572 001 Feb 07, 2012

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	+ ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144 001</u>	Apr 30, 1998
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A064144 002</u>	Apr 30, 1998
<u>AP</u>	+	<u>40MG/VIAL</u>	<u>A064144 003</u>	Aug 11, 2009
<u>AP</u>	BEDFORD	<u>5MG/VIAL</u>	<u>A064117 001</u>	Apr 19, 1995

## PRESCRIPTION DRUG PRODUCT LIST

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

<b>AP</b>		<b>20MG/VIAL</b>	<b>A064117 002</b>	Apr 19, 1995
<b>AP</b>	HIKMA MAPLE	<b>5MG/VIAL</b>	<b>A064180 001</b>	Dec 23, 1999
<b>AP</b>		<b>20MG/VIAL</b>	<b>A064180 002</b>	Dec 23, 1999

MITOTANE

TABLET; ORAL

LYSODREN

+ BRISTOL MYERS SQUIBB 500MG N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<b>AP</b>	EUROHLTH INTL SARL	<b>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</b>	<b>A076611 001</b>	Apr 11, 2006
<b>AP</b>		<b>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</b>	<b>A076611 002</b>	Apr 11, 2006
<b>AP</b>		<b>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</b>	<b>A076611 003</b>	Apr 11, 2006
<b>AP</b>	FRESENIUS KABI USA	<b>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</b>	<b>A077496 001</b>	Apr 11, 2006
<b>AP</b>		<b>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</b>	<b>A077496 002</b>	Apr 11, 2006
<b>AP</b>		<b>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</b>	<b>A077496 003</b>	Apr 11, 2006
<b>AP</b>	+ HOSPIRA	<b>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</b>	<b>A076871 001</b>	Apr 11, 2006
<b>AP</b>	+	<b>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</b>	<b>A076871 002</b>	Apr 11, 2006
<b>AP</b>	+	<b>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</b>	<b>A076871 003</b>	Apr 11, 2006
<b>AP</b>	MYLAN INSTITUTIONAL	<b>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</b>	<b>A078980 001</b>	Apr 13, 2009
<b>AP</b>		<b>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</b>	<b>A078980 002</b>	Apr 13, 2009
<b>AP</b>	MYLAN LABS LTD	<b>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</b>	<b>A201014 001</b>	Dec 11, 2012
<b>AP</b>	TEVA PHARMS USA	<b>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</b>	<b>A077356 001</b>	Apr 11, 2006
<b>AP</b>		<b>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</b>	<b>A077356 002</b>	Apr 11, 2006
<b>AP</b>		<b>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</b>	<b>A077356 003</b>	Apr 11, 2006

MIVACURIUM CHLORIDE

SOLUTION; INTRAVENOUS

MIVACRON

	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098 004	Jan 22, 1992
	+	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098 005	Jan 22, 1992

MODAFINIL

TABLET; ORAL

MODAFINIL

<b>AB</b>	ALEMBIC LTD	<b>100MG</b>	<b>A202700 001</b>	Oct 18, 2012
<b>AB</b>		<b>200MG</b>	<b>A202700 002</b>	Oct 18, 2012
<b>AB</b>	APOTEX INC	<b>100MG</b>	<b>A077667 001</b>	Feb 03, 2014
<b>AB</b>		<b>200MG</b>	<b>A077667 002</b>	Feb 03, 2014
<b>AB</b>	AUROBINDO PHARMA LTD	<b>100MG</b>	<b>A202566 001</b>	Sep 27, 2012
<b>AB</b>		<b>200MG</b>	<b>A202566 002</b>	Sep 27, 2012
<b>AB</b>	CARLSBAD	<b>100MG</b>	<b>A076715 001</b>	Nov 01, 2012
<b>AB</b>		<b>200MG</b>	<b>A076715 002</b>	Nov 01, 2012
<b>AB</b>	HIKMA PHARMS	<b>100MG</b>	<b>A090543 001</b>	Sep 26, 2012
<b>AB</b>		<b>200MG</b>	<b>A090543 002</b>	Sep 26, 2012
<b>AB</b>	MYLAN PHARMS INC	<b>100MG</b>	<b>A076594 001</b>	Jul 16, 2012
<b>AB</b>		<b>200MG</b>	<b>A076594 002</b>	Jul 16, 2012
<b>AB</b>	ORCHID HLTHCARE	<b>100MG</b>	<b>A078963 001</b>	Sep 26, 2012
<b>AB</b>		<b>200MG</b>	<b>A078963 002</b>	Sep 26, 2012

PROVIGIL

<b>AB</b>	CEPHALON	<b>100MG</b>	<b>N020717 001</b>	Dec 24, 1998
<b>AB</b>	+	<b>200MG</b>	<b>N020717 002</b>	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<b>AB</b>	APOTEX INC	<b>7.5MG</b>	<b>A078454 001</b>	Jun 02, 2008
<b>AB</b>		<b>15MG</b>	<b>A078454 002</b>	Jun 02, 2008
<b>AB</b>	GLENMARK GENERICS	<b>7.5MG</b>	<b>A090416 001</b>	Mar 30, 2010
<b>AB</b>		<b>15MG</b>	<b>A090416 002</b>	Mar 30, 2010
<b>AB</b>	PADDOCK LLC	<b>7.5MG</b>	<b>A077536 001</b>	Nov 30, 2006
<b>AB</b>		<b>15MG</b>	<b>A077536 002</b>	Nov 30, 2006
<b>AB</b>	TEVA	<b>7.5MG</b>	<b>A076204 001</b>	May 08, 2003
<b>AB</b>		<b>15MG</b>	<b>A076204 002</b>	May 08, 2003

UNIVASC

<b>AB</b>	UCB INC	<b>7.5MG</b>	<b>N020312 001</b>	Apr 19, 1995
<b>AB</b>	+	<b>15MG</b>	<b>N020312 002</b>	Apr 19, 1995

## PRESCRIPTION DRUG PRODUCT LIST

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE  
COREPHARMA5MG  
10MG  
25MGA090453 001 Mar 20, 2015  
A090453 002 Mar 20, 2015  
A090453 003 Mar 20, 2015

+

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

MERCK SHARP DOHME

0.10MG/INH  
0.20MG/INHN205641 001 Apr 25, 2014  
N205641 002 Apr 25, 2014

+

CREAM; TOPICAL

ELOCONAB + MERCK SHARP DOHME0.1%N019625 001 May 06, 1987AB0.1%N019625 002 Apr 19, 2013MOMETASONE FUROATEAB FOUGERA PHARMS0.1%A076171 001 Apr 08, 2005AB G AND W LABS0.1%A077447 001 May 22, 2006AB GLENMARK GENERICS0.1%A078541 001 May 28, 2008AB TARO0.1%A076679 001 Dec 21, 2004AB TOLMAR0.1%A076591 001 Apr 18, 2007

LOTION; TOPICAL

ELOCONAB + MERCK SHARP DOHME0.1%N019796 001 Mar 30, 1989MOMETASONE FUROATEAB FOUGERA PHARMS0.1%A075919 001 Nov 29, 2007AB G AND W LABS0.1%A077678 001 Nov 21, 2007AB GLENMARK GENERICS0.1%A090506 001 Aug 09, 2010AB PERRIGO0.1%A077180 001 Apr 06, 2005AB TARO0.1%A076788 001 Mar 15, 2006AB TOLMAR0.1%A076499 001 Nov 21, 2007

OINTMENT; TOPICAL

ELOCONAB + MERCK SHARP DOHME0.1%N019543 001 Apr 30, 1987MOMETASONE FUROATEAB FOUGERA PHARMS0.1%A077061 001 Mar 28, 2005AB G AND W LABS0.1%A077401 001 Jun 20, 2006AB GLENMARK GENERICS0.1%A078571 001 May 28, 2008AB PERRIGO NEW YORK0.1%A076067 001 Mar 18, 2002AB TOLMAR0.1%A076481 001 Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

MERCK SHARP DOHME

0.11MG/INH  
0.22MG/INHN021067 002 Feb 01, 2008  
N021067 001 Mar 30, 2005

+

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

+ MERCK SHARP DOHME

EQ 0.05MG BASE/SPRAY

N020762 001 Oct 01, 1997

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUMAB AJANTA PHARMA LTDEQ 4MG BASE/PACKETA203438 001 Jul 31, 2015AB DR REDDYS LABS LTDEQ 4MG BASE/PACKETA202906 001 Sep 17, 2012AB MYLAN PHARMS INCEQ 4MG BASE/PACKETA202776 001 Dec 18, 2012AB TEVA PHARMSEQ 4MG BASE/PACKETA090955 001 Aug 03, 2012SINGULAIRAB + MERCKEQ 4MG BASE/PACKETN021409 001 Jul 26, 2002

TABLET; ORAL

MONTELUKAST SODIUMAB ACCORD HLTHCAREEQ 10MG BASEA202717 001 Sep 21, 2012AB AJANTA PHARMA LTDEQ 10MG BASEA203432 001 Jul 31, 2015AB AMNEAL PHARMSEQ 10MG BASEA204604 001 Sep 04, 2015AB ANBISON LAB CO LTDEQ 10MG BASEA205683 001 Jan 12, 2016AB APOTEX CORPEQ 10MG BASEA201294 001 Aug 03, 2012AB AUROBINDO PHARMA LTDEQ 10MG BASEA202468 001 Aug 03, 2012AB DR REDDYS LABS LTDEQ 10MG BASEA201582 001 Aug 06, 2012AB GLENMARK GENERICSEQ 10MG BASEA090926 001 Aug 03, 2012AB HETERO LABS LTD VEQ 10MG BASEA202843 001 Sep 10, 2014AB KREMERS URBAN PHARMSEQ 10MG BASEA201522 001 Aug 03, 2012AB MACLEODS PHARMS LTDEQ 10MG BASEA203366 001 Sep 11, 2014AB MYLAN PHARMS INCEQ 10MG BASEA079103 001 Aug 03, 2012

## PRESCRIPTION DRUG PRODUCT LIST

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

<u>AB</u>	ROXANE	<u>EQ 10MG BASE</u>	<u>A090655 001</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889 001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605 001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515 001</u>	Aug 03, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 10MG BASE</u>	<u>A204290 001</u>	Oct 08, 2015
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 10MG BASE</u>	<u>A202859 001</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 10MG BASE</u>	<u>A091576 001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+ MERCK	<u>EQ 10MG BASE</u>	<u>N020829 002</u>	Feb 20, 1998
-----------	---------	---------------------	--------------------	--------------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A203328 001</u>	Jul 31, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203328 002</u>	Jul 31, 2015
<u>AB</u>	ANBISON LAB CO LTD	<u>EQ 4MG BASE</u>	<u>A205695 001</u>	Nov 05, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A205695 002</u>	Nov 05, 2015
<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A201508 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201508 002</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096 002</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581 001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581 002</u>	Aug 06, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 4MG BASE</u>	<u>A204093 001</u>	May 22, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204093 002</u>	May 22, 2015
<u>AB</u>	JUBILANT GENERICS	<u>EQ 4MG BASE</u>	<u>A203795 001</u>	Feb 27, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203795 002</u>	Feb 27, 2015
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 4MG BASE</u>	<u>A200405 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405 002</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A203582 001</u>	Mar 12, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203582 002</u>	Mar 12, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE</u>	<u>A079142 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079142 002</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 4MG BASE</u>	<u>A091128 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091128 002</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414 002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723 002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984 002</u>	Aug 03, 2012
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 4MG BASE</u>	<u>A203037 001</u>	Oct 30, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203037 002</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 4MG BASE</u>	<u>A091588 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091588 002</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	MERCK	<u>EQ 4MG BASE</u>	<u>N020830 002</u>	Mar 03, 2000
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N020830 001</u>	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

<u>AB1</u>	+ ACTAVIS LABS UT INC	<u>10MG</u>	<u>N020616 008</u>	Apr 20, 2007
<u>AB1</u>		<u>20MG</u>	<u>N020616 001</u>	Jul 03, 1996
<u>AB1</u>		<u>30MG</u>	<u>N020616 004</u>	Mar 09, 2001
<u>AB1</u>		<u>40MG</u>	<u>N020616 009</u>	Jul 09, 2012
<u>AB1</u>		<u>50MG</u>	<u>N020616 002</u>	Jul 03, 1996
<u>AB1</u>		<u>60MG</u>	<u>N020616 005</u>	Mar 09, 2001
<u>AB1</u>		<u>70MG</u>	<u>N020616 010</u>	Jul 09, 2012
<u>AB1</u>		<u>80MG</u>	<u>N020616 006</u>	Oct 27, 2006
<u>AB1</u>	+	<u>100MG</u>	<u>N020616 003</u>	Jul 03, 1996
<u>AB1</u>	+	<u>200MG</u>	<u>N020616 007</u>	Feb 27, 2007

MORPHINE SULFATE

<u>AB1</u>	PAR PHARM INC	<u>20MG</u>	<u>A200812 001</u>	Nov 10, 2011
<u>AB1</u>		<u>30MG</u>	<u>A200812 002</u>	Nov 10, 2011
<u>AB1</u>		<u>50MG</u>	<u>A200812 003</u>	Nov 10, 2011
<u>AB1</u>		<u>60MG</u>	<u>A200812 004</u>	Nov 10, 2011
<u>AB1</u>		<u>80MG</u>	<u>A200812 005</u>	Nov 10, 2011
<u>AB1</u>		<u>100MG</u>	<u>A200812 006</u>	Nov 10, 2011
<u>AB1</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A202718 001</u>	Dec 29, 2014
<u>AB1</u>		<u>30MG</u>	<u>A202718 002</u>	Dec 29, 2014
<u>AB1</u>		<u>40MG</u>	<u>A202718 007</u>	Jun 03, 2015

## PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB1</u>		<u>50MG</u>	<u>A202718</u>	<u>003</u>	Dec 29, 2014
<u>AB1</u>		<u>60MG</u>	<u>A202718</u>	<u>004</u>	Dec 29, 2014
<u>AB1</u>		<u>70MG</u>	<u>A202718</u>	<u>008</u>	Jun 03, 2015
<u>AB1</u>		<u>80MG</u>	<u>A202718</u>	<u>005</u>	Dec 29, 2014
<u>AB1</u>		<u>100MG</u>	<u>A202718</u>	<u>006</u>	Dec 29, 2014
<u>AB1</u>	UPSHER SMITH	<u>10MG</u>	<u>A202104</u>	<u>001</u>	Jun 03, 2013
<u>AB1</u>		<u>20MG</u>	<u>A202104</u>	<u>002</u>	Jun 03, 2013
<u>AB1</u>		<u>30MG</u>	<u>A202104</u>	<u>003</u>	Jun 03, 2013
<u>AB1</u>		<u>50MG</u>	<u>A202104</u>	<u>004</u>	Jun 03, 2013
<u>AB1</u>		<u>60MG</u>	<u>A202104</u>	<u>005</u>	Jun 03, 2013
<u>AB1</u>		<u>80MG</u>	<u>A202104</u>	<u>006</u>	Jun 03, 2013
<u>AB1</u>		<u>100MG</u>	<u>A202104</u>	<u>007</u>	Jun 03, 2013
	KADIAN				
	ACTAVIS LABS UT INC	130MG	N020616	011	Jul 09, 2012
		150MG	N020616	012	Jul 09, 2012
	MORPHINE SULFATE				
	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
		45MG	A079040	002	Jan 16, 2013
		60MG	A079040	003	Jan 16, 2013
		75MG	A079040	004	Jan 16, 2013
		90MG	A079040	005	Jan 16, 2013
	+	120MG	A079040	006	Jan 16, 2013
	INJECTABLE; INJECTION				
	<u>ASTRAMORPH PF</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/ML</u>	<u>A071050</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>0.5MG/ML</u>	<u>A071051</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071052</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071053</u>	<u>001</u>	Oct 07, 1986
	<u>DURAMORPH PF</u>				
<u>AP</u>	+ EUROHLTH INTL SARL	<u>0.5MG/ML</u>	<u>N018565</u>	<u>001</u>	Sep 18, 1984
<u>AP</u>	+ "	<u>1MG/ML</u>	<u>N018565</u>	<u>002</u>	Sep 18, 1984
	<u>MORPHINE SULFATE</u>				
<u>AP</u>	EUROHLTH INTL SARL	<u>4MG/ML</u>	<u>A205758</u>	<u>001</u>	May 21, 2015
<u>AP</u>		<u>8MG/ML</u>	<u>A205758</u>	<u>002</u>	May 21, 2015
<u>AP</u>		<u>10MG/ML</u>	<u>A205758</u>	<u>003</u>	May 21, 2015
<u>AP</u>	HOSPIRA	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>		<u>1MG/ML</u>	<u>A071850</u>	<u>001</u>	May 11, 1988
<u>AP</u>		<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>	+	<u>1MG/ML</u>	<u>N019916</u>	<u>001</u>	Oct 30, 1992
<u>AP</u>	+ HOSPIRA INC	<u>4MG/ML</u>	<u>N202515</u>	<u>002</u>	Nov 14, 2011
<u>AP</u>	+	<u>8MG/ML</u>	<u>N202515</u>	<u>003</u>	Nov 14, 2011
<u>AP</u>	+	<u>10MG/ML</u>	<u>N202515</u>	<u>004</u>	Nov 14, 2011
	INFUMORPH				
	+ EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991
	+	25MG/ML	N018565	004	Jul 19, 1991
	MORPHINE SULFATE				
	+ HOSPIRA	5MG/ML	N019916	002	Oct 27, 2006
	+ HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011
	+	15MG/ML	N202515	005	Nov 14, 2011
	+ MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS				
	MORPHINE SULFATE				
	+ BD RX	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
	+	4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
	+	5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
	+	8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
	+	10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013
	SOLUTION; ORAL				
	<u>MORPHINE SULFATE</u>				
<u>AA</u>	MALLINCKRODT INC	<u>100MG/5ML</u>	<u>A202348</u>	<u>001</u>	Jul 15, 2011
<u>AA</u>	PADDOCK LLC	<u>100MG/5ML</u>	<u>A201574</u>	<u>001</u>	Aug 06, 2012
<u>AA</u>	ROXANE	<u>10MG/5ML</u>	<u>N022195</u>	<u>001</u>	Mar 17, 2008
<u>AA</u>		<u>20MG/5ML</u>	<u>N022195</u>	<u>002</u>	Mar 17, 2008
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N022195</u>	<u>003</u>	Jan 25, 2010
<u>AA</u>	SUN PHARM INDS INC	<u>10MG/5ML</u>	<u>A201011</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>		<u>20MG/5ML</u>	<u>A201011</u>	<u>002</u>	Feb 05, 2014
<u>AA</u>	TRIS PHARMA INC	<u>10MG/5ML</u>	<u>A203518</u>	<u>001</u>	May 12, 2015
<u>AA</u>		<u>100MG/5ML</u>	<u>A203518</u>	<u>002</u>	May 12, 2015

## PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

<u>AA</u>	VINTAGE PHARMS LLC	<u>10MG/5ML</u>	<u>A202309 001</u>	Nov 25, 2015
<u>AA</u>		<u>20MG/5ML</u>	<u>A202310 001</u>	Oct 30, 2015
<u>AA</u>	VISTAPHARM	<u>10MG/5ML</u>	<u>A201947 001</u>	Jan 05, 2012
<u>AA</u>		<u>20MG/5ML</u>	<u>A201947 002</u>	Jan 05, 2012
	LANNETT HOLDINGS INC	100MG/5ML	N201517 001	Jun 23, 2011

TABLET;ORAL

MORPHINE SULFATE

	ROXANE	15MG	N022207 001	Mar 17, 2008
	+	30MG	N022207 002	Mar 17, 2008

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A203849 001</u>	Apr 06, 2015
<u>AB</u>		<u>30MG</u>	<u>A203849 002</u>	Apr 06, 2015
<u>AB</u>		<u>60MG</u>	<u>A203849 003</u>	Apr 06, 2015
<u>AB</u>		<u>100MG</u>	<u>A203849 004</u>	Apr 06, 2015
<u>AB</u>		<u>200MG</u>	<u>A203849 005</u>	Apr 06, 2015
<u>AB</u>	DAVA PHARMS INC	<u>15MG</u>	<u>A075407 001</u>	Jan 28, 2000
<u>AB</u>	MALLINCKRODT	<u>15MG</u>	<u>A076412 001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412 002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412 003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438 001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438 002</u>	Jul 03, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A200824 001</u>	Oct 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A200824 002</u>	Oct 18, 2011
<u>AB</u>		<u>60MG</u>	<u>A200824 003</u>	Oct 18, 2011
<u>AB</u>		<u>100MG</u>	<u>A200824 004</u>	Oct 18, 2011
<u>AB</u>		<u>200MG</u>	<u>A200824 005</u>	Oct 18, 2011
<u>AB</u>	NESHER PHARMS	<u>15MG</u>	<u>A076733 001</u>	May 19, 2004
<u>AB</u>		<u>30MG</u>	<u>A076720 002</u>	Dec 23, 2005
<u>AB</u>		<u>60MG</u>	<u>A076720 001</u>	May 19, 2004
<u>AB</u>		<u>100MG</u>	<u>A077855 001</u>	Sep 27, 2007
<u>AB</u>		<u>200MG</u>	<u>A077855 002</u>	Sep 27, 2007
<u>AB</u>	NOVEL LABS INC	<u>15MG</u>	<u>A203602 001</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A203602 002</u>	Dec 16, 2015
<u>AB</u>		<u>60MG</u>	<u>A203602 003</u>	Dec 16, 2015
<u>AB</u>		<u>100MG</u>	<u>A203602 004</u>	Dec 16, 2015
<u>AB</u>		<u>200MG</u>	<u>A203602 005</u>	Dec 16, 2015
<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862 001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862 002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862 003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769 001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769 002</u>	Jul 02, 1998
<u>AB</u>	SUN PHARM INDS LTD	<u>15MG</u>	<u>A078761 001</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A078761 002</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A078761 003</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A078761 004</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A078761 005</u>	May 11, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295 001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295 002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295 003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295 004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295 005</u>	Sep 15, 2000

MS CONTIN

<u>AB</u>	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516 003</u>	Sep 12, 1989
<u>AB</u>		<u>30MG</u>	<u>N019516 001</u>	May 29, 1987
<u>AB</u>		<u>60MG</u>	<u>N019516 002</u>	Apr 08, 1988
<u>AB</u>	+	<u>100MG</u>	<u>N019516 004</u>	Jan 16, 1990
<u>AB</u>		<u>200MG</u>	<u>N019516 005</u>	Nov 08, 1993

MORPHABOND

	IDT	15MG	N206544 001	Oct 02, 2015
		30MG	N206544 002	Oct 02, 2015
		60MG	N206544 003	Oct 02, 2015
	+	100MG	N206544 004	Oct 02, 2015

## PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

ALPHARMA PHARMS	20MG; 0.8MG	N022321 001	Aug 13, 2009
	30MG; 1.2MG	N022321 002	Aug 13, 2009
	50MG; 2MG	N022321 003	Aug 13, 2009
+	60MG; 2.4MG	N022321 004	Aug 13, 2009
	80MG; 3.2MG	N022321 005	Aug 13, 2009
	100MG; 4MG	N022321 006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+ BAYER HLTHCARE 400MG/250ML (1.6MG/ML) N021277 001 Nov 30, 2001

MOXIFLOXACIN HYDROCHLORIDE

+ FRESENIUS KABI USA EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML) N205572 001 Apr 03, 2015

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

<b>AT1</b>	LUPIN LTD	<b>EQ 0.5% BASE</b>	<b>A202867 001</b>	Sep 04, 2014
<b>AT1</b>	WATSON LABS INC	<b>EQ 0.5% BASE</b>	<b>A202525 001</b>	Mar 06, 2015

VIGAMOX

<b>AT1</b>	+ ALCON PHARMS LTD	<b>EQ 0.5% BASE</b>	<b>N021598 001</b>	Apr 15, 2003
------------	--------------------	---------------------	--------------------	--------------

MOXEZA

<b>AT2</b>	+ ALCON PHARMS LTD	<b>EQ 0.5% BASE</b>	<b>N022428 001</b>	Nov 19, 2010
------------	--------------------	---------------------	--------------------	--------------

MOXIFLOXACIN HYDROCHLORIDE

<b>AT2</b>	LUPIN LTD	<b>EQ 0.5% BASE</b>	<b>A204079 001</b>	May 28, 2015
------------	-----------	---------------------	--------------------	--------------

TABLET; ORAL

AVELOX

<b>AB</b>	+ BAYER HLTHCARE	<b>EQ 400MG BASE</b>	<b>N021085 001</b>	Dec 10, 1999
-----------	------------------	----------------------	--------------------	--------------

MOXIFLOXACIN HYDROCHLORIDE

<b>AB</b>	AUROBINDO PHARMA LTD	<b>EQ 400MG BASE</b>	<b>A202632 001</b>	Mar 04, 2014
<b>AB</b>	DR REDDYS LABS LTD	<b>EQ 400MG BASE</b>	<b>A076938 001</b>	Mar 04, 2014
<b>AB</b>	MYLAN PHARMS INC	<b>EQ 400MG BASE</b>	<b>A204635 001</b>	Aug 31, 2015
<b>AB</b>	TEVA PHARMS USA	<b>EQ 400MG BASE</b>	<b>A077437 001</b>	Feb 18, 2014
<b>AB</b>	TORRENT PHARMS LTD	<b>EQ 400MG BASE</b>	<b>A200160 001</b>	Apr 03, 2014

MUPIROICIN

OINTMENT; TOPICAL

BACTROBAN

<b>AB</b>	+ GLAXOSMITHKLINE	<b>2%</b>	<b>N050591 001</b>	Dec 31, 1987
-----------	-------------------	-----------	--------------------	--------------

MUPIROICIN

<b>AB</b>	FOUGERA PHARMS	<b>2%</b>	<b>A065192 001</b>	Nov 30, 2005
<b>AB</b>	GLENMARK PHARMS	<b>2%</b>	<b>A090480 001</b>	Jun 08, 2011
<b>AB</b>	PERRIGO NEW YORK	<b>2%</b>	<b>A065123 001</b>	Nov 07, 2003
<b>AB</b>	TARO	<b>2%</b>	<b>A065170 001</b>	Sep 23, 2005
<b>AB</b>	TEVA	<b>2%</b>	<b>A065085 001</b>	Nov 07, 2003

CENTANY

<b>BX</b>	PERRIGO NEW YORK	<b>2%</b>	<b>N050788 001</b>	Dec 04, 2002
-----------	------------------	-----------	--------------------	--------------

MUPIROICIN CALCIUM

CREAM; TOPICAL

BACTROBAN

<b>AB</b>	+ GLAXOSMITHKLINE	<b>EQ 2% BASE</b>	<b>N050746 001</b>	Dec 11, 1997
-----------	-------------------	-------------------	--------------------	--------------

MUPIROICIN

<b>AB</b>	GLENMARK GENERICS	<b>EQ 2% BASE</b>	<b>A201587 001</b>	Jan 24, 2013
-----------	-------------------	-------------------	--------------------	--------------

OINTMENT; NASAL

BACTROBAN

+ GLAXOSMITHKLINE EQ 2% BASE N050703 001 Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT

<b>AB</b>	+ ROCHE PALO	<b>250MG</b>	<b>N050722 001</b>	May 03, 1995
-----------	--------------	--------------	--------------------	--------------

MYCOPHENOLATE MOFETIL

<b>AB</b>	ACCORD HLTHCARE	<b>250MG</b>	<b>A090253 001</b>	May 04, 2009
<b>AB</b>	ALKEM LABS LTD	<b>250MG</b>	<b>A200197 001</b>	Jun 13, 2013
<b>AB</b>	APOTEX CORP	<b>250MG</b>	<b>A090419 001</b>	Apr 22, 2009
<b>AB</b>	CADISTA PHARMS	<b>250MG</b>	<b>A090762 001</b>	Dec 15, 2014
<b>AB</b>	MYLAN	<b>250MG</b>	<b>A065520 001</b>	May 04, 2009
<b>AB</b>	ROXANE	<b>250MG</b>	<b>A065410 001</b>	Jul 29, 2008
<b>AB</b>	SANDOZ	<b>250MG</b>	<b>A065379 001</b>	Oct 15, 2008
<b>AB</b>	STRIDES PHARMA	<b>250MG</b>	<b>A090055 001</b>	Jun 10, 2010
<b>AB</b>	TEVA PHARMS	<b>250MG</b>	<b>A065491 001</b>	May 06, 2009
<b>AB</b>	VINTAGE PHARMS LLC	<b>250MG</b>	<b>A090111 001</b>	Dec 22, 2009



## PRESCRIPTION DRUG PRODUCT LIST

MYCOPHENOLATE MOFETIL

SUSPENSION; ORAL

CELLCEPT

<b>AB</b>	+ ROCHE PALO	<b>200MG/ML</b>	<b>N050759 001</b>	Oct 01, 1998
-----------	--------------	-----------------	--------------------	--------------

MYCOPHENOLATE MOFETIL

<b>AB</b>	ALKEM LABS LTD	<b>200MG/ML</b>	<b>A203005 001</b>	Nov 14, 2014
-----------	----------------	-----------------	--------------------	--------------

TABLET; ORAL

CELLCEPT

<b>AB</b>	+ ROCHE PALO	<b>500MG</b>	<b>N050723 001</b>	Jun 19, 1997
-----------	--------------	--------------	--------------------	--------------

MYCOPHENOLATE MOFETIL

<b>AB</b>	ACCORD HLTHCARE	<b>500MG</b>	<b>A065416 001</b>	May 04, 2009
-----------	-----------------	--------------	--------------------	--------------

<b>AB</b>	ALKEM LABS LTD	<b>500MG</b>	<b>A091249 001</b>	Nov 04, 2011
-----------	----------------	--------------	--------------------	--------------

<b>AB</b>	APOTEX	<b>500MG</b>	<b>A090499 001</b>	Apr 22, 2009
-----------	--------	--------------	--------------------	--------------

<b>AB</b>	CADISTA PHARMS	<b>500MG</b>	<b>A090661 001</b>	Dec 15, 2014
-----------	----------------	--------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>500MG</b>	<b>A065521 001</b>	May 04, 2009
-----------	-------	--------------	--------------------	--------------

<b>AB</b>	ROXANE	<b>500MG</b>	<b>A065413 001</b>	Jul 29, 2008
-----------	--------	--------------	--------------------	--------------

<b>AB</b>	SANDOZ	<b>500MG</b>	<b>A065451 001</b>	Oct 15, 2008
-----------	--------	--------------	--------------------	--------------

<b>AB</b>	STRIDES PHARMA	<b>500MG</b>	<b>A090456 001</b>	Jun 10, 2010
-----------	----------------	--------------	--------------------	--------------

<b>AB</b>	TEVA PHARMS	<b>500MG</b>	<b>A065457 001</b>	May 04, 2009
-----------	-------------	--------------	--------------------	--------------

<b>AB</b>	VINTAGE PHARMS LLC	<b>500MG</b>	<b>A090606 001</b>	Jul 16, 2010
-----------	--------------------	--------------	--------------------	--------------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

	+ ROCHE PALO	500MG/VIAL	N050758 001	Aug 12, 1998
--	--------------	------------	-------------	--------------

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

<b>AB</b>	APOTEX INC	<b>180MG</b>	<b>A091558 001</b>	Aug 21, 2012
-----------	------------	--------------	--------------------	--------------

<b>AB</b>		<b>360MG</b>	<b>A091558 002</b>	Aug 19, 2014
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<b>180MG</b>	<b>A091248 002</b>	Jan 08, 2014
-----------	------------------	--------------	--------------------	--------------

<b>AB</b>		<b>360MG</b>	<b>A091248 001</b>	Jan 08, 2014
-----------	--	--------------	--------------------	--------------

<b>AB</b>	TEVA PHARMS USA	<b>180MG</b>	<b>A202720 001</b>	Oct 30, 2014
-----------	-----------------	--------------	--------------------	--------------

<b>AB</b>		<b>360MG</b>	<b>A202720 002</b>	Oct 30, 2014
-----------	--	--------------	--------------------	--------------

MYFORTIC

<b>AB</b>	NOVARTIS	<b>180MG</b>	<b>N050791 001</b>	Feb 27, 2004
-----------	----------	--------------	--------------------	--------------

<b>AB</b>	+	<b>360MG</b>	<b>N050791 002</b>	Feb 27, 2004
-----------	---	--------------	--------------------	--------------

NABILONE

CAPSULE; ORAL

CESAMET

	+ MEDA PHARMS	1MG	N018677 001	Dec 26, 1985
--	---------------	-----	-------------	--------------

NABUMETONE

TABLET; ORAL

NABUMETONE

<b>AB</b>	APOTEX INC	<b>500MG</b>	<b>A090427 001</b>	Dec 30, 2011
-----------	------------	--------------	--------------------	--------------

<b>AB</b>		<b>750MG</b>	<b>A090427 002</b>	Dec 30, 2011
-----------	--	--------------	--------------------	--------------

<b>AB</b>	INVAGEN PHARMS	<b>500MG</b>	<b>A078671 001</b>	Mar 07, 2008
-----------	----------------	--------------	--------------------	--------------

<b>AB</b>		<b>750MG</b>	<b>A078671 002</b>	Mar 07, 2008
-----------	--	--------------	--------------------	--------------

<b>AB</b>	LUPIN LTD	<b>500MG</b>	<b>A090445 001</b>	Jan 12, 2011
-----------	-----------	--------------	--------------------	--------------

<b>AB</b>		<b>750MG</b>	<b>A090445 002</b>	Jan 12, 2011
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<b>500MG</b>	<b>A090516 001</b>	Jul 12, 2010
-----------	------------------	--------------	--------------------	--------------

<b>AB</b>		<b>750MG</b>	<b>A090516 002</b>	Jul 12, 2010
-----------	--	--------------	--------------------	--------------

<b>AB</b>	PAR PHARM	<b>500MG</b>	<b>A076009 001</b>	Jan 24, 2003
-----------	-----------	--------------	--------------------	--------------

<b>AB</b>		<b>750MG</b>	<b>A076009 002</b>	Jan 24, 2003
-----------	--	--------------	--------------------	--------------

<b>AB</b>	SANDOZ	<b>500MG</b>	<b>A075280 001</b>	Feb 25, 2002
-----------	--------	--------------	--------------------	--------------

<b>AB</b>		<b>750MG</b>	<b>A075280 002</b>	Feb 25, 2002
-----------	--	--------------	--------------------	--------------

<b>AB</b>	TEVA	<b>500MG</b>	<b>A075189 001</b>	May 26, 2000
-----------	------	--------------	--------------------	--------------

<b>AB</b>	+	<b>750MG</b>	<b>A075189 002</b>	Sep 24, 2001
-----------	---	--------------	--------------------	--------------

<b>AB</b>	WATSON LABS	<b>500MG</b>	<b>A091083 001</b>	Jun 13, 2011
-----------	-------------	--------------	--------------------	--------------

<b>AB</b>		<b>750MG</b>	<b>A091083 002</b>	Jun 13, 2011
-----------	--	--------------	--------------------	--------------

NADOLOL

TABLET; ORAL

CORGARD

<b>AB</b>	US WORLD MEDS LLC	<b>20MG</b>	<b>N018063 005</b>	Oct 28, 1986
-----------	-------------------	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>N018063 001</b>	
-----------	--	-------------	--------------------	--

<b>AB</b>	+	<b>80MG</b>	<b>N018063 002</b>	
-----------	---	-------------	--------------------	--

NADOLOL

<b>AB</b>	INVAGEN PHARMS	<b>20MG</b>	<b>A203455 001</b>	Dec 18, 2015
-----------	----------------	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A203455 002</b>	Dec 18, 2015
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>80MG</b>	<b>A203455 003</b>	Dec 18, 2015
-----------	--	-------------	--------------------	--------------

<b>AB</b>	IVAX SUB TEVA PHARMS	<b>20MG</b>	<b>A074229 001</b>	Aug 30, 1996
-----------	----------------------	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

NADOLOL

TABLET; ORAL

NADOLOL

<u>AB</u>		<u>40MG</u>	<u>A074229 002</u>	Aug 30, 1996
<u>AB</u>		<u>80MG</u>	<u>A074255 001</u>	Jan 24, 1996
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074172 001</u>	Oct 31, 1993
<u>AB</u>		<u>40MG</u>	<u>A074172 002</u>	Oct 31, 1993
<u>AB</u>		<u>80MG</u>	<u>A074172 003</u>	Oct 31, 1993
<u>AB</u>	ORION CORP ORION	<u>40MG</u>	<u>A201893 001</u>	Sep 16, 2015
<u>AB</u>		<u>80MG</u>	<u>A201893 002</u>	Sep 16, 2015
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A074501 001</u>	Nov 09, 1995
<u>AB</u>		<u>40MG</u>	<u>A074501 002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501 003</u>	Nov 09, 1995

NAFARELIN ACETATE

SPRAY, METERED; NASAL

SYNAREL

+ GD SEARLE LLC

EQ 0.2MG BASE/SPRAY

N019886 001 Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL</u>	<u>A090560 001</u>	Oct 03, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090560 002</u>	Oct 03, 2011
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091613 001</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091613 002</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091614 001</u>	Dec 26, 2012
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A090002 001</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090002 002</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090005 001</u>	Apr 20, 2011
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A200002 001</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200002 002</u>	Apr 07, 2014
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A090582 001</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090582 002</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090580 001</u>	Aug 24, 2012
<u>AP</u>	+ SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062527 002</u>	Aug 02, 1984
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062732 001</u>	Dec 23, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062527 003</u>	Aug 02, 1984
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062732 002</u>	Dec 23, 1986
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062527 004</u>	Aug 02, 1984
	NALLPEN IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655 001	Oct 31, 1989
	+	EQ 2GM BASE/100ML	N050655 002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

<u>AB</u>	TARO	<u>2%</u>	<u>A206901 001</u>	Jan 06, 2016
	<u>NAFTIN</u>			
<u>AB</u>	+ MERZ PHARMS	<u>2%</u>	<u>N019599 002</u>	Jan 13, 2012
	+	1%	N019599 001	Feb 29, 1988
	GEL; TOPICAL			
	NAFTIN			
	+ MERZ PHARMS	1%	N019356 001	Jun 18, 1990
	+	2%	N204286 001	Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA	<u>10MG/ML</u>	<u>A070914 001</u>	Feb 03, 1989
<u>AP</u>	+	<u>10MG/ML</u>	<u>A070915 001</u>	Feb 03, 1989
<u>AP</u>	+	<u>20MG/ML</u>	<u>A070916 001</u>	Feb 03, 1989
<u>AP</u>	+	<u>20MG/ML</u>	<u>A070918 001</u>	Feb 03, 1989

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

+ ARAZENECA PHARMS

EQ 12.5MG BASE

N204760 001 Sep 16, 2014

+

EQ 25MG BASE

N204760 002 Sep 16, 2014

## PRESCRIPTION DRUG PRODUCT LIST

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

<b>AP</b>	EUROHLTH INTL SARL	<b>0.4MG/ML</b>	<b>A070299 001</b>	Sep 24, 1986
<u>NALOXONE HYDROCHLORIDE</u>				
<b>AP</b>	+ HOSPIRA	<b>0.4MG/ML</b>	<b>A070172 001</b>	Sep 24, 1986
<b>AP</b>	+	<b>0.4MG/ML</b>	<b>A070254 001</b>	Jan 07, 1987
<b>AP</b>	+	<b>0.4MG/ML</b>	<b>A070256 001</b>	Jan 07, 1987
<b>AP</b>	+	<b>0.4MG/ML</b>	<b>A070257 001</b>	Jan 07, 1987
<b>AP</b>	INTL MEDICATION	<b>0.4MG/ML</b>	<b>A070639 001</b>	Sep 24, 1986
<b>AP</b>	+	<b>1MG/ML</b>	<b>A072076 001</b>	Mar 24, 1988
<b>AP</b>	MYLAN INSTITUTIONAL	<b>0.4MG/ML</b>	<b>A204997 001</b>	Mar 06, 2014
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS				
EVZIO				
	+ KALEO INC	0.4MG/0.4ML	N205787 001	Apr 03, 2014
SPRAY, METERED; NASAL				
NARCAN				
	+ ADAPT PHARMA	4MG/SPRAY	N208411 001	Nov 18, 2015

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

<b>AB</b>	GAVIS PHARMS	<b>EQ 0.5MG BASE; EQ 50MG BASE</b>	<b>A075735 001</b>	Jul 11, 2001
<b>AB</b>	SUN PHARM INDS LTD	<b>EQ 0.5MG BASE; EQ 50MG BASE</b>	<b>A075523 001</b>	Mar 17, 2000
<b>AB</b>	+ WATSON LABS	<b>EQ 0.5MG BASE; EQ 50MG BASE</b>	<b>A074736 001</b>	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+ ALKERMES

380MG/VIAL

N021897 001 Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

<b>AB</b>	ACCORD HLTHCARE	<b>50MG</b>	<b>A091205 001</b>	Aug 17, 2011
<b>AB</b>	BARR	<b>50MG</b>	<b>A074918 001</b>	May 08, 1998
<b>AB</b>	ELITE LABS	<b>50MG</b>	<b>A075274 001</b>	May 26, 1999
<b>AB</b>	MALLINCKRODT	<b>50MG</b>	<b>A076264 002</b>	Mar 22, 2002
<b>AB</b>	SUN PHARMA GLOBAL	<b>50MG</b>	<b>A090356 001</b>	Feb 24, 2012
<u>REVIA</u>				
<b>AB</b>	+ TEVA WOMENS	<b>50MG</b>	<b>N018932 001</b>	Nov 20, 1984
NALTREXONE HYDROCHLORIDE				
	MALLINCKRODT	25MG	A076264 001	Mar 22, 2002
		100MG	A076264 003	Mar 22, 2002

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

+ PHARMAFORCE

200MG/ML

A091252 001 Aug 30, 2010

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

+ AKORN INC

0.1%

A083590 001

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

<b>AB</b>	+ PEDIAPHARM INC	<b>25MG/ML</b>	<b>N018965 001</b>	Mar 23, 1987
-----------	------------------	----------------	--------------------	--------------

NAPROXEN

<b>AB</b>	ROXANE	<b>25MG/ML</b>	<b>A074190 001</b>	Mar 30, 1994
-----------	--------	----------------	--------------------	--------------

TABLET; ORAL

NAPROSYN

<b>AB</b>	ROCHE PALO	<b>250MG</b>	<b>N017581 002</b>	
<b>AB</b>		<b>375MG</b>	<b>N017581 003</b>	
<b>AB</b>	+	<b>500MG</b>	<b>N017581 004</b>	Apr 15, 1982

NAPROXEN

<b>AB</b>	AMNEAL PHARMS NY	<b>250MG</b>	<b>A075927 001</b>	Dec 18, 2001
<b>AB</b>		<b>375MG</b>	<b>A075927 002</b>	Dec 18, 2001
<b>AB</b>		<b>500MG</b>	<b>A075927 003</b>	Dec 18, 2001
<b>AB</b>	AUROBINDO PHARMA USA	<b>250MG</b>	<b>A200429 001</b>	Nov 08, 2011
<b>AB</b>		<b>375MG</b>	<b>A200429 002</b>	Nov 08, 2011
<b>AB</b>		<b>500MG</b>	<b>A200429 003</b>	Nov 08, 2011
<b>AB</b>	GLENMARK GENERICS	<b>250MG</b>	<b>A078250 001</b>	Mar 28, 2007
<b>AB</b>		<b>375MG</b>	<b>A078250 002</b>	Mar 28, 2007

## PRESCRIPTION DRUG PRODUCT LIST

## NAPROXEN

TABLET; ORAL

NAPROXEN

<u>AB</u>		<u>500MG</u>	<u>A078250 003</u>	Mar 28, 2007
<u>AB</u>	HIKMA INTL PHARMS	<u>250MG</u>	<u>A076494 001</u>	Jan 14, 2004
<u>AB</u>		<u>375MG</u>	<u>A076494 002</u>	Jan 14, 2004
<u>AB</u>		<u>500MG</u>	<u>A076494 003</u>	Jan 14, 2004
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A091305 001</u>	Aug 24, 2011
<u>AB</u>		<u>375MG</u>	<u>A091305 002</u>	Aug 24, 2011
<u>AB</u>		<u>500MG</u>	<u>A091305 003</u>	Aug 24, 2011
<u>AB</u>	MARKSANS PHARMA	<u>250MG</u>	<u>A091416 001</u>	Feb 14, 2011
<u>AB</u>		<u>375MG</u>	<u>A091416 002</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A091416 003</u>	Feb 14, 2011
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A074121 001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074121 002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074121 003</u>	Dec 21, 1993
<u>AB</u>	PERRIGO R AND D	<u>250MG</u>	<u>A077339 001</u>	Apr 27, 2005
<u>AB</u>		<u>375MG</u>	<u>A077339 002</u>	Apr 27, 2005
<u>AB</u>		<u>500MG</u>	<u>A077339 003</u>	Apr 27, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A074140 001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074140 002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074140 003</u>	Dec 21, 1993
<u>AB</u>	TEVA	<u>250MG</u>	<u>A074201 001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074201 002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074201 003</u>	Dec 21, 1993
<u>AB</u>	ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620 001</u>	Jun 07, 2007
<u>AB</u>		<u>375MG</u>	<u>A078620 002</u>	Jun 07, 2007
<u>AB</u>		<u>500MG</u>	<u>A078620 003</u>	Jun 07, 2007

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

<u>AB</u>	+ ROCHE PALO	<u>375MG</u>	<u>N020067 002</u>	Oct 14, 1994
<u>AB</u>	+	<u>500MG</u>	<u>N020067 003</u>	Oct 14, 1994

NAPROXEN

<u>AB</u>	INVAGEN PHARMS	<u>375MG</u>	<u>A091432 001</u>	Sep 19, 2011
<u>AB</u>		<u>500MG</u>	<u>A091432 002</u>	Sep 19, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>375MG</u>	<u>A075390 001</u>	Apr 19, 2001
<u>AB</u>		<u>500MG</u>	<u>A075390 002</u>	Apr 19, 2001
<u>AB</u>	PLIVA	<u>375MG</u>	<u>A075337 001</u>	May 26, 1999
<u>AB</u>		<u>500MG</u>	<u>A075337 002</u>	May 26, 1999
<u>AB</u>	SANDOZ	<u>375MG</u>	<u>A075061 001</u>	Feb 18, 1998
<u>AB</u>		<u>500MG</u>	<u>A075061 002</u>	Feb 18, 1998
<u>AB</u>	TEVA	<u>375MG</u>	<u>A075227 001</u>	Jun 30, 1998
<u>AB</u>		<u>500MG</u>	<u>A075227 002</u>	Jun 30, 1998

## NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

<u>AB</u>	HOFFMANN LA ROCHE	<u>EQ 250MG BASE</u>	<u>N018164 001</u>	
-----------	-------------------	----------------------	--------------------	--

ANAPROX DS

<u>AB</u>	+ HOFFMANN LA ROCHE	<u>EQ 500MG BASE</u>	<u>N018164 003</u>	Sep 30, 1987
-----------	---------------------	----------------------	--------------------	--------------

NAPROXEN SODIUM

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432 001</u>	Apr 25, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078432 002</u>	Apr 25, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629 001</u>	Oct 31, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A200629 002</u>	Oct 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486 001</u>	Jul 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078486 002</u>	Jul 26, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078314 001</u>	Apr 27, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078314 002</u>	Apr 27, 2007
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A074480 002</u>	Feb 18, 1998
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074480 001</u>	May 14, 1996
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A074198 001</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074198 002</u>	Dec 21, 1993

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

<u>AB</u>	ALVOGEN MALTA	<u>EQ 375MG BASE</u>	<u>N020353 001</u>	Jan 05, 1996
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N020353 002</u>	Jan 05, 1996

NAPROXEN SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 375MG BASE</u>	<u>A075416 002</u>	Apr 23, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075416 001</u>	Aug 27, 2002

## NAPRELAN

+	ALVOGEN MALTA	EQ 750MG BASE	N020353 003	Jan 05, 1996
---	---------------	---------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926 002	May 14, 2015
+	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763 002</u>	Feb 10, 1998
<u>AB</u>	+	<u>EQ 2.5MG BASE</u>	<u>N020763 001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>	APOTEX CORP	<u>EQ 1MG BASE</u>	<u>A091373 001</u>	Apr 22, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091373 002</u>	Apr 22, 2011
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502 001</u>	Feb 28, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A200502 002</u>	Feb 28, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 1MG BASE</u>	<u>A202431 001</u>	May 31, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A202431 002</u>	May 31, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441 001</u>	Apr 30, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091441 002</u>	Apr 30, 2012
<u>AB</u>	PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326 001</u>	Jul 08, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326 002</u>	Jul 08, 2010
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A090381 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381 002</u>	Jul 07, 2010
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A090288 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090288 002</u>	Jul 07, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552 001</u>	Feb 14, 2011
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078751 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A078751 002</u>	Jul 07, 2010

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+	ALCON	5%	N050514 001
---	-------	----	-------------

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	ALVOGEN MALTA	<u>60MG</u>	<u>A205055 001</u>	Dec 11, 2015
<u>AB</u>		<u>120MG</u>	<u>A205055 002</u>	Dec 11, 2015
<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461 002</u>	Sep 09, 2009
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463 002</u>	Sep 09, 2009
<u>AB</u>	WATSON LABS	<u>60MG</u>	<u>A077462 001</u>	Mar 30, 2011
<u>AB</u>		<u>120MG</u>	<u>A077462 002</u>	Mar 30, 2011
	<u>STARLIX</u>			
<u>AB</u>	NOVARTIS	<u>60MG</u>	<u>N021204 001</u>	Dec 22, 2000
<u>AB</u>	+	<u>120MG</u>	<u>N021204 002</u>	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

FOREST LABS	EQ 2.5MG BASE	N021742 002	Dec 17, 2007
	EQ 5MG BASE	N021742 003	Dec 17, 2007
	EQ 10MG BASE	N021742 004	Dec 17, 2007
+	EQ 20MG BASE	N021742 005	Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIIL

<u>AT</u>	+	ALLERGAN	<u>2%</u>	<u>N021009 001</u>	Dec 08, 1999
<u>AT</u>		<u>NEDOCROMIL SODIUM</u>			
<u>AT</u>		AKORN	<u>2%</u>	<u>A090638 001</u>	Aug 22, 2012

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

<u>AB</u>	SUN PHARM INDS LTD	<u>50MG</u>	<u>A076409 001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076409 002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076409 003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076409 004</u>	Sep 16, 2003
<u>AB</u>		<u>250MG</u>	<u>A076409 005</u>	Sep 16, 2003
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076037 001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076037 002</u>	Sep 16, 2003

## PRESCRIPTION DRUG PRODUCT LIST

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

<b>AB</b>		<b>150MG</b>	<b>A076037 003</b>	Sep 16, 2003
<b>AB</b>		<b>200MG</b>	<b>A076037 004</b>	Sep 16, 2003
<b>AB</b>	+	<b>250MG</b>	<b>A076037 005</b>	Sep 16, 2003
BX	DR REDDYS LABS INC	50MG	A076309 001	Sep 16, 2003
BX		100MG	A076309 002	Sep 16, 2003
BX		150MG	A076309 003	Sep 16, 2003
BX		200MG	A076309 004	Sep 16, 2003
BX		250MG	A076309 005	Sep 16, 2003

NELARABINE

INJECTABLE; IV (INFUSION)

ARRANON

+ NOVARTIS PHARMS CORP 250MG/50ML (5MG/ML) N021877 001 Oct 28, 2005

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+ AGOURON EQ 250MG BASE N020779 001 Mar 14, 1997

+ EQ 625MG BASE N021503 001 Apr 30, 2003

NEOMYCIN SULFATE

SOLUTION; ORAL

NEO-FRADIN

+ X GEN PHARMS EQ 87.5MG BASE/5ML A065010 001 May 23, 2002

TABLET; ORAL

NEOMYCIN SULFATE

<b>AA</b>	OMAN PHARM PRODUCTS	<b>500MG</b>	<b>A065468 001</b>	Mar 29, 2010
<b>AA</b>	+	<b>500MG</b>	<b>A060304 001</b>	
<b>AA</b>	X GEN PHARMS	<b>500MG</b>	<b>A065220 001</b>	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

<b>AT</b>	WATSON LABS	<b>EQ 40MG BASE/ML; 200,000 UNITS/ML</b>	<b>A062664 001</b>	Apr 08, 1986
<b>AT</b>	X GEN PHARMS	<b>EQ 40MG BASE/ML; 200,000 UNITS/ML</b>	<b>A065106 001</b>	Jan 31, 2006
<b>AT</b>		<b>EQ 40MG BASE/ML; 200,000 UNITS/ML</b>	<b>A065108 001</b>	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

<b>AT</b>	+	MONARCH PHARMS	<b>EQ 40MG BASE/ML; 200,000 UNITS/ML</b>	<b>A060707 001</b>
-----------	---	----------------	--	--------------------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

<b>AP</b>	+	ECLAT PHARMS LLC	<b>5MG/10ML (0.5MG/ML)</b>	<b>N204078 001</b>	May 31, 2013
<b>AP</b>	+		<b>10MG/10ML (1MG/ML)</b>	<b>N204078 002</b>	May 31, 2013

NEOSTIGMINE METHYLSULFATE

<b>AP</b>	EUROHLTH INTL SARL	<b>5MG/10ML (0.5MG/ML)</b>	<b>A207042 001</b>	Dec 28, 2015
<b>AP</b>		<b>10MG/10ML (1MG/ML)</b>	<b>A207042 002</b>	Dec 28, 2015
	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629 001	Jan 08, 2015
		10MG/10ML (1MG/ML)	N203629 002	Jan 08, 2015

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

+ ALCON RES LTD 0.3% N203491 001 Oct 16, 2012

NEVANAC

+ ALCON PHARMS LTD 0.1% N021862 001 Aug 19, 2005

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

+ SCIOS LLC 1.5MG/VIAL N020920 001 Aug 10, 2001

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

AKYNZEO

+ HELSINN HLTHCARE 300MG; EQ 0.5MG BASE N205718 001 Oct 10, 2014

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

<b>AA</b>	AUROBINDO	<b>50MG/5ML</b>	<b>A077702 001</b>	May 22, 2012
-----------	-----------	-----------------	--------------------	--------------

VIRAMUNE

<b>AA</b>	+	BOEHRINGER INGELHEIM	<b>50MG/5ML</b>	<b>N020933 001</b>	Sep 11, 1998
-----------	---	----------------------	-----------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A203021</u>	<u>001</u>	May 22, 2012
<u>AB</u>	AUROBINDO	<u>200MG</u>	<u>A077521</u>	<u>001</u>	May 22, 2012
<u>AB</u>	CIPLA	<u>200MG</u>	<u>A077956</u>	<u>001</u>	May 22, 2012
<u>AB</u>	HETERO LABS LTD III	<u>200MG</u>	<u>A078584</u>	<u>001</u>	May 22, 2012
<u>AB</u>	MICRO LABS LTD	<u>200MG</u>	<u>A203080</u>	<u>001</u>	May 22, 2012
<u>AB</u>	MYLAN LABS	<u>200MG</u>	<u>A078864</u>	<u>001</u>	May 22, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>200MG</u>	<u>A202523</u>	<u>001</u>	May 22, 2012
<u>AB</u>	PRINSTON INC	<u>200MG</u>	<u>A078644</u>	<u>001</u>	May 22, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>200MG</u>	<u>A203176</u>	<u>001</u>	May 22, 2012
<u>AB</u>	STRIDES PHARMA	<u>200MG</u>	<u>A078195</u>	<u>001</u>	May 22, 2012

VIRAMUNE

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>200MG</u>	<u>N020636</u>	<u>001</u>	Jun 21, 1996
-----------	------------------------	--------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

<u>AB</u>	ALVOGEN MALTA	<u>100MG</u>	<u>A204621</u>	<u>002</u>	Nov 09, 2015
<u>AB</u>		<u>400MG</u>	<u>A204621</u>	<u>001</u>	Jul 10, 2015
<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A205258</u>	<u>001</u>	Apr 03, 2014
<u>AB</u>	CIPLA LTD	<u>400MG</u>	<u>A206448</u>	<u>001</u>	Oct 15, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A206271</u>	<u>001</u>	Nov 09, 2015
<u>AB</u>		<u>400MG</u>	<u>A205651</u>	<u>001</u>	Oct 27, 2014
<u>AB</u>	SANDOZ INC	<u>400MG</u>	<u>A203411</u>	<u>001</u>	Apr 03, 2014

VIRAMUNE XR

<u>AB</u>	BOEHRINGER INGELHEIM	<u>100MG</u>	<u>N201152</u>	<u>002</u>	Nov 08, 2012
<u>AB</u>	+	<u>400MG</u>	<u>N201152</u>	<u>001</u>	Mar 25, 2011

NIACIN

TABLET; ORAL

NIACIN

<u>AA</u>	WOCKHARDT	<u>500MG</u>	<u>A081134</u>	<u>001</u>	Apr 28, 1992
-----------	-----------	--------------	----------------	------------	--------------

NIACOR

<u>AA</u>	+ UPSHER SMITH	<u>500MG</u>	<u>A040378</u>	<u>001</u>	May 03, 2000
-----------	----------------	--------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NIACIN

<u>AB</u>	AMNEAL PHARMS	<u>500MG</u>	<u>A203578</u>	<u>001</u>	Jul 24, 2015
<u>AB</u>		<u>750MG</u>	<u>A204178</u>	<u>001</u>	Dec 11, 2015
<u>AB</u>		<u>1GM</u>	<u>A203578</u>	<u>002</u>	Jul 24, 2015
<u>AB</u>	BARR	<u>500MG</u>	<u>A076378</u>	<u>001</u>	Apr 26, 2005
<u>AB</u>		<u>750MG</u>	<u>A076378</u>	<u>002</u>	Apr 26, 2005
<u>AB</u>		<u>1GM</u>	<u>A076250</u>	<u>001</u>	Apr 14, 2005
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A090860</u>	<u>001</u>	Mar 20, 2014
<u>AB</u>		<u>750MG</u>	<u>A090892</u>	<u>001</u>	Mar 20, 2014
<u>AB</u>		<u>1GM</u>	<u>A090446</u>	<u>001</u>	Mar 20, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>500MG</u>	<u>A200484</u>	<u>001</u>	Apr 23, 2014
<u>AB</u>		<u>750MG</u>	<u>A201273</u>	<u>001</u>	Apr 23, 2014
<u>AB</u>		<u>1GM</u>	<u>A200484</u>	<u>002</u>	Apr 23, 2014

NIASPAN

<u>AB</u>	ABBVIE	<u>500MG</u>	<u>N020381</u>	<u>002</u>	Jul 28, 1997
<u>AB</u>	+	<u>750MG</u>	<u>N020381</u>	<u>003</u>	Jul 28, 1997
<u>AB</u>	+	<u>1GM</u>	<u>N020381</u>	<u>004</u>	Jul 28, 1997

NIACIN; SIMVASTATIN

TABLET, EXTENDED RELEASE; ORAL

## SIMCOR

+	ABBVIE	500MG; 20MG	N022078	001	Feb 15, 2008
+		500MG; 40MG	N022078	004	Jul 28, 2010
+		750MG; 20MG	N022078	002	Feb 15, 2008
+		1GM; 20MG	N022078	003	Feb 15, 2008
+		1GM; 40MG	N022078	005	Jul 28, 2010

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

<u>AB</u>	CHIESI USA INC	<u>20MG</u>	<u>N019488</u>	<u>001</u>	Dec 21, 1988
<u>AB</u>	+	<u>30MG</u>	<u>N019488</u>	<u>002</u>	Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>20MG</u>	<u>A074439</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>		<u>20MG</u>	<u>A074540</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>30MG</u>	<u>A074439</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>		<u>30MG</u>	<u>A074540</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>	EPIC PHARMA	<u>20MG</u>	<u>A074928</u>	<u>001</u>	Mar 19, 1998
<u>AB</u>		<u>30MG</u>	<u>A074928</u>	<u>002</u>	Mar 19, 1998

## PRESCRIPTION DRUG PRODUCT LIST

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074642</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>		<u>30MG</u>	<u>A074642</u>	<u>002</u>	Jul 18, 1996

INJECTABLE; INJECTION

CARDENE

<u>AP</u>	+ CHIESI USA INC	<u>25MG/10ML (2.5MG/ML)</u>	<u>N019734</u>	<u>001</u>	Jan 30, 1992
-----------	------------------	-----------------------------	----------------	------------	--------------

NICARDIPINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A078714</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>	EXELA PHARMA SCIENCE	<u>25MG/10ML (2.5MG/ML)</u>	<u>N022276</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>	LUITPOLD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090534</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	MYLAN INSTITUTIONAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090664</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	NAVINTA LLC	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090125</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	SUN PHARMA GLOBAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>N078405</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	WOCKHARDT	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090671</u>	<u>001</u>	Nov 17, 2009

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+ CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008
------------------	-----------------------	---------	-----	--------------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+ CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008
------------------	-----------------------	---------	-----	--------------

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008
------------------	-----------------------	---------	-----	--------------

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008
------------------	-----------------------	---------	-----	--------------

NICOTINE

INHALANT; ORAL

NICOTROL

+ PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997
------------------------	---------------	---------	-----	--------------

SPRAY, METERED; NASAL

NICOTROL

+ PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996
--------------	-------------	---------	-----	--------------

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579</u>	<u>001</u>	Jan 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A072556</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	HERITAGE PHARMA	<u>10MG</u>	<u>A202644</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202644</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	INTERGEL PHARM	<u>10MG</u>	<u>A072781</u>	<u>001</u>	Jul 30, 1993

PROCARDIA

<u>AB</u>	+ PFIZER	<u>10MG</u>	<u>N018482</u>	<u>001</u>	
-----------	----------	-------------	----------------	------------	--

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

<u>AB1</u>	BAYER HLTHCARE	<u>30MG</u>	<u>N020198</u>	<u>001</u>	Apr 21, 1993
<u>AB1</u>	+	<u>60MG</u>	<u>N020198</u>	<u>002</u>	Apr 21, 1993
<u>AB1</u>	+	<u>90MG</u>	<u>N020198</u>	<u>003</u>	Apr 21, 1993

AFEDITAB CR

<u>AB1</u>	WATSON LABS	<u>30MG</u>	<u>A075128</u>	<u>001</u>	Mar 10, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075659</u>	<u>001</u>	Oct 26, 2001

NIFEDIPINE

<u>AB1</u>	MYLAN	<u>30MG</u>	<u>A201071</u>	<u>001</u>	Dec 03, 2010
<u>AB1</u>		<u>60MG</u>	<u>A201071</u>	<u>002</u>	Dec 03, 2010
<u>AB1</u>		<u>90MG</u>	<u>A201071</u>	<u>003</u>	Dec 03, 2010
<u>AB1</u>	PAR PHARM	<u>30MG</u>	<u>A077899</u>	<u>001</u>	Dec 13, 2006
<u>AB1</u>		<u>60MG</u>	<u>A077899</u>	<u>002</u>	Dec 13, 2006
<u>AB1</u>		<u>90MG</u>	<u>A077899</u>	<u>003</u>	May 25, 2012
<u>AB1</u>	VALEANT INTL	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000
<u>AB1</u>		<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002
<u>AB2</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A090602</u>	<u>001</u>	Sep 13, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090602</u>	<u>002</u>	Sep 13, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090602</u>	<u>003</u>	Sep 13, 2010
<u>AB2</u>	MYLAN	<u>30MG</u>	<u>A090649</u>	<u>001</u>	Jun 21, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090649</u>	<u>002</u>	Jun 21, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090649</u>	<u>003</u>	Jun 21, 2010
<u>AB2</u>	OSMOTICA PHARM	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005
<u>AB2</u>		<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005
<u>AB2</u>		<u>90MG</u>	<u>A077410</u>	<u>001</u>	Oct 03, 2007
<u>AB2</u>	TWI PHARMS INC	<u>30MG</u>	<u>A203126</u>	<u>001</u>	Apr 03, 2014
<u>AB2</u>		<u>60MG</u>	<u>A203126</u>	<u>002</u>	Apr 03, 2014



## PRESCRIPTION DRUG PRODUCT LIST

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

<b>AB2</b>		<b>90MG</b>	<b>A203126 003</b>	Apr 03, 2014
<b>AB2</b>	VALEANT PHARMS NORTH	<b>30MG</b>	<b>A075289 002</b>	Feb 06, 2001
<b>AB2</b>		<b>60MG</b>	<b>A075289 001</b>	Sep 27, 2000

PROCARDIA XL

<b>AB2</b>	PFIZER	<b>30MG</b>	<b>N019684 001</b>	Sep 06, 1989
<b>AB2</b>		<b>60MG</b>	<b>N019684 002</b>	Sep 06, 1989
<b>AB2</b>	+	<b>90MG</b>	<b>N019684 003</b>	Sep 06, 1989

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL

TASIGNA

	NOVARTIS	EQ 150MG BASE	N022068 002	Jun 17, 2010
+		EQ 200MG BASE	N022068 001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

+	CONCORDIA PHARMS INC	150MG	N020169 002	Apr 30, 1999
---	----------------------	-------	-------------	--------------

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

<b>AB</b>	+	BANNER LIFE SCIENCES	<b>30MG</b>	<b>A076740 001</b>	Jan 17, 2008
<b>AB</b>		BARR LABS INC	<b>30MG</b>	<b>A077811 001</b>	May 02, 2007
<b>AB</b>		SOFGEN PHARMS	<b>30MG</b>	<b>A201832 001</b>	Jul 24, 2015
<b>AB</b>		SUN PHARM INDS INC	<b>30MG</b>	<b>A077067 001</b>	Apr 17, 2007
<b>AB</b>		THEPHARMANETWORK LLC	<b>30MG</b>	<b>A090103 001</b>	Apr 07, 2014

SOLUTION;ORAL

NYMALIZE

+	ARBOR PHARMS LLC	60MG/20ML	N203340 001	May 10, 2013
---	------------------	-----------	-------------	--------------

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832 001	Oct 15, 2014
+		EQ 150MG BASE	N205832 002	Oct 15, 2014

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

<b>AB</b>	MYLAN	<b>8.5MG</b>	<b>A091001 001</b>	Jan 26, 2011
<b>AB</b>		<b>17MG</b>	<b>A091001 002</b>	Jan 26, 2011
<b>AB</b>		<b>34MG</b>	<b>A091001 004</b>	Jan 26, 2011

SULAR

<b>AB</b>	+	SHIONOGI INC	<b>8.5MG</b>	<b>N020356 008</b>	Jan 02, 2008
<b>AB</b>	+		<b>17MG</b>	<b>N020356 007</b>	Jan 02, 2008
<b>AB</b>	+		<b>34MG</b>	<b>N020356 005</b>	Jan 02, 2008

NISOLDIPINE

	MYLAN	20MG	A079051 001	Jul 25, 2008
		25.5MG	A091001 003	Jan 26, 2011
+		30MG	A079051 002	Jul 25, 2008
+		40MG	A079051 003	Jul 25, 2008

NITAZOXANIDE

FOR SUSPENSION;ORAL

ALINIA

+	ROMARK	100MG/5ML	N021498 001	Nov 22, 2002
---	--------	-----------	-------------	--------------

TABLET;ORAL

ALINIA

+	ROMARK	500MG	N021497 001	Jul 21, 2004
---	--------	-------	-------------	--------------

NITISINONE

CAPSULE;ORAL

ORFADIN

	SWEDISH ORPHAN	2MG	N021232 001	Jan 18, 2002
		5MG	N021232 002	Jan 18, 2002
+		10MG	N021232 003	Jan 18, 2002

## PRESCRIPTION DRUG PRODUCT LIST

NITRIC OXIDE

GAS; INHALATION

INOMAX

+ INO

800PPM

N020845 003 Dec 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTINAB + SHIONOGI INC25MG/5MLN009175 001NITROFURANTOINAB AMNEAL PHARMS25MG/5MLA201679 001 May 11, 2011AB NOVEL LABS INC25MG/5MLA201693 001 Sep 08, 2014AB SUN PHARM INDS INC25MG/5MLA201355 001 Aug 14, 2013NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTINAB ALVOGEN MALTA25MGN016620 003AB50MGN016620 001AB +100MGN016620 002NITROFURANTOINAB ACTAVIS LABS FL INC25MGA091095 001 Jun 18, 2015AB50MGA091095 002 Jun 18, 2015AB100MGA091095 003 Jun 18, 2015AB IVAX SUB TEVA PHARMS50MGA073671 001 Jan 28, 1993AB100MGA073652 001 Jan 28, 1993AB MYLAN50MGA074967 001 Jul 09, 1997AB100MGA077025 001 Aug 18, 2004NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBIDAB + ALVOGEN INC75MG; 25MGN020064 001 Dec 24, 1991NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)AB MYLAN75MG; 25MGA076648 001 Mar 22, 2004AB SANDOZ75MG; 25MGA077066 001 Apr 05, 2005AB WATSON LABS INC75MG; 25MGA202250 001 Jul 08, 2015NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

+ MIST PHARMS LLC

0.4MG/SPRAY

N021780 001 Nov 02, 2006

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRANAB1 MEDICIS0.2MG/HRA089772 001 Aug 30, 1996AB10.4MG/HRA089773 001 Aug 30, 1996AB1 VALEANT PHARMS0.1MG/HRA089771 001 Aug 30, 1996AB10.6MG/HRA089774 001 Aug 30, 1996NITRO-DURAB1 + MERCK SHARP DOHME0.1MG/HRN020145 001 Apr 04, 1995AB1 +0.2MG/HRN020145 002 Apr 04, 1995AB1 +0.4MG/HRN020145 004 Apr 04, 1995AB1 +0.6MG/HRN020145 005 Apr 04, 1995NITROGLYCERINAB2 HERCON PHARM0.2MG/HRA089884 001 Oct 30, 1998AB20.4MG/HRA089885 001 Oct 30, 1998AB20.6MG/HRA089886 001 Oct 30, 1998AB2 + MYLAN TECHNOLOGIES0.2MG/HRA074559 003 Aug 30, 1996AB2 +0.4MG/HRA074559 002 Aug 30, 1996AB2 +0.6MG/HRA074559 001 Aug 30, 1996

NITRO-DUR

+ MERCK SHARP DOHME

0.3MG/HR

N020145 003 Apr 04, 1995

+

0.8MG/HR

N020145 006 Apr 04, 1995

NITROGLYCERIN

+ MYLAN TECHNOLOGIES

0.1MG/HR

A074559 004 Feb 06, 1998

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%AP + BAXTER HLTHCARE10MG/100MLN019970 001 Dec 29, 1989AP +20MG/100MLN019970 002 Dec 29, 1989AP +40MG/100MLN019970 003 Dec 29, 1989AP HOSPIRA10MG/100MLA071846 001 Aug 31, 1990AP20MG/100MLA071847 001 Aug 31, 1990AP40MG/100MLA071848 001 Aug 31, 1990

## PRESCRIPTION DRUG PRODUCT LIST

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN

+ LUITPOLD

5MG/ML

A072034 001 May 24, 1988

OINTMENT; INTRA-ANAL

RECTIV

+ FOREST LABS INC

0.4%

N021359 001 Jun 21, 2011

OINTMENT; TRANSDERMAL

NITROGLYCERIN

+ FOUGERA

2%

A087355 001 Jul 08, 1988

SPRAY, METERED; SUBLINGUAL

NITROGLYCERIN**AB** PERRIGO ISRAEL**0.4MG/SPRAY****A091496 001** Sep 20, 2013NITROLINGUAL PUMPSPRAY**AB** + POHL BOSKAMP**0.4MG/SPRAY****N018705 002** Jan 10, 1997

TABLET; SUBLINGUAL

NITROSTAT

PFIZER PHARMS

0.3MG

N021134 001 May 01, 2000

0.4MG

N021134 002 May 01, 2000

+

0.6MG

N021134 003 May 01, 2000

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE**AB** ANI PHARMS INC**150MG****A075668 001** Sep 12, 2002**AB****300MG****A075668 002** Sep 12, 2002**AB** DR REDDYS LABS LTD**150MG****A077314 001** Sep 15, 2005**AB****300MG****A077314 002** Sep 15, 2005**AB** GLENMARK GENERICS**150MG****A090618 001** Jul 15, 2011**AB****300MG****A090618 002** Jul 15, 2011**AB** MYLAN PHARMS INC**150MG****A075806 001** Jul 05, 2002**AB** +**300MG****A075806 002** Jul 05, 2002**AB** SANDOZ**150MG****A076178 001** Jul 05, 2002**AB****300MG****A076178 002** Jul 05, 2002**AB** WATSON LABS**150MG****A075616 001** Jul 09, 2002**AB****300MG****A075616 002** Jul 09, 2002

SOLUTION; ORAL

AXID**AA** + BRAINTREE**15MG/ML****N021494 001** May 25, 2004NIZATIDINE**AA** AMNEAL PHARMS**15MG/ML****A090576 001** Nov 18, 2009NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED**AP** + HOSPIRA**EQ 1MG BASE/ML****N007513 001**NOREPINEPHRINE BITARTRATE**AP** BEDFORD**EQ 1MG BASE/ML****A040462 001** Oct 31, 2003**AP** CLARIS LIFESCIENCES**EQ 1MG BASE/ML****A040859 001** Mar 27, 2012**AP** TEVA PHARMS USA**EQ 1MG BASE/ML****A040455 001** Mar 03, 2003NORETHINDRONE

TABLET; ORAL-28

CAMILA**AB1** BARR**0.35MG****A076177 001** Oct 21, 2002HEATHER**AB1** GLENMARK GENERICS**0.35MG****A090454 001** Apr 23, 2010NOR-QD**AB1** + ACTAVIS LABS UT INC**0.35MG****N017060 001**NORETHINDRONE**AB1** HAUPT PHARMA**0.35MG****A202260 001** Aug 01, 2013**AB1** JAI PHARMA LTD**0.35MG****A201483 001** Jun 24, 2013**AB1** LUPIN LTD**0.35MG****A091325 001** Sep 19, 2011**AB1** NOVAST LABS LTD**0.35MG****A202014 001** Sep 13, 2013ERRIN**AB2** BARR**0.35MG****A076225 001** Oct 21, 2002JENCYCLA**AB2** LUPIN LTD**0.35MG****A091323 001** Mar 28, 2013MICRONOR**AB2** + JANSSEN PHARMS**0.35MG****N016954 001**NORETHINDRONE**AB2** GLENMARK GENERICS**0.35MG****A091209 001** Jul 21, 2010**AB2** JAI PHARMA LTD**0.35MG****A200980 001** Jun 12, 2013**AB2** NOVAST LABS**0.35MG****A200961 001** Sep 13, 2013

## PRESCRIPTION DRUG PRODUCT LIST

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

<u>AB</u>	+	DURAMED RES	<u>5MG</u>	<u>N018405</u>	<u>001</u>	Apr 21, 1982
-----------	---	-------------	------------	----------------	------------	--------------

NORETHINDRONE ACETATE

<u>AB</u>		AMNEAL PHARMS	<u>5MG</u>	<u>A200275</u>	<u>001</u>	Jul 30, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A204236</u>	<u>001</u>	Jan 08, 2016
<u>AB</u>		BARR	<u>5MG</u>	<u>A075951</u>	<u>001</u>	May 25, 2001
<u>AB</u>		GLENMARK GENERICS	<u>5MG</u>	<u>A091090</u>	<u>001</u>	Jul 21, 2010

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AB</u>		MYLAN	<u>EQ 10MG BASE</u>	<u>A074234</u>	<u>001</u>	Jul 26, 1993
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A074234</u>	<u>002</u>	Jul 26, 1993
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A074234</u>	<u>003</u>	Jul 26, 1993
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A074234</u>	<u>004</u>	Jul 26, 1993
<u>AB</u>		TARO	<u>EQ 10MG BASE</u>	<u>A075520</u>	<u>004</u>	May 08, 2000
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A075520</u>	<u>003</u>	May 08, 2000
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A075520</u>	<u>001</u>	May 08, 2000
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A075520</u>	<u>002</u>	May 08, 2000
<u>AB</u>		TEVA	<u>EQ 10MG BASE</u>	<u>A074132</u>	<u>001</u>	Mar 27, 1995
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A074132</u>	<u>002</u>	Mar 27, 1995
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A074132</u>	<u>003</u>	Mar 27, 1995
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A074132</u>	<u>004</u>	Mar 27, 1995
<u>AB</u>		WATSON LABS	<u>EQ 10MG BASE</u>	<u>A073553</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A073554</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A073555</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A073556</u>	<u>001</u>	Mar 30, 1992

PAMELOR

<u>AB</u>		MALLINCKRODT LLC	<u>EQ 10MG BASE</u>	<u>N018013</u>	<u>001</u>	
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>N018013</u>	<u>002</u>	
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>N018013</u>	<u>004</u>	
<u>AB</u>	+		<u>EQ 75MG BASE</u>	<u>N018013</u>	<u>003</u>	

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AA</u>	+	PHARM ASSOC	<u>EQ 10MG BASE/5ML</u>	<u>A075606</u>	<u>001</u>	Aug 28, 2000
<u>AA</u>		TARO	<u>EQ 10MG BASE/5ML</u>	<u>A077965</u>	<u>001</u>	Jun 20, 2006

NYSTATIN

CREAM; TOPICAL

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949</u>	<u>001</u>	Jun 13, 1988
<u>AT</u>		FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062129</u>	<u>001</u>	
<u>AT</u>		G AND W LABS INC	<u>100,000 UNITS/GM</u>	<u>A061966</u>	<u>001</u>	
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225</u>	<u>001</u>	
<u>AT</u>	+	TARO	<u>100,000 UNITS/GM</u>	<u>A064022</u>	<u>001</u>	Jan 29, 1993
<u>AT</u>		VINTAGE	<u>100,000 UNITS/GM</u>	<u>A065315</u>	<u>001</u>	May 31, 2006

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840</u>	<u>001</u>	Nov 13, 1987
<u>AT</u>	+	FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062124</u>	<u>002</u>	Sep 23, 1982
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472</u>	<u>001</u>	Feb 13, 1984

POWDER; TOPICAL

NYSTATIN

<u>AT</u>	+	COASTAL PHARMS	<u>100,000 UNITS/GM</u>	<u>A065203</u>	<u>001</u>	Jul 15, 2004
<u>AT</u>		GAVIS PHARMS	<u>100,000 UNITS/GM</u>	<u>A065138</u>	<u>001</u>	Jul 23, 2004
<u>AT</u>		UPSHER SMITH	<u>100,000 UNITS/GM</u>	<u>A065183</u>	<u>001</u>	May 03, 2005
<u>AT</u>		X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175</u>	<u>001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>		PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118</u>	<u>001</u>	Aug 16, 1996
-----------	--	-------------	-------------------------	----------------	------------	--------------

SUSPENSION; ORAL

NYSTATIN

<u>AA</u>		FOUGERA	<u>100,000 UNITS/ML</u>	<u>A062517</u>	<u>001</u>	Jun 07, 1984
<u>AA</u>		G AND W LABS INC	<u>100,000 UNITS/ML</u>	<u>A062349</u>	<u>001</u>	Jul 14, 1982
<u>AA</u>		HI TECH PHARMA	<u>100,000 UNITS/ML</u>	<u>A064042</u>	<u>001</u>	Feb 28, 1994
<u>AA</u>		PHARM ASSOC	<u>100,000 UNITS/ML</u>	<u>A203621</u>	<u>001</u>	Jan 07, 2016
<u>AA</u>		TARO	<u>100,000 UNITS/ML</u>	<u>A062876</u>	<u>001</u>	Feb 29, 1988
<u>AA</u>		VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148</u>	<u>001</u>	Jun 28, 2005
<u>AA</u>		VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>001</u>	Jun 25, 1998
<u>AA</u>			<u>100,000 UNITS/ML</u>	<u>A065422</u>	<u>001</u>	Mar 07, 2011
<u>AA</u>	+	WOCKHARDT	<u>100,000 UNITS/ML</u>	<u>A062512</u>	<u>001</u>	Oct 29, 1984

## PRESCRIPTION DRUG PRODUCT LIST

NYSTATIN

TABLET; ORAL

NYSTATIN

<u>AA</u>	HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474 001</u>	Dec 22, 1983
<u>AA</u>	MUTUAL PHARM	<u>500,000 UNITS</u>	<u>A062838 001</u>	Dec 22, 1988
<u>AA</u>	+ TEVA	<u>500,000 UNITS</u>	<u>A062506 001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

	+ ODYSSEY PHARMS	100,000 UNITS	A062615 001	Oct 17, 1985
--	------------------	---------------	-------------	--------------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062367 001</u>	May 28, 1985
-----------	------------------	------------------------------	--------------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062599 001</u>	Oct 08, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A062364 001</u>	Dec 22, 1987

OINTMENT; TOPICAL

MYKACET

<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062733 001</u>	Mar 09, 1987
-----------	------------------	------------------------------	--------------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062602 001</u>	Oct 09, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A063305 001</u>	Mar 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	+ EUROHLTH INTL SARL	<u>EQ 0.2MG BASE/ML</u>	<u>A076330 001</u>	Apr 08, 2005
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A076330 002</u>	Apr 08, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077450 001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450 002</u>	Feb 10, 2006
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A091041 001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A091041 002</u>	Nov 12, 2013
<u>AP</u>	SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077329 001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.05MG BASE/ML</u>	<u>A077372 001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077329 002</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077372 002</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077330 001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077373 001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077329 003</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077372 003</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077331 001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077373 002</u>	Aug 14, 2007
<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957 001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957 002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959 001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957 003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959 002</u>	Nov 21, 2005
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.2MG BASE/ML</u>	<u>A090986 001</u>	May 11, 2011
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A090986 002</u>	May 11, 2011

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	+ EUROHLTH INTL SARL	<u>EQ 0.05MG BASE/ML</u>	<u>A076313 001</u>	Mar 28, 2005
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML</u>	<u>A076313 003</u>	Mar 28, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A076313 002</u>	Mar 28, 2005
<u>AP</u>		<u>EQ 0.05MG BASE/ML</u>	<u>A077457 001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457 002</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457 003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198 001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198 002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198 003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A090834 001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834 002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834 003</u>	Nov 12, 2013
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.05MG BASE/ML</u>	<u>A090985 001</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090985 002</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090985 003</u>	May 11, 2011

SANDOSTATIN

<u>AP</u>	+ NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667 001</u>	Oct 21, 1988
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>N019667 002</u>	Oct 21, 1988
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>N019667 004</u>	Jun 12, 1991
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>N019667 003</u>	Oct 21, 1988
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>N019667 005</u>	Jun 12, 1991

## PRESCRIPTION DRUG PRODUCT LIST

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

SANDOSTATIN LAR

NOVARTIS

EQ 10MG BASE/VIAL

N021008 001 Nov 25, 1998

EQ 20MG BASE/VIAL

N021008 002 Nov 25, 1998

+

EQ 30MG BASE/VIAL

N021008 003 Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOXAT + ALLERGAN0.3%N019921 001 Jul 30, 1993OFLOXACINAT AKORN0.3%A076407 001 Apr 15, 2008AT ALCON PHARMS LTD0.3%A076231 001 May 14, 2004AT ALTAIRE PHARMS INC0.3%A202692 001 Apr 29, 2013AT BAUSCH AND LOMB0.3%A076622 001 May 14, 2004AT FDC LTD0.3%A078559 001 Feb 25, 2009AT FERA PHARMS0.3%A076830 001 Aug 31, 2004AT HI TECH PHARMA0.3%A076615 001 May 14, 2004

SOLUTION/DROPS; OTIC

FLOXIN OTICAT + DAIICHI0.3%N020799 001 Dec 16, 1997OFLOXACINAT ALCON PHARMS LTD0.3%A078222 001 Mar 17, 2008AT APOTEX INC0.3%A076527 001 Sep 28, 2007AT BAUSCH AND LOMB0.3%A076128 001 Mar 17, 2008AT FERA PHARMS0.3%A090395 001 Aug 11, 2009AT HI TECH PHARMA0.3%A076616 001 Mar 17, 2008

TABLET; ORAL

OFLOXACINAB CADILA PHARMS LTD200MGA091656 001 Sep 18, 2014AB CADILA PHARMS LTD300MGA091656 002 Sep 18, 2014AB CADILA PHARMS LTD400MGA091656 003 Sep 18, 2014AB DR REDDYS LABS LTD200MGA077098 001 Feb 10, 2006AB DR REDDYS LABS LTD300MGA077098 002 Feb 10, 2006AB DR REDDYS LABS LTD400MGA077098 003 Feb 10, 2006AB LARKEN LABS400MGA076093 003 Sep 02, 2003AB TEVA200MGA076182 001 Sep 02, 2003AB TEVA300MGA076182 002 Sep 02, 2003AB +400MGA076182 003 Sep 02, 2003OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINEAP LUITPOLD10MG/VIALA201741 001 Mar 20, 2012AP SANDOZ INC10MG/VIALA201588 001 Oct 24, 2011ZYPREXAAP + LILLY10MG/VIALN021253 001 Mar 29, 2004

TABLET; ORAL

OLANZAPINEAB ALKEM LABS LTD2.5MGA202295 001 Oct 20, 2015AB ALKEM LABS LTD5MGA202295 002 Oct 20, 2015AB ALKEM LABS LTD7.5MGA202295 003 Oct 20, 2015AB ALKEM LABS LTD10MGA202295 004 Oct 20, 2015AB ALKEM LABS LTD15MGA202295 005 Oct 20, 2015AB ALKEM LABS LTD20MGA202295 006 Oct 20, 2015AB APOTEX INC2.5MGA090798 001 Apr 23, 2012AB APOTEX INC5MGA090798 002 Apr 23, 2012AB APOTEX INC7.5MGA090798 003 Apr 23, 2012AB APOTEX INC10MGA090798 004 Apr 23, 2012AB APOTEX INC15MGA090798 005 Apr 23, 2012AB APOTEX INC20MGA090798 006 Apr 23, 2012AB AUROBINDO PHARMA LTD2.5MGA202050 001 Apr 23, 2012AB AUROBINDO PHARMA LTD5MGA202050 002 Apr 23, 2012AB AUROBINDO PHARMA LTD7.5MGA202050 003 Apr 23, 2012AB AUROBINDO PHARMA LTD10MGA202050 004 Apr 23, 2012AB AUROBINDO PHARMA LTD15MGA202050 005 Apr 23, 2012AB AUROBINDO PHARMA LTD20MGA202050 006 Apr 23, 2012AB DR REDDYS LABS LTD2.5MGA076255 001 Apr 23, 2012AB DR REDDYS LABS LTD5MGA076255 002 Apr 23, 2012AB DR REDDYS LABS LTD7.5MGA076255 003 Apr 23, 2012AB DR REDDYS LABS LTD10MGA076255 004 Apr 23, 2012AB DR REDDYS LABS LTD15MGA076133 001 Apr 23, 2012

## PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>		<u>20MG</u>	<u>A076133</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>	IVAX PHARMS INC	<u>20MG</u>	<u>A077301</u>	<u>001</u>	Apr 29, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A202862</u>	<u>001</u>	Aug 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202862</u>	<u>002</u>	Aug 15, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202862</u>	<u>003</u>	Aug 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202862</u>	<u>004</u>	Aug 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A202862</u>	<u>005</u>	Aug 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A202862</u>	<u>006</u>	Aug 15, 2014
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076866</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076866</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076866</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076866</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076866</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076866</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A076000</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>5MG</u>	<u>A076000</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A076000</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076000</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076000</u>	<u>005</u>	Oct 24, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A091434</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091434</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091434</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091434</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091434</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091434</u>	<u>006</u>	Apr 23, 2012

ZYPREXA

<u>AB</u>	LILLY	<u>2.5MG</u>	<u>N020592</u>	<u>001</u>	Sep 30, 1996
<u>AB</u>	+	<u>5MG</u>	<u>N020592</u>	<u>002</u>	Sep 30, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N020592</u>	<u>003</u>	Sep 30, 1996
<u>AB</u>		<u>10MG</u>	<u>N020592</u>	<u>004</u>	Sep 30, 1996
<u>AB</u>		<u>15MG</u>	<u>N020592</u>	<u>005</u>	Sep 09, 1997
<u>AB</u>		<u>20MG</u>	<u>N020592</u>	<u>006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203708</u>	<u>001</u>	May 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A203708</u>	<u>002</u>	May 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A203708</u>	<u>003</u>	May 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A203708</u>	<u>004</u>	May 15, 2014
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243</u>	<u>004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076534</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200221</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221</u>	<u>004</u>	Sep 12, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203044</u>	<u>001</u>	Feb 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A203044</u>	<u>002</u>	Feb 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A203044</u>	<u>003</u>	Feb 20, 2015

## PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

<u>AB</u>		<u>20MG</u>	<u>A203044</u>	<u>004</u>	Feb 20, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A202285</u>	<u>001</u>	May 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A202285</u>	<u>002</u>	May 12, 2014
<u>AB</u>		<u>15MG</u>	<u>A202285</u>	<u>003</u>	May 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A202285</u>	<u>004</u>	May 12, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A202937</u>	<u>001</u>	Mar 02, 2015
<u>AB</u>		<u>10MG</u>	<u>A202937</u>	<u>002</u>	Mar 02, 2015
<u>AB</u>		<u>15MG</u>	<u>A202937</u>	<u>003</u>	Mar 02, 2015
<u>AB</u>		<u>20MG</u>	<u>A202937</u>	<u>004</u>	Mar 02, 2015
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881</u>	<u>001</u>	Feb 28, 2012
<u>AB</u>		<u>10MG</u>	<u>A090881</u>	<u>002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881</u>	<u>003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881</u>	<u>004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415</u>	<u>003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415</u>	<u>004</u>	Oct 25, 2011
	<u>ZYPREXA ZYDIS</u>				
<u>AB</u>	+ LILLY	<u>5MG</u>	<u>N021086</u>	<u>001</u>	Apr 06, 2000
<u>AB</u>		<u>10MG</u>	<u>N021086</u>	<u>002</u>	Apr 06, 2000
<u>AB</u>		<u>15MG</u>	<u>N021086</u>	<u>003</u>	Apr 06, 2000
<u>AB</u>		<u>20MG</u>	<u>N021086</u>	<u>004</u>	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
	+	EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLAPARIB

CAPSULE;ORAL

LYNPARZA

	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014
--	--------------------	------	---------	-----	--------------

OLIVE OIL; SOYBEAN OIL

INJECTABLE;INJECTION

CLINOLIPID 20%

	+ BAXTER HLTHCARE	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013
--	-------------------	------------------------------------	---------	-----	--------------

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

	DAIICHI SANKYO	5MG	N021286	001	Apr 25, 2002
		20MG	N021286	003	Apr 25, 2002
	+	40MG	N021286	004	Apr 25, 2002

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION

STRIVERDI RESPIMAT

	+ BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014
--	------------------------	----------------------	---------	-----	--------------

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

	+ BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015
--	------------------------	---	---------	-----	--------------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

<u>AT</u>	APOTEX INC	<u>EQ 0.1% BASE</u>	<u>A078350</u>	<u>001</u>	Dec 07, 2015
<u>AT</u>	AUROBINDO PHARMA LTD	<u>EQ 0.1% BASE</u>	<u>A204812</u>	<u>001</u>	Dec 18, 2015
<u>AT</u>	BARR LABS INC	<u>EQ 0.2% BASE</u>	<u>A090848</u>	<u>001</u>	Jul 13, 2015
<u>AT</u>	NOVEL LABS INC	<u>EQ 0.1% BASE</u>	<u>A206306</u>	<u>001</u>	Dec 07, 2015
<u>AT</u>	USV NORTH AMERICA	<u>EQ 0.1% BASE</u>	<u>A203152</u>	<u>001</u>	Dec 07, 2015
<u>AT</u>	ZACH SYSTEM SPA	<u>EQ 0.1% BASE</u>	<u>A204706</u>	<u>001</u>	Dec 07, 2015
	<u>PATADAY</u>				
<u>AT</u>	+ ALCON PHARMS LTD	<u>EQ 0.2% BASE</u>	<u>N021545</u>	<u>001</u>	Dec 22, 2004



## PRESCRIPTION DRUG PRODUCT LIST

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PATANOL

<b>AT</b>	+ ALCON	<b>EQ 0.1% BASE</b>	<b>N020688 001</b>	Dec 18, 1996
	PAZEO			

	+ ALCON RES LTD	EQ 0.7% BASE	N206276 001	Jan 30, 2015
	SPRAY, METERED;NASAL			

OLOPATADINE HYDROCHLORIDE

<b>AB</b>	APOTEX INC	<b>0.665MG/SPRAY</b>	<b>A091572 001</b>	Oct 08, 2014
-----------	------------	----------------------	--------------------	--------------

PATANASE

<b>AB</b>	+ ALCON PHARMS LTD	<b>0.665MG/SPRAY</b>	<b>N021861 001</b>	Apr 15, 2008
-----------	--------------------	----------------------	--------------------	--------------

OLSALAZINE SODIUM

CAPSULE;ORAL

DIPENTUM

	+ MEDA PHARMS	250MG	N019715 001	Jul 31, 1990
--	---------------	-------	-------------	--------------

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS

SYNRIBO

	+ IVAX INTL	3.5MG/VIAL	N203585 001	Oct 26, 2012
--	-------------	------------	-------------	--------------

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL

TECHNIVIE

	+ ABBVIE INC	12.5MG;75MG;50MG	N207931 001	Jul 24, 2015
--	--------------	------------------	-------------	--------------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

<b>AB</b>	+ SMITHKLINE BEECHAM	<b>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</b>	<b>N021654 001</b>	Nov 10, 2004
-----------	----------------------	---	--------------------	--------------

OMEGA-3-ACID ETHYL ESTERS

<b>AB</b>	AMNEAL PHARMS	<b>1 GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</b>	<b>A204940 001</b>	Nov 27, 2015
-----------	---------------	--	--------------------	--------------

<b>AB</b>	APOTEX INC	<b>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</b>	<b>A090973 001</b>	Sep 30, 2014
-----------	------------	---	--------------------	--------------

<b>AB</b>	PAR PHARM INC	<b>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</b>	<b>A091018 001</b>	Jun 24, 2014
-----------	---------------	---	--------------------	--------------

<b>AB</b>	TEVA PHARMS USA	<b>1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS</b>	<b>A091028 001</b>	Apr 07, 2014
-----------	-----------------	---	--------------------	--------------

OMTRYG

	+ TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977 001	Apr 23, 2014
--	---------	--	-------------	--------------

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

	+ ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060 001	May 05, 2014
--	----------------------	--	-------------	--------------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

<b>AB</b>	ACTAVIS LABS FL INC	<b>10MG</b>	<b>A075347 001</b>	May 30, 2008
-----------	---------------------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A075347 002</b>	May 30, 2008
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A075347 003</b>	May 30, 2008
-----------	--	-------------	--------------------	--------------

<b>AB</b>	APOTEX	<b>10MG</b>	<b>A076048 001</b>	Oct 22, 2007
-----------	--------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A076048 002</b>	Oct 22, 2007
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A076048 003</b>	Jan 21, 2009
-----------	--	-------------	--------------------	--------------

<b>AB</b>	AUROBINDO PHARMA USA	<b>10MG</b>	<b>A203270 001</b>	Aug 19, 2015
-----------	----------------------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A203270 002</b>	Aug 19, 2015
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A203270 003</b>	Aug 19, 2015
-----------	--	-------------	--------------------	--------------

<b>AB</b>	DR REDDYS LABS LTD	<b>10MG</b>	<b>A075576 003</b>	Oct 22, 2007
-----------	--------------------	-------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A078490 002</b>	Mar 16, 2009
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A075576 002</b>	Oct 22, 2007
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A078490 003</b>	Mar 16, 2009
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A075576 001</b>	Jan 21, 2009
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A078490 001</b>	Apr 17, 2009
-----------	--	-------------	--------------------	--------------

<b>AB</b>	GLENMARK GENERICS	<b>10MG</b>	<b>A091672 001</b>	Oct 31, 2014
-----------	-------------------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A091672 002</b>	Oct 31, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A091672 003</b>	Oct 31, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>	IMPAX LABS	<b>10MG</b>	<b>A075785 001</b>	Oct 22, 2007
-----------	------------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A075785 002</b>	Oct 22, 2007
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A075785 003</b>	Jan 21, 2009
-----------	--	-------------	--------------------	--------------

<b>AB</b>	KREMERS URBAN PHARMS	<b>10MG</b>	<b>A075410 001</b>	Nov 01, 2002
-----------	----------------------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A075410 002</b>	Nov 01, 2002
-----------	--	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

<u>AB</u>		<u>40MG</u>	<u>A075410 003</u>	Jan 23, 2009
<u>AB</u>	LUPIN LTD	<u>40MG</u>	<u>A202384 001</u>	Aug 25, 2015
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075876 001</u>	May 29, 2003
<u>AB</u>		<u>20MG</u>	<u>A075876 002</u>	May 29, 2003
<u>AB</u>		<u>40MG</u>	<u>A075876 003</u>	Jan 21, 2009
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075757 001</u>	Jan 28, 2003
<u>AB</u>		<u>20MG</u>	<u>A075757 002</u>	Jan 28, 2003
<u>AB</u>		<u>40MG</u>	<u>A076515 001</u>	Jan 21, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>10MG</u>	<u>A091352 001</u>	Nov 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A091352 002</u>	Nov 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A091352 003</u>	Nov 19, 2012

PRILOSEC

<u>AB</u>	ASTRAZENECA PHARMS	<u>10MG</u>	<u>N019810 003</u>	Oct 05, 1995
<u>AB</u>	+	<u>20MG</u>	<u>N019810 001</u>	Sep 14, 1989
<u>AB</u>	+	<u>40MG</u>	<u>N019810 002</u>	Jan 15, 1998

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N022056 001	Mar 20, 2008
+		EQ 10MG BASE/PACKET	N022056 002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	PAR PHARM	<u>20MG;1.1GM</u>	<u>A078966 001</u>	May 25, 2010
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A078966 002</u>	May 25, 2010

ZEGERID

<u>AB</u>	SANTARUS INC	<u>20MG;1.1GM</u>	<u>N021849 001</u>	Feb 27, 2006
<u>AB</u>	+	<u>40MG;1.1GM</u>	<u>N021849 002</u>	Feb 27, 2006

FOR SUSPENSION;ORAL

ZEGERID

	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636 001	Jun 15, 2004
+		40MG/PACKET;1.68GM/PACKET	N021636 002	Dec 21, 2004

ONDANSETRON

FILM;ORAL

ZUPLENZ

	GALENA BIOPHARMA INC	4MG	N022524 001	Jul 02, 2010
+		8MG	N022524 002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

<u>AB</u>	AUROBINDO PHARMA	<u>4MG</u>	<u>A090469 001</u>	Apr 12, 2010
<u>AB</u>		<u>8MG</u>	<u>A090469 002</u>	Apr 12, 2010
<u>AB</u>	BARR	<u>4MG</u>	<u>A076693 001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076693 002</u>	Jun 25, 2007
<u>AB</u>	GLENMARK GENERICS	<u>4MG</u>	<u>A078152 001</u>	Jun 27, 2007
<u>AB</u>		<u>8MG</u>	<u>A078152 002</u>	Jun 27, 2007
<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078139 001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A078139 002</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078050 001</u>	Aug 13, 2007
<u>AB</u>		<u>8MG</u>	<u>A078050 002</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077557 001</u>	Aug 02, 2007
<u>AB</u>		<u>8MG</u>	<u>A077557 002</u>	Aug 02, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>4MG</u>	<u>A078602 001</u>	Feb 24, 2011
<u>AB</u>		<u>8MG</u>	<u>A078602 002</u>	Feb 24, 2011
<u>AB</u>	TEVA	<u>4MG</u>	<u>A076810 001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076810 002</u>	Jun 25, 2007

ZOFRAN ODT

<u>AB</u>	NOVARTIS PHARMS CORP	<u>4MG</u>	<u>N020781 001</u>	Jan 27, 1999
<u>AB</u>	+	<u>8MG</u>	<u>N020781 002</u>	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206846 001</u>	Jul 13, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202599 001</u>	Dec 21, 2012
<u>AP</u>	BEDFORD	<u>EQ 2MG BASE/ML</u>	<u>A076967 001</u>	Dec 26, 2006
<u>AP</u>	CLARIS PHARMASERVICE	<u>EQ 2MG BASE/ML</u>	<u>A078288 001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A090424 001</u>	Apr 16, 2010
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 2MG BASE/ML</u>	<u>A077365 001</u>	Dec 26, 2006

## PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076974 001</u>	Dec 26, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224 001</u>	Sep 25, 2009
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A090648 001</u>	Jun 15, 2012
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781 001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473 001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077840 001</u>	Jan 19, 2007
<u>AP</u>	LANNETT	<u>EQ 2MG BASE/ML</u>	<u>A090883 001</u>	Aug 05, 2010
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079039 001</u>	Nov 18, 2008
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078257 001</u>	Apr 23, 2008
<u>AP</u>	QILU PHARM CO LTD	<u>EQ 2MG BASE/ML</u>	<u>A203711 001</u>	Sep 08, 2014
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077430 001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS (IN)	<u>EQ 2MG BASE/ML</u>	<u>A077172 001</u>	Dec 26, 2006
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076876 001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577 001</u>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202600 001</u>	Dec 21, 2012
<u>AP</u>	BD RX	<u>EQ 2MG BASE/ML</u>	<u>A202253 001</u>	Jul 19, 2013
<u>AP</u>	BEDFORD LABS	<u>EQ 2MG BASE/ML</u>	<u>A077011 001</u>	Dec 26, 2006
<u>AP</u>	CLARIS PHARMASERVICE	<u>EQ 2MG BASE/ML</u>	<u>A078287 001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078945 001</u>	Jan 03, 2013
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 2MG BASE/ML</u>	<u>A077541 001</u>	Dec 26, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972 001</u>	Dec 26, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780 001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548 001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079032 001</u>	Nov 18, 2008
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078244 001</u>	Apr 23, 2008
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077551 001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173 001</u>	Dec 26, 2006
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076759 001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716 001</u>	Dec 26, 2006

ZOFRAN

<u>AP</u>	+ NOVARTIS PHARMS CORP	<u>EQ 2MG BASE/ML</u>	<u>N020007 001</u>	Jan 04, 1991
-----------	------------------------	-----------------------	--------------------	--------------

ZOFRAN PRESERVATIVE FREE

<u>AP</u>	+ NOVARTIS PHARMS CORP	<u>EQ 2MG BASE/ML</u>	<u>N020007 003</u>	Dec 10, 1993
-----------	------------------------	-----------------------	--------------------	--------------

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483 001</u>	Jan 31, 2011
<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127 001</u>	Jun 25, 2007
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776 001</u>	Nov 28, 2007
<u>AA</u>	ROXANE	<u>EQ 4MG BASE/5ML</u>	<u>A076960 001</u>	Dec 26, 2006
<u>AA</u>	SILARX	<u>EQ 4MG BASE/5ML</u>	<u>A091342 001</u>	Jan 27, 2011
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009 001</u>	Nov 30, 2007

ZOFRAN

<u>AA</u>	+ NOVARTIS PHARMS CORP	<u>EQ 4MG BASE/5ML</u>	<u>N020605 001</u>	Jan 24, 1997
-----------	------------------------	------------------------	--------------------	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306 002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539 001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539 002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539 003</u>	Jul 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183 003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183 002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183 001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535 003</u>	Jun 25, 2007
<u>AB</u>	IPCA LABS LTD	<u>EQ 4MG BASE</u>	<u>A203761 001</u>	Jan 23, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A203761 002</u>	Jan 23, 2014
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076930 004</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851 002</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112 003</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077517 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517 002</u>	Jun 25, 2007

## PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517 003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050 002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252 003</u>	Jun 25, 2007

ZOFRAN

<u>AB</u>	NOVARTIS PHARMS CORP	<u>EQ 4MG BASE</u>	<u>N020103 001</u>	Dec 31, 1992
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N020103 002</u>	Dec 31, 1992
<u>AB</u>	+	<u>EQ 24MG BASE</u>	<u>N020103 003</u>	Aug 27, 1999
	ONDANSETRON HYDROCHLORIDE DR REDDYS LABS LTD	EQ 16MG BASE	A076183 004	Dec 26, 2006

ORITAVANCIN DIPHOSPHATE

POWDER; IV (INFUSION)

ORBACTIV

	+	THE MEDICINES CO	EQ 400MG BASE/VIAL	N206334 001	Aug 06, 2014
--	---	------------------	--------------------	-------------	--------------

ORLISTAT

CAPSULE; ORAL

XENICAL

	+	HOFFMANN LA ROCHE	120MG	N020766 001	Apr 23, 1999
--	---	-------------------	-------	-------------	--------------

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

<u>AP</u>	+	AKORN	<u>30MG/ML</u>	<u>A040484 001</u>	May 24, 2006
<u>AP</u>		EUROHLTH INTL SARL	<u>30MG/ML</u>	<u>A040463 001</u>	Mar 04, 2003
<u>AP</u>		SAGENT PHARMS	<u>30MG/ML</u>	<u>A090585 001</u>	Aug 30, 2011
<u>AP</u>		WATSON LABS	<u>30MG/ML</u>	<u>A084779 001</u>	Mar 15, 1982

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

<u>AB</u>		GAVIS PHARMS	<u>100MG</u>	<u>A040284 001</u>	Jun 19, 1998
<u>AB</u>		IMPAX PHARMS	<u>100MG</u>	<u>A040368 001</u>	Jun 23, 2000
<u>AB</u>		INVAGEN PHARMS	<u>100MG</u>	<u>A091158 001</u>	Jul 27, 2012
<u>AB</u>	+	SANDOZ	<u>100MG</u>	<u>A040327 001</u>	Feb 15, 2000
<u>AB</u>		TEDOR PHARMA INC	<u>100MG</u>	<u>A040249 001</u>	Jan 29, 1999

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

TAMIFLU

		ROCHE	EQ 30MG BASE	N021087 003	Jul 02, 2007
			EQ 45MG BASE	N021087 002	Jul 02, 2007
	+		EQ 75MG BASE	N021087 001	Oct 27, 1999

FOR SUSPENSION; ORAL

TAMIFLU

	+	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011
--	---	-------	----------------	-------------	--------------

OSIMERTINIB MESYLATE

TABLET; ORAL

TAGRISSO

		ASTRAZENECA PHARMS	EQ 40MG BASE	N208065 001	Nov 13, 2015
	+		EQ 80MG BASE	N208065 002	Nov 13, 2015

OSPEMIFENE

TABLET; ORAL

OSPHENA

	+	SHIONOGI INC	60MG	N203505 001	Feb 26, 2013
--	---	--------------	------	-------------	--------------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201539 001</u>	Jan 18, 2013
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A201539 002</u>	Jan 18, 2013
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A201538 001</u>	Jan 18, 2013
<u>AP</u>		HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A203950 001</u>	Dec 11, 2015
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A203950 002</u>	Dec 11, 2015
<u>AP</u>		MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091486 001</u>	Aug 25, 2014
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091486 002</u>	Aug 25, 2014
<u>AP</u>		SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091246 001</u>	Mar 30, 2012
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091246 002</u>	Mar 30, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A091245 001</u>	Mar 30, 2012
<u>AP</u>	+	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A061490 003</u>	

## PRESCRIPTION DRUG PRODUCT LIST

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A061490 004</u>	
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL</u>	<u>A061490 006</u>	May 09, 1991
		BACTOCILL IN PLASTIC CONTAINER			
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640 001	Oct 26, 1989
	+		EQ 40MG BASE/ML	N050640 002	Oct 26, 1989

POWDER; INTRAVENOUS

OXACILLIN SODIUM

<u>AP</u>	+	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062737 001</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062737 002</u>	Dec 23, 1986

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

<u>AP</u>	+	SANOFI AVENTIS US	<u>50MG/10ML (5MG/ML)</u>	<u>N021759 001</u>	Jan 31, 2005
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N021759 002</u>	Jan 31, 2005

OXALIPLATIN

<u>AP</u>		ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078803 001</u>	Aug 08, 2012
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078803 002</u>	Aug 08, 2012
<u>AP</u>		EBEWE PHARMA	<u>50MG/10ML (5MG/ML)</u>	<u>A078812 001</u>	Aug 07, 2009
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078812 002</u>	Aug 07, 2009
<u>AP</u>		FRESENIUS KABI ONCOL	<u>50MG/10ML (5MG/ML)</u>	<u>A078811 001</u>	Jun 10, 2010
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078811 002</u>	Jun 10, 2010
<u>AP</u>			<u>50MG/VIAL</u>	<u>A078810 001</u>	Aug 07, 2009
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078810 002</u>	Aug 07, 2009
<u>AP</u>		FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>A078819 001</u>	Jun 02, 2010
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078819 002</u>	Jun 02, 2010
<u>AP</u>		HOSPIRA INC	<u>50MG/VIAL</u>	<u>A078815 001</u>	Sep 30, 2009
<u>AP</u>			<u>100MG/VIAL</u>	<u>A078815 002</u>	Sep 30, 2009
<u>AP</u>		HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813 001</u>	Aug 07, 2009
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078813 002</u>	Aug 07, 2009
<u>AP</u>		JIANGSU HENGRUI MED	<u>50MG/10ML (5MG/ML)</u>	<u>A203869 001</u>	Jun 18, 2014
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A203869 002</u>	Jun 18, 2014
<u>AP</u>		MYLAN LABS LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358 001</u>	Aug 07, 2012
<u>AP</u>			<u>50MG/VIAL</u>	<u>A200979 001</u>	Aug 08, 2012
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A091358 002</u>	Aug 07, 2012
<u>AP</u>			<u>100MG/VIAL</u>	<u>A200979 002</u>	Aug 08, 2012
<u>AP</u>		SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817 001</u>	Jan 24, 2011
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A078817 002</u>	Jan 24, 2011
<u>AP</u>	+	SUN PHARMA GLOBAL	<u>50MG/VIAL</u>	<u>A078818 001</u>	Aug 07, 2009
<u>AP</u>			<u>50MG/10ML (5MG/ML)</u>	<u>A202922 001</u>	Apr 08, 2014
<u>AP</u>	+		<u>100MG/VIAL</u>	<u>A078818 002</u>	Aug 07, 2009
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A202922 002</u>	Apr 08, 2014
<u>AP</u>	+	TEVA PHARMS	<u>50MG/10ML (5MG/ML)</u>	<u>N022160 001</u>	Aug 07, 2009
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N022160 002</u>	Aug 07, 2009
		ELOXATIN			
	+	SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759 003	Nov 17, 2006

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>		GEMINI LABS LLC	<u>2.5MG</u>	<u>N013718 001</u>	
<u>AB</u>	+		<u>10MG</u>	<u>N013718 002</u>	Nov 05, 2001

OXANDROLONE

<u>AB</u>		PAR PHARM	<u>2.5MG</u>	<u>A077827 001</u>	Jun 22, 2007
<u>AB</u>			<u>10MG</u>	<u>A077827 002</u>	Jun 22, 2007
<u>AB</u>		UPSHER SMITH	<u>2.5MG</u>	<u>A076761 001</u>	Dec 01, 2006
<u>AB</u>			<u>10MG</u>	<u>A078033 001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+	GD SEARLE	<u>600MG</u>	<u>N018841 004</u>	Oct 29, 1992
-----------	---	-----------	--------------	--------------------	--------------

OXAPROZIN

<u>AB</u>		APOTEX INC	<u>600MG</u>	<u>A075987 001</u>	Sep 02, 2004
<u>AB</u>		DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855 001</u>	Jan 31, 2001
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846 001</u>	May 13, 2002
<u>AB</u>		SANDOZ	<u>600MG</u>	<u>A075845 001</u>	Jan 31, 2001
<u>AB</u>		SUN PHARM INDS INC	<u>600MG</u>	<u>A075844 001</u>	Jan 03, 2002
<u>AB</u>		TEVA	<u>600MG</u>	<u>A075849 001</u>	Jul 03, 2002

## PRESCRIPTION DRUG PRODUCT LIST

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072251 001</u>	Apr 14, 1988
<u>AB</u>		<u>15MG</u>	<u>A072252 001</u>	Apr 14, 1988
<u>AB</u>	+	<u>30MG</u>	<u>A072253 001</u>	Apr 14, 1988
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A071813 001</u>	Apr 19, 1988
<u>AB</u>		<u>15MG</u>	<u>A071756 001</u>	Apr 19, 1988
<u>AB</u>		<u>30MG</u>	<u>A071814 001</u>	Apr 19, 1988

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961 001</u>	Sep 17, 2012
<u>AB</u>	ROXANE	<u>300MG/5ML</u>	<u>A201193 001</u>	Oct 03, 2012
<u>AB</u>	SUN PHARM INDS LTD	<u>300MG/5ML</u>	<u>A078734 001</u>	Jun 26, 2009
<u>AB</u>	+	<u>300MG/5ML</u>	<u>N021285 001</u>	May 25, 2001

TRILEPTAL

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>	APOTEX INC	<u>150MG</u>	<u>A077747 001</u>	Apr 09, 2008
<u>AB</u>		<u>300MG</u>	<u>A077747 002</u>	Apr 09, 2008
<u>AB</u>		<u>600MG</u>	<u>A077747 003</u>	Apr 09, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069 001</u>	Jan 11, 2008
<u>AB</u>		<u>300MG</u>	<u>A078069 002</u>	Jan 11, 2008
<u>AB</u>		<u>600MG</u>	<u>A078069 003</u>	Jan 11, 2008
<u>AB</u>	CADISTA PHARMS	<u>150MG</u>	<u>A090239 001</u>	Jan 25, 2010
<u>AB</u>		<u>300MG</u>	<u>A090239 002</u>	Jan 25, 2010
<u>AB</u>		<u>600MG</u>	<u>A090239 003</u>	Jan 25, 2010
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A077802 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077802 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077802 003</u>	Oct 09, 2007
<u>AB</u>	ROXANE	<u>150MG</u>	<u>A077795 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077795 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077795 003</u>	Oct 09, 2007
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794 003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801 001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801 002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801 003</u>	Nov 15, 2007
<u>AB</u>	+	<u>150MG</u>	<u>N021014 001</u>	Jan 14, 2000
<u>AB</u>		<u>300MG</u>	<u>N021014 002</u>	Jan 14, 2000
<u>AB</u>		<u>600MG</u>	<u>N021014 003</u>	Jan 14, 2000

TRILEPTAL

TABLET, EXTENDED RELEASE; ORAL

OXTELLAR XR

SUPERNUS PHARMS

+

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+ FOUGERA PHARMS

LOTION; TOPICAL

OXISTAT

+ FOUGERA PHARMS

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+ WARNER CHILCOTT LLC

+

600MG

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYBUTYNIN

<u>AB</u>	BARR LABS DIV TEVA	<u>3.9MG/24HR</u>	<u>A090526 001</u>	Mar 04, 2014
<u>AB</u>	+	<u>3.9MG/24HR</u>	<u>N021351 002</u>	Feb 26, 2003
	GEL, METERED; TRANSDERMAL			
	GELNIQUE 3%			
	+			
	ACTAVIS LABS UT INC	3%	<u>N202513 001</u>	Dec 07, 2011

## PRESCRIPTION DRUG PRODUCT LIST

OXYBUTYRNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ ACTAVIS LABS UT INC 10% (100MG/PACKET)

N022204 001 Jan 27, 2009

SYRUP; ORAL

OXYBUTYRNIN CHLORIDE

<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137</u>	<u>001</u>	Dec 18, 1998
<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A074520</u>	<u>001</u>	Mar 29, 1996
<u>AA</u>	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682</u>	<u>001</u>	Dec 28, 2004
<u>AA</u>	+ WOCKHARDT	<u>5MG/5ML</u>	<u>A074868</u>	<u>001</u>	Feb 12, 1997

TABLET; ORAL

OXYBUTYRNIN CHLORIDE

<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	USL PHARMA	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996
<u>AB</u>	+ VINTAGE PHARMS	<u>5MG</u>	<u>A075079</u>	<u>001</u>	Oct 31, 1997

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	JANSSEN PHARMS	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>		<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998
<u>AB</u>	+	<u>15MG</u>	<u>N020897</u>	<u>003</u>	Jun 22, 1999

OXYBUTYRNIN CHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A204010</u>	<u>001</u>	Nov 23, 2015
<u>AB</u>		<u>10MG</u>	<u>A204010</u>	<u>002</u>	Nov 23, 2015
<u>AB</u>		<u>15MG</u>	<u>A204010</u>	<u>003</u>	Nov 23, 2015
<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745</u>	<u>002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745</u>	<u>003</u>	May 09, 2007
<u>AB</u>		<u>15MG</u>	<u>A076745</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A076644</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A076644</u>	<u>002</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A202773</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A203107</u>	<u>001</u>	Jul 26, 2012
<u>AB</u>	LANNETT HOLDINGS INC	<u>5MG</u>	<u>A203823</u>	<u>001</u>	Aug 01, 2014
<u>AB</u>	+ LEHIGH VALLEY	<u>5MG</u>	<u>N200534</u>	<u>001</u>	Oct 20, 2010
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204752</u>	<u>001</u>	Aug 24, 2015

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS INC	<u>5MG/5ML</u>	<u>A204979</u>	<u>001</u>	Jun 01, 2015
<u>AA</u>	COASTAL PHARMS	<u>100MG/5ML</u>	<u>A204092</u>	<u>001</u>	Jun 05, 2014
<u>AA</u>	LANNETT HOLDINGS INC	<u>100MG/5ML</u>	<u>A204085</u>	<u>001</u>	Sep 09, 2014
<u>AA</u>	LEHIGH VALLEY	<u>5MG/5ML</u>	<u>N200535</u>	<u>002</u>	Aug 22, 2013
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N200535</u>	<u>001</u>	Oct 20, 2010
<u>AA</u>	NOVEL LABS INC	<u>100MG/5ML</u>	<u>A204603</u>	<u>001</u>	Apr 29, 2015
<u>AA</u>	ROXANE	<u>5MG/5ML</u>	<u>A204037</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>		<u>100MG/5ML</u>	<u>A203208</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>	+ VISTAPHARM	<u>5MG/5ML</u>	<u>N201194</u>	<u>001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537</u>	<u>001</u>	Jul 30, 2012
<u>AA</u>	WOCKHARDT BIO AG	<u>5MG/5ML</u>	<u>A206456</u>	<u>001</u>	Jun 16, 2015

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A076636</u>	<u>003</u>	Apr 07, 2015
<u>AB</u>		<u>15MG</u>	<u>A076636</u>	<u>001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636</u>	<u>002</u>	Feb 06, 2004
<u>AB</u>	ALVOGEN INC	<u>5MG</u>	<u>A202116</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116</u>	<u>003</u>	Dec 30, 2011
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203638</u>	<u>001</u>	Jun 03, 2014
<u>AB</u>		<u>10MG</u>	<u>A203638</u>	<u>002</u>	Jun 03, 2014
<u>AB</u>		<u>15MG</u>	<u>A203638</u>	<u>003</u>	Jun 03, 2014
<u>AB</u>		<u>20MG</u>	<u>A203638</u>	<u>004</u>	Jun 03, 2014
<u>AB</u>		<u>30MG</u>	<u>A203638</u>	<u>005</u>	Jun 03, 2014
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009

## PRESCRIPTION DRUG PRODUCT LIST

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A091393 003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393 004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393 005</u>	Aug 31, 2009
<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A091313 001</u>	Feb 18, 2011
<u>AB</u>		<u>15MG</u>	<u>A091313 002</u>	Feb 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A091313 003</u>	Feb 18, 2011
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A090895 001</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A090895 002</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A090895 003</u>	Aug 24, 2009
<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A202662 001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A202662 002</u>	Sep 22, 2015
<u>AB</u>		<u>15MG</u>	<u>A202662 003</u>	Sep 22, 2015
<u>AB</u>		<u>30MG</u>	<u>A202662 004</u>	Sep 22, 2015
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A076758 003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758 001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758 002</u>	Jun 30, 2004
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A077290 001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290 002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290 003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290 004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290 005</u>	Dec 08, 2005
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490 001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490 002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490 003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490 004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490 005</u>	Mar 09, 2011
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659 001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659 005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659 002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659 004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659 003</u>	Apr 10, 2009
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712 003</u>	Mar 02, 2009
<u>AB</u>		<u>10MG</u>	<u>A077712 004</u>	Apr 13, 2015
<u>AB</u>		<u>15MG</u>	<u>A077712 001</u>	Jan 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077712 005</u>	Apr 13, 2015
<u>AB</u>		<u>30MG</u>	<u>A077712 002</u>	Jan 31, 2007

ROXICODONE

<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>N021011 003</u>	May 15, 2009
<u>AB</u>	+	<u>15MG</u>	<u>N021011 001</u>	Aug 31, 2000
<u>AB</u>		<u>30MG</u>	<u>N021011 002</u>	Aug 31, 2000

OXAYDO

	EGALET US INC	5MG	N202080 001	Jun 17, 2011
		7.5MG	N202080 002	Jun 17, 2011

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

	PURDUE PHARMA LP	10MG	N022272 001	Apr 05, 2010
		15MG	N022272 002	Apr 05, 2010
		20MG	N022272 003	Apr 05, 2010
		30MG	N022272 004	Apr 05, 2010
	+	40MG	N022272 005	Apr 05, 2010
		60MG	N022272 006	Apr 05, 2010
		80MG	N022272 007	Apr 05, 2010

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

	+ MEDA PHARMS	50MG	N016848 001	
--	---------------	------	-------------	--

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

	+ ENDO PHARMS	1MG/ML	N011707 002	
--	---------------	--------	-------------	--

TABLET; ORAL

OPANA

<u>AB</u>	ENDO PHARMS	<u>5MG</u>	<u>N021611 001</u>	Jun 22, 2006
<u>AB</u>	+	<u>10MG</u>	<u>N021611 002</u>	Jun 22, 2006
<u>AB</u>		<u>5MG</u>	<u>A203601 001</u>	Jan 30, 2013
<u>AB</u>	AVANTHI INC	<u>10MG</u>	<u>A203601 002</u>	Jan 30, 2013
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A201187 001</u>	Dec 15, 2014



## PRESCRIPTION DRUG PRODUCT LIST

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A201187</u>	<u>002</u>	Dec 15, 2014
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A202321</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>10MG</u>	<u>A202321</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A090964</u>	<u>001</u>	Sep 27, 2010
<u>AB</u>		<u>10MG</u>	<u>A090964</u>	<u>002</u>	Sep 27, 2010
<u>AB</u>	TEVA	<u>5MG</u>	<u>A091443</u>	<u>002</u>	Feb 15, 2011
<u>AB</u>		<u>10MG</u>	<u>A091443</u>	<u>001</u>	Feb 15, 2011

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A079046</u>	<u>003</u>	Jul 11, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A079046</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>10MG</u>	<u>A079046</u>	<u>004</u>	Jul 11, 2013
<u>AB</u>		<u>15MG</u>	<u>A079046</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>		<u>20MG</u>	<u>A079046</u>	<u>005</u>	Jul 11, 2013
<u>AB</u>		<u>30MG</u>	<u>A079046</u>	<u>006</u>	Jul 11, 2013
<u>AB</u>		<u>40MG</u>	<u>A079046</u>	<u>007</u>	Jul 11, 2013
<u>AB</u>	IMPAX LABS	<u>5MG</u>	<u>A079087</u>	<u>001</u>	Jun 14, 2010
<u>AB</u>		<u>7.5MG</u>	<u>A079087</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>		<u>10MG</u>	<u>A079087</u>	<u>003</u>	Jun 14, 2010
<u>AB</u>		<u>15MG</u>	<u>A079087</u>	<u>004</u>	Dec 21, 2010
<u>AB</u>		<u>20MG</u>	<u>A079087</u>	<u>005</u>	Jun 14, 2010
<u>AB</u>		<u>30MG</u>	<u>A079087</u>	<u>006</u>	Jul 22, 2010
<u>AB</u>		<u>40MG</u>	<u>A079087</u>	<u>007</u>	Jun 14, 2010
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A202946</u>	<u>001</u>	Jun 27, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202946</u>	<u>002</u>	Jun 27, 2014
<u>AB</u>		<u>10MG</u>	<u>A202946</u>	<u>003</u>	Jun 27, 2014
<u>AB</u>		<u>15MG</u>	<u>A202946</u>	<u>004</u>	Jun 27, 2014
<u>AB</u>		<u>20MG</u>	<u>A202946</u>	<u>005</u>	Jun 27, 2014
<u>AB</u>		<u>30MG</u>	<u>A202946</u>	<u>006</u>	Jun 27, 2014
<u>AB</u>		<u>40MG</u>	<u>A202946</u>	<u>007</u>	Jun 27, 2014
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A200792</u>	<u>001</u>	Oct 24, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A200792</u>	<u>002</u>	Oct 24, 2014
<u>AB</u>		<u>10MG</u>	<u>A200792</u>	<u>003</u>	Oct 24, 2014
<u>AB</u>		<u>15MG</u>	<u>A200792</u>	<u>004</u>	Oct 24, 2014
<u>AB</u>		<u>20MG</u>	<u>A200792</u>	<u>005</u>	Oct 24, 2014
<u>AB</u>		<u>30MG</u>	<u>A200792</u>	<u>006</u>	Oct 24, 2014
<u>AB</u>		<u>40MG</u>	<u>A200792</u>	<u>007</u>	Oct 24, 2014
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A200822</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200822</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>10MG</u>	<u>A200822</u>	<u>004</u>	Jul 15, 2013
<u>AB</u>		<u>15MG</u>	<u>A200822</u>	<u>005</u>	Jul 15, 2013
<u>AB</u>		<u>20MG</u>	<u>A200822</u>	<u>006</u>	Jul 15, 2013
<u>AB</u>		<u>30MG</u>	<u>A200822</u>	<u>007</u>	Jul 15, 2013
<u>AB</u>		<u>40MG</u>	<u>A200822</u>	<u>001</u>	Jul 15, 2013
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A203506</u>	<u>001</u>	Apr 24, 2015
<u>AB</u>		<u>7.5MG</u>	<u>A203506</u>	<u>002</u>	Apr 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A203506</u>	<u>003</u>	Apr 24, 2015
<u>AB</u>		<u>15MG</u>	<u>A203506</u>	<u>004</u>	Apr 24, 2015
<u>AB</u>		<u>20MG</u>	<u>A203506</u>	<u>005</u>	Apr 24, 2015
<u>AB</u>		<u>30MG</u>	<u>A203506</u>	<u>006</u>	Apr 24, 2015
<u>AB</u>		<u>40MG</u>	<u>A203506</u>	<u>007</u>	Apr 24, 2015
	OPANA ER				
	ENDO PHARMS	5MG	N201655	001	Dec 09, 2011
		7.5MG	N201655	002	Dec 09, 2011
		10MG	N201655	003	Dec 09, 2011
		15MG	N201655	004	Dec 09, 2011
		20MG	N201655	005	Dec 09, 2011
		30MG	N201655	006	Dec 09, 2011
	+	40MG	N201655	007	Dec 09, 2011

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

+ PFIZER EQ 5MG BASE/GM; 10,000 UNITS/GM A061015 001

## PRESCRIPTION DRUG PRODUCT LIST

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

<u>AP</u>	+	EUROHLTH INTL SARL	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018243 001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018243 002</u>	Jan 10, 2007
<u>AP</u>	+	FRESENIUS KABI USA	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018248 001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018248 002</u>	
<u>AP</u>		HIKMA FARMACEUTICA	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>A200219 001</u>	Feb 13, 2013

PITOCIN

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018261 001</u>	
<u>AP</u>			<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018261 002</u>	Jul 27, 2007
		OXYTOCIN			
	+	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248 003	Jul 27, 2007
		PITOCIN			
		PAR STERILE PRODUCTS	500USP UNITS/50ML (10USP UNITS/ML)	N018261 003	Sep 05, 2012

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+ ABRAXIS BIOSCIENCE 100MG/VIAL

N021660 001 Jan 07, 2005

INJECTABLE; INJECTION

PACLITAXEL

<u>AP</u>		ACTAVIS TOTOWA	<u>6MG/ML</u>	<u>A090130 001</u>	Dec 09, 2009
<u>AP</u>		EBEWE PHARMA	<u>6MG/ML</u>	<u>A078167 001</u>	Dec 26, 2007
<u>AP</u>		EUROHLTH INTL SARL	<u>6MG/ML</u>	<u>A075190 001</u>	Jan 28, 2002
<u>AP</u>		FRESENIUS KABI ONCOL	<u>6MG/ML</u>	<u>A077574 001</u>	Nov 27, 2006
<u>AP</u>	+	HOSPIRA	<u>6MG/ML</u>	<u>A076131 001</u>	May 08, 2002
<u>AP</u>		MYLAN LABS LTD	<u>6MG/ML</u>	<u>A091540 001</u>	Sep 29, 2011
<u>AP</u>		TEVA PHARMS	<u>6MG/ML</u>	<u>A075184 001</u>	Jan 25, 2002

TAXOL

<u>AP</u>		HQ SPCLT PHARMA	<u>6MG/ML</u>	<u>N020262 001</u>	Dec 29, 1992
-----------	--	-----------------	---------------	--------------------	--------------

PALBOCICLIB

CAPSULE; ORAL

IBRANCE

		PFIZER INC	75MG	N207103 001	Feb 03, 2015
			100MG	N207103 002	Feb 03, 2015
	+		125MG	N207103 003	Feb 03, 2015

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

<u>AB</u>		JANSSEN PHARMS	<u>1.5MG</u>	<u>N021999 006</u>	Aug 26, 2008
<u>AB</u>			<u>3MG</u>	<u>N021999 001</u>	Dec 19, 2006
<u>AB</u>	+		<u>6MG</u>	<u>N021999 002</u>	Dec 19, 2006
<u>AB</u>			<u>9MG</u>	<u>N021999 003</u>	Dec 19, 2006

PALIPERIDONE

<u>AB</u>		ACTAVIS LABS FL INC	<u>1.5MG</u>	<u>A202645 001</u>	Aug 03, 2015
<u>AB</u>			<u>3MG</u>	<u>A202645 002</u>	Aug 03, 2015
<u>AB</u>			<u>6MG</u>	<u>A202645 003</u>	Aug 03, 2015
<u>AB</u>			<u>9MG</u>	<u>A202645 004</u>	Aug 03, 2015
<u>AB</u>		MYLAN PHARMS INC	<u>1.5MG</u>	<u>A203802 001</u>	Sep 24, 2015
<u>AB</u>			<u>3MG</u>	<u>A203802 002</u>	Sep 24, 2015
<u>AB</u>			<u>6MG</u>	<u>A203802 003</u>	Sep 24, 2015
<u>AB</u>			<u>9MG</u>	<u>A203802 004</u>	Sep 24, 2015

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

		JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001	Jul 31, 2009
			78MG/0.5ML (78MG/0.5ML)	N022264 002	Jul 31, 2009
	+		117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009
			156MG/ML (156MG/ML)	N022264 004	Jul 31, 2009
			234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009

INVEGA TRINZA

		JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946 001	May 18, 2015
			410MG/1.315ML (311.79MG/ML)	N207946 002	May 18, 2015
			546MG/1.75ML (312MG/ML)	N207946 003	May 18, 2015
	+		819MG/2.625ML (312MG/ML)	N207946 004	May 18, 2015

## PRESCRIPTION DRUG PRODUCT LIST

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

<u>AP</u>	+	HELINN HLTHCARE	<u>EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)</u>	<u>N021372 002</u>	Feb 29, 2008
<u>AP</u>	+		<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>N021372 001</u>	Jul 25, 2003
<u>PALONOSETRON HYDROCHLORIDE</u>					
<u>AP</u>		SANDOZ INC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A202521 001</u>	Oct 13, 2015
<u>AP</u>		TEVA PHARMS USA	<u>EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)</u>	<u>A090713 002</u>	Oct 13, 2015
<u>AP</u>			<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A090713 001</u>	Oct 13, 2015

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>		AREVA PHARMS	<u>30MG/VIAL</u>	<u>A077433 001</u>	Nov 26, 2008
<u>AP</u>			<u>60MG/VIAL</u>	<u>A077433 002</u>	Nov 26, 2008
<u>AP</u>			<u>90MG/VIAL</u>	<u>A077433 003</u>	Nov 26, 2008
<u>AP</u>		EUROHLTH INTL SARL	<u>30MG/VIAL</u>	<u>A075290 001</u>	Apr 30, 2001
<u>AP</u>	+		<u>30MG/10ML (3MG/ML)</u>	<u>N021113 001</u>	Mar 04, 2002
<u>AP</u>			<u>90MG/VIAL</u>	<u>A075290 003</u>	Apr 30, 2001
<u>AP</u>	+		<u>90MG/10ML (9MG/ML)</u>	<u>N021113 002</u>	Mar 04, 2002
<u>AP</u>		FRESENIUS KABI USA	<u>30MG/VIAL</u>	<u>A075773 001</u>	May 06, 2002
<u>AP</u>			<u>30MG/10ML (3MG/ML)</u>	<u>A076207 001</u>	May 17, 2002
<u>AP</u>			<u>90MG/VIAL</u>	<u>A075773 002</u>	May 06, 2002
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A076207 002</u>	May 17, 2002
<u>AP</u>	+	HOSPIRA	<u>30MG/10ML (3MG/ML)</u>	<u>A075841 001</u>	Jun 27, 2002
<u>AP</u>	+		<u>60MG/10ML (6MG/ML)</u>	<u>A075841 002</u>	Jun 27, 2002
<u>AP</u>	+		<u>90MG/10ML (9MG/ML)</u>	<u>A075841 003</u>	Jun 27, 2002
<u>AP</u>		LUITPOLD	<u>30MG/10ML (3MG/ML)</u>	<u>A078942 001</u>	Jul 25, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078942 002</u>	Jul 25, 2008
<u>AP</u>		MUSTAFA NEVZAT	<u>30MG/10ML (3MG/ML)</u>	<u>A078373 001</u>	Dec 23, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078373 002</u>	Dec 23, 2008
<u>AP</u>		MYLAN LABS LTD	<u>30MG/10ML (3MG/ML)</u>	<u>A078520 001</u>	Oct 31, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078520 002</u>	Oct 31, 2008
<u>AP</u>		PLIVA LACHEMA	<u>30MG/10ML (3MG/ML)</u>	<u>A078156 001</u>	Aug 19, 2008
<u>AP</u>			<u>60MG/10ML (6MG/ML)</u>	<u>A078156 002</u>	Aug 19, 2008
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A078156 003</u>	Aug 19, 2008
<u>AP</u>		SUN PHARMA GLOBAL	<u>30MG/VIAL</u>	<u>A077703 001</u>	Dec 24, 2008
<u>AP</u>			<u>90MG/VIAL</u>	<u>A077703 002</u>	Dec 24, 2008
<u>AP</u>		TEVA PHARMS USA	<u>30MG/10ML (3MG/ML)</u>	<u>A076153 001</u>	Mar 27, 2002
<u>AP</u>			<u>90MG/10ML (9MG/ML)</u>	<u>A076153 002</u>	Mar 27, 2002

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

## CREON

		ABBVIE	12,000USP UNITS\;38,000USP UNITS\;60,000USP UNITS\	N020725 002	Apr 30, 2009
			15,000USP UNITS\;3,000USP UNITS\;9,500USP UNITS\	N020725 004	Jul 12, 2011
			19,000USP UNITS\;30,000USP UNITS\;6,000USP UNITS\	N020725 001	Apr 30, 2009
			114,000USP UNITS;180,000USP UNITS;36,000USP UNITS	N020725 005	Mar 14, 2013
	+		120,000USP UNITS\;24,000USP UNITS\;76,000USP UNITS\	N020725 003	Apr 30, 2009

## PANCREAZE

		JANSSEN PHARMS	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523 005	Mar 07, 2014
			17,500USP UNITS;4,200USP UNITS;10,000USP UNITS	N022523 001	Apr 12, 2010
			43,750USP UNITS;10,500USP UNITS;25,000USP UNITS	N022523 002	Apr 12, 2010
	+		61,000USP UNITS;21,000USP UNITS;37,000USP UNITS	N022523 003	Apr 12, 2010
			70,000USP UNITS;16,800USP UNITS;40,000USP UNITS	N022523 004	Apr 12, 2010

## PERTZYE

		DIGESTIVE CARE INC	30,250USP UNITS;8,000USP UNITS;28,750USP UNITS	N022175 001	May 17, 2012
	+		60,500USP UNITS;16,000USP UNITS;57,500USP UNITS	N022175 002	May 17, 2012

## ULTRESA

		FOREST LABS INC	13,800USP UNITS;27,600USP UNITS;27,600USP UNITS	N022222 001	Mar 01, 2012
			20,700USP UNITS;41,400USP UNITS;41,400	N022222 002	Mar 01, 2012

## PRESCRIPTION DRUG PRODUCT LIST

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

ULTRESA

		USP UNITS			
+		23,000USP UNITS;46,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012

ZENPEP

	FOREST LABS INC	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014
		10,000USP UNITS;16,000USP UNITS;3,000USP UNITS	N022210	005	Jun 15, 2011
		10,000USP UNITS;34,000USP UNITS;55,000USP UNITS	N022210	002	Aug 27, 2009
		15,000USP UNITS;51,000USP UNITS;82,000USP UNITS	N022210	003	Aug 27, 2009
		17,000USP UNITS;27,000USP UNITS;5,000USP UNITS	N022210	001	Aug 27, 2009
		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009
+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011

TABLET;ORAL

VIOKACE

	FOREST LABS INC	10440USPU;39150USPU;39150USPU	N022542	001	Mar 01, 2012
+		20880USPU;78300USPU;78300USPU	N022542	002	Mar 01, 2012

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A072320</u>	<u>001</u>	Jan 19, 1989
<u>AP</u>	+ TEVA PHARMS USA	<u>1MG/ML</u>	<u>A072759</u>	<u>001</u>	Jul 31, 1990
<u>AP</u>	+	<u>2MG/ML</u>	<u>A072760</u>	<u>001</u>	Jul 31, 1990

PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015
		EQ 15MG BASE	N205353	002	Feb 23, 2015
+		EQ 20MG BASE	N205353	003	Feb 23, 2015

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PROTONIX

+	WYETH PHARMS INC	EQ 40MG BASE	N022020	001	Nov 14, 2007
---	------------------	--------------	---------	-----	--------------

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

<u>AP</u>	AKORN INC	<u>EQ 40MG BASE/VIAL</u>	<u>A079197</u>	<u>001</u>	Nov 08, 2012
<u>AP</u>	SANDOZ INC	<u>EQ 40MG BASE/VIAL</u>	<u>A090296</u>	<u>001</u>	Jul 14, 2015

PROTONIX IV

<u>AP</u>	+ WYETH PHARMS INC	<u>EQ 40MG BASE/VIAL</u>	<u>N020988</u>	<u>001</u>	Mar 22, 2001
-----------	--------------------	--------------------------	----------------	------------	--------------

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 20MG BASE</u>	<u>A090797</u>	<u>001</u>	Feb 07, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090797</u>	<u>002</u>	Feb 07, 2011
<u>AB</u>	APOTEX INC	<u>EQ 20MG BASE</u>	<u>A090807</u>	<u>001</u>	May 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090807</u>	<u>002</u>	May 02, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A202038</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202038</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A077619</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077619</u>	<u>002</u>	Jan 19, 2011
<u>AB</u>	HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A202882</u>	<u>001</u>	Sep 10, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202882</u>	<u>002</u>	Sep 10, 2014
<u>AB</u>	JUBILANT GENERICS	<u>EQ 20MG BASE</u>	<u>A090901</u>	<u>001</u>	Aug 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090901</u>	<u>002</u>	Aug 30, 2011
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 20MG BASE</u>	<u>A078281</u>	<u>001</u>	Jan 20, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078281</u>	<u>002</u>	Jan 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A200821</u>	<u>001</u>	Feb 16, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A200821</u>	<u>002</u>	Feb 16, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090970</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090970</u>	<u>002</u>	Jan 19, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 20MG BASE</u>	<u>A202052</u>	<u>001</u>	Dec 02, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202052</u>	<u>002</u>	Dec 02, 2014
<u>AB</u>	PERRIGO R AND D	<u>EQ 20MG BASE</u>	<u>A203024</u>	<u>001</u>	May 07, 2014
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 20MG BASE</u>	<u>A200794</u>	<u>001</u>	May 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A200794</u>	<u>002</u>	May 02, 2012

## PRESCRIPTION DRUG PRODUCT LIST

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE</u>	<u>A077058 001</u>	Sep 10, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077058 002</u>	Sep 10, 2007
<u>AB</u>	TEVA	<u>EQ 20MG BASE</u>	<u>A077056 001</u>	Aug 02, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077056 002</u>	Aug 02, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 20MG BASE</u>	<u>A090074 001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090074 002</u>	Jan 19, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 20MG BASE</u>	<u>A091231 001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091231 002</u>	Jan 19, 2011
<u>PROTONIX</u>				
<u>AB</u>	WYETH PHARMS INC	<u>EQ 20MG BASE</u>	<u>N020987 002</u>	Jun 12, 2001
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020987 001</u>	Feb 02, 2000

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

<u>AB</u>	AMNEAL PHARMS	<u>1MCG</u>	<u>A204327 001</u>	Jan 13, 2016
<u>AB</u>		<u>2MCG</u>	<u>A204327 002</u>	Jan 13, 2016
<u>AB</u>		<u>4MCG</u>	<u>A204327 003</u>	Jan 13, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1MCG</u>	<u>A207672 001</u>	Jan 14, 2016
<u>AB</u>		<u>2MCG</u>	<u>A207672 002</u>	Jan 14, 2016
<u>AB</u>		<u>4MCG</u>	<u>A207672 003</u>	Jan 14, 2016
<u>AB</u>	BANNER LIFE SCIENCES	<u>1MCG</u>	<u>A202539 001</u>	Mar 27, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202539 002</u>	Mar 27, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202539 003</u>	Mar 27, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>1MCG</u>	<u>A091412 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A091412 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A091412 003</u>	Jun 24, 2014
<u>AB</u>	RISING PHARMS INC	<u>1MCG</u>	<u>A202124 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202124 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202124 003</u>	Jun 24, 2014
<u>AB</u>	TEVA PHARMS USA	<u>1MCG</u>	<u>A090829 001</u>	Sep 27, 2013
<u>AB</u>		<u>2MCG</u>	<u>A090829 002</u>	Sep 27, 2013
<u>AB</u>		<u>4MCG</u>	<u>A090829 003</u>	Sep 27, 2013

ZEMPLAR

<u>AB</u>	ABBVIE	<u>1MCG</u>	<u>N021606 001</u>	May 26, 2005
<u>AB</u>		<u>2MCG</u>	<u>N021606 002</u>	May 26, 2005
<u>AB</u>	+	<u>4MCG</u>	<u>N021606 003</u>	May 26, 2005

SOLUTION; INTRAVENOUS

PARICALCITOL

<u>AP</u>	HIKMA PHARMS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N205917 001</u>	Nov 18, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N205917 002</u>	Nov 18, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N205917 003</u>	Nov 18, 2014
<u>AP</u>	HOSPIRA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N201657 001</u>	Oct 21, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N201657 002</u>	Oct 21, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N201657 003</u>	Oct 21, 2014
<u>AP</u>	SANDOZ CANADA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A091108 001</u>	Jul 27, 2011
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A091108 002</u>	Jul 27, 2011
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A091108 003</u>	Jul 27, 2011

ZEMPLAR

<u>AP</u>	+	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N020819 002</u>	Feb 01, 2000
<u>AP</u>	+	<u>0.005MG/ML (0.005MG/ML)</u>	<u>N020819 001</u>	Apr 17, 1998
<u>AP</u>	+	<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N020819 003</u>	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173 001</u>	Dec 14, 2007
<u>AA</u>	+	<u>EQ 250MG BASE</u>	<u>A064171 001</u>	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

<u>AB</u>	+	<u>APOTEX TECHNOLOGIES</u>	<u>EQ 10MG BASE/5ML</u>	<u>N020710 001</u>	Jun 25, 1997
-----------	---	----------------------------	-------------------------	--------------------	--------------

TABLET; ORAL

PAROXETINE

<u>AB</u>	PRINSTON INC	<u>EQ 10MG BASE</u>	<u>A203854 001</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203854 002</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203854 003</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203854 004</u>	Oct 31, 2014

## PRESCRIPTION DRUG PRODUCT LIST

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356 001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356 002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356 003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356 004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406 001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406 002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406 003</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406 004</u>	Jul 25, 2007
<u>AB</u>	JUBILANT GENERICS	<u>EQ 10MG BASE</u>	<u>A205528 001</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205528 002</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A205528 003</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205528 004</u>	Nov 27, 2015
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902 001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902 002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902 003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902 004</u>	Mar 13, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075716 001</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075716 002</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075716 003</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075716 004</u>	Mar 08, 2004
<u>AB</u>	PROSAM LABS	<u>EQ 10MG BASE</u>	<u>A076968 001</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076968 002</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076968 003</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076968 004</u>	Jun 21, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 10MG BASE</u>	<u>A078194 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078194 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078194 003</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078194 004</u>	Jun 29, 2007
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076618 001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618 002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618 003</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076618 004</u>	Aug 15, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584 001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584 002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584 003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584 004</u>	Mar 07, 2007

PAXIL

<u>AB</u>	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE</u>	<u>N020031 001</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020031 002</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N020031 003</u>	Dec 29, 1992
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020031 005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091427 001</u>	Apr 14, 2011

PAXIL CR

<u>AB</u>	APOTEX TECHNOLOGIES	<u>EQ 12.5MG BASE</u>	<u>N020936 001</u>	Feb 16, 1999
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N020936 002</u>	Feb 16, 1999
<u>AB</u>	+	<u>EQ 37.5MG BASE</u>	<u>N020936 003</u>	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

+ NOVEN THERAP

EQ 7.5MG BASE

N204516 001 Jun 28, 2013

TABLET; ORAL

PEXEVA

NOVEN THERAP

EQ 10MG BASE

N021299 001 Jul 03, 2003

EQ 20MG BASE

N021299 002 Jul 03, 2003

EQ 30MG BASE

N021299 003 Jul 03, 2003

+

EQ 40MG BASE

N021299 004 Jul 03, 2003

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS

SIGNIFOR

NOVARTIS

EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)

N200677 001 Dec 14, 2012

EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)

N200677 002 Dec 14, 2012

+

EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)

N200677 003 Dec 14, 2012

## PRESCRIPTION DRUG PRODUCT LIST

PASIREOTIDE PAMOATE

POWDER; INTRAMUSCULAR

SIGNIFOR LAR

NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255 001	Dec 15, 2014
	EQ 40MG BASE/VIAL	N203255 002	Dec 15, 2014
+	EQ 60MG BASE/VIAL	N203255 003	Dec 15, 2014

PATIROMER SORBITE X CALCIUM

POWDER; ORAL

VELTASSA

RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739 001	Oct 21, 2015
	EQ 16.8GM BASE/PACKET	N205739 002	Oct 21, 2015
+	EQ 25.2GM BASE/PACKET	N205739 003	Oct 21, 2015

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+ NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465 001	Oct 19, 2009
------------------------	---------------	-------------	--------------

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+ SIGMA TAU	250 UNITS/ML	N019818 001	Mar 21, 1990
-------------	--------------	-------------	--------------

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+ VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004
----------------------	----------------------	-------------	--------------

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+ PHARMACIA AND UPJOHN	10MG/VIAL	N021106 001	Mar 25, 2003
+	15MG/VIAL	N021106 002	Mar 25, 2003
+	20MG/VIAL	N021106 003	Mar 25, 2003
+	25MG/VIAL	N021106 004	Jul 31, 2014
+	30MG/VIAL	N021106 005	Jul 31, 2014

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+ LILLY	EQ 100MG BASE/VIAL	N021462 002	Sep 07, 2007
+	EQ 500MG BASE/VIAL	N021462 001	Feb 04, 2004

PENCICLOVIR SODIUM

CREAM; TOPICAL

DENA VIR

+ DENCO ASSET	1%	N020629 001	Sep 24, 1996
---------------	----	-------------	--------------

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

+ ATON	250MG	N019853 001	
--------	-------	-------------	--

TABLET; ORAL

DEPEN

+ MEDA PHARMS	250MG	N019854 001	
---------------	-------	-------------	--

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC + KING PHARMS	600,000 UNITS/ML	N050141 001	
------------------	------------------	-------------	--

PERMAPEN

BC PFIZER	600,000 UNITS/ML	A060014 001	
-----------	------------------	-------------	--

BICILLIN L-A

+ KING PHARMS	300,000 UNITS/ML	N050141 003	
---------------	------------------	-------------	--

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+ KING PHARMS	150,000 UNITS/ML; 150,000 UNITS/ML	N050138 002	
---------------	------------------------------------	-------------	--

+	300,000 UNITS/ML; 300,000 UNITS/ML	N050138 001	
---	------------------------------------	-------------	--

BICILLIN C-R 900/300

+ KING PHARMS	900,000 UNITS/2ML; 300,000 UNITS/2ML	N050138 003	
---------------	--------------------------------------	-------------	--

## PRESCRIPTION DRUG PRODUCT LIST

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

<u>AP</u>	HANFORD GC	<u>5,000,000 UNITS/VIAL</u>	<u>A065149 002</u>	Jul 23, 2009
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065149 003</u>	Jul 23, 2009
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>5,000,000 UNITS/VIAL</u>	<u>A065448 001</u>	Aug 18, 2009
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065448 002</u>	Aug 18, 2009
<u>AP</u>	SANDOZ	<u>5,000,000 UNITS/VIAL</u>	<u>A065079 002</u>	Aug 30, 2002
<u>AP</u>		<u>20,000,000 UNITS/VIAL</u>	<u>A065079 003</u>	Aug 30, 2002

PFIZERPEN

<u>AP</u>	+ PFIZER	<u>5,000,000 UNITS/VIAL</u>	<u>A060657 002</u>	
<u>AP</u>	+	<u>20,000,000 UNITS/VIAL</u>	<u>A060657 003</u>	
	PENICILLIN G POTASSIUM			
	HANFORD GC	1,000,000 UNITS/VIAL	A065149 001	Jul 23, 2009
	PENICILLIN G POTASSIUM IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	20,000 UNITS/ML	N050638 001	Jun 25, 1990
	+	40,000 UNITS/ML	N050638 002	Jun 25, 1990
	+	60,000 UNITS/ML	N050638 003	Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

+	KING PHARMS	300,000 UNITS/ML	A060101 002	
+		600,000 UNITS/ML	A060101 001	

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

+	SANDOZ	5,000,000 UNITS/VIAL	A065068 001	Feb 26, 2001
---	--------	----------------------	-------------	--------------

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

<u>AA</u>	DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062981 001</u>	Feb 10, 1989
<u>AA</u>		<u>EQ 250MG BASE/5ML</u>	<u>A062981 002</u>	Feb 10, 1989

PENICILLIN-VK

<u>AA</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A060456 001</u>	
<u>AA</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>A060456 002</u>	

TABLET; ORAL

PENICILLIN V POTASSIUM

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A065435 001</u>	Apr 29, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065435 002</u>	Apr 29, 2008
<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062936 001</u>	Nov 25, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062935 001</u>	Nov 23, 1988
<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE</u>	<u>A090549 001</u>	Oct 11, 2013
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090549 002</u>	Oct 11, 2013
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064071 001</u>	Nov 30, 1995
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A064071 002</u>	Nov 30, 1995

PENICILLIN-VK

<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A060711 002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A060711 003</u>	

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

+	FRESENIUS KABI USA	300MG/VIAL	N019887 001	Jun 15, 1989
---	--------------------	------------	-------------	--------------

INJECTABLE; INJECTION

PENTAM

+	FRESENIUS KABI USA	300MG/VIAL	N019264 001	Oct 16, 1984
---	--------------------	------------	-------------	--------------

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+	HOSPIRA	EQ 30MG BASE/ML	N016194 001	
---	---------	-----------------	-------------	--

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001	
---	------------	---------	-------------	--



## PRESCRIPTION DRUG PRODUCT LIST

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ JANSSEN PHARMS

100MG

N020193 001 Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENTAP + HOSPIRA INC10MG/VIALN020122 001 Oct 11, 1991PENTOSTATINAP EUROHLTH INTL SARL10MG/VIALA077841 001 Aug 07, 2007AP MYLAN INSTITUTIONAL10MG/VIALA203554 001 Sep 19, 2014PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINEAB APOTEX400MGA075191 001 Jun 09, 1999AB IMPAX LABS400MGA075093 001 Aug 10, 1999AB MYLAN400MGA074425 001 Jul 08, 1997AB PLIVA400MGA074874 001 May 25, 1999AB VALEANT PHARMS400MGA075028 001 Jul 20, 1998PENTOXILAB UPSHER SMITH400MGA074962 001 Mar 31, 1999PERAMIVIR

SOLUTION; IV (INFUSION)

RAPIVAB

+ BIOCRYST

200MG/20ML (10MG/ML)

N206426 001 Dec 19, 2014

PERAMPANEL

TABLET; ORAL

FYCOMPA

EISAI INC

2MG

N202834 001 Oct 22, 2012

4MG

N202834 002 Oct 22, 2012

6MG

N202834 003 Oct 22, 2012

8MG

N202834 004 Oct 22, 2012

10MG

N202834 005 Oct 22, 2012

+

12MG

N202834 006 Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ LANTHEUS MEDCL

6.52MG/ML

N021064 001 Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEONAB SYMPLMED PHARMS LLC2MGN020184 001 Dec 30, 1993AB4MGN020184 002 Dec 30, 1993AB +8MGN020184 003 Dec 30, 1993PERINDOPRIL ERBUMINEAB ANI PHARMS INC2MGA078138 001 Nov 10, 2009AB4MGA078138 002 Nov 10, 2009AB8MGA078138 003 Nov 10, 2009AB APOTEX2MGA090463 001 Aug 30, 2010AB4MGA090463 002 Aug 30, 2010AB8MGA090463 003 Aug 30, 2010AB AUROBINDO PHARMA2MGA079070 001 Nov 10, 2009AB4MGA079070 002 Nov 10, 2009AB8MGA079070 003 Nov 10, 2009AB LUPIN LTD2MGA078263 001 Jan 27, 2010AB4MGA078263 002 Jan 27, 2010AB8MGA078263 003 Jan 27, 2010AB ROXANE2MGA090072 001 Nov 10, 2009AB4MGA090072 002 Nov 10, 2009AB8MGA090072 003 Nov 10, 2009PERMETHRIN

CREAM; TOPICAL

ELIMITEAB + RENAISSANCE PHARMA5%N019855 001 Aug 25, 1989PERMETHRINAB ACTAVIS MID ATLANTIC5%A074806 001 Jan 23, 1998AB PERRIGO NEW YORK5%A076369 001 Apr 21, 2003

## PRESCRIPTION DRUG PRODUCT LIST

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

<u>AB</u>	INDICUS PHARMA	<u>2MG</u>	<u>A205973 001</u>	Dec 17, 2015
<u>AB</u>		<u>4MG</u>	<u>A205973 002</u>	Dec 17, 2015
<u>AB</u>		<u>8MG</u>	<u>A205973 003</u>	Dec 17, 2015
<u>AB</u>		<u>16MG</u>	<u>A205973 004</u>	Dec 17, 2015
<u>AB</u>	SANDOZ	<u>2MG</u>	<u>A089683 001</u>	Dec 08, 1988
<u>AB</u>		<u>4MG</u>	<u>A089684 001</u>	Dec 08, 1988
<u>AB</u>		<u>8MG</u>	<u>A089685 001</u>	Dec 08, 1988
<u>AB</u>	+	<u>16MG</u>	<u>A089686 001</u>	Dec 08, 1988
<u>AB</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A040226 001</u>	Dec 31, 1998
<u>AB</u>		<u>4MG</u>	<u>A040226 002</u>	Dec 31, 1998
<u>AB</u>		<u>8MG</u>	<u>A040226 003</u>	Dec 31, 1998
<u>AB</u>		<u>16MG</u>	<u>A040226 004</u>	Dec 31, 1998

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

+ SANDOZ

105MG

N018074 001

TABLET; ORAL

BONTRIL PDM

<u>AA</u>	+	VALEANT	<u>35MG</u>	<u>A085272 001</u>
-----------	---	---------	-------------	--------------------

PHENDIMETRAZINE TARTRATE

<u>AA</u>	ELITE LABS INC	<u>35MG</u>	<u>A040762 001</u>	Jan 28, 2008
<u>AA</u>	KVK TECH	<u>35MG</u>	<u>A091042 001</u>	Aug 31, 2010
<u>AA</u>	MIKART	<u>35MG</u>	<u>A089452 001</u>	Oct 30, 1991
<u>AA</u>	SANDOZ	<u>35MG</u>	<u>A085588 001</u>	

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

<u>AB</u>	+	PARKE DAVIS	<u>EQ 15MG BASE</u>	<u>N011909 002</u>
-----------	---	-------------	---------------------	--------------------

PHENELZINE SULFATE

<u>AB</u>	NOVEL LABS INC	<u>EQ 15MG BASE</u>	<u>A200181 001</u>	Dec 08, 2010
-----------	----------------	---------------------	--------------------	--------------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

<u>AB</u>	+	CONCORDIA PHARMS INC	<u>10MG</u>	<u>N008708 001</u>
-----------	---	----------------------	-------------	--------------------

PHENOXYBENZAMINE HYDROCHLORIDE

<u>AB</u>	ROXANE	<u>10MG</u>	<u>A201050 001</u>	Jul 16, 2012
-----------	--------	-------------	--------------------	--------------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

<u>AA</u>	+	TEVA	<u>37.5MG</u>	<u>A088023 001</u>	Aug 02, 1983
-----------	---	------	---------------	--------------------	--------------

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	BARR	<u>15MG</u>	<u>A090591 001</u>	Mar 18, 2010	
<u>AA</u>		<u>30MG</u>	<u>A090591 002</u>	Mar 18, 2010	
<u>AA</u>	ELITE LABS	<u>15MG</u>	<u>A202248 001</u>	Sep 28, 2012	
<u>AA</u>		<u>30MG</u>	<u>A202248 002</u>	Sep 28, 2012	
<u>AA</u>	INVAGEN PHARMS	<u>15MG</u>	<u>A202858 001</u>	Feb 14, 2014	
<u>AA</u>		<u>30MG</u>	<u>A202858 002</u>	Feb 14, 2014	
<u>AA</u>		<u>30MG</u>	<u>A204414 001</u>	May 05, 2014	
<u>AA</u>		<u>37.5MG</u>	<u>A202846 001</u>	Feb 05, 2014	
<u>AA</u>	KEN LIFESCIENCE	<u>15MG</u>	<u>A205019 001</u>	Dec 05, 2014	
<u>AA</u>		<u>30MG</u>	<u>A205019 002</u>	Dec 05, 2014	
<u>AA</u>		<u>37.5MG</u>	<u>A205017 001</u>	Sep 25, 2014	
<u>AA</u>	KVK TECH	<u>15MG</u>	<u>A040886 002</u>	Mar 31, 2008	
<u>AA</u>		<u>30MG</u>	<u>A040875 001</u>	Mar 21, 2008	
<u>AA</u>		<u>30MG</u>	<u>A040886 001</u>	Mar 31, 2008	
<u>AA</u>		<u>37.5MG</u>	<u>A040887 001</u>	Apr 24, 2008	
<u>AA</u>	LANNETT	<u>15MG</u>	<u>A087022 002</u>	Jan 20, 2012	
<u>AA</u>		<u>30MG</u>	<u>A087022 001</u>	Feb 03, 1983	
<u>AA</u>		<u>30MG</u>	<u>A091359 001</u>	Jul 16, 2010	
<u>AA</u>	LANNETT HOLDINGS INC	<u>37.5MG</u>	<u>A201961 001</u>	Jul 20, 2011	
<u>AA</u>	MIKAH PHARMA LLC	<u>37.5MG</u>	<u>A040228 001</u>	Jun 19, 1997	
<u>AA</u>	MUTUAL PHARM	<u>30MG</u>	<u>A040525 001</u>	Oct 23, 2003	
<u>AA</u>	+	SANDOZ	<u>15MG</u>	<u>A087190 002</u>	
<u>AA</u>	+		<u>30MG</u>	<u>A086945 001</u>	Jul 20, 1983
<u>AA</u>	+		<u>30MG</u>	<u>A087190 001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

ADIPEX-P

<b>AA</b>	+ TEVA	<b>37.5MG</b>	<b>A085128</b>	<b>001</b>	
<u>PHENTERMINE HYDROCHLORIDE</u>					
<b>AA</b>	AUROLIFE PHARMA LLC	<b>37.5MG</b>	<b>A203068</b>	<b>001</b>	Aug 06, 2014
<b>AA</b>	BARR	<b>37.5MG</b>	<b>A090470</b>	<b>001</b>	Aug 31, 2009
<b>AA</b>	ELITE LABS	<b>37.5MG</b>	<b>A200272</b>	<b>001</b>	Jan 31, 2011
<b>AA</b>	INVAGEN PHARMS	<b>37.5MG</b>	<b>A202942</b>	<b>001</b>	Feb 05, 2014
<b>AA</b>	KEN LIFESCIENCE	<b>37.5MG</b>	<b>A205008</b>	<b>001</b>	Sep 25, 2014
<b>AA</b>	KVK TECH	<b>37.5MG</b>	<b>A040876</b>	<b>001</b>	Mar 31, 2008
<b>AA</b>	LANNETT	<b>37.5MG</b>	<b>A040555</b>	<b>001</b>	Apr 15, 2005
<b>AA</b>	MIKAH PHARMA	<b>37.5MG</b>	<b>A040190</b>	<b>001</b>	May 30, 1997
<b>AA</b>	MIRROR PHARMS	<b>37.5MG</b>	<b>A091451</b>	<b>001</b>	Sep 21, 2012
<b>AA</b>	MUTUAL PHARM	<b>37.5MG</b>	<b>A040526</b>	<b>001</b>	Oct 23, 2003
<b>AA</b>	SUN PHARM INDS INC	<b>37.5MG</b>	<b>A040790</b>	<b>001</b>	Aug 21, 2007
<b>AA</b>	VINTAGE PHARMS	<b>37.5MG</b>	<b>A040377</b>	<b>001</b>	Jan 04, 2002

TABLET, ORALLY DISINTEGRATING; ORAL  
SUPRENZA

	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011
		30MG	N202088	002	Jun 13, 2011
	+	37.5MG	N202088	003	Mar 27, 2012

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

## QSYMIA

	VIVUS	EQ 3.75MG BASE; 23MG	N022580	001	Jul 17, 2012
		EQ 7.5MG BASE; 46MG	N022580	002	Jul 17, 2012
		EQ 11.25MG BASE; 69MG	N022580	003	Jul 17, 2012
	+	EQ 15MG BASE; 92MG	N022580	004	Jul 17, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

## PHENTERMINE RESIN COMPLEX

	+ LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
	+	EQ 30MG BASE	A040872	002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

<b>AP</b>	EUROHLTH INTL SARL	<b>5MG/VIAL</b>	<b>A040235</b>	<b>001</b>	Mar 11, 1998
<u>REGITINE</u>					
<b>AP</b>	+ NOVARTIS	<b>5MG/VIAL</b>	<b>N008278</b>	<b>003</b>	
ORAVERSE					
	+ SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

## PHENYLEPHRINE HYDROCHLORIDE

	+ WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012
VAZCULEP					
	ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014
		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014
	+	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014

SOLUTION/DROPS; OPHTHALMIC

## PHENYLEPHRINE HYDROCHLORIDE

	+ AKORN INC	2.5%	N207926	001	Jan 15, 2015
	+	10%	N207926	002	Jan 15, 2015
	+ PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013
	+	10%	N203510	002	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

<b>AA</b>	HI-TECH PHARMACAL	<b>5MG/5ML; 6.25MG/5ML</b>	<b>A040675</b>	<b>001</b>	Dec 23, 2014
<b>AA</b>	VINTAGE	<b>5MG/5ML; 6.25MG/5ML</b>	<b>A040654</b>	<b>001</b>	Dec 07, 2006
<u>PROMETH VC PLAIN</u>					
<b>AA</b>	+ G AND W LABS INC	<b>5MG/5ML; 6.25MG/5ML</b>	<b>A088761</b>	<b>001</b>	Nov 08, 1984
<u>PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE</u>					
<b>AA</b>	AMNEAL PHARMS	<b>5MG/5ML; 6.25MG/5ML</b>	<b>A040902</b>	<b>001</b>	Aug 25, 2009

## PRESCRIPTION DRUG PRODUCT LIST

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

<b>AB</b>	+	PARKE DAVIS	<b>125MG/5ML</b>	<b>N008762 001</b>	
<b>PHENYTOIN</b>					
<b>AB</b>		TARO	<b>125MG/5ML</b>	<b>A040521 001</b>	Mar 08, 2004
<b>AB</b>		VISTAPHARM	<b>125MG/5ML</b>	<b>A040342 001</b>	Jan 31, 2001
<b>AB</b>			<b>125MG/5ML</b>	<b>A040610 001</b>	Aug 18, 2005
<b>AB</b>		WOCKHARDT	<b>125MG/5ML</b>	<b>A040420 001</b>	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

<b>AB</b>	+	PFIZER PHARMS	<b>50MG</b>	<b>A084427 001</b>	
<b>PHENYTOIN</b>					
<b>AB</b>		COREPHARMA	<b>50MG</b>	<b>A040884 001</b>	Nov 28, 2014
<b>AB</b>		MYLAN PHARMS INC	<b>50MG</b>	<b>A200691 001</b>	Dec 26, 2012
<b>AB</b>		TARO	<b>50MG</b>	<b>A200565 001</b>	Apr 17, 2014

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

<b>AB</b>	+	PARKE DAVIS	<b>30MG EXTENDED</b>	<b>A084349 001</b>	
<b>AB</b>	+		<b>100MG EXTENDED</b>	<b>A084349 002</b>	
<b>EXTENDED PHENYTOIN SODIUM</b>					
<b>AB</b>		AMNEAL PHARMS NY	<b>100MG EXTENDED</b>	<b>A040765 001</b>	Nov 12, 2008
<b>AB</b>		MYLAN	<b>100MG EXTENDED</b>	<b>A040298 001</b>	Dec 28, 1998
<b>AB</b>		SUN PHARM INDS	<b>200MG EXTENDED</b>	<b>A040731 001</b>	Jun 30, 2008
<b>AB</b>			<b>300MG EXTENDED</b>	<b>A040731 002</b>	Jun 30, 2008
<b>AB</b>		SUN PHARM INDS (IN)	<b>100MG EXTENDED</b>	<b>A040621 001</b>	Dec 11, 2006
<b>AB</b>		TARO	<b>100MG EXTENDED</b>	<b>A040684 001</b>	Sep 05, 2006

PHENYTEK

<b>AB</b>		MYLAN	<b>200MG EXTENDED</b>	<b>A040298 002</b>	Dec 06, 2001
<b>AB</b>	+		<b>300MG EXTENDED</b>	<b>A040298 003</b>	Dec 06, 2001

PHENYTOIN SODIUM

<b>AB</b>		AUROBINDO PHARMA LTD	<b>100MG EXTENDED</b>	<b>A204309 001</b>	Jun 10, 2015
-----------	--	----------------------	-----------------------	--------------------	--------------

INJECTABLE; INJECTION

PHENYTOIN SODIUM

<b>AP</b>	+	EUROHLTH INTL SARL	<b>50MG/ML</b>	<b>A084307 001</b>	
<b>AP</b>		HOSPIRA	<b>50MG/ML</b>	<b>A089521 001</b>	Mar 17, 1987
<b>AP</b>		LUITPOLD	<b>50MG/ML</b>	<b>A040781 001</b>	Dec 04, 2007
<b>AP</b>		X-GEN PHARMS	<b>50MG/ML</b>	<b>A040573 001</b>	Sep 13, 2006

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

<b>BP</b>	+	INTL MEDICATION	<b>1MG/0.5ML</b>	<b>A083722 001</b>	
<b>VITAMIN K1</b>					
<b>BP</b>	+	HOSPIRA	<b>1MG/0.5ML</b>	<b>A087954 001</b>	Jul 25, 1983
	+		<b>10MG/ML</b>	<b>A087955 001</b>	Jul 25, 1983

TABLET; ORAL

MEPHYTON

	+	VALEANT PHARMS	<b>5MG</b>	<b>N010104 003</b>	
--	---	----------------	------------	--------------------	--

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

		ALCON RES	<b>1%</b>	<b>N200890 001</b>	Jun 22, 2010
			<b>2%</b>	<b>N200890 002</b>	Jun 22, 2010
	+		<b>4%</b>	<b>N200890 003</b>	Jun 22, 2010

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

<b>AB</b>		ELAN PHARMA INTL LTD	<b>5MG</b>	<b>A076746 001</b>	Nov 16, 2004
<b>AB</b>		IMPAX LABS	<b>5MG</b>	<b>A077248 001</b>	Mar 31, 2006
<b>AB</b>			<b>7.5MG</b>	<b>A077248 002</b>	Mar 31, 2006
<b>AB</b>		LANNETT	<b>5MG</b>	<b>A077220 001</b>	Oct 14, 2005
<b>AB</b>			<b>7.5MG</b>	<b>A077220 002</b>	May 06, 2009
<b>AB</b>		ROXANE	<b>5MG</b>	<b>A076963 001</b>	Dec 22, 2004
<b>AB</b>			<b>7.5MG</b>	<b>A076963 002</b>	Feb 27, 2007

SALAGEN

<b>AB</b>		EISAI INC	<b>5MG</b>	<b>N020237 001</b>	Mar 22, 1994
<b>AB</b>	+		<b>7.5MG</b>	<b>N020237 002</b>	Apr 18, 2003

## PRESCRIPTION DRUG PRODUCT LIST

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

+ VALEANT BERMUDA 1% N021302 001 Dec 13, 2001

PIMOZIDE

TABLET; ORAL

ORAPAB TEVA 1MG N017473 003 Aug 27, 1997AB + 2MG N017473 001 Jul 31, 1984PIMOZIDEAB PAR PHARM 1MG A204521 001 Sep 28, 2015AB 2MG A204521 002 Sep 28, 2015PINDOLOL

TABLET; ORAL

PINDOLOLAB MUTUAL PHARM 5MG A074063 001 Jan 27, 1994AB 10MG A074063 002 Jan 27, 1994AB MYLAN PHARMS INC 5MG A074019 001 Sep 03, 1992AB + 10MG A074019 002 Sep 03, 1992AB NOSTRUM LABS INC 5MG A205415 001 Jan 13, 2016AB 10MG A205415 002 Jan 13, 2016PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOSAB TAKEDA PHARMS USA EQ 15MG BASE N021073 001 Jul 15, 1999AB EQ 30MG BASE N021073 002 Jul 15, 1999AB + EQ 45MG BASE N021073 003 Jul 15, 1999PIOGLITAZONE HYDROCHLORIDEAB ACCORD HLTHCARE EQ 15MG BASE A200044 001 Feb 13, 2013AB EQ 30MG BASE A200044 002 Feb 13, 2013AB EQ 45MG BASE A200044 003 Feb 13, 2013AB AUROBINDO PHARMA LTD EQ 15MG BASE A200268 001 Feb 13, 2013AB EQ 30MG BASE A200268 002 Feb 13, 2013AB EQ 45MG BASE A200268 003 Feb 13, 2013AB BRECKENRIDGE PHARM EQ 15MG BASE A078472 001 Feb 13, 2013AB EQ 30MG BASE A078472 002 Feb 13, 2013AB EQ 45MG BASE A078472 003 Feb 13, 2013AB DR REDDYS LABS LTD EQ 15MG BASE A078383 001 Mar 12, 2013AB EQ 30MG BASE A078383 002 Mar 12, 2013AB EQ 45MG BASE A078383 003 Mar 12, 2013AB LUPIN LTD EQ 15MG BASE A204133 001 Apr 07, 2014AB EQ 30MG BASE A204133 002 Apr 07, 2014AB EQ 45MG BASE A204133 003 Apr 07, 2014AB MACLEODS PHARMS LTD EQ 15MG BASE A202467 001 Feb 06, 2013AB EQ 30MG BASE A202467 002 Feb 06, 2013AB EQ 45MG BASE A202467 003 Feb 06, 2013AB MYLAN PHARMS INC EQ 15MG BASE A076801 001 Aug 17, 2012AB EQ 30MG BASE A076801 002 Aug 17, 2012AB EQ 45MG BASE A076801 003 Aug 17, 2012AB SANDOZ EQ 15MG BASE A078670 001 Feb 13, 2013AB EQ 30MG BASE A078670 002 Feb 13, 2013AB EQ 45MG BASE A078670 003 Feb 13, 2013AB TEVA PHARMS USA EQ 15MG BASE A077210 001 Jan 10, 2014AB EQ 30MG BASE A077210 002 Jan 10, 2014AB EQ 45MG BASE A077210 003 Jan 10, 2014AB TORRENT PHARMS LTD EQ 15MG BASE A091298 001 Feb 13, 2013AB EQ 30MG BASE A091298 002 Feb 13, 2013AB EQ 45MG BASE A091298 003 Feb 13, 2013AB WATSON LABS EQ 15MG BASE A076798 001 Oct 26, 2012AB EQ 30MG BASE A076798 002 Oct 26, 2012AB EQ 45MG BASE A076798 003 Oct 26, 2012AB ZYDUS PHARMS USA INC EQ 15MG BASE A202456 001 Feb 13, 2013AB EQ 30MG BASE A202456 002 Feb 13, 2013AB EQ 45MG BASE A202456 003 Feb 13, 2013

## PRESCRIPTION DRUG PRODUCT LIST

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114 001	Nov 14, 2003
+		EQ 3GM BASE/VIAL	A065114 002	Nov 14, 2003
+		EQ 4GM BASE/VIAL	A065114 003	Nov 14, 2003
+		EQ 40GM BASE/VIAL	A065157 001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<b>AP</b>	AUROBINDO PHARMA LTD	<b>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</b>	<b>A065498 001</b>	May 23, 2011
<b>AP</b>		<b>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</b>	<b>A065498 002</b>	May 23, 2011
<b>AP</b>		<b>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</b>	<b>A065498 003</b>	May 23, 2011
<b>AP</b>	HOSPIRA INC	<b>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</b>	<b>A065386 001</b>	Sep 15, 2009
<b>AP</b>		<b>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</b>	<b>A065386 002</b>	Sep 15, 2009
<b>AP</b>		<b>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</b>	<b>A065386 003</b>	Sep 15, 2009
<b>AP</b>		<b>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</b>	<b>A065446 001</b>	Sep 15, 2009
<b>AP</b>	ISTITUTO BIO ITA SPA	<b>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</b>	<b>A065523 001</b>	May 31, 2011
<b>AP</b>		<b>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</b>	<b>A065523 002</b>	May 31, 2011
<b>AP</b>		<b>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</b>	<b>A065523 003</b>	May 31, 2011
<b>AP</b>		<b>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</b>	<b>A090498 001</b>	May 31, 2011
<b>AP</b>	MYLAN LABS LTD	<b>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</b>	<b>A065458 001</b>	Aug 15, 2014
<b>AP</b>		<b>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</b>	<b>A065458 002</b>	Aug 15, 2014
<b>AP</b>		<b>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</b>	<b>A065458 003</b>	Aug 15, 2014
<b>AP</b>	SANDOZ	<b>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</b>	<b>A065362 001</b>	Oct 21, 2010
<b>AP</b>		<b>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</b>	<b>A065363 001</b>	Oct 21, 2010
<b>AP</b>		<b>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</b>	<b>A065362 002</b>	Oct 21, 2010
<b>AP</b>		<b>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</b>	<b>A065363 002</b>	Oct 21, 2010
<b>AP</b>		<b>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</b>	<b>A065362 003</b>	Oct 21, 2010
<b>AP</b>		<b>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</b>	<b>A065363 003</b>	Oct 21, 2010

ZOSYN

<b>AP</b>	+	WYETH PHARMS INC	<b>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</b>	<b>N050684 001</b>	Oct 22, 1993
<b>AP</b>	+		<b>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</b>	<b>N050684 002</b>	Oct 22, 1993
<b>AP</b>	+		<b>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</b>	<b>N050684 003</b>	Oct 22, 1993
<b>AP</b>	+		<b>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</b>	<b>N050684 004</b>	Oct 22, 1993
		ZOSYN IN PLASTIC CONTAINER			
	+	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750 001	Feb 24, 1998
	+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750 002	Feb 24, 1998
	+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750 003	Feb 24, 1998

INJECTABLE; IV (INFUSION)

PIPERACILLIN AND TAZOBACTAM

	SANDOZ INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557 001	Oct 29, 2014
--	------------	--------------------------------------	-------------	--------------

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+	GENENTECH INC	267MG	N022535 001	Oct 15, 2014
---	---------------	-------	-------------	--------------

PIROXICAM

CAPSULE; ORAL

FELDENE

<b>AB</b>	PFIZER	<b>10MG</b>	<b>N018147 002</b>	Apr 06, 1982
<b>AB</b>	+	<b>20MG</b>	<b>N018147 003</b>	Apr 06, 1982
		<b>PIROXICAM</b>		
<b>AB</b>	MUTUAL PHARM	<b>10MG</b>	<b>A073535 001</b>	Mar 12, 1993
<b>AB</b>	MYLAN	<b>10MG</b>	<b>A074102 001</b>	Jul 31, 1992
<b>AB</b>		<b>20MG</b>	<b>A074102 002</b>	Jul 31, 1992
<b>AB</b>	MYLAN PHARMS INC	<b>10MG</b>	<b>A074116 001</b>	Jun 15, 1993
<b>AB</b>		<b>20MG</b>	<b>A074118 001</b>	Jun 15, 1993
<b>AB</b>	TEVA	<b>10MG</b>	<b>A074131 001</b>	Dec 11, 1992
<b>AB</b>		<b>20MG</b>	<b>A074131 002</b>	Dec 11, 1992

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

	KOWA CO	EQ 1MG BASE	N022363 001	Aug 03, 2009
		EQ 2MG BASE	N022363 002	Aug 03, 2009
+		EQ 4MG BASE	N022363 003	Aug 03, 2009

## PRESCRIPTION DRUG PRODUCT LIST

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

MOZOBIL

+ GENZYME

24MG/1.2ML (20MG/ML)

N022311 001 Dec 15, 2008

PODOFILOX

GEL;TOPICAL

CONDYLOX

+ ACTAVIS LABS UT INC

0.5%

N020529 001 Mar 13, 1997

SOLUTION;TOPICAL

CONDYLOXAT + ACTAVIS LABS UT INC0.5%N019795 001 Dec 13, 1990PODOFILOXAT BAUSCH AND LOMB INC0.5%A090184 001 Jul 21, 2010AT PADDOCK LLC0.5%A075600 001 Jan 29, 2002POLIDOCANOL

SOLUTION;INTRAVENOUS

ASCLERA

CHEMISCH FBRK KRSSLR

10MG/2ML (5MG/ML)

N021201 001 Mar 30, 2010

+

VARITHENA

+ PROVENISIS

20MG/2ML (10MG/ML)

N021201 002 Mar 30, 2010

180MG/18ML (10MG/ML)

N205098 001 Nov 25, 2013

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAXAA KREMERS URBAN PHARMS17GM/SCOOPFULA076652 001 Jul 02, 2004POLYETHYLENE GLYCOL 3350AA BRECKENRIDGE PHARM17GM/SCOOPFULA077736 001 May 26, 2006AA NEXGEN PHARMA INC17GM/SCOOPFULA077706 001 Sep 27, 2006AA PADDOCK LLC17GM/SCOOPFULA077893 001 May 26, 2006POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

LAX-LYTE WITH FLAVOR PACKSAA PADDOCK LLC420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTA079232 001 Feb 25, 2010NULYTELYAA + BRAINTREE420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTN019797 001 Apr 22, 1991NULYTELY-FLAVOREDAA + BRAINTREE420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTN019797 002 Nov 18, 1994PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDEAA MYLAN420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTA090409 001 Apr 02, 2010AA NOVEL LABS INC420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTA090019 001 May 27, 2009AA STRIDES ARCOLAB LTD420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTA204559 001 Apr 13, 2015TRILYTEAA MEDA PHARMS420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTA076491 001 Feb 05, 2004POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

GOLYTELYAA + BRAINTREE236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOTN019011 001 Jul 13, 1984PEG 3350 AND ELECTROLYTESAA MYLAN236GM;2.97GM;6.74GM;5.86GM;22.74GMA090928 001 Jan 28, 2010AA NOVEL LABS INC236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOTA090231 001 Jun 01, 2009AA240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOTA090186 001 Jun 01, 2009

COLYTE

MEDA PHARMS

227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT

N018983 010 Jan 31, 1989

COLYTE WITH FLAVOR PACKS

MEDA PHARMS

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT

N018983 012 Oct 08, 1998

GOLYTELY

+ BRAINTREE

227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET

N019011 002 Jun 02, 1992

## PRESCRIPTION DRUG PRODUCT LIST

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

<u>AP</u>	SAGENT STRIDES	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A090110 001</u>	Jun 29, 2011
<u>POLYMYXIN B SULFATE</u>				
<u>AP</u>	+ EUROHLTH INTL SARL	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A060716 001</u>	
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A065372 001</u>	Jan 10, 2008
<u>AP</u>	X GEN PHARMS	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A063000 001</u>	Sep 30, 1994
<u>AP</u>	KELLIA PHARMS APS	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A202766 001</u>	Jan 15, 2014

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

<u>AT</u>	+ ALLERGAN	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>N050567 001</u>	Oct 20, 1988
<u>TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE</u>				
<u>AT</u>	AKORN INC	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A065006 001</u>	Dec 17, 1998
<u>AT</u>	ALCON RES LTD	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A064211 001</u>	Apr 13, 1998
<u>AT</u>	BAUSCH AND LOMB	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A064120 001</u>	Feb 14, 1997

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

	CELGENE	1MG	N204026 001	Feb 08, 2013
		2MG	N204026 002	Feb 08, 2013
		3MG	N204026 003	Feb 08, 2013
	+	4MG	N204026 004	Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

	ARIAD	EQ 15MG BASE	N203469 001	Dec 14, 2012
		EQ 30MG BASE	N203469 003	Apr 23, 2015
	+	EQ 45MG BASE	N203469 002	Dec 14, 2012

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

	+ CHIESI USA INC	80MG/ML	N020744 001	Nov 18, 1999
--	------------------	---------	-------------	--------------

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

	CONCORDIA LABS INC	75MG/VIAL	N020451 001	Dec 27, 1995
--	--------------------	-----------	-------------	--------------

POSACONAZOLE

SOLUTION; IV (INFUSION)

NOXAFIL

	+ MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596 001	Mar 13, 2014
--	---------------------	------------------------	-------------	--------------

SUSPENSION; ORAL

NOXAFIL

	+ SCHERING	40MG/ML	N022003 001	Sep 15, 2006
--	------------	---------	-------------	--------------

TABLET, DELAYED RELEASE; ORAL

NOXAFIL

	+ MERCK SHARP DOHME	100MG	N205053 001	Nov 25, 2013
--	---------------------	-------	-------------	--------------

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

<u>AP</u>	EXELA PHARMA SCS LLC	<u>2MEQ/ML</u>	<u>A206203 001</u>	Dec 29, 2015
<u>AP</u>	+ HOSPIRA	<u>2MEQ/ML</u>	<u>N018896 001</u>	Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

<u>AB</u>	UPSHER SMITH	<u>8MEQ</u>	<u>A203106 001</u>	Jul 10, 2015
<u>AB</u>		<u>10MEQ</u>	<u>A203106 002</u>	Jul 10, 2015

MICRO-K

<u>AB</u>	NESHER PHARMS	<u>8MEQ</u>	<u>N018238 001</u>	
-----------	---------------	-------------	--------------------	--

MICRO-K 10

<u>AB</u>	NESHER PHARMS	<u>10MEQ</u>	<u>N018238 002</u>	May 14, 1984
-----------	---------------	--------------	--------------------	--------------

POTASSIUM CHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>8MEQ</u>	<u>A077419 001</u>	Jun 02, 2008
<u>AB</u>	+	<u>10MEQ</u>	<u>A077419 002</u>	Jun 02, 2008
<u>AB</u>	AMNEAL PHARMS	<u>10MEQ</u>	<u>A202128 001</u>	Feb 22, 2013
<u>AB</u>	ANCHEN PHARMS	<u>8MEQ</u>	<u>A202886 001</u>	Dec 26, 2013
<u>AB</u>		<u>10MEQ</u>	<u>A202886 002</u>	Dec 26, 2013



## PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

<u>AB</u>	LUPIN LTD	<u>8MEQ</u>	<u>A203002</u>	<u>001</u>	Dec 18, 2015
<u>AB</u>		<u>10MEQ</u>	<u>A203002</u>	<u>002</u>	Dec 18, 2015
<u>AB</u>	PADDOCK LLC	<u>8MEQ</u>	<u>A200185</u>	<u>001</u>	May 18, 2011
<u>AB</u>		<u>10MEQ</u>	<u>A200185</u>	<u>002</u>	May 18, 2011
<u>AB</u>	PHARMACEUTICS INTL	<u>8MEQ</u>	<u>A205549</u>	<u>001</u>	Dec 08, 2015
<u>AB</u>		<u>10MEQ</u>	<u>A205549</u>	<u>002</u>	Dec 08, 2015

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

PHARMA RES SOFTWARE

20MEQ

N208019 001 Aug 19, 2015

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

<u>AP</u>	B BRAUN	<u>2MEQ/ML</u>	<u>A085870</u>	<u>001</u>	
<u>AP</u>	BAXTER HLTHCARE	<u>2MEQ/ML</u>	<u>A085499</u>	<u>001</u>	
<u>AP</u>	FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A080225</u>	<u>001</u>	
<u>AP</u>	+ HOSPIRA	<u>2MEQ/ML</u>	<u>A080205</u>	<u>001</u>	

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>14.9MG/ML</u>	<u>N019904</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>		<u>746MG/100ML</u>	<u>N019904</u>	<u>005</u>	Dec 17, 1990
<u>AP</u>	HOSPIRA	<u>14.9MG/ML</u>	<u>N020161</u>	<u>005</u>	Nov 30, 1992
<u>AP</u>		<u>745MG/100ML</u>	<u>N020161</u>	<u>001</u>	Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>29.8MG/ML</u>	<u>N019904</u>	<u>002</u>	Dec 26, 1989
<u>AP</u>		<u>1.49GM/100ML</u>	<u>N019904</u>	<u>006</u>	Dec 17, 1990
<u>AP</u>	+ HOSPIRA	<u>29.8MG/ML</u>	<u>N020161</u>	<u>006</u>	Aug 11, 1998
<u>AP</u>		<u>1.49GM/100ML</u>	<u>N020161</u>	<u>002</u>	Nov 30, 1992

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>2.24GM/100ML</u>	<u>N019904</u>	<u>003</u>	Dec 26, 1989
<u>AP</u>	+ HOSPIRA	<u>2.24GM/100ML</u>	<u>N020161</u>	<u>003</u>	Aug 11, 1998

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>2.98GM/100ML</u>	<u>N019904</u>	<u>004</u>	Dec 26, 1989
<u>AP</u>	+ HOSPIRA	<u>2.98GM/100ML</u>	<u>N020161</u>	<u>004</u>	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A088901</u>	<u>001</u>	Jan 25, 1985
<u>AP</u>		<u>2MEQ/ML</u>	<u>A088908</u>	<u>001</u>	Jan 25, 1985

POTASSIUM CHLORIDE

+ FRESENIUS KABI USA

3MEQ/ML

A080225 003

SOLUTION;ORAL

POTASSIUM CHLORIDE

PHARMA-MED INC

20MEQ/15ML

N206814 001 Dec 22, 2014

+

40MEQ/15ML

N206814 002 Dec 22, 2014

TABLET, EXTENDED RELEASE;ORAL

KLOR-CON M10

<u>AB1</u>	UPSHER SMITH LABS	<u>10MEQ</u>	<u>A074726</u>	<u>002</u>	Aug 09, 2000
------------	-------------------	--------------	----------------	------------	--------------

KLOR-CON M20

<u>AB1</u>	+ UPSHER SMITH LABS	<u>20MEQ</u>	<u>A074726</u>	<u>001</u>	Nov 20, 1998
------------	---------------------	--------------	----------------	------------	--------------

POTASSIUM CHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>10MEQ</u>	<u>A075604</u>	<u>001</u>	Apr 10, 2002
<u>AB1</u>		<u>20MEQ</u>	<u>A075604</u>	<u>002</u>	Apr 10, 2002
<u>AB1</u>	ADARE PHARMS INC	<u>20MEQ</u>	<u>A076368</u>	<u>001</u>	Aug 18, 2004

KLOR-CON

<u>AB2</u>	UPSHER-SMITH LABS	<u>8MEQ</u>	<u>N019123</u>	<u>001</u>	Apr 17, 1986
<u>AB2</u>		<u>10MEQ</u>	<u>N019123</u>	<u>002</u>	Apr 17, 1986

POTASSIUM CHLORIDE

<u>AB2</u>	MYLAN PHARMS INC	<u>8MEQ</u>	<u>A204662</u>	<u>001</u>	Aug 21, 2014
<u>AB2</u>		<u>10MEQ</u>	<u>A204662</u>	<u>002</u>	Aug 21, 2014
<u>AB2</u>	PADDOCK LLC	<u>8MEQ</u>	<u>A205993</u>	<u>001</u>	Nov 05, 2015
<u>AB2</u>		<u>10MEQ</u>	<u>A205993</u>	<u>002</u>	Nov 05, 2015

K-TAB

BC	ABBVIE	8MEQ	N018279	002	Aug 01, 1988
BC		10MEQ	N018279	001	
BC		20MEQ	N018279	003	Nov 25, 2013
	KLOR-CON M15				
	UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003

## PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<b>AP</b>	HOSPIRA	<b>149MG/100ML;450MG/100ML</b>	<b>A078446 001</b>	Sep 10, 2008
-----------	---------	--------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<b>AP</b>	+ BAXTER HLTHCARE	<b>150MG/100ML;450MG/100ML</b>	<b>N017648 005</b>	Nov 26, 2002
-----------	-------------------	--------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<b>150MG/100ML;900MG/100ML</b>	<b>N019708 004</b>	Sep 29, 1989
-----------	---------	--------------------------------	--------------------	--------------

<b>AP</b>	BAXTER HLTHCARE	<b>150MG/100ML;900MG/100ML</b>	<b>N017648 001</b>	
-----------	-----------------	--------------------------------	--------------------	--

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>300MG/100ML;900MG/100ML</b>	<b>N017648 002</b>	
-----------	-----------------	--------------------------------	--------------------	--

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<b>AP</b>	HOSPIRA	<b>149MG/100ML;900MG/100ML</b>	<b>N019686 001</b>	Oct 17, 1988
-----------	---------	--------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<b>AP</b>	HOSPIRA	<b>298MG/100ML;900MG/100ML</b>	<b>N019686 002</b>	Oct 17, 1988
-----------	---------	--------------------------------	--------------------	--------------

	POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%			
	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648 003	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

<b>AB</b>	COREPHARMA	<b>5MEQ</b>	<b>A077440 001</b>	Jun 09, 2006
-----------	------------	-------------	--------------------	--------------

<b>AB</b>		<b>10MEQ</b>	<b>A077440 002</b>	Jun 09, 2006
-----------	--	--------------	--------------------	--------------

<b>AB</b>	ZYDUS PHARMS USA INC	<b>5MEQ</b>	<b>A203546 001</b>	Aug 06, 2014
-----------	----------------------	-------------	--------------------	--------------

<b>AB</b>		<b>10MEQ</b>	<b>A203546 002</b>	Aug 06, 2014
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>15MEQ</b>	<b>A203546 003</b>	Aug 06, 2014
-----------	--	--------------	--------------------	--------------

UROCI-T-K

<b>AB</b>	MISSION PHARMA	<b>5MEQ</b>	<b>N019071 001</b>	Aug 30, 1985
-----------	----------------	-------------	--------------------	--------------

<b>AB</b>		<b>10MEQ</b>	<b>N019071 002</b>	Aug 31, 1992
-----------	--	--------------	--------------------	--------------

<b>AB</b>	+	<b>15MEQ</b>	<b>N019071 003</b>	Dec 30, 2009
-----------	---	--------------	--------------------	--------------

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

BETADINE

	+ ALCON PHARMS LTD	5%	N018634 001	Dec 17, 1986
--	--------------------	----	-------------	--------------

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

	ALLOS	20MG/ML (20MG/ML)	N022468 001	Sep 24, 2009
--	-------	-------------------	-------------	--------------

	+	40MG/2ML (20MG/ML)	N022468 002	Sep 24, 2009
--	---	--------------------	-------------	--------------

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

	+ MERIDIAN MEDCL TECHN	300MG/ML	N018986 001	Apr 26, 1983
--	------------------------	----------	-------------	--------------

PROTOPAM CHLORIDE

	+ BAXTER HLTHCARE CORP	1GM/VIAL	N014134 001	
--	------------------------	----------	-------------	--

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

<b>AB</b>	BOEHRINGER INGELHEIM	<b>0.125MG</b>	<b>N020667 001</b>	Jul 01, 1997
-----------	----------------------	----------------	--------------------	--------------

<b>AB</b>	+	<b>0.25MG</b>	<b>N020667 002</b>	Jul 01, 1997
-----------	---	---------------	--------------------	--------------

<b>AB</b>		<b>0.5MG</b>	<b>N020667 006</b>	Feb 12, 1998
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>0.75MG</b>	<b>N020667 007</b>	Jul 30, 2007
-----------	--	---------------	--------------------	--------------

<b>AB</b>		<b>1MG</b>	<b>N020667 003</b>	Jul 01, 1997
-----------	--	------------	--------------------	--------------

<b>AB</b>		<b>1.5MG</b>	<b>N020667 005</b>	Jul 01, 1997
-----------	--	--------------	--------------------	--------------

PRAMIPEXOLE DIHYDROCHLORIDE

<b>AB</b>	ACTAVIS GRP PTC	<b>0.125MG</b>	<b>A091254 001</b>	Nov 30, 2010
-----------	-----------------	----------------	--------------------	--------------

<b>AB</b>		<b>0.25MG</b>	<b>A091254 002</b>	Nov 30, 2010
-----------	--	---------------	--------------------	--------------

<b>AB</b>		<b>0.5MG</b>	<b>A091254 003</b>	Nov 30, 2010
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>0.75MG</b>	<b>A091254 004</b>	Nov 30, 2010
-----------	--	---------------	--------------------	--------------

<b>AB</b>		<b>1MG</b>	<b>A091254 005</b>	Nov 30, 2010
-----------	--	------------	--------------------	--------------

<b>AB</b>		<b>1.5MG</b>	<b>A091254 006</b>	Nov 30, 2010
-----------	--	--------------	--------------------	--------------

<b>AB</b>	ALEMBIC LTD	<b>0.125MG</b>	<b>A078894 001</b>	Oct 08, 2010
-----------	-------------	----------------	--------------------	--------------

<b>AB</b>		<b>0.25MG</b>	<b>A078894 002</b>	Oct 08, 2010
-----------	--	---------------	--------------------	--------------

<b>AB</b>		<b>0.5MG</b>	<b>A078894 003</b>	Oct 08, 2010
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>1MG</b>	<b>A078894 004</b>	Oct 08, 2010
-----------	--	------------	--------------------	--------------

<b>AB</b>		<b>1.5MG</b>	<b>A078894 005</b>	Oct 08, 2010
-----------	--	--------------	--------------------	--------------

<b>AB</b>	APOTEX INC	<b>0.125MG</b>	<b>A090151 001</b>	Apr 30, 2012
-----------	------------	----------------	--------------------	--------------

<b>AB</b>		<b>0.25MG</b>	<b>A090151 002</b>	Apr 30, 2012
-----------	--	---------------	--------------------	--------------

<b>AB</b>		<b>0.5MG</b>	<b>A090151 003</b>	Apr 30, 2012
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>0.75MG</b>	<b>A090151 006</b>	Apr 30, 2012
-----------	--	---------------	--------------------	--------------

<b>AB</b>		<b>1MG</b>	<b>A090151 004</b>	Apr 30, 2012
-----------	--	------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>1.5MG</u>	<u>A090151</u>	<u>005</u>	Apr 30, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A202633</u>	<u>001</u>	Oct 26, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202633</u>	<u>002</u>	Oct 26, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202633</u>	<u>003</u>	Oct 26, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A202633</u>	<u>004</u>	Oct 26, 2012
<u>AB</u>		<u>1MG</u>	<u>A202633</u>	<u>005</u>	Oct 26, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202633</u>	<u>006</u>	Oct 26, 2012
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077724</u>	<u>001</u>	Feb 19, 2008
<u>AB</u>		<u>0.25MG</u>	<u>A077724</u>	<u>002</u>	Feb 19, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077724</u>	<u>003</u>	Feb 19, 2008
<u>AB</u>		<u>1MG</u>	<u>A077724</u>	<u>004</u>	Feb 19, 2008
<u>AB</u>		<u>1.5MG</u>	<u>A077724</u>	<u>005</u>	Feb 19, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.125MG</u>	<u>A091450</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091450</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091450</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A091450</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091450</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090781</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090781</u>	<u>006</u>	Sep 11, 2015
<u>AB</u>		<u>1MG</u>	<u>A090781</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.125MG</u>	<u>A202164</u>	<u>001</u>	Sep 20, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202164</u>	<u>002</u>	Sep 20, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202164</u>	<u>003</u>	Sep 20, 2012
<u>AB</u>		<u>1MG</u>	<u>A202164</u>	<u>004</u>	Sep 20, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202164</u>	<u>005</u>	Sep 20, 2012
<u>AB</u>	MYLAN	<u>0.125MG</u>	<u>A077854</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A077854</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A077854</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090764</u>	<u>001</u>	Apr 09, 2010
<u>AB</u>		<u>1MG</u>	<u>A077854</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A077854</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	SANDOZ	<u>0.125MG</u>	<u>A090190</u>	<u>001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090190</u>	<u>002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090190</u>	<u>003</u>	Jul 06, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090190</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090190</u>	<u>004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090190</u>	<u>005</u>	Jul 06, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>0.125MG</u>	<u>A203855</u>	<u>001</u>	Oct 28, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A203855</u>	<u>002</u>	Oct 28, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A203855</u>	<u>003</u>	Oct 28, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A203855</u>	<u>004</u>	Oct 28, 2014
<u>AB</u>		<u>1MG</u>	<u>A203855</u>	<u>005</u>	Oct 28, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A203855</u>	<u>006</u>	Oct 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A202702</u>	<u>001</u>	Jun 03, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A202702</u>	<u>002</u>	Jun 03, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A202702</u>	<u>003</u>	Jun 03, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202702</u>	<u>004</u>	Jun 03, 2014
<u>AB</u>		<u>1MG</u>	<u>A202702</u>	<u>005</u>	Jun 03, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202702</u>	<u>006</u>	Jun 03, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A091683</u>	<u>001</u>	Mar 27, 2013
<u>AB</u>		<u>0.25MG</u>	<u>A091683</u>	<u>002</u>	Mar 27, 2013
<u>AB</u>		<u>0.5MG</u>	<u>A091683</u>	<u>003</u>	Mar 27, 2013
<u>AB</u>		<u>0.75MG</u>	<u>A091683</u>	<u>004</u>	Mar 27, 2013
<u>AB</u>		<u>1MG</u>	<u>A091683</u>	<u>005</u>	Mar 27, 2013
<u>AB</u>		<u>1.5MG</u>	<u>A091683</u>	<u>006</u>	Mar 27, 2013
<u>AB</u>	TEVA PHARMS	<u>0.125MG</u>	<u>A090241</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090241</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090241</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090241</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090241</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090241</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090865</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865</u>	<u>005</u>	Oct 08, 2010

## PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>1.5MG</u>	<u>A090865</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920</u>	<u>001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920</u>	<u>002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920</u>	<u>003</u>	Jul 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078920</u>	<u>004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920</u>	<u>005</u>	Jul 06, 2010

TABLET, DELAYED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	SANDOZ INC	<u>0.375MG</u>	<u>A202353</u>	<u>001</u>	Dec 04, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202353</u>	<u>002</u>	Dec 04, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202353</u>	<u>003</u>	Dec 04, 2014
<u>AB</u>		<u>3MG</u>	<u>A202353</u>	<u>004</u>	Dec 04, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202353</u>	<u>005</u>	Dec 04, 2014

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>0.375MG</u>	<u>N022421</u>	<u>001</u>	Feb 19, 2010
<u>AB</u>		<u>0.75MG</u>	<u>N022421</u>	<u>002</u>	Feb 19, 2010
<u>AB</u>		<u>1.5MG</u>	<u>N022421</u>	<u>003</u>	Feb 19, 2010
<u>AB</u>		<u>2.25MG</u>	<u>N022421</u>	<u>006</u>	Jun 17, 2011
<u>AB</u>		<u>3MG</u>	<u>N022421</u>	<u>004</u>	Feb 19, 2010
<u>AB</u>		<u>3.75MG</u>	<u>N022421</u>	<u>007</u>	Jun 17, 2011
<u>AB</u>		<u>4.5MG</u>	<u>N022421</u>	<u>005</u>	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>0.375MG</u>	<u>A202206</u>	<u>001</u>	Feb 06, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202206</u>	<u>002</u>	Feb 06, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202206</u>	<u>003</u>	Feb 06, 2014
<u>AB</u>		<u>2.25MG</u>	<u>A202206</u>	<u>004</u>	Feb 06, 2014
<u>AB</u>		<u>3MG</u>	<u>A202206</u>	<u>005</u>	Feb 06, 2014
<u>AB</u>		<u>3.75MG</u>	<u>A202206</u>	<u>006</u>	Feb 06, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202206</u>	<u>007</u>	Feb 06, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>0.375MG</u>	<u>A203354</u>	<u>001</u>	Aug 07, 2015
<u>AB</u>		<u>0.75MG</u>	<u>A203354</u>	<u>002</u>	Aug 07, 2015
<u>AB</u>		<u>1.5MG</u>	<u>A203354</u>	<u>003</u>	Aug 07, 2015
<u>AB</u>		<u>3MG</u>	<u>A203354</u>	<u>004</u>	Aug 07, 2015
<u>AB</u>		<u>4.5MG</u>	<u>A203354</u>	<u>005</u>	Aug 07, 2015

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
	+	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

EFFIENT

	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009
	+	EQ 10MG BASE	N022307	002	Jul 10, 2009

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>20MG</u>	<u>N019898</u>	<u>003</u>	Oct 31, 1991
<u>AB</u>		<u>40MG</u>	<u>N019898</u>	<u>004</u>	Mar 22, 1993
<u>AB</u>	+	<u>80MG</u>	<u>N019898</u>	<u>008</u>	Dec 18, 2001

PRAVASTATIN SODIUM

<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076341</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	CIPLA LTD	<u>10MG</u>	<u>A077904</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917</u>	<u>001</u>	Jan 08, 2008

## PRESCRIPTION DRUG PRODUCT LIST

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>		<u>20MG</u>	<u>A077917 002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917 003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917 004</u>	Jan 08, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A077013 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077013 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077013 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077013 004</u>	Dec 28, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A079187 001</u>	May 27, 2010
<u>AB</u>		<u>20MG</u>	<u>A079187 002</u>	May 27, 2010
<u>AB</u>		<u>40MG</u>	<u>A079187 003</u>	May 27, 2010
<u>AB</u>		<u>80MG</u>	<u>A079187 004</u>	May 27, 2010
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076397 003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076397 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076397 001</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491 001</u>	Feb 11, 2008
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056 001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056 002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056 003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793 001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939 004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939 003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939 002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939 001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751 001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751 002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751 003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751 004</u>	Apr 30, 2008

PRAZIOUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER HLTHCARE

600MG

N018714 001 Dec 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442 002</u>	
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N017442 003</u>	
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N017442 001</u>	

PRAZOSIN HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071994 001</u>	Sep 12, 1988
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A072575 003</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072575 002</u>	May 16, 1989
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A072575 001</u>	May 16, 1989
<u>AB</u>	TEVA PHARMS	<u>EQ 2MG BASE</u>	<u>A071995 001</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A071745 001</u>	Sep 12, 1988

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

<u>AB</u>	+	VALEANT BERMUDA	<u>0.1%</u>	<u>N020279 001</u>	Oct 29, 1993
-----------	---	-----------------	-------------	--------------------	--------------

PREDNICARBATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077287 001</u>	Sep 19, 2006
-----------	----------------	-------------	--------------------	--------------

OINTMENT; TOPICAL

DERMATOP

<u>AB</u>	+	VALEANT PHARMS NORTH	<u>0.1%</u>	<u>N019568 001</u>	Sep 23, 1991
-----------	---	----------------------	-------------	--------------------	--------------

PREDNICARBATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077236 001</u>	Mar 09, 2007
-----------	----------------	-------------	--------------------	--------------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

<u>AA</u>	ALPHARMA	<u>15MG/5ML</u>	<u>A040323 001</u>	May 13, 1999	
<u>AA</u>	+	HI TECH PHARMA CO	<u>15MG/5ML</u>	<u>A040401 001</u>	Feb 27, 2003
<u>AA</u>	PHARM ASSOC	<u>15MG/5ML</u>	<u>A040399 001</u>	Mar 05, 2003	
<u>AA</u>	VINTAGE	<u>15MG/5ML</u>	<u>A040775 001</u>	Sep 21, 2007	
<u>AA</u>	WOCKHARDT	<u>15MG/5ML</u>	<u>A040313 001</u>	Sep 10, 2003	

PRELONE

<u>AA</u>	TEVA	<u>15MG/5ML</u>	<u>A089081 001</u>	Feb 04, 1986
-----------	------	-----------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE  
+ WATSON LABS 5MG A080354 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

**AB** ALCON **1%** **N017469 001**

PRED FORTE

**AB** + ALLERGAN **1%** **N017011 001**

PRED MILD

+ ALLERGAN 0.12% N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

+ ALLERGAN 0.2%;10% A087748 001 Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+ ALLERGAN 0.2%;10% N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

**AA** + CONCORDIA PHARMS INC **EQ 15MG BASE/5ML** **A075117 001** Dec 14, 2000

PEDIAPRED

**AA** + SETON PHARM **EQ 5MG BASE/5ML** **N019157 001** May 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

**AA** AMNEAL PHARMS **EQ 15MG BASE/5ML** **A078345 001** Mar 10, 2009

**AA** HI TECH PHARMA **EQ 5MG BASE/5ML** **A075183 001** Mar 26, 2003

**AA** PADDOCK LLC **EQ 5MG BASE/5ML** **A075988 001** May 25, 2004

**AA** PHARM ASSOC **EQ 15MG BASE/5ML** **A076913 001** Apr 25, 2005

**AA** VINTAGE **EQ 15MG BASE/5ML** **A079010 001** May 26, 2009

**AA** WOCKHARDT **EQ 5MG BASE/5ML** **A075099 001** Jun 28, 2002

**AA** **EQ 15MG BASE/5ML** **A076895 001** Oct 04, 2004

+ MISSION PHARMA EQ 25MG BASE/5ML A091396 001 Sep 13, 2010

+ PHARM ASSOC EQ 10MG BASE/5ML A078465 001 Mar 07, 2008

+ EQ 20MG BASE/5ML A078988 001 Jun 09, 2008

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

+ BAUSCH AND LOMB EQ 0.9% PHOSPHATE A040070 001 Jul 29, 1994

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

**AB** CONCORDIA PHARMS INC **EQ 10MG BASE** **N021959 001** Jun 01, 2006

**AB** **EQ 15MG BASE** **N021959 002** Jun 01, 2006

**AB** + **EQ 30MG BASE** **N021959 003** Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE

**AB** MYLAN PHARMS INC **EQ 10MG BASE** **A202179 001** Apr 10, 2013

**AB** **EQ 15MG BASE** **A202179 002** Apr 10, 2013

**AB** **EQ 30MG BASE** **A202179 003** Apr 10, 2013

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

**AT** ALCON PHARMS LTD **EQ 0.23% PHOSPHATE;10%** **A073630 001** May 27, 1993

**AT** + BAUSCH AND LOMB **EQ 0.23% PHOSPHATE;10%** **A074449 001** Dec 29, 1995

PREDNISONE

SOLUTION; ORAL

PREDNISONE

+ ROXANE 5MG/5ML A088703 001 Nov 08, 1984

PREDNISONE INTENSOL

+ ROXANE 5MG/ML A088810 001 Feb 20, 1985

TABLET; ORAL

PREDNISONE

**AB** CONTRACT PHARMACAL **5MG** **A080209 001**

**AB** HIKMA PHARMS **2.5MG** **A040538 001** Jan 08, 2004

**AB** **5MG** **A080292 001**

**AB** **10MG** **A088832 001** Dec 04, 1985

**AB** **20MG** **A083677 001**

**AB** **50MG** **A088465 001** Jun 01, 1984

**AB** JUBILANT CADISTA **1MG** **A040611 001** Jun 06, 2005

**AB** **5MG** **A040362 002** Aug 29, 2001

**AB** **10MG** **A040362 001** Aug 29, 2001

## PRESCRIPTION DRUG PRODUCT LIST

PREDNISON

TABLET; ORAL

PREDNISON

<u>AB</u>		<u>20MG</u>	<u>A040362</u>	<u>003</u>	Jun 29, 2005
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A089245</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>10MG</u>	<u>A089246</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A089247</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>	+ ROXANE	<u>1MG</u>	<u>A087800</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>2.5MG</u>	<u>A087801</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>5MG</u>	<u>A080352</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>A084122</u>	<u>001</u>	
<u>AB</u>	+	<u>20MG</u>	<u>A087342</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084283</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>1MG</u>	<u>A040584</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040581</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>5MG</u>	<u>A040256</u>	<u>001</u>	Jul 12, 2002
<u>AB</u>		<u>10MG</u>	<u>A040256</u>	<u>002</u>	Jul 12, 2002
<u>AB</u>		<u>20MG</u>	<u>A040392</u>	<u>001</u>	Feb 12, 2003
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A080356</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085162</u>	<u>001</u>	
<u>AB</u>		<u>20MG</u>	<u>A085161</u>	<u>001</u>	

TABLET, DELAYED RELEASE; ORAL

RAYOS

	HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012
		2MG	N202020	002	Jul 26, 2012
	+	5MG	N202020	003	Jul 26, 2012

PREGABALIN

CAPSULE; ORAL

LYRICA

	PF PRISM CV	25MG	N021446	001	Dec 30, 2004
		50MG	N021446	002	Dec 30, 2004
		75MG	N021446	003	Dec 30, 2004
		100MG	N021446	004	Dec 30, 2004
		150MG	N021446	005	Dec 30, 2004
		200MG	N021446	006	Dec 30, 2004
		225MG	N021446	007	Dec 30, 2004
	+	300MG	N021446	008	Dec 30, 2004

SOLUTION; ORAL

LYRICA

	+ PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010
--	---------------	---------	---------	-----	--------------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

	+ SEPTODONT INC	4%	A079235	001	Sep 29, 2010
--	-----------------	----	---------	-----	--------------

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

<u>AB</u>	+ SANOFI AVENTIS US	<u>EQ 15MG BASE</u>	<u>N008316</u>	<u>001</u>	
<u>AB</u>	ALVOGEN INC	<u>EQ 15MG BASE</u>	<u>A203924</u>	<u>001</u>	Feb 03, 2014
<u>AB</u>	BAYSHORE PHARMS LLC	<u>EQ 15MG BASE</u>	<u>A204476</u>	<u>001</u>	Feb 25, 2014

PRIMIDONE

TABLET; ORAL

MYSOLINE

<u>AB</u>	+ VALEANT	<u>50MG</u>	<u>N009170</u>	<u>003</u>	
<u>AB</u>		<u>250MG</u>	<u>N009170</u>	<u>002</u>	

PRIMIDONE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A040866</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>		<u>250MG</u>	<u>A040866</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>	HIKMA PHARMS LLC	<u>250MG</u>	<u>A040667</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>	IMPAX LABS	<u>50MG</u>	<u>A040717</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>		<u>250MG</u>	<u>A040717</u>	<u>002</u>	Feb 12, 2008
<u>AB</u>	LANNETT	<u>50MG</u>	<u>A084903</u>	<u>002</u>	May 24, 2001
<u>AB</u>		<u>250MG</u>	<u>A084903</u>	<u>001</u>	
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A040626</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>250MG</u>	<u>A040626</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040586</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>250MG</u>	<u>A040586</u>	<u>002</u>	Feb 24, 2005
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A083551</u>	<u>001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

PROBENECID

TABLET; ORAL

PROBALAN**AB** LANNETT **500MG** **A080966 001**PROBENECID**AB** + MYLAN **500MG** **A084211 002****AB** WATSON LABS **500MG** **A084442 004** Mar 29, 1983PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

+ HOSPIRA 100MG/ML A089069 001 Feb 12, 1986

+ 500MG/ML A089070 001 Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+ SIGMA TAU EQ 50MG BASE N016785 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO**AB** PADDOCK LLC **25MG** **A040246 001** Jun 28, 2000PROCHLORPERAZINE**AB** + G AND W LABS **25MG** **A040058 001** Nov 24, 1993PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE**AP** BEDFORD **EQ 5MG BASE/ML** **A040540 001** May 28, 2004**AP** EMCURE PHARMS LTD **EQ 5MG BASE/ML** **A204147 001** Oct 15, 2013**AP** + EUROHLTH INTL SARL **EQ 5MG BASE/ML** **A089903 001** Aug 29, 1989PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE**AB** MYLAN **EQ 5MG BASE** **A040185 002** Oct 28, 1996**AB** **EQ 10MG BASE** **A040185 001** Oct 28, 1996**AB** SANDOZ **EQ 5MG BASE** **A040101 001** Jul 19, 1996**AB** + **EQ 10MG BASE** **A040101 002** Jul 19, 1996**AB** TEVA PHARMS **EQ 5MG BASE** **A040120 001** Jul 11, 1996**AB** **EQ 10MG BASE** **A040120 002** Jul 11, 1996PROCOMP**AB** JUBILANT CADISTA **EQ 5MG BASE** **A040268 001** Feb 27, 1998**AB** **EQ 10MG BASE** **A040268 002** Feb 27, 1998PROGESTERONE

CAPSULE; ORAL

PROGESTERONE**AB** BANNER LIFE SCIENCES **100MG** **A200900 001** Aug 16, 2013**AB** **200MG** **A200900 002** Aug 16, 2013**AB** SOFGEN PHARMS **100MG** **A200456 001** Sep 28, 2012**AB** **200MG** **A200456 002** Sep 28, 2012**AB** TEVA PHARMS **100MG** **A202121 001** Feb 29, 2012**AB** **200MG** **A202121 002** Feb 29, 2012PROMETRIUM**AB** ABBVIE INC **100MG** **N019781 001** May 14, 1998**AB** + **200MG** **N019781 002** Oct 15, 1999

GEL; VAGINAL

CRINONE

+ ACTAVIS LABS UT INC 4% N020701 001 Jul 31, 1997

+ 8% N020701 002 Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE**AO** + ACTAVIS LABS UT INC **50MG/ML** **N017362 002****AO** FRESENIUS KABI USA **50MG/ML** **A075906 001** Apr 25, 2001**AO** HIKMA FARMACEUTICA **50MG/ML** **A091033 001** Oct 28, 2010**AO** LUITPOLD **50MG/ML** **A090845 001** Jun 22, 2009

INSERT; VAGINAL

ENDOMETRIN

+ FERRING 100MG N022057 001 Jun 21, 2007



## PRESCRIPTION DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	+	EUROHLTH INTL SARL	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>		X-GEN PHARMS	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>			<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		G AND W LABS	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	+		<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>		PERRIGO NEW YORK	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>			<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>		TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>			<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
<u>AB</u>		WATSON LABS INC	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>			<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003

PROMETHEGAN

+ G AND W LABS

50MG

A087165 001 Aug 14, 1987

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>		AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>		HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>		SUN PHARM INDS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>		TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>		TRIS PHARMA INC	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012
<u>AA</u>		VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006

PROMETHAZINE PLAIN

<u>AA</u>	+	WOCKHARDT	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982
-----------	---	-----------	-------------------	----------------	------------	--------------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARMS NY	<u>12.5MG</u>	<u>A091179</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>			<u>25MG</u>	<u>A091179</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>			<u>50MG</u>	<u>A091179</u>	<u>003</u>	Dec 13, 2010
<u>AB</u>		HERITAGE PHARMA	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>			<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>			<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>		IMPAX LABS	<u>12.5MG</u>	<u>A040724</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>			<u>25MG</u>	<u>A040724</u>	<u>002</u>	Feb 12, 2008
<u>AB</u>			<u>50MG</u>	<u>A040791</u>	<u>001</u>	May 20, 2008
<u>AB</u>		KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>			<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>			<u>50MG</u>	<u>A040713</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		MYLAN	<u>12.5MG</u>	<u>A091054</u>	<u>001</u>	Aug 30, 2011
<u>AB</u>			<u>25MG</u>	<u>A091054</u>	<u>002</u>	Aug 30, 2011
<u>AB</u>			<u>50MG</u>	<u>A091054</u>	<u>003</u>	Aug 30, 2011
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A084176</u>	<u>003</u>	
<u>AB</u>	+		<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>		SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>			<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>			<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>		VINTAGE PHARMS	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>			<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>			<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>		WATSON LABS	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>			<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>		ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>			<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>			<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>		PAR PHARM	<u>225MG</u>	<u>A078540</u>	<u>001</u>	Oct 18, 2010
<u>AB</u>			<u>325MG</u>	<u>A078540</u>	<u>002</u>	Oct 18, 2010
<u>AB</u>			<u>425MG</u>	<u>A078540</u>	<u>003</u>	Oct 18, 2010
<u>AB</u>		WATSON LABS INC	<u>225MG</u>	<u>A202688</u>	<u>001</u>	Aug 24, 2015
<u>AB</u>			<u>325MG</u>	<u>A202688</u>	<u>002</u>	Aug 24, 2015
<u>AB</u>			<u>425MG</u>	<u>A202688</u>	<u>003</u>	Aug 24, 2015

RYTHMOL SR

<u>AB</u>		GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416</u>	<u>001</u>	Sep 04, 2003
<u>AB</u>			<u>325MG</u>	<u>N021416</u>	<u>002</u>	Sep 04, 2003
<u>AB</u>	+		<u>425MG</u>	<u>N021416</u>	<u>003</u>	Sep 04, 2003

## PRESCRIPTION DRUG PRODUCT LIST

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A076550 001</u>	Apr 23, 2004
<u>AB</u>		<u>225MG</u>	<u>A076550 002</u>	Apr 23, 2004
<u>AB</u>		<u>300MG</u>	<u>A076550 003</u>	Apr 23, 2004
<u>AB</u>	MUTUAL PHARM	<u>150MG</u>	<u>A075998 001</u>	Nov 29, 2001
<u>AB</u>		<u>225MG</u>	<u>A075998 002</u>	Nov 29, 2001
<u>AB</u>		<u>300MG</u>	<u>A075998 003</u>	Nov 29, 2001
<u>AB</u>	VINTAGE PHARMS	<u>150MG</u>	<u>A075938 001</u>	Oct 17, 2002
<u>AB</u>		<u>225MG</u>	<u>A075938 002</u>	Oct 17, 2002
<u>AB</u>		<u>300MG</u>	<u>A075938 003</u>	Oct 17, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075203 001</u>	Oct 24, 2000
<u>AB</u>		<u>225MG</u>	<u>A075203 002</u>	Oct 24, 2000

RYTHMOL

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>150MG</u>	<u>N019151 001</u>	Nov 27, 1989
<u>AB</u>		<u>225MG</u>	<u>N019151 003</u>	Nov 20, 1992
<u>AB</u>	+	<u>300MG</u>	<u>N019151 002</u>	Nov 27, 1989

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+ ROXANE 15MG

A080927 002

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

<u>AT</u>	+	ALCON	<u>0.5%</u>	<u>A080027 001</u>
-----------	---	-------	-------------	--------------------

PROPARACAINE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>0.5%</u>	<u>A040277 001</u>	Mar 16, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A040074 001</u>	Sep 29, 1995

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

<u>AB</u>	+	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N019627 002</u>	Jun 11, 1996
-----------	---	--------------------	----------------	--------------------	--------------

PROPOFOL

<u>AB</u>	HOSPIRA	<u>10MG/ML</u>	<u>A077908 001</u>	Mar 17, 2006
<u>AB</u>	TEVA PHARMS USA	<u>10MG/ML</u>	<u>A075102 001</u>	Jan 04, 1999
<u>AB</u>	WATSON LABS INC	<u>10MG/ML</u>	<u>A205307 001</u>	Dec 22, 2015

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

<u>AB</u>	CRANFORD PHARMS LLC	<u>60MG</u>	<u>N018553 004</u>	Mar 18, 1987
<u>AB</u>		<u>80MG</u>	<u>N018553 002</u>	Apr 19, 1983
<u>AB</u>		<u>120MG</u>	<u>N018553 003</u>	Apr 19, 1983
<u>AB</u>	+	<u>160MG</u>	<u>N018553 001</u>	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>60MG</u>	<u>A078494 001</u>	Aug 10, 2007
<u>AB</u>		<u>80MG</u>	<u>A078494 002</u>	Aug 10, 2007
<u>AB</u>		<u>120MG</u>	<u>A078494 003</u>	Aug 10, 2007
<u>AB</u>		<u>160MG</u>	<u>A078494 004</u>	Aug 10, 2007
<u>AB</u>	MYLAN	<u>60MG</u>	<u>A078022 001</u>	Feb 15, 2007
<u>AB</u>		<u>80MG</u>	<u>A078022 002</u>	Feb 15, 2007
<u>AB</u>		<u>120MG</u>	<u>A078022 003</u>	Feb 15, 2007
<u>AB</u>		<u>160MG</u>	<u>A078022 004</u>	Feb 15, 2007
<u>AB</u>	NORTEC DEV ASSOC	<u>60MG</u>	<u>A078065 001</u>	Jan 26, 2007
<u>AB</u>		<u>80MG</u>	<u>A078065 002</u>	Jan 26, 2007
<u>AB</u>		<u>120MG</u>	<u>A078065 003</u>	Jan 26, 2007
<u>AB</u>		<u>160MG</u>	<u>A078065 004</u>	Jan 26, 2007
<u>AB</u>	RP SCHERER	<u>60MG</u>	<u>A078703 001</u>	Jul 15, 2011
<u>AB</u>		<u>80MG</u>	<u>A078703 002</u>	Jul 15, 2011
<u>AB</u>		<u>120MG</u>	<u>A078703 003</u>	Jul 15, 2011
<u>AB</u>		<u>160MG</u>	<u>A078703 004</u>	Jul 15, 2011
<u>AB</u>	UPSHER SMITH	<u>60MG</u>	<u>A078311 001</u>	Mar 06, 2009
<u>AB</u>		<u>80MG</u>	<u>A078311 002</u>	Mar 06, 2009
<u>AB</u>		<u>120MG</u>	<u>A078311 003</u>	Mar 06, 2009
<u>AB</u>		<u>160MG</u>	<u>A078311 004</u>	Mar 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A090321 001</u>	Mar 25, 2011
<u>AB</u>		<u>80MG</u>	<u>A090321 002</u>	Mar 25, 2011
<u>AB</u>		<u>120MG</u>	<u>A090321 003</u>	Mar 25, 2011
<u>AB</u>		<u>160MG</u>	<u>A090321 004</u>	Mar 25, 2011

## PRESCRIPTION DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INNOPRAN XL

BX	GLAXOSMITHKLINE LLC	80MG	N021438	001	Mar 12, 2003
BX		120MG	N021438	002	Mar 12, 2003

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

<b>AP</b>	+	BAXTER HLTHCARE CORP	<u>1MG/ML</u>	<b><u>N016419</u></b>	<b><u>001</u></b>	
<b>AP</b>		BEDFORD	<u>1MG/ML</u>	<b><u>A075792</u></b>	<b><u>001</u></b>	Aug 29, 2000
<b>AP</b>		FRESENIUS KABI USA	<u>1MG/ML</u>	<b><u>A075826</u></b>	<b><u>001</u></b>	Aug 31, 2001
<b>AP</b>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<b><u>A077760</u></b>	<b><u>001</u></b>	Jan 31, 2008
<b>AP</b>		SANDOZ	<u>1MG/ML</u>	<b><u>A076400</u></b>	<b><u>001</u></b>	Feb 26, 2003

SOLUTION;ORAL

HEMANGEOL

+	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014
---	--------------------	-----------	---------	-----	--------------

PROPRANOLOL HYDROCHLORIDE

+	ROXANE	20MG/5ML	A070979	001	May 15, 1987
---	--------	----------	---------	-----	--------------

+		40MG/5ML	A070690	001	May 15, 1987
---	--	----------	---------	-----	--------------

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

<b>AB</b>		IPCA LABS LTD	<u>10MG</u>	<b><u>A078955</u></b>	<b><u>001</u></b>	Jun 02, 2008
<b>AB</b>			<u>20MG</u>	<b><u>A078955</u></b>	<b><u>002</u></b>	Jun 02, 2008
<b>AB</b>			<u>40MG</u>	<b><u>A078955</u></b>	<b><u>003</u></b>	Jun 02, 2008
<b>AB</b>			<u>60MG</u>	<b><u>A078955</u></b>	<b><u>004</u></b>	Jun 02, 2008
<b>AB</b>			<u>80MG</u>	<b><u>A078955</u></b>	<b><u>005</u></b>	Jun 02, 2008
<b>AB</b>		MYLAN	<u>10MG</u>	<b><u>A070213</u></b>	<b><u>002</u></b>	Nov 19, 1985
<b>AB</b>			<u>20MG</u>	<b><u>A070213</u></b>	<b><u>003</u></b>	Nov 19, 1985
<b>AB</b>			<u>40MG</u>	<b><u>A070213</u></b>	<b><u>001</u></b>	Nov 19, 1985
<b>AB</b>			<u>60MG</u>	<b><u>A070213</u></b>	<b><u>005</u></b>	Apr 08, 2011
<b>AB</b>			<u>80MG</u>	<b><u>A070213</u></b>	<b><u>004</u></b>	Nov 19, 1985
<b>AB</b>		NORTHSTAR HLTHCARE	<u>10MG</u>	<b><u>A078213</u></b>	<b><u>001</u></b>	Jan 10, 2008
<b>AB</b>			<u>20MG</u>	<b><u>A078213</u></b>	<b><u>002</u></b>	Jan 10, 2008
<b>AB</b>			<u>40MG</u>	<b><u>A078213</u></b>	<b><u>003</u></b>	Jan 10, 2008
<b>AB</b>			<u>60MG</u>	<b><u>A078213</u></b>	<b><u>004</u></b>	Jan 10, 2008
<b>AB</b>			<u>80MG</u>	<b><u>A078213</u></b>	<b><u>005</u></b>	Jan 10, 2008
<b>AB</b>		PLIVA	<u>10MG</u>	<b><u>A071972</u></b>	<b><u>001</u></b>	Apr 06, 1988
<b>AB</b>			<u>20MG</u>	<b><u>A071973</u></b>	<b><u>001</u></b>	Apr 06, 1988
<b>AB</b>			<u>40MG</u>	<b><u>A071974</u></b>	<b><u>001</u></b>	Apr 06, 1988
<b>AB</b>			<u>60MG</u>	<b><u>A071975</u></b>	<b><u>001</u></b>	Apr 06, 1988
<b>AB</b>	+		<u>80MG</u>	<b><u>A071976</u></b>	<b><u>001</u></b>	Apr 06, 1988
<b>AB</b>		VINTAGE PHARMS	<u>10MG</u>	<b><u>A070217</u></b>	<b><u>001</u></b>	Aug 01, 1986
<b>AB</b>			<u>20MG</u>	<b><u>A070218</u></b>	<b><u>001</u></b>	Aug 01, 1986
<b>AB</b>			<u>40MG</u>	<b><u>A070219</u></b>	<b><u>001</u></b>	Aug 01, 1986
<b>AB</b>			<u>60MG</u>	<b><u>A070220</u></b>	<b><u>001</u></b>	Sep 24, 1986
<b>AB</b>			<u>80MG</u>	<b><u>A070221</u></b>	<b><u>001</u></b>	Apr 14, 1986
<b>AB</b>		WATSON LABS	<u>10MG</u>	<b><u>A070175</u></b>	<b><u>001</u></b>	May 13, 1986
<b>AB</b>			<u>20MG</u>	<b><u>A070176</u></b>	<b><u>001</u></b>	May 13, 1986
<b>AB</b>			<u>40MG</u>	<b><u>A070177</u></b>	<b><u>001</u></b>	May 13, 1986
<b>AB</b>			<u>80MG</u>	<b><u>A070178</u></b>	<b><u>001</u></b>	May 13, 1986

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+	DAVA PHARMS INC	50MG	N006188	001

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

+	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987
---	--------------------	---------	---------	-----	--------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

<b>AB</b>		EPIC PHARMA LLC	<u>5MG</u>	<b><u>A202220</u></b>	<b><u>001</u></b>	Nov 19, 2012
<b>AB</b>			<u>10MG</u>	<b><u>A202220</u></b>	<b><u>002</u></b>	Nov 19, 2012
<b>AB</b>		ROXANE	<u>5MG</u>	<b><u>A078913</u></b>	<b><u>001</u></b>	Sep 16, 2008
<b>AB</b>			<u>10MG</u>	<b><u>A078913</u></b>	<b><u>002</u></b>	Sep 16, 2008
<b>AB</b>		SIGMAPHARM LABS LLC	<u>5MG</u>	<b><u>A090462</u></b>	<b><u>001</u></b>	May 03, 2010
<b>AB</b>			<u>10MG</u>	<b><u>A090462</u></b>	<b><u>002</u></b>	May 03, 2010

VIVACTIL

<b>AB</b>		ODYSSEY PHARMS	<u>5MG</u>	<b><u>A073644</u></b>	<b><u>001</u></b>	Aug 24, 1995
<b>AB</b>	+		<u>10MG</u>	<b><u>A073645</u></b>	<b><u>001</u></b>	Aug 24, 1995

## PRESCRIPTION DRUG PRODUCT LIST

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u>	+	DAVA PHARMS INC	<u>500MG</u>	<u>A080157</u>	<u>001</u>	
<u>AB</u>		MIKART	<u>500MG</u>	<u>A081319</u>	<u>001</u>	Jun 30, 1992

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u>	+	VALEANT PHARM INTL	<u>5MG/ML</u>	<u>N009830</u>	<u>001</u>	
-----------	---	--------------------	---------------	----------------	------------	--

REGONOL

<u>AP</u>		SANDOZ	<u>5MG/ML</u>	<u>N017398</u>	<u>001</u>	
-----------	--	--------	---------------	----------------	------------	--

SYRUP; ORAL

MESTINON

+ VALEANT PHARMS

60MG/5ML

N015193 001

TABLET; ORAL

MESTINON

<u>AB</u>	+	VALEANT PHARMS LLC	<u>60MG</u>	<u>N009829</u>	<u>002</u>	
-----------	---	--------------------	-------------	----------------	------------	--

PYRIDOSTIGMINE BROMIDE

<u>AB</u>		IMPAX LABS	<u>60MG</u>	<u>A040502</u>	<u>001</u>	Apr 24, 2003
-----------	--	------------	-------------	----------------	------------	--------------

<u>AB</u>		ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A205650</u>	<u>001</u>	Jun 22, 2015
-----------	--	----------------------	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

MESTINON

<u>AB</u>	+	VALEANT PHARMS LLC	<u>180MG</u>	<u>N011665</u>	<u>001</u>	
-----------	---	--------------------	--------------	----------------	------------	--

PYRIDOSTIGMINE BROMIDE

<u>AB</u>		ALVOGEN INC	<u>180MG</u>	<u>A204737</u>	<u>001</u>	Jun 26, 2015
-----------	--	-------------	--------------	----------------	------------	--------------

<u>AB</u>		IMPAX LABS INC	<u>180MG</u>	<u>A203184</u>	<u>001</u>	Sep 15, 2015
-----------	--	----------------	--------------	----------------	------------	--------------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

+ FRESENIUS KABI USA

100MG/ML

A080618 001

PRIMETHAMINE

TABLET; ORAL

DARAPRIM

+ TURING PHARMS AG

25MG

N008578 001

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 25MG BASE</u>	<u>A202152</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A202152</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A202152</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A202152</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A202152</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A202152</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		ACTAVIS GRP PTC	<u>EQ 25MG BASE</u>	<u>A201762</u>	<u>001</u>	Feb 27, 2013
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A201762</u>	<u>002</u>	Feb 27, 2013
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A201762</u>	<u>003</u>	Feb 27, 2013
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A201762</u>	<u>004</u>	Feb 27, 2013
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A201762</u>	<u>005</u>	Feb 27, 2013
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A201762</u>	<u>006</u>	Feb 27, 2013
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A201762</u>	<u>007</u>	Feb 27, 2013
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A203390</u>	<u>001</u>	Oct 28, 2014
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A203390</u>	<u>002</u>	Oct 28, 2014
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A203390</u>	<u>003</u>	Oct 28, 2014
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A203390</u>	<u>004</u>	Oct 28, 2014
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A203390</u>	<u>005</u>	Oct 28, 2014
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A203390</u>	<u>006</u>	Oct 28, 2014
<u>AB</u>		ALKEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A201504</u>	<u>001</u>	Feb 12, 2013
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A201504</u>	<u>002</u>	Feb 12, 2013
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A201504</u>	<u>003</u>	Feb 12, 2013
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A201504</u>	<u>004</u>	Feb 12, 2013
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A201504</u>	<u>005</u>	Feb 12, 2013
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A201504</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A201504</u>	<u>007</u>	Feb 12, 2013
<u>AB</u>		APOTEX INC	<u>EQ 25MG BASE</u>	<u>A090960</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A090960</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090960</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A090960</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A090960</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A090960</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A091388</u>	<u>001</u>	Mar 27, 2012

## PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091388 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091388 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091388 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091388 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091388 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A091388 007</u>	Mar 27, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A077380 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077380 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077380 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077380 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077380 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077380 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077380 007</u>	Mar 27, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 25MG BASE</u>	<u>A203150 001</u>	Nov 26, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201109 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201109 006</u>	Mar 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A090323 001</u>	Mar 27, 2012
<u>AB</u>	ROXANE	<u>EQ 25MG BASE</u>	<u>A090120 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090749 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090749 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090749 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090749 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090749 005</u>	Mar 27, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679 001</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078679 002</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078679 003</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078679 004</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078679 005</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078679 006</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078679 007</u>	Dec 14, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 25MG BASE</u>	<u>A201190 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201190 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201190 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201190 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201190 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201190 006</u>	Mar 27, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077745 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077745 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077745 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077745 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077745 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077745 007</u>	Mar 27, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A200363 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200363 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200363 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A200363 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A200363 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A200363 006</u>	Mar 27, 2012
<u>SEROQUEL</u>				
<u>AB</u>	+ ASTRAZENECA PHARMS	<u>EQ 25MG BASE</u>	<u>N020639 001</u>	Sep 26, 1997
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N020639 007</u>	Oct 04, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N020639 002</u>	Sep 26, 1997
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>N020639 003</u>	Sep 26, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020639 005</u>	Jul 26, 2000
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>N020639 006</u>	Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL

## SEROQUEL XR

	ASTRAZENECA	EQ 50MG BASE	N022047 001	May 17, 2007
		EQ 150MG BASE	N022047 005	Aug 11, 2008
	+	EQ 200MG BASE	N022047 002	May 17, 2007
		EQ 300MG BASE	N022047 003	May 17, 2007
		EQ 400MG BASE	N022047 004	May 17, 2007

## PRESCRIPTION DRUG PRODUCT LIST

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

<u>AB</u>	PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885 001</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N019885 002</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N019885 003</u>	Nov 19, 1991
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N019885 004</u>	Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 5MG BASE</u>	<u>A076049 001</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076049 002</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076049 003</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076049 004</u>	Jan 14, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202725 001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202725 002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202725 003</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202725 004</u>	Apr 29, 2013
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457 001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078457 002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078457 003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457 004</u>	Aug 24, 2007
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690 001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690 002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690 003</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077690 004</u>	Jun 20, 2006
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076694 001</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076694 002</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076694 003</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076694 004</u>	Dec 23, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 5MG BASE</u>	<u>A076607 001</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090800 001</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076607 002</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090800 002</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076607 003</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090800 003</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076607 004</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090800 004</u>	Jun 18, 2009
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A075504 001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075504 002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075504 003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075504 004</u>	Aug 24, 2007

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+ LILLY

80MG/ML

N007529 002 Feb 10, 1989

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

EX + MUTUAL PHARM

324MG

A089338 001 Feb 11, 1987

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATEAB MUTUAL PHARM200MGA081030 001 Apr 14, 1989AB300MGA081031 001 Apr 14, 1989AB SANDOZ200MGA088072 002AB300MGA088072 001 Sep 26, 1983AB + WATSON LABS200MGA083288 001AB +300MGA085583 001

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+ G AND W LABS INC

300MG

A040045 001 Jun 30, 1994

QUININE SULFATE

CAPSULE; ORAL

QUALAQUINAB + MUTUAL PHARM CO INC324MGN021799 001 Aug 12, 2005QUININE SULFATEAB AMNEAL PHARMS324MGA203729 001 Jul 15, 2015AB LUPIN LTD324MGA203112 001 Apr 24, 2015AB MYLAN PHARMS INC324MGA202581 001 Dec 14, 2012AB RICONPHARMA LLC324MGA204372 001 Jul 22, 2015AB TEVA PHARMS324MGA091661 001 Sep 28, 2012

## PRESCRIPTION DRUG PRODUCT LIST

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

EISAI INC

5MG

N204736 001 Mar 26, 2013

+

10MG

N204736 002 Mar 26, 2013

TABLET, DELAYED RELEASE;ORAL

ACIPHEXAB + EISAI INC20MGN020973 002 Aug 19, 1999RABEPRAZOLE SODIUMAB AMNEAL PHARMS20MGA204179 001 Jul 31, 2015AB BRECKENRIDGE PHARM20MGA204237 001 Nov 18, 2015AB DR REDDYS LABS LTD20MGA076824 001 Nov 08, 2013AB KREMERS URBAN DEV20MGA090678 001 Nov 08, 2013AB LUPIN LTD20MGA078964 001 Nov 08, 2013AB MYLAN PHARMS INC20MGA076885 001 Nov 08, 2013AB TEVA PHARMS USA20MGA076822 001 Nov 08, 2013AB TORRENT PHARMS LTD20MGA202376 001 Nov 08, 2013RADIUM RA-223 DICHLORIDE

SOLUTION;INTRAVENOUS

XOFIGO

+ BAYER HLTHCARE

162mCi/6ML (27mCi/ML)

N203971 001 May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTAAB + LILLY60MGN020815 001 Dec 09, 1997RALOXIFENE HYDROCHLORIDEAB AUROBINDO PHARMA LTD60MGA204310 001 Aug 28, 2015AB INVAGEN PHARMS60MGA090842 001 Sep 24, 2014AB TEVA PHARMS USA60MGA078193 001 Mar 04, 2014AB WATSON LABS INC60MGA200825 001 Jan 21, 2015RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

+ MERCK SHARP DOHME

EQ 100MG BASE/PACKET

N205786 001 Dec 20, 2013

TABLET;ORAL

ISENTRESS

+ MERCK SHARP DOHME

EQ 400MG BASE

N022145 001 Oct 12, 2007

TABLET, CHEWABLE;ORAL

ISENTRESS

MERCK SHARP DOHME

EQ 25MG BASE

N203045 001 Dec 21, 2011

+

EQ 100MG BASE

N203045 002 Dec 21, 2011

RAMELTEON

TABLET;ORAL

RAMELTEONAB ACTAVIS LABS FL INC8MGA091610 001 Aug 19, 2015AB TEVA PHARMS USA8MGA091693 001 Jul 26, 2013ROZEREMAB + TAKEDA PHARMS USA8MGN021782 001 Jul 22, 2005RAMIPRIL

CAPSULE;ORAL

ALTACEAB KING PHARMS1.25MGN019901 001 Jan 28, 1991AB2.5MGN019901 002 Jan 28, 1991AB5MGN019901 003 Jan 28, 1991AB +10MGN019901 004 Jan 28, 1991RAMIPRILAB ACCORD HLTHCARE INC1.25MGA202392 001 Apr 15, 2014AB2.5MGA202392 002 Apr 15, 2014AB5MGA202392 003 Apr 15, 2014AB10MGA202392 004 Apr 15, 2014AB APOTEX1.25MGA079116 001 Jun 20, 2008AB2.5MGA079116 002 Jun 20, 2008AB5MGA079116 003 Jun 20, 2008AB10MGA079116 004 Jun 20, 2008AB AUROBINDO PHARMA LTD1.25MGA091604 001 Jun 08, 2011AB2.5MGA091604 002 Jun 08, 2011AB5MGA091604 003 Jun 08, 2011AB10MGA091604 004 Jun 08, 2011AB DR REDDYS LABS LTD1.25MGA078191 001 Jun 18, 2008AB2.5MGA078191 002 Jun 18, 2008

## PRESCRIPTION DRUG PRODUCT LIST

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

<u>AB</u>		<u>5MG</u>	<u>A078191</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A078191</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1.25MG</u>	<u>A078745</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078745</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A078745</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A078745</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	LUPIN	<u>1.25MG</u>	<u>A077626</u>	<u>001</u>	Jun 09, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077626</u>	<u>002</u>	Jun 09, 2008
<u>AB</u>		<u>5MG</u>	<u>A077626</u>	<u>003</u>	Jun 09, 2008
<u>AB</u>		<u>10MG</u>	<u>A077626</u>	<u>004</u>	Jun 09, 2008
<u>AB</u>	ROXANE	<u>1.25MG</u>	<u>A077900</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077900</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077900</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077900</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	SANDOZ	<u>1.25MG</u>	<u>A077514</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077514</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077514</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077514</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	TEVA PHARMS	<u>1.25MG</u>	<u>A077470</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077470</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077470</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077470</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A076549</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>		<u>2.5MG</u>	<u>A076549</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>5MG</u>	<u>A076549</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>		<u>10MG</u>	<u>A076549</u>	<u>004</u>	Oct 24, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078832</u>	<u>002</u>	Sep 02, 2008
<u>AB</u>		<u>5MG</u>	<u>A078832</u>	<u>003</u>	Sep 02, 2008
<u>AB</u>		<u>10MG</u>	<u>A078832</u>	<u>004</u>	Sep 02, 2008

TABLET; ORAL

RAMIPRIL

APOTEX INC

+

1.25MG	A091069	001	Dec 02, 2015
2.5MG	A091069	002	Dec 02, 2015
5MG	A091069	003	Dec 02, 2015
10MG	A091069	004	Dec 02, 2015

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 25MG BASE/ML</u>	<u>A074777</u>	<u>001</u>	Mar 02, 2005
<u>AP</u>		<u>EQ 25MG BASE/ML</u>	<u>A077458</u>	<u>001</u>	Feb 16, 2006
<u>AP</u>	ZYDUS PHARMS USA INC	<u>25MG/ML</u>	<u>A091534</u>	<u>001</u>	Feb 22, 2013

ZANTAC

<u>AP</u>	+	CONCORDIA PHARMS INC	<u>EQ 25MG BASE/ML</u>	<u>N019090</u>	<u>001</u>	Oct 19, 1984
-----------	---	----------------------	------------------------	----------------	------------	--------------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 15MG BASE/ML</u>	<u>A076124</u>	<u>001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312</u>	<u>001</u>	Sep 02, 2008
<u>AA</u>	AUROBINDO PHARM	<u>EQ 15MG BASE/ML</u>	<u>A090623</u>	<u>001</u>	Jul 28, 2010
<u>AA</u>	BIO PHARM INC	<u>EQ 15MG BASE/ML</u>	<u>A090102</u>	<u>001</u>	May 26, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684</u>	<u>001</u>	Aug 27, 2009
<u>AA</u>	CARACO	<u>EQ 15MG BASE/ML</u>	<u>A091091</u>	<u>001</u>	Sep 20, 2011
<u>AA</u>	HI TECH PHARMA	<u>EQ 15MG BASE/ML</u>	<u>A091078</u>	<u>001</u>	Mar 22, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	SILARX	<u>EQ 15MG BASE/ML</u>	<u>A091288</u>	<u>001</u>	Dec 09, 2010
<u>AA</u>	TARO	<u>EQ 15MG BASE/ML</u>	<u>A077476</u>	<u>001</u>	Jun 13, 2011
<u>AA</u>	TOLMAR	<u>EQ 15MG BASE/ML</u>	<u>A090054</u>	<u>001</u>	Nov 15, 2010
<u>AA</u>	VINTAGE PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078890</u>	<u>001</u>	Jul 01, 2010
<u>AA</u>	WOCKHARDT	<u>EQ 15MG BASE/ML</u>	<u>A079211</u>	<u>001</u>	May 26, 2009
<u>AA</u>		<u>EQ 15MG BASE/ML</u>	<u>A079212</u>	<u>001</u>	Feb 23, 2009

ZANTAC

<u>AA</u>	+	GLAXO GRP LTD	<u>EQ 15MG BASE/ML</u>	<u>N019675</u>	<u>001</u>	Dec 30, 1988
-----------	---	---------------	------------------------	----------------	------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824 001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824 002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680 001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680 002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705 001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705 002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 150MG BASE</u>	<u>A078542 001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542 002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165 001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165 002</u>	Sep 30, 1998
<u>AB</u>	MYLAN	<u>EQ 150MG BASE</u>	<u>A074023 001</u>	Aug 22, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074023 002</u>	Aug 22, 1997
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180 001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180 002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467 001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467 002</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488 001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488 002</u>	Jul 31, 1997
<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A075208 001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208 002</u>	Dec 17, 1998
	<u>ZANTAC 150</u>			
<u>AB</u>	GLAXO GRP LTD	<u>EQ 150MG BASE</u>	<u>N018703 001</u>	Jun 09, 1983
	<u>ZANTAC 300</u>			
<u>AB</u>	+ GLAXO GRP LTD	<u>EQ 300MG BASE</u>	<u>N018703 002</u>	Dec 09, 1985

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

<u>AB</u>	GILEAD	<u>500MG</u>	<u>N021526 002</u>	Jan 27, 2006
<u>AB</u>	+	<u>1GM</u>	<u>N021526 001</u>	Feb 12, 2007
	<u>RANOLAZINE</u>			
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A201046 001</u>	Jul 29, 2013
<u>AB</u>		<u>1GM</u>	<u>A201046 002</u>	Jul 29, 2013

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

<u>AB</u>	TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641 001</u>	May 16, 2006
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>N021641 002</u>	May 16, 2006
	<u>RASAGILINE MESYLATE</u>			
<u>AB</u>	APOTEX INC	<u>EQ 0.5MG BASE</u>	<u>A201950 001</u>	Sep 12, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201950 002</u>	Sep 12, 2013

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

+	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161 001	Apr 10, 2008
---	----------	-----------------------	-------------	--------------

REGORAFENIB

TABLET; ORAL

STIVARGA

+	BAYER HLTHCARE	40MG	N203085 001	Sep 27, 2012
---	----------------	------	-------------	--------------

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630 001	Jul 12, 1996
		EQ 2MG BASE/VIAL	N020630 002	Jul 12, 1996
+		EQ 5MG BASE/VIAL	N020630 003	Jul 12, 1996

REPAGLINIDE

TABLET; ORAL

PRANDIN

<u>AB</u>	NOVO NORDISK INC	<u>0.5MG</u>	<u>N020741 001</u>	Dec 22, 1997
<u>AB</u>		<u>1MG</u>	<u>N020741 002</u>	Dec 22, 1997
<u>AB</u>	+	<u>2MG</u>	<u>N020741 003</u>	Dec 22, 1997
	<u>REPAGLINIDE</u>			
<u>AB</u>	ACTAVIS TOTOWA	<u>0.5MG</u>	<u>A090008 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A090008 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090008 003</u>	Jan 22, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A203820 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A203820 002</u>	Jan 22, 2014

## PRESCRIPTION DRUG PRODUCT LIST

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

<u>AB</u>		<u>2MG</u>	<u>A203820</u>	<u>003</u>	Jan 22, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A090252</u>	<u>001</u>	Aug 23, 2013
<u>AB</u>		<u>1MG</u>	<u>A090252</u>	<u>002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090252</u>	<u>003</u>	Jan 22, 2014
<u>AB</u>	PADDOCK LLC	<u>0.5MG</u>	<u>A201189</u>	<u>001</u>	Jul 17, 2013
<u>AB</u>		<u>1MG</u>	<u>A201189</u>	<u>002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A201189</u>	<u>003</u>	Jan 22, 2014
<u>AB</u>	SANDOZ INC	<u>0.5MG</u>	<u>A078555</u>	<u>001</u>	Nov 22, 2013
<u>AB</u>		<u>1MG</u>	<u>A078555</u>	<u>002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A078555</u>	<u>003</u>	Jan 22, 2014
<u>AB</u>	STANDARD CHEM PHARM	<u>0.5MG</u>	<u>A091517</u>	<u>001</u>	Apr 24, 2015
<u>AB</u>		<u>1MG</u>	<u>A091517</u>	<u>002</u>	Apr 24, 2015
<u>AB</u>		<u>2MG</u>	<u>A091517</u>	<u>003</u>	Apr 24, 2015
<u>AB</u>	SUN PHARM INDS INC	<u>1MG</u>	<u>A077571</u>	<u>002</u>	Jul 11, 2013
<u>AB</u>		<u>2MG</u>	<u>A077571</u>	<u>003</u>	Jul 11, 2013

RESERPINE

TABLET; ORAL

## RESERPINE

BP	SANDOZ	0.1MG	N009838	001	
BP	+	0.25MG	N009838	002	

RETAPAMULIN

OINTMENT; TOPICAL

## ALTABAX

	+	GLAXO GRP LTD	1%	N022055	001	Apr 12, 2007
--	---	---------------	----	---------	-----	--------------

RIBAVIRIN

CAPSULE; ORAL

REBETOL

<u>AB</u>	+	MERCK SHARP DOHME	<u>200MG</u>	<u>N020903</u>	<u>002</u>	Jul 25, 2001
-----------	---	-------------------	--------------	----------------	------------	--------------

RIBASPHERE

<u>AB</u>		THREE RIVERS PHARMS	<u>200MG</u>	<u>A076203</u>	<u>001</u>	Apr 06, 2004
-----------	--	---------------------	--------------	----------------	------------	--------------

RIBAVARIN

<u>AB</u>		AUROBINDO PHARMA	<u>200MG</u>	<u>A079117</u>	<u>001</u>	Sep 17, 2009
-----------	--	------------------	--------------	----------------	------------	--------------

RIBAVIRIN

<u>AB</u>		SANDOZ	<u>200MG</u>	<u>A076192</u>	<u>001</u>	Apr 06, 2004
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>200MG</u>	<u>A076277</u>	<u>001</u>	Oct 04, 2004
-----------	--	------	--------------	----------------	------------	--------------

<u>AB</u>		ZYDUS PHARMS USA	<u>200MG</u>	<u>A077224</u>	<u>001</u>	Oct 28, 2005
-----------	--	------------------	--------------	----------------	------------	--------------

FOR SOLUTION; INHALATION

## VIRAZOLE

	+	VALEANT PHARM INTL	6GM/VIAL	N018859	001	Dec 31, 1985
--	---	--------------------	----------	---------	-----	--------------

SOLUTION; ORAL

## REBETOL

	+	SCHERING	40MG/ML	N021546	001	Jul 29, 2003
--	---	----------	---------	---------	-----	--------------

TABLET; ORAL

COPEGUS

<u>AB</u>		ROCHE	<u>200MG</u>	<u>N021511</u>	<u>001</u>	Dec 03, 2002
-----------	--	-------	--------------	----------------	------------	--------------

RIBAVIRIN

<u>AB</u>		AUROBINDO PHARMA	<u>200MG</u>	<u>A079111</u>	<u>001</u>	Sep 17, 2009
-----------	--	------------------	--------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>200MG</u>	<u>A077743</u>	<u>001</u>	Oct 03, 2006
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>		SANDOZ INC	<u>200MG</u>	<u>A202546</u>	<u>001</u>	Aug 12, 2014
-----------	--	------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>400MG</u>	<u>A202546</u>	<u>002</u>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A202546</u>	<u>003</u>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>600MG</u>	<u>A202546</u>	<u>004</u>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>200MG</u>	<u>A077053</u>	<u>001</u>	Dec 05, 2005
-----------	--	------	--------------	----------------	------------	--------------

<u>AB</u>		THREE RIVERS PHARMS	<u>200MG</u>	<u>A077456</u>	<u>001</u>	Dec 05, 2005
-----------	--	---------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>400MG</u>	<u>A077456</u>	<u>002</u>	Dec 05, 2005
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>	+		<u>600MG</u>	<u>A077456</u>	<u>003</u>	Dec 05, 2005
-----------	---	--	--------------	----------------	------------	--------------

<u>AB</u>		ZYDUS PHARMS USA	<u>200MG</u>	<u>A077094</u>	<u>001</u>	Dec 05, 2005
-----------	--	------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>400MG</u>	<u>A077094</u>	<u>002</u>	Mar 16, 2007
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A077094</u>	<u>004</u>	Apr 18, 2008
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>600MG</u>	<u>A077094</u>	<u>003</u>	Mar 16, 2007
-----------	--	--	--------------	----------------	------------	--------------

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>150MG</u>	<u>N050689</u>	<u>001</u>	Dec 23, 1992
-----------	---	----------------------	--------------	----------------	------------	--------------

RIFABUTIN

<u>AB</u>		LUPIN LTD	<u>150MG</u>	<u>A090033</u>	<u>001</u>	Feb 24, 2014
-----------	--	-----------	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

RIFAMPIN

CAPSULE; ORAL

RIFADIN

<u>AB</u>	SANOFI AVENTIS US	<u>150MG</u>	<u>A062303</u>	<u>001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N050420</u>	<u>001</u>	
<u>RIFAMPIN</u>					
<u>AB</u>	LANNETT	<u>150MG</u>	<u>A065390</u>	<u>001</u>	Mar 28, 2008
<u>AB</u>		<u>300MG</u>	<u>A065390</u>	<u>002</u>	Mar 28, 2008
<u>AB</u>	LUPIN PHARMS	<u>150MG</u>	<u>A090034</u>	<u>001</u>	Aug 21, 2013
<u>AB</u>		<u>300MG</u>	<u>A090034</u>	<u>002</u>	Aug 21, 2013
<u>AB</u>	SANDOZ	<u>150MG</u>	<u>A064150</u>	<u>002</u>	Jan 02, 1998
<u>AB</u>		<u>300MG</u>	<u>A064150</u>	<u>001</u>	May 28, 1997
<u>AB</u>	VERSAPHARM	<u>150MG</u>	<u>A065028</u>	<u>001</u>	Mar 14, 2001
<u>AB</u>		<u>300MG</u>	<u>A065028</u>	<u>002</u>	Mar 14, 2001
<u>RIMACTANE</u>					
<u>AB</u>	PROSAM LABS	<u>300MG</u>	<u>N050429</u>	<u>001</u>	

INJECTABLE; INJECTION

RIFADIN

<u>AP</u>	+	SANOFI AVENTIS US	<u>600MG/VIAL</u>	<u>N050627</u>	<u>001</u>	May 25, 1989
<u>RIFAMPIN</u>						
<u>AP</u>		BEDFORD	<u>600MG/VIAL</u>	<u>A064217</u>	<u>001</u>	Oct 29, 1999
<u>AP</u>		EMCURE PHARMS LTD	<u>600MG/VIAL</u>	<u>A204101</u>	<u>001</u>	Aug 18, 2014
<u>AP</u>		FRESENIUS KABI USA	<u>600MG/VIAL</u>	<u>A091181</u>	<u>001</u>	Aug 21, 2014
<u>AP</u>		MYLAN LABS LTD	<u>600MG/VIAL</u>	<u>A065421</u>	<u>001</u>	May 22, 2008
<u>AP</u>		VERSAPHARM INC	<u>600MG/VIAL</u>	<u>A065502</u>	<u>001</u>	Sep 21, 2010

RIFAPENTINE

TABLET; ORAL

PRIFTIN

+	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998
---	-------------------	-------	---------	-----	--------------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+	SALIX PHARMS	200MG	N021361	001	May 25, 2004
+		550MG	N022554	001	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011
---	---------------	--------------	---------	-----	--------------

RILUZOLE

TABLET; ORAL

RILUTEK

<u>AB</u>	+	COVIS PHARMA SARL	<u>50MG</u>	<u>N020599</u>	<u>001</u>	Dec 12, 1995
<u>RILUZOLE</u>						
<u>AB</u>		APOTEX CORP	<u>50MG</u>	<u>A091300</u>	<u>001</u>	Jun 18, 2013
<u>AB</u>		GLENMARK GENERICS	<u>50MG</u>	<u>A091394</u>	<u>001</u>	Jun 18, 2013
<u>AB</u>		IMPAX LABS	<u>50MG</u>	<u>A076173</u>	<u>001</u>	Jan 29, 2003
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A203042</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		SUN PHARM INDS LTD	<u>50MG</u>	<u>A091417</u>	<u>001</u>	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

<u>AB</u>	+	CARACO	<u>100MG</u>	<u>N019649</u>	<u>001</u>	Sep 17, 1993
<u>RIMANTADINE HYDROCHLORIDE</u>						
<u>AB</u>		IMPAX LABS	<u>100MG</u>	<u>A076132</u>	<u>001</u>	Aug 30, 2002

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

+	ALCON	1%	N020474	001	Dec 30, 1994
---	-------	----	---------	-----	--------------

RIOCIGUAT

TABLET; ORAL

ADEMPAS

	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013
		1MG	N204819	002	Oct 08, 2013
		1.5MG	N204819	003	Oct 08, 2013
		2MG	N204819	004	Oct 08, 2013
+		2.5MG	N204819	005	Oct 08, 2013

## PRESCRIPTION DRUG PRODUCT LIST

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

<u>AB</u>	WARNER CHILCOTT LLC	<u>5MG</u>	<u>N020835 002</u>	Apr 14, 2000
<u>AB</u>		<u>30MG</u>	<u>N020835 001</u>	Mar 27, 1998
<u>AB</u>	+	<u>35MG</u>	<u>N020835 003</u>	May 25, 2002
<u>AB</u>	+	<u>150MG</u>	<u>N020835 005</u>	Apr 22, 2008

RISEDRONATE SODIUM

<u>AB</u>	APOTEX INC	<u>35MG</u>	<u>A090877 001</u>	Nov 30, 2015
<u>AB</u>		<u>75MG</u>	<u>A090877 002</u>	Jun 10, 2014
<u>AB</u>		<u>150MG</u>	<u>A090877 003</u>	Jun 10, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A200296 001</u>	Nov 30, 2015
<u>AB</u>		<u>30MG</u>	<u>A200296 002</u>	Nov 30, 2015
<u>AB</u>		<u>35MG</u>	<u>A200296 003</u>	Nov 30, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203533 001</u>	Dec 09, 2015
<u>AB</u>		<u>30MG</u>	<u>A203533 002</u>	Dec 09, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A200477 001</u>	Nov 30, 2015
<u>AB</u>		<u>30MG</u>	<u>A200477 002</u>	Nov 30, 2015
<u>AB</u>		<u>35MG</u>	<u>A200477 003</u>	Nov 30, 2015
<u>AB</u>		<u>75MG</u>	<u>A200477 004</u>	Jun 10, 2014
<u>AB</u>		<u>150MG</u>	<u>A200477 005</u>	Jun 10, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090886 001</u>	Nov 30, 2015
<u>AB</u>		<u>30MG</u>	<u>A090886 002</u>	Nov 30, 2015
<u>AB</u>		<u>35MG</u>	<u>A090886 003</u>	Nov 30, 2015
<u>AB</u>		<u>75MG</u>	<u>A090886 004</u>	Jun 10, 2014
<u>AB</u>		<u>150MG</u>	<u>A090886 005</u>	Jun 10, 2014
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A077132 001</u>	Oct 05, 2007
<u>AB</u>		<u>30MG</u>	<u>A077132 002</u>	Oct 05, 2007
<u>AB</u>		<u>35MG</u>	<u>A077132 003</u>	Oct 05, 2007
<u>AB</u>		<u>150MG</u>	<u>A079215 001</u>	Jun 13, 2014

TABLET, DELAYED RELEASE; ORAL

ATELVIA

<u>AB</u>	+	WARNER CHILCOTT LLC	<u>35MG</u>	<u>N022560 001</u>	Oct 08, 2010
-----------	---	---------------------	-------------	--------------------	--------------

RISEDRONATE SODIUM

<u>AB</u>	TEVA PHARMS USA	<u>35MG</u>	<u>A203217 001</u>	May 18, 2015
-----------	-----------------	-------------	--------------------	--------------

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346 004	Apr 12, 2007
+		25MG/VIAL	N021346 001	Oct 29, 2003
		37.5MG/VIAL	N021346 002	Oct 29, 2003
		50MG/VIAL	N021346 003	Oct 29, 2003

SOLUTION; ORAL

RISPERDAL

<u>AA</u>	+	JANSSEN PHARMS	<u>1MG/ML</u>	<u>N020588 001</u>	Jun 10, 1996
-----------	---	----------------	---------------	--------------------	--------------

RISPERIDONE

<u>AA</u>	AMNEAL PHARMS	<u>1MG/ML</u>	<u>A091384 001</u>	May 25, 2011
<u>AA</u>	ANI PHARMS INC	<u>1MG/ML</u>	<u>A076440 001</u>	Jan 30, 2009
<u>AA</u>	APOTEX INC	<u>1MG/ML</u>	<u>A077719 001</u>	Jul 29, 2009
<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A078452 001</u>	Sep 04, 2009
<u>AA</u>	BIO PHARM INC	<u>1MG/ML</u>	<u>A078909 001</u>	Jul 29, 2009
<u>AA</u>	PRECISION DOSE	<u>1MG/ML</u>	<u>A076797 001</u>	Jun 28, 2010
<u>AA</u>	ROXANE	<u>1MG/ML</u>	<u>A076904 001</u>	Jul 29, 2009
<u>AA</u>	SILARX PHARMS INC	<u>1MG/ML</u>	<u>A202386 001</u>	Jan 12, 2015
<u>AA</u>	TARO	<u>1MG/ML</u>	<u>A090347 001</u>	Feb 07, 2011
<u>AA</u>	TRIS PHARMA INC	<u>1MG/ML</u>	<u>A079059 001</u>	Dec 12, 2012
<u>AA</u>	VINTAGE	<u>1MG/ML</u>	<u>A079158 001</u>	Dec 03, 2010
<u>AA</u>	WOCKHARDT	<u>1MG/ML</u>	<u>A078744 001</u>	Oct 08, 2009

TABLET; ORAL

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.25MG</u>	<u>N020272 008</u>	May 10, 1999
<u>AB</u>		<u>0.5MG</u>	<u>N020272 007</u>	Jan 27, 1999
<u>AB</u>	+	<u>1MG</u>	<u>N020272 001</u>	Dec 29, 1993
<u>AB</u>		<u>2MG</u>	<u>N020272 002</u>	Dec 29, 1993
<u>AB</u>		<u>3MG</u>	<u>N020272 003</u>	Dec 29, 1993
<u>AB</u>		<u>4MG</u>	<u>N020272 004</u>	Dec 29, 1993

RISPERIDONE

<u>AB</u>	AJANTA PHARMA LTD	<u>0.25MG</u>	<u>A201003 001</u>	Aug 24, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A201003 002</u>	Aug 24, 2011
<u>AB</u>		<u>1MG</u>	<u>A201003 003</u>	Aug 24, 2011
<u>AB</u>		<u>2MG</u>	<u>A201003 004</u>	Aug 24, 2011
<u>AB</u>		<u>3MG</u>	<u>A201003 005</u>	Aug 24, 2011

## PRESCRIPTION DRUG PRODUCT LIST

## RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>4MG</u>	<u>A201003</u>	<u>006</u>	Aug 24, 2011
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077953</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077953</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A077953</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A077953</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A077953</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A077953</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>0.25MG</u>	<u>A078269</u>	<u>001</u>	Oct 08, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078269</u>	<u>002</u>	Oct 08, 2008
<u>AB</u>		<u>1MG</u>	<u>A078269</u>	<u>003</u>	Oct 08, 2008
<u>AB</u>		<u>2MG</u>	<u>A078269</u>	<u>004</u>	Oct 08, 2008
<u>AB</u>		<u>3MG</u>	<u>A078269</u>	<u>005</u>	Oct 08, 2008
<u>AB</u>		<u>4MG</u>	<u>A078269</u>	<u>006</u>	Oct 08, 2008
<u>AB</u>	CIPLA	<u>0.25MG</u>	<u>A077543</u>	<u>001</u>	May 18, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077543</u>	<u>002</u>	May 18, 2011
<u>AB</u>		<u>1MG</u>	<u>A077543</u>	<u>003</u>	May 18, 2011
<u>AB</u>		<u>2MG</u>	<u>A077543</u>	<u>004</u>	May 18, 2011
<u>AB</u>		<u>3MG</u>	<u>A077543</u>	<u>005</u>	May 18, 2011
<u>AB</u>		<u>4MG</u>	<u>A077543</u>	<u>006</u>	May 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.25MG</u>	<u>A076879</u>	<u>001</u>	Oct 24, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076879</u>	<u>002</u>	Oct 24, 2008
<u>AB</u>		<u>1MG</u>	<u>A076879</u>	<u>003</u>	Oct 24, 2008
<u>AB</u>		<u>2MG</u>	<u>A076879</u>	<u>004</u>	Oct 24, 2008
<u>AB</u>		<u>3MG</u>	<u>A076879</u>	<u>005</u>	Oct 24, 2008
<u>AB</u>		<u>4MG</u>	<u>A076879</u>	<u>006</u>	Oct 24, 2008
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A076288</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076288</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A076288</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A076288</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A076288</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A076288</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.25MG</u>	<u>A077769</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077769</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A077769</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A077769</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A077769</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A077769</u>	<u>006</u>	Oct 16, 2008
<u>AB</u>	PRINSTON INC	<u>0.25MG</u>	<u>A077493</u>	<u>001</u>	Nov 29, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077493</u>	<u>002</u>	Nov 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A077493</u>	<u>003</u>	Nov 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A077493</u>	<u>004</u>	Nov 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A077493</u>	<u>005</u>	Nov 29, 2011
<u>AB</u>		<u>4MG</u>	<u>A077493</u>	<u>006</u>	Nov 29, 2011
<u>AB</u>	PROSAM LABS	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>		<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>		<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>		<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>		<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>0.25MG</u>	<u>A078036</u>	<u>001</u>	Mar 10, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078036</u>	<u>002</u>	Mar 10, 2014
<u>AB</u>		<u>1MG</u>	<u>A078036</u>	<u>003</u>	Mar 10, 2014
<u>AB</u>		<u>2MG</u>	<u>A078036</u>	<u>004</u>	Mar 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A078036</u>	<u>005</u>	Mar 10, 2014
<u>AB</u>		<u>4MG</u>	<u>A078036</u>	<u>006</u>	Mar 10, 2014
<u>AB</u>	TEVA	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008

## PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A076996</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>1MG</u>	<u>A076996</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>2MG</u>	<u>A076996</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>3MG</u>	<u>A076996</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>		<u>4MG</u>	<u>A076996</u>	<u>005</u>	Apr 19, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>		<u>3MG</u>	<u>A077328</u>	<u>004</u>	Nov 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077328</u>	<u>005</u>	Nov 30, 2009
<u>AB</u>	JUBILANT GENERICS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>		<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A091537</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>		<u>0.5MG</u>	<u>A091537</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>1MG</u>	<u>A091537</u>	<u>002</u>	Mar 30, 2011
<u>AB</u>		<u>2MG</u>	<u>A091537</u>	<u>003</u>	Mar 30, 2011
<u>AB</u>		<u>3MG</u>	<u>A091537</u>	<u>004</u>	Mar 30, 2011
<u>AB</u>		<u>4MG</u>	<u>A091537</u>	<u>005</u>	Mar 30, 2011
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A077494</u>	<u>001</u>	Apr 30, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A078464</u>	<u>003</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078464</u>	<u>004</u>	Apr 08, 2013

## PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

<u>AB</u>		<u>3MG</u>	<u>A078474 001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078464 005</u>	Apr 08, 2013
<u>AB</u>		<u>4MG</u>	<u>A078474 002</u>	Aug 06, 2010
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A076908 001</u>	Mar 12, 2012
<u>AB</u>		<u>1MG</u>	<u>A076908 002</u>	Mar 12, 2012
<u>AB</u>		<u>2MG</u>	<u>A076908 003</u>	Mar 12, 2012
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516 001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516 003</u>	May 01, 2009

RITONAVIR

CAPSULE;ORAL

NORVIR

+ ABBVIE

100MG

N020945 001 Jun 29, 1999

SOLUTION;ORAL

NORVIR

+ ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET;ORAL

NORVIR

<u>AB</u>	+	ABBVIE	<u>100MG</u>	<u>N022417 001</u>	Feb 10, 2010
-----------	---	--------	--------------	--------------------	--------------

RITONAVIR

<u>AB</u>		ROXANE	<u>100MG</u>	<u>A202573 001</u>	Jan 15, 2015
-----------	--	--------	--------------	--------------------	--------------

RIVAROXABAN

TABLET;ORAL

XARELTO

JANSSEN PHARMS

10MG

N022406 001 Jul 01, 2011

15MG

N022406 002 Nov 04, 2011

+

20MG

N022406 003 Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

<u>AB</u>		NOVARTIS	<u>4.6MG/24HR</u>	<u>N022083 001</u>	Jul 06, 2007
<u>AB</u>	+		<u>9.5MG/24HR</u>	<u>N022083 002</u>	Jul 06, 2007
<u>AB</u>			<u>13.3MG/24HR</u>	<u>N022083 005</u>	Aug 31, 2012

RIVASTIGMINE

<u>AB</u>		ALVOGEN PINE BROOK	<u>4.6MG/24HR</u>	<u>A204403 001</u>	Sep 03, 2015
<u>AB</u>			<u>9.5MG/24HR</u>	<u>A204403 002</u>	Sep 03, 2015
<u>AB</u>			<u>13.3MG/24HR</u>	<u>A204403 003</u>	Aug 31, 2015

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELON

<u>AB</u>	+	NOVARTIS	<u>EQ 1.5MG BASE</u>	<u>N020823 003</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>N020823 004</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>N020823 005</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>N020823 006</u>	Apr 21, 2000

RIVASTIGMINE TARTRATE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A091689 001</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A091689 002</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A091689 003</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091689 004</u>	Jun 12, 2012
<u>AB</u>		APOTEX INC	<u>EQ 1.5MG BASE</u>	<u>A091072 001</u>	May 16, 2013
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A091072 002</u>	May 16, 2013
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A091072 003</u>	May 16, 2013
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091072 004</u>	May 16, 2013
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130 001</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A077130 002</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A077130 003</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A077130 004</u>	Oct 31, 2007
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203148 001</u>	Aug 22, 2014
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A203148 002</u>	Aug 22, 2014
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A203148 003</u>	Aug 22, 2014
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A203148 004</u>	Aug 22, 2014
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 1.5MG BASE</u>	<u>A090879 001</u>	Jun 10, 2015
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A090879 002</u>	Jun 10, 2015
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A090879 003</u>	Jun 10, 2015
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A090879 004</u>	Jun 10, 2015
<u>AB</u>		SUN PHARM INDS	<u>EQ 1.5MG BASE</u>	<u>A077131 001</u>	Oct 22, 2007
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A077131 002</u>	Oct 22, 2007
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A077131 003</u>	Oct 22, 2007

## PRESCRIPTION DRUG PRODUCT LIST

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077131 004</u>	Oct 22, 2007
<u>AB</u>	WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077129 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077129 003</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077129 004</u>	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020864 001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020864 002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202244 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202244 002</u>	Dec 31, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202490 002</u>	Dec 31, 2012
<u>AB</u>	CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A077526 001</u>	Mar 26, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077526 002</u>	Mar 26, 2013
<u>AB</u>	EMCURE PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A204090 001</u>	Nov 26, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204090 002</u>	Nov 26, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201967 002</u>	Dec 31, 2012
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A204339 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204339 002</u>	Jul 01, 2013
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203252 001</u>	Dec 31, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203252 002</u>	Dec 31, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203147 001</u>	Feb 11, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203147 002</u>	Feb 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201993 002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A200482 002</u>	Dec 31, 2012
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A079230 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079230 002</u>	Dec 31, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A202047 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202047 002</u>	Dec 31, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077263 002</u>	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020865 001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020865 002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202477 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202477 002</u>	Jul 01, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203062 002</u>	Jul 01, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201914 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201914 002</u>	Jul 01, 2013
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203334 001</u>	Oct 16, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203334 002</u>	Oct 16, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203146 001</u>	Sep 19, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203146 002</u>	Sep 19, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A078173 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078173 002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203478 002</u>	Jul 01, 2013
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A078739 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078739 002</u>	Jul 01, 2013

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651 001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651 002</u>	Dec 29, 2008
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519 002</u>	Nov 26, 2008
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A079199 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199 002</u>	Nov 26, 2008
<u>AP</u>	SAGENT PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A091458 001</u>	Jul 28, 2010



## PRESCRIPTION DRUG PRODUCT LIST

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458 002</u>	Jul 28, 2010
<u>AP</u>	+ SANDOZ	<u>50MG/5ML (10MG/ML)</u>	<u>A079195 001</u>	Dec 05, 2008
<u>AP</u>	+ TAMARANG	<u>100MG/10ML (10MG/ML)</u>	<u>A079195 002</u>	Dec 05, 2008
<u>AP</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A091115 001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115 002</u>	Aug 27, 2012
<u>AP</u>	TEVA PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078717 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078717 002</u>	Nov 26, 2008

ROFLUMILAST

TABLET; ORAL

DALIRESP

+ ASTRAZENECA PHARMS 500MCG N022522 001 Feb 28, 2011

ROLAPITANT HYDROCHLORIDE

TABLET; ORAL

VARUBI

+ TESARO INC EQ 90MG BASE N206500 001 Sep 01, 2015

ROMIDEPSIN

POWDER; IV (INFUSION)

ISTODAX

+ CELGENE 10MG/VIAL N022393 001 Nov 05, 2009

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 0.25MG BASE</u>	<u>N020658 001</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>N020658 002</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N020658 003</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N020658 004</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>N020658 006</u>	Jan 27, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N020658 007</u>	Jan 27, 1999
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N020658 005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429 001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429 002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429 003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429 004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429 005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429 006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429 007</u>	Mar 24, 2010
<u>AB</u>	APOTEX	<u>EQ 0.25MG BASE</u>	<u>A079165 001</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079165 002</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079165 003</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079165 004</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079165 005</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079165 006</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079165 007</u>	Feb 07, 2012
<u>AB</u>	G AND W LABS INC	<u>EQ 0.25MG BASE</u>	<u>A077460 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077460 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077460 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077460 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077460 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077460 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077460 007</u>	May 19, 2008
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135 001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135 002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135 003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135 004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135 005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135 006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135 007</u>	Feb 25, 2010
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881 007</u>	May 19, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A079229 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229 002</u>	Nov 28, 2012

## PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229 003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229 004</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229 005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229 006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229 007</u>	Nov 28, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 0.25MG BASE</u>	<u>A078110 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110 007</u>	Jul 11, 2008
<u>AB</u>	ROXANE	<u>EQ 0.25MG BASE</u>	<u>A077852 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077852 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852 007</u>	May 19, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 0.25MG BASE</u>	<u>A079050 001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050 002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050 003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050 004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050 005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050 006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050 007</u>	May 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 0.25MG BASE</u>	<u>A090411 001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411 002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411 003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411 004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411 005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411 006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411 007</u>	Jun 01, 2009

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 2MG BASE</u>	<u>N022008 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N022008 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>N022008 006</u>	Apr 10, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N022008 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N022008 005</u>	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090869 001</u>	May 17, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090869 002</u>	May 17, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090869 003</u>	May 17, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090869 004</u>	May 17, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090869 005</u>	May 17, 2012
<u>AB</u>	ALEMBIC LTD	<u>EQ 2MG BASE</u>	<u>A202786 001</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202786 002</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202786 003</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202786 004</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A202786 005</u>	Apr 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2MG BASE</u>	<u>A201576 001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201576 002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201576 003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201576 004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201576 005</u>	Jun 06, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A200462 001</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200462 003</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200462 004</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200462 005</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200462 006</u>	Oct 15, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A201047 001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201047 003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201047 004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201047 005</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201047 006</u>	Jun 06, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 2MG BASE</u>	<u>A200431 001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200431 002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200431 003</u>	Jun 06, 2012

## PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200431 004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200431 005</u>	Jun 06, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 2MG BASE</u>	<u>A091395 001</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091395 002</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091395 003</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A091395 004</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A091395 005</u>	Aug 27, 2012
	MYLAN PHARMS INC	EQ 3MG BASE	A200462 002	Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

NAROPIN

<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>N020533 001</u>	Sep 24, 1996
<u>AP</u>		<u>5MG/ML</u>	<u>N020533 003</u>	Sep 24, 1996
<u>AP</u>		<u>7.5MG/ML</u>	<u>N020533 004</u>	Sep 24, 1996
<u>AP</u>	+	<u>10MG/ML</u>	<u>N020533 005</u>	Sep 24, 1996

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>2MG/ML</u>	<u>A090194 001</u>	Sep 23, 2014
<u>AP</u>		<u>5MG/ML</u>	<u>A090194 002</u>	Sep 23, 2014
<u>AP</u>		<u>7.5MG/ML</u>	<u>A090194 003</u>	Sep 23, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A090194 004</u>	Sep 23, 2014
<u>AP</u>	NAVINTA LLC	<u>5MG/ML</u>	<u>A078601 002</u>	Jul 17, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A078601 003</u>	Jul 17, 2014
<u>AP</u>	SAGENT STRIDES	<u>2MG/ML</u>	<u>A090318 001</u>	Sep 23, 2014
<u>AP</u>		<u>5MG/ML</u>	<u>A090318 002</u>	Sep 23, 2014
<u>AP</u>		<u>7.5MG/ML</u>	<u>A090318 003</u>	Sep 23, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A090318 004</u>	Sep 23, 2014

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

<u>AB</u>	SB PHARMCO	<u>EQ 2MG BASE</u>	<u>N021071 002</u>	May 25, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N021071 003</u>	May 25, 1999
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N021071 004</u>	May 25, 1999

ROSIGLITAZONE MALEATE

<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076747 001</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076747 002</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076747 003</u>	Jan 25, 2013

ROSUVASTATIN CALCIUM

TABLET;ORAL

## CRESTOR

	IPR	5MG	N021366 002	Aug 12, 2003
		10MG	N021366 003	Aug 12, 2003
		20MG	N021366 004	Aug 12, 2003
	+	40MG	N021366 005	Aug 12, 2003

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

## NEUPRO

	UCB INC	1MG/24HR	N021829 004	Apr 02, 2012
	+	2MG/24HR	N021829 001	May 09, 2007
		3MG/24HR	N021829 005	Apr 02, 2012
		4MG/24HR	N021829 002	May 09, 2007
		6MG/24HR	N021829 003	May 09, 2007
		8MG/24HR	N021829 006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE;INJECTION

## CARDIOGEN-82

	BRACCO	N/A	N019414 001	Dec 29, 1989
--	--------	-----	-------------	--------------

RUFINAMIDE

SUSPENSION;ORAL

## BANZEL

	+	EISAI INC	40MG/ML	N201367 001	Mar 03, 2011
--	---	-----------	---------	-------------	--------------

TABLET;ORAL

## BANZEL

	EISAI INC	200MG	N021911 002	Nov 14, 2008
	+	400MG	N021911 003	Nov 14, 2008

## PRESCRIPTION DRUG PRODUCT LIST

RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

INCYTE CORP

EQ 5MG BASE

N202192 001 Nov 16, 2011

EQ 10MG BASE

N202192 002 Nov 16, 2011

EQ 15MG BASE

N202192 003 Nov 16, 2011

EQ 20MG BASE

N202192 004 Nov 16, 2011

+

EQ 25MG BASE

N202192 005 Nov 16, 2011

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+ QOL MEDCL

8,500 IU/ML

N020772 001 Apr 09, 1998

SACUBITRIL; VALSARTAN

TABLET; ORAL

ENTRESTO

NOVARTIS PHARMS CORP

24MG; 26MG

N207620 001 Jul 07, 2015

49MG; 51MG

N207620 002 Jul 07, 2015

+

97MG; 103MG

N207620 003 Jul 07, 2015

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+ GLAXOSMITHKLINE

EQ 0.05MG BASE/INH

N020692 001 Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ LANTHEUS MEDICAL

50mCi/ML

N020570 001 Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

+ BIOMARIN PHARM

100MG/PACKET

N205065 001 Dec 19, 2013

500MG/PACKET

N205065 002 Oct 27, 2015

TABLET; ORAL

KUVAN

+ BIOMARIN PHARM

100MG

N022181 001 Dec 13, 2007

SAQUINAVIR MESYLATE

CAPSULE; ORAL

INVIRASE

+ HOFFMANN LA ROCHE

EQ 200MG BASE

N020628 001 Dec 06, 1995

TABLET; ORAL

INVIRASE

+ HOFFMANN-LA ROCHE

EQ 500MG BASE

N021785 001 Dec 17, 2004

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

+ ASTRAZENECA AB

EQ 2.5MG BASE

N022350 001 Jul 31, 2009

+

EQ 5MG BASE

N022350 002 Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

SCOPOLAMINE**AB** PERRIGO PHARMS CO**1MG/72HR****A078830 001** Jan 30, 2015**TRANSDERM SCOP****AB** + NOVARTIS**1MG/72HR****N017874 001**SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ MARATHON PHARMS

50MG

A086101 001 Oct 03, 1983

+

100MG

A086101 002 Oct 03, 1983

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+ CHIRHOCLIN

16MCG/VIAL

N021256 001 Apr 09, 2004

40MCG/VIAL

N021256 002 Jun 21, 2007

## PRESCRIPTION DRUG PRODUCT LIST

SELEGILINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EMSAM

+ SOMERSET	6MG/24HR	N021336 001	Feb 27, 2006
	9MG/24HR	N021336 002	Feb 27, 2006
	12MG/24HR	N021336 003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

ELDEPRYL

<b>AB</b> + SOMERSET	<b>5MG</b>	<b>N020647 001</b>	May 15, 1996
----------------------	------------	--------------------	--------------

SELEGILINE HYDROCHLORIDE

<b>AB</b> APOTEX	<b>5MG</b>	<b>A075321 001</b>	Dec 04, 1998
------------------	------------	--------------------	--------------

<b>AB</b> DAVA PHARMS INC	<b>5MG</b>	<b>A075352 001</b>	Nov 30, 1998
---------------------------	------------	--------------------	--------------

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

<b>AB</b> + APOTEX INC	<b>5MG</b>	<b>A074871 001</b>	Jun 06, 1997
------------------------	------------	--------------------	--------------

<b>AB</b> MYLAN	<b>5MG</b>	<b>A074866 001</b>	Nov 26, 1997
-----------------	------------	--------------------	--------------

<b>AB</b> STASON	<b>5MG</b>	<b>A074912 001</b>	Apr 30, 1998
------------------	------------	--------------------	--------------

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

+ VALEANT PHARM INTL	1.25MG	N021479 001	Jun 14, 2006
----------------------	--------	-------------	--------------

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

<b>AT</b> PERRIGO NEW YORK	<b>2.5%</b>	<b>A089996 001</b>	Jan 10, 1991
----------------------------	-------------	--------------------	--------------

<b>AT</b> WOCKHARDT	<b>2.5%</b>	<b>A088228 001</b>	Sep 01, 1983
---------------------	-------------	--------------------	--------------

SELSUN

<b>AT</b> + CHATTEM	<b>2.5%</b>	<b>N007936 001</b>	
---------------------	-------------	--------------------	--

SELEXIPAG

TABLET;ORAL

UPTRAVI

ACTELION PHARMS LTD	0.2MG	N207947 001	Dec 21, 2015
---------------------	-------	-------------	--------------

	0.4MG	N207947 002	Dec 21, 2015
--	-------	-------------	--------------

	0.6MG	N207947 003	Dec 21, 2015
--	-------	-------------	--------------

	0.8MG	N207947 004	Dec 21, 2015
--	-------	-------------	--------------

	1MG	N207947 005	Dec 21, 2015
--	-----	-------------	--------------

	1.2MG	N207947 006	Dec 21, 2015
--	-------	-------------	--------------

	1.4MG	N207947 007	Dec 21, 2015
--	-------	-------------	--------------

+	1.6MG	N207947 008	Dec 21, 2015
---	-------	-------------	--------------

SERTACONAZOLE NITRATE

CREAM;TOPICAL

ERTACZO

+ VALEANT LUXEMBOURG	2%	N021385 001	Dec 10, 2003
----------------------	----	-------------	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

SERTRALINE HYDROCHLORIDE

<b>AA</b> AUROBINDO PHARMA	<b>EQ 20MG BASE/ML</b>	<b>A078861 001</b>	Oct 31, 2008
----------------------------	------------------------	--------------------	--------------

ZOLOFT

<b>AA</b> + PFIZER	<b>EQ 20MG BASE/ML</b>	<b>N020990 001</b>	Dec 07, 1999
--------------------	------------------------	--------------------	--------------

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

<b>AB</b> ACCORD HLTHCARE	<b>EQ 25MG BASE</b>	<b>A202825 001</b>	Nov 07, 2014
---------------------------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 50MG BASE</b>	<b>A202825 002</b>	Nov 07, 2014
-----------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 100MG BASE</b>	<b>A202825 003</b>	Nov 07, 2014
-----------	----------------------	--------------------	--------------

<b>AB</b> APOTEX INC	<b>EQ 25MG BASE</b>	<b>A076882 001</b>	Feb 06, 2007
----------------------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 50MG BASE</b>	<b>A076882 002</b>	Feb 06, 2007
-----------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 100MG BASE</b>	<b>A076882 003</b>	Feb 06, 2007
-----------	----------------------	--------------------	--------------

<b>AB</b> AUROBINDO PHARMA	<b>EQ 25MG BASE</b>	<b>A077206 001</b>	Feb 06, 2007
----------------------------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 50MG BASE</b>	<b>A077206 002</b>	Feb 06, 2007
-----------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 100MG BASE</b>	<b>A077206 003</b>	Feb 06, 2007
-----------	----------------------	--------------------	--------------

<b>AB</b> AUSTARPHARMA LLC	<b>EQ 25MG BASE</b>	<b>A078677 001</b>	Mar 04, 2009
----------------------------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 50MG BASE</b>	<b>A078677 002</b>	Mar 04, 2009
-----------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 100MG BASE</b>	<b>A078677 003</b>	Mar 04, 2009
-----------	----------------------	--------------------	--------------

<b>AB</b> INVAGEN PHARMS	<b>EQ 25MG BASE</b>	<b>A077397 001</b>	Feb 06, 2007
--------------------------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 50MG BASE</b>	<b>A077397 002</b>	Feb 06, 2007
-----------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 100MG BASE</b>	<b>A077397 003</b>	Feb 06, 2007
-----------	----------------------	--------------------	--------------

<b>AB</b> LUPIN	<b>EQ 25MG BASE</b>	<b>A077670 001</b>	Feb 06, 2007
-----------------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 50MG BASE</b>	<b>A077670 002</b>	Feb 06, 2007
-----------	---------------------	--------------------	--------------

<b>AB</b>	<b>EQ 100MG BASE</b>	<b>A077670 003</b>	Feb 06, 2007
-----------	----------------------	--------------------	--------------

<b>AB</b> MYLAN	<b>EQ 25MG BASE</b>	<b>A076671 001</b>	Feb 06, 2007
-----------------	---------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076671 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076671 003</u>	Feb 06, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078626 001</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078626 002</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078626 003</u>	Jan 31, 2008
<u>AB</u>	PROSAM LABS	<u>EQ 25MG BASE</u>	<u>A078175 001</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078175 002</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078175 003</u>	Jul 21, 2010
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 25MG BASE</u>	<u>A078108 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078108 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078108 003</u>	Feb 06, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 25MG BASE</u>	<u>A077977 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077977 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077977 003</u>	Feb 06, 2007
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076465 001</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076465 002</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076465 003</u>	Aug 11, 2006
<u>AB</u>	TORRENT PHARMS	<u>EQ 25MG BASE</u>	<u>A077765 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077765 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077765 003</u>	Feb 06, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403 003</u>	Jan 08, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077106 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077106 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077106 003</u>	Feb 06, 2007

ZOLOFT

<u>AB</u>	PFIZER	<u>EQ 25MG BASE</u>	<u>N019839 005</u>	Mar 06, 1996
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N019839 001</u>	Dec 30, 1991
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N019839 002</u>	Dec 30, 1991
	SERTRALINE HYDROCHLORIDE			
	SUN PHARM INDS LTD	EQ 150MG BASE	A077977 004	Feb 06, 2007
		EQ 200MG BASE	A077977 005	Feb 06, 2007

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

RENVELA

GENZYME

800MG/PACKET

N022318 001 Aug 12, 2009

+

2.4GM/PACKET

N022318 002 Feb 18, 2009

TABLET; ORAL

RENVELA

+ GENZYME

800MG

N022127 001 Oct 19, 2007

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

GENZYME

400MG

N021179 001 Jul 12, 2000

+

800MG

N021179 002 Jul 12, 2000

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

<u>AN</u>	BAXTER HLTHCARE	<u>100%</u>	<u>A075895 001</u>	Jul 02, 2002
<u>AN</u>	HALOCARBON PRODS	<u>100%</u>	<u>A078650 001</u>	Nov 19, 2007
<u>AN</u>	SHANGHAI HENGRUI	<u>100%</u>	<u>A203793 001</u>	Nov 03, 2015

SOJOURN

<u>AN</u>	PIRAMAL CRITICAL	<u>100%</u>	<u>A077867 001</u>	May 02, 2007
-----------	------------------	-------------	--------------------	--------------

ULTANE

<u>AN</u>	+	ABBVIE	<u>100%</u>	<u>N020478 001</u>	Jun 07, 1995
-----------	---	--------	-------------	--------------------	--------------

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

+ PFIZER

EQ 10MG BASE/ML

N203109 001 Aug 30, 2012

SOLUTION; INTRAVENOUS

REVATIO

<u>AP</u>	+	PFIZER	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>N022473 001</u>	Nov 18, 2009
-----------	---	--------	---	--------------------	--------------

SILDENAFIL CITRATE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>A203988 001</u>	Apr 01, 2015
-----------	----------------------	---	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

SILDENAFIL CITRATE

TABLET;ORAL

REVATIO

<b>AB</b>	+	PFIZER	<b>EQ 20MG BASE</b>	<b>N021845 001</b>	Jun 03, 2005
-----------	---	--------	---------------------	--------------------	--------------

SILDENAFIL CITRATE

<b>AB</b>		ACTAVIS GRP PTC	<b>EQ 20MG BASE</b>	<b>A200149 001</b>	Feb 25, 2013
<b>AB</b>		AMNEAL PHARMS	<b>EQ 20MG BASE</b>	<b>A202025 001</b>	Feb 28, 2013
<b>AB</b>		APOTEX CORP	<b>EQ 20MG BASE</b>	<b>A091379 001</b>	Nov 06, 2012
<b>AB</b>		AUROBINDO PHARMA LTD	<b>EQ 20MG BASE</b>	<b>A203963 001</b>	Nov 18, 2015
<b>AB</b>		DR REDDYS LABS LTD	<b>EQ 20MG BASE</b>	<b>A202598 001</b>	Nov 06, 2012
<b>AB</b>		HETERO LABS LTD V	<b>EQ 20MG BASE</b>	<b>A203623 001</b>	Nov 26, 2014
<b>AB</b>		MACLEODS PHARMS LTD	<b>EQ 20MG BASE</b>	<b>A203814 001</b>	Dec 17, 2013
<b>AB</b>		MYLAN PHARMS INC	<b>EQ 20MG BASE</b>	<b>A201150 001</b>	Nov 09, 2012
<b>AB</b>		TEVA PHARMS	<b>EQ 20MG BASE</b>	<b>A078380 001</b>	Jan 07, 2013
<b>AB</b>		TORRENT PHARMS LTD	<b>EQ 20MG BASE</b>	<b>A091479 001</b>	Nov 06, 2012
<b>AB</b>		WATSON LABS INC	<b>EQ 20MG BASE</b>	<b>A202503 001</b>	Nov 06, 2012

VIAGRA

		PFIZER IRELAND	EQ 25MG BASE	N020895 001	Mar 27, 1998
			EQ 50MG BASE	N020895 002	Mar 27, 1998
	+		EQ 100MG BASE	N020895 003	Mar 27, 1998

SILODOSIN

CAPSULE;ORAL

RAPAFLO

	+	ACTAVIS LABS UT INC	4MG	N022206 001	Oct 08, 2008
			8MG	N022206 002	Oct 08, 2008

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

<b>AB</b>	+	KING PHARMS	<b>1%</b>	<b>N017381 001</b>	
<b>AB</b>		DR REDDYS LA	<b>1%</b>	<b>N018578 001</b>	Feb 25, 1982
<b>AB</b>		THEPHARMANETWORK LLC	<b>1%</b>	<b>N018810 001</b>	Dec 23, 1985
BX		DR REDDYS LA	<b>1%</b>	N018578 003	Jul 11, 1990

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

	+	JANSSEN PRODS	EQ 150MG BASE	N205123 001	Nov 22, 2013
--	---	---------------	---------------	-------------	--------------

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

<b>AB</b>		ACCORD HLTHCARE	<b>5MG</b>	<b>A078155 005</b>	Apr 05, 2013
<b>AB</b>			<b>10MG</b>	<b>A078155 002</b>	Feb 26, 2008
<b>AB</b>			<b>20MG</b>	<b>A078155 003</b>	Feb 26, 2008
<b>AB</b>			<b>40MG</b>	<b>A078155 004</b>	Feb 26, 2008
<b>AB</b>			<b>80MG</b>	<b>A078155 001</b>	Feb 26, 2008
<b>AB</b>		AUROBINDO PHARMA	<b>5MG</b>	<b>A077691 001</b>	Dec 20, 2006
<b>AB</b>			<b>10MG</b>	<b>A077691 002</b>	Dec 20, 2006
<b>AB</b>			<b>20MG</b>	<b>A077691 003</b>	Dec 20, 2006
<b>AB</b>			<b>40MG</b>	<b>A077691 004</b>	Dec 20, 2006
<b>AB</b>			<b>80MG</b>	<b>A077691 005</b>	Dec 20, 2006
<b>AB</b>		BIOCON LIMITED	<b>5MG</b>	<b>A078034 001</b>	Dec 20, 2006
<b>AB</b>			<b>10MG</b>	<b>A078034 002</b>	Dec 20, 2006
<b>AB</b>			<b>20MG</b>	<b>A078034 003</b>	Dec 20, 2006
<b>AB</b>			<b>40MG</b>	<b>A078034 004</b>	Dec 20, 2006
<b>AB</b>			<b>80MG</b>	<b>A078034 005</b>	Dec 20, 2006
<b>AB</b>		DR REDDYS LABS INC	<b>5MG</b>	<b>A077752 005</b>	Jan 23, 2008
<b>AB</b>			<b>10MG</b>	<b>A077752 001</b>	Dec 20, 2006
<b>AB</b>			<b>20MG</b>	<b>A077752 002</b>	Dec 20, 2006
<b>AB</b>			<b>40MG</b>	<b>A077752 003</b>	Dec 20, 2006
<b>AB</b>			<b>80MG</b>	<b>A077752 004</b>	Dec 20, 2006
<b>AB</b>		HETERO LABS LTD III	<b>5MG</b>	<b>A200895 001</b>	Nov 25, 2014
<b>AB</b>			<b>10MG</b>	<b>A200895 002</b>	Nov 25, 2014
<b>AB</b>			<b>20MG</b>	<b>A200895 003</b>	Nov 25, 2014
<b>AB</b>			<b>40MG</b>	<b>A200895 004</b>	Nov 25, 2014
<b>AB</b>			<b>80MG</b>	<b>A200895 005</b>	Nov 25, 2014
<b>AB</b>		IVAX SUB TEVA PHARMS	<b>5MG</b>	<b>A076052 001</b>	Jun 23, 2006
<b>AB</b>			<b>10MG</b>	<b>A076052 002</b>	Jun 23, 2006
<b>AB</b>			<b>20MG</b>	<b>A076052 003</b>	Jun 23, 2006

## PRESCRIPTION DRUG PRODUCT LIST

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>		<u>40MG</u>	<u>A076052</u>	<u>004</u>	Jun 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076052</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	MICRO LABS LTD	<u>5MG</u>	<u>A090383</u>	<u>001</u>	Sep 16, 2011
<u>AB</u>		<u>10MG</u>	<u>A090383</u>	<u>002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383</u>	<u>003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090868</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>10MG</u>	<u>A090868</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>20MG</u>	<u>A090868</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		<u>40MG</u>	<u>A090868</u>	<u>004</u>	Jun 08, 2010
<u>AB</u>		<u>80MG</u>	<u>A090868</u>	<u>005</u>	Jun 08, 2010
<u>AB</u>	PROSAM LABS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A076285</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076285</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076285</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076285</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076285</u>	<u>005</u>	Jun 23, 2006
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006

ZOCOR

<u>AB</u>	MERCK	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+ BRACCO

0.005MG/VIAL

N017697 001

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+ MEDIGENE AG

15%

N021902 001 Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ PF PRISM CV

1MG/ML

N021083 001 Sep 15, 1999

TABLET; ORAL

RAPAMUNE

<u>AB</u>	PF PRISM CV	<u>0.5MG</u>	<u>N021110</u>	<u>004</u>	Jan 25, 2010
<u>AB</u>		<u>1MG</u>	<u>N021110</u>	<u>001</u>	Aug 25, 2000
<u>AB</u>	+	<u>2MG</u>	<u>N021110</u>	<u>002</u>	Aug 22, 2002

SIROLIMUS

<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A201578</u>	<u>001</u>	Oct 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A201578</u>	<u>002</u>	Oct 27, 2014
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A201676</u>	<u>003</u>	Jan 08, 2014



## PRESCRIPTION DRUG PRODUCT LIST

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006
	EQ 50MG BASE	N021995 002	Oct 16, 2006
+	EQ 100MG BASE	N021995 003	Oct 16, 2006

SODIUM ACETATE ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA	2MEQ/ML	N018893 001	May 04, 1983
-----------	---------	-------------	--------------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

AMMONUL

+ MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645 001	Feb 17, 2005
-----------	-----------------------------	-------------	--------------

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

+ HOSPIRA	0.9MEQ/ML	A077394 001	Nov 09, 2005
+	1MEQ/ML	A077394 002	Nov 09, 2005

SODIUM CHLORIDE

INJECTABLE; INJECTION

**BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

<b><u>AP</u></b>	FRESENIUS KABI USA	<b><u>9MG/ML</u></b>	<b><u>A088911 001</u></b>	Feb 07, 1985
------------------	--------------------	----------------------	---------------------------	--------------

<b><u>AP</u></b>	+ HOSPIRA	<b><u>9MG/ML</u></b>	<b><u>N018800 001</u></b>	Oct 29, 1982
------------------	-----------	----------------------	---------------------------	--------------

**SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER**

<b><u>AP</u></b>	B BRAUN	<b><u>450MG/100ML</u></b>	<b><u>N019635 001</u></b>	Mar 09, 1988
------------------	---------	---------------------------	---------------------------	--------------

<b><u>AP</u></b>	BAXTER HLTHCARE	<b><u>450MG/100ML</u></b>	<b><u>N018016 001</u></b>	
------------------	-----------------	---------------------------	---------------------------	--

<b><u>AP</u></b>	HOSPIRA	<b><u>450MG/100ML</u></b>	<b><u>N018090 001</u></b>	
------------------	---------	---------------------------	---------------------------	--

<b><u>AP</u></b>		<b><u>450MG/100ML</u></b>	<b><u>N019759 001</u></b>	Jun 08, 1988
------------------	--	---------------------------	---------------------------	--------------

**SODIUM CHLORIDE 0.9%**

<b><u>AP</u></b>	EUROHLTH INTL SARL	<b><u>9MG/ML</u></b>	<b><u>A201850 001</u></b>	Jan 20, 2012
------------------	--------------------	----------------------	---------------------------	--------------

**SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

<b><u>AP</u></b>	+ B BRAUN	<b><u>900MG/100ML</u></b>	<b><u>N017464 001</u></b>	
------------------	-----------	---------------------------	---------------------------	--

<b><u>AP</u></b>	+	<b><u>900MG/100ML</u></b>	<b><u>N019635 002</u></b>	Mar 09, 1988
------------------	---	---------------------------	---------------------------	--------------

<b><u>AP</u></b>	+ BAXTER HLTHCARE	<b><u>9MG/ML</u></b>	<b><u>N016677 004</u></b>	Oct 30, 1985
------------------	-------------------	----------------------	---------------------------	--------------

<b><u>AP</u></b>		<b><u>9MG/ML</u></b>	<b><u>N020178 002</u></b>	Dec 07, 1992
------------------	--	----------------------	---------------------------	--------------

<b><u>AP</u></b>	+	<b><u>900MG/100ML</u></b>	<b><u>N016677 001</u></b>	
------------------	---	---------------------------	---------------------------	--

<b><u>AP</u></b>	+	<b><u>900MG/100ML</u></b>	<b><u>N020178 001</u></b>	Dec 07, 1992
------------------	---	---------------------------	---------------------------	--------------

<b><u>AP</u></b>	+ FRESENIUS KABI USA	<b><u>9MG/ML</u></b>	<b><u>A088912 001</u></b>	Jan 10, 1985
------------------	----------------------	----------------------	---------------------------	--------------

<b><u>AP</u></b>	FRESENIUS MEDCL	<b><u>900MG/100ML</u></b>	<b><u>A078177 001</u></b>	Apr 12, 2007
------------------	-----------------	---------------------------	---------------------------	--------------

<b><u>AP</u></b>	HAEMONETICS	<b><u>900MG/100ML</u></b>	<b><u>A076316 001</u></b>	Oct 27, 2004
------------------	-------------	---------------------------	---------------------------	--------------

<b><u>AP</u></b>	+ HOSPIRA	<b><u>9MG/ML</u></b>	<b><u>N018803 001</u></b>	Oct 29, 1982
------------------	-----------	----------------------	---------------------------	--------------

<b><u>AP</u></b>	+	<b><u>9MG/ML</u></b>	<b><u>N019217 001</u></b>	Jul 13, 1984
------------------	---	----------------------	---------------------------	--------------

<b><u>AP</u></b>		<b><u>9MG/ML</u></b>	<b><u>N019465 002</u></b>	Jul 15, 1985
------------------	--	----------------------	---------------------------	--------------

<b><u>AP</u></b>	+	<b><u>900MG/100ML</u></b>	<b><u>N016366 001</u></b>	
------------------	---	---------------------------	---------------------------	--

<b><u>AP</u></b>	+	<b><u>900MG/100ML</u></b>	<b><u>N019465 001</u></b>	Jul 15, 1985
------------------	---	---------------------------	---------------------------	--------------

<b><u>AP</u></b>	+	<b><u>900MG/100ML</u></b>	<b><u>N019480 001</u></b>	Sep 17, 1985
------------------	---	---------------------------	---------------------------	--------------

<b><u>AP</u></b>	+ TARO PHARMS IRELAND	<b><u>9MG/ML</u></b>	<b><u>A077407 001</u></b>	Aug 11, 2006
------------------	-----------------------	----------------------	---------------------------	--------------

SODIUM CHLORIDE 0.9%

MEDEFIL INC	90MG/10ML (9MG/ML)	N202832 006	Jan 06, 2012
-------------	--------------------	-------------	--------------

SODIUM CHLORIDE 0.9%

EUROHLTH INTL SARL	9MG/ML	A201833 001	Sep 24, 2013
--------------------	--------	-------------	--------------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569 001	Jul 27, 2006
--------------------	---------------------	-------------	--------------

	1012.5MG/125ML (9MG/ML)	N021569 002	Jul 27, 2006
--	-------------------------	-------------	--------------

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML	N019022 001	Nov 01, 1983
-----------------	-----------	-------------	--------------

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML	N019022 002	Nov 01, 1983
-----------------	-----------	-------------	--------------

SODIUM CHLORIDE IN PLASTIC CONTAINER

HOSPIRA	2.5MEQ/ML	N018897 001	Jul 20, 1984
---------	-----------	-------------	--------------

SOLUTION; IRRIGATION

**SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

<b><u>AT</u></b>	B BRAUN	<b><u>900MG/100ML</u></b>	<b><u>N016733 001</u></b>	
------------------	---------	---------------------------	---------------------------	--

<b><u>AT</u></b>	BAXTER HLTHCARE	<b><u>900MG/100ML</u></b>	<b><u>N017427 001</u></b>	
------------------	-----------------	---------------------------	---------------------------	--

<b><u>AT</u></b>		<b><u>900MG/100ML</u></b>	<b><u>N017867 001</u></b>	
------------------	--	---------------------------	---------------------------	--

<b><u>AT</u></b>	HOSPIRA	<b><u>900MG/100ML</u></b>	<b><u>N017514 001</u></b>	
------------------	---------	---------------------------	---------------------------	--

<b><u>AT</u></b>		<b><u>900MG/100ML</u></b>	<b><u>N018314 001</u></b>	
------------------	--	---------------------------	---------------------------	--

## PRESCRIPTION DRUG PRODUCT LIST

SODIUM CHLORIDE

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE 900MG/100ML

N019319 002 May 17, 1985

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECITAB + SANOFI AVENTIS US 62.5MG/5ML N020955 001 Feb 18, 1999SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSEAB EUROHLTH INTL SARL 62.5MG/5ML A078215 001 Mar 31, 2011SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18AP 3D IMAGING DRUG 10-200mCi/ML A203777 001 Oct 19, 2015AP BIOMEDCL RES FDN 10-200mCi/ML A204351 001 Jan 09, 2015AP CARDINAL HEALTH 414 10-200mCi/ML A203780 001 Jul 30, 2015AP ESSENTIAL ISOTOPES 10-200mCi/ML A204541 001 Oct 29, 2014AP GLOBAL ISOTOPES LLC 10-200mCi/ML A204464 001 Oct 21, 2014AP HOT SHOTS NM LLC 10-200mCi/ML A204530 001 Jul 29, 2015AP + HOUSTON CYCLOTRON 10-200mCi/ML A203544 001 Dec 26, 2012AP IBA MOLECULAR N AM 10-200mCi/ML A203592 001 Aug 18, 2015AP MIDWEST MEDCL 10-200mCi/ML A204440 001 Nov 17, 2015AP MIPS CRF 10-200mCi/ML A204517 001 Jul 21, 2015AP NCM USA BRONX LLC 10-200mCi/ML A204513 001 Nov 28, 2014AP PETNET 10-200mCi/ML A203890 001 Sep 28, 2015AP PRECISION NUCLEAR 10-200mCi/ML A204542 001 Feb 27, 2015AP SHERTECH LABS LLC 10-200mCi/ML A204315 001 Sep 22, 2014AP SPECTRON MRC LLC 10-200mCi/ML A203912 001 Apr 22, 2015AP TRIAD ISOTOPES INC 10-200mCi/ML A203968 001 Oct 23, 2015AP UCSF RODIOPHARM 10-200mCi/ML A204437 001 Mar 13, 2014AP UIHC PET IMAGING 10-200mCi/ML A204462 001 Nov 17, 2015AP UNIV TX MD ANDERSON 10-200mCi/ML A203247 001 Dec 23, 2013AP UNIV UTAH CYCLOTRON 10-200mCi/ML A204497 001 Apr 20, 2015

+ MCPRF 10-91.5mCi/ML A203605 001 Jun 28, 2013

THE FEINSTEIN INST 20-600mCi/ML A204328 001 Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123AA + CARDINAL HEALTH 418 100uCi N018671 001 May 27, 1982AA + 200uCi N018671 002 May 27, 1982AA MALLINKRODT NUCLEAR 100uCi A071909 001 Feb 28, 1989AA 200uCi A071910 001 Feb 28, 1989SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ MALLINKRODT NUCLEAR 0.8-100mCi

N016517 001

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE 0.009-0.1mCi

N021305 006 May 19, 2005

SOLUTION; ORAL

HICON

+ JUBILANT DRAXIMAGE 250-1000mCi

N021305 007 Dec 05, 2011

SODIUM IODIDE I 131

+ MALLINKRODT NUCLEAR 3.5-150mCi/VIAL

N016515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE IN PLASTIC CONTAINER

+ HOSPIRA 5MEQ/ML

N018947 001 Sep 05, 1984

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS 300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+ HOPE PHARMS 300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML (250MG/ML)

N201444 001 Jan 14, 2011

## PRESCRIPTION DRUG PRODUCT LIST

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

+ HOSPIRA

25MG/ML

A071961 001 Aug 01, 1988

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ PHARMS

500MG/ML

N021196 001 Jul 17, 2002

SODIUM PHENYL BUTYRATE

POWDER; ORAL

**BUPHENYL****AB** + HYPERION THERAPS INC**3GM/TEASPOONFUL****N020573 001** Apr 30, 1996**SODIUM PHENYL BUTYRATE****AB** SIGMAPHARM LABS LLC**3GM/TEASPOONFUL****A202819 001** Mar 22, 2013

TABLET; ORAL

**BUPHENYL****AB** + HYPERION THERAPS INC**500MG****N020572 001** May 13, 1996**SODIUM PHENYL BUTYRATE****AB** AMPOLGEN**500MG****A090910 001** Nov 18, 2011SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+ SALIX PHARMS

0.398GM; 1.102GM

N021892 001 Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+ HOSPIRA

142MG/ML; 276MG/ML

N018892 001 May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

**KALEXATE****AA** KVK TECH**454GM/BOT****A040905 001** Mar 30, 2009**KAYEXALATE****AA** + CONCORDIA PHARMS INC**453.6GM/BOT****N011287 001****KIONEX****AA** PADDOCK LLC**454GM/BOT****A040029 001** Feb 06, 1998**SODIUM POLYSTYRENE SULFONATE****AA** CAROLINA MEDCL**454GM/BOT****A089910 001** Jan 19, 1989**AA** CEDAR PHARMS**453.6GM/BOT****A090313 001** Dec 21, 2011**AA** EPIC PHARMA LLC**453.6GM/BOT****A202333 001** Mar 19, 2014**AA** NUVO PHARM INC**454GM/BOT****A204071 001** Nov 28, 2014

KALEXATE

KVK TECH

15GM/BOT

A040905 002 Apr 03, 2015

SODIUM POLYSTYRENE SULFONATE

NUVO PHARM INC

15GM/BOT

A204071 002 Nov 28, 2014

SUSPENSION; ORAL, RECTAL

**KIONEX****AA** PADDOCK LLC**15GM/60ML****A040028 001** Sep 17, 2007**SODIUM POLYSTYRENE SULFONATE****AA** PADDOCK LLC**15GM/60ML****A090590 001** May 13, 2011**AA** ROXANE**15GM/60ML****A089049 001** Nov 17, 1986**SPS****AA** + CAROLINA MEDCL**15GM/60ML****A087859 001** Dec 08, 1982SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

+ MYLAN INSTITUTIONAL

20MG/2ML (10MG/ML)

A040541 001 Nov 12, 2004

+

60MG/2ML (30MG/ML)

A040541 002 Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS

12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012

SOFOSBUVIR

TABLET; ORAL

SOVALDI

+ GILEAD SCIENCES INC

400MG

N204671 001 Dec 06, 2013

## PRESCRIPTION DRUG PRODUCT LIST

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

<b>AB</b>	TEVA PHARMS USA	<b>5MG</b>	<b>A091464 001</b>	Apr 02, 2014
<b>AB</b>		<b>10MG</b>	<b>A091464 002</b>	Apr 02, 2014
<b>VESICARE</b>				
<b>AB</b>	ASTELLAS	<b>5MG</b>	<b>N021518 001</b>	Nov 19, 2004
<b>AB</b>	+	<b>10MG</b>	<b>N021518 002</b>	Nov 19, 2004

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

## GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280 006	Aug 24, 1995
GENOTROPIN PRESERVATIVE FREE					
BX		PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280 004	Aug 24, 1995
HUMATROPE					
BX	+	LILLY	5MG/VIAL	N019640 004	Mar 08, 1987
BX			6MG/VIAL	N019640 005	Feb 04, 1999
NORDITROPIN FLEXPRO					
BX		NOVO NORDISK INC	5MG/1.5ML	N021148 008	Mar 01, 2010
BX			10MG/1.5ML	N021148 009	Mar 01, 2010
OMNITROPE					
BX		SANDOZ	1.5MG/VIAL	N021426 002	May 30, 2006
BX			5MG/1.5ML	N021426 003	Jan 16, 2008
BX			5.8MG/VIAL	N021426 001	May 30, 2006
BX			10MG/1.5ML	N021426 004	Aug 25, 2008
SAIZEN					
BX		EMD SERONO	5MG/VIAL	N019764 002	Oct 08, 1996
SEROSTIM					
BX		EMD SERONO	4MG/VIAL	N020604 003	Jul 25, 1997
BX			5MG/VIAL	N020604 002	Aug 23, 1996
BX			6MG/VIAL	N020604 001	Aug 23, 1996
VALTROPIN					
BX		LG LIFE	5MG/VIAL	N021905 001	Apr 19, 2007
ZOMACTON					
BX	+	FERRING	5MG/VIAL	N019774 002	Jan 04, 2002
BX			10MG/VIAL	N019774 003	Mar 07, 2012
GENOTROPIN					
	+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280 007	Oct 23, 1996
GENOTROPIN PRESERVATIVE FREE					
		PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280 001	Jan 27, 1998
			0.4MG/VIAL	N020280 002	Jan 27, 1998
			0.6MG/VIAL	N020280 003	Jan 27, 1998
			0.8MG/VIAL	N020280 005	Jan 27, 1998
			1MG/VIAL	N020280 008	Jan 27, 1998
			1.2MG/VIAL	N020280 009	Jan 27, 1998
			1.4MG/VIAL	N020280 010	Jan 27, 1998
			1.6MG/VIAL	N020280 011	Jan 27, 1998
			1.8MG/VIAL	N020280 012	Jan 27, 1998
	+		2MG/VIAL	N020280 013	Jan 27, 1998
HUMATROPE					
	+	LILLY	12MG/VIAL	N019640 006	Feb 04, 1999
	+		24MG/VIAL	N019640 007	Feb 04, 1999
NORDITROPIN FLEXPRO					
		NOVO NORDISK INC	15MG/1.5ML	N021148 010	Mar 01, 2010
			30MG/3ML	N021148 011	Jan 23, 2015
NUTROPIN AQ NUSPIN					
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522 003	Jan 03, 2008
	+		10MG/2ML (5MG/ML)	N020522 005	Jan 03, 2008
	+		20MG/2ML (10MG/ML)	N020522 004	Jan 03, 2008
NUTROPIN AQ PEN					
	+	GENENTECH	10MG/2ML (5MG/ML)	N020522 002	Apr 22, 2002
	+		20MG/2ML (10MG/ML)	N020522 006	Jan 03, 2008
SAIZEN					
	+	EMD SERONO	8.8MG/VIAL	N019764 003	Aug 29, 2000
ZORBTIVE					
	+	EMD SERONO	8.8MG/VIAL	N021597 004	Dec 01, 2003

## PRESCRIPTION DRUG PRODUCT LIST

SONIDEGIB PHOSPHATE

CAPSULE; ORAL

ODOMZO

+ NOVARTIS PHARMS CORP EQ 200MG BASE

N205266 001 Jul 24, 2015

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

+ BAYER HLTHCARE EQ 200MG BASE

N021923 001 Dec 20, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML

N017863 001

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML

N016741 001

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+ ALTATHERA PHARMS LLC 150MG/10ML (15MG/ML)

N022306 001 Jul 02, 2009

SOLUTION; ORAL

SOTYLIZE

+ ARBOR PHARMS LLC 5MG/ML (5MG/ML)

N205108 001 Oct 22, 2014

TABLET; ORAL

BETAPACE**AB1** COVIS PHARMA SARL**80MG****N019865 001** Oct 30, 1992**AB1** **120MG****N019865 005** Apr 20, 1994**AB1** + **160MG****N019865 002** Oct 30, 1992**AB1** **240MG****N019865 003** Oct 30, 1992SORINE**AB1** UPSHER SMITH**80MG****A075500 001** Apr 27, 2001**AB1** **120MG****A075500 004** Apr 27, 2001**AB1** **160MG****A075500 002** Apr 27, 2001**AB1** **240MG****A075500 003** Apr 27, 2001SOTALOL HYDROCHLORIDE**AB1** APOTEX INC**80MG****A076140 001** Sep 26, 2002**AB1** **120MG****A076140 002** Sep 26, 2002**AB1** **160MG****A076140 003** Sep 26, 2002**AB1** **240MG****A076140 004** Sep 26, 2002**AB1** IMPAX PHARMS**80MG****A075663 001** Nov 07, 2000**AB1** **120MG****A075663 002** Nov 07, 2000**AB1** **160MG****A075663 003** Nov 07, 2000**AB1** **240MG****A075663 004** Nov 07, 2000**AB1** MYLAN**80MG****A075237 001** May 01, 2000**AB1** **80MG****A075725 001** Dec 19, 2000**AB1** **120MG****A075237 002** May 01, 2000**AB1** **120MG****A075725 002** Dec 19, 2000**AB1** **160MG****A075237 003** May 01, 2000**AB1** **160MG****A075725 003** Dec 19, 2000**AB1** **240MG****A075237 004** May 01, 2000**AB1** **240MG****A075725 004** Dec 19, 2000**AB1** SANDOZ**80MG****A075366 001** May 01, 2000**AB1** **120MG****A075366 002** May 01, 2000**AB1** **160MG****A075366 003** May 01, 2000**AB1** **240MG****A075366 004** May 01, 2000**AB1** TEVA**80MG****A075429 001** May 01, 2000**AB1** **120MG****A075429 002** May 01, 2000**AB1** **160MG****A075429 003** May 01, 2000**AB1** **240MG****A075429 004** May 01, 2000**AB1** VINTAGE PHARMS**80MG****A075563 001** Nov 07, 2003**AB1** **120MG****A075563 002** Nov 07, 2003**AB1** **160MG****A075563 003** Nov 07, 2003**AB1** **240MG****A075563 004** Nov 07, 2003BETAPACE AF**AB2** COVIS PHARMA SARL**80MG****N021151 001** Feb 22, 2000**AB2** **120MG****N021151 002** Feb 22, 2000**AB2** + **160MG****N021151 003** Feb 22, 2000SOTALOL HYDROCHLORIDE**AB2** APOTEX**80MG****A076214 001** Aug 27, 2003**AB2** **120MG****A076214 002** Aug 27, 2003**AB2** **160MG****A076214 003** Aug 27, 2003**AB2** EPIC PHARMA INC**80MG****A077070 001** Nov 04, 2005**AB2** **120MG****A077070 002** Nov 04, 2005

## PRESCRIPTION DRUG PRODUCT LIST

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

<u>AB2</u>		<u>160MG</u>	<u>A077070 003</u>	Nov 04, 2005
<u>AB2</u>	MYLAN	<u>80MG</u>	<u>A077616 001</u>	Feb 07, 2007
<u>AB2</u>		<u>120MG</u>	<u>A077616 002</u>	Feb 07, 2007
<u>AB2</u>		<u>160MG</u>	<u>A077616 003</u>	Feb 07, 2007
<u>AB2</u>	TEVA	<u>80MG</u>	<u>A076883 001</u>	Jul 26, 2004
<u>AB2</u>		<u>120MG</u>	<u>A076883 002</u>	Jul 26, 2004
<u>AB2</u>		<u>160MG</u>	<u>A076883 003</u>	Jul 26, 2004

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u>	+ FRESENIUS	<u>10%</u>	<u>N017643 001</u>	
	<u>INTRALIPID 20%</u>			
<u>AP</u>	+ FRESENIUS	<u>20%</u>	<u>N018449 001</u>	
<u>AP</u>	+	<u>20%</u>	<u>N020248 001</u>	Aug 07, 1996
	<u>INTRALIPID 30%</u>			
<u>AP</u>	+ FRESENIUS	<u>30%</u>	<u>N019942 001</u>	Dec 30, 1993
	<u>NUTRILIPID 10%</u>			
<u>AP</u>	+ B BRAUN	<u>10%</u>	<u>N019531 001</u>	May 28, 1993
	<u>NUTRILIPID 20%</u>			
<u>AP</u>	+ B BRAUN	<u>20%</u>	<u>N019531 002</u>	May 28, 1993

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+ PARAPRO LLC	<u>0.9%</u>	<u>N022408 001</u>	Jan 18, 2011
--	---------------	-------------	--------------------	--------------

SPIRONOLACTONE

TABLET; ORAL

ALDACTONE

<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N012151 009</u>	Dec 30, 1983
<u>AB</u>		<u>50MG</u>	<u>N012151 008</u>	Dec 30, 1982
<u>AB</u>	+	<u>100MG</u>	<u>N012151 010</u>	Dec 30, 1983
	<u>SPIRONOLACTONE</u>			
<u>AB</u>	ACTAVIS ELIZABETH	<u>25MG</u>	<u>A040353 003</u>	Mar 15, 2006
<u>AB</u>		<u>50MG</u>	<u>A040353 001</u>	Jul 29, 1999
<u>AB</u>		<u>100MG</u>	<u>A040353 002</u>	Jul 29, 1999
<u>AB</u>	AMNEAL PHARMS	<u>25MG</u>	<u>A091426 001</u>	Jun 08, 2010
<u>AB</u>		<u>50MG</u>	<u>A091426 002</u>	Jun 08, 2010
<u>AB</u>		<u>100MG</u>	<u>A091426 003</u>	Jun 08, 2010
<u>AB</u>	JUBILANT GENERICS	<u>25MG</u>	<u>A203253 001</u>	Apr 23, 2014
<u>AB</u>		<u>50MG</u>	<u>A203253 002</u>	Apr 23, 2014
<u>AB</u>		<u>100MG</u>	<u>A203253 003</u>	Apr 23, 2014
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A089424 001</u>	Jul 23, 1986
<u>AB</u>		<u>50MG</u>	<u>A089424 002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>A089424 003</u>	Aug 11, 1999
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A040424 001</u>	Aug 20, 2001
<u>AB</u>		<u>50MG</u>	<u>A040424 002</u>	Aug 20, 2001
<u>AB</u>		<u>100MG</u>	<u>A040424 003</u>	Aug 20, 2001
<u>AB</u>	ORION CORP ORION	<u>25MG</u>	<u>A202187 001</u>	Mar 06, 2014
<u>AB</u>		<u>50MG</u>	<u>A202187 002</u>	Mar 06, 2014
<u>AB</u>		<u>100MG</u>	<u>A202187 003</u>	Mar 06, 2014
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A086809 001</u>	
<u>AB</u>	VINTAGE	<u>25MG</u>	<u>A040750 001</u>	Aug 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A040750 002</u>	Aug 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A040750 003</u>	Aug 29, 2006

STAVUDINE

CAPSULE; ORAL

STAVUDINE

<u>AB</u>	AUROBINDO PHARMA	<u>15MG</u>	<u>A077672 003</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A077672 004</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A077672 001</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A077672 002</u>	Dec 29, 2008
<u>AB</u>	HETERO LABS LTD III	<u>15MG</u>	<u>A078957 001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A078957 002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A078957 003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A078957 004</u>	Dec 29, 2008
<u>AB</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A078775 001</u>	Jan 05, 2009
<u>AB</u>		<u>40MG</u>	<u>A078775 002</u>	Jan 05, 2009
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A079069 001</u>	Dec 29, 2008

## PRESCRIPTION DRUG PRODUCT LIST

STAVUDINE

CAPSULE; ORAL

STAVUDINE

<u>AB</u>		<u>20MG</u>	<u>A079069 002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A079069 003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A079069 004</u>	Dec 29, 2008

ZERIT

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412 002</u>	Jun 24, 1994
<u>AB</u>		<u>20MG</u>	<u>N020412 003</u>	Jun 24, 1994
<u>AB</u>		<u>30MG</u>	<u>N020412 004</u>	Jun 24, 1994
<u>AB</u>	+	<u>40MG</u>	<u>N020412 005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A077774 001</u>	Dec 29, 2008
<u>AA</u>	CIPLA LTD	<u>1MG/ML</u>	<u>A078030 001</u>	Mar 20, 2009

ZERIT

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>1MG/ML</u>	<u>N020413 001</u>	Sep 06, 1996
-----------	---	----------------------	---------------	--------------------	--------------

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018802 001</u>	Oct 27, 1982
-----------	---	---------	-------------	--------------------	--------------

STERILE WATER FOR INJECTION

<u>AP</u>		EUROHLTH INTL SARL	<u>100%</u>	<u>A206369 001</u>	Sep 02, 2015
-----------	--	--------------------	-------------	--------------------	--------------

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>100%</u>	<u>N019633 001</u>	Feb 29, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>100%</u>	<u>N018632 001</u>	Jun 30, 1982
<u>AP</u>	+		<u>100%</u>	<u>N018632 002</u>	Apr 19, 1988
<u>AP</u>		FRESENIUS KABI USA	<u>100%</u>	<u>A088400 001</u>	Jan 16, 1984
<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018233 001</u>	
<u>AP</u>	+		<u>100%</u>	<u>N018801 001</u>	Oct 27, 1982
<u>AP</u>	+		<u>100%</u>	<u>N019869 001</u>	Dec 26, 1989
<u>AP</u>		TARO PHARMS IRELAND	<u>100%</u>	<u>A077393 001</u>	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>		BAXTER HLTHCARE	<u>100%</u>	<u>N017428 001</u>	
-----------	--	-----------------	-------------	--------------------	--

STERILE WATER IN PLASTIC CONTAINER

<u>AT</u>		B BRAUN	<u>100%</u>	<u>N016734 001</u>	
<u>AT</u>		BAXTER HLTHCARE	<u>100%</u>	<u>N017866 001</u>	
<u>AT</u>		HOSPIRA	<u>100%</u>	<u>N017513 001</u>	
<u>AT</u>			<u>100%</u>	<u>N018313 001</u>	

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

+ X GEN PHARMS

EQ 1GM BASE/VIAL

A064210 001 Jun 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+ TEVA PHARMS USA

1GM/VIAL

N050577 001 May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON

<u>AP</u>	+	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N020134 001</u>	Jun 18, 1993
-----------	---	---------------	----------------	--------------------	--------------

STRONTIUM CHLORIDE SR-89

<u>AP</u>		BIO NUCLEONICS	<u>1mCi/ML</u>	<u>A075941 001</u>	Jan 06, 2003
-----------	--	----------------	----------------	--------------------	--------------

SUCCIMER

CAPSULE; ORAL

CHEMET

+ RECORDATI RARE

100MG

N019998 002 Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

<u>AP</u>	+	SANDOZ	<u>20MG/ML</u>	<u>N008453 002</u>	
-----------	---	--------	----------------	--------------------	--

QUELICIN

<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845 006</u>	
-----------	---	---------	----------------	--------------------	--

QUELICIN PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845 001</u>	
-----------	---	---------	----------------	--------------------	--

## PRESCRIPTION DRUG PRODUCT LIST

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+ FOREST LABS INC

1GM/10ML

N019183 001 Dec 16, 1993

TABLET; ORAL

CARAFATE**AB** + FOREST LABS INC**1GM****N018333 001**SUCRALFATE**AB** MYLAN PHARMS INC**1GM****A074415 001** Jun 08, 1998**AB** TEVA**1GM****A070848 001** Mar 29, 1996SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE; ORAL

VELPHORO

+ VIFOR FRESENIUS

500MG

N205109 001 Nov 27, 2013

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE**AP** + AKORN**EQ 0.05MG BASE/ML****N019050 001** May 04, 1984SUFENTANIL CITRATE**AP** EUROHLTH INTL SARL**EQ 0.05MG BASE/ML****A074413 001** Dec 15, 1995**AP** HOSPIRA**EQ 0.05MG BASE/ML****A074534 001** Dec 11, 1996SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

ORGANON SUB MERCK

200MG/2ML (100MG/ML)

N022225 002 Dec 15, 2015

+

500MG/5ML (100MG/ML)

N022225 001 Dec 15, 2015

SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+ RANBAXY

1%

N018737 001 Feb 28, 1989

SOLUTION; TOPICAL

EXELDERM

+ RANBAXY

1%

N018738 001 Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON**AB** + VALEANT PHARMS NORTH**10%****N019931 001** Dec 23, 1996SULFACETAMIDE SODIUM**AB** FOUGERA PHARMS**10%****A077015 001** Nov 17, 2006**AB** PERRIGO CO TENNESSEE**10%****A078649 001** Mar 23, 2009**AB** TARO**10%****A078668 001** May 20, 2009

OINTMENT; OPHTHALMIC

SULFACETAMIDE SODIUM

+ PERRIGO CO TENNESSEE

10%

A080029 001

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10**AT** + ALLERGAN**10%****A080028 001**SULFACETAMIDE SODIUM**AT** AKORN**10%****A040215 001** May 25, 1999**AT** ALCON PHARMS LTD**10%****A089560 001** Oct 18, 1988**AT** BAUSCH AND LOMB**10%****A040066 001** Dec 28, 1994SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

+ SANDOZ

500MG

A040091 001 Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+ TEVA PHARMS USA

80MG/ML; 16MG/ML

A073303 001 Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM**AB** AUROBINDO PHARMA**200MG/5ML; 40MG/5ML****A091348 001** Jun 08, 2010**AB** + HI TECH PHARMA**200MG/5ML; 40MG/5ML****A074650 001** Dec 29, 1997**AB** VINTAGE**200MG/5ML; 40MG/5ML****A077785 001** Jan 24, 2007SULFATRIM PEDIATRIC**AB** STI PHARMA LLC**200MG/5ML; 40MG/5ML****N018615 001** Jan 07, 1983



## PRESCRIPTION DRUG PRODUCT LIST

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

BACTRIM

<b>AB</b>	MUTUAL PHARM	<b>400MG; 80MG</b>	<b>N017377 001</b>	
-----------	--------------	--------------------	--------------------	--

BACTRIM DS

<b>AB</b>	+ MUTUAL PHARM	<b>800MG; 160MG</b>	<b>N017377 002</b>	
-----------	----------------	---------------------	--------------------	--

SEPTRA

<b>AB</b>	MONARCH PHARMS	<b>400MG; 80MG</b>	<b>N017376 001</b>	
-----------	----------------	--------------------	--------------------	--

SEPTRA DS

<b>AB</b>	MONARCH PHARMS	<b>800MG; 160MG</b>	<b>N017376 002</b>	
-----------	----------------	---------------------	--------------------	--

SULFAMETHOXAZOLE AND TRIMETHOPRIM

<b>AB</b>	AMNEAL PHARMS NY	<b>400MG; 80MG</b>	<b>A076899 001</b>	Jan 27, 2005
-----------	------------------	--------------------	--------------------	--------------

<b>AB</b>		<b>800MG; 160MG</b>	<b>A076899 002</b>	Jan 27, 2005
-----------	--	---------------------	--------------------	--------------

<b>AB</b>	AUROBINDO PHARMA	<b>400MG; 80MG</b>	<b>A090624 001</b>	Feb 16, 2010
-----------	------------------	--------------------	--------------------	--------------

<b>AB</b>		<b>800MG; 160MG</b>	<b>A090624 002</b>	Feb 16, 2010
-----------	--	---------------------	--------------------	--------------

<b>AB</b>	GLENMARK GENERICS	<b>400MG; 80MG</b>	<b>A090828 002</b>	Dec 22, 2010
-----------	-------------------	--------------------	--------------------	--------------

<b>AB</b>		<b>800MG; 160MG</b>	<b>A090828 001</b>	Dec 22, 2010
-----------	--	---------------------	--------------------	--------------

<b>AB</b>	MUTUAL PHARM	<b>800MG; 160MG</b>	<b>A071017 001</b>	Aug 25, 1986
-----------	--------------	---------------------	--------------------	--------------

<b>AB</b>	VINTAGE	<b>400MG; 80MG</b>	<b>A078060 002</b>	Jan 25, 2007
-----------	---------	--------------------	--------------------	--------------

<b>AB</b>		<b>800MG; 160MG</b>	<b>A078060 001</b>	Jan 25, 2007
-----------	--	---------------------	--------------------	--------------

<b>AB</b>	VISTA PHARMS	<b>400MG; 80MG</b>	<b>A076817 001</b>	Oct 07, 2005
-----------	--------------	--------------------	--------------------	--------------

<b>AB</b>		<b>800MG; 160MG</b>	<b>A076817 002</b>	Oct 07, 2005
-----------	--	---------------------	--------------------	--------------

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

<b>AB</b>	TEVA	<b>800MG; 160MG</b>	<b>A070037 001</b>	Jun 02, 1987
-----------	------	---------------------	--------------------	--------------

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

<b>AB</b>	TEVA PHARMS	<b>400MG; 80MG</b>	<b>A070030 001</b>	Jun 02, 1987
-----------	-------------	--------------------	--------------------	--------------

SULFANILAMIDE

CREAM; VAGINAL

AVC

	+ MEDA PHARMS	15%	N006530 003	Jan 27, 1987
--	---------------	-----	-------------	--------------

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

	+ PHARMACIA AND UPJOHN	250MG/5ML	A086983 001	
--	------------------------	-----------	-------------	--

TABLET; ORAL

AZULFIDINE

<b>AB</b>	+ PHARMACIA AND UPJOHN	<b>500MG</b>	<b>N007073 001</b>	
-----------	------------------------	--------------	--------------------	--

SULFASALAZINE

<b>AB</b>	VINTAGE PHARMS	<b>500MG</b>	<b>A040349 001</b>	Jan 11, 2002
-----------	----------------	--------------	--------------------	--------------

<b>AB</b>	WATSON LABS	<b>500MG</b>	<b>A085828 001</b>	
-----------	-------------	--------------	--------------------	--

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

<b>AB</b>	+ PHARMACIA AND UPJOHN	<b>500MG</b>	<b>N007073 002</b>	Apr 06, 1983
-----------	------------------------	--------------	--------------------	--------------

SULFASALAZINE

<b>AB</b>	VINTAGE PHARMS	<b>500MG</b>	<b>A075339 001</b>	Jan 11, 2002
-----------	----------------	--------------	--------------------	--------------

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION; INTRAVENOUS

LUMASON

	+ BRACCO	60.7MG/25MG	N203684 001	Oct 15, 2014
--	----------	-------------	-------------	--------------

SULINDAC

TABLET; ORAL

SULINDAC

<b>AB</b>	EPIC PHARMA	<b>150MG</b>	<b>A072710 001</b>	Mar 25, 1991
-----------	-------------	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A072711 001</b>	Mar 25, 1991
-----------	--	--------------	--------------------	--------------

<b>AB</b>	HERITAGE PHARMS INC	<b>150MG</b>	<b>A073262 002</b>	Sep 06, 1991
-----------	---------------------	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A073262 001</b>	Sep 06, 1991
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MUTUAL PHARM	<b>150MG</b>	<b>A072050 001</b>	Apr 17, 1991
-----------	--------------	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A072051 001</b>	Apr 17, 1991
-----------	--	--------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>150MG</b>	<b>A073039 002</b>	Jun 22, 1993
-----------	-------	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A073039 001</b>	Jun 22, 1993
-----------	--	--------------	--------------------	--------------

<b>AB</b>	WATSON LABS	<b>150MG</b>	<b>A071891 001</b>	Apr 03, 1990
-----------	-------------	--------------	--------------------	--------------

<b>AB</b>		<b>200MG</b>	<b>A071795 001</b>	Apr 03, 1990
-----------	--	--------------	--------------------	--------------

SUMATRIPTAN

SPRAY; NASAL

IMITREX

	+ GLAXOSMITHKLINE	5MG/SPRAY	N020626 001	Aug 26, 1997
--	-------------------	-----------	-------------	--------------

		20MG/SPRAY	N020626 003	Aug 26, 1997
--	--	------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>N020080 002</u>	Feb 01, 2006
<u>AB</u>	+		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080 003</u>	Dec 23, 1996

SUMATRIPTAN SUCCINATE

<u>AB</u>		ANTARES PHARMA INC	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A078319 001</u>	Dec 10, 2015
<u>AB</u>			<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078319 002</u>	Dec 10, 2015
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090495 001</u>	Jan 29, 2014
<u>AB</u>		SUN PHARMA GLOBAL	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090358 001</u>	Jun 21, 2011

IMITREX

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080 001</u>	Dec 28, 1992
-----------	---	-----------------	--	--------------------	--------------

SUMATRIPTAN SUCCINATE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A202758 001</u>	Apr 23, 2013
<u>AP</u>		BEDFORD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123 001</u>	Feb 06, 2009
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242 001</u>	Mar 02, 2009
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A200183 001</u>	Sep 16, 2013
<u>AP</u>		INJECTALIA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090310 001</u>	Aug 11, 2010
<u>AP</u>		MYLAN LABS LTD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A203322 001</u>	Apr 14, 2014
<u>AP</u>		PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332 001</u>	Oct 09, 2009
<u>AP</u>		PAR STERILE PRODUCTS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077871 001</u>	Jul 09, 2009
<u>AP</u>		SAGENT AGILA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090641 001</u>	Jul 28, 2010
<u>AP</u>		SAGENT STRIDES	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090314 001</u>	Jun 10, 2010
<u>AP</u>		TEVA PHARMS USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077907 001</u>	Feb 06, 2009
<u>AP</u>		WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593 001</u>	Feb 06, 2009

ALSUMA

BX		MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010
----	--	----------------	-------------------------------------	-------------	--------------

SUMAVEL DOSEPRO

BX	+	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239 002	Nov 26, 2013
----	---	-------------------	------------------------------------	-------------	--------------

BX	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009
----	---	--	-------------------------------------	-------------	--------------

SYSTEM; IONTOPHORESIS

ZECURITY

+ TEVA BRANDED PHARM

			EQ 6.5MG BASE/4HR	N202278 001	Jan 17, 2013
--	--	--	-------------------	-------------	--------------

TABLET; ORAL

IMITREX

<u>AB</u>		GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132 002</u>	Jun 01, 1995
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>N020132 003</u>	Jun 01, 1995
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N020132 001</u>	Jun 01, 1995

SUMATRIPTAN SUCCINATE

<u>AB</u>		APOTEX INC	<u>EQ 25MG BASE</u>	<u>A200263 001</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A200263 002</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A200263 003</u>	Jun 19, 2012
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327 001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078327 002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078327 003</u>	Aug 10, 2009
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847 001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A076847 002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A076847 003</u>	Aug 10, 2009
<u>AB</u>		HIKMA PHARMS	<u>EQ 25MG BASE</u>	<u>A078298 001</u>	May 21, 2013
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078298 002</u>	May 21, 2013
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078298 003</u>	May 21, 2013
<u>AB</u>		MYLAN	<u>EQ 25MG BASE</u>	<u>A077744 001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077744 002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077744 003</u>	Aug 10, 2009
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284 001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078284 002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078284 003</u>	Aug 10, 2009
<u>AB</u>		SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295 001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078295 002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078295 003</u>	Aug 10, 2009
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 25MG BASE</u>	<u>A076554 001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A076554 002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A076572 001</u>	Feb 09, 2009
<u>AB</u>		WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933 001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A076933 002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A076933 003</u>	Aug 10, 2009

## PRESCRIPTION DRUG PRODUCT LIST

SUNITINIB MALATE

CAPSULE; ORAL

SUNITINIB MALATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 12.5MG BASE</u>	<u>A201275 001</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A201275 002</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A201275 003</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201275 004</u>	Jan 30, 2014

SUTENT

<u>AB</u>	CPPI CV	<u>EQ 12.5MG BASE</u>	<u>N021938 001</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N021938 002</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>N021938 004</u>	Mar 31, 2009
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N021938 003</u>	Jan 26, 2006

SUVOREXANT

TABLET; ORAL

BELSOMRA

MERCK SHARP DOHME

		5MG	N204569 001	Aug 13, 2014
		10MG	N204569 002	Aug 13, 2014
		15MG	N204569 003	Aug 13, 2014
	+	20MG	N204569 004	Aug 13, 2014

TACROLIMUS

CAPSULE; ORAL

PROGRAF

<u>AB</u>	ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708 003</u>	Aug 24, 1998
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N050708 001</u>	Apr 08, 1994
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N050708 002</u>	Apr 08, 1994

TACROLIMUS

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A091195 001</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A091195 002</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091195 003</u>	Aug 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509 001</u>	May 12, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090509 002</u>	May 12, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090509 003</u>	May 12, 2010
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596 001</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090596 002</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090596 003</u>	Sep 17, 2010
<u>AB</u>	PANACEA BIOTEC LTD	<u>EQ 0.5MG BASE</u>	<u>A090802 001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090802 002</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090802 003</u>	Sep 28, 2012
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A065461 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A065461 003</u>	Aug 10, 2009
<u>AB</u>	STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A090687 001</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090687 002</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090687 003</u>	Jul 22, 2014

CAPSULE, EXTENDED RELEASE; ORAL

ASTAGRAF XL

ASTELLAS

		EQ 0.5MG BASE	N204096 001	Jul 19, 2013
		EQ 1MG BASE	N204096 002	Jul 19, 2013
	+	EQ 5MG BASE	N204096 003	Jul 19, 2013

INJECTABLE; INJECTION

PROGRAF

+ ASTELLAS

OINTMENT; TOPICAL

PROTOPIC

<u>AB</u>	+	ASTELLAS	<u>0.03%</u>	<u>N050777 001</u>	Dec 08, 2000
<u>AB</u>	+		<u>0.1%</u>	<u>N050777 002</u>	Dec 08, 2000

TACROLIMUS

<u>AB</u>	FOUGERA PHARMS INC	<u>0.03%</u>	<u>A200744 001</u>	Sep 09, 2014
<u>AB</u>		<u>0.1%</u>	<u>A200744 002</u>	Sep 09, 2014

TABLET, EXTENDED RELEASE; ORAL

ENVARUS XR

VELOXIS PHARMS INC

		EQ 0.75MG BASE	N206406 001	Jul 10, 2015
		EQ 1MG BASE	N206406 002	Jul 10, 2015
	+	EQ 4MG BASE	N206406 003	Jul 10, 2015

TADALAFIL

TABLET; ORAL

ADCIRCA

+ ELI LILLY CO

CIALIS

LILLY

		20MG	N022332 001	May 22, 2009
		2.5MG	N021368 004	Jan 07, 2008
		5MG	N021368 001	Nov 21, 2003

## PRESCRIPTION DRUG PRODUCT LIST

TADALAFILTABLET; ORAL  
CIALIS

	10MG	N021368 002	Nov 21, 2003
+	20MG	N021368 003	Nov 21, 2003

TAFLUPROSTSOLUTION/DROPS; OPHTHALMIC  
ZIOPTAN

+	OAK PHARMS INC	0.0015%	N202514 001	Feb 10, 2012
---	----------------	---------	-------------	--------------

TALCAEROSOL, METERED; INTRAPLEURAL  
SCLEROSOL

+	BRYAN	400MG/SPRAY	N020587 001	Dec 24, 1997
---	-------	-------------	-------------	--------------

POWDER; INTRAPLEURAL  
TALC

+	BRYAN	5GM/BOT	N021388 001	Dec 15, 2003
---	-------	---------	-------------	--------------

TALIGLUCERASE ALFAPOWDER; IV (INFUSION)  
ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012
---	--------	----------------	-------------	--------------

TAMOXIFEN CITRATESOLUTION; ORAL  
SOLTAMOX

	DARA BIOSCIENCES	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005
--	------------------	------------------	-------------	--------------

TABLET; ORAL

TAMOXIFEN CITRATE

<b>AB</b>	ACTAVIS LABS FL INC	<b>EQ 10MG BASE</b>	<b>A070929 001</b>	Feb 20, 2003	
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A076179 001</b>	Feb 20, 2003	
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A070929 002</b>	Feb 20, 2003	
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A076179 002</b>	Feb 20, 2003	
<b>AB</b>	APOTEX	<b>EQ 10MG BASE</b>	<b>A090878 001</b>	Sep 23, 2011	
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A090878 002</b>	Sep 23, 2011	
<b>AB</b>	MYLAN	<b>EQ 10MG BASE</b>	<b>A074732 002</b>	Feb 20, 2003	
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A074732 001</b>	Feb 20, 2003	
<b>AB</b>	TEVA	<b>EQ 10MG BASE</b>	<b>A075797 001</b>	Feb 20, 2003	
<b>AB</b>	+	TEVA PHARMS	<b>EQ 20MG BASE</b>	<b>A074858 001</b>	Feb 20, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

<b>AB</b>	+	BOEHRINGER INGELHEIM	<b>0.4MG</b>	<b>N020579 001</b>	Apr 15, 1997
-----------	---	----------------------	--------------	--------------------	--------------

**TAMSULOSIN HYDROCHLORIDE**

<b>AB</b>		ANCHEN PHARMS	<b>0.4MG</b>	<b>A202010 001</b>	Jan 04, 2013
<b>AB</b>		AUROBINDO PHARMA LTD	<b>0.4MG</b>	<b>A202433 001</b>	Apr 30, 2013
<b>AB</b>		IMPAX LABS	<b>0.4MG</b>	<b>A090377 001</b>	Mar 02, 2010
<b>AB</b>		MYLAN	<b>0.4MG</b>	<b>A090408 001</b>	Apr 27, 2010
<b>AB</b>		SANDOZ	<b>0.4MG</b>	<b>A078015 001</b>	Apr 27, 2010
<b>AB</b>		SUN PHARM INDS LTD	<b>0.4MG</b>	<b>A090931 001</b>	Jul 15, 2010
<b>AB</b>		SYNTHON PHARMS	<b>0.4MG</b>	<b>A078801 001</b>	Apr 27, 2010
<b>AB</b>		TEVA PHARMS	<b>0.4MG</b>	<b>A077630 001</b>	Apr 27, 2010
<b>AB</b>		WOCKHARDT	<b>0.4MG</b>	<b>A078938 001</b>	Apr 27, 2010
<b>AB</b>		ZYDUS PHARMS USA INC	<b>0.4MG</b>	<b>A078225 001</b>	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+	DEPOMED INC	EQ 20MG BASE/ML	N203794 001	Oct 15, 2012
---	-------------	-----------------	-------------	--------------

TABLET; ORAL

NUCYNTA

	DEPOMED INC	EQ 50MG BASE	N022304 001	Nov 20, 2008
--	-------------	--------------	-------------	--------------

		EQ 75MG BASE	N022304 002	Nov 20, 2008
--	--	--------------	-------------	--------------

+		EQ 100MG BASE	N022304 003	Nov 20, 2008
---	--	---------------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

	DEPOMED INC	EQ 50MG BASE	N200533 001	Aug 25, 2011
--	-------------	--------------	-------------	--------------

		EQ 100MG BASE	N200533 002	Aug 25, 2011
--	--	---------------	-------------	--------------

		EQ 150MG BASE	N200533 003	Aug 25, 2011
--	--	---------------	-------------	--------------

		EQ 200MG BASE	N200533 004	Aug 25, 2011
--	--	---------------	-------------	--------------

+		EQ 250MG BASE	N200533 005	Aug 25, 2011
---	--	---------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

<u>TASIMELTEON</u>			
CAPSULE; ORAL			
HETLIOZ			
	+ VANDA PHARMS INC	20MG	N205677 001 Jan 31, 2014
<u>TAVABOROLE</u>			
SOLUTION; TOPICAL			
KERYDIN			
	+ ANACOR PHARMS INC	5%	N204427 001 Jul 07, 2014
<u>TAZAROTENE</u>			
AEROSOL, FOAM; TOPICAL			
FABIOR			
	+ STIEFEL LABS INC	0.1%	N202428 001 May 11, 2012
CREAM; TOPICAL			
AVAGE			
	+ ALLERGAN	0.1%	N021184 003 Sep 30, 2002
TAZORAC			
	+ ALLERGAN	0.05%	N021184 001 Sep 29, 2000
	+	0.1%	N021184 002 Sep 29, 2000
GEL; TOPICAL			
TAZORAC			
	+ ALLERGAN	0.05%	N020600 001 Jun 13, 1997
	+	0.1%	N020600 002 Jun 13, 1997
<u>TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT</u>			
INJECTABLE; INJECTION			
PULMOLITE			
BS	JUBILANT DRAXIMAGE	N/A	N017776 001
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT			
BS	DRAXIMAGE	N/A	N017881 001 Dec 30, 1987
<u>TECHNETIUM TC-99M BICISATE KIT</u>			
INJECTABLE; INJECTION			
NEUROLITE			
	LANTHEUS MEDCL	N/A	N020256 001 Nov 23, 1994
<u>TECHNETIUM TC-99M DISOFENIN KIT</u>			
INJECTABLE; INJECTION			
HEPATOLITE			
	PHARMALUCENCE	N/A	N018467 001 Mar 16, 1982
<u>TECHNETIUM TC-99M EXAMETAZIME KIT</u>			
INJECTABLE; INJECTION			
CERETEC			
	+ GE HEALTHCARE	N/A	N019829 001 Dec 30, 1988
<u>TECHNETIUM TC-99M MEBROFENIN KIT</u>			
INJECTABLE; INJECTION			
<b>CHOLETEC</b>			
<b>AP</b>	+ BRACCO	<b>N/A</b>	<b>N018963 001</b> Jan 21, 1987
<b>TECHNETIUM TC-99M MEBROFENIN</b>			
<b>AP</b>	PHARMALUCENCE	<b>N/A</b>	<b>A078242 001</b> Jan 29, 2008
<u>TECHNETIUM TC-99M MEDRONATE</u>			
INJECTABLE; INJECTION			
DRAXIMAGE MDP-25			
	+ JUBILANT DRAXIMAGE	N/A	N018035 002 Feb 27, 2004
<u>TECHNETIUM TC-99M MEDRONATE KIT</u>			
INJECTABLE; INJECTION			
<b>CIS-MDP</b>			
<b>AP</b>	PHARMALUCENCE	<b>N/A</b>	<b>N018124 001</b>
<b>MDP-BRACCO</b>			
<b>AP</b>	BRACCO	<b>N/A</b>	<b>N018107 001</b>
<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>			
INJECTABLE; INJECTION			
TECHNESCAN MAG3			
	+ MALLINKRODT NUCLEAR	N/A	N019882 001 Jun 15, 1990
<u>TECHNETIUM TC-99M OXIDRONATE KIT</u>			
INJECTABLE; INJECTION			
TECHNESCAN			
	+ MALLINKRODT NUCLEAR	N/A	N018321 001

## PRESCRIPTION DRUG PRODUCT LIST

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA

<b>AP</b>	JUBILANT DRAXIMAGE	<b>N/A</b>	<b>N017714 001</b>	
-----------	--------------------	------------	--------------------	--

DTPA

<b>AP</b>	DRAXIMAGE	<b>N/A</b>	<b>N018511 001</b>	Dec 29, 1989
-----------	-----------	------------	--------------------	--------------

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO

<b>AP</b>	PHARMALUCENCE	<b>N/A</b>	<b>N019039 001</b>	Jun 30, 1987
-----------	---------------	------------	--------------------	--------------

TECHNESCAN PYP KIT

<b>AP</b>	MALLINKRODT NUCLEAR	<b>N/A</b>	<b>N017538 001</b>	
-----------	---------------------	------------	--------------------	--

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

	MALLINKRODT NUCLEAR	<b>N/A</b>	<b>N019981 001</b>	Jun 10, 1991
--	---------------------	------------	--------------------	--------------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

<b>AP</b>	+ LANTHEUS MEDCL	<b>N/A</b>	<b>N019785 001</b>	Dec 21, 1990
-----------	------------------	------------	--------------------	--------------

TECHNETIUM TC 99M SESTAMIBI

<b>AP</b>	CARDINAL HEALTH 414	<b>N/A</b>	<b>A078809 001</b>	Apr 28, 2009
-----------	---------------------	------------	--------------------	--------------

<b>AP</b>	DRAXIMAGE	<b>N/A</b>	<b>A078806 001</b>	Apr 29, 2009
-----------	-----------	------------	--------------------	--------------

<b>AP</b>	PHARMALUCENCE	<b>10-30mCi</b>	<b>A079157 001</b>	Jul 10, 2009
-----------	---------------	-----------------	--------------------	--------------

TECHNETIUM TC-99M SESTAMIBI

<b>AP</b>	MALLINKRODT NUCLEAR	<b>N/A</b>	<b>A078098 001</b>	Sep 22, 2008
-----------	---------------------	------------	--------------------	--------------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

TECHNELITE

	+ LANTHEUS MEDCL	1-20 CI/GENERATOR	<b>N017771 002</b>	Feb 12, 2014
--	------------------	-------------------	--------------------	--------------

ULTRA-TECHNEKOW FM

	+ MALLINCKRODT	1-19 CI/GENERATOR	<b>N017243 003</b>	Feb 18, 2014
--	----------------	-------------------	--------------------	--------------

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

	+ GE HEALTHCARE	68-2703mCi/GENERATOR	<b>N017693 002</b>	Dec 13, 2013
--	-----------------	----------------------	--------------------	--------------

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

	GE HEALTHCARE	<b>N/A</b>	<b>N017944 001</b>	May 18, 1982
--	---------------	------------	--------------------	--------------

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

	+ PHARMALUCENCE	<b>N/A</b>	<b>N017858 001</b>	
--	-----------------	------------	--------------------	--

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW

	+ GE HEALTHCARE	<b>N/A</b>	<b>N020372 001</b>	Feb 09, 1996
--	-----------------	------------	--------------------	--------------

MYOVIEW 30ML

	+ GE HEALTHCARE	<b>N/A</b>	<b>N020372 002</b>	Jul 07, 2005
--	-----------------	------------	--------------------	--------------

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

	+ NAVIDEA BIOPHARMS	<b>N/A</b>	<b>N202207 001</b>	Mar 13, 2013
--	---------------------	------------	--------------------	--------------

TEDIZOLID PHOSPHATE

POWDER; IV (INFUSION)

SIVEXTRO

	+ CUBIST PHARMS LLC	200MG/VIAL	<b>N205436 001</b>	Jun 20, 2014
--	---------------------	------------	--------------------	--------------

TABLET; ORAL

SIVEXTRO

	+ CUBIST PHARMS LLC	200MG	<b>N205435 001</b>	Jun 20, 2014
--	---------------------	-------	--------------------	--------------

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

	+ NPS PHARMS INC	5MG/VIAL	<b>N203441 001</b>	Dec 21, 2012
--	------------------	----------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

VIBATIV

THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009
+	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009

TELBIVUDINE

TABLET; ORAL

TYZEKA

+	NOVARTIS	600MG	N022011	001	Oct 25, 2006
---	----------	-------	---------	-----	--------------

TELITHROMYCIN

TABLET; ORAL

KETEK

SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005
+	400MG	N021144	001	Apr 01, 2004

TELMISARTAN

TABLET; ORAL

MICARDIS

<b>AB</b>	BOEHRINGER INGELHEIM	<b>20MG</b>	<b>N020850</b>	<b>003</b>	Apr 04, 2000
<b>AB</b>		<b>40MG</b>	<b>N020850</b>	<b>001</b>	Nov 10, 1998
<b>AB</b>	+	<b>80MG</b>	<b>N020850</b>	<b>002</b>	Nov 10, 1998

TELMISARTAN

<b>AB</b>	ALEMBIC PHARMS LTD	<b>20MG</b>	<b>A202130</b>	<b>001</b>	Jul 07, 2014
<b>AB</b>		<b>40MG</b>	<b>A202130</b>	<b>002</b>	Jul 07, 2014
<b>AB</b>		<b>80MG</b>	<b>A202130</b>	<b>003</b>	Jul 07, 2014
<b>AB</b>	AMNEAL PHARMS	<b>20MG</b>	<b>A204415</b>	<b>001</b>	Sep 08, 2015
<b>AB</b>		<b>40MG</b>	<b>A204415</b>	<b>002</b>	Sep 08, 2015
<b>AB</b>		<b>80MG</b>	<b>A204415</b>	<b>003</b>	Sep 08, 2015
<b>AB</b>	AUROBINDO PHARMA LTD	<b>20MG</b>	<b>A206511</b>	<b>001</b>	Sep 03, 2015
<b>AB</b>		<b>40MG</b>	<b>A206511</b>	<b>002</b>	Sep 03, 2015
<b>AB</b>		<b>80MG</b>	<b>A206511</b>	<b>003</b>	Sep 03, 2015
<b>AB</b>	GLENMARK GENERICS	<b>20MG</b>	<b>A090032</b>	<b>001</b>	Jul 07, 2014
<b>AB</b>		<b>40MG</b>	<b>A090032</b>	<b>002</b>	Jul 07, 2014
<b>AB</b>		<b>80MG</b>	<b>A090032</b>	<b>003</b>	Jul 07, 2014
<b>AB</b>	INVENTIA HLTHCARE	<b>20MG</b>	<b>A205150</b>	<b>001</b>	Oct 30, 2015
<b>AB</b>		<b>40MG</b>	<b>A205150</b>	<b>002</b>	Oct 30, 2015
<b>AB</b>		<b>80MG</b>	<b>A205150</b>	<b>003</b>	Oct 30, 2015
<b>AB</b>	MYLAN PHARMS INC	<b>20MG</b>	<b>A202397</b>	<b>001</b>	Jul 07, 2014
<b>AB</b>		<b>40MG</b>	<b>A202397</b>	<b>002</b>	Jul 07, 2014
<b>AB</b>		<b>80MG</b>	<b>A202397</b>	<b>003</b>	Jul 07, 2014
<b>AB</b>	SANDOZ INC	<b>20MG</b>	<b>A203867</b>	<b>001</b>	Nov 03, 2014
<b>AB</b>		<b>40MG</b>	<b>A203867</b>	<b>002</b>	Nov 03, 2014
<b>AB</b>		<b>80MG</b>	<b>A203867</b>	<b>003</b>	Nov 03, 2014
<b>AB</b>	TORRENT PHARMS LTD	<b>20MG</b>	<b>A203171</b>	<b>001</b>	Jul 07, 2014
<b>AB</b>		<b>40MG</b>	<b>A203171</b>	<b>002</b>	Jul 07, 2014
<b>AB</b>		<b>80MG</b>	<b>A203171</b>	<b>003</b>	Jul 07, 2014
<b>AB</b>	WATSON LABS	<b>20MG</b>	<b>A078710</b>	<b>001</b>	Jan 08, 2014
<b>AB</b>		<b>40MG</b>	<b>A078710</b>	<b>002</b>	Jan 08, 2014
<b>AB</b>		<b>80MG</b>	<b>A078710</b>	<b>003</b>	Jan 08, 2014
<b>AB</b>	ZYDUS PHARMS USA INC	<b>20MG</b>	<b>A203325</b>	<b>001</b>	Aug 26, 2014
<b>AB</b>		<b>40MG</b>	<b>A203325</b>	<b>002</b>	Aug 26, 2014
<b>AB</b>		<b>80MG</b>	<b>A203325</b>	<b>003</b>	Aug 26, 2014

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

<b>AB</b>	MALLINCKRODT INC	<b>7.5MG</b>	<b>N018163</b>	<b>003</b>	Oct 25, 1991
<b>AB</b>		<b>15MG</b>	<b>N018163</b>	<b>001</b>	
<b>AB</b>		<b>22.5MG</b>	<b>N018163</b>	<b>004</b>	Nov 02, 2004
<b>AB</b>	+	<b>30MG</b>	<b>N018163</b>	<b>002</b>	

TEMAZEPAM

<b>AB</b>	ACTAVIS ELIZABETH	<b>15MG</b>	<b>A071638</b>	<b>001</b>	Aug 07, 1987
<b>AB</b>		<b>30MG</b>	<b>A071620</b>	<b>001</b>	Aug 07, 1987
<b>AB</b>	MUTUAL PHARM	<b>7.5MG</b>	<b>A078581</b>	<b>001</b>	Sep 08, 2009
<b>AB</b>		<b>22.5MG</b>	<b>A071175</b>	<b>002</b>	Sep 14, 2009
<b>AB</b>	MYLAN	<b>7.5MG</b>	<b>A070920</b>	<b>002</b>	May 21, 2010
<b>AB</b>		<b>15MG</b>	<b>A070920</b>	<b>004</b>	Jul 07, 1986
<b>AB</b>		<b>22.5MG</b>	<b>A070920</b>	<b>003</b>	Jun 12, 2009
<b>AB</b>		<b>30MG</b>	<b>A070920</b>	<b>001</b>	Jul 10, 1986
<b>AB</b>	NOVEL LABS INC	<b>7.5MG</b>	<b>A071457</b>	<b>002</b>	Jun 22, 2012
<b>AB</b>		<b>15MG</b>	<b>A071456</b>	<b>001</b>	Apr 21, 1987
<b>AB</b>		<b>22.5MG</b>	<b>A071457</b>	<b>003</b>	Jun 22, 2012

## PRESCRIPTION DRUG PRODUCT LIST

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

<u>AB</u>		<u>30MG</u>	<u>A071457 001</u>	Apr 21, 1987
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A071427 001</u>	Jan 12, 1988
<u>AB</u>		<u>30MG</u>	<u>A071428 001</u>	Jan 12, 1988
<u>AB</u>	VINTAGE PHARMS	<u>7.5MG</u>	<u>A201781 001</u>	Jun 04, 2015
<u>AB</u>		<u>15MG</u>	<u>A201781 002</u>	Jun 04, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A201781 003</u>	Jun 04, 2015
<u>AB</u>		<u>30MG</u>	<u>A201781 004</u>	Jun 04, 2015

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

<u>AB</u>	MERCK SHARP DOHME	<u>5MG</u>	<u>N021029 001</u>	Aug 11, 1999
<u>AB</u>		<u>20MG</u>	<u>N021029 002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>N021029 003</u>	Aug 11, 1999
<u>AB</u>		<u>140MG</u>	<u>N021029 005</u>	Oct 19, 2006
<u>AB</u>		<u>180MG</u>	<u>N021029 006</u>	Oct 19, 2006
<u>AB</u>	+	<u>250MG</u>	<u>N021029 004</u>	Aug 11, 1999

TEMOZOLOMIDE

<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203691 001</u>	May 08, 2015
<u>AB</u>		<u>20MG</u>	<u>A203691 002</u>	May 08, 2015
<u>AB</u>		<u>100MG</u>	<u>A203691 003</u>	May 08, 2015
<u>AB</u>		<u>140MG</u>	<u>A203691 004</u>	May 08, 2015
<u>AB</u>		<u>180MG</u>	<u>A203691 005</u>	May 08, 2015
<u>AB</u>		<u>250MG</u>	<u>A203691 006</u>	May 08, 2015
<u>AB</u>	BARR	<u>5MG</u>	<u>A078879 001</u>	Mar 01, 2010
<u>AB</u>		<u>20MG</u>	<u>A078879 002</u>	Mar 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078879 003</u>	Mar 01, 2010
<u>AB</u>		<u>140MG</u>	<u>A078879 005</u>	Mar 01, 2010
<u>AB</u>		<u>180MG</u>	<u>A078879 006</u>	Mar 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078879 004</u>	Mar 01, 2010
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A201742 001</u>	Feb 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A201742 002</u>	Feb 12, 2014
<u>AB</u>		<u>100MG</u>	<u>A201742 003</u>	Feb 12, 2014
<u>AB</u>		<u>140MG</u>	<u>A201742 004</u>	Feb 12, 2014
<u>AB</u>		<u>180MG</u>	<u>A201742 005</u>	Feb 12, 2014
<u>AB</u>		<u>250MG</u>	<u>A201742 006</u>	Feb 12, 2014

POWDER; INTRAVENOUS

TEMODAR

	+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009
--	---	-------------------	------------	-------------	--------------

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TORISEL

	+	PF PRISM CV	25MG/ML (25MG/ML)	N022088 001	May 30, 2007
--	---	-------------	-------------------	-------------	--------------

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

	+	HQ SPECLT PHARMA	10MG/ML	N020119 001	Jul 14, 1992
--	---	------------------	---------	-------------	--------------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

	+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577 001	Jan 18, 2012
--	---	---------------------	---------------	-------------	--------------

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

<u>AB</u>	TEVA PHARMS USA	<u>300MG</u>	<u>A091612 001</u>	Mar 18, 2015	
<u>AB</u>	+	GILEAD SCIENCES INC	<u>300MG</u>	<u>N021356 001</u>	Oct 26, 2001
		150MG	N021356 002	Jan 18, 2012	
		200MG	N021356 003	Jan 18, 2012	
		250MG	N021356 004	Jan 18, 2012	

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075498 001</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075498 002</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075498 003</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075498 004</u>	Apr 12, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A075614 002</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075614 001</u>	Jan 30, 2001



## PRESCRIPTION DRUG PRODUCT LIST

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075614 003</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075614 004</u>	Jan 30, 2001
<u>AB</u>	JUBILANT CADISTA	<u>EQ 1MG BASE</u>	<u>A075317 001</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075317 002</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075317 003</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075317 004</u>	Dec 20, 2004
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075140 002</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075140 003</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075140 001</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075140 004</u>	Feb 11, 2000
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A074823 001</u>	Mar 30, 1998
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>A074823 002</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A074823 003</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A074823 004</u>	Mar 30, 1998

TERBINAFINE HYDROCHLORIDE

GRANULE; ORAL

LAMISIL

NOVARTIS

EQ 125MG BASE/PACKET

N022071 001 Sep 28, 2007

+

EQ 187.5MG BASE/PACKET

N022071 002 Sep 28, 2007

TABLET; ORAL

LAMISIL

<u>AB</u>	+	NOVARTIS	<u>EQ 250MG BASE</u>	<u>N020539 001</u>	May 10, 1996
-----------	---	----------	----------------------	--------------------	--------------

TERBINAFINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A078199 001</u>	Jul 02, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A078297 001</u>	Jul 02, 2007
<u>AB</u>	BRECKENRIDGE PHARM	<u>EQ 250MG BASE</u>	<u>A077714 001</u>	Jun 04, 2010
<u>AB</u>	CIPLA LTD	<u>EQ 250MG BASE</u>	<u>A077137 001</u>	Jul 02, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 250MG BASE</u>	<u>A076390 001</u>	Jul 02, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078157 001</u>	Jul 02, 2007
<u>AB</u>	HARRIS PHARM	<u>EQ 250MG BASE</u>	<u>A077919 001</u>	Jul 02, 2007
<u>AB</u>	INVAGEN PHARMS	<u>EQ 250MG BASE</u>	<u>A077533 001</u>	Jul 02, 2007
<u>AB</u>	MYLAN	<u>EQ 250MG BASE</u>	<u>A077195 001</u>	Jul 02, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A078163 001</u>	Jul 02, 2007
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A076377 001</u>	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

<u>AP</u>	AKORN	<u>1MG/ML</u>	<u>A078151 001</u>	Jan 07, 2008	
<u>AP</u>	+	BEDFORD	<u>1MG/ML</u>	<u>A076770 001</u>	Apr 23, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076887 001</u>	May 26, 2004	
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630 001</u>	May 20, 2009	
<u>AP</u>	UNITED BIOMEDCL	<u>1MG/ML</u>	<u>A200122 001</u>	Nov 08, 2013	

TABLET; ORAL

TERBUTALINE SULFATE

<u>AB</u>	IMPAX LABS	<u>2.5MG</u>	<u>A075877 001</u>	Jun 26, 2001
<u>AB</u>	+	<u>5MG</u>	<u>A075877 002</u>	Jun 26, 2001
<u>AB</u>	LANNETT	<u>2.5MG</u>	<u>A077152 001</u>	Mar 25, 2005
<u>AB</u>		<u>5MG</u>	<u>A077152 002</u>	Mar 25, 2005

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

<u>AB</u>	+	JANSSEN PHARMS	<u>0.8%</u>	<u>N019964 001</u>	Feb 21, 1991
-----------	---	----------------	-------------	--------------------	--------------

TERAZOL 7

<u>AB</u>	+	JANSSEN PHARMS	<u>0.4%</u>	<u>N019579 001</u>	Dec 31, 1987
-----------	---	----------------	-------------	--------------------	--------------

TERCONAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>0.4%</u>	<u>A076712 001</u>	Feb 18, 2005
<u>AB</u>	TARO	<u>0.4%</u>	<u>A076043 001</u>	Jan 19, 2005
<u>AB</u>		<u>0.8%</u>	<u>A075953 001</u>	Apr 06, 2004
BX	+	NYCOMED US	0.8%	N021735 001 Oct 01, 2004

SUPPOSITORY; VAGINAL

TERAZOL 3

<u>AB</u>	+	JANSSEN PHARMS	<u>80MG</u>	<u>N019641 001</u>	May 24, 1988
-----------	---	----------------	-------------	--------------------	--------------

TERCONAZOLE

<u>AB</u>	PERRIGO NEW YORK	<u>80MG</u>	<u>A077149 001</u>	Mar 17, 2006
<u>AB</u>	TARO	<u>80MG</u>	<u>A077553 001</u>	Mar 09, 2007

## PRESCRIPTION DRUG PRODUCT LIST

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

SANOFI AVENTIS US

7MG

N202992 001 Sep 12, 2012

+

14MG

N202992 002 Sep 12, 2012

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

+ LILLY

0.6MG/2.4ML (0.25MG/ML)

N021318 002 Jun 25, 2008

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

+ THERATECHNOLOGIES

EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+ ACTAVIS LABS UT INC

2MG/24HR

N020489 003 Oct 20, 2011

+

4MG/24HR

N020489 004 Oct 20, 2011

GEL; TRANSDERMAL

ANDROGELAB1 ABBVIE25MG/2.5GM PACKETN021015 001 Feb 28, 2000AB1 +50MG/5GM PACKETN021015 002 Feb 28, 2000TESTOSTERONEAB1 ACTAVIS LABS UT INC25MG/2.5GM PACKETA076737 001 Jan 27, 2006AB150MG/5GM PACKETA076737 002 Jan 27, 2006AB1

PAR PHARM

25MG/2.5GM PACKETA076744 001 May 23, 2007AB150MG/5GM PACKETA076744 002 May 23, 2007AB1

PERRIGO ISRAEL

25MG/2.5GM PACKETN203098 002 Jan 31, 2013AB150MG/5GM PACKETN203098 003 Jan 31, 2013TESTIMAB2 + AUXILIUM PHARMS50MG/5GM PACKETN021454 001 Oct 31, 2002VOGELXOAB2 UPSHER SMITH50MG/5GM PACKETN204399 002 Jun 04, 2014

TESTOSTERONE

BX ANI PHARMS INC

25MG/2.5GM PACKET

N202763 001 Feb 14, 2012

BX

50MG/5GM PACKET

N202763 002 Feb 14, 2012

ANDROGEL

ABBVIE

1.62% (20.25MG/1.25GM PACKET)

N022309 002 Sep 07, 2012

+

1.62% (40.5MG/2.5GM PACKET)

N022309 003 Sep 07, 2012

GEL, METERED; NASAL

NATESTO

ENDO VENTURES LTD

5.5MG/0.122GM ACTUATION

N205488 001 May 28, 2014

GEL, METERED; TRANSDERMAL

ANDROGELAB + ABBVIE1.62% (20.25MG/1.25GM ACTUATION)N022309 001 Apr 29, 2011AB +12.5MG/1.25GM ACTUATIONN021015 003 Sep 26, 2003FORTESTAAB + ENDO PHARMS10MG/0.5GM ACTUATIONN021463 001 Dec 29, 2010TESTOSTERONEAB ACTAVIS LABS UT INC10MG/0.5GM ACTUATIONA204571 001 Aug 05, 2015AB12.5MG/1.25GM ACTUATIONA076737 003 Mar 09, 2015AB

PERRIGO ISRAEL

12.5MG/1.25GM ACTUATIONN203098 001 Jan 31, 2013AB1.62% (20.25MG/1.25GM ACTUATION)A204268 001 Aug 04, 2015

VOGELXO

BX UPSHER SMITH

12.5MG/1.25GM ACTUATION

N204399 003 Jun 04, 2014

PELLET; IMPLANTATION

TESTOPEL

+ ACTIENT PHARMS

75MG

A080911 001

SOLUTION, METERED; TRANSDERMAL

AXIRON

+ ELI LILLY AND CO

30MG/1.5ML ACTUATION

N022504 001 Nov 23, 2010

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ AUXILIUM PHARMS LLC

30MG

N021543 001 Jun 19, 2003

## PRESCRIPTION DRUG PRODUCT LIST

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

<u>AO</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>A085635</u>	<u>002</u>	
<u>AO</u>	+		<u>200MG/ML</u>	<u>A085635</u>	<u>003</u>	

TESTOSTERONE CYPIONATE

<u>AO</u>		BEDFORD	<u>100MG/ML</u>	<u>A090387</u>	<u>001</u>	Jul 15, 2010
<u>AO</u>			<u>200MG/ML</u>	<u>A090387</u>	<u>002</u>	Jul 15, 2010
<u>AO</u>		HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091244</u>	<u>001</u>	May 01, 2012
<u>AO</u>		MYLAN INSTITUTIONAL	<u>200MG/ML</u>	<u>A040652</u>	<u>001</u>	Dec 11, 2006
<u>AO</u>		PADDOCK LLC	<u>200MG/ML</u>	<u>A040530</u>	<u>001</u>	Jan 31, 2005
<u>AO</u>		SANDOZ	<u>100MG/ML</u>	<u>A040615</u>	<u>001</u>	Aug 10, 2006
<u>AO</u>			<u>200MG/ML</u>	<u>A040615</u>	<u>002</u>	Aug 10, 2006
<u>AO</u>		SUN PHARM INDS LTD	<u>100MG/ML</u>	<u>A201720</u>	<u>001</u>	Jun 03, 2013
<u>AO</u>			<u>200MG/ML</u>	<u>A201720</u>	<u>002</u>	Jun 03, 2013
<u>AO</u>		WATSON LABS	<u>200MG/ML</u>	<u>A086030</u>	<u>001</u>	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

<u>AO</u>	+	ENDO PHARMS	<u>200MG/ML</u>	<u>N009165</u>	<u>003</u>	
-----------	---	-------------	-----------------	----------------	------------	--

TESTOSTERONE ENANTHATE

<u>AO</u>		HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091120</u>	<u>001</u>	Sep 18, 2012
<u>AO</u>		MYLAN INSTITUTIONAL	<u>200MG/ML</u>	<u>A040647</u>	<u>001</u>	Oct 05, 2009
<u>AO</u>		PADDOCK LLC	<u>200MG/ML</u>	<u>A040575</u>	<u>001</u>	Jun 14, 2006
<u>AO</u>		WATSON LABS	<u>200MG/ML</u>	<u>A085598</u>	<u>001</u>	

TESTOSTERONE UNDECANOATE

INJECTABLE; INTRAMUSCULAR

AVEED

+	ENDO PHARMS INC	750MG/3ML (250MG/ML)		<u>N022219</u>	<u>001</u>	Mar 05, 2014
---	-----------------	----------------------	--	----------------	------------	--------------

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

<u>AB</u>		SUN PHARMA GLOBAL	<u>12.5MG</u>	<u>A206129</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>			<u>25MG</u>	<u>A206129</u>	<u>002</u>	Aug 17, 2015

XENAZINE

<u>AB</u>		VALEANT PHARMS NORTH	<u>12.5MG</u>	<u>N021894</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>	+		<u>25MG</u>	<u>N021894</u>	<u>002</u>	Aug 15, 2008

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

<u>AB</u>		HERITAGE PHARMS INC	<u>250MG</u>	<u>N050278</u>	<u>003</u>	
<u>AB</u>	+		<u>500MG</u>	<u>N050278</u>	<u>001</u>	

TETRACYCLINE HYDROCHLORIDE

<u>AB</u>		IMPAX LABS	<u>250MG</u>	<u>A060469</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A060469</u>	<u>003</u>	
<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A061837</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A061837</u>	<u>002</u>	
		IMPAX LABS	100MG	A060469	002	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	FOUGERA PHARMS	0.05%		A086576	002	
		0.1%		A086576	001	

SPRAY; NASAL

TYZINE

+	FOUGERA PHARMS	0.1%		A086576	003	
---	----------------	------	--	---------	-----	--

THALIDOMIDE

CAPSULE; ORAL

THALOMID

	CELGENE	50MG		N020785	001	Jul 16, 1998
		100MG		N020785	002	Jan 17, 2003
		150MG		N020785	004	Jan 10, 2007
+		200MG		N020785	003	Jan 17, 2003

## PRESCRIPTION DRUG PRODUCT LIST

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

<u>AP</u>	+	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N018110 002</u>	Feb 27, 1996
<u>AP</u>	+	LANTHEUS MEDCL	<u>1mCi/ML</u>	<u>N017806 001</u>	
<u>AP</u>	+	MALLINKRODT NUCLEAR	<u>1mCi/ML</u>	<u>N018150 001</u>	

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

<u>AP</u>	+	LANTHEUS MEDCL	<u>2mCi/ML</u>	<u>N017806 002</u>	Oct 09, 1998
-----------	---	----------------	----------------	--------------------	--------------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

		ACTIENT PHARMS	100MG	A087942 001	Aug 22, 1983
			200MG	A087943 001	Aug 22, 1983
			300MG	A087944 001	Aug 22, 1983
	+		400MG	A081034 001	Feb 28, 1992

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>40MG/100ML</u>	<u>N019826 001</u>	Aug 14, 1992
-----------	---	---------	-------------------	--------------------	--------------

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>80MG/100ML</u>	<u>N019826 002</u>	Aug 14, 1992
-----------	---	---------	-------------------	--------------------	--------------

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>160MG/100ML</u>	<u>N019826 003</u>	Aug 14, 1992
-----------	---	---------	--------------------	--------------------	--------------

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>320MG/100ML</u>	<u>N019826 006</u>	Aug 14, 1992
-----------	---	---------	--------------------	--------------------	--------------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	HOSPIRA INC	<u>4MG/ML</u>	<u>N019211 007</u>	Dec 14, 1984
<u>AP</u>	+		<u>40MG/100ML</u>	<u>N019211 001</u>	Dec 14, 1984
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N019211 003</u>	Dec 14, 1984
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019211 006</u>	Jan 20, 1988

SOLUTION; ORAL

THEOPHYLLINE

<u>AA</u>	+	SILARX	<u>80MG/15ML</u>	<u>A091156 001</u>	Apr 13, 2011
<u>AA</u>		TRIS PHARMA INC	<u>80MG/15ML</u>	<u>A091586 001</u>	Jun 15, 2012

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

	+	SUN PHARM INDS INC	80MG/15ML	A085186 001	
--	---	--------------------	-----------	-------------	--

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

<u>AB</u>		SUN PHARM INDS INC	<u>100MG</u>	<u>A088320 001</u>	Feb 21, 1985
<u>AB</u>			<u>200MG</u>	<u>A088321 001</u>	Feb 21, 1985

THEOPHYLLINE

<u>AB</u>		ALEMBIC LTD	<u>300MG</u>	<u>A090430 001</u>	Oct 27, 2010
<u>AB</u>			<u>450MG</u>	<u>A090430 002</u>	Oct 27, 2010
<u>AB</u>		GLENMARK GENERICS	<u>400MG</u>	<u>A090355 001</u>	Jul 13, 2010
<u>AB</u>			<u>600MG</u>	<u>A090355 002</u>	Jul 13, 2010
<u>AB</u>		MYLAN PHARMS INC	<u>400MG</u>	<u>A040560 003</u>	Apr 21, 2006
<u>AB</u>	+		<u>600MG</u>	<u>A040560 002</u>	Apr 21, 2006
<u>AB</u>	+	PLIVA	<u>100MG</u>	<u>A089807 001</u>	Apr 30, 1990
<u>AB</u>	+		<u>200MG</u>	<u>A089808 001</u>	Apr 30, 1990
<u>AB</u>			<u>300MG</u>	<u>A089763 001</u>	Apr 30, 1990
<u>AB</u>		RHODES PHARMS	<u>600MG</u>	<u>A040086 001</u>	Apr 15, 1996
<u>AB</u>	+	TEVA PHARMS	<u>450MG</u>	<u>A081236 001</u>	Nov 09, 1992

UNIPHYL

<u>AB</u>		RHODES PHARMS	<u>400MG</u>	<u>A087571 001</u>	Sep 01, 1982
-----------	--	---------------	--------------	--------------------	--------------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

<u>AP</u>	+	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A080556 001</u>	
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091623 001</u>	Jun 25, 2012

THIOGUANINE

TABLET; ORAL

THIOGUANINE

	+	ASPEN GLOBAL INC	40MG	N012429 001	
--	---	------------------	------	-------------	--

## PRESCRIPTION DRUG PRODUCT LIST

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A089953 004</u>	Aug 01, 1986
<u>AB</u>		<u>25MG</u>	<u>A089953 003</u>	Aug 01, 1986
<u>AB</u>		<u>50MG</u>	<u>A089953 002</u>	Aug 01, 1986
<u>AB</u>		<u>100MG</u>	<u>A089953 001</u>	Oct 07, 1988
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A088004 002</u>	Mar 15, 1983
<u>AB</u>		<u>25MG</u>	<u>A088004 003</u>	Mar 15, 1983
<u>AB</u>		<u>50MG</u>	<u>A088004 004</u>	Mar 15, 1983
<u>AB</u>	+	<u>100MG</u>	<u>A088004 001</u>	Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

+ EUROHLTH INTL SARL 15MG/VIAL A075547 001 Apr 02, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

<u>AB</u>	PFIZER	<u>1MG</u>	<u>N016584 001</u>	
<u>AB</u>		<u>2MG</u>	<u>N016584 002</u>	
<u>AB</u>	+	<u>5MG</u>	<u>N016584 003</u>	
<u>AB</u>		<u>10MG</u>	<u>N016584 004</u>	

THIOTHIXENE

<u>AB</u>	MYLAN	<u>1MG</u>	<u>A071093 002</u>	Jun 23, 1987
<u>AB</u>		<u>2MG</u>	<u>A071093 003</u>	Jun 23, 1987
<u>AB</u>		<u>5MG</u>	<u>A071093 004</u>	Jun 23, 1987
<u>AB</u>		<u>10MG</u>	<u>A071093 001</u>	Jun 23, 1987
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A071610 001</u>	Jun 24, 1987
<u>AB</u>		<u>2MG</u>	<u>A071570 001</u>	Jun 24, 1987
<u>AB</u>		<u>5MG</u>	<u>A071529 001</u>	Jun 24, 1987
<u>AB</u>		<u>10MG</u>	<u>A071530 001</u>	Jun 24, 1987

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

+ GENZYME 1.1MG/VIAL N020898 001 Nov 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

<u>AB</u>	CEPHALON	<u>2MG</u>	<u>N020646 005</u>	Apr 16, 1999
<u>AB</u>	+	<u>4MG</u>	<u>N020646 001</u>	Sep 30, 1997
<u>AB</u>	SUN PHARM INDS	<u>2MG</u>	<u>A077555 001</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A077555 002</u>	Nov 04, 2011
	GABITRIL			
	CEPHALON	12MG	N020646 002	Sep 30, 1997
		16MG	N020646 003	Sep 30, 1997

TICAGRELOR

TABLET; ORAL

BRILINTA

ASTRAZENECA LP 60MG N022433 002 Sep 03, 2015  
+ 90MG N022433 001 Jul 20, 2011TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>250MG</u>	<u>A075089 001</u>	Jul 01, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>250MG</u>	<u>A075526 001</u>	Sep 26, 2002
<u>AB</u>	+	<u>250MG</u>	<u>A075149 001</u>	Aug 20, 1999

TIGECYCLINE

INJECTABLE; IV (INFUSION)

TIGECYCLINE

<u>AP</u>	SANDOZ INC	<u>50MG/VIAL</u>	<u>A091620 001</u>	May 27, 2015
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>N021821 001</u>	Jun 15, 2005

## PRESCRIPTION DRUG PRODUCT LIST

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

+	OAK PHARMS INC	EQ 0.25% BASE	N020439	001	Mar 31, 1995
+		EQ 0.5% BASE	N020439	002	Mar 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

<b>AB</b>	ALCON RES LTD	<b>EQ 0.25% BASE</b>	<b>N020963</b>	<b>001</b>	Oct 21, 1998
<b>AB</b>		<b>EQ 0.5% BASE</b>	<b>N020963</b>	<b>002</b>	Oct 21, 1998
<b><u>TIMOPTIC-XE</u></b>					
<b>AB</b>	+	VALEANT PHARMS LLC	<b>EQ 0.25% BASE</b>	<b>N020330</b>	<b>001</b> Nov 04, 1993
<b>AB</b>	+		<b>EQ 0.5% BASE</b>	<b>N020330</b>	<b>002</b> Nov 04, 1993

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

<b>AT</b>	ALCON RES LTD	<b>EQ 0.25% BASE</b>	<b>A074261</b>	<b>001</b>	Apr 28, 1995
<b>AT</b>	BAUSCH AND LOMB	<b>EQ 0.25% BASE</b>	<b>A074778</b>	<b>001</b>	Mar 25, 1997
<b>AT</b>	FDC LTD	<b>EQ 0.25% BASE</b>	<b>A077259</b>	<b>001</b>	Apr 30, 2008
<b>AT</b>	PACIFIC PHARMA	<b>EQ 0.25% BASE</b>	<b>A074746</b>	<b>001</b>	Mar 25, 1997
<b>AT</b>	WOCKHARDT	<b>EQ 0.25% BASE</b>	<b>A078771</b>	<b>001</b>	Sep 28, 2009

TIMOPTIC

<b>AT</b>	+	ATON	<b>EQ 0.25% BASE</b>	<b>N018086</b>	<b>001</b>
<b><u>TIMOLOL MALEATE</u></b>					
<b>AT1</b>	AKORN	<b>EQ 0.5% BASE</b>	<b>A074466</b>	<b>001</b>	Mar 25, 1997
<b>AT1</b>		<b>EQ 0.5% BASE</b>	<b>A074516</b>	<b>001</b>	Mar 25, 1997
<b>AT1</b>	ALCON RES LTD	<b>EQ 0.5% BASE</b>	<b>A074262</b>	<b>001</b>	Apr 28, 1995
<b>AT1</b>	BAUSCH AND LOMB	<b>EQ 0.5% BASE</b>	<b>A074776</b>	<b>001</b>	Mar 25, 1997
<b>AT1</b>	FDC LTD	<b>EQ 0.5% BASE</b>	<b>A077259</b>	<b>002</b>	Apr 30, 2008
<b>AT1</b>	HI TECH PHARMA	<b>EQ 0.5% BASE</b>	<b>A075163</b>	<b>001</b>	Sep 10, 2002
<b>AT1</b>	PACIFIC PHARMA	<b>EQ 0.5% BASE</b>	<b>A074747</b>	<b>001</b>	Mar 25, 1997
<b>AT1</b>	WOCKHARDT	<b>EQ 0.5% BASE</b>	<b>A078771</b>	<b>002</b>	Sep 28, 2009

TIMOPTIC

<b>AT1</b>	+	ATON	<b>EQ 0.5% BASE</b>	<b>N018086</b>	<b>002</b>
<b><u>ISTALOL</u></b>					
<b>AT2</b>	+	BAUSCH AND LOMB	<b>EQ 0.5% BASE</b>	<b>N021516</b>	<b>001</b> Jun 04, 2004

TIMOLOL MALEATE

<b>AT2</b>	APOTEX INC	<b>EQ 0.5% BASE</b>	<b>A204936</b>	<b>001</b>	Apr 17, 2015
TIMOPTIC IN OCUDOSE					
	+	ATON	EQ 0.25% BASE	N019463	001 Nov 05, 1986
	+		EQ 0.5% BASE	N019463	002 Nov 05, 1986
TABLET; ORAL					
TIMOLOL MALEATE					
	MYLAN	5MG	A072668	002	Jun 08, 1990
		10MG	A072668	003	Jun 08, 1990
	+	20MG	A072668	001	Jun 08, 1990

TINIDAZOLE

TABLET; ORAL

TINDAMAX

<b>AB</b>	MISSION PHARMA	<b>250MG</b>	<b>N021618</b>	<b>001</b>	May 17, 2004
<b>AB</b>	+	<b>500MG</b>	<b>N021618</b>	<b>002</b>	May 17, 2004

TINIDAZOLE

<b>AB</b>	EDENBRIDGE PHARMS	<b>250MG</b>	<b>A203808</b>	<b>001</b>	Aug 04, 2015
<b>AB</b>		<b>500MG</b>	<b>A203808</b>	<b>002</b>	Aug 04, 2015
<b>AB</b>	NOVEL LABS INC	<b>250MG</b>	<b>A202044</b>	<b>001</b>	Apr 30, 2012
<b>AB</b>		<b>500MG</b>	<b>A202044</b>	<b>002</b>	Apr 30, 2012
<b>AB</b>	ROXANE	<b>250MG</b>	<b>A201172</b>	<b>001</b>	Apr 30, 2012
<b>AB</b>		<b>500MG</b>	<b>A201172</b>	<b>002</b>	Apr 30, 2012
<b>AB</b>	UNIQUE PHARM LABS	<b>250MG</b>	<b>A202489</b>	<b>001</b>	Oct 09, 2013
<b>AB</b>		<b>500MG</b>	<b>A202489</b>	<b>002</b>	Oct 09, 2013

TIOPRONIN

TABLET; ORAL

THIOLA

+	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988
---	----------------	-------	---------	-----	--------------

TIOTROPIUM BROMIDE

POWDER; INHALATION

SPIRIVA

+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004
---	----------------------	---------------------	---------	-----	--------------

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015
--	----------------------	-----------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

+

EQ 0.0025MG BASE/INH

N021936 001 Sep 24, 2014

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET; ORAL

LONSURF

TAIHO ONCOLOGY

EQ 6.14MG BASE; 15MG

N207981 001 Sep 22, 2015

+

EQ 8.19MG BASE; 20MG

N207981 002 Sep 22, 2015

TIPRANAVIR

CAPSULE; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM

250MG

N021814 001 Jun 22, 2005

SOLUTION; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM

100MG/ML

N022292 001 Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)

N020913 002 May 17, 2002

+

EQ 12.5MG BASE/250ML (EQ 0.05MG  
BASE/ML)

N020913 003 Apr 20, 2000

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEX INCEQ 2MG BASEA078868 001 Feb 03, 2012ABEQ 4MG BASEA078868 002 Feb 03, 2012ABEQ 6MG BASEA078868 003 Feb 03, 2012AB MYLAN PHARMS INCEQ 2MG BASEA091502 001 Nov 09, 2012ABEQ 4MG BASEA091502 002 Nov 09, 2012ABEQ 6MG BASEA091502 003 Nov 09, 2012ZANAFLEXAB ACORDAEQ 2MG BASEN021447 001 Aug 29, 2002ABEQ 4MG BASEN021447 002 Aug 29, 2002AB +EQ 6MG BASEN021447 003 Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEXEQ 2MG BASEA076533 001 Jan 16, 2004ABEQ 4MG BASEA076533 002 Jan 16, 2004AB COREPHARMAEQ 2MG BASEA076347 001 Oct 11, 2002ABEQ 4MG BASEA076347 002 Oct 11, 2002AB DR REDDYS LABS INCEQ 2MG BASEA076286 001 Jul 03, 2002ABEQ 4MG BASEA076286 002 Jul 03, 2002AB MYLANEQ 2MG BASEA076354 001 Mar 28, 2003ABEQ 4MG BASEA076354 002 Mar 28, 2003AB PROSAM LABSEQ 2MG BASEA076281 001 Oct 20, 2003ABEQ 4MG BASEA076281 002 Oct 20, 2003AB SANDOZ INCEQ 2MG BASEA076280 001 Nov 26, 2002ABEQ 4MG BASEA076280 002 Jun 27, 2002AB SUN PHARM INDS INCEQ 2MG BASEA076416 001 Sep 29, 2003ABEQ 4MG BASEA076416 002 Sep 29, 2003AB TEVAEQ 2MG BASEA076284 001 Jul 03, 2002ABEQ 4MG BASEA076284 002 Jul 03, 2002AB UNICHEM LABS LTDEQ 2MG BASEA091283 001 Nov 28, 2012ABEQ 4MG BASEA091283 002 Nov 28, 2012ZANAFLEXAB + ACORDAEQ 4MG BASEN020397 001 Nov 27, 1996TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+ ALCON

0.3%

N050555 001

POWDER; INHALATION

TOBI PODHALER

+ NOVARTIS

28MG

N201688 001 Mar 22, 2013

SOLUTION; INHALATION

KITABIS PAKAN PULMOFLOW INC300MG/5MLN205433 001 Dec 02, 2014TOBIAN + NOVARTIS PHARMS300MG/5MLN050753 001 Dec 22, 1997

## PRESCRIPTION DRUG PRODUCT LIST

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

<b>AN</b>	AKORN INC	<b>300MG/5ML</b>	<b>A201422 001</b>	May 28, 2014
<b>AN</b>	AMNEAL PHARMS	<b>300MG/5ML</b>	<b>A205501 001</b>	Jul 13, 2015
<b>AN</b>	TEVA PHARMS USA	<b>300MG/5ML</b>	<b>A091589 001</b>	Oct 10, 2013

BETHKIS

	CHIESI USA INC	300MG/4ML	N201820 001	Oct 12, 2012
--	----------------	-----------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

AKTOB

<b>AT</b>	AKORN	<b>0.3%</b>	<b>A064096 001</b>	Jan 31, 1996
-----------	-------	-------------	--------------------	--------------

TOBRAMYCIN

<b>AT</b>	BAUSCH AND LOMB	<b>0.3%</b>	<b>A064052 001</b>	Nov 29, 1993
<b>AT</b>	FERA PHARMS	<b>0.3%</b>	<b>A065026 001</b>	Sep 11, 2001

TOBEX

<b>AT</b>	ALCON	<b>0.3%</b>	<b>A062535 001</b>	Dec 13, 1984
<b>AT</b>	+ ALCON LABS INC	<b>0.3%</b>	<b>N050541 001</b>	

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

<b>AP</b>	AKORN	<b>EQ 40MG BASE/ML</b>	<b>A205179 001</b>	Sep 16, 2014
<b>AP</b>	FRESENIUS KABI USA	<b>EQ 10MG BASE/ML</b>	<b>A065122 001</b>	Nov 29, 2002
<b>AP</b>	+	<b>EQ 40MG BASE/ML</b>	<b>A065122 002</b>	Nov 29, 2002
<b>AP</b>		<b>EQ 1.2GM BASE/VIAL</b>	<b>N050789 001</b>	Jul 13, 2004
<b>AP</b>	HIKMA MAPLE	<b>EQ 40MG BASE/ML</b>	<b>A063117 001</b>	Apr 26, 1991
<b>AP</b>	+ HOSPIRA	<b>EQ 10MG BASE/ML</b>	<b>A063112 001</b>	Apr 30, 1991
<b>AP</b>		<b>EQ 40MG BASE/ML</b>	<b>A063111 001</b>	Apr 30, 1991
<b>AP</b>	MYLAN LABS LTD	<b>EQ 40MG BASE/ML</b>	<b>A065407 001</b>	Mar 11, 2008
<b>AP</b>	TEVA PHARMS USA	<b>EQ 40MG BASE/ML</b>	<b>A063100 001</b>	Jan 30, 1992
<b>AP</b>	+ X GEN PHARMS	<b>EQ 1.2GM BASE/VIAL</b>	<b>A065013 001</b>	Aug 17, 2001
<b>AP</b>	XELLIA PHARMS APS	<b>EQ 1.2GM BASE/VIAL</b>	<b>A205685 001</b>	Sep 16, 2014

TOBRAMYCIN SULFATE (PHARMACY BULK)

+	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120 001	Nov 29, 2002
---	--------------------	-----------------	-------------	--------------

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	HOSPIRA	EQ 1.2MG BASE/ML	A063081 003	Jul 31, 1990
+		EQ 1.6MG BASE/ML	A063081 006	Jun 02, 1993
+		EQ 80MG BASE/100ML	A063081 001	Jul 31, 1990

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+	PF PRISM CV	EQ 5MG BASE	N203214 001	Nov 06, 2012
---	-------------	-------------	-------------	--------------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

	MYLAN PHARMS INC	250MG	A070259 001	Jan 02, 1986
+		500MG	A070259 003	Mar 17, 1986

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001	
---	------------------	-------	-------------	--

TOLCAPONE

TABLET; ORAL

TASMAR

<b>AB</b>	+ VALEANT PHARMS LLC	<b>100MG</b>	<b>N020697 001</b>	Jan 29, 1998
-----------	----------------------	--------------	--------------------	--------------

TOLCAPONE

<b>AB</b>	PAR PHARM INC	<b>100MG</b>	<b>A204584 001</b>	Mar 26, 2015
-----------	---------------	--------------	--------------------	--------------

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

<b>AB</b>	MYLAN	<b>EQ 400MG BASE</b>	<b>A073393 001</b>	May 27, 1993
<b>AB</b>	+ TEVA	<b>EQ 400MG BASE</b>	<b>A073290 001</b>	Nov 27, 1991

TABLET; ORAL

TOLMETIN SODIUM

<b>AB</b>	MUTUAL PHARM	<b>EQ 200MG BASE</b>	<b>A073310 001</b>	Nov 27, 1991
<b>AB</b>	+ MYLAN	<b>EQ 600MG BASE</b>	<b>A074473 001</b>	Aug 30, 1994



## PRESCRIPTION DRUG PRODUCT LIST

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROL LA

<b>AB</b>	PHARMACIA AND UPJOHN	<b>2MG</b>	<b>N021228 001</b>	Dec 22, 2000
<b>AB</b>	+	<b>4MG</b>	<b>N021228 002</b>	Dec 22, 2000

TOLTERODINE TARTRATE

<b>AB</b>	MYLAN PHARMS INC	<b>2MG</b>	<b>A201486 001</b>	Oct 31, 2013
<b>AB</b>		<b>4MG</b>	<b>A201486 002</b>	Oct 31, 2013
<b>AB</b>	TORRENT PHARMS LTD	<b>2MG</b>	<b>A203016 001</b>	Aug 11, 2015
<b>AB</b>		<b>4MG</b>	<b>A203016 002</b>	Aug 11, 2015

TABLET;ORAL

DETROL

<b>AB</b>	PHARMACIA AND UPJOHN	<b>1MG</b>	<b>N020771 001</b>	Mar 25, 1998
<b>AB</b>	+	<b>2MG</b>	<b>N020771 002</b>	Mar 25, 1998

TOLTERODINE TARTRATE

<b>AB</b>	APOTEX CORP	<b>1MG</b>	<b>A200164 001</b>	Sep 25, 2012
<b>AB</b>		<b>2MG</b>	<b>A200164 002</b>	Sep 25, 2012
<b>AB</b>	IVAX SUB TEVA PHARMS	<b>1MG</b>	<b>A077006 001</b>	Feb 23, 2015
<b>AB</b>		<b>2MG</b>	<b>A077006 002</b>	Feb 23, 2015
<b>AB</b>	MACLEODS PHARMS LTD	<b>1MG</b>	<b>A203409 001</b>	Aug 31, 2015
<b>AB</b>		<b>2MG</b>	<b>A203409 002</b>	Aug 31, 2015
<b>AB</b>	MYLAN PHARMS INC	<b>1MG</b>	<b>A202641 001</b>	Nov 27, 2012
<b>AB</b>		<b>2MG</b>	<b>A202641 002</b>	Nov 27, 2012

TOLVAPTAN

TABLET;ORAL

SAMSCA

	OTSUKA AMERICA PHARM	15MG	N022275 001	May 19, 2009
	+	30MG	N022275 002	May 19, 2009

TOPIRAMATE

CAPSULE;ORAL

TOPAMAX

<b>AB</b>	JANSSEN PHARMS	<b>15MG</b>	<b>N020844 001</b>	Oct 26, 1998
<b>AB</b>	+	<b>25MG</b>	<b>N020844 002</b>	Oct 26, 1998

TOPIRAMATE

<b>AB</b>	MYLAN	<b>15MG</b>	<b>A078418 001</b>	Oct 14, 2009
<b>AB</b>		<b>25MG</b>	<b>A078418 002</b>	Oct 14, 2009
<b>AB</b>	TEVA	<b>15MG</b>	<b>A076575 001</b>	Apr 17, 2009
<b>AB</b>		<b>25MG</b>	<b>A076575 002</b>	Apr 17, 2009
<b>AB</b>	WATSON LABS	<b>15MG</b>	<b>A077868 001</b>	Apr 15, 2009
<b>AB</b>		<b>25MG</b>	<b>A077868 002</b>	Apr 15, 2009
<b>AB</b>	ZYDUS PHARMS USA INC	<b>15MG</b>	<b>A078877 001</b>	Oct 14, 2009
<b>AB</b>		<b>25MG</b>	<b>A078877 002</b>	Oct 14, 2009

CAPSULE, EXTENDED RELEASE;ORAL

QUDEXY XR

	UPSHER SMITH	25MG	N205122 001	Mar 11, 2014
		50MG	N205122 002	Mar 11, 2014
		100MG	N205122 003	Mar 11, 2014
		150MG	N205122 004	Mar 11, 2014
	+	200MG	N205122 005	Mar 11, 2014

TROKENDI XR

	SUPERNUS PHARMS	25MG	N201635 001	Aug 16, 2013
		50MG	N201635 002	Aug 16, 2013
		100MG	N201635 003	Aug 16, 2013
	+	200MG	N201635 004	Aug 16, 2013

TABLET;ORAL

TOPAMAX

<b>AB</b>	JANSSEN PHARMS	<b>25MG</b>	<b>N020505 004</b>	Dec 24, 1996
<b>AB</b>		<b>50MG</b>	<b>N020505 005</b>	Dec 24, 1996
<b>AB</b>	+	<b>100MG</b>	<b>N020505 001</b>	Dec 24, 1996
<b>AB</b>		<b>200MG</b>	<b>N020505 002</b>	Dec 24, 1996

TOPIRAMATE

<b>AB</b>	ACCORD HLTHCARE	<b>25MG</b>	<b>A076311 001</b>	Mar 27, 2009
<b>AB</b>		<b>50MG</b>	<b>A076311 002</b>	Mar 27, 2009
<b>AB</b>		<b>100MG</b>	<b>A076311 003</b>	Mar 27, 2009
<b>AB</b>		<b>200MG</b>	<b>A076311 004</b>	Mar 27, 2009
<b>AB</b>	ACTIVIS TOTOWA LLC	<b>25MG</b>	<b>A078637 001</b>	Feb 27, 2013
<b>AB</b>		<b>50MG</b>	<b>A078637 002</b>	Feb 27, 2013
<b>AB</b>		<b>100MG</b>	<b>A078637 003</b>	Feb 27, 2013
<b>AB</b>		<b>200MG</b>	<b>A078637 004</b>	Feb 27, 2013
<b>AB</b>	APOTEX INC	<b>25MG</b>	<b>A077733 001</b>	Mar 27, 2009
<b>AB</b>		<b>50MG</b>	<b>A077733 002</b>	Mar 27, 2009

## PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>		<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078462</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078462</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078462</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078462</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A076343</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076343</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076343</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	LUPIN	<u>25MG</u>	<u>A078410</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>50MG</u>	<u>A078410</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>100MG</u>	<u>A078410</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>		<u>200MG</u>	<u>A078410</u>	<u>004</u>	Sep 11, 2013
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076314</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076314</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076314</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076314</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	SUN PHARMA GLOBAL	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162</u>	<u>004</u>	Feb 19, 2013
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078499</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499</u>	<u>002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499</u>	<u>003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499</u>	<u>004</u>	Jan 07, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCAMTIN

NOVARTIS PHARMS CORP

EQ 0.25MG BASE

N020981 001 Oct 11, 2007

+

EQ 1MG BASE

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCAMTINAP + NOVARTIS PHARMS CORPEQ 4MG BASE/VIALN020671 001 May 28, 1996TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/VIAL</u>	<u>A202351</u>	<u>001</u>	Jun 26, 2013
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620</u>	<u>001</u>	Dec 02, 2010
<u>AP</u>	CHEM WERTH INC	<u>EQ 4MG BASE/VIAL</u>	<u>A201166</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>	CIPLA LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091199</u>	<u>001</u>	Dec 01, 2010
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191</u>	<u>001</u>	Mar 09, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091542</u>	<u>001</u>	Aug 28, 2012

## PRESCRIPTION DRUG PRODUCT LIST

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284 001</u>	Jan 26, 2011
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A202203 001</u>	Aug 29, 2013

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582 001</u>	Feb 02, 2011
<u>AP</u>	TEVA PHARMS USA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N022453 001</u>	Dec 20, 2012

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+ PROSTRAKAN INC

EQ 60MG BASE

N020497 001 May 29, 1997

TORSEMIDE

TABLET; ORAL

DEMADEX

<u>AB</u>	MEDA PHARMS	<u>5MG</u>	<u>N020136 001</u>	Aug 23, 1993
<u>AB</u>		<u>10MG</u>	<u>N020136 002</u>	Aug 23, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020136 003</u>	Aug 23, 1993
<u>AB</u>		<u>100MG</u>	<u>N020136 004</u>	Aug 23, 1993

TORSEMIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A076894 001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894 002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894 003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894 004</u>	May 31, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249 001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249 002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249 003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249 004</u>	Oct 17, 2007
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A079234 001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234 002</u>	Jan 27, 2009
<u>AB</u>		<u>20MG</u>	<u>A079234 003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234 004</u>	Jan 27, 2009
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A076226 001</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A076226 002</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A076226 003</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A076226 004</u>	May 27, 2003
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346 001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346 002</u>	May 30, 2003
<u>AB</u>		<u>20MG</u>	<u>A076346 003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346 004</u>	Oct 19, 2004
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A076943 001</u>	Mar 01, 2005
<u>AB</u>		<u>10MG</u>	<u>A076943 002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943 003</u>	Mar 01, 2005
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A078478 001</u>	Feb 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078478 002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078478 003</u>	Feb 26, 2008
<u>AB</u>		<u>100MG</u>	<u>A078478 004</u>	Feb 26, 2008
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110 001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110 002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110 003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110 004</u>	May 14, 2002
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A090613 001</u>	Mar 22, 2011
<u>AB</u>		<u>10MG</u>	<u>A090613 002</u>	Mar 22, 2011
<u>AB</u>		<u>20MG</u>	<u>A090613 003</u>	Mar 22, 2011
<u>AB</u>		<u>100MG</u>	<u>A090613 004</u>	Mar 22, 2011

TRABECTEDIN

POWDER; IV (INFUSION)

YONDELIS

+ JANSSEN PRODS

1MG/VIAL

N207953 001 Oct 23, 2015

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+ CIPHER PHARMS INC

100MG

N022370 001 May 07, 2010

150MG

N022370 004 Aug 01, 2011

200MG

N022370 002 May 07, 2010

300MG

N022370 003 May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>50MG</u>	<u>A202390 001</u>	May 16, 2013
-----------	---------------------	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ALLIED PHARMA INC	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A203494</u>	<u>001</u>	Mar 31, 2014
<u>AB</u>	CSPC OUYI PHARM CO	<u>50MG</u>	<u>A091498</u>	<u>001</u>	Mar 29, 2013
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>50MG</u>	<u>A205702</u>	<u>001</u>	Sep 25, 2015
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A075983</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A076100</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A075980</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	NORTHSTAR HLTHCARE	<u>50MG</u>	<u>A078935</u>	<u>001</u>	May 26, 2010
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAM

<u>AB</u>	+ JANSSEN PHARMS	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995
-----------	------------------	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A204421</u>	<u>001</u>	Oct 20, 2015
<u>AB1</u>		<u>200MG</u>	<u>A204421</u>	<u>002</u>	Oct 20, 2015
<u>AB1</u>		<u>300MG</u>	<u>A204421</u>	<u>003</u>	Oct 20, 2015
<u>AB1</u>	LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>		<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>		<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A205257</u>	<u>001</u>	Dec 22, 2015
<u>AB1</u>		<u>200MG</u>	<u>A205257</u>	<u>002</u>	Dec 22, 2015
<u>AB1</u>		<u>300MG</u>	<u>A205257</u>	<u>003</u>	Dec 22, 2015
<u>AB1</u>	PAR PHARM INC	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009
<u>AB1</u>		<u>200MG</u>	<u>A078783</u>	<u>002</u>	Nov 13, 2009
<u>AB1</u>		<u>300MG</u>	<u>A078783</u>	<u>003</u>	Sep 20, 2011
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A201384</u>	<u>001</u>	Dec 07, 2011
<u>AB1</u>		<u>200MG</u>	<u>A201384</u>	<u>002</u>	Dec 07, 2011
<u>AB1</u>		<u>300MG</u>	<u>A201384</u>	<u>003</u>	Dec 07, 2011

ULTRAM ER

<u>AB1</u>	+ VALEANT INTL	<u>100MG</u>	<u>N021692</u>	<u>001</u>	Sep 08, 2005
<u>AB1</u>		<u>200MG</u>	<u>N021692</u>	<u>002</u>	Sep 08, 2005
<u>AB1</u>		<u>300MG</u>	<u>N021692</u>	<u>003</u>	Sep 08, 2005

TRAMADOL HYDROCHLORIDE

<u>AB2</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091609</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A091609</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A091609</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A200491</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A200491</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A200491</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	+ SUN PHARMA GLOBAL	<u>100MG</u>	<u>A091607</u>	<u>001</u>	Dec 30, 2011
<u>AB2</u>		<u>200MG</u>	<u>A091607</u>	<u>002</u>	Dec 30, 2011
<u>AB2</u>		<u>300MG</u>	<u>A091607</u>	<u>003</u>	Dec 30, 2011

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

	NOVARTIS PHARMS CORP	EQ 0.5MG	N204114	001	May 29, 2013
		EQ 1MG	N204114	002	May 29, 2013
	+	EQ 2MG	N204114	003	May 29, 2013

TRANDOLAPRIL

TABLET; ORAL

MAVIK

<u>AB</u>	ABBVIE	<u>1MG</u>	<u>N020528</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>		<u>2MG</u>	<u>N020528</u>	<u>002</u>	Apr 26, 1996
<u>AB</u>	+	<u>4MG</u>	<u>N020528</u>	<u>003</u>	Apr 26, 1996

TRANDOLAPRIL

<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	EPIC PHARMA	<u>1MG</u>	<u>A078508</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508</u>	<u>002</u>	Jun 18, 2008

## PRESCRIPTION DRUG PRODUCT LIST

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A078320 001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078320 002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078320 003</u>	Jun 12, 2007
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522 001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522 002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077522 003</u>	Jun 12, 2007
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A078346 001</u>	Apr 28, 2008
<u>AB</u>		<u>2MG</u>	<u>A078346 002</u>	Apr 28, 2008
<u>AB</u>		<u>4MG</u>	<u>A078346 003</u>	Apr 28, 2008
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489 001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489 002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489 003</u>	Dec 12, 2006
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A077805 001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077805 002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077805 003</u>	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

<u>AB</u>	ABBVIE	<u>1MG;240MG</u>	<u>N020591 003</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;180MG</u>	<u>N020591 001</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;240MG</u>	<u>N020591 004</u>	Oct 22, 1996
<u>AB</u>	+	<u>4MG;240MG</u>	<u>N020591 002</u>	Oct 22, 1996

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>1MG;240MG</u>	<u>A079135 004</u>	Aug 30, 2010
<u>AB</u>		<u>2MG;180MG</u>	<u>A079135 001</u>	May 26, 2010
<u>AB</u>		<u>2MG;240MG</u>	<u>A079135 002</u>	May 26, 2010
<u>AB</u>		<u>4MG;240MG</u>	<u>A079135 003</u>	May 05, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>N019281 001</u>	Dec 30, 1986
		<u>TRANEXAMIC ACID</u>			
<u>AP</u>		ACIC FINE CHEMS	<u>100MG/ML</u>	<u>A202436 001</u>	Feb 11, 2014
<u>AP</u>		EMCURE PHARMS LTD	<u>100MG/ML</u>	<u>A203521 001</u>	Aug 12, 2014
<u>AP</u>		FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A091596 001</u>	Mar 02, 2012
<u>AP</u>		LUITPOLD	<u>100MG/ML</u>	<u>A201885 001</u>	Aug 10, 2011
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091657 001</u>	Nov 03, 2011
<u>AP</u>		VERSAPHARM INC	<u>100MG/ML</u>	<u>A202373 001</u>	Nov 17, 2011
<u>AP</u>		X-GEN PHARMS INC	<u>100MG/ML</u>	<u>A201580 001</u>	Jun 14, 2013

TABLET; ORAL

LYSTEDA

<u>AB</u>	+	FERRING PHARMS AS	<u>650MG</u>	<u>N022430 001</u>	Nov 13, 2009
		<u>TRANEXAMIC ACID</u>			
<u>AB</u>		ACTAVIS LABS FL INC	<u>650MG</u>	<u>A202093 001</u>	Dec 27, 2012
<u>AB</u>		APOTEX INC	<u>650MG</u>	<u>A202286 001</u>	Jan 27, 2014
<u>AB</u>		MYLAN	<u>650MG</u>	<u>A205133 001</u>	Sep 21, 2015

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

<u>AB</u>	+	CONCORDIA PHARMS INC	<u>EQ 10MG BASE</u>	<u>N012342 003</u>	Aug 16, 1985
		<u>TRANLYCYPROMINE SULFATE</u>			
<u>AB</u>		PAR PHARM	<u>EQ 10MG BASE</u>	<u>A040640 001</u>	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

<u>AT</u>	+	ALCON PHARMS LTD	<u>0.004%</u>	<u>N021994 001</u>	Sep 21, 2006
		<u>TRAVOPROST</u>			
<u>AT</u>		APOTEX INC	<u>0.004%</u>	<u>A203431 001</u>	Jul 10, 2015
		+	0.004%	<u>A091340 001</u>	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>		ALVOGEN	<u>50MG</u>	<u>A071636 001</u>	Apr 18, 1988
<u>AB</u>			<u>100MG</u>	<u>A071514 001</u>	Apr 18, 1988
<u>AB</u>		APOTEX	<u>50MG</u>	<u>A071258 001</u>	Mar 25, 1987
<u>AB</u>	+	APOTEX INC	<u>100MG</u>	<u>A071196 001</u>	Mar 25, 1987
<u>AB</u>			<u>150MG</u>	<u>A071196 002</u>	Apr 26, 1999

## PRESCRIPTION DRUG PRODUCT LIST

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>		<u>300MG</u>	<u>A071196 003</u>	Apr 26, 1999
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A073137 002</u>	Mar 24, 1993
<u>AB</u>		<u>100MG</u>	<u>A073137 001</u>	Mar 24, 1993
<u>AB</u>		<u>150MG</u>	<u>A073137 003</u>	Dec 22, 1995
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A090514 001</u>	Jun 02, 2009
<u>AB</u>		<u>100MG</u>	<u>A090514 002</u>	Jun 02, 2009
<u>AB</u>		<u>150MG</u>	<u>A090514 003</u>	Jun 02, 2009
<u>AB</u>		<u>300MG</u>	<u>A090514 004</u>	Jun 02, 2009
<u>AB</u>	PLIVA	<u>150MG</u>	<u>A071525 001</u>	Mar 09, 1988
<u>AB</u>	TEVA PHARMS USA	<u>50MG</u>	<u>A071523 001</u>	Dec 11, 1987
<u>AB</u>		<u>100MG</u>	<u>A071524 001</u>	Dec 11, 1987
<u>AB</u>	TORRENT PHARMS LTD	<u>50MG</u>	<u>A202180 001</u>	Nov 27, 2013
<u>AB</u>		<u>100MG</u>	<u>A202180 002</u>	Nov 27, 2013
<u>AB</u>		<u>150MG</u>	<u>A202180 003</u>	Nov 27, 2013
<u>AB</u>		<u>300MG</u>	<u>A202180 004</u>	Nov 27, 2013
<u>AB</u>	VINTAGE	<u>50MG</u>	<u>A072192 001</u>	Feb 02, 1989
<u>AB</u>		<u>100MG</u>	<u>A072193 001</u>	Feb 02, 1989

TREPROSTINILINJECTABLE; IV (INFUSION), SUBCUTANEOUS  
REMODULIN

	UNITED THERAP	1MG/ML	N021272 001	May 21, 2002
		2.5MG/ML	N021272 002	May 21, 2002
		5MG/ML	N021272 003	May 21, 2002
	+	10MG/ML	N021272 004	May 21, 2002
	SOLUTION; INHALATION			
	TYVASO			
	+	UNITED THERAP	0.6MG/ML	N022387 001
				Jul 30, 2009

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE; ORAL

ORENITRAM

	UNITED THERAP	EQ 0.125MG BASE	N203496 001	Dec 20, 2013
		EQ 0.25MG BASE	N203496 002	Dec 20, 2013
		EQ 1MG BASE	N203496 003	Dec 20, 2013
	+	EQ 2.5MG BASE	N203496 004	Dec 20, 2013

TRETINOIN

CAPSULE; ORAL

TRETINOIN

<u>AB</u>	ANCHEN PHARMS	<u>10MG</u>	<u>A201687 001</u>	Oct 24, 2012
<u>AB</u>	+	BARR LABS INC	<u>10MG</u>	<u>A077684 001</u>
				Jun 22, 2007

CREAM; TOPICAL

AVITA

<u>AB</u>	MYLAN PHARMS INC	<u>0.025%</u>	<u>N020404 003</u>	Jan 14, 1997
-----------	------------------	---------------	--------------------	--------------

RETIN-A

<u>AB</u>	+	VALEANT BERMUDA	<u>0.025%</u>	<u>N019049 001</u>
<u>AB</u>	+	VALEANT PHARMS NORTH	<u>0.1%</u>	<u>N017340 001</u>
				Sep 16, 1988

TRETINOIN

<u>AB</u>	MATAWAN PHARMS	<u>0.025%</u>	<u>A075264 001</u>	Dec 24, 1998
<u>AB</u>		<u>0.1%</u>	<u>A075213 001</u>	Dec 24, 1998

RETIN-A

<u>AB1</u>	+	VALEANT BERMUDA	<u>0.05%</u>	<u>N017522 001</u>
------------	---	-----------------	--------------	--------------------

TRETINOIN

<u>AB1</u>	MATAWAN PHARMS	<u>0.05%</u>	<u>A075265 001</u>	Dec 24, 1998
------------	----------------	--------------	--------------------	--------------

RENOVA

<u>AB2</u>	+	VALEANT PHARMS NORTH	<u>0.05%</u>	<u>N019963 001</u>
				Dec 29, 1995

TRETINOIN

<u>AB2</u>	SUNEVA MEDCL	<u>0.05%</u>	<u>A076498 001</u>	Sep 15, 2005
	RENOVA			
	+	VALEANT PHARMS NORTH	0.02%	N021108 001
	TRETINOIN			Aug 31, 2000
	+	WATSON LABS INC	0.0375%	A090098 001
			0.075%	A202209 001
				Oct 11, 2012

GEL; TOPICAL

ATRALIN

<u>AB</u>	+	DOW PHARM	<u>0.05%</u>	<u>N022070 001</u>
				Jul 26, 2007

RETIN-A

<u>AB</u>	+	VALEANT INTL	<u>0.01%</u>	<u>N017955 001</u>
<u>AB</u>	+		<u>0.025%</u>	<u>N017579 002</u>

## PRESCRIPTION DRUG PRODUCT LIST

TRETINOIN

GEL; TOPICAL

RETIN-A MICRO

<u>AB</u>	+	VALEANT INTL	<u>0.04%</u>	<u>N020475</u>	<u>002</u>	May 10, 2002
<u>AB</u>	+		<u>0.1%</u>	<u>N020475</u>	<u>001</u>	Feb 07, 1997

TRETINOIN

<u>AB</u>		MATAWAN PHARMS	<u>0.01%</u>	<u>A075589</u>	<u>001</u>	Jun 11, 2002
<u>AB</u>			<u>0.025%</u>	<u>A075529</u>	<u>001</u>	Feb 22, 2000
<u>AB</u>		SPEAR PHARMS INC	<u>0.04%</u>	<u>A202567</u>	<u>001</u>	Jul 17, 2013
<u>AB</u>			<u>0.05%</u>	<u>A207955</u>	<u>001</u>	Aug 13, 2015
<u>AB</u>			<u>0.1%</u>	<u>A202026</u>	<u>001</u>	Jul 17, 2013
		AVITA				
BT		MYLAN	0.025%	N020400	001	Jan 29, 1998
		RETIN-A-MICRO				
		+ VALEANT INTL	0.08%	N020475	003	Jan 28, 2014
		SOLUTION; TOPICAL				
		RETIN-A				
		+ VALEANT INTL	0.05%	N016921	001	

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	+	FOUGERA PHARMS	<u>0.025%</u>	<u>A085692</u>	<u>001</u>	
<u>AT</u>	+		<u>0.1%</u>	<u>A085692</u>	<u>003</u>	
<u>AT</u>	+		<u>0.5%</u>	<u>A085692</u>	<u>002</u>	
<u>AT</u>		G AND W LABS	<u>0.025%</u>	<u>A089797</u>	<u>001</u>	May 31, 1991
<u>AT</u>			<u>0.1%</u>	<u>A089798</u>	<u>001</u>	May 31, 1991
<u>AT</u>		PERRIGO NEW YORK	<u>0.025%</u>	<u>A086415</u>	<u>001</u>	
<u>AT</u>			<u>0.1%</u>	<u>A086414</u>	<u>001</u>	
<u>AT</u>			<u>0.5%</u>	<u>A086413</u>	<u>001</u>	
<u>AT</u>		TARO	<u>0.1%</u>	<u>A040039</u>	<u>001</u>	Nov 26, 1997
<u>AT</u>		VINTAGE	<u>0.025%</u>	<u>A040671</u>	<u>001</u>	Jun 09, 2006
<u>AT</u>			<u>0.1%</u>	<u>A040671</u>	<u>002</u>	Jun 09, 2006

TRIDERM

<u>AT</u>		CROWN LABS	<u>0.025%</u>	<u>A088042</u>	<u>002</u>	Mar 25, 2015
<u>AT</u>			<u>0.1%</u>	<u>A088042</u>	<u>001</u>	Mar 19, 1984
<u>AT</u>			<u>0.5%</u>	<u>A088042</u>	<u>003</u>	Mar 25, 2015

INJECTABLE; INJECTION

KENALOG-10

APOTHECON

10MG/ML

N012041 001

KENALOG-40

+ APOTHECON

40MG/ML

N014901 001

INJECTABLE; INTRAVITREAL

TRIESENCE

+ ALCON

40MG/ML (40MG/ML)

N022048 001 Nov 29, 2007

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>		FOUGERA PHARMS	<u>0.025%</u>	<u>A040467</u>	<u>001</u>	Apr 21, 2003
<u>AT</u>			<u>0.1%</u>	<u>A040467</u>	<u>002</u>	Apr 21, 2003
<u>AT</u>		G AND W LABS INC	<u>0.1%</u>	<u>A089129</u>	<u>001</u>	Aug 14, 1986
<u>AT</u>		VERSAPHARM INC	<u>0.025%</u>	<u>A202374</u>	<u>001</u>	May 08, 2013
<u>AT</u>			<u>0.1%</u>	<u>A202374</u>	<u>002</u>	May 08, 2013
<u>AT</u>		VINTAGE	<u>0.1%</u>	<u>A040672</u>	<u>002</u>	Dec 13, 2006
<u>AT</u>	+	WOCKHARDT	<u>0.1%</u>	<u>A088451</u>	<u>001</u>	Apr 03, 1985
<u>AT</u>	+	WOCKHARDT EU OPERATN	<u>0.025%</u>	<u>A088450</u>	<u>001</u>	Apr 01, 1985

OINTMENT; TOPICAL

KENALOG

<u>AT</u>		DELCOR ASSET CORP	<u>0.025%</u>	<u>N011600</u>	<u>003</u>	
<u>AT</u>			<u>0.1%</u>	<u>N011600</u>	<u>001</u>	

TRIAMCINOLONE ACETONIDE

<u>AT</u>		FOUGERA PHARMS	<u>0.025%</u>	<u>A085691</u>	<u>001</u>	
<u>AT</u>			<u>0.1%</u>	<u>A085691</u>	<u>003</u>	
<u>AT</u>			<u>0.5%</u>	<u>A085691</u>	<u>002</u>	
<u>AT</u>		G AND W LABS	<u>0.025%</u>	<u>A089795</u>	<u>001</u>	Dec 23, 1988
<u>AT</u>			<u>0.1%</u>	<u>A089796</u>	<u>001</u>	Dec 23, 1988
<u>AT</u>	+	PERRIGO NEW YORK	<u>0.025%</u>	<u>A087356</u>	<u>001</u>	
<u>AT</u>	+		<u>0.1%</u>	<u>A087357</u>	<u>001</u>	
<u>AT</u>	+		<u>0.5%</u>	<u>A087385</u>	<u>001</u>	
<u>AT</u>		TARO	<u>0.1%</u>	<u>A040037</u>	<u>001</u>	Sep 30, 1994
		TRIAMCINOLONE ACETONIDE IN ABSORBASE				
		+ CAROLINA MEDCL	0.05%	A089595	001	Mar 23, 1995

## PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

<b>AT</b>	LYNE	<u>0.1%</u>	<u>A040771</u>	<u>001</u>	Jul 01, 2010
<b>AT</b>	+ TARO	<u>0.1%</u>	<u>A070730</u>	<u>001</u>	Oct 01, 1986

SPRAY; TOPICAL

KENALOG

<b>AT</b>	+ SUN PHARM INDS LTD	<u>0.147MG/GM</u>	<u>N012104</u>	<u>001</u>	
-----------	----------------------	-------------------	----------------	------------	--

TRIAMCINOLONE ACETONIDE

<b>AT</b>	PERRIGO UK FINCO	<u>0.147MG/GM</u>	<u>A205782</u>	<u>001</u>	Apr 13, 2015
-----------	------------------	-------------------	----------------	------------	--------------

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

TEVA PHARMS

0.055MG/SPRAY

A078104 001 Jul 30, 2009

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+ SANDOZ

5MG/ML

N016466 001

+

20MG/ML

N016466 002

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

CONCORDIA PHARMS INC

50MG

N013174 001

+

100MG

N013174 002

TRIAZOLAM

TABLET; ORAL

HALCION

<b>AB</b>	PHARMACIA AND UPJOHN	<u>0.125MG</u>	<u>N017892</u>	<u>003</u>	Apr 26, 1985
-----------	----------------------	----------------	----------------	------------	--------------

<b>AB</b>	+	<u>0.25MG</u>	<u>N017892</u>	<u>001</u>	Nov 15, 1982
-----------	---	---------------	----------------	------------	--------------

TRIAZOLAM

<b>AB</b>	MYLAN PHARMS INC	<u>0.125MG</u>	<u>A074031</u>	<u>001</u>	Mar 25, 1994
-----------	------------------	----------------	----------------	------------	--------------

<b>AB</b>		<u>0.25MG</u>	<u>A074031</u>	<u>002</u>	Mar 25, 1994
-----------	--	---------------	----------------	------------	--------------

<b>AB</b>	ROXANE	<u>0.125MG</u>	<u>A074224</u>	<u>001</u>	Jun 01, 1994
-----------	--------	----------------	----------------	------------	--------------

<b>AB</b>		<u>0.25MG</u>	<u>A074224</u>	<u>002</u>	Jun 01, 1994
-----------	--	---------------	----------------	------------	--------------

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

+ ATON

250MG

N019194 001 Nov 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

<b>AB</b>	MYLAN	<u>EQ 1MG BASE</u>	<u>A040209</u>	<u>001</u>	Jul 07, 1997
-----------	-------	--------------------	----------------	------------	--------------

<b>AB</b>		<u>EQ 2MG BASE</u>	<u>A040209</u>	<u>002</u>	Jul 07, 1997
-----------	--	--------------------	----------------	------------	--------------

<b>AB</b>		<u>EQ 5MG BASE</u>	<u>A040209</u>	<u>003</u>	Jul 07, 1997
-----------	--	--------------------	----------------	------------	--------------

<b>AB</b>	+	<u>EQ 10MG BASE</u>	<u>A040209</u>	<u>004</u>	Jul 07, 1997
-----------	---	---------------------	----------------	------------	--------------

<b>AB</b>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A085785</u>	<u>001</u>	
-----------	--------	--------------------	----------------	------------	--

<b>AB</b>		<u>EQ 2MG BASE</u>	<u>A085786</u>	<u>001</u>	
-----------	--	--------------------	----------------	------------	--

<b>AB</b>		<u>EQ 5MG BASE</u>	<u>A085789</u>	<u>001</u>	
-----------	--	--------------------	----------------	------------	--

<b>AB</b>		<u>EQ 10MG BASE</u>	<u>A085788</u>	<u>001</u>	
-----------	--	---------------------	----------------	------------	--

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

<b>AT</b>	ALCON PHARMS LTD	<u>1%</u>	<u>A074311</u>	<u>001</u>	Oct 06, 1995
-----------	------------------	-----------	----------------	------------	--------------

VIROPTIC

<b>AT</b>	+ MONARCH PHARMS	<u>1%</u>	<u>N018299</u>	<u>001</u>	
-----------	------------------	-----------	----------------	------------	--

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

<b>AA</b>	MIKART	<u>2MG/5ML</u>	<u>A040251</u>	<u>001</u>	Sep 27, 1999
-----------	--------	----------------	----------------	------------	--------------

<b>AA</b>	+ PHARM ASSOC	<u>2MG/5ML</u>	<u>A040177</u>	<u>001</u>	Apr 17, 1997
-----------	---------------	----------------	----------------	------------	--------------

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

<b>AA</b>	NATCO PHARMA LTD	<u>2MG</u>	<u>A091630</u>	<u>001</u>	Nov 17, 2010
-----------	------------------	------------	----------------	------------	--------------

<b>AA</b>		<u>5MG</u>	<u>A091630</u>	<u>002</u>	Nov 17, 2010
-----------	--	------------	----------------	------------	--------------

<b>AA</b>	VINTAGE PHARMS	<u>2MG</u>	<u>A040254</u>	<u>001</u>	Dec 24, 1998
-----------	----------------	------------	----------------	------------	--------------

<b>AA</b>		<u>5MG</u>	<u>A040254</u>	<u>002</u>	Dec 24, 1998
-----------	--	------------	----------------	------------	--------------

<b>AA</b>	+ WATSON LABS	<u>2MG</u>	<u>A084363</u>	<u>001</u>	
-----------	---------------	------------	----------------	------------	--

<b>AA</b>	+	<u>5MG</u>	<u>A084364</u>	<u>001</u>	
-----------	---	------------	----------------	------------	--



## PRESCRIPTION DRUG PRODUCT LIST

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+ ABBVIE

150MG

N005856 009

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN**AB** + KING PHARMS**300MG****N017531 006** Dec 13, 2001TRIMETHOBENZAMIDE HYDROCHLORIDE**AB** GAVIS PHARMS**300MG****A076546 001** Aug 20, 2003**AB** MUTUAL PHARMA**300MG****A076570 001** Aug 28, 2003

INJECTABLE; INJECTION

TIGAN**AP** + PAR STERILE PRODUCTS**100MG/ML****N017530 001**TRIMETHOBENZAMIDE HYDROCHLORIDE**AP** LUITPOLD**100MG/ML****A091330 001** Mar 08, 2011TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE**AP** LUITPOLD**100MG/ML****A091329 001** Mar 08, 2011TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM**AB** NOVEL LABS INC**100MG****A091437 001** Jun 15, 2011**AB** + TEVA**100MG****N018679 001** Jul 30, 1982**AB** WATSON LABS**100MG****A070049 001** Jun 06, 1985TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+ FSC

EQ 50MG BASE/5ML

N074973 001 Jan 24, 2000

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL**AB** ODYSSEY PHARMS**EQ 25MG BASE****N016792 001****AB** +**EQ 50MG BASE****N016792 002****AB****EQ 100MG BASE****N016792 003** Sep 15, 1982TRIMIPRAMINE MALEATE**AB** MIKAH PHARMA**EQ 25MG BASE****A077361 001** Aug 02, 2006**AB****EQ 50MG BASE****A077361 002** Aug 02, 2006**AB****EQ 100MG BASE****A077361 003** Aug 02, 2006TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+ ACTAVIS LABS UT INC

EQ 3.75MG BASE/VIAL

N020715 001 Jun 15, 2000

+

EQ 11.25MG BASE/VIAL

N021288 001 Jun 29, 2001

+

EQ 22.5MG BASE/VIAL

N022437 001 Mar 10, 2010

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+ HOSPIRA

3.6GM/100ML

N013025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL**AT** + ALCON**0.5%****A084305 001****AT** +**1%****A084306 001**TROPICACYL**AT** AKORN**0.5%****A040314 001** Sep 29, 2000**AT****1%****A040315 001** Sep 29, 2000TROPICAMIDE**AT** BAUSCH AND LOMB**0.5%****A040067 001** Jul 27, 1994**AT****1%****A040064 001** Jul 27, 1994TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIUM CHLORIDE**AB** ACTAVIS LABS FL INC**60MG****A091289 001** Oct 12, 2012**AB** PADDOCK LLC**60MG****A201291 001** May 24, 2013**AB** SANDOZ INC**60MG****A091635 001** Apr 29, 2015

TABLET; ORAL

TROSPIUM CHLORIDE**AB** APOTEX**20MG****A091513 001** Dec 06, 2011

## PRESCRIPTION DRUG PRODUCT LIST

TROSPIUM CHLORIDE

TABLET; ORAL

TROSPIUM CHLORIDE

<b>AB</b>	GLENMARK GENERICS	<b>20MG</b>	<b>A091575 001</b>	Aug 13, 2010
<b>AB</b>	PADDOCK LLC	<b>20MG</b>	<b>A091573 001</b>	Nov 17, 2010

TRYPAN BLUESOLUTION; OPHTHALMIC  
MEMBRANEBLUE

+	DORC	0.15%	N022278 001	Feb 20, 2009
	VISIONBLUE			
+	DORC	0.06%	N021670 001	Dec 16, 2004

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA

+	LAB HRA PHARMA	30MG	N022474 001	Aug 13, 2010
---	----------------	------	-------------	--------------

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382 001	Apr 30, 2014
---	-------------------	---------------------	-------------	--------------

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH; EQ 0.025MG BASE/INH	N203975 001	Dec 18, 2013
---	-----------------	--	-------------	--------------

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+	R-TECH UENO LTD	0.15%	N021214 001	Aug 03, 2000
---	-----------------	-------	-------------	--------------

UREA, C-14

CAPSULE; ORAL

PYTEST

+	AVENT	1uCi	N020617 001	May 09, 1997
---	-------	------	-------------	--------------

PYTEST KIT

+	AVENT	1uCi	N020617 002	May 09, 1997
---	-------	------	-------------	--------------

URIDINE TRIACETATE

GRANULE; ORAL

VISTOGARD

+	WELLSTAT THERAP	10GM/PACKET	N208159 001	Dec 11, 2015
---	-----------------	-------------	-------------	--------------

XURIDEN

+	WELLSTAT THERAP	2GM/PACKET	N208169 001	Sep 04, 2015
---	-----------------	------------	-------------	--------------

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+	FERRING	75 IU/VIAL	N021289 001	May 06, 2002
---	---------	------------	-------------	--------------

URSODIOL

CAPSULE; ORAL

ACTIGALL

<b>AB</b>	+	ACTAVIS LABS UT INC	<b>300MG</b>	<b>N019594 002</b>	Dec 31, 1987
-----------	---	---------------------	--------------	--------------------	--------------

URSODIOL

<b>AB</b>		COREPHARMA	<b>300MG</b>	<b>A077895 001</b>	Jul 27, 2006
<b>AB</b>		EPIC PHARMA	<b>300MG</b>	<b>A075517 001</b>	Mar 14, 2000
<b>AB</b>		LANNETT	<b>300MG</b>	<b>A079082 001</b>	Dec 15, 2008
<b>AB</b>		MYLAN	<b>300MG</b>	<b>A090530 001</b>	Feb 17, 2010
<b>AB</b>		TEVA PHARMS	<b>300MG</b>	<b>A075592 001</b>	May 25, 2000

TABLET; ORAL

URSO 250

<b>AB</b>		FOREST LABS INC	<b>250MG</b>	<b>N020675 001</b>	Dec 10, 1997
-----------	--	-----------------	--------------	--------------------	--------------

URSO FORTE

<b>AB</b>	+	FOREST LABS INC	<b>500MG</b>	<b>N020675 002</b>	Jul 21, 2004
-----------	---	-----------------	--------------	--------------------	--------------

URSODIOL

<b>AB</b>		GLENMARK GENERICS	<b>250MG</b>	<b>A090801 001</b>	Jul 12, 2011
<b>AB</b>			<b>500MG</b>	<b>A090801 002</b>	Jul 12, 2011
<b>AB</b>		IMPAX LABS INC	<b>250MG</b>	<b>A200826 001</b>	Dec 23, 2011
<b>AB</b>			<b>500MG</b>	<b>A200826 002</b>	Dec 23, 2011
<b>AB</b>		PAR PHARM	<b>250MG</b>	<b>A202540 001</b>	Feb 14, 2013
<b>AB</b>			<b>500MG</b>	<b>A202540 002</b>	Feb 14, 2013

## PRESCRIPTION DRUG PRODUCT LIST

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

<b>AB</b>	APOTEX INC	<u>EQ 500MG BASE</u>	<u>A090500 001</u>	Apr 04, 2014
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A090500 002</u>	Apr 04, 2014
<b>AB</b>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A090682 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A090682 002</u>	May 24, 2010
<b>AB</b>	CIPLA LTD	<u>EQ 500MG BASE</u>	<u>A077135 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A077135 002</u>	May 24, 2010
<b>AB</b>	DR REDDYS LABS LTD	<u>EQ 500MG BASE</u>	<u>A079012 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A079012 002</u>	May 24, 2010
<b>AB</b>	HETERO LABS LTD V	<u>EQ 500MG BASE</u>	<u>A203047 001</u>	Apr 08, 2015
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A203047 002</u>	Apr 08, 2015
<b>AB</b>	JUBILANT GENERICS	<u>EQ 500MG BASE</u>	<u>A201506 001</u>	Apr 03, 2012
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A201506 002</u>	Apr 03, 2012
<b>AB</b>	MYLAN	<u>EQ 500MG BASE</u>	<u>A078070 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A078070 002</u>	May 24, 2010
<b>AB</b>	MYLAN PHARMS INC	<u>EQ 500MG BASE</u>	<u>A078518 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A078518 002</u>	May 24, 2010
<b>AB</b>	ROXANE	<u>EQ 500MG BASE</u>	<u>A078656 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A078656 002</u>	May 24, 2010
<b>AB</b>	SANDOZ	<u>EQ 500MG BASE</u>	<u>A077478 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A077478 002</u>	May 24, 2010
<b>AB</b>	SUN PHARM INDS LTD	<u>EQ 500MG BASE</u>	<u>A076588 001</u>	Jan 31, 2007
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A076588 002</u>	Jan 31, 2007
<b>AB</b>	TEVA PHARMS	<u>EQ 500MG BASE</u>	<u>A077655 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A077655 002</u>	May 24, 2010
<b>AB</b>	WATSON LABS INC	<u>EQ 500MG BASE</u>	<u>A090370 001</u>	Mar 16, 2011
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A090370 002</u>	Mar 16, 2011
<b>AB</b>	WOCKHARDT	<u>EQ 500MG BASE</u>	<u>A090216 001</u>	May 24, 2010
<b>AB</b>		<u>EQ 1GM BASE</u>	<u>A090216 002</u>	May 24, 2010

VALTREX

<b>AB</b>	GLAXOSMITHKLINE	<u>EQ 500MG BASE</u>	<u>N020487 001</u>	Jun 23, 1995
<b>AB</b>	+	<u>EQ 1GM BASE</u>	<u>N020487 002</u>	Jun 23, 1995

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+ HOFFMANN LA ROCHE

50MG/ML

N022257 001 Aug 28, 2009

TABLET; ORAL

VALCYTE

<b>AB</b>	+	HOFFMANN LA ROCHE	<u>EQ 450MG BASE</u>	<u>N021304 001</u>	Mar 29, 2001
-----------	---	-------------------	----------------------	--------------------	--------------

VALGANCICLOVIR HYDROCHLORIDE

<b>AB</b>	DR REDDYS LABS LTD	<u>EQ 450MG BASE</u>	<u>A203511 001</u>	Nov 04, 2014
<b>AB</b>	ENDO PHARMS INC	<u>EQ 450MG BASE</u>	<u>A200790 001</u>	Nov 04, 2014

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

<b>AP</b>	+	ABBVIE	<u>EQ 100MG BASE/ML</u>	<u>N020593 001</u>	Dec 30, 1996
-----------	---	--------	-------------------------	--------------------	--------------

VALPROATE SODIUM

<b>AP</b>	BEDFORD	<u>EQ 100MG BASE/ML</u>	<u>A076295 001</u>	Nov 14, 2002
<b>AP</b>	FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539 001</u>	Jun 26, 2003
<b>AP</b>	HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523 001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

<b>AB</b>	+	ABBVIE	<u>250MG</u>	<u>N018081 001</u>	
-----------	---	--------	--------------	--------------------	--

VALPROIC ACID

<b>AB</b>	BANNER LIFE SCIENCES	<u>250MG</u>	<u>A073484 001</u>	Jun 29, 1993
<b>AB</b>	CATALENT	<u>250MG</u>	<u>A073229 001</u>	Oct 29, 1991
<b>AB</b>	SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037 001</u>	Feb 22, 2013

SYRUP; ORAL

DEPAKENE

<b>AA</b>	+	ABBVIE	<u>250MG/5ML</u>	<u>N018082 001</u>	
-----------	---	--------	------------------	--------------------	--

VALPROIC ACID

<b>AA</b>	ALPHARMA	<u>250MG/5ML</u>	<u>A075782 001</u>	Dec 22, 2000
<b>AA</b>	ANI PHARMS INC	<u>250MG/5ML</u>	<u>A073178 001</u>	Aug 25, 1992
<b>AA</b>	HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060 001</u>	Jan 13, 1995
<b>AA</b>	PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379 001</u>	Dec 15, 2000
<b>AA</b>	SUN PHARM INDS INC	<u>250MG/5ML</u>	<u>A090517 001</u>	May 28, 2010
<b>AA</b>	VINTAGE	<u>250MG/5ML</u>	<u>A077960 001</u>	Oct 13, 2006
<b>AA</b>	WOCKHARDT	<u>250MG/5ML</u>	<u>A070868 001</u>	Jul 01, 1986

## PRESCRIPTION DRUG PRODUCT LIST

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

+ ENDO PHARM

40MG/ML

N020892 001 Sep 25, 1998

VALSARTAN

TABLET; ORAL

DIOVAN

<u>AB</u>	NOVARTIS	<u>40MG</u>	<u>N021283 004</u>	Aug 14, 2002
<u>AB</u>		<u>80MG</u>	<u>N021283 001</u>	Jul 18, 2001
<u>AB</u>		<u>160MG</u>	<u>N021283 002</u>	Jul 18, 2001
<u>AB</u>	+	<u>320MG</u>	<u>N021283 003</u>	Jul 18, 2001

VALSARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>40MG</u>	<u>A091367 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A091367 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A091367 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A091367 004</u>	Jan 05, 2015
<u>AB</u>	AMNEAL PHARMS	<u>40MG</u>	<u>A204011 001</u>	Jan 11, 2016
<u>AB</u>		<u>80MG</u>	<u>A204011 002</u>	Jan 11, 2016
<u>AB</u>		<u>160MG</u>	<u>A204011 003</u>	Jan 11, 2016
<u>AB</u>		<u>320MG</u>	<u>A204011 004</u>	Jan 11, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>40MG</u>	<u>A202223 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A202223 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A202223 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A202223 004</u>	Jan 05, 2015
<u>AB</u>	HETERO LABS LTD V	<u>40MG</u>	<u>A203311 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A203311 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A203311 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A203311 004</u>	Jan 05, 2015
<u>AB</u>	IVAX PHARMS	<u>40MG</u>	<u>A077530 001</u>	Jan 04, 2016
<u>AB</u>		<u>80MG</u>	<u>A077530 002</u>	Jan 04, 2016
<u>AB</u>		<u>160MG</u>	<u>A077530 003</u>	Jan 04, 2016
<u>AB</u>		<u>320MG</u>	<u>A077530 004</u>	Jan 04, 2016
<u>AB</u>	JUBILANT GENERICS	<u>40MG</u>	<u>A203536 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A203536 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A203536 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A203536 004</u>	Jan 05, 2015
<u>AB</u>	LUPIN LTD	<u>40MG</u>	<u>A201677 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A201677 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A201677 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A201677 004</u>	Jan 05, 2015
<u>AB</u>	MYLAN LABS LTD	<u>40MG</u>	<u>A090866 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A090866 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A090866 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A090866 004</u>	Jan 05, 2015
<u>AB</u>	OHM LABS INC	<u>40MG</u>	<u>A077492 001</u>	Jun 26, 2014
<u>AB</u>		<u>80MG</u>	<u>A077492 002</u>	Jun 26, 2014
<u>AB</u>		<u>160MG</u>	<u>A077492 003</u>	Jun 26, 2014
<u>AB</u>		<u>320MG</u>	<u>A077492 004</u>	Jun 26, 2014
<u>AB</u>	PRINSTON INC	<u>40MG</u>	<u>A204821 001</u>	Jun 09, 2015
<u>AB</u>		<u>80MG</u>	<u>A204821 002</u>	Jun 09, 2015
<u>AB</u>		<u>160MG</u>	<u>A204821 003</u>	Jun 09, 2015
<u>AB</u>		<u>320MG</u>	<u>A204821 004</u>	Jun 09, 2015
<u>AB</u>	TORRENT PHARMS LTD	<u>40MG</u>	<u>A202728 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A202728 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A202728 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A202728 004</u>	Jan 05, 2015
<u>AB</u>	WATSON LABS INC	<u>40MG</u>	<u>A090642 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A090642 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A090642 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A090642 004</u>	Jan 05, 2015

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>EQ 125MG BASE</u>	<u>N050606 001</u>	Apr 15, 1986
<u>AB</u>	+	<u>EQ 250MG BASE</u>	<u>N050606 002</u>	Apr 15, 1986
	<u>VANCOMYCIN HYDROCHLORIDE</u>			
<u>AB</u>	AKORN	<u>EQ 125MG BASE</u>	<u>A065478 001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065478 002</u>	Apr 09, 2012
<u>AB</u>	FRESENIUS KABI USA	<u>EQ 125MG BASE</u>	<u>A065453 001</u>	Jun 18, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065453 002</u>	Jun 18, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 125MG BASE</u>	<u>A090439 001</u>	Jan 28, 2015

## PRESCRIPTION DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A090439 002</u>	Jan 28, 2015
<u>AB</u>	STRIDES PHARMA	<u>EQ 125MG BASE</u>	<u>A065490 001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065490 002</u>	Apr 09, 2012
<u>AB</u>	WATSON LABS	<u>EQ 125MG BASE</u>	<u>A065510 001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065510 002</u>	Apr 09, 2012

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>	CUSTOPHARM INC	<u>EQ 5GM BASE/VIAL</u>	<u>A204125 001</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A204125 002</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A204107 001</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A204107 002</u>	Dec 28, 2015
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A202275 001</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202275 002</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A202464 001</u>	Oct 09, 2013
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A202274 001</u>	Oct 31, 2013
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A062663 001</u>	Mar 17, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062663 002</u>	Jul 31, 1987
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A062663 003</u>	Jun 03, 1988
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062663 004</u>	Nov 28, 1997
<u>AP</u>	+ HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062911 001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062931 001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>A062912 002</u>	Jan 07, 2009
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>A062933 002</u>	May 27, 2009
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062912 001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062933 001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A063076 001</u>	Dec 21, 1990
<u>AP</u>	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455 001</u>	Apr 29, 2009
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>EQ 500MG BASE/VIAL</u>	<u>A065401 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065401 002</u>	Jun 30, 2008
<u>AP</u>	MYLAN LABS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065397 001</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065397 002</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A065432 001</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091469 001</u>	Jul 01, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091554 001</u>	Sep 19, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837 001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A200837 002</u>	Sep 02, 2014
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A090250 001</u>	Apr 27, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090250 002</u>	Apr 27, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048 001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201048 002</u>	Aug 10, 2012
<u>AP</u>	TEVA PHARMS USA	<u>EQ 500MG BASE/VIAL</u>	<u>A201251 001</u>	Dec 23, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A201251 002</u>	Dec 23, 2015
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A201250 001</u>	Dec 23, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201250 002</u>	Dec 23, 2015
<u>AP</u>	XELLIA PHARMS APS	<u>EQ 500MG BASE/VIAL</u>	<u>A091377 001</u>	Sep 09, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091377 002</u>	Sep 09, 2015
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A206243 001</u>	Dec 23, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A206243 002</u>	Dec 23, 2015
	VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671 001	Apr 29, 1993
	+	EQ 750MG BASE/150ML	N050671 002	Dec 20, 2010
	POWDER; IV (INFUSION)			
	VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER			
	SAMSON MEDCL	EQ 100GM BASE	A091532 001	Jan 06, 2016

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011
	+	300MG	N022405 002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

<u>AB</u>	BAYER HLTHCARE	<u>2.5MG</u>	<u>N021400 003</u>	Aug 19, 2003
<u>AB</u>		<u>5MG</u>	<u>N021400 001</u>	Aug 19, 2003
<u>AB</u>		<u>10MG</u>	<u>N021400 002</u>	Aug 19, 2003
<u>AB</u>	+	<u>20MG</u>	<u>N021400 004</u>	Aug 19, 2003

VARDENAFIL HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A091347 001</u>	May 03, 2012
-----------	-------------	--------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

VARDENAFIL HYDROCHLORIDE

<u>AB</u>		<u>5MG</u>	<u>A091347</u>	<u>002</u>	May 03, 2012
<u>AB</u>		<u>10MG</u>	<u>A091347</u>	<u>003</u>	May 03, 2012
<u>AB</u>		<u>20MG</u>	<u>A091347</u>	<u>004</u>	May 03, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

<u>AB</u>	+	BAYER HLTHCARE	<u>10MG</u>	<u>N200179</u>	<u>001</u>	Jun 17, 2010
-----------	---	----------------	-------------	----------------	------------	--------------

VARDENAFIL HYDROCHLORIDE

<u>AB</u>		WATSON LABS INC	<u>10MG</u>	<u>A203689</u>	<u>001</u>	Apr 22, 2015
-----------	--	-----------------	-------------	----------------	------------	--------------

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

		PFIZER INC	EQ 0.5MG BASE	N021928	001	May 10, 2006
	+		EQ 1MG BASE	N021928	002	May 10, 2006

VASOPRESSIN

SOLUTION; IV (INFUSION)

VASOSTRICT

	+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014
--	---	----------------------	-------------------------	---------	-----	--------------

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>		BEDFORD	<u>10MG/VIAL</u>	<u>A075549</u>	<u>001</u>	Jun 13, 2000
<u>AP</u>			<u>20MG/VIAL</u>	<u>A075549</u>	<u>002</u>	Jun 13, 2000
<u>AP</u>		HOSPIRA	<u>10MG/VIAL</u>	<u>A075164</u>	<u>001</u>	Oct 21, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A075164</u>	<u>002</u>	Oct 21, 1999
<u>AP</u>		MUSTAFA NEVZAT	<u>10MG/VIAL</u>	<u>A078274</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>			<u>20MG/VIAL</u>	<u>A078274</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>		MYLAN LABS LTD	<u>10MG/VIAL</u>	<u>A090243</u>	<u>001</u>	May 11, 2010
<u>AP</u>			<u>20MG/VIAL</u>	<u>A090243</u>	<u>002</u>	May 11, 2010
<u>AP</u>	+	SUN PHARMA GLOBAL	<u>10MG/VIAL</u>	<u>A079001</u>	<u>001</u>	Jun 17, 2009
<u>AP</u>	+		<u>20MG/VIAL</u>	<u>A079001</u>	<u>002</u>	Jun 17, 2009
<u>AP</u>		TEVA PHARMS USA	<u>10MG/VIAL</u>	<u>A074688</u>	<u>001</u>	Aug 25, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A074688</u>	<u>002</u>	Aug 25, 1999

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIV

		SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010
--	--	---------------------	----------------	---------	-----	--------------

VEMURAFENIB

TABLET; ORAL

ZELBORAF

	+	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011
--	---	-------------------	-------	---------	-----	--------------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

<u>AB</u>		WYETH PHARMS INC	<u>EQ 37.5MG BASE</u>	<u>N020699</u>	<u>001</u>	Oct 20, 1997
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>N020699</u>	<u>002</u>	Oct 20, 1997
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N020699</u>	<u>004</u>	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		ANCHEN PHARMS	<u>EQ 37.5MG BASE</u>	<u>A078087</u>	<u>001</u>	Mar 16, 2012
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A078087</u>	<u>002</u>	Mar 16, 2012
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A078087</u>	<u>003</u>	Mar 16, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 37.5MG BASE</u>	<u>A200834</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A200834</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A200834</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 37.5MG BASE</u>	<u>A078421</u>	<u>001</u>	May 06, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A078421</u>	<u>002</u>	May 06, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A078421</u>	<u>003</u>	May 06, 2011
<u>AB</u>		MYLAN	<u>EQ 37.5MG BASE</u>	<u>A078789</u>	<u>001</u>	Jun 01, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A078789</u>	<u>002</u>	Jun 01, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A078789</u>	<u>003</u>	Jun 01, 2011
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A091123</u>	<u>001</u>	Jul 11, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A091123</u>	<u>002</u>	Jul 11, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A091123</u>	<u>003</u>	Jul 11, 2011
<u>AB</u>		TEVA	<u>EQ 37.5MG BASE</u>	<u>A076565</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A076565</u>	<u>002</u>	Jun 28, 2010
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A076565</u>	<u>003</u>	Jun 28, 2010
<u>AB</u>		TORRENT PHARMS LLC	<u>EQ 37.5MG BASE</u>	<u>A090899</u>	<u>001</u>	Jun 01, 2011

## PRESCRIPTION DRUG PRODUCT LIST

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090899 002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090899 003</u>	Jun 01, 2011
<u>AB</u>	VALEANT PHARMS NORTH	<u>EQ 37.5MG BASE</u>	<u>A090071 001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090071 002</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090071 003</u>	Apr 15, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 37.5MG BASE</u>	<u>A078865 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078865 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078865 003</u>	Apr 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 37.5MG BASE</u>	<u>A090174 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090174 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090174 003</u>	Apr 14, 2011

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A078932 001</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078932 002</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078932 003</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078932 004</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078932 005</u>	Dec 14, 2010
<u>AB</u>	AMNEAL PHARMS	<u>EQ 25MG BASE</u>	<u>A079098 001</u>	May 11, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A079098 002</u>	May 11, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A079098 003</u>	May 11, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A079098 004</u>	May 11, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A079098 005</u>	May 11, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555 001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090555 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555 003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555 004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555 005</u>	Apr 07, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301 005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554 001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554 002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554 003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554 004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554 005</u>	Jan 09, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166 005</u>	Jun 13, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 25MG BASE</u>	<u>A078627 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627 005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690 001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690 002</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076690 003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690 004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690 005</u>	Aug 03, 2006
<u>AB</u>	VINTAGE	<u>EQ 25MG BASE</u>	<u>A090027 001</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090027 002</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090027 003</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090027 004</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090027 005</u>	Aug 04, 2010
<u>AB</u>	YAOPHARMA CO LTD	<u>EQ 25MG BASE</u>	<u>A202036 001</u>	May 28, 2015
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A202036 002</u>	May 28, 2015
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202036 003</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A202036 004</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202036 005</u>	May 28, 2015
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653 005</u>	Jun 13, 2008

## PRESCRIPTION DRUG PRODUCT LIST

VENLAFAXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104 001</u>	May 20, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N022104 002</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022104 003</u>	May 20, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 37.5MG BASE</u>	<u>A091272 001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272 002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272 003</u>	Aug 18, 2010
	OSMOTICA PHARM	EQ 225MG BASE	N022104 004	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A078306 001</u>	Aug 09, 2007
<u>AB</u>		<u>120MG</u>	<u>A075138 001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138 002</u>	Apr 20, 1999
<u>AB</u>		<u>200MG</u>	<u>A078306 002</u>	Aug 09, 2007
<u>AB</u>		<u>240MG</u>	<u>A075138 003</u>	Apr 20, 1999
<u>AB</u>		<u>300MG</u>	<u>A078306 003</u>	Aug 09, 2007

VERELAN

<u>AB</u>	RECRO GAINESVILLE	<u>120MG</u>	<u>N019614 001</u>	May 29, 1990
<u>AB</u>		<u>180MG</u>	<u>N019614 003</u>	Jan 09, 1992
<u>AB</u>		<u>240MG</u>	<u>N019614 002</u>	May 29, 1990

VERELAN PM

<u>AB</u>	RECRO GAINESVILLE	<u>100MG</u>	<u>N020943 001</u>	Nov 25, 1998
<u>AB</u>		<u>200MG</u>	<u>N020943 002</u>	Nov 25, 1998
<u>AB</u>	+	<u>300MG</u>	<u>N020943 003</u>	Nov 25, 1998
	VERELAN			
	+ RECRO GAINESVILLE	360MG	N019614 004	May 10, 1996

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	+	<u>HOSPIRA</u>	<u>10MG/4ML (2.5MG/ML)</u>	<u>A070738 001</u>	May 06, 1987
<u>AP</u>	+		<u>5MG/2ML (2.5MG/ML)</u>	<u>A075136 001</u>	Oct 20, 1998
<u>AP</u>	+		<u>5MG/2ML (2.5MG/ML)</u>	<u>A070737 001</u>	May 06, 1987
<u>AP</u>	+		<u>10MG/4ML (2.5MG/ML)</u>	<u>A070737 002</u>	May 06, 1987

TABLET;ORAL

CALAN

<u>AB</u>	GD SEARLE LLC	<u>40MG</u>	<u>N018817 003</u>	Feb 23, 1988
<u>AB</u>		<u>80MG</u>	<u>N018817 001</u>	Sep 10, 1984
<u>AB</u>	+	<u>120MG</u>	<u>N018817 002</u>	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>40MG</u>	<u>A071881 002</u>	Oct 14, 2015
<u>AB</u>		<u>80MG</u>	<u>A071880 001</u>	Apr 05, 1988
<u>AB</u>		<u>120MG</u>	<u>A071881 001</u>	Apr 05, 1988
<u>AB</u>	MYLAN	<u>80MG</u>	<u>A071483 002</u>	Feb 15, 1989
<u>AB</u>		<u>120MG</u>	<u>A071483 001</u>	Feb 15, 1989
<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A072924 001</u>	Jun 29, 1993
<u>AB</u>		<u>80MG</u>	<u>A070995 001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A070994 001</u>	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

<u>AB</u>	+	PFIZER	<u>120MG</u>	<u>N019152 003</u>	Mar 06, 1991
<u>AB</u>	+		<u>180MG</u>	<u>N019152 002</u>	Dec 15, 1989
<u>AB</u>	+		<u>240MG</u>	<u>N019152 001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	APOTEX CORP	<u>120MG</u>	<u>A200878 001</u>	Apr 20, 2012
<u>AB</u>		<u>180MG</u>	<u>A200878 002</u>	Apr 20, 2012
<u>AB</u>		<u>240MG</u>	<u>A200878 003</u>	Apr 20, 2012
<u>AB</u>	GLENMARK GENERICS	<u>120MG</u>	<u>A090700 001</u>	Aug 03, 2011
<u>AB</u>		<u>180MG</u>	<u>A090700 002</u>	Aug 03, 2011
<u>AB</u>		<u>240MG</u>	<u>A078906 001</u>	Sep 17, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568 002</u>	Oct 10, 1997
<u>AB</u>		<u>180MG</u>	<u>A074330 001</u>	Jan 31, 1994
<u>AB</u>		<u>240MG</u>	<u>A073568 001</u>	Jul 31, 1992
<u>AB</u>	MYLAN	<u>120MG</u>	<u>A074587 002</u>	Feb 21, 1997
<u>AB</u>		<u>180MG</u>	<u>A074587 003</u>	Sep 09, 1997
<u>AB</u>		<u>240MG</u>	<u>A074587 001</u>	Mar 23, 1996
<u>AB</u>	PAR PHARM	<u>120MG</u>	<u>A075072 001</u>	May 25, 1999
<u>AB</u>		<u>240MG</u>	<u>A075072 003</u>	May 25, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>120MG</u>	<u>A090529 001</u>	Dec 30, 2011
<u>AB</u>		<u>180MG</u>	<u>A090529 002</u>	Dec 30, 2011
<u>AB</u>		<u>240MG</u>	<u>A090529 003</u>	Dec 30, 2011



## PRESCRIPTION DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

COVERA-HS

BC	+	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996
BC	+		240MG	N020552	002	Feb 26, 1996

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000
--	---	--------------------	-----------	---------	-----	--------------

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

	+	LUNDBECK LLC	500MG/PACKET	N022006	001	Aug 21, 2009
--	---	--------------	--------------	---------	-----	--------------

TABLET;ORAL

SABRIL

	+	LUNDBECK LLC	500MG	N020427	001	Aug 21, 2009
--	---	--------------	-------	---------	-----	--------------

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

	+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011
			20MG	N022567	002	Jan 21, 2011
			40MG	N022567	003	Jan 21, 2011

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VINBLASTINE SULFATE

	+	EUROHLTH INTL SARL	10MG/VIAL	A089395	001	Apr 09, 1987
	+	FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987

VINCRIStINE SULFATE

INJECTABLE;INJECTION

**VINCRIStINE SULFATE PFS**

<b>AP</b>	+	HOSPIRA	<b>1MG/ML</b>	<b>A071484</b>	<b>001</b>	Apr 19, 1988
-----------	---	---------	---------------	----------------	------------	--------------

<b>AP</b>		TEVA PHARMS USA	<b>1MG/ML</b>	<b>A075493</b>	<b>001</b>	Sep 01, 1999
-----------	--	-----------------	---------------	----------------	------------	--------------

INJECTABLE, LIPOSOMAL;INTRAVENOUS

MARQIBO KIT

	+	TALON THERAP	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012
--	---	--------------	------------------	---------	-----	--------------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

**NAVELBINE**

<b>AP</b>	+	PIERRE FABRE	<b>EQ 10MG BASE/ML</b>	<b>N020388</b>	<b>001</b>	Dec 23, 1994
-----------	---	--------------	------------------------	----------------	------------	--------------

**VINORELBINE TARTRATE**

<b>AP</b>		ACTAVIS TOTOWA	<b>EQ 10MG BASE/ML</b>	<b>A078011</b>	<b>001</b>	Jul 22, 2009
-----------	--	----------------	------------------------	----------------	------------	--------------

<b>AP</b>		BEDFORD	<b>EQ 10MG BASE/ML</b>	<b>A076461</b>	<b>001</b>	Dec 11, 2003
-----------	--	---------	------------------------	----------------	------------	--------------

<b>AP</b>		DR REDDYS LABS LTD	<b>EQ 10MG BASE/ML</b>	<b>A202017</b>	<b>001</b>	Sep 12, 2013
-----------	--	--------------------	------------------------	----------------	------------	--------------

<b>AP</b>		EUROHLTH INTL SARL	<b>EQ 10MG BASE/ML</b>	<b>A075992</b>	<b>001</b>	Jun 10, 2003
-----------	--	--------------------	------------------------	----------------	------------	--------------

<b>AP</b>		FRESENIUS KABI USA	<b>EQ 10MG BASE/ML</b>	<b>A076849</b>	<b>001</b>	Apr 18, 2005
-----------	--	--------------------	------------------------	----------------	------------	--------------

<b>AP</b>		HOSPIRA	<b>EQ 10MG BASE/ML</b>	<b>A076827</b>	<b>001</b>	Jun 02, 2005
-----------	--	---------	------------------------	----------------	------------	--------------

<b>AP</b>		JIANGSU HANSON PHARM	<b>EQ 10MG BASE/ML</b>	<b>A091106</b>	<b>001</b>	Sep 26, 2012
-----------	--	----------------------	------------------------	----------------	------------	--------------

<b>AP</b>		MYLAN LABS LTD	<b>EQ 10MG BASE/ML</b>	<b>A200148</b>	<b>001</b>	Aug 31, 2012
-----------	--	----------------	------------------------	----------------	------------	--------------

<b>AP</b>		TEVA PHARMS USA	<b>EQ 10MG BASE/ML</b>	<b>A076028</b>	<b>001</b>	Feb 03, 2003
-----------	--	-----------------	------------------------	----------------	------------	--------------

VISMODEGIB

CAPSULE;ORAL

ERIVEDGE

	+	GENENTECH	150MG	N203388	001	Jan 30, 2012
--	---	-----------	-------	---------	-----	--------------

VITAMIN A PALMITATE

INJECTABLE;INJECTION

AQUASOL A

	+	HOSPIRA	EQ 50,000 UNITS BASE/ML	N006823	001	
--	---	---------	-------------------------	---------	-----	--

VORAPAXAR SULFATE

TABLET;ORAL

ZONTIVITY

	+	MERCK SHARP DOHME	EQ 2.08MG BASE	N204886	001	May 08, 2014
--	---	-------------------	----------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

VORICONAZOLE

FOR SUSPENSION;ORAL

VFENDAB + PF PRISM CV 200MG/5ML N021630 001 Dec 19, 2003VORICONAZOLEAB MYLAN PHARMS INC 200MG/5ML A202361 001 May 28, 2013  
INJECTABLE;IV (INFUSION)VFENDAP + PF PRISM CV 200MG/VIAL N021267 001 May 24, 2002VORICONAZOLEAP SANDOZ INC 200MG/VIAL A090862 001 May 30, 2012  
TABLET;ORALVFENDAB PF PRISM CV 50MG N021266 001 May 24, 2002AB + 200MG N021266 002 May 24, 2002VORICONAZOLEAB GLENMARK PHARMS LTD 50MG A203503 001 Sep 02, 2015AB 200MG A203503 002 Sep 02, 2015AB MYLAN PHARMS INC 50MG A090547 001 Apr 22, 2010AB 200MG A090547 002 Apr 22, 2010AB SANDOZ INC 50MG A200265 001 Dec 12, 2011AB 200MG A200265 002 Dec 12, 2011AB TEVA PHARMS 50MG A091658 001 Apr 06, 2012AB 200MG A091658 002 Apr 06, 2012VORINOSTAT

CAPSULE;ORAL

ZOLINZA+ MERCK 100MG N021991 001 Oct 06, 2006VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

BRINTELLIXTAKEDA PHARMS USA EQ 5MG BASE N204447 001 Sep 30, 2013EQ 10MG BASE N204447 002 Sep 30, 2013EQ 15MG BASE N204447 003 Sep 30, 2013+ EQ 20MG BASE N204447 004 Sep 30, 2013WARFARIN SODIUM

TABLET;ORAL

COUMADINAB BRISTOL MYERS SQUIBB 1MG N009218 022 Mar 01, 1990AB 2MG N009218 013AB 2.5MG N009218 018AB 3MG N009218 025 Nov 18, 1996AB 4MG N009218 023 Aug 24, 1993AB 5MG N009218 007AB 6MG N009218 026 Nov 18, 1996AB 7.5MG N009218 016AB + 10MG N009218 005JANTOVENAB USL PHARMA 1MG A040416 001 Oct 02, 2003AB 2MG A040416 002 Oct 02, 2003AB 2.5MG A040416 003 Oct 02, 2003AB 3MG A040416 004 Oct 02, 2003AB 4MG A040416 005 Oct 02, 2003AB 5MG A040416 006 Oct 02, 2003AB 6MG A040416 007 Oct 02, 2003AB 7.5MG A040416 008 Oct 02, 2003AB 10MG A040416 009 Oct 02, 2003WARFARIN SODIUMAB AMNEAL PHARMS 1MG A202202 001 Mar 04, 2013AB 2MG A202202 002 Mar 04, 2013AB 2.5MG A202202 003 Mar 04, 2013AB 3MG A202202 004 Mar 04, 2013AB 4MG A202202 005 Mar 04, 2013AB 5MG A202202 006 Mar 04, 2013AB 6MG A202202 007 Mar 04, 2013AB 7.5MG A202202 008 Mar 04, 2013AB 10MG A202202 009 Mar 04, 2013AB BARR 1MG A040145 001 Mar 26, 1997AB 2MG A040145 002 Mar 26, 1997AB 2.5MG A040145 003 Mar 26, 1997AB 3MG A040145 008 Nov 05, 1998

## PRESCRIPTION DRUG PRODUCT LIST

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>		<u>4MG</u>	<u>A040145 004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145 005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145 009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145 006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145 007</u>	Mar 26, 1997
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090935 001</u>	May 25, 2011
<u>AB</u>		<u>2MG</u>	<u>A090935 002</u>	May 25, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090935 003</u>	May 25, 2011
<u>AB</u>		<u>3MG</u>	<u>A090935 004</u>	May 25, 2011
<u>AB</u>		<u>4MG</u>	<u>A090935 005</u>	May 25, 2011
<u>AB</u>		<u>5MG</u>	<u>A090935 006</u>	May 25, 2011
<u>AB</u>		<u>6MG</u>	<u>A090935 007</u>	May 25, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A090935 008</u>	May 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090935 009</u>	May 25, 2011
<u>AB</u>	IPCA LABS LTD	<u>1MG</u>	<u>A200104 001</u>	Jun 27, 2013
<u>AB</u>		<u>2MG</u>	<u>A200104 002</u>	Jun 27, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A200104 003</u>	Jun 27, 2013
<u>AB</u>		<u>3MG</u>	<u>A200104 004</u>	Jun 27, 2013
<u>AB</u>		<u>4MG</u>	<u>A200104 005</u>	Jun 27, 2013
<u>AB</u>		<u>5MG</u>	<u>A200104 006</u>	Jun 27, 2013
<u>AB</u>		<u>6MG</u>	<u>A200104 007</u>	Jun 27, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200104 008</u>	Jun 27, 2013
<u>AB</u>		<u>10MG</u>	<u>A200104 009</u>	Jun 27, 2013
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A040415 001</u>	Sep 27, 2004
<u>AB</u>		<u>2MG</u>	<u>A040415 002</u>	Sep 27, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040415 003</u>	Sep 29, 2004
<u>AB</u>		<u>3MG</u>	<u>A040415 004</u>	Sep 27, 2004
<u>AB</u>		<u>4MG</u>	<u>A040415 005</u>	Sep 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A040415 006</u>	Sep 27, 2004
<u>AB</u>		<u>6MG</u>	<u>A040415 007</u>	Sep 27, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A040415 008</u>	Sep 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A040415 009</u>	Sep 27, 2004
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616 009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616 001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616 002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616 003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616 004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616 005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616 006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616 007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616 008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301 002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301 003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301 004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301 005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301 006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301 007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301 008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301 009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301 001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663 001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663 002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663 003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663 004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663 005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663 006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663 007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663 008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663 009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

<u>AA</u>	LANTHEUS MEDCL	<u>20mCi/VIAL</u>	<u>N017284 002</u>	
		10mCi/VIAL	N017284 001	

## PRESCRIPTION DRUG PRODUCT LIST

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	PAR PHARM INC	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996

ZAFIRLUKAST

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	PFIZER	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999

ZALEPLON

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>	HIKMA PHARMS LLC	<u>5MG</u>	<u>A078147</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>10MG</u>	<u>A078147</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077238</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077238</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077239</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077239</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UPSHER SMITH	<u>5MG</u>	<u>A078706</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078706</u>	<u>002</u>	Jun 06, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

+	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999
---	-----------------	-----	---------	-----	--------------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004

ZIDOVDINE

CAPSULE; ORAL

RETROVIR

<u>AB</u>	+	VIIV HLTHCARE	<u>100MG</u>	<u>N019655</u>	<u>001</u>	Mar 19, 1987
<u>AB</u>		<u>ZIDOVDINE</u>				
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A078128</u>	<u>001</u>	Mar 27, 2006	
<u>AB</u>	CIPLA LTD	<u>100MG</u>	<u>A078349</u>	<u>001</u>	May 23, 2007	

INJECTABLE; INJECTION

RETROVIR

<u>AP</u>	+	VIIV HLTHCARE	<u>10MG/ML</u>	<u>N019951</u>	<u>001</u>	Feb 02, 1990
<u>AP</u>		<u>ZIDOVDINE</u>				
<u>AP</u>	LUITPOLD	<u>10MG/ML</u>	<u>A091457</u>	<u>001</u>	May 06, 2010	

SYRUP; ORAL

RETROVIR

<u>AA</u>	+	VIIV HLTHCARE	<u>50MG/5ML</u>	<u>N019910</u>	<u>001</u>	Sep 28, 1989
<u>AA</u>		<u>ZIDOVDINE</u>				
<u>AA</u>	AUROBINDO	<u>50MG/5ML</u>	<u>A077268</u>	<u>001</u>	Sep 19, 2005	
<u>AA</u>	CIPLA LTD	<u>50MG/5ML</u>	<u>A077981</u>	<u>001</u>	Jun 26, 2008	

TABLET; ORAL

ZIDOVDINE

<u>AB</u>	AUROBINDO	<u>300MG</u>	<u>A077267</u>	<u>001</u>	Sep 19, 2005	
<u>AB</u>	CIPLA	<u>300MG</u>	<u>A090561</u>	<u>001</u>	Oct 27, 2010	
<u>AB</u>	+	HETERO LABS LTD III	<u>300MG</u>	<u>A090092</u>	<u>001</u>	Apr 25, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>300MG</u>	<u>A078922</u>	<u>001</u>	Feb 14, 2008	
<u>AB</u>	ROXANE	<u>300MG</u>	<u>A076844</u>	<u>001</u>	Sep 19, 2005	
<u>AB</u>	SUNSHINE LAKE	<u>300MG</u>	<u>A202058</u>	<u>001</u>	Oct 07, 2011	

## PRESCRIPTION DRUG PRODUCT LIST

ZILEUTON

TABLET;ORAL

ZYFLO

+ CHIESI USA INC 600MG N020471 003 Dec 09, 1996

TABLET, EXTENDED RELEASE;ORAL

ZYFLO CR

+ CHIESI USA INC 600MG N022052 001 May 30, 2007

ZINC ACETATE

CAPSULE;ORAL

GALZIN

TEVA

EQ 25MG ZINC N020458 001 Jan 28, 1997

+ EQ 50MG ZINC N020458 002 Jan 28, 1997

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 1MG ZINC/ML N018959 001 Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

<b>AB</b>	+	PFIZER	<b>EQ 20MG BASE</b>	<b>N020825 001</b>	Feb 05, 2001
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>N020825 002</b>	Feb 05, 2001
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>N020825 003</b>	Feb 05, 2001
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>N020825 004</b>	Feb 05, 2001

ZIPRASIDONE HYDROCHLORIDE

<b>AB</b>		APOTEX CORP	<b>EQ 20MG BASE</b>	<b>A077561 001</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A077561 002</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A077561 003</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A077561 004</b>	Mar 02, 2012
<b>AB</b>		DR REDDYS LABS INC	<b>EQ 20MG BASE</b>	<b>A077565 001</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A077565 002</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A077565 003</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A077565 004</b>	Mar 02, 2012
<b>AB</b>		LUPIN PHARMS	<b>EQ 20MG BASE</b>	<b>A077560 001</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A077560 002</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A077560 003</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A077560 004</b>	Mar 02, 2012
<b>AB</b>		MYLAN PHARMS INC	<b>EQ 20MG BASE</b>	<b>A202395 001</b>	Oct 10, 2013
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A202395 002</b>	Oct 10, 2013
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A202395 003</b>	Oct 10, 2013
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A202395 004</b>	Oct 10, 2013
<b>AB</b>		SANDOZ INC	<b>EQ 20MG BASE</b>	<b>A077562 001</b>	Jun 01, 2012
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A077562 002</b>	Jun 01, 2012
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A077562 003</b>	Jun 01, 2012
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A077562 004</b>	Jun 01, 2012
<b>AB</b>		WOCKHARDT LTD	<b>EQ 20MG BASE</b>	<b>A090348 001</b>	Sep 05, 2012
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A090348 002</b>	Sep 05, 2012
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A090348 003</b>	Sep 05, 2012
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A090348 004</b>	Sep 05, 2012

ZIPRASIDONE MESYLATE

INJECTABLE;INTRAMUSCULAR

GEODON

+ PFIZER EQ 20MG BASE/ML N020919 001 Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

RECLAST

<b>AP</b>	+	NOVARTIS	<b>EQ 5MG BASE/100ML</b>	<b>N021817 001</b>	Apr 16, 2007
-----------	---	----------	--------------------------	--------------------	--------------

ZOLEDRONIC ACID

<b>AP</b>		ACS DOBFAR INFO SA	<b>EQ 4MG BASE/100ML</b>	<b>N203231 001</b>	Aug 02, 2013
<b>AP</b>			<b>EQ 5MG BASE/100ML</b>	<b>A202828 001</b>	Sep 23, 2013
<b>AP</b>		ACTAVIS INC	<b>EQ 4MG BASE/5ML</b>	<b>A202472 001</b>	Mar 04, 2013
<b>AP</b>		AKORN	<b>EQ 5MG BASE/100ML</b>	<b>A200918 001</b>	Aug 21, 2014
<b>AP</b>		AKORN INC	<b>EQ 4MG BASE/5ML</b>	<b>A202548 001</b>	May 22, 2014
<b>AP</b>		APOTEX INC	<b>EQ 5MG BASE/100ML</b>	<b>A204367 001</b>	Dec 24, 2015
<b>AP</b>		DR REDDYS LABS LTD	<b>EQ 4MG BASE/5ML</b>	<b>A091186 001</b>	Mar 04, 2013
<b>AP</b>			<b>EQ 5MG BASE/100ML</b>	<b>A091363 001</b>	Mar 29, 2013
<b>AP</b>		EMCURE PHARMS LTD	<b>EQ 4MG BASE/5ML</b>	<b>A201783 001</b>	Mar 12, 2013
<b>AP</b>			<b>EQ 5MG BASE/100ML</b>	<b>A201801 001</b>	Mar 29, 2013
<b>AP</b>		FRESENIUS KABI USA	<b>EQ 4MG BASE/5ML</b>	<b>A091516 001</b>	Apr 23, 2015
<b>AP</b>		GLAND PHARMA LTD	<b>EQ 4MG BASE/5ML</b>	<b>A202930 001</b>	Aug 05, 2013
<b>AP</b>		HIKMA FARMACEUTICA	<b>EQ 4MG BASE/5ML</b>	<b>A202182 001</b>	Jun 03, 2013

## PRESCRIPTION DRUG PRODUCT LIST

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOLEDRONIC ACID

<u>AP</u>	HOSPIRA INC	<u>EQ 4MG BASE/5ML</u>	<u>A090621 001</u>	Mar 19, 2015
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202837 001</u>	Apr 05, 2013
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202650 001</u>	Mar 04, 2013
<u>AP</u>	PHARMACEUTICS	<u>EQ 4MG BASE/5ML</u>	<u>A091170 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163 001</u>	Aug 05, 2013
<u>AP</u>	PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A202571 001</u>	May 07, 2013
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091493 001</u>	Nov 24, 2014
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>EQ 4MG BASE/VIAL</u>	<u>A090018 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 4MG BASE/5ML</u>	<u>A202746 001</u>	Mar 04, 2013
<u>AP</u>	USV NORTH AMERICA	<u>EQ 4MG BASE/5ML</u>	<u>A202923 001</u>	Sep 04, 2014

ZOMETA

<u>AP</u>	+ NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N021223 002</u>	Mar 07, 2003
<u>AP</u>		<u>EQ 4MG BASE/100ML</u>	<u>N021223 003</u>	Jun 17, 2011

SOLUTION; IV (INFUSION)

ZOLEDRONIC ACID

HOSPIRA INC

EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)

N204016 001 Dec 28, 2015

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

ASTRAZENECA

2.5MG/SPRAY

N021450 003 Sep 16, 2013

+

5MG/SPRAY

N021450 004 Sep 30, 2003

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A204232 001</u>	Sep 30, 2015
<u>AB</u>		<u>5MG</u>	<u>A204232 002</u>	Sep 30, 2015
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202078 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202078 002</u>	May 14, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A201779 002</u>	May 14, 2013
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A204284 001</u>	Apr 09, 2014
<u>AB</u>		<u>5MG</u>	<u>A204284 002</u>	Apr 09, 2014
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202279 001</u>	Nov 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A202279 002</u>	Nov 20, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A203772 001</u>	Sep 30, 2015
<u>AB</u>		<u>5MG</u>	<u>A203772 002</u>	Sep 30, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A203186 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A203186 002</u>	May 14, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>2.5MG</u>	<u>A203476 001</u>	Nov 13, 2014
<u>AB</u>		<u>5MG</u>	<u>A203476 002</u>	Nov 13, 2014
<u>AB</u>	TEVA PHARMS USA	<u>2.5MG</u>	<u>A090861 001</u>	Mar 04, 2014
<u>AB</u>		<u>5MG</u>	<u>A090861 002</u>	Mar 04, 2014

ZOMIG

<u>AB</u>	IPR	<u>2.5MG</u>	<u>N020768 001</u>	Nov 25, 1997
<u>AB</u>		<u>5MG</u>	<u>N020768 002</u>	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202476 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202476 002</u>	May 14, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A202560 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202560 002</u>	May 14, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202956 001</u>	Sep 17, 2015
<u>AB</u>		<u>5MG</u>	<u>A202956 002</u>	Sep 17, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A204336 001</u>	Oct 22, 2015
<u>AB</u>		<u>5MG</u>	<u>A204336 002</u>	Oct 22, 2015
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG</u>	<u>A202890 001</u>	May 15, 2013
<u>AB</u>		<u>5MG</u>	<u>A202890 002</u>	May 15, 2013

ZOMIG-ZMT

<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N021231 001</u>	Feb 13, 2001
<u>AB</u>		<u>5MG</u>	<u>N021231 002</u>	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED; ORAL

ZOLPIMIST

+ AMHERST PHARMS LLC

5MG/SPRAY

N022196 001 Dec 19, 2008

TABLET; ORAL

AMBIEN

<u>AB</u>	SANOFI AVENTIS US	<u>5MG</u>	<u>N019908 001</u>	Dec 16, 1992
<u>AB</u>		<u>10MG</u>	<u>N019908 002</u>	Dec 16, 1992

## PRESCRIPTION DRUG PRODUCT LIST

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077884</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077884</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078413</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>10MG</u>	<u>A078413</u>	<u>002</u>	May 04, 2007
<u>AB</u>	CARLSBAD	<u>5MG</u>	<u>A077990</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077990</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077388</u>	<u>001</u>	Jul 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077388</u>	<u>002</u>	Jul 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A078184</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>		<u>10MG</u>	<u>A078184</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>	LEK PHARMS DD	<u>5MG</u>	<u>A077322</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077322</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076578</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076578</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077214</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077214</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A077359</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077359</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A078055</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A078055</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076410</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076410</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A077903</u>	<u>001</u>	Aug 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A077903</u>	<u>002</u>	Aug 17, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A078616</u>	<u>001</u>	Nov 21, 2008
<u>AB</u>		<u>10MG</u>	<u>A078616</u>	<u>002</u>	Nov 21, 2008
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A078426</u>	<u>001</u>	May 15, 2007
<u>AB</u>		<u>10MG</u>	<u>A078426</u>	<u>002</u>	May 15, 2007

TABLET; SUBLINGUAL

INTERMEZZO

<u>AB</u>	PURDUE PHARMA	<u>1.75MG</u>	<u>N022328</u>	<u>001</u>	Nov 23, 2011
<u>AB</u>	+	<u>3.5MG</u>	<u>N022328</u>	<u>002</u>	Nov 23, 2011

ZOLPIDEM TARTRATE

<u>AB</u>	NOVEL LABS INC	<u>1.75MG</u>	<u>A204299</u>	<u>001</u>	Jun 03, 2015
<u>AB</u>		<u>3.5MG</u>	<u>A204299</u>	<u>002</u>	Jun 03, 2015
	EDLUAR				
	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009
	+	10MG	N021997	002	Mar 13, 2009

TABLET, EXTENDED RELEASE; ORAL

AMBIEN CR

<u>AB</u>	SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774</u>	<u>002</u>	Sep 02, 2005
<u>AB</u>	+	<u>12.5MG</u>	<u>N021774</u>	<u>001</u>	Sep 02, 2005

ZOLPIDEM TARTRATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>6.25MG</u>	<u>A078179</u>	<u>002</u>	Oct 13, 2010
<u>AB</u>		<u>12.5MG</u>	<u>A078179</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>6.25MG</u>	<u>A090153</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A090153</u>	<u>002</u>	Mar 25, 2013
<u>AB</u>	ANCHEN PHARMS	<u>6.25MG</u>	<u>A078148</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078148</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>	APOTEX INC	<u>6.25MG</u>	<u>A200266</u>	<u>001</u>	Sep 10, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A200266</u>	<u>002</u>	Sep 10, 2013
<u>AB</u>	LUPIN LTD	<u>6.25MG</u>	<u>A078970</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A078970</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>	SANDOZ	<u>6.25MG</u>	<u>A090107</u>	<u>001</u>	Jul 01, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A090107</u>	<u>002</u>	Jul 01, 2011
<u>AB</u>	SYNTHON PHARMS	<u>6.25MG</u>	<u>A078483</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078483</u>	<u>002</u>	Jun 06, 2011

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

<u>AB</u>	EISAI INC	<u>25MG</u>	<u>N020789</u>	<u>003</u>	Aug 22, 2003
<u>AB</u>		<u>50MG</u>	<u>N020789</u>	<u>002</u>	Aug 22, 2003
<u>AB</u>	+	<u>100MG</u>	<u>N020789</u>	<u>001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	BANNER LIFE SCIENCES	<u>25MG</u>	<u>A077813</u>	<u>001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813</u>	<u>002</u>	Aug 16, 2006

## PRESCRIPTION DRUG PRODUCT LIST

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

<u>AB</u>		<u>100MG</u>	<u>A077813</u>	<u>003</u>	Aug 16, 2006
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651</u>	<u>001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651</u>	<u>002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651</u>	<u>003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869</u>	<u>003</u>	May 31, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077637</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077637</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077637</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A077647</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077647</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077647</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634</u>	<u>002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634</u>	<u>003</u>	Mar 17, 2006
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A077636</u>	<u>003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625</u>	<u>001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625</u>	<u>003</u>	Oct 16, 2006



## OTC DRUG PRODUCT LIST

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS

120MG

N018060 001

325MG

A072344 001 Mar 27, 1992

325MG

N018060 003 Dec 18, 1986

650MG

A072237 001 Mar 27, 1992

650MG

N018060 002

ACETAMINOPHEN

PERRIGO NEW YORK

120MG

A070607 001 Apr 06, 1987

650MG

A070608 001 Dec 01, 1986

TARO PHARMS NORTH

120MG

N018337 003 Sep 12, 1983

325MG

N018337 002

+

650MG

N018337 001

INFANTS' FEVERALL

TARO PHARMS NORTH

80MG

N018337 004 Aug 26, 1992

NEOPAP

POLYMEDICA

120MG

N016401 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS

650MG

A076200 001 Mar 19, 2002

PERRIGO

650MG

A075077 001 Feb 25, 2000

SUN PHARM INDS LTD

650MG

A078569 001 Dec 14, 2011

TYLENOL

+ J AND J CONSUMER INC

650MG

N019872 001 Jun 08, 1994

+

650MG

N019872 002 Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO

250MG; 250MG; 65MG

A075794 001 Nov 26, 2001

EXCEDRIN (MIGRAINE)

+ NOVARTIS

250MG; 250MG; 65MG

N020802 001 Jan 14, 1998

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+ 3M

61%; 1%

N021074 001 Jun 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT

GUARDIAN DRUG

80MG; 20MG

A071793 001 Sep 04, 1987

GAVISCON

SANOFI AVENTIS US

80MG; 20MG

N018685 001 Dec 09, 1983

+

160MG; 40MG

N018685 002 Dec 09, 1983

ASPIRIN

CAPSULE; ORAL

ASPIRIN

+ PLX PHARMA

325MG

N203697 001 Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+ LOREAL USA

2%; 2%; 10%

N021502 001 Jul 21, 2006

CAPITAL SOLEIL 15

+ LOREAL USA

2%; 3%; 10%

N021501 001 Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL

ANTHELIOS 20

+ LOREAL USA

2%; 2%; 10%; 2%

N021471 001 Oct 05, 2006

ANTHELIOS 40

+ LOREAL USA

2%; 3%; 10%; 5%

N022009 001 Mar 31, 2008

+

2%; 3%; 10%; 5%

N022009 002 Oct 29, 2009

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+ BAYER HEALTHCARE LLC

3%; 7.5%; 3%

N020045 001 Dec 07, 1992

## OTC DRUG PRODUCT LIST

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+ STAND HOMEOPATH 5% N020532 001 Aug 26, 1996

BUDESONIDE

SPRAY, METERED; NASAL

RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY N020746 003 Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1% N021307 001 Dec 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER 2% N020421 001 Dec 21, 1995

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG A077355 001 Feb 06, 2008

PEPCID COMPLETE

+ J AND J CONSUMER INC 800MG;10MG;165MG N020958 001 Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES 5MG N022429 001 Jul 23, 2009

+ 10MG N022429 004 Jul 23, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES 5MG N022429 003 Jul 23, 2009

+ 10MG N022429 002 Jul 23, 2009

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS 5MG/5ML A090765 002 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML A090750 002 Feb 02, 2010

BIO PHARM INC 5MG/5ML A090474 002 Mar 30, 2009

CYPRESS PHARM 5MG/5ML A090300 001 Oct 10, 2008

PERRIGO R AND D 5MG/5ML A204226 001 Sep 09, 2013

5MG/5ML A090254 002 Apr 09, 2008

SILARX 5MG/5ML A091130 001 Apr 22, 2011

SUN PHARM INDS INC 5MG/5ML A091327 001 Oct 17, 2011

TARO 5MG/5ML A090182 002 Apr 22, 2008

5MG/5ML A201546 001 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS 5MG/5ML A090765 001 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML A090750 001 Feb 02, 2010

BIO PHARM INC 5MG/5ML A090474 001 Mar 30, 2009

CYPRESS PHARM 5MG/5ML A090300 002 Oct 10, 2008

PERRIGO R AND D 5MG/5ML A090254 001 Apr 09, 2008

SILARX 5MG/5ML A091130 002 Apr 22, 2011

SUN PHARM INDS INC 5MG/5ML A091327 002 Oct 17, 2011

TARO 5MG/5ML A090182 001 Apr 22, 2008

5MG/5ML A201546 002 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 002 Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG/5ML N022155 002 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG/5ML N022155 001 Nov 16, 2007

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY 5MG A078780 001 Jan 21, 2010

10MG A078780 004 Jan 21, 2010

APOTEX INC 5MG A078317 001 Dec 27, 2007

10MG A078317 002 Dec 27, 2007

AUROBINDO PHARMA LTD 5MG A090760 001 Aug 05, 2015

10MG A090760 003 Aug 05, 2015

CADISTA PHARMS 5MG A078933 001 Jun 15, 2010

10MG A078933 002 Jun 15, 2010

CIPLA LTD 5MG A077318 001 Jul 25, 2013

10MG A077318 002 Jul 25, 2013

## OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

## TABLET;ORAL

## CETIRIZINE HYDROCHLORIDE ALLERGY

CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
	10MG	A202277	004	Mar 11, 2014
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

## CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009

## CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
	10MG	A090760	004	Aug 05, 2015
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

## ZYRTEC ALLERGY

J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007
+	10MG	N019835	004	Nov 16, 2007

## ZYRTEC HIVES RELIEF

J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007

## TABLET, CHEWABLE;ORAL

## CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015
	10MG	A091116	002	Feb 19, 2015
SANDOZ	5MG	A078692	001	Feb 14, 2008

## OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

+		10MG	A078692	002	Feb 14, 2008
	SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011
		10MG	A090142	002	Aug 30, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015
		10MG	A091116	004	Feb 19, 2015
	SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011
		10MG	A090142	004	Aug 30, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	PAR PHARM INC	10MG	A205490	001	Sep 02, 2015
	ZYRTEC ALLERGY				
+	J AND J CONSUMER INC	10MG	N022578	001	Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
	SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008
	SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
	ZYRTEC-D 12 HOUR				
+	J AND J CONSUMER INC	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+	XTTRIUM	4%	N019127	001	Dec 24, 1984
---	---------	----	---------	-----	--------------

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+	SAGE PRODS	2%	N021669	001	Apr 25, 2005
---	------------	----	---------	-----	--------------

SOLUTION;TOPICAL

BRIAN CARE

	SOAPCO	4%	A071419	001	Dec 17, 1987
--	--------	----	---------	-----	--------------

CHG SCRUB

	ECOLAB	4%	N019258	002	Jul 22, 1986
--	--------	----	---------	-----	--------------

CIDA-STAT

	ECOLAB	2%	N019258	001	Jul 22, 1986
--	--------	----	---------	-----	--------------

DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997
--	-------------------	-------	---------	-----	--------------

EXIDINE

+	XTTRIUM	2%	N019422	001	Dec 17, 1985
		4%	N019125	001	Dec 24, 1984

HIBICLENS

+	MOLNLYCKE HLTH	4%	N017768	001	
---	----------------	----	---------	-----	--

HIBISTAT

+	MOLNLYCKE HLTH	0.5%	N018300	001	
---	----------------	------	---------	-----	--

SPONGE;TOPICAL

BIOSCRUB

	GRIFFEN	4%	N019822	001	Mar 31, 1989
--	---------	----	---------	-----	--------------

CHLORHEXIDINE GLUCONATE

	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989
--	------------------	----	---------	-----	--------------

PHARMASEAL SCRUB CARE

+	CAREFUSION	4%	N019793	001	Dec 02, 1988
---	------------	----	---------	-----	--------------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+	CAREFUSION	2%;70% (3ML)	N020832	001	Jul 14, 2000
+		2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+		2%;70% (26ML)	N020832	006	Nov 21, 2006

CHLORAPREP ONE-STEP FREPP

+	CAREFUSION	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
---	------------	----------------	---------	-----	--------------

CHLORAPREP WITH TINT

+	CAREFUSION	2%;70% (26ML)	N020832	002	May 03, 2005
+		2%;70% (10.5ML)	N020832	005	Apr 03, 2006
+		2%;70% (3ML)	N020832	007	Oct 10, 2006

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+	CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
---	------------	-----------------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP SINGLE SWABSTICK				
+ CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005
CHLORAPREP TRIPLE SWABSTICK				
+ CAREFUSION	2%;70% (5.25ML)	N021555	003	Jun 10, 2009
PREVANTICS MAXI SWABSTICK				
+ PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
PREVANTICS SWAB				
+ PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
PREVANTICS SWABSTICK				
+ PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON				
+ BAYER HEALTHCARE LLC	12MG	N007638	002	
CHLORPHENIRAMINE MALEATE				
AVANTHI INC	12MG	A040829	001	May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY AND CONGESTION RELIEF				
+ PFIZER	4MG;200MG;10MG	N022113	001	Dec 21, 2011

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS				
+ PFIZER	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004

TABLET; ORAL

ADVIL ALLERGY SINUS				
+ PFIZER	2MG;200MG;30MG	N021441	001	Dec 19, 2002

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON				
+ BAYER HEALTHCARE LLC	8MG;120MG	N018397	001	

CIMETIDINE

TABLET; ORAL

CIMETIDINE				
APOTEX	100MG	A074948	001	Jun 19, 1998
	200MG	A074948	002	Jul 26, 2002
CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998
	200MG	A074963	001	Jun 19, 1998
IVAX SUB TEVA PHARMS	200MG	A075345	001	Jun 16, 1999
PERRIGO	200MG	A075285	001	Oct 29, 1998
TAGAMET HB				
+ MEDTECH PRODUCTS	200MG	N020238	002	Aug 21, 1996

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE				
PERRIGO	1.34MG	A074512	001	Nov 22, 1995
SANDOZ	1.34MG	A073458	001	Oct 31, 1993
TAVIST-1				
+ NOVARTIS	1.34MG	N020925	001	Aug 21, 1992

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE				
ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993
TARO	1%	A072641	001	Dec 04, 1995
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	1%	N018230	002	Dec 26, 1991
TRIVAGIZOLE 3				
TARO	2%	N021143	001	Apr 12, 2000
CREAM, TABLET; TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ BAYER HEALTHCARE LLC	200MG;200MG	N020526	002	Jul 29, 1996

## OTC DRUG PRODUCT LIST

CLOTRIMAZOLE

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC 100MG;100MG

N020289 002 Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER HEALTHCARE LLC 1%;100MG

N020389 002 Jun 23, 1994

TABLET;VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 100MG

N017717 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG

N020525 001 Jul 29, 1996

MYCELEX-7

BAYER HEALTHCARE LLC 100MG

N018182 002 Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

+ BAUSCH AND LOMB 5.2MG/SPRAY

A075702 001 Jul 03, 2001

PERRIGO 5.2MG/SPRAY

A075427 001 Dec 12, 2001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC 6MG;120MG

A078648 001 Feb 27, 2013

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL INC 30MG;600MG

A091070 001 Aug 31, 2015

60MG;1.2GM

A091070 002 Aug 31, 2015

MUCINEX DM

RECKITT BENCKISER 30MG;600MG

N021620 002 Apr 29, 2004

+ 60MG;1.2GM

N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+ RECKITT BENCKISER EQ 30MG HBR/5ML

N018658 001 Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC EQ 30MG HBR/5ML

A091135 001 May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+ PFIZER 38MG;200MG

N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

DR REDDYS LABS LTD 38MG;200MG

A090619 001 Jul 08, 2009

PERRIGO R AND D 38MG;200MG

A079113 001 Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+ PFIZER 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

N021393 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

A090397 001 Nov 22, 2010

STRIDES PHARMA 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

A200888 001 Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE 25MG;220MG

N205352 001 Jan 17, 2014

DOCOSANOL

CREAM;TOPICAL

ABREVA

+ GLAXOSMITHKLINE 10%

N020941 001 Jul 25, 2000

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

LNK 25MG

A040564 001 Aug 27, 2004

PERRIGO 25MG

A040167 001 Sep 18, 1996

UNISOM

+ CHATTEM 25MG

N018066 001

## OTC DRUG PRODUCT LIST

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM 24HR

+ ASTRAZENECA LP EQ 20MG BASE

N204655 001 Mar 28, 2014

TABLET, DELAYED RELEASE;ORAL

NEXIUM 24HR

+ ASTRAZENECA LP EQ 20MG BASE

N207920 01 Nov 23, 2015

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

DR REDDYS LABS LTD 10MG

A075758 001 Aug 17, 2001

20MG

A077367 001 Sep 25, 2006

IVAX SUB TEVA PHARMS 10MG

A075512 001 Jul 26, 2001

MYLAN 10MG

A075674 001 Dec 21, 2001

PERRIGO 10MG

A075400 001 Mar 18, 2005

20MG

A077351 001 Sep 25, 2006

SUN PHARM INDS LTD 10MG

A090283 001 Nov 17, 2009

20MG

A090283 002 Nov 17, 2009

TEVA 10MG

A075312 001 May 31, 2001

WOCKHARDT 10MG

A077146 001 Mar 07, 2005

20MG

A090837 001 Aug 04, 2010

PEPCID AC

J AND J CONSUMER INC 10MG

N020325 001 Apr 28, 1995

+ 20MG

N020325 002 Sep 23, 2003

PEPCID AC

J AND J CONSUMER INC 10MG

N020902 001 Aug 05, 1999

TABLET, CHEWABLE;ORAL

FAMOTIDINE

PERRIGO 10MG

A075715 001 Aug 22, 2003

PEPCID AC

+ J AND J CONSUMER INC 20MG

N020801 002 Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG/5ML

N201373 001 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG/5ML

N201373 002 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC 30MG/5ML

A203330 001 Nov 18, 2014

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

ACTAVIS MID ATLANTIC 30MG/5ML

A203330 002 Nov 18, 2014

TABLET;ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US 60MG

N020872 007 Jan 24, 2011

+ 180MG

N020872 010 Jan 24, 2011

ALLEGRA HIVES

SANOFI AVENTIS US 60MG

N020872 008 Jan 24, 2011

+ 180MG

N020872 009 Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US 30MG

N020872 005 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US 30MG

N020872 006 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC 30MG

A202039 001 Nov 19, 2014

DR REDDYS LABS LTD 30MG

A076502 004 Apr 12, 2011

MYLAN 30MG

A077081 004 Jul 21, 2011

SUN PHARM INDS 30MG

A091567 002 Feb 06, 2012

TEVA 30MG

A076447 004 Apr 13, 2011

WOCKHARDT LTD 30MG

A079112 002 Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 30MG

A076502 005 Apr 12, 2011

MYLAN 30MG

A077081 005 Jul 21, 2011

SUN PHARM INDS 30MG

A091567 001 Feb 06, 2012

TEVA 30MG

A076447 005 Apr 13, 2011

WOCKHARDT LTD 30MG

A079112 001 Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC 60MG

A202039 002 Nov 19, 2014

180MG

A202039 003 Nov 19, 2014

DR REDDYS LABS LTD 60MG

A076502 006 Apr 12, 2011

180MG

A076502 008 Apr 12, 2011

MYLAN 60MG

A077081 006 Jul 21, 2011

## OTC DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

	180MG	A077081	008	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
	180MG	A204507	003	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
	180MG	A091567	006	Feb 06, 2012
TEVA	60MG	A076447	006	Apr 13, 2011
	180MG	A076447	008	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
	180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
	180MG	A076502	009	Apr 12, 2011
MYLAN	60MG	A077081	007	Jul 21, 2011
	180MG	A077081	009	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
	180MG	A204507	005	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
	180MG	A091567	005	Feb 06, 2012
TEVA	60MG	A076447	007	Apr 13, 2011
	180MG	A076447	009	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
	180MG	A079112	005	Feb 08, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011
---------------------	------	---------	-----	--------------

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011
---------------------	------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013
--------------------	------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013
--------------------	------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011
---------------------	------------	---------	-----	--------------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011
---------------------	-------------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	60MG;120MG	A076667	001	Nov 18, 2014
--------------------	------------	---------	-----	--------------

	180MG;240MG	A079043	002	Jun 22, 2011
--	-------------	---------	-----	--------------

SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015
-------------------	------------	---------	-----	--------------

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014
------------------------	--------------	---------	-----	--------------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

ACTAVIS LABS FL INC	1.2GM	A091009	002	Sep 03, 2015
---------------------	-------	---------	-----	--------------

PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011
-----------------	-------	---------	-----	--------------

MUCINEX

RECKITT BENCKISER	600MG	N021282	001	Jul 12, 2002
-------------------	-------	---------	-----	--------------

+	1.2GM	N021282	002	Dec 18, 2002
---	-------	---------	-----	--------------

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC	600MG;60MG	A091071	001	May 27, 2015
---------------------	------------	---------	-----	--------------

	1.2GM;120MG	A091071	002	May 27, 2015
--	-------------	---------	-----	--------------

MUCINEX D

RECKITT BENCKISER	600MG;60MG	N021585	001	Jun 22, 2004
-------------------	------------	---------	-----	--------------

+	1.2GM;120MG	N021585	002	Jun 22, 2004
---	-------------	---------	-----	--------------



## OTC DRUG PRODUCT LIST

IBUPROFEN

## CAPSULE;ORAL

ADVIL LIQUI-GELS

+ PFIZER

EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 001 Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+ PFIZER

EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 002 Mar 16, 2000

## IBUPROFEN

AMNEAL PHARMS

EQ 200MG FREE ACID AND POTASSIUM SALT

A202300 001 Dec 23, 2011

BANNER LIFE SCIENCES

EQ 200MG FREE ACID AND POTASSIUM SALT

A078682 001 Mar 24, 2009

+ CONTRACT PHARMACAL

200MG

A074782 001 Jul 06, 1998

MARKSANS PHARMA

EQ 200MG FREE ACID AND POTASSIUM SALT

A079205 001 Jun 26, 2009

P AND L DEV LLC

EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009

## MIDOL LIQUID GELS

+ BANNER LIFE SCIENCES

200MG

N021472 001 Oct 18, 2002

## SUSPENSION;ORAL

CHILDREN'S ADVIL

PFIZER

100MG/5ML

N020589 001 Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

PFIZER

100MG/5ML

N020589 002 Nov 07, 1997

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH

100MG/5ML

N021604 001 Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO

100MG/5ML

A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN

+ J AND J CONSUMER INC

100MG/5ML

N020516 001 Jun 16, 1995

## IBUPROFEN

ACTAVIS MID ATLANTIC

100MG/5ML

A074916 001 Apr 30, 1999

AMNEAL PHARMS

100MG/5ML

A200457 001 Aug 18, 2011

## SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+ J AND J CONSUMER INC

40MG/ML

N020603 001 Jun 10, 1996

## IBUPROFEN

PERRIGO

40MG/ML

A075217 001 Dec 16, 1998

TRIS PHARMA INC

40MG/ML

A079058 001 Aug 31, 2009

## PEDIATRIC ADVIL

+ PFIZER

100MG/2.5ML

N020812 001 Jan 30, 1998

## TABLET;ORAL

ADVIL

PFIZER

200MG

N018989 001 May 18, 1984

IBU-TAB 200

ALRA

200MG

A071057 001 Aug 11, 1988

## IBUPROFEN

AMNEAL PHARMS

200MG

A079233 001 Mar 18, 2014

AMNEAL PHARMS NY

200MG

A071333 001 Feb 17, 1987

200MG

A072199 001 May 23, 1988

AVEMA PHARMA

200MG

A076460 001 Nov 26, 2003

CONTRACT PHARMACAL

200MG

A071732 001 Sep 10, 1987

200MG

A071735 001 Sep 10, 1987

200MG

A072299 001 Jul 01, 1988

200MG

A074931 001 Jul 20, 1998

200MG

A075661 001 Dec 12, 2001

DR REDDYS LA

200MG

A076117 001 Nov 20, 2001

DR REDDYS LABS INC

100MG

A079174 001 Dec 10, 2010

GRANULES INDIA

200MG

A079174 001 Dec 10, 2010

LNK

100MG

A076741 001 Jun 17, 2004

200MG

A075010 001 Mar 01, 1999

200MG

A075139 001 Mar 01, 1999

MARKSANS PHARMA

200MG

A091237 001 Feb 08, 2011

200MG

A091239 001 Feb 01, 2011

MCNEIL

200MG

A073019 001 Mar 30, 1994

MERRO PHARM

200MG

A070985 001 Oct 02, 1987

OHM

200MG

A071163 001 Jul 15, 1986

PAR PHARM

200MG

A070481 001 Sep 24, 1986

PERRIGO

200MG

A072096 001 Dec 08, 1987

200MG

A075995 001 Mar 14, 2002

PERRIGO R AND D

200MG

A077349 001 Jun 21, 2005

SVADS HOLDINGS SA

200MG

A079129 001 Mar 28, 2011

200MG

A091355 001 Apr 04, 2011

VINTAGE PHARMS

200MG

A071229 001 Apr 01, 1987

200MG

A071639 001 Feb 02, 1988

## IBUPROHM

OHM LABS

200MG

A071214 001 Dec 01, 1986

## OTC DRUG PRODUCT LIST

IBUPROFEN

## TABLET;ORAL

JUNIOR STRENGTH ADVIL PFIZER	100MG	N020267 002	Dec 13, 1996
JUNIOR STRENGTH IBUPROFEN PERRIGO	100MG	A075367 001	Apr 22, 1999
JUNIOR STRENGTH MOTRIN J AND J CONSUMER INC	100MG	N020602 001	Jun 10, 1996
MOTRIN IB + J AND J CONSUMER INC	200MG	N019012 003	Dec 17, 1990
PROFEN CONTRACT PHARMACAL	200MG	A071265 001	Oct 15, 1986
TAB-PROFEN PERRIGO	200MG	A072095 001	Dec 08, 1987
<u>TABLET, CHEWABLE;ORAL</u>			
CHILDREN'S ADVIL PFIZER	50MG	N020944 001	Dec 18, 1998
CHILDREN'S MOTRIN J AND J CONSUMER INC	50MG	N020601 001	Nov 15, 1996
IBUPROFEN PERRIGO	50MG 100MG	A076359 001 A076359 002	Jan 16, 2004 Jan 16, 2004
JUNIOR STRENGTH ADVIL PFIZER	100MG	N020944 002	Dec 18, 1998
JUNIOR STRENGTH MOTRIN + J AND J CONSUMER INC	100MG	N020601 003	Nov 15, 1996

IBUPROFEN SODIUM

## TABLET;ORAL

ADVIL + PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803 001	Jun 12, 2012
IBUPROFEN SODIUM PERRIGO R AND D	EQ 200MG BASE	A206581 001	Aug 03, 2015

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

## TABLET;ORAL

ADVIL CONGESTION RELIEF + PFIZER	200MG;10MG	N022565 001	May 27, 2010
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE PERRIGO R AND D	200MG;10MG	A203200 001	Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

## CAPSULE;ORAL

ADVIL COLD AND SINUS + PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374 001	May 30, 2002
----------------------------------	---	-------------	--------------

## SUSPENSION;ORAL

CHILDREN'S ADVIL COLD PFIZER	100MG/5ML;15MG/5ML	N021373 001	Apr 18, 2002
CHILDREN'S MOTRIN COLD + J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128 001	Aug 01, 2000
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE PERRIGO	100MG/5ML;15MG/5ML	A076478 001	Nov 05, 2003

## TABLET;ORAL

ADVIL COLD AND SINUS + PFIZER	200MG;30MG	N019771 001	Sep 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE CONTRACT PHARMACAL	200MG;30MG	A075588 001	Apr 08, 2002
DR REDDYS LABS LTD	200MG;30MG	A077628 001	Aug 14, 2006
IBUPROHM COLD AND SINUS OHM LABS	200MG;30MG	A074567 001	Apr 17, 2001
SINE-AID IB J AND J CONSUMER INC	200MG;30MG	N019899 001	Dec 31, 1992

INSULIN RECOMBINANT HUMAN

## INJECTABLE;INJECTION

HUMULIN R + LILLY	100 UNITS/ML	N018780 001	Oct 28, 1982
HUMULIN R PEN + LILLY	100 UNITS/ML	N018780 005	Aug 06, 1998
NOVOLIN R + NOVO NORDISK INC	100 UNITS/ML	N019938 001	Jun 25, 1991

## OTC DRUG PRODUCT LIST

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30

+ LILLY 30 UNITS/ML; 70 UNITS/ML N019717 001 Apr 25, 1989

HUMULIN 70/30 PEN

+ LILLY 30 UNITS/ML; 70 UNITS/ML N019717 002 Aug 06, 1998

NOVOLIN 70/30

+ NOVO NORDISK INC 30 UNITS/ML; 70 UNITS/ML N019991 001 Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N

+ LILLY 100 UNITS/ML N018781 001 Oct 28, 1982

NOVOLIN N

+ NOVO NORDISK INC 100 UNITS/ML N019959 001 Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+ 3M EQ 0.7% IODINE; 74% (6ML) N021586 001 Sep 29, 2006

+ EQ 0.7% IODINE; 74% (26ML) N021586 002 Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ JOHNSON AND JOHNSON 1% N020310 001 Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+ BAUSCH AND LOMB EQ 0.025% BASE N021996 001 Dec 01, 2006

EQ 0.035% BASE N021996 002 Feb 11, 2015

KETOTIFEN FUMARATE

AKORN EQ 0.025% BASE A077958 001 Jul 26, 2007

ALCON PHARMS LTD EQ 0.025% BASE A077200 001 Sep 02, 2008

ZADITOR

+ ALCON PHARMA EQ 0.025% BASE N021066 002 Oct 19, 2006

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD 15MG A202194 001 May 18, 2012

NATCO PHARMA LTD 15MG A203306 001 Jan 13, 2016

PERRIGO R AND D 15MG A202319 001 May 18, 2012

WOCKHARDT LTD 15MG A202727 001 May 18, 2012

PREVACID 24 HR

+ NOVARTIS 15MG N022327 001 May 18, 2009

LEVONORGESTREL

TABLET; ORAL

ATHENTIA NEXT

AUROBINDO PHARMA LTD 1.5MG A206867 001 Dec 08, 2015

FALLBACK SOLO

LUPIN LTD 1.5MG A201446 001 Jun 19, 2014

LEVONORGESTREL

JAI PHARMA LTD 1.5MG A202739 001 Oct 31, 2014

LOTUS PHARM CO LTD 1.5MG A202246 001 Jun 05, 2015

NOVEL LABS INC 1.5MG A202508 001 Feb 22, 2013

OC PHARMA 1.5MG A202380 001 May 29, 2015

PERRIGO R AND D 0.75MG A090740 001 Dec 30, 2010

1.5MG A202334 001 Aug 20, 2014

+ WATSON LABS 0.75MG A078665 001 Aug 28, 2009

WATSON LABS INC 1.5MG A200670 001 Jul 12, 2012

OPCICON ONE-STEP

SUN PHARM INDS LTD 1.5MG A202635 001 Sep 11, 2014

PLAN B

+ TEVA BRANDED PHARM 0.75MG N021045 002 Aug 24, 2006

PLAN B ONE-STEP

+ TEVA BRANDED PHARM 1.5MG N021998 001 Jul 10, 2009

## OTC DRUG PRODUCT LIST

LOPERAMIDE HYDROCHLORIDE

## CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE  
BANNER LIFE SCIENCES1MG  
2MGN021855 001 Aug 04, 2005  
N021855 002 Aug 04, 2005

+

## SOLUTION; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC

1MG/5ML

N019487 001 Mar 01, 1988

LOPERAMIDE HYDROCHLORIDE

HI TECH PHARMA

1MG/5ML

A074352 001 Nov 17, 1995

PERRIGO

1MG/5ML

A073243 001 Jan 21, 1992

ROXANE

1MG/5ML

A073079 001 Apr 30, 1992

WOCKHARDT

1MG/5ML

A074730 001 Aug 28, 1997

## SUSPENSION; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC

1MG/7.5ML

N019487 002 Jul 08, 2004

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D

1MG/7.5ML

A091292 001 May 20, 2011

## TABLET; ORAL

IMODIUM A-D

+ J AND J CONSUMER INC

2MG

N019860 001 Nov 22, 1989

LOPERAMIDE HYDROCHLORIDE

AUROBINDO PHARMA LTD

2MG

A206548 001 Dec 15, 2015

CONTRACT PHARMACAL

2MG

A073254 001 Jul 30, 1993

LNK

2MG

A076497 001 Jun 10, 2003

OHM LABS

2MG

A074091 001 Dec 10, 1992

PERRIGO

2MG

A075232 001 Jan 06, 2000

## TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC

2MG

N020448 001 Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

## TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC

2MG;125MG

N021140 001 Nov 30, 2000

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD

2MG;125MG

A077500 001 Sep 06, 2006

## TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC

2MG;125MG

N020606 001 Jun 26, 1996

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

PERRIGO

2MG;125MG

A076029 001 Aug 30, 2002

LORATADINE

## CAPSULE; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC

10MG

N021952 001 Jun 16, 2008

## SUSPENSION; ORAL

LORATADINE

+ TARO

1MG/ML

N021734 001 Oct 04, 2005

## SYRUP; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC

1MG/ML

N020641 002 Nov 27, 2002

LORATADINE

PERRIGO

1MG/ML

A075728 001 Aug 20, 2004

SILARX

1MG/ML

A077421 001 Jun 29, 2006

TARO

1MG/ML

A076805 001 Aug 20, 2004

TEVA

1MG/ML

A201865 001 Jul 31, 2015

WOCKHARDT

1MG/ML

A075505 001 Nov 07, 2003

A075815 001 Aug 20, 2004

## TABLET; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC

10MG

N019658 002 Nov 27, 2002

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC

10MG

N019658 003 Nov 19, 2003

LORATADINE

APOTEX INC

10MG

A076471 001 Feb 14, 2006

MYLAN

10MG

A075790 001 Nov 07, 2008

10MG

A076154 001 Aug 20, 2003

10MG

A078447 001 Aug 12, 2011

PERRIGO

10MG

A076301 001 Jan 25, 2004

SANDOZ

10MG

A075209 001 Jan 21, 2003

SUN PHARM INDS LTD

10MG

A076134 001 Aug 18, 2003

## OTC DRUG PRODUCT LIST

LORATADINE

TABLET, CHEWABLE;ORAL				
CHILDREN'S CLARITIN				
+ BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006
TABLET, ORALLY DISINTEGRATING;ORAL				
ALAVERT				
PFIZER	10MG	N021375	001	Dec 19, 2002
CLARITIN HIVES RELIEF REDITAB				
+ BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003
CLARITIN REDITABS				
+ BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006
+	10MG	N020704	002	Nov 27, 2002
LORATADINE				
ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003
IMPAX LABS	10MG	A076011	001	Sep 29, 2003
PFIZER	10MG	A075822	001	Feb 10, 2003
LORATADINE REDIDOSE				
SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
CLARITIN-D				
+ BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002
CLARITIN-D 24 HOUR				
+ BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002
LORATADINE AND PSEUDOEPHEDRINE SULFATE				
ACTAVIS LABS FL INC	10MG;240MG	A075706	001	Feb 21, 2003
IMPAX LABS	5MG;120MG	A076050	001	Jan 30, 2003
	10MG;240MG	A075989	001	Mar 04, 2004
SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL				
SALONPAS				
+ HISAMITSU PHARM CO	3%;10%	N022029	001	Feb 20, 2008
	3%;10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL				
MICONAZOLE 3 COMBINATION PACK				
PERRIGO	2%;4%	A076357	001	Mar 30, 2004
MONISTAT 3 COMBINATION PACK				
MEDTECH PRODUCTS	2%;4%	N021261	003	Jun 17, 2003
MONISTAT 3 COMBINATION PACK (PREFILLED)				
+ MEDTECH PRODUCTS	2%;4%	N021261	001	Feb 02, 2001
CREAM;VAGINAL				
MICONAZOLE 3				
TARO	4%	A076773	001	Mar 02, 2005
MICONAZOLE 7				
ACTAVIS MID ATLANTIC	2%	A074164	001	Mar 29, 1996
MICONAZOLE NITRATE				
G AND W LABS INC	2%	A074366	001	Feb 22, 1996
PERRIGO	2%	A074760	001	May 15, 1997
PERRIGO R AND D	4%	A091366	001	Jan 15, 2010
TARO	2%	A074444	001	Jan 13, 1997
MONISTAT 3				
+ MEDTECH PRODUCTS	4%	N020827	001	Mar 30, 1998
MONISTAT 7				
+ MEDTECH PRODUCTS	2%	N017450	002	Feb 15, 1991
CREAM, SUPPOSITORY;TOPICAL, VAGINAL				
M-ZOLE 3 COMBINATION PACK				
ACTAVIS MID ATLANTIC	2%;200MG	A074926	001	Apr 16, 1999
MICONAZOLE 7 COMBINATION PACK				
G AND W LABS	100MG;2%	A076585	001	Mar 26, 2004
MICONAZOLE NITRATE				
PERRIGO R AND D	1.2GM;2%	A079114	001	Jun 02, 2010
MICONAZOLE NITRATE COMBINATION PACK				
PERRIGO	200MG;200MG	A075329	001	Apr 20, 1999
MONISTAT 1 COMBINATION PACK				
+ MEDTECH PRODUCTS	1.2GM;2%	N021308	001	Jun 29, 2001
MONISTAT 7 COMBINATION PACK				
+ MEDTECH PRODUCTS	100MG;2%	N020288	002	Apr 26, 1993

## OTC DRUG PRODUCT LIST

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT-3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%;200MG

N020670 002 Apr 16, 1996

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC 100MG

A073507 001 Nov 19, 1993

G AND W LABS 100MG

A074414 001 Apr 30, 1997

+ PERRIGO 100MG

A074395 001 Mar 20, 1997

MONISTAT 7

+ MEDTECH PRODUCTS 100MG

N018520 002 Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 001 Jan 20, 2006

MINOXIDIL

PERRIGO ISRAEL 5%

A091344 001 Apr 28, 2011

WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC 2%

A074588 001 Apr 05, 1996

HI TECH PHARMA 2%

A074731 001 Dec 24, 1996

PERRIGO 2%

A075357 001 Jul 30, 1999

WOCKHARDT 2%

A074767 001 Feb 28, 1997

MINOXIDIL (FOR WOMEN)

HI TECH PHARMA 2%

A074731 002 May 11, 2005

PERRIGO 2%

A075357 002 Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC 5%

A075518 001 Nov 17, 2000

AVACOR PRODS 5%

A075619 001 Nov 17, 2000

PERRIGO 5%

A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5%

A075737 001 Mar 15, 2002

WOCKHARDT 5%

A075438 001 Feb 27, 2003

ROGAINE (FOR MEN)

+ JOHNSON AND JOHNSON 2%

N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+ JOHNSON AND JOHNSON 2%

N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+ JOHNSON AND JOHNSON 5%

N020834 001 Nov 14, 1997

THEROXIDIL

EI INC 2%

A078176 001 Nov 09, 2007

5%

A076239 001 Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC 0.025%;0.3%

A202795 001 Jan 24, 2013

ALTAIRE PHARMS INC 0.02675%;0.315%

A078208 001 Sep 27, 2010

NAPHCN-A

+ ALCON 0.025%;0.3%

N020226 001 Jun 08, 1994

OPCON-A

+ BAUSCH AND LOMB 0.02675%;0.315%

N020065 001 Jun 08, 1994

VISINE-A

+ JOHNSON AND JOHNSON 0.025%;0.3%

N020485 001 Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BANNER LIFE SCIENCES EQ 200MG BASE

N021920 001 Feb 17, 2006

TABLET;ORAL

ALEVE

+ BAYER EQ 200MG BASE

N020204 002 Jan 11, 1994

NAPROXEN SODIUM

AMNEAL PHARMS NY EQ 200MG BASE

A079096 001 Dec 16, 2008

CONTRACT PHARMACAL EQ 200MG BASE

A074635 001 Jan 13, 1997

EQ 200MG BASE

A074789 001 Feb 27, 1997

DR REDDYS LABS INC EQ 200MG BASE

A075168 001 Jul 28, 1998

GRANULES INDIA EQ 200MG BASE

A091353 001 Sep 20, 2011

MARKSANS PHARMA EQ 200MG BASE

A090545 001 Mar 16, 2011

PERRIGO EQ 200MG BASE

A074661 001 Jan 13, 1997

SUN PHARM INDS LTD EQ 200MG BASE

A091183 001 May 20, 2011

## OTC DRUG PRODUCT LIST

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS &amp; COLD

+ BAYER

200MG;120MG

N021076 001 Nov 29, 1999

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC

EQ 220MG BASE;120MG

A077381 001 Sep 27, 2006

PERRIGO

EQ 200MG BASE;120MG

A076518 001 Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+ DR REDDYS LABS INC

7MG/24HR

N020076 004 Nov 12, 1999

+

14MG/24HR

N020076 005 Nov 12, 1999

+

21MG/24HR

N020076 006 Nov 12, 1999

NICODERM CQ

+ SANOFI AVENTIS US

7MG/24HR

N020165 006 Aug 02, 1996

+

14MG/24HR

N020165 005 Aug 02, 1996

+

21MG/24HR

N020165 004 Aug 02, 1996

NICOTINE

AVEVA

7MG/24HR

A074612 002 Jul 28, 2003

14MG/24HR

A074612 003 Oct 20, 1997

21MG/24HR

A074612 001 Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

+ GLAXOSMITHKLINE

EQ 2MG BASE

N018612 002 Feb 09, 1996

EQ 2MG BASE

N018612 004 Sep 25, 2000

+

EQ 4MG BASE

N020066 002 Feb 09, 1996

EQ 4MG BASE

N020066 004 Sep 25, 2000

NICORETTE (MINT)

GLAXOSMITHKLINE

EQ 2MG BASE

N018612 003 Dec 23, 1998

EQ 4MG BASE

N020066 003 Dec 23, 1998

NICOTINE POLACRILEX

ACTAVIS LABS NY INC

EQ 2MG BASE

A074507 001 Mar 15, 1999

EQ 2MG BASE

A076569 001 Jul 29, 2004

EQ 2MG BASE

A078699 001 Dec 29, 2008

EQ 2MG BASE

A079216 001 Jul 08, 2009

EQ 4MG BASE

A074707 001 Mar 19, 1999

EQ 4MG BASE

A076568 002 Jul 29, 2004

EQ 4MG BASE

A078697 001 Dec 29, 2008

EQ 4MG BASE

A079038 001 Jul 08, 2009

EQ 4MG BASE

A079219 001 Jul 08, 2009

PERRIGO

EQ 2MG BASE

A076775 001 Sep 16, 2004

EQ 2MG BASE

A076776 001 Sep 16, 2004

EQ 2MG BASE

A076777 001 Sep 16, 2004

EQ 4MG BASE

A076778 001 Sep 16, 2004

EQ 4MG BASE

A076779 001 Sep 16, 2004

EQ 4MG BASE

A076789 001 Sep 16, 2004

PERRIGO R AND D

EQ 2MG BASE

A078325 001 Oct 30, 2006

EQ 2MG BASE

A078547 001 May 24, 2007

EQ 2MG BASE

A078967 001 Apr 23, 2008

EQ 2MG BASE

A091349 001 Jul 20, 2011

EQ 4MG BASE

A078326 001 Oct 30, 2006

EQ 4MG BASE

A078546 001 May 24, 2007

EQ 4MG BASE

A078968 001 Apr 23, 2008

EQ 4MG BASE

A091354 001 Jul 20, 2011

WATSON LABS

EQ 2MG BASE

A079044 001 Jul 08, 2009

THRIVE

NOVARTIS

EQ 2MG BASE

A077658 001 Jun 19, 2007

EQ 4MG BASE

A077656 001 Jun 19, 2007

TROCHE/LOZENGE;ORAL

COMMIT

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N021330 001 Oct 31, 2002

+

EQ 4MG BASE

N021330 002 Oct 31, 2002

NICORETTE

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N022360 001 May 18, 2009

+

EQ 4MG BASE

N022360 002 May 18, 2009

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE

A077007 001 Jan 31, 2006

EQ 2MG BASE

A090711 001 Jul 10, 2009

EQ 2MG BASE

A090821 001 Jul 10, 2009

EQ 2MG BASE

A203690 001 Oct 09, 2012

## OTC DRUG PRODUCT LIST

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

EQ 4MG BASE	A077007 002	Jan 31, 2006
EQ 4MG BASE	A090711 002	Jul 10, 2009
EQ 4MG BASE	A090821 002	Jul 10, 2009
EQ 4MG BASE	A203690 002	Oct 09, 2012

NIZATIDINE

TABLET;ORAL

AXID AR

+ PFIZER

75MG

N020555 001 May 09, 1996

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+ MAYER LABS INC

1GM

N018683 001 Apr 01, 1983

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+ DEXCEL PHARMA

20MG

N022032 001 Dec 04, 2007

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

+ DR REDDYS LABS LTD

EQ 20MG BASE

A078878 001 Jun 05, 2009

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

PERRIGO R AND D

EQ 20MG BASE

A204152 001 Jul 30, 2015

PRILOSEC OTC

+ ASTRAZENECA PHARMS

EQ 20MG BASE

N021229 001 Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+ BAYER HEALTHCARE LLC

20MG;1.1GM

N022281 001 Dec 01, 2009

FOR SUSPENSION;ORAL

ZEGERID OTC

+ BAYER HEALTHCARE LLC

20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013

ORLISTAT

CAPSULE;ORAL

ALLI

+ GLAXOSMITHKLINE CONS

60MG

N021887 001 Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ BAYER HEALTHCARE LLC

3.9MG/24HR

N202211 001 Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

BAYER HEALTHCARE LLC

0.025%

N018471 001 May 30, 1986

VISINE L.R.

+ JOHNSON AND JOHNSON

0.025%

N019407 001 Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL

NIX

+ MEDTECH PRODUCTS

1%

N019918 001 May 02, 1990

PERMETHRIN

ACTAVIS MID ATLANTIC

1%

A075014 001 Mar 28, 2000

PERRIGO NEW YORK

1%

A076090 001 Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

KREMERS URBAN PHARMS

17GM/PACKET

A090600 001 Oct 06, 2009

17GM/SCOOPFUL

A090600 002 Oct 06, 2009

MIRALAX

+ BAYER HEALTHCARE LLC

17GM/SCOOPFUL

N022015 001 Oct 06, 2006

POLYETHYLENE GLYCOL 3350

ANI PHARMS INC

17GM/SCOOPFUL

A202850 001 Dec 15, 2015

MYLAN

17GM/PACKET

A078915 001 Oct 06, 2009

17GM/SCOOPFUL

A078915 002 Oct 06, 2009



## OTC DRUG PRODUCT LIST

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

NEXGEN PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
PAR PHARM	17GM/SCOOPFUL	A079214	001	Jan 31, 2013
PERRIGO R AND D	17GM/PACKET	A090685	001	Oct 06, 2009
	17GM/SCOOPFUL	A090685	002	Oct 06, 2009
RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012

POTASSIUM IODIDE

SOLUTION;ORAL

THYROSHIELD

+ ARCO PHARMS LLC	65MG/ML	A077218	001	Jan 12, 2005
-------------------	---------	---------	-----	--------------

TABLET;ORAL

IOSAT

ANBEX	65MG	N018664	002	May 12, 2011
-------	------	---------	-----	--------------

	130MG	N018664	001	Oct 14, 1982
--	-------	---------	-----	--------------

THYROSAFE

+ RECIP	65MG	A076350	001	Sep 10, 2002
---------	------	---------	-----	--------------

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+ ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989
-----------------------	----	---------	-----	--------------

SPONGE;TOPICAL

E-Z SCRUB 201

+ BECTON DICKINSON	20%	N019240	001	Nov 29, 1985
--------------------	-----	---------	-----	--------------

E-Z SCRUB 241

+ BECTON DICKINSON	10%	N019476	001	Jan 07, 1987
--------------------	-----	---------	-----	--------------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO	120MG	A075153	001	Feb 26, 1999
---------	-------	---------	-----	--------------

SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005
--------------------	-------	---------	-----	--------------

SUDAFED 12 HOUR

+ MCNEIL CONS	120MG	A073585	001	Oct 31, 1991
---------------	-------	---------	-----	--------------

SUDAFED 24 HOUR

+ J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992
------------------------	-------	---------	-----	--------------

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

+ SCHERING PLOUGH	120MG	N018191	001	
-------------------	-------	---------	-----	--

PURIFIED WATER

SOLUTION;OPHTHALMIC

PUR-WASH

+ NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011
------------------	-------	---------	-----	--------------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE	A200172	001	May 31, 2012
------------	---------------	---------	-----	--------------

CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
--------------------	--------------	---------	-----	--------------

DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
--------------------	--------------	---------	-----	--------------

	EQ 150MG BASE	A078192	001	Aug 31, 2007
--	---------------	---------	-----	--------------

IVAX SUB TEVA PHARMS	EQ 75MG BASE	A075296	001	Jan 14, 2000
----------------------	--------------	---------	-----	--------------

MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
-------	--------------	---------	-----	--------------

PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
---------	--------------	---------	-----	--------------

PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
-----------------	---------------	---------	-----	--------------

	EQ 150MG BASE	A091429	002	May 11, 2011
--	---------------	---------	-----	--------------

SHASUN CHEMS	EQ 75MG BASE	A201745	001	Feb 29, 2012
--------------	--------------	---------	-----	--------------

SVADS HOLDINGS SA	EQ 150MG BASE	A200536	001	Jun 28, 2011
-------------------	---------------	---------	-----	--------------

TORPHARM	EQ 75MG BASE	A075167	001	May 04, 2000
----------	--------------	---------	-----	--------------

WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
-----------	--------------	---------	-----	--------------

ZANTAC 150

+ BOEHRINGER INGELHEIM	EQ 150MG BASE	N021698	001	Aug 31, 2004
------------------------	---------------	---------	-----	--------------

	EQ 150MG BASE	N021698	002	Mar 13, 2007
--	---------------	---------	-----	--------------

ZANTAC 75

BOEHRINGER INGELHEIM	EQ 75MG BASE	N020520	001	Dec 19, 1995
----------------------	--------------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE

+ BLAIREX

0.9%

N019912 001 Sep 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE

0.24%; 0.3%

N020231 001 Jul 11, 1997

TERBINAFINE

GEL; TOPICAL

LAMISIL AT

+ NOVARTIS

1%

N021958 001 Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

+ NOVARTIS

1%

N020980 001 Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO

1%

A077511 001 Jul 02, 2007

SOLUTION; TOPICAL

LAMISIL AT

+ NOVARTIS

1%

N021124 001 Mar 17, 2000

SPRAY; TOPICAL

LAMISIL AT

+ NOVARTIS

1%

N021124 002 Mar 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL

TIOCONAZOLE

PERRIGO

6.5%

A075915 001 Nov 21, 2001

VAGISTAT-1

+ NOVARTIS

6.5%

N020676 001 Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

NASACORT ALLERGY 24 HOUR

+ SANOFI AVENTIS US

0.055MG/SPRAY

N020468 002 Oct 11, 2013

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS

N760305

Jun 30, 1978

MANUFACTURING INC

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

NONE

HAEMONETICS

A710497

Nov 06, 1987

MANUFACTURING INC

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N160918

Mar 17, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL

A110057

May 11, 2012

SYSTEMS, INC

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS

N800077

Nov 06, 1980

MANUFACTURING INC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER  
FENWAL INC

N900223 Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER  
FENWAL INC

N900224 Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD  
COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS

N040083 Nov 21, 2005

NONE

TERUMO BCT INC

A070025 Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401 Dec 06, 1977

N811012 Jun 28, 1983

HAEMONETICS

N800222 Aug 23, 1982

MANUFACTURING INC

TERUMO MEDICAL CORP

N781211 Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:  
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION  
FENWAL INC

N811104 May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:  
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION  
TERUMO MEDICAL CORP

N880217 Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:  
AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;  
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS 0.042GM/100ML;0.276GM/100ML;

N820915 Oct 19, 1984

MANUFACTURING INC 0.410GM/100ML;0.30GM/100ML;  
1.10GM/100ML;0.588GM/100ML

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:  
AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;  
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP 0.042GM/100ML;0.285GM/100ML;  
0.718GM/100ML;0.017GM/100ML;  
0.396GM/100ML;0.588GM/100ML

N820915 Sep 22, 1983

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS  
CORPORATION

N980123

Mar 03, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL  
LABORATORIES INC

N010409

Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

TERUMO MEDICAL CORP

N770923

Jan 20, 1978

N781214

Feb 08, 1980

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715

Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC 10GM/100ML;5GM/100ML

A720563

Oct 30, 1992

NONE

B BRAUN MEDICAL INC 10GM/100ML;5GM/100ML

N160767

Apr 06, 1970

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC 10GM/100ML;0.9GM/100ML

A720562

Oct 30, 1992

NONE

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML

N160767

Apr 06, 1970

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

NONE

B BRAUN MEDICAL INC 6GM/100ML;0.9 GM/100ML

N090024

Aug 18, 1969

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC 6GM/100ML

N200952

Mar 31, 1999

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC 6GM/100ML;0.9GM/100ML A740193 Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML N890105 Apr 04, 1991

NONE

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML A740283 Oct 21, 1998

TEVA PARENTERAL 6GM/100ML;0.9GM/100ML A740592 Nov 12, 1998

MEDICINES INC

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE  
INFUSED DIRECTLY TO THE PATIENT.

NONE

B. BRAUN MEDICAL A110013 Jan 09, 2015

VOLUVEN

FRESENIUS KABI 6GM/100ML;0.9GM/100ML N070012 Dec 27, 2007  
DEUTSCHLAND GMBHISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINERSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE  
INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION

HAEMONETICS CORP N90067 Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND  
SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL

HAEMONETICS CORP N110059 Apr 25, 2013

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

PENTASPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML N890104 Apr 04, 1991

RED BLOOD CELL PROCESSING SOLUTIONSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE  
INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL

CITRA LABS LLC N950522 Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE,  
DIBASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATESTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE  
INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION

FENWAL INC. 2.26G/500ML; 2.21G/500ML; 1.59G/500ML; N080041 Dec 09, 2009  
1.53G/500ML; 0.465G/500ML

**DISCONTINUED DRUG PRODUCT LIST**ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995

EQ 400MG BASE A074007 002 Oct 18, 1995

ACETAMINOPHEN

INJECTABLE; INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM 100MG/ML N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS 120MG A072218 001 Mar 27, 1992

ACETAMINOPHEN

ABLE 120MG A073106 001 Feb 27, 1995

325MG A073107 001 Feb 27, 1995

650MG A073108 001 Feb 27, 1995

ROXANE 120MG A071010 001 May 12, 1987

650MG A071011 001 May 12, 1987

TYLENOL

J AND J CONSUMER INC 120MG N017756 002

650MG N017756 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD 650MG A090205 001 Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART 150MG; 180MG; 15MG A081095 001 Oct 26, 1990

150MG; 180MG; 30MG A081096 001 Oct 26, 1990

150MG; 180MG; 60MG A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS 150MG; 180MG; 15MG A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS 150MG; 180MG; 30MG A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS 150MG; 180MG; 60MG A085638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS 325MG; 50MG A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT 650MG; 50MG A088991 001 Jun 28, 1985

PHRENILIN FORTE

VALEANT 650MG; 50MG A088831 001 Jun 19, 1985

TENCON

MALLINCKRODT 650MG; 50MG A089405 001 May 15, 1990

TRIAPRIN

DUNHALL 325MG; 50MG A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY 325MG; 50MG A089568 001 Oct 05, 1988

WATSON LABS 325MG; 50MG A087550 001 Oct 19, 1984

BUTAPAP

MIKART 650MG; 50MG A089988 001 Oct 26, 1992

PHRENILIN

VALEANT 325MG; 50MG A087811 001 Jun 19, 1985

SEDAPAP

MAYRAND 650MG; 50MG A088944 001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE 325MG; 50MG; 40MG A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM 325MG; 50MG; 40MG A088743 001 Jul 18, 1985

325MG; 50MG; 40MG A088765 001 Mar 27, 1985

325MG; 50MG; 40MG A089067 001 Apr 19, 1985

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; BUTALBITAL; CAFFEINE

## CAPSULE; ORAL

## BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

HIKMA PHARMS LLC	500MG; 50MG; 40MG	A040261	001	Oct 28, 1998
MALLINCKRODT	325MG; 50MG; 40MG	A088758	001	Mar 27, 1985

## BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS	325MG; 50MG; 40MG	A088825	001	Dec 05, 1984
--------------	-------------------	---------	-----	--------------

## ESGIC-PLUS

MIKART	500MG; 50MG; 40MG	A040085	001	Mar 28, 1996
--------	-------------------	---------	-----	--------------

## FEMCET

MALLINCKRODT	325MG; 50MG; 40MG	A089102	001	Jun 19, 1985
--------------	-------------------	---------	-----	--------------

## MEDIGESIC PLUS

US CHEM	325MG; 50MG; 40MG	A089115	001	Jan 14, 1986
---------	-------------------	---------	-----	--------------

## TRIAD

MALLINCKRODT	325MG; 50MG; 40MG	A089023	001	Jun 19, 1985
--------------	-------------------	---------	-----	--------------

## TABLET; ORAL

## BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE	325MG; 50MG; 40MG	A040390	001	Jul 23, 2001
------	-------------------	---------	-----	--------------

	500MG; 50MG; 40MG	A040394	001	Jul 23, 2001
--	-------------------	---------	-----	--------------

GILBERT LABS	325MG; 50MG; 40MG	A087629	001	Nov 13, 1984
--------------	-------------------	---------	-----	--------------

HIKMA PHARMS LLC	500MG; 50MG; 40MG	A040336	001	Aug 18, 1999
------------------	-------------------	---------	-----	--------------

MIKART	750MG; 50MG; 40MG	A040496	001	Dec 23, 2003
--------	-------------------	---------	-----	--------------

MIRROR PHARMS	325MG; 50MG; 40MG	A040864	001	Dec 01, 2008
---------------	-------------------	---------	-----	--------------

MIRROR PHARMS LLC	500MG; 50MG; 40MG	A040883	001	Dec 23, 2008
-------------------	-------------------	---------	-----	--------------

MUTUAL PHARM	325MG; 50MG; 40MG	A040601	001	Jul 29, 2005
--------------	-------------------	---------	-----	--------------

VINTAGE PHARMS	500MG; 50MG; 40MG	A040513	001	Aug 25, 2003
----------------	-------------------	---------	-----	--------------

WATSON LABS	325MG; 50MG; 40MG	A089536	001	Feb 16, 1988
-------------	-------------------	---------	-----	--------------

	500MG; 50MG; 40MG	A040267	001	Jul 30, 1998
--	-------------------	---------	-----	--------------

## ESGIC

FOREST PHARMS	325MG; 50MG; 40MG	A089660	001	Dec 23, 1988
---------------	-------------------	---------	-----	--------------

## ESGIC-PLUS

MIKART	500MG; 50MG; 40MG	A089451	001	May 23, 1988
--------	-------------------	---------	-----	--------------

## FIORICET

ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984
---------------------	-------------------	---------	-----	--------------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

## CAPSULE; ORAL

## BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE	325MG; 50MG; 40MG; 30MG	A076528	001	Aug 21, 2003
------	-------------------------	---------	-----	--------------

## PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT	325MG; 50MG; 40MG; 30MG	A074911	001	Aug 22, 2001
---------	-------------------------	---------	-----	--------------

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

## CAPSULE; ORAL

## ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART	356.4MG; 30MG; 16MG	A040109	001	Aug 26, 1997
--------	---------------------	---------	-----	--------------

WRASER PHARMS LLC	356.4MG; 30MG; 16MG	A040688	001	Apr 03, 2007
-------------------	---------------------	---------	-----	--------------

## DHC PLUS

PHARM RES ASSOC	356.4MG; 30MG; 16MG	A088584	001	Mar 04, 1986
-----------------	---------------------	---------	-----	--------------

## SYNALGOS-DC-A

LEITNER PHARMS	356.4MG; 30MG; 16MG	A089166	001	May 14, 1986
----------------	---------------------	---------	-----	--------------

## TABLET; ORAL

## ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC	712.8MG; 60MG; 32MG	A040701	001	Apr 03, 2007
-----------------	---------------------	---------	-----	--------------

MIKART	712.8MG; 60MG; 32MG	A040316	001	Apr 28, 1999
--------	---------------------	---------	-----	--------------

WEST-WARD PHARM CORP	712.8MG; 60MG; 32MG	A040637	001	Sep 22, 2006
----------------------	---------------------	---------	-----	--------------

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET; ORAL

## TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS	500MG; EQ 0.25MG BASE; 30MG	N021082	001	Mar 01, 2001
----------	-----------------------------	---------	-----	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

## CAPSULE; ORAL

## ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA	300MG; 15MG	A088537	001	Jun 04, 1984
------	-------------	---------	-----	--------------

	300MG; 30MG	A088324	001	Dec 29, 1983
--	-------------	---------	-----	--------------

	300MG; 60MG	A088599	001	Jun 01, 1984
--	-------------	---------	-----	--------------

## PHENAPHEN W/ CODEINE NO. 2

ROBINS AH	325MG; 15MG	A084444	001	
-----------	-------------	---------	-----	--

## PHENAPHEN W/ CODEINE NO. 3

ROBINS AH	325MG; 30MG	A084445	001	
-----------	-------------	---------	-----	--

## PHENAPHEN W/ CODEINE NO. 4

ROBINS AH	325MG; 60MG	A084446	001	
-----------	-------------	---------	-----	--



## DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

## CAPSULE; ORAL

PROVAL #3

SOLVAY 325MG; 30MG A085685 001

TYLENOL W/ CODEINE NO. 3 ORTHO MCNEIL PHARM 300MG; 30MG A087422 001

TYLENOL W/ CODEINE NO. 4 ORTHO MCNEIL PHARM 300MG; 60MG A087421 001

## SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACTAVIS MID ATLANTIC 120MG/5ML; 12MG/5ML A085861 001

DAVA PHARMS INC 120MG/5ML; 12MG/5ML A040098 001 Sep 20, 1996

ROXANE 120MG/5ML; 12MG/5ML A086366 001

TYLENOL W/ CODEINE ORTHO MCNEIL PHARM 120MG/5ML; 12MG/5ML A085057 001

## SUSPENSION; ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC 120MG/5ML; 12MG/5ML A085883 001

## TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE 300MG; 30MG A040452 001 Aug 01, 2002

ABLE 300MG; 60MG A040459 001 Aug 01, 2002

AM THERAP 300MG; 15MG A089478 001 Mar 03, 1987

AM THERAP 300MG; 15MG A089481 001 Mar 03, 1987

AM THERAP 300MG; 30MG A089479 001 Mar 03, 1987

AM THERAP 300MG; 30MG A089482 001 Mar 03, 1987

AM THERAP 300MG; 60MG A089480 001 Mar 03, 1987

AM THERAP 300MG; 60MG A089483 001 Mar 03, 1987

DURAMED PHARMS BARR 300MG; 15MG A040223 001 Nov 18, 1997

DURAMED PHARMS BARR 300MG; 15MG A088353 001 Feb 06, 1984

DURAMED PHARMS BARR 300MG; 30MG A040223 002 Nov 18, 1997

DURAMED PHARMS BARR 300MG; 30MG A088354 001 Feb 06, 1984

DURAMED PHARMS BARR 300MG; 60MG A040223 003 Nov 18, 1997

DURAMED PHARMS BARR 300MG; 60MG A088355 001 Feb 06, 1984

EVERYLIFE 325MG; 30MG A085217 001

HALSEY 300MG; 15MG A083871 001

HALSEY 300MG; 30MG A083872 001

HALSEY 300MG; 60MG A086549 001

KV PHARM 300MG; 30MG A085288 001

KV PHARM 300MG; 60MG A085365 001

KV PHARM 325MG; 15MG A085364 001

KV PHARM 325MG; 45MG \*\*Federal Register A085363 001

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

LEDERLE 300MG; 30MG A087141 001

MIKART 300MG; 30MG A089238 001 Feb 25, 1986

MIKART 300MG; 60MG A089244 001 Feb 25, 1986

MIKART 650MG; 30MG A089231 001 Mar 03, 1986

MIKART 650MG; 60MG A089363 001 Sep 09, 1991

MUTUAL PHARM 300MG; 15MG A085795 001

MUTUAL PHARM 300MG; 15MG A089671 001 Feb 10, 1988

MUTUAL PHARM 300MG; 30MG A085794 001

MUTUAL PHARM 300MG; 30MG A089672 001 Feb 10, 1988

MUTUAL PHARM 300MG; 60MG A087653 001 Apr 13, 1982

MUTUAL PHARM 300MG; 60MG A089673 001 Feb 10, 1988

PURACAP PHARM 300MG; 30MG A087762 001 Dec 10, 1982

PUREPAC PHARM 300MG; 30MG A086681 001

PUREPAC PHARM 300MG; 30MG A089080 001 Jul 17, 1986

PUREPAC PHARM 300MG; 60MG A086683 001

ROXANE 300MG; 15MG A084659 001

ROXANE 300MG; 30MG A084656 001

ROXANE 300MG; 60MG A084667 001

ROXANE 500MG; 15MG A089511 001 Apr 25, 1989

ROXANE 500MG; 30MG A089512 001 Apr 25, 1989

ROXANE 500MG; 60MG A089513 001 Apr 25, 1989

SANDOZ 300MG; 15MG A087433 001

SANDOZ 300MG; 30MG A081250 001 Jul 16, 1992

SANDOZ 300MG; 30MG A085291 002

SANDOZ 300MG; 30MG A085917 001

SANDOZ 300MG; 60MG A081249 001 Jul 16, 1992

SANDOZ 300MG; 60MG A085964 001

SANDOZ 300MG; 60MG A087423 001

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

## ACETAMINOPHEN AND CODEINE PHOSPHATE

SUPERPHARM	300MG;15MG	A089183 001	Oct 18, 1985
	300MG;30MG	A089184 001	Oct 18, 1985
	300MG;30MG	A089253 001	May 19, 1986
	300MG;60MG	A089185 001	Oct 18, 1985
	300MG;60MG	A089254 001	May 19, 1986
USL PHARMA	300MG;30MG	A087919 001	Jun 22, 1982
	300MG;60MG	A087920 001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896 001	
VITARINE	300MG;30MG	A085676 001	
WARNER CHILCOTT	300MG;15MG	A085992 001	
	300MG;30MG	A085218 002	
	300MG;60MG	A087306 001	
WATSON LABS	300MG;15MG	A087277 001	May 26, 1982
	300MG;15MG	A089997 001	Dec 28, 1994
	300MG;30MG	A087276 001	May 26, 1982
	300MG;30MG	A089998 001	Dec 28, 1994
	300MG;60MG	A087275 001	May 26, 1982
	300MG;60MG	A089999 001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443 001	Jan 22, 2003
	300MG;30MG	A040443 002	Jan 22, 2003
	300MG;60MG	A040443 003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360 001	
	300MG;60MG	A085607 001	
CAPITAL AND CODEINE			
CARNRICK	325MG;30MG	A083643 001	
CODRIX			
WATSON LABS FLORIDA	500MG;15MG	A040447 001	Feb 26, 2003
	500MG;30MG	A040441 001	Mar 27, 2003
	500MG;60MG	A040488 001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3			
GLAXOSMITHKLINE	300MG;30MG	A083951 001	
EMPRACET W/ CODEINE PHOSPHATE #4			
GLAXOSMITHKLINE	300MG;60MG	A083951 002	
PAPA-DEINE #3			
VANGARD	300MG;30MG	A088037 001	Mar 20, 1984
PAPA-DEINE #4			
VANGARD	300MG;60MG	A088715 001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE			
ROBINS AH	650MG;30MG	A085856 001	
TYLENOL W/ CODEINE			
ORTHO MCNEIL PHARM	325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 001	
	325MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 002	
	325MG;30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 003	
	325MG;60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 004	
TYLENOL W/ CODEINE NO. 1			
JANSSEN PHARMS	300MG;7.5MG	A085055 001	
TYLENOL W/ CODEINE NO. 2			
JANSSEN PHARMS	300MG;15MG	A085055 002	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

## DRIXORAL PLUS

SCHERING PLOUGH	500MG;3MG;60MG	N019453 001	May 22, 1987
-----------------	----------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; HYDROCODONE BITARTRATE

## CAPSULE; ORAL

## ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS	500MG; 5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG; 5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG; 5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG; 5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG; 5MG	A088956	001	Jul 19, 1985
	500MG; 5MG	A089006	001	Aug 09, 1985
MIKART	500MG; 5MG	A081067	001	Nov 30, 1989
	500MG; 5MG	A081068	001	Nov 30, 1989
	500MG; 5MG	A081069	001	Nov 30, 1989
	500MG; 5MG	A081070	001	Nov 30, 1989
	500MG; 5MG	A089008	001	Feb 21, 1986
LORCET-HD				
MALLINCKRODT	500MG; 5MG	A087336	001	Jul 08, 1982
SOLUTION; ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG/15ML; 7.5MG/15ML	A040418	001	Jun 27, 2001
MALLINCKRODT INC	500MG/15ML; 10MG/15ML	A040508	001	Aug 29, 2003
MIKART	500MG/15ML; 5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML; 5MG/15ML	A089557	001	Apr 29, 1992
	500MG/15ML; 7.5MG/15ML	A081051	001	Aug 28, 1992
NESHER PHARMS	500MG/15ML; 7.5MG/15ML	A040366	001	Jan 23, 2002
PHARM ASSOC	500MG/15ML; 7.5MG/15ML	A040182	001	Mar 13, 1998
VINTAGE PHARMS	500MG/15ML; 7.5MG/15ML	A040520	001	Oct 30, 2003

## TABLET; ORAL

## ANEXSIA

MALLINCKRODT	500MG; 5MG	A089160	001	Apr 23, 1987
	750MG; 10MG	A040468	001	Oct 31, 2002
ANEXSIA 7.5/650				
MALLINCKRODT	650MG; 7.5MG	A089725	001	Sep 30, 1987
CO-GESIC				
UCB INC	500MG; 5MG	A087757	001	May 03, 1982
DURADYNE DHC				
FOREST PHARMS	500MG; 5MG	A087809	001	Mar 17, 1983
HY-PHEN				
ASCHER	500MG; 5MG	A087677	001	May 03, 1982
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG; 5MG	A040478	001	Nov 08, 2002
	325MG; 7.5MG	A040464	001	Oct 23, 2002
	325MG; 10MG	A040464	002	Oct 23, 2002
	500MG; 5MG	A040477	001	Nov 06, 2002
	500MG; 7.5MG	A040490	001	May 21, 2003
	500MG; 10MG	A040473	001	Nov 06, 2002
	650MG; 7.5MG	A040474	001	Jan 02, 2003
	650MG; 10MG	A040476	001	Oct 23, 2002
	750MG; 7.5MG	A040469	001	Oct 25, 2002
ACTAVIS LABS FL INC	500MG; 10MG	A040148	002	Feb 14, 1997
AMNEAL PHARMS NY	500MG; 5MG	A040729	001	Aug 25, 2006
	500MG; 7.5MG	A040748	001	Aug 25, 2006
	500MG; 10MG	A040813	001	Feb 23, 2007
	650MG; 7.5MG	A040754	001	Aug 25, 2006
	650MG; 10MG	A040757	001	Aug 25, 2006
	750MG; 7.5MG	A040769	001	Aug 28, 2006
BARR	500MG; 2.5MG	A040307	001	Jul 26, 2000
	500MG; 5MG	A040308	001	Jul 26, 2000
	500MG; 5MG	A088577	001	Dec 21, 1984
	500MG; 7.5MG	A040307	002	Jul 26, 2000
	500MG; 10MG	A040309	001	Jul 26, 2000
	650MG; 7.5MG	A040307	003	Jul 26, 2000
	650MG; 10MG	A040307	004	Jul 26, 2000
	750MG; 7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG; 5MG	A090265	001	Dec 23, 2008
	500MG; 7.5MG	A090265	002	Dec 23, 2008
	500MG; 10MG	A090265	003	Dec 23, 2008
	650MG; 7.5MG	A090380	001	Dec 23, 2008
	650MG; 10MG	A090380	002	Dec 23, 2008

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996
	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; HYDROCODONE BITARTRATE

## TABLET; ORAL

## TYCOLET

ORTHO MCNEIL PHARM	500MG; 5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG; 5MG	A085667	001	
ABBVIE	500MG; 5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG; 7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG; 10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG; 5MG	A040288	001	Nov 27, 1998
	400MG; 7.5MG	A040288	002	Nov 27, 1998
	400MG; 10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## CAPSULE; ORAL

## OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	500MG; 5MG	A040199	001	Dec 30, 1998
BARR	500MG; 5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG; 5MG	A040289	001	Mar 16, 1999
HALSEY	500MG; 5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG; 5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG; 5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG; 5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG; 5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG; 5MG	A040234	001	Oct 30, 1997
ROXILOX				
ROXANE	500MG; 5MG	A040061	001	Jul 03, 1995
TYLOX				
JANSSEN PHARMS	500MG; 5MG	A088790	001	Dec 12, 1984
TYLOX-325				
ORTHO MCNEIL PHARM	325MG; 5MG	A088246	001	Nov 08, 1984

## SOLUTION; ORAL

## OXYCODONE AND ACETAMINOPHEN

MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006
------------------	--------------------	---------	-----	--------------

## TABLET; ORAL

## OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 2.5MG	A085910	001	
OXYCODONE 5/APAP 500				
BRISTOL MYERS SQUIBB	500MG; 5MG	A085911	001	

## OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	325MG; 5MG	A040203	001	Mar 15, 1999
	325MG; 7.5MG	A040800	001	Apr 03, 2012
	325MG; 10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007
	650MG; 10MG	A040789	002	Nov 27, 2007
BARR	325MG; 5MG	A087406	001	
COASTAL PHARMS	500MG; 7.5MG	A090177	005	Oct 20, 2008
	650MG; 10MG	A090177	006	Oct 20, 2008
DURAMED PHARMS BARR	325MG; 5MG	A040272	001	Jun 30, 1998
MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004
	650MG; 10MG	A040550	002	Jun 30, 2004
MIKART	400MG; 2.5MG	A040679	001	May 16, 2006
	400MG; 5MG	A040687	001	Apr 27, 2006
	400MG; 7.5MG	A040698	001	Apr 27, 2006
	400MG; 10MG	A040692	001	Apr 27, 2006
	500MG; 10MG	A040676	001	Apr 19, 2006
WATSON LABS	500MG; 7.5MG	A040371	001	Dec 29, 2000
	650MG; 10MG	A040371	002	Dec 29, 2000

## PERCOCET

VINTAGE PHARMS LLC	325MG; 5MG	A085106	002	
	500MG; 7.5MG	A040341	001	Jul 26, 1999
	650MG; 10MG	A040341	002	Jul 26, 1999

## ROXICET 5/500

ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989
--------	------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG; 4.5MG; 0.38MG	A085375	001
--------------------	----------------------	---------	-----

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

GAVIS PHARMS	650MG; EQ 25MG BASE	A076202	001	Aug 02, 2002
--------------	---------------------	---------	-----	--------------

WATSON LABS	650MG; EQ 25MG BASE	A074699	001	Mar 24, 2000
-------------	---------------------	---------	-----	--------------

TALACEN

SANOFI AVENTIS US	650MG; EQ 25MG BASE	N018458	001	Sep 23, 1982
-------------------	---------------------	---------	-----	--------------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET

AAIPHARMA LLC	325MG; 32.5MG	N016844	001
---------------	---------------	---------	-----

DOLENE AP-65

LEDERLE	650MG; 65MG	A085100	001
---------	-------------	---------	-----

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG; 32MG	A083689	001
-------	-------------	---------	-----

	650MG; 65MG	A083978	001
--	-------------	---------	-----

SANDOZ	650MG; 65MG	A089959	001	Jul 18, 1989
--------	-------------	---------	-----	--------------

VINTAGE PHARMS	650MG; 65MG	A040507	001	Jul 30, 2003
----------------	-------------	---------	-----	--------------

WATSON LABS	650MG; 65MG	A040139	001	Dec 16, 1996
-------------	-------------	---------	-----	--------------

WYGESIC

CARACO	650MG; 65MG	A084999	001
--------	-------------	---------	-----

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

XANODYNE PHARM	500MG; 100MG	A076429	001	Sep 10, 2003
----------------	--------------	---------	-----	--------------

DARVOCET-N 100

XANODYNE PHARM	650MG; 100MG	N017122	002
----------------	--------------	---------	-----

DARVOCET-N 50

XANODYNE PHARM	325MG; 50MG	N017122	001
----------------	-------------	---------	-----

PROPACET 100

TEVA	650MG; 100MG	A070107	001	Jun 12, 1985
------	--------------	---------	-----	--------------

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE	650MG; 100MG	A075838	001	Jul 11, 2001
------	--------------	---------	-----	--------------

ACTAVIS ELIZABETH	650MG; 100MG	A070910	001	Jan 02, 1987
-------------------	--------------	---------	-----	--------------

CORNERSTONE	325MG; 100MG	A076743	001	May 07, 2004
-------------	--------------	---------	-----	--------------

	500MG; 100MG	A076750	001	Jun 28, 2004
--	--------------	---------	-----	--------------

HALSEY	325MG; 50MG	A072105	001	May 13, 1988
--------	-------------	---------	-----	--------------

	650MG; 100MG	A072106	001	May 13, 1988
--	--------------	---------	-----	--------------

IVAX SUB TEVA PHARMS	650MG; 100MG	A070146	001	Aug 02, 1985
----------------------	--------------	---------	-----	--------------

MALLINCKRODT	650MG; 100MG	A075738	001	Feb 02, 2001
--------------	--------------	---------	-----	--------------

MIRROR PHARMS	650MG; 100MG	A077821	001	Feb 11, 2008
---------------	--------------	---------	-----	--------------

MUTUAL PHARM	325MG; 50MG	A070115	001	Jun 12, 1985
--------------	-------------	---------	-----	--------------

	650MG; 100MG	A070116	001	Jun 12, 1985
--	--------------	---------	-----	--------------

	650MG; 100MG	A070615	001	Mar 21, 1986
--	--------------	---------	-----	--------------

	650MG; 100MG	A070771	001	Mar 21, 1986
--	--------------	---------	-----	--------------

	650MG; 100MG	A070775	001	Mar 21, 1986
--	--------------	---------	-----	--------------

MYLAN	650MG; 100MG	A072195	001	Feb 16, 1988
-------	--------------	---------	-----	--------------

MYLAN PHARMS INC	650MG; 100MG	A070145	001	Jun 12, 1985
------------------	--------------	---------	-----	--------------

SANDOZ	650MG; 100MG	A070443	001	Jan 23, 1986
--------	--------------	---------	-----	--------------

SUPERPHARM	650MG; 100MG	A071319	001	Jan 06, 1987
------------	--------------	---------	-----	--------------

TEVA	650MG; 100MG	A070732	001	Jan 03, 1986
------	--------------	---------	-----	--------------

	650MG; 100MG	A074119	001	Dec 19, 1994
--	--------------	---------	-----	--------------

VINTAGE PHARMS	325MG; 50MG	A074843	002	Feb 15, 2001
----------------	-------------	---------	-----	--------------

	650MG; 100MG	A074843	001	Feb 12, 1997
--	--------------	---------	-----	--------------

WATSON LABS	325MG; 50MG	A070398	001	Dec 18, 1986
-------------	-------------	---------	-----	--------------

	650MG; 100MG	A070399	001	Dec 18, 1986
--	--------------	---------	-----	--------------

WATSON LABS FLORIDA	500MG; 100MG	A077196	001	Jun 28, 2005
---------------------	--------------	---------	-----	--------------

	650MG; 100MG	A076609	001	Nov 16, 2004
--	--------------	---------	-----	--------------

WOCKHARDT LTD	325MG; 50MG	A077677	001	Mar 16, 2007
---------------	-------------	---------	-----	--------------

	650MG; 100MG	A077677	002	Mar 16, 2007
--	--------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN  
WATSON LABS 325MG; 37.5MG

A076914 001 Jul 26, 2006

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

ALRA 250MG

A083320 001

ASCOT 250MG

A087686 001 Oct 20, 1982

SUN PHARM INDS 250MG

A089753 001 Jun 22, 1988

VANGARD 250MG

A087654 001 Feb 05, 1982

WATSON LABS 250MG

A084498 002

250MG

A088882 001 Oct 22, 1985

DIAMOX

TEVA BRANDED PHARM 125MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N008943 001

250MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N008943 002

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA EQ 500MG BASE/VIAL

A040108 001 Oct 30, 1995

DIAMOX

TEVA WOMENS EQ 500MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N009388 001 Dec 05, 1990

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

ACTAVIS MID ATLANTIC 2%

A087146 001

ACETIC ACID

KV PHARM 2%

A085493 001

ORLEX

WARNER CHILCOTT 2%

A086845 001

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

PHARMAFAIR 2%; 0.79%

A088606 001 Aug 21, 1985

DOMEBORO

BAYER PHARMS 2%; 0.79%

A084476 001

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER PHARMS 2%; 0.05%

N017914 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETIC ACID W/ HYDROCORTISONE

KV PHARM 2%; 1%

A085492 001

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB 2%; 1%

A040097 001 Oct 31, 1994

WOCKHARDT 2%; 1%

A040168 001 Aug 30, 1996

ORLEX HC

WARNER CHILCOTT 2%; 1%

A086844 001

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

BAYER PHARMS 2%; 1%; EQ 0.35% BASE

N050238 001

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

ANI PHARMS INC 250MG

A070869 001 Feb 09, 1987

500MG

A070870 001 Feb 09, 1987

USL PHARMA 250MG

A070753 001 Nov 03, 1986

500MG

A070754 001 Nov 03, 1986

WATSON LABS 250MG

A071893 001 Nov 25, 1987

## DISCONTINUED DRUG PRODUCT LIST

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

	500MG	A071894 001	Nov 25, 1987
DYMELOR			
LILLY	250MG	N013378 002	
	500MG	N013378 001	

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING

20MG N012254 002

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM

53% N009008 001

ACETYLCOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL

NOVARTIS

20MG/VIAL N016211 001

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA

10% A071364 001 May 01, 1989

20% A071365 001 May 01, 1989

ROXANE

10% A072323 001 Apr 30, 1992

10% A072621 001 Sep 30, 1992

20% A072324 001 Apr 30, 1992

20% A072622 001 Sep 30, 1992

MUCOMYST

APOTHECON

10% N013601 002

20% N013601 001

MUCOSIL-10

DEY

10% A070575 001 Oct 14, 1986

MUCOSIL-20

DEY

20% A070576 001 Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON

10%; 0.05% N017366 001

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS

0.1MG N009436 001

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING

2MG/GM N012470 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

200MG A074906 001 Aug 26, 1997

DAVA PHARMS INC

200MG A074872 001 Apr 22, 1997

HERITAGE PHARMS INC

200MG A074889 001 Oct 31, 1997

IVAX SUB TEVA PHARMS

200MG A074674 001 Apr 22, 1997

LEK PHARM

200MG A074750 001 Apr 22, 1997

MYLAN

200MG A074977 001 Apr 13, 1998

ROXANE

200MG A074570 002 Apr 22, 1997

TEVA

200MG A074828 001 Apr 22, 1997

TEVA PHARMS

200MG A074914 001 Nov 26, 1997

WATSON LABS

200MG A075101 001 Apr 15, 1998

TABLET; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

400MG A074870 001 Jun 05, 1997

800MG A074870 002 Jun 05, 1997

DAVA PHARMS INC

400MG A074834 001 Apr 24, 1997

800MG A074834 002 Apr 24, 1997

HERITAGE PHARMS INC

400MG A074891 001 Oct 31, 1997

800MG A074891 002 Oct 31, 1997



## DISCONTINUED DRUG PRODUCT LIST

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

IVAX SUB TEVA PHARMS	400MG	A074836 001	Apr 22, 1997
	800MG	A074836 002	Apr 22, 1997
LEK PHARM	400MG	A074658 001	Apr 22, 1997
	800MG	A074658 002	Apr 22, 1997
MYLAN	400MG	A074976 001	Apr 13, 1998
	800MG	A074976 002	Apr 13, 1998
TEVA	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A074556 001	Apr 22, 1997
TEVA PHARMS	400MG	A075021 001	Mar 18, 1998
	800MG	A075021 002	Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE	EQ 50MG BASE/ML	A075114 001	Jul 26, 1999
ACYCLOVIR SODIUM			
APOTHECON	EQ 500MG BASE/VIAL	A074897 001	Feb 27, 1998
	EQ 1GM BASE/VIAL	A074897 002	Feb 27, 1998
HIKMA MAPLE	EQ 500MG BASE/VIAL	A074913 001	Oct 15, 1997
	EQ 1GM BASE/VIAL	A074913 002	Oct 15, 1997
HOSPIRA	EQ 25MG BASE/ML	A074720 001	Apr 22, 1997
	EQ 50MG BASE/ML	A075065 001	Feb 25, 1999
	EQ 500MG BASE/VIAL	A074663 001	Apr 22, 1997
	EQ 500MG BASE/VIAL	A074758 001	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074663 002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074758 002	Apr 22, 1997
TEVA PARENTERAL	EQ 50MG BASE/ML	A075627 001	Mar 28, 2001
	EQ 500MG BASE/VIAL	A074969 001	Aug 26, 1997
	EQ 1GM BASE/VIAL	A074969 002	Aug 26, 1997

ZOVIRAX

GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603 003	Aug 30, 1983
	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603 001	Oct 22, 1982
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603 002	Jun 29, 1989

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

GALDERMA LABS LP	0.1%	N020338 001	May 31, 1996
------------------	------	-------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

EUROHLTH INTL SARL	3MG/ML	A076501 001	Jun 16, 2004
TEVA PHARMS USA	3MG/ML	A076564 001	Jun 16, 2004
	3MG/ML	A078676 001	Jul 31, 2008
WOCKHARDT	3MG/ML	A090220 001	Jul 20, 2009

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER	EQ 200MG BASE/VIAL	N020760 001	Dec 18, 1997
	EQ 300MG BASE/VIAL	N020760 002	Dec 18, 1997

ALBENDAZOLE

TABLET, CHEWABLE; ORAL

ALBENZA

AMEDRA PHARMS LLC	200MG	N207844 001	Jun 11, 2015
-------------------	-------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

ISO TEX	100uCi/VIAL	N017835	001
	250uCi/VIAL	N017835	002
	500uCi/VIAL	N017835	003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS	2.5uCi/AMP	N017846	001
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125			
MALLINCKRODT	6.67uCi/ML	N017844	003
	10uCi/ML	N017844	001
	100uCi/ML	N017844	002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX	2mCi/VIAL	N017837	003
	5uCi/AMP	N017837	004
	20uCi/AMP	N017837	005

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988
-----------------	---------------	---------	-----	--------------

SOLUTION; INHALATION

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995
APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010
	EQ 0.042% BASE	A078623	002	Apr 05, 2010
	EQ 0.083% BASE	A075717	001	Feb 02, 2007
	EQ 0.5% BASE	A076391	001	Apr 01, 2003
BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
PROVENTIL				
SCHERING	EQ 0.083% BASE	N019243	002	Jan 14, 1987
	EQ 0.5% BASE	N019243	001	Jan 14, 1987
VENTOLIN				
GLAXOSMITHKLINE	EQ 0.083% BASE	N019773	001	Apr 23, 1992
	EQ 0.5% BASE	N019269	002	Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
SCHERING	EQ 2MG BASE/5ML	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML	N019621	001	Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072859	001	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989

**DISCONTINUED DRUG PRODUCT LIST**ALBUTEROL SULFATE

## TABLET; ORAL

## ALBUTEROL SULFATE

PLIVA	EQ 2MG BASE	A072316 001	Dec 05, 1989
	EQ 4MG BASE	A072317 001	Dec 05, 1989
SANDOZ	EQ 2MG BASE	A072151 001	Dec 05, 1989
	EQ 4MG BASE	A072152 001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619 001	Dec 05, 1989
	EQ 2MG BASE	A072779 001	Jun 25, 1993
	EQ 2MG BASE	A072938 001	Mar 30, 1990
	EQ 4MG BASE	A072620 001	Dec 05, 1989
	EQ 4MG BASE	A072780 001	Jun 25, 1993
	EQ 4MG BASE	A072939 001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120 001	Sep 29, 1992
	EQ 4MG BASE	A073121 001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817 001	Jan 09, 1990
	EQ 4MG BASE	A072818 001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629 001	Jan 31, 1991
	EQ 2MG BASE	A072764 001	Aug 28, 1991
	EQ 4MG BASE	A072630 001	Jan 31, 1991
	EQ 4MG BASE	A072765 001	Aug 28, 1991
PROVENTIL			
SCHERING	EQ 2MG BASE	N017853 001	May 07, 1982
	EQ 4MG BASE	N017853 002	May 07, 1982
VENTOLIN			
GLAXOSMITHKLINE	EQ 2MG BASE	N019112 001	Jul 10, 1986
	EQ 4MG BASE	N019112 002	Jul 10, 1986
TABLET, EXTENDED RELEASE; ORAL			
PROVENTIL			
SCHERING	EQ 4MG BASE	N019383 001	Jul 13, 1987
VOLMAX			
MURO	EQ 4MG BASE	N019604 002	Dec 23, 1992
	EQ 8MG BASE	N019604 001	Dec 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

## AEROSOL, METERED; INHALATION

## COMBIVENT

BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH; 0.018MG/INH	N020291 001	Oct 24, 1996
----------------------	---------------------------------	-------------	--------------

## SOLUTION; INHALATION

## ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC	EQ 0.083% BASE; 0.017%	A077117 001	Dec 31, 2007
SANDOZ INC	EQ 0.083% BASE; 0.017%	A076867 001	Dec 21, 2006

ALCLOMETASONE DIPROPIONATE

## CREAM; TOPICAL

## ACLOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018707 001	Dec 14, 1982
----------------	--	-------------	--------------

## OINTMENT; TOPICAL

## ACLOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018702 001	Dec 14, 1982
----------------	--	-------------	--------------

ALCOHOL

## INJECTABLE; INJECTION

## ALCOHOL 5% IN DEXTROSE 5%

MILES	5ML/100ML	A083483 001	
-------	-----------	-------------	--

ALCOHOL; DEXTROSE

## INJECTABLE; INJECTION

## ALCOHOL 10% AND DEXTROSE 5%

B BRAUN	10ML/100ML; 5GM/100ML	N004589 006	
ALCOHOL 5% AND DEXTROSE 5%			
B BRAUN	5ML/100ML; 5GM/100ML	N004589 004	
ALCOHOL 5% IN D5-W			
HOSPIRA	5ML/100ML; 5GM/100ML	A083263 001	
ALCOHOL 5% IN DEXTROSE 5% IN WATER			
BAXTER HLTHCARE	5ML/100ML; 5GM/100ML	A083256 001	

## DISCONTINUED DRUG PRODUCT LIST

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

MYLAN

EQ 35MG BASE

A078638 001 Aug 04, 2008

EQ 70MG BASE

A078638 002 Aug 04, 2008

SANDOZ

EQ 5MG BASE

A075871 001 Apr 22, 2009

EQ 10MG BASE

A075871 002 Apr 22, 2009

EQ 35MG BASE

A075871 004 Apr 22, 2009

EQ 40MG BASE

A075871 003 Apr 22, 2009

EQ 70MG BASE

A075871 005 Apr 22, 2009

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

FOSAMAX

MERCK AND CO INC

EQ 5MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020560 003 Apr 25, 1997

EQ 10MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020560 001 Sep 29, 1995

EQ 35MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020560 004 Oct 20, 2000

EQ 40MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020560 002 Sep 29, 1995

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

WOCKHARDT LTD

10MG

A090221 001 Aug 10, 2012

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME

10 UNITS/ML

N020057 004 May 08, 1992

80 UNITS/ML

N020057 003 Apr 05, 1991

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

NOVARTIS

EQ 150MG BASE; EQ 5MG BASE

N022545 001 Aug 26, 2010

EQ 150MG BASE; EQ 10MG BASE

N022545 002 Aug 26, 2010

EQ 300MG BASE; EQ 5MG BASE

N022545 003 Aug 26, 2010

EQ 300MG BASE; EQ 10MG BASE

N022545 004 Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

NOVARTIS

EQ 150MG BASE; EQ 5MG BASE; 12.5MG

N200045 001 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 12.5MG

N200045 002 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 25MG

N200045 003 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 12.5MG

N200045 004 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 25MG

N200045 005 Dec 21, 2010

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

NOVARTIS

EQ 150MG BASE; 160MG

N022217 001 Sep 16, 2009

EQ 300MG BASE; 320MG

N022217 002 Sep 16, 2009

ALKAVERVIR

TABLET; ORAL

VERILOID

3M

2MG

N007336 002

3MG

N007336 003

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

MUTUAL PHARM

100MG

A070466 001 Dec 24, 1985

300MG

A070467 001 Dec 24, 1985

PURACAP PHARM

100MG

A070150 001 Dec 10, 1985

300MG

A070147 001 Dec 10, 1985

## DISCONTINUED DRUG PRODUCT LIST

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

PUREPAC PHARM	100MG	A070579 001	Apr 14, 1986
	300MG	A070580 001	Apr 14, 1986
SANDOZ	100MG	A070268 001	Dec 31, 1985
	300MG	A070269 001	Dec 31, 1985
SUPERPHARM	100MG	A070950 001	Nov 30, 1988
	300MG	A070951 001	Nov 30, 1988
WATSON LABS	100MG	N018241 001	Nov 16, 1984
	100MG	N018785 001	Sep 28, 1984
	300MG	N018241 002	Nov 16, 1984
	300MG	N018785 002	Sep 28, 1984
LOPURIN			
ABBOTT	100MG	N018297 001	
	300MG	N018297 002	

ALPRAZOLAM

SOLUTION; ORAL

ALPRAZOLAM

ROXANE	0.5MG/5ML	A074314 001	Oct 31, 1993
--------	-----------	-------------	--------------

TABLET; ORAL

ALPRAZOLAM

ANI PHARMS INC	0.25MG	A074085 001	Feb 16, 1994
	0.5MG	A074085 002	Feb 16, 1994
	1MG	A074085 003	Feb 16, 1994
	2MG	A074085 004	Feb 26, 1996
IVAX SUB TEVA PHARMS	0.25MG	A074294 001	Jul 29, 1994
	0.5MG	A074294 002	Jul 29, 1994
	1MG	A074294 003	Jul 29, 1994
	2MG	A074294 004	Jul 29, 1994
ROXANE	0.25MG	A074199 001	Oct 19, 1993
	0.5MG	A074199 002	Oct 19, 1993
	1MG	A074199 003	Oct 19, 1993
WATSON LABS	0.25MG	A074456 001	Aug 31, 1995
	0.25MG	A074479 001	Jan 21, 1997
	0.5MG	A074456 002	Aug 31, 1995
	0.5MG	A074479 002	Jan 21, 1997
	1MG	A074456 003	Aug 31, 1995
	1MG	A074479 003	Jan 21, 1997

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

ANI PHARMS INC	0.5MG	A077979 001	Feb 28, 2007
	1MG	A077979 002	Feb 28, 2007
	2MG	A077979 003	Feb 28, 2007
	3MG	A077979 004	Feb 28, 2007
SANDOZ INC	0.5MG	A077777 001	Jun 30, 2006
	1MG	A077777 002	Jun 30, 2006
	2MG	A077777 003	Jun 30, 2006
	3MG	A077777 004	Jun 30, 2006
VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007
	1MG	A078442 002	Oct 15, 2007
	2MG	A078442 003	Oct 15, 2007
	3MG	A078442 004	Oct 15, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

UCB INC	0.25MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021726 001	Jan 19, 2005
	0.5MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021726 002	Jan 19, 2005
	1MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021726 003	Jan 19, 2005
	2MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021726 004	Jan 19, 2005

**DISCONTINUED DRUG PRODUCT LIST**ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PFIZER

0.005MG/ML

N020755 001 Oct 31, 1997

0.01MG/ML

N020755 002 Oct 01, 1997

0.02MG/ML

N020755 003 Oct 01, 1997

EDEX

AUXILIUM PHARMS LLC

0.005MG/VIAL

N020649 001 Jun 12, 1997

ALSEROXYLON

TABLET; ORAL

RAUTENSIN

NOVARTIS

2MG

N009215 001

RAUWILOID

3M

2MG

N008867 001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX

80MG; 20MG

A089449 001 Nov 27, 1987

FOAMICON

NOVARTIS

80MG; 20MG

A072687 001 Jun 28, 1989

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH

100MG

A077659 001 Feb 23, 2006

WATSON LABS

100MG

A071382 001 Jan 21, 1987

SYMADINE

SOLVAY

100MG

A071000 001 Sep 04, 1986

SYMMETREL

ENDO PHARMS

100MG

N016020 001

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

G AND W LABS INC

50MG/5ML

A072655 001 Oct 30, 1990

SILARX

50MG/5ML

A076352 001 Sep 10, 2004

TEVA PHARMS

50MG/5ML

A073115 001 Aug 23, 1991

VINTAGE

50MG/5ML

A077992 001 Dec 12, 2006

SYMMETREL

ENDO PHARMS

50MG/5ML

N016023 002

TABLET; ORAL

SYMMETREL

ENDO PHARMS

100MG

N018101 001

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

SANOFI AVENTIS US

10MG

N010155 002

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

ASTELLAS

0.025%

N018116 001

0.1%

N018116 002

LOTION; TOPICAL

CYCLOCORT

ASTELLAS

0.1%

N019729 001 Jun 13, 1988

OINTMENT; TOPICAL

CYCLOCORT

ASTELLAS

0.1%

N018498 001

AMDINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE

250MG/VIAL

N050565 001 Dec 21, 1984

500MG/VIAL

N050565 002 Dec 21, 1984

1GM/VIAL

N050565 003 Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

CLINIGEN HLTHCARE

375MG/VIAL

N020221 002 Sep 10, 1999

## DISCONTINUED DRUG PRODUCT LIST

AMIKACIN SULFATE

## INJECTABLE; INJECTION

## AMIKACIN SULFATE

ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
HIKMA MAPLE	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992
HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997
AMIKIN				
APOTHECON	EQ 50MG BASE/ML	A062311	001	
	EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
	EQ 50MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050495	001	
	EQ 250MG BASE/ML	A062311	002	
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
	EQ 250MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050495	002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618	001	Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

## TABLET; ORAL

## AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ	EQ 5MG ANHYDROUS; 50MG	A073357	001	Nov 27, 1991
TEVA	EQ 5MG ANHYDROUS; 50MG	A070795	001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS; 50MG	A073334	001	Jul 19, 1991
HYDRO-RIDE				
PAR PHARM	EQ 5MG ANHYDROUS; 50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50				
MERCK	EQ 5MG ANHYDROUS; 50MG	N018201	001	

AMINO ACIDS

## INJECTABLE; INJECTION

## AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984
AMINOSYN 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984
AMINOSYN II 3.5%				
HOSPIRA	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986
AMINOSYN II 5%				
HOSPIRA	5% (5GM/100ML)	N019438	002	Apr 03, 1986
AMINOSYN-HBC 7% IN PLASTIC CONTAINER				
ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
BRANCHAMIN 4%				
BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984
BRANCHAMIN 4% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984
FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984

**DISCONTINUED DRUG PRODUCT LIST**AMINO ACIDS

## INJECTABLE; INJECTION

NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957 003	Aug 09, 1982	
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986	
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML)	N020107 001	Feb 05, 1993	
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957 002	Aug 09, 1982	
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493 007	Oct 15, 1982	
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493 006		
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493 004		
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493 005		

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714 001	Sep 12, 1988	
HOSPIRA INC	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683 001	Nov 07, 1988	
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714 002	Sep 12, 1988	
HOSPIRA INC	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683 002	Nov 07, 1988	
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714 004	Sep 12, 1988	
HOSPIRA INC	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683 003	Nov 07, 1988	
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 2.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714 003	Sep 12, 1988	
HOSPIRA INC	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 2.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683 004	Nov 07, 1988	

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 25GM/100ML	N019118 001	Oct 11, 1984	
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 5GM/100ML	N019120 001	Oct 11, 1984	
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 25GM/100ML	N019119 001	Oct 11, 1984	
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 25GM/100ML	N019505 002	Nov 07, 1986	
HOSPIRA	3.5%; 25GM/100ML	N019713 006	Sep 09, 1988	
HOSPIRA	3.5%; 25GM/100ML	N019681 001	Nov 01, 1988	
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 5GM/100ML	N019506 001	Nov 07, 1986	
HOSPIRA	3.5%; 5GM/100ML	N019713 002	Sep 09, 1988	
HOSPIRA	3.5%; 5GM/100ML	N019681 002	Nov 01, 1988	
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 10GM/100ML	N019713 001	Sep 09, 1988	
HOSPIRA	4.25%; 10GM/100ML	N019681 004	Nov 01, 1988	
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 20GM/100ML	N019713 004	Sep 09, 1988	
HOSPIRA	4.25%; 20GM/100ML	N019681 005	Nov 01, 1988	
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 25GM/100ML	N019504 002	Nov 07, 1986	
HOSPIRA	4.25%; 25GM/100ML	N019713 005	Sep 09, 1988	
HOSPIRA	4.25%; 25GM/100ML	N019681 003	Nov 01, 1988	



**DISCONTINUED DRUG PRODUCT LIST**AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN II 5% IN DEXTROSE	25% IN PLASTIC CONTAINER		
ABBOTT	5%;25GM/100ML	N019565 001	Dec 17, 1986
	5%;25GM/100ML	N019713 003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681 006	Nov 01, 1988
TRAVASOL 2.75% IN DEXTROSE	10% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%;10GM/100ML	N019520 002	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE	15% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%;15GM/100ML	N019520 003	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE	20% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%;20GM/100ML	N019520 004	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE	25% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%;25GM/100ML	N019520 005	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE	5% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%;5GM/100ML	N019520 001	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE	10% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%;10GM/100ML	N019520 007	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE	15% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%;15GM/100ML	N019520 008	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE	20% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%;20GM/100ML	N019520 009	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE	25% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%;25GM/100ML	N019520 010	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE	5% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%;5GM/100ML	N019520 006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE	10% IN PLASTIC CONTAINER		
ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712 002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682 003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE	25% IN PLASTIC CONTAINER		
ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 002	Dec 16, 1986
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE	25% IN PLASTIC CONTAINER		
ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE	5% IN PLASTIC CONTAINER		
ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712 001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 001	Nov 01, 1988
AMINOSYN II 4.25% M IN DEXTROSE	10% IN PLASTIC CONTAINER		
ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE	10% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 002	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE	15% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 003	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE	20% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 004	Oct 23, 1995

**DISCONTINUED DRUG PRODUCT LIST**AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 005	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML; 216MG/100ML;112MG/100ML	N020147 001	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 007	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 008	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 009	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 010	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML; 297MG/100ML;77MG/100ML	N020147 006	Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER			
ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N018804 002	May 15, 1984
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N018875 002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M			
HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789 005	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER			
ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML ;49MG/100ML	N019493 001	Oct 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

## INJECTABLE; INJECTION

VEINAMINE 8%			
HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38 8MG/100ML	N017957 001	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 7% W/ ELECTROLYTES			
HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/100ML;4 10MG/100ML	N019437 006	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M			
HOSPIRA	3.5%;30MG/100ML;97MG/100ML;120MG/100ML; 49MG/100ML	N019437 007	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER			
BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N020177 001	Oct 23, 1995
TRAVASOL 3.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N017493 003	
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N020173 001	Oct 27, 1995
TRAVASOL 5.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N017493 001	

## DISCONTINUED DRUG PRODUCT LIST

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML;594MG/100ML N020173 002 Oct 27, 1995  
L;154MG/100ML

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML;594MG/100ML N017493 002  
L;154MG/100MLAMINOCAPROIC ACID

## INJECTABLE; INJECTION

AMICAR

CLOVER PHARMS 250MG/ML \*\*Federal Register N015229 002  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

AMINOCAPROIC ACID

ABRAXIS PHARM 250MG/ML A070522 001 Jun 17, 1986

BAXTER HLTHCARE 250MG/ML N018590 001 Oct 29, 1982

HOSPIRA 250MG/ML A070888 001 Jun 16, 1988

AMINOGLUTETHIMIDE

## TABLET; ORAL

CYTADREN

NOVARTIS 250MG N018202 001

AMINOHIPPURATE SODIUM

## INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

MERCCK 20% N005619 001

AMINOPHYLLINE

## ENEMA; RECTAL

SOMOPHYLLIN

FISONS 300MG/5ML N018232 001 Apr 02, 1982

## INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC 25MG/ML A087243 001 May 24, 1982

25MG/ML A087621 001 May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM 25MG/ML A084568 001

25MG/ML A087200 001

25MG/ML A087250 001 Jan 06, 1982

25MG/ML A087886 001 Aug 30, 1983

25MG/ML A088407 001 Jan 25, 1984

ELKINS SINN 25MG/ML A087239 001

HOSPIRA 25MG/ML A087601 001 Jul 23, 1982

INTL MEDICATION 25MG/ML A087209 001 Feb 01, 1982

25MG/ML A087867 001 Nov 10, 1983

25MG/ML A087868 001 Nov 10, 1983

KING PHARMS 25MG/ML A086606 001

LUITPOLD 25MG/ML A087240 001

LYPHOMED 25MG/ML A087431 001

PHARMA SERVE NY 25MG/ML A087387 001 Jun 03, 1983

25MG/ML A087392 001 Dec 15, 1983

SMITH AND NEPHEW 25MG/ML A088429 001 May 30, 1985

25MG/ML A088749 001 May 30, 1985

TEVA PARENTERAL 25MG/ML A081142 001 Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA 100MG/100ML A088147 002 May 03, 1983

200MG/100ML A088147 003 May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA 100MG/100ML N018924 001 Dec 12, 1984

200MG/100ML N018924 002 Dec 12, 1984

400MG/100ML N018924 003 Dec 12, 1984

500MG/100ML N018924 004 Dec 12, 1984

## SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE 105MG/5ML A088156 001 Dec 05, 1983

ROXANE 105MG/5ML A088126 001 Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC 105MG/5ML A087727 001 Apr 16, 1982

SOMOPHYLLIN

FISONS 105MG/5ML A086466 001

## DISCONTINUED DRUG PRODUCT LIST

AMINOPHYLLINE

## SOLUTION; ORAL

## SOMOPHYLLIN-DF

FISONS

105MG/5ML

A087045 001

## SUPPOSITORY; RECTAL

## TRUPHYLLINE

G AND W LABS

250MG

A085498 001 Mar 23, 1983

500MG

A085498 002 Jan 03, 1983

## TABLET; ORAL

## AMINOPHYLLIN

GD SEARLE LLC

100MG

N002386 002

200MG

N002386 003

## AMINOPHYLLINE

ASCOT

100MG

A087522 001 Feb 12, 1982

200MG

A087523 001 Feb 12, 1982

BARR

100MG

A088297 001 Aug 19, 1983

200MG

A088298 001 Aug 19, 1983

DURAMED PHARMS BARR

100MG

A088182 001 Mar 31, 1983

200MG

A088183 001 Mar 31, 1983

HALSEY

100MG

A084674 001

HIKMA INTL PHARMS

100MG

A084540 001

200MG

A085003 001

IMPAX LABS

100MG

A084574 001

200MG

A084576 001

KV PHARM

100MG

A085284 001

200MG

A085289 001

LANNETT

100MG

A084588 001

200MG

A084588 002

PAL PAK

100MG

A084533 001

PANRAY

100MG

A084552 001

200MG

A084552 002

PUREPAC PHARM

100MG

A084699 001

200MG

A085333 001

ROXANE

100MG

A087500 001 Feb 09, 1982

200MG

A087501 001 Feb 09, 1982

SANDOZ

100MG

A085261 003

100MG

A085262 002

200MG

A085261 002

VALEANT PHARM INTL

200MG

A084563 001

VANGARD

100MG

A088314 001 Oct 03, 1983

200MG

A088319 001 Oct 03, 1983

VINTAGE PHARMS

100MG

A085409 001

200MG

A085410 001

WATSON LABS

100MG

A085567 001

200MG

A085564 001

## TABLET, DELAYED RELEASE; ORAL

## AMINOPHYLLINE

IMPAX LABS

100MG

A084577 001

200MG

A084575 001

TABLICAPS

100MG

A084632 002

VALE

100MG

A084531 001

200MG

A084530 001

## TABLET, EXTENDED RELEASE; ORAL

## PHYLLOCONTIN

PHARM RES ASSOC

225MG

A086760 001

AMINOSALICYLATE SODIUM

## POWDER; ORAL

## P.A.S. SODIUM

CENTURY PHARMS

4GM/PACKET

A080947 001

## SODIUM AMINOSALICYLATE

HEXCEL

100%

A080097 001

## TABLET; ORAL

## PARASAL SODIUM

PANRAY

500MG

N006811 006

1GM

N006811 011

## SODIUM P.A.S.

LANNETT

500MG

A080138 002

## TEEBACIN

CONSOLIDATED MIDLAND

500MG

N007320 002

**DISCONTINUED DRUG PRODUCT LIST**AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL

NEOPASALATE

MEDPOINTE PHARM HLC 846MG;112MG A080059 002

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY 500MG N006811 001

1GM N006811 002

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB EQ 500MG BASE/GM N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

BEDFORD 50MG/ML A076018 001 Oct 15, 2002

BEDFORD LABS 50MG/ML A076299 001 Oct 24, 2002

BEN VENUE 50MG/ML A076088 001 Oct 15, 2002

HOSPIRA 50MG/ML A076108 001 Oct 15, 2002

INTL MEDICATION SYS 50MG/ML N021594 001 Feb 04, 2004

PAR STERILE PRODUCTS 50MG/ML A076394 001 Apr 25, 2003

TEVA PHARMS USA 50MG/ML A076163 001 Sep 05, 2003

CORDARONE

WYETH PHARMS INC 50MG/ML N020377 001 Aug 03, 1995

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

TEVA 200MG A074895 001 Apr 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE 40MG/ML A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS 10MG/ML A085594 001

ELAVIL

ASTRAZENECA 10MG/ML N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB 10MG A086454 001

25MG A086454 002

50MG A086454 003

75MG A086454 004

100MG A086454 005

AMITRIL

WARNER CHILCOTT 10MG A083939 001

25MG A083937 001

50MG A083938 002

75MG A084957 001

100MG A085093 001

150MG A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP 25MG A088672 001 Nov 20, 1984

50MG A088673 001 Nov 20, 1984

75MG A088674 001 Nov 20, 1984

100MG A088675 001 Nov 20, 1984

ANI PHARMS INC 10MG A084910 003

25MG A085031 001

50MG A085032 001

75MG A085030 001

COPLEY PHARM 10MG A088421 001 Apr 30, 1984

25MG A088422 001 Apr 30, 1984

50MG A088423 001 Apr 30, 1984

75MG A088424 001 Apr 30, 1984

100MG A088425 001 Apr 30, 1984

150MG A088426 001 Apr 30, 1984

HALSEY 10MG A085923 001

25MG A085922 001

50MG A085925 001

50MG A087557 001 Mar 05, 1982

## DISCONTINUED DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

## AMITRIPTYLINE HYDROCHLORIDE

	75MG	A085926 001	May 20, 1983
	100MG	A085927 001	May 20, 1983
LEDERLE	10MG	A086744 001	
	10MG	A087366 001	Jan 04, 1982
	25MG	A086746 001	
	25MG	A087367 001	May 03, 1982
	50MG	A086743 001	
	50MG	A087181 001	Jan 04, 1982
	75MG	A086745 001	
	75MG	A087369 001	Jan 04, 1982
	100MG	A086747 001	
	100MG	A087368 001	May 03, 1982
	150MG	A087370 001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744 001	
	25MG	A085627 001	
	50MG	A085745 001	
	75MG	A085743 001	
	100MG	A085742 002	May 11, 1982
	150MG	A089423 001	Feb 17, 1987
PAR PHARM	10MG	A088697 001	Sep 25, 1984
	25MG	A088698 001	Sep 25, 1984
	50MG	A088699 001	Sep 25, 1984
	75MG	A088700 001	Sep 25, 1984
	100MG	A088701 001	Sep 25, 1984
	150MG	A088702 001	Sep 25, 1984
PLIVA	10MG	A088883 001	Sep 26, 1984
	25MG	A088884 001	Sep 26, 1984
	50MG	A088885 001	Sep 26, 1984
	75MG	A088886 001	Sep 26, 1984
	100MG	A088887 001	Sep 26, 1984
	150MG	A088888 001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075 001	Sep 16, 1983
	10MG	A088084 001	Jul 18, 1983
	25MG	A088076 001	May 20, 1983
	25MG	A088085 001	Jul 18, 1983
	50MG	A088077 001	Sep 16, 1983
	50MG	A088105 001	Jul 18, 1983
	75MG	A088078 001	Sep 16, 1983
	75MG	A088106 001	Jul 18, 1983
	100MG	A088079 001	Sep 16, 1983
	100MG	A088107 001	Jul 18, 1983
ROXANE	10MG	A086002 001	
	10MG	A086144 001	
	25MG	A085944 001	
	25MG	A086145 001	
	50MG	A085945 001	
	50MG	A086143 001	
	75MG	A086004 001	
	75MG	A086147 001	
	100MG	A086003 001	
	100MG	A086146 001	
	150MG	A086090 001	
	150MG	A086148 001	
SUPERPHARM	10MG	A088853 001	Nov 13, 1984
	25MG	A088854 001	Nov 13, 1984
	50MG	A088855 001	Nov 13, 1984
	75MG	A088856 001	Nov 13, 1984
	100MG	A088857 001	Nov 13, 1984
TEVA	10MG	A086610 001	
	25MG	A086859 001	
	50MG	A086857 001	
	75MG	A086860 001	
	100MG	A085836 001	
	100MG	A086854 001	
	150MG	A086853 001	
UCB INC	10MG	A085864 001	
	25MG	A085935 001	
	50MG	A085936 001	
	75MG	A086337 001	

**DISCONTINUED DRUG PRODUCT LIST**AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

## AMITRIPTYLINE HYDROCHLORIDE

	100MG	A086336	001	
	150MG	A086335	001	
USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982
	75MG	A087617	001	Feb 05, 1982
	100MG	A087639	001	Feb 08, 1982
WATSON LABS	10MG	A085816	001	
	10MG	A088620	001	Mar 02, 1984
	25MG	A085817	001	
	25MG	A088621	001	Mar 02, 1984
	50MG	A085815	001	
	50MG	A088622	001	Mar 02, 1984
	75MG	A085819	001	
	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	
ELAVIL				
ASTRAZENECA	10MG	N012703	001	
	25MG	N012703	003	
	50MG	N012703	004	
	75MG	N012703	005	
	100MG	N012703	006	
	150MG	N012703	007	
ENDEP				
ROCHE	10MG	A083639	001	
	25MG	A083639	002	
	50MG	A083639	003	
	75MG	A083639	004	
	100MG	A083639	005	
	150MG	A085303	001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

## CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MUTUAL PHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988
LIMBITROL				
HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG	N016949	001	
LIMBITROL DS				
HERITAGE PHARMS INC	EQ 25MG BASE;10MG	N016949	002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

## ETRAFON 2-10

SCHERING	10MG;2MG	N014713	007	
ETRAFON 2-25				
SCHERING	25MG;2MG	N014713	004	
ETRAFON-A				
SCHERING	10MG;4MG	N014713	002	
ETRAFON-FORTE				
SCHERING	25MG;4MG	N014713	006	

## PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
	10MG;4MG	A070937	001	Sep 11, 1986
	25MG;2MG	A070936	001	Sep 11, 1986
	25MG;4MG	A070938	001	Sep 11, 1986
	50MG;4MG	A070939	001	Sep 12, 1986
MUTUAL PHARM	10MG;2MG	A071077	001	Nov 12, 1986
	10MG;4MG	A071078	001	Nov 12, 1986

## DISCONTINUED DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

## TABLET; ORAL

## PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	25MG; 2MG	A070297	001	Nov 12, 1986
	25MG; 4MG	A071079	001	Nov 12, 1986
PAR PHARM	10MG; 2MG	A070565	001	Sep 11, 1986
	10MG; 4MG	A070620	001	Sep 11, 1986
	25MG; 2MG	A070621	001	Sep 11, 1986
	25MG; 4MG	A070595	001	Sep 11, 1986
	50MG; 4MG	A070574	001	Sep 11, 1986
SANDOZ	10MG; 2MG	A071062	001	Nov 27, 1987
	10MG; 4MG	A071862	001	Dec 21, 1987
	25MG; 2MG	A071063	001	Nov 27, 1987
	25MG; 4MG	A071064	001	Nov 27, 1987
	50MG; 4MG	A071863	001	Dec 21, 1987
WATSON LABS	10MG; 2MG	A070373	001	Aug 25, 1986
	10MG; 2MG	A072539	001	Feb 15, 1989
	10MG; 2MG	A073007	001	Oct 17, 1991
	10MG; 4MG	A070375	001	Aug 25, 1986
	10MG; 4MG	A072540	001	Feb 15, 1989
	10MG; 4MG	A073009	001	Oct 17, 1991
	25MG; 2MG	A070374	001	Aug 25, 1986
	25MG; 2MG	A072541	001	Feb 15, 1989
	25MG; 2MG	A073008	001	Oct 17, 1991
	25MG; 4MG	A070376	001	Aug 25, 1986
	25MG; 4MG	A072134	001	Feb 15, 1989
	25MG; 4MG	A073010	001	Oct 17, 1991
	50MG; 4MG	A070377	001	Nov 04, 1986
	50MG; 4MG	A071558	001	Mar 02, 1987
	50MG; 4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10				
NEW RIVER	10MG; 2MG	N014715	004	
TRIAVIL 2-25				
NEW RIVER	25MG; 2MG	N014715	002	
TRIAVIL 4-10				
NEW RIVER	10MG; 4MG	N014715	003	
TRIAVIL 4-25				
NEW RIVER	25MG; 4MG	N014715	005	
TRIAVIL 4-50				
NEW RIVER	50MG; 4MG	N014715	006	

AMLEXANOX

## PASTE; DENTAL

## APHTHASOL

## ULURU

5%

N020511 001 Dec 17, 1996

## PATCH; TOPICAL

## AMLEXANOX

## ULURU

2MG

N021727 001 Sep 29, 2004

AMLODIPINE BESYLATE

## TABLET; ORAL

## AMLODIPINE BESYLATE

## GEDEON RICHTER USA

EQ 2.5MG BASE

A077333 001 Jul 17, 2007

EQ 5MG BASE

A077333 002 Jul 17, 2007

EQ 10MG BASE

A077333 003 Jul 17, 2007

## GENPHARM

EQ 2.5MG BASE

A077362 001 Jul 09, 2007

EQ 5MG BASE

A077362 002 Jul 09, 2007

EQ 10MG BASE

A077362 003 Jul 09, 2007

## MUTUAL PHARMA

EQ 2.5MG BASE

A078081 001 Jan 31, 2008

EQ 5MG BASE

A078081 002 Jan 31, 2008

EQ 10MG BASE

A078081 003 Jan 31, 2008

## PURACAP PHARM

EQ 2.5MG BASE

A078131 001 Sep 04, 2007

EQ 5MG BASE

A078131 002 Sep 04, 2007

EQ 10MG BASE

A078131 003 Sep 04, 2007

## SANDOZ

EQ 2.5MG BASE

A076859 001 Sep 10, 2007

EQ 5MG BASE

A076859 002 Sep 10, 2007

EQ 10MG BASE

A076859 003 Sep 10, 2007

## SYNTHON PHARMS

EQ 2.5MG BASE

A077080 001 Jun 27, 2007

EQ 5MG BASE

A077080 002 Jun 27, 2007

EQ 10MG BASE

A077080 003 Jun 27, 2007

## TABLET, ORALLY DISINTEGRATING; ORAL

## AMLODIPINE BESYLATE

## SYNTHON PHARMS

EQ 2.5MG BASE

N022026 001 Sep 27, 2007



## DISCONTINUED DRUG PRODUCT LIST

AMLODIPINE BESYLATE

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

EQ 5MG BASE  
EQ 10MG BASEN022026 002 Sep 27, 2007  
N022026 003 Sep 27, 2007AMLODIPINE MALEATE

TABLET;ORAL

AMVAZ

DR REDDYS LABS INC 2.5MG  
5MG  
10MGN021435 001 Oct 31, 2003  
N021435 002 Oct 31, 2003  
N021435 003 Oct 31, 2003AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

CENTRAL RADIOPHARM 3.75-260mCi/ML

A204539 001 Jun 23, 2015

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE

ABBOTT 5MEQ/ML

A083130 001

GD SEARLE LLC 3MEQ/ML

A086205 001

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

MCGAW 900MG/100ML

N006580 001

AMMONIUM CHLORIDE 2.14%

B BRAUN 40MEQ/100ML

A085734 001

AMODIAQUINE HYDROCHLORIDE

TABLET;ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS EQ 200MG BASE

N006441 001

AMOXAPINE

TABLET;ORAL

AMOXAPINE

SANDOZ 25MG  
50MG  
100MG  
150MG  
WATSON LABS 25MG  
50MG  
100MG  
150MGA072943 001 Jun 28, 1991  
A072944 001 Jun 28, 1991  
A072878 001 Jun 28, 1991  
A072879 001 Jun 28, 1991  
A072418 001 May 11, 1989  
A072419 001 May 11, 1989  
A072420 001 May 11, 1989  
A072421 001 May 11, 1989

ASENDIN

LEDERLE 25MG  
50MG  
100MG  
150MGN018021 001  
N018021 002  
N018021 003  
N018021 004AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

LABS ATRAL 250MG  
500MG  
MYLAN 250MG  
500MG  
TEVA 250MG  
250MG  
500MG  
500MGA062528 001 Aug 07, 1985  
A062528 002 Aug 07, 1985  
A062067 001  
A062067 002  
A062853 001 Dec 22, 1987  
A063030 001 Feb 28, 1989  
A062854 001 Dec 22, 1987  
A063031 001 Feb 28, 1989

AMOXIL

GLAXOSMITHKLINE 250MG  
500MGN050459 001  
N050459 002

TRIMOX

APOTHECON 250MG  
250MG  
250MG  
250MG  
500MG  
500MG  
500MG  
500MGA061885 001  
A062098 001  
A062152 001  
A063099 001 Mar 20, 1992  
A061885 002  
A062098 002  
A062152 002  
A063099 002 Mar 20, 1992

UTIMOX

PARKE DAVIS 250MG

A062107 001

## DISCONTINUED DRUG PRODUCT LIST

AMOXICILLIN

## CAPSULE; ORAL

## UTIMOX

500MG A062107 002

## WYMOX

WYETH AYERST 250MG A062120 001

500MG A062120 002

## FOR SUSPENSION; ORAL

## AMOXICILLIN

AM ANTIBIOTICS 125MG/5ML A062059 001

250MG/5ML A062059 002

MYLAN 125MG/5ML A062090 001

250MG/5ML A062090 002

SUN PHARM INDS LTD 200MG/5ML A065113 001 Nov 29, 2002

400MG/5ML A065113 002 Nov 29, 2002

TEVA 125MG/5ML A062946 001 Nov 01, 1988

250MG/5ML A063001 001 Jan 06, 1989

## AMOXIL

GLAXOSMITHKLINE 50MG/ML N050460 005

125MG/5ML N050460 001

250MG/5ML N050460 002

## LAROTID

GLAXOSMITHKLINE 50MG/ML N050460 006

## POLYMOX

APOTHECON 125MG/5ML A061851 001

125MG/5ML A062323 001

250MG/5ML A061851 002

250MG/5ML A062323 002

## TRIMOX

APOTHECON 50MG/ML A061886 001

125MG/5ML A061886 002

125MG/5ML A062099 001

125MG/5ML A062154 001

125MG/5ML A062885 001 Mar 08, 1988

250MG/5ML A061886 003

250MG/5ML A062099 002

250MG/5ML A062154 002

250MG/5ML A062885 002 Mar 08, 1988

## UTIMOX

PARKE DAVIS 125MG/5ML A062127 001

250MG/5ML A062127 002

## WYMOX

WYETH AYERST 125MG/5ML A062131 001

250MG/5ML A062131 002

## TABLET; ORAL

## AMOXICILLIN

DAVA PHARMS INC 875MG A065344 001 Jan 15, 2009

## TABLET, CHEWABLE; ORAL

## AMOXICILLIN

APOTHECON 125MG A064131 001 May 06, 1996

250MG A064131 002 May 06, 1996

DAVA PHARMS INC 125MG A064139 001 Jan 29, 1996

250MG A064139 002 Jan 29, 1996

SUN PHARM INDS LTD 200MG A065060 001 Nov 29, 2000

400MG A065060 002 Nov 29, 2000

TEVA 125MG A064031 001 Dec 19, 1996

250MG A064031 002 Dec 19, 1996

## AMOXIL

DR REDDYS LABS INC 200MG N050761 001 Apr 15, 1999

400MG N050761 002 Apr 15, 1999

## TABLET, FOR SUSPENSION; ORAL

## AMOXICILLIN

AUROBINDO PHARMA LTD 200MG A065324 001 Jan 17, 2007

400MG A065324 002 Jan 17, 2007

## DISPERMOX

RANBAXY LABS LTD 200MG A065080 002 Aug 11, 2003

400MG A065080 001 Aug 11, 2003

600MG A065159 001 Dec 04, 2003

## DISCONTINUED DRUG PRODUCT LIST

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

APOTEX INC	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009
	500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009
	875MG;EQ 125MG BASE	A065317 003	Oct 20, 2008
SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109 001	Nov 04, 2002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESE

TEVA	1.25MG;1.25MG;1.25MG;1.25MG **Federal	A083564 001	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
	2.5MG;2.5MG;2.5MG;2.5MG **Federal	A083564 002	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
	3.75MG;3.75MG;3.75MG;3.75MG **Federal	A083564 003	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
	5MG;5MG;5MG;5MG **Federal	A083564 004	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

TABLET; ORAL

DELCOBESE

TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A083563 004	
	2.5MG;2.5MG;2.5MG;2.5MG	A083563 003	
	3.75MG;3.75MG;3.75MG;3.75MG	A083563 002	
	5MG;5MG;5MG;5MG	A083563 001	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 10

TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **Federal	N011522 007	Feb 13, 1996
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 12.5

TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG	N011522 012	Aug 31, 2000
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 15

TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **Federal	N011522 013	Aug 31, 2000
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 20

TEVA WOMENS	5MG;5MG;5MG;5MG **Federal	N011522 008	Feb 13, 1996
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 30

TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **Federal	N011522 010	May 12, 1997
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 5

TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **Federal	N011522 009	May 12, 1997
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 7.5

TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG	N011522 011	Aug 31, 2000
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472 001	Sep 30, 2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040472 002	Sep 30, 2003
	5MG;5MG;5MG;5MG	A040472 003	Sep 30, 2003

**DISCONTINUED DRUG PRODUCT LIST**AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

7.5MG; 7.5MG; 7.5MG; 7.5MG

A040472 004 Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5

UCB INC

EQ 6.25MG BASE; EQ 6.25MG BASE

N010093 007

BIPHETAMINE 20

UCB INC

EQ 10MG BASE; EQ 10MG BASE

N010093 003

BIPHETAMINE 7.5

UCB INC

EQ 3.75MG BASE; EQ 3.75MG BASE

N010093 009

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT

5MG

A083901 001 Aug 31, 1984

10MG

A083901 002 Aug 31, 1984

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

APOTHECON

3%

N050314 001

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT

50MG/VIAL

A064141 001 Dec 23, 1996

ABRAXIS PHARM

50MG/VIAL

A062728 001 Apr 13, 1987

TEVA PARENTERAL

50MG/VIAL

A064062 001 Mar 31, 1995

FUNGIZONE

APOTHECON

50MG/VIAL

A060517 001

LOTION; TOPICAL

FUNGIZONE

APOTHECON

3%

A060570 001

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON

3%

N050313 001

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB

100MG/ML

N050341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

APOTHECON

EQ 125MG BASE/VIAL

A062860 001 Feb 05, 1988

EQ 250MG BASE/VIAL

A062860 002 Feb 05, 1988

EQ 500MG BASE/VIAL

A062860 003 Feb 05, 1988

EQ 1GM BASE/VIAL

A062860 004 Feb 05, 1988

EQ 2GM BASE/VIAL

A062860 005 Feb 05, 1988

CONSOLIDATED PHARM

EQ 125MG BASE/VIAL

A061936 005

EQ 250MG BASE/VIAL

A061936 001

EQ 500MG BASE/VIAL

A061936 002

EQ 1GM BASE/VIAL

A061936 003

EQ 2GM BASE/VIAL

A061936 004

HANFORD GC

EQ 125MG BASE/VIAL

A063143 001 Apr 15, 1993

EQ 500MG BASE/VIAL

A063147 001 Apr 15, 1993

EQ 1GM BASE/VIAL

A063139 001 Apr 15, 1993

EQ 2GM BASE/VIAL

A063141 001 Apr 15, 1993

HIKMA MAPLE

EQ 125MG BASE/VIAL

A062692 001 Jun 24, 1986

EQ 250MG BASE/VIAL

A062692 002 Jun 24, 1986

EQ 500MG BASE/VIAL

A062692 003 Jun 24, 1986

EQ 1GM BASE/VIAL

A062692 004 Jun 24, 1986

EQ 2GM BASE/VIAL

A062692 005 Jun 24, 1986

EQ 10GM BASE/VIAL

A062692 006 Jun 24, 1986

INTL MEDICATION

EQ 1GM BASE/VIAL

A062634 002 Jan 09, 1987

EQ 2GM BASE/VIAL

A062634 003 Jan 09, 1987

LILLY

EQ 500MG BASE/VIAL

A062565 001 Apr 04, 1985

EQ 1GM BASE/VIAL

A062565 002 Apr 04, 1985

EQ 2GM BASE/VIAL

A062565 003 Jun 24, 1986

WATSON LABS INC

EQ 125MG BASE/VIAL

A062816 001 Oct 24, 1988

EQ 250MG BASE/VIAL

A062816 002 Oct 24, 1988

EQ 500MG BASE/VIAL

A062816 003 Oct 24, 1988

EQ 1GM BASE/VIAL

A062816 004 Oct 24, 1988

EQ 2GM BASE/VIAL

A062816 005 Oct 24, 1988

**DISCONTINUED DRUG PRODUCT LIST**AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

EQ 10GM BASE/VIAL A062994 001 Sep 15, 1988

OMNIPEN-N

WYETH AYERST

EQ 125MG BASE/VIAL A060626 001

EQ 125MG BASE/VIAL A062718 001 Dec 16, 1986

EQ 250MG BASE/VIAL A060626 002

EQ 250MG BASE/VIAL A062718 002 Dec 16, 1986

EQ 500MG BASE/VIAL A060626 003

EQ 500MG BASE/VIAL A062718 003 Dec 16, 1986

EQ 1GM BASE/VIAL A060626 004

EQ 1GM BASE/VIAL A062718 004 Dec 16, 1986

EQ 2GM BASE/VIAL A060626 005

EQ 2GM BASE/VIAL A062718 005 Dec 16, 1986

PENBRITIN-S

WYETH AYERST

EQ 125MG BASE/VIAL N050072 001

EQ 250MG BASE/VIAL N050072 002

EQ 500MG BASE/VIAL N050072 003

EQ 1GM BASE/VIAL N050072 004

EQ 2GM BASE/VIAL N050072 005

EQ 4GM BASE/VIAL N050072 006

POLYCILLIN-N

BRISTOL

EQ 125MG BASE/VIAL N050309 001

EQ 250MG BASE/VIAL N050309 002

EQ 500MG BASE/VIAL N050309 003

EQ 1GM BASE/VIAL N050309 004

EQ 2GM BASE/VIAL N050309 005

TOTACILLIN-N

GLAXOSMITHKLINE

EQ 125MG BASE/VIAL A060677 001

EQ 250MG BASE/VIAL A060677 002

EQ 500MG BASE/VIAL A060677 003

EQ 1GM BASE/VIAL A060677 004

EQ 1GM BASE/VIAL A062727 001 Dec 19, 1986

EQ 2GM BASE/VIAL A060677 005

EQ 2GM BASE/VIAL A062727 002 Dec 19, 1986

EQ 10GM BASE/VIAL A060677 006

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

PFIZER

EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL N050608 003 Dec 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS

EQ 250MG BASE A062041 001

EQ 500MG BASE A062041 002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 250MG BASE A061602 001

EQ 500MG BASE A061602 002

IVAX SUB TEVA PHARMS

EQ 250MG BASE A060765 001

EQ 500MG BASE A060765 002

LEDERLE

EQ 250MG BASE A062208 001

EQ 500MG BASE A062208 002

MYLAN

EQ 250MG BASE A061755 001

EQ 500MG BASE A061755 002

PUREPAC PHARM

EQ 250MG BASE A061853 001

EQ 500MG BASE A061853 002

TEVA

EQ 250MG BASE A061502 001

EQ 500MG BASE A061502 002

VITARINE

EQ 250MG BASE A061387 001

EQ 500MG BASE A061387 003

OMNIPEN (AMPICILLIN)

WYETH AYERST

250MG A060624 001

500MG A060624 002

PENBRITIN

WYETH AYERST

EQ 250MG BASE A060908 001

EQ 500MG BASE A060908 002

PFIZERPEN-A

PFIZER

EQ 250MG BASE A062050 001

EQ 500MG BASE A062050 002

## DISCONTINUED DRUG PRODUCT LIST

AMPICILLIN/AMPICILLIN TRIHYDRATE

## CAPSULE; ORAL

## POLYCILLIN

BRISTOL	EQ 250MG BASE	N050310 001
	EQ 500MG BASE	N050310 002

## PRINCIPEN

APOTHECON	EQ 250MG BASE	A062888 001	Mar 04, 1988
	EQ 500MG BASE	A062888 002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392 001	
	EQ 500MG BASE	A061392 002	

## PRINCIPEN '250'

APOTHECON	EQ 250MG BASE	A062157 002
	EQ 250MG BASE	N050056 001

## PRINCIPEN '500'

APOTHECON	EQ 500MG BASE	A062157 001
	EQ 500MG BASE	N050056 002

## TOTACILLIN

GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001
	EQ 250MG BASE	A062212 001
	EQ 500MG BASE	A060060 002
	EQ 500MG BASE	A062212 002

## FOR SUSPENSION; ORAL

## AMCILL

PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001
	EQ 250MG BASE/5ML	A062030 002

## AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061601 001
	EQ 250MG BASE/5ML	A061601 002
MYLAN	EQ 125MG BASE/5ML	A061829 002
	EQ 250MG BASE/5ML	A061829 001
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980 001
	EQ 250MG BASE/5ML	A061980 002
TEVA	EQ 125MG BASE/5ML	A061370 001
	EQ 250MG BASE/5ML	A061370 002

## OMNIPEN (AMPICILLIN)

WYETH AYERST	100MG/ML	A060625 001
	125MG/5ML	A060625 002
	250MG/5ML	A060625 003
	500MG/5ML	A060625 004

## PENBRITIN

WYETH AYERST	EQ 100MG BASE/ML	N050019 001
	EQ 125MG BASE/5ML	N050019 002
	EQ 250MG BASE/5ML	N050019 003

## PFIZERPEN-A

PFIZER	EQ 125MG BASE/5ML	A062049 001
	EQ 250MG BASE/5ML	A062049 002

## POLYCILLIN

APOTHECON	EQ 125MG BASE/5ML	A062297 001
	EQ 250MG BASE/5ML	A062297 002
BRISTOL	EQ 100MG BASE/ML	N050308 004
	EQ 125MG BASE/5ML	N050308 001
	EQ 250MG BASE/5ML	N050308 002
	EQ 500MG BASE/5ML	N050308 003

## PRINCIPEN

APOTHECON	EQ 100MG BASE/ML	A061394 001
	EQ 125MG BASE/5ML	A061394 002
	EQ 250MG BASE/5ML	A061394 003

## PRINCIPEN '125'

APOTHECON	EQ 125MG BASE/5ML	A060127 002
	EQ 125MG BASE/5ML	A062151 001

## PRINCIPEN '250'

APOTHECON	EQ 250MG BASE/5ML	A060127 001
	EQ 250MG BASE/5ML	A062151 002

## TOTACILLIN

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666 001
	EQ 125MG BASE/5ML	A062223 001
	EQ 250MG BASE/5ML	A060666 002
	EQ 250MG BASE/5ML	A062223 002

## TABLET, CHEWABLE; ORAL

## POLYCILLIN

BRISTOL	EQ 125MG BASE	N050093 001
---------	---------------	-------------

**DISCONTINUED DRUG PRODUCT LIST**AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

PRINCIPEN W/ PROBENECID

APOTHECON

EQ 389MG BASE;111MG

A062150 001

EQ 389MG BASE;111MG

N050488 001

FOR SUSPENSION; ORAL

POLYCILLIN-PRB

APOTHECON

EQ 3.5GM BASE/BOT;1GM/BOT

A061898 001

BRISTOL

EQ 3.5GM BASE/BOT;1GM/BOT

N050457 001

PROBAMPACIN

G AND W LABS INC

EQ 3.5GM BASE/BOT;1GM/BOT

A061741 001

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

GLAXOSMITHKLINE

50MG

N021007 001 Apr 15, 1999

150MG

N021007 002 Apr 15, 1999

SOLUTION; ORAL

AGENERASE

GLAXOSMITHKLINE

15MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021039 001 Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

SHIRE LLC

EQ 1MG BASE

N020333 002 Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

ROXANE

EQ 0.5MG BASE

A076489 001 Apr 18, 2005

EQ 1MG BASE

A076489 002 Apr 18, 2005

SANDOZ INC

EQ 0.5MG BASE

A076683 001 Apr 18, 2005

EQ 1MG BASE

A076683 002 Apr 18, 2005

WATSON LABS

EQ 0.5MG BASE

A076417 001 Apr 18, 2005

EQ 1MG BASE

A076417 002 Apr 18, 2005

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

IMPAX LABS INC

1MG

A091242 001 May 31, 2012

KREMERS URBAN PHARMS

1MG

A091331 001 Jan 05, 2011

SYNTHON PHARMS

1MG

A078322 001 Jun 28, 2010

WATSON LABS

1MG

A078984 001 Jun 28, 2010

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK

EQ 25MG BASE

N010585 002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK

25MG/ML

N010520 003

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING

50MG

N010909 003

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%;0.05%

N018746 002 Jul 11, 1994

## DISCONTINUED DRUG PRODUCT LIST

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

US WORLDMEDS

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

APROTININ

INJECTABLE; INJECTION

TRASYLOL

BAYER HLTHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS

0.05MG/ML

N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020227 002 May 23, 1997

10,000 UNITS/0.5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020227 001 May 23, 1997

ARGATROBAN

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

SANDOZ

125MG/125ML (1MG/ML)

N201743 001 May 09, 2011

ARIPIPIRAZOLE

SOLUTION; ORAL

ABILIFY

OTSUKA

1MG/ML \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021713 001 Dec 10, 2004

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

OTSUKA

20MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021729 004 Jun 07, 2006

30MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

MYLAN PHARMS INC

50MG

A200043 001 Jun 01, 2012

150MG

A200043 002 Jun 01, 2012

250MG

A200043 003 Jun 01, 2012

WATSON LABS INC

100MG

A200156 002 Aug 29, 2012

200MG

A200156 004 Aug 29, 2012

NUVIGIL

CEPHALON

100MG

N021875 002 Mar 26, 2009

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE

50MG/ML; 0.03MG/ML; 0.0025MG/ML; 7.5MG/ML;  
100  
IU/ML; 0.2MG/ML; 20MG/ML; 2MG/ML; 1.8MG/ML;

N006071 003 Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2  
0  
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018440 002 Aug 08, 1985



## DISCONTINUED DRUG PRODUCT LIST

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

HOSPIRA

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2  
0  
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N008809 004 Aug 08, 1985

MVC PLUS

WATSON LABS

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2  
0  
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018439 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

HOSPIRA

20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2  
0  
IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/M

N008809 005 Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

IGI LABS INC

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15M  
G/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4  
MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10  
MG/VIAL

N018933 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001  
MG/VIAL; 400  
IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 17MG/VI  
AL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/  
VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ  
2, 300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A

N020176 001 Dec 29, 1993

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC  
NOVEL LABS INC 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM

A090145 001 Jan 25, 2012

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER 500MG

N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER 650MG

N016030 001

MEASURIN

BAYER 650MG

N016030 002

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS 650MG; 50MG

A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

MUTUAL PHARM 325MG; 50MG; 40MG

A078149 001 Jun 13, 2007

WATSON LABS 325MG; 50MG; 40MG

A086231 002 Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH 325MG; 50MG; 40MG

A086710 002 Aug 23, 1983

HALSEY 325MG; 50MG; 40MG

A089448 001 Dec 01, 1986

IVAX PHARMS 325MG; 50MG; 40MG

A085441 002 Oct 31, 1984

PURACAP PHARM 325MG; 50MG; 40MG

A087048 002 Dec 09, 1983

QUANTUM PHARMICS 325MG; 50MG; 40MG

A088972 001 Jun 18, 1985

SANDOZ 325MG; 50MG; 40MG

A086398 002 Apr 06, 1984

WATSON LABS 325MG; 50MG; 40MG

A086237 002 Mar 23, 1984

FIORINAL

ACTAVIS LABS UT INC 325MG; 50MG; 40MG

N017534 003 Apr 16, 1986

## DISCONTINUED DRUG PRODUCT LIST

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

LANORINAL

LANNETT

325MG; 50MG; 40MG

A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC

325MG; 50MG; 40MG; 30MG

A075351 001 Mar 05, 1999

WATSON LABS

325MG; 50MG; 40MG; 30MG

A074359 001 Aug 31, 1995

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ

385MG; 30MG; 25MG

A074817 001 Nov 27, 1996

INVAGESIC FORTE

SANDOZ

770MG; 60MG; 50MG

A074817 002 Nov 27, 1996

NORGESIC

MEDICIS

385MG; 30MG; 25MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N013416 003 Oct 27, 1982

NORGESIC FORTE

MEDICIS

770MG; 60MG; 50MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N013416 004 Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

STEVENS J

385MG; 30MG; 25MG

A074988 001 Apr 30, 1999

770MG; 60MG; 50MG

A074988 002 Apr 30, 1999

ORPHENGESIC

PRINSTON INC

385MG; 30MG; 25MG

A075141 001 May 29, 1998

ORPHENGESIC FORTE

PRINSTON INC

770MG; 60MG; 50MG

A075141 002 May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA

389MG; 32.4MG; 65MG

A084553 002 Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM

389MG; 32.4MG; 32MG

N010996 006 Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM

389MG; 32.4MG; 65MG

N010996 007 Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS

389MG; 32.4MG; 65MG

A083077 002 Dec 07, 1984

SANDOZ

389MG; 32.4MG; 65MG

A080044 002 Sep 16, 1983

TEVA

389MG; 32.4MG; 65MG

A089025 001 Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ

389MG; 32.4MG; 65MG

A083101 002 Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS

389MG; 32.4MG; 65MG

A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND

WATSON LABS

325MG; 200MG

A088809 001 Oct 03, 1985

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

MIRROR PHARMS

325MG; 200MG; 16MG

A040860 001 Jan 07, 2010

PROSAM LABS

325MG; 200MG; 16MG

A040283 001 Dec 29, 1998

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA

500MG; 5MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT

500MG; 5MG

A086333 001 Sep 14, 1983

## DISCONTINUED DRUG PRODUCT LIST

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

CARACO	325MG;200MG	N011702 003	Dec 29, 1983
MEPRO-ASPIRIN			
SANDOZ	325MG;200MG	A089127 001	Mar 02, 1987
MEPROBAMATE AND ASPIRIN			
PAR PHARM	325MG;200MG	A089126 001	Aug 19, 1986
MICRAININ			
MEDPOINTE PHARM HLC	325MG;200MG	A084978 001	
Q-GESIC			
QUANTUM PHARMICS	325MG;200MG	A088740 001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS	325MG;400MG	A087211 001	Dec 22, 1982
MCNEIL	325MG;400MG	A089193 001	Feb 12, 1986
PAR PHARM	325MG;400MG	A089657 001	Nov 04, 1988
ROBAXISAL			
ROBINS AH	325MG;400MG	N012281 001	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY	325MG;4.5MG;0.38MG	A087464 001	Jul 01, 1982
OXYCODONE AND ASPIRIN			
MUTUAL PHARM	325MG;4.5MG;0.38MG	A040260 001	Jul 17, 1998
	325MG;4.5MG;0.38MG	A087794 001	May 26, 1982
WATSON LABS	325MG;4.5MG;0.38MG	A040255 001	Feb 27, 1998
OXYCODONE AND ASPIRIN (HALF-STRENGTH)			
ROXANE	325MG;2.25MG;0.19MG	A087742 001	Jun 04, 1982
PERCODAN			
ENDO PHARMS	325MG;4.5MG;0.38MG	N007337 006	
PERCODAN-DEMI			
ENDO PHARMS	325MG;2.25MG;0.19MG	N007337 005	
ROXIPRIN			
ROXANE	325MG;4.5MG;0.38MG	A087743 001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

SANOFI AVENTIS US	325MG;EQ 12.5MG BASE	N016891 001	
-------------------	----------------------	-------------	--

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	325MG,N/A;N/A,80MG	N021387 006	Jun 24, 2003
TABLET, TABLET, TABLET; ORAL			
PRAVIGARD PAC (COPACKAGED)			
BRISTOL MYERS SQUIBB	81MG,N/A;N/A,20MG	N021387 001	Jun 24, 2003
	81MG,N/A;N/A,40MG	N021387 002	Jun 24, 2003
	81MG,N/A;N/A,80MG	N021387 003	Jun 24, 2003
	325MG,N/A;N/A,20MG	N021387 004	Jun 24, 2003
	325MG,N/A;N/A,40MG	N021387 005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG;65MG	N010996 005	
----------------	------------	-------------	--

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016829 001	
---------------	-------------	-------------	--

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016863 001	
---------------	-------------	-------------	--

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

BRISTOL MYERS SQUIBB	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021567 001	Jun 20, 2003
----------------------	--	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

ATENOLOL

## INJECTABLE; INJECTION

## TENORMIN

ASTRAZENECA	0.5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019058 001	Sep 13, 1989
-------------	--	-------------	--------------

## TABLET; ORAL

## ATENOLOL

ABLE	25MG	A076907 001	Jul 30, 2004
	50MG	A076907 002	Jul 30, 2004
	100MG	A076907 003	Jul 30, 2004
APOTHECON	50MG	A073317 001	Mar 20, 1992
	100MG	A073318 001	Mar 20, 1992
DAVA PHARMS INC	25MG	A074099 001	Apr 28, 1992
	MYLAN	25MG	A074126 003
50MG		A074126 001	Mar 23, 1994
100MG		A074126 002	Mar 23, 1994
NOSTRUM LABS	50MG	A074127 001	Feb 21, 1995
	100MG	A074127 002	Feb 21, 1995
PLIVA	25MG	A074101 001	Jul 17, 1997
	50MG	A074101 002	Jul 17, 1997
	100MG	A074101 003	Jul 17, 1997
SANDOZ	25MG	A074265 001	Feb 28, 1994
	50MG	A074265 002	Feb 28, 1994
	100MG	A074265 003	Feb 28, 1994
SCS	50MG	A073676 001	Oct 30, 1992
	100MG	A073676 002	Oct 30, 1992
TEVA	50MG	A073315 001	May 28, 1993
	100MG	A073316 001	May 28, 1993
TEVA PHARMS	50MG	A074120 001	Feb 24, 1995
	100MG	A074120 002	Feb 24, 1995
WATSON LABS	50MG	A073352 001	Dec 27, 1991
	100MG	A073353 001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

## TABLET; ORAL

## ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG; 25MG	A074404 001	May 14, 1998
	100MG; 25MG	A074404 002	May 14, 1998
PLIVA	50MG; 25MG	A074107 001	Sep 24, 1997
	100MG; 25MG	A074107 002	Sep 24, 1997

ATOMOXETINE HYDROCHLORIDE

## CAPSULE; ORAL

## ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC	18MG	A079017 001	Sep 17, 2010
	25MG	A079017 002	Sep 17, 2010
	40MG	A079017 003	Sep 17, 2010
	60MG	A079017 004	Sep 17, 2010
	80MG	A079017 005	Sep 17, 2010
	100MG	A079017 006	Sep 17, 2010

## STRATTERA

LILLY	5MG	N021411 001	Nov 26, 2002
-------	-----	-------------	--------------

ATORVASTATIN CALCIUM

## TABLET; ORAL

## ATORVASTATIN CALCIUM

TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012
	EQ 20MG BASE	A078773 002	May 29, 2012
	EQ 40MG BASE	A078773 003	May 29, 2012
	EQ 80MG BASE	A078773 004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

## TABLET; ORAL

## LIPTRUZET

MERCK SHARP DOHME	EQ 10MG BASE; 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200153 001	May 03, 2013
	EQ 20MG BASE; 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200153 002	May 03, 2013
	EQ 40MG BASE; 10MG **Federal Register determination that product was not	N200153 003	May 03, 2013

## DISCONTINUED DRUG PRODUCT LIST

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

discontinued or withdrawn for safety or efficacy reasons\*\*

EQ 80MG BASE;10MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N200153 004 May 03, 2013

ATOVAQUONE

TABLET; ORAL

MEPRON

GLAXOSMITHKLINE LLC

250MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020259 001 Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE

10MG/ML

A074824 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074753 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074632 001 Dec 23, 1996

10MG/ML

A074740 001 Mar 28, 1997

TEVA PARENTERAL

10MG/ML

A074784 001 Jun 11, 1997

WATSON LABS INC

10MG/ML

A074945 001 Jul 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE

10MG/ML

A074825 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074768 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074633 001 Dec 23, 1996

10MG/ML

A074639 001 Mar 25, 1997

10MG/ML

A074741 001 Mar 28, 1997

WATSON LABS INC

10MG/ML

A074944 001 Jul 28, 1998

TRACRIUM

HOSPIRA

10MG/ML \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N018831 002 Jun 20, 1985

TRACRIUM PRESERVATIVE FREE

HOSPIRA

10MG/ML \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N018831 001 Nov 23, 1983

ATROPINE

INJECTABLE; INJECTION

ATROPINE

ABBVIE

EQ 2MG SULFATE/0.7ML

A071295 001 Jan 30, 1987

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY

EQ 0.36MG BASE/INH

N020056 001 Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

SEBELA IRELAND LTD

0.025MG;0.5MG

N017744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP

0.025MG;2.5MG

A086440 001

SOLUTION; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG/5ML;2.5MG/5ML

A085735 001

LOMANATE

ALPHARMA US PHARMS

0.025MG/5ML;2.5MG/5ML

A085746 001

LOMOTIL

GD SEARLE LLC

0.025MG/5ML;2.5MG/5ML

N012699 001

TABLET; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG;2.5MG

A085737 001

DI-ATRO

MD PHARM

0.025MG;2.5MG

A085266 001

**DISCONTINUED DRUG PRODUCT LIST**ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

## TABLET; ORAL

## DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE	0.025MG;2.5MG	A040395 001	Nov 27, 2000
ANI PHARMS INC	0.025MG;2.5MG	A086727 001	
ASCOT	0.025MG;2.5MG	A087934 001	Jul 19, 1983
HEATHER	0.025MG;2.5MG	A086798 001	
HIKMA PHARMS LLC	0.025MG;2.5MG	A087765 001	Mar 15, 1982
INWOOD LABS	0.025MG;2.5MG	A085509 001	
KV PHARM	0.025MG;2.5MG	A085659 001	
LEDERLE	0.025MG;2.5MG	A086950 001	
MUTUAL PHARM	0.025MG;2.5MG	A085506 001	
PARKE DAVIS	0.025MG;2.5MG	A087131 001	
PVT FORM	0.025MG;2.5MG	A085766 001	
R AND S PHARMA	0.025MG;2.5MG	A085035 001	
ROXANE	0.025MG;2.5MG	A086057 001	
SANDOZ	0.025MG;2.5MG	A086173 001	
USL PHARMA	0.025MG;2.5MG	A087842 001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG;2.5MG	A087195 001	Feb 16, 1982
WATSON LABS	0.025MG;2.5MG	A085876 001	
LO-TROL			
VANGARD	0.025MG;2.5MG	A088009 001	Mar 25, 1983
LOGEN			
SUPERPHARM	0.025MG;2.5MG	A088962 001	May 10, 1985
LOW-QUEL			
HALSEY	0.025MG;2.5MG	A085211 001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

## INJECTABLE; INJECTION

## ENLON-PLUS

MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677 001	Nov 06, 1991
---------------------	-------------------	-------------	--------------

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ATROPINE AND DEMEROL

ABBVIE	0.4MG/ML;50MG/ML	A087853 001	Nov 26, 1982
	0.4MG/ML;75MG/ML	A087847 001	Nov 26, 1982
	0.4MG/ML;100MG/ML	A087848 001	Nov 26, 1982

## MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST	0.4MG/ML;50MG/ML	A085121 001	
	0.4MG/ML;75MG/ML	A085121 002	
	0.4MG/ML;100MG/ML	A085121 003	

ATROPINE; PRALIDOXIME CHLORIDE

## INJECTABLE; INTRAMUSCULAR

## ATNAA

US ARMY	2.1MG/0.7ML;600MG/0.7ML;600MG/0.7ML	N021175 001	Jan 17, 2002
---------	-------------------------------------	-------------	--------------

AZATADINE MALEATE

## TABLET; ORAL

## OPTIMINE

SCHERING	1MG	N017601 001	
----------	-----	-------------	--

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

## TABLET, EXTENDED RELEASE; ORAL

## TRINALIN

SCHERING	1MG;120MG	N018506 001	Mar 23, 1982
----------	-----------	-------------	--------------

AZATHIOPRINE

## TABLET; ORAL

## IMURAN

PROMETHEUS LABS	25MG	N016324 002	
-----------------	------	-------------	--

AZATHIOPRINE SODIUM

## INJECTABLE; INJECTION

## IMURAN

PROMETHEUS LABS	EQ 100MG BASE/VIAL	N017391 001	
-----------------	--------------------	-------------	--

AZELASTINE HYDROCHLORIDE

## SPRAY, METERED; NASAL

## ASTEPRO

MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203 001	Oct 15, 2008
-------------	-----------------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

PFIZER

EQ 250MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N050670 001 Nov 01, 1991

FOR SUSPENSION; ORAL

AZITHROMYCIN

SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

INJECTABLE; INJECTION

AZITHROMYCIN

PLIVA HRVATSKA DOO

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

TEVA PARENTERAL

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER

EQ 1GM BASE, N/A; N/A, EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

BAYER PHARMS

EQ 2GM BASE/VIAL

A062388 001 Sep 08, 1982

EQ 2GM BASE/VIAL

A062417 001 Oct 12, 1982

EQ 2GM BASE/VIAL

N050562 001 Sep 03, 1982

EQ 3GM BASE/VIAL

A062388 002 Sep 08, 1982

EQ 3GM BASE/VIAL

A062417 002 Oct 12, 1982

EQ 3GM BASE/VIAL

N050562 002 Sep 03, 1982

EQ 4GM BASE/VIAL

A062388 003 Sep 08, 1982

EQ 4GM BASE/VIAL

A062417 003 Oct 12, 1982

EQ 4GM BASE/VIAL

N050562 003 Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

BRISTOL MYERS SQUIBB

500MG/VIAL

N050580 001 Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB

10MG/ML

N050632 003 May 24, 1989

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

PFIZER

125MG/5ML

N050556 001 Mar 23, 1982

TABLET; ORAL

SPECTROBID

PFIZER

400MG

N050520 001

800MG

N050520 002 Sep 12, 1983

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

PFIZER

50,000 UNITS/VIAL

A060282 001

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN

500 UNITS/GM

A060734 001

BACITRACIN

LILLY

500 UNITS/GM

A060687 001

PHARMADERM

500 UNITS/GM

A062158 001

PHARMAFAIR

500 UNITS/GM

A062453 001 Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE

500 UNITS/GM

A062799 001 May 14, 1987

NASKA

500 UNITS/GM

A062857 001 Nov 13, 1987

POWDER; FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001

BACITRACIN

APOTHEKERNES

5,000,000 UNITS/BOT

A061699 001

PADDOCK LLC

5,000,000 UNITS/BOT

A062456 001 Jul 27, 1983

**DISCONTINUED DRUG PRODUCT LIST**BACITRACIN ZINC

POWDER;FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS

500,000 UNITS/BOT

A061737 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CORTISPORIN

CITRON PHARMA LLC

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050416 002

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE &amp; HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062389 001 Jul 02, 1982

OINTMENT;TOPICAL

NEOMYCIN &amp; POLYMYXIN B SULFATES &amp; BACITRACIN ZINC &amp; HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062381 001 Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

LANABIOTIC

COMBE

400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM

A062499 001 Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR

400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062386 001 Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062167 001

NEO-POLYCIN

DOW PHARM

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060647 001

NEOSPORIN

CITRON PHARMA LLC

400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050417 001

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062833 001 Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

GLAXOSMITHKLINE

10,000 UNITS/GM;2,000,000 UNITS/GM

N050167 002 Mar 01, 1985

OINTMENT;OPHTHALMIC

OCUMYCIN

PHARMAFAIR

500 UNITS/GM;10,000 UNITS/GM

A062430 001 Apr 08, 1983

POLYSPORIN

MONARCH PHARMS

500 UNITS/GM;10,000 UNITS/GM

A061229 001

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA

500 UNITS/GM;10,000 UNITS/GM

A062849 001 Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060731 002

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A061048 001

BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL

LANABIOTIC

COMBE

500 UNITS/GM;5,000 UNITS/GM

N050598 001 Sep 22, 1986



## DISCONTINUED DRUG PRODUCT LIST

BACLOFEN

TABLET; ORAL

BACLOFEN

TEVA	10MG	A073043 001	Feb 27, 1992
	20MG	A073044 001	Feb 27, 1992
USL PHARMA	10MG	A071260 001	May 06, 1988
	20MG	A071261 001	May 06, 1988
WATSON LABS	10MG	A073092 001	Jan 28, 1994
	10MG	A074698 001	Aug 20, 1996
	20MG	A073093 001	Jan 28, 1994
	20MG	A074698 002	Aug 20, 1996

Lioresal

NOVARTIS	10MG	N017851 001	
	20MG	N017851 003	Jan 20, 1982

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

UCB INC	10MG	N021589 001	Oct 30, 2003
	20MG	N021589 002	Oct 30, 2003

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

GLAXOSMITHKLINE	0.042MG/INH	N018153 001	
-----------------	-------------	-------------	--

VANCERIL

SCHERING	0.042MG/INH	N017573 001	
----------	-------------	-------------	--

VANCERIL DOUBLE STRENGTH

SCHERING	0.084MG/INH	N020486 001	Dec 24, 1996
----------	-------------	-------------	--------------

AEROSOL, METERED; NASAL

BECONASE

GLAXOSMITHKLINE	0.042MG/INH	N018584 001	
-----------------	-------------	-------------	--

VANCENASE

SCHERING	0.042MG/INH	N018521 001	
----------	-------------	-------------	--

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

VANCENASE AQ

SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589 001	Dec 23, 1987
	EQ 0.084MG DIPROP/SPRAY	N020469 001	Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

GENPHARM	5MG	A076476 001	Feb 11, 2004
	10MG	A076476 002	Feb 11, 2004
	20MG	A076476 003	Feb 11, 2004
	40MG	A076476 004	Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MYLAN PHARMS INC	5MG; 6.25MG	A076612 001	Feb 11, 2004
	10MG; 12.5MG	A076612 002	Feb 11, 2004
	20MG; 12.5MG	A076612 003	Feb 11, 2004
	20MG; 25MG	A076612 004	Feb 11, 2004

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

APOTHECON	10MG	N012164 003	
-----------	------	-------------	--

NATURETIN-2.5

APOTHECON	2.5MG	N012164 001	
-----------	-------	-------------	--

NATURETIN-5

APOTHECON	5MG	N012164 002	
-----------	-----	-------------	--

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND	0.4%	A084149 001	
------------------	------	-------------	--

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

SAVAGE LABS	500MG/7.5ML	N018366 001	Dec 29, 1983
-------------	-------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

BENZONATATE

CAPSULE; ORAL

BENZONATATE

NESHER PHARMS

100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

TESSALON

PFIZER

200MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N011210 003 Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZAACLIN

VALEANT BERMUDA

5%;EQ 1% BASE

N050756 002 Apr 20, 2007

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

COREPHARMA

50MG

A040714 001 Oct 29, 2007

DIDREX

PHARMACIA AND UPJOHN

25MG

N012427 003

50MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N012427 002

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

PFIZER

EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG

EQ 100MG BASE

N016818 006

BENZTHIAZIDE

TABLET; ORAL

AQUATAG

SOLVAY

25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM

50MG

A083206 001

EXNA

AH ROBINS INC

50MG

N012489 001

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

LANNETT HOLDINGS INC

0.5MG

A088877 001 Apr 11, 1985

1MG

A088894 001 Apr 11, 1985

2MG

A088895 001 Apr 11, 1985

MUTUAL PHARM

1MG

A081264 001 Jan 23, 1992

2MG

A081265 001 Jan 23, 1992

PROSAM LABS

0.5MG

A040699 001 Feb 14, 2008

1MG

A040705 001 Feb 14, 2008

2MG

A040706 001 Feb 14, 2008

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

MERCK

0.5MG

N009193 004

1MG

N009193 003

2MG

N009193 002

**DISCONTINUED DRUG PRODUCT LIST**BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001 Dec 28, 1990

300MG

N019001 002 Dec 28, 1990

400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE

30MG

N017589 001

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING

0.2%

N014762 001

SYRUP; ORAL

CELESTONE

MERCK SHARP DOHME

0.6MG/5ML

N014215 002

TABLET; ORAL

CELESTONE

SCHERING

0.6MG

N012657 003

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N016998 002

GEL; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017244 001

LOTION; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017528 001

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N018089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072536 001 Jan 31, 1990

EQ 0.05% BASE

A074579 001 Nov 26, 1997

PHARMADERM

EQ 0.05% BASE

N019136 001 Jun 26, 1984

TARO

EQ 0.05% BASE

A071143 001 Jun 17, 1987

TEVA

EQ 0.05% BASE

A071476 001 Aug 10, 1987

DIPROSONE

SCHERING

EQ 0.05% BASE

N017536 001

CREAM, AUGMENTED; TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 001 Jan 31, 1986

DISC; TOPICAL

DIPROSONE

SCHERING

EQ 0.1% BASE

N017829 001

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 002 Nov 22, 1991

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ALPHARMA US PHARMS

EQ 0.05% BASE

A071085 001 Feb 03, 1987

G AND W LABS INC

EQ 0.05% BASE

A071882 001 Jun 06, 1988

PHARMADERM

EQ 0.05% BASE

A070274 001 Aug 12, 1985

TARO

EQ 0.05% BASE

A072276 001 Aug 24, 1988

**DISCONTINUED DRUG PRODUCT LIST**BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

EQ 0.05% BASE

A074272 001 Sep 30, 1994

DIPROSONE

SCHERING

EQ 0.05% BASE

N017781 001

OINTMENT; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072526 001 Jan 31, 1990

PHARMADERM

EQ 0.05% BASE

N019140 001 Sep 04, 1984

TEVA

EQ 0.05% BASE

A071477 001 Aug 10, 1987

DIPROSONE

SCHERING

EQ 0.05% BASE

N017691 001

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS

EQ 3MG BASE/ML

A085738 001

CELESTONE

SCHERING

EQ 3MG BASE/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N017561 001

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO

EQ 0.1% BASE

N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK

EQ 0.1% BASE

A070053 001 Jun 10, 1986

PHARMADERM

EQ 0.1% BASE

N018860 002 Aug 31, 1983

PHARMAFAIR

EQ 0.1% BASE

A070485 001 May 29, 1987

TARO

EQ 0.1% BASE

A070062 001 May 14, 1985

BETATREX

SAVAGE LABS

EQ 0.1% BASE

N018862 001 Aug 31, 1983

VALISONE

SCHERING

EQ 0.01% BASE

N016322 002

EQ 0.1% BASE

N016322 001

LOTION; TOPICAL

BETAMETHASONE VALERATE

PHARMADERM

EQ 0.1% BASE

N018870 001 Aug 31, 1983

PHARMAFAIR

EQ 0.1% BASE

A070484 001 May 29, 1987

TEVA PHARMS

EQ 0.1% BASE

A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS

EQ 0.1% BASE

N018867 001 Aug 31, 1983

VALISONE

SCHERING

EQ 0.1% BASE

N016932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK

EQ 0.1% BASE

A071478 001 Dec 23, 1987

PHARMADERM

EQ 0.1% BASE

N018864 001 Aug 31, 1983

PHARMAFAIR

EQ 0.1% BASE

A070486 001 May 29, 1987

BETATREX

SAVAGE LABS

EQ 0.1% BASE

N018863 001 Aug 31, 1983

VALISONE

SCHERING

EQ 0.1% BASE

N016740 001

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC

EQ 0.5% BASE

A075446 001 Sep 28, 2000

TABLET; ORAL

KERLONE

SANOFI AVENTIS US

10MG

N019507 001 Oct 27, 1989

20MG

N019507 002 Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US

5MG; 12.5MG

N019807 001 Oct 30, 1992

10MG; 12.5MG

N019807 002 Oct 30, 1992

## DISCONTINUED DRUG PRODUCT LIST

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC PILO

ALCON

EQ 0.25% BASE;1.75%

N020619 001 Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY

50MG/ML

N009344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

ODYSSEY PHARMS

5MG/ML \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N006536 001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE

5MG

A040492 001 Jul 27, 2004

10MG

A040483 001 Jul 27, 2004

25MG

A040485 001 Jul 27, 2004

50MG

A040509 001 Jul 27, 2004

ACTAVIS ELIZABETH

5MG

A040552 001 Oct 28, 2004

10MG

A040553 001 Oct 28, 2004

25MG

A040554 001 Oct 28, 2004

50MG

A040551 001 Oct 28, 2004

ASCOT

10MG

A088288 001 Jun 08, 1983

25MG

A088289 001 Jun 08, 1983

IVAX SUB TEVA PHARMS

25MG

A084689 001

LANNETT

5MG

A084702 001

10MG

A084712 001

25MG

A084074 001

SANDOZ

5MG

A084353 001

10MG

A084378 001

10MG

A084379 001

25MG

A084383 001

25MG

A084384 001

WATSON LABS

5MG

A084402 001

5MG

A085230 002

5MG

A085841 001

10MG

A084408 001

10MG

A085228 001

10MG

A085842 001

25MG

A084441 001

25MG

A085229 001

25MG

A085839 001

50MG

A087397 001

50MG

A087444 001

MYOTONACHOL

GLENWOOD

5MG

A084188 001

10MG

A084188 003

25MG

A084188 004

URECHOLINE

ODYSSEY PHARMS

5MG

N006536 003

10MG

N006536 002

25MG

N006536 004

50MG

N006536 005

BETHANIDINE SULFATE

TABLET; ORAL

TENATHAN

ROBINS AH

10MG

N017675 001

25MG

N017675 002

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

KUDCO IRELAND

50MG

A077995 001 Jul 06, 2009

ROXANE

50MG

A078285 001 Mar 24, 2011

SYNTHON PHARMS

50MG

A077973 001 Jul 06, 2009

## DISCONTINUED DRUG PRODUCT LIST

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

LUMIGAN

ALLERGAN

0.03% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021275 001 Mar 16, 2001

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL

AKINETON

ABBVIE

2MG

N012003 001

BIPERIDEN LACTATE

INJECTABLE;INJECTION

AKINETON

ABBVIE

5MG/ML

N012418 002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

HALFLYTELY

BRAINTREE

5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM  
;N/A,5.6GM \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021551 003 Jul 16, 2010

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

PROMETHEUS LABS

262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,5  
00MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N050719 001 Aug 15, 1996

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

MUTUAL PHARM

5MG

A075474 001 Oct 25, 2002

10MG

A075474 002 Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH

2.5MG;6.25MG

A075672 001 Sep 25, 2000

5MG;6.25MG

A075672 002 Sep 25, 2000

10MG;6.25MG

A075672 003 Sep 25, 2000

APOTHECON

2.5MG;6.25MG

A075642 002 Dec 27, 2000

5MG;6.25MG

A075642 001 Dec 27, 2000

10MG;6.25MG

A075642 003 Dec 27, 2000

IVAX SUB TEVA PHARMS

2.5MG;6.25MG

A075632 001 Sep 27, 2000

5MG;6.25MG

A075632 002 Sep 27, 2000

10MG;6.25MG

A075632 003 Sep 27, 2000

SANDOZ

2.5MG;6.25MG

A075527 001 Sep 25, 2000

5MG;6.25MG

A075527 003 Sep 25, 2000

10MG;6.25MG

A075527 002 Sep 25, 2000

TEVA

2.5MG;6.25MG

A075686 001 Jan 19, 2001

5MG;6.25MG

A075686 002 Jan 19, 2001

10MG;6.25MG

A075686 003 Jan 19, 2001

WATSON LABS

2.5MG;6.25MG

A075469 001 Sep 25, 2000

5MG;6.25MG

A075469 002 Sep 25, 2000

10MG;6.25MG

A075469 003 Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED;INHALATION

TORNALATE

SANOFI AVENTIS US

0.37MG/INH

N018770 001 Dec 28, 1984

SOLUTION;INHALATION

TORNALATE

SANOFI AVENTIS US

0.2%

N019548 001 Feb 19, 1992

**DISCONTINUED DRUG PRODUCT LIST**BLEOMYCIN SULFATE

## INJECTABLE; INJECTION

## BLENOXANE

BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL	N050443	001	
	EQ 30 UNITS BASE/VIAL	N050443	002	Sep 07, 1995

## BLEOMYCIN SULFATE

PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007
TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
	EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996

BRETYLIUM TOSYLATE

## INJECTABLE; INJECTION

## BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
HIKMA MAPLE	50MG/ML	A070545	001	May 14, 1986
	50MG/ML	A070546	001	May 14, 1986
HOSPIRA	50MG/ML	N019030	001	Apr 29, 1986
	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988

## BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986

## BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
	400MG/100ML	N019008	003	Apr 29, 1986
	800MG/100ML	N019008	001	Apr 29, 1986

## BRETYLOL

HOSPIRA	50MG/ML	N017954	001	
---------	---------	---------	-----	--

BRIMONIDINE TARTRATE

## SOLUTION/DROPS; OPHTHALMIC

## ALPHAGAN

ALLERGAN	0.2%	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997

## BRIMONIDINE TARTRATE

TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004
-----------------	------	---------	-----	--------------

BROMFENAC SODIUM

## SOLUTION/DROPS; OPHTHALMIC

## BROMDAY

BAUSCH AND LOMB INC	EQ 0.09% ACID **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021664	002	Oct 16, 2010
---------------------	--	---------	-----	--------------

## XIBROM

BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005
---------------------	---------------	---------	-----	--------------

BROMOCRIPTINE MESYLATE

## CAPSULE; ORAL

## BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998
-----------	-------------	---------	-----	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE

## CAPSULE; ORAL

## AMBODRYL

PARKE DAVIS	25MG	N007984	001	
-------------	------	---------	-----	--

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

## SYRUP; ORAL

## AMBENYL

FOREST LABS	12.5MG/5ML; 10MG/5ML	N009319	006	Jan 10, 1984
-------------	----------------------	---------	-----	--------------

## BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML; 10MG/5ML	A088343	001	Aug 15, 1984
--------------------	----------------------	---------	-----	--------------

## BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT	12.5MG/5ML; 10MG/5ML	A088626	001	Oct 12, 1984
-----------	----------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

BROMPHENIRAMINE MALEATE

## ELIXIR; ORAL

## BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936	001	
KV PHARM	2MG/5ML	A085466	001	
PHARM ASSOC	2MG/5ML	A087517	001	
USL PHARMA	2MG/5ML	A087964	001	Jan 25, 1983

## INJECTABLE; INJECTION

## BROMPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A083821	001	
	100MG/ML	A083820	001	

## DIMETANE-TEN

WYETH AYERST	10MG/ML	N011418	002	
--------------	---------	---------	-----	--

## TABLET; ORAL

## BROMPHENIRAMINE MALEATE

BARR	4MG	A084468	001	
IVAX SUB TEVA PHARMS	4MG	A084351	001	
NEWTRON PHARMS	4MG	A086987	001	
NEXGEN PHARMA INC	4MG	A086187	001	
PAR PHARM	4MG	A087009	001	
PIONEER PHARMS	4MG	A088604	001	Jul 13, 1984
SANDOZ	4MG	A083215	001	
VITARINE	4MG	A085850	001	
WATSON LABS	4MG	A083123	001	
	4MG	A085769	001	

## DIMETANE

WYETH CONS	4MG	N010799	003	
------------	-----	---------	-----	--

## TABLET, EXTENDED RELEASE; ORAL

## DIMETANE

WYETH CONS	8MG	N010799	010	Jun 10, 1983
	12MG	N010799	011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

## SYRUP; ORAL

## BROMANATE DM

ALPHARMA US PHARMS	2MG/5ML; 10MG/5ML; 30MG/5ML	A088722	001	Mar 07, 1985
--------------------	-----------------------------	---------	-----	--------------

## BROMFED-DM

WOCKHARDT	2MG/5ML; 10MG/5ML; 30MG/5ML	A089681	001	Dec 22, 1988
-----------	-----------------------------	---------	-----	--------------

## DIMETANE-DX

ROBINS AH	2MG/5ML; 10MG/5ML; 30MG/5ML	N019279	001	Aug 24, 1984
-----------	-----------------------------	---------	-----	--------------

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA	16MG; 240MG	N019672	001	Mar 29, 1996
------	-------------	---------	-----	--------------

BUCLIZINE HYDROCHLORIDE

## TABLET; ORAL

## BUCLADIN-S

STUART PHARMS	50MG	N010911	006	
---------------	------	---------	-----	--

BUDESONIDE

## AEROSOL, METERED; NASAL

## RHINOCORT

ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994
-------------	-------------	---------	-----	--------------

## POWDER, METERED; INHALATION

## PULMICORT

ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
	0.32MG/INH	N020441	003	Jun 24, 1997

## SUSPENSION; INHALATION

## BUDESONIDE

APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009
	0.5MG/2ML	A078202	002	Mar 30, 2009

BUMETANIDE

## INJECTABLE; INJECTION

## BUMETANIDE

HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997

## BUMEX

VALIDUS PHARMS INC	0.25MG/ML	N018226	001	Feb 28, 1983
--------------------	-----------	---------	-----	--------------



**DISCONTINUED DRUG PRODUCT LIST**BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011
-------------------	------------------------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

HOSPIRA	0.75%	A070587 001	Mar 03, 1987
---------	-------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA	0.075%	N019978 001	Sep 03, 1992
---------	--------	-------------	--------------

	0.114%	N019978 002	Sep 03, 1992
--	--------	-------------	--------------

	0.23%	N019978 003	Sep 03, 1992
--	-------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED	0.25%	A076012 001	Jan 09, 2002
----------------	-------	-------------	--------------

	0.5%	A076012 002	Jan 09, 2002
--	------	-------------	--------------

	0.75%	A076012 003	Jan 09, 2002
--	-------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA	0.25%; 0.005MG/ML	A071166 001	Jun 16, 1988
---------	-------------------	-------------	--------------

	0.5%; 0.005MG/ML	A071169 001	Jun 16, 1988
--	------------------	-------------	--------------

	0.75%; 0.005MG/ML	A071171 001	Jun 16, 1988
--	-------------------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML); EQ 1% (100MG/10ML)	N021496 001	May 23, 2003
----------------------	---	-------------	--------------

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBUTEX

INDIVIOR INC	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020732 002	Oct 08, 2002
--------------	--	-------------	--------------

	EQ 8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020732 003	Oct 08, 2002
--	--	-------------	--------------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

INDIVIOR INC	EQ 2MG BASE; EQ 0.5MG BASE	N020733 001	Oct 08, 2002
--------------	----------------------------	-------------	--------------

	EQ 8MG BASE; EQ 2MG BASE	N020733 002	Oct 08, 2002
--	--------------------------	-------------	--------------

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ	75MG	A075613 002	Oct 10, 2000
--------	------	-------------	--------------

	100MG	A075613 001	Oct 10, 2000
--	-------	-------------	--------------

TEVA	75MG	A075310 001	Nov 29, 1999
------	------	-------------	--------------

	100MG	A075310 002	Nov 29, 1999
--	-------	-------------	--------------

WELLBUTRIN

GLAXOSMITHKLINE	50MG	N018644 001	Dec 30, 1985
-----------------	------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

ACTAVIS LABS FL INC	300MG	A077715 002	Jun 13, 2007
---------------------	-------	-------------	--------------

IMPAX LABS	300MG	A077415 002	Dec 15, 2006
------------	-------	-------------	--------------

SANDOZ	100MG	A076845 001	Jul 14, 2005
--------	-------	-------------	--------------

	150MG	A076834 001	Jul 14, 2005
--	-------	-------------	--------------

	150MG	A076845 002	Jul 14, 2005
--	-------	-------------	--------------

WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012
---------------	-------	-------------	--------------

	150MG	A201331 002	Aug 30, 2012
--	-------	-------------	--------------

	200MG	A201331 003	Aug 30, 2012
--	-------	-------------	--------------

WELLBUTRIN SR

GLAXOSMITHKLINE	50MG	N020358 001	Oct 04, 1996
-----------------	------	-------------	--------------

ZYBAN

GLAXOSMITHKLINE	100MG	N020711 002	May 14, 1997
-----------------	-------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

## CAPSULE; ORAL

## BUSPAR

BRISTOL MYERS SQUIBB	5MG	N021190 001	Dec 20, 2000
	7.5MG	N021190 002	Dec 20, 2000
	10MG	N021190 003	Dec 20, 2000
	15MG	N021190 004	Dec 20, 2000

## TABLET; ORAL

## BUSPAR

BRISTOL MYERS SQUIBB	5MG	N018731 001	Sep 29, 1986
	10MG	N018731 002	Sep 29, 1986
	15MG	N018731 003	Apr 22, 1996
	30MG	N018731 004	Apr 22, 1996

## BUSPIRONE HYDROCHLORIDE

## APOTEX

5MG	A075521 001	Apr 05, 2002
10MG	A075521 002	Apr 05, 2002
15MG	A075521 003	Apr 05, 2002

## EGIS

5MG	A075119 001	Mar 14, 2002
10MG	A075119 002	Mar 14, 2002
15MG	A075119 003	Jan 23, 2003

## IVAX SUB TEVA PHARMS

5MG	A075385 001	Mar 01, 2002
10MG	A075385 002	Mar 01, 2002
15MG	A075385 003	Mar 01, 2002

## NESHER PHARMS

5MG	A075572 001	Feb 27, 2002
10MG	A075572 002	Feb 27, 2002
15MG	A075572 003	Feb 27, 2002

## PROSAM LABS

5MG	A075388 001	May 09, 2002
10MG	A075388 002	May 09, 2002
15MG	A075388 003	May 09, 2002

## SANDOZ

5MG	A075413 001	Mar 19, 2002
10MG	A075413 002	Mar 19, 2002
15MG	A075413 003	Mar 19, 2002

BUTABARBITAL SODIUM

## CAPSULE; ORAL

## BUTICAPS

MEDPOINTE PHARM HLC	15MG	A085381 001
	30MG	A085381 002
	50MG	A085381 003
	100MG	A085381 004

## ELIXIR; ORAL

## BUTABARB

ALPHARMA US PHARMS	30MG/5ML	A085873 001
--------------------	----------	-------------

## BUTABARBITAL SODIUM

WOCKHARDT	30MG/5ML	A085383 001
-----------	----------	-------------

## BUTALAN

LANNETT	33.3MG/5ML	A085880 001
---------	------------	-------------

## BUTISOL SODIUM

MEDA PHARMS	30MG/5ML	A085380 001
-------------	----------	-------------

## SARISOL

HALSEY	30MG/5ML	A084723 001
--------	----------	-------------

## TABLET; ORAL

## BUTABARBITAL

BUNDY	30MG	A085550 001
-------	------	-------------

## BUTABARBITAL SODIUM

SANDOZ	15MG	A084292 003	Feb 09, 1982
	15MG	A085938 001	
	30MG	A084272 002	
	30MG	A085934 001	
SOLVAY	16.2MG	A083606 001	
	32.4MG	A083898 001	
	48.6MG	A083897 001	
	97.2MG	A083896 001	
TEVA	15MG	A088632 001	May 18, 1985
	30MG	A088631 001	May 01, 1985
WATSON LABS	15MG	A085764 001	
	30MG	A085772 001	
WHITEWORTH TOWN PLSN	15MG	A083325 002	
	30MG	A083337 001	

## BUTISOL SODIUM

MEDA PHARMS	15MG	N000793 002
	50MG	N000793 003
	100MG	N000793 005

**DISCONTINUED DRUG PRODUCT LIST**BUTABARBITAL SODIUM

TABLET; ORAL

SARISOL NO. 1			
HALSEY	15MG	A084719	001
SARISOL NO. 2			
HALSEY	30MG	A084719	002
SODIUM BUTABARBITAL			
HIKMA PHARMS LLC	15MG	A085418	001
	30MG	A085432	001
IVAX SUB TEVA PHARMS	15MG	A083484	001
	30MG	A084040	001
LANNETT	15MG	A085849	001
	30MG	A085866	001
	100MG	A085881	001
MARSHALL PHARMA	16.2MG	A083524	001
	32.4MG	A083858	001

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

MYLAN

1%

N021408 001 Oct 17, 2002

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

ELAN PHARMA INTL LTD

2%

N019881 001 Feb 07, 1997

FEMSTAT

ROCHE PALO

2%

N019215 001 Nov 25, 1985

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO

100MG

N019359 001 Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

APOTEX INC

2MG/ML

A075697 001 Oct 23, 2001

HIKMA FARMACEUTICA

2MG/ML

A078247 001 Apr 29, 2009

HOSPIRA

1MG/ML

A075342 001 Nov 04, 1999

1MG/ML

A075559 001 Mar 20, 2000

2MG/ML

A075342 002 Nov 04, 1999

2MG/ML

A075559 002 Mar 20, 2000

BUTORPHANOL TARTRATE PRESERVATIVE FREE

APOTEX INC

1MG/ML

A075695 001 Oct 23, 2001

2MG/ML

A075695 002 Oct 23, 2001

HOSPIRA

1MG/ML

A074620 001 Jan 22, 1997

1MG/ML

A075170 001 Sep 28, 1998

2MG/ML

A074620 002 Jan 22, 1997

2MG/ML

A075170 002 Sep 28, 1998

STADOL

APOTHECON

2MG/ML

N017857 004

STADOL PRESERVATIVE FREE

APOTHECON

1MG/ML

N017857 001

2MG/ML

N017857 002

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB

1MG/SPRAY

N019890 001 Dec 12, 1991

CABERGOLINE

TABLET; ORAL

DOSTINEX

PHARMACIA AND UPJOHN

0.5MG

N020664 001 Dec 23, 1996

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

NOVARTIS

100MG; 2MG

N009000 002

TABLET; ORAL

CAFERGOT

NOVARTIS

100MG; 1MG

N006620 001

WIGRAINE

ORGANON USA INC

100MG; 1MG

A086562 001

## DISCONTINUED DRUG PRODUCT LIST

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

ORGANON USA INC

0.02MG

N018312 001

0.05MG

N018312 002

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

LEO PHARMA AS

0.005%

N020273 001 Dec 29, 1993

SOLUTION; TOPICAL

DOVONEX

LEO PHARM

0.005% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020611 001 Mar 03, 1997

CALCITONIN HUMAN

INJECTABLE; INJECTION

CIBACALCIN

NOVARTIS

0.5MG/VIAL

N018470 001 Oct 31, 1986

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCIMAR

SANOFI AVENTIS US

200 IU/ML

N017769 001

400 IU/VIAL

N017497 001

CALCITONIN-SALMON

IGI LABS INC

200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

MYLAN IRELAND LTD

100 IU/ML

N017808 001 Jul 03, 1986

CALCITRIOL

INJECTABLE; INJECTION

CALCIJEX

ABBVIE

0.001MG/ML

N018874 001 Sep 25, 1986

0.002MG/ML

N018874 002 Sep 25, 1986

CALCITRIOL

AKORN

0.002MG/ML

A078066 002 Jan 29, 2008

FRESENIUS KABI USA

0.001MG/ML

A075836 001 Dec 31, 2002

0.002MG/ML

A075836 002 Dec 31, 2002

FRESENIUS MEDCL

0.001MG/ML

A075766 001 Feb 20, 2003

0.002MG/ML

A075766 002 Feb 20, 2003

HOSPIRA

0.001MG/ML

A075816 001 Jan 16, 2004

0.002MG/ML

A075816 002 Jan 16, 2004

LUITPOLD

0.001MG/ML

A075746 001 Sep 26, 2003

0.002MG/ML

A075746 002 Sep 26, 2003

SAGENT PHARMS

0.001MG/ML

A077102 001 Feb 08, 2006

TEVA PARENTERAL

0.001MG/ML

A075823 001 Mar 31, 2003

0.002MG/ML

A075823 002 Mar 31, 2003

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

FRESENIUS MEDCL

EQ 84.5MG CALCIUM

N021160 001 Apr 02, 2001

EQ 169MG CALCIUM

N021160 002 Apr 02, 2001

TABLET; ORAL

CALCIUM ACETATE

ROXANE

EQ 169MG CALCIUM

A077693 001 Jan 30, 2008

PHOSLO

FRESENIUS MEDCL

EQ 169MG CALCIUM

N019976 001 Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

WARNER CHILCOTT

EQ 500MG BASE, N/A; N/A, 35MG \*\*Federal  
Register determination that product was  
not discontinued or withdrawn for  
safety or efficacy reasons\*\*

N021823 001 Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE

3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;  
3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/100  
0ML; 7.07GM/1000ML (5000ML)

N021703 012 Oct 10, 2008

**DISCONTINUED DRUG PRODUCT LIST**CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 005	Oct 25, 2006
-----------------	---	-------------	--------------

## PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 008	Oct 25, 2006
-----------------	--	-------------	--------------

## PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 007	Oct 25, 2006
-----------------	--	-------------	--------------

## PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 009	Oct 25, 2006
-----------------	---	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

## SOLUTION; IRRIGATION

## NAVSTEL

ALCON PHARMS LTD	0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N022193 001	Jul 24, 2008
------------------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML	N019864 001	Jun 10, 1993
---------	---	-------------	--------------

## ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML	N018271 001	
---------	---	-------------	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

## INJECTABLE; INJECTION

## ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019867 001	Dec 20, 1993
---------	---	-------------	--------------

## ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018269 002	Jan 17, 1983
---------	---	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

## PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390 001	
-----------------	--	-------------	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## SOLUTION; INTRAPERITONEAL

## DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 006	Jan 29, 1986
---------	---	-------------	--------------

## DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 001	
---------	---	-------------	--

## DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 003	
---------	--	-------------	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## SOLUTION; INTRAPERITONEAL

## DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460 002	
---------	---	-------------	--

## DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 008	Jan 29, 1986
---------	--	-------------	--------------

## DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 4.25GM/100ML; 15MG/100ML;	N018460 004	
---------	---------------------------------------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

560MG/100ML; 390MG/100ML

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS

18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5  
38MG/100ML; 448MG/100ML

A020374 001 Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS

18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5  
38MG/100ML; 448MG/100ML

A020374 002 Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS

18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5  
38MG/100ML; 448MG/100ML

A020374 003 Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS

18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML;  
538MG/100ML; 448MG/100ML

A020374 004 Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN

20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/1  
00ML; 600MG/100ML

N018258 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN

33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/1  
00ML

N018256 001

BAXTER HLTHCARE

33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/1  
00ML

N016695 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN

4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100  
ML; 62MG/100ML

N019634 002 Feb 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN

20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/1  
00ML; 310MG/100ML

N017510 001

MILES

20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/1  
00ML; 310MG/100ML

N018499 001

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA

20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/  
100ML; 310MG/100ML

N019685 005 Oct 17, 1988

20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/  
100ML; 310MG/100ML

N019685 006 Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA

20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/  
100ML; 310MG/100ML

N019685 007 Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA

20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/  
100ML; 310MG/100ML

N019685 003 Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA

20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/  
100ML; 310MG/100ML

N019685 001 Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL

25.7MG/100ML; 1.5GM/100ML; 538MG/100ML; 44  
8MG/100ML

N019395 001 Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL

25.7MG/100ML; 2.5GM/100ML; 538MG/100ML; 44  
8MG/100ML

N019395 002 Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL

25.7MG/100ML; 4.25GM/100ML; 538MG/100ML; 4  
48MG/100ML

N019395 003 Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT

16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML;  
16.1MG/ML

N019399 001 Jun 16, 1986

**DISCONTINUED DRUG PRODUCT LIST**CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN

35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/  
100ML; 500MG/100ML; 74MG/100ML

N018899 001 Oct 31, 1983

35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/  
100ML; 500MG/100ML; 74MG/100ML

N019718 001 Sep 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

BAXTER HLTHCARE

36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML;  
640MG/100ML; 496MG/100ML; 89.6MG/100ML

N017438 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN

20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG/  
/100ML

N018725 001 Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

B BRAUN

33MG/100ML; 30MG/100ML; 860MG/100ML

N018721 001 Nov 09, 1982

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

ABBOTT

33MG/100ML; 30MG/100ML; 860MG/100ML

N018462 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/  
/100ML

N019485 001 Oct 24, 1985

B BRAUN

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/  
/100ML

N018023 001

MILES

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/  
/100ML

N018417 001

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/  
/100ML

N019933 001 Aug 29, 1989

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

ABBOTT

EQ 90MG CALCIUM/5ML

A080001 001

EQ 90MG CALCIUM/5ML

A083159 001

ABRAXIS PHARM

EQ 90MG CALCIUM/5ML

A089373 001 Apr 30, 1987

LILLY

EQ 90MG CALCIUM/5ML

N006470 001

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE

0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML

N016847 001

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE

0.35MG/ML; 140.1MG/ML; 461.8MG/ML

N017506 001

CANDICIDIN

OINTMENT; VAGINAL

VANOBI

SANOFI AVENTIS US

0.6MG/GM

A061596 001

TABLET; VAGINAL

VANOBI

SANOFI AVENTIS US

3MG

A061613 001

CAPTOPRIL

TABLET; ORAL

CAPOTEN

PAR PHARM

12.5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N018343 005 Jan 17, 1985

25MG \*\*Federal Register determination  
that product was not discontinued or

N018343 002

## DISCONTINUED DRUG PRODUCT LIST

CAPTOPRIL

TABLET;ORAL

CAPOTEN

	withdrawn for safety or efficacy reasons**			
	37.5MG	N018343	006	Sep 17, 1986
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	001	
	75MG	N018343	007	Jun 13, 1995
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	003	
	150MG	N018343	004	Jun 13, 1995
CAPTOPRIL				
APOTHECON	12.5MG	A074472	001	Mar 31, 1995
	25MG	A074472	002	Mar 31, 1995
	50MG	A074472	003	Mar 31, 1995
	100MG	A074472	004	Mar 31, 1995
DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996
	25MG	A074423	002	Feb 13, 1996
	50MG	A074423	003	Feb 13, 1996
	100MG	A074423	004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996
	12.5MG	A074462	001	Feb 13, 1996
	12.5MG	A074483	001	Feb 13, 1996
	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074433	002	Feb 13, 1996
	25MG	A074462	002	Feb 13, 1996
	25MG	A074483	002	Feb 13, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074433	003	Feb 13, 1996
	50MG	A074462	003	Feb 13, 1996
	50MG	A074483	003	Feb 13, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074433	004	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
	100MG	A074483	004	Feb 13, 1996
	100MG	A074590	003	Aug 30, 1996
PAR PHARM	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996
	25MG	A074477	002	Feb 13, 1996
	50MG	A074477	003	Feb 13, 1996
	100MG	A074477	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	12.5MG	A074519	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996
	25MG	A074519	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	50MG	A074519	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
	100MG	A074519	004	Feb 13, 1996
VINTAGE PHARMS LLC	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996
WATSON LABS	12.5MG	A074451	001	Feb 13, 1996
	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074451	002	Feb 13, 1996
	25MG	A074576	002	Apr 23, 1996



## DISCONTINUED DRUG PRODUCT LIST

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

50MG	A074451 003	Feb 13, 1996
50MG	A074576 003	Apr 23, 1996
100MG	A074451 004	Feb 13, 1996
100MG	A074576 004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

APOTHECON

25MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 001	Oct 12, 1984
--	-------------	--------------

CAPOZIDE 25/25

APOTHECON

25MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 002	Oct 12, 1984
--	-------------	--------------

CAPOZIDE 50/15

APOTHECON

50MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 004	Oct 12, 1984
--	-------------	--------------

CAPOZIDE 50/25

APOTHECON

50MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 003	Oct 12, 1984
--	-------------	--------------

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS

25MG;15MG

A075055 001 Jun 18, 1998

25MG;25MG

A075055 002 Jun 18, 1998

50MG;15MG

A075055 004 Jun 18, 1998

50MG;25MG

A075055 003 Jun 18, 1998

VINTAGE PHARMS LLC

25MG;15MG

A074788 001 Dec 29, 1997

25MG;25MG

A074788 002 Dec 29, 1997

50MG;15MG

A074788 004 Dec 29, 1997

50MG;25MG

A074788 003 Dec 29, 1997

WATSON LABS

50MG;25MG

A074832 001 Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR

0.01%

A070292 001 May 21, 1986

CARBASTAT

NOVARTIS

0.01%

A073677 001 Apr 28, 1995

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

TARO

100MG/5ML

A075875 001 Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH

200MG

A071696 001 Nov 09, 1987

INWOOD LABS

200MG

A070231 001 Aug 14, 1986

PLIVA

200MG

A071479 001 Jul 24, 1987

USL PHARMA

200MG

A070300 001 May 15, 1986

WARNER CHILCOTT

200MG

A070429 001 Jan 02, 1987

TERIL

TARO

200MG

A076525 001 Sep 26, 2003

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

JUBILANT CADISTA

100MG

A071940 001 Feb 01, 1988

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG

EQ 1GM BASE/VIAL

N050306 001

EQ 2GM BASE/VIAL

N050306 004

EQ 5GM BASE/VIAL

N050306 002

EQ 10GM BASE/VIAL

N050306 006

EQ 30GM BASE/VIAL

N050306 007

PYOPEN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050298 001

EQ 2GM BASE/VIAL

N050298 002

## DISCONTINUED DRUG PRODUCT LIST

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

PYOPEN

EQ 5GM BASE/VIAL	N050298 003
EQ 10GM BASE/VIAL	N050298 006
EQ 20GM BASE/VIAL	N050298 007

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

PFIZER

EQ 382MG BASE N050435 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

SANDOZ

10MG;100MG A073586 001 Jun 29, 1995

25MG;100MG A073587 001 Jun 29, 1995

25MG;250MG A073620 001 Jun 29, 1995

SCS

10MG;100MG A074080 001 Mar 25, 1994

25MG;100MG A074080 002 Mar 25, 1994

25MG;250MG A074080 003 Mar 25, 1994

WATSON LABS

10MG;100MG A073381 001 Sep 28, 1993

25MG;100MG A073382 001 Sep 28, 1993

25MG;250MG A073383 001 Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM

50MG;200MG A076663 001 Jun 24, 2004

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY

10MG;100MG A076643 001 Jun 10, 2005

25MG;100MG A076643 002 Jun 10, 2005

25MG;250MG A076643 003 Jun 10, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

IMPAX LABS

10MG;100MG A090631 001 Jun 08, 2010

25MG;100MG A090631 002 Jun 08, 2010

25MG;250MG A090631 003 Jun 08, 2010

PARCOPA

UCB INC

10MG;100MG \*\*Federal Register A076699 001 Aug 27, 2004

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

25MG;100MG \*\*Federal Register A076699 002 Aug 27, 2004

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

25MG;250MG \*\*Federal Register A076699 003 Aug 27, 2004

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

MCNEIL

4MG/5ML \*\*Federal Register N008955 001

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

TABLET; ORAL

CLISTIN

ORTHO MCNEIL PHARM

4MG N008915 001

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

CIPLA LTD

50MG/VIAL A077383 001 Jan 27, 2006

150MG/VIAL A077383 002 Jan 27, 2006

450MG/VIAL A077383 003 Jan 27, 2006

EUROHLTH INTL SARL

50MG/VIAL A076099 001 Oct 14, 2004

150MG/VIAL A076099 002 Oct 14, 2004

450MG/VIAL A076099 003 Oct 14, 2004

FRESENIUS KABI USA

50MG/VIAL A076235 001 Oct 14, 2004

150MG/VIAL A076235 002 Oct 14, 2004

450MG/VIAL A076235 003 Oct 14, 2004

HOSPIRA

50MG/VIAL A076473 001 Oct 27, 2004

150MG/VIAL A076473 002 Oct 27, 2004

**DISCONTINUED DRUG PRODUCT LIST**CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

	450MG/VIAL	A076473 003	Oct 27, 2004
MYLAN LABS LTD	50MG/VIAL	A091510 001	May 29, 2012
	150MG/VIAL	A091510 002	May 29, 2012
	450MG/VIAL	A091510 003	May 29, 2012
PLIVA	50MG/VIAL	A076602 001	Nov 16, 2004
	150MG/VIAL	A076602 002	Nov 16, 2004
	450MG/VIAL	A076602 003	Nov 16, 2004
SANDOZ	50MG/VIAL	A076959 001	Mar 18, 2005
	150MG/VIAL	A076959 002	Mar 18, 2005
	450MG/VIAL	A076959 003	Mar 18, 2005
WATSON LABS	50MG/VIAL	A076162 001	Oct 14, 2004
	150MG/VIAL	A076162 002	Oct 14, 2004
	450MG/VIAL	A076162 003	Oct 14, 2004
PARAPLATIN			
CORDEN PHARMA	50MG/VIAL	N019880 001	Mar 03, 1989
	150MG/VIAL	N019880 002	Mar 03, 1989
	450MG/VIAL	N019880 003	Mar 03, 1989

INJECTABLE; IV (INFUSION)

CARBOPLATIN

FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247 001	Oct 21, 2004
	50MG/5ML (10MG/ML)	A077266 001	Feb 15, 2006
	150MG/15ML (10MG/ML)	A077247 002	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077266 002	Feb 15, 2006
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679 001	Feb 25, 2009
	150MG/15ML (10MG/ML)	A077679 002	Feb 25, 2009
	450MG/45ML (10MG/ML)	A077679 003	Feb 25, 2009
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389 001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389 002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389 003	Mar 30, 2007
PARAPLATIN			
CORDENPHARMA	50MG/5ML (10MG/ML)	N020452 001	Jul 14, 2003
	150MG/15ML (10MG/ML)	N020452 002	Jul 14, 2003
	450MG/45ML (10MG/ML)	N020452 003	Jul 14, 2003
	600MG/60ML (10MG/ML)	N020452 004	Jan 15, 2004

CARISOPRODOL

CAPSULE; ORAL

SOMA

MEDA PHARMS	250MG	N011792 003	
-------------	-------	-------------	--

TABLET; ORAL

CARISOPRODOL

ABLE	350MG	A040421 001	Jun 21, 2001
COREPHARMA	350MG	A040397 001	Sep 21, 2000
HIKMA INTL PHARMS	350MG	A040124 001	Jan 24, 1996
PIONEER PHARMS	350MG	A089390 001	Oct 13, 1988
PROSAM LABS	350MG	A040188 001	Mar 07, 1997
SANDOZ	350MG	A081025 001	Apr 13, 1989
	350MG	A089566 001	Aug 30, 1988
WATSON LABS	350MG	A040152 001	Dec 03, 1996
	350MG	A085433 001	
	350MG	A086179 001	
RELA			
SCHERING	350MG	N012155 001	

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST	50MG/ML	N014173 001	
--------------	---------	-------------	--

TABLET; ORAL

PROKETAZINE

WYETH AYERST	12.5MG	N012768 001	
	25MG	N012768 002	
	50MG	N012768 004	

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE	100MG	N018550 002	Dec 31, 1987
	150MG	N018550 003	Dec 31, 1987

## DISCONTINUED DRUG PRODUCT LIST

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC

1%

A076097 001 Feb 06, 2002

TABLET;ORAL

CARTROL

ABBVIE

2.5MG

N019204 001 Dec 28, 1988

5MG

N019204 002 Dec 28, 1988

10MG

N019204 003 Dec 28, 1988

CARVEDILOL

TABLET;ORAL

CARVEDILOL

HIKMA

3.125MG

A077887 001 Sep 07, 2007

6.25MG

A077887 002 Sep 07, 2007

12.5MG

A077887 003 Sep 07, 2007

25MG

A077887 004 Sep 07, 2007

WOCKHARDT LTD

3.125MG

A078786 001 Dec 22, 2009

6.25MG

A078786 002 Dec 22, 2009

12.5MG

A078786 003 Dec 22, 2009

25MG

A078786 004 Dec 22, 2009

CEFACTOR

CAPSULE;ORAL

CECLOR

LILLY

EQ 250MG BASE

N050521 001

EQ 500MG BASE

N050521 002

CEFACTOR

CEPH INTL

EQ 250MG BASE

A062205 001

EQ 500MG BASE

A062205 002

DAVA PHARMS INC

EQ 250MG BASE

A064107 001 Apr 27, 1995

EQ 500MG BASE

A064107 002 Apr 27, 1995

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A064061 001 Apr 27, 1995

EQ 500MG BASE

A064061 002 Apr 27, 1995

RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997

EQ 500MG BASE

A064156 002 Aug 28, 1997

TEVA

EQ 250MG BASE

A064081 001 Sep 16, 1996

EQ 250MG BASE

A064145 001 Jun 24, 1996

EQ 500MG BASE

A064081 002 Sep 16, 1996

EQ 500MG BASE

A064145 002 Jun 24, 1996

WATSON LABS INC

EQ 250MG BASE

A064148 001 May 23, 1996

EQ 500MG BASE

A064148 002 May 23, 1996

FOR SUSPENSION;ORAL

CECLOR

LILLY

EQ 125MG BASE/5ML

N050522 001

EQ 250MG BASE/5ML

N050522 002

CEFACTOR

DAVA PHARMS INC

EQ 125MG BASE/5ML

A064114 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064115 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064116 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064110 001 Apr 28, 1995

FACTA FARMA

EQ 125MG BASE/5ML

A062206 001

EQ 187MG BASE/5ML

A062206 003 Apr 20, 1988

EQ 250MG BASE/5ML

A062206 002

EQ 375MG BASE/5ML

A062206 004 Apr 20, 1988

IVAX SUB TEVA PHARMS

EQ 125MG BASE/5ML

A064087 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064086 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064085 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064070 001 Apr 28, 1995

RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997

WATSON LABS INC

EQ 125MG BASE/5ML

A064204 001 Feb 18, 1998

EQ 187MG BASE/5ML

A064205 001 Feb 18, 1998

EQ 250MG BASE/5ML

A064206 001 Feb 18, 1998

EQ 375MG BASE/5ML

A064207 001 Feb 18, 1998

TABLET, CHEWABLE;ORAL

RANICLOR

RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003

EQ 187MG BASE

A065092 002 Dec 22, 2003

EQ 250MG BASE

A065092 003 Dec 22, 2003

EQ 375MG BASE

A065092 004 Dec 22, 2003

## DISCONTINUED DRUG PRODUCT LIST

CEFACTOR

TABLET, EXTENDED RELEASE;ORAL

CECLOR CD

LILLY	EQ 375MG BASE	N050673 001	Jun 28, 1996
	EQ 500MG BASE	N050673 002	Jun 28, 1996

CEFACTOR

WORLD GEN	EQ 500MG BASE	A065057 001	Jan 05, 2001
-----------	---------------	-------------	--------------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017 001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999
TEVA	EQ 500MG BASE	A062695 001	Feb 10, 1989

DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512 002	
	EQ 500MG BASE	N050512 001	

ULTRACEF

BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982
---------	---------------	-------------	--------------

FOR SUSPENSION;ORAL

CEFADROXIL

ANI PHARMS INC	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006
	EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
	EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML	A062334 001	
	EQ 250MG BASE/5ML	A062334 002	
	EQ 500MG BASE/5ML	A062334 003	

DURICEF

WARNER CHILCOTT	EQ 125MG BASE/5ML	N050527 002	
	EQ 250MG BASE/5ML	N050527 003	
	EQ 500MG BASE/5ML	N050527 001	

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982

TABLET;ORAL

CEFADROXIL

RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999
---------	-------------	-------------	--------------

DURICEF

WARNER CHILCOTT	EQ 1GM BASE	N050528 001	
-----------------	-------------	-------------	--

ULTRACEF

APOTHECON	EQ 1GM BASE	A062390 001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408 001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE;INJECTION

MANDOL

LILLY	EQ 500MG BASE/VIAL	N050504 001	
	EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504 002	
	EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504 003	
	EQ 10GM BASE/VIAL	N050504 004	

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

ANCEF

GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 001	
	EQ 500MG BASE/VIAL	N050461 002	
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 003	
	EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 004	
	EQ 10GM BASE/VIAL	N050461 005	

## DISCONTINUED DRUG PRODUCT LIST

CEFAZOLIN SODIUM

## INJECTABLE; INJECTION

## ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 004	Jun 08, 1983

## ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

## CEFAZOLIN AND DEXTROSE

B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000
---------	--------------------	-------------	--------------

## CEFAZOLIN SODIUM

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987

AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
	EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008

BEDFORD	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
	EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988

CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009

FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A064169 001	Aug 14, 1998

	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A064169 002	Aug 14, 1998
--	--	-------------	--------------

	EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
-----------------	------------------	-------------	--------------

HIKMA MAPLE	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988

STERI PHARMA	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991

TEVA PHARMS	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989
-------------	--------------------	-------------	--------------

	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989
--	--------------------	-------------	--------------

	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989
--	------------------	-------------	--------------

	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990
--	------------------	-------------	--------------

	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990
--	-------------------	-------------	--------------

WATSON LABS INC	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989
-----------------	--------------------	-------------	--------------

	EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
--	--------------------	-------------	--------------

	EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
--	------------------	-------------	--------------

	EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
--	------------------	-------------	--------------

	EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
--	-------------------	-------------	--------------

	EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
--	-------------------	-------------	--------------

## KEFZOL

ACS DOBFAR	EQ 250MG BASE/VIAL	A061773 001	
------------	--------------------	-------------	--

	EQ 20GM BASE/VIAL	A061773 005	Sep 08, 1987
--	-------------------	-------------	--------------

LILLY	EQ 500MG BASE/VIAL	A062557 001	Sep 10, 1985
-------	--------------------	-------------	--------------

	EQ 1GM BASE/VIAL	A062557 002	Sep 10, 1985
--	------------------	-------------	--------------

CEFDINIR

## CAPSULE; ORAL

## OMNICEF

ABBVIE	300MG	N050739 001	Dec 04, 1997
--------	-------	-------------	--------------

## FOR SUSPENSION; ORAL

## OMNICEF

ABBVIE	125MG/5ML	N050749 001	Dec 04, 1997
--------	-----------	-------------	--------------

	250MG/5ML	N050749 002	Jul 29, 2004
--	-----------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

SANDOZ

EQ 500MG BASE/VIAL

A090291 001 Dec 21, 2010

EQ 1GM BASE/VIAL

A090291 002 Dec 21, 2010

EQ 2GM BASE/VIAL

A090291 003 Dec 21, 2010

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

LEDERLE

100MG/5ML

N050622 001 Apr 28, 1989

TABLET; ORAL

SUPRAX

LEDERLE

200MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N050621 001 Apr 28, 1989

400MG

N050621 002 Apr 28, 1989

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM

EQ 500MG BASE/VIAL

N050571 001 Dec 30, 1987

EQ 1GM BASE/VIAL

N050571 002 Dec 30, 1987

EQ 2GM BASE/VIAL

N050571 003 Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

N050637 001 Dec 11, 1989

EQ 2GM BASE/VIAL

N050637 002 Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN

EQ 20MG BASE/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N050683 001 Dec 29, 1992

EQ 40MG BASE/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N050683 002 Dec 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

N050579 001 May 23, 1984

EQ 1GM BASE/VIAL

A063295 001 Jul 26, 1993

EQ 1GM BASE/VIAL

N050579 002 May 23, 1984

EQ 2GM BASE/VIAL

N050579 003 May 23, 1984

EQ 10GM BASE/VIAL

N050579 004 May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER

EQ 1GM BASE/VIAL

A063333 001 Mar 31, 1995

EQ 1GM BASE/VIAL

N050551 001 Nov 18, 1982

EQ 2GM BASE/VIAL

A063333 002 Mar 31, 1995

EQ 2GM BASE/VIAL

N050551 002 Nov 18, 1982

EQ 10GM BASE/VIAL

N050551 003 Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER

EQ 20MG BASE/ML

N050613 002 Jul 31, 1987

EQ 40MG BASE/ML

N050613 001 Jul 23, 1986

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON

500MG/VIAL

A062579 001 Nov 26, 1984

1GM/VIAL

A062579 002 Nov 26, 1984

2GM/VIAL

A062579 003 Nov 26, 1984

10GM/VIAL

A062579 004 Nov 26, 1984

20GM/VIAL

A062579 005 Nov 26, 1984

BRISTOL

500MG/VIAL

N050554 001 May 24, 1984

1GM/VIAL

N050554 002 May 24, 1984

2GM/VIAL

N050554 003 May 24, 1984

10GM/VIAL

N050554 004 May 24, 1984

20GM/VIAL

N050554 005 May 24, 1984

**DISCONTINUED DRUG PRODUCT LIST**CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200 001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200 002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200 003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201 001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201 002	Mar 24, 2000
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER			
B BRAUN	EQ 2GM BASE	N050792 001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER			
B BRAUN	EQ 1GM BASE	N050792 002	Jul 29, 2004
CEFOTAXIME SODIUM			
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517 001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517 002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517 003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516 001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348 001	Jan 25, 2010
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596 001	May 20, 1985
	EQ 40MG BASE/ML	N050596 003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

IGI LABS INC	EQ 1GM BASE/VIAL	A063293 001	Apr 29, 1993
	EQ 1GM BASE/VIAL	N050588 001	Dec 27, 1985
	EQ 2GM BASE/VIAL	A063293 002	Apr 29, 1993
	EQ 2GM BASE/VIAL	N050588 002	Dec 27, 1985
	EQ 10GM BASE/VIAL	N050588 003	Apr 25, 1988
CEFOTAN IN PLASTIC CONTAINER			
IGI LABS INC	EQ 20MG BASE/ML	N050694 002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694 001	Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA	EQ 1GM BASE/VIAL	N050601 001	Dec 30, 1988
--------	------------------	-------------	--------------

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065012 001	Jul 03, 2000
	EQ 2GM BASE/VIAL	A065012 002	Jul 03, 2000
	EQ 10GM BASE/VIAL	A065011 001	Jul 03, 2000
MEFOXIN			
MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757 001	Jan 08, 1987
	EQ 1GM BASE/VIAL	N050517 001	
	EQ 2GM BASE/VIAL	A062757 002	Jan 08, 1987
	EQ 2GM BASE/VIAL	N050517 002	
	EQ 10GM BASE/VIAL	N050517 003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
MERCK	EQ 20MG BASE/ML	N050581 003	Sep 20, 1984
	EQ 40MG BASE/ML	N050581 004	Sep 20, 1984
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
MERCK	EQ 20MG BASE/ML	N050581 002	Sep 20, 1984
	EQ 40MG BASE/ML	N050581 001	Sep 20, 1984

CEFPYRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPYRAMIDE SODIUM

WYETH AYERST	EQ 1GM BASE/VIAL	N050633 002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633 003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633 005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO	EQ 50MG BASE/5ML	N050688 002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688 001	Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N050675 001	Aug 07, 1992
	EQ 100MG BASE/5ML	N050675 002	Aug 07, 1992



## DISCONTINUED DRUG PRODUCT LIST

CEFPODOXIME PROXETIL

TABLET; ORAL

BANAN

SANKYO	EQ 100MG BASE	N050687 001	Aug 07, 1992
	EQ 200MG BASE	N050687 002	Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992
	EQ 200MG BASE	N050674 002	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006
	250MG/5ML	A065202 002	Jun 30, 2006

CEFZIL

CORDEN PHARMA	125MG/5ML	N050665 001	Dec 23, 1991
	250MG/5ML	N050665 002	Dec 23, 1991

TABLET; ORAL

CEFPROZIL

RANBAXY LABS LTD	250MG	A065198 001	Dec 13, 2006
	500MG	A065198 002	Dec 13, 2006

CEFZIL

CORDEN PHARMA	250MG	N050664 001	Dec 23, 1991
	500MG	N050664 002	Dec 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AUROBINDO PHARMA LTD	500MG/VIAL	A065481 001	May 28, 2010
	1GM/VIAL	A065481 002	May 28, 2010
	2GM/VIAL	A065481 003	May 28, 2010
	6GM/VIAL	A065482 001	May 28, 2010

CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N050646 001	Sep 27, 1990
	1GM/VIAL	N050646 002	Sep 27, 1990
	2GM/VIAL	N050646 003	Sep 27, 1990
	10GM/VIAL	N050646 004	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322 001	Nov 07, 1995
	1GM/VIAL	A064006 001	Mar 31, 1992
	2GM/VIAL	A063322 002	Nov 07, 1995
	2GM/VIAL	A064006 002	Mar 31, 1992
	6GM/VIAL	A064008 001	Mar 31, 1992
	10GM/VIAL	A064008 002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655 001	Nov 20, 1985
	2GM/VIAL	A062655 002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739 001	Jul 10, 1986
	2GM/VIAL	A062739 002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221 001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221 002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221 003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

IGI LABS INC	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989
--------------	-----------------	-------------	--------------

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS	EQ 500MG BASE/VIAL	N050560 001	Sep 15, 1983
	EQ 1GM BASE/VIAL	A063294 002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560 002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294 003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560 003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560 005	Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589 001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589 002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589 003	Apr 13, 1995
----------	-----------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX IN PLASTIC CONTAINER

EQ 40MG BASE/ML N050589 004 Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AGILA SPECLTS EQ 10GM BASE/VIAL A091068 001 Jan 07, 2013

AUROBINDO PHARMA LTD EQ 10GM BASE/VIAL A065504 001 Jul 31, 2008

FRESENIUS KABI USA EQ 10GM BASE/VIAL A065252 001 Feb 15, 2006

TEVA EQ 10GM BASE/VIAL A065274 001 May 01, 2006

ROCEPHIN

HOFFMANN LA ROCHE EQ 250MG BASE/VIAL A063239 001 Aug 13, 1993

EQ 500MG BASE/VIAL A062654 001 Apr 30, 1987

EQ 1GM BASE/VIAL A062654 002 Apr 30, 1987

EQ 2GM BASE/VIAL A062654 003 Apr 30, 1987

EQ 10GM BASE/VIAL N050585 005 Dec 21, 1984

ROCHE EQ 250MG BASE/VIAL A062510 001 Mar 12, 1985

EQ 500MG BASE/VIAL A062510 002 Mar 12, 1985

EQ 1GM BASE/VIAL A062510 003 Mar 12, 1985

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

HOFFMANN LA ROCHE EQ 10MG BASE/ML N050624 001 Feb 11, 1987

EQ 20MG BASE/ML N050624 002 Feb 11, 1987

EQ 40MG BASE/ML N050624 003 Feb 11, 1987

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AUROBINDO PHARMA LTD EQ 250MG BASE/VIAL A065505 001 Jul 31, 2008

EQ 500MG BASE/VIAL A065505 002 Jul 31, 2008

EQ 1GM BASE/VIAL A065505 003 Jul 31, 2008

EQ 2GM BASE/VIAL A065505 004 Jul 31, 2008

CEPHAZONE PHARMA EQ 250MG BASE/VIAL A065294 001 Mar 26, 2007

EQ 500MG BASE/VIAL A065294 002 Mar 26, 2007

EQ 1GM BASE/VIAL A065294 003 Mar 26, 2007

EQ 2GM BASE/VIAL A065294 004 Mar 26, 2007

FACTA FARMA EQ 1GM BASE/VIAL A065268 001 Feb 28, 2007

EQ 2GM BASE/VIAL A065268 002 Feb 28, 2007

FRESENIUS KABI USA EQ 250MG BASE/VIAL A065245 001 Feb 15, 2006

EQ 500MG BASE/VIAL A065245 002 Feb 15, 2006

EQ 1GM BASE/VIAL A065245 003 Feb 15, 2006

EQ 2GM BASE/VIAL A065245 004 Feb 15, 2006

TEVA EQ 1GM BASE/VIAL A065262 001 Jun 29, 2006

EQ 2GM BASE/VIAL A065262 002 Jun 29, 2006

TEVA PHARMS USA EQ 250MG BASE/VIAL A065227 001 Mar 15, 2007

EQ 500MG BASE/VIAL A065227 002 Mar 15, 2007

EQ 1GM BASE/VIAL A065227 003 Mar 15, 2007

EQ 2GM BASE/VIAL A065227 004 Mar 15, 2007

ROCEPHIN

HOFFMANN LA ROCHE EQ 250MG BASE/VIAL N050585 001 Dec 21, 1984

EQ 500MG BASE/VIAL N050585 002 Dec 21, 1984

EQ 1GM BASE/VIAL N050585 003 Dec 21, 1984

EQ 2GM BASE/VIAL N050585 004 Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE EQ 500MG BASE/VIAL, N/A; N/A, 1% N050585 007 May 08, 1996

EQ 1GM BASE/VIAL, N/A; N/A, 1% N050585 006 May 08, 1996

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

RANBAXY LABS LTD EQ 125MG BASE A065043 003 Feb 15, 2002

EQ 250MG BASE A065043 002 Feb 15, 2002

EQ 500MG BASE A065043 001 Feb 15, 2002

SANDOZ EQ 250MG BASE A065126 001 Oct 28, 2003

EQ 500MG BASE A065126 002 Oct 28, 2003

**DISCONTINUED DRUG PRODUCT LIST**CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035 002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036 001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251 001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251 002	Dec 30, 2009

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591 002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591 003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592 002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590 002	Jan 10, 1986
-------	--------------------	-------------	--------------

ZINACEF IN PLASTIC CONTAINER

CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989
----------------------	-----------------	-------------	--------------

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035 001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591 001	Jan 10, 1986
------------	--------------------	-------------	--------------

INJECTABLE; INTRAVENOUS

KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592 001	Jan 10, 1986
-------	--------------------	-------------	--------------

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590 001	Jan 10, 1986
-------	--------------------	-------------	--------------

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757 002	Dec 28, 1982
	300GM/BOT	N018757 003	Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973 001	Nov 08, 1988
	EQ 250MG BASE	A063063 001	Sep 29, 1989
	EQ 250MG BASE	A063186 001	Dec 30, 1994
	EQ 500MG BASE	A062974 001	Nov 23, 1988
	EQ 500MG BASE	A063063 002	Sep 29, 1989
	EQ 500MG BASE	A063186 002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773 001	Jun 26, 1987
	EQ 500MG BASE	A062775 001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118 001	
	EQ 500MG BASE	A062118 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969 001	
	EQ 500MG BASE	A061969 002	
PUREPAC PHARM	EQ 250MG BASE	A062809 001	Apr 22, 1987
	EQ 500MG BASE	A062809 002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870 001	Mar 17, 1988
	EQ 500MG BASE	A062869 001	Mar 17, 1988
TEVA	EQ 250MG BASE	A062760 001	Apr 24, 1987
	EQ 250MG BASE	A062821 001	Feb 05, 1988
	EQ 500MG BASE	A062761 001	Apr 24, 1987
	EQ 500MG BASE	A062823 001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872 001	Jun 20, 1988
	EQ 500MG BASE	A062871 001	Jul 05, 1988

KEFLEX

SHIONOGI INC	EQ 333MG BASE	N050405 004	May 12, 2006
--------------	---------------	-------------	--------------

FOR SUSPENSION; ORAL

CEPHALEXIN

APOTHECON	EQ 125MG BASE/5ML	A062986 001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987 001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778 001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777 001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML	A062117 001	

**DISCONTINUED DRUG PRODUCT LIST**CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

	EQ 125MG BASE/5ML	A062117 002	
	EQ 250MG BASE/5ML	A062117 003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444 001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444 002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081 001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081 002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767 001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873 001	May 23, 1988
	EQ 250MG BASE/5ML	A062768 001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867 001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779 001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781 001	Dec 22, 1987
YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336 001	Jul 25, 2007
	EQ 250MG BASE/5ML	A065336 002	Jul 25, 2007
KEFLEX			
SHIONOGI INC	EQ 100MG BASE/ML	N050406 003	
	EQ 125MG BASE/5ML	N050406 001	
	EQ 250MG BASE/5ML	N050406 002	

TABLET;ORAL

CEPHALEXIN

BARR	EQ 250MG BASE	A062826 001	Aug 17, 1987
	EQ 500MG BASE	A062827 001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863 001	Aug 11, 1988
	EQ 500MG BASE	A062863 002	Aug 11, 1988
	EQ 1GM BASE	A062863 003	Aug 11, 1988
KEFLET			
LILLY	EQ 250MG BASE	A062745 001	Dec 01, 1986
	EQ 250MG BASE	N050440 003	Feb 26, 1987
	EQ 500MG BASE	A062745 002	Dec 01, 1986
	EQ 500MG BASE	N050440 001	
	EQ 1GM BASE	N050440 002	

TABLET, FOR SUSPENSION;ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003
	EQ 250MG BASE	A065100 001	Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL

KEFTAB

LILLY	EQ 250MG BASE	N050614 001	Oct 29, 1987
	EQ 333MG BASE	N050614 003	May 16, 1988
	EQ 500MG BASE	N050614 002	Oct 29, 1987

CEPHALOGLYCIN

CAPSULE;ORAL

KAFOCIN

LILLY	250MG	N050219 001	
-------	-------	-------------	--

CEPHALOTHIN SODIUM

INJECTABLE;INJECTION

CEPHALOTHIN

INTL MEDICATION	EQ 500MG BASE/VIAL	A062426 001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426 002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426 003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426 004	May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT	EQ 1GM BASE/VIAL	A062547 001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548 001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547 002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548 002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666 002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666 001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464 001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464 002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464 003	May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422 005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730 001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422 004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 006	Jul 16, 1991

## DISCONTINUED DRUG PRODUCT LIST

CEPHALOTHIN SODIUM

## INJECTABLE; INJECTION

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

EQ 40MG BASE/ML

A062730 002 Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 001 Jan 31, 1984

EQ 40MG BASE/ML

A062422 002 Jan 31, 1984

KEFLIN

LILLY

EQ 1GM BASE/VIAL

N050482 001

EQ 2GM BASE/VIAL

N050482 002

EQ 4GM BASE/VIAL

N050482 003

EQ 20GM BASE/VIAL

N050482 007

KEFLIN IN PLASTIC CONTAINER

LILLY

EQ 1GM BASE/VIAL

A062549 001 Sep 10, 1985

EQ 2GM BASE/VIAL

A062549 002 Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A062435 001 Nov 15, 1983

EQ 2GM BASE/VIAL

A062435 002 Nov 15, 1983

EQ 10GM BASE/VIAL

A062435 003 Nov 15, 1983

CEPHAPIRIN SODIUM

## INJECTABLE; INJECTION

CEFADYL

APOTHECON

EQ 500MG BASE/VIAL

A062961 001 Sep 20, 1988

EQ 500MG BASE/VIAL

N050446 005

EQ 1GM BASE/VIAL

A061769 001

EQ 1GM BASE/VIAL

A062724 001 Dec 23, 1986

EQ 1GM BASE/VIAL

A062961 002 Sep 20, 1988

EQ 1GM BASE/VIAL

N050446 001

EQ 2GM BASE/VIAL

A061769 002

EQ 2GM BASE/VIAL

A062724 002 Dec 23, 1986

EQ 2GM BASE/VIAL

A062961 003 Sep 20, 1988

EQ 2GM BASE/VIAL

N050446 002

EQ 4GM BASE/VIAL

A061769 003

EQ 4GM BASE/VIAL

A062961 004 Sep 20, 1988

EQ 4GM BASE/VIAL

N050446 003

EQ 20GM BASE/VIAL

N050446 004

CEPHAPIRIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062723 001 Nov 17, 1986

EQ 1GM BASE/VIAL

A062723 002 Nov 17, 1986

EQ 2GM BASE/VIAL

A062723 003 Nov 17, 1986

EQ 4GM BASE/VIAL

A062723 004 Nov 17, 1986

EQ 20GM BASE/VIAL

A062723 005 Nov 17, 1986

HIKMA MAPLE

EQ 500MG BASE/VIAL

A062720 001 Jul 02, 1987

EQ 1GM BASE/VIAL

A062720 002 Jul 02, 1987

EQ 2GM BASE/VIAL

A062720 003 Jul 02, 1987

EQ 20GM BASE/VIAL

A062720 004 Jul 02, 1987

CEPHRADINE

## CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE

250MG

A061859 001

500MG

A061859 002

CEPHRADINE

BARR

250MG

A062850 001 Apr 22, 1988

500MG

A062851 001 Apr 22, 1988

IVAX SUB TEVA PHARMS

250MG

A062762 001 Mar 06, 1987

500MG

A062762 002 Mar 06, 1987

TEVA

250MG

A062683 001 Jan 09, 1987

500MG

A062683 002 Jan 09, 1987

VITARINE

250MG

A062813 001 Feb 25, 1988

500MG

A062813 002 Feb 25, 1988

VELOSEF

APOTHECON

250MG

A061764 001

500MG

A061764 002

VELOSEF '250'

ERSANA

250MG

N050548 001

VELOSEF '500'

ERSANA

500MG

N050548 002

## FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE

125MG/5ML

A061866 001

250MG/5ML

A061866 002

## DISCONTINUED DRUG PRODUCT LIST

CEPHRADINE

FOR SUSPENSION; ORAL

CEPHRADINE

BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987

VELOSEF '125'

APOTHECON	125MG/5ML	A061763	001	
-----------	-----------	---------	-----	--

VELOSEF '250'

APOTHECON	250MG/5ML	A061763	002	
-----------	-----------	---------	-----	--

INJECTABLE; INJECTION

VELOSEF

APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB	1GM	N050530	001	
----------------------	-----	---------	-----	--

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS	0.05MG	N020740	001	Jun 26, 1997
	0.1MG	N020740	002	Jun 26, 1997
	0.2MG	N020740	003	Jun 26, 1997
	0.3MG	N020740	004	Jun 26, 1997
	0.4MG	N020740	005	May 24, 1999
	0.8MG	N020740	006	Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN	0.02MG/ML	N018296	001	
----------------------	-----------	---------	-----	--

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010
APOTEX INC	5MG/5ML	A078412	001	Jun 18, 2008
AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009
RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008
APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008
APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH	5MG	A078615	003	Dec 28, 2007
	10MG	A078615	004	Dec 28, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC	5MG	A077631	004	Jan 11, 2008
	10MG	A077631	003	Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC	5MG	A077631	001	Jan 11, 2008
	10MG	A077631	002	Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

J AND J CONSUMER INC	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621	003	Nov 16, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621	004	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

J AND J CONSUMER INC	5MG **Federal Register determination that product was not discontinued or	N021621	005	Nov 16, 2007
----------------------	---	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

CHILDREN'S ZYRTEC HIVES RELIEF

withdrawn for safety or efficacy  
reasons\*\*10MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021621 006 Nov 16, 2007

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

EMD SERONO INC

EQ 3MG BASE/ML

N021197 002 Aug 11, 2000

CETYL ALCOHOL; COLFOSKERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE

12MG/VIAL; 108MG/VIAL; 8MG/VIAL

N020044 001 Aug 02, 1990

CHENODIOL

TABLET; ORAL

CHENIX

SIGMA TAU

250MG

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP; ORAL

ULO

3M

25MG/5ML

N012126 001

CHLORAMPHENICOL

CAPSULE; ORAL

AMPHICOL

FERRANTE

100MG

A060058 001

CHLOROMYCETIN

PARKEDALE

50MG

A060591 001

100MG

A060591 003

CREAM; TOPICAL

CHLOROMYCETIN

PARKE DAVIS

1%

N050183 001

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

PARKEDALE

25MG/VIAL

N050143 001

INJECTABLE; INJECTION

CHLOROMYCETIN

PARKE DAVIS

250MG/ML

N050153 001

OINTMENT; OPHTHALMIC

CHLORAMPHENICOL

ALTANA

1%

A060133 001

CHLOROFAIR

PHARMAFAIR

1%

A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE

1%

N050156 001

CHLOROPTIC S.O.P.

ALLERGAN

1%

A061187 001

ECONOCHLOR

ALCON

1%

A061648 001

SOLUTION/DROPS; OPHTHALMIC

CHLORAMPHENICOL

AKORN

0.5%

A062042 001

ALCON

0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR

0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN

0.5%

N050091 001

ECONOCHLOR

ALCON

0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE

0.5%

A061220 001

OPTOMYCIN

OPTOPICS

0.5%

A062171 001 Mar 31, 1982

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

PARKEDALE

0.5%

N050205 001

**DISCONTINUED DRUG PRODUCT LIST**CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS	EQ 150MG BASE/5ML	A062301	001
	EQ 150MG BASE/5ML	N050152	001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN	EQ 1GM BASE/VIAL	A062406	001	Nov 09, 1982
-------------	------------------	---------	-----	--------------

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT	EQ 1GM BASE/VIAL	A062278	001
----------------	------------------	---------	-----

CHLOROMYCETIN

PARKEDALE	EQ 1GM BASE/VIAL	N050155	001
-----------	------------------	---------	-----

MYCHEL-S

ANGUS	EQ 1GM BASE/VIAL	A060132	001
-------	------------------	---------	-----

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS	10MG/GM; 666 UNITS/GM; 1 UNITS/GM	N050294	001
-------------	-----------------------------------	---------	-----

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE	12.5MG/VIAL; 25MG/VIAL	N050202	001
-----------	------------------------	---------	-----

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE	10MG/GM; 5MG/GM; 10,000 UNITS/GM	N050201	002
-----------	----------------------------------	---------	-----

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CHLOROMYXIN

PARKE DAVIS	1%; 10,000 UNITS/GM	N050203	002
-------------	---------------------	---------	-----

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN	1%; 0.5%	A061188	001
----------	----------	---------	-----

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL

LIBRELEAS

VALEANT PHARM INTL	30MG	N017813	001	Sep 12, 1983
--------------------	------	---------	-----	--------------

TABLET; ORAL

LIBRITABS

VALEANT PHARM INTL	5MG	A085482	001
--------------------	-----	---------	-----

	10MG	A085481	001
--	------	---------	-----

	25MG	A085488	001
--	------	---------	-----

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT	5MG	A085447	001
--------	-----	---------	-----

	5MG	A085517	001
--	-----	---------	-----

	10MG	A085447	002
--	------	---------	-----

	10MG	A085518	001
--	------	---------	-----

	25MG	A085447	003
--	------	---------	-----

	25MG	A085513	001
--	------	---------	-----

CHLORDIAZACHEL

RACHELLE	5MG	A085086	001
----------	-----	---------	-----

	10MG	A084639	001
--	------	---------	-----

	25MG	A085087	001
--	------	---------	-----

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT	5MG	A087525	001	Jan 07, 1982
-------	-----	---------	-----	--------------

	10MG	A087524	001	Jan 07, 1982
--	------	---------	-----	--------------

	25MG	A087512	001	Jan 07, 1982
--	------	---------	-----	--------------

FERRANTE	5MG	A085118	001
----------	-----	---------	-----

	10MG	A085119	001
--	------	---------	-----

	25MG	A085120	001
--	------	---------	-----

HALSEY	5MG	A085340	001
--------	-----	---------	-----

	10MG	A085339	001
--	------	---------	-----

	25MG	A084685	001
--	------	---------	-----

HIKMA PHARMS LLC	5MG	A085014	001
------------------	-----	---------	-----



**DISCONTINUED DRUG PRODUCT LIST**CHLORDIAZEPOXIDE HYDROCHLORIDE

## CAPSULE; ORAL

## CHLORDIAZEPOXIDE HYDROCHLORIDE

	10MG	A085000	001	
	25MG	A085294	001	
IMPAX LABS	5MG	A086213	001	
	10MG	A085113	001	
	25MG	A086212	001	
IVAX SUB TEVA PHARMS	5MG	A083741	001	
	10MG	A083742	001	
	25MG	A083570	001	
LEDERLE	5MG	A086892	001	
	5MG	A087234	001	
	10MG	A086876	001	
	10MG	A087037	001	
	25MG	A086893	001	
	25MG	A087231	001	
MAST MM	10MG	A086217	001	
MYLAN	5MG	A084886	001	
	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SANDOZ	5MG	A084678	001	
	5MG	A084919	001	
	10MG	A084041	001	
	10MG	A084920	001	
	25MG	A084679	002	
	25MG	A084823	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
USL PHARMA	5MG	A084644	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WATSON LABS	5MG	A086383	001	
	10MG	A086294	001	
	25MG	A086382	001	
LIBRIUM				
VALEANT PHARM INTL	5MG	N012249	002	
	10MG	N012249	001	
	25MG	N012249	003	
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	

## INJECTABLE; INJECTION

## LIBRIUM

VALEANT PHARMS LLC 100MG/AMP N012301 001

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

## TABLET; ORAL

## MENRIUM 10-4

ROCHE 10MG; 0.4MG N014740 006

## MENRIUM 5-2

ROCHE 5MG; 0.2MG N014740 002

**DISCONTINUED DRUG PRODUCT LIST**CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 5-4

ROCHE

5MG;0.4MG

N014740 004

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

APOTEX INC

0.12%

A075561 001 Nov 14, 2000

SOLUTION; TOPICAL

EXIDINE

XTRTRIUM

2.5%

N019421 001 Dec 17, 1985

MICRODERM

J AND J

4%

A072255 001 Apr 15, 1991

PREVACARE R

J AND J

0.5%

A072292 001 Jan 28, 1992

STERI-STAT

MATRIX MEDCL

4%

A070104 001 Jul 24, 1986

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL

4%

N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON

4%

A073416 001 Mar 14, 2000

HIBICLENS

MOLNLYCKE HLTH

4% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N018423 001

MICRODERM

J AND J

4%

A072295 001 Feb 28, 1991

CHLORMERODRIN HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

BRACCO

0.6-1.4mCi/ML

N017269 001

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

SANOFI AVENTIS US

100MG

N011467 003

200MG

N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

FRESENIUS KABI USA

2%

N009435 003

3%

N009435 004

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US

EQ 40MG BASE/ML

N006002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

MD PHARM

EQ 150MG BASE

A087228 001

PUREPAC PHARM

EQ 150MG BASE

A080886 001

TEVA

EQ 150MG BASE

A087504 001 Jan 13, 1982

WATSON LABS

EQ 150MG BASE

A087979 001 Dec 21, 1982

EQ 300MG BASE

A088030 001 Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US

EQ 300MG BASE;EQ 45MG BASE

N014860 002

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING

250MG

A085569 001

HIKMA INTL PHARMS

250MG

A086028 001 Jul 14, 1982

500MG

A087736 001 Jul 14, 1982

LEDERLE

250MG

A086940 001

500MG

A086938 001

SANDOZ

250MG

A085485 001

WATSON LABS

250MG

A085165 001

## DISCONTINUED DRUG PRODUCT LIST

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

250MG	A085173	001	
250MG	A086795	001	Aug 15, 1983
500MG	A084026	001	Sep 01, 1982
500MG	A086796	001	Aug 15, 1983

DIURIL

OAK PHARMS AKORN

250MG	N011145	004	
500MG	N011145	002	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK

150MG; 250MG	N016016	001	
--------------	---------	-----	--

ALDOCLOR-250

MERCK

250MG; 250MG	N016016	002	
--------------	---------	-----	--

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM

150MG; 250MG	A070783	001	Nov 06, 1987
250MG; 250MG	A070654	001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

HIKMA PHARMS LLC

250MG; 0.125MG	A088557	001	Dec 22, 1983
500MG; 0.125MG	A088365	001	Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS

250MG; 0.125MG	A084853	001	
500MG; 0.125MG	A088151	001	Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN

250MG; 0.125MG	A087744	001	May 06, 1982
500MG; 0.125MG	A087745	001	May 06, 1982

DIUPRES-250

MERCK

250MG; 0.125MG	N011635	003	Aug 26, 1987
----------------	---------	-----	--------------

DIUPRES-500

MERCK

500MG; 0.125MG	N011635	006	Aug 26, 1987
----------------	---------	-----	--------------

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS

12MG	A084652	001	
------	---------	-----	--

TACE

SANOFI AVENTIS US

12MG	N008102	004	
25MG	N011444	001	
72MG	N016235	001	

CHLOROXYLINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB

2%	N017594	001	
----	---------	-----	--

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PHARMACIA AND UPJOHN

400MG	N014217	002	
-------	---------	-----	--

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

SANDOZ

12MG	A070797	001	Aug 12, 1988
------	---------	-----	--------------

TELDRIN

GLAXOSMITHKLINE

8MG	N017369	001	
12MG	N017369	002	

INJECTABLE; INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH

10MG/ML	N008826	001	
100MG/ML	N008794	001	

CHLORPHENIRAMINE MALEATE

BEL MAR

10MG/ML	A080821	001	
---------	---------	-----	--

ELKINS SINN

10MG/ML	A080797	001	
---------	---------	-----	--

WATSON LABS

10MG/ML	A083593	001	
---------	---------	-----	--

10MG/ML	A086096	001	
---------	---------	-----	--

100MG/ML	A086095	001	
----------	---------	-----	--

PYRIDAMAL 100

BEL MAR

100MG/ML	A083733	001	
----------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

CHLORPHENIRAMINE MALEATE

SYRUP; ORAL

CHLOR-TRIMETON

SCHERING 2MG/5ML N006921 006

CHLORPHENIRAMINE MALEATE

PHARM ASSOC 2MG/5ML A087520 001 Feb 10, 1982

TABLET; ORAL

ANTAGONATE

BAYER PHARMS 4MG A083381 001

CHLOR-TRIMETON

SCHERING 4MG N006921 002

CHLORPHENIRAMINE MALEATE

ANABOLIC 4MG A083078 001

BELL PHARMA 4MG A083062 001

ELKINS SINN 4MG A080938 001

IMPAX LABS 4MG A080809 001

IVAX SUB TEVA PHARMS 4MG A080779 001

KV PHARM 4MG A087164 001

LEDERLE 4MG A086941 001

MUTUAL PHARM 4MG A080700 001

NEWTRON PHARMS 4MG A086519 001

PANRAY 4MG A083243 001

PHARMAVITE 4MG A085104 001

PHARMERAL 4MG A083753 001

PIONEER PHARMS 4MG A088556 001 Jul 13, 1984

PUREPAC PHARM 4MG A086306 001

PVT FORM 4MG A080786 001

ROXANE 4MG A080626 001

SANDOZ 4MG A080961 001

VITARINE 4MG A085837 001

WATSON LABS 4MG A080696 001

4MG A080791 001

4MG A085139 001

4MG A083787 001

WEST WARD

KLOROMIN

HALSEY 4MG A083629 001

PHENETRON

LANNETT 4MG A080846 001

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

BAYER HEALTHCARE LLC 8MG N007638 001

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA 16MG N019746 002 Nov 18, 1994

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV

GRAHAM DM 12MG;75MG N018793 001 Apr 25, 1985

COLD CAPSULE V

GRAHAM DM 8MG;75MG N018794 001 Apr 23, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIAMINIC-12

NOVARTIS 12MG;75MG N018115 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA 12MG;120MG N018935 001 Apr 15, 1985

ISOCLOR

FISONS 8MG;120MG N018747 001 Mar 06, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS 8MG;120MG N019428 001 Aug 02, 1988

GRAHAM DM 8MG;120MG N018844 001 Mar 20, 1985

12MG;120MG N018843 001 Mar 18, 1985

KV PHARM 12MG;120MG A071455 001 Mar 01, 1989

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

UCB INC EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML N021369 001 Jun 21, 2004

PENNTUSS

FISONS EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML N018928 001 Aug 14, 1985

**DISCONTINUED DRUG PRODUCT LIST**CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE

PARKE DAVIS

EQ 65MG BASE

N014696 001

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

GLAXOSMITHKLINE

25MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N009149 024

100MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N009149 033

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

GLAXOSMITHKLINE

30MG

N011120 016

75MG

N011120 017

150MG

N011120 018

200MG

N011120 019

300MG

N011120 020

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

100MG/ML

A086863 001

PHARM ASSOC

30MG/ML

A040231 001 Dec 30, 1999

100MG/ML

A040224 001 Jan 26, 1999

WOCKHARDT

30MG/ML

A087032 001 Jul 08, 1982

100MG/ML

A087053 001

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

CYCLE PHARMS LTD

30MG/ML

A088157 001 Apr 27, 1983

100MG/ML

A088158 001 Apr 27, 1983

SONAZINE

SANDOZ

30MG/ML

A080983 004

100MG/ML

A080983 005

THORAZINE

GLAXOSMITHKLINE

30MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N009149 032

100MG/ML \*\*Federal Register

N009149 043

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM

25MG/ML

A084911 001

MARSAM PHARMS LLC

25MG/ML

A089563 001 Apr 15, 1988

WATSON LABS

25MG/ML

A080365 001

25MG/ML

A085591 001

WYETH AYERST

25MG/ML

A080370 001

THORAZINE

GLAXOSMITHKLINE

25MG/ML

N009149 011

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A086712 001

SONAZINE

SANDOZ

10MG/5ML

A083040 001

THORAZINE

GLAXOSMITHKLINE

10MG/5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N009149 022

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT

10MG

A084414 001

25MG

A084415 001

50MG

A084411 001

100MG

A084412 001

200MG

A084413 001

CYCLE PHARMS LTD

10MG

A085331 001

25MG

A085331 002

**DISCONTINUED DRUG PRODUCT LIST**CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

	50MG	A085331 003	
	100MG	A085331 004	
	200MG	A085331 005	
IVAX SUB TEVA PHARMS	10MG	A083549 001	
	25MG	A083549 002	
	50MG	A083549 003	
	100MG	A083574 001	
	200MG	A083575 001	
KV PHARM	10MG	A085750 002	Jan 04, 1982
	25MG	A085751 001	
	50MG	A085484 001	
	100MG	A085752 001	
	200MG	A085748 002	Jan 04, 1982
LEDERLE	10MG	A084803 001	
	25MG	A084801 001	
	50MG	A084800 001	
	100MG	A084789 001	
	200MG	A084802 001	
PUREPAC PHARM	10MG	A080403 004	
	25MG	A080403 001	
	50MG	A080403 002	
	100MG	A080403 003	
	200MG	A080403 005	
PVT FORM	25MG	A080340 001	
	50MG	A080340 002	
	200MG	A080340 003	
SANDOZ	10MG	A080439 001	
	25MG	A080439 002	
	50MG	A080439 003	
	100MG	A080439 004	
	200MG	A080439 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982
PROMAPAR			
PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	
THORAZINE			
GLAXOSMITHKLINE	10MG	N009149 002	
	25MG	N009149 007	
	50MG	N009149 013	
	100MG	N009149 018	
	200MG	N009149 020	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A089446 001	Nov 17, 1986
	250MG	A088813 001	Oct 19, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A089447 001	Nov 17, 1986
DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987

## DISCONTINUED DRUG PRODUCT LIST

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
SANDOZ	100MG	A088725 001	Aug 31, 1984
	250MG	A084669 001	
	250MG	A088726 001	Aug 31, 1984
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
TEVA PHARMS USA	250MG	A087353 001	
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS INC	100MG	A088852 001	Sep 26, 1984
	250MG	A088826 001	Sep 26, 1984
GLUCAMIDE			
TEVA PHARMS USA	250MG	A088641 001	Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE	100MG/5ML	N016149 002	
-------	-----------	-------------	--

INJECTABLE; INJECTION

TARACTAN

ROCHE	12.5MG/ML	N012487 001	
-------	-----------	-------------	--

TABLET; ORAL

TARACTAN

ROCHE	10MG	N012486 005	
	25MG	N012486 004	
	50MG	N012486 003	
	100MG	N012486 001	

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE	1%	N050404 001	
---------	----	-------------	--

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT	25MG	A087364 001	
	50MG	A087384 001	
ASCOT	25MG	A087698 001	Oct 20, 1982
	50MG	A087699 001	Oct 20, 1982
BARR LABS INC	25MG	A088902 001	Sep 19, 1985
	50MG	A088903 001	Sep 19, 1985
DAVA PHARMS INC	25MG	A087451 001	
	50MG	A087450 001	
G AND W LABS INC	50MG	A088651 001	May 30, 1985
IVAX PHARMS	25MG	A087555 001	
	25MG	A088164 001	Jan 09, 1984
	50MG	A087176 001	
	50MG	A087947 001	Feb 27, 1984
KV PHARM	25MG	A087311 001	
	50MG	A087312 001	
MUTUAL PHARM	25MG	A087292 001	
	25MG	A089285 001	Jul 21, 1986
	25MG	A089738 001	Sep 19, 1988
	50MG	A087293 001	
	50MG	A089739 001	Sep 19, 1988
PIONEER PHARMS	50MG	A089591 001	Jul 21, 1988
PUREPAC PHARM	25MG	A088139 001	Jul 16, 1986
	50MG	A088140 001	Aug 11, 1983
SANDOZ	25MG	A087380 001	
	50MG	A087118 001	
	50MG	A087381 001	
SUPERPHARM	25MG	A087473 001	Feb 09, 1983
	50MG	A087247 001	Feb 09, 1983

## DISCONTINUED DRUG PRODUCT LIST

CHLORTHALIDONE

TABLET; ORAL

## CHLORTHALIDONE

USL PHARMA	25MG	A089051 001	Jun 01, 1987
	50MG	A089052 001	Jun 01, 1987
VANGARD	25MG	A088012 001	Jul 14, 1982
	50MG	A088073 001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515 001	Jan 24, 1983
	50MG	A087516 001	Feb 09, 1983
WATSON LABS	25MG	A087050 001	
	25MG	A087100 001	
	25MG	A087296 001	
	25MG	A087706 001	
	50MG	A087029 001	
	50MG	A087082 001	
	50MG	A087521 001	
	50MG	A087689 001	
HYGROTON			
SANOFI AVENTIS US	25MG	N012283 004	
	50MG	N012283 003	
THALITONE			
CITRON PHARMA LLC	15MG	N019574 001	Dec 20, 1988
	25MG	N019574 002	Feb 12, 1992
MONARCH PHARMS	25MG	A088051 001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

## CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG; 0.1MG	A071179 001	Dec 16, 1987
	15MG; 0.2MG	A071178 001	Dec 16, 1987
	15MG; 0.3MG	A071142 001	Dec 16, 1987
COMBIPRES			
BOEHRINGER INGELHEIM	15MG; 0.1MG	N017503 001	
	15MG; 0.2MG	N017503 002	
	15MG; 0.3MG	N017503 003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

## LOPRESSIDONE

NOVARTIS	25MG; 100MG	N019451 001	Dec 31, 1987
	25MG; 200MG	N019451 002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

## DEMI-REGROTON

SANOFI AVENTIS US	25MG; 0.125MG	N015103 002	
REGROTON			
SANOFI AVENTIS US	50MG; 0.25MG	N015103 001	

CHLORZOXAZONE

TABLET; ORAL

## CHLORZOXAZONE

ACTAVIS ELIZABETH	250MG	A088928 001	May 08, 1987
	500MG	A040113 001	Sep 29, 1995
MUTUAL PHARM	500MG	A089970 001	Sep 27, 1990
OHM LABS	250MG	A081298 001	Dec 29, 1993
	500MG	A081299 001	Dec 29, 1993
PAR PHARM	250MG	A087981 001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592 001	Jan 06, 1989
	500MG	A089948 001	Jan 06, 1989
SANDOZ	250MG	A089852 001	May 04, 1988
	500MG	A089853 001	May 04, 1988
WATSON LABS	250MG	A086901 001	
	250MG	A086948 001	Aug 09, 1982
	500MG	A040137 001	Aug 09, 1996
	500MG	A081019 001	Jul 29, 1991
	500MG	A081040 001	Aug 22, 1989
PARAFLEX			
ORTHO MCNEIL PHARM	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011300 003	
PARAFON FORTE DSC			
JANSSEN R AND D	500MG	N011529 002	Jun 15, 1987



## DISCONTINUED DRUG PRODUCT LIST

CHLORZOXAZONE

TABLET; ORAL

STRIFON FORTE DSC  
FERNDALE LABS

500MG

A081008 001 Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS

EQ 4GM RESIN/BAR

A071621 001 May 26, 1988

EQ 4GM RESIN/BAR

A071739 001 May 26, 1988

POWDER; ORAL

CHOLESTYRAMINE

ANI PHARMS INC

EQ 4GM RESIN/PACKET

A074554 001 Oct 02, 1996

EQ 4GM RESIN/SCOOPFUL

A074554 002 Oct 02, 1996

IVAX SUB TEVA PHARMS

EQ 4GM RESIN/PACKET

A074771 001 Jul 09, 1997

EQ 4GM RESIN/SCOOPFUL

A074771 002 Jul 09, 1997

TEVA

EQ 4GM RESIN/PACKET

A074347 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074347 002 May 28, 1998

CHOLESTYRAMINE LIGHT

TEVA

EQ 4GM RESIN/PACKET

A074348 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074348 002 May 28, 1998

TEVA PHARMS

EQ 4GM RESIN/PACKET

A074555 001 Sep 30, 1998

EQ 4GM RESIN/SCOOPFUL

A074555 002 Sep 30, 1998

LOCHOLEST

SANDOZ

EQ 4GM RESIN/PACKET

A074561 001 Aug 15, 1996

EQ 4GM RESIN/SCOOPFUL

A074561 002 Aug 15, 1996

LOCHOLEST LIGHT

SANDOZ

EQ 4GM RESIN/PACKET

A074562 001 Aug 15, 1996

EQ 4GM RESIN/SCOOPFUL

A074562 002 Aug 15, 1996

QUESTRAN

BRISTOL MYERS

EQ 4GM RESIN/PACKET

N016640 001

EQ 4GM RESIN/SCOOPFUL

N016640 003

QUESTRAN LIGHT

BRISTOL MYERS

EQ 4GM RESIN/PACKET

N019669 001 Dec 05, 1988

EQ 4GM RESIN/SCOOPFUL

N019669 003 Dec 05, 1988

TABLET; ORAL

QUESTRAN

APOTHECON

EQ 800MG RESIN

A073403 002 Dec 27, 1999

EQ 1GM RESIN

A073403 001 Apr 28, 1994

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

EMD SERONO

0.25MG/VIAL

N021149 001 Sep 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM

EQ 0.004MG CHROMIUM/ML

N019271 001 May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

MALLINKRODT NUCLEAR

5mCi/ML

N017084 001

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

CHART MEDCL

4,000 UNITS/VIAL

N018663 002 Aug 21, 1984

10,000 UNITS/VIAL \*\*Federal Register

N018663 001 Nov 10, 1982

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

DISCASE

ABBOTT

12,500 UNITS/VIAL

N018625 001 Jan 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ALPHA CHYMAR

SOLA BARNES HIND

750 UNITS/VIAL

N011837 001

CATARASE

CIBA

300 UNITS/VIAL

N016938 001

NOVARTIS

150 UNITS/VIAL

N018121 001

ZOLYSE

ALCON

750 UNITS/VIAL

N011903 001

**DISCONTINUED DRUG PRODUCT LIST**CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007
TEVA PHARMS	8%	A078079	001	Sep 18, 2007

CIDOFOVIR

INJECTABLE; INJECTION

VISTIDE

GILEAD SCIENCES INC	EQ 75MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020638	001	Jun 26, 1996
---------------------	--	---------	-----	--------------

CILASTATIN SODIUM; IMPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	A062756	001	Jan 08, 1987
	EQ 500MG BASE/VIAL; 500MG/VIAL	A062756	002	Jan 08, 1987

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCK	EQ 750MG BASE/VIAL; 750MG/VIAL	N050630	002	Dec 14, 1990
-------	--------------------------------	---------	-----	--------------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004
COREPHARMA	50MG	A077150	001	Mar 11, 2005
	100MG	A077022	001	Nov 23, 2004
IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
MUTUAL PHARM	50MG	A077208	002	Mar 29, 2006
	100MG	A077208	001	Mar 29, 2006

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999
-----------------	------------	---------	-----	--------------

TABLET; ORAL

CIMETIDINE

CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994
	400MG	A074361	002	Dec 23, 1994
	800MG	A074371	001	Dec 23, 1994
DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995
	400MG	A074340	002	Jun 23, 1995
	800MG	A074339	001	Jun 23, 1995
IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	200MG	A074424	001	Jul 28, 1995
	300MG	A074401	002	May 30, 1995
	300MG	A074424	002	Jul 28, 1995
	400MG	A074401	003	May 30, 1995
	400MG	A074424	003	Jul 28, 1995
	800MG	A074402	001	May 30, 1995
	800MG	A074424	004	Jul 28, 1995
LEK PHARMS	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995
	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
PERRIGO	100MG	A074972	001	Jun 19, 1998
PLIVA	200MG	A074568	001	Feb 27, 1997
	300MG	A074568	002	Feb 27, 1997
	400MG	A074568	003	Feb 27, 1997
SANDOZ	200MG	A074100	001	Jan 31, 1995
	200MG	A074506	001	Jan 24, 1996
	300MG	A074100	002	Jan 31, 1995
	300MG	A074506	002	Jan 24, 1996
	400MG	A074100	003	Jan 31, 1995
	400MG	A074506	003	Jan 24, 1996
	800MG	A074100	004	Jan 31, 1995
	800MG	A074506	004	Jan 24, 1996
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995
	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995

## DISCONTINUED DRUG PRODUCT LIST

CIMETIDINE

## TABLET; ORAL

## CIMETIDINE

VINTAGE PHARMS LLC	200MG	A074281 001	May 17, 1994
	300MG	A074281 002	May 17, 1994
	400MG	A074281 003	May 17, 1994
	800MG	A074329 001	May 17, 1994
WATSON LABS	200MG	A075425 001	Jul 29, 1999
WATSON LABS INC	200MG	A074349 001	Aug 30, 1996
	300MG	A074349 002	Aug 30, 1996
	400MG	A074349 003	Aug 30, 1996
	800MG	A074316 001	Feb 28, 1996

## TAGAMET

GLAXOSMITHKLINE	200MG **Federal Registration determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017920 002	
	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017920 003	
	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017920 004	Dec 14, 1983
	800MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017920 005	Apr 30, 1986

## TAGAMET HB

MEDTECH PRODUCTS	100MG	N020238 001	Jun 19, 1995
------------------	-------	-------------	--------------

CIMETIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422 001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353 001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252 001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
HOSPIRA	EQ 6MG BASE/ML	A074269 001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468 005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468 006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468 003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468 004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468 001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468 002	Dec 29, 1994

## TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N017939 002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
GLAXOSMITHKLINE	EQ 6MG BASE/ML	N019434 001	Oct 31, 1985

## SOLUTION; ORAL

## CIMETIDINE HYDROCHLORIDE

ANI PHARMS INC	EQ 300MG BASE/5ML	A074859 001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110 001	Jun 18, 1998
APOTEX INC	EQ 300MG BASE/5ML	A075560 001	Mar 15, 2000
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541 001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML	A074176 001	Jun 01, 1994
VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994

## TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/5ML	N017924 001	
-----------------	-------------------	-------------	--

CINOXACIN

## CAPSULE; ORAL

## CINOXACIN

LILLY	250MG	N018067 001	
	500MG	N018067 002	

## CINOXACIN

TEVA	250MG	A073005 001	Feb 28, 1992
	500MG	A073006 001	Feb 28, 1992

**DISCONTINUED DRUG PRODUCT LIST**CIPROFLOXACIN

## INJECTABLE; INJECTION

## CIPRO

BAYER HLTHCARE	1200MG/120ML (10MG/ML)	N019847	003	Dec 26, 1990
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAYER PHARMS	200MG/100ML	N019858	001	Dec 26, 1990

## CIPROFLOXACIN

BEDFORD LABS	200MG/20ML (10MG/ML)	A076992	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076992	002	Aug 28, 2006
	1200MG/120ML (10MG/ML)	A076993	001	Aug 28, 2006
FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076484	002	Aug 28, 2006
TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006

## CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA	200MG/100ML	A076757	001	Apr 21, 2008
--------------------	-------------	---------	-----	--------------

## CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	A077888	001	Mar 18, 2008
	400MG/200ML	A077888	002	Mar 18, 2008
BEDFORD	200MG/100ML	A078114	001	Mar 18, 2008
	400MG/200ML	A078114	002	Mar 18, 2008
TEVA PHARMS	200MG/100ML	A077138	001	Mar 18, 2008
	400MG/200ML	A077138	002	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## CIPROFLOXACIN HYDROCHLORIDE

APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004
------------	--------------	---------	-----	--------------

## TABLET; ORAL

## CIPROFLOXACIN HYDROCHLORIDE

BARR	EQ 250MG BASE	A074124	001	Jun 09, 2004
	EQ 500MG BASE	A074124	002	Jun 09, 2004
	EQ 750MG BASE	A074124	003	Jun 09, 2004
NOSTRUM LABS	EQ 250MG BASE	A076138	001	Jun 09, 2004
	EQ 500MG BASE	A076138	002	Jun 09, 2004
	EQ 750MG BASE	A076138	003	Jun 09, 2004
PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005
	EQ 250MG BASE	A076426	002	Jun 15, 2005
	EQ 500MG BASE	A076426	003	Jun 15, 2005
	EQ 750MG BASE	A076426	004	Jun 15, 2005
SANDOZ	EQ 100MG BASE	A075939	001	Mar 03, 2005
	EQ 250MG BASE	A075939	002	Jun 09, 2004
	EQ 250MG BASE	A076593	002	Jun 09, 2004
	EQ 500MG BASE	A075939	003	Jun 09, 2004
	EQ 500MG BASE	A076593	003	Jun 09, 2004
	EQ 750MG BASE	A075939	004	Jun 09, 2004
	EQ 750MG BASE	A076593	004	Jun 09, 2004
TEVA	EQ 250MG BASE	A076136	001	Jun 09, 2004
	EQ 500MG BASE	A076136	002	Jun 09, 2004
	EQ 750MG BASE	A076136	003	Jun 09, 2004

## TABLET, EXTENDED RELEASE; ORAL

## PROQUIN XR

DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005
-------------	---------------	---------	-----	--------------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## CIPRO XR

BAYER HLTHCARE	212.6MG; EQ 287.5MG BASE	N021473	001	Dec 13, 2002
	425.2MG; EQ 574.9MG BASE	N021473	002	Aug 28, 2003

## CIPROFLOXACIN EXTENDED RELEASE

DR REDDYS LABS LTD	212.6MG; EQ 287.5MG BASE	A077701	002	Oct 31, 2007
SANDOZ	212.6MG; EQ 287.5MG BASE	A078712	001	Dec 11, 2007

CISAPRIDE MONOHYDRATE

## SUSPENSION; ORAL

## PROPULSID

JANSSEN PHARMS	EQ 1MG BASE/ML	N020398	001	Sep 15, 1995
----------------	----------------	---------	-----	--------------

## TABLET; ORAL

## PROPULSID

JANSSEN PHARMS	EQ 10MG BASE	N020210	001	Jul 29, 1993
	EQ 20MG BASE	N020210	002	Dec 23, 1993

**DISCONTINUED DRUG PRODUCT LIST**CISAPRIDE MONOHYDRATE

TABLET, ORALLY DISINTEGRATING;ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA

EQ 20MG BASE

N020767 001 Nov 07, 1997

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

BEDFORD

10MG/VIAL

A074713 001 Nov 14, 2000

50MG/VIAL

A074713 002 Nov 14, 2000

TEVA PHARMS USA

1MG/ML

A074814 001 May 16, 2000

PLATINOL

HQ SPCLT PHARMA

10MG/VIAL

N018057 001

50MG/VIAL

N018057 002

PLATINOL-AQ

HQ SPCLT PHARMA

0.5MG/ML

N018057 003 Jul 18, 1984

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CELEXA

FOREST LABS

EQ 10MG BASE/5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021046 001 Dec 22, 1999

CITALOPRAM HYDROBROMIDE

APOTEX INC

EQ 10MG BASE/5ML

A077601 001 Nov 15, 2005

TABLET;ORAL

CELEXA

FOREST LABS

EQ 60MG BASE

N020822 004 Jul 17, 1998

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH

EQ 10MG BASE

A077033 001 Oct 28, 2004

EQ 20MG BASE

A077033 002 Oct 28, 2004

EQ 40MG BASE

A077033 003 Oct 28, 2004

COREPHARMA

EQ 10MG BASE

A077036 001 Oct 28, 2004

EQ 20MG BASE

A077036 002 Oct 28, 2004

EQ 40MG BASE

A077036 003 Oct 28, 2004

MUTUAL PHARM

EQ 10MG BASE

A077052 001 Jul 03, 2006

EQ 20MG BASE

A077052 002 Jul 03, 2006

EQ 40MG BASE

A077052 003 Jul 03, 2006

NATCO PHARMA LTD

EQ 20MG BASE

A077141 002 Apr 10, 2008

EQ 40MG BASE

A077141 001 Apr 10, 2008

ROXANE

EQ 10MG BASE

A077041 001 Nov 23, 2004

EQ 20MG BASE

A077041 002 Nov 23, 2004

EQ 40MG BASE

A077041 003 Nov 23, 2004

SANDOZ

EQ 10MG BASE

A077035 001 Oct 28, 2004

EQ 10MG BASE

A077040 001 Aug 17, 2005

EQ 20MG BASE

A077035 002 Oct 28, 2004

EQ 20MG BASE

A077040 002 Aug 17, 2005

EQ 40MG BASE

A077035 003 Oct 28, 2004

EQ 40MG BASE

A077040 003 Aug 17, 2005

TARO

EQ 10MG BASE

A077278 001 Mar 22, 2006

EQ 20MG BASE

A077278 002 Mar 22, 2006

EQ 40MG BASE

A077278 003 Mar 22, 2006

TEVA PHARMS

EQ 10MG BASE

A077213 001 Mar 31, 2006

EQ 20MG BASE

A077213 002 Mar 31, 2006

EQ 40MG BASE

A077213 003 Mar 31, 2006

WATSON LABS

EQ 10MG BASE

A077034 001 Jun 30, 2005

EQ 20MG BASE

A077034 002 Jun 30, 2005

EQ 40MG BASE

A077034 003 Jun 30, 2005

TABLET, ORALLY DISINTEGRATING;ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL

EQ 10MG BASE

N021763 001 Dec 20, 2005

EQ 20MG BASE

N021763 002 Dec 20, 2005

EQ 40MG BASE

N021763 003 Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION;IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE

3.24GM/100ML;380MG/100ML;430MG/100ML

N018519 001 Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA

3.24GM/100ML;380MG/100ML;430MG/100ML

N018904 001 May 27, 1983

## DISCONTINUED DRUG PRODUCT LIST

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

JANSSEN PHARMS

1MG/ML \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020229 001 Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBVIE

187MG/5ML

N050698 003 Sep 30, 1998

TABLET; ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS

250MG

A065137 001 May 31, 2005

500MG

A065137 002 May 31, 2005

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

ABBVIE

500MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N050775 001 Mar 03, 2000

CLARITHROMYCIN

RANBAXY

1GM

A065210 001 Jan 26, 2005

SANDOZ

500MG

A065250 001 Aug 25, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

GLAXOSMITHKLINE

EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL

A062691 001 Dec 19, 1986

EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL

N050590 001 Apr 01, 1985

EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL

N050590 002 Apr 01, 1985

EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL

N050590 003 Aug 18, 1987

TIMENTIN IN PLASTIC CONTAINER

GLAXOSMITHKLINE

EQ 100MG BASE/100ML; EQ 3GM BASE/100ML

N050658 001 Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC

EQ 0.5MG BASE/5ML

A074075 001 Oct 31, 1993

APOTEX INC

EQ 0.5MG BASE/5ML

A075703 001 Nov 27, 2000

SILARX

EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997

TEVA PHARMS

EQ 0.5MG BASE/5ML

A073095 001 Apr 21, 1992

TAVIST

NOVARTIS

EQ 0.5MG BASE/5ML

N018675 001 Jun 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

ANI PHARMS INC

1.34MG

A073282 001 Jan 31, 1992

1.34MG

A073282 002 Dec 03, 1992

TAVIST

NOVARTIS

2.68MG

N017661 001

TAVIST-1

NOVARTIS

1.34MG

N017661 002

1.34MG

N017661 003 Aug 21, 1992

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE

2.5MG

N010355 001

5MG

N010355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE

A061809 001

EQ 150MG BASE

A061809 002

CLINDAMYCIN HYDROCHLORIDE

TEVA

EQ 75MG BASE

A063027 001 Sep 20, 1989

WATSON LABS

EQ 75MG BASE

A063082 001 Jul 31, 1991

**DISCONTINUED DRUG PRODUCT LIST**CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 75MG BASE/5ML A061827 001

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 2% BASE N050680 001 Aug 11, 1992

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN EQ 150MG BASE/ML A061839 001

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM EQ 150MG BASE/ML A062747 001 Jun 03, 1988

BEDFORD EQ 150MG BASE/ML A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB EQ 150MG BASE/ML A062908 001 Feb 01, 1989

HIKMA MAPLE EQ 150MG BASE/ML A062806 001 Oct 15, 1987

EQ 150MG BASE/ML A062953 001 Apr 21, 1988

EQ 150MG BASE/ML A063068 001 Aug 28, 1989

IGI LABS INC EQ 150MG BASE/ML A062928 001 Feb 13, 1989

LOCH EQ 150MG BASE/ML A062905 001 May 09, 1988

MARSAM PHARMS LLC EQ 150MG BASE/ML A062913 001 Oct 20, 1988

SOLOPAK EQ 150MG BASE/ML A062819 001 Mar 15, 1988

EQ 150MG BASE/ML A062852 001 Mar 17, 1988

TEVA PARENTERAL EQ 150MG BASE/ML A063041 001 Dec 29, 1989

EQ 150MG BASE/ML A063282 001 May 29, 1992

WATSON LABS EQ 150MG BASE/ML A062900 001 Jun 08, 1988

EQ 150MG BASE/ML A063079 001 Mar 05, 1990

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM EQ 12MG BASE/ML N050636 001 Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE EQ 6MG BASE/ML A065027 001 Jun 29, 2001

EQ 12MG BASE/ML A065027 002 Jun 29, 2001

EQ 18MG BASE/ML A065027 003 Jun 29, 2001

BAXTER HLTHCARE EQ 6MG BASE/ML N050648 001 Dec 29, 1989

EQ 12MG BASE/ML N050648 002 Dec 29, 1989

EQ 900MG BASE/100ML N050648 003 Dec 29, 1989

SOLUTION;TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN EQ 1% BASE A062363 001 Feb 08, 1982

CLINDAMYCIN PHOSPHATE

BOCA PHARMA LLC EQ 1% BASE A062944 001 Jan 11, 1989

RENAISSANCE PHARMA EQ 1% BASE A064108 001 Sep 27, 1996

VINTAGE PHARMS EQ 1% BASE A062930 001 Jun 28, 1989

CLIOQUINOL; NYSTATIN

OINTMENT;TOPICAL

NYSTAFORM

BAYER PHARMS 10MG/GM;100,000 UNITS/GM N050235 001

CLOBAZAM

TABLET;ORAL

ONFI

LUNDBECK LLC 5MG N202067 001 Oct 21, 2011

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

RENAISSANCE PHARMA 0.05% A075338 001 Feb 09, 2001

TEVA PHARMS USA 0.05% A074087 001 Feb 16, 1994

CLOBETASOL PROPIONATE (EMOLLIENT)

RENAISSANCE PHARMA 0.05% A075733 001 Aug 22, 2001

TEMOVATE

FOUGERA PHARMS 0.05% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\* N019322 001 Dec 27, 1985

TEMOVATE E

FOUGERA PHARMS 0.05% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\* N020340 001 Jun 17, 1994

GEL;TOPICAL

TEMOVATE

FOUGERA PHARMS 0.05% \*\*Federal Register determination N020337 001 Apr 29, 1994

## DISCONTINUED DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

GEL; TOPICAL

TEMOVATE

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC 0.05%

A074128 001 Aug 03, 1994

RENAISSANCE PHARMA 0.05%

A075057 001 Aug 12, 1998

SOLUTION; TOPICAL

TEMOVATE

FOUGERA PHARMS

0.05% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N019966 001 Feb 22, 1990

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

NOVARTIS

100MG

N019500 001 Dec 15, 1986

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

WYETH AYERST

500MG

N016099 002

CLOFIBRATE

BANNER PHARMACAPS

500MG

A073396 001 Mar 20, 1992

SANDOZ

500MG

A072191 001 May 02, 1988

TEVA

500MG

A072600 001 Jul 25, 1991

USL PHARMA

500MG

A070531 001 Jun 16, 1986

WATSON LABS

500MG

A071603 001 Sep 18, 1987

CLOMIPHENE CITRATE

TABLET; ORAL

MILOPHENE

MILEX

50MG

A072196 001 Dec 20, 1988

SEROPHENE

EMD SERONO

50MG

N018361 001 Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

SANDOZ

25MG

A074953 001 Jun 25, 1997

50MG

A074953 002 Jun 25, 1997

75MG

A074953 003 Jun 25, 1997

TEVA

25MG

A074849 001 Apr 04, 1997

50MG

A074849 002 Apr 04, 1997

75MG

A074849 003 Apr 04, 1997

WATSON LABS

25MG

A074600 001 Nov 27, 1996

25MG

A074751 001 Sep 30, 1998

50MG

A074600 002 Nov 27, 1996

50MG

A074751 002 Sep 30, 1998

75MG

A074600 003 Nov 27, 1996

75MG

A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

APOTEX INC

0.5MG

A075468 001 Oct 06, 2000

1MG

A075468 002 Oct 06, 2000

2MG

A075468 003 Oct 06, 2000

SANDOZ

0.5MG

A074925 001 Sep 30, 1997

1MG

A074925 002 Sep 30, 1997

2MG

A074925 003 Sep 30, 1997

TEVA

0.5MG

A074920 001 Aug 04, 1998

1MG

A074920 002 Aug 04, 1998

2MG

A074920 003 Aug 04, 1998

KLONOPIN

ROCHE

0.125MG

N017533 005 Apr 09, 1997

0.25MG

N017533 006 Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

ROCHE

0.125MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or

N020813 001 Dec 23, 1997



**DISCONTINUED DRUG PRODUCT LIST**CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL  
 KLONOPIN RAPIDLY DISINTEGRATING

efficacy reasons\*\*

0.25MG \*\*Federal Register determination N020813 002 Dec 23, 1997  
 that product was not discontinued or  
 withdrawn for safety or efficacy  
 reasons\*\*

0.5MG \*\*Federal Register determination N020813 003 Dec 23, 1997  
 that product was not discontinued or  
 withdrawn for safety or efficacy  
 reasons\*\*

1MG \*\*Federal Register determination N020813 004 Dec 23, 1997  
 that product was not discontinued or  
 withdrawn for safety or efficacy  
 reasons\*\*

2MG \*\*Federal Register determination N020813 005 Dec 23, 1997  
 that product was not discontinued or  
 withdrawn for safety or efficacy  
 reasons\*\*

CLONIDINE

SUSPENSION, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.09MG BASE/ML N022499 001 Dec 03, 2009

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.17MG BASE N022500 001 Dec 03, 2009

EQ 0.26MG BASE N022500 002 Dec 03, 2009

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP 0.1MG A070881 001 Jul 08, 1986

0.2MG A070882 001 Jul 08, 1986

0.3MG A070883 001 Jul 08, 1986

DAVA PHARMS INC 0.1MG A071783 001 Apr 05, 1988

0.2MG A071784 001 Apr 05, 1988

0.3MG A071785 001 Apr 05, 1988

DURAMED PHARMS BARR 0.1MG A071103 001 Aug 14, 1986

0.2MG A071102 001 Aug 14, 1986

0.3MG A071101 001 Aug 14, 1986

INTERPHARM 0.1MG A071252 001 Oct 01, 1986

0.2MG A071253 001 Oct 01, 1986

0.3MG A071254 001 Oct 01, 1986

PAR PHARM 0.1MG A070461 001 Jul 08, 1986

0.2MG A070460 001 Jul 08, 1986

0.3MG A070459 001 Jul 08, 1986

SANDOZ 0.1MG A070887 001 Aug 31, 1988

0.2MG A070886 001 Aug 31, 1988

0.3MG A071294 001 Aug 31, 1988

TEVA 0.1MG A070747 001 Jul 08, 1986

0.2MG A070702 001 Jul 08, 1986

0.3MG A070659 001 Jul 08, 1986

WARNER CHILCOTT 0.1MG A072138 001 Jun 13, 1988

0.2MG A072139 001 Jun 13, 1988

0.3MG A072140 001 Jun 13, 1988

WATSON LABS 0.1MG A070395 001 Mar 23, 1987

0.1MG A070965 001 Jul 08, 1986

0.2MG A070396 001 Mar 23, 1987

0.2MG A070964 001 Jul 08, 1986

0.3MG A070397 001 Mar 23, 1987

0.3MG A070963 001 Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH 0.2MG A202792 002 May 15, 2015

0.2MG A203320 002 May 15, 2015

ANCHEN PHARMS 0.1MG A202983 001 Apr 02, 2014

0.2MG A202983 002 Apr 02, 2014

CLONIDINE HYDROCHLORIDE

ANCHEN PHARMS 0.2MG A202984 002 Sep 30, 2013

JENLOGA

CONCORDIA PHARMS INC 0.1MG N022331 001 Sep 30, 2009

0.2MG N022331 002 May 25, 2010

## DISCONTINUED DRUG PRODUCT LIST

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KAPVAY

CONCORDIA PHARMS INC 0.2MG N022331 004 Sep 28, 2010

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE 3.75MG A071777 001 Jul 14, 1987

7.5MG A071778 001 Jul 14, 1987

15MG A071779 001 Jul 14, 1987

AM THERAP 3.75MG A071429 001 Jun 23, 1987

7.5MG A071430 001 Jun 23, 1987

15MG A071431 001 Jun 23, 1987

DAVA PHARMS INC 3.75MG A071742 001 Dec 14, 1987

7.5MG A071743 001 Dec 14, 1987

15MG A071744 001 Dec 14, 1987

GD SEARLE LLC 3.75MG A071727 001 Dec 18, 1987

7.5MG A071728 001 Dec 18, 1987

15MG A071729 001 Dec 18, 1987

MYLAN 3.75MG A071509 001 Oct 19, 1987

7.5MG A071510 001 Oct 19, 1987

15MG A071511 001 Oct 19, 1987

PUREPAC PHARM 3.75MG A071924 001 Apr 25, 1988

7.5MG A071925 001 Apr 25, 1988

15MG A071926 001 Apr 25, 1988

QUANTUM PHARMICS 3.75MG A071549 001 Sep 12, 1988

7.5MG A071550 001 Sep 12, 1988

15MG A071522 001 Sep 12, 1988

SANDOZ 3.75MG A072219 001 Aug 26, 1988

7.5MG A072220 001 Aug 26, 1988

15MG A072112 001 Aug 26, 1988

USL PHARMA 3.75MG A071242 001 Jun 23, 1987

7.5MG A071243 001 Jun 23, 1987

15MG A071244 001 Jun 23, 1987

WARNER CHILCOTT 3.75MG A071774 001 Mar 01, 1988

7.5MG A071775 001 Mar 01, 1988

15MG A071776 001 Mar 01, 1988

WATSON LABS 3.75MG A071878 001 Mar 15, 1988

7.5MG A071879 001 Mar 15, 1988

15MG A071860 001 Mar 15, 1988

TRANXENE

RECORDATI RARE 3.75MG N017105 001

7.5MG N017105 002

15MG N017105 003

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE 3.75MG A071780 001 Jun 26, 1987

7.5MG A071781 001 Jun 26, 1987

15MG A071782 001 Jun 26, 1987

AM THERAP 3.75MG A071747 001 Jun 23, 1987

7.5MG A071748 001 Jun 23, 1987

15MG A071749 001 Jun 23, 1987

LEDERLE 3.75MG A072013 001 Dec 15, 1987

7.5MG A072014 001 Dec 15, 1987

15MG A072015 001 Dec 15, 1987

PUREPAC PHARM 3.75MG A072330 001 Aug 08, 1988

7.5MG A072331 001 Aug 08, 1988

15MG A072332 001 Aug 08, 1988

QUANTUM PHARMICS 3.75MG A071730 001 Oct 26, 1987

7.5MG A071731 001 Oct 26, 1987

15MG A071702 001 Oct 26, 1987

SANDOZ 3.75MG A072512 001 May 11, 1990

7.5MG A072513 001 May 11, 1990

15MG A072514 001 May 11, 1990

WARNER CHILCOTT 3.75MG A071828 001 Mar 03, 1988

7.5MG A071829 001 Mar 03, 1988

15MG A071830 001 Mar 03, 1988

WATSON LABS 3.75MG A071852 001 Feb 09, 1988

7.5MG A071853 001 Feb 09, 1988

15MG A071854 001 Feb 09, 1988

**DISCONTINUED DRUG PRODUCT LIST**CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

TRANXENE SD

RECORDATI RARE	11.25MG	N017105 005
	22.5MG	N017105 004

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN

SCHERING PLOUGH	1%	N017619 001
-----------------	----	-------------

MYCELEX

BAYER HEALTHCARE LLC	1%	N018183 001
----------------------	----	-------------

LOTION; TOPICAL

LOTRIMIN

SCHERING	1%	N018813 001	Feb 17, 1984
----------	----	-------------	--------------

SOLUTION; TOPICAL

LOTRIMIN

SCHERING PLOUGH	1%	N017613 001
-----------------	----	-------------

MYCELEX

BAYER HLTHCARE	1%	N018181 001
----------------	----	-------------

TABLET; VAGINAL

GYNIX

TEVA PHARMS	100MG	A073249 001	Feb 13, 1998
-------------	-------	-------------	--------------

MYCELEX-G

BAYER PHARMS	500MG	N019069 001	Apr 19, 1985
--------------	-------	-------------	--------------

TROCHE/LOZENGE; ORAL

MYCELEX

BAYER HLTHCARE	10MG	N018713 001	Jun 17, 1983
----------------	------	-------------	--------------

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

APOTHECON	EQ 250MG BASE	A061452 001
-----------	---------------	-------------

	EQ 500MG BASE	A061452 002
--	---------------	-------------

TEVA	EQ 250MG BASE	A062240 001
------	---------------	-------------

	EQ 500MG BASE	A062240 002
--	---------------	-------------

CLOXAPEN

GLAXOSMITHKLINE	EQ 250MG BASE	A061806 001
-----------------	---------------	-------------

	EQ 250MG BASE	A062233 001
--	---------------	-------------

	EQ 500MG BASE	A061806 002
--	---------------	-------------

	EQ 500MG BASE	A062233 002
--	---------------	-------------

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM

TEVA	EQ 125MG BASE/5ML	A062268 001
------	-------------------	-------------

	EQ 125MG BASE/5ML	A062978 001	Apr 06, 1989
--	-------------------	-------------	--------------

TEGOPEN

APOTHECON	EQ 125MG BASE/5ML	A061453 001
-----------	-------------------	-------------

	EQ 125MG BASE/5ML	N050192 001
--	-------------------	-------------

CLOZAPINE

TABLET; ORAL

CLOZAPINE

PAR PHARM	25MG	A075162 001	Apr 26, 2005
-----------	------	-------------	--------------

	100MG	A075162 002	Apr 26, 2005
--	-------	-------------	--------------

SANDOZ	25MG	A074546 001	Aug 30, 1996
--------	------	-------------	--------------

	100MG	A074546 002	Aug 30, 1996
--	-------	-------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ PHARMS III	50MG	N021590 003	Jun 03, 2005
-----------------	------	-------------	--------------

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-57 KIT

BRACCO	N/A; N/A; N/A; N/A	N016089 001
--------	--------------------	-------------

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-60 KIT

BRACCO	N/A; N/A; N/A; N/A	N016090 001
--------	--------------------	-------------

**DISCONTINUED DRUG PRODUCT LIST**CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE ANI PHARMS	10MG/5ML; 5MG/5ML; 6.25MG/5ML	N008306 005	Apr 02, 1984
PHERAZINE VC W/ CODEINE HALSEY	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088870 001	Mar 02, 1987
PROMETHAZINE VC W/ CODEINE CENCI	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088816 001	Nov 22, 1985
WOCKHARDT	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088896 001	Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ CODEINE ANI PHARMS	10MG/5ML; 6.25MG/5ML	N008306 004	Apr 02, 1984
PHERAZINE W/ CODEINE HALSEY	10MG/5ML; 6.25MG/5ML	A088739 001	Dec 23, 1988
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A089647 001	Dec 22, 1988
PROMETHAZINE W/ CODEINE CENCI	10MG/5ML; 6.25MG/5ML	A088814 001	Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIFED W/ CODEINE GLAXOSMITHKLINE	10MG/5ML; 30MG/5ML; 1.25MG/5ML	N012575 003	Apr 04, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE CENCI	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A089018 001	Jul 23, 1986
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE WOCKHARDT	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A088833 001	Nov 16, 1984

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE ROXANE	30MG/5ML	N202245 001	Jun 30, 2011
---------------------------	----------	-------------	--------------

COLCHICINE; PROBENECID

TABLET; ORAL

COLBENEMID MERCK	0.5MG; 500MG	N012383 001	
PROBEN-C WATSON LABS	0.5MG; 500MG	A085552 001	
PROBENECID AND COLCHICINE ANI PHARMS INC	0.5MG; 500MG	A083734 001	
BEECHAM	0.5MG; 500MG	A084321 001	
IMPAX LABS	0.5MG; 500MG	A083720 002	
SANDOZ	0.5MG; 500MG	A086130 001	
PROBENECID W/ COLCHICINE LEDERLE	0.5MG; 500MG	A086954 001	
WATSON LABS	0.5MG; 500MG	A083221 001	

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL DAIICHI SANKYO	375MG	N021141 001	May 26, 2000
---------------------------	-------	-------------	--------------

COLISTIN SULFATE

SUSPENSION; ORAL

COLY-MYCIN S PARKE DAVIS	EQ 25MG BASE/5ML	N050355 001	
-----------------------------	------------------	-------------	--

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697 001	Dec 29, 2005
-------------------------------	-------------------	-------------	--------------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

CU-7 GD SEARLE LLC	89MG	N017408 001	
TATUM-T GD SEARLE LLC	120MG	N018205 001	

**DISCONTINUED DRUG PRODUCT LIST**CORTICOTROPIN

## INJECTABLE; INJECTION

## ACTH

PARKEDALE	25 UNITS/VIAL	N008317 002
	40 UNITS/VIAL	N008317 004

## ACTHAR

SANOFI AVENTIS US	25 UNITS/VIAL	N007504 002
	40 UNITS/VIAL	N007504 003

## CORTICOTROPIN

ORGANICS LAGRANGE	40 UNITS/ML	N010831 001
	80 UNITS/ML	N010831 002

WATSON LABS

40 UNITS/VIAL

A088772 001 Nov 21, 1984

## H.P. ACTHAR GEL

MALLINCKRODT ARD	40 UNITS/ML	N008372 006
------------------	-------------	-------------

## PURIFIED CORTROPHIN GEL

ORGANON USA INC	40 UNITS/ML	N008975 001
	80 UNITS/ML	N008975 002

CORTICOTROPIN-ZINC HYDROXIDE

## INJECTABLE; INJECTION

## CORTROPHIN-ZINC

ORGANON USA INC	40 UNITS/ML	N009854 001
-----------------	-------------	-------------

CORTISONE ACETATE

## INJECTABLE; INJECTION

## CORTISONE ACETATE

PHARMACIA AND UPJOHN	25MG/ML	N008126 002
----------------------	---------	-------------

WATSON LABS	25MG/ML	A083147 003
-------------	---------	-------------

	25MG/ML	A085677 001
--	---------	-------------

	50MG/ML	A083147 004
--	---------	-------------

	50MG/ML	A085677 002
--	---------	-------------

## CORTONE

MERCK	25MG/ML	N007110 002
-------	---------	-------------

	50MG/ML	N007110 003
--	---------	-------------

## TABLET; ORAL

## CORTISONE ACETATE

BARR	25MG	A083471 001
------	------	-------------

ELKINS SINN	25MG	A080836 001
-------------	------	-------------

EVERYLIFE	25MG	A084246 001
-----------	------	-------------

HEATHER	25MG	A085736 001
---------	------	-------------

IMPAX LABS	25MG	N009458 001
------------	------	-------------

INWOOD LABS	25MG	A080731 001
-------------	------	-------------

IVAX SUB TEVA PHARMS	25MG	A080630 001
----------------------	------	-------------

	25MG	A083536 001
--	------	-------------

LANNETT	25MG	A080694 001
---------	------	-------------

PANRAY	5MG	N008284 002
--------	-----	-------------

	25MG	N008284 001
--	------	-------------

PHARMACIA AND UPJOHN	5MG	N008126 003
----------------------	-----	-------------

	10MG	N008126 004
--	------	-------------

	25MG	N008126 001
--	------	-------------

PUREPAC PHARM	25MG	A080493 001
---------------	------	-------------

VITARINE	25MG	A080333 001
----------	------	-------------

WATSON LABS	25MG	A085884 001
-------------	------	-------------

WHITEWORTH TOWN PLSN	25MG	A080341 001
----------------------	------	-------------

## CORTONE

MERCK	25MG	N007750 003
-------	------	-------------

COSYNTROPIN

## SOLUTION; INTRAVENOUS

## COSYNTROPIN

SANDOZ	0.25MG/ML (0.25MG/ML)	N022028 001 Feb 21, 2008
--------	-----------------------	--------------------------

CROMOLYN SODIUM

## AEROSOL, METERED; INHALATION

## INTAL

KING PFIZER	0.8MG/INH	N018887 001 Dec 05, 1985
-------------	-----------	--------------------------

## CAPSULE; INHALATION

## INTAL

SANOFI AVENTIS US	20MG **Federal Register determination	N016990 001
-------------------	---------------------------------------	-------------

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

## DISCONTINUED DRUG PRODUCT LIST

CROMOLYN SODIUM

CAPSULE; ORAL

GASTROCROM

UCB INC

100MG

N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS

100MG/5ML

A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

10MG/ML

A075067 001 Jul 19, 1999

APOTEX INC

10MG/ML

A075333 001 Apr 30, 2002

PHARMASCIENCE INC

10MG/ML

A075437 001 Apr 21, 2000

ROXANE

10MG/ML

A075175 001 Sep 30, 1999

WATSON LABS

10MG/ML

A076469 001 Jun 17, 2005

INTAL

KING PHARMS

10MG/ML

N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

APOTEX INC

4%

A075615 001 Jan 26, 2001

CROMOPTIC

KING PHARMS

4%

A075088 001 Apr 27, 1999

OPTICROM

ALLERGAN

4% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N018155 001 Oct 03, 1984

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

5.2MG/SPRAY

A074800 001 Jul 26, 2001

HH AND P

5.2MG/SPRAY

A077976 001 Sep 07, 2007

NASALCROM

BLACKSMITH BRANDS

5.2MG/SPRAY \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020463 001 Jan 03, 1997

CRYPTENAMINE ACETATES

INJECTABLE; INJECTION

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT/ML

N008814 001

CRYPTENAMINE TANNATES

TABLET; ORAL

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT

N009217 001

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

ABRAXIS PHARM

EQ 0.4MG COPPER/ML

N019350 001 May 05, 1987

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

PAR PHARM

0.5MG/INH

N019722 001 Nov 05, 1996

INJECTABLE; INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN

1MG/ML

N006798 001

BETALIN 12

LILLY

0.1MG/ML

A080855 001

1MG/ML

A080855 002

COBAVITE

WATSON LABS

0.1MG/ML

A083013 001

1MG/ML

A083064 001

CYANOCOBALAMIN

ABRAXIS PHARM

0.03MG/ML

A080510 003

0.1MG/ML

A080510 001

1MG/ML

A080510 002

AKORN

1MG/ML

A087969 001 Nov 10, 1983

DELL LABS

0.03MG/ML

A080689 001

0.1MG/ML

A080689 002

1MG/ML

A080689 003

EUROHLTH INTL SARL

1MG/ML

A080515 002

FRESENIUS KABI USA

0.1MG/ML

A080557 002

LUITPOLD

0.03MG/ML

A080668 001

## DISCONTINUED DRUG PRODUCT LIST

CYANOCOBALAMIN

## INJECTABLE; INJECTION

## CYANOCOBALAMIN

LYPHOMED	1MG/ML	A083075	001	
MYLAN INSTITUTIONAL	1MG/ML	A040451	001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564	001	
SOLOPAK	1MG/ML	A087551	001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085	002	
WATSON LABS	0.1MG/ML	A080573	002	
	0.1MG/ML	A083120	001	
	1MG/ML	A080573	001	
	1MG/ML	A083120	002	
WYETH AYERST	0.1MG/ML	A080554	001	
	1MG/ML	A080554	002	

## REDISOL

MERCK	1MG/ML	N006668	010	
-------	--------	---------	-----	--

## RUBIVITE

BEL MAR	0.03MG/ML	N010791	004	
	0.05MG/ML	N010791	001	
	0.1MG/ML	N010791	002	
	0.12MG/ML	N010791	005	
	1MG/ML	N010791	003	

## RUBRAMIN PC

BRISTOL MYERS SQUIBB	0.1MG/ML	N006799	002	
	1MG/ML	N006799	004	
	1MG/ML	N006799	010	Apr 28, 1988

## RUVITE

SAVAGE LABS	1MG/ML	A080570	002	
-------------	--------	---------	-----	--

## VI-TWEL

BAYER HLTHCARE	1MG/ML	N007012	002	
----------------	--------	---------	-----	--

## SPRAY, METERED; NASAL

## CALOMIST

PAR PHARM	25MCG/SPRAY	N022102	001	Jul 27, 2007
-----------	-------------	---------	-----	--------------

## TABLET; ORAL

## CYANOCOBALAMIN

WEST WARD	1MG	A084264	001	
-----------	-----	---------	-----	--

CYANOCOBALAMIN CO-57

## CAPSULE; ORAL

## RUBRATOPE-57

BRACCO	0.5-1uCi	N016089	002	
--------	----------	---------	-----	--

CYANOCOBALAMIN CO-60

## CAPSULE; ORAL

## RUBRATOPE-60

BRACCO	0.5-1uCi	N016090	002	
--------	----------	---------	-----	--

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

## N/A; N/A

## DICOPAC KIT

GE HEALTHCARE	N/A; N/A; N/A	N017406	001	
---------------	---------------	---------	-----	--

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

## N/A; N/A

## CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT	0.1MG; 0.5uCi; 60MG	N016635	001	
--------------	---------------------	---------	-----	--

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

## INJECTABLE; INJECTION

## DEPINAR

ARMOUR PHARM	0.5MG/ML; 2.3MG/ML; 1MG/ML	N011208	001	
--------------	----------------------------	---------	-----	--

CYCLACILLIN

## FOR SUSPENSION; ORAL

## CYCLAPEN-W

WYETH AYERST	125MG/5ML	N050508	001	
	250MG/5ML	N050508	002	
	500MG/5ML	N050508	003	

## TABLET; ORAL

## CYCLACILLIN

TEVA	250MG	A062895	001	Aug 04, 1988
	500MG	A062895	002	Aug 04, 1988

## CYCLAPEN-W

WYETH AYERST	250MG	N050509	001	
	500MG	N050509	002	

## DISCONTINUED DRUG PRODUCT LIST

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE

GLAXOSMITHKLINE 50MG/ML N009495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

PROSAM LABS 5MG A077291 001 Feb 03, 2006

SANDOZ 5MG A072854 002 Feb 03, 2006

10MG A072854 001 Nov 19, 1991

10MG A073683 001 Feb 26, 1993

WATSON LABS 10MG A073143 001 Nov 27, 1991

10MG A074436 001 Nov 30, 1994

FLEXERIL

JANSSEN RES AND DEV 5MG N017821 001

10MG N017821 002

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

AKORN 1% A085555 001

AKPENTOLATE

AKORN 2% A040165 001 Jan 13, 1997

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD 1% A089162 001 Jan 24, 1991

SOLA BARNES HIND 1% A084150 001

1% A084863 001

PENTOLAIR

PHARMAFAIR 0.5% A088643 001 Feb 09, 1987

1% A088150 001 Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE 100MG/VIAL A088371 001 Jul 03, 1986

200MG/VIAL A088372 001 Jul 03, 1986

500MG/VIAL A088373 001 Jul 03, 1986

1GM/VIAL A088374 001 Sep 24, 1986

CYTOXAN

BAXTER HLTHCARE 100MG/VIAL N012142 001

200MG/VIAL N012142 002

CYTOXAN (LYOPHILIZED)

BAXTER HLTHCARE 500MG/VIAL N012142 008 Jan 04, 1984

1GM/VIAL N012142 010 Sep 24, 1985

2GM/VIAL N012142 009 Dec 10, 1985

LYOPHILIZED CYTOXAN

BAXTER HLTHCARE 100MG/VIAL N012142 006 Dec 05, 1985

200MG/VIAL N012142 007 Dec 10, 1985

NEOSAR

BEDFORD 100MG/VIAL A087442 001 Feb 16, 1982

200MG/VIAL A087442 002 Feb 16, 1982

500MG/VIAL A087442 003 Feb 16, 1982

1GM/VIAL A087442 004 Jul 08, 1983

2GM/VIAL A087442 005 Mar 30, 1989

TEVA PARENTERAL 100MG/VIAL A040015 001 Apr 29, 1993

200MG/VIAL A040015 002 Apr 29, 1993

500MG/VIAL A040015 003 Apr 29, 1993

1GM/VIAL A040015 004 Apr 29, 1993

2GM/VIAL A040015 005 Apr 29, 1993

TABLET; ORAL

CYTOXAN

BAXTER HLTHCARE 25MG N012141 002

50MG N012141 001

CYCLOSPORINE

CAPSULE; ORAL

NEORAL

NOVARTIS 50MG N050715 003 Jul 14, 1995

SOLUTION; ORAL

CYCLOSPORINE

APOTEX INC 100MG/ML A065167 001 Jan 05, 2005



**DISCONTINUED DRUG PRODUCT LIST**CYCLOTHIAZIDE

TABLET; ORAL

ANHYDRON

LILLY

2MG

N013157 002

FLUIDIL

PHARMACIA AND UPJOHN

2MG

N018173 001

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL

PAGITANE

LILLY

1.25MG

N008951 001

2.5MG

N008951 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

2MG/5ML

A086833 001

HALSEY

2MG/5ML

A089199 001 Jul 03, 1986

MORTON GROVE

2MG/5ML

A087001 001 Nov 04, 1982

NASKA

2MG/5ML

A089021 001 Dec 21, 1987

PERIACTIN

MERCCK

2MG/5ML

N013220 002

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP

4MG

A088798 001 Feb 15, 1985

ASCOT

4MG

A087685 001 Oct 25, 1982

DURAMED PHARMS BARR

4MG

A088232 001 Oct 25, 1983

HALSEY

4MG

A089057 001 Jul 03, 1986

KV PHARM

4MG

A086737 001

MD PHARM

4MG

A087566 001 Nov 10, 1982

MYLAN

4MG

A086678 001

PIONEER PHARMS

4MG

A087839 001 Feb 08, 1984

PLIVA

4MG

A088205 001 Jul 26, 1983

SANDOZ

4MG

A086808 001

SUPERPHARM

4MG

A087405 001

TG UNITED LABS

4MG

A088212 001 May 26, 1983

VITARINE

4MG

A087284 001

WATSON LABS

4MG

A085245 001

4MG

A086165 001

4MG

A086580 001

PERIACTIN

MERCCK

4MG

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

HOSPIRA

7.25% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N019523 001 Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

TEVA PARENTERAL

100MG/VIAL

N016793 001

500MG/VIAL

N016793 002

1GM/VIAL

N016793 003 Dec 21, 1987

2GM/VIAL

N016793 004 Dec 21, 1987

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM

100MG/VIAL

A070962 001 Aug 28, 1986

200MG/VIAL

A070990 001 Aug 28, 1986

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

KING PHARMS

420MG/VIAL; 180MG/VIAL

N050748 002 Aug 24, 2000

## DISCONTINUED DRUG PRODUCT LIST

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

PFIZER INC

7,500 IU/0.75ML

N020287 008 Apr 04, 2002

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER INC

10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007

95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

ASPEN GLOBAL INC

750 UNITS/0.6ML

N020430 001 Dec 24, 1996

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP

200MG

A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US

50MG

N017557 003

100MG

N017557 004

200MG

N017557 002

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

FERA PHARMS

0.5%

N019849 001 Dec 31, 1990

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

CUBICIN

CUBIST

250MG/VIAL

N021572 001 Sep 12, 2003

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

JANSSEN PRODS

EQ 300MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021976 001 Jun 23, 2006

EQ 400MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021976 003 Oct 21, 2008

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

SANOFI AVENTIS US

EQ 20MG BASE/VIAL

A061876 001

WYETH AYERST

EQ 20MG BASE/VIAL

N050484 001

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL

EQ 20MG BASE/VIAL

A064212 001 Jun 23, 1998

EQ 50MG BASE/VIAL

A064212 002 May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION

SYNCURINE

GLAXOSMITHKLINE

1MG/ML

N006931 002

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

WATSON LABS

500MG/VIAL

A076806 001 Mar 31, 2006

2GM/VIAL

A076806 002 Mar 31, 2006

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

MERCK

0.125%

N011860 002

0.25%

N011860 001

DEMECLOXYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE

150MG

N050262 001

SYRUP; ORAL

DECLOMYCIN

LEDERLE

75MG/5ML

N050257 001

**DISCONTINUED DRUG PRODUCT LIST**DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

COREPHARMA	75MG	N050261	001
	150MG	N050261	002
	300MG	N050261	003

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBVIE	0.1MG	N010796	001
	0.25MG	N010796	002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBVIE	0.125MG; 25MG	N012148	001
--------	---------------	---------	-----

ORETICYL 50

ABBVIE	0.125MG; 50MG	N012148	003
--------	---------------	---------	-----

ORETICYL FORTE

ABBVIE	0.25MG; 25MG	N012148	002
--------	--------------	---------	-----

DESERPIDINE; METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT	0.25MG; 5MG	N012775	001
--------	-------------	---------	-----

ENDURONYL FORTE

ABBOTT	0.5MG; 5MG	N012775	002
--------	------------	---------	-----

METHYLCLOTHIAZIDE AND DESERPIDINE

WATSON LABS	0.25MG; 5MG	A088486	001	Aug 10, 1984
-------------	-------------	---------	-----	--------------

	0.5MG; 5MG	A088452	001	Aug 10, 1984
--	------------	---------	-----	--------------

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US	25MG	N013621	001
-------------------	------	---------	-----

	50MG	N013621	002
--	------	---------	-----

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC	100MG	A071803	001	May 29, 1997
----------------	-------	---------	-----	--------------

USL PHARMA	25MG	A071864	001	Sep 09, 1987
------------	------	---------	-----	--------------

	50MG	A071865	001	Sep 09, 1987
--	------	---------	-----	--------------

	75MG	A071866	001	Sep 09, 1987
--	------	---------	-----	--------------

	100MG	A071867	001	Sep 09, 1987
--	-------	---------	-----	--------------

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS	0.2MG/ML	N009282	002
----------	----------	---------	-----

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

FERRING PHARMS INC	0.015MG/ML	N018938	002	Apr 25, 1995
--------------------	------------	---------	-----	--------------

DESMOPRESSIN ACETATE

BEDFORD	0.004MG/ML	A074575	001	Feb 18, 2000
---------	------------	---------	-----	--------------

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD	0.004MG/ML	A074574	001	Feb 18, 2000
---------	------------	---------	-----	--------------

SOLUTION; NASAL

CONCENTRAID

FERRING	0.01%	N019776	001	Dec 26, 1990
---------	-------	---------	-----	--------------

SPRAY, METERED; NASAL

DDAVP

FERRING PHARMS INC	0.01MG/SPRAY	N017922	002	Feb 06, 1989
--------------------	--------------	---------	-----	--------------

STIMATE

CSL BEHRING	0.15MG/SPRAY	N020355	001	Mar 07, 1994
-------------	--------------	---------	-----	--------------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC	0.15MG; 0.03MG	N020071	001	Dec 10, 1992
-----------------	----------------	---------	-----	--------------

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR	0.15MG; 0.03MG	A075256	001	Aug 12, 1999
---------------------	----------------	---------	-----	--------------

ORTHO-CEPT

JANSSEN PHARMS	0.15MG; 0.03MG	N020301	001	Dec 14, 1992
----------------	----------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

TEVA BRANDED PHARM

0.15MG, N/A; 0.02MG, 0.01MG; 0.02MG, 0.01MG

N020713 001 Apr 22, 1998

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

TARO PHARMS NORTH

0.25% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N017856 001

TOPICORT LP

TARO PHARMS NORTH

0.05%

N018309 001

GEL; TOPICAL

TOPICORT

TARO PHARMS NORTH

0.05%

N018586 001 Mar 29, 1982

OINTMENT; TOPICAL

DESOXIMETASONE

ALTANA

0.25%

A073440 001 Apr 01, 1998

TOPICORT

TARO PHARMS NORTH

0.25%

N018763 001 Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC

5MG/ML

N001104 001

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS

125MG

N005151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS

25MG/ML

N008822 001

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

TEVA PHARMS USA

EQ 50MG BASE

N205208 001 Oct 11, 2013

EQ 100MG BASE

N205208 002 Oct 11, 2013

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT

0.01% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

A083296 002

DECASPRAY

MERCK

0.04% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N012731 002

ELIXIR; ORAL

DECADRON

MERCK

0.5MG/5ML

N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS

0.5MG/5ML

A088997 001 Oct 10, 1986

HEXADROL

ORGANON USA INC

0.5MG/5ML

N012674 001

GEL; TOPICAL

DECADERM

MERCK

0.1%

N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS

0.1%

A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

MERCK

0.25MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N011664 004

## DISCONTINUED DRUG PRODUCT LIST

DEXAMETHASONE

TABLET; ORAL

DECADRON

0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 001	
0.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 002	
1.5MG	N011664 003	
4MG	N011664 005	
6MG	N011664 006	Jul 30, 1982

DEXAMETHASONE

IMPAX LABS	0.75MG	A085376 001	
MUTUAL PHARM	0.25MG	A084013 001	
	0.25MG	A084764 001	
	0.5MG	A084084 001	
	0.5MG	A084766 001	
	0.75MG	A084081 001	
	0.75MG	A084765 001	
	1.5MG	A084086 001	
	1.5MG	A084763 001	
PAR PHARM	0.25MG	A088149 001	Apr 28, 1983
PHOENIX LABS NY	0.75MG	A083806 001	
PVT FORM	0.75MG	A083420 001	
ROXANE	0.25MG	A084614 001	
SANDOZ	0.75MG	A080399 001	
UPSHER SMITH	0.75MG	A087534 001	
	1.5MG	A087533 001	
WATSON LABS	0.25MG	A085455 001	
	0.5MG	A085458 001	
	0.75MG	A080968 001	
	0.75MG	A084457 001	
	0.75MG	A085818 001	
	1.5MG	A085456 001	
	1.5MG	A085840 001	
WHITEWORTH TOWN PLSN	0.75MG	A084327 001	
DEXONE 0.5			
SOLVAY	0.5MG	A084991 001	
DEXONE 0.75			
SOLVAY	0.75MG	A084993 001	
DEXONE 1.5			
SOLVAY	1.5MG	A084990 001	
DEXONE 4			
SOLVAY	4MG	A084992 001	
HEXADROL			
ORGANON USA INC	0.5MG	N012675 004	
	0.75MG	N012675 007	
	1.5MG	N012675 009	
	4MG	N012675 010	

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

MERCCK

EQ 8MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016675 001	
---	-------------	--

DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML	A084315 001	
EQ 16MG BASE/ML	A087711 001	May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH	N014242 001	
------------------------	-------------	--

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH	N013413 001	
------------------------	-------------	--

CREAM; TOPICAL

DECADRON

MERCCK

EQ 0.1% PHOSPHATE	N011983 002	
-------------------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**DEXAMETHASONE SODIUM PHOSPHATE

## INJECTABLE; INJECTION

## DECADRON

MERCK	EQ 4MG PHOSPHATE/ML	N012071 002	
	EQ 24MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012071 004	

## DEXACEN-4

CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342 001	
-------------	---------------------	-------------	--

## DEXAMETHASONE

ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448 001	Jan 25, 1984
FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469 001	Jan 25, 1984

## DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 4MG PHOSPHATE/ML	A084493 001	
BEL MAR	EQ 4MG PHOSPHATE/ML	A084752 001	
DELL LABS	EQ 4MG PHOSPHATE/ML	A083161 001	
EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282 001	
INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522 001	Feb 17, 1984
LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065 001	
TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125 001	Aug 31, 1990
	EQ 10MG PHOSPHATE/ML	A081126 001	Aug 31, 1990
WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702 001	
	EQ 4MG PHOSPHATE/ML	A084355 001	
	EQ 4MG PHOSPHATE/ML	A089169 001	Apr 09, 1986
	EQ 10MG PHOSPHATE/ML	A087668 001	Jul 01, 1982
	EQ 24MG PHOSPHATE/ML	A085606 001	
WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641 001	

## HEXADROL

ORGANON USA INC	EQ 4MG PHOSPHATE/ML	N014694 002	
	EQ 10MG PHOSPHATE/ML	N014694 003	
	EQ 20MG PHOSPHATE/ML	N014694 004	

## OINTMENT; OPHTHALMIC

## DECADRON

MERCK	EQ 0.05% PHOSPHATE	N011977 001	
-------	--------------------	-------------	--

## DEXAIR

PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001	Dec 28, 1982
------------	--------------------	-------------	--------------

## MAXIDEX

ALCON	EQ 0.05% PHOSPHATE	A083342 001	
-------	--------------------	-------------	--

## SOLUTION/DROPS; OPHTHALMIC

## DEXAIR

PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001	Dec 15, 1983
------------	-------------------	-------------	--------------

## DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001	
	EQ 0.1% PHOSPHATE	A084173 001	

## SOLUTION/DROPS; OPHTHALMIC, OTIC

## DECADRON

MERCK	EQ 0.1% PHOSPHATE	N011984 001	
-------	-------------------	-------------	--

## SOLUTION/DROPS; OTIC

## DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 0.1% PHOSPHATE	A084855 001	
-------	-------------------	-------------	--

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DECADRON W/ XYLOCAINE

MERCK	EQ 4MG PHOSPHATE/ML; 10MG/ML	N013334 002	
-------	------------------------------	-------------	--

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

## OINTMENT; OPHTHALMIC

## NEODECADRON

MERCK	EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM	N050324 001	
-------	--------------------------------------	-------------	--

## SOLUTION/DROPS; OPHTHALMIC

## NEODECADRON

MERCK	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N050322 001	
-------	-------------------------------------	-------------	--

## NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A064055 001	Oct 30, 1995
-----------------	-------------------------------------	-------------	--------------

## NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A062714 001	Jul 21, 1986
PHARMAFAIR	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A062539 001	Jan 10, 1985

**DISCONTINUED DRUG PRODUCT LIST**DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

DEXACIDIN

NOVARTIS

0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062566 001 Feb 22, 1985

DEXASPORIN

PHARMAFAIR

0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062411 001 May 16, 1983

SUSPENSION/DROPS;OPHTHALMIC

DEXACIDIN

NOVARTIS

0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062544 001 Oct 29, 1984

DEXASPORIN

PHARMAFAIR

0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062428 001 May 18, 1983

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD

0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062721 001 Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL

DISOMER

SCHERING

2MG/5ML

N011814 002

TABLET;ORAL

DISOMER

SCHERING

2MG

N011814 001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL

DISOPHROL

SCHERING

2MG;60MG

N012394 002

TABLET, EXTENDED RELEASE;ORAL

BROMPHERIL

COPLEY PHARM

6MG;120MG

A089116 001 Jan 22, 1987

DISOBROM

SANDOZ

6MG;120MG

A070770 001 Sep 30, 1991

DISOPHROL

SCHERING PLOUGH

6MG;120MG

N013483 004 Sep 13, 1982

DRIXORAL

SCHERING PLOUGH

6MG;120MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N013483 003 Sep 13, 1982

RESPORAL

PIONEER PHARMS

6MG;120MG

A089139 001 Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLARAMINE

SCHERING

2MG/5ML

A086837 001 Jul 19, 1982

TABLET;ORAL

DEXCHLORPHENIRAMINE MALEATE

ANI PHARMS INC

2MG

A088682 001 Jan 17, 1986

POLARAMINE

SCHERING

2MG

A086835 001

DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DEXAMPEX

TEVA

15MG

A085355 001

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

ABLE

5MG

A076814 001 Aug 25, 2004

10MG

A076814 002 Aug 25, 2004

15MG

A076814 003 Aug 25, 2004

ELIXIR;ORAL

DEXEDRINE

GLAXOSMITHKLINE

5MG/5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

A083902 001

TABLET;ORAL

DEXAMPEX

TEVA

5MG

A083735 001

10MG

A083735 002

DEXEDRINE

GLAXOSMITHKLINE

5MG

A084935 001

DEXTROAMPHETAMINE SULFATE

HALSEY

10MG

A083930 001

LANNETT

5MG

A083903 001

**DISCONTINUED DRUG PRODUCT LIST**DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

	10MG	A083903 003	
	15MG	A085652 001	
MAST MM	5MG	A086521 001	
NESHER PHARMS	5MG	A040365 001	Oct 31, 2002
	10MG	A040367 001	Oct 31, 2002
PUREPAC PHARM	5MG	A084125 001	
SANDOZ	5MG	A085370 001	
	10MG	A085371 001	
VINTAGE PHARMS LLC	5MG	A040299 001	May 13, 1999
VITARINE	5MG	A084986 001	
	10MG	A085892 001	
DEXTROSTAT			
SHIRE	5MG	A084051 001	
	10MG	A084051 002	
FERNDEX			
FERNDALE LABS	5MG	A084001 001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY	15MG/5ML; 6.25MG/5ML	A088913 001	Mar 02, 1987
PROMETHAZINE HYDROCHLORIDE AND DESTROMETHORPHAN HYDROBROMIDE			
ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265 002	Apr 02, 1984
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE			
AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575 001	Feb 08, 2011
TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687 001	Jun 28, 2012

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046 001	
MILES	10GM/100ML	N018504 001	
DEXTROSE 2.5% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML	N018358 001	
	2.5GM/100ML	N019626 001	Feb 02, 1988
DEXTROSE 38.5% IN PLASTIC CONTAINER			
ABBOTT	38.5GM/100ML	N018923 001	Sep 19, 1984
DEXTROSE 5% IN PLASTIC CONTAINER			
DHL	5GM/100ML	N019971 001	Sep 28, 1995
DEXTROSE 50% IN PLASTIC CONTAINER			
HOSPIRA	50GM/100ML	N019894 001	Dec 26, 1989
DEXTROSE 60%			
B BRAUN	60GM/100ML	N017995 002	Sep 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER			
B BRAUN	60GM/100ML	N017995 001	
BAXTER HLTHCARE	60GM/100ML	N020047 002	Jul 02, 1991
HOSPIRA	60GM/100ML	N019346 001	Jan 25, 1985
DEXTROSE 7.7% IN PLASTIC CONTAINER			
B BRAUN	7.7GM/100ML	N019626 003	Feb 02, 1988

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019025 001	Dec 27, 1984
---------	---	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N018273 001	
---------	---	-------------	--

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843 001	Aug 09, 1993
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N018274 001	



**DISCONTINUED DRUG PRODUCT LIST**DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

## INJECTABLE; INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017451 001
-----------------	--	-------------

DEXTROSE; POTASSIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 37MG/100ML	N019699 001	Sep 29, 1989
---------	-----------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML	N018744 001	Nov 09, 1982
	5GM/100ML; 75MG/100ML	N019699 002	Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N019699 003	Sep 29, 1989
---------	------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML	N018744 002	Nov 09, 1982
---------	------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML	N018744 003	Nov 09, 1982
	5GM/100ML; 220MG/100ML	N019699 005	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML	N018744 004	Nov 09, 1982
---------	------------------------	-------------	--------------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

## INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 111MG/100ML; 256MG/100ML; 146MG/100ML; 207MG/100ML	N019514 001	May 08, 1986
---------	---	-------------	--------------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML	N018270 001
---------	--	-------------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	N018840 001	Jun 29, 1983
-----------------	---	-------------	--------------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML; 75MG/100ML; 200MG/100ML	N018268 009
---------	------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 200MG/100ML	N018268 004
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML	N018268 005
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 200MG/100ML	N018268 006
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML; 330MG/100ML	N018268 011	Jan 18, 1986
---------	------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 330MG/100ML	N018268 012	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML	N018268 013	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 330MG/100ML	N018268 014	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML; 75MG/100ML; 450MG/100ML	N018268 010
---------	------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 450MG/100ML	N018268 001
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML	N018268 002
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 450MG/100ML	N018268 003
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 450MG/100ML	N018008 003
-----------------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008 001
-----------------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 450MG/100ML	N018008 002
-----------------	------------------------------------	-------------

## DISCONTINUED DRUG PRODUCT LIST

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;200MG/100ML	N018386	001
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;450MG/100ML	N018229	001
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;900MG/100ML	N018047	001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;450MG/100ML	N018030	001
HOSPIRA	2.5GM/100ML;450MG/100ML	N018096	001
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;900MG/100ML	N018376	001
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	3.3GM/100ML;300MG/100ML	N018055	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML	N018030	005
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;200MG/100ML	N018030	004
MILES	5GM/100ML;200MG/100ML	N018399	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;225MG/100ML	N019482	001 Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;300MG/100ML	N019486	001 Oct 04, 1985
MILES	5GM/100ML;300MG/100ML	N018501	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;330MG/100ML	N018030	003
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;450MG/100ML	N019484	001 Oct 04, 1985
B BRAUN	5GM/100ML;450MG/100ML	N018030	002
MILES	5GM/100ML;450MG/100ML	N018400	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;900MG/100ML	N019483	001 Oct 04, 1985
B BRAUN	5GM/100ML;900MG/100ML	N018026	001
MILES	5GM/100ML;900MG/100ML	N018500	001

DEXTROTHYROXINE SODIUM

## TABLET; ORAL

CHOLOXIN			
ABBVIE	1MG	N012302	005
	2MG	N012302	002
	4MG	N012302	004
	6MG	N012302	006

DEZOCINE

## INJECTABLE; INJECTION

DALGAN			
ASTRAZENECA	5MG/ML	N019082	001 Dec 29, 1989
	10MG/ML	N019082	002 Dec 29, 1989
	15MG/ML	N019082	003 Dec 29, 1989

DIATRIZOATE MEGLUMINE

## INJECTABLE; INJECTION

ANGIOVIST 282			
BAYER HLTHCARE	60%	A087726	001 Sep 23, 1982
CARDIOGRAFIN			
BRACCO	85%	N011620	002
DIATRIZOATE MEGLUMINE			
BRACCO	76%	N010040	017
HYPaque			
GE HEALTHCARE	30%	N016403	002
	60%	N016403	001
RENO-60			
BRACCO	60%	N010040	016
RENO-DIP			
BRACCO	30%	N010040	012
UROVIST MEGLUMINE DIU/CT			
BAYER HLTHCARE	30%	A087739	001 Sep 23, 1982
SOLUTION; URETERAL			
RENO-30			
BRACCO	30%	N010040	021
UROVIST CYSTO			
BAYER HLTHCARE	30%	A087729	001 Sep 23, 1982

## DISCONTINUED DRUG PRODUCT LIST

DIATRIZOATE MEGLUMINE

SOLUTION; URETERAL

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE

30%

A087731 001 Sep 23, 1982

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE

30%

N016403 003

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE

52%;8%

A087724 001 Sep 23, 1982

ANGIOVIST 370

BAYER HLTHCARE

66%;10%

A087723 001 Sep 23, 1982

DIATRIZOATE-60

INTL MEDICATION

52%;8%

A088166 001 Jun 17, 1983

HYPAQUE-76

GE HEALTHCARE

66%;10%

A086505 001

HYPAQUE-M, 75%

GE HEALTHCARE

50%;25%

N010220 003

HYPAQUE-M, 90%

GE HEALTHCARE

60%;30%

N010220 002

MD-60

MALLINCKRODT

52%;8%

A087074 001

MD-76

MALLINCKRODT

66%;10%

A087073 001

RENOCAL-76

BRACCO

66%;10%

A089347 001 Jun 01, 1988

RENOGRAFIN-60

BRACCO

52%;8%

N010040 006

RENOVIST

BRACCO

34.3%;35%

N010040 020

RENOVIST II

BRACCO

28.5%;29.1%

N010040 019

SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE

66%;10%

A087728 001 Sep 23, 1982

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE

100%

N011386 001

INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE

25%

N009561 003

50%

N009561 001

MD-50

MALLINCKRODT

50%

A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE

50%

A087725 001 Sep 23, 1982

SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE

40%

N011386 003

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE

20%

N009561 002

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE

15MG

N018179 001

GEL; RECTAL

DIASAT

VALEANT PHARMS NORTH

5MG/ML (5MG/ML) \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020648 002 Jul 29, 1997

10MG/2ML (5MG/ML)

N020648 003 Jul 29, 1997

15MG/3ML (5MG/ML)

N020648 004 Jul 29, 1997

20MG/4ML (5MG/ML)

N020648 005 Jul 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM

5MG/ML

A070662 001 Jun 25, 1986

HIKMA MAPLE

5MG/ML

A070311 001 Dec 16, 1985

## DISCONTINUED DRUG PRODUCT LIST

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

	5MG/ML	A070312	001	Dec 16, 1985
	5MG/ML	A070313	001	Dec 16, 1985
	5MG/ML	A071308	001	Jul 17, 1987
	5MG/ML	A071309	001	Jul 17, 1987
	5MG/ML	A071310	001	Jul 17, 1987
HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987
MARSAM PHARMS LLC	5MG/ML	A072371	001	Jan 29, 1993
PARENTA PHARMS	5MG/ML	A076815	001	Apr 15, 2004
US ARMY	5MG/ML	N020124	001	Dec 05, 1990
WARNER CHILCOTT	5MG/ML	A071613	001	Oct 22, 1987
	5MG/ML	A071614	001	Oct 22, 1987
WATSON LABS	5MG/ML	A070296	001	Feb 12, 1986
	5MG/ML	A070911	001	Aug 28, 1986
	5MG/ML	A070912	001	Aug 28, 1986
	5MG/ML	A070930	001	Dec 01, 1986
WATSON LABS INC	5MG/ML	A072370	001	Jan 29, 1993
	5MG/ML	A072397	001	Jan 29, 1993

DIZAC

PHARMACIA AND UPJOHN	5MG/ML	N019287	001	Jun 18, 1993
----------------------	--------	---------	-----	--------------

VALIUM

ROCHE	5MG/ML	N016087	001	
-------	--------	---------	-----	--

TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH	2MG	A070781	001	Mar 19, 1986
	5MG	A070706	001	Mar 19, 1986
	10MG	A070707	001	Mar 19, 1986
DAVA PHARMS INC	2MG	A070226	001	Sep 26, 1985
	5MG	A070227	001	Sep 26, 1985
	10MG	A070228	001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894	001	Aug 27, 1986
	5MG	A070895	001	Aug 27, 1986
	10MG	A070896	001	Aug 27, 1986
FERNDALE LABS	2MG	A070903	001	Apr 01, 1987
	5MG	A070904	001	Apr 01, 1987
	10MG	A070905	001	Apr 01, 1987
HALSEY	2MG	A070987	001	Aug 15, 1986
	5MG	A070996	001	Aug 15, 1986
	10MG	A070956	001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360	001	Sep 04, 1985
	5MG	A070361	001	Sep 04, 1985
	10MG	A070362	001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402	001	Apr 25, 1989
PAR PHARM	2MG	A070462	001	Feb 25, 1986
	5MG	A070463	001	Feb 25, 1986
	10MG	A070464	001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
	5MG	A070788	001	Aug 02, 1988
	10MG	A070776	001	Aug 02, 1988
ROXANE	2MG	A070356	001	Jun 17, 1986
	5MG	A070357	001	Jun 17, 1986
	10MG	A070358	001	Jun 17, 1986
SANDOZ	2MG	A070302	001	Dec 20, 1985
	5MG	A070303	001	Dec 20, 1985
	10MG	A070304	001	Dec 20, 1985
TEVA PHARMS	5MG	A070153	001	Nov 01, 1985
WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
	5MG	A070210	001	Sep 04, 1985
	10MG	A070222	001	Sep 04, 1985
WATSON LABS	2MG	A070456	001	Nov 01, 1985
	5MG	A070457	001	Nov 01, 1985
	10MG	A070458	001	Nov 01, 1985

Q-PAM

QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
	2MG	A072431	001	Apr 29, 1988
	5MG	A070424	001	Dec 12, 1985
	5MG	A072432	001	Apr 29, 1988
	10MG	A070425	001	Dec 12, 1985
	10MG	A072433	001	Apr 29, 1988

## DISCONTINUED DRUG PRODUCT LIST

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM

50MG

N017425 001

100MG

N017425 002

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM

15MG/ML

A071519 001 Aug 26, 1987

HYPERSTAT

SCHERING

15MG/ML

N016996 001

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCAINE

NOVARTIS

2.5MG/ML

N006203 001

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

TARO

50MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N011366 001

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

NOVARTIS

25MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020142 001 Nov 24, 1993

DICLOFENAC POTASSIUM

MUTUAL PHARM

50MG

A075470 001 Feb 21, 2002

SANDOZ

50MG

A075582 001 Feb 23, 2001

WATSON LABS

50MG

A075152 001 Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

APOTEX INC

0.1%

A077600 001 Nov 13, 2008

FALCON PHARMS

0.1%

N020809 001 May 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

NOSTRUM LABS

50MG

A074986 001 Feb 26, 1999

75MG

A074986 002 Feb 26, 1999

PLIVA

50MG

A074432 002 Jul 29, 1999

75MG

A074432 003 Jul 29, 1999

ROXANE

25MG

A074391 001 Jun 29, 1995

50MG

A074391 002 Jun 29, 1995

75MG

A074391 003 Jun 29, 1995

TEVA

50MG

A074723 001 Mar 30, 1999

75MG

A074390 001 Aug 15, 1996

TEVA PHARMS

25MG

A074459 001 Jun 25, 1997

50MG

A074459 002 Jun 25, 1997

75MG

A074459 003 Jun 25, 1997

VOLTAREN

NOVARTIS

25MG

N019201 001 Jul 28, 1988

50MG

N019201 002 Jul 28, 1988

75MG

N019201 003 Jul 28, 1988

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

PATHOCIL

WYETH AYERST

EQ 250MG BASE

N050011 002

EQ 500MG BASE

N050011 003 Mar 28, 1983

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

APOTHECON

EQ 62.5MG BASE/5ML

A061455 001

DYNAPEN

APOTHECON

EQ 62.5MG BASE/5ML

N050337 002

**DISCONTINUED DRUG PRODUCT LIST**DICLOXACILLIN SODIUM

FOR SUSPENSION;ORAL

PATHOCIL

WYETH AYERST

EQ 62.5MG BASE/5ML

N050092 001

DICUMAROL

CAPSULE;ORAL

DICUMAROL

LILLY

25MG

N005509 003

50MG

N005509 001

TABLET;ORAL

DICUMAROL

ABBVIE

25MG

N005545 003

50MG

N005545 004

100MG

N005545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS LLC

10MG

A040204 001 Feb 28, 1997

MUTUAL PHARM

10MG

A084505 001 Oct 21, 1986

PIONEER PHARMS

10MG

A089361 001 Jan 10, 1989

WATSON LABS

10MG

A083179 001 Feb 12, 1986

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A080614 001 Feb 11, 1986

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A084479 001

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS LLC

20MG

A040161 001 Oct 01, 1996

MUTUAL PHARM

20MG

A084600 001 Jul 29, 1985

PIONEER PHARMS

20MG

A088585 001 Aug 20, 1986

WATSON LABS

20MG

A084361 001 Feb 06, 1986

DIDANOSINE

FOR SOLUTION;ORAL

VIDEX

BRISTOL MYERS SQUIBB

100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

TABLET, CHEWABLE;ORAL

VIDEX

BRISTOL MYERS SQUIBB

25MG

N020154 002 Oct 09, 1991

50MG

N020154 003 Oct 09, 1991

100MG

N020154 004 Oct 09, 1991

150MG

N020154 005 Oct 09, 1991

200MG

N020154 006 Oct 28, 1999

DIENESTROL

CREAM;VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM

0.01%

N006110 005

DV

SANOFI AVENTIS US

0.01%

A083518 001

ESTRAGUARD

SOLVAY

0.01%

A084436 001

SUPPOSITORY;VAGINAL

DV

SANOFI AVENTIS US

0.7MG

A083517 001

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL

HETRAZAN

LEDERLE

50MG

N006459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

SANDOZ

25MG

A085916 001

TEVA

25MG

A088642 001 Sep 20, 1984

TG UNITED LABS

25MG

A088267 001 Aug 25, 1983

25MG

A088268 001 Aug 25, 1983

**DISCONTINUED DRUG PRODUCT LIST**DIETHYLPROPION HYDROCHLORIDE

## TABLET; ORAL

## DIETHYLPROPION HYDROCHLORIDE

UCB INC	25MG	A085544 001
WATSON LABS	25MG	A085741 001

## TENUATE

SANOFI AVENTIS US	25MG	N017668 001
-------------------	------	-------------

## TEPANIL

3M	25MG	N011673 001
----	------	-------------

## TABLET, EXTENDED RELEASE; ORAL

## TENUATE

SANOFI AVENTIS US	75MG	N017669 001
-------------------	------	-------------

## TEPANIL TEN-TAB

3M	75MG	N017956 001
----	------	-------------

DIETHYLSTILBESTROL

## INJECTABLE; INJECTION

## STILBESTROL

BRISTOL MYERS SQUIBB	0.2MG/ML	N004056 003
	0.5MG/ML	N004056 004
	1MG/ML	N004056 005
	5MG/ML	N004056 006

## SUPPOSITORY; VAGINAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004040 001
	0.5MG	N004040 002

## STILBESTROL

BRISTOL MYERS SQUIBB	0.1MG	N004056 001
	0.5MG	N004056 002

## TABLET; ORAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004041 002
	0.5MG	N004041 003
	1MG	N004041 004
	5MG	N004041 005

## STILBESTROL

TABLICAPS	0.5MG	A083004 001
	1MG	A083002 001
	5MG	A083006 001

## STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056 007
	0.25MG	N004056 017
	0.5MG	N004056 008
	1MG	N004056 009
	5MG	N004056 010

## TABLET, DELAYED RELEASE; ORAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004039 002
	0.25MG	N004039 005
	0.5MG	N004039 003
	1MG	N004039 004
	5MG	N004039 006

## STILBESTROL

TABLICAPS	0.5MG	A083003 001
	1MG	A083005 001
	5MG	A083007 001

## STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056 011
	0.5MG	N004056 012
	1MG	N004056 013
	5MG	N004056 014

DIETHYLSTILBESTROL DIPHOSPHATE

## INJECTABLE; INJECTION

## STILPHOSTROL

BAYER PHARMS	250MG/5ML	N010010 001
--------------	-----------	-------------

## TABLET; ORAL

## STILPHOSTROL

BAYER PHARMS	50MG	N010010 002
--------------	------	-------------

**DISCONTINUED DRUG PRODUCT LIST**DIFLORASONE DIACETATE

## CREAM; TOPICAL

## DIFLORASONE DIACETATE

FOUGERA PHARMS	0.05%	A075187 001	Mar 30, 1998
FLORONE			
PHARMACIA AND UPJOHN	0.05%	N017741 001	
FLORONE E			
PHARMACIA AND UPJOHN	0.05%	N019259 001	Aug 28, 1985
PSORCON			
TARO PHARMS NORTH	0.05%	N020205 001	Nov 20, 1992
OINTMENT; TOPICAL			
PSORCON			
PHARMACIA AND UPJOHN	0.05%	N019260 001	Aug 28, 1985
PSORCON E			
PHARMACIA AND UPJOHN	0.05%	N017994 001	

DIFLUNISAL

## TABLET; ORAL

## DIFLUNISAL

PUREPAC PHARM	250MG	A074285 001	May 07, 1996
	500MG	A074285 002	May 07, 1996
ROXANE	250MG	A073562 001	Nov 27, 1992
	500MG	A073563 001	Nov 27, 1992
SANDOZ	500MG	A074604 001	Jun 10, 1996
TEVA	250MG	A073679 001	Jul 31, 1992
WATSON LABS	250MG	A074400 001	Jul 17, 1997
	500MG	A074400 002	Jul 17, 1997
DOLOBID			
MERCK	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018445 001	Apr 19, 1982
	500MG	N018445 002	Apr 19, 1982

DIGITOXIN

## INJECTABLE; INJECTION

## CRYSTODIGIN

LILLY	0.2MG/ML	A084100 005	
-------	----------	-------------	--

DIGOXIN

## CAPSULE; ORAL

## LANOXICAPS

GLAXOSMITHKLINE LLC	0.05MG	N018118 002	Jul 26, 1982
	0.1MG	N018118 003	Jul 26, 1982
	0.15MG	N018118 004	Sep 24, 1984
	0.2MG	N018118 001	Jul 26, 1982

## INJECTABLE; INJECTION

## DIGOXIN

ABRAXIS PHARM	0.25MG/ML	A083217 001	
HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996
	0.25MG/ML	A040206 001	Aug 28, 1998
WYETH AYERST	0.25MG/ML	A084386 001	
DIGOXIN PEDIATRIC			
HOSPIRA	0.1MG/ML	A040092 001	Apr 25, 1996

## TABLET; ORAL

## LANOXIN

CONCORDIA PHARMS INC	0.375MG	N020405 005	Sep 30, 1997
	0.5MG	N020405 006	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## EMBOLEX

NOVARTIS	0.5MG/0.5ML; 2,500 UNITS/0.5ML; 5.33MG/0.5ML	N018885 001	Nov 30, 1984
	0.5MG/0.7ML; 5,000 UNITS/0.7ML; 7.46MG/0.7ML	N018885 002	Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## CARDIZEM SR

BIOVAIL	60MG	N019471 001	Jan 23, 1989
	90MG	N019471 002	Jan 23, 1989
	120MG	N019471 003	Jan 23, 1989
	180MG	N019471 004	Jan 23, 1989



## DISCONTINUED DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## DILACOR XR

ACTAVIS LABS UT INC	120MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020092	001	May 29, 1992
	180MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020092	002	May 29, 1992
	240MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020092	003	May 29, 1992

## DILT-CD

## APOTEX

120MG	A076151	001	May 20, 2004
180MG	A076151	002	May 20, 2004
240MG	A076151	003	May 20, 2004
300MG	A076151	004	May 20, 2004

## DILTIAZEM HYDROCHLORIDE

## BIOVAIL

60MG	A074845	001	Sep 15, 1999
90MG	A074845	002	Sep 15, 1999
120MG	A074845	003	Sep 15, 1999
120MG	N020939	001	Jan 28, 2000
180MG	N020939	002	Jan 28, 2000
240MG	N020939	003	Jan 28, 2000
300MG	N020939	004	Jan 28, 2000
360MG	N020939	005	Sep 14, 2001
420MG	N020939	006	Sep 14, 2001

## NESHER PHARMS

120MG	A076563	002	Sep 12, 2006
180MG	A076563	003	Sep 12, 2006
240MG	A076563	004	Sep 12, 2006
300MG	A076563	005	Sep 12, 2006
360MG	A076563	006	Sep 12, 2006
420MG	A076563	001	Sep 12, 2006

## TEVA

60MG	A074079	001	Nov 30, 1993
90MG	A074079	002	Nov 30, 1993
120MG	A074079	003	Nov 30, 1993

## INJECTABLE; INJECTION

## CARDIZEM

## BIOVAIL

100MG/VIAL	N020792	001	Sep 05, 1997
------------	---------	-----	--------------

## BIOVAIL LABS INTL

5MG/ML	N020027	001	Oct 24, 1991
--------	---------	-----	--------------

25MG/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020027	003	Aug 18, 1995
-----------	--	---------	-----	--------------

## DILTIAZEM HYDROCHLORIDE

## HOSPIRA

5MG/ML	A075004	001	Feb 16, 2000
5MG/ML	A075106	001	Apr 29, 1999

## MYLAN LABS LTD

5MG/ML	A075375	001	Sep 30, 1999
--------	---------	-----	--------------

## TEVA PHARMS USA

5MG/ML	A074894	001	Aug 26, 1997
--------	---------	-----	--------------

## TABLET; ORAL

## DILTIAZEM HYDROCHLORIDE

## APOTHECON

30MG	A074051	001	Mar 31, 1993
60MG	A074051	002	Mar 31, 1993
90MG	A074051	003	Mar 31, 1993
120MG	A074051	004	Mar 31, 1993

## DAVA PHARMS INC

30MG	A074093	001	Nov 05, 1992
60MG	A074093	002	Nov 05, 1992
90MG	A074093	003	Nov 05, 1992
120MG	A074093	004	Nov 05, 1992

## IVAX SUB TEVA PHARMS

30MG	A074168	001	Mar 03, 1995
60MG	A074168	002	Mar 03, 1995
90MG	A074168	003	Mar 03, 1995
120MG	A074168	004	Mar 03, 1995

## TEVA

30MG	A074084	001	Feb 25, 1994
60MG	A074084	002	Feb 25, 1994

## TEVA PHARMS

30MG	A074067	001	Nov 05, 1992
60MG	A074067	002	Nov 05, 1992
90MG	A074067	003	Nov 05, 1992
120MG	A074067	004	Nov 05, 1992

## DISCONTINUED DRUG PRODUCT LIST

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE;ORAL

TIAMATE

MERCK	EQ 120MG HCL	N020506 001	Oct 04, 1996
	EQ 180MG HCL	N020506 002	Oct 04, 1996
	EQ 240MG HCL	N020506 003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE;ORAL

TECZEM

BIOVAIL	EQ 180MG HCL;5MG	N020507 001	Oct 04, 1996
---------	------------------	-------------	--------------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767 001	
WATSON LABS	50MG/ML	A080615 001	
	50MG/ML	A083531 001	
WYETH AYERST	50MG/ML	A084316 001	

LIQUID;ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715 001	
------	------------	-------------	--

TABLET;ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841 001	
NEXGEN PHARMA INC	50MG	A085985 001	
WATSON LABS	50MG	A085166 001	

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

IMCOR PHARMS CO	0.92MG/VIAL;0.092MG/VIAL	N021191 001	May 31, 2002
-----------------	--------------------------	-------------	--------------

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434 001	
----------------------	----------------	-------------	--

DIPHEMANIL METHYLSULFATE

TABLET;ORAL

PRANTAL

SCHERING	100MG	N008114 004	
----------	-------	-------------	--

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

BENADRYL

MCNEIL CONS	25MG	N005845 007	
	50MG	N005845 001	

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA	25MG	A080519 004	
	50MG	A080519 003	
ANABOLIC	50MG	A083275 001	
ELKINS SINN	25MG	A085701 001	
	50MG	A085701 002	
HALSEY	50MG	A087914 001	Jun 04, 1984
HEATHER	25MG	A084524 001	
	50MG	A083953 001	
HIKMA PHARMS LLC	50MG	A083567 001	
IMPAX LABS	25MG	A080807 001	
	50MG	A080807 002	
IVAX SUB TEVA PHARMS	25MG	A080762 001	
	50MG	A080762 002	
LANNETT	25MG	A080868 001	
	50MG	A080868 002	
LEDERLE	25MG	A086874 001	
	50MG	A086875 001	
LNK	25MG	A087977 001	Jan 27, 1983
	50MG	A087978 001	Jan 27, 1983
MK LABS	25MG	A083087 001	
	50MG	A083087 002	
MUTUAL PHARM	25MG	A084506 001	
	25MG	A089488 001	Jan 02, 1987
	50MG	A089489 001	Jan 02, 1987
NEWTRON PHARMS	25MG	A086543 001	
	50MG	A086544 001	

## DISCONTINUED DRUG PRODUCT LIST

DIPHENHYDRAMINE HYDROCHLORIDE

## CAPSULE; ORAL

## DIPHENHYDRAMINE HYDROCHLORIDE

NEXGEN PHARMA INC	25MG	A083634	001	
PERRIGO	25MG	A083061	001	
	50MG	A083061	002	
PIONEER PHARMS	25MG	A089101	001	Dec 20, 1985
	50MG	A088880	001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156	001	
	50MG	A085150	001	
PVT FORM	25MG	A083027	001	
	50MG	A083027	002	
ROXANE	50MG	A080635	001	
SANDOZ	25MG	A080832	001	
	25MG	A080845	002	
	50MG	A080832	002	
	50MG	A080845	001	
SUPERPHARM	25MG	A089040	001	May 15, 1985
	50MG	A089041	001	May 15, 1985
TEVA	25MG	A085874	001	
	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A080727	001	
	50MG	A083797	002	
	50MG	A085083	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	

## ELIXIR; ORAL

## BELIX

HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983
--------	------------	---------	-----	--------------

## BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004	
-------------	------------	---------	-----	--

## DIBENIL

CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983
-------	------------	---------	-----	--------------

## DIPHEN

USL PHARMA	12.5MG/5ML	A084640	001	
------------	------------	---------	-----	--

## DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	
PUREPAC PHARM	12.5MG/5ML	A083237	001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001	
ROXANE	12.5MG/5ML	A080643	001	

## HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763	002	
--------------------	------------	---------	-----	--

## INJECTABLE; INJECTION

## BENADRYL

MCNEIL CONS	10MG/ML	N006146	001	
	50MG/ML	N006146	002	

## BENADRYL PRESERVATIVE FREE

MCNEIL CONS	50MG/ML	N009486	001	
-------------	---------	---------	-----	--

## DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR	10MG/ML	A080822	001	
HIKMA MAPLE	50MG/ML	A083183	001	
LYPHOMED	10MG/ML	A087066	001	
WATSON LABS	10MG/ML	A083533	001	
WATSON LABS INC	10MG/ML	A080873	001	
	50MG/ML	A080873	002	
WYETH AYERST	50MG/ML	A080577	001	

## DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586	002	
---------------	---------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

DIPHENHYDRAMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATION	50MG/ML	A084094	001	
WATSON LABS INC	50MG/ML	A080873	003	

## SYRUP; ORAL

## ANTITUSSIVE

PERRIGO	12.5MG/5ML	A071292	001	Apr 10, 1987
---------	------------	---------	-----	--------------

## BELDIN

HALSEY	12.5MG/5ML	A089179	001	Jun 05, 1986
--------	------------	---------	-----	--------------

## BENYLIN

PARKE DAVIS	12.5MG/5ML	N006514	004	
-------------	------------	---------	-----	--

## DIPHEN

MORTON GROVE	12.5MG/5ML	A070118	001	Oct 01, 1985
--------------	------------	---------	-----	--------------

## DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS	12.5MG/5ML	A070497	001	Apr 25, 1989
--------------------	------------	---------	-----	--------------

CUMBERLAND SWAN	12.5MG/5ML	A073611	001	Aug 20, 1992
-----------------	------------	---------	-----	--------------

HI TECH PHARMA	12.5MG/5ML	A072416	001	Sep 28, 1990
----------------	------------	---------	-----	--------------

## HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A070205	001	Jan 28, 1986
--------------------	------------	---------	-----	--------------

## SILPHEN

SILARX	12.5MG/5ML	A072646	001	Feb 27, 1992
--------	------------	---------	-----	--------------

## VICKS FORMULA 44

WARNER CHILCOTT	12.5MG/5ML	A070524	001	Jan 14, 1987
-----------------	------------	---------	-----	--------------

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

## SOLUTION; ORAL

## BENYLIN

PARKE DAVIS	12.5MG/5ML; 30MG/5ML	N019014	001	Jun 11, 1985
-------------	----------------------	---------	-----	--------------

DIPHENIDOL HYDROCHLORIDE

## TABLET; ORAL

## VONTROL

GLAXOSMITHKLINE	EQ 25MG BASE	N016033	001	
-----------------	--------------	---------	-----	--

DIPHENYLPYRALINE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## HISPRIL

GLAXOSMITHKLINE	5MG	N011945	001	
-----------------	-----	---------	-----	--

DIPIVEFRIN HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## AKPRO

AKORN	0.1%	A074382	001	Sep 29, 1995
-------	------	---------	-----	--------------

## DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB	0.1%	A074188	001	May 19, 1995
-----------------	------	---------	-----	--------------

FALCON PHARMS	0.1%	A073636	001	Jun 30, 1994
---------------	------	---------	-----	--------------

## PROPINE

ALLERGAN	0.1%	N018239	001	
----------	------	---------	-----	--

DIPYRIDAMOLE

## INJECTABLE; INJECTION

## DIPYRIDAMOLE

HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997
---------	--------	---------	-----	--------------

MYLAN LABS LTD	5MG/ML	A075769	001	Nov 27, 2002
----------------	--------	---------	-----	--------------

TEVA PHARMS USA	5MG/ML	A074952	001	Nov 26, 1997
-----------------	--------	---------	-----	--------------

## IV PERSANTINE

BOEHRINGER INGELHEIM	5MG/ML	N019817	001	Dec 13, 1990
----------------------	--------	---------	-----	--------------

## TABLET; ORAL

## DIPYRIDAMOLE

GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991
-------------------	------	---------	-----	--------------

	50MG	A089000	001	Feb 05, 1991
--	------	---------	-----	--------------

	75MG	A089001	001	Feb 05, 1991
--	------	---------	-----	--------------

PROSAM LABS	25MG	A040542	001	Apr 21, 2006
-------------	------	---------	-----	--------------

	50MG	A040542	002	Apr 21, 2006
--	------	---------	-----	--------------

	75MG	A040542	003	Apr 21, 2006
--	------	---------	-----	--------------

PUREPAC PHARM	50MG	A089426	001	Jul 12, 1990
---------------	------	---------	-----	--------------

	75MG	A089427	001	Jul 12, 1990
--	------	---------	-----	--------------

SANDOZ	25MG	A086944	002	Apr 16, 1991
--------	------	---------	-----	--------------

	50MG	A087562	001	Feb 25, 1992
--	------	---------	-----	--------------

	75MG	A087561	001	Feb 25, 1992
--	------	---------	-----	--------------

WATSON LABS	50MG	A087160	001	Jun 07, 1996
-------------	------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL

DYNABAC

LILLY RES LABS 250MG N050678 001 Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

INTERPHARM EQ 100MG BASE A071190 001 Jan 15, 1987

EQ 150MG BASE A071191 001 Jan 15, 1987

IVAX SUB TEVA PHARMS EQ 100MG BASE A070186 001 Nov 18, 1985

EQ 150MG BASE A070187 001 Nov 18, 1985

MUTUAL PHARM EQ 100MG BASE A070351 001 Dec 17, 1985

EQ 150MG BASE A070352 001 Dec 17, 1985

MYLAN EQ 100MG BASE A070138 001 Jun 14, 1985

EQ 150MG BASE A070139 001 Jun 14, 1985

SANDOZ EQ 100MG BASE A070470 001 Dec 10, 1985

EQ 150MG BASE A070471 001 Dec 10, 1985

SUPERPHARM EQ 100MG BASE A070940 001 Feb 09, 1987

EQ 150MG BASE A070941 001 Feb 09, 1987

WATSON LABS EQ 100MG BASE A070240 001 Feb 02, 1986

EQ 150MG BASE A070241 001 Feb 02, 1986

CAPSULE, EXTENDED RELEASE;ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS EQ 150MG BASE A071200 001 Dec 15, 1987

DISULFIRAM

TABLET;ORAL

ANTABUSE

TEVA WOMENS 250MG N007883 003

500MG N007883 002

DISULFIRAM

PAR PHARM 250MG A088792 001 Aug 14, 1984

500MG A088793 001 Aug 14, 1984

WATSON LABS 250MG A086889 001

250MG A087973 001 Aug 05, 1983

500MG A086890 001

500MG A087974 001 Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE CP

ABBOTT EQ 250MG BASE N019794 001 Jul 11, 1990

EQ 500MG BASE N019794 002 Jul 11, 1990

DIVALPROEX SODIUM

MYLAN EQ 125MG VALPROIC ACID A077254 001 Jul 29, 2008

EQ 250MG VALPROIC ACID A077254 002 Jul 29, 2008

EQ 500MG VALPROIC ACID A077254 003 Jul 29, 2008

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

G AND W LABS INC EQ 500MG VALPROIC ACID A078700 001 Aug 03, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE EQ 12.5MG BASE/ML A074381 001 Sep 26, 1996

HOSPIRA EQ 1.25GM BASE/100ML A074634 001 Sep 27, 1996

IGI LABS INC EQ 12.5MG BASE/ML A074098 001 Feb 21, 1995

LUITPOLD EQ 12.5MG BASE/ML A074545 001 Jun 25, 1998

TEVA PARENTERAL EQ 12.5MG BASE/ML A074206 001 Oct 19, 1993

WATSON LABS EQ 12.5MG BASE/ML A074114 001 Nov 30, 1993

WATSON LABS INC EQ 12.5MG BASE/ML A074279 001 Feb 18, 1998

EQ 12.5MG BASE/ML A074995 001 Mar 31, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA EQ 50MG BASE/100ML N020269 001 Oct 19, 1993

EQ 100MG BASE/100ML N020269 002 Oct 19, 1993

EQ 200MG BASE/100ML N020269 003 Oct 19, 1993

DOBUTREX

LILLY EQ 12.5MG BASE/ML N017820 002

## DISCONTINUED DRUG PRODUCT LIST

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012
	80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012

TAXOTERE

SANOFI AVENTIS US	40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020449 001	May 14, 1996
-------------------	---	-------------	--------------

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

EISAI INC	5MG/5ML	N021719 001	Oct 18, 2004
-----------	---------	-------------	--------------

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011
	10MG	A201335 002	Aug 29, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

MUTUAL PHARM	5MG	A077975 002	Dec 11, 2009
	10MG	A077975 001	Dec 11, 2009

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656 001	Jan 24, 1989
	80MG/ML	A070657 001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012 001	Jun 12, 1985
	40MG/ML	A070058 001	Mar 20, 1985
	80MG/ML	A070013 001	Jun 12, 1985
	80MG/ML	A070059 001	Mar 20, 1985
	160MG/ML	A070364 001	Dec 04, 1985
BAXTER HLTHCARE	40MG/ML	N018398 001	
	80MG/ML	N018398 002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403 001	May 23, 1996
IGI LABS INC	40MG/ML	A070087 001	Oct 23, 1985
	40MG/ML	N018656 001	Jun 28, 1983
	80MG/ML	A070089 001	Oct 23, 1985
	80MG/ML	A070090 001	Oct 23, 1985
	80MG/ML	A070091 001	Oct 23, 1985
	160MG/ML	A070092 001	Oct 23, 1985
	160MG/ML	A070093 001	Oct 23, 1985
	160MG/ML	A070094 001	Oct 23, 1985
INTL MEDICATION	40MG/ML	N018014 001	
LYPHOMED	40MG/ML	N018549 001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011 001	Aug 29, 1985
	40MG/ML	A070046 001	Aug 29, 1985
	80MG/ML	A070047 001	Aug 29, 1985
TEVA PARENTERAL	40MG/ML	A072999 001	Oct 23, 1991
	80MG/ML	A073000 001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558 001	Sep 20, 1985
	40MG/ML	N018138 001	
	80MG/ML	A070559 001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%			
HOSPIRA	1.6MG/ML	N020542 001	Aug 30, 1995
INTROPIN			
HOSPIRA	40MG/ML	N017395 001	
	80MG/ML	N017395 002	
	160MG/ML	N017395 003	

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

APOTEX INC	EQ 2% BASE	A078395 001	Oct 28, 2008
------------	------------	-------------	--------------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

APOTEX INC	EQ 2% BASE; EQ 0.5% BASE	A078201 001	Oct 28, 2008
------------	--------------------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

NUROMAX

ABBVIE

EQ 1MG BASE/ML

N019946 001 Mar 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS

20MG/ML

A073529 001 Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH

EQ 1MG BASE

A075574 001 Oct 18, 2000

EQ 2MG BASE

A075574 002 Oct 18, 2000

EQ 4MG BASE

A075574 003 Oct 18, 2000

EQ 8MG BASE

A075574 004 Oct 18, 2000

GENPHARM

EQ 1MG BASE

A075466 001 Oct 18, 2000

EQ 2MG BASE

A075466 002 Oct 18, 2000

EQ 4MG BASE

A075466 003 Oct 18, 2000

EQ 8MG BASE

A075466 004 Oct 18, 2000

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A075453 001 Oct 18, 2000

EQ 2MG BASE

A075453 002 Oct 18, 2000

EQ 4MG BASE

A075453 003 Oct 18, 2000

EQ 8MG BASE

A075453 004 Oct 18, 2000

NESHER PHARMS

EQ 1MG BASE

A075609 001 Oct 18, 2000

EQ 2MG BASE

A075609 002 Oct 18, 2000

EQ 4MG BASE

A075609 003 Oct 18, 2000

EQ 8MG BASE

A075609 004 Oct 18, 2000

SANDOZ

EQ 1MG BASE

A075432 001 Oct 18, 2000

EQ 1MG BASE

A075646 001 Oct 18, 2000

EQ 2MG BASE

A075432 002 Oct 18, 2000

EQ 2MG BASE

A075646 002 Oct 18, 2000

EQ 4MG BASE

A075432 003 Oct 18, 2000

EQ 4MG BASE

A075646 003 Oct 18, 2000

EQ 8MG BASE

A075432 004 Oct 18, 2000

EQ 8MG BASE

A075646 004 Oct 18, 2000

TEVA

EQ 1MG BASE

A075353 001 Jan 12, 2001

EQ 2MG BASE

A075353 002 Jan 12, 2001

EQ 4MG BASE

A075353 003 Jan 12, 2001

EQ 8MG BASE

A075353 004 Jan 12, 2001

WATSON LABS INC

EQ 1MG BASE

A075426 001 Oct 18, 2000

EQ 2MG BASE

A075426 002 Oct 18, 2000

EQ 4MG BASE

A075426 003 Oct 18, 2000

EQ 8MG BASE

A075426 004 Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC

EQ 10MG BASE

A071685 001 Jan 05, 1988

EQ 25MG BASE

A071686 001 Jan 05, 1988

EQ 50MG BASE

A071673 001 Jan 05, 1988

EQ 75MG BASE

A071674 001 Jan 05, 1988

EQ 100MG BASE

A071675 001 Jan 05, 1988

EQ 150MG BASE

A071676 001 Jan 05, 1988

MUTUAL PHARM

EQ 25MG BASE

A071502 001 Feb 18, 1988

EQ 50MG BASE

A071653 001 Feb 18, 1988

EQ 75MG BASE

A071654 001 Feb 18, 1988

EQ 100MG BASE

A071521 001 Feb 18, 1988

NEW RIVER

EQ 10MG BASE

N016987 001

EQ 25MG BASE

N016987 002

EQ 50MG BASE

N016987 003

EQ 75MG BASE

N016987 006

EQ 100MG BASE

N016987 004

EQ 150MG BASE

N016987 007 Apr 13, 1987

PAR PHARM

EQ 10MG BASE

A071697 001 Nov 09, 1987

EQ 25MG BASE

A071437 001 Nov 09, 1987

EQ 50MG BASE

A071595 001 Nov 09, 1987

EQ 75MG BASE

A071608 001 Nov 09, 1987

EQ 100MG BASE

A071422 001 Nov 09, 1987

PUREPAC PHARM

EQ 10MG BASE

A073054 001 Dec 28, 1990

EQ 25MG BASE

A072109 001 Dec 28, 1990

EQ 50MG BASE

A073055 001 Dec 28, 1990

EQ 75MG BASE

A072386 001 Sep 08, 1988

**DISCONTINUED DRUG PRODUCT LIST**DOXEPIN HYDROCHLORIDE

## CAPSULE; ORAL

## DOXEPIN HYDROCHLORIDE

	EQ 100MG BASE	A072110 001	Sep 08, 1988
	EQ 150MG BASE	A072387 001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972 001	Sep 29, 1987
	EQ 25MG BASE	A070973 001	Sep 29, 1987
	EQ 50MG BASE	A070931 001	Sep 29, 1987
	EQ 75MG BASE	A070932 001	Sep 29, 1987
	EQ 100MG BASE	A072375 001	Mar 15, 1989
	EQ 150MG BASE	A072376 001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 50MG BASE	A072987 001	Mar 29, 1991
	EQ 75MG BASE	A071326 001	Apr 30, 1987
	EQ 75MG BASE	A071763 001	Feb 09, 1988
	EQ 100MG BASE	A070955 001	May 15, 1986
	EQ 100MG BASE	A071239 001	Apr 30, 1987
	EQ 150MG BASE	A071764 001	Feb 09, 1988
SINEQUAN			
PFIZER	EQ 10MG BASE	N016798 003	
	EQ 25MG BASE	N016798 001	
	EQ 50MG BASE	N016798 002	
	EQ 75MG BASE	N016798 006	
	EQ 100MG BASE	N016798 005	
	EQ 150MG BASE	N016798 007	
CONCENTRATE; ORAL			
DOXEPIN HYDROCHLORIDE			
PHARM ASSOC	EQ 10MG BASE/ML	A075924 001	Jan 15, 2004
SINEQUAN			
PFIZER	EQ 10MG BASE/ML	N017516 001	

DOXORUBICIN HYDROCHLORIDE

## INJECTABLE; INJECTION

## ADRIAMYCIN PFS

PHARMACIA AND UPJOHN	2MG/ML	A063165 001	Jan 30, 1991
	200MG/100ML	A063165 002	Jan 30, 1991
DOXORUBICIN HYDROCHLORIDE			
PHARMACIA AND UPJOHN	10MG/VIAL	N050467 001	
	20MG/VIAL	N050467 003	May 20, 1985
	50MG/VIAL	N050467 002	
	150MG/VIAL	N050467 004	Jul 22, 1987
RUBEX			
BRISTOL MYERS SQUIBB	10MG/VIAL	A062926 001	Apr 13, 1989
	50MG/VIAL	A062926 002	Apr 13, 1989
	100MG/VIAL	A062926 003	Apr 13, 1989

DOXYCYCLINE

## CAPSULE; ORAL

## DOXYCYCLINE

PAR PHARM	EQ 75MG BASE	A065055 004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000
	EQ 100MG BASE	A065032 002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041 001	Apr 28, 2000
	EQ 100MG BASE	A065041 002	Apr 28, 2000
FOR SUSPENSION; ORAL			
DOXYCHEL			
RACHELLE	EQ 25MG BASE/5ML	A061720 001	
TABLET; ORAL			
DOXYCYCLINE			
MUTUAL PHARM	EQ 50MG BASE	A065471 001	Apr 17, 2009
	EQ 75MG BASE	A065471 002	Apr 17, 2009



## DISCONTINUED DRUG PRODUCT LIST

DOXYCYCLINE

## TABLET; ORAL

## DOXYCYCLINE

	EQ 100MG BASE	A065471 003	Apr 17, 2009
SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006
	EQ 75MG BASE	A065353 002	Nov 27, 2006
	EQ 100MG BASE	A065353 003	Nov 27, 2006

DOXYCYCLINE HYCLATE

## CAPSULE; ORAL

## DOXY-LEMMON

TEVA	EQ 50MG BASE	A062497 001	Aug 23, 1984
	EQ 100MG BASE	A062497 002	Jun 15, 1984

## DOXYCYCLINE HYCLATE

HALSEY	EQ 50MG BASE	A062119 002	May 24, 1985
	EQ 100MG BASE	A062119 001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463 001	Dec 07, 1983
	EQ 100MG BASE	A062463 002	Dec 07, 1983
INTERPHARM	EQ 50MG BASE	A062763 001	Sep 02, 1988
	EQ 100MG BASE	A062763 002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418 001	Jan 28, 1983
	EQ 100MG BASE	A062418 002	Jan 28, 1983
PAR PHARM	EQ 50MG BASE	A062434 001	Oct 19, 1984
	EQ 100MG BASE	A062442 001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631 001	Jul 24, 1986
	EQ 100MG BASE	A062631 002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479 001	Dec 23, 1983
	EQ 100MG BASE	A062479 002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469 001	Oct 31, 1984
	EQ 100MG BASE	A062469 002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594 001	Dec 05, 1985
	EQ 100MG BASE	A062594 002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717 001	
	EQ 50MG BASE	A062142 001	
	EQ 100MG BASE	A061717 002	
	EQ 100MG BASE	A062142 002	

## PERIOSTAT

COLLAGENEX	EQ 20MG BASE	N050744 001	Sep 30, 1998
------------	--------------	-------------	--------------

## VIBRAMYCIN

PFIZER	EQ 50MG BASE	N050007 001	
--------	--------------	-------------	--

## CAPSULE, COATED PELLETS; ORAL

## DOXYCYCLINE HYCLATE

PLIVA	EQ 100MG BASE	A063187 001	Jun 30, 1992
-------	---------------	-------------	--------------

## CAPSULE, DELAYED RELEASE; ORAL

## DORYX

MAYNE PHARMA INTL	EQ 75MG BASE	N050582 002	Aug 13, 2001
	EQ 100MG BASE	N050582 001	Jul 22, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062653 001	Oct 30, 1985

## INJECTABLE; INJECTION

## DOXYCHEL HYCLATE

RACHELLE	EQ 100MG BASE/VIAL	A061953 001	
----------	--------------------	-------------	--

## DOXYCYCLINE

EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062569 002	Mar 09, 1988

## DOXYCYCLINE HYCLATE

HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989
	EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989

## VIBRAMYCIN

PFIZER	EQ 100MG BASE/VIAL	N050442 002	
	EQ 200MG BASE/VIAL	N050442 001	

## TABLET; ORAL

## DOXY-LEMMON

TEVA	EQ 100MG BASE	A062581 001	Mar 15, 1985
------	---------------	-------------	--------------

## DOXYCYCLINE HYCLATE

BLU CARIBE INC	EQ 50MG BASE	A062269 003	
HEATHER	EQ 100MG BASE	A062462 001	May 11, 1983
INTERPHARM	EQ 100MG BASE	A062764 001	Sep 02, 1988
MUTUAL PHARM	EQ 100MG BASE	A062391 001	Sep 30, 1982
SUPERPHARM	EQ 100MG BASE	A062494 001	Feb 20, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062593 001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392 001	Mar 31, 1983
	EQ 100MG BASE	A062392 002	Mar 31, 1983

**DISCONTINUED DRUG PRODUCT LIST**DOXYCYCLINE HYCLATE

TABLET; ORAL

PERIOSTAT

GALDERMA LABS LP

EQ 20MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N050783 001 Feb 02, 2001

VIBRA-TABS

PFIZER

EQ 100MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N050533 001

DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER

25MG

N019440 001 Feb 05, 1986

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US

12.5MG

N006412 015

25MG

N006412 014

DOXY-SLEEP-AID

PAR PHARM

25MG

A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM

25MG

A088900 002 Feb 12, 1988

QUANTUM PHARMICS

25MG

A088603 001 Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US

10MG;10MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N010598 002

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY

50MG/ML

N012936 001

DRONABINOL

CAPSULE; ORAL

DRONABINOL

INSYS THERAP

2.5MG

A078501 001 Aug 19, 2011

5MG

A078501 002 Aug 19, 2011

10MG

A078501 003 Aug 19, 2011

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM

2.5MG/ML

A070992 001 Nov 17, 1986

ASTRAZENECA

2.5MG/ML

A070993 001 Nov 17, 1986

HOSPIRA

2.5MG/ML

A072018 001 Oct 20, 1988

HOSPIRA

2.5MG/ML

A071645 001 Apr 07, 1988

IGI LABS INC

2.5MG/ML

A072272 001 Aug 31, 1995

IGI LABS INC

2.5MG/ML

A072019 001 Oct 19, 1988

IGI LABS INC

2.5MG/ML

A072020 001 Oct 19, 1988

IGI LABS INC

2.5MG/ML

A072021 001 Oct 19, 1988

LUITPOLD

2.5MG/ML

A072335 001 Oct 24, 1988

SMITH AND NEPHEW

2.5MG/ML

A071750 001 Sep 06, 1988

SOLOPAK

2.5MG/ML

A071754 001 Sep 06, 1988

SOLOPAK

2.5MG/ML

A071755 001 Sep 06, 1988

WATSON LABS

2.5MG/ML

A073520 001 Nov 27, 1991

WATSON LABS

2.5MG/ML

A073521 001 Nov 27, 1991

WATSON LABS

2.5MG/ML

A073523 001 Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA

2.5MG/ML;EQ 0.05MG BASE/ML

A072026 001 Apr 13, 1989

ASTRAZENECA

2.5MG/ML;EQ 0.05MG BASE/ML

A072027 001 Apr 13, 1989

ASTRAZENECA

2.5MG/ML;EQ 0.05MG BASE/ML

A072028 001 Apr 13, 1989

HOSPIRA

2.5MG/ML;EQ 0.05MG BASE/ML

A071982 001 May 04, 1988

INNOVAR

AKORN MFG

2.5MG/ML;EQ 0.05MG BASE/ML

N016049 001

## DISCONTINUED DRUG PRODUCT LIST

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

ASTRAZENECA

0.5% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N009925 002

1% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N009925 001

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY

5MG

N017388 001

10MG

N017388 002

DYPHYLLINE

ELIXIR; ORAL

NEOTHYLLINE

TEVA

160MG/15ML

N007794 003

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA

250MG/ML

N009088 001

TABLET; ORAL

DILOR

SAVAGE LABS

200MG

A084514 001

DILOR-400

SAVAGE LABS

400MG

A084751 001

NEOTHYLLINE

TEVA

200MG

N007794 001

400MG

N007794 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

WYETH PHARMS INC

0.03%

N011963 002

0.06%

N011963 004

0.25%

N011963 003

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE

MERZ PHARMS LLC

1%

N018751 001 Dec 23, 1982

EDETATE CALCIUM DISODIUM

TABLET; ORAL

CALCIUM DISODIUM VERSENATE

MEDICIS

500MG

N008922 002

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA

10MG/ML

A040131 001 Feb 24, 1998

WATSON LABS

10MG/ML

A040044 001 Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS

10MG/ML

A040043 001 Mar 20, 1996

REVERSOL

ORGANON USA INC

10MG/ML

A089624 001 May 13, 1988

TENSILON

IGI LABS INC

10MG/ML

N007959 001

TENSILON PRESERVATIVE FREE

IGI LABS INC

10MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N007959 002

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

100MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020972 002 Sep 17, 1998

## DISCONTINUED DRUG PRODUCT LIST

EFAVIRENZ

TABLET; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021360 001	Feb 01, 2002
----------------------	---	-------------	--------------

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORNIDYL

SANOFI AVENTIS US	200MG/ML	N019879 002	Nov 28, 1990
-------------------	----------	-------------	--------------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

APOTHECON	2.5MG	A075583 001	Aug 22, 2000
	5MG	A075583 002	Aug 22, 2000
	10MG	A075583 003	Aug 22, 2000
	20MG	A075583 004	Aug 22, 2000
IVAX SUB TEVA PHARMS	2.5MG	A075482 001	Aug 22, 2000
	5MG	A075482 002	Aug 22, 2000
	10MG	A075482 003	Aug 22, 2000
	20MG	A075482 004	Aug 22, 2000
KRKA DD NOVO MESTO	2.5MG	A075370 001	Aug 22, 2000
	5MG	A075370 002	Aug 22, 2000
	10MG	A075369 001	Aug 22, 2000
	20MG	A075369 002	Aug 22, 2000
MYLAN	2.5MG	A075472 001	Aug 22, 2000
	5MG	A075472 002	Aug 22, 2000
	10MG	A075472 003	Aug 22, 2000
	20MG	A075472 004	Aug 22, 2000
SANDOZ	2.5MG	A075048 001	Aug 22, 2000
	5MG	A075048 002	Aug 22, 2000
	10MG	A075048 003	Aug 22, 2000
	20MG	A075048 004	Aug 22, 2000
SANDOZ INC	2.5MG	A075621 001	Aug 22, 2000
	5MG	A075621 002	Aug 22, 2000
	10MG	A075621 003	Aug 22, 2000
	20MG	A075621 004	Aug 22, 2000
SUN PHARM INDS LTD	2.5MG	A075556 001	Aug 22, 2000
	5MG	A075556 002	Aug 22, 2000
	10MG	A075556 003	Aug 22, 2000
	20MG	A075556 004	Aug 22, 2000
WATSON LABS	2.5MG	A075501 001	Aug 22, 2000
	5MG	A075501 002	Aug 22, 2000
	10MG	A075501 003	Aug 22, 2000
	20MG	A075501 004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

ASTRAZENECA	5MG; 2.5MG	N020668 002	Oct 28, 1998
	5MG; 5MG	N020668 001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG; 12.5MG	A075736 001	Mar 25, 2003
	10MG; 25MG	A075736 002	Mar 25, 2003
SANDOZ INC	5MG; 12.5MG	A076116 001	Sep 19, 2001
	10MG; 25MG	A076116 002	Sep 19, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456 001	Aug 22, 2000
	1.25MG/ML	A075571 001	Aug 22, 2000

VASOTEC

BIOVAIL LABS INTL	1.25MG/ML	N019309 001	Feb 09, 1988
-------------------	-----------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT

99.9%

A070803 001 Sep 08, 1987

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US

200MG

N019616 004 Dec 31, 1991

400MG

N019616 005 Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US

90MG/0.6ML (150MG/ML) \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020164 006 Jun 02, 2000

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING

0.25MG/INH

N016803 001

EPINEPHRINE

ARMSTRONG PHARMS

0.2MG/INH

A087907 001 May 23, 1984

PRIMATENE MIST

WYETH CONS

0.2MG/INH

N016126 001

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

FOREST LABS

1.5MG/AMP

N007942 003 Feb 05, 1999

5MG/ML

N007942 001

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPECLT

0.15MG/DELIVERY

N019430 004 Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPECLT

0.3MG/DELIVERY

N019430 003 Aug 03, 1995

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS

0.3MG/INH

N016126 002

MEDIHALER-EPI

3M

0.3MG/INH

N010374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA

0.005MG/ML; 1%

N017751 006

0.005MG/ML; 1.5%

N017751 007

DENTSPLY PHARM

0.005MG/ML; 1.5%

N021384 001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA

0.005MG/ML; 4%

N014763 008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA

0.005MG/ML; 0.5%

N017751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE

0.01MG/ML; 2%

A084720 001

0.02MG/ML; 2%

A084732 001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EUROHLTH INTL SARL

0.01MG/ML; 1%

A080406 001

0.01MG/ML; 2%

A080406 002

GRAHAM CHEM

0.01MG/ML; 2%

A080504 004 Oct 19, 1983

0.02MG/ML; 2%

A080504 005 Oct 19, 1983

HOSPIRA

0.005MG/ML; 1%

A089649 001 Jun 21, 1988

0.005MG/ML; 1.5%

A089650 001 Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT

0.01MG/ML; 1%

A083154 001

BEL MAR

0.01MG/ML; 1%

A080820 001

0.01MG/ML; 2%

A080757 001

**DISCONTINUED DRUG PRODUCT LIST**EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE				
DELL LABS	0.01MG/ML;1%	A083389	001	
	0.01MG/ML;2%	A083390	001	
INTL MEDICATION	0.01MG/ML;1%	A086402	001	
WATSON LABS	0.01MG/ML;1%	A080377	003	
	0.01MG/ML;1%	A085463	001	
	0.01MG/ML;2%	A080377	004	
LIDOCATON				
PHARMATON	0.01MG/ML;2%	A084729	001	Aug 17, 1983
	0.02MG/ML;2%	A084728	001	Aug 17, 1983
XYLOCAINE DENTAL WITH EPINEPHRINE				
DENTSPLY PHARM	0.01MG/ML;2%	N021381	001	
	0.02MG/ML;2%	N021381	002	
XYLOCAINE W/ EPINEPHRINE				
ASTRAZENECA	0.005MG/ML;1%	N010418	006	
	0.005MG/ML;1.5%	N010418	010	
	0.005MG/ML;2%	N010418	008	
FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003	
PATCH; IONTOPHORESIS, TOPICAL				
LIDOSITE TOPICAL SYSTEM KIT				
VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504	001	May 06, 2004
SOLUTION; IONTOPHORESIS				
IONTOCAINE				
IOMED	0.01MG/ML;2%	N020530	001	Dec 21, 1995
SOLUTION; IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
EMPI	0.01MG/ML;2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE				
BEL MAR	0.02MG/ML;1%	A080758	001	
	0.02MG/ML;2%	A080759	001	

EPIRUBICIN HYDROCHLORIDE

## INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE				
EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007
	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007
INJECTABLE; IV (INFUSION)				
EPIRUBICIN HYDROCHLORIDE				
HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006
	200MG/VIAL	N050807	002	Sep 15, 2006

EPLERENONE

## TABLET; ORAL

INSPRA				
GD SEARLE LLC	100MG	N021437	003	Sep 27, 2002

EPROSARTAN MESYLATE

## TABLET; ORAL

TEVETEN				
ABBVIE	EQ 300MG BASE	N020738	004	Dec 22, 1997

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

## TABLET; ORAL

TEVETEN HCT				
ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001
	600MG;25MG	N021268	002	Nov 01, 2001

ERGOCALCIFEROL

## CAPSULE; ORAL

DELTALIN				
LILLY	50,000 IU	A080884	001	
VITAMIN D				
CHASE CHEM	50,000 IU	A080747	001	
EVERYLIFE	50,000 IU	A080956	001	
IMPAX LABS	50,000 IU	A080951	001	

## DISCONTINUED DRUG PRODUCT LIST

ERGOCALCIFEROL

CAPSULE; ORAL

VITAMIN D

LANNETT	50,000 IU	A080825	001
VITARINE	50,000 IU	A084053	001
WEST WARD	50,000 IU	A083102	001

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS	1MG	N018706	001	Jan 18, 1983
----------	-----	---------	-----	--------------

SOLUTION; ORAL

HYDERGINE

NOVARTIS	1MG/ML	N018418	001
----------	--------	---------	-----

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM	1MG	A088891	001	Nov 01, 1985
--------------	-----	---------	-----	--------------

WATSON LABS	1MG	A086433	001	May 27, 1982
-------------	-----	---------	-----	--------------

	1MG	A087244	001	Aug 16, 1982
--	-----	---------	-----	--------------

GERIMAL

WATSON LABS

1MG	A088207	001	Mar 22, 1984
-----	---------	-----	--------------

HYDERGINE

NOVARTIS

0.5MG	N017993	003
-------	---------	-----

TABLET; SUBLINGUAL

ALKERGOT

SANDOZ

0.5MG	A085153	001
-------	---------	-----

1MG	A087417	001
-----	---------	-----

CIRCANOL

3M

0.5MG	A084868	001
-------	---------	-----

1MG	A085809	001
-----	---------	-----

DEAPRIL-ST

BRISTOL MYERS SQUIBB

1MG	A085020	002
-----	---------	-----

ERGOLOID MESYLATES

KV PHARM

0.5MG	A085899	001
-------	---------	-----

0.5MG	A086265	001
-------	---------	-----

1MG	A085900	001
-----	---------	-----

1MG	A086264	001
-----	---------	-----

0.5MG	A086984	001
-------	---------	-----

1MG	A086985	001
-----	---------	-----

0.5MG	A087407	001
-------	---------	-----

1MG	A087552	001
-----	---------	-----

0.5MG	A089233	001	Sep 23, 1986
-------	---------	-----	--------------

1MG	A089234	001	Sep 23, 1986
-----	---------	-----	--------------

0.5MG	A088013	001	Sep 20, 1982
-------	---------	-----	--------------

1MG	A088014	001	Sep 20, 1982
-----	---------	-----	--------------

0.5MG	A084930	001
-------	---------	-----

0.5MG	A087233	001
-------	---------	-----

1MG	A085177	001
-----	---------	-----

1MG	A087183	001
-----	---------	-----

GERIMAL

WATSON LABS

0.5MG	A086189	001
-------	---------	-----

1MG	A086188	001
-----	---------	-----

HYDERGINE

NOVARTIS

0.5MG	N009087	002
-------	---------	-----

1MG	N009087	001
-----	---------	-----

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS

0.5MG	A087186	001
-------	---------	-----

1MG	A087185	001
-----	---------	-----

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER ERGOTAMINE

3M

0.36MG/INH	N012102	001
------------	---------	-----

TABLET; SUBLINGUAL

ERGOSTAT

WATSON LABS INC

2MG	A088337	001	Jun 08, 1984
-----	---------	-----	--------------

WIGRETTES

ORGANON USA INC

2MG	A086750	001	Jul 29, 1982
-----	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

MYLAN PHARMS INC

EQ 25MG BASE

A091002 001 Jun 11, 2014

EQ 100MG BASE

A091002 002 Jun 11, 2014

EQ 150MG BASE

A091002 003 Jun 11, 2014

TEVA PHARMS USA

EQ 100MG BASE

A091059 002 Aug 28, 2015

EQ 150MG BASE

A091059 003 Aug 28, 2015

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

PARKE DAVIS

250MG

A062546 001 Jul 25, 1985

250MG

A062618 001 Sep 25, 1985

WARNER CHILCOTT LLC

250MG

A062338 001

ERYC 125

PARKE DAVIS

125MG

A062648 001 Oct 24, 1985

ERYC SPRINKLES

HOSPIRA

125MG

N050593 001 Jul 22, 1985

ERYTHROMYCIN

BARR

250MG

A063098 001 May 04, 1989

GEL;TOPICAL

E-GLADES

RENAISSANCE PHARMA

2%

A065009 001 Mar 18, 2002

EMGEL

ALTANA

2%

A063107 001 Aug 23, 1991

LOTION;TOPICAL

E-SOLVE 2

SYOSSET

2%

A062467 001 Jul 03, 1985

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

PHARMADERM

5MG/GM

A062446 001 Sep 26, 1983

PHARMAFAIR

5MG/GM

A062481 001 Apr 05, 1984

ILOTYCIN

DISTA

0.5%

N050368 001

POWDER;FOR RX COMPOUNDING

ERYTHROMYCIN

PADDOCK LLC

100%

N050610 001 Nov 07, 1986

SOLUTION;TOPICAL

A/T/S

TARO PHARMS NORTH

2%

A062405 001 Nov 18, 1982

ERYDERM

ARBOR PHARMS INC

2%

A062290 001

ERYMAX

MERZ PHARMS

2%

A062508 002 Jul 11, 1985

ERYTHRA-DERM

PADDOCK LLC

2%

A062687 001 Feb 05, 1988

ERYTHROMYCIN

ALPHARMA US PHARMS

1.5%

A062328 001 Apr 19, 1982

2%

A062326 001 Apr 19, 1982

2%

A062327 001 Apr 19, 1982

2%

A062342 001 Feb 25, 1982

2%

A062957 001 Jul 21, 1988

BAUSCH AND LOMB

2%

A064039 001 Jan 27, 1994

LILLY

2%

N050532 001

PHARMAFAIR

1.5%

A062485 001 Jul 11, 1984

2%

A062616 001 Jul 25, 1985

RENAISSANCE PHARMA

2%

A064127 001 Feb 14, 1997

SANSAC

DOW PHARM

2%

A062522 001 Jan 24, 1985

STATICIN

WESTWOOD SQUIBB

1.5%

N050526 001

T-STAT

WESTWOOD SQUIBB

2%

A062436 001 Mar 09, 1983

SWAB;TOPICAL

C-SOLVE-2

IVAX SUB TEVA PHARMS

2%

A062751 001 Jul 30, 1993

ERYCETTE

JOHNSON AND JOHNSON

2%

N050594 001 Feb 15, 1985

ERYTHROMYCIN

FOUGERA PHARMS

2%

A065320 001 Jul 25, 2006

RENAISSANCE PHARMA

2%

A064128 001 Jul 03, 1996



**DISCONTINUED DRUG PRODUCT LIST**ERYTHROMYCIN

SWAB; TOPICAL

T-STAT

WESTWOOD SQUIBB 2%

A062748 001 Jul 23, 1987

TABLET, DELAYED RELEASE; ORAL

E-BASE

BARR 333MG

A063028 001 May 15, 1990

333MG

A063086 001 May 15, 1990

500MG

A062999 001 Nov 25, 1988

E-MYCIN

ARBOR PHARMS INC 250MG

A060272 001

333MG

A060272 002

ILOTYCIN

DISTA 250MG

A061910 001

R-P MYCIN

SOLVAY 250MG

A061659 001

ROBIMYCIN

ROBINS AH 250MG

A061633 001

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE

BARR EQ 125MG BASE

A062162 001

EQ 250MG BASE

A062162 002

IVAX SUB TEVA PHARMS EQ 250MG BASE

A062237 001

WATSON LABS EQ 250MG BASE

A062087 001

ILOSONE

LILLY EQ 125MG BASE

A061897 001

EQ 250MG BASE

A061897 002

FOR SUSPENSION; ORAL

ILOSONE

DISTA EQ 125MG BASE/5ML

A061893 001

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS EQ 125MG BASE/5ML

A062353 001 Nov 18, 1982

EQ 250MG BASE/5ML

A062409 001 Dec 16, 1982

G AND W LABS INC EQ 125MG BASE/5ML

A062169 001 Oct 17, 1990

EQ 250MG BASE/5ML

A062169 002 Oct 17, 1990

LIFE LABS EQ 250MG BASE/5ML

A062362 001 Dec 17, 1982

ILOSONE

LILLY EQ 125MG BASE/5ML

A061894 001

EQ 125MG BASE/5ML

N050010 001

EQ 250MG BASE/5ML

A061894 002

EQ 250MG BASE/5ML

N050010 002

SUSPENSION/DROPS; ORAL

ILOSONE

LILLY EQ 100MG BASE/ML

A061894 003

TABLET; ORAL

ILOSONE

LILLY EQ 500MG BASE

A061896 001

TABLET, CHEWABLE; ORAL

ILOSONE

DISTA EQ 125MG BASE

A061895 001

EQ 250MG BASE

A061895 002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL

ILOSONE SULFA

LILLY EQ 125MG BASE/5ML; EQ 600MG BASE/5ML

N050599 001 Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

ANI PHARMS INC EQ 200MG BASE/5ML

A062055 001

PEDIAMYCIN

ROSS LABS EQ 200MG BASE/5ML

A062305 001

SUSPENSION; ORAL

E-MYCIN E

PHARMACIA AND UPJOHN EQ 200MG BASE/5ML

A062198 001

EQ 400MG BASE/5ML

A062198 002

E.E.S. 200

ARBOR PHARMS LLC EQ 200MG BASE/5ML

A061639 001

**DISCONTINUED DRUG PRODUCT LIST**ERYTHROMYCIN ETHYLSUCCINATE

## SUSPENSION; ORAL

E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE/5ML A061639 002

## ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS EQ 200MG BASE/5ML A062200 001

EQ 400MG BASE/5ML A062200 002

DISTA EQ 200MG BASE/5ML A062177 001

EQ 400MG BASE/5ML A062177 002

NASKA EQ 400MG BASE/5ML A062674 001 Mar 10, 1987

PARKE DAVIS EQ 200MG BASE/5ML A062231 001

EQ 400MG BASE/5ML A062231 002

PHARMAFAIR EQ 200MG BASE/5ML A062559 001 Mar 15, 1985

EQ 400MG BASE/5ML A062558 001 Mar 15, 1985

## PEDIAMYCIN

ARBOR PHARMS LLC EQ 200MG BASE/5ML A062304 001

## PEDIAMYCIN 400

ARBOR PHARMS LLC EQ 400MG BASE/5ML A062304 002

## WYAMYCIN E

WYETH AYERST EQ 200MG BASE/5ML A062123 002

EQ 400MG BASE/5ML A062123 001

## SUSPENSION/DROPS; ORAL

## PEDIAMYCIN

ROSS LABS EQ 100MG BASE/2.5ML A062305 002

## TABLET; ORAL

E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE A061905 001

## ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 400MG BASE A062256 001

MYLAN EQ 400MG BASE A062847 001 Sep 14, 1988

## TABLET, CHEWABLE; ORAL

E.E.S.

ARBOR PHARMS INC EQ 200MG BASE N050297 002

## ERYPED

ARBOR PHARMS INC EQ 200MG BASE N050297 003 Jul 05, 1988

## PEDIAMYCIN

ROSS LABS EQ 200MG BASE A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

## GRANULE; ORAL

## ERYZOLE

ALRA EQ 200MG BASE/5ML; EQ 600MG BASE/5ML A062758 001 Jun 15, 1988

## PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML; EQ 600MG BASE/5ML N050529 001

ERYTHROMYCIN GLUCEPTATE

## INJECTABLE; INJECTION

## ILOTYCIN GLUCEPTATE

DISTA EQ 250MG BASE/VIAL N050370 001

EQ 500MG BASE/VIAL N050370 002

EQ 1GM BASE/VIAL N050370 003

ERYTHROMYCIN LACTOBIONATE

## INJECTABLE; INJECTION

## ERYTHROCIN

ABBOTT EQ 500MG BASE/VIAL A062586 001 Jan 04, 1988

EQ 1GM BASE/VIAL A062586 002 Jan 04, 1988

HOSPIRA EQ 500MG BASE/VIAL N050182 002

EQ 1GM BASE/VIAL N050182 003

EQ 1GM BASE/VIAL N050609 002 Sep 24, 1986

## ERYTHROMYCIN

ELKINS SINN EQ 500MG BASE/VIAL A062563 001 Mar 28, 1985

EQ 1GM BASE/VIAL A062563 002 Mar 28, 1985

## ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 500MG BASE/VIAL A062604 001 Nov 24, 1986

EQ 1GM BASE/VIAL A062604 002 Nov 24, 1986

BAXTER HLTHCARE EQ 500MG BASE/VIAL A062993 001 May 09, 1989

EQ 1GM BASE/VIAL A062993 002 May 09, 1989

TEVA PARENTERAL EQ 500MG BASE/VIAL A063253 001 Jul 30, 1993

EQ 1GM BASE/VIAL A063253 002 Jul 30, 1993

## DISCONTINUED DRUG PRODUCT LIST

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL	EQ 250MG BASE	A061304 001	
	EQ 250MG BASE	A061887 001	

ERYPAR

PARKE DAVIS	EQ 250MG BASE	A062032 001	
	EQ 500MG BASE	A062032 002	
WARNER CHILCOTT	EQ 250MG BASE	A062322 001	

ERYTHROCIN STEARATE

ARBOR PHARMS LLC	EQ 125MG BASE	A060359 002	
	EQ 500MG BASE	A060359 003	

ERYTHROMYCIN STEARATE

ANI PHARMS INC	EQ 250MG BASE	A061591 001	
	EQ 500MG BASE	A061461 002	
	EQ 500MG BASE	A063179 001	May 15, 1990
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061461 001	
LEDERLE	EQ 250MG BASE	A062089 001	
	EQ 500MG BASE	A062089 002	
MYLAN	EQ 250MG BASE	A061505 001	
	EQ 500MG BASE	A061505 002	
PUREPAC PHARM	EQ 250MG BASE	A061743 001	
WATSON LABS	EQ 250MG BASE	A062121 002	
	EQ 500MG BASE	A062121 001	

ETHRIL 250

BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605 001	
----------------------	---------------	-------------	--

ETHRIL 500

BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605 002	
----------------------	---------------	-------------	--

PFIZER-E

PFIZER	EQ 250MG BASE	A061791 001	
	EQ 500MG BASE	A061791 002	

WYAMYCIN S

WYETH AYERST	EQ 250MG BASE	A061675 001	
	EQ 500MG BASE	A061675 002	

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC	EQ 5MG BASE	A077660 001	Jul 31, 2007
	EQ 10MG BASE	A077660 002	Jul 31, 2007
	EQ 20MG BASE	A077660 003	Jul 31, 2007

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988
	20MG/ML	N019386 007	May 28, 2003

ESTAZOLAM

TABLET; ORAL

PROSOM

ABBOTT	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019080 001	Dec 26, 1990
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019080 002	Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847 001	Aug 04, 1998
	0.0375MG/24HR	N020847 002	Aug 04, 1998
	0.05MG/24HR	N020847 003	Aug 04, 1998
	0.075MG/24HR	N020847 004	Aug 04, 1998
	0.1MG/24HR	N020847 005	Aug 04, 1998

ESTRADIOL

ORTHO MCNEIL PHARM	0.05MG/24HR	N021048 001	Sep 20, 1999
	0.075MG/24HR	N021048 002	Sep 20, 1999
	0.1MG/24HR	N021048 003	Sep 20, 1999

FEMPATCH

PARKE DAVIS	0.025MG/24HR	N020417 001	Dec 03, 1996
-------------	--------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

VIVELLE

NOVARTIS	0.025MG/24HR	N020323 005	Aug 16, 2000
	0.0375MG/24HR	N020323 001	Oct 28, 1994
	0.075MG/24HR	N020323 003	Oct 28, 1994

GEL;TOPICAL

ESTROGEL

ASCEND THERAPS US	0.06%	N021166 001	Feb 09, 2004
-------------------	-------	-------------	--------------

TABLET;ORAL

ESTRACE

BRISTOL MYERS SQUIBB	0.5MG	A081295 001	Jun 30, 1993
	1MG	A084499 001	
	2MG	A084500 001	

ESTRADIOL

EPIC PHARMA INC	0.5MG	A040275 001	Dec 29, 1998
	1MG	A040275 002	Dec 29, 1998
	2MG	A040275 003	Dec 29, 1998
LANNETT HOLDINGS INC	0.5MG	A040138 001	Jan 30, 1998
	1MG	A040138 002	Jan 30, 1998
	2MG	A040138 003	Jan 30, 1998

GYNODIOL

DURAMED PHARMS BARR	0.5MG	A040212 001	Dec 29, 1997
	1MG	A040212 002	Dec 29, 1997
	1.5MG	A040212 003	Dec 29, 1997
	2MG	A040212 004	Dec 29, 1997

INNOFEM

NOVO NORDISK INC	0.5MG	A040312 001	Nov 19, 1999
	1MG	A040312 002	Nov 19, 1999
	2MG	A040312 003	Nov 19, 1999

TABLET;VAGINAL

ESTRADIOL

AMNEAL PHARMS	10MCG	A205256 001	May 29, 2015
---------------	-------	-------------	--------------

VAGIFEM

NOVO NORDISK INC	25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020908 001	Mar 26, 1999
------------------	--	-------------	--------------

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN	1MG/ML	A085470 001	
	3MG/ML	A085470 002	

ESTRADIOL CYPIONATE

WATSON LABS	5MG/ML	A085620 001	
-------------	--------	-------------	--

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE;INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874 001	Oct 05, 2000
----------------------	----------------------	-------------	--------------

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTADIOL

PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968 001	
----------------------	----------------	-------------	--

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS	2MG/ML;50MG/ML	A085603 001	Mar 13, 1986
-------------	----------------	-------------	--------------

ESTRADIOL VALERATE

INJECTABLE;INJECTION

ESTRADIOL VALERATE

SANDOZ	10MG/ML	A040628 001	Oct 04, 2007
	20MG/ML	A040628 002	Oct 04, 2007
	40MG/ML	A040628 003	Oct 04, 2007
WATSON LABS	10MG/ML	A083546 001	
	40MG/ML	A083714 001	
WATSON LABS INC	20MG/ML	A083547 001	

**DISCONTINUED DRUG PRODUCT LIST**ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DITATE-DS

SAVAGE LABS	8MG/ML; 180MG/ML	A086423	001
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE			
WATSON LABS	4MG/ML; 90MG/ML	A085865	001
	8MG/ML; 180MG/ML	A085860	001

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

TEVA WOMENS	1MG, 1MG; 1MG, 1MG; N/A, 0.09MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021040	001	Oct 22, 1999
-------------	--	---------	-----	--------------

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

WYETH PHARMS INC	2.5MG	N004782	002
------------------	-------	---------	-----

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008
-------------	------------	---------	-----	--------------

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN; CYCRIN 14/14)

WYETH PHARMS INC	0.625MG; 0.625MG; N/A, 5MG	N020303	002	Dec 30, 1994
------------------	----------------------------	---------	-----	--------------

PREMPRO (PREMARIN; CYCRIN)

WYETH PHARMS INC	0.625MG; 0.625MG; 2.5MG; 2.5MG	N020303	001	Dec 30, 1994
------------------	--------------------------------	---------	-----	--------------

ESTROGENS, CONJUGATED; MeproBamate

TABLET; ORAL

MILPREM-200

MEDPOINTE PHARM HLC	0.45MG; 200MG	N011045	002
---------------------	---------------	---------	-----

MILPREM-400

MEDPOINTE PHARM HLC	0.45MG; 400MG	N011045	001
---------------------	---------------	---------	-----

PMB 200

WYETH AYERST	0.45MG; 200MG	N010971	005
--------------	---------------	---------	-----

PMB 400

WYETH AYERST	0.45MG; 400MG	N010971	003
--------------	---------------	---------	-----

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB	0.3MG	A083266	001
----------------------	-------	---------	-----

	0.625MG	A083266	002
--	---------	---------	-----

	1.25MG	A083266	003
--	--------	---------	-----

	2.5MG	A083266	004
--	-------	---------	-----

ESTERIFIED ESTROGENS

PVT FORM

	0.625MG	A083414	001
--	---------	---------	-----

	1.25MG	A083765	001
--	--------	---------	-----

	2.5MG	A085907	001
--	-------	---------	-----

SANDOZ	1.25MG	A085302	001
--------	--------	---------	-----

ESTRATAB

SOLVAY	0.3MG	A086715	001
--------	-------	---------	-----

	0.625MG	A083209	001
--	---------	---------	-----

	1.25MG	A083856	001
--	--------	---------	-----

	2.5MG	A083857	001
--	-------	---------	-----

EVEX			
------	--	--	--

ROCHE PALO	0.625MG	A084215	001
------------	---------	---------	-----

	1.25MG	A083376	002
--	--------	---------	-----

FEMOGEN			
---------	--	--	--

PVT FORM	0.625MG	A085076	001
----------	---------	---------	-----

	1.25MG	A085008	001
--	--------	---------	-----

	2.5MG	A085007	001
--	-------	---------	-----

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE

WYETH AYERST	2MG/ML	A083488	001
--------------	--------	---------	-----

ESTRONE			
---------	--	--	--

WATSON LABS	2MG/ML	A083397	001
-------------	--------	---------	-----

	5MG/ML	A085239	001
--	--------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

ESTRONE

INJECTABLE; INJECTION

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS	2MG/ML	A085237	001	Nov 23, 1982
THEELIN				
PARKEDEALE	1MG/ML	N003977	001	
	2MG/ML	N003977	002	
	5MG/ML	N003977	003	

ESTROPIPATE

CREAM; VAGINAL

OGEN

PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001	
----------------------	----------	---------	-----	--

TABLET; ORAL

ESTROPIPATE

DURAMED PHARMS BARR	0.75MG	A040296	001	Nov 01, 1999
	1.5MG	A040296	002	Nov 01, 1999
	3MG	A040296	003	Nov 01, 1999
MYLAN	3MG	A040359	003	Aug 26, 1999
WATSON LABS	6MG	A081216	001	Sep 23, 1993
ORTHO-EST				
SUN PHARM INDS INC	0.75MG	A089567	001	Feb 27, 1991
	1.5MG	A089582	001	Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

WOCKHARDT LTD	1MG	A091165	001	Jul 14, 2011
	2MG	A091165	002	Jul 14, 2011
	3MG	A091165	003	Jul 14, 2011

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

ATON	50MG	N016092	002	
------	------	---------	-----	--

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

STI PHARMA LLC	200MG	N016320	002	
	500MG	N016320	004	

ETHCHLORVYNOL

CAPSULE; ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS	100MG	A084463	001	
	200MG	A084463	002	
	500MG	A084463	003	
	750MG	A084463	004	
PLACIDYL				
ABBVIE	100MG	N010021	004	
	200MG	N010021	007	
	500MG	N010021	002	
	750MG	N010021	010	

ETHINAMATE

CAPSULE; ORAL

VALMID

DISTA	500MG	N009750	001	
-------	-------	---------	-----	--

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

SCHERING	0.02MG	N005292	001	
	0.05MG	N005292	002	
	0.5MG	N005292	003	
FEMINONE				
PHARMACIA AND UPJOHN	0.05MG	N016649	001	
LYNORAL				
ORGANON USA INC	0.01MG	N005490	003	
	0.05MG	N005490	002	

**DISCONTINUED DRUG PRODUCT LIST**ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

## TABLET;ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC

0.035MG;1MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC

0.05MG;1MG

N016927 001

ZOVIA 1/35E-21

WATSON LABS

0.035MG;1MG

A072720 001 Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG;1MG

A072722 001 Dec 30, 1991

## TABLET;ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC

0.035MG;1MG

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC

0.05MG;1MG

N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

## TABLET;ORAL-28

NORQUEST FE

GD SEARLE LLC

0.035MG;75MG;1MG

N018926 001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

## TABLET;ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS

0.05MG;75MG;1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS

0.05MG;75MG;2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

## TABLET;ORAL

LYBREL

WYETH PHARMS INC

0.02MG;0.09MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021864 001 May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM

0.05MG;0.25MG

N020946 001 Sep 01, 1998

## TABLET;ORAL-21

ALESSE

WYETH PHARMS

0.02MG;0.1MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020683 001 Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR

0.02MG;0.1MG

A075796 002 Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1  
25MG

A075809 001 Jul 16, 2001

LESSINA-21

BARR

0.02MG;0.1MG

A075803 001 Mar 20, 2002

LEVLITE

BAYER HLTHCARE

0.02MG;0.1MG

N020860 001 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG;0.1MG

A075862 001 Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS

0.03MG;0.15MG

A073592 001 Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM

0.03MG;0.15MG

N018668 001 May 10, 1982

PORTIA-21

BARR

0.03MG;0.15MG

A075866 001 May 23, 2002

TRIPHASIL-21

WYETH PHARMS

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1  
25MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N019192 001 Nov 01, 1984

TRIVORA-21

WATSON LABS

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1  
25MG

A074538 001 Dec 18, 1997

## TABLET;ORAL-28

ALESSE

WYETH PHARMS

0.02MG;0.1MG

N020683 002 Mar 27, 1997

## DISCONTINUED DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

LEVLITE

BAYER HLTHCARE	0.02MG;0.1MG	N020860 002	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL			
BARR	0.02MG;0.1MG	A075862 002	Apr 29, 2003
NORDETTE-28			
TEVA BRANDED PHARM	0.03MG;0.15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018782 001	Jul 21, 1982
TRIPHASIL-28			
WYETH PHARMS INC	0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.125MG	N019190 001	Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021180 001	Nov 20, 2001
----------------	---	-------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR	0.035MG;0.4MG	A076198 001	Apr 22, 2004
BREVICON 21-DAY			
ACTAVIS LABS UT INC	0.035MG;0.5MG	N017566 001	
GENCEPT 10/11-21			
BARR	0.035MG;0.035MG;0.5MG;1MG	A072694 001	Feb 28, 1992
MODICON 21			
ORTHO MCNEIL PHARM	0.035MG;0.5MG	N017488 001	
N.E.E. 1/35 21			
LPI	0.035MG;1MG	A071541 001	Dec 14, 1987
NORCEPT-E 1/35 21			
ORTHO MCNEIL PHARM	0.035MG;1MG	A071545 001	Feb 09, 1989
NORETHIN 1/35E-21			
WATSON LABS	0.035MG;1MG	A071480 001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL			
WATSON LABS	0.035MG;0.4MG	A078379 001	Feb 23, 2010
	0.035MG;0.5MG	A070684 001	Jan 29, 1987
	0.035MG;1MG	A070685 001	Jan 29, 1987
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
WATSON LABS	0.035MG;0.035MG;0.5MG;1MG	A071043 001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
WATSON LABS	0.035MG;0.035MG;0.5MG;1MG	A071041 001	Sep 24, 1991
NORTREL 0.5/35-21			
BARR	0.035MG;0.5MG	A072692 001	Feb 28, 1992
ORTHO-NOVUM 1/35-21			
ORTHO MCNEIL PHARM	0.035MG;1MG	N017489 002	
ORTHO-NOVUM 10/11-21			
ORTHO MCNEIL JANSSEN	0.035MG;0.035MG;0.5MG;1MG	N018354 001	Jan 11, 1982
ORTHO-NOVUM 7/14-21			
ORTHO MCNEIL PHARM	0.035MG;0.035MG;0.5MG;1MG	N019004 001	Apr 04, 1984
ORTHO-NOVUM 7/7/7-21			
JANSSEN PHARMS	0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG	N018985 001	Apr 04, 1984
OVCON-35			
WARNER CHILCOTT	0.035MG;0.4MG	N018127 001	
OVCON-50			
WARNER CHILCOTT	0.05MG;1MG	N018128 001	
TRI-NORINYL 21-DAY			
ACTAVIS LABS UT INC	0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG	N018977 001	Apr 13, 1984
TABLET; ORAL-28			
GENCEPT 10/11-28			
BARR	0.035MG;0.035MG;0.5MG;1MG	A072697 001	Feb 28, 1992
N.E.E. 1/35 28			
LPI	0.035MG;1MG	A071542 001	Dec 14, 1987
NORCEPT-E 1/35 28			
ORTHO MCNEIL PHARM	0.035MG;1MG	A071546 001	Feb 09, 1989
NORETHIN 1/35E-28			
WATSON LABS	0.035MG;1MG	A071481 001	Apr 12, 1988



**DISCONTINUED DRUG PRODUCT LIST**ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A076393 001 Feb 04, 2010

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS 0.035MG,0.035MG;0.035MG,0.035MG;0.5MG,1MG;0.5MG,1MG A071042 001 Sep 24, 1991

ORTHO-NOVUM 10/11-28

ORTHO MCNEIL JANSSEN 0.035MG;0.035MG;0.5MG;1MG N018354 002 Jan 11, 1982

ORTHO-NOVUM 7/14-28

ORTHO MCNEIL PHARM 0.035MG;0.035MG;0.5MG;1MG N019004 002 Apr 04, 1984

OVCON-35

WARNER CHILCOTT LLC 0.035MG;0.4MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\* N017716 001

OVCON-50

WARNER CHILCOTT LLC 0.05MG;1MG N017576 001

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

WARNER CHILCOTT 0.02MG;1MG N204426 001 Apr 19, 2013

TABLET;ORAL

FEMHRT

WARNER CHILCOTT LLC 0.005MG;1MG N021065 002 Oct 15, 1999

TABLET;ORAL-21

ESTROSTEP 21

WARNER CHILCOTT LLC 0.02MG;0.035MG;0.03MG;1MG;1MG;1MG N020130 001 Oct 09, 1996

NORLESTRIN 21 1/50

PARKE DAVIS 0.05MG;1MG N016749 001

NORLESTRIN 21 2.5/50

PARKE DAVIS 0.05MG;2.5MG N016852 001

TABLET;ORAL-28

NORLESTRIN 28 1/50

PARKE DAVIS 0.05MG;1MG N016723 001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21

ORTHO CYCLEN-21

JANSSEN PHARMS 0.035MG;0.25MG N019653 001 Dec 29, 1989

ORTHO TRI-CYCLEN

JANSSEN PHARMS 0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG N019697 002 Jul 03, 1992

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

WATSON LABS 0.025MG;0.025MG;0.025MG;0.18MG;0.215MG;0.25MG A090479 001 Mar 09, 2011

0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG A076626 001 Aug 17, 2006

0.035MG;0.25MG A076627 001 Aug 17, 2006

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LO/OVRAL

WYETH PHARMS INC 0.03MG;0.3MG N017612 001

LOW-OGESTREL-21

WATSON LABS 0.03MG;0.3MG A075288 001 Jul 28, 1999

OGESTREL 0.5/50-21

WATSON LABS 0.05MG;0.5MG A075406 001 Dec 15, 1999

OVRAL

WYETH PHARMS 0.05MG;0.5MG N016672 001

TABLET;ORAL-28

OVRAL-28

WYETH PHARMS 0.05MG;0.5MG N016806 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET;ORAL

PARSIDOL

PARKE DAVIS 10MG N009078 003

50MG N009078 006

100MG N009078 008

## DISCONTINUED DRUG PRODUCT LIST

ETHOTOIN

TABLET; ORAL

PEGANONE

RECORDATI RARE 500MG N010841 003

ETHOXZOLAMIDE

TABLET; ORAL

CARDRASE

PHARMACIA AND UPJOHN 62.5MG N011047 002

125MG N011047 001

ETHAMIDE

ALLERGAN 125MG N016144 001

ETHYLESTRENOL

ELIXIR; ORAL

MAXIBOLIN

ORGANON USA INC 2MG/5ML N014006 002

TABLET; ORAL

MAXIBOLIN

ORGANON USA INC 2MG N014005 002

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20

OVULEN

GD SEARLE LLC 1MG; 0.1MG N016029 002

TABLET; ORAL-21

OVULEN-21

GD SEARLE LLC 1MG; 0.1MG N016029 003

TABLET; ORAL-28

OVULEN-28

GD SEARLE LLC 1MG; 0.1MG N016705 001

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA 0.5% N017751 003

1% N017751 005

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

MGI PHARMA INC 50MG/ML N019545 001 Apr 20, 1987

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AAIPHARMA LLC 300MG A074929 001 Jan 30, 1998

ANI PHARMS INC 200MG A074899 001 Jul 08, 1997

300MG A074899 002 Jul 08, 1997

MYLAN 200MG A074932 001 May 16, 1997

200MG A075071 001 Sep 30, 1998

300MG A074932 002 May 16, 1997

300MG A075071 002 Sep 30, 1998

SANDOZ 200MG A074840 001 Aug 29, 1997

200MG A074942 001 Sep 30, 1997

300MG A074840 002 Aug 29, 1997

300MG A074942 002 Sep 30, 1997

VINTAGE PHARMS LLC 200MG A074842 001 Jul 17, 1997

300MG A074842 002 Jul 17, 1997

WATSON LABS 200MG A074844 001 Dec 23, 1997

300MG A074844 002 Dec 23, 1997

LODINE

WYETH PHARMS INC 200MG N018922 002 Jan 31, 1991

300MG N018922 003 Jan 31, 1991

TABLET; ORAL

ETODOLAC

IVAX SUB TEVA PHARMS 400MG A074883 001 Feb 28, 1997

500MG A074883 002 Nov 20, 1998

LEHIGH VALLEY 400MG A074927 001 Oct 30, 1997

MYLAN 400MG A075012 001 Sep 30, 1998

500MG A075012 002 Sep 30, 1998

PROSAM LABS 400MG A074819 001 Feb 28, 1997

500MG A074819 002 Apr 28, 1998

RANBAXY LABS LTD 400MG A075226 001 Nov 24, 1998

500MG A075226 002 Nov 24, 1998

## DISCONTINUED DRUG PRODUCT LIST

ETODOLAC

## TABLET; ORAL

## ETODOLAC

SANDOZ	400MG	A074839 001	Jul 11, 1997
	400MG	A074846 001	Feb 28, 1997
TEVA	400MG	A074847 001	Apr 23, 1999
	500MG	A074847 002	Apr 23, 1999
VINTAGE PHARMS LLC	400MG	A074841 001	Jun 27, 1997
WATSON LABS	400MG	A074892 001	Apr 16, 1997
	400MG	A075069 001	Apr 16, 1998
	500MG	A074892 002	Oct 29, 1998

## LODINE

WYETH PHARMS INC	400MG	N018922 004	Jul 29, 1993
	500MG	N018922 005	Jun 28, 1996

## TABLET, EXTENDED RELEASE; ORAL

## ETODOLAC

ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000
SANDOZ	400MG	A075943 001	Jul 26, 2002
	500MG	A075943 002	Jul 26, 2002
	600MG	A075943 003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829 001	Nov 30, 2001
	500MG	A075829 002	Nov 30, 2001

## LODINE XL

WYETH PHARMS INC	400MG	N020584 001	Oct 25, 1996
	500MG	N020584 003	Jan 20, 1998
	600MG	N020584 002	Oct 25, 1996

ETONOGESTREL

## IMPLANT; IMPLANTATION

## IMPLANON

ORGANON USA INC	68MG/IMPLANT	N021529 001	Jul 17, 2006
-----------------	--------------	-------------	--------------

ETOPOSIDE

## CAPSULE; ORAL

## VEPESID

DAVA PHARMS INC	50MG	N019557 001	Dec 30, 1986
	100MG	N019557 002	Dec 30, 1986

## INJECTABLE; INJECTION

## ETOPOSIDE

HOSPIRA	20MG/ML	A074320 001	Aug 30, 1995
	20MG/ML	A074351 001	Aug 30, 1995
PHARMACHEMIE BV	20MG/ML	A074227 001	Feb 22, 1996
PIERRE FABRE	20MG/ML	A074813 001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510 001	Jun 29, 1995
TEVA PHARMS USA	20MG/ML	A074284 001	Feb 10, 1994
WATSON LABS	20MG/ML	A074228 001	Oct 15, 1996
WATSON LABS INC	20MG/ML	A074968 001	Jan 09, 1998

## TOPOSAR

TEVA PARENTERAL	20MG/ML	A074166 001	Feb 27, 1995
-----------------	---------	-------------	--------------

## VEPESID

CORDEN PHARMA	20MG/ML	N018768 001	Nov 10, 1983
---------------	---------	-------------	--------------

ETOPOSIDE PHOSPHATE

## INJECTABLE; INJECTION

## ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N020906 001	Feb 27, 1998
	EQ 1GM BASE/VIAL	N020906 002	Feb 27, 1998

ETRETINATE

## CAPSULE; ORAL

## TEGISON

ROCHE	10MG	N019369 001	Sep 30, 1986
	25MG	N019369 002	Sep 30, 1986

EVANS BLUE

## INJECTABLE; INJECTION

## EVANS BLUE

PARKE DAVIS	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008041 001	
-------------	---	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**EZETIMIBE

TABLET; ORAL

EZETIMIBE

GLENMARK PHARMS LTD 10MG A078560 001 Jun 26, 2015

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

APOTEX INC 10MG/ML A075942 001 Aug 02, 2002

APOTHECON 10MG/ML A075707 001 Apr 16, 2001

EUROHLTH INTL SARL 10MG/ML A075799 001 Apr 30, 2002

HOSPIRA 10MG/ML A075705 001 Apr 16, 2001

10MG/ML A075870 001 Nov 23, 2001

10MG/ML A075905 001 Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

APOTEX INC 10MG/ML A076324 001 Nov 27, 2002

APOTHECON 10MG/ML A075708 001 Apr 16, 2001

HIKMA MAPLE 10MG/ML A075789 001 Apr 30, 2002

HOSPIRA 10MG/ML A075669 001 Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

APOTEX INC 10MG/ML A076322 001 Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE 0.4MG/ML A075729 001 Dec 17, 2001

PEPCID

MERCK 10MG/ML N019510 001 Nov 04, 1986

PEPCID PRESERVATIVE FREE

MERCK 10MG/ML N019510 004 Nov 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

MERCK SHARP DOHME 0.4MG/ML N020249 001 Feb 18, 1994

TABLET; ORAL

FAMOTIDINE

ACTAVIS ELIZABETH 20MG A075650 001 Sep 14, 2001

40MG A075650 002 Sep 14, 2001

APOTEX 10MG A075610 001 Mar 12, 2002

MUTUAL PHARM 20MG A075639 002 Dec 12, 2001

40MG A075639 001 Dec 12, 2001

MYLAN PHARMS INC 20MG A075457 001 Apr 18, 2001

40MG A075457 002 Apr 18, 2001

SANDOZ 10MG A076101 001 Oct 21, 2002

20MG A075302 001 Apr 16, 2001

20MG A075607 001 May 10, 2001

20MG A075793 001 Apr 16, 2001

40MG A075302 002 Apr 16, 2001

40MG A075607 002 May 10, 2001

40MG A075793 002 Apr 16, 2001

WATSON LABS 10MG A075404 001 Nov 28, 2001

20MG A075062 002 Apr 16, 2001

40MG A075062 001 Apr 16, 2001

TABLET, CHEWABLE; ORAL

PEPCID AC

J AND J CONSUMER INC 10MG N020801 001 Sep 24, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

UCB INC 20MG N021712 001 Sep 24, 2004

40MG N021712 002 Sep 24, 2004

PEPCID RPD

MERCK 20MG N020752 001 May 28, 1998

40MG N020752 002 May 28, 1998

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

WOCKHARDT LTD 2.5MG A091484 001 Aug 15, 2012

5MG A091484 002 Aug 15, 2012

10MG A091484 003 Aug 15, 2012

PLENDIL

ASTRAZENECA 2.5MG N019834 004 Sep 22, 1994

5MG N019834 001 Jul 25, 1991

10MG N019834 002 Jul 25, 1991

## DISCONTINUED DRUG PRODUCT LIST

FENOFIBRATE

## CAPSULE; ORAL

ANTARA (MICRONIZED)					
LUPIN ATLANTIS	87MG	N021695	002	Nov 30,	2004
LIPIDIL					
ABBVIE	100MG	N019304	001	Dec 31,	1993
LIPOFEN					
CIPHER PHARMS INC	100MG	N021612	002	Jan 11,	2006
TRICOR (MICRONIZED)					
ABBVIE	67MG	N019304	002	Feb 09,	1998
	134MG	N019304	003	Jun 30,	1999
	200MG	N019304	004	Jun 30,	1999

## TABLET; ORAL

FENOFIBRATE					
MYLAN	107MG	A076520	002	Dec 29,	2005
TRICOR					
ABBOTT	54MG	N021203	001	Sep 04,	2001
	160MG	N021203	003	Sep 04,	2001
TRIGLIDE					
SKYEPHARMA AG	50MG	N021350	001	May 07,	2005

FENOLDOPAM MESYLATE

## INJECTABLE; INJECTION

FENOLDOPAM MESYLATE					
LUITPOLD	EQ 10MG BASE/ML	A076656	001	Dec 01,	2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826	001	Mar 07,	2007

FENOPROFEN CALCIUM

## CAPSULE; ORAL

FENOPROFEN CALCIUM					
AM THERAP	EQ 200MG BASE	A072307	001	Aug 22,	1988
	EQ 300MG BASE	A072308	001	Aug 22,	1988
HALSEY	EQ 200MG BASE	A072355	001	Aug 17,	1988
	EQ 300MG BASE	A072356	001	Aug 17,	1988
PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22,	1988
	EQ 300MG BASE	A072438	001	Aug 22,	1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17,	1988
	EQ 300MG BASE	A071738	001	Aug 17,	1988
SANDOZ	EQ 200MG BASE	A072394	001	Oct 17,	1988
	EQ 300MG BASE	A072395	001	Oct 17,	1988
WARNER CHILCOTT	EQ 200MG BASE	A072946	001	Apr 30,	1991
	EQ 300MG BASE	A072472	001	Apr 30,	1991
WATSON LABS	EQ 200MG BASE	A072294	001	Aug 17,	1988
	EQ 200MG BASE	A072981	001	Aug 19,	1991
	EQ 300MG BASE	A072293	001	Aug 17,	1988
	EQ 300MG BASE	A072982	001	Aug 19,	1991
NALFON					
XSPIRE	EQ 300MG BASE	N017604	002		

## TABLET; ORAL

FENOPROFEN CALCIUM					
ACTAVIS ELIZABETH	EQ 600MG BASE	A072274	001	May 02,	1988
AM THERAP	EQ 600MG BASE	A072309	001	Aug 17,	1988
DAVA PHARMS INC	EQ 600MG BASE	A072326	001	Aug 17,	1988
HALSEY	EQ 600MG BASE	A072357	001	Aug 17,	1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29,	1988
MUTUAL PHARM	EQ 600MG BASE	A072902	001	Dec 21,	1990
PAR PHARM	EQ 600MG BASE	A072429	001	Aug 17,	1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17,	1988
SANDOZ	EQ 600MG BASE	A072396	001	Oct 17,	1988
USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17,	1988
WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17,	1988
	EQ 600MG BASE	A072407	001	Aug 17,	1988
	EQ 600MG BASE	A072602	001	Oct 11,	1988
NALFON					
DISTA	EQ 600MG BASE	N017710	001		

FENTANYL

## FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100					
NOVEN	100MCG/HR	A077775	004	Oct 16,	2009
FENTANYL-25					
NOVEN	25MCG/HR	A077775	001	Oct 16,	2009

**DISCONTINUED DRUG PRODUCT LIST**FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-50

NOVEN

50MCG/HR

A077775 002 Oct 16, 2009

FENTANYL-75

NOVEN

75MCG/HR

A077775 003 Oct 16, 2009

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

BIODELIVERY SCI INTL

EQ 0.2MG BASE

N022266 001 Jul 16, 2009

EQ 0.4MG BASE

N022266 002 Jul 16, 2009

EQ 0.6MG BASE

N022266 003 Jul 16, 2009

EQ 0.8MG BASE

N022266 004 Jul 16, 2009

EQ 1.2MG BASE

N022266 005 Jul 16, 2009

INJECTABLE;INJECTION

FENTANYL CITRATE

ABBOTT

EQ 0.05MG BASE/ML

A070636 001 Apr 30, 1990

EQ 0.05MG BASE/ML

A070637 001 Apr 30, 1990

WATSON LABS

EQ 0.05MG BASE/ML

A073488 001 Jun 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

WATSON LABS INC

EQ 0.05MG BASE/ML

A074917 001 Feb 03, 1998

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

WATSON LABS

EQ 0.1MG BASE

A079075 001 Jan 07, 2011

EQ 0.2MG BASE

A079075 002 Jan 07, 2011

EQ 0.4MG BASE

A079075 003 Jan 07, 2011

EQ 0.6MG BASE

A079075 004 Jan 07, 2011

EQ 0.8MG BASE

A079075 005 Jan 07, 2011

FENTORA

CEPHALON

EQ 0.3MG BASE

N021947 006 Mar 02, 2007

TROCHE/LOZENGE;ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE

N020195 007 Oct 30, 1995

EQ 0.2MG BASE

N020195 001 Oct 04, 1993

EQ 0.3MG BASE

N020195 002 Oct 04, 1993

EQ 0.4MG BASE

N020195 003 Oct 04, 1993

FERRIC AMMONIUM CITRATE

FOR SOLUTION;ORAL

FERRISELTZ

OTSUKA

600MG/PACKET

N020292 001 Oct 14, 1997

FERROUS CITRATE, FE-59

INJECTABLE;INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML

N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE;ORAL

FOLVRON

LEDERLE

182MG;0.33MG

N006012 003

FERUMOXIDES

INJECTABLE;INJECTION

FERIDEX I.V.

AMAG PHARMS INC

EQ 11.2MG IRON/ML

N020416 001 Aug 30, 1996

FERUMOXSIIL

SUSPENSION;ORAL

GASTROMARK

AMAG PHARMS INC

EQ 0.175MG IRON/ML

N020410 001 Dec 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL

ALLEGRA

SANOFI AVENTIS US

60MG

N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR

60MG

A076169 001 Jul 13, 2005

## DISCONTINUED DRUG PRODUCT LIST

FIBRINOGEN, I-125

INJECTABLE; INJECTION

IBRIN

GE HEALTHCARE	154uCi/VIAL	N017879	001
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR			
ABBOTT	140uCi/ML	N017787	001

FINASTERIDE

TABLET; ORAL

FINASTERIDE

IVAX SUB TEVA PHARMS	5MG	A076340	001	Jun 19, 2006
----------------------	-----	---------	-----	--------------

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

URISPAS

ORTHO MCNEIL JANSSEN	100MG	N016769	001
----------------------	-------	---------	-----

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

APOTEX INC	50MG	A079164	001	Jul 09, 2009
	100MG	A079164	002	Jul 09, 2009
	150MG	A079164	003	Jul 09, 2009
SANDOZ	50MG	A076030	001	Oct 28, 2002
	100MG	A076030	002	Oct 28, 2002
	150MG	A076030	003	Oct 28, 2002
TAMBOCOR				
CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988
	100MG	N018830	001	Oct 31, 1985
	150MG	N018830	003	Jun 03, 1988
	200MG	N018830	002	Oct 31, 1985

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

HOSPIRA	500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016929	001
---------	--	---------	-----

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006
	200MG/5ML	A076918	002	Dec 18, 2006

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005
TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005

TABLET; ORAL

FLUCONAZOLE

GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
	100MG	A076432	002	Jul 29, 2004
	150MG	A076432	003	Jul 29, 2004
	200MG	A076432	004	Jul 29, 2004
MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
	100MG	A076042	002	Jul 29, 2004
	150MG	A076042	003	Jul 29, 2004
	200MG	A076042	004	Jul 29, 2004
PLIVA	50MG	A076424	001	Jul 29, 2004
	100MG	A076424	002	Jul 29, 2004
	150MG	A076424	003	Jul 29, 2004
	200MG	A076424	004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
	100MG	A076386	002	Jul 29, 2004
	150MG	A076386	003	Jul 29, 2004
	200MG	A076386	004	Jul 29, 2004
ROXANE	50MG	A076213	001	Jul 29, 2004

**DISCONTINUED DRUG PRODUCT LIST**FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

	100MG	A076213 002	Jul 29, 2004
	150MG	A076213 003	Jul 29, 2004
	200MG	A076213 004	Jul 29, 2004
SANDOZ	50MG	A076086 001	Jul 29, 2004
	100MG	A076086 002	Jul 29, 2004
	150MG	A076086 003	Jul 29, 2004
	200MG	A076086 004	Jul 29, 2004

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

GENZYME CORP

50MG/VIAL

N020038 001 Apr 18, 1991

TABLET; ORAL

OFORTA

SANOFI AVENTIS US

10MG

N022273 001 Dec 18, 2008

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F18

DOWNSTATE CLINCL

4-40mCi/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020306 001 Aug 19, 1994

4-90mCi/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020306 002 Sep 25, 2001

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

WEILL MEDCL COLL

10-100mCi/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021768 001 Aug 05, 2004

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

CITRON PHARMA LLC

0.1MG

N010060 001

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

CLARIS PHARMASERVICE

0.5MG/5ML (0.1MG/ML)  
1MG/10ML (0.1MG/ML)  
0.5MG/5ML (0.1MG/ML)  
1MG/10ML (0.1MG/ML)

A076755 002 Oct 12, 2004

A076755 001 Oct 12, 2004

A076589 002 Oct 12, 2004

A076589 001 Oct 12, 2004

ROMAZICON

HOFFMANN LA ROCHE

1MG/10ML (0.1MG/ML) \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020073 001 Dec 20, 1991

0.5MG/5ML (0.1MG/ML) \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020073 002 Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS

0.03%

N016379 001

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO

0.25MG/INH

N018340 001 Aug 17, 1984

SPRAY, METERED; NASAL

NASALIDE

IVAX RES

0.025MG/SPRAY

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995



## DISCONTINUED DRUG PRODUCT LIST

FLUOCINOLONE ACETONIDE

## CREAM; TOPICAL

## FLUCET

ALPHARMA US PHARMS	0.025%	A088360	001	Jan 16, 1984
--------------------	--------	---------	-----	--------------

## FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.01%	A088361	001	Jan 16, 1984
--------------------	-------	---------	-----	--------------

PERRIGO NEW YORK	0.01%	A086810	001	Mar 04, 1982
------------------	-------	---------	-----	--------------

	0.025%	A086811	001	Mar 04, 1982
--	--------	---------	-----	--------------

PHARMADERM	0.01%	A088047	001	Dec 16, 1982
------------	-------	---------	-----	--------------

	0.025%	A088045	001	Dec 16, 1982
--	--------	---------	-----	--------------

PHARMAFAIR	0.01%	A088499	001	Aug 02, 1984
------------	-------	---------	-----	--------------

	0.025%	A088506	001	Aug 02, 1984
--	--------	---------	-----	--------------

TARO	0.01%	A040035	001	Oct 31, 1994
------	-------	---------	-----	--------------

	0.01%	A087102	001	Apr 27, 1982
--	-------	---------	-----	--------------

	0.025%	A040042	001	Oct 31, 1994
--	--------	---------	-----	--------------

USL PHARMA	0.01%	A088757	001	Feb 11, 1985
------------	-------	---------	-----	--------------

	0.025%	A088756	001	Mar 28, 1985
--	--------	---------	-----	--------------

## FLUONID

ALLERGAN HERBERT	0.025%	A087156	002	Sep 06, 1984
------------------	--------	---------	-----	--------------

## FLUOTREX

SAVAGE LABS	0.01%	A088174	001	May 06, 1983
-------------	-------	---------	-----	--------------

	0.025%	A088173	001	Mar 09, 1983
--	--------	---------	-----	--------------

## SYNALAR-HP

MEDIMETRIKS PHARMS	0.2%	N016161	002	
--------------------	------	---------	-----	--

## GEL; TOPICAL

## FLUONID

ALLERGAN HERBERT	0.025%	A087300	001	May 27, 1982
------------------	--------	---------	-----	--------------

## OINTMENT; TOPICAL

## FLUOCINOLONE ACETONIDE

PHARMADERM	0.025%	A088046	001	Dec 16, 1982
------------	--------	---------	-----	--------------

PHARMAFAIR	0.025%	A088507	001	Feb 27, 1984
------------	--------	---------	-----	--------------

USL PHARMA	0.025%	A088742	001	Feb 08, 1985
------------	--------	---------	-----	--------------

## FLUONID

ALLERGAN HERBERT	0.025%	A087157	001	Sep 06, 1984
------------------	--------	---------	-----	--------------

## FLUOTREX

SAVAGE LABS	0.025%	A088172	001	Mar 09, 1983
-------------	--------	---------	-----	--------------

## SOLUTION; TOPICAL

## FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982
--------------------	-------	---------	-----	--------------

BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993
-----------------	-------	---------	-----	--------------

MORTON GROVE	0.01%	A088312	001	Jan 27, 1984
--------------	-------	---------	-----	--------------

PHARMADERM	0.01%	A088048	001	Dec 16, 1982
------------	-------	---------	-----	--------------

PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984
------------	-------	---------	-----	--------------

## FLUONID

ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983
------------------	-------	---------	-----	--------------

## FLUOTREX

SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983
-------------	-------	---------	-----	--------------

FLUOCINONIDE

## CREAM; TOPICAL

## FLUOCINONIDE

PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988
------------------	-------	---------	-----	--------------

TARO	0.05%	A071500	001	Jun 10, 1987
------	-------	---------	-----	--------------

## FLUOCINONIDE EMULSIFIED BASE

G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995
------------------	-------	---------	-----	--------------

## LIDEX

CNTY LINE PHARMS	0.05%	N016908	002	
------------------	-------	---------	-----	--

## LIDEX-E

CNTY LINE PHARMS	0.05%	N016908	003	
------------------	-------	---------	-----	--

## GEL; TOPICAL

## LIDEX

CNTY LINE PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017373	001	
------------------	--	---------	-----	--

## OINTMENT; TOPICAL

## LIDEX

CNTY LINE PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016909	002	
------------------	--	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

FLUOCINONIDE

SOLUTION; TOPICAL

FLUOCINONIDE

TARO

0.05%

A072857 001 Aug 02, 1989

TEVA PHARMS

0.05%

A072522 001 Sep 28, 1990

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

NOVARTIS

25%

N017869 001

FLUOROMETHOLONE

CREAM; TOPICAL

OXYLONE

PHARMACIA AND UPJOHN

0.025%

N011748 001

SUSPENSION/DROPS; OPHTHALMIC

FLUOR-OP

NOVARTIS

0.1%

A070185 001 Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE

ALCON

0.1%; 0.3%

N050628 001 Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

FML-S

ALLERGAN

0.1%; 10%

N019525 001 Sep 29, 1989

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN

50MG/ML

A081222 001 Jun 28, 1991

50MG/ML

N017959 001

TEVA PARENTERAL

50MG/ML

A040023 001 Oct 18, 1991

50MG/ML

A081225 001 Aug 28, 1991

FLUOROURACIL

ABIC

50MG/ML

A088929 001 Mar 04, 1986

ABRAXIS PHARM

50MG/ML

A089152 001 Mar 21, 1986

50MG/ML

A089428 001 Jan 12, 1987

50MG/ML

A089519 001 Mar 12, 1987

BEDFORD

50MG/ML

A089508 001 Jan 26, 1988

EBEWE PHARMA

500MG/10ML (50MG/ML)

A040772 001 Aug 11, 2008

FRESENIUS KABI USA

50MG/ML

A040291 001 Mar 24, 1999

50MG/ML

A040379 001 Nov 15, 2000

MARCHAR

50MG/ML

A087791 001 Jan 18, 1983

SMITH AND NEPHEW

50MG/ML

A088766 001 Dec 28, 1984

50MG/ML

A088767 001 Dec 28, 1984

50MG/ML

A089434 001 Mar 26, 1987

SPECTRUM PHARMS

50MG/ML

A087792 001 Oct 13, 1982

VALEANT

500MG/10ML (50MG/ML)

N012209 001

SOLUTION; TOPICAL

FLUOROPLEX

ELORAC

1%

N016765 001

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

MUTUAL PHARMA

EQ 10MG BASE

A075787 001 Jan 29, 2002

EQ 20MG BASE

A075787 002 Jan 29, 2002

WATSON LABS

EQ 10MG BASE

A075662 001 Jan 29, 2002

EQ 20MG BASE

A075662 002 Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

ANI PHARMS INC

EQ 10MG BASE

A076287 001 May 20, 2008

EQ 20MG BASE

A076287 002 May 20, 2008

BARR

EQ 40MG BASE

A076251 001 May 18, 2005

CARLSBAD

EQ 10MG BASE

A076022 001 Jan 30, 2002

EQ 20MG BASE

A076022 002 Jan 30, 2002

CR DOUBLE CRANE

EQ 10MG BASE

A076165 001 Feb 01, 2002

EQ 20MG BASE

A076165 002 Feb 01, 2002

PAR PHARM

EQ 10MG BASE

A076922 001 Dec 16, 2004

EQ 20MG BASE

A076922 002 Dec 16, 2004

SANDOZ

EQ 10MG BASE

A075807 001 Jan 29, 2002

EQ 10MG BASE

A077469 001 Nov 17, 2008

EQ 20MG BASE

A075807 002 Jan 29, 2002

## DISCONTINUED DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

## CAPSULE; ORAL

## FLUOXETINE HYDROCHLORIDE

	EQ 20MG BASE	A077469 002	Nov 17, 2008
WOCKHARDT LTD	EQ 10MG BASE	A078143 001	Jan 16, 2008
	EQ 20MG BASE	A078143 002	Jan 16, 2008
	EQ 40MG BASE	A078143 003	Jan 16, 2008

## PROZAC

ELI LILLY AND CO	EQ 60MG BASE	N018936 004	Jun 15, 1999
------------------	--------------	-------------	--------------

## SARAFEM

ELI LILLY AND CO	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018936 007	Jul 06, 2000
	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018936 008	Jul 06, 2000

## SOLUTION; ORAL

## FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690 001	Jan 31, 2002
APOTEX INC	EQ 20MG BASE/5ML	A075292 001	Feb 07, 2002
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525 001	Jun 27, 2002

## PROZAC

LILLY	EQ 20MG BASE/5ML	N020101 001	Apr 24, 1991
-------	------------------	-------------	--------------

## TABLET; ORAL

## FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810 001	Feb 01, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865 001	Feb 28, 2002
	EQ 40MG BASE	A075865 003	Aug 30, 2004
SANDOZ	EQ 10MG BASE	A076024 001	Jan 29, 2002

## PROZAC

LILLY	EQ 10MG BASE	N020974 001	Mar 09, 1999
	EQ 20MG BASE	N020974 002	Mar 09, 1999

FLUOXYMESTERONE

## TABLET; ORAL

## ANDROID-F

VALEANT PHARM INTL	10MG	A087196 001	
--------------------	------	-------------	--

## FLUOXYMESTERONE

VALEANT PHARM INTL	10MG	A088221 001	May 05, 1983
WATSON LABS	2MG	A088260 001	Dec 06, 1983
	5MG	A088265 001	Dec 06, 1983
	10MG	A088309 001	Dec 06, 1983

## HALOTESTIN

PHARMACIA AND UPJOHN	2MG	N010611 002	
	5MG	N010611 006	
	10MG	N010611 010	

## ORA-TESTRYL

BRISTOL MYERS SQUIBB	2MG	N011359 001	
	5MG	N011359 002	

FLUPHENAZINE DECANOATE

## INJECTABLE; INJECTION

## FLUPHENAZINE DECANOATE

HOSPIRA	25MG/ML	A074966 001	Apr 16, 1998
MYLAN LABS LTD	25MG/ML	A075918 001	Aug 17, 2001
TEVA PARENTERAL	25MG/ML	A074795 001	Sep 10, 1996
PROLIXIN DECANOATE			
BRISTOL MYERS SQUIBB	25MG/ML	N016727 001	

FLUPHENAZINE ENANTHATE

## INJECTABLE; INJECTION

## PROLIXIN ENANTHATE

APOTHECON	25MG/ML	N016110 001	
-----------	---------	-------------	--

FLUPHENAZINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	5MG/ML	A073058 001	Aug 30, 1991
PERMITIL			
SCHERING	5MG/ML	N016008 001	
PROLIXIN			
APOTHECON	5MG/ML	A070533 001	Nov 07, 1985

**DISCONTINUED DRUG PRODUCT LIST**FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC

2.5MG/5ML

A081310 001 Apr 29, 1993

PROLIXIN

APOTHECON

2.5MG/5ML

N012145 003

INJECTABLE; INJECTION

PROLIXIN

APOTHECON

2.5MG/ML

N011751 005

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS

1MG

A088555 001 Dec 18, 1987

2.5MG

A088544 001 Dec 18, 1987

5MG

A088527 001 Dec 18, 1987

10MG

A088550 001 Dec 18, 1987

PERMITIL

SCHERING

0.25MG

N012034 001

2.5MG

N012034 004

5MG

N012034 005

10MG

N012034 006

PROLIXIN

APOTHECON

1MG

N011751 004

2.5MG

N011751 001

5MG

N011751 003

10MG

N011751 002

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING

1MG

N012419 004

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN

1.5MG

N012259 002

FLURANDRENOLIDE

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS

0.05%

A087203 001 Apr 29, 1982

OINTMENT; TOPICAL

CORDRAN

AQUA PHARMS

0.025% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N012806 004

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN-N

LILLY

0.05%;EQ 3.5MG BASE/GM

N050346 001

OINTMENT; TOPICAL

CORDRAN-N

LILLY

0.05%;EQ 3.5MG BASE/GM

N050345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL

15MG

N016721 001

30MG

N016721 002

FLURAZEPAM HYDROCHLORIDE

HALSEY

15MG

A071808 001 Jan 07, 1988

30MG

A071809 001 Jan 07, 1988

HIKMA PHARMS LLC

15MG

A071107 001 Dec 08, 1986

30MG

A071108 001 Dec 08, 1986

MUTUAL PHARM

15MG

A070454 001 Aug 04, 1986

30MG

A070455 001 Aug 04, 1986

PAR PHARM

15MG

A070444 001 Mar 20, 1986

30MG

A070445 001 Mar 20, 1986

PUREPAC PHARM

15MG

A071927 001 Sep 09, 1987

30MG

A071551 001 Sep 09, 1987

SANDOZ

15MG

A071716 001 Jul 31, 1991

30MG

A071717 001 Jul 31, 1991

SUPERPHARM

15MG

A071659 001 Aug 04, 1988

30MG

A071660 001 Aug 04, 1988

USL PHARMA

15MG

A070562 001 Jul 09, 1987

30MG

A070563 001 Jul 09, 1987

**DISCONTINUED DRUG PRODUCT LIST**FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

WARNER CHILCOTT	15MG	A071767 001	Dec 04, 1987
	30MG	A071768 001	Dec 04, 1987
WATSON LABS	15MG	A071205 001	Nov 25, 1986
	15MG	A072368 001	Mar 30, 1989
	30MG	A071068 001	Nov 25, 1986
	30MG	A072369 001	Mar 30, 1989

FLURBIPROFEN

TABLET; ORAL

ANSAID

PHARMACIA AND UPJOHN	50MG	N018766 002	Oct 31, 1988
	100MG	N018766 003	Oct 31, 1988

FLURBIPROFEN

IVAX SUB TEVA PHARMS	50MG	A074411 001	May 31, 1995
	100MG	A074411 002	May 31, 1995
PLIVA	50MG	A074647 001	Apr 01, 1997
	100MG	A074647 002	Apr 01, 1997
SANDOZ	50MG	A074448 001	Jul 28, 1995
	100MG	A074448 002	Jul 28, 1995
TEVA	50MG	A074405 002	May 24, 1995
	100MG	A074405 001	May 24, 1995
THERAGEN	100MG	A074560 002	May 16, 1997

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

SCHERING	125MG	N018554 001	Jan 27, 1989
FLUTAMIDE			
SANDOZ	125MG	A075818 001	Sep 18, 2001

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020548 001	Mar 27, 1996
	0.11MG/INH	N020548 002	Mar 27, 1996
	0.22MG/INH	N020548 003	Mar 27, 1996

CREAM; TOPICAL

CUTIVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019958 001	Dec 18, 1990
----------------	--	-------------	--------------

FLUTICASONE PROPIONATE

NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004
---------------	-------	-------------	--------------

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

TARO PHARM INDS	0.005%	A077145 001	Jun 14, 2005
-----------------	--------	-------------	--------------

POWDER; INHALATION

FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020549 001	Nov 07, 1997
	0.088MG/INH	N020549 002	Nov 07, 1997
	0.22MG/INH	N020549 003	Nov 07, 1997

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH	25MG	A075901 001	Dec 28, 2000
	50MG	A075901 002	Dec 28, 2000
	100MG	A075901 003	Dec 28, 2000
ANI PHARMS INC	25MG	A075898 001	Mar 12, 2001
	50MG	A075898 002	Mar 12, 2001
	100MG	A075898 003	Mar 12, 2001
MUTUAL PHARM	25MG	A076125 001	Apr 29, 2002
	50MG	A076125 002	Apr 29, 2002
	100MG	A076125 003	Apr 29, 2002
MYLAN	50MG	A075950 001	Oct 15, 2001
	100MG	A075950 002	Oct 15, 2001
SANDOZ	25MG	A075887 001	Jan 05, 2001
	50MG	A075887 002	Jan 05, 2001
	100MG	A075887 003	Jan 05, 2001
SUN PHARM INDS INC	25MG	A075900 001	Feb 23, 2006
	50MG	A075900 002	Feb 23, 2006

## DISCONTINUED DRUG PRODUCT LIST

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

	100MG	A075900 003	Feb 23, 2006
SYNTHON PHARMS	25MG	A075899 001	Jan 17, 2001
	50MG	A075899 002	Jan 17, 2001
	100MG	A075899 003	Jan 17, 2001
WATSON LABS	25MG	A075894 001	Apr 18, 2001
	50MG	A075894 002	Apr 18, 2001
	100MG	A075894 003	Apr 18, 2001
LUVOX			
SOLVAY	25MG	N020243 001	Dec 05, 1994
	50MG	N020243 002	Dec 05, 1994
	100MG	N020243 003	Dec 05, 1994
	150MG	N020243 004	Dec 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE	5MG/ML	A081066 001	Dec 29, 1993
FOLVITE			
HIKMA (MAPLE)	5MG/ML	N005897 008	

TABLET; ORAL

FOLIC ACID

BARR	1MG	A089177 001	Jan 08, 1986
EVERYLIFE	1MG	A080755 001	
HALSEY	1MG	A083598 001	
IMPAX LABS	1MG	A080686 001	
IVAX SUB TEVA PHARMS	1MG	A083000 001	
JUBILANT CADISTA	1MG	A040514 001	Jun 14, 2005
LANNETT	1MG	A080816 001	
LILLY	1MG	N006135 003	
MK LABS	1MG	A083526 001	
MUTUAL PHARM	1MG	A040582 001	Jul 18, 2005
NEXGEN PHARMA INC	1MG	A084915 001	
PHARMERAL	1MG	A084158 001	
PIONEER PHARMS	1MG	A088949 001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784 001	
SANDOZ	1MG	A084472 001	
TABLICAPS	1MG	A083133 002	
UDL	1MG	A088199 001	Mar 29, 1983
USL PHARMA	1MG	A087828 001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903 001	
VANGARD	1MG	A088730 001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296 001	
WATSON LABS	1MG	A083141 001	
	1MG	A085141 002	
WHITEWORTH TOWN PLSN	1MG	A080691 002	
FOLICET			
MISSION PHARMA	1MG	A087438 001	
FOLVITE			
HIKMA (MAPLE)	1MG	N005897 004	

FOLLITROPIN ALFA/BETA

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

FOLLISTIM

ORGANON USA INC	75 IU/VIAL	N020582 001	Sep 29, 1997
	150 IU/VIAL	N020582 002	Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC	150 IU/0.18ML	N021211 003	Feb 11, 2004
GONAL-F			
EMD SERONO	37.5 IU/VIAL	N020378 003	May 25, 2000
	37.5 IU/VIAL	N021765 001	Mar 25, 2004
	75 IU/VIAL	N020378 001	Sep 29, 1997
	150 IU/VIAL	N020378 002	Sep 29, 1997
	150 IU/VIAL	N021765 003	Mar 25, 2004

**DISCONTINUED DRUG PRODUCT LIST**FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

MYLAN INSTITUTIONAL 1.5GM/1.5ML (1GM/ML) A079033 001 Apr 07, 2009

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS 6.6MG/ML N020961 001 Aug 26, 1998

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

NOVARTIS 0.0085MG/INH N021592 001 Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

MERCK AND CO INC EQ 115MG BASE/VIAL N022023 001 Jan 25, 2008

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

RANBAXY LABS LTD 10MG A076580 001 Apr 23, 2004

20MG A076580 002 Apr 23, 2004

40MG A076580 003 Apr 23, 2004

SANDOZ 10MG A076188 001 Oct 08, 2004

20MG A076188 002 Oct 08, 2004

40MG A076188 003 Oct 08, 2004

WATSON LABS 10MG A076987 001 Dec 23, 2004

10MG A077531 001 Aug 31, 2006

20MG A076987 002 Dec 23, 2004

20MG A077531 002 Aug 31, 2006

40MG A076987 003 Dec 23, 2004

40MG A077531 003 Aug 31, 2006

MONOPRIL

BRISTOL MYERS SQUIBB 10MG N019915 002 May 16, 1991

20MG N019915 003 May 16, 1991

40MG N019915 004 Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

MYLAN 10MG; 12.5MG A077705 001 Aug 14, 2006

20MG; 12.5MG A077705 002 Aug 14, 2006

TEVA 10MG; 12.5MG A076945 001 Jul 05, 2006

20MG; 12.5MG A076945 002 Jul 05, 2006

WATSON LABS 10MG; 12.5MG A077144 001 Aug 16, 2005

20MG; 12.5MG A077144 002 Aug 16, 2005

MONOPRIL-HCT

BRISTOL MYERS SQUIBB 10MG; 12.5MG N020286 002 Nov 30, 1994

20MG; 12.5MG N020286 001 Nov 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

APOTEX INC EQ 50MG PHENYTOIN NA/ML A078126 001 Aug 06, 2007

TEVA PHARMS USA EQ 50MG PHENYTOIN NA/ML A076886 001 Aug 06, 2007

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC 1050MG/30ML (35MG/ML) N022244 001 Dec 12, 2008

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE 50MG/15ML N011323 002

TABLET; ORAL

FUROXONE

SHIRE 100MG N011270 002

## DISCONTINUED DRUG PRODUCT LIST

FUROSEMIDE

## INJECTABLE; INJECTION

## FUROSEMIDE

ABRAXIS PHARM	10MG/ML	N018507 001	Jul 30, 1982
	10MG/ML	N019036 001	Aug 13, 1984
ASTRAZENECA	10MG/ML	A070014 001	Sep 09, 1985
HIKMA MAPLE	10MG/ML	A071439 001	Sep 14, 1990
	10MG/ML	N018267 001	
HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987
	10MG/ML	A072080 001	Aug 13, 1991
	10MG/ML	A074337 001	Oct 31, 1994
IGI LABS INC	10MG/ML	A070095 001	Sep 09, 1985
	10MG/ML	A070096 001	Sep 09, 1985
INTL MEDICATION	10MG/ML	N018025 001	
MARSAM PHARMS LLC	10MG/ML	A074017 001	Jun 30, 1994
ORGANON USA INC	10MG/ML	A070017 001	Dec 15, 1986
SMITH AND NEPHEW	10MG/ML	A070023 001	Feb 05, 1986
	10MG/ML	A070078 001	Feb 05, 1986
WARNER CHILCOTT	10MG/ML	N018420 001	Feb 26, 1982
WATSON LABS	10MG/ML	A070019 001	Sep 22, 1986
	10MG/ML	A070604 001	Jan 02, 1987
WYETH AYERST	10MG/ML	N018670 001	Jul 20, 1982

## LASIX

## SOLUTION; ORAL

## LASIX

SANOFI AVENTIS US	10MG/ML	N016363 001	
-------------------	---------	-------------	--

## TABLET; ORAL

## FUROSEMIDE

DAVA PHARMS INC	20MG	N018415 001	Jul 27, 1982
	40MG	N018415 002	Jul 27, 1982
	80MG	N018415 003	Nov 26, 1984
INTL MEDICATION	20MG	N018753 001	Feb 28, 1984
	40MG	N018753 002	Feb 28, 1984
KALAPHARM	20MG	N018868 001	Jun 28, 1983
	40MG	N018868 002	Jun 28, 1983
MUTUAL PHARM	20MG	A070043 001	Sep 26, 1985
	40MG	N018790 001	Nov 29, 1983
	80MG	A070100 001	Jan 26, 1988
SANDOZ	40MG	N018750 002	Jul 30, 1984
SUPERPHARM	20MG	N018370 002	Jun 26, 1984
	40MG	N018370 001	Feb 10, 1983
WARNER CHILCOTT	20MG	N018419 001	Jan 31, 1983
	40MG	N018419 002	Jan 31, 1983
	80MG	N018419 003	Nov 13, 1984
WATSON LABS	20MG	A070412 001	Feb 26, 1986
	20MG	A070449 001	Nov 22, 1985
	20MG	A071379 001	Jan 02, 1987
	20MG	N018369 001	May 14, 1982
	40MG	A070413 001	Feb 26, 1986
	40MG	A070450 001	Nov 22, 1985
	40MG	N018369 002	May 14, 1982
	80MG	A070528 001	Jan 07, 1986
	80MG	A071594 001	Feb 09, 1988

GABAPENTIN

## CAPSULE; ORAL

## GABAPENTIN

IVAX SUB TEVA PHARMS	100MG	A075477 001	Mar 23, 2005
	300MG	A075477 002	Mar 23, 2005
	400MG	A075477 003	Mar 23, 2005
MUTUAL PHARM	100MG	A076537 001	Jun 30, 2005
	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005
WATSON LABS	100MG	A075485 003	May 11, 2007
	300MG	A075485 002	May 11, 2007
	400MG	A075485 001	May 11, 2007



## DISCONTINUED DRUG PRODUCT LIST

GABAPENTIN

TABLET; ORAL

GABAPENTIN

HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011
	800MG	A078782 002	Jul 21, 2011
RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	600MG	A076877 001	Jul 06, 2006
	800MG	A076120 002	Jan 27, 2006
	800MG	A076877 002	Jul 06, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066 001	Sep 05, 2007
---------------	-------------------------	-------------	--------------

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009
	EQ 8MG BASE	A077585 002	Sep 15, 2009
	EQ 12MG BASE	A077585 003	Sep 15, 2009
YABAO PHARM	EQ 4MG BASE	A077604 001	Feb 06, 2009
	EQ 8MG BASE	A077604 002	Feb 06, 2009
	EQ 12MG BASE	A077604 003	Feb 06, 2009

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842 001	
	100MG/ML	N007842 002	

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700 001	
NEOSCAN			
GE HEALTHCARE	2mCi/ML	N017655 001	

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

CHAPTER 7 TRUSTEE	25MG/ML	N019961 002	Jan 17, 1991
-------------------	---------	-------------	--------------

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

ROCHE PALO	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 001	Dec 22, 1994
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 002	Dec 12, 1997
GANCICLOVIR			
RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003
	500MG	A076457 002	Jun 27, 2003

IMPLANT; IMPLANTATION

VITRASERT

BAUSCH AND LOMB	4.5MG	N020569 001	Mar 04, 1996
-----------------	-------	-------------	--------------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A076222 001	Jul 16, 2003
--------------------	--------------------	-------------	--------------

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

APOTEX INC	0.3%	A079084 001	Aug 19, 2011
------------	------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**GEFITINIB

TABLET; ORAL

IRESSA

ASTRAZENECA

250MG

N021399 001 May 05, 2003

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN

300MG

A073466 001 Jan 25, 1993

PUREPAC PHARM

300MG

A072929 001 Jan 29, 1993

LOPID

PFIZER PHARMS

200MG

N018422 001

300MG

N018422 002

TABLET; ORAL

GEMFIBROZIL

MYLAN

600MG

A074452 001 Feb 16, 1995

PUREPAC PHARM

600MG

A074360 001 Aug 31, 1994

SANDOZ

600MG

A074615 001 Sep 29, 1995

WATSON LABS

600MG

A074156 001 Oct 24, 1994

600MG

A074442 001 Apr 28, 1995

GEMTUZUMAB\_OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

WYETH PHARMS INC

5MG/VIAL

N021174 001 May 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING

EQ 0.1% BASE

A060462 001

GENTAFAIR

PHARMAFAIR

EQ 0.1% BASE

A062458 001 Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS

EQ 0.1% BASE

A062471 001 Sep 27, 1983

G AND W LABS INC

EQ 0.1% BASE

A064056 001 Apr 29, 1994

PHARMADERM

EQ 1MG BASE/GM

A062530 001 Jul 05, 1984

INJECTABLE; INJECTION

APOGEN

KING PHARMS

EQ 10MG BASE/ML

A062289 001

EQ 40MG BASE/ML

A062289 002

BRISTAGEN

BRISTOL

EQ 40MG BASE/ML

A062288 001

GARAMYCIN

SCHERING

EQ 1MG BASE/ML

A061716 002

EQ 10MG BASE/ML

A061739 001

EQ 40MG BASE/ML

A061716 001

GENTAFAIR

PHARMAFAIR

EQ 40MG BASE/ML

A062493 001 Aug 28, 1985

GENTAMICIN

INTL MEDICATION

EQ 1MG BASE/ML

A062325 003 Jun 23, 1982

EQ 40MG BASE/ML

A062325 001

EQ 100MG BASE/100ML

A062325 004 Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT

EQ 1.2MG BASE/ML

A062413 001 Aug 11, 1983

EQ 1.4MG BASE/ML

A062413 002 Aug 11, 1983

EQ 1.6MG BASE/ML

A062413 003 Aug 11, 1983

EQ 1.8MG BASE/ML

A062413 004 Aug 11, 1983

EQ 2MG BASE/ML

A062413 005 Aug 11, 1983

EQ 60MG BASE/100ML

A062413 006 Aug 11, 1983

EQ 70MG BASE/100ML

A062413 007 Aug 11, 1983

EQ 80MG BASE/100ML

A062413 008 Aug 11, 1983

EQ 90MG BASE/100ML

A062413 009 Aug 11, 1983

EQ 100MG BASE/100ML

A062413 010 Aug 11, 1983

FRESENIUS KABI USA

EQ 10MG BASE/ML

A062356 001 Mar 04, 1982

EQ 40MG BASE/ML

A062356 002 Mar 04, 1982

HIKMA MAPLE

EQ 10MG BASE/ML

A062251 002

EQ 40MG BASE/ML

A062251 001

KALAPHARM

EQ 40MG BASE/ML

A062354 001 Apr 05, 1982

PHARM SPEC

EQ 40MG BASE/ML

A062340 001 Mar 28, 1983

SOLOPAK

EQ 10MG BASE/ML

A062507 001 Jun 06, 1985

EQ 40MG BASE/ML

A062507 002 Jun 06, 1985

TEVA PARENTERAL

EQ 10MG BASE/ML

A063149 001 Nov 21, 1991

EQ 40MG BASE/ML

A063106 002 Nov 21, 1991

WATSON LABS

EQ 10MG BASE/ML

A062318 002

## DISCONTINUED DRUG PRODUCT LIST

GENTAMICIN SULFATE

## INJECTABLE; INJECTION

## GENTAMICIN SULFATE

	EQ 40MG BASE/ML	A062318	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	

## GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814	004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814	005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814	006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814	007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814	008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814	009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814	010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814	011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814	012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814	013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814	014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414	002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414	004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414	005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062414	006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414	007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062414	009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986

## U-GENCIN

PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	

## INJECTABLE; INTRATHECAL

## GARAMYCIN

SCHERING	EQ 2MG BASE/ML	N050505	001	
----------	----------------	---------	-----	--

## OINTMENT; OPHTHALMIC

## GARAMYCIN

SCHERING	EQ 0.3% BASE	N050425	001	
----------	--------------	---------	-----	--

## GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984
----------	--------------	---------	-----	--------------

## GENTAFAIR

PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983
------------	----------------	---------	-----	--------------

## OINTMENT; TOPICAL

## GARAMYCIN

SCHERING	EQ 0.1% BASE	A060463	001	
----------	--------------	---------	-----	--

## GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983
------------	--------------	---------	-----	--------------

## GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
--------------------	--------------	---------	-----	--------------

G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994
------------------	--------------	---------	-----	--------------

PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984
------------	--------------	---------	-----	--------------

## SOLUTION/DROPS; OPHTHALMIC

## GARAMYCIN

SCHERING	EQ 0.3% BASE	N050039	002	
----------	--------------	---------	-----	--

## GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984
----------	--------------	---------	-----	--------------

## GENTAFAIR

PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983
------------	--------------	---------	-----	--------------

## GENTAMICIN SULFATE

ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985
------------------	--------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

GENTAMICIN SULFATE

SOLUTION/DROPS;OPHTHALMIC

GENTAMICIN SULFATE

PACO

EQ 3MG BASE/ML

A062932 001 Nov 07, 1988

GENTIAN VIOLET

SUPPOSITORY;VAGINAL

GVS

SAVAGE LABS

0.4%

A083513 001

TAMPON;VAGINAL

GENAPAX

KEY PHARMS

5MG

A085017 001

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA

20MG/VIAL

N020622 001 Dec 20, 1996

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

COREPHARMA

1MG

A077274 001 Oct 06, 2005

2MG

A077274 002 Oct 06, 2005

4MG

A077274 003 Oct 06, 2005

HIKMA PHARMS

1MG

A078952 001 Aug 01, 2013

2MG

A078952 002 Aug 01, 2013

4MG

A078952 003 Aug 01, 2013

MYLAN

1MG

A077486 001 Feb 10, 2006

2MG

A077486 002 Feb 10, 2006

4MG

A077486 003 Feb 10, 2006

RANBAXY

3MG

A077366 001 Oct 06, 2005

6MG

A077366 002 Oct 06, 2005

RANBAXY LABS LTD

1MG

A076875 001 Oct 06, 2005

2MG

A076875 002 Oct 06, 2005

4MG

A076875 003 Oct 06, 2005

8MG

A076875 004 Oct 06, 2005

WATSON LABS

1MG

A077280 001 Feb 03, 2006

2MG

A077280 002 Feb 03, 2006

4MG

A077280 003 Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDARYL

SB PHARMC0

1MG;4MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021700 001 Nov 23, 2005

2MG;4MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021700 002 Nov 23, 2005

2MG;8MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021700 004 Mar 30, 2007

4MG;4MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021700 003 Nov 23, 2005

4MG;8MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021700 005 Mar 30, 2007

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

ANI PHARMS INC

5MG

A074387 001 Mar 04, 1996

10MG

A074387 002 Mar 04, 1996

BARR LABS INC

5MG

A074619 001 Apr 04, 1997

10MG

A074619 002 Apr 04, 1997

SANDOZ

5MG

A074542 001 Jun 20, 1995

10MG

A074542 002 Jun 20, 1995

VINTAGE PHARMS LLC

5MG

A074378 001 Nov 28, 1994

10MG

A074378 002 Nov 28, 1994

WATSON LABS

5MG

A074370 001 Nov 22, 1994

10MG

A074370 002 Nov 22, 1994

## DISCONTINUED DRUG PRODUCT LIST

GLIPIZIDE

TABLET; ORAL

GLUCOTROL

PFIZER

2.5MG

N017783 003 May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

METAGLIP

BRISTOL MYERS SQUIBB

2.5MG; 250MG

N021460 001 Oct 21, 2002

2.5MG; 500MG

N021460 002 Oct 21, 2002

5MG; 500MG

N021460 003 Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

LILLY

EQ 1MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N012122 001

EQ 10MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N012122 002

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

SANOFI AVENTIS US

500MG

N009519 008

TABLET; ORAL

DORIDEN

SANOFI AVENTIS US

250MG

N009519 002

500MG

N009519 005

GLUTETHIMIDE

HALSEY

250MG

A089458 001 Oct 10, 1986

LANNETT

500MG

A089459 001 Oct 10, 1986

LANNETT

250MG

A083475 001

500MG

A085571 001

SANDOZ

500MG

A083234 002

UCB INC

500MG

A085171 001

VITARINE

500MG

A087297 001

WATSON LABS

500MG

A084362 001

500MG

A085763 001

GLYBURIDE

TABLET; ORAL

GLYBURIDE

ACTAVIS ELIZABETH

1.5MG

A075947 001 Nov 14, 2002

3MG

A075947 002 Nov 14, 2002

6MG

A075947 003 Nov 14, 2002

GLYBURIDE (MICRONIZED)

SANDOZ

1.5MG

A075174 001 Jun 22, 1998

3MG

A075174 002 Jun 22, 1998

SANOFI AVENTIS US

1.5MG

N020055 001 Apr 17, 1992

3MG

N020055 002 Apr 17, 1992

6MG

N020055 003 Mar 08, 2000

GLYNASE

PHARMACIA AND UPJOHN

4.5MG

N020051 003 Sep 24, 1993

MICRONASE

PHARMACIA AND UPJOHN

1.25MG

N017498 001 May 01, 1984

2.5MG

N017498 002 May 01, 1984

5MG

N017498 003 May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

BRISTOL MYERS SQUIBB

1.25MG; 250MG

N021178 001 Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

TEVA

1.25MG; 250MG

A076821 001 Jan 27, 2005

2.5MG; 500MG

A076821 002 Jan 27, 2005

5MG; 500MG

A076821 003 Jan 27, 2005

**DISCONTINUED DRUG PRODUCT LIST**GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522	001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633	001	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475	001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393	001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169	001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947	001	Jun 24, 1983
ROBINUL				
ROBINS AH	0.2MG/ML	N014764	001	

TABLET; ORAL

GLYCOPYRROLATE

COREPHARMA	1MG	A040568	001	Dec 22, 2004
	2MG	A040568	002	Dec 22, 2004
HIKMA PHARMS LLC	1MG	A040836	001	Mar 05, 2009
	2MG	A040836	002	Mar 05, 2009
WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

HIKMA (MAPLE)	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

FERRING	5,000 UNITS/VIAL	N017055	001	
	10,000 UNITS/VIAL	N017055	002	
	20,000 UNITS/VIAL	N017055	003	

CHORIONIC GONADOTROPIN

BEL MAR	5,000 UNITS/VIAL	N017054	001	
	10,000 UNITS/VIAL	N017054	002	
FERRING	2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
	5,000 UNITS/VIAL	N017016	006	
	15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016	004	
FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067	001	
	15,000 UNITS/VIAL	N017067	004	
	20,000 UNITS/VIAL	N017067	003	

FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001	
----------------------	-------------------	---------	-----	--

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCIN

DOW PHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060427	001	
-----------	--	---------	-----	--

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062818	001	Oct 11, 1988
--------	--	---------	-----	--------------

WATSON LABS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062788	001	Jun 11, 1987
-------------	--	---------	-----	--------------

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062383	001	Aug 31, 1982
------------	--	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**GRANISETRON HYDROCHLORIDE

## INJECTABLE; INJECTION

## GRANISETRON HYDROCHLORIDE

APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007
CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008
SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008

## GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007
-----------------	---------------------------------	-------------	--------------

## KYTRIL

ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020239 003	Sep 17, 2004
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N020239 004	Mar 11, 1994
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020239 001	Dec 29, 1993
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N020239 002	Mar 11, 1994
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

## SOLUTION; ORAL

## GRANISOL

PEDIATRAX	EQ 2MG BASE/10ML	A078334 001	Feb 28, 2008
-----------	------------------	-------------	--------------

## KYTRIL

ROCHE	EQ 2MG BASE/10ML	N021238 001	Jun 27, 2001
-------	------------------	-------------	--------------

## TABLET; ORAL

## GRANISETRON HYDROCHLORIDE

BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007
------	-------------	-------------	--------------

## KYTRIL

ROCHE	EQ 1MG BASE **Federal Register determination that product was not withdrawn or discontinued for safety or efficacy reasons**	N020305 001	Mar 16, 1995
	EQ 2MG BASE **Federal Register determination that product was not withdrawn or discontinued for safety or efficacy reasons**	N020305 002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

## TABLET; ORAL

## RAXAR

OTSUKA	EQ 200MG BASE	N020695 001	Nov 06, 1997
	EQ 400MG BASE	N020695 002	May 14, 1998
	EQ 600MG BASE	N020695 003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

## CAPSULE; ORAL

## GRISACTIN

WYETH AYERST	125MG	N050051 002	
	250MG	N050051 001	

## SUSPENSION; ORAL

## GRIFULVIN V

JOHNSON AND JOHNSON	125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050448 001	
---------------------	--	-------------	--

## TABLET; ORAL

## FULVICIN-U/F

ELORAC	250MG	A060569 002	
	500MG	A060569 001	

## GRIFULVIN V

J AND J	125MG	A060618 001	
	250MG	A060618 002	
	500MG	A060618 003	
VALEANT LUXEMBOURG	125MG	A062279 001	
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy	A062279 002	

**DISCONTINUED DRUG PRODUCT LIST**GRISEOFULVIN, MICROCRYSTALLINE

TABLET;ORAL

GRIFULVIN V

reasons\*\*

GRISACTIN

WYETH AYERST

500MG

A060212 001

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG

125MG/5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

A062483 001 Jan 26, 1984

TABLET;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG

500MG

A062279 003

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

ELORAC

125MG

A061996 001

250MG

A061996 002

FULVICIN P/G 165

ELORAC

165MG

A061996 003 Apr 06, 1982

FULVICIN P/G 330

ELORAC

330MG

A061996 004 Apr 06, 1982

GRISACTIN ULTRA

WYETH AYERST

125MG

A062178 001

165MG

A062438 001 Nov 17, 1983

250MG

A062178 002

330MG

A062438 002 Nov 17, 1983

ULTRAGRIS-165

PLIVA

165MG

A062645 001 Jun 30, 1992

ULTRAGRIS-330

PLIVA

330MG

A062646 001 Jun 30, 1992

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

ANI PHARMS INC

EQ 4MG BASE

A074267 001 Jun 01, 1994

EQ 8MG BASE

A074267 002 Jun 01, 1994

SANDOZ

EQ 4MG BASE

A074517 001 Sep 30, 1998

EQ 8MG BASE

A074517 002 Sep 30, 1998

WATSON LABS

EQ 4MG BASE

A074025 001 Feb 28, 1994

EQ 8MG BASE

A074025 002 Feb 28, 1994

WYTENSIN

WYETH AYERST

EQ 4MG BASE

N018587 001 Sep 07, 1982

EQ 8MG BASE

N018587 002 Sep 07, 1982

EQ 16MG BASE

N018587 003 Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL

HYLOREL

PHARMACIA AND UPJOHN

10MG

N018104 001 Dec 29, 1982

25MG

N018104 002 Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS

EQ 10MG SULFATE

A086113 001 Mar 26, 1985

EQ 25MG SULFATE

A086114 001 Mar 26, 1985

ISMELIN

NOVARTIS

EQ 10MG SULFATE

N012329 001

EQ 25MG SULFATE

N012329 002

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ESIMIL

NOVARTIS

10MG;25MG

N013553 001



## DISCONTINUED DRUG PRODUCT LIST

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS

EQ 1MG BASE

A074762 001 Jun 25, 1997

EQ 2MG BASE

A074762 002 Jun 25, 1997

TENEX

PROMIUS PHARMA

EQ 3MG BASE

N019032 003 Nov 07, 1988

HALAZEPAM

TABLET; ORAL

PAXIPAM

SCHERING

20MG

N017736 003

40MG

N017736 004

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

RANBAXY

0.1%

N018234 001

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB

0.025%

N018125 001

SOLUTION; TOPICAL

HALOG

RANBAXY

0.1%

N017823 001

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

G AND W LABS INC

0.05%

A077109 001 Jun 14, 2005

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

ORTHO MCNEIL

0.5MG

N015921 001

1MG

N015921 002

2MG

N015921 003

5MG

N015921 004

10MG

N015921 005

20MG

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

CYCLE PHARMS LTD

0.5MG

A071128 001 Feb 17, 1987

1MG

A071129 001 Feb 17, 1987

5MG

A071131 001 Feb 17, 1987

10MG

A071132 001 May 12, 1987

20MG

A071133 001 May 12, 1987

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

2MG

A071218 001 Dec 04, 1986

5MG

A071219 001 Dec 04, 1986

10MG

A071220 001 Jul 07, 1987

20MG

A071221 001 Jul 07, 1987

LEDERLE

0.5MG

A072727 001 Sep 19, 1989

1MG

A072728 001 Sep 19, 1989

2MG

A072729 001 Sep 19, 1989

5MG

A072730 001 Sep 19, 1989

10MG

A072731 001 Sep 19, 1989

20MG

A072732 001 Sep 19, 1989

MUTUAL PHARM

0.5MG

A071156 001 Jan 02, 1987

1MG

A071157 001 Jan 02, 1987

2MG

A071172 001 Jan 02, 1987

5MG

A071212 001 Jan 07, 1988

10MG

A071173 001 Jan 07, 1988

20MG

A071177 001 Jan 07, 1988

PAR PHARM

20MG

A071328 001 Jul 20, 1987

PUREPAC PHARM

0.5MG

A071071 001 Nov 03, 1986

## DISCONTINUED DRUG PRODUCT LIST

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROXANE	2MG	A071130	001	Feb 17, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071233	001	Nov 03, 1986
	1MG	A071234	001	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071236	001	Nov 03, 1986
	10MG	A071237	001	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987
HALOPERIDOL INTENSOL				
CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988

INJECTABLE; INJECTION

HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187	001	Jan 20, 1987
CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516	001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517	001	Feb 25, 1993
SANDOZ	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802	001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801	001	Dec 14, 1987

**DISCONTINUED DRUG PRODUCT LIST**HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

	EQ 5MG BASE/ML	A070864 001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713 001	May 17, 1988
	EQ 5MG BASE/ML	A070714 001	May 17, 1988
	EQ 5MG BASE/ML	A070744 001	May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536 001	Nov 02, 1995
----------------------	----------------	-------------	--------------

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016942 001	
-----------------	----	-------------	--

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016943 001	
-----------------	----	-------------	--

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST	99.99%	N011338 001	
--------------	--------	-------------	--

HALOTHANE

BH	99.99%	A084977 001	
----	--------	-------------	--

HALOCARBON	99.99%	A080810 001	
------------	--------	-------------	--

HOSPIRA	99.99%	A083254 001	
---------	--------	-------------	--

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US	25,000 UNITS/ML	N018237 001	
-------------------	-----------------	-------------	--

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA	100 UNITS/ML	N005264 010	
INTL MEDICATION	10 UNITS/ML	A086357 001	
	500 UNITS/ML	A086357 002	
LUITPOLD	10 UNITS/ML	A089063 001	Oct 09, 1985
	100 UNITS/ML	A089064 001	Oct 09, 1985
PARKE DAVIS	10 UNITS/ML	N017346 006	
SMITH AND NEPHEW	10 UNITS/ML	A087904 001	Apr 20, 1983
	10 UNITS/ML	A087958 001	Apr 20, 1983
	10 UNITS/ML	A088458 001	Jul 26, 1984
	10 UNITS/ML	A088580 001	Oct 25, 1984
	100 UNITS/ML	A087906 001	Apr 20, 1983
	100 UNITS/ML	A087959 001	Apr 20, 1983
	100 UNITS/ML	A088460 001	Jul 26, 1984
	100 UNITS/ML	A088581 001	Oct 25, 1984
SOLOPAK	10 UNITS/ML	A087903 001	Apr 20, 1983
	10 UNITS/ML	A088457 001	Oct 25, 1984
	100 UNITS/ML	A087905 001	Apr 20, 1983
	100 UNITS/ML	A088459 001	Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM	1,000 UNITS/ML	N017033 001	
	1,000 UNITS/ML	N017979 001	
	5,000 UNITS/ML	N017979 003	
	10,000 UNITS/ML	N017979 002	
AKORN	1,000 UNITS/ML	N017486 001	
	5,000 UNITS/ML	N017486 002	
	10,000 UNITS/ML	N017486 003	
	20,000 UNITS/ML	N017486 004	
	40,000 UNITS/ML	N017486 005	
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130 001	
	5,000 UNITS/ML	N017130 002	
	10,000 UNITS/ML	N017130 003	
	20,000 UNITS/ML	N017130 004	
DELL LABS	1,000 UNITS/ML	N017540 001	
	5,000 UNITS/ML	N017540 002	
	10,000 UNITS/ML	N017540 003	
	20,000 UNITS/ML	N017540 004	
	40,000 UNITS/ML	N017540 005	
EUROHLTH INTL SARL	1,000 UNITS/ML	N017007 001	

## DISCONTINUED DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	2,500 UNITS/ML	N017007 007	
	5,000 UNITS/ML	N017007 002	
	5,000 UNITS/0.5ML	N017007 010	
	5,000 UNITS/0.5ML	N017037 013	Apr 07, 1986
	7,500 UNITS/ML	N017007 003	
	10,000 UNITS/ML	N017007 004	
	15,000 UNITS/ML	N017007 005	
	20,000 UNITS/ML	N017007 006	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651 005	
	5,000 UNITS/ML	N017029 002	
	10,000 UNITS/ML	N017651 003	
	20,000 UNITS/ML	N017651 008	
HOSPIRA	2,500 UNITS/ML	A088099 001	Apr 28, 1983
	10,000 UNITS/ML	A040095 001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521 001	
	10,000 UNITS/ML	N005521 002	
	20,000 UNITS/ML	N005521 004	
LUITPOLD	1,000 UNITS/ML	A087452 001	Oct 31, 1983
ORGANON USA INC	1,000 UNITS/ML	N000552 008	
	5,000 UNITS/ML	N000552 009	
	10,000 UNITS/ML	N000552 010	
PARKE DAVIS	1,000 UNITS/ML	N017346 001	
	5,000 UNITS/ML	N017346 002	
	7,500 UNITS/ML	N017346 003	
	10,000 UNITS/ML	N017346 004	
	20,000 UNITS/ML	N017346 005	
PHARM SPEC	1,000 UNITS/ML	N017780 001	
	5,000 UNITS/ML	N017780 002	
	10,000 UNITS/ML	N017780 003	
	20,000 UNITS/ML	N017780 004	
	40,000 UNITS/ML	N017780 005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570 001	
	5,000 UNITS/ML	N004570 002	
	10,000 UNITS/ML	N004570 003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239 001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043 001	
	5,000 UNITS/ML	A087077 001	
	5,000 UNITS/0.5ML	A087395 001	
	10,000 UNITS/ML	A087107 001	
	10,000 UNITS/0.5ML	A087363 001	
WATSON LABS	1,000 UNITS/ML	N017064 002	
	2,500 UNITS/ML	N017064 015	
	3,000 UNITS/ML	N017064 016	
	4,000 UNITS/ML	N017064 017	
	5,000 UNITS/ML	N017064 003	
	6,000 UNITS/ML	N017064 018	
	7,500 UNITS/ML	N017064 019	
	10,000 UNITS/ML	N017064 004	
	20,000 UNITS/ML	N017064 005	
	40,000 UNITS/ML	N017064 006	
WATSON LABS INC	1,000 UNITS/ML	A040007 001	Jun 07, 1996
	1,000 UNITS/ML	A040008 001	Oct 10, 1995
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130 001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042 001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%			
HOSPIRA	10,000 UNITS/100ML	N018911 006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%			
HOSPIRA	10,000 UNITS/100ML	N018911 001	Jan 30, 1985
	10,000 UNITS/100ML	N018916 005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%			
HOSPIRA	10,000 UNITS/100ML	N018911 003	Jan 30, 1985
	10,000 UNITS/100ML	N018916 002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911 007	Jan 30, 1985

## DISCONTINUED DRUG PRODUCT LIST

HEPARIN SODIUM

## INJECTABLE; INJECTION

HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS	IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.45%			
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
WATSON LABS INC	1,000 UNITS/ML	A089464	001	Jun 03, 1986
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986
PANHEPRIN				
HOSPIRA	1,000 UNITS/ML	N005264	004	

**DISCONTINUED DRUG PRODUCT LIST**HEPARIN SODIUM

INJECTABLE; INJECTION

PANHEPRIN

5,000 UNITS/ML	N005264 006
10,000 UNITS/ML	N005264 007
20,000 UNITS/ML	N005264 008
40,000 UNITS/ML	N005264 009

SODIUM HEPARIN

ABRAXIS PHARM

5,000 UNITS/ML	N017033 002
10,000 UNITS/ML	N017033 003
20,000 UNITS/ML	N017033 004

BAXTER HLTHCARE

1,000 UNITS/ML	N017036 001	Mar 04, 1988
----------------	-------------	--------------

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL

EQ 112.5MG AMPICIL/ML	A061398 001
EQ 112.5MG AMPICIL/5ML	N050060 001
EQ 112.5MG AMPICIL/ML	N050060 003
EQ 225MG AMPICIL/5ML	A061398 002

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K

BRISTOL

EQ 225MG AMPICIL	A061396 001
EQ 450MG AMPICIL	A061396 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL

VESTAL LABS

0.23%	N017424 001
-------	-------------

TURGEX

XTTRIUM

3%	N018375 001
----	-------------

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS

3%	N017411 001
----	-------------

PHISOHEX

SANOFI AVENTIS US

3%	N008402 001
----	-------------

SOY-DOME

BAYER PHARMS

3%	N017405 001
----	-------------

TURGEX

XTTRIUM

3%	N019055 001	Nov 30, 1984
----	-------------	--------------

SOAP; TOPICAL

GAMOPHEN

ARBROOK

2%	N006270 003
----	-------------

SOLUTION; TOPICAL

DIAL

DIAL

0.25%	N017421 002
-------	-------------

GERMA-MEDICA

HUNTINGTON LABS

1%	N017412 001
----	-------------

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%	N017412 002
-------	-------------

SEPTI-SOFT

CALGON

0.25%	N017460 001
-------	-------------

SEPTISOL

VESTAL LABS

0.25%	N017423 001
-------	-------------

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG	N017452 001
-------	-------------

HEXASCRUB

PROF DSPLS

3%	N018363 001
----	-------------

PHISO-SCRUB

SANOFI AVENTIS US

3%	N017446 001
----	-------------

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG	N017413 001
-------	-------------

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN

MEDPOINTE PHARM HLC

20MG/ML	N009789 003
---------	-------------

**DISCONTINUED DRUG PRODUCT LIST**HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL

ABBVIE	25MG	N010599	001
--------	------	---------	-----

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAIN

MERCK	5%	N008472	001
-------	----	---------	-----

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

LILLY	EQ 0.1MG BASE/ML	N000734	003
	EQ 0.2MG BASE/ML	N000734	002
	EQ 1MG BASE/ML	N000734	001

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

SHIRE

EQ 0.2MG BASE/ML	N019836	001	Dec 24, 1991
EQ 0.5MG BASE/ML	N019836	002	Dec 24, 1991
EQ 1MG BASE/ML	N019836	003	Dec 24, 1991

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA	10MG	A086308	001
----------------	------	---------	-----

HOMAPIN-5

MISSION PHARMA	5MG	A086309	001
----------------	-----	---------	-----

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA	3MG	A086310	001
----------------	-----	---------	-----

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

ENDO PHARMS	1.5MG/5ML; 5MG/5ML	N005213	002	Jul 26, 1988
-------------	--------------------	---------	-----	--------------

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS	1.5MG/5ML; 5MG/5ML	A040285	001	Jul 19, 1999
----------------------	--------------------	---------	-----	--------------

HYDROPANE

HALSEY	1.5MG/5ML; 5MG/5ML	A088066	001	Jun 28, 1985
--------	--------------------	---------	-----	--------------

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH	1.5MG; 5MG	A040295	001	Dec 01, 2000
-------------------	------------	---------	-----	--------------

HYCODAN

ENDO PHARMS	1.5MG; 5MG	N005213	001	Jul 26, 1988
-------------	------------	---------	-----	--------------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

AKORN INC	150 UNITS/ML	N021716	001	Oct 25, 2005
-----------	--------------	---------	-----	--------------

VITRASE

BAUSCH AND LOMB	6,200 UNITS/VIAL	N021640	001	May 05, 2004
-----------------	------------------	---------	-----	--------------

WYDASE

BAXTER HLTHCARE	150 UNITS/ML	N006343	002
-----------------	--------------	---------	-----

150 UNITS/VIAL **Federal Register	N006343	006
-----------------------------------	---------	-----

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

1,500 UNITS/VIAL **Federal Register	N006343	005
-------------------------------------	---------	-----

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

NOVARTIS	20MG/ML	N008303	003
----------	---------	---------	-----

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM	20MG/ML	A089532	001	Aug 11, 1987
---------------	---------	---------	-----	--------------

SMITH AND NEPHEW	20MG/ML	A088518	001	Apr 20, 1984
------------------	---------	---------	-----	--------------

SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985
---------	---------	---------	-----	--------------

TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000
-----------------	---------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

APRESOLINE

NOVARTIS	10MG	N008303	004	
	25MG	N008303	001	
	50MG	N008303	002	
	100MG	N008303	005	

DRALZINE

TEVA	25MG	A084301	001	
------	------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984
	50MG	A088649	001	Oct 18, 1984
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010
	25MG	A040858	002	Feb 26, 2010
	50MG	A040858	003	Feb 26, 2010
	100MG	A040858	004	Feb 26, 2010
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	
IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	10MG	A089359	001	Jul 25, 1986
	25MG	A084106	002	
	25MG	A089258	001	May 05, 1986
	50MG	A084107	002	
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SANDOZ	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
TG UNITED LABS	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS	25MG; 25MG	A084735	001	
	50MG; 50MG	A084810	001	
	100MG; 50MG	A084811	001	

HYDRA-ZIDE

PAR PHARM	100MG; 50MG	A088961	001	Oct 21, 1985
-----------	-------------	---------	-----	--------------



## DISCONTINUED DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

## CAPSULE; ORAL

## HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG; 25MG	A087608	001	Feb 08, 1982
	50MG; 50MG	A087213	001	Feb 08, 1982
	100MG; 50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG; 25MG	A089200	001	Feb 09, 1987
	50MG; 50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG; 25MG	A085457	001	Mar 04, 1982
	50MG; 50MG	A085446	001	Mar 04, 1982
	100MG; 50MG	A085440	001	Mar 04, 1982
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50				
IVAX PHARMS	100MG; 50MG	A088358	001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25				
IVAX PHARMS	25MG; 25MG	A088356	001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50				
IVAX PHARMS	50MG; 50MG	A088357	001	Apr 10, 1984

## TABLET; ORAL

## APRESOLINE-ESIDRIX

NOVARTIS	25MG; 15MG	N012026	002	
----------	------------	---------	-----	--

## HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG; 15MG	A085827	001	
-------------	------------	---------	-----	--

## HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG; 15MG	A085373	001	
-------------	------------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

## TABLET; ORAL

## CAM-AP-ES

TG UNITED LABS	25MG; 15MG; 0.1MG	A084897	001	
----------------	-------------------	---------	-----	--

## HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS	25MG; 15MG; 0.1MG	A084291	001	
----------------------	-------------------	---------	-----	--

## HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN	25MG; 15MG; 0.1MG	A087085	001	
-------	-------------------	---------	-----	--

## HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	25MG; 15MG; 0.1MG	A085771	001	
-------------	-------------------	---------	-----	--

## HYDRAP-ES

SANDOZ	25MG; 15MG; 0.1MG	A084876	001	
--------	-------------------	---------	-----	--

## HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS	25MG; 15MG; 0.1MG	A083770	001	
-------------	-------------------	---------	-----	--

## HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS	25MG; 15MG; 0.1MG	A083877	001	
----------------------	-------------------	---------	-----	--

## RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MUTUAL PHARM	25MG; 15MG; 0.1MG	A088570	001	Apr 10, 1984
--------------	-------------------	---------	-----	--------------

SOLVAY	25MG; 15MG; 0.1MG	A088376	001	Oct 28, 1983
--------	-------------------	---------	-----	--------------

WATSON LABS	25MG; 15MG; 0.1MG	A085549	001	
-------------	-------------------	---------	-----	--

	25MG; 15MG; 0.1MG	A087556	001	
--	-------------------	---------	-----	--

## RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE	25MG; 15MG; 0.1MG	A087709	001	May 13, 1982
---------	-------------------	---------	-----	--------------

## SER-A-GEN

SOLVAY	25MG; 15MG; 0.1MG	A087210	001	
--------	-------------------	---------	-----	--

## SER-AP-ES

NOVARTIS	25MG; 15MG; 0.1MG	N012193	005	
----------	-------------------	---------	-----	--

## UNIPRES

SOLVAY	25MG; 15MG; 0.1MG	A085893	001	
--------	-------------------	---------	-----	--

	25MG; 15MG; 0.1MG	A086298	001	
--	-------------------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE; RESERPINE

## TABLET; ORAL

## DRALSERP

SANDOZ	25MG; 0.1MG	A084617	001	
--------	-------------	---------	-----	--

## SERPASIL-APRESOLINE

NOVARTIS	25MG; 0.1MG	N009296	004	
----------	-------------	---------	-----	--

	50MG; 0.2MG	N009296	002	
--	-------------	---------	-----	--

HYDROCHLOROTHIAZIDE

## CAPSULE; ORAL

## HYDROCHLOROTHIAZIDE

HIKMA INTL PHARMS	12.5MG	A077885	001	Nov 26, 2007
-------------------	--------	---------	-----	--------------

## SOLUTION; ORAL

## HYDROCHLOROTHIAZIDE

MORTON GROVE	50MG/5ML	A089661	001	Jun 20, 1988
--------------	----------	---------	-----	--------------

ROXANE	50MG/5ML	A088587	001	Jul 02, 1984
--------	----------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE INTENSOL

ROXANE 100MG/ML

A088588 001 Jul 02, 1984

TABLET; ORAL

ESIDRIX

NOVARTIS

25MG

N011793 005

50MG

N011793 008

100MG

N011793 009

HYDRO-D

HALSEY

25MG

A086504 001

50MG

A083891 002

HYDROCHLOROTHIAZIDE

ABC HOLDING

50MG

A085672 001

ACTAVIS ELIZABETH

25MG

A085054 002

50MG

A085208 001

ALRA

25MG

A086369 001

50MG

A083554 001

ASCOT

25MG

A087539 001 Feb 03, 1982

50MG

A087540 001 Feb 03, 1982

BARR

50MG

A084771 001

DAVA PHARMS INC

100MG

A087060 001

ELKINS SINN

50MG

A085152 002

HEATHER

50MG

A084135 001

HIKMA PHARMS LLC

25MG

A084878 002 Jul 12, 2006

IMPAX LABS

25MG

A084029 001

50MG

A083607 002

100MG

A085098 001

INWOOD LABS

25MG

A084776 001

25MG

A085067 001

50MG

A084776 002

IVAX SUB TEVA PHARMS

50MG

A084658 001

100MG

A085022 001

MAST MM

25MG

A086192 001

50MG

A086192 002

MUTUAL PHARM

25MG

A083972 001

50MG

A083972 002

100MG

A083972 003

MYLAN

25MG

A084880 001

50MG

A085112 001

PVT FORM

50MG

A086597 001

ROXANE

25MG

A085004 001

50MG

A084536 002

50MG

A085005 001

SANDOZ

25MG

A083899 001

25MG

A087565 001 Mar 09, 1982

50MG

A084912 001

50MG

A085219 001

SOLVAY

25MG

A085323 001

SUPERPHARM

25MG

A088827 001 Dec 28, 1984

50MG

A088828 001 Dec 28, 1984

100MG

A088829 001 Dec 28, 1984

TEVA

25MG

A088924 001 Feb 07, 1985

50MG

A088923 001 Feb 07, 1985

TG UNITED LABS

25MG

A085683 001

50MG

A083965 001

USL PHARMA

25MG

A087827 001 Apr 19, 1982

50MG

A087752 001 Apr 19, 1982

VANGARD

25MG

A087638 001

50MG

A087610 001

WARNER CHILCOTT

25MG

A087586 001 May 03, 1982

50MG

A087587 001 May 03, 1982

WATSON LABS

25MG

A081189 001 Jan 24, 1992

25MG

A083458 001

25MG

A085232 002

50MG

A083232 001

50MG

A083456 001

50MG

A085233 001

50MG

A086087 001

50MG

A086594 001

100MG

A081190 001 Jan 24, 1992

100MG

A085099 001

## DISCONTINUED DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	100MG	A087002 001
WEST WARD	25MG	A084899 001
WHITEWORTH TOWN PLSN	25MG	A083809 002
	50MG	A083809 001
	100MG	A085347 001
HYDRODIURIL		
MERCK	25MG	N011835 003
	50MG	N011835 006
	100MG	N011835 007
ORETIC		
ABBVIE	25MG	N011971 001
ZIDE		
SOLVAY	50MG	A083925 001

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

SANOFI AVENTIS US	12.5MG;75MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758 001	Sep 30, 1997
	25MG;300MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758 004	Mar 15, 2005

IRBESARTAN AND HYDROCHLOROTHIAZIDE

TEVA	25MG;300MG		A077369 003	Mar 30, 2012
------	------------	--	-------------	--------------

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING	25MG;100MG		N019046 001	Apr 06, 1987
	25MG;200MG		N019046 002	Apr 06, 1987
	25MG;300MG		N019046 003	Apr 06, 1987
	25MG;400MG		N019046 004	Apr 06, 1987
TRANDATE HCT				
GLAXOSMITHKLINE	25MG;100MG		N019174 001	Apr 10, 1987
	25MG;200MG		N019174 002	Apr 10, 1987
	25MG;300MG		N019174 003	Apr 10, 1987
	25MG;400MG		N019174 004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ	12.5MG;10MG		A075926 001	Jul 01, 2002
	12.5MG;20MG		A075926 002	Jul 01, 2002
	25MG;20MG		A075926 003	Jul 01, 2002
TEVA	12.5MG;10MG		A075869 001	Jul 01, 2002
	12.5MG;20MG		A075869 002	Jul 01, 2002
	25MG;20MG		A075869 003	Jul 01, 2002
PRINZIDE				
MERCK	12.5MG;10MG		N019778 003	Nov 18, 1993
	12.5MG;20MG		N019778 001	Feb 16, 1989
	25MG;20MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019778 002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

WATSON LABS	12.5MG;50MG		A200180 001	Jan 12, 2011
	12.5MG;100MG		A200180 002	Jan 12, 2011
	25MG;100MG		A200180 003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK	15MG;250MG		N013402 001
ALDORIL 25			
MERCK	25MG;250MG		N013402 002
ALDORIL D30			
MERCK	30MG;500MG		N013402 003

**DISCONTINUED DRUG PRODUCT LIST**HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL D50

MERCK

50MG; 500MG

N013402 004

METHYLDOPA AND HYDROCHLOROTHIAZIDE

DAVA PHARMS INC

15MG; 250MG

A072507 001 Jun 02, 1989

25MG; 250MG

A072508 001 Jun 02, 1989

30MG; 500MG

A072509 001 Jun 02, 1989

50MG; 500MG

A072510 001 Jun 02, 1989

IVAX SUB TEVA PHARMS

15MG; 250MG

A071458 001 Mar 08, 1988

25MG; 250MG

A071459 001 Mar 08, 1988

30MG; 500MG

A071460 001 Mar 08, 1988

50MG; 500MG

A071461 001 Mar 08, 1988

PAR PHARM

15MG; 250MG

A070616 001 Feb 02, 1987

25MG; 250MG

A070612 001 Feb 02, 1987

30MG; 500MG

A070613 001 Feb 02, 1987

50MG; 500MG

A070614 001 Feb 02, 1987

PARKE DAVIS

15MG; 250MG

A071897 001 Nov 23, 1987

25MG; 250MG

A071898 001 Nov 23, 1987

30MG; 500MG

A071899 001 Nov 23, 1987

50MG; 500MG

A071900 001 Nov 23, 1987

PUREPAC PHARM

15MG; 250MG

A070853 001 Oct 08, 1986

25MG; 250MG

A070688 001 Apr 24, 1986

30MG; 500MG

A070854 001 Oct 08, 1986

50MG; 500MG

A070689 001 Apr 24, 1986

SANDOZ

15MG; 250MG

A070182 001 Jan 15, 1986

15MG; 250MG

A070829 001 Mar 09, 1987

25MG; 250MG

A070183 001 Jan 15, 1986

25MG; 250MG

A070830 001 Mar 09, 1987

30MG; 500MG

A070543 001 Jan 15, 1986

50MG; 500MG

A070544 001 Jan 15, 1986

TEVA

15MG; 250MG

A071819 001 Apr 08, 1988

25MG; 250MG

A071820 001 Apr 08, 1988

30MG; 500MG

A071821 001 Apr 08, 1988

50MG; 500MG

A071822 001 Apr 08, 1988

WATSON LABS

15MG; 250MG

A070365 001 Mar 19, 1986

15MG; 250MG

A070958 001 Feb 06, 1989

15MG; 250MG

A071920 001 Aug 29, 1988

25MG; 250MG

A070366 001 Apr 16, 1986

25MG; 250MG

A070959 001 Jan 19, 1989

25MG; 250MG

A071921 001 Aug 29, 1988

30MG; 500MG

A070367 001 Mar 19, 1986

30MG; 500MG

A071069 001 Jan 19, 1989

30MG; 500MG

A071922 001 Aug 29, 1988

50MG; 500MG

A070368 001 Apr 16, 1986

50MG; 500MG

A070960 001 Feb 06, 1989

50MG; 500MG

A071923 001 Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

US PHARMS HOLDINGS I

50MG; 100MG

N018303 003 Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

PADDOCK LLC

12.5MG; 7.5MG

A090096 001 Sep 25, 2008

12.5MG; 15MG

A090096 002 Sep 25, 2008

25MG; 15MG

A090096 003 Sep 25, 2008

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE

NOVARTIS

25MG; 5MG

N018872 001 Jul 22, 1987

25MG; 10MG

N018872 002 Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST

50MG; 120MG

N019059 002 Jul 03, 1985

INDERIDE LA 160/50

WYETH AYERST

50MG; 160MG

N019059 003 Jul 03, 1985

INDERIDE LA 80/50

WYETH AYERST

50MG; 80MG

N019059 001 Jul 03, 1985

**DISCONTINUED DRUG PRODUCT LIST**HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

## TABLET; ORAL

INDERIDE-40/25				
WYETH PHARMS INC	25MG; 40MG		N018031	001
INDERIDE-80/25				
WYETH PHARMS INC	25MG; 80MG		N018031	002
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE				
DURAMED PHARMS BARR	25MG; 40MG		A071126	001 Mar 02, 1987
	25MG; 80MG		A071127	001 Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
ACTAVIS ELIZABETH	25MG; 40MG		A070851	001 May 15, 1986
	25MG; 80MG		A070852	001 May 15, 1986
ANI PHARMS INC	25MG; 40MG		A070704	001 Oct 01, 1986
	25MG; 80MG		A070705	001 Oct 01, 1986
IVAX SUB TEVA PHARMS	25MG; 40MG		A071552	001 Dec 01, 1988
	25MG; 80MG		A071553	001 Dec 01, 1988
SANDOZ	25MG; 40MG		A071060	001 Aug 26, 1987
	25MG; 80MG		A071061	001 Aug 26, 1987
WARNER CHILCOTT	25MG; 40MG		A071771	001 Jan 26, 1988
	25MG; 80MG		A071772	001 Jan 26, 1988
WATSON LABS	25MG; 40MG		A070301	001 Apr 18, 1986
	25MG; 40MG		A071498	001 Dec 18, 1991
	25MG; 80MG		A070305	001 Apr 18, 1986
	25MG; 80MG		A071501	001 Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

## TABLET; ORAL

H.R.-50				
WHITEWORTH TOWN PLSN	50MG; 0.125MG		A085338	001
HYDRO-RESERP				
ABC HOLDING	50MG; 0.125MG		A084714	002 Jun 29, 1982
HYDRO-SERP "25"				
SANDOZ	25MG; 0.125MG		A084827	001
HYDRO-SERP "50"				
SANDOZ	50MG; 0.125MG		A085213	001
HYDROCHLOROTHIAZIDE W/ RESERPINE				
IVAX SUB TEVA PHARMS	25MG; 0.1MG		A083572	001
	25MG; 0.125MG		A083571	001
	50MG; 0.1MG		A083568	001
	50MG; 0.125MG		A083573	001
PHARMERAL	25MG; 0.125MG		A085421	001
	50MG; 0.125MG		A085420	001
ROXANE	50MG; 0.125MG		A084603	001
WATSON LABS	25MG; 0.125MG		A084466	001
	25MG; 0.125MG		A085317	001
	25MG; 0.125MG		A086330	002
	50MG; 0.125MG		A083666	001
	50MG; 0.125MG		A084467	001
	50MG; 0.125MG		A086331	001
HYDROPRES 25				
MERCK	25MG; 0.125MG		N011958	002
HYDROPRES 50				
MERCK	50MG; 0.125MG		N011958	003
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG; 0.125MG		A084580	001
	50MG; 0.125MG		A084579	001
SANDOZ	50MG; 0.125MG		A088200	001 Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG; 0.125MG		A088189	001 May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG; 0.1MG		N011878	003
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG; 0.1MG		N011878	005

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

## TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE				
ASCOT	25MG; 25MG		A088025	001 Nov 23, 1984
MUTUAL PHARM	25MG; 25MG		A087267	001
PUREPAC PHARM	25MG; 25MG		A087999	001 Nov 06, 1985
SANDOZ	25MG; 25MG		A086881	001
SUPERPHARM	25MG; 25MG		A089137	001 Aug 26, 1985
WATSON LABS	25MG; 25MG		A087398	001

**DISCONTINUED DRUG PRODUCT LIST**HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

IVAX PHARMS	25MG; 25MG	A087004 002	May 24, 1982
LEDERLE	25MG; 25MG	A087511 001	
PARKE DAVIS	25MG; 25MG	A087948 001	Feb 22, 1983
PUREPAC PHARM	25MG; 25MG	A088054 001	Aug 18, 1983
UPSHER SMITH	25MG; 25MG	A087553 001	
USL PHARMA	25MG; 25MG	A087651 001	
VANGARD	25MG; 25MG	A087655 001	
WATSON LABS	25MG; 25MG	A085974 001	
	25MG; 25MG	A086026 001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK	25MG; 10MG	N018061 001	
-------	------------	-------------	--

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

GLAXOSMITHKLINE LLC	25MG; 50MG	N016042 002	
---------------------	------------	-------------	--

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC	25MG; 37.5MG	A074970 001	Jan 06, 1998
NOVARTIS	25MG; 37.5MG	A074857 001	Sep 09, 1997
VITARINE	25MG; 50MG	A071737 001	Feb 12, 1988

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG; 75MG	A072022 001	Apr 17, 1988
QUANTUM PHARMICS	50MG; 75MG	A071980 001	Apr 17, 1988
WATSON LABS	50MG; 75MG	A071969 001	Apr 17, 1988

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

ALPHARMA US PHARMS	5MG/5ML; 25MG/5ML	A075103 001	Sep 29, 2000
--------------------	-------------------	-------------	--------------

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL

MAGNACORT

PFIZER	0.5%	N010554 001	
--------	------	-------------	--

HYDROCORTISONE

AEROSOL; TOPICAL

AEROSEB-HC

ALLERGAN HERBERT	0.5%	A085805 001	
------------------	------	-------------	--

CREAM; TOPICAL

CORT-DOME

BAYER PHARMS	0.5%	N009585 003	
	1%	N009585 001	

DERMACORT

MONARCH PHARMS	1%	A083011 002	
----------------	----	-------------	--

ELDECORT

VALEANT PHARM INTL	1%	A080459 001	
	2.5%	A084055 001	

FLEXICORT

WESTWOOD SQUIBB	0.5%	A087136 003	Apr 08, 1982
	1%	A087136 002	Apr 08, 1982
	2.5%	A087136 001	Apr 08, 1982

H-CORT

PHARM ASSOC	0.5%	A086823 001	
-------------	------	-------------	--

HC #1

BAYER PHARMS	0.5%	A080438 001	
--------------	------	-------------	--

HC #4

BAYER PHARMS	1%	A080438 002	
--------------	----	-------------	--

HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080482 003	
	1%	A080482 004	

HI-COR

C AND M PHARMA	2.5%	A080483 001	
----------------	------	-------------	--

HYDROCORTISONE

ALPHARMA US PHARMS	2.5%	A089754 001	Feb 01, 1989
ALTANA	0.5%	A080848 002	
	1%	A080848 003	
AMBIX	1%	A086080 001	

## DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

## CREAM; TOPICAL

HYDROCORTISONE	2.5%	A086271	001	
EVERYLIFE	0.5%	A080452	001	
	1%	A080452	002	
G AND W LABS	1%	A084059	001	
INGRAM PHARM	0.5%	A080456	002	
	1%	A080456	003	
IVAX PHARMS	1%	A085733	001	
NASKA	1%	A089706	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084970	002	
	1%	A085026	001	
PHARMADERM	1%	A088845	001	Feb 27, 1986
	2.5%	A089413	001	Dec 16, 1986
PHARMAFAIR	1%	A087838	001	Jul 28, 1982
STIEFEL	1%	A086170	001	
SYOSSET	0.5%	A085527	001	
TARO	0.5%	A086154	001	
	1%	A086155	001	
TEVA	0.5%	A080400	002	
	1%	A080400	003	
	1%	A085191	001	
	2.5%	A080400	004	
TOPIDERM	1%	A089273	001	Feb 17, 1989
USL PHARMA	1%	A088027	001	Sep 27, 1983
	2.5%	A088029	001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496	002	
HYTONE				
VALEANT INTL	1%	A080472	003	
	2.5%	A080472	004	
NOGENIC HC				
IVAX PHARMS	1%	A087427	001	Apr 04, 1988
NUTRACORT				
DOW PHARM	0.5%	A080442	002	
	1%	A080442	003	
PENECORT				
ALLERGAN HERBERT	1%	A088216	001	Jun 06, 1984
PROTOCORT				
MONARCH PHARMS	1%	A083011	001	
SYNACORT				
MEDICIS	0.5%	A087459	001	
GEL; TOPICAL				
NUTRACORT				
HEALTHPOINT	1%	A084698	001	
PENECORT				
ALLERGAN HERBERT	1%	A088215	001	Jun 06, 1984
INJECTABLE; INJECTION				
CORTEF				
PHARMACIA AND UPJOHN	50MG/ML	N009864	001	
LOTION; TOPICAL				
ACTICORT				
BAKER NORTON	1%	A086535	001	
ALA-CORT				
CROWN LABS	1%	A083201	001	
BALNEOL-HC				
SOLVAY	1%	A088041	001	Dec 03, 1982
BETA-HC				
BETA DERMAC	1%	A089495	001	Jan 25, 1988
CETACORT				
DOW PHARM	0.5%	A080426	002	
	1%	A080426	001	
CORT-DOME				
BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	
DERMACORT				
SOLVAY	0.5%	A084573	002	
	1%	A086462	001	
EPICORT				
BLULINE	0.5%	A083219	002	
GLYCORT				
HERAN	1%	A087489	001	Oct 03, 1983

## DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

## LOTION; TOPICAL

## H-CORT

PHARM ASSOC	0.5%	A086824	001	
-------------	------	---------	-----	--

## HYDROCORTISONE

ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
--------------------	------	---------	-----	--------------

	1%	A087315	001	Jun 07, 1982
--	----	---------	-----	--------------

MERICON	0.5%	A085282	001	
---------	------	---------	-----	--

	1%	A085282	002	Feb 26, 1987
--	----	---------	-----	--------------

NASKA	1%	A089705	001	Apr 25, 1988
-------	----	---------	-----	--------------

PERRIGO NEW YORK	0.5%	A085662	001	
------------------	------	---------	-----	--

	1%	A085663	001	
--	----	---------	-----	--

TARO	1%	A089024	001	Feb 12, 1986
------	----	---------	-----	--------------

## HYTONE

VALEANT INTL	1%	A080473	003	
--------------	----	---------	-----	--

	2.5%	A080473	004	Nov 30, 1982
--	------	---------	-----	--------------

## NUTRACORT

DOW PHARM	0.5%	A080443	002	
-----------	------	---------	-----	--

	1%	A080443	003	
--	----	---------	-----	--

## STIE-CORT

PERRIGO CO	1%	A089066	001	Nov 25, 1985
------------	----	---------	-----	--------------

## OINTMENT; TOPICAL

## CORTRIL

PFIZER GLOBAL	1%	N009176	001	
---------------	----	---------	-----	--

	2.5%	N009176	002	
--	------	---------	-----	--

## HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080481	001	
----------------	------	---------	-----	--

	1%	A080481	002	
--	----	---------	-----	--

## HYDROCORTISONE

ALTANA	0.5%	A080489	002	
--------	------	---------	-----	--

	1%	A080489	003	
--	----	---------	-----	--

AMBIX	1%	A086079	001	
-------	----	---------	-----	--

	2.5%	A086272	001	
--	------	---------	-----	--

NASKA	1%	A089704	001	Mar 10, 1988
-------	----	---------	-----	--------------

PERRIGO NEW YORK	0.5%	A084969	003	
------------------	------	---------	-----	--

	1%	A085028	001	
--	----	---------	-----	--

PHARMADERM	1%	A088842	001	Feb 09, 1987
------------	----	---------	-----	--------------

TARO	0.5%	A086256	001	
------	------	---------	-----	--

	2.5%	A040310	001	Dec 29, 2000
--	------	---------	-----	--------------

USL PHARMA	1%	A088061	001	Sep 27, 1983
------------	----	---------	-----	--------------

	2.5%	A088039	001	Sep 27, 1983
--	------	---------	-----	--------------

## HYTONE

DERMIK LABS	1%	A080474	003	
-------------	----	---------	-----	--

	2.5%	A080474	004	
--	------	---------	-----	--

## PENECORT

ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984
------------------	------	---------	-----	--------------

## POWDER; FOR RX COMPOUNDING

## H-CORT

TORCH	100%	A087834	001	Mar 29, 1982
-------	------	---------	-----	--------------

## HYDRO-RX

X GEN PHARMS	100%	A085982	001	
--------------	------	---------	-----	--

## HYDROCORTISONE

PADDOCK LLC	100%	A088082	001	Apr 08, 1983
-------------	------	---------	-----	--------------

## SOLUTION; TOPICAL

## PENECORT

ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984
------------------	----	---------	-----	--------------

## TEXACORT

MISSION PHARMA	1%	A080425	001	
----------------	----	---------	-----	--

## TABLET; ORAL

## CORTRIL

PFIZER	10MG	N009127	005	
--------	------	---------	-----	--

	20MG	N009127	003	
--	------	---------	-----	--

## HYDROCORTISONE

BARR	20MG	A083999	001	
------	------	---------	-----	--

ELKINS SINN	20MG	A080624	001	
-------------	------	---------	-----	--

FERRANTE	10MG	A080568	001	
----------	------	---------	-----	--

	20MG	A080568	002	
--	------	---------	-----	--

IMPAX LABS	20MG	A080781	001	
------------	------	---------	-----	--

INWOOD LABS	20MG	A080732	001	
-------------	------	---------	-----	--

LANNETT	20MG	A085070	001	
---------	------	---------	-----	--

NEXGEN PHARMA INC	20MG	A083140	001	
-------------------	------	---------	-----	--

PANRAY	10MG	N009659	001	
--------	------	---------	-----	--



## DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

## TABLET; ORAL

## HYDROCORTISONE

	20MG	N009659 002	
PARKE DAVIS	20MG	A084243 001	
PUREPAC PHARM	10MG	A084247 003	Aug 31, 1982
	20MG	A080395 001	
	20MG	A084247 002	
ROXANE	10MG	A088539 001	Mar 21, 1984
SANDOZ	20MG	A080642 002	
WATSON LABS	20MG	A080355 001	
WHITEWORTH TOWN PLSN	10MG	A080344 001	
	20MG	A080344 002	
HYDROCORTONE			
MERCK	10MG	N008506 007	
	20MG	N008506 011	

## TABLET; VAGINAL

## CORTRIL

PFIPHARMECS	10MG	N009796 001	
-------------	------	-------------	--

HYDROCORTISONE ACETATE

## CREAM; TOPICAL

## HEMSOL-HC

ABLE	1%	A081274 001	Jun 19, 1992
------	----	-------------	--------------

## HYDROCORTISONE ACETATE

CENCI	1%	A080419 001	Jan 25, 1982
PARKE DAVIS	1%	A089914 001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050 001	
	1%	A086052 001	

## INJECTABLE; INJECTION

## CORTEF ACETATE

PHARMACIA AND UPJOHN	50MG/ML	N009378 002	
----------------------	---------	-------------	--

## CORTRIL

PFIZER	25MG/ML	N009164 001	
--------	---------	-------------	--

## HYDROCORTISONE ACETATE

AKORN	25MG/ML	N009637 001	
	50MG/ML	N009637 002	
BEL MAR	25MG/ML	A083739 001	
	50MG/ML	A083739 002	
WATSON LABS	25MG/ML	A083128 001	
	25MG/ML	A083759 001	
	50MG/ML	A083759 002	
	50MG/ML	A085214 001	

## HYDROCORTONE

MERCK	25MG/ML	N008228 001	
	50MG/ML	N008228 004	

## LOTION; TOPICAL

## DRICORT

INGRAM PHARM	0.5%	A086207 001	
--------------	------	-------------	--

## OINTMENT; OPHTHALMIC

## HYDROCORTISONE ACETATE

FERA PHARMS	0.5%	A080828 001	
-------------	------	-------------	--

## OINTMENT; OPHTHALMIC, OTIC

## HYDROCORTONE

MERCK	1.5%	N009018 003	
-------	------	-------------	--

## OINTMENT; TOPICAL

## CORTEF ACETATE

PHARMACIA AND UPJOHN	1%	N008917 002	
	2.5%	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008917 001

## PASTE; TOPICAL

## ORABASE HCA

COLGATE	0.5%	A083205 001	
---------	------	-------------	--

## POWDER; FOR RX COMPOUNDING

## HYDROCORTISONE ACETATE

X GEN PHARMS	100%	A085981 001	
--------------	------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049	001
	2.5%;EQ 3.5MG BASE/GM	A061049	002

OINTMENT; OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610	001
	1.5%;EQ 3.5MG BASE/GM	A060610	002

OINTMENT; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751	001
	1%;EQ 3.5MG BASE/GM	A060751	002
	2.5%;EQ 3.5MG BASE/GM	A060751	003

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

AKORN	1.5%;EQ 3.5MG BASE/ML	A060188	001
-------	-----------------------	---------	-----

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612	002
	1.5%;EQ 3.5MG BASE/ML	A060612	001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTRIL

PFIZER	1.5%;EQ 5MG BASE/ML	A061016	001
--------	---------------------	---------	-----

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988
----------------	-------	---------	-----	--------------

LOTION; TOPICAL

PRAMOSONE

FERNDAL LABS	0.5%;1%	A083213	002
--------------	---------	---------	-----

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

FOUGERA PHARMS	1%;10%	A080505	001
----------------	--------	---------	-----

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N018795	001	Jan 07, 1983
------------	------	---------	-----	--------------

OINTMENT; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N019106	001	Jul 03, 1984
------------	------	---------	-----	--------------

SOLUTION; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N019819	001	Sep 15, 1988
------------	------	---------	-----	--------------

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900	001
----------------------	------------------	---------	-----

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCK	EQ 50MG BASE/ML	N012052	001
-------	-----------------	---------	-----

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT

EQ 100MG BASE/VIAL	A085928	001	
EQ 100MG BASE/VIAL	A089577	001	Apr 11, 1989
EQ 250MG BASE/VIAL	A089578	001	Apr 11, 1989
EQ 500MG BASE/VIAL	A089579	001	Apr 11, 1989
EQ 1GM BASE/VIAL	A089580	001	Apr 11, 1989

HOSPIRA

EQ 100MG BASE/VIAL	A085929	001
EQ 250MG BASE/VIAL	A085930	001
EQ 500MG BASE/VIAL	A085931	001
EQ 1GM BASE/VIAL	A085932	001

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 100MG BASE/VIAL	A088667	001	Jun 08, 1984
EQ 100MG BASE/VIAL	A088712	001	Jun 08, 1984
EQ 250MG BASE/VIAL	A088668	001	Jun 08, 1984

**DISCONTINUED DRUG PRODUCT LIST**HYDROCORTISONE SODIUM SUCCINATE

## INJECTABLE; INJECTION

## HYDROCORTISONE SODIUM SUCCINATE

	EQ 500MG BASE/VIAL	A088669 001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A088670 001	Jun 08, 1984
BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A086619 001	
	EQ 250MG BASE/VIAL	A087567 001	
	EQ 500MG BASE/VIAL	A087568 001	
	EQ 1GM BASE/VIAL	A087569 001	
INTL MEDICATION	EQ 100MG BASE/VIAL	A087532 001	Mar 19, 1982
WATSON LABS	EQ 100MG BASE/VIAL	A084737 002	
	EQ 100MG BASE/VIAL	A084738 001	
	EQ 250MG BASE/VIAL	A084737 001	
	EQ 500MG BASE/VIAL	A084747 001	
	EQ 1GM BASE/VIAL	A084748 001	

HYDROCORTISONE VALERATE

## CREAM; TOPICAL

## HYDROCORTISONE VALERATE

G AND W LABS INC	0.2%	A074489 001	Aug 12, 1998
WESTCORT			
RANBAXY	0.2%	N017950 001	
OINTMENT; TOPICAL			
HYDROCORTISONE VALERATE			
FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001
WESTCORT			
RANBAXY	0.2%	N018726 001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

## CREAM; TOPICAL

## NEO-CORT-DOME

BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237 006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237 005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## SOLUTION/DROPS; OTIC

## NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394 001	Sep 29, 1982
OTOCORT			
WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730 002	
SUSPENSION/DROPS; OPHTHALMIC			
CORTISPORIN			
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169 001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623 001	Sep 24, 1985
SUSPENSION/DROPS; OTIC			
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617 001	Sep 18, 1985
OTICAIR			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399 001	Nov 18, 1982
OTOBIONE			
SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816 001	
OTOCORT			
ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521 001	Jul 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

## SOLUTION/DROPS; OTIC

## OTOBiotic

SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302 001	
PYOCIDIN			
FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606 001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

## OINTMENT; OPHTHALMIC

## ACHROMYCIN

LEDERLE	1.5%;1%	N050272 001	
---------	---------	-------------	--

HYDROCORTISONE; UREA

## CREAM; TOPICAL

## ALPHADERM

BIOGLAN	1%;10%	A086008 001	
CALMURID HC			
PHARMACIA AND UPJOHN	1%;10%	A083947 001	

## DISCONTINUED DRUG PRODUCT LIST

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

WYETH AYERST

50MG

A083383 001

HYDROFLUMETHIAZIDE

PAR PHARM

50MG

A088850 001 May 31, 1985

WATSON LABS

50MG

A088031 001 Apr 06, 1983

50MG

A088528 001 Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA

50MG; 0.125MG

A088195 001 Oct 26, 1983

WATSON LABS

25MG; 0.125MG

A088127 001 Mar 22, 1983

50MG; 0.125MG

A088110 001 Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS

50MG; 0.125MG

A088932 001 Jan 11, 1985

PAR PHARM

50MG; 0.125MG

A088907 001 Sep 20, 1985

SALUTENSIN

SHIRE

50MG; 0.125MG

N012359 003

SALUTENSIN-DEMI

SHIRE

25MG; 0.125MG

N012359 004

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

PURDUE PHARMA LP

12MG

N021044 001 Sep 24, 2004

16MG

N021044 002 Sep 24, 2004

24MG

N021044 003 Sep 24, 2004

32MG

N021044 004 Sep 24, 2004

INJECTABLE; INJECTION

DILAUDID-HP

PURDUE PHARM PRODS

250MG/VIAL

N019034 002 Aug 04, 1994

HYDROMORPHONE HYDROCHLORIDE

WATSON LABS

10MG/ML

A074317 001 Aug 23, 1995

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS

2MG

A077311 001 Nov 09, 2005

4MG

A077311 002 Nov 09, 2005

8MG

A077311 003 Nov 09, 2005

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCK

1MG/ML

A080778 001

CYANOKIT

SERB SAS

2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM

1MG/ML

A084921 001

WATSON LABS

1MG/ML

A085528 001

HYDROXOMIN

BEL MAR

1MG/ML

A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIE

PHARMICS

1%

N000004 004

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

SANDOZ

200MG

A040150 001 Jan 27, 1996

WATSON LABS

200MG

A040133 001 Nov 30, 1995

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

BRISTOL MYERS SQUIBB

125MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N010347 004

125MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N016911 001

250MG/ML \*\*Federal Register

N010347 002

## DISCONTINUED DRUG PRODUCT LIST

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

250MG/ML \*\*Federal Register

N016911 002

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

HYDROXYPROGESTERONE CAPROATE

ACTAVIS LABS UT INC 125MG/ML

N017439 001

250MG/ML

N017439 002

AKORN 125MG/ML

N018004 001

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US 225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR 250MG

A075143 002 Sep 21, 2000

BARR LABS INC 250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE 500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR 1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE 50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA 25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE 25MG/ML

A085551 001

FRESENIUS KABI USA 25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA 25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR 25MG/ML

A088862 001 Feb 14, 1986

25MG/ML

A089106 001 Feb 14, 1986

50MG/ML

A088881 001 Feb 14, 1986

50MG/ML

A089107 001 Feb 14, 1986

SMITH AND NEPHEW 25MG/ML

A087592 001

SOLOPAK 25MG/ML

A086822 001

25MG/ML

A087591 001

50MG/ML

A087310 001

50MG/ML

A087593 001

50MG/ML

A087595 001

50MG/ML

A087596 001

WATSON LABS 25MG/ML

A085778 001

25MG/ML

A087274 001

50MG/ML

A085779 001

50MG/ML

A087274 002

WYETH AYERST 25MG/ML

A086258 001

50MG/ML

A086258 002

ORGATRAX

ORGANON USA INC 25MG/ML

A087014 001

50MG/ML

A087014 002

VISTARIL

PFIZER 25MG/ML

N011111 001

50MG/ML

N011111 002

SYRUP; ORAL

ATARAX

ROERIG 10MG/5ML

N010485 001

HYDROXYZINE HYDROCHLORIDE

ALPHARMA US PHARMS 10MG/5ML

A088785 001 Feb 03, 1988

KV PHARM 10MG/5ML

A087730 001 Jul 01, 1982

STI PHARMA LLC 10MG/5ML

A086880 001

**DISCONTINUED DRUG PRODUCT LIST**HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

ATARAX

PFIZER	10MG	N010392 001
	25MG	N010392 004
	50MG	N010392 006
	100MG	N010392 005

HYDROXYZINE HYDROCHLORIDE

ABLE	10MG	A040559 001	Jul 22, 2004
	25MG	A040562 001	Jul 22, 2004
	50MG	A040563 001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071 001	Jul 22, 1986
	25MG	A089072 001	Jul 22, 1986
	50MG	A089073 001	Jul 22, 1986
HALSEY	10MG	A089366 001	May 02, 1988
	25MG	A089117 001	May 02, 1988
	50MG	A089396 001	May 02, 1988
IVAX PHARMS	10MG	A087216 001	
	25MG	A087410 001	
	50MG	A087411 001	
KV PHARM	10MG	A087819 001	Jun 23, 1982
	25MG	A087820 001	Jun 23, 1982
	50MG	A087821 001	Jun 23, 1982
	100MG	A087822 001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409 001	Nov 15, 1983
	10MG	A089381 001	May 19, 1986
	25MG	A087857 001	Apr 18, 1983
	25MG	A089382 001	May 19, 1986
	50MG	A087860 001	Apr 18, 1983
	50MG	A089383 001	May 19, 1986
	100MG	A087862 001	Apr 18, 1983
PLIVA	100MG	A081054 001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120 001	Sep 25, 1984
	25MG	A088121 001	Sep 25, 1984
	50MG	A088122 001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540 001	Oct 22, 1985
	25MG	A088551 001	Oct 22, 1985
	50MG	A088529 001	Oct 22, 1985
SANDOZ	10MG	A087246 002	
	10MG	A087869 001	Dec 20, 1982
	25MG	A085247 001	
	25MG	A087870 001	Dec 20, 1982
	50MG	A087245 001	
	50MG	A087871 001	Dec 20, 1982
SUPERPHARM	10MG	A088794 001	Dec 05, 1984
	25MG	A088795 001	Dec 05, 1984
	50MG	A088796 001	Dec 05, 1984
USL PHARMA	10MG	A089121 001	Mar 20, 1986
	25MG	A089122 001	Mar 20, 1986
	50MG	A089123 001	Mar 20, 1986
VINTAGE	10MG	A087602 001	Jan 22, 1982
	25MG	A087603 001	Jan 22, 1982
	50MG	A087604 001	Jan 22, 1982
WATSON LABS	10MG	A081149 001	Mar 18, 1994
	10MG	A086827 001	
	10MG	A088348 001	Sep 15, 1983
	25MG	A081150 001	Mar 18, 1994
	25MG	A086829 001	
	25MG	A088349 001	Sep 15, 1983
	50MG	A081151 001	Mar 18, 1994
	50MG	A086836 001	
	50MG	A088350 001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"

TEVA	EQ 25MG HCL	A088713 001	Mar 04, 1985
------	-------------	-------------	--------------

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR	EQ 25MG HCL	A088593 001	Feb 29, 1984
	EQ 50MG HCL	A088594 001	Feb 29, 1984
	EQ 100MG HCL	A088595 001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761 001	Mar 05, 1982
	EQ 50MG HCL	A087760 001	Mar 05, 1982

## DISCONTINUED DRUG PRODUCT LIST

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

PAR PHARM	EQ 25MG HCL	A087656 001	Jun 11, 1982
	EQ 25MG HCL	A089145 001	Mar 17, 1986
	EQ 50MG HCL	A087657 001	Jun 11, 1982
	EQ 50MG HCL	A089146 001	Mar 17, 1986
	EQ 100MG HCL	A087658 001	Jun 11, 1982
SANDOZ	EQ 25MG HCL	A081127 001	Jun 28, 1991
	EQ 50MG HCL	A081128 001	Jun 28, 1991
	EQ 100MG HCL	A081129 001	Jun 28, 1991
SUPERPHARM	EQ 25MG HCL	A089031 001	Jan 02, 1987
	EQ 50MG HCL	A089032 001	Jan 02, 1987
	EQ 100MG HCL	A089033 001	Jan 02, 1987
VANGARD	EQ 25MG HCL	A088392 001	Sep 19, 1983
	EQ 50MG HCL	A088393 001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165 001	Jul 31, 1991
	EQ 25MG HCL	A086698 001	
	EQ 25MG HCL	A086840 001	Jul 01, 1982
	EQ 50MG HCL	A086695 001	
	EQ 50MG HCL	A086705 001	Jul 01, 1982
	EQ 50MG HCL	A087767 001	Aug 16, 1982
	EQ 100MG HCL	A086697 001	
	EQ 100MG HCL	A086728 001	Oct 05, 1982
	EQ 100MG HCL	A087790 001	Aug 16, 1982
VISTARIL			
PFIZER	EQ 100MG HCL	N011459 006	
SUSPENSION; ORAL			
VISTARIL			
PFIZER	EQ 25MG HCL/5ML	N011795 001	

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

HOFFMANN LA ROCHE	EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021455 001	May 16, 2003
-------------------	--	-------------	--------------

IBUPROFEN

CAPSULE; ORAL

MIDOL

BAYER	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A070626 001	Sep 02, 1987
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A071002 001	Sep 02, 1987
SOLUTION; INTRAVENOUS			
CALDOLOR			
CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009
SUSPENSION; ORAL			
CHILDREN'S ADVIL			
WYETH CONS	100MG/5ML	N019833 002	Sep 19, 1989
IBU			
ABBOTT	100MG/5ML	N019784 001	Dec 18, 1989
MOTRIN			
MCNEIL CONSUMER	100MG/5ML	N019842 001	Sep 19, 1989
SUSPENSION/DROPS; ORAL			
MOTRIN			
MCNEIL	40MG/ML	N020476 001	May 25, 1995
TABLET; ORAL			
ACHES-N-PAIN			
LEDERLE	200MG	A071065 001	May 28, 1987
CAP-PROFEN			
PERRIGO	200MG	A072097 001	Dec 08, 1987
IBU			
BASF	400MG	A070083 001	Feb 22, 1985
	400MG	N018197 001	
	600MG	A070088 001	Feb 08, 1985
	600MG	A070099 001	Mar 29, 1985
	800MG	A070745 001	Jul 23, 1986

## DISCONTINUED DRUG PRODUCT LIST

IBUPROFEN

TABLET; ORAL

IBU-TAB

ALRA 800MG A071965 001 Aug 11, 1988

IBUPRIN

PLIVA 200MG A071773 001 Jul 16, 1987

IBUPROFEN

ABBOTT 600MG A070556 001 Jun 14, 1985

800MG A071264 001 Jul 25, 1986

ANI PHARMS INC 200MG A071144 001 Jan 20, 1987

200MG A072901 001 Dec 19, 1991

200MG A072903 001 Dec 19, 1991

CONTRACT PHARMACAL 200MG A073691 001 Feb 25, 1994

HALSEY 200MG A071027 001 Sep 29, 1987

300MG A071028 001 Mar 23, 1987

400MG A071029 001 Mar 23, 1987

600MG A071030 001 Mar 23, 1987

800MG A072137 001 Feb 05, 1988

IVAX SUB TEVA PHARMS 200MG A071154 001 Oct 27, 1987

200MG A072040 001 Apr 29, 1988

400MG A071145 001 Sep 23, 1986

600MG A071146 001 Sep 23, 1986

800MG A071769 001 May 08, 1987

LEDERLE 400MG A070629 001 Sep 19, 1986

600MG A070630 001 Sep 19, 1986

LEINER 300MG A071266 001 Oct 15, 1986

MCNEIL 400MG A070081 001 Jun 16, 1986

600MG A070476 001 Jun 16, 1986

MUTUAL PHARM 200MG A070493 001 Dec 24, 1985

200MG A070908 001 Sep 26, 1986

200MG A071462 001 Oct 02, 1986

400MG A070079 001 Jul 24, 1985

600MG A070080 001 Jul 24, 1985

800MG A071448 001 Feb 18, 1987

MYLAN 200MG A071870 001 May 05, 1988

400MG A070045 001 Sep 24, 1985

600MG A070057 001 Sep 24, 1985

800MG A071999 001 Dec 03, 1987

NORTHSTAR HLTHCARE 400MG A078132 001 Sep 10, 2007

600MG A078132 002 Sep 10, 2007

800MG A078132 003 Sep 10, 2007

OHM LABS 400MG A070818 001 Dec 26, 1985

PAR PHARM 200MG A071575 001 May 08, 1987

300MG A070328 001 Aug 06, 1985

400MG A070329 001 Aug 06, 1985

600MG A070330 001 Aug 06, 1985

800MG A070986 001 Jul 25, 1986

PERRIGO 200MG A072098 001 Dec 08, 1987

PLIVA 400MG A071666 001 Jun 18, 1987

600MG A071667 001 Jun 18, 1987

800MG A071668 001 Jun 18, 1987

PUREPAC PHARM 200MG A071122 001 Oct 03, 1986

200MG A071664 001 Feb 03, 1987

300MG A071123 001 Sep 19, 1986

400MG A071124 001 Sep 19, 1986

600MG A071125 001 Sep 19, 1986

800MG A071964 001 Feb 01, 1988

SANDOZ 200MG A070733 001 Sep 19, 1986

200MG A071807 001 Feb 25, 1988

200MG A074525 001 Dec 15, 1995

200MG A074533 001 Dec 15, 1995

300MG A070734 001 Jun 12, 1986

400MG A070735 001 Jun 12, 1986

400MG A072064 001 Jan 14, 1988

600MG A070736 001 Jun 12, 1986

600MG A072065 001 Jan 14, 1988

800MG A071938 001 Jan 14, 1988

800MG A072169 001 Dec 11, 1987

SUPERPHARM 600MG A070709 001 Apr 25, 1986

TEVA 200MG A073141 001 May 29, 1992

400MG A073343 001 Jun 30, 1992

600MG A073344 001 Jun 30, 1992



## DISCONTINUED DRUG PRODUCT LIST

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	800MG	A073345 001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249 001	Jan 10, 1989
	300MG	A071230 001	Oct 22, 1986
	400MG	A071231 001	Oct 22, 1986
	600MG	A071232 001	Oct 22, 1986
	800MG	A072004 001	Nov 18, 1987
WATSON LABS	200MG	A070435 001	Mar 05, 1986
	200MG	A071765 001	Sep 04, 1987
	200MG	A071905 001	Mar 08, 1988
	300MG	A071338 001	Dec 01, 1986
	400MG	A070038 001	Sep 06, 1985
	400MG	A070436 001	Aug 21, 1985
	600MG	A070041 001	Sep 06, 1985
	600MG	A070437 001	Aug 21, 1985
	800MG	A071547 001	Jul 02, 1987
	800MG	A071911 001	Oct 13, 1987

IBUPROHM

OHM LABS

400MG	A070469 001	Aug 29, 1985
-------	-------------	--------------

MEDIPREN

MCNEIL

200MG	A070475 001	Feb 06, 1986
200MG	A071215 001	Jun 26, 1986

MIDOL

BAYER

200MG	A070591 001	Sep 02, 1987
200MG	A071001 001	Sep 02, 1987

MOTRIN

MCNEIL CONSUMER

300MG	N017463 003	
400MG	N017463 002	
600MG	N017463 004	
800MG	N017463 005	May 22, 1985
100MG	N020418 001	Nov 16, 1994

MCNEIL PED

MOTRIN MIGRAINE PAIN

J AND J CONSUMER INC

200MG	N019012 004	Feb 25, 2000
-------	-------------	--------------

NUPRIN

BRISTOL MYERS

200MG	A072035 001	Feb 16, 1988
200MG	A072036 001	Feb 16, 1988
200MG	N019012 001	May 18, 1984
200MG	N019012 002	Jul 29, 1987

J AND J CONSUMER INC

RUFEN

BASF

600MG	N018197 002	Mar 05, 1984
-------	-------------	--------------

TABLET, CHEWABLE; ORAL

MOTRIN

MCNEIL PED

50MG	N020135 001	Nov 16, 1994
100MG	N020135 002	Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

FOREST LABS

400MG; 5MG	N021378 001	Nov 26, 2004
------------	-------------	--------------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN

5MG/VIAL	N050661 002	Sep 27, 1990
10MG/VIAL	N050661 001	Sep 27, 1990
20MG/VIAL	N050661 003	Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

SANDOZ

1MG/ML	A091293 001	Mar 29, 2011
--------	-------------	--------------

TEVA PARENTERAL

5MG/VIAL	A065037 003	May 01, 2002
10MG/VIAL	A065037 002	May 01, 2002
20MG/VIAL	A065037 001	May 01, 2002

IDOXURIDINE

OINTMENT; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.5%	N015868 001	
------	-------------	--

SOLUTION/DROPS; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.1%	N013934 001	
------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE

1GM/VIAL; 100MG/ML

N019763 003 Oct 10, 1992

3GM/VIAL; 100MG/ML

N019763 004 Oct 10, 1992

ILOPROST

SOLUTION; INHALATION

VENTAVIS

ACTELION PHARMS LTD

20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

NOVARTIS

EQ 50MG BASE

N021335 001 May 10, 2001

EQ 100MG BASE

N021335 002 May 10, 2001

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS

25MG/ML

A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS

12.5MG/ML

N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE

10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

PAR PHARM

25MG

A089497 001 Jul 14, 1987

PROSAM LABS

10MG

A040753 001 Feb 28, 2008

25MG

A040752 001 Feb 28, 2008

50MG

A040751 001 Feb 28, 2008

ROXANE

10MG

A083799 001

25MG

A083799 002

50MG

A083799 003

SANDOZ

10MG

A085200 001

25MG

A084869 002

50MG

A085133 001

TEVA

10MG

A083729 001

25MG

A083729 004

50MG

A083729 003

USL PHARMA

25MG

A087776 001 Feb 10, 1982

VANGARD

10MG

A088036 001 Nov 03, 1982

25MG

A087619 001 Feb 09, 1982

50MG

A087631 001 Jan 04, 1982

WATSON LABS

10MG

A085220 001

10MG

A085875 001

25MG

A084252 002

25MG

A085878 001

50MG

A085221 001

50MG

A085877 001

WEST WARD

25MG

A088222 001 May 26, 1983

50MG

A088223 001 May 26, 1983

JANIMINE

ABBOTT

10MG

N017895 001

25MG

N017895 002

50MG

N017895 003

PRAMINE

ALRA

10MG

A083827 001

25MG

A083827 002

50MG

A083827 003

PRESAMINE

SANOFI AVENTIS US

10MG

N011836 006

25MG

N011836 003

50MG

N011836 007

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP

EQ 5MG BASE/ML

A075542 001 May 10, 2000

HOSPIRA

EQ 5MG BASE/ML

A074616 001 Aug 03, 1998

INOCOR

SANOFI AVENTIS US

EQ 5MG BASE/ML

N018700 001 Jul 31, 1984

## DISCONTINUED DRUG PRODUCT LIST

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AMERIGEN PHARMS LTD	1.25MG	A075201 001	Dec 04, 1998
	2.5MG	A075201 002	Dec 04, 1998
ANI PHARMS INC	1.25MG	A074498 002	Feb 12, 1998
	2.5MG	A074498 001	Oct 31, 1996
SANDOZ	1.25MG	A074594 001	May 23, 1996
	2.5MG	A074594 002	May 23, 1996
TEVA	1.25MG	A074665 001	Apr 04, 1997
	2.5MG	A074665 002	Apr 04, 1997
WATSON LABS	1.25MG	A074585 001	Sep 26, 1996
	2.5MG	A074585 002	Sep 26, 1996

LOZOL

SANOFI AVENTIS US	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 002	Apr 29, 1993
	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

LILLY	EQ 50MG BASE	N019693 001	Dec 29, 1989
	EQ 75MG BASE	N019693 002	Dec 29, 1989
	EQ 100MG BASE	N019693 003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME	EQ 100MG BASE	N020685 006	Apr 19, 2000
	EQ 333MG BASE	N020685 005	Dec 17, 1998

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN	10MG/VIAL	N011525 003	
	40MG/VIAL	N011525 004	
	50MG/VIAL	N011525 002	

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

TEVA	25MG	A070266 001	Nov 07, 1985
	50MG	A070267 001	Nov 07, 1985

INDOCIN

IROKO PHARMS LLC	25MG	N016059 001	
	50MG	N016059 002	

INDOMETHACIN

ABLE	25MG	A076666 001	Dec 17, 2003
	50MG	A076666 002	Dec 17, 2003
CYCLE PHARMS LTD	25MG	A070353 001	Jun 18, 1985
	50MG	A070354 001	Jun 18, 1985
DURAMED PHARMS BARR	25MG	A070326 001	Oct 18, 1985
	50MG	A070327 001	Oct 18, 1985
HALSEY	25MG	A070782 001	Jun 03, 1987
	50MG	A070635 001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730 001	May 04, 1984
	50MG	N018730 002	May 04, 1984
MUTUAL PHARM	25MG	A070067 001	Oct 03, 1986
	25MG	A070899 001	Feb 09, 1987
	50MG	A070068 001	Oct 03, 1986
	50MG	A070900 001	Feb 09, 1987
MYLAN	50MG	N018858 002	Apr 20, 1984
PARKE DAVIS	25MG	N018806 001	Nov 23, 1984
	50MG	N018806 002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813 001	Aug 11, 1986
	50MG	A070592 001	Aug 11, 1986
PLIVA	25MG	A071148 001	Mar 18, 1987
	50MG	A071149 001	Mar 18, 1987
SUPERPHARM	25MG	A070487 001	Oct 10, 1986
	50MG	A070488 001	Oct 10, 1986

**DISCONTINUED DRUG PRODUCT LIST**INDOMETHACIN

## CAPSULE; ORAL

## INDOMETHACIN

TEVA	25MG	A071342 001	Apr 18, 1988
	50MG	A071343 001	Apr 18, 1988
VINTAGE	25MG	N018829 002	Aug 06, 1984
	50MG	A070651 001	Mar 05, 1986
	50MG	N018829 001	Aug 06, 1984
WATSON LABS	25MG	A070529 001	Oct 18, 1985
	25MG	A070784 001	Aug 20, 1986
	25MG	A072996 001	Jul 31, 1991
	25MG	N018690 001	Jul 31, 1984
	50MG	A070530 001	Oct 18, 1985
	50MG	A070785 001	Aug 20, 1986
	50MG	A071635 001	May 18, 1987
	50MG	A072997 001	Jul 31, 1991
	50MG	N018690 002	Jul 31, 1984

## CAPSULE, EXTENDED RELEASE; ORAL

## INDOCIN SR

IROKO PHARMS	75MG	N018185 001	Feb 23, 1982
--------------	------	-------------	--------------

## INDOMETHACIN

ABLE	75MG	A076114 001	Feb 06, 2002
INWOOD LABS	75MG	A072410 001	Mar 15, 1989

## SUPPOSITORY; RECTAL

## INDOCIN

IROKO PHARMS	50MG	N017814 001	Aug 13, 1984
--------------	------	-------------	--------------

## SUSPENSION; ORAL

## INDOMETHACIN

CYCLE PHARMS LTD	25MG/5ML	A071412 001	Mar 18, 1987
------------------	----------	-------------	--------------

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

## INJECTABLE; SUBCUTANEOUS

## NOVOLOG MIX 50/50

NOVO NORDISK INC	50 UNITS/ML; 50 UNITS/ML	N021810 001	Aug 26, 2008
------------------	--------------------------	-------------	--------------

## NOVOLOG MIX 70/30 PENFILL

NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172 002	Nov 01, 2001
------------------	--	-------------	--------------

	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172 003	Nov 01, 2001
--	--	-------------	--------------

INSULIN ASPART RECOMBINANT

## INJECTABLE; SUBCUTANEOUS

## NOVOLOG INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 004	Apr 23, 2004
------------------	------------------------------	-------------	--------------

INSULIN DETEMIR RECOMBINANT

## INJECTABLE; SUBCUTANEOUS

## LEVEMIR INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 003	Jun 16, 2005
------------------	------------------------------	-------------	--------------

## LEVEMIR PENFILL

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 004	Jun 16, 2005
------------------	------------------------------	-------------	--------------

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

## INJECTABLE; INJECTION

## HUMALOG MIX 50/50 PEN

LILLY	50 UNITS/ML; 50 UNITS/ML	N021018 003	Dec 22, 1999
-------	--------------------------	-------------	--------------

## HUMALOG MIX 75/25 PEN

LILLY	75 UNITS/ML; 25 UNITS/ML	N021017 003	Dec 22, 1999
-------	--------------------------	-------------	--------------

INSULIN LISPRO RECOMBINANT

## INJECTABLE; INJECTION

## HUMALOG PEN

LILLY	100 UNITS/ML	N020563 002	Aug 06, 1998
-------	--------------	-------------	--------------

INSULIN PORK

## INJECTABLE; INJECTION

## Iletin I

LILLY	500 UNITS/ML	N017931 001	
-------	--------------	-------------	--

## INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017926 001	
------------------	-------------	-------------	--

## REGULAR INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017926 003	
------------------	--------------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR ILETIN II

LILLY

100 UNITS/ML

N018478 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

ILETIN II

LILLY

500 UNITS/ML

N018344 002

REGULAR ILETIN II (PORK)

LILLY

100 UNITS/ML

N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018381 001

VELOSULIN

NOVO NORDISK INC

100 UNITS/ML

N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N018195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR

LILLY

100 UNITS/ML

N019529 001 Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC

100 UNITS/ML

N021028 001 Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER

1MG/INH

N021868 001 Jan 27, 2006

3MG/INH

N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

LILLY

50 UNITS/ML; 50 UNITS/ML

N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R

NOVO NORDISK INC

100 UNITS/ML

N018778 001 Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC

100 UNITS/ML

N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

BAYER PHARMS

30 UNITS/ML; 70 UNITS/ML

N019585 001 Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N019441 001 Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017929 001

100 UNITS/ML

N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)

LILLY

40 UNITS/ML

N017936 001

100 UNITS/ML

N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH ILETIN II

LILLY

100 UNITS/ML

N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC

100 UNITS/ML

N018194 001

NPH ILETIN II (PORK)

LILLY

100 UNITS/ML

N018345 001

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018623 001

**DISCONTINUED DRUG PRODUCT LIST**INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK INC

100 UNITS/ML

N019449 001 May 30, 1986

NOVOLIN N

NOVO NORDISK INC

100 UNITS/ML

N019065 001 Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION

PROTAMINE ZINC &amp; ILETIN I (BEEF-PORK)

LILLY

40 UNITS/ML

N017932 001

100 UNITS/ML

N017932 002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY

100 UNITS/ML

N018476 001

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB

40 UNITS/ML

N017928 001

100 UNITS/ML

N017928 003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY

100 UNITS/ML

N018346 001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION

LENTE INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017998 001

100 UNITS/ML

N017998 003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION

ULTRALENTE INSULIN

NOVO NORDISK INC

100 UNITS/ML

N017997 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION

ULTRALENTE

NOVO NORDISK INC

100 UNITS/ML

N018385 001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U

LILLY

40 UNITS/ML

N019571 001 Jun 10, 1987

100 UNITS/ML

N019571 002 Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION

SEMILENTE INSULIN

NOVO NORDISK INC

100 UNITS/ML

N017996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION

SEMILENTE

NOVO NORDISK INC

100 UNITS/ML

N018382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION

LENTE ILETIN II

LILLY

100 UNITS/ML

N018477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION

LENTARD

NOVO NORDISK INC

100 UNITS/ML

N018384 001

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

NOVO NORDISK INC

100 UNITS/ML

N018383 001

LENTE ILETIN II (PORK)

LILLY

100 UNITS/ML

N018347 001

**DISCONTINUED DRUG PRODUCT LIST**INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L

LILLY

100 UNITS/ML

N019377 002 Sep 30, 1985

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N018777 001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX

100MG/ML

N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE

10GM/100ML

N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE

2.3mCi/ML

N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT

750MG

N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO

65%

N017902 001

RENOVUE-DIP

BRACCO

24%

N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO

10.3%

N009321 007

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO

20%

N009321 001

IODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE

1mCi/ML

N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIPURAN I 131

MALLINCKRODT

0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO

1-2mCi/VIAL

N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE

0.2mCi/ML

N017313 001

IO DOXAMATE MEGLUMINE

INJECTABLE; INJECTION

CHOLOVUE

BRACCO

9.9%

N018077 001

40.3%

N018076 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

IMP

1mCi/ML

N019432 001 Dec 24, 1987

**DISCONTINUED DRUG PRODUCT LIST**IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 210

GE HEALTHCARE

45.3%

N018956 006 Jun 30, 1989

SOLUTION; URETHRAL

OMNIPAQUE 70

GE HEALTHCARE

15.1%

N018956 007 Jun 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

BAXTER HLTHCARE

41%

A074629 001 Nov 06, 1996

51%

A074629 004 Mar 31, 1998

61%

A074629 002 Nov 06, 1996

76%

A074629 003 Nov 06, 1996

HOSPIRA

61%

A074734 001 Dec 10, 1996

76%

A074734 002 Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING

41%

A074881 001 Jul 28, 2000

HOSPIRA

41%

A074898 001 Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA

41%

A074636 001 Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING

51%

A074881 002 Jul 28, 2000

FRESENIUS KABI USA

51%

A074679 001 Apr 02, 1997

HOSPIRA

51%

A074898 002 Dec 30, 1997

51%

A075005 001 Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA

51%

A074636 002 Dec 30, 1997

IOPAMIDOL-300

ABBVIE

61%

A074638 001 Apr 30, 1997

COOK IMAGING

61%

A074881 003 Jul 28, 2000

FRESENIUS KABI USA

61%

A074679 002 Apr 02, 1997

HOSPIRA

61%

A074898 003 Dec 30, 1997

61%

A075005 002 Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA

61%

A074636 003 Dec 30, 1997

61%

A074637 001 Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING

76%

A074881 004 Jul 28, 2000

FRESENIUS KABI USA

76%

A074679 003 Apr 02, 1997

HOSPIRA

76%

A074898 004 Dec 30, 1997

76%

A075005 003 Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA

76%

A074636 004 Dec 30, 1997

ISOVUE-128

BRACCO

26%

N018735 005 Oct 21, 1986

ISOVUE-200

BRACCO

41%

N020327 001 Oct 12, 1994

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

GE HEALTHCARE

500MG

N008032 001

IOPHENDYLATE

INJECTABLE; INJECTION

PANTOPAQUE

ALCON

100%

N005319 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

MALLINCKRODT

52%; 26%

N016783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY

MALLINCKRODT

80%

N013319 001

CONRAY 325

MALLINCKRODT

54.3%

N017685 001

CONRAY 400

MALLINCKRODT

66.8%

N014295 001



**DISCONTINUED DRUG PRODUCT LIST**IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

BAYER HLTHCARE 40.6% N019580 001 Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE 51.3% N019580 002 Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988

OPTIRAY 240

LIEBEL-FLARSHEIM 51% N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

GUERBET 39.3%; 19.6% N018905 002 Jul 26, 1985

IPODATE CALCIUM

GRANULE; ORAL

ORAGRAFIN CALCIUM

BRACCO 3GM/PACKET N012968 001

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE 500MG A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO 500MG N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.018MG/INH N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.02% N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC 0.02% A075111 001 Apr 22, 1999

APOTEX INC 0.02% A075441 001 Mar 28, 2001

PHARMASCIENCE INC 0.02% A075507 001 Jan 19, 2001

ROXANE 0.02% A075867 001 Jul 22, 2002

TEVA PHARMS USA 0.02% A075313 001 Feb 07, 2000

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

APOTEX INC 0.021MG/SPRAY A076156 001 Apr 18, 2003

0.042MG/SPRAY A076155 001 Apr 18, 2003

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

SANDOZ 40MG/2ML (20MG/ML) A077994 001 Feb 27, 2008

100MG/5ML (20MG/ML) A077994 002 Feb 27, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

IRON DEXTRAN

SANOFI AVENTIS US EQ 50MG IRON/ML N010787 002

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML) N021135 005 Mar 29, 2013

EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML) N021135 003 Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON 1% A086711 001

BRONKOSOL

SANOFI AVENTIS US 0.25% N012339 009

1% N012339 008

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS 1% A087101 001

ASTRAZENECA 0.062% A087937 001 Nov 15, 1982

0.062% A089614 001 Jun 13, 1991

**DISCONTINUED DRUG PRODUCT LIST**ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

	0.125%	A087938	001	Nov 15, 1982
	0.125%	A089615	001	Jun 13, 1991
	0.167%	A088470	001	Mar 14, 1984
	0.167%	A089616	001	Jun 13, 1991
	0.2%	A088471	001	Mar 14, 1984
	0.2%	A089617	001	Jun 13, 1991
	0.25%	A088472	001	Mar 14, 1984
	0.25%	A089618	001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
	0.14%	A088145	001	Mar 26, 1984
	0.25%	A088146	001	Aug 01, 1983
DEY	0.08%	A088187	001	Dec 03, 1982
	0.1%	A087389	001	
	0.17%	A087390	001	
	0.25%	A088188	001	Dec 03, 1982
	1%	A086763	001	
INTL MEDICATION	0.077%	A086651	001	
	0.08%	A086651	002	
	0.1%	A086651	003	
	0.143%	A086651	004	
	0.167%	A086651	005	
	0.2%	A086651	006	
	0.25%	A086651	007	
	1%	A086651	008	
PARKE DAVIS	0.5%	A085997	001	
	1%	A085889	001	
ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

SANOFI AVENTIS US 0.34MG/INH

N012339 007

ISOETHARINE MESYLATE

ALPHARMA US PHARMS 0.34MG/INH

A087858 001 Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

WATSON LABS INC 99.9%

A074393 001 May 12, 1995

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK 0.025%

N010656 001

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ 100MG/ML

N008662 001

RIMIFON

ROCHE 25MG/ML

N008420 002

100MG/ML

N008420 003

SYRUP; ORAL

ISONIAZID

MIKART 50MG/5ML

A081118 001 Jul 21, 1997

LANIAZID

LANNETT 50MG/5ML

A089243 001 Feb 03, 1986

RIMIFON

ROCHE 50MG/5ML

N008420 001

**DISCONTINUED DRUG PRODUCT LIST**ISONIAZID

## TABLET; ORAL

## DOW-ISONIAZID

DOW PHARM 300MG A080330 002

## HYZYD

MEDPOINTE PHARM HLC 100MG A080134 003  
300MG A080134 004

## INH

NOVARTIS 300MG A080935 001

## ISONIAZID

DURAMED PHARMS BARR 100MG A088231 001 Mar 17, 1983  
300MG A088119 001 Mar 17, 1983

HALSEY 50MG A083632 001

HIKMA INTL PHARMS 100MG A080212 001  
300MG A087425 001

IMPAX LABS 100MG A080153 001

IVAX SUB TEVA PHARMS 100MG A080270 001

300MG A083610 001

LILLY 100MG N008499 002

300MG N008499 003

MIKART 100MG A040090 001 Jun 26, 1997

300MG A040090 002 Jun 26, 1997

MK LABS 100MG A080941 001

MUTUAL PHARM 100MG A080136 001

300MG A083633 001

NEXGEN PHARMA INC 100MG A084050 001

PANRAY 50MG N008428 001

100MG N008428 002

300MG N008428 003

PERRIGO 100MG A083060 001

PHARMAVITE 100MG A085091 001

PHOENIX LABS NY 50MG A080368 001

100MG A080368 002

PUREPAC PHARM 50MG A080132 003 Jul 14, 1982

100MG A080132 004 Jul 14, 1982

WATSON LABS 50MG A080522 001

100MG A080401 001

100MG A080523 001

100MG A085790 001

300MG A080521 001

300MG A083178 001

300MG A085784 001

100MG A080120 002

## WHITEWORTH TOWN PLSN

## LANIAZID

LANNETT 50MG A080140 001

100MG A080140 002

## NYDRAZID

BRISTOL MYERS SQUIBB 100MG N008392 003

## STANOZIDE

EVERYLIFE 100MG A080126 001

300MG A080126 002

ISONIAZID; RIFAMPIN

## CAPSULE; ORAL

## RIFAMPIN AND ISONIAZID

HIKMA INTL PHARMS 150MG; 300MG A065221 001 Jul 29, 2005

ISOPROPAMIDE IODIDE

## TABLET; ORAL

## DARBID

GLAXOSMITHKLINE EQ 5MG BASE N010744 001

ISOPROTERENOL HYDROCHLORIDE

## AEROSOL, METERED; INHALATION

## ISOPROTERENOL HYDROCHLORIDE

3M 0.12MG/INH N010375 004

ALPHARMA US PHARMS 0.12MG/INH A085904 001

## ISUPREL

SANOFI AVENTIS US 0.103MG/INH N011178 001

## DISC; INHALATION

## NORISODRINE AEROTROL

ABBOTT 0.25% N016814 001

## DISCONTINUED DRUG PRODUCT LIST

ISOPROTERENOL HYDROCHLORIDE

## INJECTABLE; INJECTION

## ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM	0.2MG/ML	A083431	001	
BAXTER HLTHCARE	0.2MG/ML	A083486	001	
HOSPIRA	0.02MG/ML	A083283	001	
	0.2MG/ML	A083346	001	
INTL MEDICATION	0.2MG/ML	A083724	001	

## SOLUTION; INHALATION

## AEROLONE

LILLY	0.25%	N007245	001	
-------	-------	---------	-----	--

## ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
	0.062%	A087936	001	Nov 18, 1982
DEY	0.5%	A086764	001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994	001	
	0.5%	A085540	001	

## ISUPREL

SANOFI AVENTIS US	0.5%	N006327	002	
	1%	N006327	003	

## VAPO-ISO

FISONS	0.5%	N016813	001	
--------	------	---------	-----	--

## TABLET; RECTAL, SUBLINGUAL

## ISUPREL

SANOFI AVENTIS US	10MG	N006328	001	
	15MG	N006328	002	

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

## AEROSOL, METERED; INHALATION

## DUO-MEDIHALER

3M	0.16MG/INH; 0.24MG/INH	N013296	001	
----	------------------------	---------	-----	--

ISOPROTERENOL SULFATE

## AEROSOL, METERED; INHALATION

## MEDIHALER-ISO

3M	0.08MG/INH	N010375	003	
----	------------	---------	-----	--

## POWDER; INHALATION

## NORISODRINE

ABBVIE	10%	N006905	003	
	25%	N006905	002	

ISOSORBIDE

## SOLUTION; ORAL

## ISMOTIC

ALCON	100GM/220ML	N017063	001	
-------	-------------	---------	-----	--

ISOSORBIDE DINITRATE

## CAPSULE, EXTENDED RELEASE; ORAL

## ISORDIL

WYETH AYERST	40MG	N012882	002	Jul 29, 1988
--------------	------	---------	-----	--------------

## TABLET; ORAL

## ISORDIL

VALEANT PHARMS NORTH	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012093	002	Jul 29, 1988
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012093	006	Jul 29, 1988
	30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012093	005	Jul 29, 1988

## ISOSORBIDE DINITRATE

## MUTUAL PHARM

	5MG	A086166	002	Sep 19, 1986
	10MG	A086169	001	Sep 19, 1986
	20MG	A086167	001	Sep 19, 1986
	30MG	A087564	001	Sep 18, 1986
SUPERPHARM	5MG	A089190	001	Feb 17, 1987
	10MG	A089191	001	Feb 17, 1987
	20MG	A089192	001	Feb 17, 1987
WATSON LABS	5MG	A086034	001	Jan 06, 1988
	10MG	A086032	001	Jan 07, 1988

## DISCONTINUED DRUG PRODUCT LIST

ISOSORBIDE DINITRATE

## TABLET; ORAL

## SORBITRATE

ASTRAZENECA	5MG	N016192 001	Apr 01, 1996
	10MG	N016192 002	Apr 01, 1996
	20MG	A086405 002	Aug 21, 1990
	30MG	A088124 001	Aug 21, 1990
	40MG	A088125 001	Aug 21, 1990

## TABLET; SUBLINGUAL

## ISORDIL

BIOVAIL	2.5MG	N012940 004	Jul 29, 1988
	5MG	N012940 003	Jul 29, 1988
	10MG	N012940 005	Jul 29, 1988

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

## ISOSORBIDE DINITRATE

HIKMA INTL PHARMS	2.5MG	A086054 001	Oct 29, 1987
	5MG	A086055 001	Nov 02, 1987
MUTUAL PHARM	2.5MG	A084204 001	Sep 18, 1986
	5MG	A086168 001	Sep 18, 1986
	10MG	A087545 001	Sep 18, 1986
SANDOZ	2.5MG	A086225 001	Feb 19, 1988
	5MG	A086222 001	Feb 19, 1988
WATSON LABS	2.5MG	A086033 001	Feb 26, 1988
	5MG	A086031 001	Sep 29, 1987

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

## SORBITRATE

ASTRAZENECA	2.5MG	N016191 002	Apr 01, 1996
	5MG	N016191 001	Apr 01, 1996

## TABLET, CHEWABLE; ORAL

## SORBITRATE

ASTRAZENECA	5MG	N016776 002	Apr 01, 1996
	10MG	N016776 003	Apr 01, 1996

## TABLET, EXTENDED RELEASE; ORAL

## ISORDIL

WYETH AYERST	40MG	N012882 001	Jul 29, 1988
--------------	------	-------------	--------------

ISOSORBIDE MONONITRATE

## TABLET; ORAL

## ISMO

PROMIUS PHARMA	20MG	N019091 001	Dec 30, 1991
----------------	------	-------------	--------------

## TABLET, EXTENDED RELEASE; ORAL

## IMDUR

SCHERING PLOUGH	30MG	N020225 001	Aug 12, 1993
	60MG	N020225 002	Aug 12, 1993
	120MG	N020225 003	Mar 30, 1995

## ISOSORBIDE MONONITRATE

ACTAVIS ELIZABETH	30MG	A075306 001	Dec 31, 1998
	60MG	A075306 002	Dec 31, 1998
ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998
IVAX SUB TEVA PHARMS	30MG	A075448 002	Aug 07, 2001
	60MG	A075448 001	Jun 19, 2000
	120MG	A075448 003	Aug 07, 2001
SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999

ISOSULFAN BLUE

## INJECTABLE; INJECTION

## LYMPHAZURIN

COVIDIEN	1%	N018310 001	
----------	----	-------------	--

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

## DISCONTINUED DRUG PRODUCT LIST

ISOTRETINOIN

CAPSULE; ORAL

ACCUTANE

HOFFMANN LA ROCHE	10MG	N018662 002	May 07, 1982
	20MG	N018662 004	Mar 28, 1983
	40MG	N018662 003	May 07, 1982

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

SMITHKLINE BEECHAM	2.5MG	N019546 001	Dec 20, 1990
	5MG	N019546 002	Dec 20, 1990

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

GLAXOSMITHKLINE LLC	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020336 001	Jun 01, 1994
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020336 002	Jun 01, 1994

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

JANSSEN PHARMS	10MG/ML	N020966 001	Mar 30, 1999
----------------	---------	-------------	--------------

IVERMECTIN

TABLET; ORAL

STROMEKTOL

MERCK SHARP DOHME	6MG	N050742 001	Nov 22, 1996
-------------------	-----	-------------	--------------

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

APOTHECON	EQ 500MG BASE	A060516 001	
	EQ 500MG BASE	A061911 001	
	EQ 500MG BASE	A062726 001	Mar 06, 1987

INJECTABLE; INJECTION

KANAMYCIN

EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324 001	
	EQ 500MG BASE/2ML	A062324 002	
	EQ 1GM BASE/3ML	A062324 003	

KANAMYCIN SULFATE

ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504 001	Apr 05, 1984
	EQ 500MG BASE/2ML	A062504 002	Apr 05, 1984
	EQ 1GM BASE/3ML	A062504 003	Apr 05, 1984
INTL MEDICATION	EQ 500MG BASE/2ML	A062466 001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466 002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML	A063021 001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022 001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025 001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668 001	May 07, 1987
	EQ 500MG BASE/2ML	A062672 001	May 07, 1987
	EQ 1GM BASE/3ML	A062669 001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605 003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605 001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605 002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092 001	Oct 11, 1989
WATSON LABS	EQ 1GM BASE/3ML	A062520 003	May 09, 1985

KANTREX

APOTHECON	EQ 75MG BASE/2ML	A061655 003	
	EQ 75MG BASE/2ML	A061901 003	
	EQ 75MG BASE/2ML	A062564 001	Sep 21, 1984
	EQ 500MG BASE/2ML	A061655 001	
	EQ 500MG BASE/2ML	A061901 001	
	EQ 500MG BASE/2ML	A062564 002	Sep 21, 1984
	EQ 1GM BASE/3ML	A061655 002	
	EQ 1GM BASE/3ML	A061901 002	
	EQ 1GM BASE/3ML	A062564 003	Sep 21, 1984

KLEBCIL

KING PHARMS	EQ 75MG BASE/2ML	A062170 001	
	EQ 500MG BASE/2ML	A062170 002	
	EQ 1GM BASE/3ML	A062170 003	

**DISCONTINUED DRUG PRODUCT LIST**KETOCONAZOLE

## CREAM; TOPICAL

## NIZORAL

JANSSEN PHARMA	2%	N019084	001	Dec 31, 1985
----------------	----	---------	-----	--------------

## SUSPENSION; ORAL

## NIZORAL

JANSSEN PHARMA	100MG/5ML	A070767	001	Nov 07, 1986
----------------	-----------	---------	-----	--------------

## TABLET; ORAL

## KETOCONAZOLE

AAIPHARMA LLC	200MG	A075341	001	Jul 27, 1999
---------------	-------	---------	-----	--------------

APOTEX	200MG	A075912	001	Jan 10, 2002
--------	-------	---------	-----	--------------

MUTUAL PHARMA	200MG	A075314	001	Jun 15, 1999
---------------	-------	---------	-----	--------------

PLIVA	200MG	A075362	001	Jun 15, 1999
-------	-------	---------	-----	--------------

TEVA	200MG	A074971	001	Jun 15, 1999
------	-------	---------	-----	--------------

## NIZORAL

JANSSEN PHARMS	200MG	N018533	001	
----------------	-------	---------	-----	--

KETOPROFEN

## CAPSULE; ORAL

## KETOPROFEN

SANDOZ	50MG	A074024	001	Dec 29, 1995
--------	------	---------	-----	--------------

	75MG	A074024	002	Dec 29, 1995
--	------	---------	-----	--------------

TEVA	25MG	A073515	001	Dec 22, 1992
------	------	---------	-----	--------------

## ORUDIS

WYETH AYERST	25MG	N018754	001	Jul 31, 1987
--------------	------	---------	-----	--------------

	50MG	N018754	002	Jan 09, 1986
--	------	---------	-----	--------------

	75MG	N018754	003	Jan 09, 1986
--	------	---------	-----	--------------

## CAPSULE, EXTENDED RELEASE; ORAL

## KETOPROFEN

ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
----------------------	-------	---------	-----	--------------

## ORUVAIL

WYETH PHARMS INC	100MG	N019816	003	Feb 08, 1995
------------------	-------	---------	-----	--------------

	150MG	N019816	002	Feb 08, 1995
--	-------	---------	-----	--------------

	200MG	N019816	001	Sep 24, 1993
--	-------	---------	-----	--------------

## FILM; ORAL

## NEXCEDE

NOVARTIS	12.5MG	N022470	001	Nov 25, 2009
----------	--------	---------	-----	--------------

## TABLET; ORAL

## ACTRON

BAYER	12.5MG	N020499	001	Oct 06, 1995
-------	--------	---------	-----	--------------

## KETOPROFEN

PERRIGO	12.5MG	A075364	001	Feb 07, 2002
---------	--------	---------	-----	--------------

## ORUDIS KT

WYETH CONS	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020429	001	Oct 06, 1995
------------	---	---------	-----	--------------

KETOROLAC TROMETHAMINE

## INJECTABLE; INJECTION

## KETOROLAC TROMETHAMINE

APOTEX INC	30MG/ML	A075626	001	Jul 24, 2001
------------	---------	---------	-----	--------------

	30MG/ML	A077201	001	Oct 14, 2005
--	---------	---------	-----	--------------

APOTHECON	15MG/ML	A075348	001	Nov 28, 2000
-----------	---------	---------	-----	--------------

	30MG/ML	A075348	002	Nov 28, 2000
--	---------	---------	-----	--------------

BEDFORD	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075222	001	Apr 26, 1999
---------	--	---------	-----	--------------

	15MG/ML	A075230	002	Oct 25, 1999
--	---------	---------	-----	--------------

	30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075222	002	Apr 26, 1999
--	--	---------	-----	--------------

	15MG/ML	A075230	001	Oct 25, 1999
--	---------	---------	-----	--------------

	30MG/ML	A075228	001	Apr 26, 1999
--	---------	---------	-----	--------------

	15MG/ML	A075631	002	Jun 29, 2001
--	---------	---------	-----	--------------

	30MG/ML	A075631	001	Jun 29, 2001
--	---------	---------	-----	--------------

EUROHLTH INTL SARL	15MG/ML	A075772	001	Jul 21, 2004
--------------------	---------	---------	-----	--------------

	30MG/ML	A075772	002	Jul 21, 2004
--	---------	---------	-----	--------------

GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
------------------	---------	---------	-----	--------------

	30MG/ML	A076722	002	Jul 27, 2004
--	---------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**KETOROLAC TROMETHAMINE

## INJECTABLE; INJECTION

## KETOROLAC TROMETHAMINE

HIKMA MAPLE	15MG/ML	A075299 001	Nov 03, 1999
	30MG/ML	A075299 002	Nov 03, 1999
HOSPIRA	15MG/ML	A074801 001	Jun 05, 1997
	30MG/ML	A074801 002	Jun 05, 1997
LUITPOLD	15MG/ML	A078145 001	Jan 14, 2008
	30MG/ML	A078145 002	Jan 14, 2008
SANDOZ	15MG/ML	A076271 001	Oct 06, 2004
SUN PHARMA GLOBAL	15MG/ML	A078737 001	Oct 06, 2008
	30MG/ML	A078737 002	Oct 06, 2008
WOCKHARDT	30MG/ML	A077943 001	Mar 27, 2007
TORADOL			
ROCHE PALO	15MG/ML	N019698 001	Nov 30, 1989
	30MG/ML	N019698 002	Nov 30, 1989

## SOLUTION/DROPS; OPHTHALMIC

## ACULAR PRESERVATIVE FREE

ALLERGAN	0.5%	N020811 001	Nov 03, 1997
----------	------	-------------	--------------

## KETOROLAC TROMETHAMINE

AKORN	0.45%	A203376 001	Feb 10, 2014
-------	-------	-------------	--------------

## TABLET; ORAL

## KETOROLAC TROMETHAMINE

CYCLE PHARMS LTD	10MG	A074790 001	Jun 26, 1997
------------------	------	-------------	--------------

WATSON LABS	10MG	A074955 001	Sep 19, 1997
-------------	------	-------------	--------------

## TORADOL

ROCHE PALO	10MG	N019645 001	Dec 20, 1991
------------	------	-------------	--------------

KETOTIFEN FUMARATE

## SOLUTION/DROPS; OPHTHALMIC

## KETOTIFEN FUMARATE

APOTEX INC	EQ 0.025% BASE	A077354 001	May 09, 2006
------------	----------------	-------------	--------------

KRYPTON, KR-81M

## GAS; INHALATION

## MPI KRYPTON 81M GENERATOR

GE HEALTHCARE	N/A	N018088 001	
---------------	-----	-------------	--

LABETALOL HYDROCHLORIDE

## INJECTABLE; INJECTION

## LABETALOL HYDROCHLORIDE

APOTHECON	5MG/ML	A075355 001	Nov 29, 1999
-----------	--------	-------------	--------------

CLARIS PHARMASERVICE	5MG/ML	A076051 001	Jul 05, 2002
----------------------	--------	-------------	--------------

HOSPIRA	5MG/ML	A075242 001	Sep 30, 1999
---------	--------	-------------	--------------

## NORMODYNE

SCHERING	5MG/ML	N018686 001	Aug 01, 1984
----------	--------	-------------	--------------

## TRANDATE

PROMETHEUS LABS	5MG/ML	N019425 001	Dec 31, 1985
-----------------	--------	-------------	--------------

## TABLET; ORAL

## LABETALOL HYDROCHLORIDE

APOTHECON	100MG	A075223 001	Nov 20, 1998
-----------	-------	-------------	--------------

	200MG	A075223 002	Nov 20, 1998
--	-------	-------------	--------------

	300MG	A075223 003	Nov 20, 1998
--	-------	-------------	--------------

TEVA	100MG	A074989 001	Sep 30, 1998
------	-------	-------------	--------------

	200MG	A074989 002	Sep 30, 1998
--	-------	-------------	--------------

	300MG	A074989 003	Sep 30, 1998
--	-------	-------------	--------------

## NORMODYNE

SCHERING	100MG	N018687 001	Aug 31, 1987
----------	-------	-------------	--------------

	200MG	N018687 002	Aug 01, 1984
--	-------	-------------	--------------

	300MG	N018687 003	Aug 01, 1984
--	-------	-------------	--------------

	400MG	N018687 004	Aug 01, 1984
--	-------	-------------	--------------

## TRANDATE

CNTY LINE PHARMS	400MG	N018716 004	Aug 01, 1984
------------------	-------	-------------	--------------

LACTULOSE

## SOLUTION; ORAL

## CHRONULAC

SANOFI AVENTIS US	10GM/15ML	N017884 001	
-------------------	-----------	-------------	--

## DUPHALAC

SOLVAY	10GM/15ML	A072372 001	Mar 22, 1989
--------	-----------	-------------	--------------

## EVALOSE

TEVA PHARMS	10GM/15ML	A073497 001	May 28, 1993
-------------	-----------	-------------	--------------

## LACTULOSE

APOTEX INC	10GM/15ML	A075911 001	Feb 21, 2002
------------	-----------	-------------	--------------



**DISCONTINUED DRUG PRODUCT LIST**LACTULOSE

SOLUTION; ORAL

LACTULOSE

MORTON GROVE

10GM/15ML

A071841 001 Sep 22, 1988

PACO

10GM/15ML

A073160 001 Aug 25, 1992

LAXILOSE

NOSTRUM LABS

10GM/15ML

A073686 001 May 28, 1993

SOLUTION; ORAL, RECTAL

ACILAC

NOSTRUM LABS

10GM/15ML

A073685 001 May 28, 1993

CEPHULAC

SANOFI AVENTIS US

10GM/15ML

N017657 001

GENERLAC

MORTON GROVE

10GM/15ML

A071842 001 Sep 27, 1988

HEPTALAC

TEVA PHARMS

10GM/15ML

A073504 001 May 28, 1993

LACTULOSE

APOTEX INC

10GM/15ML

A076645 001 Jul 28, 2003

PACO

10GM/15ML

A072029 001 Aug 25, 1992

ROXANE

10GM/15ML

A073590 001 May 29, 1992

SOLVAY

10GM/15ML

N017906 001

PORTALAC

SOLVAY

10GM/15ML

A072374 001 Mar 22, 1989

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL

DUTREBIS

MERCK SHARP DOHME

150MG; EQ 300MG BASE

N206510 001 Feb 06, 2015

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

GLAXOSMITHKLINE LLC

50MG

N020241 006 Dec 27, 1994

250MG

N020241 004 Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA

25MG

A078669 001 Apr 08, 2011

100MG

A078669 002 Apr 08, 2011

150MG

A078669 003 Apr 08, 2011

200MG

A078669 004 Apr 08, 2011

HIKMA PHARMS

25MG

A078134 001 Apr 19, 2011

100MG

A078134 002 Apr 19, 2011

150MG

A078134 003 Apr 19, 2011

200MG

A078134 004 Apr 19, 2011

MATRIX LABS LTD

25MG

A078443 001 Feb 11, 2009

100MG

A078443 002 Feb 11, 2009

150MG

A078443 003 Feb 11, 2009

200MG

A078443 004 Feb 11, 2009

MYLAN

25MG

A077428 001 Jan 27, 2009

100MG

A077428 002 Jan 27, 2009

150MG

A077428 003 Jan 27, 2009

200MG

A077428 004 Jan 27, 2009

PHARMASCIENCE INC

25MG

A078310 001 Feb 04, 2009

100MG

A078310 002 Feb 04, 2009

150MG

A078310 003 Feb 04, 2009

200MG

A078310 004 Feb 04, 2009

ROXANE

25MG

A077392 001 Jan 27, 2009

100MG

A077392 002 Jan 27, 2009

150MG

A077392 003 Jan 27, 2009

200MG

A077392 004 Jan 27, 2009

SANDOZ

25MG

A078645 001 Jan 27, 2009

100MG

A078645 002 Jan 27, 2009

150MG

A078645 003 Jan 27, 2009

200MG

A078645 004 Jan 27, 2009

WOCKHARDT

25MG

A078982 001 Jan 27, 2009

100MG

A078982 002 Jan 27, 2009

150MG

A078982 003 Jan 27, 2009

200MG

A078982 004 Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC

100MG

N020764 003 Aug 24, 1998

LAMOTRIGINE

SANDOZ

5MG

A078409 002 Jan 22, 2009

25MG

A078409 003 Jan 22, 2009

## DISCONTINUED DRUG PRODUCT LIST

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

TAKEDA PHARMS NA	15MG/PACKET	N021281 001	May 03, 2001
	30MG/PACKET	N021281 002	May 03, 2001

INJECTABLE; INTRAVENOUS

PREVACID IV

TAKEDA PHARMS NA	30MG/VIAL	N021566 001	May 27, 2004
------------------	-----------	-------------	--------------

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

ANI PHARMS INC	15MG	A078730 001	Oct 15, 2010
	30MG	A078730 002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA	15MG, N/A; N/A, 250MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021507 002	Nov 14, 2003
------------------	-----------------------	--	-------------	--------------

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA	15MG, N/A; N/A, 375MG		N021507 003	Nov 14, 2003
------------------	-----------------------	--	-------------	--------------

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA	15MG, N/A; N/A, 500MG		N021507 004	Nov 14, 2003
------------------	-----------------------	--	-------------	--------------

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004
-----------	---------------	-------------	--------------

LAPYRIUM CHLORIDE; UNDECOYLUM CHLORIDE IODINE COMPLEX

SOLUTION; TOPICAL

VIRAC REX

CHESEBROUGH PONDS	0.5%; 1.8%	N011914 001	
-------------------	------------	-------------	--

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

APOTEX INC	0.005%	A077697 001	Mar 22, 2011
------------	--------	-------------	--------------

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

SANDOZ	10MG	A077085 001	Sep 13, 2005
	10MG	A077087 001	Sep 13, 2005
	20MG	A077085 002	Sep 13, 2005
	20MG	A077087 002	Sep 13, 2005

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION

REFLUDAN

BAYER HLTHCARE	50MG/VIAL	N020807 001	Mar 06, 1998
----------------	-----------	-------------	--------------

LETROZOLE

TABLET; ORAL

LETROZOLE

ACTAVIS TOTOWA	2.5MG	A090292 001	Jul 13, 2011
IMPAX LABS	2.5MG	A091638 001	Jun 03, 2011
SYNTHON PHARMS	2.5MG	A090196 001	Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL

LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL	N008107 003	Jan 30, 1987
---------	-------------------	-------------	--------------

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML	A089352 001	Jun 01, 1988
	EQ 50MG BASE/VIAL	A089353 001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939 001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL	A070480 001	Jan 02, 1987
	EQ 100MG BASE/VIAL	A081224 001	Jun 03, 1994
HOSPIRA	EQ 3MG BASE/ML	N008107 001	
	EQ 50MG BASE/VIAL	N008107 002	
	EQ 100MG BASE/VIAL	N008107 004	May 23, 1988
	EQ 350MG BASE/VIAL	N008107 005	Apr 05, 1989
PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262 001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628 001	Apr 17, 1997

## DISCONTINUED DRUG PRODUCT LIST

LEUCOVORIN CALCIUM

## INJECTABLE; INJECTION

## LEUCOVORIN CALCIUM

	EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993
LEUCOVORIN CALCIUM PRESERVATIVE FREE				
HOSPIRA	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A040147	001	Jun 25, 1997
LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999
WELLCOVORIN				
GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
	EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
	EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989

## TABLET; ORAL

## LEUCOVORIN CALCIUM

COREPHARMA				
	EQ 5MG BASE	A074544	001	Aug 28, 1997
	EQ 25MG BASE	A074544	002	Aug 28, 1997
PAR PHARM				
	EQ 5MG BASE	A071600	001	Oct 14, 1987
	EQ 25MG BASE	A071598	001	Oct 14, 1987
PHARMACHEMIE				
	EQ 5MG BASE	A073099	001	Mar 28, 1997
	EQ 25MG BASE	A073101	001	Mar 28, 1997
SANDOZ	EQ 15MG BASE	A075327	001	Mar 24, 1999
XANODYNE PHARM				
	EQ 5MG BASE	N018459	001	Jan 30, 1986
	EQ 10MG BASE	A071962	001	Nov 19, 1987
	EQ 15MG BASE	A071104	001	Mar 04, 1987
WELLCOVORIN				
GLAXOSMITHKLINE				
	EQ 5MG BASE	N018342	001	Jul 08, 1983
	EQ 25MG BASE	N018342	002	Jul 08, 1983

LEUPROLIDE ACETATE

## IMPLANT; IMPLANTATION

## VIADUR

ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088	001	Mar 03, 2000
----------------------	--------------	---------	-----	--------------

## INJECTABLE; INJECTION

## LEUPROLIDE ACETATE

GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001
LUPRON				
ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985
LUPRON DEPOT				
ABBVIE ENDOCRINE INC	3.75MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020011	001	Oct 22, 1990
LUPRON DEPOT-PED				
ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL; 3.75MG/VIAL, 7.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020263	003	Apr 16, 1993
	7.5MG/VIAL, 7.5MG/VIAL; 7.5MG/VIAL, 7.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020263	004	Apr 16, 1993

LEVALLORPHAN TARTRATE

## INJECTABLE; INJECTION

## LORFAN

ROCHE	1MG/ML	N010423	001	
-------	--------	---------	-----	--

LEVAMISOLE HYDROCHLORIDE

## TABLET; ORAL

## ERGAMISOL

JANSSEN PHARMA	EQ 50MG BASE	N020035	001	Jun 18, 1990
----------------	--------------	---------	-----	--------------

LEVETIRACETAM

## SOLUTION; ORAL

## LEVETIRACETAM

APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011
------------	----------	---------	-----	--------------

## TABLET; ORAL

## LEVETIRACETAM

ACTAVIS LABS FL INC	250MG	A077408	001	Mar 02, 2009
---------------------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

	500MG	A077408 002	Mar 02, 2009
	750MG	A077408 003	Mar 02, 2009
MYLAN	250MG	A078731 001	Feb 10, 2009
	500MG	A078731 002	Feb 10, 2009
	750MG	A078731 003	Feb 10, 2009
	1GM	A078731 004	Feb 10, 2009
SANDOZ	250MG	A077324 001	Jan 15, 2009
	500MG	A077324 002	Jan 15, 2009
	750MG	A077324 003	Jan 15, 2009
	1GM	A077324 004	Jan 15, 2009
WATSON LABS INC	250MG	A078797 002	Jan 15, 2009
	500MG	A078797 003	Jan 15, 2009
	750MG	A078797 004	Jan 15, 2009
	1GM	A078797 001	Jan 15, 2009

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

SANDOZ	500MG	A091668 001	Nov 01, 2012
	750MG	A091668 002	Nov 01, 2012

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

ALCON PHARMS LTD	EQ 0.5% BASE	N021114 001	Feb 23, 2000
------------------	--------------	-------------	--------------

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

APOTEX INC	0.25%	A075473 001	Aug 03, 2000
	0.5%	A075475 001	Aug 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997 001	Aug 05, 1999
	EQ 5MG BASE/ML	N020997 002	Aug 05, 1999
	EQ 7.5MG BASE/ML	N020997 003	Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

NOVARTIS	EQ 0.05% BASE	N020219 001	Nov 10, 1993
----------	---------------	-------------	--------------

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

TEVA PHARMS USA	200MG/ML	A075881 001	Mar 29, 2001
-----------------	----------	-------------	--------------

SOLUTION; ORAL

CARNITOR

SIGMA TAU	1GM/10ML	N018948 002	Apr 27, 1988
-----------	----------	-------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

SANDOZ	5MG	A090486 001	Mar 26, 2013
--------	-----	-------------	--------------

LEVODOPA

CAPSULE; ORAL

BENDOPA

VALEANT PHARM INTL	100MG	N016948 003	
	250MG	N016948 001	
	500MG	N016948 002	

DOPAR

SHIRE	100MG	N016913 003	
	250MG	N016913 001	
	500MG	N016913 002	

LARODOPA

ROCHE	100MG	N016912 002	
	250MG	N016912 001	
	500MG	N016912 006	

TABLET; ORAL

DOPAR

SHIRE	250MG	N016913 004	
	500MG	N016913 005	

**DISCONTINUED DRUG PRODUCT LIST**LEVODOPA

TABLET; ORAL

LARODOPA

ROCHE

100MG

N016912 005

250MG

N016912 003

500MG

N016912 004

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AKORN

EQ 500MG/20ML (EQ 25MG/ML)

A091644 001 Jun 20, 2011

EQ 750MG/30ML (EQ 25MG/ML)

A091644 002 Jun 20, 2011

SOLUTION/DROPS; OPHTHALMIC

IQUIX

SANTEN

1.5% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N021571 001 Mar 01, 2004

LEVOFLOXACIN

APOTEX INC

0.5%

A078282 001 Dec 20, 2010

QUIXIN

SANTEN

0.5% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N021199 001 Aug 18, 2000

TABLET; ORAL

LEVOFLOXACIN

WATSON LABS INC

250MG

A201484 001 Nov 22, 2013

500MG

A201484 002 Nov 22, 2013

750MG

A201484 003 Nov 22, 2013

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

SPECTRUM PHARMS

EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)  
\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020140 002 Apr 29, 2011

EQ 250MG BASE/25ML (EQ 10MG BASE/ML)  
\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020140 003 Apr 29, 2011

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX

20MG/ML

N015865 001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

ROXANE

10MG/ML \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020315 001 Jul 09, 1993

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

SOLVAY

0.05MG/ML; 2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%

N012125 002

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

NOVOCOL

0.05MG/ML; 2%

A084697 001

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

GRAHAM CHEM

0.05MG/ML; 2%

A084850 002 Oct 21, 1983

POLOCAINE W/ LEVONORDEFRIN

DENTSPLY PHARM

0.05MG/ML; 2%

A089517 001 Apr 14, 1988

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%; 0.4%

N008592 007

**DISCONTINUED DRUG PRODUCT LIST**LEVONORGESTREL

## IMPLANT; IMPLANTATION

## JADELLE

POPULATION COUNCIL	75MG/IMPLANT	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020544	001	Nov 01, 1996
--------------------	--------------	--	---------	-----	--------------

## LEVONORGESTREL

WYETH PHARMS INC	75MG/IMPLANT		N020627	001	Aug 15, 1996
------------------	--------------	--	---------	-----	--------------

## NORPLANT

POPULATION COUNCIL	36MG/IMPLANT		N019897	001	Dec 10, 1990
--------------------	--------------	--	---------	-----	--------------

## NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC	36MG/IMPLANT		N020088	001	Dec 10, 1990
------------------	--------------	--	---------	-----	--------------

## TABLET; ORAL

## LEVONORGESTREL

LUPIN LTD	0.75MG		A091328	001	Jan 23, 2013
-----------	--------	--	---------	-----	--------------

WATSON LABS	0.75MG		A078666	001	Jun 24, 2009
-------------	--------	--	---------	-----	--------------

## PLAN B

TEVA BRANDED PHARM	0.75MG		N021045	001	Jul 28, 1999
--------------------	--------	--	---------	-----	--------------

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

## CAPSULE; ORAL

## NOVRAD

LILLY	EQ 50MG BASE		N012928	006	
-------	--------------	--	---------	-----	--

	EQ 100MG BASE		N012928	004	
--	---------------	--	---------	-----	--

## SUSPENSION; ORAL

## NOVRAD

LILLY	EQ 50MG BASE/5ML		N012928	002	
-------	------------------	--	---------	-----	--

LEVORPHANOL TARTRATE

## INJECTABLE; INJECTION

## LEVO-DROMORAN

VALEANT PHARM INTL	2MG/ML		N008719	001	Dec 19, 1991
--------------------	--------	--	---------	-----	--------------

## TABLET; ORAL

## LEVO-DROMORAN

VALEANT PHARM INTL	2MG		N008720	001	Dec 19, 1991
--------------------	-----	--	---------	-----	--------------

LEVOTHYROXINE SODIUM

## TABLET; ORAL

## LEVOLET

VINTAGE	0.025MG		N021137	001	Jun 06, 2003
---------	---------	--	---------	-----	--------------

	0.05MG		N021137	002	Jun 06, 2003
--	--------	--	---------	-----	--------------

	0.075MG		N021137	003	Jun 06, 2003
--	---------	--	---------	-----	--------------

	0.088MG		N021137	004	Jun 06, 2003
--	---------	--	---------	-----	--------------

	0.1MG		N021137	005	Jun 06, 2003
--	-------	--	---------	-----	--------------

	0.112MG		N021137	006	Jun 06, 2003
--	---------	--	---------	-----	--------------

	0.125MG		N021137	007	Jun 06, 2003
--	---------	--	---------	-----	--------------

	0.137MG		N021137	008	Jun 06, 2003
--	---------	--	---------	-----	--------------

	0.15MG		N021137	009	Jun 06, 2003
--	--------	--	---------	-----	--------------

	0.175MG		N021137	010	Jun 06, 2003
--	---------	--	---------	-----	--------------

	0.2MG		N021137	011	Jun 06, 2003
--	-------	--	---------	-----	--------------

	0.3MG		N021137	012	Jun 06, 2003
--	-------	--	---------	-----	--------------

## LEVOTHYROXINE SODIUM

## MERCK KGAA

	0.025MG		A076752	001	Jun 16, 2005
--	---------	--	---------	-----	--------------

	0.05MG		A076752	002	Jun 16, 2005
--	--------	--	---------	-----	--------------

	0.075MG		A076752	003	Jun 16, 2005
--	---------	--	---------	-----	--------------

	0.088MG		A076752	004	Jun 16, 2005
--	---------	--	---------	-----	--------------

	0.1MG		A076752	005	Jun 16, 2005
--	-------	--	---------	-----	--------------

	0.112MG		A076752	006	Jun 16, 2005
--	---------	--	---------	-----	--------------

	0.125MG		A076752	007	Jun 16, 2005
--	---------	--	---------	-----	--------------

	0.15MG		A076752	008	Jun 16, 2005
--	--------	--	---------	-----	--------------

	0.175MG		A076752	009	Jun 16, 2005
--	---------	--	---------	-----	--------------

	0.2MG		A076752	010	Jun 16, 2005
--	-------	--	---------	-----	--------------

	0.3MG		A076752	011	Jun 16, 2005
--	-------	--	---------	-----	--------------

## LEVOXYL

## KING PHARMS R AND D

	0.3MG		N021301	012	May 25, 2001
--	-------	--	---------	-----	--------------

## NOVOTHYROX

## MERCK KGAA

	0.025MG		N021292	001	May 31, 2002
--	---------	--	---------	-----	--------------

	0.05MG		N021292	002	May 31, 2002
--	--------	--	---------	-----	--------------

	0.075MG		N021292	003	May 31, 2002
--	---------	--	---------	-----	--------------

	0.088MG		N021292	004	May 31, 2002
--	---------	--	---------	-----	--------------

	0.1MG		N021292	005	May 31, 2002
--	-------	--	---------	-----	--------------

	0.112MG		N021292	006	May 31, 2002
--	---------	--	---------	-----	--------------

	0.125MG		N021292	007	May 31, 2002
--	---------	--	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM

TABLET; ORAL

NOVOTHYROX

0.137MG	N021292 008	May 31, 2002
0.15MG	N021292 009	May 31, 2002
0.175MG	N021292 010	May 31, 2002
0.2MG	N021292 011	May 31, 2002
0.3MG	N021292 012	May 31, 2002

LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

ASTRAZENECA

10%

N014394 001

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH

N020575 001 May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5%

A084944 001

5%

A084946 001

5%

A084947 001

LIDOCAINE

BELMORA LLC

5%

A080210 001

XYLOCAINE

ASTRAZENECA

5%

N008048 001

PATCH; TOPICAL

DENTIPATCH

NOVEN

46.1MG/PATCH

N020575 002 May 21, 1996

SOLUTION; TOPICAL

XYLOCAINE

ASTRAZENECA

5%

N014127 001

SUPPOSITORY; RECTAL

XYLOCAINE

ASTRAZENECA

100MG

N013077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE

2%

A084721 001

LIDOCAINE HYDROCHLORIDE

ABBOTT

10%

A087980 001 Feb 02, 1983

20%

A089362 001 May 25, 1988

ABRAXIS PHARM

1%

A080420 001

1%

A086761 001

1.5%

A080420 005

2%

A080420 002

2%

A080420 004

2%

A086761 002

2%

N017508 001

4%

N017508 002

20%

N017508 004

AKORN

1%

A085037 001

2%

A085037 002

BEL MAR

1%

A080710 001

2%

A080760 001

DELL LABS

1%

A083387 001

2%

A083388 001

ELKINS SINN

0.5%

A085131 001

4%

A084626 001

EUROHLTH INTL SARL

1%

A080407 001

2%

A080407 002

GD SEARLE LLC

1%

A083135 001

2%

A083135 002

GRAHAM CHEM

2%

A080504 001

HOSPIRA

1%

A040013 001 Jun 23, 1995

1.5%

A088330 001 May 17, 1984

2%

A088331 001 May 17, 1984

INTL MEDICATION

1%

N017701 002

2%

N017701 001

1GM/VIAL

N018543 001

2GM/VIAL

N018543 002

LUITPOLD

2%

A083198 001

LYPHOMED

1%

A080390 001

## DISCONTINUED DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE			
	2%	A080390	002
MILES	1%	A080414	001
	2%	A080414	002
WATSON LABS	1%	A080377	001
	1%	A083627	001
	2%	A080377	002
	2%	A083627	002
WYETH AYERST	1%	A083083	001
	2%	A083083	002
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	100MG/100ML	N018461	001
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	200MG/100ML	N018967	001 Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%			
HOSPIRA	200MG/100ML	A083158	005
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	200MG/100ML	N018954	001 Jul 09, 1985
HOSPIRA	200MG/100ML	N018388	001
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	400MG/100ML	N018967	002 Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%			
HOSPIRA	400MG/100ML	A083158	006
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	800MG/100ML	N018967	003 Mar 30, 1984
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER			
HOSPIRA	1.5%	A088326	001 Jul 31, 1984
	10%	A088367	001 Jul 31, 1984
	20%	A088368	001 Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE			
EUROHLTH INTL SARL	1%	A084625	001
	2%	A084625	002
INTL MEDICATION	4%	N017702	002
LIDOCATON			
PHARMATON	2%	A084727	001 Aug 17, 1983
LIDOPEN			
MERIDIAN MEDCL TECHN	10%	N017549	001
XYLOCAINE			
ASTRAZENECA	1%	N010418	005
	1.5%	N010418	009
	2%	N010418	007
XYLOCAINE DENTAL			
DENTSPLY PHARM	2%	N021380	001
XYLOCAINE PRESERVATIVE FREE			
FRESENIUS KABI USA	10%	N016801	003
INJECTABLE; SPINAL			
XYLOCAINE 1.5% W/ DEXTROSE 7.5%			
FRESENIUS KABI USA	1.5%	N016297	001
XYLOCAINE 5% W/ GLUCOSE 7.5%			
ASTRAZENECA	5%	N010496	002 Jul 07, 1982
JELLY; TOPICAL			
ANESTACON			
BANNER LIFE SCIENCES	2%	A080429	001
LIDOCAINE HYDROCHLORIDE			
G AND W LABS INC	2%	A081318	001 Apr 29, 1993
SOLUTION; ORAL			
LIDOCAINE HYDROCHLORIDE VISCOUS			
ACTAVIS MID ATLANTIC	2%	A086578	001
INTL MEDICATION	2%	A086389	001 Feb 02, 1982
SOLUTION; TOPICAL			
LARYNGOTRACHEAL ANESTHESIA KIT			
KENDALL IL	4%	A087931	001 Jun 10, 1983
LIDOCAINE HYDROCHLORIDE			
PACO	4%	A089688	001 Jun 30, 1989
LTA II KIT			
HOSPIRA	4%	A088542	001 Jul 31, 1984
PEDIATRIC LTA KIT			
ABBOTT	2%	A088572	001 Jul 31, 1984
HOSPIRA	2%	A085995	001



**DISCONTINUED DRUG PRODUCT LIST**LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER

2%; 50MG/ML

A060567 001

2%; 125MG/ML

A060567 002

LIDOCAINE; PRILOCAINE

DISC; TOPICAL

EMLA

ASTRAZENECA

2.5%; 2.5%

N020962 001 Feb 04, 1998

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

PHARMACIA AND UPJOHN

EQ 250MG BASE

N050316 001

EQ 500MG BASE

N050316 002

INJECTABLE; INJECTION

LINCOMYCIN HYDROCHLORIDE

WATSON LABS

EQ 300MG BASE/ML

A063180 001 Apr 16, 1991

LINDANE

CREAM; TOPICAL

KWELL

REED AND CARNRICK

1%

A084218 001

1%

N006309 001

LOTION; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084989 001

KWELL

REED AND CARNRICK

1%

A084218 002

1%

N006309 003

SCABENE

STIEFEL

1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084988 001

KWELL

REED AND CARNRICK

1%

A084219 001

1%

N010718 001

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLID

TABLET; ORAL

ZYVOX

PHARMACIA AND UPJOHN

400MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4; T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.0075MG; 0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.015MG; 0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.03MG; 0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.045MG; 0.045MG

N016680 004

THYROLAR-5

FOREST LABS

0.0625MG; 0.25MG

N016807 006

LISINAPRIL

TABLET; ORAL

LISINAPRIL

SANDOZ

2.5MG

A075903 001 Jul 01, 2002

2.5MG

A075999 001 Jul 01, 2002

5MG

A075903 002 Jul 01, 2002

5MG

A075999 002 Jul 01, 2002

## DISCONTINUED DRUG PRODUCT LIST

LISINAPRILTABLET; ORAL  
LISINAPRIL

10MG	A075903 003	Jul 01, 2002	
10MG	A075999 003	Jul 01, 2002	
20MG	A075903 004	Jul 01, 2002	
20MG	A075999 004	Jul 01, 2002	
30MG	A075903 005	Jul 01, 2002	
30MG	A075999 005	Jul 01, 2002	
40MG	A075903 006	Jul 01, 2002	
40MG	A075999 006	Jul 01, 2002	
TEVA	2.5MG	A075783 001	Jul 01, 2002
	5MG	A075783 002	Jul 01, 2002
	10MG	A075783 003	Jul 01, 2002
	20MG	A075783 004	Jul 01, 2002
	30MG	A075783 005	Jul 01, 2002
	40MG	A075783 006	Jul 01, 2002
PRINIVIL			
MERCK	2.5MG	N019558 006	Jan 28, 1994

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH			
NOVEN THERAP	300MG	N016860 001	
LITHIUM CARBONATE			
ABLE	150MG	A076823 001	Jun 29, 2004
	300MG	A076121 001	Sep 27, 2001
	300MG	A076823 002	Jun 29, 2004
	600MG	A076823 003	Jun 29, 2004
APOTEX INC	300MG	A076795 001	Nov 22, 2004
HIKMA PHARMS LLC	600MG	A078763 001	Apr 15, 2008
USL PHARMA	300MG	A072542 001	Feb 01, 1989
WATSON LABS	300MG	A070407 001	Mar 19, 1987
LITHONATE			
SOLVAY	300MG	N016782 001	
TABLET; ORAL			
ESKALITH			
JDS PHARMS	300MG	N017971 001	
LITHANE			
BAYER PHARMS	300MG	N018833 001	Jul 18, 1985
LITHIUM CARBONATE			
HIKMA INTL PHARMS	300MG	A078715 001	Dec 28, 2010
PFIZER	300MG	N016834 001	
LITHOTABS			
SOLVAY	300MG	N016980 001	
TABLET, EXTENDED RELEASE; ORAL			
ESKALITH CR			
JDS PHARMS	450MG	N018152 001	Mar 29, 1982
LITHIUM CARBONATE			
ABLE	300MG	A076382 001	Apr 21, 2003
BARR	300MG	A076170 001	Jun 10, 2002
	450MG	A076366 001	Aug 21, 2003
HIKMA INTL PHARMS	450MG	A076490 001	Jun 17, 2003

LITHIUM CITRATE

SYRUP; ORAL

LITHONATE			
SOLVAY	EQ 300MG CARBONATE/5ML	N017672 001	

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL

MAXAQUIN			
PHARMACIA	EQ 400MG BASE	N020013 001	Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM			
J AND J CONSUMER INC	2MG	N017690 001	
LOPERAMIDE HYDROCHLORIDE			
ROXANE	2MG	A073080 001	Nov 27, 1991
SANDOZ	2MG	A072993 001	Aug 28, 1992
TEVA	2MG	A073122 001	Aug 30, 1991

**DISCONTINUED DRUG PRODUCT LIST**LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM

JANSSEN PHARMS 1MG/5ML N019037 001 Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

ALPHARMA US PHARMS 1MG/5ML A073187 001 Sep 15, 1992

DURAMED PHARMS BARR 1MG/5ML A074991 001 Dec 29, 1997

TEVA 1MG/5ML A073478 001 Jun 23, 1995

WATSON LABS 1MG/5ML A073062 001 May 28, 1993

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

ABLE 2MG A073528 001 Nov 30, 1993

PERRIGO 2MG A074194 001 Oct 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

KALETRA

ABBVIE 133.3MG; 33.3MG N021226 001 Sep 15, 2000

LORACARBEF

CAPSULE; ORAL

LORABID

KING PHARMS 200MG N050668 001 Dec 31, 1991

400MG N050668 002 Apr 05, 1996

FOR SUSPENSION; ORAL

LORABID

KING PHARMS 100MG/5ML N050667 001 Dec 31, 1991

200MG/5ML N050667 002 Dec 31, 1991

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF

BAYER HEALTHCARE LLC 1MG/ML \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N020641 003 Nov 19, 2003

LORATADINE

APOTEX INC 1MG/ML A075565 001 Oct 05, 2004

RANBAXY LABS LTD 1MG/ML A076529 001 Aug 20, 2004

TABLET; ORAL

LORATADINE

PERRIGO 10MG N021512 001 Jun 24, 2004

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC 5MG; 120MG A076208 001 Jan 28, 2004

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN 2MG/ML A074974 001 Jul 23, 1998

BEDFORD 2MG/ML A077076 001 Jul 13, 2005

4MG/ML A077076 002 Jul 13, 2005

DAVA PHARMS INC 2MG/ML A074793 001 Mar 16, 2000

4MG/ML A074793 002 Mar 16, 2000

HIKMA MAPLE 2MG/ML A074496 001 Sep 28, 1998

4MG/ML A074496 002 Sep 28, 1998

HOSPIRA 2MG/ML A074280 001 May 27, 1994

2MG/ML A074300 001 Apr 12, 1994

4MG/ML A074280 002 May 27, 1994

4MG/ML A074300 003 Mar 19, 1997

WATSON LABS 2MG/ML A074276 001 Apr 15, 1994

4MG/ML A074276 002 Apr 15, 1994

WATSON LABS INC 1MG/0.5ML A074551 003 Sep 12, 1996

2MG/ML A074535 001 Sep 12, 1996

2MG/ML A074551 001 Sep 12, 1996

4MG/ML A074535 002 Sep 12, 1996

4MG/ML A074551 002 Sep 12, 1996

SOLUTION; ORAL

LORAZEPAM

ROXANE 0.5MG/5ML A074648 001 Mar 18, 1997

TABLET; ORAL

LORAZ

QUANTUM PHARMICS 0.5MG A070200 001 Aug 09, 1985

## DISCONTINUED DRUG PRODUCT LIST

LORAZEPAM

TABLET; ORAL

LORAZ

1MG

A070201 001 Aug 09, 1985

2MG

A070202 001 Aug 09, 1985

LORAZEPAM

AM THERAP

0.5MG

A070727 001 Mar 07, 1986

1MG

A070728 001 Mar 07, 1986

2MG

A070729 001 Mar 07, 1986

HALSEY

0.5MG

A071434 001 Sep 01, 1987

1MG

A071435 001 Sep 01, 1987

2MG

A071436 001 Sep 01, 1987

MUTUAL PHARM

0.5MG

A070472 001 Dec 10, 1985

0.5MG

A072553 001 Mar 29, 1991

1MG

A070473 001 Dec 10, 1985

1MG

A072554 001 Mar 29, 1991

2MG

A070474 001 Dec 10, 1985

2MG

A072555 001 Mar 29, 1991

PAR PHARM

0.5MG

A070675 001 Dec 01, 1986

1MG

A070676 001 Dec 01, 1986

2MG

A070677 001 Dec 01, 1986

SANDOZ

0.5MG

A071193 001 Apr 15, 1988

1MG

A071194 001 Apr 15, 1988

2MG

A071195 001 Apr 15, 1988

SUPERPHARM

0.5MG

A071245 001 Feb 09, 1987

1MG

A071246 001 Feb 09, 1987

2MG

A071247 001 Feb 09, 1987

USL PHARMA

1MG

A070539 001 Dec 22, 1986

2MG

A070540 001 Dec 22, 1986

WARNER CHILCOTT

1MG

A071038 001 Jan 12, 1988

2MG

A071039 001 Jan 12, 1988

WATSON LABS

0.5MG

A071086 001 Mar 23, 1987

0.5MG

A071117 001 Jul 24, 1986

1MG

A071087 001 Mar 23, 1987

1MG

A071118 001 Jul 24, 1986

2MG

A071088 001 Mar 23, 1987

2MG

A071110 001 Jul 24, 1986

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS

0.5%

N020841 001 Mar 09, 1998

LOVASTATIN

TABLET; ORAL

MEVACOR

MERCK

10MG

N019643 002 Mar 28, 1991

20MG

N019643 003 Aug 31, 1987

40MG

N019643 004 Dec 14, 1988

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

COVIS PHARMA SARL

10MG

N021316 001 Jun 26, 2002

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

ACTAVIS LABS UT INC

EQ 25MG BASE/ML

N017658 001

INJECTABLE; INJECTION

LOXITANE IM

ACTAVIS LABS UT INC

EQ 50MG BASE/ML

N018039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

ACTAVIS LABS UT INC

EQ 5MG BASE

N017525 001

EQ 10MG BASE

N017525 002

EQ 25MG BASE

N017525 003

EQ 50MG BASE

N017525 004

TABLET; ORAL

LOXITANE

ACTAVIS LABS UT INC

EQ 10MG BASE

N017525 006

EQ 25MG BASE

N017525 007

EQ 50MG BASE

N017525 008

## DISCONTINUED DRUG PRODUCT LIST

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

DISCOVERY LABS

8.5ML

N021746 001 Mar 06, 2012

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

EMD SERONO

75 IU/VIAL

N021322 001 Oct 08, 2004

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS

0.185MG/ML

N016755 001

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE

32MG/100ML; 128MG/100ML; 234MG/100ML

N019047 001 Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML

N019006 001 Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML

N018252 001

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC

14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N018406 001

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC

30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N018406 002 Jul 08, 1982

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE

30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML

N019326 001 Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS

343MG; 20MG; 750MG

N022456 001 Dec 04, 2009

343MG; 40MG; 750MG

N022456 002 Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS

700MG; 20MG; 600MG

N021850 001 Mar 24, 2006

700MG; 40MG; 600MG

N021850 002 Mar 24, 2006

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

BRAINTREE LABS

1.6GM; 210GM; 0.74GM; 3.13GM; 2.86GM; 5.6GM; 17.5GM

N203595 001 Jan 18, 2013

MALATHION

LOTION; TOPICAL

MALATHION

MYLAN PHARMS INC

0.5%

A078743 001 Mar 06, 2009

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

GE HEALTHCARE

37.9MG/ML

N020652 001 Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO

3.49MG/GM

N020686 001 Dec 19, 1997

## DISCONTINUED DRUG PRODUCT LIST

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

ABRAXIS PHARM

EQ 0.1MG MANGANESE/ML

N019228 001 May 05, 1987

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

B BRAUN

10GM/100ML

N016080 002

HOSPIRA

10GM/100ML

N016269 002

MILES

10GM/100ML

N016472 002

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

B BRAUN

10GM/100ML

N016080 006

MANNITOL 15%

B BRAUN

15GM/100ML

N016080 003

HOSPIRA

15GM/100ML

N016269 003

MILES

15GM/100ML

N016472 005

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

B BRAUN

15GM/100ML

N016080 005

MANNITOL 20%

B BRAUN

20GM/100ML

N014738 001

20GM/100ML

N016080 004

HOSPIRA

20GM/100ML

N016269 004

MILES

20GM/100ML

N016472 004

MANNITOL 25%

ABRAXIS PHARM

12.5GM/50ML

A086754 001

HOSPIRA

12.5GM/50ML

N016269 005

IGI LABS INC

12.5GM/50ML

A089239 001 May 06, 1987

12.5GM/50ML

A089240 001 May 06, 1987

MERCK

12.5GM/50ML

N005620 001

WATSON LABS

12.5GM/50ML

A087460 001 Jun 27, 1983

MANNITOL 5%

B BRAUN

5GM/100ML

N016080 001

HOSPIRA

5GM/100ML

N016269 001

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN

5GM/100ML

N016080 007

POWDER; INHALATION

ARIDOL KIT

PHARMAXIS LTD

N/A, 5MG, 10MG, 20MG, 40MG

N022368 001 Oct 05, 2010

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN

5GM/100ML

N016704 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA

540MG/100ML; 2.7GM/100ML

A080224 001

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA

540MG/100ML; 2.7GM/100ML

N017636 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS

25MG

N017543 001

50MG

N017543 002

75MG

N017543 003 Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP

25MG

A072129 001 Jan 14, 1988

50MG

A072130 001 Jan 14, 1988

75MG

A072131 001 Jan 14, 1988

WATSON LABS

25MG

A071943 001 Dec 30, 1987

25MG

A072162 001 Jun 01, 1988

50MG

A071944 001 Dec 30, 1987

50MG

A072163 001 Jun 01, 1988

75MG

A071945 001 Dec 30, 1987

75MG

A072164 001 Jun 01, 1988

MASOPROCOL

CREAM; TOPICAL

ACTINEX

UNIV AZ CANCER CTR

10%

N019940 001 Sep 04, 1992

## DISCONTINUED DRUG PRODUCT LIST

MAZINDOL

TABLET; ORAL

MAZANOR

WYETH AYERST

1MG

N017980 002

2MG

N017980 001

SANOREX

NOVARTIS

1MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017247 001

2MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017247 002

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

JANSSEN PHARMS

100MG

N017481 001

MEBUTAMATE

TABLET; ORAL

DORMATE

MEDPOINTE PHARM HLC

600MG

N017374 001

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

TARGACEPT

2.5MG

N010251 001

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPLEX

INSMED

36MG/0.6ML

N021884 001 Dec 12, 2005

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

CITRON PHARMA LLC

12.5MG

N010721 006

25MG

N010721 004

50MG

N010721 001 Jan 20, 1982

MECLIZINE HYDROCHLORIDE

ABC HOLDING

12.5MG

A085253 001

25MG

A085252 001

AMNEAL PHARMS

50MG

A201451 003 Feb 23, 2011

ANABOLIC

25MG

A085891 001

ANI PHARMS INC

12.5MG

A084975 001

25MG

A084657 001

BUNDY

12.5MG

A084382 001

25MG

A084872 001

IVAX SUB TEVA PHARMS

12.5MG

A083784 001

KV PHARM

12.5MG

A085524 001

25MG

A085523 001

MYLAN PHARMS INC

50MG

A202640 003 Sep 17, 2012

PAR PHARM

50MG

A089674 001 Mar 31, 1988

PLIVA

12.5MG

A088732 001 Dec 11, 1985

25MG

A088734 001 Dec 11, 1985

SUPERPHARM

12.5MG

A089113 001 Aug 20, 1985

25MG

A089114 001 Aug 20, 1985

UDL

12.5MG

A088256 001 Jun 13, 1983

25MG

A088257 001 Jun 13, 1983

VANGARD

12.5MG

A087877 001 Apr 20, 1982

25MG

A087620 001 Jan 04, 1982

VINTAGE PHARMS

12.5MG

A040179 001 Jan 30, 1997

25MG

A040179 002 Jan 30, 1997

WATSON LABS

12.5MG

A085195 001

12.5MG

A085269 001

25MG

A085740 001

TABLET, CHEWABLE; ORAL

ANTIVERT

CITRON PHARMA LLC

25MG

N010721 005

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

25MG

A084976 001

NEXGEN PHARMA INC

25MG

A086392 001

PLIVA

25MG

A088733 001 Dec 11, 1985

**DISCONTINUED DRUG PRODUCT LIST**MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

JOHNSON AND JOHNSON 1%

N050518 001

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLODIUM

QUANTUM PHARMICS

EQ 50MG BASE

A071380 001 Jul 14, 1987

EQ 100MG BASE

A071381 001 Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP

EQ 50MG BASE

A071362 001 Feb 10, 1987

EQ 100MG BASE

A071363 001 Feb 10, 1987

BARR

EQ 50MG BASE

A072848 001 Mar 20, 1989

EQ 100MG BASE

A072809 001 Mar 20, 1989

PAR PHARM

EQ 50MG BASE

A072077 001 Mar 10, 1988

EQ 100MG BASE

A072078 001 Mar 10, 1988

SANDOZ

EQ 50MG BASE

A072262 001 Nov 29, 1988

EQ 100MG BASE

A072263 001 Nov 29, 1988

USL PHARMA

EQ 50MG BASE

A071007 001 Mar 25, 1988

EQ 100MG BASE

A071008 001 Mar 25, 1988

VITARINE

EQ 50MG BASE

A071710 001 Jun 15, 1988

EQ 100MG BASE

A071684 001 Jun 15, 1988

WATSON LABS

EQ 50MG BASE

A070400 001 Nov 25, 1986

EQ 50MG BASE

A071468 001 Apr 15, 1987

EQ 50MG BASE

A071640 001 Aug 11, 1987

EQ 100MG BASE

A070401 001 Nov 25, 1986

EQ 100MG BASE

A071469 001 Apr 15, 1987

EQ 100MG BASE

A071641 001 Aug 11, 1987

MECLOMEN

PARKE DAVIS

EQ 50MG BASE

N018006 001

EQ 100MG BASE

N018006 002

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

PHARMACIA AND UPJOHN

100MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N012541 002

MEDROXYPROGESTERONE ACETATE

TEVA PHARMS USA

150MG/ML

A076552 001 Oct 27, 2004

TABLET; ORAL

AMEN

AMARIN PHARMS

10MG

A083242 001

CURRETAB

SOLVAY

10MG

A085686 001

CYCRIN

ESI

2.5MG

A081239 001 Oct 30, 1992

5MG

A081240 001 Oct 30, 1992

10MG

A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR

2.5MG

A040311 001 Dec 01, 1999

5MG

A040311 002 Dec 01, 1999

10MG

A040311 003 Dec 01, 1999

USL PHARMA

10MG

A088484 001 Jul 26, 1984

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN

1%

N016624 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

ROCHE

250MG

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

HIKMA PHARMS LLC

250MG

A077699 001 Apr 21, 2010

US ARMY WALTER REED

250MG

N019578 001 May 02, 1989



## DISCONTINUED DRUG PRODUCT LIST

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

APOTEX INC

40MG/ML

A077404 001 Feb 16, 2006

TABLET; ORAL

MEGACE

BRISTOL MYERS SQUIBB

20MG

N016979 001

40MG

N016979 002

MEGESTROL ACETATE

TEVA

40MG

A074745 001 Feb 27, 1998

USL PHARMA

20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

MELOXICAM

TABLET; ORAL

MELOXICAM

COREPHARMA

7.5MG

A077930 001 Jul 19, 2006

15MG

A077930 002 Jul 19, 2006

CR DOUBLE CRANE

7.5MG

A078039 001 Dec 14, 2006

15MG

A078039 002 Dec 14, 2006

MUTUAL PHARM

7.5MG

A077935 001 Jul 19, 2006

15MG

A077935 002 Jul 19, 2006

MYLAN

7.5MG

A077934 001 Jul 20, 2006

15MG

A077934 002 Jul 20, 2006

ROXANE

7.5MG

A077925 001 Jul 19, 2006

15MG

A077925 002 Jul 19, 2006

YABAO PHARM

7.5MG

A077933 001 Jul 19, 2006

15MG

A077933 002 Jul 19, 2006

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL

EQ 50MG BASE/VIAL

A090299 001 Oct 27, 2009

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

ORCHID HLTHCARE

5MG

A090044 001 Mar 12, 2012

10MG

A090044 002 Mar 12, 2012

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY

10MG/ML

N005725 001

SYNKAYVITE

ROCHE

5MG/ML

N003718 004

10MG/ML

N003718 006

37.5MG/ML

N003718 008

TABLET; ORAL

SYNKAYVITE

ROCHE

5MG

N003718 010

MENADIONE

TABLET; ORAL

MENADIONE

LILLY

5MG

N002139 003

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

HUMEGON

ORGANON USA INC

75 IU/VIAL; 75 IU/VIAL

N020328 001 Sep 01, 1994

150 IU/VIAL; 150 IU/VIAL

N020328 002 Sep 01, 1994

MENOTROPINS

FERRING

75 IU/VIAL; 75 IU/VIAL

A073598 001 Jan 30, 1997

150 IU/VIAL; 150 IU/VIAL

A073599 001 Jan 30, 1997

PERGONAL

SERONO

75 IU/AMP; 75 IU/AMP

N017646 001

150 IU/AMP; 150 IU/AMP

N017646 002 May 20, 1985

REPRONEX

FERRING

150 IU/VIAL; 150 IU/VIAL

N021047 002 Aug 27, 1999

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

FERRING

75 IU/VIAL; 75 IU/VIAL

N021047 001 Aug 27, 1999

## DISCONTINUED DRUG PRODUCT LIST

MEPENZOLATE BROMIDE

SOLUTION; ORAL

CANTIL

SANOFI AVENTIS US 25MG/5ML N010679 004

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

SANOFI AVENTIS US 25MG/ML N005010 007  
 50MG/ML N005010 002  
 75MG/ML N005010 009  
 100MG/ML N005010 003

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML A080388 001  
 50MG/ML A080385 001  
 50MG/ML A080387 001  
 75MG/ML A080389 001  
 100MG/ML A080386 001

BAXTER HLTHCARE

25MG/ML A088279 001 Jun 15, 1984  
 50MG/ML A088280 001 Jun 15, 1984  
 75MG/ML A088281 001 Jun 15, 1984  
 100MG/ML A088282 001 Jun 15, 1984

IGI LABS INC

25MG/ML A089781 001 Mar 31, 1989  
 50MG/ML A089782 001 Mar 31, 1989  
 50MG/ML A089783 001 Mar 31, 1989  
 50MG/ML A089784 001 Mar 31, 1989  
 75MG/ML A089785 001 Mar 31, 1989  
 100MG/ML A089786 001 Mar 31, 1989  
 100MG/ML A089787 001 Mar 31, 1989  
 100MG/ML A089788 001 Mar 31, 1989

INTL MEDICATION

10MG/ML A086332 001

PARKE DAVIS

50MG/ML A080364 002  
 75MG/ML A080364 003  
 100MG/ML A080364 001

WATSON LABS

50MG/ML A073444 001 Mar 17, 1992  
 100MG/ML A073445 001 Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML A040305 001 Mar 10, 1999

INTL MEDICATION

10MG/ML A081309 001 Aug 30, 1993

MALLINCKRODT

10MG/ML A040163 001 May 12, 1997

WATSON LABS

10MG/ML A073443 001 Mar 17, 1992

SYRUP; ORAL

DEMEROL

SANOFI AVENTIS US 50MG/5ML N005010 005

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR

50MG A040318 001 Oct 05, 1999  
 100MG A040318 002 Oct 05, 1999

MUTUAL PHARM

50MG A080448 001  
 100MG A080448 002

WATSON LABS

50MG A040186 001 Jun 30, 1997  
 100MG A040186 002 Jun 30, 1997

WYETH AYERST

50MG A080454 001

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

EUROHLTH INTL SARL 25MG/ML; 25MG/ML N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP EQ 15MG BASE/ML N008248 002

EQ 30MG BASE/ML N008248 001

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

NOVARTIS 100MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\* N006008 001

**DISCONTINUED DRUG PRODUCT LIST**MEPIVACAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE			
SOLVAY	3%	A084777 002	Apr 18, 1982
CARBOCAINE			
EASTMAN KODAK	3%	N012125 003	
MEPIVACAINE HYDROCHLORIDE			
GRAHAM CHEM	3%	A083559 001	
INTL MEDICATION	1%	A087509 001	Oct 05, 1982
WATSON LABS	1%	A088769 001	Nov 20, 1984
	2%	A088770 001	Nov 20, 1984
POLOCAINE			
DENTSPLY PHARM	3%	A088653 001	Aug 21, 1984

MEPREDNISONE

## TABLET; ORAL

BETAPAR			
SCHERING	4MG	N016053 002	

MEPROBAMATE

## CAPSULE; ORAL

EQUANIL			
WYETH AYERST	400MG	N012455 002	

## CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN			
MEDPOINTE PHARM HLC	200MG	N011284 001	
	400MG	N011284 002	

## TABLET; ORAL

AMOSENE			
FERNDAL LABS	400MG	A084030 001	
BAMATE			
ALRA	200MG	A080380 001	
	400MG	A080380 002	

EQUANIL			
WYETH AYERST	200MG	N010028 005	
	400MG	N010028 004	

MEPRIAM			
TEVA	400MG	N016069 001	

## MEPROBAMATE

BARR	600MG	A084230 001	
ELKINS SINN	200MG	N015426 002	
	400MG	N015426 001	
HEATHER	400MG	N016928 003	
	600MG	A084329 001	
IMPAX LABS	200MG	N014322 002	
	400MG	N014322 001	
IVAX SUB TEVA PHARMS	200MG	N015438 001	
	400MG	N015438 002	
	600MG	A084181 001	
IVC INDS	400MG	A084153 001	
LANNETT	200MG	N014882 002	
	400MG	N014882 001	
LEDERLE	400MG	A086299 001	
LEE KM	400MG	A089538 001	Nov 25, 1987
MALLARD	400MG	N015072 002	
MK LABS	200MG	N014368 004	
	400MG	N014368 002	
MUTUAL PHARM	200MG	A080699 001	
	400MG	A080699 002	
MYLAN	400MG	A083618 001	
NEXGEN PHARMA INC	200MG	A084220 001	
	400MG	A084589 001	
PARKE DAVIS	200MG	A084744 001	
	400MG	A084744 002	
PERRIGO	200MG	A084546 001	
	400MG	A084547 001	
PHARMAVITE	400MG	A084438 001	
PUREPAC PHARM	200MG	A084804 001	
	400MG	A084804 002	
PVT FORM	400MG	N014601 001	
ROXANE	600MG	A084332 001	
SANDOZ	200MG	N014547 002	
	400MG	A080655 001	

## DISCONTINUED DRUG PRODUCT LIST

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	400MG	N014547 001	
SCHERER LABS	400MG	A083343 001	
SOLVAY	200MG	A084435 001	
STANLABS PHARM	200MG	N014474 002	
	400MG	N014474 004	
TABLICAPS	400MG	A083494 001	
TARO	200MG	A200998 001	May 23, 2011
	400MG	A200998 002	May 23, 2011
USL PHARMA	200MG	A087825 001	Mar 18, 1982
	400MG	A087826 001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139 006	
	400MG	N015139 005	
VANGARD	400MG	A088011 001	Jul 14, 1982
WATSON LABS	200MG	A085720 001	
	400MG	A085721 001	
	600MG	A084274 001	
	600MG	A085719 001	
WEST WARD	200MG	N015417 003	
	400MG	N015417 002	
WHITEWORTH TOWN PLSN	200MG	A083830 001	
	400MG	A083442 001	
MILTOWN			
MEDPOINTE PHARM HLC	200MG	N009698 004	
	400MG	N009698 002	
	600MG	A083919 001	
NEURAMATE			
HALSEY	200MG	N014359 002	
	400MG	N014359 001	
TRANMEP			
SOLVAY	400MG	A084369 001	
	400MG	N016249 001	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

AQUA PHARMS 2%; 0.01% N020922 001 Dec 10, 1999

MERCAPTOPYRINE

TABLET; ORAL

PURINETHOL

TEVA

50MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\* N009053 002

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION

MERSALYL-THEOPHYLLINE

WATSON LABS 100MG/ML; 50MG/ML A084875 001

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

FOREST LABS LLC 500MG N021252 001 Jan 05, 2001

ROWASA

MEDA PHARMS 500MG N019919 001 Dec 18, 1990

TABLET, DELAYED RELEASE; ORAL

ASACOL

WARNER CHILCOTT LLC 400MG N019651 001 Jan 31, 1992

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

NOVARTIS EQ 25MG BASE/ML N016997 001

INJECTABLE; INJECTION

SERENTIL

NOVARTIS EQ 25MG BASE/ML N016775 001

TABLET; ORAL

SERENTIL

NOVARTIS EQ 10MG BASE N016774 001

EQ 25MG BASE N016774 002

EQ 50MG BASE N016774 003

## DISCONTINUED DRUG PRODUCT LIST

MESORIDAZINE BESYLATE

TABLET; ORAL

SERENTIL

EQ 100MG BASE

N016774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

ACTAVIS LABS UT INC 0.1MG; 2MG

N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

WATSON LABS 0.05MG; 1MG

A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG; 1MG

A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

ACTAVIS LABS UT INC 0.05MG; 1MG

N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC 0.08MG; 1MG

N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM 0.05MG; 1MG

N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM 0.08MG; 1MG

N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM 0.06MG; 10MG

N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM 0.1MG; 2MG

N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

WATSON LABS 0.05MG; 1MG

A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG; 1MG

A070759 001 Jul 01, 1988

NORINYL 1+80 28-DAY

GD SEARLE LLC 0.08MG; 1MG

N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN 0.05MG; 1MG

N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM 0.08MG; 1MG

N016715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL

ENOVID

GD SEARLE LLC 0.075MG; 5MG  
0.15MG; 9.85MG

N010976 008

N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC 0.075MG; 5MG

N010976 004

ENOVID-E

GD SEARLE LLC 0.1MG; 2.5MG

N010976 006

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC 0.1MG; 2.5MG

N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM 0.65MG/INH

N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM 0.4%

N018761 002 Oct 10, 1986

0.6%

N018761 001 Jun 30, 1983

5%

N017659 001

METAPROTERENOL SULFATE

APOTEX INC 0.4%

A075402 001 Feb 28, 2001

0.6%

A075403 001 Feb 28, 2001

ASTRAZENECA 0.4%

A071275 001 Jul 27, 1988

0.6%

A071018 001 Jul 27, 1988

DEY 0.33%

A071806 001 Aug 05, 1988

0.5%

A071805 001 Aug 05, 1988

5%

A070805 001 Aug 17, 1987

MYLAN SPECLT 0.4%

A071786 001 Aug 05, 1988

0.6%

A070804 001 Aug 17, 1987

NEPHRON 0.4%

A071855 001 Jul 14, 1988

0.6%

A071726 001 Jul 14, 1988

WOCKHARDT 0.4%

A075586 001 May 30, 2002

## DISCONTINUED DRUG PRODUCT LIST

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

0.6%	A075586	002	May 30, 2002
5%	A072190	001	Jun 07, 1988

PROMETA

MURO

5%	A073340	001	Mar 30, 1992
----	---------	-----	--------------

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG/5ML	N017571	001	
----------	---------	-----	--

METAPROTERENOL SULFATE

APOTEX INC

10MG/5ML	A075235	001	Jan 27, 2000
----------	---------	-----	--------------

G AND W LABS INC

10MG/5ML	A072761	001	Feb 27, 1992
----------	---------	-----	--------------

10MG/5ML	A073034	001	Aug 30, 1991
----------	---------	-----	--------------

MORTON GROVE

10MG/5ML	A071656	001	Oct 13, 1987
----------	---------	-----	--------------

WOCKHARDT

10MG/5ML	A074702	001	Mar 24, 1997
----------	---------	-----	--------------

PROMETA

MURO

10MG/5ML	A072023	001	Sep 15, 1988
----------	---------	-----	--------------

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG	N015874	002	
------	---------	-----	--

20MG	N015874	001	
------	---------	-----	--

METAPROTERENOL SULFATE

AM THERAP

10MG	A072054	001	Jun 23, 1988
------	---------	-----	--------------

20MG	A072055	001	Jun 23, 1988
------	---------	-----	--------------

TEVA

10MG	A072519	001	Mar 30, 1990
------	---------	-----	--------------

20MG	A072520	001	Mar 30, 1990
------	---------	-----	--------------

USL PHARMA

10MG	A071013	001	Jan 25, 1988
------	---------	-----	--------------

20MG	A071014	001	Jan 25, 1988
------	---------	-----	--------------

WATSON LABS

10MG	A073013	001	Jan 31, 1991
------	---------	-----	--------------

20MG	A072795	001	Jan 31, 1991
------	---------	-----	--------------

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

MERCCK

EQ 10MG BASE/ML	N009509	002	Dec 22, 1987
-----------------	---------	-----	--------------

METARAMINOL BITARTRATE

ABRAXIS PHARM

EQ 10MG BASE/ML	A080431	001	
-----------------	---------	-----	--

ELKINS SINN

EQ 10MG BASE/ML	A083363	001	
-----------------	---------	-----	--

GD SEARLE LLC

EQ 10MG BASE/ML	A086418	001	
-----------------	---------	-----	--

EQ 20MG BASE/ML	A086418	002	
-----------------	---------	-----	--

METAXALONE

TABLET; ORAL

METAXALONE

COREPHARMA

640MG	N022503	001	Jun 01, 2015
-------	---------	-----	--------------

SKELAXIN

KING PHARMS

400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013217	001	
---	---------	-----	--

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

BRISTOL MYERS SQUIBB

625MG	N020357	003	Nov 05, 1998
-------	---------	-----	--------------

750MG	N020357	004	Nov 05, 1998
-------	---------	-----	--------------

METFORMIN HYDROCHLORIDE

BARR

500MG	A075971	001	Jan 25, 2002
-------	---------	-----	--------------

850MG	A075971	002	Jan 25, 2002
-------	---------	-----	--------------

1GM	A075971	003	Jan 25, 2002
-----	---------	-----	--------------

IPCA LABS LTD

500MG	A078422	001	Aug 06, 2007
-------	---------	-----	--------------

850MG	A078422	002	Aug 06, 2007
-------	---------	-----	--------------

1GM	A078422	003	Aug 06, 2007
-----	---------	-----	--------------

IVAX SUB TEVA PHARMS

500MG	A075975	001	Jan 24, 2002
-------	---------	-----	--------------

625MG	A075975	004	Jan 24, 2002
-------	---------	-----	--------------

750MG	A075975	005	Jan 24, 2002
-------	---------	-----	--------------

850MG	A075975	002	Jan 24, 2002
-------	---------	-----	--------------

1GM	A075975	003	Jan 24, 2002
-----	---------	-----	--------------

TEVA

500MG	A076328	001	Dec 16, 2002
-------	---------	-----	--------------

850MG	A076328	002	Dec 16, 2002
-------	---------	-----	--------------

1GM	A076328	003	Dec 16, 2002
-----	---------	-----	--------------

WATSON LABS

500MG	A075979	001	Jan 24, 2002
-------	---------	-----	--------------

850MG	A075979	002	Jan 24, 2002
-------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

1GM

A075979 003 Jan 24, 2002

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH

500MG

A076450 001 Oct 01, 2004

750MG

A076878 001 Apr 13, 2005

BARR

500MG

A076496 001 Nov 25, 2005

IVAX SUB TEVA PHARMS

500MG

A076545 001 Dec 01, 2003

MUTUAL PHARM

500MG

A077124 001 Dec 21, 2005

RANBAXY LABS LTD

500MG

A076413 001 Jun 18, 2004

750MG

A077211 001 Jun 29, 2005

SANDOZ

500MG

A076223 001 Dec 14, 2004

TORRENT PHARMS LTD

750MG

A079226 001 Feb 18, 2010

WATSON LABS INC

500MG

A076818 001 Dec 14, 2004

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

SB PHARMCO

500MG;EQ 1MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021410 001 Oct 10, 2002

500MG;EQ 2MG BASE

N021410 002 Oct 10, 2002

500MG;EQ 4MG BASE

N021410 003 Oct 10, 2002

1GM;EQ 2MG BASE

N021410 004 Aug 25, 2003

1GM;EQ 4MG BASE

N021410 005 Aug 25, 2003

METHACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC

EQ 140MG BASE

A060641 001

EQ 280MG BASE

A060641 002

SYRUP;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC

EQ 70MG BASE/5ML

A060641 003

METHADONE HYDROCHLORIDE

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

ROXANE

10MG/30ML

N006134 004

TABLET;ORAL

METHADONE HYDROCHLORIDE

ROXANE

5MG

A088108 001 Mar 08, 1983

10MG

A088109 001 Mar 08, 1983

40MG

A074081 001 Apr 28, 1995

SANDOZ

5MG

A040241 001 May 29, 1998

TABLET, DISPERSIBLE;ORAL

WESTADONE

SANDOZ

2.5MG

N017108 001

TABLET, EFFERVESCENT;ORAL

WESTADONE

SANDOZ

5MG

N017108 002

10MG

N017108 003

40MG

N017108 004

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

METHAMPEX

TEVA

10MG

A083889 001

METHAMPHETAMINE HYDROCHLORIDE

ABLE

5MG

A040529 001 Feb 25, 2004

REXAR

5MG

A084931 001

TEVA

10MG

A084931 002

TEVA

5MG

A086359 001

TABLET, EXTENDED RELEASE;ORAL

DESOXYN

RECORDATI RARE

5MG

N005378 004

10MG

N005378 003

15MG

N005378 005

## DISCONTINUED DRUG PRODUCT LIST

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

SHIRE

50MG

N007390 001

METHARBITAL

TABLET; ORAL

GEMONIL

ABBVIE

100MG

N008322 001

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

APPLIED ANAL

25MG

A040011 001 Jul 17, 1997

50MG

A040011 002 Jul 17, 1997

SANDOZ

25MG

A040102 001 Aug 28, 1996

50MG

A040102 002 Aug 28, 1996

NEPTAZANE

LEDERLE

25MG

N011721 002 Nov 25, 1991

50MG

N011721 001

METHDILAZINE

TABLET, CHEWABLE; ORAL

TACARYL

WESTWOOD SQUIBB

3.6MG

N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS

4MG/5ML

A087122 001

TACARYL

WESTWOOD SQUIBB

4MG/5ML

N011950 007

TABLET; ORAL

TACARYL

WESTWOOD SQUIBB

8MG

N011950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHCILLIN

APOTHECON

EQ 900MG BASE/VIAL

A061449 001

EQ 900MG BASE/VIAL

N050117 001

EQ 3.6GM BASE/VIAL

A061449 002

EQ 3.6GM BASE/VIAL

N050117 002

EQ 5.4GM BASE/VIAL

A061449 003

EQ 5.4GM BASE/VIAL

N050117 003

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

CEDAR PHARMS

15MG

A040619 003 Jul 12, 2005

20MG

A040547 004 Feb 18, 2005

MYLAN

20MG

A040350 003 Jun 07, 2001

TAPAZOLE

KING PHARMS

5MG

N007517 002

10MG

N007517 004

METHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS

1MG

N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

MARSAM PHARMS LLC

100MG/ML

A089849 001 Dec 27, 1991

WATSON LABS

100MG/ML

A086459 001

TABLET; ORAL

DELAXIN

FERNDAL LABS

500MG

A085454 001

FORBAXIN

FOREST LABS

750MG

A085136 001

METHOCARBAMOL

ABLE

500MG

A040413 001 Mar 17, 2003

750MG

A040413 002 Mar 17, 2003

AM THERAP

500MG

A089417 001 Feb 11, 1987

750MG

A089418 001 Feb 11, 1987



## DISCONTINUED DRUG PRODUCT LIST

METHOCARBAMOL

TABLET; ORAL

## METHOCARBAMOL

ASCOT	500MG	A087660 001	Oct 27, 1982
	750MG	A087661 001	Oct 27, 1982
CLONMEL HLTHCARE	500MG	A085961 001	
	750MG	A085963 001	
HEATHER	500MG	A084675 001	
	750MG	A084924 001	
IMPAX LABS	500MG	A084927 001	
	750MG	A084928 001	
INWOOD LABS	500MG	A085137 001	
IVAX SUB TEVA PHARMS	500MG	A084648 001	
	750MG	A084649 001	
KV PHARM	500MG	A085660 001	
	750MG	A085658 001	
MUTUAL PHARM	500MG	A084488 001	
	750MG	A084486 001	
MYLAN	500MG	A084259 001	
	750MG	A084323 001	
NYLOS	750MG	A085033 001	
PIONEER PHARMS	500MG	A088731 001	Dec 13, 1985
	750MG	A089082 001	Dec 13, 1985
PURACAP PHARM	500MG	A084231 002	
	750MG	A084471 001	
PUREPAC PHARM	500MG	A085718 001	
	750MG	A085718 002	
ROXANE	500MG	A088646 001	Feb 29, 1984
	750MG	A088647 001	Feb 29, 1984
SANDOZ	500MG	A087283 001	
	750MG	A087282 001	
SOLVAY	500MG	A084448 001	
	750MG	A084449 001	
SUPERPHARM	500MG	A087589 001	Jan 22, 1982
	750MG	A087590 001	Jan 22, 1982
TABLICAPS	500MG	A084846 001	
UPSHER SMITH	500MG	A087453 001	
	750MG	A087454 001	
WATSON LABS	500MG	A083605 001	
	500MG	A085180 001	
	750MG	A083605 002	
	750MG	A085192 001	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

## BREVITAL SODIUM

PAR STERILE PRODUCTS	5GM/VIAL	N011559 003	
----------------------	----------	-------------	--

METHOTREXATE SODIUM

INJECTABLE; INJECTION

## ABITREXATE

ABIC	EQ 25MG BASE/ML	A089161 001	Mar 10, 1987
	EQ 50MG BASE/VIAL	A089354 001	Jul 17, 1987
	EQ 100MG BASE/VIAL	A089355 001	Jul 17, 1987
	EQ 250MG BASE/VIAL	A089356 001	Jul 17, 1987

## FOLEX

PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695 001	Apr 08, 1983
	EQ 50MG BASE/VIAL	A087695 002	Apr 08, 1983
	EQ 100MG BASE/VIAL	A087695 003	Apr 08, 1983
	EQ 250MG BASE/VIAL	A088954 001	Oct 24, 1985

## FOLEX PFS

PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242 001	Aug 23, 1991
	EQ 25MG BASE/ML	A089180 001	Jan 03, 1986

## METHOTREXATE LPF

HOSPIRA	EQ 25MG BASE/ML	N011719 007	Mar 31, 1982
---------	-----------------	-------------	--------------

## METHOTREXATE PRESERVATIVE FREE

HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719 014	Apr 13, 2005
	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N011719 013	Apr 13, 2005
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719 011	Apr 13, 2005

## DISCONTINUED DRUG PRODUCT LIST

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ 2.5MG BASE/ML

A089323 001 Jun 13, 1986

EQ 20MG BASE/VIAL

A088935 001 Oct 11, 1985

EQ 25MG BASE/ML

A089263 001 Jun 13, 1986

EQ 25MG BASE/ML

A089322 001 Jun 13, 1986

EQ 50MG BASE/VIAL

A088936 001 Oct 11, 1985

EQ 100MG BASE/VIAL

A088937 001 Oct 11, 1985

HOSPIRA

EQ 2.5MG BASE/ML

N011719 004

EQ 20MG BASE/VIAL

N011719 001

EQ 25MG BASE/ML

N011719 005

EQ 50MG BASE/VIAL

N011719 003

EQ 100MG BASE/VIAL

N011719 006

NORBROOK

EQ 25MG BASE/ML

A088648 001 May 09, 1986

PHARMACHEMIE USA

EQ 25MG BASE/ML

A089158 001 Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA

EQ 1GM BASE/VIAL

N011719 009 Apr 07, 1988

MEXATE

BRISTOL

EQ 20MG BASE/VIAL

A086358 001

EQ 50MG BASE/VIAL

A086358 002

EQ 100MG BASE/VIAL

A086358 003

EQ 250MG BASE/VIAL

A086358 004

MEXATE-AQ

BRISTOL MYERS

EQ 25MG BASE/ML

A088760 001 Feb 14, 1985

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB

EQ 25MG BASE/ML

A089887 001 Apr 14, 1989

TABLET; ORAL

METHOTREXATE SODIUM

DURAMED PHARMS BARR

EQ 2.5MG BASE

A040233 001 Jun 17, 1999

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE

10MG/ML

N006772 002

20MG/ML

N006772 001

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

SANDOZ

10MG

A087781 001 Jun 08, 1982

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM

2.5MG

A080970 001

PAMINE

FOUGERA PHARMS

2.5MG

N008848 001

PAMINE FORTE

FOUGERA PHARMS

5MG

N008848 002 Mar 25, 2003

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC

5MG

N017364 001

ENDURON

ABBVIE

2.5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N012524 001

5MG

N012524 004

METHYCLOTHIAZIDE

IVAX PHARMS

2.5MG

A087913 001 Jun 03, 1982

5MG

A087786 001 May 18, 1982

MYLAN

2.5MG

A087671 001 Aug 17, 1982

PAR PHARM

2.5MG

A089135 001 Feb 12, 1986

5MG

A089136 001 Feb 12, 1986

SANDOZ

2.5MG

A089835 001 Aug 18, 1988

5MG

A089837 001 Aug 18, 1988

USL PHARMA

5MG

A088745 001 Mar 21, 1985

WATSON LABS

2.5MG

A085487 001 Mar 11, 1982

2.5MG

A088750 001 Sep 06, 1984

5MG

A085476 001 Mar 11, 1982

5MG

A088724 001 Sep 06, 1984

**DISCONTINUED DRUG PRODUCT LIST**METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT

5MG; 25MG

N016047 001

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC

2.5MG; 0.1MG

N012708 005

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

GALDERMA LABS LP

EQ 16.8% BASE

N021415 001 Jul 27, 2004

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK

250MG/5ML

N018389 001

TABLET; ORAL

ALDOMET

MERCK

125MG

N013400 003

250MG

N013400 001

500MG

N013400 002

METHYLDOPA

ACCORD HLTHCARE

125MG

A070070 003 Oct 15, 1985

DURAMED PHARMS BARR

250MG

A071006 001 Dec 16, 1986

500MG

A071009 001 Dec 16, 1986

HALSEY

125MG

A071751 001 Mar 28, 1988

250MG

A071752 001 Mar 28, 1988

500MG

A071753 001 Mar 28, 1988

MUTUAL PHARM

125MG

A070073 001 Oct 09, 1986

250MG

A070060 001 Oct 09, 1986

500MG

A070074 001 Oct 09, 1986

PAR PHARM

125MG

A070535 001 Jan 02, 1987

250MG

A070536 001 Jan 02, 1987

500MG

A070537 001 Jan 02, 1987

PARKE DAVIS

125MG

A070331 001 Apr 15, 1986

250MG

A070332 001 Apr 15, 1986

500MG

A070333 001 Apr 15, 1986

PLIVA

125MG

A072126 001 Jul 07, 1988

250MG

A072127 001 Jul 07, 1988

500MG

A072128 001 Jul 07, 1988

PUREPAC PHARM

125MG

A070749 001 Feb 07, 1986

250MG

A070750 001 Feb 07, 1986

500MG

A070452 001 Feb 07, 1986

ROXANE

125MG

A070192 001 Apr 25, 1986

250MG

A070193 001 Apr 25, 1986

500MG

A070194 001 Apr 25, 1986

SANDOZ

125MG

A071700 001 Mar 02, 1988

250MG

N018934 001 Jun 29, 1984

500MG

N018934 002 Jun 29, 1984

SUPERPHARM

250MG

A070669 001 Jun 23, 1989

500MG

A070670 001 Jun 23, 1989

TEVA

125MG

A071105 001 Dec 05, 1986

250MG

A071106 001 Dec 05, 1986

500MG

A071067 001 Dec 05, 1986

WATSON LABS

125MG

A070245 001 Feb 25, 1986

125MG

A070260 001 Jun 24, 1985

250MG

A070246 001 Feb 25, 1986

250MG

A070261 001 Jun 24, 1985

250MG

A070703 001 Jun 06, 1986

500MG

A070247 001 Feb 25, 1986

500MG

A070262 001 Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

MERCK

50MG/ML

N013401 001

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM

50MG/ML

A070652 001 Jun 03, 1986

BAXTER HLTHCARE

50MG/ML

A070291 001 Jul 01, 1986

HOSPIRA

50MG/ML

A070691 001 Jun 19, 1987

50MG/ML

A070698 001 Jun 15, 1987

**DISCONTINUED DRUG PRODUCT LIST**METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002

TABLET, CHEWABLE; ORAL

METHYLIN

MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003
	5MG	N021475	002	Apr 15, 2003
	10MG	N021475	003	Apr 15, 2003

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

UCB INC	10MG	A040306	001	Oct 20, 1999
---------	------	---------	-----	--------------

METHYLPHENIDATE HYDROCHLORIDE

ABLE	20MG	A076032	001	May 09, 2001
ACTAVIS ELIZABETH	20MG	A075450	001	Dec 21, 2001
WATSON LABS	20MG	A040410	001	Feb 09, 2001

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

PHARMACIA AND UPJOHN	24MG	N011153	005	
----------------------	------	---------	-----	--

METHYLPREDNISOLONE

HEATHER	4MG	A085650	001	
PAR PHARM	16MG	A089207	001	Apr 25, 1988
	24MG	A089208	001	Apr 25, 1988
	32MG	A089209	001	Apr 25, 1988
SANDOZ	4MG	A087341	001	
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL

MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
----------------------	----------	---------	-----	--

INJECTABLE; INJECTION

M-PREDROL

BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%	N012421	001	
	1%	N012421	002	

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002	
	1%;EQ 3.5MG BASE/GM	A060611	001	

**DISCONTINUED DRUG PRODUCT LIST**METHYLPREDNISOLONE SODIUM SUCCINATE

## INJECTABLE; INJECTION

## A-METHAPRED

ABBOTT

EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991

HOSPIRA

EQ 40MG BASE/VIAL	A085853	001	
EQ 125MG BASE/VIAL	A085855	001	
EQ 500MG BASE/VIAL	A085854	001	
EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987
EQ 1GM BASE/VIAL	A085852	001	
EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987

## METHYLPREDNISOLONE

ELKINS SINN

EQ 125MG BASE/VIAL	A086906	002	
EQ 500MG BASE/VIAL	A086906	003	
EQ 1GM BASE/VIAL	A086906	004	

ORGANON USA INC

EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982

## METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986

BEDFORD LABS

EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007
EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007
EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007

ELKINS SINN

EQ 40MG BASE/VIAL	A086906	001	
-------------------	---------	-----	--

INTL MEDICATION

EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983

TEVA PARENTERAL

EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992

WATSON LABS

EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

## OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001
----------------------	-----------------------	---------	-----

METHYLTESTOSTERONE

## CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER

10MG	A084967	001	
------	---------	-----	--

VIRILON

STAR PHARMS FL

10MG	A087750	001	Nov 24, 1982
------	---------	-----	--------------

## TABLET; BUCCAL

ANDROID 5

VALEANT PHARM INTL

5MG	A087222	001	
-----	---------	-----	--

ORETON

SCHERING

10MG	A080281	001	
------	---------	-----	--

## TABLET; BUCCAL, SUBLINGUAL

METANDREN

NOVARTIS

5MG	N003240	004	
10MG	N003240	001	
10MG	N003240	005	
25MG	N003240	003	

## METHYLTESTOSTERONE

IMPAX LABS

10MG	A084287	001	
------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

METHYLTESTOSTERONE

TABLET;BUCCAL, SUBLINGUAL

METHYLTESTOSTERONE

LILLY	10MG	A080256	001
	25MG	A080256	002
PUREPAC PHARM	10MG	A080308	001
	10MG	A080475	001
	10MG	A080475	002
	25MG	A080475	003
PVT FORM	5MG	A083836	001
TABLICAPS	10MG	A085125	001
USL PHARMA	10MG	A080271	001

TABLET;ORAL

METHYLTESTOSTERONE

INWOOD LABS	10MG	A080839	001
	25MG	A080973	001
KV PHARM	10MG	A084312	001
LANNETT	10MG	A087092	001
	25MG	A087111	001
			Nov 05, 1982
			Jan 27, 1983
PARKE DAVIS	10MG	A084244	001
	25MG	A084241	001
PUREPAC PHARM	10MG	A080309	001
	25MG	A080310	001
PVT FORM	5MG	A080214	001
	10MG	A080214	002
	25MG	A080214	003
TABLICAPS	10MG	A080313	001
	25MG	A085270	001
WATSON LABS	10MG	A080933	001
	25MG	A080931	001
WEST WARD	10MG	A084331	001
	25MG	A084331	002
	25MG	A084642	001
ORETON METHYL			
SCHERING	10MG	N003158	001
	25MG	N003158	002

METHYPRYLON

CAPSULE;ORAL

NOLUDAR

ROCHE	300MG	N009660	008
-------	-------	---------	-----

ELIXIR;ORAL

NOLUDAR

ROCHE	50MG/5ML	N009660	007
-------	----------	---------	-----

TABLET;ORAL

NOLUDAR

ROCHE	50MG	N009660	002
	200MG	N009660	004

METHYSERGIDE MALEATE

TABLET;ORAL

SANSERT

NOVARTIS	2MG	N012516	001
----------	-----	---------	-----

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE;ORAL

METOCLOPRAMIDE INTENSOL

ROXANE	EQ 10MG BASE/ML	A072995	001	Jan 30, 1992
--------	-----------------	---------	-----	--------------

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD	EQ 5MG BASE/ML	A072155	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072244	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072247	001	May 18, 1992
HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
	EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
	EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
	EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
	EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991
	EQ 5MG BASE/ML	A074147	001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987

## DISCONTINUED DRUG PRODUCT LIST

METOCLOPRAMIDE HYDROCHLORIDE

## INJECTABLE; INJECTION

## REGLAN

EUROHLTH INTL SARL	EQ 5MG BASE/ML	N017862 001	
	EQ 10MG BASE/ML	N017862 004	May 28, 1987

## SOLUTION; ORAL

## METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340 001	Aug 18, 1988
MORTON GROVE	EQ 5MG BASE/5ML	A070949 001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665 001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038 001	Dec 05, 1988
TEVA	EQ 5MG BASE/5ML	A070819 001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315 001	Jun 30, 1993

## REGLAN

ROBINS AH	EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018821 001	Mar 25, 1983
-----------	--	-------------	--------------

## TABLET; ORAL

## CLOPRA

QUANTUM PHARMICS	EQ 5MG BASE	A072384 001	Jun 02, 1988
	EQ 10MG BASE	A070294 001	Jul 29, 1985

## CLOPRA-"YELLOW"

QUANTUM PHARMICS	EQ 10MG BASE	A070632 001	Oct 28, 1985
------------------	--------------	-------------	--------------

## MAXOLON

KING PHARMS	EQ 10MG BASE	A070106 001	Mar 04, 1986
-------------	--------------	-------------	--------------

## METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL	EQ 10MG BASE	A072639 001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906 001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213 001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660 001	Feb 10, 1987
	EQ 10MG BASE	A071536 001	Apr 28, 1993
PAR PHARM	EQ 10MG BASE	A070342 001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436 001	Jun 22, 1989
	EQ 5MG BASE	A074478 001	Oct 05, 1995
	EQ 10MG BASE	A070850 001	Feb 03, 1987
	EQ 10MG BASE	A072215 001	Jan 30, 1990
	EQ 10MG BASE	A074478 002	Oct 05, 1995
SCHERING	EQ 10MG BASE	A070598 001	Feb 02, 1987
SUPERPHARM	EQ 10MG BASE	A070926 001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339 001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363 001	Mar 02, 1987
	EQ 10MG BASE	A070453 001	Jun 06, 1986
	EQ 10MG BASE	A070511 001	Jan 22, 1986
	EQ 10MG BASE	A070645 001	May 11, 1987

## TABLET, ORALLY DISINTEGRATING; ORAL

## METOZOLV ODT

SALIX PHARMS	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022246 002	Sep 04, 2009
--------------	---	-------------	--------------

## REGLAN ODT

MEDA PHARMS	EQ 5MG BASE	N021793 001	Jun 10, 2005
	EQ 10MG BASE	N021793 002	Jun 10, 2005

METOCURINE IODIDE

## INJECTABLE; INJECTION

## METUBINE IODIDE

LILLY	2MG/ML	N006632 003	
-------	--------	-------------	--

METOLAZONE

## TABLET; ORAL

## DIULO

GD SEARLE LLC	2.5MG	N018535 001	
	5MG	N018535 002	
	10MG	N018535 003	

## METOLAZONE

ROXANE	10MG	A076482 002	Apr 29, 2004
TEVA	2.5MG	A076600 001	Jan 06, 2004
	5MG	A076833 001	Mar 01, 2004
	10MG	A075543 003	Dec 24, 2003
WATSON LABS	10MG	A076891 001	Jul 21, 2004

## MYKROX

UCB INC	0.5MG	N019532 001	Oct 30, 1987
---------	-------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE;ORAL

LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N019786 001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786 002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786 003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786 004	Dec 27, 1989

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

NESHER PHARMS	EQ 25MG TARTRATE	A077779 001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176 001	May 14, 2008
	EQ 100MG TARTRATE	A076640 002	May 18, 2007
	EQ 200MG TARTRATE	A076640 001	May 18, 2007
SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969 002	May 18, 2007
	EQ 100MG TARTRATE	A076969 003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969 004	Mar 20, 2008

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

WATSON LABS	1MG/ML	A074032 001	Dec 21, 1993
-------------	--------	-------------	--------------

TABLET; ORAL

METOPROLOL TARTRATE

APOTHECON	50MG	A074258 001	Jan 27, 1994
	100MG	A074258 002	Jan 27, 1994
MYLAN	50MG	A073666 001	Dec 21, 1993
	100MG	A073666 002	Dec 21, 1993
PRINSTON INC	50MG	A074453 001	Apr 27, 1995
	100MG	A074453 002	Apr 27, 1995
PUREPAC PHARM	50MG	A074380 001	Jul 29, 1994
	100MG	A074380 002	Jul 29, 1994
TEVA	50MG	A074143 001	Sep 30, 1994
	100MG	A074143 002	Sep 30, 1994
TEVA PHARMS	50MG	A074333 001	Jan 27, 1994
	100MG	A074333 002	Jan 27, 1994

METRIZAMIDE

INJECTABLE; INJECTION

AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982 003	Sep 12, 1983
	3.75GM/VIAL	N017982 001	
	6.75GM/VIAL	N017982 002	
	13.5GM/VIAL	N017982 004	Sep 12, 1983

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE	375MG	A076505 001	Nov 13, 2003
------	-------	-------------	--------------

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

PFIZER	500MG/100ML	N018353 002	
--------	-------------	-------------	--

METRO I.V.

B BRAUN	500MG/100ML	N018674 001	Aug 31, 1982
---------	-------------	-------------	--------------

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889 001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071 001	Dec 03, 1984
EUROHLTH INTL SARL	500MG/100ML	N018907 001	Mar 30, 1984
INTL MEDICATION	500MG/100ML	A070004 001	May 08, 1985
WATSON LABS	500MG/100ML	A070042 001	Dec 20, 1984
	500MG/100ML	A070170 001	Apr 01, 1986

TABLET; ORAL

METROMIDOL

LABS AF	250MG	A074523 001	Oct 24, 1996
	500MG	A074523 002	Oct 24, 1996

METRONIDAZOLE

ABLE	250MG	A076519 001	Jun 27, 2003
	500MG	A076519 002	Jun 27, 2003
HALSEY	250MG	A070021 001	Apr 02, 1985
	500MG	A070593 001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517 001	
	500MG	N018517 002	May 05, 1982



**DISCONTINUED DRUG PRODUCT LIST**METRONIDAZOLE

## TABLET; ORAL

## METRONIDAZOLE

LNK	250MG	N019029 001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818 001	Feb 16, 1983
	500MG	N018818 002	Feb 16, 1983
PAR PHARM	250MG	N018845 001	Aug 18, 1983
	500MG	N018930 001	Aug 18, 1983
SANDOZ	250MG	N018620 001	Mar 04, 1982
	250MG	N018740 001	Oct 22, 1982
	500MG	N018620 002	Jun 02, 1983
	500MG	N018740 002	Oct 22, 1982
SUPERPHARM	250MG	A070008 001	Dec 11, 1984
	500MG	A070009 001	Dec 11, 1984
VIVIMED LABS	250MG	A070040 001	Jan 29, 1985
	500MG	A070039 001	Jan 29, 1985
WATSON LABS	250MG	N018599 001	Sep 17, 1982
	250MG	N018764 001	Sep 17, 1982
	500MG	N018599 002	Feb 13, 1984
	500MG	N018764 002	Dec 20, 1982
PROTOSTAT			
ORTHO MCNEIL PHARM	250MG	N018871 001	Mar 02, 1983
	500MG	N018871 002	Mar 02, 1983
SATRIC			
SAVAGE LABS	250MG	A070029 001	Mar 19, 1985
	500MG	A070731 001	Jun 08, 1987

## TABLET, EXTENDED RELEASE; ORAL

## METRONIDAZOLE

ABLE	750MG	A076462 001	Jun 25, 2003
------	-------	-------------	--------------

METRONIDAZOLE HYDROCHLORIDE

## INJECTABLE; INJECTION

## FLAGYL I.V.

PFIZER	EQ 500MG BASE/VIAL	N018353 001	
METRONIDAZOLE HYDROCHLORIDE			
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295 001	Oct 15, 1985

METYRAPONE

## TABLET; ORAL

## METOPIRONE

HRA PHARMA	250MG	N012911 001	
------------	-------	-------------	--

MEXILETINE HYDROCHLORIDE

## CAPSULE; ORAL

## MEXILETINE HYDROCHLORIDE

IDT AUSTRALIA LTD	150MG	A074450 001	May 16, 1996
	200MG	A074450 002	May 16, 1996
	250MG	A074450 003	May 16, 1996
WATSON LABS	150MG	A074711 001	Feb 26, 1997
	150MG	A074865 001	Apr 13, 1998
	200MG	A074711 002	Feb 26, 1997
	200MG	A074865 002	Apr 13, 1998
	250MG	A074711 003	Feb 26, 1997
	250MG	A074865 003	Apr 13, 1998
MEXITIL			
BOEHRINGER INGELHEIM	150MG	N018873 002	Dec 30, 1985
	200MG	N018873 003	Dec 30, 1985
	250MG	N018873 004	Dec 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

## INJECTABLE; INJECTION

## MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333 001	
	EQ 1GM BASE/VIAL	A062372 005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549 001	
	EQ 2GM BASE/VIAL	A062333 002	
	EQ 2GM BASE/VIAL	A062372 001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549 002	
	EQ 3GM BASE/VIAL	A062333 003	
	EQ 3GM BASE/VIAL	A062372 002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697 001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549 003	
	EQ 4GM BASE/VIAL	A062333 004	
	EQ 4GM BASE/VIAL	A062372 003	May 13, 1982

**DISCONTINUED DRUG PRODUCT LIST**MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

EQ 4GM BASE/VIAL	A062697 002	Jan 22, 1987
EQ 4GM BASE/VIAL	N050549 004	
EQ 20GM BASE/VIAL	A062372 004	Mar 02, 1988
EQ 20GM BASE/VIAL	N050549 005	Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA

10MG/ML

N018040 001

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS

2%

N017494 001

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA

2%

A074136 001 Jan 04, 1995

TEVA PHARMS

2%

A074030 001 Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC

2%, 100MG

A074586 001 Jul 17, 1997

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS

2%

N017739 001

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS

100MG

N018592 001 Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

APOTHECON

EQ 1MG BASE/ML

A075620 001 Nov 01, 2000

EQ 5MG BASE/ML

A075620 002 Nov 01, 2000

EQ 5MG BASE/ML

A075641 001 Oct 19, 2000

BEDFORD

EQ 5MG BASE/ML

A075249 001 Jun 23, 2000

BEN VENUE

EQ 5MG BASE/ML

A075455 001 Jun 20, 2000

CLARIS PHARMASERVICE

EQ 1MG BASE/ML

A075637 001 Oct 31, 2000

EQ 5MG BASE/ML

A075637 002 Oct 31, 2000

HOSPIRA

EQ 1MG BASE/ML

A075396 001 Jun 20, 2000

EQ 5MG BASE/ML

A075396 002 Jun 20, 2000

EQ 5MG BASE/ML

A075484 001 Jun 20, 2000

HOSPIRA INC

EQ 1MG BASE/ML

A075409 002 Jun 20, 2000

EQ 5MG BASE/ML

A075409 001 Jun 20, 2000

IGI LABS INC

EQ 5MG BASE/ML

A075263 001 Jun 26, 2000

INTL MEDICATED

EQ 1MG BASE/ML

A076144 001 Jan 26, 2005

EQ 5MG BASE/ML

A076144 002 Jan 26, 2005

INTL MEDICATION

EQ 1MG BASE/ML

A076020 001 Jul 16, 2004

EQ 5MG BASE/ML

A076020 002 Jul 16, 2004

WOCKHARDT

EQ 1MG BASE/ML

A078141 001 May 30, 2008

EQ 1MG BASE/ML

A078511 001 Nov 10, 2008

EQ 5MG BASE/ML

A078141 002 May 30, 2008

EQ 5MG BASE/ML

A078511 002 Nov 10, 2008

VERSED

HLR

EQ 1MG BASE/ML

N018654 002 May 26, 1987

EQ 5MG BASE/ML

N018654 001 Dec 20, 1985

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

APOTEX INC

EQ 2MG BASE/ML

A077115 001 Sep 09, 2005

VERSED

ROCHE

EQ 2MG BASE/ML

N020942 001 Oct 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

SHIRE LLC

2.5MG

N019815 001 Sep 06, 1996

5MG

N019815 002 Sep 06, 1996

10MG

N019815 003 Mar 20, 2002

**DISCONTINUED DRUG PRODUCT LIST**MILRINONE LACTATE

## INJECTABLE; INJECTION

## MILRINONE LACTATE

APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004
EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075852	001	May 28, 2002
HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002
	EQ 1MG BASE/ML	A075884	001	May 28, 2002
MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005
BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002
HIKMA MAPLE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002
PRIMACOR				
SANOFI AVENTIS US	EQ 1MG BASE/ML	N019436	001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER				
SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994
	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994
	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994
	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

## CAPSULE; ORAL

## DYNACIN

CNTY LINE PHARMS	EQ 50MG BASE	A063066	001	Aug 14, 1990
------------------	--------------	---------	-----	--------------

## MINOCIN

PRECISION DERMAT	EQ 75MG BASE	N050649	003	Feb 12, 2001
TRIAx PHARMS	EQ 50MG BASE	N050315	002	
	EQ 100MG BASE	N050315	001	

## CAPSULE, EXTENDED RELEASE; ORAL

## XIMINO

SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012
	EQ 67.5MG BASE	N201922	002	Jul 11, 2012
	EQ 90MG BASE	N201922	003	Jul 11, 2012
	EQ 112.5MG BASE	N201922	004	Jul 11, 2012
	EQ 135MG BASE	N201922	005	Jul 11, 2012

## INJECTABLE; INJECTION

## MINOCIN

LEDERLE	EQ 100MG BASE/VIAL	A062139	001	
---------	--------------------	---------	-----	--

## SUSPENSION; ORAL

## MINOCIN

PRECISION DERMAT	EQ 50MG BASE/5ML	N050445	001	
------------------	------------------	---------	-----	--

## TABLET; ORAL

## MINOCYCLINE HYDROCHLORIDE

TRIAx PHARMS	EQ 50MG BASE	N050451	003	Aug 10, 1982
	EQ 100MG BASE	N050451	002	Aug 10, 1982

## TABLET, EXTENDED RELEASE; ORAL

## MINOCYCLINE HYDROCHLORIDE

LUPIN LTD	EQ 55MG BASE	A091424	002	Nov 30, 2011
SOLODYN				
MEDICIS	EQ 45MG BASE	N050808	001	May 08, 2006
	EQ 90MG BASE	N050808	002	May 08, 2006
	EQ 135MG BASE	N050808	003	May 08, 2006

MINOXIDIL

## SOLUTION; TOPICAL

## MINOXIDIL (FOR MEN)

APOTEX INC	2%	A074924	001	Apr 29, 1998
BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
COPELY PHARM	2%	A074500	001	May 23, 1996
SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
TEVA	2%	A074589	001	Apr 05, 1996

## MINOXIDIL (FOR WOMEN)

APOTEX INC	2%	A074924	002	Apr 29, 1998
SIGHT PHARMS	2%	A074743	001	Oct 18, 1996

## MINOXIDIL EXTRA STRENGTH (FOR MEN)

APOTEX INC	5%	A075839	001	Oct 01, 2001
------------	----	---------	-----	--------------

## TABLET; ORAL

## LONITEN

PHARMACIA AND UPJOHN	2.5MG	N018154	001	
	10MG	N018154	003	

## MINODYL

QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
	10MG	A071534	001	Mar 19, 1987

**DISCONTINUED DRUG PRODUCT LIST**MINOXIDIL

TABLET; ORAL

MINOXIDIL

ROYCE LABS	2.5MG	A071799 001	Nov 10, 1987
	10MG	A071796 001	Nov 10, 1987
USL PHARMA	2.5MG	A071537 001	Dec 16, 1988

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241 001	Jun 25, 2003
	15MG	A076308 001	Jun 20, 2003
	30MG	A076241 002	Jun 25, 2003
	30MG	A076308 002	Jun 20, 2003
	45MG	A076241 003	Jun 25, 2003
	45MG	A076308 003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244 001	Dec 22, 2003
	30MG	A076244 002	Dec 22, 2003
	45MG	A076244 003	Dec 22, 2003
ROXANE	15MG	A076270 001	Jun 19, 2003
	30MG	A076270 002	Jun 19, 2003
	45MG	A076270 003	Jun 19, 2003
SANDOZ	15MG	A076189 001	Jun 19, 2003
	30MG	A076189 002	Jun 19, 2003
	45MG	A076189 003	Jun 19, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689 001	Aug 31, 2005
	15MG	A077959 001	Feb 14, 2011
	30MG	A076689 002	Aug 31, 2005
	30MG	A077959 002	Feb 14, 2011
	45MG	A076689 003	Aug 31, 2005
	45MG	A077959 003	Feb 14, 2011

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA	20MG/VIAL	A064106 001	Nov 29, 1995
MITOZYTREX			
SUPERGEN	5MG/VIAL	N050763 001	Nov 14, 2002
MUTAMYCIN			
BRISTOL	5MG/VIAL	N050450 001	
	20MG/VIAL	N050450 002	
BRISTOL MYERS	5MG/VIAL	A062336 001	
	20MG/VIAL	A062336 002	
	40MG/VIAL	A062336 003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008
NOVANTRONE			
EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297 001	Dec 23, 1987
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	N019297 002	Dec 23, 1987
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N019297 003	Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE	EQ 0.5MG BASE/ML	N020098 002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098 003	Jan 22, 1992

MIVACURIUM CHLORIDE

MYLAN LABS LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009
----------------	----------------	-------------	--------------

SOLUTION; INTRAVENOUS

MIVACRON

ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML)	N020098 001	Jan 22, 1992
--------	---------------------------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

ENDO PHARMS

5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017111 001

10MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017111 002

25MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017111 003

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS

20MG/ML

N017938 001

TABLET; ORAL

MOBAN

ENDO PHARMS

5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017111 004

10MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017111 005

25MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017111 006

50MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017111 007

100MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017111 008

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

TARO

0.1%

A076624 001 Dec 03, 2004

MONOBENZONE

CREAM; TOPICAL

BENOQUIN

VALEANT PHARM INTL

20%

N008173 003

MONOCTANOIN

LIQUID; PERFUSION, BILIARY

MOCTANIN

ETHITEK

100%

N019368 001 Oct 29, 1985

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

SHIRE

200MG

N019753 001 Jun 19, 1990

250MG

N019753 002 Jun 19, 1990

300MG

N019753 003 Jun 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

KING PHARMS LLC

30MG

N021260 001 Mar 20, 2002

45MG

N021260 005 Dec 18, 2008

60MG

N021260 002 Mar 20, 2002

75MG

N021260 006 Dec 18, 2008

90MG

N021260 003 Mar 20, 2002

120MG

N021260 004 Mar 20, 2002

INJECTABLE; INJECTION

MORPHINE SULFATE

HOSPIRA

0.5MG/ML

N019917 001 Oct 30, 1992

MALLINCKRODT

1MG/ML

N020631 001 Jul 03, 1996

2MG/ML

N020631 002 Jul 03, 1996

WATSON LABS

0.5MG/ML

A073373 001 Sep 30, 1991

## DISCONTINUED DRUG PRODUCT LIST

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

0.5MG/ML

A073375 001 Sep 30, 1991

1MG/ML

A073374 001 Sep 30, 1991

1MG/ML

A073376 001 Sep 30, 1991

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

PACIRA PHARMS INC

10MG/ML (10MG/ML)

N021671 001 May 18, 2004

15MG/1.5ML (10MG/ML)

N021671 002 May 18, 2004

20MG/2ML (10MG/ML)

N021671 003 May 18, 2004

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

WATSON LABS

100MG

A075656 001 Jan 30, 2001

ORAMORPH SR

XANODYNE PHARMS INC

15MG

N019977 004 Nov 23, 1994

30MG

N019977 001 Aug 15, 1991

60MG

N019977 002 Aug 15, 1991

100MG

N019977 003 Aug 15, 1991

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY

EQ 250MG BASE/VIAL

N050550 001

EQ 500MG BASE/VIAL

N050550 002

EQ 1GM BASE/VIAL

N050550 003

EQ 2GM BASE/VIAL

N050550 004

EQ 10GM BASE/VIAL

N050550 008

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD

250MG

A091315 001 Oct 27, 2011

ZYDUS PHARMS USA INC

250MG

A065433 001 May 04, 2009

TABLET; ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD

500MG

A090464 001 Sep 13, 2010

ZYDUS PHARMS USA INC

500MG

A065477 001 May 04, 2009

NABUMETONE

TABLET; ORAL

NABUMETONE

COPLY PHARM

750MG

A075179 001 Jun 06, 2000

DR REDDYS LABS LTD

500MG

A078420 001 Sep 24, 2008

750MG

A078420 002 Sep 24, 2008

PROSAM LABS

500MG

A079093 001 Feb 27, 2009

750MG

A079093 002 Feb 27, 2009

SANDOZ

500MG

A075590 001 Feb 25, 2002

750MG

A075590 002 Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM

500MG

N019583 001 Dec 24, 1991

750MG

N019583 002 Dec 24, 1991

NADOLOL

TABLET; ORAL

CORCARD

US WORLD MEDS LLC

120MG

N018063 003

160MG

N018063 004

NADOLOL

IVAX SUB TEVA PHARMS

120MG

A074255 002 Jan 24, 1996

160MG

A074255 003 Jan 24, 1996

TEVA PHARMS

80MG

A074368 001 Aug 31, 1994

120MG

A074368 002 Aug 31, 1994

160MG

A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE

N050111 001

FOR SOLUTION; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE/5ML

N050199 001

## DISCONTINUED DRUG PRODUCT LIST

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

APOTHECON

EQ 500MG BASE/VIAL

A061984 001

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

SANDOZ

EQ 500MG BASE/VIAL

A062527 001 Aug 02, 1984

WATSON LABS INC

EQ 500MG BASE/VIAL

A062844 001 Oct 26, 1988

EQ 1GM BASE/VIAL

A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001 Sep 29, 1988

NALLPEN

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

A061999 001

EQ 1GM BASE/VIAL

A061999 002

EQ 1GM BASE/VIAL

A062755 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A061999 003

EQ 2GM BASE/VIAL

A062755 002 Dec 19, 1986

EQ 10GM BASE/VIAL

A061999 004

UNIPEN

WYETH AYERST

EQ 500MG BASE/VIAL

A062717 001 Dec 16, 1986

EQ 500MG BASE/VIAL

N050320 001

EQ 1GM BASE/VIAL

A062717 002 Dec 16, 1986

EQ 2GM BASE/VIAL

A062717 004 Dec 16, 1986

EQ 2GM BASE/VIAL

N050320 003

EQ 4GM BASE/VIAL

N050320 004

EQ 10GM BASE/VIAL

N050320 005

EQ 20GM BASE/VIAL

N050320 006

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST

EQ 1GM BASE/VIAL

N050320 002

TABLET; ORAL

UNIPEN

WYETH AYERST

EQ 500MG BASE

N050462 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM

10MG/ML

A070751 001 Jul 02, 1986

20MG/ML

A070752 001 Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT

20MG/ML

A070917 001 Feb 03, 1989

ABBVIE

1.5MG/ML

N020200 001 Mar 12, 1993

BARR

10MG/ML

A074471 001 Mar 19, 1998

20MG/ML

A074471 002 Mar 19, 1998

IGI LABS INC

10MG/ML

A072070 001 Apr 10, 1989

10MG/ML

A072071 001 Apr 10, 1989

10MG/ML

A072072 001 Apr 10, 1989

20MG/ML

A072073 001 Apr 10, 1989

20MG/ML

A072074 001 Apr 10, 1989

20MG/ML

A072075 001 Apr 10, 1989

NUBAIN

ENDO PHARMS

10MG/ML

N018024 001

20MG/ML

N018024 002 May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US

250MG/5ML

N017430 001

TABLET; ORAL

NALIDIXIC ACID

MUTUAL PHARM

250MG

A070270 001 Jun 29, 1988

500MG

A070271 001 Jun 29, 1988

1GM

A070272 001 Jun 29, 1988

WATSON LABS

250MG

A071936 001 Jun 29, 1988

500MG

A072061 001 Jun 29, 1988

1GM

A071919 001 Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US

250MG

N014214 002

500MG

N014214 004

1GM

N014214 005

## DISCONTINUED DRUG PRODUCT LIST

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995
	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

HIKMA MAPLE	0.4MG/ML	A070298	001	Sep 24, 1986
	0.4MG/ML	A070496	001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
	0.02MG/ML	A070189	001	Sep 24, 1986
	0.4MG/ML	A070190	001	Sep 24, 1986
	0.4MG/ML	A070191	001	Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
	0.02MG/ML	A070661	001	Nov 17, 1986
	0.4MG/ML	A070649	001	Nov 17, 1986
	1MG/ML	A071604	001	Dec 16, 1988
ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
HIKMA MAPLE	0.02MG/ML	A071272	001	May 24, 1988
	1MG/ML	A071273	001	May 24, 1988
	1MG/ML	A071274	001	May 24, 1988
	1MG/ML	A071287	001	May 24, 1988
HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
	0.02MG/ML	A070252	001	Jan 16, 1987
	0.02MG/ML	A070253	001	Jan 16, 1987
	0.4MG/ML	A070255	001	Jan 07, 1987
IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989
	0.02MG/ML	A072083	001	Apr 11, 1989
	0.02MG/ML	A072084	001	Apr 11, 1989
	0.02MG/ML	A072085	001	Apr 11, 1989
	0.4MG/ML	A072086	001	Apr 11, 1989
	0.4MG/ML	A072087	001	Apr 11, 1989
	0.4MG/ML	A072088	001	Apr 11, 1989
	0.4MG/ML	A072089	001	Apr 11, 1989
	0.4MG/ML	A072090	001	Apr 11, 1989
	1MG/ML	A072091	001	Apr 11, 1989
	1MG/ML	A072092	001	Apr 11, 1989
	1MG/ML	A072093	001	Apr 11, 1989
INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
	1MG/ML	A072115	001	Apr 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
	0.4MG/ML	A071681	001	Nov 17, 1987
	0.4MG/ML	A071682	001	Nov 17, 1987
SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
	0.4MG/ML	A071683	001	Nov 17, 1987
WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987

NARCAN

ADAPT	0.02MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	002	
	0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	001	
	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	003	Jun 14, 1982
BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
	1MG/ML	A071084	001	Jul 28, 1988
	1MG/ML	A071311	001	Jul 28, 1988

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARGINIQ

PURDUE PHARMA LP	5MG; 10MG	N205777	001	Jul 23, 2014
	10MG; 20MG	N205777	002	Jul 23, 2014
	20MG; 40MG	N205777	003	Jul 23, 2014



**DISCONTINUED DRUG PRODUCT LIST**NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN NX

SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE	N018733 001	Dec 16, 1982
-------------------	----------------------------	-------------	--------------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

SANDOZ	50MG	A075434 001	Mar 08, 2000
--------	------	-------------	--------------

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

ASPEN GLOBAL INC	50MG/ML	N013132 001	Jun 12, 1986
	100MG/ML	N013132 002	Jun 12, 1986
	200MG/ML	N013132 003	Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM	100MG/ML	A088290 001	Oct 03, 1983
	200MG/ML	A088317 001	Oct 14, 1983
AKORN	100MG/ML	A087519 001	Sep 28, 1983
WATSON LABS	50MG/ML	A086385 001	Jan 13, 1984
	50MG/ML	A087598 001	Oct 06, 1983
	50MG/ML	A088554 001	Feb 10, 1986
	100MG/ML	A086598 001	Jan 13, 1984
	100MG/ML	A087599 001	Oct 06, 1983
	200MG/ML	A088128 001	Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

ORGANON USA INC	25MG/ML	N011891 001	
	50MG/ML	N011891 002	

NANDROLONE PHENPROPIONATE

WATSON LABS	25MG/ML	A086386 001	Jun 17, 1983
	50MG/ML	A087488 001	Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

ALLERGAN	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080248 001	
----------	---	-------------	--

NAFAZAIR

BAUSCH AND LOMB	0.1%	A040073 001	May 25, 1994
PHARMAFAIR	0.1%	A088101 001	Apr 15, 1983

NAPHCN FORTE

ALCON	0.1%	A080229 001	
-------	------	-------------	--

OPCON

BAUSCH AND LOMB	0.1%	A087506 001	
-----------------	------	-------------	--

VASOCON

NOVARTIS	0.1%	A080235 002	Mar 24, 1983
----------	------	-------------	--------------

NAPROXEN

TABLET; ORAL

NAPROXEN

DAVA PHARMS INC	250MG	A074105 001	Dec 21, 1993
	250MG	A074410 001	Apr 28, 1995
	375MG	A074105 002	Dec 21, 1993
	375MG	A074410 002	Apr 28, 1995
	500MG	A074105 003	Dec 21, 1993
	500MG	A074410 003	Apr 28, 1995
HAMILTON PHARMS	250MG	A074110 001	Oct 30, 1992
	375MG	A074110 002	Oct 30, 1992
	500MG	A074110 003	Oct 30, 1992
IVAX SUB TEVA PHARMS	250MG	A074111 001	Feb 28, 1995
	375MG	A074111 002	Feb 28, 1995
	500MG	A074111 003	Feb 28, 1995
PLIVA	250MG	A074182 001	Jun 27, 1996
	375MG	A074182 002	Jun 27, 1996
	500MG	A074182 003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263 001	Dec 21, 1993
	375MG	A074263 002	Dec 21, 1993
	500MG	A074263 003	Dec 21, 1993
ROXANE	250MG	A074211 001	Feb 28, 1994

## DISCONTINUED DRUG PRODUCT LIST

NAPROXEN

TABLET; ORAL

NAPROXEN

	375MG	A074211 002	Feb 28, 1994
	500MG	A074211 003	Feb 28, 1994
TEVA	250MG	A074129 001	Dec 21, 1993
	250MG	A074216 001	Apr 11, 1996
	375MG	A074129 002	Dec 21, 1993
	375MG	A074216 002	Apr 11, 1996
	500MG	A074129 003	Dec 21, 1993
	500MG	A074216 003	Apr 11, 1996
TEVA PHARMS	250MG	A074207 001	Dec 21, 1993
	375MG	A074207 002	Dec 21, 1993
	500MG	A074207 003	Dec 21, 1993
WATSON LABS	250MG	A074163 001	Feb 10, 1995
	250MG	A074457 001	May 31, 1995
	375MG	A074163 002	Feb 10, 1995
	375MG	A074457 002	May 31, 1995
	500MG	A074163 003	Feb 10, 1995
	500MG	A074457 003	May 31, 1995

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936 001	Feb 24, 1998
	500MG	A074936 002	Feb 24, 1998

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544 001	Aug 22, 2003
	EQ 500MG BASE	A076544 002	Aug 22, 2003
HAMILTON PHARMS	EQ 250MG BASE	A074106 001	Aug 31, 1993
	EQ 500MG BASE	A074106 002	Aug 31, 1993
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230 001	Mar 14, 1995
	EQ 500MG BASE	A074230 002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367 001	Aug 31, 1994
	EQ 500MG BASE	A074367 002	Aug 31, 1994
PLIVA	EQ 250MG BASE	A074242 001	Jun 20, 1996
	EQ 500MG BASE	A074242 002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319 001	Mar 20, 1995
	EQ 500MG BASE	A074319 002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257 001	Dec 21, 1993
	EQ 500MG BASE	A074257 002	Dec 21, 1993
SANDOZ	EQ 200MG BASE	A074646 001	Jan 13, 1997
	EQ 250MG BASE	A074162 001	Dec 21, 1993
	EQ 250MG BASE	A074495 001	Dec 05, 1994
	EQ 500MG BASE	A074162 002	Dec 21, 1993
	EQ 500MG BASE	A074495 002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142 001	Dec 21, 1993
	EQ 500MG BASE	A074142 002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289 001	Jan 27, 1994
	EQ 500MG BASE	A074289 002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195 001	Dec 21, 1993
	EQ 250MG BASE	A074455 001	May 31, 1995
	EQ 500MG BASE	A074195 002	Dec 21, 1993
	EQ 500MG BASE	A074455 002	May 31, 1995

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

TEVA PHARMS	60MG	A077467 001	Sep 09, 2009
	120MG	A077467 002	Sep 09, 2009

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

ALKEM LABS LTD	EQ 2.5MG BASE	A203741 001	Jun 24, 2015
	EQ 5MG BASE	A203741 002	Jun 24, 2015
	EQ 10MG BASE	A203741 003	Jun 24, 2015
	EQ 20MG BASE	A203741 004	Jun 24, 2015
AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659 001	Apr 16, 2015
	EQ 5MG BASE	A203659 002	Apr 16, 2015
	EQ 10MG BASE	A203659 003	Apr 16, 2015
	EQ 20MG BASE	A203659 004	Apr 16, 2015
INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828 001	Jul 29, 2015

**DISCONTINUED DRUG PRODUCT LIST**NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

	EQ 5MG BASE	A203828 002	Jul 29, 2015
	EQ 10MG BASE	A203828 003	Jul 29, 2015
	EQ 20MG BASE	A203828 004	Jul 29, 2015
WATSON LABS INC	EQ 2.5MG BASE	A203683 001	Nov 27, 2015
	EQ 5MG BASE	A203683 002	Nov 27, 2015
	EQ 10MG BASE	A203683 003	Nov 27, 2015
	EQ 20MG BASE	A203683 004	Nov 27, 2015

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS	1.75MG/INH	N019660 001	Dec 30, 1992
-------------	------------	-------------	--------------

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997
-------------------	------	-------------	--------------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

IDT AUSTRALIA LTD	50MG	A076072 001	Sep 16, 2003
	100MG	A076072 002	Sep 16, 2003
	150MG	A076072 003	Sep 16, 2003
	200MG	A076072 004	Sep 16, 2003
	250MG	A076072 005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
	100MG	A075763 002	Sep 16, 2003
	150MG	A075763 003	Sep 16, 2003
	200MG	A075763 004	Sep 16, 2003
	250MG	A075763 005	Sep 16, 2003
MYLAN	100MG	A076129 002	Sep 16, 2003
	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003
	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SANDOZ	50MG	A076302 001	Sep 16, 2003
	100MG	A076302 002	Sep 16, 2003
	150MG	A076302 003	Sep 16, 2003
	200MG	A076302 004	Sep 16, 2003
	250MG	A076302 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003
SERZONE			
BRISTOL MYERS SQUIBB	50MG	N020152 001	Dec 22, 1994
	100MG	N020152 002	Dec 22, 1994
	150MG	N020152 003	Dec 22, 1994
	200MG	N020152 004	Dec 22, 1994
	250MG	N020152 005	Dec 22, 1994
	300MG	N020152 006	Dec 22, 1994

NEFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

AGOURON	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997
---------	-----------------------	-------------	--------------

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS	100%	A061579 001	
--------------	------	-------------	--

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001	
----------------------	--------------------	-------------	--

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001	
----------------------	---------------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**NEOMYCIN SULFATE

TABLET; ORAL

NEOBIOTIC

PFIZER	EQ 350MG BASE	A060475	001
NEOMYCIN SULFATE			
BRISTOL MYERS SQUIBB	500MG	A060365	001
LANNETT	500MG	A060607	001
LILLY	500MG	A060385	001
ROXANE	500MG	A062173	001
SANDOZ	500MG	A061586	001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050176	002	Jan 14, 1985
-----------------	-----------------------------------	---------	-----	--------------

OINTMENT; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050344	002
-------	-----------------------------------	---------	-----

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML; 16,250 UNITS/ML	A062339	001	Nov 30, 1984
	EQ 3.5MG BASE/ML; 16,250 UNITS/ML	N050456	001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

ALLERGAN	EQ 0.35% BASE; 10,000 UNITS/ML; 0.5%	N050081	002
----------	--------------------------------------	---------	-----

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM; 0.25%	A061039	002
	EQ 3.5MG BASE/GM; 0.5%	A061039	001

SUSPENSION/DROPS; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML; 0.25%	A061037	001
----------------------	-------------------------	---------	-----

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

NEO-HYDELTRASOL

MERCK	EQ 3.5MG BASE/GM; EQ 0.25% PHOSPHATE	N050378	001
-------	--------------------------------------	---------	-----

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYTRES A

SAVAGE LABS	EQ 3.5MG BASE/GM; 0.1%	A062598	001	Jul 21, 1986
-------------	------------------------	---------	-----	--------------

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM; 0.1%	A062600	001	Jul 21, 1986
---------	------------------------	---------	-----	--------------

PHARMADERM	EQ 3.5MG BASE/GM; 0.1%	A062595	001	Jul 21, 1986
------------	------------------------	---------	-----	--------------

OINTMENT; TOPICAL

MYTRES A

SAVAGE LABS	EQ 3.5MG BASE/GM; 0.1%	A062609	001	May 23, 1986
-------------	------------------------	---------	-----	--------------

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM; 0.1%	A062608	001	May 23, 1986
---------	------------------------	---------	-----	--------------

PHARMADERM	EQ 3.5MG BASE/GM; 0.1%	A062607	001	May 23, 1986
------------	------------------------	---------	-----	--------------

NETILMICIN SULFATE

INJECTABLE; INJECTION

NETROMYCIN

SCHERING	EQ 10MG BASE/ML	N050544	001	Feb 28, 1983
	EQ 25MG BASE/ML	N050544	002	Feb 28, 1983
	EQ 100MG BASE/ML	N050544	003	Feb 28, 1983

NIACIN

CAPSULE; ORAL

WAMPOCAP

MEDPOINTE PHARM HLC	500MG	N011073	003
---------------------	-------	---------	-----

TABLET; ORAL

NIACIN

EVERYLIFE	500MG	A083203	001
HALSEY	500MG	A083453	001
HIKMA PHARMS LLC	500MG	A083718	001
IMPAX LABS	500MG	A083115	001
IVAX SUB TEVA PHARMS	500MG	A083180	001
MK LABS	500MG	A083525	001
PUREPAC PHARM	500MG	A083271	001

## DISCONTINUED DRUG PRODUCT LIST

NIACIN

TABLET; ORAL

NIACIN

SANDOZ	500MG	A083306	001	
TABLICAPS	500MG	A084237	001	
WATSON LABS	500MG	A083136	001	
	500MG	A083305	001	
	500MG	A085172	001	

NICOLAR

SANOFI AVENTIS US	500MG	A083823	001	
-------------------	-------	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

ABBVIE	375MG	N020381	001	Jul 28, 1997
--------	-------	---------	-----	--------------

NIASPAN TITRATION STARTER PACK

ABBVIE	375MG	N020381	005	Jul 28, 1997
--------	-------	---------	-----	--------------

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL

TPN

INTL MINERALS	15MG/5ML; 3.75MG/5ML; 600MG/5ML	N008378	003	
---------------	---------------------------------	---------	-----	--

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

WATSON LABS	20MG	A074670	001	Oct 28, 1996
	30MG	A074670	002	Oct 28, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

CHIESI USA INC	30MG	N020005	001	Feb 21, 1992
	45MG	N020005	002	Feb 21, 1992
	60MG	N020005	003	Feb 21, 1992

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

NICLOCIDE

BAYER PHARMS	500MG	N018669	001	May 14, 1982
--------------	-------	---------	-----	--------------

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

MCNEIL CONS	15MG/16HR	N020536	001	Jul 03, 1996
PROSTEP				
AVEVA	11MG/24HR	N019983	003	Dec 23, 1998
	22MG/24HR	N019983	004	Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC	EQ 2MG BASE	A076568	001	Jul 29, 2004
	EQ 4MG BASE	A076569	002	Jul 29, 2004
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009
	EQ 4MG BASE	A077850	001	Feb 18, 2009

NIFEDIPINE

CAPSULE; ORAL

ADALAT

BAYER PHARMS	10MG	N019478	001	Nov 27, 1985
	20MG	N019478	002	Sep 17, 1986

NIFEDIPINE

CATALENT	10MG	A073250	001	Oct 08, 1991
	20MG	A074045	001	Apr 30, 1992
CHASE LABS NJ	10MG	A072409	001	Jul 04, 1990
	20MG	A073421	001	Jun 19, 1991
TEVA	10MG	A072651	001	Feb 19, 1992

PROCARDIA

PFIZER	20MG	N018482	002	Jul 24, 1986
--------	------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

MARTEC USA LLC	90MG	A075414	003	Mar 23, 2004
MYLAN	30MG	A075108	001	Dec 17, 1999

## DISCONTINUED DRUG PRODUCT LIST

NILUTAMIDE

TABLET; ORAL

NILANDRON

CONCORDIA PHARMS INC 50MG N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE; ORAL

NIMOTOP

BAYER PHARMS 30MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N018869 001 Dec 28, 1988NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

SHIONOGI INC 10MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N020356 001 Feb 02, 1995  
20MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N020356 002 Feb 02, 1995  
25.5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N020356 006 Jan 02, 2008  
30MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N020356 003 Feb 02, 1995  
40MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N020356 004 Feb 02, 1995NITRIC OXIDE

GAS; INHALATION

INOMAX

INO 100PPM N020845 002 Dec 23, 1999

NITROFURANTOIN

CAPSULE; ORAL

NITROFURANTOIN

WATSON LABS 50MG A084326 001  
100MG A084326 002

TABLET; ORAL

FURADANTIN

PROCTER AND GAMBLE 50MG N008693 001  
100MG N008693 002

FURALAN

LANNETT 50MG A080017 001  
100MG A080017 002

NITROFURANTOIN

ELKINS SINN 50MG A080003 001  
100MG A080003 002  
IVAX SUB TEVA PHARMS 50MG A080078 002  
100MG A080078 001  
SANDOZ 50MG A080043 001  
100MG A080043 002  
WATSON LABS 50MG A080447 001  
50MG A085797 001  
100MG A080447 002  
100MG A085796 001  
WHITWORTH TOWN PLSN 100MG A084085 002NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE EQ 180MG BASE/VIAL N012402 001

**DISCONTINUED DRUG PRODUCT LIST**NITROFURANTOIN, MACROCRYSTALLINE

## CAPSULE; ORAL

## NITROFURANTOIN

MYLAN	100MG	A074967	002	Jul 09, 1997
SANDOZ	25MG	A074336	001	Jan 25, 1995
	50MG	A074336	002	Jan 25, 1995
	100MG	A074336	003	Jan 25, 1995
WATSON LABS	25MG	A073696	001	Dec 31, 1992
	50MG	A073696	002	Dec 31, 1992
	100MG	A073696	003	Dec 31, 1992

## NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS	50MG	A070248	001	Jun 24, 1988
	100MG	A070249	001	Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

## CAPSULE; ORAL

## NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

RANBAXY LABS LTD	75MG; 25MG	A076951	001	Mar 30, 2005
------------------	------------	---------	-----	--------------

NITROFURAZONE

## CREAM; TOPICAL

## FURACIN

SHIRE	0.2%	A083789	001	
-------	------	---------	-----	--

## DRESSING; TOPICAL

## ACTIN-N

SHERWOOD MEDCL	0.2%	N017343	001	
----------------	------	---------	-----	--

## OINTMENT; TOPICAL

## FURACIN

SHIRE	0.2%	N005795	001	
-------	------	---------	-----	--

## NITROFURAZONE

AMBIX	0.2%	A086077	001	
LANNETT	0.2%	A084393	001	
PERRIGO NEW YORK	0.2%	A084968	001	
TARO	0.2%	A086156	001	
WENDT	0.2%	A086766	001	

## POWDER; TOPICAL

## FURACIN

SHIRE	0.2%	A083791	001	
-------	------	---------	-----	--

## SOLUTION; TOPICAL

## NITROFURAZONE

PERRIGO NEW YORK	0.2%	A085130	001	
WENDT	0.2%	A087081	001	

NITROGLYCERIN

## AEROSOL; SUBLINGUAL

## NITROLINGUAL

POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985
--------------	-------------	---------	-----	--------------

## FILM, EXTENDED RELEASE; TRANSDERMAL

## NITROGLYCERIN

KREMERS URBAN PHARMS	0.2MG/HR	A075115	001	Aug 10, 2004
	0.4MG/HR	A075115	002	Aug 10, 2004
MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999
	0.2MG/HR	A074992	003	Nov 12, 1999
	0.4MG/HR	A074992	002	Nov 12, 1999
	0.6MG/HR	A074992	001	Nov 12, 1999

## TRANSDERM-NITRO

NOVARTIS	0.1MG/HR	N020144	001	Feb 27, 1996
	0.2MG/HR	N020144	002	Feb 27, 1996
	0.4MG/HR	N020144	003	Feb 27, 1996
	0.6MG/HR	N020144	004	Feb 27, 1996
	0.8MG/HR	N020144	005	Feb 27, 1996

## INJECTABLE; INJECTION

## NITRO IV

POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983
--------------	--------	---------	-----	--------------

## NITRO-BID

SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982
	10MG/ML	A071159	001	Feb 28, 1990

## NITROGLYCERIN

ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
	5MG/ML	A071203	001	May 08, 1987
HOSPIRA	5MG/ML	N018531	001	
INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
LUITPOLD	5MG/ML	A071492	001	May 24, 1988
SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986

**DISCONTINUED DRUG PRODUCT LIST**NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN

	5MG/ML	A070634	001	Jun 19, 1986
NITROGLYCERIN IN DEXTROSE 5%				
HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
NITROL				
RORER	0.8MG/ML	N018774	001	Jan 19, 1983
NITRONAL				
POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
NITROSTAT				
PARKE DAVIS	0.8MG/ML	N018588	001	
	5MG/ML	A070863	001	Jan 08, 1987
	5MG/ML	N018588	002	Dec 23, 1983
	10MG/ML	A070871	001	Jan 08, 1987
	10MG/ML	A070872	001	Jan 08, 1987
TRIDIL				
HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
	5MG/ML	N018537	001	

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
	300MG	N019508	002	Apr 12, 1988
NIZATIDINE				
ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002
	300MG	A075461	002	Jul 08, 2002
APOTEX INC	150MG	A076383	001	Jan 23, 2003
	300MG	A076383	002	Jan 23, 2003
MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002
	300MG	A075934	002	Jul 09, 2002

NONOXYNOL-9

AEROSOL; VAGINAL

DELFIN

PERSONAL PRODS	12.5%	N014349	002	
----------------	-------	---------	-----	--

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM	EQ 1MG BASE/ML	A040522	001	Sep 30, 2004
---------------	----------------	---------	-----	--------------

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK	EQ 0.033MG BASE/ML; 2%; 0.4%	N008592	003	
---------------	------------------------------	---------	-----	--

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS	5MG	N010895	002	
-------------	-----	---------	-----	--

NORETHINDRONE ACETATE

TABLET; ORAL

NORLUTATE

PARKE DAVIS	5MG	N012184	002	
-------------	-----	---------	-----	--

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK	0.3%	N019757	001	Jun 17, 1991
-------	------	---------	-----	--------------

TABLET; ORAL

NOROXIN

MERCK	400MG	N019384	002	Oct 31, 1986
-------	-------	---------	-----	--------------

NORGESTREL

TABLET; ORAL

OVRETTE

LABORATOIRE HRA	0.075MG	N017031	001	
-----------------	---------	---------	-----	--



**DISCONTINUED DRUG PRODUCT LIST**NORTRIPTYLINE HYDROCHLORIDE

## CAPSULE; ORAL

## AVENTYL HYDROCHLORIDE

LILLY	EQ 10MG BASE	N014684 001
	EQ 25MG BASE	N014684 002

## NORTRIPTYLINE HYDROCHLORIDE

## SANDOZ

EQ 10MG BASE	A074054 001	Dec 31, 1992
EQ 10MG BASE	A074835 001	Jun 30, 1997
EQ 25MG BASE	A074054 002	Dec 31, 1992
EQ 25MG BASE	A074835 002	Jun 30, 1997
EQ 50MG BASE	A074054 003	Dec 31, 1992
EQ 50MG BASE	A074835 003	Jun 30, 1997
EQ 75MG BASE	A074054 004	Dec 31, 1992
EQ 75MG BASE	A074835 004	Jun 30, 1997

## TEVA

EQ 10MG BASE	A073667 001	Apr 11, 1996
EQ 25MG BASE	A073667 002	Apr 11, 1996
EQ 50MG BASE	A073667 003	Apr 11, 1996
EQ 75MG BASE	A073667 004	Apr 11, 1996

## SOLUTION; ORAL

## AVENTYL

## RANBAXY

EQ 10MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014685 001
--	-------------

## PAMELOR

## MALLINCKRODT INC

EQ 10MG BASE/5ML	N018012 001
------------------	-------------

NYSTATIN

## CREAM; TOPICAL

## CANDEX

## BAYER PHARMS

100,000 UNITS/GM	A061810 001
------------------	-------------

## MYCOSTATIN

## DELCOR ASSET CORP

100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060575 001
--	-------------

## MYKINAC

## ALPHARMA US PHARMS

100,000 UNITS/GM	A062387 001	Jul 29, 1982
------------------	-------------	--------------

## NILSTAT

## LEDERLE

100,000 UNITS/GM	A061445 001
------------------	-------------

## NYSTATIN

## TARO

100,000 UNITS/GM	A062457 001	Jul 28, 1983
------------------	-------------	--------------

## LOTION; TOPICAL

## CANDEX

## BAYER PHARMS

100,000 UNITS/ML	N050233 001
------------------	-------------

## OINTMENT; TOPICAL

## MYCOSTATIN

## DELCOR ASSET CORP

100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060571 001
--	-------------

## MYKINAC

## ALPHARMA US PHARMS

100,000 UNITS/GM	A062731 001	Sep 22, 1986
------------------	-------------	--------------

## NILSTAT

## LEDERLE

100,000 UNITS/GM	A061444 001
------------------	-------------

## PASTILLE; ORAL

## MYCOSTATIN

## BRISTOL MYERS SQUIBB

200,000 UNITS	N050619 001	Apr 09, 1987
---------------	-------------	--------------

## POWDER; ORAL

## BARSTATIN 100

## BARLAN

100%	A062489 001	Apr 27, 1988
------	-------------	--------------

## NILSTAT

## DAVA PHARMS INC

100%	N050576 001	Dec 22, 1983
------	-------------	--------------

## NYSTATIN

## PADDOCK LLC

100%	A062613 001	Nov 26, 1985
------	-------------	--------------

## POWDER; TOPICAL

## MYCOSTATIN

## DELCOR ASSET CORP

100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060578 001
--	-------------

## NYSTATIN

## NESHER PHARMS

100,000 UNITS/GM	A065321 001	Aug 18, 2006
------------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**NYSTATIN

## SUPPOSITORY; VAGINAL

## NYSERT

WARNER CHILCOTT	100,000 UNITS	N050478	001
-----------------	---------------	---------	-----

## SUSPENSION; ORAL

## MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001
-------------------	------------------	---------	-----

## NILSTAT

GLENMARK GENERICS	100,000 UNITS/ML	N050299	001
-------------------	------------------	---------	-----

## NYSTATIN

ALPHARMA US PHARMS	100,000 UNITS/ML	A062571	001	Oct 29, 1985
--------------------	------------------	---------	-----	--------------

G AND W LABS INC	100,000 UNITS/ML	A062776	001	Dec 17, 1987
------------------	------------------	---------	-----	--------------

MORTON GROVE	100,000 UNITS/ML	A062835	001	Nov 19, 1987
--------------	------------------	---------	-----	--------------

PHARMADERM	100,000 UNITS/ML	A062518	001	Jul 06, 1984
------------	------------------	---------	-----	--------------

PHARMAFAIR	100,000 UNITS/ML	A062541	001	Jan 16, 1985
------------	------------------	---------	-----	--------------

ROXANE	100,000 UNITS/ML	A062832	001	Dec 27, 1991
--------	------------------	---------	-----	--------------

TEVA	100,000 UNITS/ML	A062670	001	Jun 18, 1987
------	------------------	---------	-----	--------------

## NYSTEX

SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984
-------------	------------------	---------	-----	--------------

## TABLET; ORAL

## MYCOSTATIN

DELCOR ASSET CORP	500,000 UNITS	A060574	001
-------------------	---------------	---------	-----

## NILSTAT

LEDERLE	500,000 UNITS	A061151	001
---------	---------------	---------	-----

## NYSTATIN

QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984
------------------	---------------	---------	-----	--------------

SANDOZ	500,000 UNITS	A062065	001
--------	---------------	---------	-----

USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985
------------	---------------	---------	-----	--------------

WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982
-------------	---------------	---------	-----	--------------

## TABLET; VAGINAL

## KOROSTATIN

HOLLAND RANTOS	100,000 UNITS	A061718	001
----------------	---------------	---------	-----

## MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS	A060577	001
-------------------	---------------	---------	-----

## NILSTAT

LEDERLE	100,000 UNITS	A061325	001
---------	---------------	---------	-----

## NYSTATIN

FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983
---------	---------------	---------	-----	--------------

PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983
------------	---------------	---------	-----	--------------

QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984
------------------	---------------	---------	-----	--------------

SANDOZ	100,000 UNITS	A061965	001
--------	---------------	---------	-----

TEVA	100,000 UNITS	A062502	001	Dec 23, 1983
------	---------------	---------	-----	--------------

WATSON LABS	100,000 UNITS	A062176	001
-------------	---------------	---------	-----

NYSTATIN; TRIAMCINOLONE ACETONIDE

## CREAM; TOPICAL

## MYCO-TRIACET II

TEVA	100,000 UNITS/GM; 0.1%	A061954	002	Sep 20, 1985
------	------------------------	---------	-----	--------------

## MYCOLOG-II

DELCOR ASSET CORP	100,000 UNITS/GM; 0.1%	A060576	002	May 01, 1985
-------------------	------------------------	---------	-----	--------------

	100,000 UNITS/GM; 0.1%	A062606	001	May 15, 1985
--	------------------------	---------	-----	--------------

## MYTRES F

SAVAGE LABS	100,000 UNITS/GM; 0.1%	A062597	001	Oct 08, 1985
-------------	------------------------	---------	-----	--------------

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	100,000 UNITS/GM; 0.1%	A063010	001	Dec 20, 1988
--------------------	------------------------	---------	-----	--------------

PERRIGO NEW YORK	100,000 UNITS/GM; 0.1%	A062186	002	Jun 06, 1985
------------------	------------------------	---------	-----	--------------

PHARMAFAIR	100,000 UNITS/GM; 0.1%	A062657	001	Jul 30, 1986
------------	------------------------	---------	-----	--------------

TARO	100,000 UNITS/GM; 0.1%	A062347	001	Mar 30, 1987
------	------------------------	---------	-----	--------------

## NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM; 0.1%	A062596	001	Oct 08, 1985
------------	------------------------	---------	-----	--------------

## OINTMENT; TOPICAL

## MYCO-TRIACET II

TEVA	100,000 UNITS/GM; 0.1%	A062045	002	Nov 26, 1985
------	------------------------	---------	-----	--------------

## MYCOLOG-II

DELCOR ASSET CORP	100,000 UNITS/GM; 0.1%	A060572	001	Jun 28, 1985
-------------------	------------------------	---------	-----	--------------

## MYTRES F

SAVAGE LABS	100,000 UNITS/GM; 0.1%	A062601	001	Oct 09, 1985
-------------	------------------------	---------	-----	--------------

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

PERRIGO NEW YORK	100,000 UNITS/GM; 0.1%	A062280	002	Oct 10, 1985
------------------	------------------------	---------	-----	--------------

PHARMAFAIR	100,000 UNITS/GM; 0.1%	A062656	001	Jul 30, 1986
------------	------------------------	---------	-----	--------------

## NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM; 0.1%	A062603	001	Oct 09, 1985
------------	------------------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**OFLOXACIN

## INJECTABLE; INJECTION

## FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087 002	Mar 31, 1992
	40MG/ML	N020087 003	Mar 31, 1992

## FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM	400MG/100ML	N020087 001	Mar 31, 1992
--------------------	-------------	-------------	--------------

## FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM	4MG/ML	N020087 004	Mar 31, 1992
	400MG/100ML	N020087 005	Mar 31, 1992

## OFLOXACIN

BEDFORD	40MG/ML	A075762 001	Jan 16, 2002
---------	---------	-------------	--------------

## SOLUTION/DROPS; OPHTHALMIC

## OFLOXACIN

APOTEX INC	0.3%	A076513 001	May 14, 2004
SANDOZ	0.3%	A076848 001	Nov 25, 2008

## TABLET; ORAL

## FLOXIN

JANSSEN PHARMS	200MG	N019735 001	Dec 28, 1990
	300MG	N019735 002	Dec 28, 1990
	400MG	N019735 003	Dec 28, 1990

## OFLOXACIN

LARKEN LABS	200MG	A076093 001	Sep 02, 2003
	300MG	A076093 002	Sep 02, 2003
RANBAXY LABS LTD	200MG	A076220 001	Sep 02, 2003
	300MG	A076220 002	Sep 02, 2003
	400MG	A076220 003	Sep 02, 2003

OMEPRAZOLE; SODIUM BICARBONATE

## FOR SUSPENSION; ORAL

## OMEPRAZOLE AND SODIUM BICARBONATE

PAR PHARM	20MG/PACKET; 1.68GM/PACKET	A079182 001	Apr 19, 2013
	40MG/PACKET; 1.68GM/PACKET	A079182 002	Apr 19, 2013

ONDANSETRON

## TABLET, ORALLY DISINTEGRATING; ORAL

## ONDANSETRON

NESHER PHARMS	4MG	A077717 001	Jun 25, 2007
	8MG	A077717 002	Jun 25, 2007
PAR PHARM	4MG	A076506 001	Dec 26, 2006
	8MG	A076506 002	Dec 26, 2006
	16MG	A077406 001	Dec 26, 2006
	24MG	A077406 002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

## INJECTABLE; INJECTION

## ONDANSETRON HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077368 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076695 001	Dec 26, 2006
LANNETT	EQ 2MG BASE/ML	A090116 001	Apr 14, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582 001	Dec 26, 2006
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544 001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007

## ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.64MG BASE/ML	A076978 001	Feb 26, 2007
---------	-------------------	-------------	--------------

## ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

APOTEX INC	EQ 2MG BASE/ML	A077343 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696 001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387 001	Dec 26, 2006
TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014 001	Mar 21, 2008

## ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N020403 001	Jan 31, 1995
-----------------	-------------------	-------------	--------------

## TABLET; ORAL

## ONDANSETRON HYDROCHLORIDE

HIKMA PHARMS LLC	EQ 4MG BASE	A077545 001	Sep 06, 2007
	EQ 8MG BASE	A077545 002	Sep 06, 2007
	EQ 24MG BASE	A077545 003	Sep 06, 2007
PAR PHARM	EQ 4MG BASE	A077303 001	Jun 25, 2007
	EQ 8MG BASE	A077303 002	Jun 25, 2007
	EQ 24MG BASE	A077303 004	Jun 25, 2007
TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011
	EQ 8MG BASE	A077729 002	Mar 28, 2011
	EQ 24MG BASE	A077729 003	Mar 28, 2011

**DISCONTINUED DRUG PRODUCT LIST**ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

IGI LABS INC 30MG/ML N013055 001

ORPHENADRINE CITRATE

WATSON LABS 30MG/ML A087062 001

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

MEDICIS 100MG N012157 001

ORPHENADRINE CITRATE

ASCOT 100MG A088067 001 Apr 06, 1983

SANDOZ 100MG A085046 001

WATSON LABS 100MG A084303 001

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M 50MG N010653 001

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE EQ 12MG BASE/ML N021246 001 Dec 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE EQ 250MG BASE A061336 001

EQ 250MG BASE A062241 001

EQ 500MG BASE A061336 002

EQ 500MG BASE A062241 002

OXACILLIN SODIUM

ANI PHARMS INC EQ 250MG BASE A062222 001

EQ 500MG BASE A062222 002

APOTHECON EQ 250MG BASE A061450 002

EQ 500MG BASE A061450 001

PROSTAPHLIN

APOTHECON EQ 500MG BASE N050118 002

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE EQ 250MG BASE/5ML A062321 001

OXACILLIN SODIUM

APOTHECON EQ 250MG BASE/5ML A061457 001

TEVA EQ 250MG BASE/5ML A062252 001

PROSTAPHLIN

APOTHECON EQ 250MG BASE/5ML N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE EQ 500MG BASE/VIAL A061334 009 Mar 26, 1982

EQ 1GM BASE/VIAL A061334 006 Mar 26, 1982

EQ 1GM BASE/VIAL A062736 001 Dec 19, 1986

EQ 2GM BASE/VIAL A061334 007 Mar 26, 1982

EQ 2GM BASE/VIAL A062736 002 Dec 19, 1986

EQ 4GM BASE/VIAL A061334 008 Mar 26, 1982

EQ 10GM BASE/VIAL A061334 010

OXACILLIN SODIUM

APOTHECON EQ 250MG BASE/VIAL N050195 001

EQ 500MG BASE/VIAL N050195 002

EQ 1GM BASE/VIAL N050195 003

EQ 2GM BASE/VIAL N050195 004

EQ 4GM BASE/VIAL N050195 005

ELKINS SINN EQ 250MG BASE/VIAL A062711 001 Feb 03, 1989

EQ 500MG BASE/VIAL A062711 002 Feb 03, 1989

EQ 1GM BASE/VIAL A062711 003 Feb 03, 1989

EQ 2GM BASE/VIAL A062711 004 Feb 03, 1989

EQ 4GM BASE/VIAL A062711 005 Feb 03, 1989

EQ 10GM BASE/VIAL A062711 006 Feb 03, 1989

ISTITUTO BIO ITA SPA EQ 125MG BASE/VIAL A062798 003 Dec 11, 1995

EQ 250MG BASE/VIAL A062798 004 Dec 11, 1995

EQ 500MG BASE/VIAL A062798 005 Dec 11, 1995

EQ 1GM BASE/VIAL A062798 001 Dec 11, 1995

EQ 2GM BASE/VIAL A062798 002 Dec 11, 1995

SANDOZ EQ 250MG BASE/VIAL A061490 001

EQ 500MG BASE/VIAL A061490 002

## DISCONTINUED DRUG PRODUCT LIST

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

WATSON LABS INC

EQ 250MG BASE/VIAL

A062856 001 Oct 26, 1988

EQ 500MG BASE/VIAL

A062856 002 Oct 26, 1988

EQ 1GM BASE/VIAL

A062856 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062856 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A062984 001 Sep 29, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

SANOFI AVENTIS US

50MG/VIAL

N021492 001 Aug 09, 2002

100MG/VIAL

N021492 002 Aug 09, 2002

OXALIPLATIN

SANDOZ

50MG/VIAL

A090849 001 Apr 28, 2011

100MG/VIAL

A090849 002 Apr 28, 2011

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

PFIZER

250MG

N018069 001

OXANDROLONE

TABLET; ORAL

OXANDROLONE

ROXANE

2.5MG

A077249 001 Jul 10, 2007

10MG

A077249 002 Jul 10, 2007

SANDOZ

2.5MG

A076897 001 Dec 01, 2006

10MG

A076897 002 Dec 01, 2006

OXAPROZIN

TABLET; ORAL

OXAPROZIN

ACTAVIS ELIZABETH

600MG

A075843 001 Oct 03, 2001

MYLAN

600MG

A075851 001 Aug 17, 2001

MYLAN PHARMS INC

600MG

A075847 001 Feb 28, 2001

SANDOZ

600MG

A075842 001 Apr 12, 2001

600MG

A075850 001 Apr 27, 2001

WATSON LABS

600MG

A075848 001 Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

GD SEARLE

600MG

N020776 001 Oct 17, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP

10MG

A071955 001 Mar 03, 1988

15MG

A071956 001 Mar 03, 1988

30MG

A071957 001 Mar 03, 1988

IVAX SUB TEVA PHARMS

10MG

A070943 001 Aug 03, 1987

15MG

A070944 001 Aug 03, 1987

30MG

A070945 001 Aug 03, 1987

MUTUAL PHARM

10MG

A071026 002 Aug 10, 1987

15MG

A071026 003 Aug 10, 1987

30MG

A071026 001 Aug 10, 1987

MYLAN

10MG

A071713 001 Oct 20, 1987

15MG

A071714 001 Oct 20, 1987

30MG

A071715 001 Oct 20, 1987

WATSON LABS

10MG

A072952 001 Sep 28, 1990

15MG

A072953 001 Sep 28, 1990

30MG

A072954 001 Sep 28, 1990

SERAX

ALPHARMA US PHARMS

10MG

N015539 002

15MG

N015539 004

30MG

N015539 006

ZAXOPAM

QUANTUM PHARMICS

10MG

A070650 001 Mar 01, 1988

15MG

A070640 001 Mar 01, 1988

30MG

A070641 001 Mar 01, 1988

**DISCONTINUED DRUG PRODUCT LIST**OXAZEPAM

TABLET; ORAL

OXAZEPAM

MUTUAL PHARM

15MG

A070683 001 Jan 16, 1987

PARKE DAVIS

15MG

A071508 001 Feb 02, 1987

WATSON LABS

15MG

A071494 001 Apr 21, 1987

SERAX

ALPHARMA US PHARMS

15MG

N015539 008

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

ANI PHARMS INC

150MG

A078005 001 Dec 11, 2007

300MG

A078005 002 Dec 11, 2007

600MG

A078005 003 Dec 11, 2007

OPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS

20MG

N018166 001 Dec 28, 1983

40MG

N018166 002 Dec 28, 1983

80MG

N018166 003 Dec 28, 1983

160MG

N018166 004 Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS

100MG/5ML

N009268 012 Nov 27, 1984

OXTRIPHYLLINE

MORTON GROVE

100MG/5ML

A088243 001 Dec 05, 1983

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS

50MG/5ML

N009268 011

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE

50MG/5ML

A088242 001 Dec 05, 1983

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS

100MG

N009268 003

200MG

N009268 007

OXTRIPHYLLINE

WATSON LABS

100MG

A087866 001 Aug 25, 1983

200MG

A087835 001 Aug 25, 1983

OXYBUTYNYN CHLORIDE

SYRUP; ORAL

DITROPAN

ORTHO MCNEIL JANSSEN

5MG/5ML

N018211 001

OXYBUTYNYN CHLORIDE

APOTEX INC

5MG/5ML

A074997 001 Oct 15, 1997

MIKART

5MG/5ML

A075039 001 Jan 29, 1999

TABLET; ORAL

DITROPAN

JANSSEN PHARMS

5MG

N017577 001

OXYBUTYNYN CHLORIDE

QUANTUM PHARMICS

5MG

A072296 001 Dec 08, 1988

USL PHARMA

5MG

A070746 001 Mar 10, 1988

WATSON LABS

5MG

A072485 001 Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ROXICODONE

ROXANE

10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

ENDO PHARMS

1.5MG/ML

N011707 001

SUPPOSITORY; RECTAL

NUMORPHAN

ENDO PHARMS

5MG

N011738 004

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

ENDO PHARMS

5MG

N021610 001 Jun 22, 2006

7.5MG

N021610 005 Feb 29, 2008

**DISCONTINUED DRUG PRODUCT LIST**OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
OPANA ER

10MG	N021610 002	Jun 22, 2006
15MG	N021610 006	Feb 29, 2008
20MG	N021610 003	Jun 22, 2006
30MG	N021610 007	Feb 29, 2008
40MG	N021610 004	Jun 22, 2006

OXYPHENBUTAZONE

TABLET;ORAL

OXYPHENBUTAZONE

WATSON LABS

100MG

A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS

100MG

N012542 004 Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET;ORAL

DARICON

PFIZER

10MG

N011612 001

OXYPHENONIUM BROMIDE

TABLET;ORAL

ANTRENYL

NOVARTIS

5MG

N008492 002

OXYTETRACYCLINE

TABLET;ORAL

TERRAMYCIN

PFIZER

250MG

N050287 001

OXYTETRACYCLINE CALCIUM

SYRUP;ORAL

TERRAMYCIN

PFIZER

EQ 125MG BASE/5ML

A060595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

OXY-KESSO-TETRA

FERRANTE

EQ 250MG BASE

A060179 001

OXYTETRACYCLINE HYDROCHLORIDE

HIKMA PHARMS LLC

EQ 250MG BASE

A060770 001

IMPAX LABS

EQ 250MG BASE

A060760 001

PROTER

EQ 250MG BASE

A060869 001

PUREPAC PHARM

EQ 250MG BASE

A060634 001

TERRAMYCIN

PFIZER

EQ 125MG BASE

N050286 001

EQ 250MG BASE

N050286 002

INJECTABLE;INJECTION

TERRAMYCIN

PFIZER

EQ 250MG BASE/VIAL

A060586 001

EQ 500MG BASE/VIAL

A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER

EQ 5MG BASE/GM;10,000 UNITS/GM

A061841 001

TABLET;VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER

EQ 100MG BASE;100,000 UNITS

A061009 001

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

TEVA PHARMS USA

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

ABBOTT

1USP UNITS/100ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N019185 004 Mar 29, 1985

2USP UNITS/100ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N019185 003 Mar 29, 1985

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

ABBOTT

2USP UNITS/100ML \*\*Federal Register

N019185 002 Mar 29, 1985

**DISCONTINUED DRUG PRODUCT LIST**OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

ABBOTT

1USP UNITS/100ML \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N019185 001 Mar 29, 1985

SYNTOCINON

NOVARTIS

10USP UNITS/ML

N018245 001

SOLUTION; NASAL

SYNTOCINON

RTRX

40USP UNITS/ML

N012285 001

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

ACCORD HLTHCARE

6MG/ML

A075436 001 Nov 12, 2004

HOSPIRA

6MG/ML

A076233 001 Aug 01, 2002

MYLAN

6MG/ML

A075278 001 Jan 25, 2002

PLIVA LACHEMA

6MG/ML

A077413 001 Mar 12, 2008

TEVA PHARMS USA

6MG/ML

A075297 001 Jan 25, 2002

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

JANSSEN PHARMS

12MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N021999 004 Dec 19, 2006

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

HELSINN HLTHCARE

EQ 0.5MG BASE \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N022233 001 Aug 22, 2008

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

NOVARTIS

30MG/VIAL

N020036 001 Oct 31, 1991

60MG/VIAL

N020036 003 May 06, 1993

90MG/VIAL

N020036 004 May 06, 1993

PAMIDRONATE DISODIUM

AESGEN

30MG/VIAL

A075594 001 May 06, 2002

90MG/VIAL

A075594 002 May 06, 2002

MN PHARMS

30MG/VIAL

A078300 001 Mar 10, 2009

90MG/VIAL

A078300 002 Mar 10, 2009

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE; ORAL

COTAZYM

ORGANON USA INC

30000USPU; 30000USPU; 8000USPU

N020580 001 Dec 09, 1996

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ELKINS SINN

1MG/ML

A072058 001 Mar 23, 1988

2MG/ML

A072059 001 Mar 23, 1988

2MG/ML

A072060 001 Mar 23, 1988

HOSPIRA

2MG/ML

A072321 001 Jan 19, 1989

IGI LABS INC

1MG/ML

A072210 001 Mar 31, 1988

2MG/ML

A072211 001 Mar 31, 1988

2MG/ML

A072212 001 Mar 31, 1988

2MG/ML

A072213 001 Mar 31, 1988

PAVULON

ORGANON USA INC

1MG/ML

N017015 002

2MG/ML

N017015 001



## DISCONTINUED DRUG PRODUCT LIST

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBVIE

150MG

N006800 003

300MG

N006800 001

SOLUTION; ORAL

PARADIONE

ABBVIE

300MG/ML

N006800 002

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY

1MG

N012772 005

2MG

N012772 006

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT

10MG

N013448 002

25MG

N013448 003

50MG

N013448 004

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

KING PFIZER

EQ 250MG BASE

A062310 001

PARKEDALE

EQ 250MG BASE

A060521 001

SYRUP; ORAL

HUMATIN

PARKE DAVIS

EQ 125MG BASE/5ML

A060522 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

APOTEX TECHNOLOGIES

EQ 10MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020885 001 Oct 09, 1998

EQ 20MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020885 002 Oct 09, 1998

EQ 30MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020885 003 Oct 09, 1998

EQ 40MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020885 004 Oct 09, 1998

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC

EQ 10MG BASE/5ML

A077395 001 Dec 05, 2006

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

ROXANE

EQ 10MG BASE

A078026 001 Jun 29, 2007

EQ 20MG BASE

A078026 002 Jun 29, 2007

EQ 30MG BASE

A078026 003 Jun 29, 2007

EQ 40MG BASE

A078026 004 Jun 29, 2007

SANDOZ

EQ 10MG BASE

A075566 001 Mar 08, 2004

EQ 20MG BASE

A075566 002 Mar 08, 2004

EQ 30MG BASE

A075566 003 Mar 08, 2004

EQ 40MG BASE

A075566 004 Mar 08, 2004

TEVA PHARMS

EQ 10MG BASE

A077082 001 Jun 29, 2007

EQ 20MG BASE

A077082 002 Jun 29, 2007

EQ 30MG BASE

A077082 003 Jun 29, 2007

EQ 40MG BASE

A077082 004 Jun 29, 2007

PAXIL

APOTEX TECHNOLOGIES

EQ 50MG BASE

N020031 004 Dec 29, 1992

**DISCONTINUED DRUG PRODUCT LIST**PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

NOVARTIS PHARMS CORP EQ 400MG BASE N022465 002 Oct 19, 2009

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA EQ 10MG BASE/ML (EQ 10MG BASE/ML) N202799 007 Mar 27, 2012

EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N202799 008 Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) N202799 001 Mar 27, 2012

EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) N202799 002 Mar 27, 2012

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) N202799 003 Mar 27, 2012

EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) N202799 004 Mar 27, 2012

EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) N202799 005 Mar 27, 2012

EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) N202799 006 Mar 27, 2012

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN 0.1% N021079 001 Sep 24, 1999

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT 18.75MG N016832 001

37.5MG N016832 002

75MG N016832 003

PEMOLINE

ACTAVIS ELIZABETH 18.75MG A075595 001 Feb 28, 2000

37.5MG A075595 002 Feb 28, 2000

75MG A075595 003 Feb 28, 2000

MALLINCKRODT 18.75MG A075726 003 Mar 30, 2001

37.5MG A075726 002 Mar 30, 2001

75MG A075726 001 Mar 30, 2001

SANDOZ 18.75MG A075286 001 Dec 27, 1999

37.5MG A075286 002 Jun 30, 1999

75MG A075286 003 Jun 30, 1999

TEVA PHARMS 18.75MG A075030 003 Feb 22, 2000

37.5MG A075030 001 Jan 29, 1999

75MG A075030 002 Jan 29, 1999

VINTAGE PHARMS 18.75MG A075328 001 Apr 19, 2000

37.5MG A075328 002 Apr 19, 2000

75MG A075328 003 Apr 19, 2000

WATSON LABS 18.75MG A075287 001 Jun 13, 2001

37.5MG A075287 002 Sep 18, 2000

75MG A075287 003 Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT 37.5MG N017703 001

PEMOLINE

ACTAVIS ELIZABETH 37.5MG A075678 001 Jul 26, 2000

TEVA PHARMS 37.5MG A075555 001 Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

AUXILIUM PHARMS LLC 10MG \*\*Federal Register determination N018976 001 Dec 30, 1987

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

20MG \*\*Federal Register determination N018976 004 Jan 05, 1989

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

ATON 125MG N019853 002

## DISCONTINUED DRUG PRODUCT LIST

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

WYETH AYERST

300,000 UNITS/ML

N050131 001

SUSPENSION; ORAL

BICILLIN

WYETH AYERST

300,000 UNITS/5ML

N050126 002

TABLET; ORAL

BICILLIN

WYETH AYERST

200,000 UNITS

N050128 001

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN

TEVA

200,000 UNITS/5ML

A060307 002

400,000 UNITS/5ML

A060307 004

PENICILLIN G POTASSIUM

MYLAN

200,000 UNITS/5ML

A060752 003

250,000 UNITS/5ML

A060752 002

400,000 UNITS/5ML

A060752 001

PUREPAC PHARM

250,000 UNITS/5ML

A061740 001

400,000 UNITS/5ML

A061740 002

PENICILLIN-2

TEVA

250,000 UNITS/5ML

A060307 003

PENTIDS '200'

APOTHECON

200,000 UNITS/5ML

A062149 001

PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149 002

PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587 001

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

APOTHECON

1,000,000 UNITS/VIAL

A060362 001

5,000,000 UNITS/VIAL

A060362 003

10,000,000 UNITS/VIAL

A060362 004

20,000,000 UNITS/VIAL

A060362 002

CONSOLIDATED PHARM

500,000 UNITS/VIAL

A060806 001

1,000,000 UNITS/VIAL

A060806 002

5,000,000 UNITS/VIAL

A060806 003

10,000,000 UNITS/VIAL

A060806 004

LILLY

200,000 UNITS/VIAL

A060384 004

500,000 UNITS/VIAL

A060384 003

1,000,000 UNITS/VIAL

A060384 002

5,000,000 UNITS/VIAL

A060384 001

20,000,000 UNITS/VIAL

A060384 005

20,000,000 UNITS/VIAL

A060601 001

PARKE DAVIS

1,000,000 UNITS/VIAL

A062003 001

5,000,000 UNITS/VIAL

A062003 002

PFIZER

20,000,000 UNITS/VIAL

A060074 003

SANDOZ

1,000,000 UNITS/VIAL \*\*Federal Register

A065079 001

Aug 30, 2002

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

WATSON LABS INC

1,000,000 UNITS/VIAL

A062991 001

Sep 13, 1988

5,000,000 UNITS/VIAL

A062991 002

Sep 13, 1988

10,000,000 UNITS/VIAL

A062991 003

Sep 13, 1988

20,000,000 UNITS/VIAL

A062991 004

Sep 13, 1988

PFIZERPEN

PFIZER

1,000,000 UNITS/VIAL \*\*Federal Register

A060657 001

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

TABLET; ORAL

PENICILLIN G POTASSIUM

APOTHECON

250,000 UNITS

A060392 003

IVAX SUB TEVA PHARMS

400,000 UNITS

A060073 004

LILLY

250,000 UNITS

A060403 001

MYLAN

200,000 UNITS

A060781 001

250,000 UNITS

A060781 002

400,000 UNITS

A060781 003

500,000 UNITS

A060781 005

800,000 UNITS

A060781 004

PUREPAC PHARM

200,000 UNITS

A061588 001

250,000 UNITS

A061588 002

**DISCONTINUED DRUG PRODUCT LIST**PENICILLIN G POTASSIUM

TABLET; ORAL

PENICILLIN G POTASSIUM

	400,000 UNITS	A061588 003
TEVA	200,000 UNITS	A060306 001
	250,000 UNITS	A060306 002
	400,000 UNITS	A060306 003
	500,000 UNITS	A060306 004
WYETH AYERST	200,000 UNITS	A060413 001
	250,000 UNITS	A060413 002
	400,000 UNITS	A060413 003
PENTIDS '200'		
APOTHECON	200,000 UNITS	A062155 001
PENTIDS '250'		
APOTHECON	250,000 UNITS	A062155 002
PENTIDS '400'		
APOTHECON	400,000 UNITS	A060392 004
	400,000 UNITS	A062155 003
PENTIDS '800'		
APOTHECON	800,000 UNITS	A060392 005
	800,000 UNITS	A062155 004
PFIZERPEN G		
PFIZER	50,000 UNITS	A060075 001
	100,000 UNITS	A060075 002
	200,000 UNITS	A060075 003
	250,000 UNITS	A060075 004
	400,000 UNITS	A060075 005
	800,000 UNITS	A060075 006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

LILLY	300,000 UNITS/ML	A060093 001
PENICILLIN G PROCAINE		
CONSOLIDATED PHARM	300,000 UNITS/ML	A060800 001
	600,000 UNITS/1.2ML	A060800 002
PARKE DAVIS	300,000 UNITS/ML	A062029 001
PFIZER	300,000 UNITS/VIAL	A060099 001
	1,500,000 UNITS/VIAL	A060099 002
PFIZERPEN-AS		
PFIZER	300,000 UNITS/ML	A060286 001
	600,000 UNITS/ML	A060286 002

PENICILLIN G SODIUM

INJECTABLE; INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935 001
COPANOS	5,000,000 UNITS/VIAL	A061051 001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046 001
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS		
PENICILLIN G SODIUM		
WATSON LABS INC	5,000,000 UNITS/VIAL	A063014 001 Sep 13, 1988

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY	125MG/0.6ML	A060002 001
-------	-------------	-------------

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A062270 001
	EQ 250MG BASE/5ML	A062270 002
BETAPEN-VK		
APOTHECON	EQ 125MG BASE/5ML	A061149 001
	EQ 250MG BASE/5ML	A061149 002
LEDERCILLIN VK		
LEDERLE	EQ 125MG BASE/5ML	A060136 001
	EQ 250MG BASE/5ML	A060136 002
PEN-VEE K		
WYETH AYERST	EQ 125MG BASE/5ML	A060007 001
	EQ 250MG BASE/5ML	A060007 002
PENAPAR-VK		
PARKE DAVIS	EQ 125MG BASE/5ML	A062002 001

## DISCONTINUED DRUG PRODUCT LIST

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PENAPAR-VK

EQ 250MG BASE/5ML A062002 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 125MG BASE/5ML A061529 001

EQ 250MG BASE/5ML A061529 002

MYLAN

EQ 125MG BASE/5ML A061624 002

EQ 250MG BASE/5ML A061624 001

PUREPAC PHARM

EQ 125MG BASE/5ML A061758 001

EQ 250MG BASE/5ML A061758 002

PFIZERPEN VK

PFIZER

EQ 125MG BASE/5ML A061815 001

EQ 250MG BASE/5ML A061815 002

V-CILLIN K

LILLY

EQ 125MG BASE/5ML A060004 001

EQ 250MG BASE/5ML A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML A061410 001

EQ 250MG BASE/5ML A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML A061206 001

EQ 125MG BASE/5ML A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML A061206 002

EQ 250MG BASE/5ML A062153 002

TABLET;ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 250MG BASE A062273 001

EQ 500MG BASE A062273 002

BETAPEN-VK

BRISTOL

EQ 250MG BASE A061150 001

EQ 500MG BASE A061150 002

LEDERCILLIN VK

LEDERLE

EQ 250MG BASE A060134 001

EQ 500MG BASE A060134 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE A060006 001

EQ 250MG BASE A060006 002

EQ 500MG BASE A060006 003

PENAPAR-VK

PARKE DAVIS

EQ 250MG BASE A062001 001

EQ 500MG BASE A062001 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 250MG BASE A061528 001

EQ 500MG BASE A061528 002

IVAX SUB TEVA PHARMS

EQ 125MG BASE A060518 001

EQ 250MG BASE A060518 002

EQ 500MG BASE A060518 003

MYLAN

EQ 250MG BASE A061530 001

EQ 500MG BASE A061530 002

PUREPAC PHARM

EQ 125MG BASE A061571 001

EQ 250MG BASE A061571 002

EQ 500MG BASE A061571 003

PFIZERPEN VK

PFIZER

EQ 250MG BASE A061836 001

EQ 500MG BASE A061836 002

UTICILLIN VK

PHARMACIA AND UPJOHN

EQ 250MG BASE A061651 001

EQ 500MG BASE A061651 002

V-CILLIN K

LILLY

EQ 125MG BASE A060003 001

EQ 250MG BASE A060003 002

EQ 500MG BASE A060003 003

VEETIDS

APOTHECON

EQ 250MG BASE A061411 001

EQ 500MG BASE A061411 002

VEETIDS '250'

APOTHECON

EQ 250MG BASE A061164 001

EQ 250MG BASE A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE A061164 002

## DISCONTINUED DRUG PRODUCT LIST

PENICILLIN V POTASSIUM

TABLET;ORAL

VEETIDS '500'

EQ 500MG BASE

A062156 001

PENTAGASTRIN

INJECTABLE;INJECTION

PEPTAVLON

WYETH AYERST

0.25MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N017048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

NEBUPENT

FRESENIUS KABI USA

600MG/VIAL

N019887 002 Mar 22, 1996

INJECTABLE;INJECTION

PENTACARINAT

ARMOUR PHARM

300MG/VIAL

A073447 001 Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE

300MG/VIAL

A073617 001 Dec 18, 1995

HOSPIRA

300MG/VIAL

A073479 001 Jun 30, 1992

WATSON LABS

300MG/VIAL

A074303 001 Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

TALWIN 50

SANOFI AVENTIS US

EQ 50MG BASE

N016732 001

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

HAMELN PHARMS

EQ 1GM BASE/5ML (EQ 200MG BASE/ML)

N021749 001 Aug 11, 2004

\*\*Federal Register determination that  
product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE;INJECTION

YTTERBIUM YB 169 DTPA

3M

2mCi/ML

N017518 001

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

HAMELN PHARMS

EQ 1GM BASE/5ML (EQ 200MG BASE/ML)

N021751 001 Aug 11, 2004

\*\*Federal Register determination that  
product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*PENTOBARBITAL

ELIXIR;ORAL

NEMBUTAL

OAK PHARMS

18.2MG/5ML

A083244 001

PENTOBARBITAL SODIUM

CAPSULE;ORAL

NEMBUTAL SODIUM

OAK PHARMS

30MG

A084095 001

50MG

A084093 001

100MG

A083245 001

PENTOBARBITAL SODIUM

LANNETT

50MG

A085937 001

LANNETT

100MG

A085915 001

VITARINE

100MG

A083284 001

WHITEWORTH TOWN PLSN

100MG

A083338 001

SODIUM PENTOBARBITAL

ANABOLIC

100MG

A084590 001

ELKINS SINN

100MG

A083368 001

EVERYLIFE

100MG

A083259 001

HALSEY

100MG

A084677 001

IVAX SUB TEVA PHARMS

50MG

A083461 001

100MG

A083461 002

PARKE DAVIS

100MG

A084156 001

PERRIGO

100MG

A084560 001

**DISCONTINUED DRUG PRODUCT LIST**PENTOBARBITAL SODIUM

## CAPSULE; ORAL

## SODIUM PENTOBARBITAL

PUREPAC PHARM	100MG	A083301	001	
VALEANT PHARM INTL	100MG	A083264	001	
WATSON LABS	100MG	A085791	001	
WYETH AYERST	100MG	A083239	001	

## INJECTABLE; INJECTION

## PENTOBARBITAL SODIUM

ELKINS SINN	50MG/ML	A083270	001	
-------------	---------	---------	-----	--

## SODIUM PENTOBARBITAL

WYETH AYERST	50MG/ML	A083261	001	
--------------	---------	---------	-----	--

## SUPPOSITORY; RECTAL

## NEMBUTAL

OAK PHARMS	30MG	A083247	001	Jan 25, 1982
	60MG	A083247	002	Jan 25, 1982
	120MG	A083247	003	Jan 25, 1982
	200MG	A083247	004	Jan 25, 1982

## TABLET; ORAL

## PENTOBARBITAL SODIUM

VITARINE	100MG	A083285	001	
----------	-------	---------	-----	--

## SODIUM PENTOBARBITAL

NEXGEN PHARMA INC	100MG	A084238	001	
-------------------	-------	---------	-----	--

PENTOLINIUM TARTRATE

## INJECTABLE; INJECTION

## ANSOLYSEN

WYETH AYERST	10MG/ML	N009372	001	
--------------	---------	---------	-----	--

PENTOXIFYLLINE

## TABLET, EXTENDED RELEASE; ORAL

## PENTOXIFYLLINE

ACTAVIS ELIZABETH	400MG	A074878	001	Jul 09, 1997
HERITAGE PHARMS INC	400MG	A074877	001	Jul 08, 1997
TEVA	400MG	A075199	001	Sep 03, 1999
WATSON LABS	400MG	A075107	001	Sep 04, 1998

## TRENTAL

SANOFI AVENTIS US	400MG	N018631	001	Aug 30, 1984
-------------------	-------	---------	-----	--------------

PERFLUBRON

## LIQUID; ORAL

## IMAGENT

ALLIANCE PHARM	100%	N020091	001	Aug 13, 1993
----------------	------	---------	-----	--------------

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

## PASTE; TOPICAL

## SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY	50%; 50%	N021084	001	Feb 17, 2000
---------	----------	---------	-----	--------------

PERGOLIDE MESYLATE

## TABLET; ORAL

## PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094	001	Sep 04, 2003
	EQ 0.25MG BASE	A076094	002	Sep 04, 2003
	EQ 1MG BASE	A076094	003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE	A076061	001	Nov 27, 2002
	EQ 0.25MG BASE	A076061	002	Nov 27, 2002
	EQ 1MG BASE	A076061	003	Nov 27, 2002

## PERMAX

VALEANT PHARM INTL	EQ 0.05MG BASE	N019385	001	Dec 30, 1988
	EQ 0.25MG BASE	N019385	002	Dec 30, 1988
	EQ 1MG BASE	N019385	003	Dec 30, 1988

PERMETHRIN

## LOTION; TOPICAL

## NIX

GLAXOSMITHKLINE	1%	N019435	001	Mar 31, 1986
-----------------	----	---------	-----	--------------

PERPHENAZINE

## CONCENTRATE; ORAL

## PERPHENAZINE

PHARM ASSOC	16MG/5ML	A040360	001	May 25, 2001
-------------	----------	---------	-----	--------------

## TRILAFON

SCHERING	16MG/5ML	N011557	001	
----------	----------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

PERPHENAZINE

INJECTABLE; INJECTION

TRILAFON

SCHERING

5MG/ML

N011213 002

SYRUP; ORAL

TRILAFON

SCHERING

2MG/5ML

N011294 002

TABLET; ORAL

PERPHENAZINE

ANI PHARMS INC

8MG

A089456 001 Sep 10, 1987

TEVA PHARMS USA

2MG

A089707 001 Sep 10, 1987

4MG

A089708 001 Sep 10, 1987

16MG

A089457 001 Sep 10, 1987

TRILAFON

SCHERING

2MG

N010775 001

4MG

N010775 002

8MG

N010775 003

16MG

N010775 004

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING

8MG

N011361 002

PHENACEMIDE

TABLET; ORAL

PHENURONE

ABBVIE

500MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N007707 001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

ROCHE

100MG; 500MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N013294 001 Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HYDROCHLORIDE

ABLE

200MG; 800MG; 160MG

N021105 001 Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

ROCHE

50MG; 500MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N019358 001 Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENAZINE

MAST MM

35MG

A086523 001

35MG

A086524 001

35MG

A086525 001

PHENDIMETRAZINE TARTRATE

SANDOZ

35MG

A085633 001

35MG

A085694 001

35MG

A085695 001

35MG

A085702 001

VITARINE

35MG

A085634 001

35MG

A085645 001

35MG

A085670 001

35MG

A086403 001

35MG

A086408 001

35MG

A086410 001

35MG

A087424 001

SPRX-3

SOLVAY

35MG

A085897 001

STATOBEX

TEVA

35MG

A085507 001

X-TROZINE

SHIRE RICHWOOD

35MG

A087394 001 Sep 22, 1982



## DISCONTINUED DRUG PRODUCT LIST

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

BONTRIL				
VALEANT	105MG	A088021	001	Sep 21, 1982
MELFIAT-105				
NUMARK	105MG	A087487	001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
SANDOZ	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET;ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
TG UNITED LABS	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	
	35MG	A084743	001	
IVAX PHARMS	35MG	A085611	001	
	35MG	A085612	001	
IVAX SUB TEVA PHARMS	35MG	A083682	001	
KV PHARM	35MG	A084138	001	
	35MG	A084141	001	
	35MG	A085525	001	
MFG CHEMISTS	35MG	A085914	001	
NEXGEN PHARMA INC	35MG	A086020	001	
NUMARK	35MG	A083790	001	
PVT FORM	35MG	A085199	001	
	35MG	A085697	001	
SANDOZ	35MG	A085402	001	
	35MG	A085497	001	
	35MG	A085830	001	
	35MG	A086365	001	
	35MG	A086370	001	
SOLVAY	35MG	A083993	001	
TG UNITED LABS	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983

## DISCONTINUED DRUG PRODUCT LIST

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

USL PHARMA	35MG	A083805	001
	35MG	A084398	001
	35MG	A084399	001
VITARINE	35MG	A085519	001
	35MG	A086005	001
	35MG	A086106	001
WATSON LABS	35MG	A085767	001
	35MG	A085768	001
	35MG	A085770	001
	35MG	A085773	001
PLEGINE			
WYETH AYERST	35MG	N012248	001
STATOBEX			
TEVA	35MG	A086013	001
STATOBEX-G			
TEVA	35MG	A085095	001
X-TROZINE			
SHIRE RICHWOOD	35MG	A086550	001
	35MG	A086551	001
	35MG	A086552	001
	35MG	A086553	001
	35MG	A086554	001

PHENINDIONE

TABLET; ORAL

HEDULIN

SANOFI AVENTIS US	50MG	N008767	002
-------------------	------	---------	-----

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460	005
----------------------	------	---------	-----

TABLET, EXTENDED RELEASE; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752	004
	75MG	N011752	003

PHENPROCOUMON

TABLET; ORAL

LIQUAMAR

ORGANON USA INC	3MG	N011228	001
-----------------	-----	---------	-----

PHENSUXIMIDE

CAPSULE; ORAL

MILONTIN

PARKE DAVIS	500MG	N008855	004
-------------	-------	---------	-----

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

FASTIN

GLAXOSMITHKLINE	30MG	N017352	001
-----------------	------	---------	-----

OBESTIN-30

FERNDAL LABS	30MG	A087144	001
--------------	------	---------	-----

OBY-TRIM

SHIRE RICHWOOD	30MG	A087764	001 Mar 18, 1982
----------------	------	---------	------------------

ONA-MAST

MAST MM	30MG	A086511	001
---------	------	---------	-----

	30MG	A086516	001
--	------	---------	-----

PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG	A085411	001
-------------	------	---------	-----

ABLE	15MG	A040497	001 Mar 13, 2003
------	------	---------	------------------

	30MG	A040403	001 Aug 30, 2001
--	------	---------	------------------

	30MG	A040427	001 Aug 30, 2001
--	------	---------	------------------

CAMALL	15MG	A086735	001
--------	------	---------	-----

	30MG	A087226	001
--	------	---------	-----

DURAMED PHARMS BARR	30MG	A088948	001 Apr 25, 1986
---------------------	------	---------	------------------

IVAX PHARMS	30MG	A086329	001
-------------	------	---------	-----

MIKAH PHARMA	15MG	A040460	001 Jan 14, 2003
--------------	------	---------	------------------

	30MG	A040227	001 Jun 18, 1997
--	------	---------	------------------

	30MG	A040448	001 Jan 22, 2003
--	------	---------	------------------

MUTUAL PHARM	37.5MG	A040527	001 Oct 23, 2003
--------------	--------	---------	------------------

SANDOZ	30MG	A087208	001
--------	------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

	30MG	A087223	001	
	37.5MG	A088414	001	Oct 19, 1983
TEVA	30MG	A086911	001	
	30MG	A087126	001	
	30MG	A087777	001	Nov 01, 1985
	30MG	A088612	001	Apr 04, 1984
	30MG	A088613	001	Apr 09, 1984
	30MG	A088614	001	Apr 09, 1984
TG UNITED INC	30MG	A040083	001	Mar 07, 1997
TG UNITED LABS	18.75MG	A088576	001	May 23, 1984
	30MG	A085417	001	
	30MG	A086732	002	
	30MG	A087215	001	
	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
USL PHARMA	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985
TABLET; ORAL				
ONA-MAST				
MAST MM	8MG	A086260	001	
PHENTERMINE HYDROCHLORIDE				
ABLE	37.5MG	A040402	001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
IVAX PHARMS	8MG	A085553	001	
SANDOZ	8MG	A085671	001	
	8MG	A085689	001	
SANDOZ INC	30MG	A088605	001	Sep 28, 1987
TG UNITED LABS	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	
WATSON LABS	8MG	A085739	001	
TORA				
SOLVAY	8MG	A084035	001	
WILPO				
SANDOZ	8MG	N012737	001	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB INC

EQ 15MG BASE

N011613 004

EQ 30MG BASE

N011613 002

PHENTERMINE RESIN 30

QUANTUM PHARMICS

EQ 30MG BASE

A089120 001 Feb 04, 1988

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC

50%

N011695 002

TABLET; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC

500MG

N011695 003

**DISCONTINUED DRUG PRODUCT LIST**PHENYLBUTAZONE

## CAPSULE; ORAL

## AZOLID

SANOFI AVENTIS US	100MG	A087260	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	009	
PHENYLBUTAZONE				
IVAX PHARMS	100MG	A088218	001	Jun 24, 1983
MUTUAL PHARM	100MG	A088994	001	Dec 04, 1985
SANDOZ	100MG	A087774	001	Jun 16, 1982
WATSON LABS	100MG	A087756	001	Dec 17, 1982

## TABLET; ORAL

## AZOLID

SANOFI AVENTIS US	100MG	A087091	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	008	
PHENYLBUTAZONE				
MUTUAL PHARM	100MG	A088863	001	Dec 04, 1985
SANDOZ	100MG	A084339	001	
WATSON LABS	100MG	A086151	001	
	100MG	A087674	001	Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

## SYRUP; ORAL

## PHENERGAN VC

ANI PHARMS	5MG/5ML; 6.25MG/5ML	N008604	003	Apr 02, 1984
PHERAZINE VC				
HALSEY	5MG/5ML; 6.25MG/5ML	A088868	001	Mar 02, 1987
PROMETHAZINE VC PLAIN				
CENCI	5MG/5ML; 6.25MG/5ML	A088815	001	Nov 22, 1985
WOCKHARDT	5MG/5ML; 6.25MG/5ML	A088897	001	Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

## SOLUTION/DROPS; OPHTHALMIC

## PREFRIN-A

ALLERGAN	0.12%; 0.1%	N007953	001	
----------	-------------	---------	-----	--

PHENYTOIN

## SUSPENSION; ORAL

## DILANTIN-30

PARKE DAVIS	30MG/5ML	N008762	002	
PHENYTOIN				
ACTAVIS MID ATLANTIC	125MG/5ML	A089892	001	Sep 25, 1992

PHENYTOIN SODIUM

## CAPSULE; ORAL

## DIPHENYLAN SODIUM

LANNETT	30MG PROMPT	A080857	001	
	100MG PROMPT	A080857	002	

## EXTENDED PHENYTOIN SODIUM

ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003
	100MG EXTENDED	A089441	001	Dec 18, 1986
WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007
WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008

## PHENYTEX

WATSON LABS	100MG EXTENDED	A088711	001	Dec 21, 1984
-------------	----------------	---------	-----	--------------

## PHENYTOIN SODIUM

PHARMERAL	100MG PROMPT	A085435	001	
WATSON LABS	100MG PROMPT	A085894	001	

## PROMPT PHENYTOIN SODIUM

ANI PHARMS INC	100MG PROMPT	A080259	001	
WATSON LABS	100MG PROMPT	A080905	001	

## INJECTABLE; INJECTION

## DILANTIN

PARKE DAVIS	50MG/ML	N010151	001	
-------------	---------	---------	-----	--

## PHENYTOIN SODIUM

FRESENIUS KABI USA	50MG/ML	A089003	001	May 31, 1985
HOSPIRA	50MG/ML	A089744	001	Dec 18, 1987
MARSAM PHARMS LLC	50MG/ML	A089501	001	Oct 13, 1987
	50MG/ML	A089779	001	Nov 27, 1992
SMITH AND NEPHEW	50MG/ML	A088519	001	Dec 19, 1984
	50MG/ML	A088521	001	Dec 18, 1984
SOLOPAK	50MG/ML	A088520	001	Dec 17, 1984
WARNER CHILCOTT	50MG/ML	A089900	001	Mar 30, 1990

**DISCONTINUED DRUG PRODUCT LIST**PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

WATSON LABS

50MG/ML

A085434 001

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

IGI LABS INC

1MG/0.5ML

N012223 002

10MG/ML

N012223 001

KONAKION

ROCHE

1MG/0.5ML

N011745 001

10MG/ML

N011745 003

PHYTONADIONE

GLAXOSMITHKLINE

1MG/0.5ML

A084060 001

10MG/ML

A084060 002

VITAMIN K1

HOSPIRA

10MG/ML

A087956 001 Jul 25, 1983

PILOCARPINE

INSERT, EXTENDED RELEASE; OPTHALMIC

OCUSERT PILO-20

AKORN

5MG

N017431 001

OCUSERT PILO-40

AKORN

11MG

N017548 001

PILOCARPINE HYDROCHLORIDE

GEL; OPTHALMIC

PILOPINE HS

ALCON

4%

N018796 001 Oct 01, 1984

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

PINDAC

LEO PHARM

12.5MG

N019456 001 Dec 28, 1989

25MG

N019456 002 Dec 28, 1989

PINDOLOL

TABLET; ORAL

PINDOLOL

G AND W LABS INC

5MG

A073661 001 Oct 31, 1993

5MG

A073687 001 Feb 26, 1993

5MG

A074123 001 Apr 17, 1997

10MG

A073661 002 Oct 31, 1993

10MG

A073687 002 Feb 26, 1993

10MG

A074123 002 Apr 17, 1997

MYLAN PHARMS INC

5MG

A074013 001 Sep 24, 1992

10MG

A074018 001 Sep 24, 1992

NOSTRUM LABS

5MG

A074474 001 Oct 28, 1996

10MG

A074474 002 Oct 28, 1996

PUREPAC PHARM

5MG

A074125 001 Apr 28, 1993

10MG

A074125 002 Apr 28, 1993

SANDOZ

5MG

A073608 001 Mar 29, 1993

10MG

A073609 001 Mar 29, 1993

WATSON LABS

5MG

A074437 001 Feb 27, 1995

10MG

A074437 002 Feb 27, 1995

VISKEN

NOVARTIS

5MG

N018285 001 Sep 03, 1982

10MG

N018285 002 Sep 03, 1982

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

ORGANON USA INC

10MG/VIAL

N019638 001 Jun 26, 1990

PIPERACETAZINE

TABLET; ORAL

QUIDE

DOW PHARM

10MG

N013615 001

25MG

N013615 002

**DISCONTINUED DRUG PRODUCT LIST**PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750 001	Oct 13, 1987
	EQ 2GM BASE/VIAL	N050545 002	
	EQ 3GM BASE/VIAL	A062750 002	Oct 13, 1987
	EQ 3GM BASE/VIAL	N050545 003	
	EQ 4GM BASE/VIAL	A062750 003	Oct 13, 1987
	EQ 4GM BASE/VIAL	N050545 004	
	EQ 40GM BASE/VIAL	N050545 006	Sep 30, 1985

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102 001	
-----------------	-------------------	-------------	--

BRYREL

SANOVI AVENTIS US	EQ 500MG BASE/5ML	N017796 001	
-------------------	-------------------	-------------	--

MULTIFUGE

BLULINE	EQ 500MG BASE/5ML	N009452 001	
---------	-------------------	-------------	--

PIPERAZINE CITRATE

ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774 001	
--------------------	-------------------	-------------	--

LANNETT	EQ 500MG BASE/5ML	A080963 001	
---------	-------------------	-------------	--

LUITPOLD	EQ 500MG BASE/5ML	A080671 001	
----------	-------------------	-------------	--

VERMIDOL

SOLVAY	EQ 500MG BASE/5ML	A080992 001	
--------	-------------------	-------------	--

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE	N009102 003	
-----------------	---------------	-------------	--

PIPERAZINE CITRATE

IMPAX LABS	EQ 250MG BASE	A080874 001	
------------	---------------	-------------	--

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000
----------------------	------------------	-------------	--------------

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT	10MG	N016245 001	
--------	------	-------------	--

	25MG	N016245 002	
--	------	-------------	--

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

MEDICIS	EQ 0.2MG BASE/INH	N020014 001	Nov 30, 1992
---------	-------------------	-------------	--------------

VALEANT PHARMS	EQ 0.2MG BASE/INH	N019009 001	Dec 30, 1986
----------------	-------------------	-------------	--------------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

CYCLE PHARMS LTD	10MG	A073651 001	Feb 26, 1993
------------------	------	-------------	--------------

	20MG	A073651 002	Feb 26, 1993
--	------	-------------	--------------

EGIS	10MG	A074808 001	Jul 08, 1997
------	------	-------------	--------------

	20MG	A074808 002	Jul 08, 1997
--	------	-------------	--------------

IVAX SUB TEVA PHARMS	10MG	A074148 001	Jun 03, 1996
----------------------	------	-------------	--------------

	20MG	A074148 002	Jun 03, 1996
--	------	-------------	--------------

MUTUAL PHARM	20MG	A073536 001	Mar 12, 1993
--------------	------	-------------	--------------

MYLAN	10MG	A074043 001	Sep 22, 1992
-------	------	-------------	--------------

	20MG	A074043 002	Sep 22, 1992
--	------	-------------	--------------

SCS	10MG	A074036 001	May 29, 1992
-----	------	-------------	--------------

	20MG	A074036 002	May 29, 1992
--	------	-------------	--------------

TEVA	10MG	A073637 001	Jan 28, 1994
------	------	-------------	--------------

	20MG	A073638 001	Jan 28, 1994
--	------	-------------	--------------

TEVA PHARMS	10MG	A074103 001	Aug 28, 1992
-------------	------	-------------	--------------

	20MG	A074103 002	Aug 28, 1992
--	------	-------------	--------------

WATSON LABS	10MG	A074287 001	May 16, 1996
-------------	------	-------------	--------------

	10MG	A074460 001	Sep 29, 1995
--	------	-------------	--------------

	20MG	A074287 002	May 16, 1996
--	------	-------------	--------------

	20MG	A074460 002	Sep 29, 1995
--	------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER

2.5MG/VIAL

N050109 001

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST

40MG/AMP

N010753 001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PADDOCK LLC

17GM/SCOOPFUL

A090567 001 Oct 15, 2009

TEVA PHARMS

17GM/SCOOPFUL

A077445 001 May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

PADDOCK LLC

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/  
BOT; 22.74GM/BOT

A090769 001 Jun 07, 2010

SOLUTION; ORAL

OCL

HOSPIRA

6GM/100ML; 75MG/100ML; 168MG/100ML; 146MG/  
100ML; 1.29GM/100ML

N019284 001 Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

MEDA PHARMS

120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKE  
T; 2.92GM/PACKET; 11.36GM/PACKET

N018983 005 Oct 26, 1984

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PAC  
KET; 5.53GM/PACKET; 21.5GM/PACKET

N018983 004 Oct 26, 1984

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/  
BOT; 22.72GM/BOT

N018983 007 Jun 12, 1987

360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACK  
ET; 8.76GM/PACKET; 34.08GM/PACKET

N018983 006 Oct 26, 1984

COLYTE-FLAVORED

MEDA PHARMS

227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53G  
M/BOT; 21.5GM/BOT

N018983 008 Nov 14, 1991

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/  
BOT; 22.72GM/BOT

N018983 009 Nov 14, 1991

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/  
BOT; 22.72GM/BOT

A090712 001 Feb 25, 2010

FOR SUSPENSION; ORAL

CO-LAV

VINTAGE PHARMS

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/  
BOT; 22.72GM/BOT

A073428 001 Jan 28, 1992

COLOVAGE

DYNAPHARM

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PAC  
KET; 5.53GM/PACKET; 21.5GM/PACKET

A071320 001 Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/  
BOT; 22.74GM/BOT

A071278 001 Nov 21, 1988

GLYCOPREP

GOLDLINE

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/  
BOT; 22.74GM/BOT

A072319 001 Dec 23, 1988

GO-EVAC

VINTAGE PHARMS

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/  
BOT; 22.74GM/BOT

A073433 001 Apr 28, 1992

PEG-LYTE

SANDOZ

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/  
BOT; 22.74GM/BOT

A073098 001 Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE

EQ 500,000 U BASE/VIAL

A062036 001

POWDER; FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS

100,000,000 UNITS/BOT

A061578 001

POLYMYXIN B SULFATE

PADDOCK LLC

100,000,000 UNITS/BOT

A062455 001 Jul 27, 1983

## DISCONTINUED DRUG PRODUCT LIST

POLYTHIAZIDE

TABLET; ORAL

RENESE

PFIZER	1MG	N012845	001
	2MG	N012845	002
	4MG	N012845	003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER	0.5MG;EQ 1MG BASE	N017986	001
	0.5MG;EQ 2MG BASE	N017986	002
	0.5MG;EQ 5MG BASE	N017986	003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER	2MG;0.25MG	N013636	001
--------	------------	---------	-----

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD	500MG	N009395	004
----------	-------	---------	-----

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL	100%	A080098	001
--------	------	---------	-----

TABLET; ORAL

PASKALIUM

GLENWOOD	1GM	N009395	003
----------	-----	---------	-----

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS	8MEQ	A073398	001	Jan 28, 1992
	10MEQ	A072427	001	Mar 28, 1990

POTASSIUM CHLORIDE

NESHER PHARMS	10MEQ	A070980	001	Feb 17, 1987
TEVA	8MEQ	A073531	001	Apr 26, 1996
	10MEQ	A073532	001	Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

KV PHARM	20MEQ/PACKET	N019561	003	Aug 26, 1988
----------	--------------	---------	-----	--------------

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM	2MEQ/ML	A080204	001	
	2MEQ/ML	A084290	001	
	2MEQ/ML	A086713	001	
	2MEQ/ML	A086714	001	
	2MEQ/ML	A087787	001	Apr 20, 1982
	2MEQ/ML	A087885	001	Feb 03, 1983
AKORN	2MEQ/ML	A088286	001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203	001	
FRESENIUS KABI USA	2MEQ/ML	A087817	001	Oct 20, 1982
GD SEARLE LLC	1MEQ/ML	A086219	001	
	2MEQ/ML	A086219	002	
	2MEQ/ML	A086220	002	
	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	
	1MEQ/ML	A083345	003	
	1.5MEQ/ML	A083345	001	
	2MEQ/ML	A083345	002	
	2.4MEQ/ML	A080205	004	
	3.2MEQ/ML	A080205	005	
INTL MEDICATION	2MEQ/ML	A083163	001	
LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	



**DISCONTINUED DRUG PRODUCT LIST**POTASSIUM CHLORIDE

## INJECTABLE; INJECTION

## POTASSIUM CHLORIDE

	4MEQ/ML	A080195 004	
PHARMA SERVE NY	2MEQ/ML	A086297 001	
	2MEQ/ML	A087362 001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208 001	
	2MEQ/ML	A089163 001	Mar 10, 1988
	2MEQ/ML	A089421 001	Jan 02, 1987
	3MEQ/ML	A086210 001	

## TABLET, EXTENDED RELEASE; ORAL

## K+10

FUTURE PAK	10MEQ	A070999 001	Oct 22, 1987
------------	-------	-------------	--------------

## K+8

FUTURE PAK	8MEQ	A070998 001	Jan 25, 1993
------------	------	-------------	--------------

## KAON CL

SAVAGE LABS	6.7MEQ	N017046 001	
-------------	--------	-------------	--

## KAON CL-10

SAVAGE LABS	10MEQ	N017046 002	
-------------	-------	-------------	--

## KLOTRIX

APOTHECON	10MEQ	N017850 001	
-----------	-------	-------------	--

## POTASSIUM CHLORIDE

COPLLEY PHARM	8MEQ	A070618 001	Sep 09, 1987
---------------	------	-------------	--------------

NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002
---------------	-------	-------------	--------------

SCHERING	10MEQ	N019439 002	Jun 13, 1986
----------	-------	-------------	--------------

	20MEQ	N019439 001	Jun 13, 1986
--	-------	-------------	--------------

## SLOW-K

NOVARTIS	8MEQ	N017476 002	
----------	------	-------------	--

## TEN-K

NOVARTIS	10MEQ	N019381 001	Apr 16, 1986
----------	-------	-------------	--------------

POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 900MG/100ML	N019708 001	Sep 29, 1989
---------	-------------------------	-------------	--------------

## POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	75MG/100ML; 900MG/100ML	N019708 002	Sep 29, 1989
---------	-------------------------	-------------	--------------

## POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	110MG/100ML; 900MG/100ML	N019708 003	Sep 29, 1989
---------	--------------------------	-------------	--------------

## POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	220MG/100ML; 900MG/100ML	N019708 005	Sep 29, 1989
---------	--------------------------	-------------	--------------

## POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	300MG/100ML; 900MG/100ML	N019708 006	Sep 29, 1989
---------	--------------------------	-------------	--------------

## SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	75MG/100ML; 900MG/100ML	N018722 001	Nov 09, 1982
---------	-------------------------	-------------	--------------

BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648 004	
-----------------	-------------------------	-------------	--

## SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	150MG/100ML; 900MG/100ML	N018722 002	Nov 09, 1982
---------	--------------------------	-------------	--------------

## SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	220MG/100ML; 900MG/100ML	N018722 003	Nov 09, 1982
---------	--------------------------	-------------	--------------

## SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	300MG/100ML; 900MG/100ML	N018722 004	Nov 09, 1982
---------	--------------------------	-------------	--------------

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

## INJECTABLE; INJECTION

## THAM-E

HOSPIRA	370MG/VIAL; 1.75GM/VIAL; 36GM/VIAL	N013025 001	
---------	------------------------------------	-------------	--

POTASSIUM CITRATE

## FOR SOLUTION; ORAL

## POTASSIUM CITRATE

UT SW MEDCTR	10MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019647 002	Oct 13, 1988
--------------	--	-------------	--------------

	20MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019647 001	Oct 13, 1988
--	--	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**POTASSIUM IODIDE

SOLUTION; ORAL

POTASSIUM IODIDE

ROXANE

1GM/ML

N018551 001 Feb 19, 1982

TABLET; ORAL

THYRO-BLOCK

MEDPOINTE PHARM HLC

130MG

N018307 001

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

MALLINCKRODT

200MG

N017551 001

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP

CLINIPAD

10%

N019382 001 Jul 25, 1989

SPONGE; TOPICAL

E-Z PREP

CLINIPAD

5%

N019382 002 Jul 25, 1989

E-Z PREP 220

CLINIPAD

5%

N019382 003 Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP

300MG/ML

N018799 001 Dec 13, 1982

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST

500MG

N014122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM

1.25MG

N020667 004 Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

WATSON LABS

0.125MG

A078551 001 Oct 08, 2010

0.25MG

A078551 002 Oct 08, 2010

0.5MG

A078551 003 Oct 08, 2010

1MG

A078551 004 Oct 08, 2010

1.5MG

A078551 005 Oct 08, 2010

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

ASTRAZENECA AB

EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)

N021332 001 Mar 16, 2005

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

BRISTOL MYERS SQUIBB

10MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N019898 002 Oct 31, 1991

PRAVASTATIN SODIUM

PLIVA HRVATSKA DOO

10MG

A077730 001 Nov 21, 2006

20MG

A077730 002 Nov 21, 2006

30MG

A077730 003 Nov 21, 2006

40MG

A077730 005 Nov 21, 2006

RANBAXY LABS LTD

10MG

A076445 001 Apr 23, 2007

20MG

A076445 002 Apr 23, 2007

40MG

A076445 003 Apr 23, 2007

80MG

A076445 004 Apr 23, 2007

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS

5MG

N018144 001

10MG

N018144 002

20MG

N018144 003 May 10, 1982

PRAZEPAM

USL PHARMA

5MG

A070427 001 Nov 06, 1987

10MG

A070428 001 Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS

10MG

N017415 001

## DISCONTINUED DRUG PRODUCT LIST

PRAZOSIN HYDROCHLORIDE

## CAPSULE; ORAL

## PRAZOSIN HYDROCHLORIDE

AM THERAP	EQ 1MG BASE	A072782 001	May 16, 1989
	EQ 2MG BASE	A072783 001	May 16, 1989
	EQ 5MG BASE	A072784 001	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705 001	May 16, 1989
	EQ 2MG BASE	A072706 001	May 16, 1989
	EQ 5MG BASE	A072707 001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991 001	May 16, 1989
	EQ 2MG BASE	A072921 001	May 16, 1989
	EQ 5MG BASE	A072992 001	May 16, 1989
SANDOZ	EQ 1MG BASE	A072576 001	May 16, 1989
	EQ 2MG BASE	A072577 001	May 16, 1989
	EQ 5MG BASE	A072578 001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352 001	May 16, 1989
	EQ 2MG BASE	A072333 001	May 16, 1989
	EQ 5MG BASE	A072609 001	May 16, 1989

## TABLET, EXTENDED RELEASE; ORAL

## MINIPRESS XL

PFIZER	2.5MG	N019775 001	Jan 29, 1992
	5MG	N019775 002	Jan 29, 1992

PREDNISOLONE

## CREAM; TOPICAL

## METI-DERM

SCHERING	0.5%	N010209 002	
----------	------	-------------	--

## SYRUP; ORAL

## PREDNISOLONE

APOTEX INC	5MG/5ML	A040570 001	Aug 25, 2005
	15MG/5ML	A040571 001	Aug 25, 2005
IVAX SUB TEVA PHARMS	15MG/5ML	A040287 001	May 28, 1999
NESHER PHARMS	5MG/5ML	A040423 001	Oct 22, 2001
	15MG/5ML	A040364 001	Apr 10, 2002
TEVA PHARMS	15MG/5ML	A040322 001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192 001	May 28, 1998

## PRELONE

MURO	5MG/5ML	A089654 001	Jan 17, 1989
------	---------	-------------	--------------

## TABLET; ORAL

## CORTALONE

HALSEY	1MG	A080304 003	
	2.5MG	A080304 002	
	5MG	A080304 001	

## DELTA-CORTEF

PHARMACIA AND UPJOHN	5MG	N009987 004	
----------------------	-----	-------------	--

## FERNISOLONE-P

FERNDAL LABS	5MG	A083941 001	
--------------	-----	-------------	--

## PREDNISOLONE

BARR	5MG	A084426 002	
BUNDY	5MG	A083675 001	
ELKINS SINN	5MG	A080625 001	
EVERYLIFE	1MG	A084439 001	
	2.5MG	A084439 002	
	5MG	A084439 003	
FERRANTE	2.5MG	A080562 001	
	5MG	A080562 002	
HEATHER	5MG	A080326 001	
IMPAX LABS	5MG	A080780 001	
INWOOD LABS	5MG	A080748 001	
IVAX SUB TEVA PHARMS	5MG	A080378 001	
LANNETT	5MG	A080531 002	
MARSHALL PHARMA	5MG	A080307 001	
PANRAY	1MG	A080351 001	
	5MG	A080351 002	
PERRIGO	5MG	A084542 001	
PHOENIX LABS NY	5MG	A080322 001	
PUREPAC PHARM	5MG	A080325 001	
PVT FORM	5MG	A080211 001	
ROXANE	5MG	A080327 002	
SANDOZ	5MG	A080339 001	
	5MG	A084773 001	
SPERTI	1MG	A080358 001	
	2.5MG	A080358 002	

## DISCONTINUED DRUG PRODUCT LIST

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

	5MG	A080358 003	
SUPERPHARM	5MG	A088892 001	Feb 26, 1985
TABLICAPS	5MG	A085170 001	
TEVA	5MG	A080398 001	
UDL	5MG	A087987 001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236 001	
VITARINE	5MG	A080534 001	
WATSON LABS	5MG	A085085 002	
	5MG	A085415 001	
	5MG	A085416 001	
WEST WARD	5MG	A080324 001	
WHITEWORTH TOWN PLSN	5MG	A080342 001	
STERANE			
PFIZER	5MG	N009996 001	

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE

SCHERING	25MG/ML	N010255 002	
----------	---------	-------------	--

PREDNISOLONE ACETATE

AKORN	25MG/ML	A083032 001	
	50MG/ML	A084492 001	
BEL MAR	25MG/ML	A083738 001	
	50MG/ML	A083738 002	
CENT PHARMS	25MG/ML	A084717 001	
	50MG/ML	A084717 002	
WATSON LABS	25MG/ML	A083398 001	
	25MG/ML	A083654 001	
	40MG/ML	A083767 001	
	50MG/ML	A083764 001	
	50MG/ML	A085781 001	

STERANE

PFIZER	25MG/ML	N011446 001	
--------	---------	-------------	--

SUSPENSION; ORAL

FLO-PRED

TARO	EQ 5MG BASE/5ML	N022067 001	Jan 17, 2008
	EQ 15MG BASE/5ML	N022067 002	Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

ALCON	0.125%	N017468 001	
-------	--------	-------------	--

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON	0.25%;10%	A087771 001	Aug 06, 1993
-------	-----------	-------------	--------------

METIMYD

SCHERING	0.5%;10%	N010210 002	Sep 09, 1984
----------	----------	-------------	--------------

PREDSULFAIR

PHARMAFAIR	0.5%;10%	A088032 001	Apr 15, 1983
------------	----------	-------------	--------------

VASOCIDIN

NOVARTIS	0.5%;10%	A088791 001	Oct 05, 1984
----------	----------	-------------	--------------

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

ALCON	0.25%;10%	A087547 001	
-------	-----------	-------------	--

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

SCHERING	0.5%;10%	N010210 001	
----------	----------	-------------	--

PREDAMIDE

AKORN	0.5%;10%	A088059 001	Jul 29, 1983
-------	----------	-------------	--------------

PREDSULFAIR

PHARMAFAIR	0.5%;10%	A088007 001	Apr 19, 1983
------------	----------	-------------	--------------

PREDSULFAIR II

PHARMAFAIR	0.2%;10%	A088837 001	Dec 24, 1985
------------	----------	-------------	--------------

SULPHRIN

BAUSCH AND LOMB	0.5%;10%	A088089 001	Dec 28, 1982
-----------------	----------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**PREDNISOLONE SODIUM PHOSPHATE

## INJECTABLE; INJECTION

HYDELTRASOL

MERCCK EQ 20MG PHOSPHATE/ML N011583 002

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS EQ 20MG PHOSPHATE/ML A080517 001

## OINTMENT; OPHTHALMIC, OTIC

HYDELTRASOL

MERCCK EQ 0.25% PHOSPHATE N011028 001

## SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

MEDICIS PHARMS EQ 15MG BASE/5ML A075250 001 Jul 12, 2002

NESHER PHARMS EQ 5MG BASE/5ML A076982 001 May 24, 2005

EQ 15MG BASE/5ML A076988 001 May 24, 2005

PHARM ASSOC EQ 5MG BASE/5ML A076123 001 Dec 23, 2002

VINTAGE PHARMS EQ 5MG BASE/5ML A078416 001 Oct 31, 2007

WE PHARMS EQ 5MG BASE/5ML A075181 001 Dec 23, 2002

## SOLUTION/DROPS; OPHTHALMIC

INFLAMASE FORTE

NOVARTIS EQ 0.9% PHOSPHATE A080751 002

INFLAMASE MILD

NOVARTIS EQ 0.11% PHOSPHATE A080751 001

METRETON

SCHERING EQ 0.5% PHOSPHATE A083834 001

PREDAIR

PHARMAFAIR EQ 0.11% PHOSPHATE A088415 001 Feb 29, 1984

PREDAIR FORTE

PHARMAFAIR EQ 0.9% PHOSPHATE A088165 001 Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AKORN EQ 0.11% PHOSPHATE A083358 001

EQ 0.9% PHOSPHATE A083358 002

ALCON PHARMS LTD EQ 0.11% PHOSPHATE A081043 001 Oct 24, 1991

EQ 0.9% PHOSPHATE A081044 001 Oct 24, 1991

BAUSCH AND LOMB EQ 0.11% PHOSPHATE A040065 001 Jul 29, 1994

SOLA BARNES HIND EQ 0.11% PHOSPHATE A084171 001

EQ 0.9% PHOSPHATE A084168 001

EQ 0.9% PHOSPHATE A084169 001

EQ 0.9% PHOSPHATE A084172 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

## SOLUTION/DROPS; OPHTHALMIC

SULSTER

AKORN EQ 0.23% PHOSPHATE;10% A074511 001 Jul 30, 1996

VASOCIDIN

NOVARTIS EQ 0.23% PHOSPHATE;10% \*\*Federal N018988 001 Aug 26, 1988

Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

PREDNISOLONE TEBUTATE

## INJECTABLE; INJECTION

HYDELTRA-TBA

MERCCK 20MG/ML N010562 001

PREDNISOLONE TEBUTATE

WATSON LABS 20MG/ML A083362 001 Feb 17, 1984

PREDNISON

## SOLUTION; ORAL

PREDNISON

WOCKHARDT 5MG/5ML A089726 001 Aug 02, 1988

## SYRUP; ORAL

LIQUID PRED

MURO 5MG/5ML A087611 002 Sep 07, 1982

## TABLET; ORAL

CORTAN

HALSEY 20MG A087480 001

DELTA-DOME

BAYER PHARMS 5MG A080293 001

DELTASONE

PHARMACIA AND UPJOHN 2.5MG N009986 005

5MG N009986 002

10MG N009986 006

20MG N009986 007

50MG N009986 008

## DISCONTINUED DRUG PRODUCT LIST

PREDNISONE

TABLET; ORAL

FERNISONE

FERNDALE LABS 5MG A083364 001

METICORTEN

SCHERING 1MG N009766 002

5MG N009766 001

ORASONE

SOLVAY 1MG A083009 001

5MG A083009 002

10MG A083009 003

20MG A083009 004

50MG A085999 001

PARACORT

PARKE DAVIS 5MG N010962 002

PREDNICEN-M

SCHWARZ PHARMA 5MG A084655 001

PREDNISONE

AM THERAP 5MG A089387 001 Nov 06, 1986

10MG A089388 001 Nov 06, 1986

20MG A089389 001 Nov 06, 1986

AMNEAL PHARMS NY 5MG A089597 001 Oct 05, 1987

10MG A089598 001 Oct 05, 1987

20MG A089599 001 Oct 05, 1987

BUNDY 5MG A083676 001

DURAMED PHARMS BARR 5MG A088394 001 Oct 04, 1983

10MG A088395 001 Oct 04, 1983

20MG A088396 001 Oct 04, 1983

ELKINS SINN 5MG A080491 001

20MG A085811 001

EVERYLIFE 1MG A084440 001

2.5MG A084440 002

5MG A084440 003

FERRANTE 2.5MG A080563 001

5MG A080563 002

HALSEY 5MG A080300 001

HEATHER 5MG A080320 001

10MG A084341 001

20MG A084417 001

20MG A085543 001

50MG A086946 001

HIKMA PHARMS 1MG A040890 001 Nov 01, 2010

IMPAX LABS 5MG A080782 001

INWOOD LABS 1MG A080328 001

2.5MG A080306 001

5MG A080279 001

IVAX SUB TEVA PHARMS 5MG A080283 001

10MG A084133 001

20MG A084134 001

KV PHARM 5MG A084236 001

LANNETT 5MG A080514 001

20MG A084275 001

LEDERLE 5MG A086968 001

MARSHALL PHARMA 5MG A080301 001

MUTUAL PHARM 5MG A080701 001

10MG A086595 001

20MG A084634 001

50MG A086596 001

NYLOS 5MG A085115 001

PANRAY 1MG A080350 001

2.5MG A080350 002

5MG A080350 003

PERRIGO 5MG A083059 001

PHARMAVITE 5MG A084662 002

PHOENIX LABS NY 5MG A080321 001

20MG A083807 001

PUREPAC PHARM 5MG A080353 001

10MG A086062 001

20MG A086061 001

PVT FORM 20MG A085151 001

REXALL 5MG A080232 001

ROXANE 20MG N017109 001

## DISCONTINUED DRUG PRODUCT LIST

PREDNISONE

TABLET; ORAL

PREDNISONE

	25MG	A087833 001	May 04, 1982
SANDOZ	5MG	A080336 002	
	5MG	A084774 001	
	10MG	A089983 001	Jan 12, 1989
	20MG	A085813 001	
	50MG	A089984 001	Jan 12, 1989
SCHERER LABS	5MG	A080371 001	
SPERTI	1MG	A080359 001	
	2.5MG	A080359 002	
	5MG	A080359 003	
SUPERPHARM	5MG	A088865 001	Oct 25, 1984
	10MG	A088866 001	Oct 25, 1984
	20MG	A088867 001	Oct 25, 1984
TEVA	5MG	A080397 001	
UDL	5MG	A087984 001	Jan 18, 1983
	10MG	A087985 001	Jan 18, 1983
	20MG	A087986 001	Jan 18, 1983
UPSHER SMITH	5MG	A087471 001	
	20MG	A087470 001	
VALEANT PHARM INTL	5MG	A080237 001	
VANGARD	5MG	A087682 001	Jan 15, 1982
	20MG	A087701 001	Jan 15, 1982
VITARINE	5MG	A080334 001	
	5MG	A080506 001	
WATSON LABS	5MG	A085084 002	
	10MG	A087773 001	Jul 13, 1982
	20MG	A086813 001	
	50MG	A086867 001	
	50MG	A087772 001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913 001	
	5MG	A080343 001	
	10MG	A089028 001	Jul 24, 1986
	20MG	A084913 002	
SERVISONE			
LEDERLE	5MG	A080223 001	

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

ASTRAZENECA	1%	N014763 004	
	2%	N014763 005	
	3%	N014763 003	
CITANEST PLAIN			
ASTRAZENECA	4%	N014763 007	
CITANEST PLAIN DENTAL			
DENTSPLY PHARM	4%	N021382 001	

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

NURO PHARMA	250MG/5ML	N010401 001	
-------------	-----------	-------------	--

TABLET; ORAL

PRIMIDONE

DR REDDYS LABS LTD	50MG	A040862 001	Oct 03, 2008
	250MG	A040862 002	Oct 03, 2008
HIKMA PHARMS LLC	50MG	A040667 001	Jul 27, 2006
WATSON LABS	250MG	A085052 001	

PROBENECID

TABLET; ORAL

BENEMID

MERCK	500MG	N007898 004	
-------	-------	-------------	--

PROBENECID

IVAX SUB TEVA PHARMS	500MG	A083740 001	May 09, 1984
LEDERLE	500MG	A086917 001	
WATSON LABS	500MG	A086150 002	Apr 23, 1982

## DISCONTINUED DRUG PRODUCT LIST

PROBUCOL

TABLET; ORAL

LORELCO

SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ASCOT	250MG	A087542	001	Jan 08, 1982
	375MG	A087697	001	Mar 01, 1983
	500MG	A087543	001	Jan 08, 1982
IDT AUSTRALIA LTD	250MG	A089219	001	Jul 01, 1986
	500MG	A089221	001	Jul 01, 1986
IVAX SUB TEVA PHARMS	250MG	A084604	001	
	375MG	A084595	001	
	500MG	A084606	001	
LANNETT	250MG	A083693	001	
	500MG	A084696	001	
LEDERLE	250MG	A086942	001	
	375MG	A086952	001	
	500MG	A086943	001	
ROXANE	250MG	A088989	001	Apr 26, 1985
	500MG	A088990	001	Apr 26, 1985
SANDOZ	375MG	A089220	001	Jul 01, 1986
VANGARD	250MG	A087643	001	Jun 01, 1982
	500MG	A087875	001	Jun 01, 1982
WATSON LABS	250MG	A083287	001	
	250MG	A083795	001	
	250MG	A085167	001	
	375MG	A084403	001	
	375MG	A087020	001	
	500MG	A084280	001	
	500MG	A084357	001	
	500MG	A087021	001	
PROCAN				
PARKE DAVIS	250MG	A085804	001	
	375MG	A087502	001	
	500MG	A085079	001	
PROCAPAN				
PANRAY	250MG	A083553	002	
PRONESTYL				
APOTHECON	250MG	N007335	001	
	375MG	N007335	004	
	500MG	N007335	003	

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A089415	001	Nov 17, 1986
	500MG/ML	A089416	001	Nov 17, 1986
HIKMA MAPLE	100MG/ML	A089029	001	Apr 17, 1986
	500MG/ML	A089030	001	Apr 17, 1986
HOSPIRA	500MG/ML	A089537	001	Aug 25, 1987
INTL MEDICATION	100MG/ML	A088636	001	Jul 31, 1984
	500MG/ML	A088637	001	Jul 31, 1984
PHARMAFAIR	100MG/ML	A088824	001	Nov 20, 1985
	500MG/ML	A088830	001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530	001	Mar 04, 1985
	500MG/ML	A088531	001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528	001	May 03, 1988
	500MG/ML	A089529	001	May 03, 1988
WATSON LABS	100MG/ML	A087079	001	
	500MG/ML	A087080	001	
PRONESTYL				
APOTHECON	100MG/ML	N007335	002	
	500MG/ML	N007335	005	

TABLET; ORAL

PRONESTYL

APOTHECON	250MG	N017371	001	
	375MG	N017371	002	
	500MG	N017371	003	



**DISCONTINUED DRUG PRODUCT LIST**PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC	250MG	A088958	001	Dec 02, 1985
	500MG	A088959	001	Dec 02, 1985
	500MG	A088974	001	Jul 22, 1985
	750MG	A089438	001	Mar 23, 1987
	1GM	A040111	001	Dec 13, 1996
IDT AUSTRALIA LTD	250MG	A089369	001	Aug 14, 1987
	500MG	A089370	001	Jan 09, 1987
	750MG	A089371	001	Aug 14, 1987
INWOOD LABS	500MG	A089840	001	Mar 06, 1989
SANDOZ	500MG	A089284	001	Jun 23, 1986
WATSON LABS	250MG	A088533	001	Dec 03, 1984
	250MG	A089026	001	Oct 22, 1985
	500MG	A088534	001	Dec 03, 1984
	500MG	A089027	001	Oct 22, 1985
	750MG	A088535	001	Nov 03, 1984
	750MG	A089042	001	Oct 22, 1985
	1GM	A089520	001	Jan 15, 1987
PROCAN SR				
PARKE DAVIS	250MG	A086468	001	
PARKE DALE	500MG	A086065	001	
	750MG	A087510	001	Apr 01, 1982
	1GM	A088489	001	Jan 16, 1985
PROCANBID				
KING PHARMS	500MG	N020545	001	Jan 31, 1996
	1GM	N020545	002	Jan 31, 1996
PRONESTYL-SR				
APOTHECON	500MG	A087361	001	

PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

NOVOCAIN

HOSPIRA	1%	A085362	003	
	2%	A085362	004	
	10%	A086797	001	
PROCAINE HYDROCHLORIDE				
ABRAXIS PHARM	1%	A080384	002	
	1%	A080421	001	
	2%	A080384	003	
	2%	A080421	002	
BEL MAR	1%	A080711	001	
	2%	A080756	001	
ELKINS SINN	1%	A083315	001	
	2%	A083315	002	
GD SEARLE LLC	1%	A086202	001	
	2%	A086202	002	
HOSPIRA	1%	A080416	001	
	2%	A080416	002	
MILES	1%	A080415	001	
	2%	A080415	002	
WATSON LABS	1%	A080658	001	
	1%	A083535	001	
	2%	A080658	002	
	2%	A083535	002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION

ACHROMYCIN

LEDERLE	40MG/VIAL;100MG/VIAL	N050276	001	
	40MG/VIAL;250MG/VIAL	N050276	003	
TETRACYN				
PFIZER	40MG/VIAL;100MG/VIAL	A060285	002	
	40MG/VIAL;250MG/VIAL	A060285	003	

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE;INJECTION

DICURIN PROCAINE

LILLY	100MG/ML;50MG/ML	N008869	001	
-------	------------------	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE	2.5MG	N011127	003	
	5MG	N011127	001	
	25MG	N011127	002	
PROCHLORPERAZINE				
ABLE	2.5MG	A040407	001	Jul 11, 2001
	5MG	A040407	002	Jul 11, 2001
	25MG	A040407	003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001	
PROCHLORPERAZINE				
ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153	001	Jun 08, 1982
PROCHLORPERAZINE EDISYLATE				
MORTON GROVE	EQ 10MG BASE/ML	A088598	001	Oct 25, 1984

INJECTABLE; INJECTION

COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/ML	N010742	002	
PROCHLORPERAZINE				
BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759	001	Oct 01, 1982
PROCHLORPERAZINE EDISYLATE				
HIKMA MAPLE	EQ 5MG BASE/ML	A089523	001	May 03, 1988
HOSPIRA	EQ 5MG BASE/ML	A089703	001	Apr 07, 1988
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675	001	Dec 05, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251	001	Dec 04, 1986
TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003
WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089605	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089606	001	Jul 08, 1987
WYETH AYERST	EQ 5MG BASE/ML	A086348	001	

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001	
PROCHLORPERAZINE EDISYLATE				
ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982
MORTON GROVE	EQ 5MG BASE/5ML	A088597	001	Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE	N011000	001	
	EQ 10MG BASE	N021019	001	Oct 06, 1999
	EQ 15MG BASE	N011000	002	
	EQ 15MG BASE	N021019	002	Oct 06, 1999
	EQ 30MG BASE	N011000	003	
	EQ 75MG BASE	N011000	004	

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE	N010571	001	
	EQ 10MG BASE	N010571	002	
	EQ 25MG BASE	N010571	003	
PROCHLORPERAZINE				
WATSON LABS	EQ 5MG BASE	A085580	001	
	EQ 10MG BASE	A085178	001	
	EQ 25MG BASE	A085579	001	

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR	EQ 5MG BASE	A040207	001	May 01, 1997
	EQ 5MG BASE	A089484	001	Jan 20, 1987
	EQ 10MG BASE	A040207	002	May 01, 1997
	EQ 10MG BASE	A089485	001	Jan 20, 1987
	EQ 25MG BASE	A089486	001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162	001	Jan 20, 1998
	EQ 10MG BASE	A040162	002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101	003	Jul 19, 1996

## DISCONTINUED DRUG PRODUCT LIST

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS

2MG

N009818 005

5MG

N009818 003

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

ABBVIE INC

300MG

N019781 003 Oct 15, 1999

INJECTABLE; INJECTION

PROGESTERONE

LILLY

25MG/ML

N009238 002

50MG/ML

N009238 001

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA

38MG

N017553 001

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST

30MG/ML

N010942 001

100MG/ML

N010942 004

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS

25MG/ML

A084510 001

50MG/ML

A084517 001

SPARINE

BAXTER HLTHCARE CORP

25MG/ML

N010349 008

50MG/ML

N010349 006

SYRUP; ORAL

SPARINE

WYETH AYERST

10MG/5ML

N010942 003

TABLET; ORAL

SPARINE

WYETH AYERST

10MG

N010348 006

25MG

N010348 001

50MG

N010348 002

100MG

N010348 003

200MG

N010348 004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST

25MG/ML

N008857 002

50MG/ML

N008857 003

PROMETHAZINE HYDROCHLORIDE

ABBOTT

25MG/ML

A084223 001

50MG/ML

A084222 001

AKORN

25MG/ML

A083955 002

50MG/ML

A083955 001

BEDFORD LABS

25MG/ML

A040524 001 Mar 17, 2004

50MG/ML

A040524 002 Mar 17, 2004

HOSPIRA

25MG/ML

A040372 001 Jun 08, 2000

50MG/ML

A040372 002 Jun 08, 2000

50MG/ML

A083838 002

LUITPOLD

25MG/ML

A040515 001 Mar 19, 2003

MARSAM PHARMS LLC

25MG/ML

A089463 001 May 02, 1988

50MG/ML

A089477 001 May 02, 1988

MYLAN INSTITUTIONAL

25MG/ML

A040471 001 Nov 21, 2002

SANDOZ

25MG/ML

A040593 001 Nov 08, 2006

50MG/ML

A040593 002 Nov 08, 2006

TEVA PHARMS USA

25MG/ML \*\*Federal Register

A040454 001 Aug 22, 2002

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

50MG/ML \*\*Federal Register

A040454 002 Aug 22, 2002

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

WATSON LABS

25MG/ML

A083532 001

25MG/ML

A084591 001

50MG/ML

A080629 002

50MG/ML

A083532 002

WOCKHARDT

25MG/ML

A040785 001 Sep 26, 2008

## DISCONTINUED DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## PROMETHAZINE HYDROCHLORIDE

	50MG/ML	A040785 002	Sep 26, 2008
--	---------	-------------	--------------

## ZIPAN-25

ALTANA	25MG/ML	A083997 001	
--------	---------	-------------	--

## ZIPAN-50

ALTANA	50MG/ML	A083997 002	
--------	---------	-------------	--

## SUPPOSITORY; RECTAL

## PHENERGAN

DELacor ASSET CORP	12.5MG	N010926 002	
--------------------	--------	-------------	--

	25MG	N010926 001	
--	------	-------------	--

	50MG	N011689 001	
--	------	-------------	--

## PROMETHACON

POLYMEDICA	25MG	A084901 001	
------------	------	-------------	--

	50MG	A084902 001	
--	------	-------------	--

## PROMETHAZINE HYDROCHLORIDE

ABLE	12.5MG	A040504 001	Apr 11, 2003
------	--------	-------------	--------------

	25MG	A040504 002	Apr 11, 2003
--	------	-------------	--------------

	50MG	A040449 001	Feb 27, 2003
--	------	-------------	--------------

## SYRUP; ORAL

## MYMETHAZINE FORTIS

USL PHARMA	25MG/5ML	A087996 001	Jan 18, 1983
------------	----------	-------------	--------------

## PROMETH FORTIS

ALPHARMA US PHARMS	25MG/5ML	A084772 001	
--------------------	----------	-------------	--

## PROMETH PLAIN

ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953 001	
----------------------	------------	-------------	--

## PROMETHAZINE

CENCI	6.25MG/5ML	A089013 001	Sep 20, 1985
-------	------------	-------------	--------------

## PROMETHAZINE HYDROCHLORIDE

KV PHARM	6.25MG/5ML	A085388 001	
----------	------------	-------------	--

	25MG/5ML	A085385 001	
--	----------	-------------	--

PHARM ASSOC	6.25MG/5ML	A087518 001	
-------------	------------	-------------	--

WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395 001	
----------------------	------------	-------------	--

## PROMETHAZINE HYDROCHLORIDE PLAIN

ANI PHARMS	6.25MG/5ML	N008381 004	Apr 18, 1984
------------	------------	-------------	--------------

	25MG/5ML **Federal Register	N008381 003	
--	-----------------------------	-------------	--

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

## TABLET; ORAL

## PHENERGAN

DELacor ASSET CORP	12.5MG	N007935 002	
--------------------	--------	-------------	--

	25MG	N007935 003	
--	------	-------------	--

	50MG	N007935 004	
--	------	-------------	--

## PROMETHAZINE HYDROCHLORIDE

ABBOTT	12.5MG	A084160 001	
--------	--------	-------------	--

	25MG	A084166 001	
--	------	-------------	--

	50MG	A084539 001	
--	------	-------------	--

ABLE	12.5MG	A040558 001	Jul 01, 2004
------	--------	-------------	--------------

	25MG	A040558 002	Jul 01, 2004
--	------	-------------	--------------

	50MG	A040558 003	Jul 01, 2004
--	------	-------------	--------------

IMPAX LABS	25MG	A084214 002	Jul 07, 1982
------------	------	-------------	--------------

IVAX SUB TEVA PHARMS	12.5MG	A083604 001	
----------------------	--------	-------------	--

	25MG	A083603 001	
--	------	-------------	--

	50MG	A083613 001	
--	------	-------------	--

LANNETT	12.5MG	A080949 001	
---------	--------	-------------	--

	25MG	A080949 002	
--	------	-------------	--

	50MG	A080949 003	
--	------	-------------	--

MUTUAL PHARM	12.5MG	A084555 001	
--------------	--------	-------------	--

	25MG	A084554 001	
--	------	-------------	--

	50MG	A084557 001	
--	------	-------------	--

PVT FORM	12.5MG	A083214 001	
----------	--------	-------------	--

	25MG	A083658 001	
--	------	-------------	--

SANDOZ	12.5MG	A084176 002	May 22, 2009
--------	--------	-------------	--------------

	12.5MG	A084233 001	
--	--------	-------------	--

	25MG	A085146 001	
--	------	-------------	--

	50MG	A085146 002	
--	------	-------------	--

TABLICAPS	12.5MG	A084080 001	
-----------	--------	-------------	--

	25MG	A084027 001	
--	------	-------------	--

TEVA	25MG	A089109 001	Sep 10, 1985
------	------	-------------	--------------

WATSON LABS	12.5MG	A083401 001	
-------------	--------	-------------	--

	12.5MG	A083712 001	
--	--------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

12.5MG	A085986	001
25MG	A083204	001
25MG	A085684	001
50MG	A083403	001
50MG	A085664	001

REMSD

BRISTOL MYERS SQUIBB

25MG	A083176	002
50MG	A083176	001

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS

150MG	A076193	001	Feb 07, 2002
225MG	A076193	002	Feb 07, 2002
300MG	A076193	003	Feb 07, 2002

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC

30MG/VIAL	N008843	001
-----------	---------	-----

TABLET; ORAL

PRO-BANTHINE

SHIRE

7.5MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008732	003
15MG		N008732	002

PROPANTHELINE BROMIDE

ASCOT

15MG	A087663	001	Oct 25, 1982
------	---------	-----	--------------

HEATHER

15MG	A085780	001
------	---------	-----

IMPAX LABS

15MG	A084541	002
------	---------	-----

MYLAN

15MG	A083706	001
------	---------	-----

PAR PHARM

15MG	A088377	001	Dec 08, 1983
------	---------	-----	--------------

PVT FORM

15MG	A080977	001
------	---------	-----

ROXANE

7.5MG	A080927	001
-------	---------	-----

SANDOZ

15MG	A080928	001
------	---------	-----

TABLICAPS

15MG	A084428	001
------	---------	-----

WATSON LABS

15MG	A083029	002
15MG	A083151	001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR

0.5%	A088087	001	Jun 07, 1983
------	---------	-----	--------------

OPHTHAINE

APOTHECON

0.5%	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008883	001
------	--	---------	-----

OPHTHETIC

ALLERGAN

0.5%	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012583	001
------	--	---------	-----

PARACAINE

OPTOPICS

0.5%	A087681	001	Aug 05, 1982
------	---------	-----	--------------

PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND

0.5%	A084144	001
------	---------	-----

0.5%	A084151	001
------	---------	-----

PROPIOLACTONE

SOLUTION; IRRIGATION

BETAPRONE

FOREST LABS

N/A	N011657	001
-----	---------	-----

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

HIKMA MAPLE

20MG/ML	N012382	002
---------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

PROPOFOL

## INJECTABLE; INJECTION

## DIPRIVAN

FRESENIUS KABI USA 10MG/ML N019627 001 Oct 02, 1989

## PROPOFOL

EUROHLTH INTL SARL 10MG/ML A074848 001 Apr 19, 2005

TEVA PARENTERAL 10MG/ML A075392 001 Sep 19, 2000

PROPOXYPHENE HYDROCHLORIDE

## CAPSULE; ORAL

## DARVON

XANODYNE PHARM 32MG N010997 001

65MG N010997 003

## DOLENE

HERITAGE PHARMS INC 65MG A080530 001

## KESSO-GESIC

MK LABS 65MG A083544 001

## PROPHENE 65

HALSEY 65MG A083538 002

## PROPOXYPHENE HYDROCHLORIDE

ALRA 65MG A083184 001

IMPAX LABS 65MG A083317 001

IVAX SUB TEVA PHARMS 32MG A083597 001

MUTUAL PHARM 65MG A083186 001

MYLAN 32MG A083528 001

65MG A040569 001 Dec 16, 2004

65MG A083299 001

NEXGEN PHARMA INC 65MG A083185 001

PAR PHARM 65MG A080269 001

PUREPAC PHARM 65MG A083278 001

PVT FORM 32MG A083464 001

65MG A083113 001

ROXANE 32MG A083089 001

65MG A083089 002

SANDOZ 32MG A084014 001

65MG A083125 002

65MG A083688 001

65MG A083870 002

65MG A086495 001

TEVA 65MG A088615 001 Oct 22, 1984

VALEANT PHARM INTL 65MG A080783 001

VINTAGE PHARMS 65MG A040908 001 Jul 17, 2009

WATSON LABS 65MG A080908 002

65MG A085190 001

WEST WARD 65MG A083501 001

WHITEWORTH TOWN PLSN 65MG A084551 001

## PROPOXYPHENE HYDROCHLORIDE 65

WARNER CHILCOTT 65MG A083786 001

PROPOXYPHENE NAPSYLATE

## SUSPENSION; ORAL

## DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

## TABLET; ORAL

## DARVON-N

XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## PROPRANOLOL HYDROCHLORIDE

INWOOD LABS 60MG A072499 001 Apr 11, 1989

80MG A072500 001 Apr 11, 1989

120MG A072501 001 Apr 11, 1989

160MG A072502 001 Apr 11, 1989

## CONCENTRATE; ORAL

## PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

## INJECTABLE; INJECTION

## PROPRANOLOL HYDROCHLORIDE

SMITH AND NEPHEW 1MG/ML A070135 001 Apr 15, 1986

1MG/ML A070137 001 Apr 15, 1986

SOLOPAK 1MG/ML A070136 001 Apr 15, 1986

## DISCONTINUED DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

## SOLUTION; ORAL

## PROPRANOLOL HYDROCHLORIDE

MORTON GROVE

20MG/5ML

A071984 001 Mar 03, 1989

40MG/5ML

A071985 001 Mar 03, 1989

## SUSPENSION; ORAL

## INDERAL

WYETH AYERST

10MG/ML

N019536 001 Dec 12, 1986

## TABLET; ORAL

## INDERAL

WYETH PHARMS INC

10MG

N016418 001

20MG

N016418 003

40MG

N016418 002

60MG

N016418 009 Oct 18, 1982

80MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N016418 004

90MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N016418 010 Oct 18, 1982

## PROPRANOLOL HYDROCHLORIDE

ANI PHARMS INC

90MG

A071977 001 Apr 06, 1988

DAVA PHARMS INC

10MG

A070125 001 Jul 30, 1985

20MG

A070126 001 Jul 30, 1985

40MG

A070127 001 Jul 30, 1985

60MG

A071495 001 Dec 31, 1987

80MG

A070128 001 Jul 30, 1985

90MG

A071496 001 Dec 31, 1987

DURAMED PHARMS BARR

10MG

A070306 001 Sep 09, 1985

20MG

A070307 001 Sep 09, 1985

40MG

A070308 001 Sep 09, 1985

60MG

A070309 001 Oct 01, 1986

80MG

A070310 001 Sep 09, 1985

90MG

A071327 001 Oct 01, 1986

INTERPHARM

10MG

A071368 001 May 05, 1987

20MG

A071369 001 May 05, 1987

40MG

A071370 001 May 05, 1987

80MG

A071371 001 May 05, 1987

IVAX SUB TEVA PHARMS

10MG

A072063 001 Jul 29, 1988

20MG

A072066 001 Jul 29, 1988

40MG

A072067 001 Jul 29, 1988

60MG

A072068 001 Jul 29, 1988

80MG

A072069 001 Jul 29, 1988

LEDERLE

10MG

A072117 001 Jun 23, 1988

20MG

A072118 001 Jun 23, 1988

40MG

A072119 001 Jun 23, 1988

80MG

A072120 001 Jun 23, 1988

MUTUAL PHARM

10MG

A070319 001 Oct 22, 1985

20MG

A070320 001 Oct 22, 1985

40MG

A070103 001 Oct 22, 1985

60MG

A070321 001 Sep 24, 1986

80MG

A070322 001 Aug 04, 1986

MYLAN

60MG

A072275 001 Jun 09, 1989

PAR PHARM

90MG

A071288 001 Oct 22, 1986

PUREPAC PHARM

10MG

A070814 001 Nov 03, 1986

20MG

A070815 001 Nov 03, 1986

40MG

A070816 001 Nov 03, 1986

60MG

A070817 001 Nov 03, 1986

80MG

A070757 001 Nov 03, 1986

ROXANE

10MG

A070516 001 Jul 07, 1986

20MG

A070517 001 Jul 07, 1986

40MG

A070518 001 Jul 07, 1986

60MG

A070519 001 Sep 24, 1986

80MG

A070520 001 Jul 07, 1986

90MG

A070521 001 Sep 24, 1986

SANDOZ

10MG

A070663 001 Jun 13, 1986

10MG

A071658 001 Jul 05, 1988

20MG

A070664 001 Jun 13, 1986

20MG

A071687 001 Jul 05, 1988

40MG

A070665 001 Jun 13, 1986

40MG

A071688 001 Jul 05, 1988

**DISCONTINUED DRUG PRODUCT LIST**PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

60MG	A070666	001	Oct 10, 1986
60MG	A072197	001	Jul 05, 1988
80MG	A070667	001	Jun 13, 1986
80MG	A071689	001	Jul 05, 1988
90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001 Aug 06, 1985
	20MG	A070121	001 Aug 06, 1985
	40MG	A070122	001 Aug 06, 1985
	60MG	A070123	001 Oct 29, 1986
	80MG	A070124	001 Aug 06, 1985
SUPERPHARM	10MG	A071515	001 Jun 08, 1988
	20MG	A071516	001 Jun 08, 1988
	40MG	A071517	001 Jun 08, 1988
	80MG	A071518	001 Jun 08, 1988
TEVA	10MG	A070232	001 Oct 07, 1987
	20MG	A070233	001 Jun 23, 1986
	40MG	A070234	001 Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001 Sep 15, 1986
	20MG	A070439	001 Sep 15, 1986
	40MG	A070440	001 Sep 15, 1986
	60MG	A070441	001 Sep 24, 1986
	80MG	A070442	001 Sep 15, 1986
WATSON LABS	10MG	A070140	001 Jul 30, 1985
	10MG	A070378	001 Mar 19, 1987
	10MG	A070548	001 Jul 10, 1986
	20MG	A070141	001 Jul 30, 1985
	20MG	A070379	001 Mar 19, 1987
	20MG	A070549	001 Apr 11, 1986
	40MG	A070142	001 Jul 30, 1985
	40MG	A070380	001 Mar 19, 1987
	40MG	A070550	001 Apr 11, 1986
	60MG	A070143	001 Jan 15, 1987
	60MG	A070381	001 Mar 19, 1987
	60MG	A071098	001 Oct 06, 1986
	60MG	A071791	001 Jul 15, 1987
	80MG	A070144	001 Jul 30, 1985
	80MG	A070382	001 Mar 19, 1987
	80MG	A070551	001 Jul 10, 1986
	90MG	A071183	001 Oct 06, 1986
	90MG	A071792	001 Jul 15, 1987

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE 50% N009309 001

DIONOSIL OILY

GLAXOSMITHKLINE 60% N009309 002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT	50MG	A084075	001
ANABOLIC	50MG	A080285	001
ANI PHARMS INC	50MG	A080215	001
HALSEY	50MG	A080015	001
HIKMA PHARMS LLC	50MG	A080154	001
IMPAX LABS	50MG	A080159	001
LANNETT	50MG	A080016	001
LILLY	50MG	N006213	001
MUTUAL PHARM	50MG	A083982	001
PERRIGO	50MG	A084543	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001



**DISCONTINUED DRUG PRODUCT LIST**PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

HIKMA MAPLE	10MG/ML	A089474	001	Nov 05, 1986
	10MG/ML	A089475	001	Nov 05, 1986
LILLY	10MG/ML	N006460	002	
PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
	250MG/VIAL	N007413	002	Aug 02, 1984

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE	5%	N005932	012	Jan 31, 1985
HYPROTIGEN 5%				
B BRAUN	5%	N006170	003	Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT	0.5MG/ML	N017638	001	
THYREL TRH				
FERRING	0.5MG/ML	N018087	001	

PROTOKYLQOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US	2MG	A083459	001	
-------------------	-----	---------	-----	--

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

TEVA WOMENS	5MG	N016012	001	
	10MG	N016012	002	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US	120MG	N017603	001	
-------------------	-------	---------	-----	--

SUDAFED 12 HOUR

GLAXOSMITHKLINE	120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017941	002	
-----------------	--	---------	-----	--

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACTIFED

GLAXOSMITHKLINE	120MG; 5MG	N018996	001	Jun 17, 1985
-----------------	------------	---------	-----	--------------

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM	120MG; 5MG	A071798	001	Mar 16, 1989
----------	------------	---------	-----	--------------

SYRUP; ORAL

ACTAHIST

CENCI	30MG/5ML; 1.25MG/5ML	A088344	001	Feb 09, 1984
-------	----------------------	---------	-----	--------------

HISTAFED

CENCI	30MG/5ML; 1.25MG/5ML	A088283	001	Apr 20, 1984
-------	----------------------	---------	-----	--------------

MYFED

USL PHARMA	30MG/5ML; 1.25MG/5ML	A088116	001	Mar 04, 1983
------------	----------------------	---------	-----	--------------

TRILITRON

NEWTRON PHARMS	30MG/5ML; 1.25MG/5ML	A088474	001	Feb 12, 1985
----------------	----------------------	---------	-----	--------------

TABLET; ORAL

ALLERFED

PVT FORM	60MG; 2.5MG	A088860	001	Jan 31, 1985
----------	-------------	---------	-----	--------------

CORPHED

SANDOZ	60MG; 2.5MG	A088602	001	Apr 11, 1985
--------	-------------	---------	-----	--------------

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ	60MG; 2.5MG	A088193	001	May 17, 1983
--------	-------------	---------	-----	--------------

TRILITRON

NEWTRON PHARMS	60MG; 2.5MG	A088515	001	Jan 09, 1985
----------------	-------------	---------	-----	--------------

TRIPHED

TEVA	60MG; 2.5MG	A088630	001	May 17, 1984
------	-------------	---------	-----	--------------

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS	60MG; 2.5MG	A088318	002	Jan 13, 1984
-------------	-------------	---------	-----	--------------

WEST WARD	60MG; 2.5MG	A088117	001	Apr 19, 1983
-----------	-------------	---------	-----	--------------

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	60MG; 2.5MG	A085273	001	Dec 12, 1984
----------------------	-------------	---------	-----	--------------

SUPERPHARM	60MG; 2.5MG	A088578	001	Feb 21, 1985
------------	-------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG;5MG A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

UCB INC EQ 60MG HCL/5ML N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

ANI PHARMS INC 30MG A040512 002 Jul 20, 2005

60MG A040512 001 Oct 08, 2003

COREPHARMA 60MG A040457 001 Dec 26, 2002

SOLVAY 30MG A089572 001 Nov 27, 1990

US ARMY 30MG N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

HEXA-BETALIN

LILLY 100MG/ML A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN 100MG/ML A087967 001 Oct 01, 1982

BEL MAR 100MG/ML A080761 001

DELL LABS 50MG/ML A083771 001

100MG/ML A083772 001

ELKINS SINN 100MG/ML A080581 001

LUITPOLD 100MG/ML A080669 001

WATSON LABS 100MG/ML A080572 001

100MG/ML A083760 001

PYRILAMINE MALEATE

TABLET;ORAL

PYRILAMINE MALEATE

IMPAX LABS 25MG A080808 001

WATSON LABS 25MG A085231 001

PYRIMETHAMINE; SULFADOXINE

TABLET;ORAL

FANSIDAR

ROCHE 25MG;500MG N018557 001

PYRITHIONE ZINC

LOTION;TOPICAL

HEAD &amp; SHOULDERS CONDITIONER

WARNER CHILCOTT 0.3% N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION;ORAL

POVAN

PARKE DAVIS EQ 50MG BASE/5ML N011964 001

TABLET;ORAL

POVAN

PARKE DAVIS EQ 50MG BASE N012485 002

QUAZEPAM

TABLET;ORAL

DORAL

SCIECURE PHARMA INC 7.5MG N018708 003 Feb 26, 1987

15MG N018708 001 Dec 27, 1985

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

ASTRAZENECA PHARMS EQ 150MG BASE N020639 004 Dec 20, 1998

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH EQ 5MG BASE A076459 001 Dec 22, 2004

EQ 10MG BASE A076459 002 Dec 22, 2004

EQ 20MG BASE A076459 003 Dec 22, 2004

EQ 40MG BASE A076459 004 Dec 22, 2004

APOTEX INC EQ 5MG BASE A076240 001 Jan 26, 2006

EQ 10MG BASE A076240 002 Jan 26, 2006

## DISCONTINUED DRUG PRODUCT LIST

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	EQ 20MG BASE	A076240 003	Jan 26, 2006
	EQ 40MG BASE	A076240 004	Jan 26, 2006
MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005
	EQ 10MG BASE	A076036 002	Jan 28, 2005
	EQ 20MG BASE	A076036 003	Jan 28, 2005
	EQ 40MG BASE	A076036 004	Jan 28, 2005
SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005
	EQ 10MG BASE	A076803 002	Mar 02, 2005
	EQ 20MG BASE	A076803 003	Mar 02, 2005
	EQ 40MG BASE	A076803 004	Mar 02, 2005

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS	0.1MG	N016768 002	
	0.2MG	N016768 003	

QUINETHAZONE

TABLET; ORAL

HYDROMOX

LEDERLE	50MG	N013264 001	
---------	------	-------------	--

QUINETHAZONE; RESERPINE

TABLET; ORAL

HYDROMOX R

LEDERLE	50MG; 0.125MG	N013927 001	
---------	---------------	-------------	--

QUINIDINE GLUCONATE

TABLET; ORAL

QUINACT

BAYER HLTHCARE	266MG	A085978 001	
	400MG	A086099 001	

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT	330MG	N017917 001	
-----------------	-------	-------------	--

QUINAGLUTE

BAYER HLTHCARE	324MG	N016647 001	
----------------	-------	-------------	--

QUINALAN

LANNETT	324MG	A088081 001	Feb 10, 1986
---------	-------	-------------	--------------

QUINATIME

WATSON LABS	324MG	A087448 001	
-------------	-------	-------------	--

QUINIDINE GLUCONATE

ASCOT	324MG	A088582 001	Jun 17, 1985
CYCLE PHARMS LTD	324MG	A088431 001	Jan 06, 1984
HALSEY	324MG	A089476 001	Apr 10, 1987
SANDOZ	324MG	A089894 001	Dec 15, 1988
SUPERPHARM	324MG	A089164 001	Nov 21, 1985
WATSON LABS	324MG	A087785 001	Jan 24, 1983
	324MG	A087810 001	Sep 29, 1982

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC	275MG	N011642 002	
-----------------	-------	-------------	--

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY	200MG	A085296 001	
	300MG	A085297 001	

QUINIDINE SULFATE

LILLY	200MG	A085103 001	
-------	-------	-------------	--

TABLET; ORAL

CIN-QUIN

SOLVAY	100MG	A085299 001	
	200MG	A084932 001	
	300MG	A085298 001	

QUINIDINE SULFATE

BARR	200MG	A084177 001	
CONTRACT PHARMACAL	200MG	A083808 001	
CYCLE PHARMS LTD	200MG	A083640 001	
	300MG	A085632 001	

## DISCONTINUED DRUG PRODUCT LIST

QUINIDINE SULFATE

## TABLET;ORAL

## QUINIDINE SULFATE

DAVA PHARMS INC	200MG	A087011	001	
ELKINS SINN	200MG	A083622	001	
EVERYLIFE	200MG	A083439	001	
HALSEY	200MG	A083583	001	
HIKMA PHARMS LLC	200MG	A083862	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LANNETT	200MG	A083743	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
MUTUAL PHARM	100MG	A081029	001	Apr 14, 1989
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

## QUINORA

KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	

## TABLET, EXTENDED RELEASE;ORAL

## QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	
------------------	-------	---------	-----	--

RABEPRAZOLE SODIUM

## TABLET, DELAYED RELEASE;ORAL

## ACIPHEX

EISAI INC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020973	001	May 29, 2002
-----------	---	---------	-----	--------------

RAMIPRIL

## CAPSULE;ORAL

## RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
	2.5MG	A077513	002	Jun 18, 2008
	5MG	A077513	003	Jun 18, 2008
	10MG	A077513	004	Jun 18, 2008
CIPLA	1.25MG	A077004	001	Aug 07, 2008
	2.5MG	A077004	002	Aug 07, 2008
	5MG	A077004	003	Aug 07, 2008
	10MG	A077004	004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
	10MG	A078849	002	Mar 06, 2009

## TABLET;ORAL

## ALTACE

KING PFIZER	1.25MG	N022021	001	Feb 27, 2007
	2.5MG	N022021	002	Feb 27, 2007
	5MG	N022021	003	Feb 27, 2007
	10MG	N022021	004	Feb 27, 2007

## RAMIPRIL

MYLAN PHARMS INC	1.25MG	A090650	001	Jun 30, 2011
	2.5MG	A090650	002	Jun 30, 2011
	5MG	A090650	003	Jun 30, 2011
	10MG	A090650	004	Jun 30, 2011
ZYDUS PHARMS USA INC	1.25MG	A090697	001	Sep 24, 2009
	2.5MG	A090697	002	Sep 24, 2009
	5MG	A090697	003	Sep 24, 2009

## DISCONTINUED DRUG PRODUCT LIST

RAMIPRIL

TABLET; ORAL

RAMIPRIL

10MG

A090697 004 Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET; ORAL

TRITEC

GLAXOSMITHKLINE

400MG

N020559 001 Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 150MG BASE

A075564 001 Oct 27, 2000

EQ 300MG BASE

A075564 002 Oct 27, 2000

TEVA

EQ 150MG BASE

A075557 001 Oct 31, 2003

EQ 300MG BASE

A075557 002 Oct 31, 2003

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE

N020095 001 Mar 08, 1994

ZANTAC 300

GLAXOSMITHKLINE

EQ 300MG BASE

N020095 002 Mar 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE/PACKET

N020251 002 Mar 31, 1994

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD

EQ 25MG BASE/ML

A074764 001 Nov 19, 2004

ZANTAC IN PLASTIC CONTAINER

COVIS INJECTABLES

EQ 1MG BASE/ML

N019593 002 Sep 27, 1991

EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 15MG BASE/ML

A077602 001 Sep 17, 2007

RANBAXY

EQ 15MG BASE/ML

A078448 001 Dec 13, 2007

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

BOEHRINGER INGELHEIM

EQ 150MG BASE

A074662 001 Aug 29, 1997

EQ 300MG BASE

A074662 002 Aug 29, 1997

MYLAN

EQ 150MG BASE

A074552 001 Jul 30, 1998

EQ 300MG BASE

A074552 002 Jul 30, 1998

RANBAXY

EQ 75MG BASE

A075254 001 Jan 14, 2000

EQ 150MG BASE

A075000 001 Jan 30, 1998

EQ 300MG BASE

A075000 002 Jan 30, 1998

SANDOZ

EQ 75MG BASE

A075519 001 Sep 26, 2002

SUN PHARM INDS LTD

EQ 75MG BASE

A075132 001 Jan 14, 2000

EQ 150MG BASE

A075439 001 Apr 19, 2000

EQ 300MG BASE

A075439 002 Apr 19, 2000

WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000

EQ 150MG BASE

A074864 001 Oct 20, 1997

EQ 300MG BASE

A074864 002 Oct 20, 1997

WATSON LABS INC

EQ 150MG BASE

A077426 001 Dec 19, 2005

EQ 300MG BASE

A077426 002 Dec 19, 2005

WOCKHARDT

EQ 75MG BASE

A078884 001 Jul 31, 2008

EQ 150MG BASE

A078653 001 Nov 26, 2007

EQ 150MG BASE

A078701 001 Nov 12, 2009

EQ 300MG BASE

A078701 002 Dec 11, 2009

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE

N020251 001 Mar 31, 1994

ZANTAC 25

GLAXO GRP LTD

EQ 25MG BASE

N020251 003 Apr 01, 2004

ZANTAC 75

BOEHRINGER INGELHEIM

EQ 75MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020745 001 Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

ORGANON USA INC

100MG/VIAL

N020984 001 Aug 18, 1999

200MG/VIAL

N020984 002 Aug 18, 1999

**DISCONTINUED DRUG PRODUCT LIST**RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

WATSON LABS INC

EQ 0.5MG BASE

A201823 001 Jul 01, 2013

EQ 1MG BASE

A201823 002 Jul 01, 2013

RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

HIWOLFIA

BOWMAN PHARMS

50MG

N009276 003

50MG

N009276 005

100MG

N009276 004

HYSERPIN

PHYS PRODS VA

50MG

N010581 001

KOGLUCCOID

PANRAY

50MG

N009278 001

100MG

N009278 002

RAUDIXIN

APOTHECON

50MG

N008842 001

100MG

N008842 002

RAUSERPIN

FERNDAL LABS

50MG

N009926 002

100MG

N009926 004

RAUVAL

PAL PAK

50MG

N009108 002

100MG

N009108 004

RAUWOLFIA SERPENTINA

BUNDY

50MG

N009477 001

100MG

N009477 002

HALSEY

50MG

A080498 001

100MG

A080498 002

IMPAX LABS

50MG

N009273 001

100MG

N009273 002

IVAX SUB TEVA PHARMS

50MG

N011521 001

100MG

N011521 002

PUREPAC PHARM

50MG

A080842 001

100MG

A080842 002

PVT FORM

50MG

A080583 001

100MG

A080583 002

SOLVAY

50MG

A080500 001

100MG

A080500 002

TABLICAPS

50MG

A083867 001

100MG

A083444 001

VALEANT PHARM INTL

50MG

N009668 001

100MG

N009668 002

WATSON LABS

50MG

A080907 001

100MG

A080914 001

WOLFINA

FOREST PHARMS

50MG

N009255 008

100MG

N009255 006

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY

0.5MG

A084736 001

TABLET; ORAL

MODERIL

PFIZER

0.25MG

N010686 003

0.5MG

N010686 006

RESERPINE

ELIXIR; ORAL

SERPASIL

NOVARTIS

0.2MG/4ML

N009115 005

INJECTABLE; INJECTION

SANDRIL

LILLY

2.5MG/ML

N010012 001

SERPASIL

NOVARTIS

2.5MG/ML

N009434 002

TABLET; ORAL

HISERPIA

BOWMAN PHARMS

0.1MG

N009631 002

0.25MG

N009631 004

## DISCONTINUED DRUG PRODUCT LIST

RESERPINE

TABLET; ORAL

RAU-SED

BRISTOL MYERS SQUIBB	0.1MG	N009357 001
	0.25MG	N009357 004
	0.5MG	N009357 006
	1MG	N009357 008

RESERPINE

BARR	0.25MG	A080721 002
BELL PHARMA	0.1MG	A083058 001
	0.25MG	A083058 002
BUNDY	0.1MG	N009663 001
	0.25MG	N009663 003
CYCLE PHARMS LTD	0.1MG	N009859 001
	0.25MG	N009859 002
ELKINS SINN	0.1MG	A083145 001
	0.25MG	A083145 002
EVERYLIFE	0.1MG	N010441 001
	0.25MG	N010441 002
	0.5MG	N010441 003
	1MG	N010441 004
HALSEY	0.1MG	A080457 002
	0.25MG	A080457 001
	1MG	A080457 003
HIKMA PHARMS LLC	0.1MG	A080975 001
	0.25MG	A080975 002
	1MG	A080975 003
IMPAX LABS	0.1MG	N009627 001
	0.25MG	N009627 002
IVAX SUB TEVA PHARMS	0.1MG	N011185 001
	0.25MG	N011185 002
MARSHALL PHARMA	0.1MG	A080492 001
	0.25MG	A080492 002
MK LABS	0.1MG	A080525 002
	0.25MG	A080525 001
MYLAN	1MG	A084974 001
PHARMAVITE	0.25MG	A084663 001
PUREPAC PHARM	0.1MG	A080753 002
	0.25MG	A080753 001
PVT FORM	0.1MG	A086117 001
	0.25MG	A080582 001
	0.25MG	A085775 001
	1MG	A080582 002
REXALL	0.25MG	A080637 001
SOLVAY	0.25MG	A080446 001
TABLICAPS	0.25MG	A085207 001
TEVA	0.1MG	A089020 001
	0.25MG	A089019 001
VALEANT PHARM INTL	0.1MG	N009667 001
	0.25MG	N009667 002
WATSON LABS	0.1MG	A080679 001
	0.25MG	A080393 001
	0.25MG	A085401 001
	1MG	A080749 001
WHITEWORTH TOWN PLSN	0.1MG	A080723 001
	0.25MG	A080723 002
	1MG	A080723 003
SANDRIL		
LILLY	0.1MG	N009376 004
	0.25MG	N009376 001
SERPALAN		
LANNETT	0.1MG	N010124 001
	0.25MG	N010124 002
SERPANRAY		
PANRAY	0.1MG	N009391 001
	0.25MG	N009391 002
	1MG	N009391 004
SERPASIL		
NOVARTIS	0.1MG	N009115 001
	0.25MG	N009115 003
	1MG	N009115 004

Mar 07, 1985

Mar 07, 1985

**DISCONTINUED DRUG PRODUCT LIST**RESERPINE

TABLET; ORAL

SERPATE

VALE	0.1MG	N009453	001
	0.25MG	N009453	002

SERPIVITE

VITARINE	0.25MG	N009645	002
----------	--------	---------	-----

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

SANOFI AVENTIS US	0.1MG; 2MG	N012972	001
-------------------	------------	---------	-----

METATENSIN #4

SANOFI AVENTIS US	0.1MG; 4MG	N012972	002
-------------------	------------	---------	-----

NAQUIVAL

SCHERING	0.1MG; 4MG	N012265	003
----------	------------	---------	-----

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS	0.1MG; 4MG	A085248	001
-------------	------------	---------	-----

RIBAVIRIN

CAPSULE; ORAL

REBETOL

MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**	N020903	001	Jun 03, 1998
-------------------	--	---------	-----	--------------

TABLET; ORAL

COPEGUS

ROCHE	400MG	N021511	002	Jun 21, 2005
-------	-------	---------	-----	--------------

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE

FOREST LABS	50MG/5ML	N019650	001	Sep 17, 1993
-------------	----------	---------	-----	--------------

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH	100MG	A076375	001	Jan 14, 2003
-------------------	-------	---------	-----	--------------

COREPHARMA	100MG	A075916	001	Nov 02, 2001
------------	-------	---------	-----	--------------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

WARNER CHILCOTT LLC	75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020835	004	Apr 16, 2007
---------------------	---	---------	-----	--------------

RISPERIDONE

TABLET; ORAL

RISPERDAL

JANSSEN PHARMS	5MG	N020272	005	Dec 29, 1993
----------------	-----	---------	-----	--------------

RISPERIDONE

CADISTA PHARMS	0.25MG	A078828	001	Mar 23, 2009
----------------	--------	---------	-----	--------------

	0.5MG	A078828	002	Mar 23, 2009
--	-------	---------	-----	--------------

	1MG	A078828	003	Mar 23, 2009
--	-----	---------	-----	--------------

	2MG	A078828	004	Mar 23, 2009
--	-----	---------	-----	--------------

	3MG	A078828	005	Mar 23, 2009
--	-----	---------	-----	--------------

	4MG	A078828	006	Mar 23, 2009
--	-----	---------	-----	--------------

RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010
------------	--------	---------	-----	--------------

	0.5MG	A077784	002	Jun 08, 2010
--	-------	---------	-----	--------------

	1MG	A077784	003	Jun 08, 2010
--	-----	---------	-----	--------------

	2MG	A077784	004	Jun 08, 2010
--	-----	---------	-----	--------------

	3MG	A077784	005	Jun 08, 2010
--	-----	---------	-----	--------------

	4MG	A077784	006	Jun 08, 2010
--	-----	---------	-----	--------------

SYNTHON PHARMS	0.25MG	A078187	001	Oct 22, 2009
----------------	--------	---------	-----	--------------

	0.5MG	A078187	002	Oct 22, 2009
--	-------	---------	-----	--------------

	1MG	A078187	003	Oct 22, 2009
--	-----	---------	-----	--------------

	2MG	A078187	004	Oct 22, 2009
--	-----	---------	-----	--------------

	3MG	A078187	005	Oct 22, 2009
--	-----	---------	-----	--------------

	4MG	A078187	006	Oct 22, 2009
--	-----	---------	-----	--------------

WATSON LABS	0.25MG	A077860	001	Dec 05, 2008
-------------	--------	---------	-----	--------------

	0.5MG	A077860	002	Dec 05, 2008
--	-------	---------	-----	--------------

	1MG	A077860	003	Dec 05, 2008
--	-----	---------	-----	--------------

	2MG	A077860	004	Dec 05, 2008
--	-----	---------	-----	--------------

	3MG	A077860	005	Dec 05, 2008
--	-----	---------	-----	--------------

	4MG	A077860	006	Dec 05, 2008
--	-----	---------	-----	--------------



## DISCONTINUED DRUG PRODUCT LIST

RISPERIDONE

TABLET; ORAL

RISPERIDONE

WEST WARD PHARMS	0.25MG	A078740 001	May 29, 2009
	0.5MG	A078740 002	May 29, 2009
	1MG	A078740 003	May 29, 2009
	2MG	A078740 004	May 29, 2009
	3MG	A078740 005	May 29, 2009
	4MG	A078740 006	May 29, 2009

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A071188 001	Jul 23, 1987
	15MG/ML	A071189 001	Jul 23, 1987
HOSPIRA	10MG/ML	A071618 001	Feb 28, 1991
	15MG/ML	A071619 001	Feb 28, 1991
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	30MG/100ML	A071438 001	Jan 22, 1991
YUTOPAR			
ASTRAZENECA	10MG/ML	N018580 001	
	15MG/ML	N018580 002	

TABLET; ORAL

YUTOPAR

ASTRAZENECA	10MG	N018555 001	
-------------	------	-------------	--

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT	100MG	N020680 001	Mar 01, 1996
--------	-------	-------------	--------------

RIVASTIGMINE TARTRATE

SOLUTION; ORAL

EXELON

NOVARTIS	EQ 2MG BASE/ML	N021025 001	Apr 21, 2000
----------	----------------	-------------	--------------

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

ORGANON USA INC	50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 001	Mar 17, 1994
	10MG/ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 002	Mar 17, 1994
	100MG/10ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 003	Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK	12.5MG/5ML	N021052 001	May 20, 1999
	25MG/5ML	N021052 002	May 20, 1999

TABLET; ORAL

VIOXX

MERCK	12.5MG	N021042 001	May 20, 1999
	25MG	N021042 002	May 20, 1999
	50MG	N021042 003	Feb 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

COREPHARMA	EQ 0.25MG BASE	A078230 001	May 20, 2008
	EQ 0.5MG BASE	A078230 002	May 20, 2008
	EQ 1MG BASE	A078230 003	May 20, 2008
	EQ 2MG BASE	A078230 004	May 20, 2008
	EQ 3MG BASE	A078230 005	May 20, 2008
	EQ 4MG BASE	A078230 006	May 20, 2008
	EQ 5MG BASE	A078230 007	May 20, 2008

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

GLAXOSMITHKLINE LLC	EQ 3MG BASE	N022008 002	Jun 13, 2008
---------------------	-------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

ROSE BENGAL SODIUM I-131

INJECTABLE; INJECTION

ROBENGATOPE

BRACCO

0.5mCi/VIAL

N016224 001

1mCi/VIAL

N016224 002

2mCi/VIAL

N016224 003

SODIUM ROSE BENGAL I 131

SORIN

0.5mCi/ML

N017318 001

RUFINAMIDE

TABLET; ORAL

BANZEL

EISAI INC

100MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021911 001 Nov 14, 2008

SAFFLOWER OIL

INJECTABLE; INJECTION

LIPOSYN 10%

ABBOTT

10% (10GM/100ML)

N018203 001

LIPOSYN 20%

ABBOTT

20% (20GM/100ML)

N018614 001

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

HOSPIRA

5%;5% (5GM/100ML)

N018997 001 Aug 27, 1984

LIPOSYN II 20%

HOSPIRA

10%;10% (10GM/100ML)

N018991 001 Aug 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

SEREVENT

GLAXOSMITHKLINE

EQ 0.021MG BASE/INH

N020236 001 Feb 04, 1994

SAQUINAVIR

CAPSULE; ORAL

FORTOVASE

HOFFMANN LA ROCHE

200MG

N020828 001 Nov 07, 1997

SARALASIN ACETATE

INJECTABLE; INJECTION

SARENIN

PROCTER AND GAMBLE

EQ 0.6MG BASE/ML

N018009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

ANABOLIC

100MG

A084422 001

BARR

100MG

A084225 001

EVERYLIFE

100MG

A085895 001

HALSEY

100MG

A084676 001

IVAX PHARMS

100MG

A085869 001

KV PHARM

100MG

A085285 001

LANNETT

50MG

A085909 001

100MG

A085903 001

PARKE DAVIS

100MG

A084762 001

PERRIGO

100MG

A084561 001

PUREPAC PHARM

100MG

A085867 001

VALEANT PHARM INTL

100MG

A085477 001

VITARINE

100MG

A085898 001

100MG

A086273 001

WATSON LABS

100MG

A085792 001

WEST WARD

100MG

A084926 001

WHITEWORTH TOWN PLSN

100MG

A085798 001

WYETH AYERST

100MG

A086390 001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN

100MG/VIAL

A083281 001

WYETH AYERST

50MG/ML

A083262 001

SECONAL SODIUM

LILLY

50MG/ML

N007392 002

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY

30MG

A086530 001

## DISCONTINUED DRUG PRODUCT LIST

SECOBARBITAL SODIUMSUPPOSITORY;RECTAL  
SECONAL SODIUM

60MG	A086530	002
120MG	A086530	003
200MG	A086530	004

SECRETININJECTABLE; INJECTION  
SECRETIN-FERRING  
FERRING

75CU/VIAL	N018290	001
-----------	---------	-----

SECRETIN SYNTHETIC PORCINEFOR SOLUTION; INTRAVENOUS  
SECREFLO  
CHIRHOCLIN

16MCG/VIAL	N021136	001	Apr 04, 2002
------------	---------	-----	--------------

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE  
LANNETT HOLDINGS INC

5MG	A075145	001	Sep 15, 2003
-----	---------	-----	--------------

TABLET; ORAL

SELEGILINE HYDROCHLORIDE  
DAVA PHARMS INC  
G AND W LABS INC

5MG	A074641	001	Aug 02, 1996
5MG	A074537	001	Aug 02, 1996

5MG	A074744	001	Jan 27, 1997
-----	---------	-----	--------------

5MG	A074756	001	Nov 25, 1998
-----	---------	-----	--------------

5MG	A074672	001	Apr 01, 1997
-----	---------	-----	--------------

5MG	N019334	001	Jun 05, 1989
-----	---------	-----	--------------

5MG	A074565	001	Aug 02, 1996
-----	---------	-----	--------------

SELENIUM SULFIDELOTION/SHAMPOO; TOPICAL  
EXSEL

ALLERGAN HERBERT	2.5%	A083892	001
------------------	------	---------	-----

SELENIUM SULFIDE

ACTAVIS MID ATLANTIC	2.5%	A084394	001
----------------------	------	---------	-----

G AND W LABS INC	2.5%	A086209	001
------------------	------	---------	-----

IVAX PHARMS	2.5%	A085777	001
-------------	------	---------	-----

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE	250uCi/ML	N017257	001
---------------	-----------	---------	-----

MALLINCKRODT	100uCi/ML	N017098	001
--------------	-----------	---------	-----

PHARMALUCENCE	500uCi/ML	N017322	001
---------------	-----------	---------	-----

SETHOTOPE

BRACCO	85-550uCi/ML	N017047	001
--------	--------------	---------	-----

SERACTIDE ACETATE

INJECTABLE; INJECTION

ACTHAR GEL-SYNTHETIC  
ARMOUR PHARM

40 UNITS/ML	N017861	001
-------------	---------	-----

80 UNITS/ML	N017861	002
-------------	---------	-----

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

EMD SERONO	EQ 0.05MG BASE/AMP **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019863	001	Dec 28, 1990
------------	---	---------	-----	--------------

EMD SERONO INC	EQ 0.5MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020443	001	Sep 26, 1997
----------------	---	---------	-----	--------------

	EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020443	002	Sep 26, 1997
--	---	---------	-----	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE  
RANBAXY LABS LTD  
ROXANE

EQ 20MG BASE/ML	A078053	001	Feb 05, 2007
-----------------	---------	-----	--------------

EQ 20MG BASE/ML	A076934	001	Jun 30, 2006
-----------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 25MG BASE	A077345 001	Feb 06, 2007
	EQ 50MG BASE	A077345 002	Feb 06, 2007
	EQ 100MG BASE	A077345 003	Feb 06, 2007
CIPLA LTD	EQ 25MG BASE	A077162 001	Feb 06, 2007
	EQ 50MG BASE	A077162 002	Feb 06, 2007
	EQ 100MG BASE	A077162 003	Feb 06, 2007
DR REDDYS LABS LTD	EQ 25MG BASE	A076442 001	Apr 30, 2007
	EQ 50MG BASE	A076442 002	Apr 30, 2007
	EQ 100MG BASE	A076442 003	Apr 30, 2007
HIKMA PHARMS	EQ 25MG BASE	A077864 001	Aug 10, 2009
	EQ 50MG BASE	A077864 002	Aug 10, 2009
	EQ 100MG BASE	A077864 003	Aug 10, 2009
IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719 003	Jun 30, 2006
	EQ 50MG BASE	A075719 001	Jun 30, 2006
	EQ 100MG BASE	A075719 002	Jun 30, 2006
MUTUAL PHARM	EQ 25MG BASE	A077818 001	Feb 06, 2007
	EQ 50MG BASE	A077818 002	Feb 06, 2007
	EQ 100MG BASE	A077818 003	Feb 06, 2007
MYLAN PHARMS INC	EQ 25MG BASE	A076540 001	Mar 20, 2007
	EQ 50MG BASE	A076540 002	Mar 20, 2007
	EQ 100MG BASE	A076540 003	Mar 20, 2007
PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299 001	Feb 06, 2007
	EQ 50MG BASE	A077299 002	Feb 06, 2007
	EQ 100MG BASE	A077299 003	Feb 06, 2007
ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007
	EQ 50MG BASE	A076881 002	Feb 06, 2007
	EQ 100MG BASE	A076881 003	Feb 06, 2007
SANDOZ	EQ 25MG BASE	A077713 001	Feb 06, 2007
	EQ 50MG BASE	A077713 002	Feb 06, 2007
	EQ 100MG BASE	A077713 003	Feb 06, 2007
WATSON LABS	EQ 25MG BASE	A077663 001	Feb 06, 2007
	EQ 50MG BASE	A077663 002	Feb 06, 2007
	EQ 100MG BASE	A077663 003	Feb 06, 2007
ZOLOFT			
PFIZER	EQ 150MG BASE	N019839 003	Dec 30, 1991
	EQ 200MG BASE	N019839 004	Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

GENZYME	403MG	N020926 001	Oct 30, 1998
---------	-------	-------------	--------------

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

MERIDIA

ABBOTT	5MG	N020632 001	Nov 22, 1997
	10MG	N020632 002	Nov 22, 1997
	15MG	N020632 003	Nov 22, 1997

SILVER SULFADIAZINE

DRESSING; TOPICAL

SILDAFLO

FRANKLIN PHARMS	1%	N019608 001	Nov 30, 1989
-----------------	----	-------------	--------------

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

BRACCO	7.5MG/ML	N020773 001	Oct 29, 1998
--------	----------	-------------	--------------

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

SANDOZ INC	5MG	A077766 001	Dec 20, 2006
	10MG	A077766 002	Dec 20, 2006
	20MG	A077766 003	Dec 20, 2006
	40MG	A077766 004	Dec 20, 2006
	80MG	A077766 005	Dec 20, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

SIMVASTATIN

SYNTHON PHARMS	10MG	N021961 001	Oct 09, 2007
	20MG	N021961 002	Oct 09, 2007
	40MG	N021961 003	Oct 09, 2007

**DISCONTINUED DRUG PRODUCT LIST**SIMVASTATIN

TABLET, ORALLY DISINTEGRATING;ORAL  
SIMVASTATIN

80MG

N021961 004 Oct 09, 2007

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL  
JUVISYNC

MERCK SHARP DOHME

10MG;EQ 50MG BASE

N202343 004 Sep 18, 2012

10MG;EQ 100MG BASE

N202343 001 Oct 07, 2011

20MG;EQ 50MG BASE

N202343 005 Sep 18, 2012

20MG;EQ 100MG BASE

N202343 002 Oct 07, 2011

40MG;EQ 50MG BASE

N202343 006 Sep 18, 2012

40MG;EQ 100MG BASE

N202343 003 Oct 07, 2011

SIROLIMUS

TABLET;ORAL  
RAPAMUNE

PF PRISM CV

5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021110 003 Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;ORAL  
UCEPHAN

B BRAUN

100MG/ML;100MG/ML

N019530 001 Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT

0.9MEQ/ML

N019443 001 Jun 03, 1986

1MEQ/ML

N019443 002 Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT;ORAL

BAROS

MALLINCKRODT INC

460MG/GM;420MG/GM

N018509 001 Aug 07, 1985

SODIUM CHLORIDE

INJECTABLE;INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM

9MG/ML

A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT

20GM/100ML

N017013 001

B BRAUN

20GM/100ML

N017038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN

450MG/100ML

N018184 001

MILES

450MG/100ML

N018503 001

SODIUM CHLORIDE 0.9%

MEDEFIL INC

18MG/2ML (9MG/ML)

N202832 002 Jan 06, 2012

22.5MG/2.5ML (9MG/ML)

N202832 003 Jan 06, 2012

27MG/3ML (9MG/ML)

N202832 004 Jan 06, 2012

45MG/5ML (9MG/ML)

N202832 005 Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT

9MG/ML

N019218 001 Jul 13, 1984

MEDEFIL INC

9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012

MILES

900MG/100ML

N018502 001

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ABRAXIS PHARM

234MG/ML

N019329 001 Apr 22, 1987

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

B BRAUN

3GM/100ML

N019635 003 Mar 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N019635 004 Mar 09, 1988

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE

450MG/100ML

N017864 001

450MG/100ML

N018497 001 Feb 19, 1982

HOSPIRA

450MG/100ML

N017670 001

450MG/100ML

N018380 001

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES

900MG/100ML

N018247 001

## DISCONTINUED DRUG PRODUCT LIST

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM

BRACCO

2mCi/VIAL

N013993 002

200uCi/ML

N013993 001

SODIUM CHROMATE CR 51

MALLINKRODT NUCLEAR

100uCi/ML

N016708 001

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

GE HEALTHCARE

2mCi/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N017042 001

SODIUM FLUORIDE F 18

NIH NCI DCTD

10-200mCi/ML

N022494 001 Jan 26, 2011

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

CARDINAL HEALTH 418

400uCi

N018671 003 May 27, 1982

GE HEALTHCARE

100uCi

N017630 001

SOLUTION; ORAL

SODIUM IODIDE I 123

GE HEALTHCARE

2mCi/ML

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS

50uCi

N017316 001

100uCi

N017316 002

MALLINKRODT NUCLEAR

0.8-100mCi

N016515 002

15-100uCi

N016517 002

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

2-200mCi

N021305 004 Nov 18, 2004

SOLUTION; ORAL

HICON

JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003

1-500mCi/0.5ML

N021305 003 Jan 24, 2003

1-1000mCi/ML

N021305 005 Apr 04, 2006

IODOTOPE

BRACCO

7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS

50mCi/ML

N017315 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N018186 001

BAXTER HLTHCARE

1.87GM/100ML

N016692 001

HOSPIRA

1.87GM/100ML

N018249 001

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N020004 001 Apr 21, 1992

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 001 Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE

50MG/VIAL

N017546 001

NITROPRESS

ABBOTT

50MG/VIAL

A071555 001 Nov 16, 1987

ABBVIE

50MG/VIAL

N018450 001

HOSPIRA

50MG/VIAL

A070566 001 Jun 09, 1986

**DISCONTINUED DRUG PRODUCT LIST**SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

ABRAXIS PHARM 50MG/VIAL A070031 001 Jan 17, 1985

BAXTER HLTHCARE 50MG/VIAL N018581 001 Jul 28, 1982

TEVA PARENTERAL 25MG/ML A073465 001 Mar 30, 1992

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO 1-8mCi/VIAL N010927 001

SODIUM PHOSPHATE P 32

MALLINCKRODT 0.67mCi/ML N011777 001

1.5mCi/VIAL N011777 002

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

VISICOL

SALIX PHARMS 0.398GM;1.102GM N021097 001 Sep 21, 2000

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC 0.398GM;1.102GM A079247 001 Dec 30, 2011

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

CITRUSPHRMA 454GM/BOT A040909 001 Dec 03, 2008

WOCKHARDT 453.6GM/BOT A088786 001 Sep 11, 1984

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE 15GM/60ML A088717 001 Sep 11, 1984

ROXANE 15GM/60ML A088453 001 Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN 30% A080516 001

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

ELKINS SINN 1% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N005970 004

3% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N005970 005

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE

US ARMY 250MG/ML N020166 001 Feb 14, 1992

SOMATREM

INJECTABLE; INJECTION

PROTROPIN

GENENTECH 5MG/VIAL N019107 001 Oct 17, 1985

10MG/VIAL N019107 002 Oct 24, 1989

SOMATROPIN

INJECTABLE; INJECTION

ASELLACRIN 10

SERONO 10 IU/VIAL N017726 001

ASELLACRIN 2

SERONO 2 IU/VIAL N017726 002 Jul 21, 1983

CRESCORMON

GENENTECH 4 IU/VIAL N017992 001

**DISCONTINUED DRUG PRODUCT LIST**SOMATROPIN RECOMBINANT

## INJECTABLE; INJECTION

ACCRETROPIN								
EMERGENT	5MG/ML (5MG/ML)		N021538	001	Jan 23, 2008			
BIO-TROPIN								
FERRING	4.8MG/VIAL		N019774	001	May 25, 1995			
HUMATROPE								
LILLY	2MG/VIAL		N019640	001	Jun 23, 1987			
NORDITROPIN								
NOVO NORDISK INC	4MG/VIAL		N019721	001	May 08, 1995			
	5MG/1.5ML		N021148	001	Jun 20, 2000			
	8MG/VIAL		N019721	002	May 08, 1995			
	10MG/1.5ML		N021148	002	Jun 20, 2000			
	15MG/1.5ML		N021148	003	Jun 20, 2000			
NORDITROPIN NORDIFLEX								
NOVO NORDISK INC	5MG/1.5ML		N021148	004	Oct 01, 2004			
	10MG/1.5ML		N021148	005	Oct 01, 2004			
	15MG/1.5ML		N021148	006	Oct 01, 2004			
	30MG/3ML		N021148	007	Mar 10, 2009			
NUTROPIN								
GENENTECH	5MG/VIAL		N020168	001	Nov 17, 1993			
	10MG/VIAL		N020168	002	Nov 17, 1993			
NUTROPIN AQ								
GENENTECH	10MG/2ML (5MG/ML)		N020522	001	Dec 29, 1995			
NUTROPIN DEPOT								
GENENTECH	13.5MG/VIAL		N021075	001	Dec 22, 1999			
	18MG/VIAL		N021075	002	Dec 22, 1999			
	22.5MG/VIAL		N021075	003	Dec 22, 1999			
SAIZEN								
EMD SERONO	4MG/VIAL		N019764	005	Jan 16, 2007			
	6MG/VIAL		N019764	001	Oct 08, 1996			
SEROSTIM								
EMD SERONO	8.8MG/VIAL		N020604	004	Sep 06, 2001			
ZORBTIVE								
EMD SERONO	4MG/VIAL		N021597	001	Dec 01, 2003			
	5MG/VIAL		N021597	002	Dec 01, 2003			
	6MG/VIAL		N021597	003	Dec 01, 2003			
INJECTABLE; SUBCUTANEOUS								
SEROSTIM LQ								
EMD SERONO	6MG/0.5ML (6MG/0.5ML)		N020604	005	Feb 11, 2005			

SORBITOL

## SOLUTION; IRRIGATION

## SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML		N018512	001	May 27, 1982			
-----------------	-----------	--	---------	-----	--------------	--	--	--

SOTALOL HYDROCHLORIDE

## TABLET; ORAL

## BETAPACE

COVIS PHARMA SARL	320MG		N019865	004	Oct 30, 1992			
-------------------	-------	--	---------	-----	--------------	--	--	--

## BETAPACE AF

COVIS PHARMA SARL	40MG		N021151	006	Apr 02, 2003			
-------------------	------	--	---------	-----	--------------	--	--	--

	60MG		N021151	007	Apr 02, 2003			
--	------	--	---------	-----	--------------	--	--	--

	100MG		N021151	005	Mar 14, 2003			
--	-------	--	---------	-----	--------------	--	--	--

## SOTALOL HYDROCHLORIDE

## MUTUAL PHARM

	80MG		A075515	001	Oct 15, 2001			
--	------	--	---------	-----	--------------	--	--	--

	80MG		A076576	001	Apr 08, 2004			
--	------	--	---------	-----	--------------	--	--	--

	120MG		A075515	004	Oct 15, 2001			
--	-------	--	---------	-----	--------------	--	--	--

	120MG		A076576	002	Apr 08, 2004			
--	-------	--	---------	-----	--------------	--	--	--

	160MG		A075515	002	Oct 15, 2001			
--	-------	--	---------	-----	--------------	--	--	--

	160MG		A076576	003	Apr 08, 2004			
--	-------	--	---------	-----	--------------	--	--	--

	240MG		A075515	003	Oct 15, 2001			
--	-------	--	---------	-----	--------------	--	--	--

WATSON LABS	80MG		A075238	001	Jul 13, 2000			
-------------	------	--	---------	-----	--------------	--	--	--

	120MG		A075238	002	Jul 13, 2000			
--	-------	--	---------	-----	--------------	--	--	--

	160MG		A075238	003	Jul 13, 2000			
--	-------	--	---------	-----	--------------	--	--	--

	240MG		A075238	004	Jul 13, 2000			
--	-------	--	---------	-----	--------------	--	--	--

SOYBEAN OIL

## INJECTABLE; INJECTION

## LIPOSYN III 10%

HOSPIRA	10%		N018969	001	Sep 24, 1984			
---------	-----	--	---------	-----	--------------	--	--	--

## LIPOSYN III 20%

HOSPIRA	20%		N018970	001	Sep 25, 1984			
---------	-----	--	---------	-----	--------------	--	--	--



**DISCONTINUED DRUG PRODUCT LIST**SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 30%

HOSPIRA

30%

N020181 001 Jan 13, 1998

SOYACAL 10%

ALPHA THERA

10%

N018465 001 Jun 29, 1983

SOYACAL 20%

ALPHA THERA

20%

N018786 001 Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE

10%

N018660 001 Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE

20%

N018758 001 Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN

200MG

N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PFIZER

EQ 2GM BASE/VIAL

N050347 001

EQ 4GM BASE/VIAL

N050347 002

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING

3MG

N020240 001 Dec 29, 1994

6MG

N020240 002 Dec 29, 1994

12MG

N020240 003 Dec 29, 1994

24MG

N020240 004 Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT

25MG

A087687 001 Oct 20, 1982

IVAX PHARMS

25MG

A087108 001

LEDERLE

25MG

A087634 001

MUTUAL PHARM

25MG

A087265 001

MYLAN

25MG

A087086 001

PUREPAC PHARM

25MG

A087998 001 Oct 14, 1983

25MG

A088053 001 Aug 25, 1983

SUPERPHARM

25MG

A089364 001 Nov 07, 1986

UPSHER SMITH

25MG

A087554 001

VANGARD

25MG

A087648 001 Feb 01, 1982

WARNER CHILCOTT

25MG

A087952 001 Nov 18, 1982

WATSON LABS

25MG

A086898 002 Mar 02, 1982

25MG

A087078 001

STANOZOLOL

TABLET; ORAL

WINSTROL

LUNDBECK INC

2MG

N012885 001 May 14, 1984

STAVUDINE

CAPSULE; ORAL

ZERIT

BRISTOL MYERS SQUIBB

5MG

N020412 001 Jun 24, 1994

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

BRISTOL MYERS SQUIBB

37.5MG

N021453 001 Dec 31, 2002

50MG

N021453 002 Dec 31, 2002

75MG

N021453 003 Dec 31, 2002

100MG

N021453 004 Dec 31, 2002

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM

100%

A089099 001 Dec 29, 1987

100%

A089100 001 Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN

100%

N019077 001 Mar 02, 1984

## DISCONTINUED DRUG PRODUCT LIST

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES 100% N018246 001

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS EQ 500MG BASE/ML A060684 001

LILLY EQ 1GM BASE/VIAL A060107 001

EQ 1GM BASE/2ML A060404 001

EQ 5GM BASE/VIAL A060107 002

PFIZER EQ 1GM BASE/VIAL A060076 001

EQ 1GM BASE/2.5ML A060111 001

EQ 5GM BASE/VIAL A060076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ 50MG/ML N008453 003

500MG/VIAL N008453 001

1GM/VIAL N008453 004

QUELICIN PRESERVATIVE FREE

HOSPIRA 50MG/ML N008845 002

100MG/ML N008845 004

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION 100MG/VIAL A085400 001 Feb 04, 1982

ORGANON USA INC 20MG/ML A080997 001

SUCOSTRIN

APOTHECON 20MG/ML N008847 001

100MG/ML N008847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS EQ 0.05MG BASE/ML A074406 001 Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN 10% A084015 001

CETAMIDE

ALCON 10% A080021 001

SODIUM SULAMYD

SCHERING 10% \*\*Federal Register determination N005963 002

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

SULFAIR 10

PHARMAFAIR 10% A088000 001 Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN 30% A080028 002

ISOPTO CETAMIDE

ALCON 15% A080020 002

OCUSULF-10

MIZA PHARMS USA 10% A080660 001

OCUSULF-30

MIZA PHARMS USA 30% A080660 002

SODIUM SULAMYD

SCHERING 10% \*\*Federal Register determination N005963 001

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

30% \*\*Federal Register determination N005963 003

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

SODIUM SULFACETAMIDE

AKORN 10% A083021 001

15% A083021 002

30% A083021 003

SOLA BARNES HIND 10% A084143 001

10% A084145 001

30% A084146 001

30% A084147 001

**DISCONTINUED DRUG PRODUCT LIST**SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULF-10				
NOVARTIS	10%		A080025	001
SULF-15				
NOVARTIS	15%		A089047	001 Oct 31, 1995
SULFACEL-15				
OPTOPICS	15%		A080024	001
SULFACETAMIDE SODIUM				
AKORN	30%		A040216	001 May 25, 1999
ALCON PHARMS LTD	30%		A089068	001 May 05, 1987
PHARMAFAIR	10%		A088947	001 May 17, 1985
SULFAIR 10				
PHARMAFAIR	10%		A087949	001 Dec 13, 1982
SULFAIR FORTE				
PHARMAFAIR	30%		A088385	001 Oct 13, 1983
SULFAIR-15				
PHARMAFAIR	15%		A088186	001 May 25, 1983
SULTEN-10				
BAUSCH AND LOMB	10%		A087818	001 Feb 03, 1983

SULFACYTINE

TABLET;ORAL

RENOQUID				
GLENWOOD	250MG		N017569	001

SULFADIAZINE

TABLET;ORAL

SULFADIAZINE				
ABBVIE	300MG		N004125	005
EVERYLIFE	500MG		A080088	001
IMPAX LABS	500MG		A080081	001
LANNETT	500MG		A080084	001
LEDERLE	500MG		N004054	001
LILLY	500MG		N004122	002

SULFADIAZINE SODIUM

INJECTABLE; INJECTION

SULFADIAZINE SODIUM				
LEDERLE	250MG/ML		N004054	002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION;ORAL

SULFONAMIDES DUPLEX				
LILLY	250MG/5ML; 250MG/5ML		N006317	007

SULFAMETER

TABLET;ORAL

SULLA				
BAYER HLTHCARE	500MG		N016000	002

SULFAMETHIZOLE

TABLET;ORAL

MICROSUL				
FOREST PHARMS	1GM		A086012	001
PROKLAR				
FOREST PHARMS	500MG		A080273	001
THIOSULFIL				
WYETH AYERST	250MG		N008565	001
	500MG		N008565	004

SULFAMETHOXAZOLE

SUSPENSION;ORAL

GANTANOL				
ROCHE	500MG/5ML		N013664	002

TABLET;ORAL

GANTANOL				
ROCHE	500MG		N012715	002
GANTANOL-DS				
ROCHE	1GM		N012715	003

SULFAMETHOXAZOLE

ASCOT	500MG		A087662	001 Oct 20, 1982
BARR	500MG		A087189	001 Jul 25, 1983
HEATHER	500MG		A086163	001
SANDOZ	500MG		A085844	001
WATSON LABS	500MG		A085053	001

**DISCONTINUED DRUG PRODUCT LIST**SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

1GM

A086000 001

UROBAK

SHIONOGI

500MG

A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

MUTUAL PHARM

80MG/ML; 16MG/ML

N018374 001

SEPTRA

MONARCH PHARMS

80MG/ML; 16MG/ML

N018452 001

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM

80MG/ML; 16MG/ML

A070223 001 Dec 29, 1987

BEDFORD

80MG/ML; 16MG/ML

A072383 001 Apr 29, 1992

HIKMA MAPLE

80MG/ML; 16MG/ML

A070627 001 Dec 29, 1987

80MG/ML; 16MG/ML

A070628 001 Dec 29, 1987

HOSPIRA

80MG/ML; 16MG/ML

A073199 001 Sep 11, 1992

WATSON LABS

80MG/ML; 16MG/ML

A071556 001 Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

MUTUAL PHARM

200MG/5ML; 40MG/5ML

N017560 001

BACTRIM PEDIATRIC

MUTUAL PHARM

200MG/5ML; 40MG/5ML

N017560 002

SEPTRA

MONARCH PHARMS

200MG/5ML; 40MG/5ML

N017598 001

SEPTRA GRAPE

MONARCH PHARMS

200MG/5ML; 40MG/5ML

N017598 002 Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ANI PHARMS INC

200MG/5ML; 40MG/5ML

A070028 001 Jun 02, 1987

TEVA

200MG/5ML; 40MG/5ML

N018812 001 Jan 28, 1983

200MG/5ML; 40MG/5ML

N018812 002 Jun 10, 1983

TEVA PHARMS

200MG/5ML; 40MG/5ML

A077612 001 Nov 13, 2006

SULFATRIM

STI PHARMA LLC

200MG/5ML; 40MG/5ML

N018615 002 Jan 07, 1983

SULMEPRIM

USL PHARMA

200MG/5ML; 40MG/5ML

A070063 001 Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA

200MG/5ML; 40MG/5ML

A070064 001 Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS

200MG/5ML; 40MG/5ML

A072289 001 May 23, 1988

200MG/5ML; 40MG/5ML

A072398 001 May 23, 1988

NASKA

200MG/5ML; 40MG/5ML

A072399 001 May 23, 1988

TABLET; ORAL

COTRIM

TEVA

400MG; 80MG

A070034 001 May 16, 1985

COTRIM D.S.

TEVA

800MG; 160MG

A070048 001 Mar 18, 1985

SULFAMETHOPRIM

NOVEL LABS INC

400MG; 80MG

A070022 001 Feb 15, 1985

SULFAMETHOPRIM-DS

NOVEL LABS INC

800MG; 160MG

A070032 001 Feb 15, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

HEATHER

400MG; 80MG

N018946 001 Aug 10, 1984

800MG; 160MG

N018946 002 Aug 10, 1984

INTERPHARM

400MG; 80MG

A071299 001 Oct 27, 1987

800MG; 160MG

A071300 001 Oct 27, 1987

MARTEC USA LLC

400MG; 80MG

A072408 001 Dec 07, 1988

MUTUAL PHARM

400MG; 80MG

A070006 001 Nov 14, 1984

400MG; 80MG

A071016 001 Aug 25, 1986

PLIVA

400MG; 80MG

A070215 001 Sep 10, 1985

800MG; 160MG

A070216 001 Sep 10, 1985

ROXANE

400MG; 80MG

A072768 001 Aug 30, 1991

SANDOZ

400MG; 80MG

A070889 001 Nov 13, 1986

400MG; 80MG

N018598 003 May 19, 1982

800MG; 160MG

A070890 001 Nov 13, 1986

TEVA

400MG; 80MG

N018242 001

800MG; 160MG

N018242 002

USL PHARMA

400MG; 80MG

A070203 001 Nov 08, 1985

800MG; 160MG

A070204 001 Nov 08, 1985

WATSON LABS

400MG; 80MG

A070002 001 Nov 07, 1984

400MG; 80MG

N018852 001 May 09, 1983

**DISCONTINUED DRUG PRODUCT LIST**SULFAMETHOXAZOLE; TRIMETHOPRIM

## TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	A070000 001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH			
MARTEC USA LLC	800MG;160MG	A072417 001	Dec 07, 1988
MUTUAL PHARM	800MG;160MG	A070007 001	Nov 14, 1984
ROXANE	800MG;160MG	A072769 001	Aug 30, 1991
SANDOZ	800MG;160MG	N018598 004	May 19, 1982
WATSON LABS	800MG;160MG	N018854 001	May 09, 1983
SULFATRIM-DS			
SUPERPHARM	800MG;160MG	A070066 001	Jun 24, 1985
SULFATRIM-SS			
SUPERPHARM	400MG;80MG	A070065 002	Jun 24, 1985
UROPLUS DS			
SHIONOGI	800MG;160MG	A071816 001	Sep 28, 1987
UROPLUS SS			
SHIONOGI	400MG;80MG	A071815 001	Sep 28, 1987

SULFANILAMIDE

## CREAM; VAGINAL

SULFANILAMIDE			
G AND W LABS INC	15%	A088718 001	Sep 19, 1985

## SUPPOSITORY; VAGINAL

AVC			
MEDA PHARMS	1.05GM	N006530 004	Jan 27, 1987

SULFAPHENAZOLE

## SUSPENSION; ORAL

SULFABID			
PHARM RES ASSOC	500MG/5ML	N013093 001	

## TABLET; ORAL

SULFABID			
PURDUE FREDERICK	500MG	N013092 002	

SULFAPYRIDINE

## TABLET; ORAL

SULFAPYRIDINE			
LILLY	500MG	N000159 001	

SULFASALAZINE

## SUSPENSION; ORAL

AZULFIDINE			
PHARMACIA AND UPJOHN	250MG/5ML	N018605 001	

## TABLET; ORAL

S.A.S.-500			
SOLVAY	500MG	A083450 001	

## SULFASALAZINE

HERITAGE PHARMS INC	500MG	A080197 001	
MUTUAL PHARM	500MG	A089590 001	Oct 19, 1987
SANDOZ	500MG	A086184 001	
SUPERPHARM	500MG	A089339 001	Oct 26, 1987
WATSON LABS	500MG	A084964 001	
	500MG	A087197 001	

## TABLET, DELAYED RELEASE; ORAL

SULFASALAZINE			
WATSON LABS	500MG	A088052 001	May 24, 1983

SULFINPYRAZONE

## CAPSULE; ORAL

## ANTURANE

NOVARTIS	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011556 004	
----------	--	-------------	--

## SULFINPYRAZONE

BARR	200MG	A087666 001	Sep 17, 1982
IVAX PHARMS	200MG	A087770 001	Nov 19, 1982
PAR PHARM	200MG	A088934 001	Sep 06, 1985
VANGARD	200MG	A088666 001	Feb 17, 1984

## TABLET; ORAL

## ANTURANE

NOVARTIS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011556 003	
----------	--	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**SULFINPYRAZONE

TABLET; ORAL

SULFINPYRAZONE

BARR	100MG	A087665 001	Sep 17, 1982
IVAX PHARMS	100MG	A087769 001	Jun 01, 1982
PAR PHARM	100MG	A088933 001	Sep 06, 1985
WATSON LABS	100MG	A087667 001	May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE	500MG	N006525 001	
-------	-------	-------------	--

SOSOL

MK LABS	500MG	A080036 001	
---------	-------	-------------	--

SOXAZOLE

ALRA	500MG	A080366 001	
------	-------	-------------	--

SULFALAR

PARKE DAVIS	500MG	A084955 001	
-------------	-------	-------------	--

SULFISOXAZOLE

ANI PHARMS INC	500MG	A080142 001	
----------------	-------	-------------	--

BARR	500MG	A084031 001	
------	-------	-------------	--

HEATHER	500MG	A080189 001	
---------	-------	-------------	--

IMPAX LABS	500MG	A080109 001	
------------	-------	-------------	--

LANNETT	500MG	A080085 001	
---------	-------	-------------	--

LEDERLE	500MG	A087649 001	
---------	-------	-------------	--

PHARMERAL	500MG	A084385 001	
-----------	-------	-------------	--

PUREPAC PHARM	500MG	A080087 001	
---------------	-------	-------------	--

ROXANE	500MG	A080082 001	
--------	-------	-------------	--

SANDOZ	500MG	A085628 001	
--------	-------	-------------	--

VALEANT PHARM INTL	500MG	A080268 002	
--------------------	-------	-------------	--

VITARINE	500MG	A087332 001	
----------	-------	-------------	--

WATSON LABS	500MG	A085534 001	
-------------	-------	-------------	--

WEST WARD	500MG	A080379 001	
-----------	-------	-------------	--

SULSOXIN

SOLVAY	500MG	A080040 001	
--------	-------	-------------	--

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE	EQ 1GM BASE/5ML	N009182 009	
-------	-----------------	-------------	--

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE	EQ 500MG BASE/5ML	N009182 004	
-------	-------------------	-------------	--

SYRUP; ORAL

GANTRISIN

ROCHE	EQ 500MG BASE/5ML	N009182 002	
-------	-------------------	-------------	--

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE	EQ 400MG BASE/ML	N006917 001	
-------	------------------	-------------	--

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N008414 002	
-------	------------	-------------	--

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N007757 002	
-------	------------	-------------	--

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND	EQ 4% BASE	A084148 001	
------------------	------------	-------------	--

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL

DIASONE SODIUM

ABBVIE	165MG	N006044 003	
--------	-------	-------------	--

SULFUR

POWDER; TOPICAL

BENSULFOID

POYTHRESS	33.32%	N002918 001	
-----------	--------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**SULINDAC

TABLET; ORAL

CLINORIL

MERCK

150MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N017911 001

200MG

N017911 002

SULINDAC

ANI PHARMS INC

150MG

A072972 001 Feb 28, 1992

200MG

A072973 001 Feb 28, 1992

SANDOZ

150MG

A072712 001 Aug 30, 1991

200MG

A072713 001 Aug 30, 1991

SUMATRIPTAN

SPRAY; NASAL

IMITREX

GLAXOSMITHKLINE

10MG/SPRAY

N020626 002 Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A079240 002 Sep 18, 2009

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A079240 001 Sep 18, 2009

SANDOZ

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078067 002 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078067 001 Feb 06, 2009

TEVA PARENTERAL

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078318 001 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078318 002 Feb 06, 2009

TABLET; ORAL

SUMATRIPTAN SUCCINATE

MYLAN

EQ 25MG BASE

A077163 001 Nov 02, 2009

EQ 50MG BASE

A077163 002 Nov 02, 2009

EQ 100MG BASE

A077163 003 Nov 02, 2009

ROXANE

EQ 25MG BASE

A078241 001 Aug 10, 2009

EQ 50MG BASE

A078241 002 Aug 10, 2009

EQ 100MG BASE

A078241 003 Aug 10, 2009

SANDOZ

EQ 25MG BASE

A076976 001 Aug 10, 2009

EQ 50MG BASE

A076976 002 Aug 10, 2009

EQ 100MG BASE

A076976 003 Aug 10, 2009

TEVA

EQ 25MG BASE

A076840 001 Feb 09, 2009

EQ 50MG BASE

A076840 002 Feb 09, 2009

EQ 100MG BASE

A076840 003 Feb 09, 2009

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC

PROFENAL

ALCON

1%

N019387 001 Dec 23, 1988

SUTILAINS

OINTMENT; TOPICAL

TRAVASE

ABBOTT

82,000 UNITS/GM \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N012828 001

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

SHIONOGI INC

EQ 10MG BASE

N020070 001 Sep 09, 1993

EQ 20MG BASE

N020070 002 Sep 09, 1993

EQ 30MG BASE

N020070 003 Sep 09, 1993

EQ 40MG BASE

N020070 004 Sep 09, 1993

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

WATSON LABS

EQ 5MG BASE

A090402 001 Jul 01, 2010

TALBUTAL

TABLET; ORAL

LOTUSATE

SANOFI AVENTIS US

120MG

N009410 005

**DISCONTINUED DRUG PRODUCT LIST**TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

ASTRAZENECA	EQ 10MG BASE	N017970 001	
	EQ 20MG BASE	N017970 002	Mar 21, 1994
TAMOXIFEN CITRATE			
AEGIS PHARMS	EQ 10MG BASE	A076398 001	Mar 31, 2003
	EQ 20MG BASE	A076398 002	Mar 31, 2003
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075740 001	Feb 20, 2003
	EQ 20MG BASE	A075740 002	Feb 20, 2003
PHARMACHEMIE	EQ 10MG BASE	A074539 001	Mar 31, 2003
ROXANE	EQ 10MG BASE	A076027 001	Feb 20, 2003
	EQ 20MG BASE	A076027 002	Feb 20, 2003
TEVA	EQ 10MG BASE	A074504 001	Apr 28, 2003
	EQ 20MG BASE	A074504 002	Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE; INJECTION

TC 99M-LUNGAGGREGATE

GE HEALTHCARE	5mCi/ML	N017848 001	
---------------	---------	-------------	--

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS	N/A	N017916 001	
---------------	-----	-------------	--

AN-MAA

PHARMALUCENCE	N/A	N017792 001	
---------------	-----	-------------	--

LUNGAGGREGATE REAGENT

GE HEALTHCARE	N/A	N017838 001	
---------------	-----	-------------	--

MACROTEC

BRACCO	N/A	N017833 001	
--------	-----	-------------	--

TECHNESCAN MAA

MALLINCKRODT	N/A	N017842 001	
--------------	-----	-------------	--

TECHNETIUM TC 99M MAA

GE HEALTHCARE	N/A	N017773 001	
---------------	-----	-------------	--

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION

MICROLITE

PHARMALUCENCE	N/A	N018263 001	Mar 25, 1983
---------------	-----	-------------	--------------

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

GE HEALTHCARE	N/A	N017775 001	
---------------	-----	-------------	--

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION

INSTANT MICROSPHERES

3M	N/A	N017832 001	
----	-----	-------------	--

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA	N/A	N020887 001	Sep 14, 1998
-----------------	-----	-------------	--------------

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA	N/A	N021012 001	Aug 03, 1999
-----------------	-----	-------------	--------------

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE	N/A	N017653 001	
---------------	-----	-------------	--

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE	N/A	N017667 001	
---------------	-----	-------------	--

OSTEOSCAN

MALLINCKRODT	N/A	N017454 001	
--------------	-----	-------------	--

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE	N/A	N017562 001	
---------------	-----	-------------	--



## DISCONTINUED DRUG PRODUCT LIST

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION

RENOTEC

BRACCO

N/A

N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB

N/A

N017907 001

TECHNESCAN GLUCEPTATE

DRAXIMAGE

N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION

TECHNESCAN HIDA

DRAXIMAGE

N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT DRAXIMAGE

N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE

N/A

N018335 001 Aug 05, 1982

OSTEOLITE

PHARMALUCENCE

N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE

N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

MPI DTPA KIT - CHELATE

GE HEALTHCARE

N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE

N/A

N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE

N/A

N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE

N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO

N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA

N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL

N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

GE HEALTHCARE

2-100mCi/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N017471 001

MALLINCKRODT

10-60mCi/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N017725 001

PHARMALUCENCE

12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

## DISCONTINUED DRUG PRODUCT LIST

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INJECTION, ORAL

MINITEC

BRACCO 0.22-2.22 CI/GENERATOR N017339 001

SOLUTION;INTRAVENOUS

TECHNELITE

LANTHEUS MEDCL 0.0083-2.7 CI/GENERATOR N017771 001

ULTRA-TECHNEKOW FM

MALLINCKRODT 0.25-3 CI/GENERATOR N017243 002

SOLUTION;INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE 830-16600mCi/GENERATOR N017693 001

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION;INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE 4mCi/ML N017456 001

SOLUTION;ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT 3mCi/ML N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL

TECHNECOLL

MALLINCKRODT N/A N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE N/A N017784 001

TESULOID

BRACCO N/A N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE;INJECTION

CARDIOTEC

BRACCO N/A N019928 001 Dec 19, 1990

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

NOVARTIS EQ 2MG BASE N021200 001 Jul 24, 2002

EQ 6MG BASE N021200 002 Jul 24, 2002

TELAPREVIR

TABLET;ORAL

INCIVEK

VERTEX PHARMS 375MG N201917 001 May 23, 2011

TELBIVUDINE

SOLUTION;ORAL

TYZEKA

NOVARTIS 100MG/5ML N022154 001 Apr 28, 2009

TEMAZEPAM

CAPSULE;ORAL

TEMAZ

QUANTUM PHARMICS 15MG A070564 001 Oct 15, 1985

30MG A070547 001 Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR 15MG A071708 001 Sep 29, 1988

30MG A071709 001 Sep 29, 1988

MUTUAL PHARM 15MG A071174 001 Jul 10, 1986

30MG A071175 001 Jul 10, 1986

USL PHARMA 15MG A070489 001 Jul 07, 1986

30MG A070490 001 Jul 07, 1986

WATSON LABS 15MG A070383 001 Mar 23, 1987

15MG A071446 001 May 21, 1993

30MG A070384 001 Mar 23, 1987

30MG A071447 001 May 21, 1993

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

HYTRIN

ABBOTT EQ 1MG BASE \*\*Federal Register N020347 001 Dec 14, 1994

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

EQ 2MG BASE \*\*Federal Register N020347 002 Dec 14, 1994

determination that product was not

**DISCONTINUED DRUG PRODUCT LIST**TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

HYTRIN

discontinued or withdrawn for safety or efficacy reasons\*\*

EQ 5MG BASE \*\*Federal Register N020347 003 Dec 14, 1994

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

EQ 10MG BASE \*\*Federal Register N020347 004 Dec 14, 1994

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES

EQ 1MG BASE A075384 001 Dec 01, 2000

EQ 2MG BASE A075384 002 Dec 01, 2000

EQ 5MG BASE A075384 003 Dec 01, 2000

EQ 10MG BASE A075384 004 Dec 01, 2000

RANBAXY LABS LTD

EQ 1MG BASE A076021 001 Aug 22, 2002

EQ 2MG BASE A076021 002 Aug 22, 2002

EQ 5MG BASE A076021 003 Aug 22, 2002

EQ 10MG BASE A076021 004 Aug 22, 2002

SANDOZ

EQ 1MG BASE A075667 001 Jul 28, 2000

EQ 2MG BASE A075667 002 Jul 28, 2000

EQ 5MG BASE A075667 003 Jul 28, 2000

EQ 10MG BASE A075667 004 Jul 28, 2000

TABLET;ORAL

HYTRIN

ABBOTT

EQ 1MG BASE N019057 001 Aug 07, 1987

EQ 2MG BASE N019057 002 Aug 07, 1987

EQ 5MG BASE N019057 003 Aug 07, 1987

EQ 10MG BASE N019057 004 Aug 07, 1987

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS

EQ 1MG BASE A074530 001 Apr 21, 2000

EQ 2MG BASE A074530 002 Apr 21, 2000

EQ 5MG BASE A074530 003 Apr 21, 2000

EQ 10MG BASE A074530 004 Apr 21, 2000

SANDOZ

EQ 1MG BASE A074315 001 Dec 31, 1998

EQ 1MG BASE A074657 001 Apr 28, 2000

EQ 2MG BASE A074315 002 Dec 31, 1998

EQ 2MG BASE A074657 002 Apr 28, 2000

EQ 5MG BASE A074315 003 Dec 31, 1998

EQ 5MG BASE A074657 003 Apr 28, 2000

EQ 10MG BASE A074315 004 Dec 31, 1998

EQ 10MG BASE A074657 004 Apr 28, 2000

TEVA

EQ 1MG BASE A074446 001 May 18, 2000

EQ 2MG BASE A074446 002 May 18, 2000

EQ 5MG BASE A074446 003 May 18, 2000

EQ 10MG BASE A074446 004 May 18, 2000

TERBINAFINE

GEL;TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS

1% N020846 001 Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

NOVARTIS

1% N020192 001 Dec 30, 1992

SOLUTION;TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS

1% N020749 001 Oct 17, 1997

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

GEDEON RICHTER USA

EQ 250MG BASE A077065 001 Jul 02, 2007

MYLAN

EQ 250MG BASE A077136 001 Jul 02, 2007

ROXANE

EQ 250MG BASE A077223 001 Jul 02, 2007

WOCKHARDT

EQ 250MG BASE A078229 001 Jul 02, 2007

**DISCONTINUED DRUG PRODUCT LIST**TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS

0.2MG/INH

N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US

0.2MG/INH

N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

AAIPHARMA LLC

1MG/ML

N018571 001

BRICANYL

SANOFI AVENTIS US

1MG/ML

N017466 001

TERBUTALINE SULFATE

TEVA PHARMS USA

1MG/ML

A076853 001 Jul 20, 2004

TABLET; ORAL

BRETHINE

LEHIGH VALLEY

2.5MG

N017849 001

5MG

N017849 002

BRICANYL

SANOFI AVENTIS US

2.5MG

N017618 001

5MG

N017618 002

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERCONAZOLE

FOUGERA PHARMS

80MG

A076850 001 Jul 12, 2006

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US

200 UNITS/VIAL

N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY

0.75MG/3ML (0.25MG/ML)

N021318 001 Nov 26, 2002

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

THERATECHNOLOGIES

EQ 2MG BASE/VIAL

N022505 002 Nov 29, 2011

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB

100MG/ML

N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB

50MG

N016118 001

250MG

N016118 002

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

ACTAVIS LABS UT INC

2.5MG/24HR

N020489 001 Sep 29, 1995

5MG/24HR

N020489 002 May 02, 1997

TESTODERM

ALZA

4MG/24HR

N019762 001 Oct 12, 1993

6MG/24HR

N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA

5MG/24HR

N020791 001 Dec 18, 1997

INJECTABLE; INJECTION

TESTOSTERONE

WATSON LABS

25MG/ML

A086420 001 May 10, 1983

50MG/ML

A086419 001 Aug 23, 1983

100MG/ML

A086417 001 Jul 07, 1983

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN

50MG/ML

A085635 001

TESTOSTERONE CYPIONATE

WATSON LABS

100MG/ML

A084401 001

100MG/ML

A086029 001

200MG/ML

A084401 002

## DISCONTINUED DRUG PRODUCT LIST

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

ENDO PHARMS

200MG/ML

N009165 001

TESTOSTERONE ENANTHATE

WATSON LABS

100MG/ML

A083667 001

100MG/ML

A085599 001

200MG/ML

A083667 002

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

BEL MAR

25MG/ML

A080741 001

50MG/ML

A080742 001

100MG/ML

A080743 001

ELKINS SINN

25MG/ML

A080276 001

LILLY

50MG/ML

A080254 002

WATSON LABS

25MG/ML

A080188 001

25MG/ML

A085490 001

50MG/ML

A080188 002

50MG/ML

A085490 002

100MG/ML

A080188 003

100MG/ML

A083595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

BRISTACYCLINE

BRISTOL

250MG

A061658 001

250MG

A061888 001

500MG

A061658 002

500MG

A061888 002

CYCLOPAR

WARNER CHILCOTT

250MG

A061725 001

250MG

A062175 001

250MG

A062332 001

500MG

A061725 002

500MG

A062332 002

PANMYCIN

PHARMACIA AND UPJOHN

250MG

A060347 001

RETET

SOLVAY

250MG

A061443 001

500MG

A061443 002

ROBITET

WYETH AYERST

250MG

A061734 001

500MG

A061734 002

SUMYCIN

APOTHECON

100MG

A060429 002

125MG

A060429 004

250MG

A060429 001

500MG

A060429 003

TETRACHEL

ANGUS

250MG

A060343 001

500MG

A060343 003

TETRACYCLINE HYDROCHLORIDE

ABBOTT

250MG

A061802 001

500MG

A061802 002

CHARTWELL CIENCA

250MG

A062752 001

Aug 12, 1988

500MG

A062752 002

Aug 12, 1988

ELKINS SINN

250MG

A060059 001

FERRANTE

125MG

A060173 001

250MG

A060173 002

HEATHER

250MG

A061148 001

500MG

A061148 002

HIKMA PHARMS LLC

250MG

A060768 001

500MG

A060768 002

IVAX SUB TEVA PHARMS

250MG

A060704 001

500MG

A060704 002

MAST MM

250MG

A062085 001

MUTUAL PHARM

250MG

A060736 001

500MG

A060736 002

MYLAN

250MG

A060783 001

500MG

A060783 002

PUREPAC PHARM

250MG

A060290 001

## DISCONTINUED DRUG PRODUCT LIST

TETRACYCLINE HYDROCHLORIDE

## CAPSULE; ORAL

## TETRACYCLINE HYDROCHLORIDE

	500MG	A060290 002	
PVT FORM	250MG	A062686 001	Jul 24, 1986
	500MG	A062686 002	Jul 24, 1986
ROXANE	500MG	A061214 002	
SANDOZ	250MG	A061471 001	
SUPERPHARM	250MG	A062540 001	Mar 21, 1985
	500MG	A062540 002	Mar 21, 1985
VALEANT PHARM INTL	250MG	A060471 001	
	500MG	A060471 002	
WARNER CHILCOTT	250MG	A062300 001	
	500MG	A062300 002	
WATSON LABS	250MG	A062103 001	
	250MG	A062343 001	
	500MG	A062103 002	
	500MG	A062343 002	
WYETH AYERST	250MG	A061685 001	
	500MG	A061685 002	

## TETRACYN

PFIPHARMECS	250MG	A060082 003	
	500MG	A060082 004	

## FIBER, EXTENDED RELEASE; PERIODONTAL

## ACTISITE

SCHIFF AND CO	12.7MG/FIBER	N050653 001	Mar 25, 1994
---------------	--------------	-------------	--------------

## FOR SOLUTION; TOPICAL

## TOPICYCLINE

SHIRE	2.2MG/ML	N050493 001	
-------	----------	-------------	--

## INJECTABLE; INJECTION

## ACHROMYCIN

LEDERLE	250MG/VIAL	N050273 002	
	500MG/VIAL	N050273 003	

## TETRACYN

PFIZER	250MG/VIAL	A060096 001	
	500MG/VIAL	A060096 002	

## OINTMENT; OPHTHALMIC

## ACHROMYCIN

STORZ	10MG/GM	N050266 001	
-------	---------	-------------	--

## SUSPENSION; ORAL

## ACHROMYCIN V

LEDERLE	125MG/5ML	N050263 002	
---------	-----------	-------------	--

## SUMYCIN

PAR PHARM	125MG/5ML	A060400 001	
-----------	-----------	-------------	--

## TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS	125MG/5ML	A060633 001	
FERRANTE	125MG/5ML	A060174 001	
PROTER	125MG/5ML	A060446 001	
PUREPAC PHARM	125MG/5ML	A060291 001	

## TETRACYN

PFIPHARMECS	125MG/5ML	A060095 001	
-------------	-----------	-------------	--

## TETRAMED

IVAX SUB TEVA PHARMS	125MG/5ML	A061468 001	
----------------------	-----------	-------------	--

## SUSPENSION/DROPS; OPHTHALMIC

## ACHROMYCIN

STORZ	1%	N050268 001	
-------	----	-------------	--

## TABLET; ORAL

## PANMYCIN

PHARMACIA AND UPJOHN	250MG	A061705 001	
	500MG	A061705 002	

## SUMYCIN

PAR PHARM	50MG	A061147 003	
	100MG	A061147 002	
	250MG	A061147 001	
	500MG	A061147 004	

TETRACYCLINE PHOSPHATE COMPLEX

## CAPSULE; ORAL

## TETREX

BRISTOL	EQ 100MG HCL	A061653 001	
	EQ 250MG HCL	A061653 002	
	EQ 250MG HCL	A061889 002	
	EQ 250MG HCL	N050212 002	

**DISCONTINUED DRUG PRODUCT LIST**TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

EQ 500MG HCL	A061653	003	
EQ 500MG HCL	A061889	001	
EQ 500MG HCL	N050212	003	

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO	1mCi/ML	N018548	001	Dec 30, 1982
TRACE LIFE	1mCi/ML	A075569	001	Nov 21, 2001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

MALLINKRODT NUCLEAR	2mCi/ML	A077698	001	Nov 09, 2006
---------------------	---------	---------	-----	--------------

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US	100MG	A085264	001	
	200MG	A085264	002	

ELIXOPHYLLIN

FOREST LABS

100MG	A085545	001	Jul 31, 1984
200MG	A083921	001	Jul 31, 1984

SOMOPHYLLIN-T

FISONS

100MG	A087155	001	Feb 25, 1985
200MG	A087155	002	Feb 25, 1985
250MG	A087155	003	Feb 25, 1985

THEOPHYLLINE

KV PHARM

100MG	A085263	001	
200MG	A085263	002	

SCHERER RP

100MG	A084731	002	Nov 07, 1986
200MG	A084731	001	Nov 07, 1986
250MG	A084731	003	Nov 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

FLEMING PHARMS

65MG	A085075	003	Nov 24, 1986
------	---------	-----	--------------

AEROLATE JR

FLEMING PHARMS

130MG	A085075	002	Nov 24, 1986
-------	---------	-----	--------------

AEROLATE SR

FLEMING PHARMS

260MG	A085075	001	Nov 24, 1986
-------	---------	-----	--------------

ELIXOPHYLLIN SR

FOREST LABS

125MG	A086826	001	Jan 29, 1985
250MG	A086826	002	Jan 29, 1985

SLO-BID

SANOFI AVENTIS US

50MG	A088269	001	Jan 31, 1985
75MG	A089539	001	May 10, 1989
100MG	A087892	001	Jan 31, 1985
125MG	A089540	001	May 10, 1989
200MG	A087893	001	Jan 31, 1985
300MG	A087894	001	Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US

60MG	A085206	001	May 24, 1982
125MG	A085203	001	May 24, 1982
250MG	A085205	001	May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM

50MG	A087763	001	Feb 27, 1985
100MG	A087194	001	
200MG	A088382	001	Feb 27, 1985
250MG	A087193	001	
300MG	A088383	001	Feb 27, 1985

THEO-DUR

SCHERING

50MG	A088022	001	Sep 10, 1985
75MG	A088015	001	Sep 10, 1985
125MG	A088016	001	Sep 10, 1985
200MG	A087995	001	Sep 10, 1985

THEOBID

WHITBY

260MG	A085983	001	Mar 20, 1985
-------	---------	-----	--------------

THEOBID JR.

WHITBY

130MG	A087854	001	Mar 20, 1985
-------	---------	-----	--------------

THEOCLEAR L.A.-130

SCHWARZ PHARMA

130MG	A086569	001	May 27, 1982
-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

## CAPSULE, EXTENDED RELEASE; ORAL

THEOCLEAR L.A.-260					
SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982	
THEOPHYL-SR					
ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985	
	250MG	A086471	001	Feb 08, 1985	
THEOPHYLLINE					
CENT PHARMS	125MG	A088654	001	Feb 12, 1985	
	250MG	A088689	001	Feb 12, 1985	
HOSPIRA	100MG	A089976	001	Jan 04, 1995	
	200MG	A089977	001	Jan 04, 1995	
	300MG	A089932	001	Jan 04, 1995	
INWOOD LABS	100MG	A040052	001	Feb 14, 1994	
	125MG	A040052	002	Feb 14, 1994	
	200MG	A040052	003	Feb 14, 1994	
	300MG	A040052	004	Feb 14, 1994	
SANDOZ	260MG	A087462	001	May 11, 1982	
THEOPHYLLINE-SR					
SCHERER RP	300MG	A088255	001	Jun 12, 1986	
THEOVENT					
SCHERING	125MG	A087010	001	Jan 31, 1985	
	250MG	A087910	001	Jan 31, 1985	

## ELIXIR; ORAL

ELIXOMIN					
CENCI	80MG/15ML	A088303	001	Jan 25, 1984	
LANOPHYLLIN					
LANNETT	80MG/15ML	A084578	001		
THEOLIXIR					
PANRAY	80MG/15ML	A084559	001		
THEOPHYL-225					
ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001		
THEOPHYLLINE					
ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988	
CENCI	80MG/15ML	A087679	001	Apr 15, 1982	
HALSEY	80MG/15ML	A085169	001		
PERRIGO	80MG/15ML	A085952	001		
PHARM ASSOC	80MG/15ML	A086720	001		
PRECISION DOSE	80MG/15ML	A085863	001		
ROXANE	80MG/15ML	A084739	001		
TARO	80MG/15ML	A089626	001	Oct 28, 1988	
WOCKHARDT	80MG/15ML	A086748	001		

## INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984	
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984	
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984	
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984	
	200MG/100ML	N019826	004	Aug 14, 1992	
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	4MG/ML	N019212	003	Nov 07, 1984	
	400MG/100ML	N019212	002	Nov 07, 1984	
	400MG/100ML	N019826	005	Aug 14, 1992	
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER					
BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982	
	40MG/100ML	N018649	001	Jul 26, 1982	
	80MG/100ML	N018649	002	Jul 26, 1982	
	160MG/100ML	N018649	003	Jul 26, 1982	
	200MG/100ML	N018649	004	Jul 26, 1982	
	320MG/100ML	N018649	006	Nov 13, 1985	
	400MG/100ML	N018649	005	Jul 26, 1982	
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER					
HOSPIRA INC	80MG/100ML	N019211	002	Dec 14, 1984	
	200MG/100ML	N019211	004	Dec 14, 1984	
	400MG/100ML	N019211	005	Dec 14, 1984	

## SOLUTION; ORAL

AEROLATE					
FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986	



## DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

## SOLUTION; ORAL

## THEOLAIR

3M

80MG/15ML

A086107 001

## THEOPHYLLINE

ROXANE

80MG/15ML

A087449 001 Sep 15, 1983

## SUSPENSION; ORAL

## ELIXICON

FOREST LABS

100MG/5ML

A085502 001

## SYRUP; ORAL

## ACCURBRON

SANOFI AVENTIS US

150MG/15ML

A088746 001 Nov 22, 1985

## AQUAPHYLLIN

FERNDALE LABS

80MG/15ML

A087917 001 Jan 18, 1983

## SLO-PHYLLIN

SANOFI AVENTIS US

80MG/15ML

A085187 001

## THEOCLEAR-80

CENT PHARMS

80MG/15ML

A087095 001 Mar 01, 1982

## THEOPHYLLINE

ALPHARMA US PHARMS

80MG/15ML

A086001 001

150MG/15ML

A086545 001

## TABLET; ORAL

## QUIBRON-T

MONARCH PHARMS

300MG

A088656 001 Aug 22, 1985

## SLO-PHYLLIN

SANOFI AVENTIS US

100MG

A085202 001

200MG

A085204 001

## THEOCLEAR-100

CENT PHARMS

100MG

A085353 002

## THEOCLEAR-200

CENT PHARMS

200MG

A085353 001

## THEOLAIR

MEDICIS

125MG

A086399 001

250MG

A086399 002

## THEOPHYL-225

ORTHO MCNEIL PHARM

225MG

A084726 001

## TABLET, CHEWABLE; ORAL

## THEOPHYL

ORTHO MCNEIL PHARM

100MG

A086506 001 Sep 12, 1985

## TABLET, EXTENDED RELEASE; ORAL

## DURAPHYL

FOREST LABS

100MG

A088503 001 Apr 03, 1985

200MG

A088504 001 Apr 03, 1985

300MG

A088505 001 Apr 03, 1985

## LABID

WARNER CHILCOTT

250MG

A087225 001

## QUIBRON-T/SR

MONARCH PHARMS

300MG

A087563 001 Jun 21, 1983

## SUSTAIRE

ROERIG

100MG

A085665 001

300MG

A085665 002

## T-PHYL

PHARM RES ASSOC

200MG

A088253 001 Aug 17, 1983

## THEO-DUR

SCHERING

100MG

A085328 001

200MG

A086998 001

300MG

A085328 002

450MG

A089131 001 Jun 25, 1986

## THEOCHRON

SUN PHARM INDS INC

300MG

A087400 002 Jan 11, 1983

## THEOLAIR-SR

3M

200MG

A088369 001 Jul 16, 1987

250MG

A086363 002 Jul 16, 1987

300MG

A088364 001 Jul 16, 1987

500MG

A089132 001 Jul 16, 1987

## THEOPHYLLINE

ABLE

300MG

A040548 001 Apr 30, 2004

400MG

A040543 001 Apr 27, 2004

450MG

A040546 001 Apr 30, 2004

600MG

A040539 001 Apr 27, 2004

INWOOD LABS

450MG

A040034 001 Apr 28, 1995

## DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

UNI-DUR

SCHERING

400MG

A089822 001 Jan 04, 1995

600MG

A089823 001 Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR;ORAL

SYNOPHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET;ORAL

ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

THIABENDAZOLE

SUSPENSION;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG/5ML

N016097 001

TABLET, CHEWABLE;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001 Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

HIKMA MAPLE

100MG/ML

A080575 001

HOSPIRA

100MG/ML

A040079 001 May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A080571 001

100MG/ML

A083534 001

200MG/ML

A080571 002

200MG/ML

A083534 002

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE;INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

THIETHYLPERAZINE MALATE

INJECTABLE;INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATE

SUPPOSITORY;RECTAL

TORECAN

NOVARTIS

10MG

N013247 001

TABLET;ORAL

TORECAN

NOVARTIS

10MG

N012753 001

THIOPENTAL SODIUM

SUSPENSION;RECTAL

PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION;ORAL

MELLARIL-S

NOVARTIS

EQ 25MG HCL/5ML

N017923 001

EQ 100MG HCL/5ML

N017923 002

## DISCONTINUED DRUG PRODUCT LIST

THIORIDAZINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## MELLARIL

NOVARTIS	30MG/ML	N011808	012
	100MG/ML	N011808	018

## THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A088229	001	Aug 23, 1983
ALPHARMA US PHARMS	30MG/ML	A087766	001	Apr 26, 1983
ANI PHARMS INC	100MG/ML	A089603	001	Nov 09, 1987
HI TECH PHARMA	30MG/ML	A040125	001	Aug 16, 1996
	100MG/ML	A040126	001	Aug 16, 1996
PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997
	100MG/ML	A040213	001	May 29, 1998
SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
	100MG/ML	A088308	001	Nov 23, 1983
TEVA PHARMS	30MG/ML	A089602	001	Nov 09, 1987
WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE INTENSOL				
ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985

## TABLET; ORAL

## MELLARIL

NOVARTIS	10MG	N011808	003
	15MG	N011808	016
	25MG	N011808	006
	50MG	N011808	011
	100MG	N011808	009
	150MG	N011808	017
	200MG	N011808	015

## THIORIDAZINE HYDROCHLORIDE

ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983
	10MG	A088493	001	May 17, 1985
	15MG	A088271	001	Apr 14, 1983
	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
	100MG	A088456	001	May 17, 1985
MUTUAL PHARM	10MG	A088375	001	Nov 18, 1983
	15MG	A088461	001	Nov 18, 1983
	25MG	A087264	001	Nov 18, 1983
	50MG	A088370	001	Nov 18, 1983
	100MG	A088379	001	Nov 16, 1983
	150MG	A088737	001	Sep 26, 1984
	200MG	A088738	001	Oct 16, 1984
MYLAN	10MG	A088332	001	Jun 27, 1983
	25MG	A088333	001	Jun 27, 1983
	50MG	A088334	001	Jun 27, 1983
	100MG	A088335	001	Nov 18, 1983
PAR PHARM	10MG	A088351	001	Dec 05, 1983
	15MG	A088352	001	Dec 05, 1983
	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SANDOZ	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088476	001	Nov 08, 1983

## DISCONTINUED DRUG PRODUCT LIST

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

10MG	A088561	001	May 11, 1984
15MG	A088345	001	Jul 28, 1983
15MG	A088477	001	Nov 08, 1983
15MG	A088562	001	May 11, 1984
25MG	A088296	001	Jul 28, 1983
25MG	A088478	001	Nov 08, 1983
25MG	A088567	001	May 11, 1984
25MG	A088755	001	Jul 24, 1984
50MG	A088323	001	Jul 28, 1983
50MG	A088479	001	Nov 08, 1983
50MG	A088563	001	May 11, 1984
100MG	A088284	001	Aug 25, 1983
100MG	A088564	001	May 11, 1984
100MG	A088736	001	Jul 24, 1984
150MG	A088410	001	Mar 05, 1984
150MG	A088869	001	Jun 28, 1985
200MG	A088381	001	Mar 14, 1984
200MG	A088872	001	Apr 26, 1985
WEST WARD	A088658	001	Mar 26, 1984
15MG	A088659	001	Mar 26, 1984
25MG	A088660	001	Mar 26, 1984
50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

IMMUNEX	15MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020058	001	Dec 22, 1994
---------	--	---------	-----	--------------

THIOTEPA

FRESENIUS KABI USA	15MG/VIAL	A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL	N011683	001	
TEVA PARENTERAL	15MG/VIAL	A075730	001	Apr 20, 2001
	30MG/VIAL	A075730	002	Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER	20MG	N016584	005	
THIOTHIXENE				
AM THERAP	1MG	A071884	001	Aug 12, 1987
	2MG	A071885	001	Aug 12, 1987
	5MG	A071886	001	Aug 12, 1987
	10MG	A071887	001	Aug 12, 1987
	20MG	A072200	001	Dec 17, 1987
WATSON LABS	1MG	A070600	001	Jun 05, 1987
	2MG	A070601	001	Jun 05, 1987
	2MG	A071626	001	Jun 25, 1987
	5MG	A070602	001	Jun 05, 1987
	5MG	A071627	001	Jun 25, 1987
	10MG	A070603	001	Jun 05, 1987
	10MG	A071628	001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER	EQ 5MG BASE/ML	N016758	001	
THIOTHIXENE HYDROCHLORIDE				
ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969	001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917	001	Sep 20, 1989
	EQ 5MG BASE/ML	A071939	001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184	001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554	001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL				
CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992

INJECTABLE; INJECTION

NAVANE

PFIZER	EQ 2MG BASE/ML	N016904	001	
	EQ 10MG BASE/VIAL	N016904	002	

## DISCONTINUED DRUG PRODUCT LIST

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS	16MG	N002245 009
	32MG	N002245 005
	65MG	N002245 002
	100MG	N002245 008
	130MG	N002245 010
	200MG	N002245 007
	325MG	N002245 004

THYROGLOBULIN

IMPAX LABS

64.8MG A080151 001

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US 10 IU/VIAL N008682 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON	6MG	N020646 006	Nov 29, 2005
	8MG	N020646 007	Nov 29, 2005
	10MG	N020646 008	Nov 29, 2005
	20MG	N020646 004	Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497 001	
	EQ 3GM BASE/VIAL	A062690 001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497 002	
	EQ 6GM BASE/VIAL	N050497 003	
	EQ 20GM BASE/VIAL	N050497 004	
	EQ 30GM BASE/VIAL	N050497 005	Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO	125MG	N019979 001	Mar 24, 1993
	250MG	N019979 002	Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	250MG	A075253 001	Aug 20, 1999
MYLAN	250MG	A075161 001	Sep 13, 1999
	250MG	A075316 001	Nov 02, 1999
SANDOZ	250MG	A075318 001	Aug 20, 1999
	250MG	A075326 001	Aug 20, 1999
WATSON LABS	250MG	A075309 001	Apr 26, 2000

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

SANOFI AVENTIS US EQ 200MG BASE N020707 001 Mar 07, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AKORN	EQ 0.25% BASE	A074465 001	Mar 25, 1997
	EQ 0.25% BASE	A074515 001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000
	EQ 0.5% BASE	A075412 001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667 001	Mar 25, 1997
	EQ 0.5% BASE	A074668 001	Mar 25, 1997

TABLET; ORAL

BLOCADREN

MERCK	5MG	N018017 001
	10MG	N018017 002
	20MG	N018017 004

TIMOLOL MALEATE

QUANTUM PHARMICS	5MG	A072466 001	May 19, 1989
	10MG	A072467 001	May 19, 1989
	20MG	A072468 001	May 19, 1989
SANDOZ	5MG	A072550 001	Apr 13, 1989
	10MG	A072551 001	Apr 13, 1989
	20MG	A072552 001	Apr 13, 1989

## DISCONTINUED DRUG PRODUCT LIST

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

TEVA	5MG	A072648 001	Jun 16, 1993
	10MG	A072649 001	Jun 16, 1993
	20MG	A072650 001	Jun 16, 1993
USL PHARMA	5MG	A072001 001	Apr 11, 1989
	10MG	A072002 001	Apr 11, 1989
	20MG	A072003 001	Apr 11, 1989
WATSON LABS	5MG	A072269 001	Apr 11, 1989
	5MG	A072917 001	Jul 31, 1991
	10MG	A072270 001	Apr 11, 1989
	10MG	A072918 001	Jul 31, 1991
	20MG	A072271 001	Apr 11, 1989
	20MG	A072919 001	Jul 31, 1991

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000
---------------	--------------	-------------	--------------

TIOCONAZOLE

CREAM; TOPICAL

TZ-3

PFIZER	1%	N018682 001	Feb 18, 1983
--------	----	-------------	--------------

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912 001	May 14, 1998
	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913 001	May 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 2MG BASE	A076283 001	Jul 12, 2002
	EQ 4MG BASE	A076283 002	Jul 12, 2002
BARR	EQ 2MG BASE	A076371 001	Apr 09, 2003
	EQ 4MG BASE	A076371 002	Apr 09, 2003
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076321 001	Sep 30, 2004
	EQ 4MG BASE	A076321 002	Sep 30, 2004
MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003
	EQ 4MG BASE	A076282 002	Dec 16, 2003
ZANAFLEX			
ACORDA	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020397 002	Feb 04, 2000

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD	0.3%	A063176 001	May 25, 1994
APOTEX INC	0.3%	A065087 001	Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY	EQ 10MG BASE/ML	A062008 004	
	EQ 10MG BASE/ML	A062707 001	Apr 29, 1987
	EQ 10MG BASE/ML	N050477 005	
	EQ 40MG BASE/ML	A062008 001	
	EQ 1.2GM BASE/VIAL	N050519 001	
TOBRAMYCIN SULFATE			
APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994
	EQ 40MG BASE/ML	A064021 002	May 31, 1994
	EQ 40MG BASE/ML	A064026 001	May 31, 1994
HIKMA MAPLE	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128 001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118 001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127 001	Nov 27, 1991
HOSPIRA	EQ 10MG BASE/ML	A063080 001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161 001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121 001	Oct 31, 1994

## DISCONTINUED DRUG PRODUCT LIST

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

	EQ 40MG BASE/ML	A063122 001	Oct 31, 1994
WATSON LABS INC	EQ 10MG BASE/ML	A062945 001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945 002	Aug 09, 1989
TOBRAMYCIN SULFATE (PHARMACY BULK)			
HOSPIRA	EQ 40MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A063116 001	May 18, 1992

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA	400MG	N018257 001	Nov 09, 1984
	600MG	N018257 002	Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR	100MG	A070162 001	Jan 14, 1986
	250MG	A070163 001	Jan 14, 1986
	500MG	A070164 001	Jan 14, 1986
DURAMED PHARMS BARR	100MG	A070165 001	Jan 10, 1986
	250MG	A070166 001	Jan 10, 1986
	500MG	A070167 001	Jan 10, 1986
G AND W LABS INC	100MG	N018894 001	Nov 02, 1984
	250MG	N018894 002	Nov 02, 1984
	500MG	N018894 003	Nov 02, 1984
INTERPHARM	250MG	A071270 001	Sep 23, 1986
	500MG	A071271 001	Sep 23, 1986
MUTUAL PHARM	100MG	A071357 001	Jul 16, 1987
	250MG	A071358 001	Jul 16, 1987
	500MG	A071359 001	Jul 16, 1987
PAR PHARM	100MG	A070159 001	Jan 06, 1986
	250MG	A070160 001	Jan 06, 1986
	500MG	A070161 001	Jan 06, 1986
SANDOZ	100MG	A071633 001	Dec 09, 1987
	250MG	A070289 001	Mar 13, 1986
	500MG	A070290 001	Mar 13, 1986
SUPERPHARM	250MG	A070763 001	Jun 16, 1986
	500MG	A070764 001	Jun 16, 1986
USL PHARMA	100MG	A071355 001	Jan 11, 1988
	250MG	A070168 001	Apr 02, 1986
	500MG	A070169 001	Apr 02, 1986
WATSON LABS	100MG	A070242 001	Aug 01, 1986
	100MG	A070513 001	Jan 09, 1986
	250MG	A070243 001	Aug 01, 1986
	250MG	A070514 001	Jan 09, 1986
	500MG	A070244 001	Aug 01, 1986
	500MG	A070515 001	Jan 09, 1986

TOLINASE

PHARMACIA AND UPJOHN	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015500 002	
	250MG	N015500 004	
	500MG	N015500 005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS	25MG/ML	N006403 005	Feb 22, 1985
----------	---------	-------------	--------------

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN	250MG	N010670 002	
	500MG	N010670 001	

TOLBUTAMIDE

ALRA	500MG	A086141 001	
ASCOT	500MG	A087541 001	Mar 01, 1983
BARR	500MG	A087121 001	
DAVA PHARMS INC	500MG	A086926 001	

**DISCONTINUED DRUG PRODUCT LIST**TOLBUTAMIDE

## TABLET; ORAL

## TOLBUTAMIDE

IVAX PHARMS	500MG	A087093	001	
PARKE DAVIS	500MG	A086047	001	
PUREPAC PHARM	500MG	A088950	001	Jun 17, 1985
SANDOZ	500MG	A086574	001	
	500MG	N012678	001	
SUPERPHARM	500MG	A088893	001	Nov 19, 1984
VANGARD	500MG	A087876	001	Apr 20, 1982
WATSON LABS	250MG	A089110	001	May 29, 1987
	500MG	A086109	001	
	500MG	A087318	001	
	500MG	A089111	001	May 29, 1987

TOLBUTAMIDE SODIUM

## INJECTABLE; INJECTION

## ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	
----------------------	------------------	---------	-----	--

TOLCAPONE

## TABLET; ORAL

## TASMAR

VALEANT PHARMS LLC	200MG	N020697	002	Jan 29, 1998
--------------------	-------	---------	-----	--------------

TOLMETIN SODIUM

## CAPSULE; ORAL

## TOLECTIN DS

ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001	
----------------------	---------------	---------	-----	--

## TOLMETIN SODIUM

ACTAVIS ELIZABETH	EQ 400MG BASE	A073308	001	Jan 24, 1992
IVAX SUB TEVA PHARMS	EQ 400MG BASE	A073392	001	Jan 24, 1992
MUTUAL PHARM	EQ 400MG BASE	A073311	001	Nov 27, 1991
SANDOZ	EQ 400MG BASE	A073462	001	Apr 30, 1992
TEVA	EQ 400MG BASE	A073519	001	May 29, 1992

## TABLET; ORAL

## TOLECTIN

ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001	
----------------------	---------------	---------	-----	--

## TOLECTIN 600

ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989
----------------------	---------------	---------	-----	--------------

## TOLMETIN SODIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A073527	001	Jun 30, 1992
G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996
	EQ 600MG BASE	A074729	001	Feb 27, 1997
SANDOZ	EQ 200MG BASE	A073588	001	Jul 31, 1992
	EQ 600MG BASE	A074002	001	Sep 27, 1993

TOLVAPTAN

## TABLET; ORAL

## SAMSCA

OTSUKA AMERICA PHARM	60MG	N022275	003	May 19, 2009
----------------------	------	---------	-----	--------------

TOPIRAMATE

## CAPSULE; ORAL

## TOPAMAX SPRINKLE

JANSSEN PHARMS	50MG	N020844	003	Oct 26, 1998
----------------	------	---------	-----	--------------

## TOPIRAMATE

BARR	15MG	A076448	001	Apr 15, 2009
	25MG	A076448	002	Apr 15, 2009
SANDOZ	15MG	A079206	001	Oct 14, 2009
	25MG	A079206	002	Oct 14, 2009

## TABLET; ORAL

## TOPAMAX

JANSSEN PHARMS	300MG	N020505	003	Dec 24, 1996
	400MG	N020505	006	Dec 24, 1996

## TOPIRAMATE

BARR	25MG	A076315	001	Mar 27, 2009
	100MG	A076315	002	Mar 27, 2009
	200MG	A076315	003	Mar 27, 2009
PLIVA HRVATSKA DOO	25MG	A077905	001	Mar 30, 2009
	50MG	A077905	002	Mar 30, 2009
	100MG	A077905	003	Mar 30, 2009
	200MG	A077905	004	Mar 30, 2009
ROXANE	25MG	A076306	001	Mar 27, 2009
	50MG	A076306	002	Mar 27, 2009



## DISCONTINUED DRUG PRODUCT LIST

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

	100MG	A076306 003	Mar 27, 2009
	200MG	A076306 004	Mar 27, 2009
WATSON LABS	25MG	A077643 001	Mar 27, 2009
	50MG	A077643 002	Mar 27, 2009
	100MG	A077643 003	Mar 27, 2009
	200MG	A077643 004	Mar 27, 2009
WOCKHARDT USA	25MG	A090353 001	Sep 01, 2010
	50MG	A090353 002	Sep 01, 2010
	100MG	A090353 003	Sep 01, 2010
	200MG	A090353 004	Sep 01, 2010
TOPIRAMATE			
HIKMA PHARMS	25MG	A091185 001	Nov 25, 2013
	50MG	A091185 002	Nov 25, 2013
	100MG	A091185 003	Nov 25, 2013
	200MG	A091185 004	Nov 25, 2013

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 4MG BASE/VIAL	A091376 001	Nov 29, 2010
SOLUTION; INTRAVENOUS			
TOPOTECAN			
SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011
	EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

ROCHE	50MG/5ML (10MG/ML)	N020137 002	Aug 23, 1993
	20MG/2ML (10MG/ML)	N020137 001	Aug 23, 1993
TORSEMIDE			
EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007 001	Jun 11, 2008
	50MG/5ML (10MG/ML)	A078007 002	Jun 11, 2008
LUITPOLD	20MG/2ML (10MG/ML)	A090656 001	Apr 21, 2010
	50MG/5ML (10MG/ML)	A090656 002	Apr 21, 2010

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACTAVIS ELIZABETH	50MG	A075960 001	Jun 19, 2002
ASTA	50MG	A075974 001	Jul 12, 2002
IVAX SUB TEVA PHARMS	50MG	A075963 001	Jul 03, 2002
SANDOZ	50MG	A075968 001	Jun 25, 2002
WATSON LABS	50MG	A075962 001	Jun 24, 2002
ULTRAM			
JANSSEN PHARMS	100MG	N020281 001	Mar 03, 1995
TABLET, EXTENDED RELEASE; ORAL			
RYZOLT			
PURDUE PHARMA	100MG	N021745 001	Dec 30, 2008
	200MG	N021745 002	Dec 30, 2008
	300MG	N021745 003	Dec 30, 2008
TABLET, ORALLY DISINTEGRATING; ORAL			
RYBIX ODT			
SHIONOGI INC	50MG	N021693 001	May 05, 2005

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

CIPLA	1MG	A077307 002	Jun 12, 2007
	2MG	A077307 001	Jun 12, 2007
	4MG	A077307 003	Jun 12, 2007
COREPHARMA	1MG	A077256 001	Jun 12, 2007
	2MG	A077256 002	Jun 12, 2007
	4MG	A077256 003	Jun 12, 2007
DR REDDYS LABS LTD	1MG	A078493 001	Aug 25, 2008
	2MG	A078493 002	Aug 25, 2008
	4MG	A078493 003	Aug 25, 2008

## DISCONTINUED DRUG PRODUCT LIST

TRANEXAMIC ACID

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN

500MG

N019280 001 Dec 30, 1986

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

IZBA

ALCON LABS INC

0.003%

N204822 001 May 15, 2014

TRAVATAN

ALCON PHARMS LTD

0.004%

N021257 001 Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

PRAGMA PHARMS LLC

50MG

N018207 001

100MG

N018207 002

150MG

N018207 003 Mar 25, 1985

300MG

N018207 004 Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP

50MG

A071139 001 Oct 29, 1986

100MG

A071140 001 Oct 29, 1986

MYLAN

50MG

A071405 001 Feb 27, 1991

100MG

A071406 001 Feb 27, 1991

QUANTUM PHARMICS

100MG

A070921 001 Dec 01, 1986

SANDOZ

50MG

A072484 001 Apr 30, 1990

100MG

A072483 001 Apr 30, 1990

TEVA

150MG

A074357 001 Apr 30, 1997

USL PHARMA

50MG

A070491 001 Apr 29, 1987

100MG

A070492 001 Apr 29, 1987

WATSON LABS

50MG

A070857 001 Oct 10, 1986

50MG

A071112 001 Nov 17, 1986

100MG

A070858 001 Oct 10, 1986

100MG

A071113 001 Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS

50MG

A070942 001 Dec 01, 1986

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

ANGELINI PHARMA

150MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N022411 001 Feb 02, 2010

300MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N022411 002 Feb 02, 2010

TRETINOIN

CAPSULE; ORAL

VESANOID

ROCHE

10MG

N020438 001 Nov 22, 1995

SOLUTION; TOPICAL

TRETINOIN

TEVA PHARMS

0.05%

A074873 001 Jun 19, 1998

WOCKHARDT

0.05%

A075260 001 Jan 25, 1999

SWAB; TOPICAL

RETIN-A

VALEANT INTL

0.05%

N016921 002

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS

1MG

N011161 009

2MG

N011161 004

4MG

N011161 007

8MG

N011161 011

16MG

N011161 010

KENACORT

DELCOR ASSET CORP

1MG

N011283 003

2MG

N011283 008

4MG

N011283 006

8MG

N011283 010

TRIAMCINOLONE

BARR

2MG

A084286 001

2MG

A084318 001

## DISCONTINUED DRUG PRODUCT LIST

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

	4MG	A084267	001
	4MG	A084319	001
	8MG	A084268	001
	8MG	A084320	001
IMPAX LABS	4MG	A084340	001
IVAX SUB TEVA PHARMS	4MG	A083750	001
MYLAN	2MG	A084406	001
PUREPAC PHARM	2MG	A084020	002
	4MG	A084020	003
ROXANE	2MG	A084708	001
	4MG	A084709	001
	8MG	A084707	001
SANDOZ	4MG	A085601	001
TEVA	4MG	A084775	001
WATSON LABS	4MG	A084270	001
	4MG	A085834	001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE

0.1MG/INH

N018117 001 Apr 23, 1982

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US

0.055MG/INH

N019798 001 Jul 11, 1991

CREAM; TOPICAL

ARISTOCORT

ASTELLAS

0.025%

A083017 003

0.1%

A083016 004

0.5%

A083015 002

ARISTOCORT A

ASTELLAS

0.025%

A083017 004

0.025%

A088818 001 Oct 16, 1984

0.1%

A083016 005

0.1%

A088819 001 Oct 16, 1984

0.5%

A083015 003

0.5%

A088820 001 Oct 16, 1984

FLUTEX

IVAX PHARMS

0.025%

A085539 001

0.1%

A085539 002

0.5%

A085539 003

KENALOG

DELCOR ASSET CORP

0.025% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N011601 003

0.1% \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N011601 006

0.5%

A083943 001

KENALOG-H

DELCOR ASSET CORP

0.1%

A086240 001

TRIACET

TEVA

0.025%

A084908 001

0.1%

A084908 002

0.5%

A084908 003

TRIACORT

SOLVAY

0.1%

A087113 001

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC

0.1%

A087798 001 Jun 04, 1982

ALPHARMA US PHARMS

0.025%

A087797 001 Jun 07, 1982

AMBIX

0.025%

A087932 001 May 09, 1983

MORTON GROVE

0.025%

A088094 001 Sep 01, 1983

0.1%

A088095 001 Sep 01, 1983

0.5%

A088096 001 Sep 01, 1983

PHARMADERM

0.025%

A087990 001 Jul 07, 1983

0.1%

A087991 001 Jul 07, 1983

0.5%

A087992 001 Jul 07, 1983

PHARMAFAIR

0.025%

A087921 001 Aug 10, 1982

0.1%

A087912 001 Aug 10, 1982

0.5%

A087922 001 Aug 10, 1982

## DISCONTINUED DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

## CREAM; TOPICAL

## TRIAMCINOLONE ACETONIDE

TARO	0.025%	A040038 001	Oct 26, 1994
	0.025%	A086277 001	
	0.1%	A086276 001	
	0.5%	A086275 001	
TOPIDERM	0.025%	A089274 001	Feb 21, 1989
	0.1%	A089275 001	Feb 21, 1989
	0.5%	A089276 001	Feb 21, 1989

## TRIALEX

## IVAX PHARMS

	0.025%	A087430 001	Nov 01, 1988
	0.1%	A087429 001	Nov 01, 1988
	0.5%	A087428 001	Nov 01, 1988

## TRYMEX

## SAVAGE LABS

	0.025%	A088196 001	Mar 25, 1983
	0.1%	A088197 001	Mar 25, 1983
	0.5%	A088198 001	Mar 25, 1983

## GEL; TOPICAL

## ARISTOGEL

## ASTELLAS

	0.1%	A083380 001	
--	------	-------------	--

## INJECTABLE; INJECTION

## TRIAMCINOLONE ACETONIDE

## PARNELL

	3MG/ML	N019503 001	Oct 16, 1987
--	--------	-------------	--------------

## SANDOZ

	10MG/ML	A090166 001	May 27, 2009
--	---------	-------------	--------------

## SANDOZ CANADA INC

	40MG/ML	A090164 001	Jun 01, 2009
--	---------	-------------	--------------

## WATSON LABS

	40MG/ML	A085825 001	
--	---------	-------------	--

## INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

## TRIVARIS

## ALLERGAN

	8MG/0.1ML (8MG/0.1ML)	N022220 001	Jun 16, 2008
--	-----------------------	-------------	--------------

## LOTION; TOPICAL

## KENALOG

## DELCOR ASSET CORP

	0.025%	A084343 001	
	0.025%	N011602 003	
	0.1%	A084343 002	
	0.1%	N011602 001	

## TRIAMCINOLONE ACETONIDE

## ALPHARMA US PHARMS

	0.025%	A087191 001	Sep 08, 1982
	0.1%	A087192 001	Sep 08, 1982

## OINTMENT; TOPICAL

## ARISTOCORT

## ASTELLAS

	0.1%	A080750 004	
	0.5%	A080745 002	

## ARISTOCORT A

## ASTELLAS

	0.1%	A080750 003	
	0.1%	A088780 001	Oct 01, 1984
	0.5%	A080745 003	
	0.5%	A088781 001	Oct 05, 1984

## FLUTEX

## IVAX PHARMS

	0.025%	A087375 001	Nov 01, 1988
	0.1%	A087377 001	Nov 01, 1988
	0.5%	A087376 001	Nov 01, 1988

## KENALOG

## DELCOR ASSET CORP

	0.5%	A083944 001	
--	------	-------------	--

## TRIAMCINOLONE ACETONIDE

## ACTAVIS MID ATLANTIC

	0.1%	A087799 001	Jun 07, 1982
--	------	-------------	--------------

## ALPHARMA US PHARMS

	0.5%	A089913 001	Dec 23, 1988
--	------	-------------	--------------

## MORTON GROVE

	0.025%	A088090 001	Sep 01, 1983
--	--------	-------------	--------------

	0.1%	A088091 001	Sep 01, 1983
--	------	-------------	--------------

	0.5%	A088092 001	Sep 01, 1983
--	------	-------------	--------------

## PHARMADERM

	0.025%	A088692 001	Aug 02, 1984
--	--------	-------------	--------------

	0.1%	A088690 001	Aug 02, 1984
--	------	-------------	--------------

## TARO

	0.025%	A040040 001	Sep 30, 1994
--	--------	-------------	--------------

	0.025%	A040374 001	Jun 05, 2001
--	--------	-------------	--------------

	0.1%	A087902 001	Dec 27, 1982
--	------	-------------	--------------

	0.5%	A040386 001	Jun 05, 2001
--	------	-------------	--------------

## TRYMEX

## SAVAGE LABS

	0.025%	A088693 001	Aug 02, 1984
	0.1%	A088691 001	Aug 02, 1984

## PASTE; DENTAL

## KENALOG IN ORABASE

## DELCOR ASSET CORP

	0.1%	N012097 001	
--	------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

PASTE; DENTAL

ORALONE

TARO

0.1%

A071383 001 Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS

0.05MG/SPRAY

N020120 001 Feb 04, 2000

NASACORT HFA

SANOFI AVENTIS US

0.055MG/SPRAY

N020784 001 Apr 07, 2004

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

SANDOZ

25MG/ML

N011685 003

40MG/ML \*\*Federal Register

N012802 001

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

TRIAMCINOLONE DIACETATE

AKORN

25MG/ML

A085122 001

40MG/ML

A086394 001

WATSON LABS

40MG/ML

A084072 001

40MG/ML

A085529 001

SYRUP; ORAL

ARISTOCORT

ASTELLAS

2MG/5ML

N011960 004

KENACORT

DELCOR ASSET CORP

EQ 4MG BASE/5ML

N012515 001

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN

0.5MG

N017892 002 Nov 15, 1982

TRIAZOLAM

WATSON LABS

0.125MG

A074445 001 Oct 20, 1995

0.25MG

A074445 002 Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US

2MG

N012594 001 Jun 16, 1988

4MG

N012594 002 Jun 16, 1988

NAQUA

SCHERING

2MG

N012265 001

4MG

N012265 002

TRICHLOREX

LANNETT

4MG

A083436 001

4MG

A085630 001

TRICHLORMAS

MAST MM

4MG

A086259 001

TRICHLORMETHIAZIDE

IMPAX LABS

4MG

A083967 001

PAR PHARM

2MG

A087007 001

4MG

A087005 001

SANDOZ

4MG

A086171 001

TG UNITED LABS

4MG

A085568 001

WATSON LABS

2MG

A083847 001

2MG

A086458 001

4MG

A083462 001

4MG

A083855 001

4MG

A085962 001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US

1.5GM/15ML

N016830 001

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US

750MG

N016809 002

## DISCONTINUED DRUG PRODUCT LIST

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE 10MG/ML N009729 001

TABLET; ORAL

PATHILON

LEDERLE 25MG N009489 005

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

GLAXOSMITHKLINE EQ 10MG BASE/ML N011552 006

TRIFLUOPERAZINE HYDROCHLORIDE

SANDOZ EQ 10MG BASE/ML A085787 001 Apr 15, 1982

WOCKHARDT EQ 10MG BASE/ML A088143 001 Jul 26, 1983

INJECTABLE; INJECTION

STELAZINE

GLAXOSMITHKLINE EQ 2MG BASE/ML N011552 005

TABLET; ORAL

STELAZINE

GLAXOSMITHKLINE EQ 1MG BASE N011552 001

EQ 2MG BASE N011552 002

EQ 5MG BASE N011552 003

EQ 10MG BASE N011552 004

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR EQ 1MG BASE A088967 001 Apr 23, 1985

EQ 2MG BASE A088968 001 Apr 23, 1985

EQ 5MG BASE A088969 001 Apr 23, 1985

EQ 10MG BASE A088970 001 Apr 23, 1985

IVAX PHARMS EQ 1MG BASE A087612 001 Nov 19, 1982

EQ 2MG BASE A087613 001 Nov 19, 1982

EQ 5MG BASE A087328 001 Nov 19, 1982

EQ 10MG BASE A087614 001 Nov 19, 1982

SANDOZ EQ 1MG BASE A040153 001 Oct 25, 1996

EQ 2MG BASE A040153 002 Oct 25, 1996

EQ 5MG BASE A040153 003 Oct 25, 1996

EQ 10MG BASE A040153 004 Oct 25, 1996

WATSON LABS EQ 1MG BASE A085975 001 Jun 23, 1988

EQ 2MG BASE A085976 001 Jun 23, 1988

EQ 5MG BASE A085973 001 Jun 23, 1988

EQ 10MG BASE A088710 001 Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON EQ 50MG HCL/5ML N011491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON 3MG/ML N011325 005

10MG/ML N011325 004

20MG/ML N011325 001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB 10MG N011123 001

25MG N011123 002

50MG N011123 003

TRIHENXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE 5MG N006773 010

5MG N012947 001

ELIXIR; ORAL

ARTANE

LEDERLE 2MG/5ML N006773 009

TRIHENXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES 2MG/5ML A089514 001 Apr 07, 1989

TABLET; ORAL

ARTANE

LEDERLE 2MG N006773 005

5MG N006773 003

**DISCONTINUED DRUG PRODUCT LIST**TRIHXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TREMIM

SCHERING	2MG	A080381	001	
	5MG	A080381	003	

TRIHXYPHENIDYL HYDROCHLORIDE

HIKMA PHARMS LLC	2MG	A040337	002	Feb 16, 2000
	5MG	A040337	001	Feb 16, 2000
NYLOS	5MG	A085622	001	
VANGARD	2MG	A088035	001	Jul 30, 1982
WATSON LABS	2MG	A040184	001	Feb 06, 1998
	2MG	A085117	001	
	5MG	A040184	002	Feb 06, 1998
	5MG	A085105	001	

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION	30MG	N018719	002	Dec 31, 1984
	60MG	N018719	001	Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 5MG BASE	N011316	004	
------------------	-------------	---------	-----	--

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316	003	
------------------	-------------------	---------	-----	--

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015	001	Feb 18, 1982
MORTON GROVE	EQ 2.5MG BASE/5ML	A088285	001	Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE	N011316	001	
------------------	---------------	---------	-----	--

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE	300MG	N005856	005	
--------	-------	---------	-----	--

SOLUTION; ORAL

TRIDIONE

ABBVIE	200MG/5ML	N005856	002	
--------	-----------	---------	-----	--

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE	50MG/ML	N008983	001	
-------	---------	---------	-----	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960	001	Apr 04, 1986
	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982

TRIMETHOPRIM

MUTUAL PHARM	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986
TEVA	200MG	A071259	001	Jun 18, 1987

TRIMPEX

ROCHE	100MG	N017952	001	
-------	-------	---------	-----	--

TRIMPEX 200

ROCHE	200MG	N017952	002	Nov 09, 1982
-------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

FSC

EQ 25MG BASE/5ML

A074374 001 Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL

N020326 001 Dec 17, 1993

EQ 200MG BASE/VIAL

N020326 002 Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001 Dec 08, 1987

EQ 50MG BASE

A071284 001 Dec 08, 1987

EQ 100MG BASE

A071285 001 Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL

5MG

N012697 001

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS

EQ 25MG HCL/5ML

N005914 004

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS

25MG

A083149 001

50MG

N005914 002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC

50MG

A083037 001

BARR

50MG

A080744 001

HEATHER

50MG

A083989 001

IMPAX LABS

50MG

A080785 001

LANNETT

50MG

A083557 001

NYLOS

50MG

A085412 001

PARKE DAVIS

25MG

A083625 001

50MG

A083626 001

WATSON LABS

50MG

A080713 001

50MG

A080790 001

50MG

A085188 001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS

50MG

N010533 002

100MG

N010533 001

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

G AND W LABS

2.86%; 3.42%; 3.7%

A088607 001 Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM

2.86%; 3.42%; 3.7%

N005794 001

TRIPLE SULFA

ALPHARMA US PHARMS

2.86%; 3.42%; 3.7%

A087864 001 Sep 01, 1982

FOUGERA

2.86%; 3.42%; 3.7%

A086424 001

PERRIGO NEW YORK

2.86%; 3.42%; 3.7%

A087285 001 Nov 15, 1982

TRYSUL

SAVAGE LABS

2.86%; 3.42%; 3.7%

A087887 001 Jul 23, 1982

VAGILIA

G AND W LABS INC

3.42%; 3.42%; 3.42%

A088821 001 Nov 09, 1987

TABLET; VAGINAL

SULTRIN

ORTHO MCNEIL PHARM

143.75MG; 172.5MG; 184MG

N005794 002

TRIPLE SULFA

FOUGERA

172.5MG; 172.5MG; 172.5MG

A088463 001 Jan 03, 1985

PHARMADERM

172.5MG; 172.5MG; 172.5MG

A088462 001 Jan 03, 1985



**DISCONTINUED DRUG PRODUCT LIST**TRIPROLIDINE HYDROCHLORIDE

## SYRUP; ORAL

## ACTIDIL

GLAXOSMITHKLINE 1.25MG/5ML

N011496 002 Jul 01, 1983

## MYIDYL

USL PHARMA 1.25MG/5ML

A087963 001 Jan 18, 1983

## TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS 1.25MG/5ML

A085940 001

HALSEY 1.25MG/5ML

A088735 001 Jan 17, 1985

PHARM ASSOC 1.25MG/5ML

A087514 001 Feb 10, 1982

## TABLET; ORAL

## ACTIDIL

GLAXOSMITHKLINE 2.5MG

N011110 002 Jul 01, 1983

## TRIPROLIDINE HYDROCHLORIDE

VITARINE 2.5MG

A085610 001

WATSON LABS 2.5MG

A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE; SULFAMETHAZINE)

## SUSPENSION; ORAL

## LANTRISUL

LANNETT 167MG/5ML; 167MG/5ML; 167MG/5ML

A080123 002

## NEOTRIZINE

LILLY 167MG/5ML; 167MG/5ML; 167MG/5ML

N006317 012

## SULFALOID

FOREST PHARMS 167MG/5ML; 167MG/5ML; 167MG/5ML

A080100 001

## SULFOSE

WYETH AYERST 167MG/5ML; 167MG/5ML; 167MG/5ML

A080013 002

## TERFONYL

BRISTOL MYERS SQUIBB 167MG/5ML; 167MG/5ML; 167MG/5ML

N006904 002

## TRIPLE SULFA

ALPHARMA US PHARMS 167MG/ML; 167MG/ML; 167MG/ML

A080280 001

## TRIPLE SULFAS

LEDERLE 167MG/5ML; 167MG/5ML; 167MG/5ML

N006920 003

## TABLET; ORAL

## NEOTRIZINE

LILLY 167MG; 167MG; 167MG

N006317 011

## SULFA-TRIPLE #2

IMPAX LABS 167MG; 167MG; 167MG

A080079 001

## SULFALOID

FOREST PHARMS 167MG; 167MG; 167MG

A080099 001

## SULFOSE

WYETH AYERST 167MG; 167MG; 167MG

A080013 001

## TERFONYL

BRISTOL MYERS SQUIBB 167MG; 167MG; 167MG

N006904 001

## TRIPLE SULFA

PUREPAC PHARM 167MG; 167MG; 167MG

A080086 001

## TRIPLE SULFAS

LEDERLE 167MG; 167MG; 167MG

N006920 002

## TRIPLE SULFOID

PAL PAK 167MG; 167MG; 167MG

A080094 001

TROGLITAZONE

## TABLET; ORAL

## PRELAY

SANKYO 200MG

N020719 001 Jan 29, 1997

300MG

N020719 003 Aug 04, 1997

400MG

N020719 002 Jan 29, 1997

## REZULIN

PFIZER PHARMS 200MG

N020720 001 Jan 29, 1997

300MG

N020720 003 Aug 04, 1997

400MG

N020720 002 Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

## SOLUTION/DROPS; OTIC

## CERUMENEX

PHARM RES ASSOC 10%

N011340 002

TROLEANDOMYCIN

## CAPSULE; ORAL

## TAO

PFIZER EQ 250MG BASE

N050336 002

## SUSPENSION; ORAL

## TAO

PFIZER EQ 125MG BASE/5ML

N050332 001

## DISCONTINUED DRUG PRODUCT LIST

TROPICAMIDE

## SOLUTION/DROPS;OPHTHALMIC

## MYDRIACYL

ALCON	0.5%	N012111 002
	1%	N012111 004

## MYDRIAFAIR

PHARMAFAIR	0.5%	A088274 001 Sep 16, 1983
	1%	A088230 001 Sep 16, 1983

## TROPICAMIDE

AKORN	1%	A088447 001 Aug 28, 1985
ALCON PHARMS LTD	1%	A089172 001 Dec 28, 1990
MIZA PHARMS USA	0.5%	A087636 001 Jul 30, 1982
	1%	A087637 001 Aug 09, 1982
WATSON LABS	0.5%	A089171 001 Dec 28, 1990

TROSPIUM CHLORIDE

## CAPSULE, EXTENDED RELEASE;ORAL

## SANCTURA XR

ALLERGAN	60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022103 001 Aug 03, 2007
----------	---	--------------------------

## TABLET;ORAL

## SANCTURA

ALLERGAN	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021595 001 May 28, 2004
----------	---	--------------------------

TROVAFLOXACIN MESYLATE

## TABLET;ORAL

## TROVAN

PFIZER	EQ 100MG BASE	N020759 001 Dec 18, 1997
	EQ 200MG BASE	N020759 002 Dec 18, 1997

TUBOCURARINE CHLORIDE

## INJECTABLE;INJECTION

## TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB	3MG/ML	N005657 001
HOSPIRA	3MG/ML	N006095 001
LILLY	3MG/ML	N006325 001

TYROPANOATE SODIUM

## CAPSULE;ORAL

## BILOPAQUE

GE HEALTHCARE	750MG	N013731 001
---------------	-------	-------------

URACIL MUSTARD

## CAPSULE;ORAL

## URACIL MUSTARD

SHIRE	1MG	N012892 001
-------	-----	-------------

UREA

## INJECTABLE;INJECTION

## STERILE UREA

HOSPIRA	40GM/VIAL	N017698 001
---------	-----------	-------------

## UREAPHIL

HOSPIRA	40GM/VIAL	N012154 001
---------	-----------	-------------

UREA C-13

## FOR SOLUTION;ORAL

## BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA	EQ 75MG/POUCH	N020586 002 May 10, 2001
----------------	---------------	--------------------------

## HELICOSOL

METABOLIC SOLUTIONS	125MG/VIAL	N021092 001 Dec 17, 1999
---------------------	------------	--------------------------

## MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA	125MG/VIAL	N020586 001 Sep 17, 1996
----------------	------------	--------------------------

## PYLORI-CHEK BREATH TEST

DXS DEVICES	100MG/VIAL	N020900 001 Feb 04, 1999
-------------	------------	--------------------------

UROFOLLITROPIN

## INJECTABLE;INTRAMUSCULAR

## METRODIN

SERONO	75 IU/AMP	N019415 002 Sep 18, 1986
	150 IU/AMP	N019415 003 Sep 18, 1986

## DISCONTINUED DRUG PRODUCT LIST

UROFOLLITROPIN

INJECTABLE; SUBCUTANEOUS

FERTINEX

SERONO

75 IU/AMP

N019415 005 Aug 23, 1996

150 IU/AMP

N019415 004 Aug 23, 1996

UROKINASE

INJECTABLE; INJECTION

KINLYTIC

MICROBIX BIOSYSTEMS

5,000 IU/VIAL

N021846 003

9,000 IU/VIAL

N021846 002

250,000 IU/VIAL

N021846 001

URSODIOL

CAPSULE; ORAL

ACTIGALL

ACTAVIS LABS UT INC

150MG

N019594 001 Dec 31, 1987

TABLET; ORAL

URSODIOL

TEVA PHARMS USA

250MG

A079184 001 May 13, 2009

500MG

A079184 002 May 13, 2009

VALDECOXIB

TABLET; ORAL

BEXTRA

GD SEARLE

10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

PAR PHARM

250MG

A070431 001 Feb 28, 1986

SCHERER RP

250MG

A070195 001 Jul 02, 1987

USL PHARMA

250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

BANNER LIFE SCIENCES

125MG

N022152 001 Jul 29, 2008

250MG

N022152 002 Jul 29, 2008

500MG

N022152 003 Jul 29, 2008

SYRUP; ORAL

VALPROIC ACID

APOTEX INC

250MG/5ML

A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE; ORAL

DIOVAN

NOVARTIS

80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983

EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE

EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 500MG BASE/VIAL

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL \*\*Federal Register

A062812 001 Nov 17, 1987

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

EQ 1GM BASE/VIAL

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL \*\*Federal Register

A062812 002 Nov 17, 1987

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

EQ 10GM BASE/VIAL \*\*Federal Register

A062812 003 Nov 17, 1987

determination that product was not

discontinued or withdrawn for safety or

## DISCONTINUED DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANOCIN HYDROCHLORIDE

efficacy reasons\*\*

VANCOLED

EUROHLTH INTL SARL

EQ 500MG BASE/VIAL

A062682 001 Jul 22, 1986

EQ 1GM BASE/VIAL

A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL

A062682 003 May 11, 1988

EQ 5GM BASE/VIAL

A062682 004 May 11, 1988

EQ 10GM BASE/VIAL

A062682 005 May 11, 1988

VANCOMYCIN HYDROCHLORIDE

HIKMA MAPLE

EQ 500MG BASE/VIAL

A062879 001 Aug 02, 1988

EQ 1GM BASE/VIAL

A062879 002 Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN

EQ 500MG BASE/VIAL

A062956 001 Aug 01, 1988

EQ 1GM BASE/VIAL

A062956 002 Aug 01, 1988

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

PARKE DAVIS

5PRESSOR UNITS/ML

N003402 001

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

ORGANON USA INC

10MG/VIAL

N018776 002 Apr 30, 1984

20MG/VIAL

N018776 003 Jan 03, 1992

VECURONIUM BROMIDE

HIKMA MAPLE

10MG/VIAL

A075218 001 Aug 23, 1999

20MG/VIAL

A075218 002 Aug 23, 1999

HOSPIRA

4MG/VIAL

A075558 001 Sep 11, 2001

WATSON LABS

10MG/VIAL

A074334 001 Aug 31, 1995

20MG/VIAL

A074334 002 Aug 31, 1995

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC

200 UNITS/VIAL

N022575 002 Feb 26, 2010

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

EQ 100MG BASE

N020699 003 Oct 20, 1997

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

EQ 12.5MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020151 001 Dec 28, 1993

EQ 25MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020151 002 Dec 28, 1993

EQ 37.5MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020151 006 Dec 28, 1993

EQ 50MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020151 003 Dec 28, 1993

EQ 75MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020151 004 Dec 28, 1993

EQ 100MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020151 005 Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

PLIVA HRVATSKA DOO

EQ 25MG BASE

A078517 001 Jun 13, 2008

EQ 37.5MG BASE

A078517 002 Jun 13, 2008

EQ 50MG BASE

A078517 003 Jun 13, 2008

EQ 75MG BASE

A078517 004 Jun 13, 2008

EQ 100MG BASE

A078517 005 Jun 13, 2008

SANDOZ

EQ 25MG BASE

A077515 001 Jun 13, 2008

EQ 37.5MG BASE

A077515 002 Jun 13, 2008

**DISCONTINUED DRUG PRODUCT LIST**VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

EQ 50MG BASE	A077515 003	Jun 13, 2008
EQ 75MG BASE	A077515 004	Jun 13, 2008
EQ 100MG BASE	A077515 005	Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

CALAN

EXELA PHARMA SCS LLC	2.5MG/ML	N018925 001	Mar 30, 1984
GD SEARLE LLC	2.5MG/ML	N019038 001	Mar 30, 1984

ISOPTIN

MT ADAMS	2.5MG/ML	N018485 001	
----------	----------	-------------	--

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM	2.5MG/ML	A070348 001	May 01, 1986
BEDFORD	2.5MG/ML	A072888 001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070577 001	Feb 02, 1987
	2.5MG/ML	A070739 001	May 06, 1987
	2.5MG/ML	A070740 001	May 06, 1987
INTL MEDICATION	2.5MG/ML	A070451 001	Dec 16, 1985
LUITPOLD	2.5MG/ML	A070225 001	Nov 12, 1985
	2.5MG/ML	A070617 001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233 001	Feb 26, 1993
	2.5MG/ML	A073485 001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696 001	Jul 31, 1987
	2.5MG/ML	A070697 001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695 001	Jul 31, 1987

TABLET; ORAL

CALAN

GD SEARLE LLC	160MG	N018817 004	Feb 23, 1988
---------------	-------	-------------	--------------

ISOPTIN

MT ADAMS	40MG	N018593 003	Nov 23, 1987
	80MG	N018593 001	Mar 08, 1982
	120MG	N018593 002	Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986
	120MG	A070468 001	Sep 24, 1986
MUTUAL PHARM	80MG	A070482 001	Sep 24, 1986
	80MG	A071489 002	Jan 13, 1988
	120MG	A070483 001	Sep 24, 1986
	120MG	A071489 001	Jan 13, 1988
PLIVA	40MG	A072751 001	Feb 23, 1996
	80MG	A072124 001	Jan 26, 1989
	120MG	A072125 001	Jan 26, 1989
SANDOZ	40MG	A073168 001	Jul 31, 1992
	80MG	A071423 001	May 24, 1988
	120MG	A071424 001	May 25, 1988
WARNER CHILCOTT	80MG	A070340 001	Sep 24, 1986
	120MG	A070341 001	Sep 24, 1986
WATSON LABS	40MG	A072799 001	Apr 28, 1989
	40MG	A072923 001	Jun 29, 1993
	80MG	A070855 001	Sep 24, 1986
	80MG	A071366 001	Oct 01, 1986
	120MG	A070856 001	Sep 24, 1986
	120MG	A071367 001	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

PLIVA	240MG	A072922 001	Mar 01, 1996
-------	-------	-------------	--------------

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691 002	
---------------------	-------------	-------------	--

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDEALE	EQ 187.4MG BASE/ML	N050523 001	
------------	--------------------	-------------	--

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDEALE	3%	N050486 001	
------------	----	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

LILLY 10MG/VIAL N012665 001

VINBLASTINE SULFATE

ABRAXIS PHARM 10MG/VIAL A089011 001 Nov 18, 1985

HOSPIRA 10MG/VIAL A089565 001 Aug 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY 1MG/VIAL N014103 001

1MG/ML N014103 003 Mar 07, 1984

5MG/VIAL N014103 002

VINCASAR PFS

TEVA PARENTERAL 1MG/ML A071426 001 Jul 17, 1987

VINCREX

BRISTOL MYERS SQUIBB 5MG/VIAL A070867 001 Jul 12, 1988

VINCRISTINE SULFATE

ABIC 1MG/ML A070873 001 Feb 19, 1987

ABRAXIS PHARM 1MG/ML A070411 001 Sep 10, 1986

FRESENIUS KABI USA 1MG/ML A076296 001 Dec 20, 2002

1MG/ML A076401 001 Oct 28, 2003

HOSPIRA 1MG/VIAL A071559 001 Apr 11, 1988

2MG/VIAL A071560 001 Apr 11, 1988

5MG/VIAL A071561 001 Apr 11, 1988

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

EBEWE PHARMA EQ 10MG BASE/ML A078408 001 Feb 13, 2008

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER EQ 1GM BASE/VIAL A061086 001

EQ 5GM BASE/VIAL A061086 002

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA 25,000USP UNITS A083080 002

50,000USP UNITS A083080 001

VITAMIN A

BANNER PHARMACAPS 50,000USP UNITS A083973 001

CHASE CHEM 50,000 IU A083351 001

EVERYLIFE 50,000 IU A083134 001

IMPAX LABS 50,000USP UNITS A080952 001

WEST WARD 50,000USP UNITS A080985 001

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP EQ 50,000 UNITS BASE A083187 001

ALPHALIN

LILLY EQ 50,000 UNITS BASE A080883 001

DEL-VI-A

DEL RAY LABS EQ 50,000 UNITS BASE A080830 001

VI-DOM-A

BAYER PHARMS EQ 50,000 UNITS BASE A080972 001

VITAMIN A

BANNER PHARMACAPS EQ 50,000 UNITS BASE A080702 001

BRISTOL MYERS SQUIBB EQ 50,000 UNITS BASE A080860 001

CHASE CHEM EQ 50,000 UNITS BASE A080746 001

EQ 50,000 UNITS BASE A083207 001

ELKINS SINN EQ 50,000 UNITS BASE A085479 001

EVERYLIFE EQ 50,000 UNITS BASE A080943 001

EQ 50,000 UNITS BASE A083114 001

IMPAX LABS EQ 50,000 UNITS BASE A080953 001

EQ 50,000 UNITS BASE A080955 001

IVAX SUB TEVA PHARMS EQ 50,000 UNITS BASE A083035 001

EQ 50,000 UNITS BASE A083190 001

MK LABS EQ 25,000 UNITS BASE A083457 002

EQ 50,000 UNITS BASE A083457 001

WEST WARD EQ 50,000 UNITS BASE A080967 001

## DISCONTINUED DRUG PRODUCT LIST

VITAMIN A PALMITATE

CAPSULE; ORAL

VITAMIN A

WHARTON LABS

EQ 50,000 UNITS BASE

A083665 001

VITAMIN A PALMITATE

ARCUM

EQ 50,000 UNITS BASE

A083311 001

EQ 50,000 UNITS BASE

A083321 001

BANNER PHARMACAPS

EQ 50,000 UNITS BASE

A083948 001

EQ 50,000 UNITS BASE

A083981 001

VITAMIN A SOLUBILIZED

TEVA

EQ 50,000 UNITS BASE

A080921 001

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR

EQ 50,000 UNITS BASE/ML

A080819 001

WARFARIN POTASSIUM

TABLET; ORAL

ATHROMBIN-K

PHARM RES ASSOC

2MG

N011771 007

5MG

N011771 004

10MG

N011771 005

25MG

N011771 006

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB

5MG/VIAL

N009218 024 Feb 07, 1995

50MG/VIAL

N009218 020

75MG/VIAL

N009218 012

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC

5MG

N011771 003

10MG

N011771 002

25MG

N011771 001

PANWARFIN

ABBOTT

2MG

N017020 001

2.5MG

N017020 002

5MG

N017020 003

7.5MG

N017020 004

10MG

N017020 005

WARFARIN SODIUM

SANDOZ

1MG

A040196 001 Sep 30, 1997

2MG

A040196 002 Sep 30, 1997

2.5MG

A040196 003 Sep 30, 1997

3MG

A040196 008 Jul 26, 2000

4MG

A040196 004 Sep 30, 1997

5MG

A040196 005 Sep 30, 1997

6MG

A040196 009 Jul 26, 2000

7.5MG

A040196 006 Sep 30, 1997

10MG

A040196 007 Sep 30, 1997

USL PHARMA

2MG

A088719 001 Jun 27, 1985

2.5MG

A088720 001 Aug 06, 1985

5MG

A088721 001 Jul 02, 1985

WATSON LABS

2MG

A086123 001 Aug 17, 1982

2.5MG

A086120 001 Aug 17, 1982

5MG

A086119 001 Aug 17, 1982

7.5MG

A086118 001 Aug 17, 1982

10MG

A086122 001 Aug 17, 1982

XENON XE-127

GAS; INHALATION

XENON XE 127

MALLINCKRODT

5mCi/VIAL

N018536 001 Oct 01, 1982

10mCi/VIAL

N018536 002 Oct 01, 1982

XENON XE-133

GAS; INHALATION

XENON XE 133

GE HEALTHCARE

1 CI/AMP

N017256 002

10mCi/VIAL

N017687 002

20mCi/VIAL

N017687 003

GEN ELECTRIC

5-100 CI/CYLINDER

N017550 001

0.25-5 CI/AMP

N017550 003

MALLINCKRODT NUCLEAR

10mCi/VIAL

N018327 001 Mar 09, 1982

## DISCONTINUED DRUG PRODUCT LIST

XENON XE-133

GAS; INHALATION

XENON XE 133

20mCi/VIAL

N018327 002 Mar 09, 1982

XENON XE 133-V.S.S.

GE HEALTHCARE

10mCi/VIAL

N017687 001

INJECTABLE; INJECTION

XENON XE 133

GE HEALTHCARE

1.3-1.7 CI/AMP

N017256 001

LANTHEUS MEDCL

6.3mCi/ML

N017283 001

SOLUTION; INHALATION, INJECTION

XENEISOL

MALLINCKRODT

18-25mCi/AMP

N017262 002

XYLOSE

POWDER; ORAL

XYLO-PFAN

SAVAGE LABS

25GM/BOT

N017605 001

XYLOSE

LYNE

25GM/BOT

N018856 001 Mar 26, 1987

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG

N020199 001 Jun 19, 1992

0.75MG

N020199 002 Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

SANDOZ

5MG

A078095 001 Jun 06, 2008

10MG

A078095 002 Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

JAZZ PHARMS INTL

200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

LIAONING CHENGDA

10MG/ML

A204538 001 Nov 26, 2013

TABLET; ORAL

RETROVIR

VIIV HLTHCARE

200MG

N020518 001 Dec 19, 1995

300MG

N020518 002 Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA

60MG

N022294 001 Jul 23, 2009

MATRIX LABS LTD

100MG

N200732 001 Feb 23, 2011

RANBAXY LABS LTD

300MG

A077327 001 Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

CHIESI USA INC

300MG

N020471 001 Dec 09, 1996

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM

EQ 1MG ZINC/ML

N019229 002 May 05, 1987

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL

GEODON

PFIZER INC

EQ 10MG BASE/ML

N021483 001 Mar 29, 2006

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

NOVARTIS

EQ 4MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021223 001 Aug 20, 2001



**DISCONTINUED DRUG PRODUCT LIST**ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD	5MG	A077985 001	Apr 23, 2007
	10MG	A077985 002	Apr 23, 2007
HIKMA	5MG	A078129 001	Apr 30, 2008
	10MG	A078129 002	Apr 30, 2008
MUTUAL PHARMA	5MG	A077288 001	Apr 23, 2007
	10MG	A077288 002	Apr 23, 2007
MYLAN PHARMS INC	5MG	A078016 001	Apr 23, 2007
	10MG	A078016 002	Apr 23, 2007
SYNTHON PHARMS	5MG	A077540 001	Apr 23, 2007
	10MG	A077540 002	Apr 23, 2007
VIVIMED LABS	5MG	A076062 001	Apr 23, 2007
	10MG	A076062 002	Apr 23, 2007
WATSON LABS	5MG	A077773 001	Apr 23, 2007
	10MG	A077773 002	Apr 23, 2007
TABLET, ORALLY DISINTEGRATING;ORAL			
TOVALT ODT			
BIOVAIL LABS INTL	5MG	N021412 001	Apr 25, 2007
	10MG	N021412 002	Apr 25, 2007

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

ANI PHARMS INC	25MG	A077639 001	Dec 22, 2005
	25MG	A077641 003	Dec 22, 2005
	50MG	A077639 002	Dec 22, 2005
	50MG	A077641 002	Dec 22, 2005
	100MG	A077639 003	Dec 22, 2005
	100MG	A077641 001	Dec 22, 2005
COREPHARMA	25MG	A077876 001	Feb 21, 2007
	50MG	A077876 002	Feb 21, 2007
	100MG	A077876 003	Feb 21, 2007
DR REDDYS LABS LTD	25MG	A077645 002	Sep 29, 2006
	50MG	A077645 003	Sep 29, 2006
	100MG	A077645 001	Dec 22, 2005
MUTUAL PHARM	25MG	A077635 001	Dec 22, 2005
	50MG	A077635 002	Dec 22, 2005
	100MG	A077635 003	Dec 22, 2005
ROXANE	25MG	A077648 001	Dec 22, 2005
	50MG	A077648 002	Dec 22, 2005
	100MG	A077648 003	Dec 22, 2005
SANDOZ	25MG	A077644 001	Dec 22, 2005
	50MG	A077644 002	Dec 22, 2005
	100MG	A077644 003	Dec 22, 2005
WATSON LABS	25MG	A077650 001	Apr 20, 2006
	50MG	A077650 002	Apr 20, 2006
	100MG	A077650 003	Apr 20, 2006

**ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of List of Orphan Designations and Approvals is available at:  
<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL  
CAPSULE OR TABLET; ORAL  
160-165MG;160-165MG;50MG  
325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;  
CODEINE PHOSPHATE  
TABLET; ORAL  
160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;  
CAFFEINE  
CAPSULE OR TABLET; ORAL  
160-165MG;160-165MG;50MG;40MG  
325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL  
TABLET; ORAL  
325MG;200MG

ACETAMINOPHEN;BUTALBITAL  
CAPSULE OR TABLET; ORAL  
325MG;50MG

ASPIRIN;CARISOPRODOL;  
CODEINE PHOSPHATE  
TABLET; ORAL  
325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE  
CAPSULE OR TABLET; ORAL  
325MG;50MG;40MG

ASPIRIN;MEPROBAMATE  
TABLET; ORAL  
325MG;200MG

AMINOPHYLLINE  
TABLET; ORAL  
100MG;200MG

ASPIRIN;METHOCARBAMOL  
TABLET; ORAL  
325MG;400MG

ASPIRIN;BUTALBITAL  
CAPSULE OR TABLET; ORAL  
325MG;50MG  
650MG;50MG

CHLOROTHIAZIDE  
TABLET; ORAL  
250MG

ASPIRIN;BUTALBITAL;CAFFEINE  
CAPSULE OR TABLET; ORAL  
325MG;50MG;40MG  
650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE  
TABLET; ORAL  
10MG;25MG;  
50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL  
TABLET; ORAL  
160MG;32MG;200MG

PREDNISONE  
TABLET; ORAL  
1MG;2.5MG;5MG;10MG;  
20MG;25MG;50MG

## APPENDIX A - PRODUCT NAME INDEX

\*\* 8 \*\*

8-MOP, METHOXSALEN

\*\* A \*\*

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE  
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE  
ABACAVIR SULFATE, ABACAVIR SULFATE  
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE  
ABELCET, AMPHOTERICIN B  
ABILIFY, ARIPIPIRAZOLE  
ABILIFY MAINTENA KIT, ARIPIPIRAZOLE  
ABLAVAR, GADOFOSVESET TRISODIUM  
ABRAXANE, PACLITAXEL  
ABREVA, DOCOSANOL (OTC)  
ABSORICA, ISOTRETINOIN  
ABSTRAL, FENTANYL CITRATE  
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM  
ACANYA, BENZOYL PEROXIDE  
ACARBOSE, ACARBOSE  
ACCOLATE, ZAFIRLUKAST  
ACCUNEB, ALBUTEROL SULFATE  
ACCUPRIL, QUINAPRIL HYDROCHLORIDE  
ACCURETIC, HYDROCHLOROTHIAZIDE  
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE  
ACEON, PERINDOPRIL ERBUMINE  
ACEPHEN, ACETAMINOPHEN (OTC)  
ACETADOTE, ACETYLCYSTEINE  
ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
ACETAMINOPHEN, ACETAMINOPHEN  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)  
ACETASOL HC, ACETIC ACID, GLACIAL  
ACETAZOLAMIDE, ACETAZOLAMIDE  
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
ACETIC ACID, ACETIC ACID, GLACIAL  
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL  
ACETYLCYSTEINE, ACETYLCYSTEINE  
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE  
ACIPHEX, RABEPRAZOLE SODIUM  
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM  
ACITRETIN, ACITRETIN  
ACTHREL, CORTICORELIN OVINE TRIFLUTATE  
ACTICLATE, DOXYCYCLINE HYCLATE  
ACTIGALL, URSODIOL  
ACTIQ, FENTANYL CITRATE  
ACTIVELLA, ESTRADIOL  
ACTONEL, RISEDRONATE SODIUM  
ACTOPLUS MET, METFORMIN HYDROCHLORIDE  
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE  
ACTOS, PIOGLITAZONE HYDROCHLORIDE  
ACULAR, KETOROLAC TROMETHAMINE  
ACULAR LS, KETOROLAC TROMETHAMINE  
ACUVAIL, KETOROLAC TROMETHAMINE  
ACYCLOVIR, ACYCLOVIR  
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM  
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM  
ACZONE, DAPSONE  
ADAGEN, PEGADEMASE BOVINE  
ADALAT CC, NIFEDIPINE  
ADAPALENE, ADAPALENE  
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE  
ADASUVE, LOXAPINE  
ADCIRCA, TADALAFIL  
ADDERALL XR 10, AMPHETAMINE ASPARTATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

ADDERALL XR 15, AMPHETAMINE ASPARTATE  
ADDERALL XR 20, AMPHETAMINE ASPARTATE  
ADDERALL XR 25, AMPHETAMINE ASPARTATE  
ADDERALL XR 30, AMPHETAMINE ASPARTATE  
ADDERALL XR 5, AMPHETAMINE ASPARTATE  
ADDYI, FLIBANSERIN  
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL  
ADEMPAS, RIOCIQUAT  
ADENOCARD, ADENOSINE  
ADENOSCAN, ADENOSINE  
ADENOSINE, ADENOSINE  
ADIPEX-P, PHENTERMINE HYDROCHLORIDE  
ADRENACLICK, EPINEPHRINE  
ADRENALIN, EPINEPHRINE  
ADREVIEW, IOBENGUANE SULFATE I-123  
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE  
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE  
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE  
ADVAIR HFA, FLUTICASONE PROPIONATE  
ADVICOR, LOVASTATIN  
ADVIL, IBUPROFEN (OTC)  
ADVIL, IBUPROFEN SODIUM (OTC)  
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)  
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
ADVIL COLD AND SINUS, IBUPROFEN (OTC)  
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)  
ADVIL LIQUI-GELS, IBUPROFEN (OTC)  
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)  
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)  
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
AEROSPAN HFA, FLUNISOLIDE  
AFEDITAB CR, NIFEDIPINE  
AFINITOR, EVEROLIMUS  
AFINITOR DISPERZ, EVEROLIMUS  
AFREZZA, INSULIN RECOMBINANT HUMAN  
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)  
AGGRASTAT, TIROFIBAN HYDROCHLORIDE  
AGGRENOL, ASPIRIN  
AGRYLIN, ANAGRELIDE HYDROCHLORIDE  
AK-FLUOR 10%, FLUORESCEIN SODIUM  
AK-FLUOR 25%, FLUORESCEIN SODIUM  
AKBETA, LEVOBUNOLOL HYDROCHLORIDE  
AKNE-MYCIN, ERYTHROMYCIN  
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE  
AKTEN, LIDOCAINE HYDROCHLORIDE  
AKTOB, TOBRAMYCIN  
AKYNZEO, NETUPITANT  
ALA-CORT, HYDROCORTISONE  
ALA-SCALP, HYDROCORTISONE  
ALAVERT, LORATADINE (OTC)  
ALAWAY, KETOTIFEN FUMARATE (OTC)  
ALBENZA, ALBENDAZOLE  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
ALCAINE, PROPARACAINE HYDROCHLORIDE  
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE  
ALDACTAZIDE, HYDROCHLOROTHIAZIDE  
ALDACTONE, SPIRONOLACTONE  
ALDARA, IMIQUIMOD  
ALECENSA, ALECTINIB HYDROCHLORIDE  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
ALEVE, NAPROXEN SODIUM (OTC)  
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)  
ALFENTA, ALFENTANIL HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

ALFENTANIL, ALFENTANIL HYDROCHLORIDE  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 ALIMTA, PEMETREXED DISODIUM  
 ALINIA, NITAZOXANIDE  
 ALKERAN, MELPHALAN  
 ALKERAN, MELPHALAN HYDROCHLORIDE  
 ALLEGRA, FEXOFENADINE HYDROCHLORIDE  
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLI, ORLISTAT (OTC)  
 ALLOPURINOL, ALLOPURINOL  
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM  
 ALLZITAL, ACETAMINOPHEN  
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE  
 ALOCRI, NEDOCROMIL SODIUM  
 ALOMIDE, LODOXAMIDE TROMETHAMINE  
 ALOPRIM, ALLOPURINOL SODIUM  
 ALORA, ESTRADIOL  
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE  
 ALOXI, PALONOSETRON HYDROCHLORIDE  
 ALPHAGAN P, BRIMONIDINE TARTRATE  
 ALPRAZOLAM, ALPRAZOLAM  
 ALPROSTADIL, ALPROSTADIL  
 ALREX, LOTEPREDNOL ETABONATE  
 ALSUMA, SUMATRIPTAN SUCCINATE  
 ALTABAX, RETAPAMULIN  
 ALTACE, RAMIPRIL  
 ALTAVERA, ETHINYL ESTRADIOL  
 ALTOPREV, LOVASTATIN  
 ALVESCO, CICLESONIDE  
 ALYACEN 1/35, ETHINYL ESTRADIOL  
 ALYACEN 7/7/7, ETHINYL ESTRADIOL  
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 AMARYL, GLIMEPIRIDE  
 AMBIEN, ZOLPIDEM TARTRATE  
 AMBIEN CR, ZOLPIDEM TARTRATE  
 AMBISOME, AMPHOTERICIN B  
 AMCINONIDE, AMCINONIDE  
 AMERGE, NARATRIPTAN HYDROCHLORIDE  
 AMICAR, AMINOCAPROIC ACID  
 AMIDATE, ETOMIDATE  
 AMIFOSTINE, AMIFOSTINE  
 AMIKACIN SULFATE, AMIKACIN SULFATE  
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE  
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE  
 AMINO ACIDS, AMINO ACIDS  
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE  
 AMINOCAPROIC, AMINOCAPROIC ACID  
 AMINOCAPROIC ACID, AMINOCAPROIC ACID  
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID  
 AMINOPHYLLINE, AMINOPHYLLINE  
 AMINOSYN 10%, AMINO ACIDS  
 AMINOSYN 10% (PH6), AMINO ACIDS  
 AMINOSYN 3.5%, AMINO ACIDS  
 AMINOSYN 3.5% M, AMINO ACIDS  
 AMINOSYN 5%, AMINO ACIDS  
 AMINOSYN 7%, AMINO ACIDS  
 AMINOSYN 7% (PH6), AMINO ACIDS  
 AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN 8.5%, AMINO ACIDS  
 AMINOSYN 8.5% (PH6), AMINO ACIDS  
 AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN II 10%, AMINO ACIDS

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS  
 AMINOSYN II 7%, AMINO ACIDS  
 AMINOSYN II 8.5%, AMINO ACIDS  
 AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN-HBC 7%, AMINO ACIDS  
 AMINOSYN-HF 8%, AMINO ACIDS  
 AMINOSYN-PF 10%, AMINO ACIDS  
 AMINOSYN-PF 7%, AMINO ACIDS  
 AMINOSYN-RF 5.2%, AMINO ACIDS  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMITIZA, LUBIPROSTONE  
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE  
 AMMONIA N 13, AMMONIA N-13  
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE  
 AMMONIUM LACTATE, AMMONIUM LACTATE  
 AMMONUL, SODIUM BENZOATE  
 AMNESTEEM, ISOTRETINOIN  
 AMOXAPINE, AMOXAPINE  
 AMOXICILLIN, AMOXICILLIN  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN PEDIATRIC, AMOXICILLIN  
 AMOXIL, AMOXICILLIN  
 AMPHADASE, HYALURONIDASE  
 AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF, AMPHETAMINE  
 AMPHOTEC, AMPHOTERICIN B  
 AMPHOTERICIN B, AMPHOTERICIN B  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE  
 AMPYRA, DALFAMPRIDINE  
 AMRINONE LACTATE, INAMRINONE LACTATE  
 AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE  
 AMYVID, FLORBETAPIR F-18  
 AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT  
 AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT  
 ANADROL-50, OXYMETHOLONE  
 ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 ANAPROX, NAPROXEN SODIUM  
 ANAPROX DS, NAPROXEN SODIUM  
 ANASTROZOLE, ANASTROZOLE  
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM  
 ANCOBON, FLUCYTOSINE  
 ANDRODERM, TESTOSTERONE  
 ANDROGEL, TESTOSTERONE  
 ANDROID 10, METHYLTESTOSTERONE  
 ANDROID 25, METHYLTESTOSTERONE  
 ANECTINE, SUCCINYLCHOLINE CHLORIDE  
 ANEXSIA 5/325, ACETAMINOPHEN  
 ANEXSIA 7.5/325, ACETAMINOPHEN  
 ANGELIQ, DROSPIRENONE  
 ANGIOMAX, BIVALIRUDIN  
 ANORO ELLIPTA, UMECLIDINIUM BROMIDE  
 ANTABUSE, DISULFIRAM  
 ANTARA (MICRONIZED), FENOFIBRATE  
 ANTHELIOS 20, AVOBENZONE (OTC)  
 ANTHELIOS 40, AVOBENZONE (OTC)  
 ANTHELIOS SX, AVOBENZONE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

ANTIZOL, FOMEPIZOLE  
ANUSOL HC, HYDROCORTISONE  
ANZEMET, DOLASETRON MESYLATE  
APIDRA, INSULIN GLULISINE RECOMBINANT  
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT  
APLENZIN, BUPROPION HYDROBROMIDE  
APOKYN, APOMORPHINE HYDROCHLORIDE  
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE  
APREPITANT, APREPITANT  
APRISO, MESALAMINE  
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE  
APTIOM, ESLICARBAZEPINE ACETATE  
APTIVUS, TIPRANAVIR  
AQUASOL A, VITAMIN A PALMITATE  
ARALEN, CHLOROQUINE PHOSPHATE  
ARANELLE, ETHINYL ESTRADIOL  
ARAVA, LEFLUNOMIDE  
ARCAPTA NEOHALER, INDACATEROL MALEATE  
ARESTIN, MINOCYCLINE HYDROCHLORIDE  
ARGATROBAN, ARGATROBAN  
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN  
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN  
ARICEPT, DONEPEZIL HYDROCHLORIDE  
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE  
ARIMIDEX, ANASTROZOLE  
ARIPIPIRAZOLE, ARIPIPIRAZOLE  
ARISTADA, ARIPIPIRAZOLE LAUROXIL  
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE  
ARIXTRA, FONDAPARINUX SODIUM  
ARNUITY ELLIPTA, FLUTICASONE FUROATE  
AROMASIN, EXEMESTANE  
ARRANON, NELARABINE  
ARTHROTEC, DICLOFENAC SODIUM  
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE  
ASACOL HD, MESALAMINE  
ASCLERA, POLIDOCANOL  
ASHLYNA, ETHINYL ESTRADIOL  
ASMANEX HFA, MOMETASONE FUROATE  
ASMANEX TWISTHALER, MOMETASONE FUROATE  
ASPIRIN, ASPIRIN (OTC)  
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN  
ASTAGRAF XL, TACROLIMUS  
ASTELIN, AZELASTINE HYDROCHLORIDE  
ASTEPRO, AZELASTINE HYDROCHLORIDE  
ASTRAMORPH PF, MORPHINE SULFATE  
ATACAND, CANDESARTAN CILEXETIL  
ATACAND HCT, CANDESARTAN CILEXETIL  
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE  
ATELVIA, RISEDRONATE SODIUM  
ATENOLOL, ATENOLOL  
ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
ATHENTIA NEXT, LEVONORGESTREL (OTC)  
ATIVAN, LORAZEPAM  
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
ATOVAQUONE, ATOVAQUONE  
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE  
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE  
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE  
ATRALIN, TRETINOIN  
ATRIDOX, DOXYCYCLINE HYCLATE  
ATRIPLA, EFAVIRENZ  
ATROPEN, ATROPINE  
ATROPINE SULFATE, ATROPINE SULFATE  
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE  
ATROVENT, IPRATROPIUM BROMIDE



## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

ATROVENT HFA, IPRATROPIUM BROMIDE  
 AUBAGIO, TERIFLUNOMIDE  
 AUGMENTIN '125', AMOXICILLIN  
 AUGMENTIN '200', AMOXICILLIN  
 AUGMENTIN '250', AMOXICILLIN  
 AUGMENTIN '400', AMOXICILLIN  
 AUGMENTIN '500', AMOXICILLIN  
 AUGMENTIN '875', AMOXICILLIN  
 AUGMENTIN ES-600, AMOXICILLIN  
 AUGMENTIN XR, AMOXICILLIN  
 AURYXIA, FERRIC CITRATE  
 AUVI-Q, EPINEPHRINE  
 AVAGARD, ALCOHOL (OTC)  
 AVAGE, TAZAROTENE  
 AVALIDE, HYDROCHLOROTHIAZIDE  
 AVANDIA, ROSIGLITAZONE MALEATE  
 AVAPRO, IRBESARTAN  
 AVC, SULFANILAMIDE  
 AVEED, TESTOSTERONE UNDECANOATE  
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE  
 AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE  
 AVIANE-28, ETHINYL ESTRADIOL  
 AVITA, TRETINOIN  
 AVODART, DUTASTERIDE  
 AVYCAZ, AVIBACTAM SODIUM  
 AXERT, ALMOTRIPTAN MALATE  
 AXID, NIZATIDINE  
 AXID AR, NIZATIDINE (OTC)  
 AXIRON, TESTOSTERONE  
 AYGESTIN, NORETHINDRONE ACETATE  
 AZACITIDINE, AZACITIDINE  
 AZACTAM, AZTREONAM  
 AZACTAM IN PLASTIC CONTAINER, AZTREONAM  
 AZASAN, AZATHIOPRINE  
 AZASITE, AZITHROMYCIN  
 AZATHIOPRINE, AZATHIOPRINE  
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
 AZELEX, AZELAIC ACID  
 AZILECT, RASAGILINE MESYLATE  
 AZITHROMYCIN, AZITHROMYCIN  
 AZOPT, BRINZOLAMIDE  
 AZOR, AMLODIPINE BESYLATE  
 AZTREONAM, AZTREONAM  
 AZULFIDINE, SULFASALAZINE  
 AZULFIDINE EN-TABS, SULFASALAZINE

\*\* B \*\*

BACIIM, BACITRACIN  
 BACITRACIN, BACITRACIN  
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC  
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN  
 BACLOFEN, BACLOFEN  
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM  
 BACTRIM, SULFAMETHOXAZOLE  
 BACTRIM DS, SULFAMETHOXAZOLE  
 BACTROBAN, MUPIROCIN  
 BACTROBAN, MUPIROCIN CALCIUM  
 BAL, DIMERCAPROL  
 BALANCED SALT, CALCIUM CHLORIDE  
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
 BALZIVA-28, ETHINYL ESTRADIOL  
 BANZEL, RUFINAMIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* B \*\*

BARACLUDE, ENTECAVIR  
BASAGLAR, INSULIN GLARGINE  
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE  
BEKYREE, DESOGESTREL  
BELBUCA, BUPRENORPHINE HYDROCHLORIDE  
BELEODAQ, BELINOSTAT  
BELSOMRA, SUVOREXANT  
BELVIQ, LORCASERIN HYDROCHLORIDE  
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
BENDEKA, BENDAMUSTINE HYDROCHLORIDE  
BENICAR, OLMESARTAN MEDOXOMIL  
BENICAR HCT, HYDROCHLOROTHIAZIDE  
BENTYL, DICYCLOMINE HYDROCHLORIDE  
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE  
BENZAFLIN, BENZOYL PEROXIDE  
BENZAMYCIN, BENZOYL PEROXIDE  
BENZAMYCIN PAK, BENZOYL PEROXIDE  
BENZONATATE, BENZONATATE  
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
BEPREVE, BEPOTASTINE BESILATE  
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE  
BETA-VAL, BETAMETHASONE VALERATE  
BETADINE, POVIDONE-IODINE  
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE  
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE  
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
BETAPACE, SOTALOL HYDROCHLORIDE  
BETAPACE AF, SOTALOL HYDROCHLORIDE  
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
BETHKIS, TOBRAMYCIN  
BETIMOL, TIMOLOL  
BETOPTIC, BETAXOLOL HYDROCHLORIDE  
BETOPTIC S, BETAXOLOL HYDROCHLORIDE  
BEXAROTENE, BEXAROTENE  
BEYAZ, DROSPIRENONE  
BIAXIN, CLARITHROMYCIN  
BICALUTAMIDE, BICALUTAMIDE  
BICILLIN C-R, PENICILLIN G BENZATHINE  
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE  
BICILLIN L-A, PENICILLIN G BENZATHINE  
BICNU, CARMUSTINE  
BIDIL, HYDRALAZINE HYDROCHLORIDE  
BILTRICIDE, PRAZIQUANTEL  
BIMATOPROST, BIMATOPROST  
BINOSTO, ALENDRONATE SODIUM  
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE  
BIVALIRUDIN, BIVALIRUDIN  
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
BLEPH-10, SULFACETAMIDE SODIUM  
BLEPHAMIDE, PREDNISOLONE ACETATE  
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE  
BLISOVI 24 FE, ETHINYL ESTRADIOL  
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL  
BLISOVI FE 1/20, ETHINYL ESTRADIOL  
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE  
BONIVA, IBANDRONATE SODIUM  
BONTRIL PDM, PHENDIMETRAZINE TARTRATE  
BOSULIF, BOSUTINIB MONOHYDRATE  
BRAVELLE, UROFOLLITROPIN

## APPENDIX A - PRODUCT NAME INDEX

## \*\* B \*\*

BREO ELLIPTA, FLUTICASON FUROATE  
 BRETILIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETILIUM TOSYLATE  
 BREVIBLOC, ESMOLOL HYDROCHLORIDE  
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
 BREVICON 28-DAY, ETHINYL ESTRADIOL  
 BREVITAL SODIUM, METHOHEXITAL SODIUM  
 BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)  
 BRIDION, SUGAMMADEX SODIUM  
 BRIELLYN, ETHINYL ESTRADIOL  
 BRILINTA, TICAGRELOR  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 BRINTELLIX, VORTIOXETINE HYDROBROMIDE  
 BRISDELLE, PAROXETINE MESYLATE  
 BROMFED-DM, BROMPHENIRAMINE MALEATE  
 BROMFENAC SODIUM, BROMFENAC SODIUM  
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE  
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,  
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)  
 BROVANA, ARFORMOTEROL TARTRATE  
 BSS, CALCIUM CHLORIDE  
 BSS PLUS, CALCIUM CHLORIDE  
 BUDESONIDE, BUDESONIDE  
 BUMETANIDE, BUMETANIDE  
 BUMEX, BUMETANIDE  
 BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE  
 BUPHENYL, SODIUM PHENYLBUTYRATE  
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 BUSULFAN, BUSULFAN  
 BUSULFEX, BUSULFAN  
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN  
 BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN  
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN  
 BUTAPAP, ACETAMINOPHEN  
 BUTISOL SODIUM, BUTABARBITAL SODIUM  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE  
 BUTRANS, BUPRENORPHINE  
 BYDUREON, EXENATIDE SYNTHETIC  
 BYETTA, EXENATIDE SYNTHETIC  
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

## \*\* C \*\*

C-SOLVE-2, ERYTHROMYCIN  
 CABERGOLINE, CABERGOLINE  
 CADUET, AMLODIPINE BESYLATE  
 CAFKIT, CAFFEINE CITRATE  
 CAFERGOT, CAFFEINE  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CALAN, VERAPAMIL HYDROCHLORIDE  
 CALAN SR, VERAPAMIL HYDROCHLORIDE  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CALCITONIN-SALMON, CALCITONIN SALMON  
 CALCITRIOL, CALCITRIOL  
 CALCIUM ACETATE, CALCIUM ACETATE  
 CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)  
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 CALCIUM DISODIUM VERSEDATE, EDETATE CALCIUM DISODIUM  
 CALDOLOR, IBUPROFEN  
 CAMBIA, DICLOFENAC POTASSIUM  
 CAMILA, NORETHINDRONE  
 CAMPRAL, ACAMPROSATE CALCIUM  
 CAMPTOSAR, IRINOTECAN HYDROCHLORIDE  
 CANASA, MESALAMINE  
 CANCIDAS, CASPOFUNGIN ACETATE  
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL  
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
 CANTIL, MEPENZOLATE BROMIDE  
 CAPASTAT SULFATE, CAPREOMYCIN SULFATE  
 CAPECITABINE, CAPECITABINE  
 CAPEX, FLUOCINOLONE ACETONIDE  
 CAPITAL AND CODEINE, ACETAMINOPHEN  
 CAPITAL SOLEIL 15, AVOBENZONE (OTC)  
 CAPRELSA, VANDETANIB  
 CAPTOPRIL, CAPTOPRIL  
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL  
 CARAC, FLUOROURACIL  
 CARAFATE, SUCRALFATE  
 CARBAGLU, CARGLUMIC ACID  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CARBATROL, CARBAMAZEPINE  
 CARBIDOPA, CARBIDOPA  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA  
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE  
 CARBOPLATIN, CARBOPLATIN  
 CARDENE, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82  
 CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT  
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 CARDIZEM, DILTIAZEM HYDROCHLORIDE  
 CARDIZEM CD, DILTIAZEM HYDROCHLORIDE  
 CARDIZEM LA, DILTIAZEM HYDROCHLORIDE  
 CARDURA, DOXAZOSIN MESYLATE  
 CARDURA XL, DOXAZOSIN MESYLATE  
 CARISOPRODOL, CARISOPRODOL  
 CARISOPRODOL AND ASPIRIN, ASPIRIN  
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN  
 CARNITOR, LEVOCARNITINE  
 CARNITOR SF, LEVOCARNITINE  
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE  
 CARTIA XT, DILTIAZEM HYDROCHLORIDE  
 CARVEDILOL, CARVEDILOL  
 CASODEX, BICALUTAMIDE  
 CATAFLAM, DICLOFENAC POTASSIUM  
 CATAPRES, CLONIDINE HYDROCHLORIDE  
 CATAPRES-TTS-1, CLONIDINE  
 CATAPRES-TTS-2, CLONIDINE  
 CATAPRES-TTS-3, CLONIDINE  
 CAVERJECT, ALPROSTADIL  
 CAVERJECT IMPULSE, ALPROSTADIL  
 CAYSTON, AZTREONAM

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CEDAX, CEFTIBUTEN DIHYDRATE  
 CEFACLOR, CEFACLOR  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM  
 CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFDINIR, CEFDINIR  
 CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE  
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE  
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE  
 CEFIXIME, CEFIXIME  
 CEFOTAXIME, CEFOTAXIME SODIUM  
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM  
 CEFOTETAN, CEFOTETAN DISODIUM  
 CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM  
 CEFOXITIN, CEFOXITIN SODIUM  
 CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM  
 CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CEFPROZIL, CEFPROZIL  
 CEFTAZIDIME, CEFTAZIDIME  
 CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME  
 CEFTIN, CEFUROXIME AXETIL  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM  
 CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM  
 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEFUROXIME SODIUM, CEFUROXIME SODIUM  
 CELEBREX, CELECOXIB  
 CELECOXIB, CELECOXIB  
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE  
 CELEXA, CITALOPRAM HYDROBROMIDE  
 CELLCEPT, MYCOPHENOLATE MOFETIL  
 CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE  
 CELONTIN, METHSUXIMIDE  
 CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A  
 CENTANY, MUPIROCIN  
 CEPHALEXIN, CEPHALEXIN  
 CERDELGA, ELIGLUSTAT TARTRATE  
 CEREBYX, FOSPHENYTOIN SODIUM  
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT  
 CEREZYME, IMIGLUCERASE  
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE  
 CERVIDIL, DINOPROSTONE  
 CESAMET, NABILONE  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE  
 CETROTIDE, CETRORELIX  
 CEVIMELINE, CEVIMELINE HYDROCHLORIDE  
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE  
 CHANTIX, VARENICLINE TARTRATE  
 CHEMET, SUCCIMER  
 CHENODIOL, CHENODIOL  
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
 CHILDREN'S ADVIL, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)  
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S CLARITIN, LORATADINE (OTC)  
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)  
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)  
CHILDREN'S MOTRIN, IBUPROFEN (OTC)  
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)  
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN  
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)  
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE  
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE  
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE  
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
CHLOROTHIAZIDE, CHLOROTHIAZIDE  
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM  
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)  
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE  
CHLORPROPAMIDE, CHLORPROPAMIDE  
CHLORTHALIDONE, CHLORTHALIDONE  
CHLORZOAZONE, CHLORZOAZONE  
CHOLAC, LACTULOSE  
CHOLBAM, CHOLIC ACID  
CHOLEDYL SA, OXTRIPHYLLINE  
CHOLESTYRAMINE, CHOLESTYRAMINE  
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE  
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT  
CHOLINE C-11, CHOLINE C-11  
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE  
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE  
CIALIS, TADALAFIL  
CICLOPIROX, CICLOPIROX  
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)  
CIDOFOVIR, CIDOFOVIR  
CILOSTAZOL, CILOSTAZOL  
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE  
CIMETIDINE, CIMETIDINE (OTC)  
CIMETIDINE, CIMETIDINE  
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
CIPRO, CIPROFLOXACIN  
CIPRO, CIPROFLOXACIN HYDROCHLORIDE  
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE  
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
CIPRODEX, CIPROFLOXACIN  
CIPROFLOXACIN, CIPROFLOXACIN  
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT  
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE  
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CISPLATIN, CISPLATIN  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE  
 CLADRIBINE, CLADRIBINE  
 CLAFORAN, CEFOTAXIME SODIUM  
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM  
 CLARAVIS, ISOTRETINOIN  
 CLARINEX, DESLORATADINE  
 CLARINEX D 24 HOUR, DESLORATADINE  
 CLARINEX-D 12 HOUR, DESLORATADINE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLARITIN, LORATADINE (OTC)  
 CLARITIN HIVES RELIEF, LORATADINE (OTC)  
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)  
 CLARITIN REDITABS, LORATADINE (OTC)  
 CLARITIN-D, LORATADINE (OTC)  
 CLARITIN-D 24 HOUR, LORATADINE (OTC)  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE  
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLEOCIN, CLINDAMYCIN PHOSPHATE  
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 CLEOCIN T, CLINDAMYCIN PHOSPHATE  
 CLEVIPREX, CLEVIDIPINE  
 CLIMARA, ESTRADIOL  
 CLIMARA PRO, ESTRADIOL  
 CLINDA-DERM, CLINDAMYCIN PHOSPHATE  
 CLINDAGEL, CLINDAMYCIN PHOSPHATE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
 CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE  
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE  
 CLINDESSE, CLINDAMYCIN PHOSPHATE  
 CLINDETS, CLINDAMYCIN PHOSPHATE  
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINOLIPID 20%, OLIVE OIL

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE  
CLOBEX, CLOBETASOL PROPIONATE  
CLODERM, CLOCORTOLONE PIVALATE  
CLOLAR, CLOFARABINE  
CLOMID, CLOMIPHENE CITRATE  
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE  
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
CLONAZEPAM, CLONAZEPAM  
CLONIDINE, CLONIDINE  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM  
CLORPRES, CHLOROTHALIDONE  
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)  
CLOTRIMAZOLE, CLOTRIMAZOLE  
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
CLOZAPINE, CLOZAPINE  
CLOZARIL, CLOZAPINE  
COARTEM, ARTEMETHER  
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE  
CODEINE SULFATE, CODEINE SULFATE  
COGENTIN, BENZTROPINE MESYLATE  
COL-PROBENECID, COLCHICINE  
COLAZAL, BALSALAZIDE DISODIUM  
COLCRYS, COLCHICINE  
COLESTID, COLESTIPOL HYDROCHLORIDE  
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE  
COLGATE TOTAL, SODIUM FLUORIDE (OTC)  
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
COLOCORT, HYDROCORTISONE  
COLY-MYCIN M, COLISTIMETHATE SODIUM  
COLY-MYCIN S, COLISTIN SULFATE  
COLYTE, POLYETHYLENE GLYCOL 3350  
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
COMBIGAN, BRIMONIDINE TARTRATE  
COMBIPATCH, ESTRADIOL  
COMBIVENT RESPIMAT, ALBUTEROL SULFATE  
COMBIVIR, LAMIVUDINE  
COMETRIQ, CABOZANTINIB S-MALATE  
COMMIT, NICOTINE POLACRILEX (OTC)  
COMPLERA, EMTRICITABINE  
COMPRO, PROCHLORPERAZINE  
COMTAN, ENTACAPONE  
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE  
CONDYLOX, PODOFILOX  
CONRAY, IOTHALAMATE MEGLUMINE  
CONRAY 30, IOTHALAMATE MEGLUMINE  
CONRAY 43, IOTHALAMATE MEGLUMINE  
CONSTILAC, LACTULOSE  
CONSTULOSE, LACTULOSE  
CONTRAVE, BUPROPION HYDROCHLORIDE  
CONZIP, TRAMADOL HYDROCHLORIDE  
COPAXONE, GLATIRAMER ACETATE  
COPEGUS, RIBAVIRIN  
CORDARONE, AMIODARONE HYDROCHLORIDE  
CORDRAN, FLURANDRENOLIDE  
CORDRAN SP, FLURANDRENOLIDE  
COREG, CARVEDILOL  
COREG CR, CARVEDILOL PHOSPHATE  
CORGARD, NADOLOL  
CORLANOR, IVABRADINE HYDROCHLORIDE  
CORLOPAM, FENOLDOPAM MESYLATE  
CORMAX, CLOBETASOL PROPIONATE



## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CORTEF, HYDROCORTISONE  
 CORTENEMA, HYDROCORTISONE  
 CORTIFOAM, HYDROCORTISONE ACETATE  
 CORTISONE ACETATE, CORTISONE ACETATE  
 CORTISPORIN, BACITRACIN ZINC  
 CORTISPORIN, HYDROCORTISONE  
 CORTISPORIN, HYDROCORTISONE ACETATE  
 CORTROSYN, COSYNTROPIN  
 CORVERT, IBUTILIDE FUMARATE  
 CORZIDE, BENDROFLUMETHIAZIDE  
 COSMEGEN, DACTINOMYCIN  
 COSOPT, DORZOLAMIDE HYDROCHLORIDE  
 COSOPT PF, DORZOLAMIDE HYDROCHLORIDE  
 COSYNTROPIN, COSYNTROPIN  
 COTELLIC, COBIMETINIB FUMARATE  
 COUMADIN, WARFARIN SODIUM  
 COVERA-HS, VERAPAMIL HYDROCHLORIDE  
 COZAAR, LOSARTAN POTASSIUM  
 CREON, PANCRELIPASE (AMYLASE  
 CRESEMBA, ISAVUCONAZONIUM SULFATE  
 CRESTOR, ROSUVASTATIN CALCIUM  
 CRINONE, PROGESTERONE  
 CRIXIVAN, INDINAVIR SULFATE  
 CROLOM, CROMOLYN SODIUM  
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 CROTAN, CROTAMITON  
 CRYSELLE, ETHINYL ESTRADIOL  
 CUBICIN, DAPTOMYCIN  
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE  
 CUPRIMINE, PENICILLAMINE  
 CUROSURF, PORACTANT ALFA  
 CUTIVATE, FLUTICASONE PROPIONATE  
 CUVPOSA, GLYCOPYRROLATE  
 CYANOCOBALAMIN, CYANOCOBALAMIN  
 CYANOKIT, HYDROXOCOBALAMIN  
 CYCLAFEM 0.5/35, ETHINYL ESTRADIOL  
 CYCLAFEM 1/35, ETHINYL ESTRADIOL  
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL  
 CYCLESSA, DESOGESTREL  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE  
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE  
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE  
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE  
 CYCLOSET, BROMOCRIPTINE MESYLATE  
 CYCLOSPORINE, CYCLOSPORINE  
 CYKLOKAPRON, TRANEXAMIC ACID  
 CYMBALTA, DULOXETINE HYDROCHLORIDE  
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
 CYSTADANE, BETAINE HYDROCHLORIDE  
 CYSTAGON, CYSTEAMINE BITARTRATE  
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE  
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE  
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE  
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE  
 CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE  
 CYTARABINE, CYTARABINE  
 CYTOMEL, LIOTHYRONINE SODIUM  
 CYTOSAR-U, CYTARABINE  
 CYTOTEC, MISOPROSTOL  
 CYTOVENE, GANCICLOVIR SODIUM  
 CYTOXAN (LYOPHILIZED), CYCLOPHOSPHAMIDE

\*\* D \*\*

## APPENDIX A - PRODUCT NAME INDEX

\*\* D \*\*

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE  
DACARBAZINE, DACARBAZINE  
DACOGEN, DECITABINE  
DACTINOMYCIN, DACTINOMYCIN  
DAKLINZA, DACLATASVIR DIHYDROCHLORIDE  
DALIRESP, ROFLUMILAST  
DALVANCE, DALBAVANCIN HYDROCHLORIDE  
DANAZOL, DANAZOL  
DANTRIUM, DANTROLENE SODIUM  
DANTROLENE SODIUM, DANTROLENE SODIUM  
DAPSONE, DAPSONE  
DAPTOMYCIN, DAPTOMYCIN  
DARAPRIM, PYRIMETHAMINE  
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE  
DASETTA 1/35, ETHINYL ESTRADIOL  
DASETTA 7/7/7, ETHINYL ESTRADIOL  
DATSCAN, IOFLUPANE I-123  
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE  
DAUNOXOME, DAUNORUBICIN CITRATE  
DAYPRO, OXAPROZIN  
DAYSEE, ETHINYL ESTRADIOL  
DAYTRANA, METHYLPHENIDATE  
DDAVP, DESMOPRESSIN ACETATE  
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
DECITABINE, DECITABINE  
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE  
DEFINITY, PERFLUTREN  
DELATESTRYL, TESTOSTERONE ENANTHATE  
DELESTROGEN, ESTRADIOL VALERATE  
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)  
DELZICOL, MESALAMINE  
DEMADEX, TORSEMIDE  
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
DEMEROL, MEPERIDINE HYDROCHLORIDE  
DEMSE, METYROSINE  
DENAVID, PENCICLOVIR SODIUM  
DENDRID, IDOXURIDINE  
DEPACON, VALPROATE SODIUM  
DEPAKENE, VALPROIC ACID  
DEPAKOTE, DIVALPROEX SODIUM  
DEPAKOTE ER, DIVALPROEX SODIUM  
DEPEN, PENICILLAMINE  
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE  
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE  
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE  
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE  
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE  
DEPOCYT, CYTARABINE  
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE  
DERMABET, BETAMETHASONE VALERATE  
DERMATOP, PREDNICARBATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* D \*\*

DERMATOP E EMOLLIENT, PREDNICARBATE  
DERMOTIC, FLUOCINOLONE ACETONIDE  
DESFERAL, DEFEROXAMINE MESYLATE  
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE  
DESLORATADINE, DESLORATADINE  
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE  
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
DESOGEN, DESOGESTREL  
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
DESONATE, DESONIDE  
DESONIDE, DESONIDE  
DESOWEN, DESONIDE  
DESOXIMETASONE, DESOXIMETASONE  
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE  
DESVENLAFAXINE, DESVENLAFAXINE  
DESVENLAFAXINE, DESVENLAFAXINE FUMARATE  
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE  
DETROL, TOLTERODINE TARTRATE  
DETROL LA, TOLTERODINE TARTRATE  
DEXAMETHASONE, DEXAMETHASONE  
DEXAMETHASONE INTENSOL, DEXAMETHASONE  
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
DEXASPORIN, DEXAMETHASONE  
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE (OTC)  
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE  
DEXEDRINE, DEXTROAMPHETAMINE SULFATE  
DEXFERRUM, IRON DEXTRAN  
DEXILANT, DEXLANSOPRAZOLE  
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
DXTROMETHORPHAN POLISTIREX, DXTROMETHORPHAN POLISTIREX (OTC)  
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 25%, DEXTROSE  
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* D \*\*

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,  
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,  
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,  
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,  
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,  
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,  
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,  
DEXTROSE 50% , DEXTROSE  
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
DIABETA, GLYBURIDE  
DIABINESE, CHLORPROPAMIDE  
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIAMOX, ACETAZOLAMIDE  
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DIASTAT, DIAZEPAM  
DIASTAT ACUDIAL, DIAZEPAM  
DIAZEPAM, DIAZEPAM  
DIAZEPAM INTENSOL, DIAZEPAM  
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE  
DICLEGIS, DOXYLAMINE SUCCINATE  
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
DICLOFENAC SODIUM , DICLOFENAC SODIUM  
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM  
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM  
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE  
DIDANOSINE, DIDANOSINE

## APPENDIX A - PRODUCT NAME INDEX

\*\* D \*\*

DIDRONEL, ETIDRONATE DISODIUM  
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE  
DIFFERIN, ADAPALENE  
DIFICID, FIDAXOMICIN  
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE  
DIFLUCAN, FLUCONAZOLE  
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
DIFLUNISAL, DIFLUNISAL  
DIGOXIN, DIGOXIN  
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE  
DILANTIN, PHENYTOIN  
DILANTIN, PHENYTOIN SODIUM  
DILANTIN-125, PHENYTOIN  
DILATRATE-SR, ISOSORBIDE DINITRATE  
DILAUDID, HYDROMORPHONE HYDROCHLORIDE  
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE  
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
DILTZAC, DILTIAZEM HYDROCHLORIDE  
DIMENHYDRINATE, DIMENHYDRINATE  
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE  
DIOVAN, VALSARTAN  
DIOVAN HCT, HYDROCHLOROTHIAZIDE  
DIPENTUM, OLSALAZINE SODIUM  
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
DIPRIVAN, PROPOFOL  
DIPROLENE, BETAMETHASONE DIPROPIONATE  
DIPROLENE AF, BETAMETHASONE DIPROPIONATE  
DIPYRIDAMOLE, DIPYRIDAMOLE  
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE  
DISULFIRAM, DISULFIRAM  
DISULFIRAM , DISULFIRAM  
DITROPAN XL, OXYBUTYNIN CHLORIDE  
DIURIL, CHLOROTHIAZIDE  
DIURIL, CHLOROTHIAZIDE SODIUM  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
DIVIGEL, ESTRADIOL  
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE  
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
DOCEFREZ, DOCETAXEL  
DOCETAXEL, DOCETAXEL  
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE  
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE  
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
DOPRAM, DOXAPRAM HYDROCHLORIDE  
DORIBAX, DORIPENEM  
DORYX, DOXYCYCLINE HYCLATE  
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
DOTAREM, GADOTERATE MEGLUMINE  
DOVONEX, CALCIPOTRIENE  
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE  
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
DOXERCALCIFEROL, DOXERCALCIFEROL  
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE  
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE  
DOXTERIC, DOXYCYCLINE HYCLATE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* D \*\*

DOXY 100, DOXYCYCLINE HYCLATE  
 DOXY 200, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 DOXYCYCLINE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)  
 DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE  
 DRISDOL, ERGOCALCIFEROL  
 DRONABINOL, DRONABINOL  
 DROPERIDOL, DROPERIDOL  
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
 DROXIA, HYDROXYUREA  
 DTIC-DOME, DACARBAZINE  
 DTPA, TECHNETIUM TC-99M PENTETATE KIT  
 DUAC, BENZOYL PEROXIDE  
 DUAVEE, BAZEDOXIFENE ACETATE  
 DUETACT, GLIMEPIRIDE  
 DUEXIS, FAMOTIDINE  
 DULERA, FORMOTEROL FUMARATE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 DUODOTE, ATROPINE  
 DUONEB, ALBUTEROL SULFATE  
 DUOPA, CARBIDOPA  
 DURACLON, CLONIDINE HYDROCHLORIDE  
 DURAGESIC-100, FENTANYL  
 DURAGESIC-12, FENTANYL  
 DURAGESIC-25, FENTANYL  
 DURAGESIC-50, FENTANYL  
 DURAGESIC-75, FENTANYL  
 DURAMORPH PF, MORPHINE SULFATE  
 DURAPREP, IODINE POVACRYLEX (OTC)  
 DUREZOL, DIFLUPREDNATE  
 DURLAZA, ASPIRIN  
 DUTASTERIDE, DUTASTERIDE  
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE  
 DUTOPROL, HYDROCHLOROTHIAZIDE  
 DUVOID, BETHANECHOL CHLORIDE  
 DYANAVAL XR, AMPHETAMINE  
 DYAZIDE, HYDROCHLOROTHIAZIDE  
 DYLOJECT, DICLOFENAC SODIUM  
 DYMISTA, AZELASTINE HYDROCHLORIDE  
 DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)  
 DYNACIN, MINOCYCLINE HYDROCHLORIDE  
 DYRENIUM, TRIAMTERENE

## \*\* E \*\*

E-Z SCRUB 201, POVIDONE-IODINE (OTC)  
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)  
 E.E.S., ERYTHROMYCIN ETHYLSUCCINATE  
 E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE  
 EC-NAPROSYN, NAPROXEN  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 ECOZA, ECONAZOLE NITRATE  
 EDARBI, AZILSARTAN KAMEDOXOMIL  
 EDARBYCLOR, AZILSARTAN KAMEDOXOMIL  
 EDECRIN, ETHACRYNATE SODIUM  
 EDECRIN, ETHACRYNIC ACID  
 EDEX, ALPROSTADIL  
 EDLUAR, ZOLPIDEM TARTRATE  
 EDURANT, RILPIVIRINE HYDROCHLORIDE  
 EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE  
 EFFIENT, PRASUGREL HYDROCHLORIDE  
 EFUDEX, FLUOROURACIL  
 EGRIFTA, TESAMORELIN ACETATE  
 ELDEPRYL, SELEGILINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* E \*\*

ELELYSO, TALIGLUCERASE ALFA  
ELESTAT, EPINASTINE HYDROCHLORIDE  
ELESTRIN, ESTRADIOL  
ELIDEL, PIMECROLIMUS  
ELIFEMME, ETHINYL ESTRADIOL  
ELIGARD, LEUPROLIDE ACETATE  
ELIMITE, PERMETHRIN  
ELINEST, ETHINYL ESTRADIOL  
ELIPHOS, CALCIUM ACETATE  
ELIQUIS, APIXABAN  
ELIXOPHYLLIN, THEOPHYLLINE  
ELLA, ULIPRISTAL ACETATE  
ELLENCEN, EPIRUBICIN HYDROCHLORIDE  
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE  
ELMIRON, PENTOSAN POLYSULFATE SODIUM  
ELOCON, MOMETASONE FUROATE  
ELOXATIN, OXALIPLATIN  
EMADINE, EMEDASTINE DIFUMARATE  
EMBEDA, MORPHINE SULFATE  
EMBELINE, CLOBETASOL PROPIONATE  
EMBELINE E, CLOBETASOL PROPIONATE  
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM  
EMEND, APREPITANT  
EMEND, FOSAPREPITANT DIMEGLUMINE  
EMLA, LIDOCAINE  
EMOQUETTE, DESOGESTREL  
EMSAM, SELEGILINE  
EMTRIVA, EMTRICITABINE  
ENABLEX, DARIFENACIN HYDROBROMIDE  
ENALAPRIL MALEATE, ENALAPRIL MALEATE  
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
ENALAPRILAT, ENALAPRILAT  
ENDOMETRIN, PROGESTERONE  
ENDOSOL EXTRA, CALCIUM CHLORIDE  
ENFLURANE, ENFLURANE  
ENJUWIA, ESTROGENS, CONJUGATED SYNTHETIC B  
ENLON, EDROPHONIUM CHLORIDE  
ENLON-PLUS, ATROPINE SULFATE  
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM  
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
ENPRESSE-28, ETHINYL ESTRADIOL  
ENSKYCE, DESOGESTREL  
ENSTILAR, BETAMETHASONE DIPROPIONATE  
ENTACAPONE, ENTACAPONE  
ENTECAVIR, ENTECAVIR  
ENTEREG, ALVIMOPAN  
ENTOCORT EC, BUDESONIDE  
ENTRESTO, SACUBITRIL  
ENULOSE, LACTULOSE  
ENVARUSUS XR, TACROLIMUS  
EOVIST, GADOXETATE DISODIUM  
EPANED KIT, ENALAPRIL MALEATE  
EPANOVA, OMEGA-3-CARBOXYLIC ACIDS  
EPIDUO, ADAPALENE  
EPIDUO FORTE, ADAPALENE  
EPIFOAM, HYDROCORTISONE ACETATE  
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
EPINEPHRINE, EPINEPHRINE HYDROCHLORIDE  
EPIPEN, EPINEPHRINE  
EPIPEN JR., EPINEPHRINE  
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
EPITOL, CARBAMAZEPINE  
EPIVIR, LAMIVUDINE  
EPIVIR-HBV, LAMIVUDINE  
EPLERENONE, EPLERENONE

## APPENDIX A - PRODUCT NAME INDEX

\*\* E \*\*

EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM  
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE  
EPTIFIBATIDE, EPTIFIBATIDE  
EPZICOM, ABACAVIR SULFATE  
EQUETRO, CARBAMAZEPINE  
ERAXIS, ANIDULAFUNGIN  
ERGOCALCIFEROL, ERGOCALCIFEROL  
ERGOLOID MESYLATES, ERGOLOID MESYLATES  
ERGOMAR, ERGOTAMINE TARTRATE  
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE  
ERIVEDGE, VISMODEGIB  
ERRIN, NORETHINDRONE  
ERTACZO, SERTACONAZOLE NITRATE  
ERY-TAB, ERYTHROMYCIN  
ERYC, ERYTHROMYCIN  
ERYGEL, ERYTHROMYCIN  
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE  
ERYTHRO-STATIN, ERYTHROMYCIN  
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE  
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE  
ERYTHROMYCIN, ERYTHROMYCIN  
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE  
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE  
ESBRIET, PIRFENIDONE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM  
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM  
ESTARYLLA, ETHINYL ESTRADIOL  
ESTAZOLAM, ESTAZOLAM  
ESTRACE, ESTRADIOL  
ESTRADERM, ESTRADIOL  
ESTRADIOL, ESTRADIOL  
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL  
ESTRADIOL AND NORGESTIMATE, ESTRADIOL  
ESTRADIOL VALERATE, ESTRADIOL VALERATE  
ESTRASORB, ESTRADIOL HEMIHYDRATE  
ESTRING, ESTRADIOL  
ESTROGEL, ESTRADIOL  
ESTROPIPATE, ESTROPIPATE  
ESTROSTEP FE, ETHINYL ESTRADIOL  
ESZOPICLONE, ESZOPICLONE  
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM  
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE  
ETHAMOLIN, ETHANOLAMINE OLEATE  
ETHOSUXIMIDE, ETHOSUXIMIDE  
ETHRANE, ENFLURANE  
ETHYOL, AMIFOSTINE  
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM  
ETODOLAC, ETODOLAC  
ETOMIDATE, ETOMIDATE  
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE  
ETOPOSIDE, ETOPOSIDE  
EURAX, CROTAMITON  
EVAMIST, ESTRADIOL  
EVEKEO, AMPHETAMINE SULFATE  
EVISTA, RALOXIFENE HYDROCHLORIDE  
EVOCLIN, CLINDAMYCIN PHOSPHATE  
EVOTAZ, ATAZANAVIR SULFATE  
EVOXAC, CEVIMELINE HYDROCHLORIDE  
EVZIO, NALOXONE HYDROCHLORIDE  
EXALGO, HYDROMORPHONE HYDROCHLORIDE  
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)



## APPENDIX A - PRODUCT NAME INDEX

## \*\* E \*\*

EXELDERM, SULCONAZOLE NITRATE  
EXELON, RIVASTIGMINE  
EXELON, RIVASTIGMINE TARTRATE  
EXEMESTANE, EXEMESTANE  
EXFORGE, AMLODIPINE BESYLATE  
EXFORGE HCT, AMLODIPINE BESYLATE  
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)  
EXJADE, DEFERASIROX  
EXPAREL, BUPIVACAINE  
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
EXTINA, KETOCONAZOLE  
EXTRANEAL, ICODEXTRIN

## \*\* F \*\*

FABIOR, TAZAROTENE  
FACTIVE, GEMIFLOXACIN MESYLATE  
FALLBACK SOLO, LEVONORGESTREL (OTC)  
FALMINA, ETHINYL ESTRADIOL  
FAMCICLOVIR, FAMCICLOVIR  
FAMOTIDINE, FAMOTIDINE (OTC)  
FAMOTIDINE, FAMOTIDINE  
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE  
FAMVIR, FAMCICLOVIR  
FANAPT, ILOPERIDONE  
FARESTON, TOREMIFENE CITRATE  
FARXIGA, DAPAGLIFLOZIN PROPANEDIOL  
FARYDAK, PANOBINOSTAT LACTATE  
FASLODEX, FULVESTRANT  
FAZACLO ODT, CLOZAPINE  
FELBAMATE, FELBAMATE  
FELBATOL, FELBAMATE  
FELDENE, PIROXICAM  
FELODIPINE, FELODIPINE  
FEMARA, LETROZOLE  
FEMCON FE, ETHINYL ESTRADIOL  
FEMHRT, ETHINYL ESTRADIOL  
FEMRING, ESTRADIOL ACETATE  
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)  
FEMTRACE, ESTRADIOL ACETATE  
FENOFIBRATE, FENOFIBRATE  
FENOFIBRATE (MICRONIZED), FENOFIBRATE  
FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
FENOGLIDE, FENOFIBRATE  
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE  
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM  
FENTANYL CITRATE, FENTANYL CITRATE  
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE  
FENTANYL-100, FENTANYL  
FENTANYL-12, FENTANYL  
FENTANYL-25, FENTANYL  
FENTANYL-37, FENTANYL  
FENTANYL-50, FENTANYL  
FENTANYL-62, FENTANYL  
FENTANYL-75, FENTANYL  
FENTANYL-87, FENTANYL  
FENTORA, FENTANYL CITRATE  
FERAHEME, FERUMOXYTOL  
FERRIPROX, DEFERIPRONE  
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX  
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE  
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE  
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* F \*\*

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
FIBRICOR, FENOFIBRIC ACID  
FINACEA, AZELAIC ACID  
FINACEA, AZELAIC ACID  
FINASTERIDE, FINASTERIDE  
FIORICET W/ CODEINE, ACETAMINOPHEN  
FIORINAL, ASPIRIN  
FIORINAL W/CODEINE, ASPIRIN  
FIRAZYR, ICATIBANT ACETATE  
FIRMAGON, DEGARELIX ACETATE  
FLAGYL, METRONIDAZOLE  
FLAGYL ER, METRONIDAZOLE  
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE  
FLAREX, FLUOROMETHOLONE ACETATE  
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE  
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE  
FLECAINIDE ACETATE, FLECAINIDE ACETATE  
FLECTOR, DICLOFENAC EPOLAMINE  
FLOLAN, EPOPROSTENOL SODIUM  
FLOMAX, TAMSULOSIN HYDROCHLORIDE  
FLONASE, FLUTICASONE PROPIONATE  
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)  
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE  
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE  
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE  
FLOVENT HFA, FLUTICASONE PROPIONATE  
FLOWTUSS, GUAIFENESIN  
FLOXIN OTIC, OFLOXACIN  
FLOXURIDINE, FLOXURIDINE  
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
FLUCONAZOLE, FLUCONAZOLE  
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
FLUCYTOSINE, FLUCYTOSINE  
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE  
FLUMADINE, RIMANTADINE HYDROCHLORIDE  
FLUMAZENIL, FLUMAZENIL  
FLUNISOLIDE, FLUNISOLIDE  
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
FLUOCINONIDE, FLUOCINONIDE  
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE  
FLUORESCITE, FLUORESCIN SODIUM  
FLUOROPLEX, FLUOROURACIL  
FLUOROURACIL, FLUOROURACIL  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLUOXYMESTERONE, FLUOXYMESTERONE  
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE  
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE  
FLURBIPROFEN, FLURBIPROFEN  
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM  
FLUTAMIDE, FLUTAMIDE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM  
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
FML, FLUOROMETHOLONE  
FML FORTE, FLUOROMETHOLONE  
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)  
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE  
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE  
FOLIC ACID, FOLIC ACID

## APPENDIX A - PRODUCT NAME INDEX

## \*\* F \*\*

FOLLISTIM AQ, FOLLITROPIN ALFA/BETA  
 FOLOTYN, PRALATREXATE  
 FOMEPIZOLE, FOMEPIZOLE  
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM  
 FORADIL, FORMOTEROL FUMARATE  
 FORANE, ISOFLURANE  
 FORFIVO XL, BUPROPION HYDROCHLORIDE  
 FORTAMET, METFORMIN HYDROCHLORIDE  
 FORTAZ, CEFTAZIDIME  
 FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM  
 FORTEO, TERIPARATIDE RECOMBINANT HUMAN  
 FORTESTA, TESTOSTERONE  
 FORTICAL, CALCITONIN SALMON RECOMBINANT  
 FOSAMAX, ALENDRONATE SODIUM  
 FOSAMAX PLUS D, ALENDRONATE SODIUM  
 FOSCARNET SODIUM, FOSCARNET SODIUM  
 FOSCAVIR, FOSCARNET SODIUM  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 FOSRENOL, LANTHANUM CARBONATE  
 FRAGMIN, DALTEPARIN SODIUM  
 FREAMINE HBC 6.9%, AMINO ACIDS  
 FREAMINE III 10%, AMINO ACIDS  
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS  
 FREAMINE III 8.5%, AMINO ACIDS  
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 FROVA, FROVATRIPTAN SUCCINATE  
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE  
 FULYZAQ, CROFELEMER  
 FURADANTIN, NITROFURANTOIN  
 FUROSEMIDE, FUROSEMIDE  
 FUSILEV, LEVOLEUCOVORIN CALCIUM  
 FUZEON, ENFUVIRTIDE  
 FYAVOLV, ETHINYL ESTRADIOL  
 FYCOMPA, PERAMPANEL

## \*\* G \*\*

GABAPENTIN, GABAPENTIN  
 GABITRIL, TIAGABINE HYDROCHLORIDE  
 GABLOFEN, BACLOFEN  
 GADAVIST, GADOBUTROL  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67  
 GALZIN, ZINC ACETATE  
 GANCICLOVIR, GANCICLOVIR SODIUM  
 GANIRELIX ACETATE, GANIRELIX ACETATE  
 GASTROCROM, CROMOLYN SODIUM  
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE  
 GATIFLOXACIN, GATIFLOXACIN  
 GATTEX KIT, TEDUGLUTIDE RECOMBINANT  
 GAVISCON, ALUMINUM HYDROXIDE (OTC)  
 GELNIQUE, OXYBUTYNIN CHLORIDE  
 GELNIQUE 3%, OXYBUTYNIN  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GEMFIBROZIL, GEMFIBROZIL  
 GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE  
 GEMZAR, GEMCITABINE HYDROCHLORIDE  
 GEN-XENE, CLORAZEPATE DIPOTASSIUM  
 GENERLAC, LACTULOSE  
 GENGRAF, CYCLOSPORINE  
 GENOPTIC, GENTAMICIN SULFATE  
 GENOTROPIN, SOMATROPIN RECOMBINANT  
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT  
 GENTAK, GENTAMICIN SULFATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* G \*\*

GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE  
 GENVOYA, COBICISTAT  
 GEODON, ZIPRASIDONE HYDROCHLORIDE  
 GEODON, ZIPRASIDONE MESYLATE  
 GIAZO, BALSALAZIDE DISODIUM  
 GILDAGIA, ETHINYL ESTRADIOL  
 GILDESS 1.5/30, ETHINYL ESTRADIOL  
 GILDESS 1/20, ETHINYL ESTRADIOL  
 GILDESS 24 FE, ETHINYL ESTRADIOL  
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL  
 GILDESS FE 1/20, ETHINYL ESTRADIOL  
 GILENYA, FINGOLIMOD  
 GILOTRIF, AFATINIB DIMALEATE  
 GLATOPA, GLATIRAMER ACETATE  
 GLEEVEC, IMATINIB MESYLATE  
 GLEOSTINE, LOMUSTINE  
 GLIADEL, CARMUSTINE  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GLIPIZIDE, GLIPIZIDE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GLOFIL-125, IOTHALAMATE SODIUM I-125  
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT  
 GLUCAGON, GLUCAGON HYDROCHLORIDE  
 GLUCAGON, GLUCAGON RECOMBINANT  
 GLUCOPHAGE, METFORMIN HYDROCHLORIDE  
 GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE  
 GLUCOTROL, GLIPIZIDE  
 GLUCOTROL XL, GLIPIZIDE  
 GLUCOVANCE, GLYBURIDE  
 GLUMETZA, METFORMIN HYDROCHLORIDE  
 GLYBURIDE, GLYBURIDE  
 GLYBURIDE (MICRONIZED), GLYBURIDE  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)  
 GLYCOLAX, POLYETHYLENE GLYCOL 3350  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 GLYDO, LIDOCAINE HYDROCHLORIDE  
 GLYNASE, GLYBURIDE  
 GLYSET, MIGLITOL  
 GLYXAMBI, EMPAGLIFLOZIN  
 GOLYTELY, POLYETHYLENE GLYCOL 3350  
 GONAL-F, FOLLITROPIN ALFA/BETA  
 GONAL-F RFF, FOLLITROPIN ALFA/BETA  
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA  
 GRALISE, GABAPENTIN  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE  
 GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZED  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZED  
 GRISEOFULVIN, ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED  
 GRISEOFULVIN, ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED  
 GUAIFENESIN, GUAIFENESIN (OTC)  
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)  
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)  
 GUANABENZ ACETATE, GUANABENZ ACETATE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE  
 GYNAZOLE-1, BUTOCONAZOLE NITRATE  
 GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* H \*\*

H.P. ACTHAR GEL, CORTICOTROPIN  
 HABITROL, NICOTINE (OTC)  
 HALAVEN, ERIBULIN MESYLATE  
 HALCION, TRIAZOLAM  
 HALDOL, HALOPERIDOL DECANOATE  
 HALDOL, HALOPERIDOL LACTATE  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 HALOG, HALCINONIDE  
 HALOPERIDOL, HALOPERIDOL  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
 HARVONI, LEDIPASVIR  
 HEATHER, NORETHINDRONE  
 HECTOROL, DOXERCALCIFEROL  
 HEMABATE, CARBOPROST TROMETHAMINE  
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPATAMINE 8%, AMINO ACIDS  
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT  
 HEPSERA, ADEFOVIR DIPIVOXIL  
 HERPLEX, IDOXURIDINE  
 HETLIOZ, TASIMELTEON  
 HEXALEN, ALTRETAMINE  
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)  
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)  
 HICON, SODIUM IODIDE I-131  
 HIPREX, METHENAMINE HIPPURATE  
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE  
 HORIZANT, GABAPENTIN ENACARBIL  
 HUMALOG, INSULIN LISPRO RECOMBINANT  
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT  
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMATROPE, SOMATROPIN RECOMBINANT  
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN R, INSULIN RECOMBINANT HUMAN  
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE  
 HYCOFENIX, GUAIFENESIN  
 HYDERGINE, ERGOLOID MESYLATES  
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDREA, HYDROXYUREA  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE  
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* H \*\*

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,  
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX  
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX  
 HYDROCORTISONE, HYDROCORTISONE  
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE  
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL  
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE  
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE  
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE  
 HYDROXYUREA, HYDROXYUREA  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN  
 HYSINGLA, HYDROCODONE BITARTRATE  
 HYZAAR, HYDROCHLOROTHIAZIDE

## \*\* I \*\*

IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IBRANCE, PALBOCICLIB  
 IBU-TAB, IBUPROFEN  
 IBU-TAB 200, IBUPROFEN (OTC)  
 IBUPROFEN, IBUPROFEN (OTC)  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)  
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)  
 IBUPROHM, IBUPROFEN (OTC)  
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)  
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE  
 IC-GREEN, INDOCYANINE GREEN  
 ICLUSIG, PONATINIB HYDROCHLORIDE  
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE  
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE  
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE  
 IDKIT:HP, CITRIC ACID  
 IFEX, IFOSFAMIDE  
 IFOSFAMIDE, IFOSFAMIDE  
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE  
 ILEVRO, NEPAFENAC  
 ILUVIEN, FLUOCINOLONE ACETONIDE  
 IMATINIB MESYLATE, IMATINIB MESYLATE  
 IMBRUVICA, IBRUTINIB  
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE  
 IMIQUIMOD, IMIQUIMOD  
 IMITREX, SUMATRIPTAN  
 IMITREX, SUMATRIPTAN SUCCINATE  
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE  
 IMODIUM, LOPERAMIDE HYDROCHLORIDE  
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMPAVIDO, MILTEFOSINE  
 IMURAN, AZATHIOPRINE  
 INAPSINE, DROPERIDOL

## APPENDIX A - PRODUCT NAME INDEX

\*\* I \*\*

INCRELEX, MECASERMIN RECOMBINANT  
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE  
INDAPAMIDE, INDAPAMIDE  
INDERAL LA, PROPRANOLOL HYDROCHLORIDE  
INDICLOR, INDIUM IN-111 CHLORIDE  
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE  
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE  
INDOCIN, INDOMETHACIN  
INDOCIN, INDOMETHACIN SODIUM  
INDOCYANINE GREEN, INDOCYANINE GREEN  
INDOMETHACIN, INDOMETHACIN  
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM  
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)  
INFASURF PRESERVATIVE FREE, CALFACTANT  
INFED, IRON DEXTRAN  
INFUMORPH, MORPHINE SULFATE  
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE  
INFUVITE PEDIATRIC, ASCORBIC ACID  
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID  
INJECTAFER, FERRIC CARBOXYMALTOSE  
INLYTA, AXITINIB  
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE  
INOMAX, NITRIC OXIDE  
INSPRA, EPLERENONE  
INTEGRILIN, EPTIFIBATIDE  
INTELENCE, ETRAVIRINE  
INTERMEZZO, ZOLPIDEM TARTRATE  
INTRALIPID 10%, SOYBEAN OIL  
INTRALIPID 20%, SOYBEAN OIL  
INTRALIPID 30%, SOYBEAN OIL  
INTROVALE, ETHINYL ESTRADIOL  
INTUNIV, GUANFACINE HYDROCHLORIDE  
INVANZ, ERTAPENEM SODIUM  
INVEGA, PALIPERIDONE  
INVEGA SUSTENNA, PALIPERIDONE PALMITATE  
INVEGA TRINZA, PALIPERIDONE PALMITATE  
INVIRASE, SAQUINAVIR MESYLATE  
INVOKAMET, CANAGLIFLOZIN  
INVOKANA, CANAGLIFLOZIN  
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
IONSYS, FENTANYL HYDROCHLORIDE  
IOPIDINE, APRACLONIDINE HYDROCHLORIDE  
IOSAT, POTASSIUM IODIDE (OTC)  
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
IPRIVASK, DESIRUDIN RECOMBINANT  
IRBESARTAN, IRBESARTAN  
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IRESSA, GEFITINIB  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
ISENTRESS, RALTEGRAVIR POTASSIUM  
ISIBLOOM, DESOGESTREL  
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE  
ISOFLURANE, ISOFLURANE  
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
ISONIAZID, ISONIAZID  
ISOPTO CARPINE, Pilocarpine HYDROCHLORIDE  
ISORDIL, ISOSORBIDE DINITRATE  
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
ISOSULFAN BLUE, ISOSULFAN BLUE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* I \*\*

ISOVUE-200, IOPAMIDOL  
 ISOVUE-250, IOPAMIDOL  
 ISOVUE-300, IOPAMIDOL  
 ISOVUE-370, IOPAMIDOL  
 ISOVUE-M 200, IOPAMIDOL  
 ISOVUE-M 300, IOPAMIDOL  
 ISRADIPINE, ISRADIPINE  
 ISTALOL, TIMOLOL MALEATE  
 ISTODAX, ROMIDEPSIN  
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE  
 ITRACONAZOLE, ITRACONAZOLE  
 IVERMECTIN, IVERMECTIN  
 IVY BLOCK, BENTOQUATAM (OTC)  
 IXEMPRA KIT, IXABEPILONE

## \*\* J \*\*

JADENU, DEFERASIROX  
 JAKAFI, RUXOLITINIB PHOSPHATE  
 JALYN, DUTASTERIDE  
 JANTOVEN, WARFARIN SODIUM  
 JANUMET, METFORMIN HYDROCHLORIDE  
 JANUMET XR, METFORMIN HYDROCHLORIDE  
 JANUVIA, SITAGLIPTIN PHOSPHATE  
 JARDIANCE, EMPAGLIFLOZIN  
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM  
 JENCYCLA, NORETHINDRONE  
 JENTADUETO, LINAGLIPTIN  
 JEVTANA KIT, CABAZITAXEL  
 JUBLIA, EFINACONAZOLE  
 JUNEL 1.5/30, ETHINYL ESTRADIOL  
 JUNEL 1/20, ETHINYL ESTRADIOL  
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL  
 JUNEL FE 1/20, ETHINYL ESTRADIOL  
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)  
 JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)  
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)  
 JUXTAPID, LOMITAPIDE MESYLATE

## \*\* K \*\*

K-TAB, POTASSIUM CHLORIDE  
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS  
 KADIAN, MORPHINE SULFATE  
 KAITLIB FE, ETHINYL ESTRADIOL  
 KALETRA, LOPINAVIR  
 KALEXATE, SODIUM POLYSTYRENE SULFONATE  
 KALYDECO, IVACAFTOR  
 KANAMYCIN SULFATE, KANAMYCIN SULFATE  
 KAPVAY, CLONIDINE HYDROCHLORIDE  
 KARBINAL ER, CARBINOXAMINE MALEATE  
 KARIVA, DESOGESTREL  
 KAYEXALATE, SODIUM POLYSTYRENE SULFONATE  
 KAZANO, ALOGLIPTIN BENZOATE  
 KEFLEX, CEPHALEXIN  
 KEFZOL, CEFAZOLIN SODIUM  
 KELNOR, ETHINYL ESTRADIOL  
 KENALOG, TRIAMCINOLONE ACETONIDE  
 KENALOG-10, TRIAMCINOLONE ACETONIDE  
 KENALOG-40, TRIAMCINOLONE ACETONIDE  
 KENGREAL, CANGRELOR  
 KEPPRA, LEVETIRACETAM  
 KEPPRA XR, LEVETIRACETAM  
 KERYDIN, TAVABOROLE  
 KETALAR, KETAMINE HYDROCHLORIDE  
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE  
 KETEK, TELITHROMYCIN



## APPENDIX A - PRODUCT NAME INDEX

## \*\* K \*\*

KETOCONAZOLE, KETOCONAZOLE  
 KETOPROFEN, KETOPROFEN  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)  
 KETOZOLE, KETOCONAZOLE  
 KEVEYIS, DICHLORPHENAMIDE  
 KHEDEZLA, DESVENLAFAXINE  
 KIMIDESS, DESOGESTREL  
 KINEVAC, SINCALIDE  
 KIONEX, SODIUM POLYSTYRENE SULFONATE  
 KITABIS PAK, TOBRAMYCIN  
 KLARON, SULFACETAMIDE SODIUM  
 KLONOPIN, CLONAZEPAM  
 KLOR-CON, POTASSIUM CHLORIDE  
 KLOR-CON M10, POTASSIUM CHLORIDE  
 KLOR-CON M15, POTASSIUM CHLORIDE  
 KLOR-CON M20, POTASSIUM CHLORIDE  
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE  
 KORLYM, MIFEPRISTONE  
 KURVELO, ETHINYL ESTRADIOL  
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE  
 KYBELLA, DEOXYCHOLIC ACID  
 KYNAMRO, MIPOMERSEN SODIUM  
 KYPROLIS, CARFILZOMIB

## \*\* L \*\*

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LAC-HYDRIN, AMMONIUM LACTATE  
 LACRISERT, HYDROXYPROPYL CELLULOSE  
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LACTULOSE, LACTULOSE  
 LAMICTAL, LAMOTRIGINE  
 LAMICTAL CD, LAMOTRIGINE  
 LAMICTAL ODT, LAMOTRIGINE  
 LAMICTAL XR, LAMOTRIGINE  
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)  
 LAMISIL, TERBINAFINE HYDROCHLORIDE  
 LAMISIL AT, TERBINAFINE (OTC)  
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)  
 LAMIVUDINE, LAMIVUDINE  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LAMPRENE, CLOFAZIMINE  
 LANIAZID, ISONIAZID  
 LANORINAL, ASPIRIN  
 LANOXIN, DIGOXIN  
 LANOXIN PEDIATRIC, DIGOXIN  
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN  
 LANTUS, INSULIN GLARGINE RECOMBINANT  
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT  
 LARIN 1.5/30, ETHINYL ESTRADIOL  
 LARIN 1/20, ETHINYL ESTRADIOL  
 LARIN 24 FE, ETHINYL ESTRADIOL  
 LARIN FE 1.5/30, ETHINYL ESTRADIOL  
 LARIN FE 1/20, ETHINYL ESTRADIOL  
 LAROTID, AMOXICILLIN  
 LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE  
 LASIX, FUROSEMIDE  
 LASTACFT, ALCAFTADINE  
 LATANOPROST, LATANOPROST

## APPENDIX A - PRODUCT NAME INDEX

\*\* L \*\*

LATISSE, BIMATOPROST  
 LATUDA, LURASIDONE HYDROCHLORIDE  
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
 LAZANDA, FENTANYL CITRATE  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LENVIMA, LENVATINIB MESYLATE  
 LESCOL, FLUVASTATIN SODIUM  
 LESCOL XL, FLUVASTATIN SODIUM  
 LESSINA-28, ETHINYL ESTRADIOL  
 LETAIRIS, AMBRISENTAN  
 LETROZOLE, LETROZOLE  
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM  
 LEUKERAN, CHLORAMBUCIL  
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 LEVAQUIN, LEVOFLOXACIN  
 LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVEMIR, INSULIN DETEMIR RECOMBINANT  
 LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT  
 LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM  
 LEVITRA, VARDENAFIL HYDROCHLORIDE  
 LEVO-T, LEVOTHYROXINE SODIUM \*\*  
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE  
 LEVOCARNITINE, LEVOCARNITINE  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM  
 LEVONEST, ETHINYL ESTRADIOL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 LEVONORGESTREL, LEVONORGESTREL  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVOPHED, NOREPINEPHRINE BITARTRATE  
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL  
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE  
 LEVOTHROID, LEVOTHYROXINE SODIUM \*\*  
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM  
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM \*\*  
 LEVOXYL, LEVOTHYROXINE SODIUM \*\*  
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE  
 LEXAPRO, ESCITALOPRAM OXALATE  
 LEXISCAN, REGADENOSON  
 LEXIVA, FOSAMPRENAVIR CALCIUM  
 LIALDA, MESALAMINE  
 LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE  
 LIDEX, FLUOCINONIDE  
 LIDOCAINE, LIDOCAINE  
 LIDOCAINE AND PRILOCAINE, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE  
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* L \*\*

LIDODERM, LIDOCAINE  
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE  
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE  
 LILETTA, LEVONORGESTREL  
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE  
 LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE  
 LINDANE, LINDANE  
 LINEZOLID, LINEZOLID  
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID  
 LINZESS, LINACLOTIDE  
 LIORESAL, BACLOFEN  
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
 LIPIODOL, ETHIODIZED OIL  
 LIPITOR, ATORVASTATIN CALCIUM  
 LIPOFEN, FENOFIBRATE  
 LISINOPRIL, LISINOPRIL  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 LITHIUM CITRATE, LITHIUM CITRATE  
 LITHOBID, LITHIUM CARBONATE  
 LITHOSTAT, ACETOHYDROXAMIC ACID  
 LIVALO, PITAVASTATIN CALCIUM  
 LO LOESTRIN FE, ETHINYL ESTRADIOL  
 LO MINASTRIN FE, ETHINYL ESTRADIOL  
 LO/OVRAL-28, ETHINYL ESTRADIOL  
 LOCID, HYDROCORTISONE BUTYRATE  
 LOCID LIPOCREAM, HYDROCORTISONE BUTYRATE  
 LODOSYN, CARBIDOPA  
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL  
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL  
 LOESTRIN 24 FE, ETHINYL ESTRADIOL  
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL  
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL  
 LOMOTIL, ATROPINE SULFATE  
 LONOX, ATROPINE SULFATE  
 LONSURF, TIPIRACIL HYDROCHLORIDE  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE  
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 LOPID, GEMFIBROZIL  
 LOPRESSOR, METOPROLOL TARTRATE  
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE  
 LOPROX, CICLOPIROX  
 LOPURIN, ALLOPURINOL  
 LORATADINE, LORATADINE (OTC)  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)  
 LORATADINE REDIDOSE, LORATADINE (OTC)  
 LORAZEPAM, LORAZEPAM  
 LORAZEPAM INTENSOL, LORAZEPAM  
 LORAZEPAM PRESERVATIVE FREE, LORAZEPAM  
 LORYNA, DROSPIRENONE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSEASONIQUE, ETHINYL ESTRADIOL  
 LOTEMAX, LOTEPRDNOL ETABONATE  
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE  
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE  
 LOTREL, AMLODIPINE BESYLATE  
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)  
 LOTRISONE, BETAMETHASONE DIPROPIONATE  
 LOTRONEX, ALOSETRON HYDROCHLORIDE  
 LOVASTATIN, LOVASTATIN  
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS  
 LOVENOX, ENOXAPARIN SODIUM  
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM

## APPENDIX A - PRODUCT NAME INDEX

## \*\* L \*\*

LOW-OGESTREL-28, ETHINYL ESTRADIOL  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 LTA II KIT, LIDOCAINE HYDROCHLORIDE  
 LUFYLLIN, DYPHYLLINE  
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES  
 LUMIGAN, BIMATOPROST  
 LUNESTA, ESZOPICLONE  
 LUPANETA PACK, LEUPROLIDE ACETATE  
 LUPRON DEPOT, LEUPROLIDE ACETATE  
 LUPRON DEPOT-PED, LEUPROLIDE ACETATE  
 LUVOX, FLUVOXAMINE MALEATE  
 LUVOX CR, FLUVOXAMINE MALEATE  
 LUXIQ, BETAMETHASONE VALERATE  
 LUZU, LULICONAZOLE  
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT  
 LYNPARZA, OLAPARIB  
 LYRICA, PREGABALIN  
 LYSODREN, MITOTANE  
 LYSTEDA, TRANEXAMIC ACID

## \*\* M \*\*

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 M.V.I. ADULT, ASCORBIC ACID  
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID  
 M.V.I. PEDIATRIC, ASCORBIC ACID  
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID  
 MACROBID, NITROFURANTOIN  
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE  
 MACUGEN, PEGAPTANIB SODIUM  
 MAFENIDE ACETATE, MAFENIDE ACETATE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE  
 MAKENA, HYDROXYPROGESTERONE CAPROATE  
 MALARONE, ATOVAQUONE  
 MALARONE PEDIATRIC, ATOVAQUONE  
 MALATHION, MALATHION  
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 25%, MANNITOL  
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE  
 MARCAINE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARINOL, DRONABINOL  
 MARLISSA, ETHINYL ESTRADIOL  
 MARPLAN, ISOCARBOXAZID  
 MARQIBO KIT, VINCRISTINE SULFATE  
 MATULANE, PROCARBAZINE HYDROCHLORIDE  
 MAVIK, TRANDOLAPRIL  
 MAXALT, RIZATRIPTAN BENZOATE  
 MAXALT-MLT, RIZATRIPTAN BENZOATE  
 MAXIDEX, DEXAMETHASONE  
 MAXIPIME, CEFEPIME HYDROCHLORIDE  
 MAXITROL, DEXAMETHASONE  
 MAXZIDE, HYDROCHLOROTHIAZIDE  
 MAXZIDE-25, HYDROCHLOROTHIAZIDE  
 MD-76R, DIATRIZOATE MEGLUMINE

## APPENDIX A - PRODUCT NAME INDEX

\*\* M \*\*

MD-GASTROVIEW, DIATRIZOATE MEGLUMINE  
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT  
MEBENDAZOLE, MEBENDAZOLE  
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE  
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM  
MEDROL, METHYLPREDNISOLONE  
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE  
MEFENAMIC ACID, MEFENAMIC ACID  
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE  
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM  
MEGACE, MEGESTROL ACETATE  
MEGACE ES, MEGESTROL ACETATE  
MEGATOPE, ALBUMIN IODINATED I-131 SERUM  
MEGESTROL ACETATE, MEGESTROL ACETATE  
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE  
MELOXICAM, MELOXICAM  
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE  
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
MEMBRANEBLUE, TRYPAN BLUE  
MEN'S ROGAINE, MINOXIDIL (OTC)  
MENEST, ESTROGENS, ESTERIFIED  
MENOPUR, MENOTROPINS (FSH)  
MENOSTAR, ESTRADIOL  
MENTAX, BUTENAFINE HYDROCHLORIDE  
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE  
MEPHYTON, PHYTONADIONE  
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE  
MEPROBAMATE, MEPROBAMATE  
MEPRON, ATOVAQUONE  
MERCAPTOPYRINE, MERCAPTOPYRINE  
MEROPENEM, MEROPENEM  
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM  
MERREM, MEROPENEM  
MESALAMINE, MESALAMINE  
MESNA, MESNA  
MESNEX, MESNA  
MESTINON, PYRIDOSTIGMINE BROMIDE  
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE  
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE  
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE  
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE  
METASTRON, STRONTIUM CHLORIDE SR-89  
METAXALONE, METAXALONE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE  
METHADOSE, METHADONE HYDROCHLORIDE  
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE  
METHAZOLAMIDE, METHAZOLAMIDE  
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE  
METHERGINE, METHYLERGONOVINE MALEATE  
METHIMAZOLE, METHIMAZOLE  
METHOCARBAMOL, METHOCARBAMOL  
METHOCARBAMOL AND ASPIRIN, ASPIRIN  
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM  
METHOTREXATE SODIUM, METHOTREXATE SODIUM  
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
METHOXSALLEN, METHOXSALLEN  
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE  
METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE  
METHYLDOPA, METHYLDOPA  
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* M \*\*

METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE  
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE  
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE  
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
METHYLPREDNISOLONE, METHYLPREDNISOLONE  
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE  
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE  
METHYLTESTOSTERONE, METHYLTESTOSTERONE  
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
METOLAZONE, METOLAZONE  
METOPIRONE, METYRAPONE  
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
METOPROLOL TARTRATE, METOPROLOL TARTRATE  
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE  
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE  
METROCREAM, METRONIDAZOLE  
METROGEL, METRONIDAZOLE  
METROGEL-VAGINAL, METRONIDAZOLE  
METROLOTION, METRONIDAZOLE  
METRONIDAZOLE, METRONIDAZOLE  
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE  
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE  
MIACALCIN, CALCITONIN SALMON  
MICARDIS, TELMISARTAN  
MICARDIS HCT, HYDROCHLOROTHIAZIDE  
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)  
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)  
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
MICONAZOLE NITRATE, MICONAZOLE NITRATE  
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MICORT-HC, HYDROCORTISONE ACETATE  
MICRO-K, POTASSIUM CHLORIDE  
MICRO-K 10, POTASSIUM CHLORIDE  
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL  
MICROGESTIN 1/20, ETHINYL ESTRADIOL  
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL  
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL  
MICRONOR, NORETHINDRONE  
MICROZIDE, HYDROCHLOROTHIAZIDE  
MIDAMOR, AMILORIDE HYDROCHLORIDE  
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE  
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
MIDOL LIQUID GELS, IBUPROFEN (OTC)  
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
MIFEPREX, MIFEPRISTONE  
MIGERGOT, CAFFEINE  
MIGLITOL, MIGLITOL  
MIGRANAL, DIHYDROERGOTAMINE MESYLATE  
MILRINONE LACTATE, MILRINONE LACTATE  
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE  
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE  
MINASTRIN 24 FE, ETHINYL ESTRADIOL  
MINIPRESS, PRAZOSIN HYDROCHLORIDE  
MINIRIN, DESMOPRESSIN ACETATE  
MINITRAN, NITROGLYCERIN  
MINIVELLE, ESTRADIOL  
MINOCIN, MINOCYCLINE HYDROCHLORIDE  
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* M \*\*

MINOXIDIL, MINOXIDIL (OTC)  
MINOXIDIL, MINOXIDIL  
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)  
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
MIOCHOL-E, ACETYLCHOLINE CHLORIDE  
MIOSTAT, CARBACHOL  
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)  
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE  
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE  
MIRENA, LEVONORGESTREL  
MIRTAZAPINE, MIRTAZAPINE  
MIRVASO, BRIMONIDINE TARTRATE  
MISOPROSTOL, MISOPROSTOL  
MITIGARE, COLCHICINE  
MITOMYCIN, MITOMYCIN  
MITOSOL, MITOMYCIN  
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
MIVACRON, MIVACURIUM CHLORIDE  
MOBIC, MELOXICAM  
MODAFINIL, MODAFINIL  
MODICON 28, ETHINYL ESTRADIOL  
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE  
MOMETASONE FUROATE, MOMETASONE FUROATE  
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 3, MICONAZOLE NITRATE (OTC)  
MONISTAT 3, MICONAZOLE NITRATE  
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)  
MONISTAT 7, MICONAZOLE NITRATE (OTC)  
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONO-LINYAH, ETHINYL ESTRADIOL  
MONODOX, DOXYCYCLINE  
MONOKET, ISOSORBIDE MONONITRATE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
MONUROL, FOSFOMYCIN TROMETHAMINE  
MORPHABOND, MORPHINE SULFATE  
MORPHINE SULFATE, MORPHINE SULFATE  
MOTOFEN, ATROPINE SULFATE  
MOTRIN IB, IBUPROFEN (OTC)  
MOVANTIK, NALOXEGOL OXALATE  
MOVIPREP, ASCORBIC ACID  
MOXATAG, AMOXICILLIN  
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE  
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
MOZOBIL, PLERIXAFOR  
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT  
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM  
MS CONTIN, MORPHINE SULFATE  
MUCINEX, GUAIFENESIN (OTC)  
MUCINEX D, GUAIFENESIN (OTC)  
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)  
MULTAQ, DRONEDARONE HYDROCHLORIDE  
MULTIHANCE, GADOBENATE DIMEGLUMINE  
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE  
MUPIROCIN, MUPIROCIN  
MUPIROCIN, MUPIROCIN CALCIUM  
MUSE, ALPROSTADIL  
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE  
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE  
MYCAMINE, MICAFUNGIN SODIUM

## APPENDIX A - PRODUCT NAME INDEX

## \*\* M \*\*

MYCELEX-7, CLOTRIMAZOLE (OTC)  
 MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 MYCOBUTIN, RIFABUTIN  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID  
 MYDRIACYL, TROPICAMIDE  
 MYFORTIC, MYCOPHENOLIC ACID  
 MYKACET, NYSTATIN  
 MYLERAN, BUSULFAN  
 MYORISAN, ISOTRETINOIN  
 MYOVIEV, TECHNETIUM TC-99M TETROFOSMIN KIT  
 MYOVIEV 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT  
 MYRBETRIQ, MIRABEGRON  
 MYSOLINE, PRIMIDONE  
 MYZILRA, ETHINYL ESTRADIOL

## \*\* N \*\*

NABUMETONE, NABUMETONE  
 NADOLOL, NADOLOL  
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE  
 NAFTIN, NAFTIFINE HYDROCHLORIDE  
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE  
 NALFON, FENOPROFEN CALCIUM  
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM  
 NALOXONE, NALOXONE HYDROCHLORIDE  
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
 NAMENDA, MEMANTINE HYDROCHLORIDE  
 NAMENDA XR, MEMANTINE HYDROCHLORIDE  
 NAMZARIC, DONEPEZIL HYDROCHLORIDE  
 NANDROLONE DECANOATE, NANDROLONE DECANOATE  
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE  
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NAPRELAN, NAPROXEN SODIUM  
 NAPROSYN, NAPROXEN  
 NAPROXEN, NAPROXEN  
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NARCAN, NALOXONE HYDROCHLORIDE  
 NARDIL, PHENELZINE SULFATE  
 NAROPIN, ROPIVACAINE HYDROCHLORIDE  
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)  
 NASCOBAL, CYANOCOBALAMIN  
 NASONEX, MOMETASONE FUROATE MONOHYDRATE  
 NATACYN, NATAMYCIN  
 NATAZIA, DIENOGEST  
 NATEGLINIDE, NATEGLINIDE  
 NATESTO, TESTOSTERONE  
 NATRECOR, NESIRITIDE RECOMBINANT  
 NATROBA, SPINOSAD  
 NAVANE, THIOTHIXENE  
 NAVELBINE, VINORELBINE TARTRATE  
 NEBUPENT, PENTAMIDINE ISETHIONATE  
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM  
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE  
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM  
 NEO-FRADIN, NEOMYCIN SULFATE  
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE



## APPENDIX A - PRODUCT NAME INDEX

## \*\* N \*\*

NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE  
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC  
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE  
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN  
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE  
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC  
NEOMYCIN SULFATE, NEOMYCIN SULFATE  
NEOPAP, ACETAMINOPHEN (OTC)  
NEOPROFEN, IBUPROFEN LYSINE  
NEORAL, CYCLOSPORINE  
NEOSPORIN, GRAMICIDIN  
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE  
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE  
NEPHRAMINE 5.4%, AMINO ACIDS  
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE  
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE  
NESINA, ALOGLIPTIN BENZOATE  
NEUPRO, ROTIGOTINE  
NEURACEQ, FLORBETABEN F-18  
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT  
NEURONTIN, GABAPENTIN  
NEVANAC, NEPAFENAC  
NEVIRAPINE, NEVIRAPINE  
NEXAVAR, SORAFENIB TOSYLATE  
NEXIUM, ESOMEPRAZOLE MAGNESIUM  
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)  
NEXIUM IV, ESOMEPRAZOLE SODIUM  
NEXPLANON, ETNOGESTREL  
NEXTERONE, AMIODARONE HYDROCHLORIDE  
NIACIN, NIACIN  
NIACOR, NIACIN  
NIASPAN, NIACIN  
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
NICODERM CQ, NICOTINE (OTC)  
NICORETTE, NICOTINE POLACRILEX (OTC)  
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)  
NICOTINE, NICOTINE (OTC)  
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
NICOTROL, NICOTINE  
NIFEDIPINE, NIFEDIPINE  
NIKKI, DROSPIRENONE  
NILANDRON, NILUTAMIDE  
NIMBEX, CISATRACURIUM BESYLATE  
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
NIMODIPINE, NIMODIPINE  
NINLARO, IXAZOMIB CITRATE  
NIPENT, PENTOSTATIN  
NISOLDIPINE, NISOLDIPINE  
NITHIODOTE, SODIUM NITRITE  
NITRO-DUR, NITROGLYCERIN  
NITROFURANTOIN, NITROFURANTOIN  
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE  
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN  
NITROGLYCERIN, NITROGLYCERIN  
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN  
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN  
NITROMIST, NITROGLYCERIN  
NITROPRESS, SODIUM NITROPRUSSIDE  
NITROSTAT, NITROGLYCERIN  
NIX, PERMETHRIN (OTC)  
NIZATIDINE, NIZATIDINE  
NIZORAL, KETOCONAZOLE  
NIZORAL A-D, KETOCONAZOLE (OTC)  
NOR-QD, NORETHINDRONE  
NORCO, ACETAMINOPHEN

## APPENDIX A - PRODUCT NAME INDEX

\*\* N \*\*

NORDITROPIN FLEXPRO, SOMATROPIN RECOMBINANT  
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE  
 NORETHINDRONE, NORETHINDRONE  
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+50 28-DAY, MESTRANOL  
 NORITATE, METRONIDAZOLE  
 NORMOCARB HF 25, MAGNESIUM CHLORIDE  
 NORMOCARB HF 35, MAGNESIUM CHLORIDE  
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 NORPACE, DISOPYRAMIDE PHOSPHATE  
 NORPACE CR, DISOPYRAMIDE PHOSPHATE  
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE  
 NORTHERA, DROXIDOPA  
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL  
 NORTREL 1/35-21, ETHINYL ESTRADIOL  
 NORTREL 1/35-28, ETHINYL ESTRADIOL  
 NORTREL 7/7/7, ETHINYL ESTRADIOL  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 NORVASC, AMLODIPINE BESYLATE  
 NORVIR, RITONAVIR  
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLOG, INSULIN ASPART RECOMBINANT  
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT  
 NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT  
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT  
 NOXAFIL, POSACONAZOLE  
 NUCYNTA, TAPENTADOL HYDROCHLORIDE  
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE  
 NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE  
 NULYTELY, POLYETHYLENE GLYCOL 3350  
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350  
 NUTRACORT, HYDROCORTISONE  
 NUTRESTORE, GLUTAMINE  
 NUTRILIPID 10%, SOYBEAN OIL  
 NUTRILIPID 20%, SOYBEAN OIL  
 NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT  
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT  
 NUVARING, ETHINYL ESTRADIOL  
 NUVESSA, METRONIDAZOLE  
 NUVIGIL, ARMODAFINIL  
 NYMALIZE, NIMODIPINE  
 NYSTATIN, NYSTATIN  
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN  
 NYSTOP, NYSTATIN

\*\* O \*\*

OBREDON, GUAIFENESIN  
 OCTOCAINE, EPINEPHRINE  
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* O \*\*

OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)  
 OCUFEN, FLURBIPROFEN SODIUM  
 OCUFLOX, OFLOXACIN  
 OCUPRESS, CARTEOLOL HYDROCHLORIDE  
 ODOMZO, SONIDEGIB PHOSPHATE  
 OFEV, NINTEDANIB ESYLATE  
 OFIRMEV, ACETAMINOPHEN  
 OFLOXACIN, OFLOXACIN  
 OGEN .625, ESTROPIPATE  
 OGEN 1.25, ESTROPIPATE  
 OGEN 2.5, ESTROPIPATE  
 OGEN 5, ESTROPIPATE  
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL  
 OLANZAPINE, OLANZAPINE  
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE  
 OLUX, CLOBETASOL PROPIONATE  
 OLUX E, CLOBETASOL PROPIONATE  
 OLYSIO, SIMEPREVIR SODIUM  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 OMEPRAZOLE, OMEPRAZOLE (OTC)  
 OMEPRAZOLE, OMEPRAZOLE  
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN  
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE  
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)  
 OMIDRIA, KETOROLAC TROMETHAMINE  
 OMNARIS, CICLESONIDE  
 OMNIPAQUE 140, IOHEXOL  
 OMNIPAQUE 180, IOHEXOL  
 OMNIPAQUE 240, IOHEXOL  
 OMNIPAQUE 300, IOHEXOL  
 OMNIPAQUE 350, IOHEXOL  
 OMNIPRED, PREDNISOLONE ACETATE  
 OMNISCAN, GADODIAMIDE  
 OMNITROPE, SOMATROPIN RECOMBINANT  
 OMTRYG, OMEGA-3-ACID ETHYL ESTERS  
 ONDANSETRON, ONDANSETRON  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONEXTON, BENZOYL PEROXIDE  
 ONFI, CLOBAZAM  
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE  
 ONIVYDE, IRINOTECAN HYDROCHLORIDE  
 ONMEL, ITRACONAZOLE  
 OPANA, OXYMORPHONE HYDROCHLORIDE  
 OPANA ER, OXYMORPHONE HYDROCHLORIDE  
 OPCICON ONE-STEP, LEVONORGESTREL (OTC)  
 OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 OPSUMIT, MACITENTAN  
 OPTIMARK, GADOVERSETAMIDE  
 OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE  
 OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
 OPTIRAY 240, IOVERSOL  
 OPTIRAY 300, IOVERSOL  
 OPTIRAY 320, IOVERSOL  
 OPTIRAY 350, IOVERSOL  
 OPTISON, ALBUMIN HUMAN  
 OPTIVAR, AZELASTINE HYDROCHLORIDE  
 ORABLOC, ARTICAIN HYDROCHLORIDE  
 ORACEA, DOXYCYCLINE  
 ORALTAG, IOHEXOL  
 ORAP, PIMOZIDE  
 ORAPRED, PREDNISOLONE SODIUM PHOSPHATE  
 ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE  
 ORAQIX, LIDOCAINE

## APPENDIX A - PRODUCT NAME INDEX

\*\* O \*\*

ORAVERSE, PHENTOLAMINE MESYLATE  
ORAVIG, MICONAZOLE  
ORBACTIV, ORITAVANCIN DIPHOSPHATE  
ORENITRAM, TREPROSTINIL DIOLAMINE  
ORETIC, HYDROCHLOROTHIAZIDE  
ORFADIN, NITISINONE  
ORKAMBI, IVACAFTOR  
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN  
ORSYTHIA, ETHINYL ESTRADIOL  
ORTHO CYCLEN-28, ETHINYL ESTRADIOL  
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL  
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL  
ORTHO-CEPT, DESOGESTREL  
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL  
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL  
ORVATEN, MIDODRINE HYDROCHLORIDE  
OSENI, ALOGLIPTIN BENZOATE  
OSMITROL 10% IN WATER, MANNITOL  
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL  
OSMITROL 15% IN WATER, MANNITOL  
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL  
OSMITROL 20% IN WATER, MANNITOL  
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL  
OSMITROL 5% IN WATER, MANNITOL  
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL  
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS  
OSPHENA, OSPEMIFENE  
OTEZLA, APREMILAST  
OTICAIR, HYDROCORTISONE  
OTIPRIO, CIPROFLOXACIN  
OTREXUP, METHOTREXATE  
OVIDE, MALATHION  
OVIDREL, CHORIOGONADOTROPIN ALFA  
OXACILLIN SODIUM, OXACILLIN SODIUM  
OXALIPLATIN, OXALIPLATIN  
OXANDRIN, OXANDROLONE  
OXANDROLONE, OXANDROLONE  
OXAPROZIN, OXAPROZIN  
OXAYDO, OXYCODONE HYDROCHLORIDE  
OXAZEPAM, OXAZEPAM  
OXCARBAZEPINE, OXCARBAZEPINE  
OXILAN-300, IOXILAN  
OXILAN-350, IOXILAN  
OXISTAT, OXICONAZOLE NITRATE  
OXSORALEN, METHOXSALEN  
OXSORALEN-ULTRA, METHOXSALEN  
OXTELLAR XR, OXCARBAZEPINE  
OXYBUTYNIN, OXYBUTYNIN  
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
OXYCET, ACETAMINOPHEN  
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
OXYCODONE AND ASPIRIN, ASPIRIN  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN  
OXYCONTIN, OXYCODONE HYDROCHLORIDE  
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
OXYTOCIN, OXYTOCIN  
OXYTROL, OXYBUTYNIN  
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)  
OZURDEX, DEXAMETHASONE

\*\* P \*\*

PACERONE, AMIODARONE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

PACLITAXEL, PACLITAXEL  
PALIPERIDONE, PALIPERIDONE  
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE  
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE  
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
PANCREAZE, PANCRELIPASE (AMYLASE)  
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE  
PANDEL, HYDROCORTISONE PROBUTATE  
PANRETIN, ALITRETINOIN  
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
PARAGARD T 380A, COPPER  
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE  
PARICALCITOL, PARICALCITOL  
PARLODEL, BROMOCRIPTINE MESYLATE  
PARNATE, TRANYLCPROMINE SULFATE  
PAROEX, CHLORHEXIDINE GLUCONATE  
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE  
PAROXETINE, PAROXETINE HYDROCHLORIDE  
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
PASER, AMINOSALICYLIC ACID  
PATADAY, OLOPATADINE HYDROCHLORIDE  
PATANASE, OLOPATADINE HYDROCHLORIDE  
PATANOL, OLOPATADINE HYDROCHLORIDE  
PAXIL, PAROXETINE HYDROCHLORIDE  
PAXIL CR, PAROXETINE HYDROCHLORIDE  
PAZEO, OLOPATADINE HYDROCHLORIDE  
PCE, ERYTHROMYCIN  
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE  
PEDIATRIC ADVIL, IBUPROFEN (OTC)  
PEDIOTIC, HYDROCORTISONE  
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350  
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL  
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL, BISACODYL  
PEGANONE, ETHOTOIN  
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM  
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM  
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE  
PENICILLIN G SODIUM, PENICILLIN G SODIUM  
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
PENICILLIN-VK, PENICILLIN V POTASSIUM  
PENLAC, CICLOPIROX  
PENNSAID, DICLOFENAC SODIUM  
PENTAM, PENTAMIDINE ISETHIONATE  
PENTASA, MESALAMINE  
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE  
PENTOSTATIN, PENTOSTATIN  
PENTOXIFYLLINE, PENTOXIFYLLINE  
PENTOXIL, PENTOXIFYLLINE  
PEPCID, FAMOTIDINE  
PEPCID AC, FAMOTIDINE (OTC)  
PEPCID AC, FAMOTIDINE (OTC)  
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)  
PERCOCET, ACETAMINOPHEN  
PERCODAN, ASPIRIN  
PERFOROMIST, FORMOTEROL FUMARATE  
PERIDEX, CHLORHEXIDINE GLUCONATE  
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS  
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
PERIOCHIP, CHLORHEXIDINE GLUCONATE  
PERIOGARD, CHLORHEXIDINE GLUCONATE  
PERMAPEN, PENICILLIN G BENZATHINE  
PERMETHRIN, PERMETHRIN (OTC)  
PERMETHRIN, PERMETHRIN  
PERPHENAZINE, PERPHENAZINE  
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

PERSANTINE, DIPYRIDAMOLE  
 PERTZYE, PANCRELIPASE (AMYLASE)  
 PEXEVA, PAROXETINE MESYLATE  
 PFIZERPEN, PENICILLIN G POTASSIUM  
 PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)  
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
 PHENELZINE SULFATE, PHENELZINE SULFATE  
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX  
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE  
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE  
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE  
 PHENYTEK, PHENYTOIN SODIUM  
 PHENYTOIN, PHENYTOIN  
 PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 PHILITH, ETHINYL ESTRADIOL  
 PHISOHEX, HEXACHLOROPHENE  
 PHOSLO GELCAPS, CALCIUM ACETATE  
 PHOSLYRA, CALCIUM ACETATE  
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE  
 PHOTOFRIN, PORFIMER SODIUM  
 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PHYTONADIONE, PHYTONADIONE  
 PICATO, INGENOL MEBUTATE  
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
 PIMOZIDE, PIMOZIDE  
 PIMTREA, DESOGESTREL  
 PINDOLOL, PINDOLOL  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIPERACILLIN, PIPERACILLIN SODIUM  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 PIRMELLA 1/35, ETHINYL ESTRADIOL  
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL  
 PIROXICAM, PIROXICAM  
 PITOCIN, OXYTOCIN  
 PLAN B, LEVONORGESTREL (OTC)  
 PLAN B, LEVONORGESTREL  
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)  
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE  
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLAVIX, CLOPIDOGREL BISULFATE  
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLETAL, CILOSTAZOL  
 PLIAGLIS, LIDOCAINE  
 PODOFILOX, PODOFILOX  
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE  
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350  
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE  
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 POLYTRIM, POLYMYXIN B SULFATE  
 POMALYST, POMALIDOMIDE  
 PONSTEL, MEFENAMIC ACID  
 PORTIA-28, ETHINYL ESTRADIOL  
 POTASSIUM ACETATE, POTASSIUM ACETATE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE



## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CITRATE, POTASSIUM CITRATE  
 POTIGA, EZOGABINE  
 POVIDONE IODINE, POVIDONE-IODINE (OTC)  
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE  
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PRAMOSONE, HYDROCORTISONE ACETATE  
 PRANDIMET, METFORMIN HYDROCHLORIDE  
 PRANDIN, REPAGLINIDE  
 PRAVACHOL, PRAVASTATIN SODIUM  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE  
 PRE-OP, HEXACHLOROPHENE  
 PRE-OP II, HEXACHLOROPHENE  
 PRE-PEN, BENZYLPENICILLOYL POLYLYSINE  
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE  
 PRECOSE, ACARBOSE  
 PRED FORTE, PREDNISOLONE ACETATE  
 PRED MILD, PREDNISOLONE ACETATE  
 PRED-G, GENTAMICIN SULFATE  
 PREDNICARBATE, PREDNICARBATE  
 PREDNISOLONE, PREDNISOLONE  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 PREDNISONE, PREDNISONE  
 PREDNISONE INTENSOL, PREDNISONE  
 PREGNYL, GONADOTROPIN, CHORIONIC  
 PRELONE, PREDNISOLONE  
 PREMARIN, ESTROGENS, CONJUGATED  
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS



## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS  
PREMPHASE 14/14, ESTROGENS, CONJUGATED  
PREMPRO, ESTROGENS, CONJUGATED  
PREPIDIL, DINOPROSTONE  
PREPOPIK, CITRIC ACID  
PRESTALIA, AMLODIPINE BESYLATE  
PREVACID, LANSOPRAZOLE  
PREVACID 24 HR, LANSOPRAZOLE (OTC)  
PREVALITE, CHOLESTYRAMINE  
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)  
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
PREVIFEM, ETHINYL ESTRADIOL  
PREVPAC, AMOXICILLIN  
PREZCOBIX, COBICISTAT  
PREZISTA, DARUNAVIR ETHANOLATE  
PRIALT, ZICONOTIDE ACETATE  
PRIFTIN, RIFAPENTINE  
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE  
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE  
PRILOSEC, OMEPRAZOLE  
PRILOSEC, OMEPRAZOLE MAGNESIUM  
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)  
PRIMAQUINE, PRIMAQUINE PHOSPHATE  
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE  
PRIMAXIN, CILASTATIN SODIUM  
PRIMIDONE, PRIMIDONE  
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE  
PRINIVIL, LISINAPRIL  
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISTIQ, DESVENLAFAXINE SUCCINATE  
PROAIR HFA, ALBUTEROL SULFATE  
PROAIR RESPICLICK, ALBUTEROL SULFATE  
PROBALAN, PROBENECID  
PROBENECID, PROBENECID  
PROBENECID AND COLCHICINE, COLCHICINE  
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE  
PROCALAMINE, AMINO ACIDS  
PROCARDIA, NIFEDIPINE  
PROCARDIA XL, NIFEDIPINE  
PROCHLORPERAZINE, PROCHLORPERAZINE  
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE  
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE  
PROCOMP, PROCHLORPERAZINE MALEATE  
PROCTOFOAM HC, HYDROCORTISONE ACETATE  
PROCYSBI, CYSTEAMINE BITARTRATE  
PROFEN, IBUPROFEN (OTC)  
PROFERDEX, IRON DEXTRAN  
PROGESTERONE, PROGESTERONE  
PROGLYCEM, DIAZOXIDE  
PROGRAF, TACROLIMUS  
PROHANCE, GADOTERIDOL  
PROHANCE MULTIPACK, GADOTERIDOL  
PROLENSA, BROMFENAC SODIUM  
PROMACTA, ELTROMBOPAG OLAMINE  
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE  
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE  
 PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE  
 PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN  
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE  
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE  
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE  
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE  
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE  
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE  
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE  
 PROMETRIUM, PROGESTERONE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE  
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE  
 PROPECIA, FINASTERIDE  
 PROPOFOL, PROPOFOL  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 PROPYLTHIOURACIL, PROPYLTHIOURACIL  
 PROSCAR, FINASTERIDE  
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS  
 PROSTIN E2, DINOPROSTONE  
 PROSTIN VR PEDIATRIC, ALPROSTADIL  
 PROTAMINE SULFATE, PROTAMINE SULFATE  
 PROTONIX, PANTOPRAZOLE SODIUM  
 PROTONIX IV, PANTOPRAZOLE SODIUM  
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE  
 PROTOPIC, TACROLIMUS  
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE  
 PROVENTIL-HFA, ALBUTEROL SULFATE  
 PROVERA, MEDROXYPROGESTERONE ACETATE  
 PROVIGIL, MODAFINIL  
 PROVOCHOLINE, METHACHOLINE CHLORIDE  
 PROZAC, FLUOXETINE HYDROCHLORIDE  
 PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE  
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 PULMICORT FLEXHALER, BUDESONIDE  
 PULMICORT RESPULES, BUDESONIDE  
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
 PUR-WASH, PURIFIED WATER (OTC)  
 PURIXAN, MERCAPTOPYRIMIDINE  
 PYLERA, BISMUTH SUBCITRATE POTASSIUM  
 PYRAZINAMIDE, PYRAZINAMIDE  
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE  
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE  
 PYTEST, UREA, C-14  
 PYTEST KIT, UREA, C-14

\*\* Q \*\*

QNASL, BECLOMETHASONE DIPROPIONATE  
 QOLIANA, BRIMONIDINE TARTRATE  
 QSYMIA, PHENTERMINE HYDROCHLORIDE  
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM  
 QUALAQUIN, QUININE SULFATE  
 QUARTETTE, ETHINYL ESTRADIOL  
 QUASENSE, ETHINYL ESTRADIOL  
 QUDEXY XR, TOPIRAMATE  
 QUELICIN, SUCCINYLCHOLINE CHLORIDE  
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* Q \*\*

QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE  
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
QUINARETIC, HYDROCHLOROTHIAZIDE  
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE  
QUINIDINE SULFATE, QUINIDINE SULFATE  
QUININE SULFATE, QUININE SULFATE  
QUTENZA, CAPSAICIN  
QVAR 40, BECLOMETHASONE DIPROPIONATE  
QVAR 80, BECLOMETHASONE DIPROPIONATE

## \*\* R \*\*

R-GENE 10, ARGININE HYDROCHLORIDE  
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)  
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE  
RAMELTEON, RAMELTEON  
RAMIPRIL, RAMIPRIL  
RANEXA, RANOLAZINE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
RANOLAZINE, RANOLAZINE  
RAPAFLO, SILODOSIN  
RAPAMUNE, SIROLIMUS  
RAPIVAB, PERAMIVIR  
RASAGILINE MESYLATE, RASAGILINE MESYLATE  
RASUVO, METHOTREXATE  
RAVICTI, GLYCEROL PHENYL BUTYRATE  
RAYOS, PREDNISONE  
RAZADYNE, GALANTAMINE HYDROBROMIDE  
RAZADYNE ER, GALANTAMINE HYDROBROMIDE  
REBETOL, RIBAVIRIN  
RECLAST, ZOLEDRONIC ACID  
RECTIV, NITROGLYCERIN  
REGITINE, PHENTOLAMINE MESYLATE  
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE  
REGONOL, PYRIDOSTIGMINE BROMIDE  
RELENZA, ZANAMIVIR  
RELISTOR, METHYLNALTREXONE BROMIDE  
RELPAX, ELETRIPTAN HYDROBROMIDE  
REMERON, MIRTAZAPINE  
REMERON SOLTAB, MIRTAZAPINE  
REMODULIN, TREPROSTINIL  
RENACIDIN, CITRIC ACID  
RENAGEL, SEVELAMER HYDROCHLORIDE  
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE  
RENOVA, TRETINOIN  
RENVELA, SEVELAMER CARBONATE  
REPAGLINIDE, REPAGLINIDE  
REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
REPREXAIN, HYDROCODONE BITARTRATE  
REQUIP, ROPINIROLE HYDROCHLORIDE  
REQUIP XL, ROPINIROLE HYDROCHLORIDE  
RESCRIPTOR, DELAVIRDINE MESYLATE  
RESCULA, UNOPROSTONE ISOPROPYL  
RESECTISOL IN PLASTIC CONTAINER, MANNITOL  
RESERPINE, RESERPINE  
RESTASIS, CYCLOSPORINE  
RESTORIL, TEMAZEPAM  
RETIN-A, TRETINOIN  
RETIN-A MICRO, TRETINOIN  
RETIN-A-MICRO, TRETINOIN  
RETISERT, FLUOCINOLONE ACETONIDE  
RETROVIR, ZIDOVUDINE  
REVATIO, SILDENAFIL CITRATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* R \*\*

REVIA, NALTREXONE HYDROCHLORIDE  
 REVLIMID, LENALIDOMIDE  
 REVONTO, DANTROLENE SODIUM  
 REXULTI, BREXPIPIRAZOLE  
 REYATAZ, ATAZANAVIR SULFATE  
 REZIRA, HYDROCODONE BITARTRATE  
 RHINOCORT ALLERGY, BUDESONIDE (OTC)  
 RIBASPHERE, RIBAVIRIN  
 RIBAVARIN, RIBAVIRIN  
 RIBAVIRIN, RIBAVIRIN  
 RIDAURA, AURANOFIN  
 RIFABUTIN, RIFABUTIN  
 RIFADIN, RIFAMPIN  
 RIFAMATE, ISONIAZID  
 RIFAMPIN, RIFAMPIN  
 RIFATER, ISONIAZID  
 RILUTEK, RILUZOLE  
 RILUZOLE, RILUZOLE  
 RIMACTANE, RIFAMPIN  
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE  
 RIMSO-50, DIMETHYL SULFOXIDE  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 RIOMET, METFORMIN HYDROCHLORIDE  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 RISPERDAL, RISPERIDONE  
 RISPERDAL CONSTA, RISPERIDONE  
 RISPERIDONE, RISPERIDONE  
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE  
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE  
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE  
 RITONAVIR, RITONAVIR  
 RIVASTIGMINE, RIVASTIGMINE  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 ROBAXIN, METHOCARBAMOL  
 ROBAXIN-750, METHOCARBAMOL  
 ROBINUL, GLYCOPYRROLATE  
 ROBINUL FORTE, GLYCOPYRROLATE  
 ROCALTROL, CALCITRIOL  
 ROCEPHIN, CEFTRIAXONE SODIUM  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 ROGAINE (FOR MEN), MINOXIDIL (OTC)  
 ROGAINE (FOR WOMEN), MINOXIDIL (OTC)  
 ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE  
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE  
 ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 ROWASA, MESALAMINE  
 ROXICET, ACETAMINOPHEN  
 ROXICODONE, OXYCODONE HYDROCHLORIDE  
 ROZEREM, RAMELTEON  
 RYANODEX, DANTROLENE SODIUM  
 RYTARY, CARBIDOPA  
 RYTHMOL, PROPAFENONE HYDROCHLORIDE  
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE  
 RYZODEG 70/30, INSULIN ASPART

\*\* S \*\*

SABRIL, VIGABATRIN  
 SAFYRAL, DROSPIRENONE  
 SAIZEN, SOMATROPIN RECOMBINANT  
 SALAGEN, PILOCARPINE HYDROCHLORIDE  
 SALONPAS, MENTHOL (OTC)  
 SALURON, HYDROFLUMETHIAZIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* S \*\*

SAMSCA, TOLVAPTAN  
SANCUSO, GRANISETRON  
SANDIMMUNE, CYCLOSPORINE  
SANDOSTATIN, OCTREOTIDE ACETATE  
SANDOSTATIN LAR, OCTREOTIDE ACETATE  
SAPHRIS, ASENAPINE MALEATE  
SARAFEM, FLUOXETINE HYDROCHLORIDE  
SAVAYSA, EDOXABAN TOSYLATE  
SAVELLA, MILNACIPRAN HYDROCHLORIDE  
SAXENDA, LIRAGLUTIDE RECOMBINANT  
SCANDONEST L, LEVONORDEFIN  
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE  
SCANLUX-300, IOPAMIDOL  
SCANLUX-370, IOPAMIDOL  
SCLEROSOL, TALC  
SCOPOLAMINE, SCOPOLAMINE  
SEASONALE, ETHINYL ESTRADIOL  
SEASONIQUE, ETHINYL ESTRADIOL  
SECONAL SODIUM, SECOBARBITAL SODIUM  
SECTRAL, ACEBUTOLOL HYDROCHLORIDE  
SEEBRI, GLYCOPYRROLATE  
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
SELENIUM SULFIDE, SELENIUM SULFIDE  
SELFEMRA, FLUOXETINE HYDROCHLORIDE  
SELSUN, SELENIUM SULFIDE  
SELZENTRY, MARAVIROC  
SEMPREX-D, ACRIVASTINE  
SENSIPAR, CINACALCET HYDROCHLORIDE  
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE  
SEPTOCAINE, ARTICAINE HYDROCHLORIDE  
SEPTRA, SULFAMETHOXAZOLE  
SEPTRA DS, SULFAMETHOXAZOLE  
SEREVENT, SALMETEROL XINAFOATE  
SEROMYCIN, CYCLOSERINE  
SEROQUEL, QUETIAPINE FUMARATE  
SEROQUEL XR, QUETIAPINE FUMARATE  
SEROSTIM, SOMATROPIN RECOMBINANT  
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
SETLAKIN, ETHINYL ESTRADIOL  
SEVOFLURANE, SEVOFLURANE  
SFWOWASA, MESALAMINE  
SHADE UVAGUARD, AVOBENZONE (OTC)  
SIGNIFOR, PASIREOTIDE DIASPARTATE  
SIGNIFOR LAR, PASIREOTIDE PAMOATE  
SILDENAFIL CITRATE, SILDENAFIL CITRATE  
SILENOR, DOXEPIN HYDROCHLORIDE  
SILVADENE, SILVER SULFADIAZINE  
SIMBRINZA, BRIMONIDINE TARTRATE  
SIMCOR, NIACIN  
SIMVASTATIN, SIMVASTATIN  
SINE-AID IB, IBUPROFEN (OTC)  
SINEMET, CARBIDOPA  
SINEMET CR, CARBIDOPA  
SINGULAIR, MONTELUKAST SODIUM  
SINOGRAFIN, DIATRIZOATE MEGLUMINE  
SIROLIMUS, SIROLIMUS  
SIRTURO, BEDAQUILINE FUMARATE  
SITAVIG, ACYCLOVIR  
SIVEXTRO, TEDIZOLID PHOSPHATE  
SKELAXIN, METAXALONE  
SKLICE, IVERMECTIN  
SKYLA, LEVONORGESTREL  
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS  
SODIUM BICARBONATE, SODIUM BICARBONATE  
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* S \*\*

SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE  
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE  
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18  
SODIUM IODIDE I 123, SODIUM IODIDE I-123  
SODIUM IODIDE I 131, SODIUM IODIDE I-131  
SODIUM IODIDE I-131, SODIUM IODIDE I-131  
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE  
SODIUM NITRITE, SODIUM NITRITE  
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE  
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE  
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE  
SODIUM THIOSULFATE, SODIUM THIOSULFATE  
SOJOURN, SEVOFLURANE  
SOLARAZE, DICLOFENAC SODIUM  
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE  
SOLODYN, MINOCYCLINE HYDROCHLORIDE  
SOLTAMOX, TAMOXIFEN CITRATE  
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE  
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE  
SOMA, CARISOPRODOL  
SOMA COMPOUND, ASPIRIN  
SOMA COMPOUND W/ CODEINE, ASPIRIN  
SOMATULINE DEPOT, LANREOTIDE ACETATE  
SOMAVERT, PEGVISOMANT  
SONATA, ZALEPLON  
SOOLANTRA, IVERMECTIN  
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL  
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL  
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL  
SORIATANE, ACITRETIN  
SORILUX, CALCIPOTRIENE  
SORINE, SOTALOL HYDROCHLORIDE  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
SOTRADECOL, SODIUM TETRADECYL SULFATE  
SOTRET, ISOTRETINOIN  
SOTYLIZE, SOTALOL HYDROCHLORIDE  
SOVALDI, SOFOSBUVIR  
SPECTRACEF, CEFDITOREN PIVOXIL  
SPIRIVA, TIOTROPIUM BROMIDE  
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE  
SPIRONOLACTONE, SPIRONOLACTONE  
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
SPORANOX, ITRACONAZOLE  
SPRINTEC, ETHINYL ESTRADIOL  
SPRITAM, LEVETIRACETAM  
SPRIX, KETOROLAC TROMETHAMINE  
SPRYCEL, DASATINIB  
SPS, SODIUM POLYSTYRENE SULFONATE  
SSD, SILVER SULFADIAZINE  
SSD AF, SILVER SULFADIAZINE  
STALEVO 100, CARBIDOPA  
STALEVO 125, CARBIDOPA  
STALEVO 150, CARBIDOPA  
STALEVO 200, CARBIDOPA  
STALEVO 50, CARBIDOPA  
STALEVO 75, CARBIDOPA  
STARLIX, NATEGLINIDE  
STAVUDINE, STAVUDINE  
STAXYN, VARDENAFIL HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* S \*\*

STENDRA, AVANAFIL  
 STERILE WATER, STERILE WATER FOR IRRIGATION  
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION  
 STIE-CORT, HYDROCORTISONE  
 STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
 STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE  
 STIVARGA, REGORAFENIB  
 STRATTERA, ATOMOXETINE HYDROCHLORIDE  
 STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE  
 STRIANT, TESTOSTERONE  
 STRIBILD, COBICISTAT  
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE  
 STROMEKTOL, IVERMECTIN  
 STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89  
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE  
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE  
 SUBSYS, FENTANYL  
 SUCRAID, SACROSIDASE  
 SUCRALFATE, SUCRALFATE  
 SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE  
 SUFENTANIL CITRATE, SUFENTANIL CITRATE  
 SULAR, NISOLDIPINE  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 SULFADIAZINE, SULFADIAZINE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE  
 SULFAMYLON, MAFENIDE ACETATE  
 SULFASALAZINE, SULFASALAZINE  
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE  
 SULINDAC, SULINDAC  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE  
 SUNITINIB MALATE, SUNITINIB MALATE  
 SUPPRELIN LA, HISTRELIN ACETATE  
 SUPRANE, DESFLURANE  
 SUPRAX, CEFIXIME  
 SUPRENZA, PHENTERMINE HYDROCHLORIDE  
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS  
 SURMONTIL, TRIMIPRAMINE MALEATE  
 SURVANTA, BERACTANT  
 SUSTIVA, EFAVIRENZ  
 SUTENT, SUNITINIB MALATE  
 SYEDA, DROSPIRENONE  
 SYMBICORT, BUDESONIDE  
 SYMBYAX, FLUOXETINE HYDROCHLORIDE  
 SYMLIN, PRAMLINTIDE ACETATE  
 SYNACORT, HYDROCORTISONE  
 SYNALAR, FLUOCINOLONE ACETONIDE  
 SYNALGOS-DC, ASPIRIN  
 SYNAREL, NAFARELIN ACETATE  
 SYNERA, LIDOCAINE  
 SYNERCID, DALFOPRISTIN  
 SYNJARDY, EMPAGLIFLOZIN  
 SYNRIBO, OMACETAXINE MEPESUCCINATE  
 SYNTHROID, LEVOTHYROXINE SODIUM \*\*  
 SYPRINE, TRIENTINE HYDROCHLORIDE

\*\* T \*\*

TAB-PROFEN, IBUPROFEN (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* T \*\*

TACLONEX, BETAMETHASONE DIPROPIONATE  
TACROLIMUS, TACROLIMUS  
TAFINLAR, DABRAFENIB MESYLATE  
TAGAMET HB, CIMETIDINE (OTC)  
TAGRISSO, OSIMERTINIB MESYLATE  
TALC, TALC  
TALWIN, PENTAZOCINE LACTATE  
TAMIFLU, OSELTAMIVIR PHOSPHATE  
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
TAPAZOLE, METHIMAZOLE  
TARCEVA, ERLOTINIB HYDROCHLORIDE  
TARGRETIN, BEXAROTENE  
TARKA, TRANDOLAPRIL  
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE  
TASMAR, TOLCAPONE  
TAVIST-1, CLEMASTINE FUMARATE (OTC)  
TAXOL, PACLITAXEL  
TAXOTERE, DOCETAXEL  
TAZICEF, CEFTAZIDIME  
TAZORAC, TAZAROTENE  
TAZTIA XT, DILTIAZEM HYDROCHLORIDE  
TECFIDERA, DIMETHYL FUMARATE  
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT  
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT  
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT  
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT  
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT  
TECHNIVIE, OMBITASVIR  
TEFLARO, CEFTAROLINE FOSAMIL  
TEGRETOL, CARBAMAZEPINE  
TEGRETOL-XR, CARBAMAZEPINE  
TEKTRUNA, ALISKIREN HEMIFUMARATE  
TEKTRUNA HCT, ALISKIREN HEMIFUMARATE  
TELMISARTAN, TELMISARTAN  
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE  
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
TEMAZEPAM, TEMAZEPAM  
TEMODAR, TEMOZOLOMIDE  
TEMOVATE, CLOBETASOL PROPIONATE  
TEMOZOLOMIDE, TEMOZOLOMIDE  
TENEX, GUANFACINE HYDROCHLORIDE  
TENOFVIR DISOPROXIL FUMARATE, TENOFVIR DISOPROXIL FUMARATE  
TENORETIC 100, ATENOLOL  
TENORETIC 50, ATENOLOL  
TENORMIN, ATENOLOL  
TENUATE, DIETHYLPROPION HYDROCHLORIDE  
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE  
TERAZOL 3, TERCONAZOLE  
TERAZOL 7, TERCONAZOLE  
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
TERBUTALINE SULFATE, TERBUTALINE SULFATE  
TERCONAZOLE, TERCONAZOLE  
TERIL, CARBAMAZEPINE  
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE  
TESSALON, BENZONATATE  
TESTIM, TESTOSTERONE  
TESTOPEL, TESTOSTERONE  
TESTOSTERONE, TESTOSTERONE



## APPENDIX A - PRODUCT NAME INDEX

\*\* T \*\*

TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE  
 TESTRED, METHYLTESTOSTERONE  
 TETRABENAZINE, TETRABENAZINE  
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE  
 TEVETEN, EPROSARTAN MESYLATE  
 TEXACORT, HYDROCORTISONE  
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201  
 THALOMID, THALIDOMIDE  
 THAM, TROMETHAMINE  
 THEO-24, THEOPHYLLINE  
 THEOCHRON, THEOPHYLLINE  
 THEOPHYLLINE, THEOPHYLLINE  
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THERMAZENE, SILVER SULFADIAZINE  
 THEROXIDIL, MINOXIDIL (OTC)  
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE  
 THIOGUANINE, THIOGUANINE  
 THIOLA, TIOPRONIN  
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE  
 THIOTEPA, THIOTEPA  
 THIOTHIXENE, THIOTHIXENE  
 THRIVE, NICOTINE POLACRILEX (OTC)  
 THYROGEN, THYROTROPIN ALFA  
 THYROLAR-0.25, LIOTRIX (T4  
 THYROLAR-0.5, LIOTRIX (T4  
 THYROLAR-1, LIOTRIX (T4  
 THYROLAR-2, LIOTRIX (T4  
 THYROLAR-3, LIOTRIX (T4  
 THYROSAFE, POTASSIUM IODIDE (OTC)  
 THYROSHIELD, POTASSIUM IODIDE (OTC)  
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE  
 TIAZAC, DILTIAZEM HYDROCHLORIDE  
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE  
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 TIGECYCLINE, TIGECYCLINE  
 TIKOSYN, DOFETILIDE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 TIMOPTIC, TIMOLOL MALEATE  
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE  
 TIMOPTIC-XE, TIMOLOL MALEATE  
 TINDAMAX, TINIDAZOLE  
 TINIDAZOLE, TINIDAZOLE  
 TIOCONAZOLE, TIOCONAZOLE (OTC)  
 TIROSINT, LEVOTHYROXINE SODIUM  
 TIS-U-SOL, MAGNESIUM SULFATE  
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 TIVICAY, DOLUTEGRAVIR SODIUM  
 TIVORBEX, INDOMETHACIN  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TOBI, TOBRAMYCIN  
 TOBI PODHALER, TOBRAMYCIN  
 TOBRADEX, DEXAMETHASONE  
 TOBRADEX ST, DEXAMETHASONE  
 TOBRAMYCIN, TOBRAMYCIN  
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE  
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE  
 TOBEX, TOBRAMYCIN  
 TODAY, NONOXYNOL-9 (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* T \*\*

TOFRANIL, IMIPRAMINE HYDROCHLORIDE  
 TOFRANIL-PM, IMIPRAMINE PAMOATE  
 TOLAK, FLUOROURACIL  
 TOLAZAMIDE, TOLAZAMIDE  
 TOLBUTAMIDE, TOLBUTAMIDE  
 TOLCAPONE, TOLCAPONE  
 TOLMETIN SODIUM, TOLMETIN SODIUM  
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
 TOPAMAX, TOPIRAMATE  
 TOPICORT, DESOXIMETASONE  
 TOPIRAMATE, TOPIRAMATE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 TOPROL-XL, METOPROLOL SUCCINATE  
 TORISEL, TEMSIROLIMUS  
 TORSEMIDE, TORSEMIDE  
 TOTECT, DEXRAZOXANE HYDROCHLORIDE  
 TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT  
 TOVIAZ, FESOTERODINE FUMARATE  
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 TRACLEER, BOSENTAN  
 TRADJENTA, LINAGLIPTIN  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRANDATE, LABETALOL HYDROCHLORIDE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 TRANSDERM SCOP, SCOPOLAMINE  
 TRANXENE, CLORAZEPATE DIPOTASSIUM  
 TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE  
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVATAN Z, TRAVOPROST  
 TRAVOPROST, TRAVOPROST  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TREANDA, BENDAMUSTINE HYDROCHLORIDE  
 TRECATOR, ETHIONAMIDE  
 TRELSTAR, TRIPTORELIN PAMOATE  
 TRESIBA, INSULIN DEGLUDEC  
 TRETINOIN, TRETINOIN  
 TREXALL, METHOTREXATE SODIUM  
 TREXIMET, NAPROXEN SODIUM  
 TREZIX, ACETAMINOPHEN  
 TRI LO SPRINTEC, ETHINYL ESTRADIOL  
 TRI-ESTARYLLA, ETHINYL ESTRADIOL  
 TRI-LEGEST 21, ETHINYL ESTRADIOL  
 TRI-LEGEST FE, ETHINYL ESTRADIOL  
 TRI-LINYAH, ETHINYL ESTRADIOL  
 TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL  
 TRI-LUMA, FLUOCINOLONE ACETONIDE  
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL  
 TRI-PREVIFEM, ETHINYL ESTRADIOL  
 TRI-SPRINTEC, ETHINYL ESTRADIOL  
 TRIACIN-C, CODEINE PHOSPHATE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
 TRIAMCINOLONE ACETONIDE IN ABSORBABLE, TRIAMCINOLONE ACETONIDE  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRIAZOLAM, TRIAZOLAM  
 TRIBENZOR, AMLODIPINE BESYLATE  
 TRICOR, FENOFIBRATE  
 TRIDERM, TRIAMCINOLONE ACETONIDE  
 TRIDIONE, TRIMETHADIONE  
 TRISENCE, TRIAMCINOLONE ACETONIDE  
 TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* T \*\*

TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE  
 TRIFLURIDINE, TRIFLURIDINE  
 TRIGLIDE, FENOFIBRATE  
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE  
 TRILEPTAL, OXCARBAZEPINE  
 TRILIPIX, CHOLINE FENOFIBRATE  
 TRILYTE, POLYETHYLENE GLYCOL 3350  
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 TRIMETHOPRIM, TRIMETHOPRIM  
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE  
 TRIOSTAT, LIOTHYRONINE SODIUM  
 TRISENOX, ARSENIC TRIOXIDE  
 TRIUMEQ, ABACAVIR SULFATE  
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)  
 TRIVORA-28, ETHINYL ESTRADIOL  
 TRIZIVIR, ABACAVIR SULFATE  
 TROKENDI XR, TOPIRAMATE  
 TROPHAMINE, AMINO ACIDS  
 TROPHAMINE 10%, AMINO ACIDS  
 TROPICACYL, TROPICAMIDE  
 TROPICAMIDE, TROPICAMIDE  
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE  
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE  
 TRUVADA, EMTRICITABINE  
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE  
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX  
 TUSSIGON, HOMATROPINE METHYLBROMIDE  
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX  
 TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX  
 TWINJECT 0.15, EPINEPHRINE  
 TWINJECT 0.3, EPINEPHRINE  
 TWYNSTA, AMLODIPINE BESYLATE  
 TYBOST, COBICISTAT  
 TYGACIL, TIGECYCLINE  
 TYKERB, LAPATINIB DITOSYLATE  
 TYLENOL, ACETAMINOPHEN (OTC)  
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN  
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN  
 TYVASO, TREPROSTINIL  
 TYZEKA, TELBIVUDINE  
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

\*\* U \*\*

U-CORT, HYDROCORTISONE ACETATE  
 UCERIS, BUDESONIDE  
 ULESFIA, BENZYL ALCOHOL  
 ULORIC, FEBUXOSTAT  
 ULTANE, SEVOFLURANE  
 ULTIVA, REMIFENTANIL HYDROCHLORIDE  
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 ULTRACET, ACETAMINOPHEN  
 ULTRAM, TRAMADOL HYDROCHLORIDE  
 ULTRAM ER, TRAMADOL HYDROCHLORIDE  
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT  
 ULTRAVATE, HALOBETASOL PROPIONATE  
 ULTRAVIST (PHARMACY BULK), IOPROMIDE  
 ULTRAVIST 150, IOPROMIDE  
 ULTRAVIST 240, IOPROMIDE  
 ULTRAVIST 300, IOPROMIDE  
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE  
 ULTRAVIST 370, IOPROMIDE  
 ULTRESA, PANCRELIPASE (AMYLASE)  
 UNASYN, AMPICILLIN SODIUM

## APPENDIX A - PRODUCT NAME INDEX

## \*\* U \*\*

UNIPHYL, THEOPHYLLINE  
 UNIRETIC, HYDROCHLOROTHIAZIDE  
 UNISOM, DOXYLAMINE SUCCINATE (OTC)  
 UNITHROID, LEVOTHYROXINE SODIUM \*\*  
 UNIVASC, MOEXIPRIL HYDROCHLORIDE  
 UPTRAVI, SELEXIPAG  
 URECHOLINE, BETHANECHOL CHLORIDE  
 UREX, METHENAMINE HIPPURATE  
 UROCIT-K, POTASSIUM CITRATE  
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE  
 URSO 250, URSODIOL  
 URSO FORTE, URSODIOL  
 URSODIOL, URSODIOL  
 UTIBRON, GLYCOPYRROLATE  
 UVADEX, METHOXSALEN

## \*\* V \*\*

VAGIFEM, ESTRADIOL  
 VAGISTAT-1, TIOCONAZOLE (OTC)  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE  
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE  
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE  
 VALIUM, DIAZEPAM  
 VALNAC, BETAMETHASONE VALERATE  
 VALPROATE SODIUM, VALPROATE SODIUM  
 VALPROIC ACID, VALPROIC ACID  
 VALSARTAN, VALSARTAN  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALSTAR PRESERVATIVE FREE, VALRUBICIN  
 VALTRES, VALACYCLOVIR HYDROCHLORIDE  
 VALTROPIN, SOMATROPIN RECOMBINANT  
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE  
 VANDAZOLE, METRONIDAZOLE  
 VANIQA, EFLORNITHINE HYDROCHLORIDE  
 VANOS, FLUOCINONIDE  
 VANTAS, HISTRELIN ACETATE  
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE  
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE  
 VARITHENA, POLIDOCANOL  
 VARUBI, ROLAPITANT HYDROCHLORIDE  
 VASCEPA, ICOSAPENT ETHYL  
 VASERETIC, ENALAPRIL MALEATE  
 VASOSTRICT, VASOPRESSIN  
 VASOTEC, ENALAPRIL MALEATE  
 VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE  
 VECTICAL, CALCITRIOL  
 VECURONIUM BROMIDE, VECURONIUM BROMIDE  
 VELCADE, BORTEZOMIB  
 VELETRI, EPOPROSTENOL SODIUM  
 VELIVET, DESOGESTREL  
 VELPHORO, SUCROFERRIC OXYHYDROXIDE  
 VELTASSA, PATIROMER SORBITE X CALCIUM  
 VELTIN, CLINDAMYCIN PHOSPHATE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VENOFER, IRON SUCROSE  
 VENTAVIS, ILOPROST  
 VENTOLIN HFA, ALBUTEROL SULFATE  
 VERAMYST, FLUTICASONE FUROATE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 VERDESO, DESONIDE  
 VEREGEN, SINECATECHINS

## APPENDIX A - PRODUCT NAME INDEX

\*\* v \*\*

VERELAN, VERAPAMIL HYDROCHLORIDE  
VERELAN PM, VERAPAMIL HYDROCHLORIDE  
VERSACLOZ, CLOZAPINE  
VESICARE, SOLIFENACIN SUCCINATE  
VEXOL, RIMEXOLONE  
VFEND, VORICONAZOLE  
VIAGRA, SILDENAFIL CITRATE  
VIBATIV, TELAVANCIN HYDROCHLORIDE  
VIBERZI, ELUXADOLINE  
VIBISONE, CYANOCOBALAMIN  
VIBRAMYCIN, DOXYCYCLINE  
VIBRAMYCIN, DOXYCYCLINE CALCIUM  
VIBRAMYCIN, DOXYCYCLINE HYCLATE  
VICOPROFEN, HYDROCODONE BITARTRATE  
VICTOZA, LIRAGLUTIDE RECOMBINANT  
VICTRELIS, BOCEPREVIR  
VIDAZA, AZACITIDINE  
VIDEX, DIDANOSINE  
VIDEX EC, DIDANOSINE  
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM  
VIENVA, ETHINYL ESTRADIOL  
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE  
VIIBRYD, VILAZODONE HYDROCHLORIDE  
VIMOVO, ESOMEPRAZOLE MAGNESIUM  
VIMPAT, LACOSAMIDE  
VINBLASTINE SULFATE, VINBLASTINE SULFATE  
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE  
VINORELBINE TARTRATE, VINORELBINE TARTRATE  
VIOKACE, PANCRELIPASE (AMYLASE  
VIORELE, DESOGESTREL  
VIRACEPT, NELFINAVIR MESYLATE  
VIRAMUNE, NEVIRAPINE  
VIRAMUNE XR, NEVIRAPINE  
VIRAZOLE, RIBAVIRIN  
VIREAD, TENOFOVIR DISOPROXIL FUMARATE  
VIROPTIC, TRIFLURIDINE  
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)  
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
VISIONBLUE, TRYPAN BLUE  
VISIPAQUE 270, IODIXANOL  
VISIPAQUE 320, IODIXANOL  
VISTARIL, HYDROXYZINE PAMOATE  
VISTOGARD, URIDINE TRIACETATE  
VISUDYNE, VERTEPORFIN  
VITAMIN D, ERGOCALCIFEROL  
VITAMIN K1, PHYTONADIONE  
VITEKTA, ELVITEGRAVIR  
VITRASE, HYALURONIDASE  
VITUZ, CHLORPHENIRAMINE MALEATE  
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE  
VIVELLE, ESTRADIOL  
VIVELLE-DOT, ESTRADIOL  
VIVITROL, NALTREXONE  
VIVLODEX, MELOXICAM  
VIZAMYL, FLUTEMETAMOL F-18  
VOGELXO, TESTOSTERONE  
VOLTAREN, DICLOFENAC SODIUM  
VOLTAREN-XR, DICLOFENAC SODIUM  
VORICONAZOLE, VORICONAZOLE  
VOSOL, ACETIC ACID, GLACIAL  
VOSOL HC, ACETIC ACID, GLACIAL  
VOSPIRE ER, ALBUTEROL SULFATE  
VOTRIENT, PAZOPANIB HYDROCHLORIDE  
VPRIV, VELAGLUCERASE ALFA  
VRAYLAR, CARIPRAZINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* V \*\*

VUMON, TENIPOSIDE  
 VUSION, MICONAZOLE NITRATE  
 VYFEMLA, ETHINYL ESTRADIOL  
 VYTORIN, EZETIMIBE  
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

\*\* W \*\*

WARFARIN SODIUM, WARFARIN SODIUM  
 WELCHOL, COLESEVELAM HYDROCHLORIDE  
 WELLBUTRIN, BUPROPION HYDROCHLORIDE  
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE  
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE  
 WERA, ETHINYL ESTRADIOL  
 WOMEN'S ROGAINE, MINOXIDIL (OTC)

\*\* X \*\*

XALATAN, LATANOPROST  
 XALKORI, CRIZOTINIB  
 XANAX, ALPRAZOLAM  
 XANAX XR, ALPRAZOLAM  
 XARELTO, RIVAROXABAN  
 XARTEMIS XR, ACETAMINOPHEN  
 XELJANZ, TOFACITINIB CITRATE  
 XELODA, CAPECITABINE  
 XENAZINE, TETRABENAZINE  
 XENICAL, ORLISTAT  
 XENON XE 133, XENON XE-133  
 XERESE, ACYCLOVIR  
 XIFAXAN, RIFAXIMIN  
 XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL  
 XOFIGO, RADIUM RA-223 DICHLORIDE  
 XOLEGEL, KETOCONAZOLE  
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE  
 XOPENEX HFA, LEVALBUTEROL TARTRATE  
 XTANDI, ENZALUTAMIDE  
 XTORO, FINAFLOXACIN  
 XULANE, ETHINYL ESTRADIOL  
 XURIDEN, URIDINE TRIACETATE  
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE  
 XYREM, SODIUM OXYBATE  
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

\*\* Y \*\*

YAELA, DROSPIRENONE  
 YASMIN, DROSPIRENONE  
 YAZ, DROSPIRENONE  
 YONDELIS, TRABECTEDIN

\*\* Z \*\*

ZADITOR, KETOTIFEN FUMARATE (OTC)  
 ZAFIRLUKAST, ZAFIRLUKAST  
 ZALEPLON, ZALEPLON  
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE  
 ZANOSAR, STREPTOZOCIN  
 ZANTAC, RANITIDINE HYDROCHLORIDE  
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)  
 ZANTAC 150, RANITIDINE HYDROCHLORIDE  
 ZANTAC 300, RANITIDINE HYDROCHLORIDE  
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)  
 ZARONTIN, ETHOSUXIMIDE  
 ZAROXOLYN, METOLAZONE

## APPENDIX A - PRODUCT NAME INDEX

\*\* Z \*\*

ZAVESCA, MIGLUSTAT  
ZEBETA, BISOPROLOL FUMARATE  
ZECUITY, SUMATRIPTAN SUCCINATE  
ZEGERID, OMEPRAZOLE  
ZEGERID OTC, OMEPRAZOLE (OTC)  
ZELAPAR, SELEGILINE HYDROCHLORIDE  
ZELBORAF, VEMURAFENIB  
ZEMPLAR, PARICALCITOL  
ZENATANE, ISOTRETINOIN  
ZENPEP, PANCRELIPASE (AMYLASE)  
ZERBAXA, CEFTOLOZANE SULFATE  
ZERIT, STAVUDINE  
ZESTORETIC, HYDROCHLOROTHIAZIDE  
ZESTRIL, LISINAPRIL  
ZETIA, EZETIMIBE  
ZETONNA, CICLESONIDE  
ZIAC, BISOPROLOL FUMARATE  
ZIAGEN, ABACAVIR SULFATE  
ZIANA, CLINDAMYCIN PHOSPHATE  
ZIDOVUDINE, ZIDOVUDINE  
ZINACEF, CEFUROXIME SODIUM  
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM  
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE  
ZINECARD, DEXRAZOXANE HYDROCHLORIDE  
ZINGO, LIDOCAINE HYDROCHLORIDE  
ZIOPTAN, TAFLUPROST  
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE  
ZIPSOR, DICLOFENAC POTASSIUM  
ZIRGAN, GANCICLOVIR  
ZITHROMAX, AZITHROMYCIN  
ZMAX, AZITHROMYCIN  
ZOCOR, SIMVASTATIN  
ZOFRAN, ONDANSETRON HYDROCHLORIDE  
ZOFRAN ODT, ONDANSETRON  
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
ZOHYDRO ER, HYDROCODONE BITARTRATE  
ZOLADEX, GOSERELIN ACETATE  
ZOLEDRONIC ACID, ZOLEDRONIC ACID  
ZOLINZA, VORINOSTAT  
ZOLMITRIPTAN, ZOLMITRIPTAN  
ZOLOFT, SERTRALINE HYDROCHLORIDE  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE  
ZOLPIMIST, ZOLPIDEM TARTRATE  
ZOMACTON, SOMATROPIN RECOMBINANT  
ZOMETA, ZOLEDRONIC ACID  
ZOMIG, ZOLMITRIPTAN  
ZOMIG-ZMT, ZOLMITRIPTAN  
ZONALON, DOXEPIN HYDROCHLORIDE  
ZONEGRAN, ZONISAMIDE  
ZONISAMIDE, ZONISAMIDE  
ZONTIVITY, VORAPAXAR SULFATE  
ZORBTIVE, SOMATROPIN RECOMBINANT  
ZORTRESS, EVEROLIMUS  
ZORVOLEX, DICLOFENAC  
ZOSYN, PIPERACILLIN SODIUM  
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM  
ZOVIA 1/35E-28, ETHINYL ESTRADIOL  
ZOVIA 1/50E-28, ETHINYL ESTRADIOL  
ZOVIRAX, ACYCLOVIR  
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE  
ZUPLENZ, ONDANSETRON  
ZURAMPIC, LESINURAD  
ZUTRIPRO, CHLORPHENIRAMINE MALEATE  
ZYBAN, BUPROPION HYDROCHLORIDE  
ZYCLARA, IMIQUIMOD

**APPENDIX A - PRODUCT NAME INDEX****\*\* Z \*\***

ZYDELIG, IDELALISIB  
ZYFLO, ZILEUTON  
ZYFLO CR, ZILEUTON  
ZYKADIA, CERITINIB  
ZYLET, LOTEPIREDNOL ETABONATE  
ZYLOPRIM, ALLOPURINOL  
ZYMAR, GATIFLOXACIN  
ZYMAXID, GATIFLOXACIN  
ZYPREXA, OLANZAPINE  
ZYPREXA RELPREVV, OLANZAPINE PAMOATE  
ZYPREXA ZYDIS, OLANZAPINE  
ZYRTEC, CETIRIZINE HYDROCHLORIDE  
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)  
ZYTIGA, ABIRATERONE ACETATE  
ZYVOX, LINEZOLID



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* 3 \*\*****3D IMAGING DRUG**

- \* 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**3M**

- \* 3M CO  
PERIDEX, CHLORHEXIDINE GLUCONATE
- \* 3M HEALTH CARE INC  
AVAGARD, ALCOHOL (OTC)  
DURAPREP, IODINE POVACRYLEX (OTC)
- \* 3M PHARMACEUTICALS INC  
PROVENTIL-HFA, ALBUTEROL SULFATE

**\*\* A \*\*****AAIPHARMA LLC**

- \* AAIPHARMA LLC  
AZASAN, AZATHIOPRINE

**ABBVIE**

- \* ABBVIE INC  
ADVICOR, LOVASTATIN  
ANDROGEL, TESTOSTERONE  
BIAXIN, CLARITHROMYCIN  
CREON, PANCRELIPASE (AMYLASE)  
CYCLOSPORINE, CYCLOSPORINE  
DEPACON, VALPROATE SODIUM  
DEPAKENE, VALPROIC ACID  
DEPAKOTE ER, DIVALPROEX SODIUM  
DEPAKOTE, DIVALPROEX SODIUM  
GENGRAF, CYCLOSPORINE  
K-TAB, POTASSIUM CHLORIDE  
KALETRA, LOPINAVIR  
MARINOL, DRONABINOL  
MAVIK, TRANDOLAPRIL  
MIVACRON, MIVACURIUM CHLORIDE  
NIASPAN, NIACIN  
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
NIMBEX, CISATRACURIUM BESYLATE  
NORVIR, RITONAVIR  
ORETIC, HYDROCHLOROTHIAZIDE  
SIMCOR, NIACIN  
SURVANTA, BERACTANT  
SYNTHROID, LEVOTHYROXINE SODIUM \*\*  
TARKA, TRANDOLAPRIL  
TEVETEN, EPROSARTAN MESYLATE  
TRICOR, FENOFIBRATE  
TRIDIONE, TRIMETHADIONE  
TRILIPIX, CHOLINE FENOFIBRATE  
ULTANE, SEVOFLURANE  
VICOPROFEN, HYDROCODONE BITARTRATE  
ZEMPLAR, PARICALCITOL

**ABBVIE ENDOCRINE**

- \* ABBVIE ENDOCRINE INC  
LUPANETA PACK, LEUPROLIDE ACETATE

**ABBVIE ENDOCRINE INC**

- \* ABBVIE ENDOCRINE INC  
LUPRON DEPOT, LEUPROLIDE ACETATE  
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

**ABBVIE INC**

- \* ABBVIE INC  
DUOPA, CARBIDOPA  
PROMETRIUM, PROGESTERONE  
TECHNIVIE, OMBITASVIR  
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM

**ABHAI**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ABHAI LLC

METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

**ABHAI INC**

\* ABHAI INC

DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

**ABRAXIS BIOSCIENCE**

\* ABRAXIS BIOSCIENCE LLC

ABRAXANE, PACLITAXEL

**ABRAXIS PHARM**

\* ABRAXIS PHARMACEUTICAL PRODUCTS

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

**ACCELRX LABS**

\* ACCELRX LABS LLC

CARISOPRODOL, CARISOPRODOL

**ACCORD HLTHCARE**

\* ACCORD HEALTHCARE INC

ALLOPURINOL, ALLOPURINOL

AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

ANASTROZOLE, ANASTROZOLE

BICALUTAMIDE, BICALUTAMIDE

BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE

CAPECITABINE, CAPECITABINE

CARBIDOPA AND LEVODOPA, CARBIDOPA

CISPLATIN, CISPLATIN

CLONAZEPAM, CLONAZEPAM

CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

CLOZAPINE, CLOZAPINE

DOCETAXEL, DOCETAXEL

DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE

ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM

ETOPOSIDE, ETOPOSIDE

FINASTERIDE, FINASTERIDE

FLUOROURACIL, FLUOROURACIL

GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

GLIMEPIRIDE, GLIMEPIRIDE

GLIPIZIDE, GLIPIZIDE

HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

LETROZOLE, LETROZOLE

LEVETIRACETAM, LEVETIRACETAM

LISINAPRIL, LISINAPRIL

METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

METHYLDOPA, METHYLDOPA

MITOMYCIN, MITOMYCIN

MONTELUKAST SODIUM, MONTELUKAST SODIUM

MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE

ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

SIMVASTATIN, SIMVASTATIN

TACROLIMUS, TACROLIMUS

TOPIRAMATE, TOPIRAMATE

TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

**ACCORD HLTHCARE INC**

\* ACCORD HEALTHCARE INC USA

FINASTERIDE, FINASTERIDE

RAMIPRIL, RAMIPRIL

TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**ACELLA PHARMS LLC**

\* ACELLA PHARMACEUTICALS LLC

GABAPENTIN, GABAPENTIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****ACI HEALTHCARE LTD**

\* ACI HEALTHCARE LTD  
GABAPENTIN, GABAPENTIN

**ACIC FINE CHEMS**

\* ACIC FINE CHEMICALS INC  
TRANEXAMIC ACID, TRANEXAMIC ACID

**ACORDA**

\* ACORDA THERAPEUTICS INC  
AMPYRA, DALFAMPRIDINE  
QUTENZA, CAPSAICIN  
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

**ACS DOBFAR**

\* ACS DOBFAR SPA  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
CEFAZOLIN SODIUM, CEFZOLIN SODIUM  
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE  
CEFOXITIN, CEFOXITIN SODIUM  
CEFTAZIDIME, CEFTAZIDIME  
CEFTRIAZONE, CEFTRIAZONE SODIUM  
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM  
KEFZOL, CEFZOLIN SODIUM  
MEROPENEM, MEROPENEM

**ACS DOBFAR INFO SA**

\* ACS DOBFAR INFO SA  
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCANAZOLE  
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ACS DOBFAR SPA**

\* ACS DOBFAR SPA  
AMPICILLIN SODIUM, AMPICILLIN SODIUM

**ACTAVIS ELIZABETH**

\* ACTAVIS ELIZABETH LLC  
ALPRAZOLAM, ALPRAZOLAM  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
CARBIDOPA AND LEVODOPA, CARBIDOPA  
CLONAZEPAM, CLONAZEPAM  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
GABAPENTIN, GABAPENTIN  
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
INDAPAMIDE, INDAPAMIDE  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
LAMOTRIGINE, LAMOTRIGINE  
LEVETIRACETAM, LEVETIRACETAM  
LOVASTATIN, LOVASTATIN  
MORPHINE SULFATE, MORPHINE SULFATE  
NIFEDIPINE, NIFEDIPINE  
OXAZEPAM, OXAZEPAM  
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* ACTAVIS ELIZABETH LLC**

PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 PROPYLTHIOURACIL, PROPYLTHIOURACIL  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 TEMAZEPAM, TEMAZEPAM  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**ACTAVIS GRP PTC****\* ACTAVIS GROUP PTC EHF**

HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

**ACTAVIS INC****\* ACTAVIS INC**

DOCETAXEL, DOCETAXEL  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 METHOXSALEN, METHOXSALEN  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ACTAVIS LABS FL INC****\* ACTAVIS LABORATORIES FL INC**

ALPRAZOLAM, ALPRAZOLAM  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CABERGOLINE, CABERGOLINE  
 CARTIA XT, DILTIAZEM HYDROCHLORIDE  
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLOZAPINE, CLOZAPINE  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE  
 DUTASTERIDE, DUTASTERIDE  
 FLUTAMIDE, FLUTAMIDE  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)  
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)  
 GUAIFENESIN, GUAIFENESIN (OTC)  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 KETOPROFEN, KETOPROFEN  
 LEVETIRACETAM, LEVETIRACETAM  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)  
 LORATADINE, LORATADINE (OTC)  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
 MIRTAZAPINE, MIRTAZAPINE  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE  
 NORCO, ACETAMINOPHEN  
 OMEPRAZOLE, OMEPRAZOLE  
 OXYCODONE AND ASPIRIN, ASPIRIN  
 PALIPERIDONE, PALIPERIDONE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RAMELTEON, RAMELTEON

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ACTAVIS LABORATORIES FL INC  
 RISPERIDONE, RISPERIDONE  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**ACTAVIS LABS NY INC**

\* ACTAVIS LABORATORIES NY INC  
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

**ACTAVIS LABS UT INC**

\* ACTAVIS LABORATORIES UT INC  
 ACTIGALL, URSODIOL  
 ALORA, ESTRADIOL  
 ANDRODERM, TESTOSTERONE  
 BREVICON 28-DAY, ETHINYL ESTRADIOL  
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
 CLONIDINE, CLONIDINE  
 CONDYLOX, PODOFILOX  
 CORDRAN, FLURANDRENOLIDE  
 CRINONE, PROGESTERONE  
 EMLA, LIDOCAINE  
 FENTANYL-100, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-75, FENTANYL  
 FIORICET W/ CODEINE, ACETAMINOPHEN  
 FIORINAL W/CODEINE, ASPIRIN  
 FIORINAL, ASPIRIN  
 GELNIQUE 3%, OXYBUTYNIN  
 GELNIQUE, OXYBUTYNIN CHLORIDE  
 INFED, IRON DEXTRAN  
 KADIAN, MORPHINE SULFATE  
 LIDOCAINE, LIDOCAINE  
 MICROZIDE, HYDROCHLOROTHIAZIDE  
 NOR-QD, NORETHINDRONE  
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+50 28-DAY, MESTRANOL  
 NUVESSA, METRONIDAZOLE  
 OXYTROL, OXYBUTYNIN  
 PROGESTERONE, PROGESTERONE  
 RAPAFLO, SILODOSIN  
 TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE  
 TENUATE, DIETHYLPROPION HYDROCHLORIDE  
 TESTOSTERONE, TESTOSTERONE  
 TRELSTAR, TRIPTORELIN PAMOATE  
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL

**ACTAVIS MID ATLANTIC**

\* ACTAVIS MID ATLANTIC LLC  
 ACETASOL HC, ACETIC ACID, GLACIAL  
 ACYCLOVIR, ACYCLOVIR  
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE  
 ADAPALENE, ADAPALENE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CICLOPIROX, CICLOPIROX  
 CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)  
 CONSTULOSE, LACTULOSE  
 DESOXIMETASONE, DESOXIMETASONE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ACTAVIS MID ATLANTIC LLC  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 ENULOSE, LACTULOSE  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE  
 HYDROCORTISONE, HYDROCORTISONE  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN, IBUPROFEN (OTC)  
 LEVETIRACETAM, LEVETIRACETAM  
 M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 NYSTATIN, NYSTATIN  
 PERMETHRIN, PERMETHRIN  
 PERMETHRIN, PERMETHRIN (OTC)  
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 VALNAC, BETAMETHASONE VALERATE

**ACTAVIS TOTOWA**

\* ACTAVIS TOTOWA LLC  
 BICALUTAMIDE, BICALUTAMIDE  
 CARBOPLATIN, CARBOPLATIN  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 FINASTERIDE, FINASTERIDE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 OXALIPLATIN, OXALIPLATIN  
 PACLITAXEL, PACLITAXEL  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 REPAGLINIDE, REPAGLINIDE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

**ACTELION PHARMS LTD**

\* ACTELION PHARMACEUTICALS LTD  
 OPSUMIT, MACITENTAN  
 TRACLEER, BOSENTAN  
 UPTRAVI, SELEXIPAG  
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE  
 VELETRI, EPOPROSTENOL SODIUM  
 VENTAVIS, ILOPROST  
 ZAVESCA, MIGLUSTAT

**ACTIENT PHARMS**

\* ACTIENT PHARMACEUTICALS LLC  
 TESTOPEL, TESTOSTERONE  
 THEO-24, THEOPHYLLINE

**ACTIVIS TOTOWA LLC**

\* ACTIVIS TOTOWA LLC  
 TOPIRAMATE, TOPIRAMATE

**ADAPT PHARMA**

\* ADAPT PHARMA INC  
 NARCAN, NALOXONE HYDROCHLORIDE

**ADARE PHARMS INC**

\* ADARE PHARMACEUTICALS INC  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**AEGERION**

\* AEGERION PHARMACEUTICALS INC  
 JUXTAPID, LOMITAPIDE MESYLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****AGOURON**

\* AGOURON PHARMACEUTICALS INC  
VIRACEPT, NELFINAVIR MESYLATE

**AIPING PHARM INC**

\* AIPING PHARMACEUTICAL INC  
FOLIC ACID, FOLIC ACID

**AJANTA PHARMA**

\* AJANTA PHARMA LTD  
LEVETIRACETAM, LEVETIRACETAM

**AJANTA PHARMA LTD**

\* AJANTA PHARMA LTD  
IRBESARTAN, IRBESARTAN  
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
RISPERIDONE, RISPERIDONE

**AKORN**

\* AKORN INC  
ADENOSINE, ADENOSINE  
AK-FLUOR 10%, FLUORESCEIN SODIUM  
AK-FLUOR 25%, FLUORESCEIN SODIUM  
AKBETA, LEVOBUNOLOL HYDROCHLORIDE  
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE  
AKTEN, LIDOCAINE HYDROCHLORIDE  
AKTOB, TOBRAMYCIN  
ALFENTA, ALFENTANIL HYDROCHLORIDE  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
ATROPINE SULFATE, ATROPINE SULFATE  
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC  
BAL, DIMERCAPROL  
BALANCED SALT, CALCIUM CHLORIDE  
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
CALCITRIOL, CALCITRIOL  
CAPASTAT SULFATE, CAPREOMYCIN SULFATE  
CARBOPLATIN, CARBOPLATIN  
CROMOLYN SODIUM, CROMOLYN SODIUM  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
ENDOSOL EXTRA, CALCIUM CHLORIDE  
ERYTHROMYCIN, ERYTHROMYCIN  
GENTAK, GENTAMICIN SULFATE  
GENTAMICIN SULFATE, GENTAMICIN SULFATE  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
IC-GREEN, INDOCYANINE GREEN  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)  
LATANOPROST, LATANOPROST  
LEVOFLOXACIN, LEVOFLOXACIN  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
LORAZEPAM, LORAZEPAM  
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM  
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC  
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC  
OFLOXACIN, OFLOXACIN  
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE  
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE  
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE  
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
TERBUTALINE SULFATE, TERBUTALINE SULFATE  
TIMOLOL MALEATE, TIMOLOL MALEATE  
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
TROPICACYL, TROPICAMIDE  
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* AKORN INC  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**AKORN INC**

\* AKORN INC  
 ACETYLCYSTEINE, ACETYLCYSTEINE  
 APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE  
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DOXERCALCIFEROL, DOXERCALCIFEROL  
 DRONABINOL, DRONABINOL  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 INAPSINE, DROPERIDOL  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE  
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE  
 TOBRAMYCIN, TOBRAMYCIN  
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ALARA PHARM**

\* ALARA PHARMACEUTICAL CORPORATION  
 LEVO-T, LEVOTHYROXINE SODIUM \*\*

**ALCON**

\* ALCON INC  
 TRIESENCE, TRIAMCINOLONE ACETONIDE

\* ALCON LABORATORIES INC  
 ALCaine, PROPARACAINE HYDROCHLORIDE  
 ALOMIDE, LODOXAMIDE TROMETHAMINE  
 BETOPTIC S, BETAXOLOL HYDROCHLORIDE  
 BETOPTIC, BETAXOLOL HYDROCHLORIDE  
 BSS PLUS, CALCIUM CHLORIDE  
 BSS, CALCIUM CHLORIDE  
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE  
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE  
 DENDRID, IDOXURIDINE  
 EMADINE, EMEDASTINE DIFUMARATE  
 FLAREX, FLUOROMETHOLONE ACETATE  
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE  
 MAXIDEX, DEXAMETHASONE  
 MAXITROL, DEXAMETHASONE  
 MIOSTAT, CARBACHOL  
 MYDRIACYL, TROPICAMIDE  
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NATACYN, NATAMYCIN  
 OMNIPRED, PREDNISOLONE ACETATE  
 PATANOL, OLOPATADINE HYDROCHLORIDE  
 TOBRADEX, DEXAMETHASONE  
 TOBREX, TOBRAMYCIN  
 VEXOL, RIMEXOLONE

**ALCON LABS INC**

\* ALCON LABORATORIES INC  
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE  
 MAXITROL, DEXAMETHASONE  
 TOBREX, TOBRAMYCIN



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****ALCON PHARMA**

\* ALCON RESEARCH LTD  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
 ZADITOR, KETOTIFEN FUMARATE (OTC)

**ALCON PHARMS LTD**

\* ALCON PHARMACEUTICALS LTD  
 AZOPT, BRINZOLAMIDE  
 BETADINE, POVIDONE-IODINE  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRODEX, CIPROFLOXACIN  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 DUREZOL, DIFLUPREDNATE  
 FLUORESCITE, FLUORESCEIN SODIUM  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)  
 MOXEZA, MOXIFLOXACIN HYDROCHLORIDE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE  
 NEVANAC, NEPAFENAC  
 OFLOXACIN, OFLOXACIN  
 PATADAY, OLOPATADINE HYDROCHLORIDE  
 PATANASE, OLOPATADINE HYDROCHLORIDE  
 QOLIANA, BRIMONIDINE TARTRATE  
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
 TOBRADEX ST, DEXAMETHASONE  
 TRAVATAN Z, TRAVOPROST  
 TRIFLURIDINE, TRIFLURIDINE  
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE

**ALCON RES**

\* ALCON RESEARCH LTD  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE  
 LATANOPROST, LATANOPROST

**ALCON RES LTD**

\* ALCON RESEARCH LTD  
 BIMATOPROST, BIMATOPROST  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 ILEVRO, NEPAFENAC  
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE  
 METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
 PAZEO, OLOPATADINE HYDROCHLORIDE  
 SIMBRINZA, BRIMONIDINE TARTRATE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 XTORO, FINAFLOXACIN

**ALEMBIC LTD**

\* ALEMBIC LTD  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 METRONIDAZOLE, METRONIDAZOLE  
 MODAFINIL, MODAFINIL  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**ALEMBIC PHARMS LTD**

\* ALEMBIC PHARMACEUTICALS LTD  
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
 ARIPIPIRAZOLE, ARIPIPIRAZOLE  
 CELECOXIB, CELECOXIB  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* ALEMBIC PHARMACEUTICALS LTD**

DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE  
 DESVENLAFAXINE, DESVENLAFAXINE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 FAMOTIDINE, FAMOTIDINE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LAMOTRIGINE, LAMOTRIGINE  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LINEZOLID, LINEZOLID  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 MEPROBAMATE, MEPROBAMATE  
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 METRONIDAZOLE, METRONIDAZOLE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TELMISARTAN, TELMISARTAN  
 VALSARTAN, VALSARTAN  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZOLMITRIPTAN, ZOLMITRIPTAN

**ALIMERA SCIENCES INC**

\* ALIMERA SCIENCES INC  
 ILUVIEN, FLUOCINOLONE ACETONIDE

**ALKEM**

\* ALKEM LABORATORIES LTD  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 GABAPENTIN, GABAPENTIN  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**ALKEM LABS LTD**

\* ALKEM LABORATORIES LTD  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEPHALEXIN, CEPHALEXIN  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE  
 GABAPENTIN, GABAPENTIN  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 LINEZOLID, LINEZOLID  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 OLANZAPINE, OLANZAPINE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

**ALKERMES**

\* ALKERMES INC  
 VIVITROL, NALTREXONE

**ALKERMES INC**

\* ALKERMES INC  
 ARISTADA, ARIPIRAZOLE LAUROXIL

**ALKOPHARMA USA**

\* ALKOPHARMA USA INC  
 AMPHOTEC, AMPHOTERICIN B

**ALLEGIANCE HLTHCARE**

\* ALLEGIANCE HEALTHCARE CORP  
 POVIDONE IODINE, POVIDONE-IODINE (OTC)

**ALLERGAN**

\* ALLERGAN  
 ACULAR LS, KETOROLAC TROMETHAMINE  
 ALPHAGAN P, BRIMONIDINE TARTRATE  
 BLEPH-10, SULFACETAMIDE SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

- \* ALLERGAN
  - GENOPTIC, GENTAMICIN SULFATE
  - ZYMAXID, GATIFLOXACIN
- \* ALLERGAN INC
  - ACULAR, KETOROLAC TROMETHAMINE
  - ACUVAIL, KETOROLAC TROMETHAMINE
  - ACZONE, DAPSONE
  - ALOCRI, NEDOCROMIL SODIUM
  - ALPHAGAN P, BRIMONIDINE TARTRATE
  - AVAGE, TAZAROTENE
  - AZELEX, AZELAIC ACID
  - COMBIGAN, BRIMONIDINE TARTRATE
  - ELESTAT, EPINASTINE HYDROCHLORIDE
  - LASTACAPT, ALCAFTADINE
  - LATISSE, BIMATOPROST
  - LUMIGAN, BIMATOPROST
  - OCUFLOX, OFLOXACIN
  - OZURDEX, DEXAMETHASONE
  - POLYTRIM, POLYMYXIN B SULFATE
  - RESTASIS, CYCLOSPORINE
  - TAZORAC, TAZAROTENE
  - ZYMAR, GATIFLOXACIN
- \* ALLERGAN PHARMACEUTICAL
  - BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
  - BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
  - BLEPHAMIDE, PREDNISOLONE ACETATE
  - FML FORTE, FLUOROMETHOLONE
  - FML, FLUOROMETHOLONE
  - HERPLEX, IDOXURIDINE
  - OCUFEN, FLURBIPROFEN SODIUM
  - PRED FORTE, PREDNISOLONE ACETATE
  - PRED MILD, PREDNISOLONE ACETATE
  - PRED-G, GENTAMICIN SULFATE
- ALLERQUEST**
- \* ALLERQUEST LLC
  - PRE-PEN, BENZYL PENICILLOYL POLYLYSINE
- ALLIED PHARMA INC**
- \* ALLIED PHARMA INC
  - CLARITHROMYCIN, CLARITHROMYCIN
  - TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
  - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
- ALLOS**
- \* ALLOS THERAPEUTICS INC
  - FOLOTYN, PRALATREXATE
- ALPHARMA**
- \* ALPHARMA USPD INC
  - PREDNISOLONE, PREDNISOLONE
  - VALPROIC ACID, VALPROIC ACID
- ALPHARMA PHARMS**
- \* ALPHARMA PHARMACEUTICALS LLC
  - EMBEDA, MORPHINE SULFATE
- ALRA**
- \* ALRA LABORATORIES INC
  - CHOLAC, LACTULOSE
  - CONSTILAC, LACTULOSE
  - GEN-XENE, CLORAZEPATE DIPOTASSIUM
  - IBU-TAB 200, IBUPROFEN (OTC)
  - IBU-TAB, IBUPROFEN
- ALTAIRE PHARMS INC**
- \* ALTAIRE PHARMACEUTICALS INC
  - DICLOFENAC SODIUM, DICLOFENAC SODIUM
  - NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
  - OFLOXACIN, OFLOXACIN
- ALTATHERA PHARMS LLC**
- \* ALTATHERA PHARMACEUTICALS LLC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ALTATHERA PHARMACEUTICALS LLC  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**ALVOGEN**

\* ALVOGEN INC  
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**ALVOGEN INC**

\* ALVOGEN INC  
ACETYLCYSTEINE, ACETYLCYSTEINE  
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
EXEMESTANE, EXEMESTANE  
MACROBID, NITROFURANTOIN  
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE  
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE

**ALVOGEN IPCO SARL**

\* ALVOGEN IPCO SARL  
ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
ATENOLOL, ATENOLOL  
TENORETIC 100, ATENOLOL  
TENORETIC 50, ATENOLOL  
TENORMIN, ATENOLOL  
ZESTORETIC, HYDROCHLOROTHIAZIDE  
ZESTRIL, LISINOPRIL

**ALVOGEN MALTA**

\* ALVOGEN MALTA OPERATIONS LTD  
CARBIDOPA, CARBIDOPA  
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE  
NAPRELAN, NAPROXEN SODIUM  
NATEGLINIDE, NATEGLINIDE  
NEVIRAPINE, NEVIRAPINE

**ALVOGEN PINE BROOK**

\* ALVOGEN PINE BROOK INC  
DISULFIRAM, DISULFIRAM  
RIVASTIGMINE, RIVASTIGMINE

**AM ANTIBIOTICS**

\* AMERICAN ANTIBIOTICS INC  
AMOXICILLIN, AMOXICILLIN

**AMAG PHARMS INC**

\* AMAG PHARMACEUTICALS INC  
FERAHEME, FERUMOXYTOL

**AMARIN PHARMS**

\* AMARIN PHARMACEUTICALS IRELAND LTD  
VASCEPA, ICOSAPENT ETHYL

**AMEDRA PHARMS**

\* AMEDRA PHARMACEUTICALS LLC  
ADRENACLICK, EPINEPHRINE  
DEXEDRINE, DEXTROAMPHETAMINE SULFATE  
HYDROCORTISONE, HYDROCORTISONE  
TWINJECT 0.15, EPINEPHRINE  
TWINJECT 0.3, EPINEPHRINE

**AMEDRA PHARMS LLC**

\* AMEDRA PHARMACEUTICALS LLC  
ALBENZA, ALBENDAZOLE  
MEBENDAZOLE, MEBENDAZOLE

**AMERIGEN PHARMS LTD**

\* AMERIGEN PHARMACEUTICALS LTD  
CARBIDOPA, CARBIDOPA

**AMGEN**

\* AMGEN INC  
SENSIPAR, CINACALCET HYDROCHLORIDE

**AMGEN INC**

\* AMGEN INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* AMGEN INC

CORLANOR, IVABRADINE HYDROCHLORIDE

**AMHERST PHARMS LLC**

\* AMHERST PHARMACEUTICALS LLC

ZOLPIMIST, ZOLPIDEM TARTRATE

**AMNEAL PHARM**

\* AMNEAL PHARMACEUTICAL

ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
 FLECAINIDE ACETATE, FLECAINIDE ACETATE  
 FOLIC ACID, FOLIC ACID  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 PRIMIDONE, PRIMIDONE

**AMNEAL PHARMS**

\* AMNEAL PHARMACEUTICALS

ACYCLOVIR, ACYCLOVIR  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 ARIPIRAZOLE, ARIPIRAZOLE  
 ATOVAQUONE, ATOVAQUONE  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 CALCIUM ACETATE, CALCIUM ACETATE  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DUTASTERIDE, DUTASTERIDE  
 ENTECAVIR, ENTECAVIR  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 FELBAMATE, FELBAMATE  
 GABAPENTIN, GABAPENTIN  
 IBUPROFEN, IBUPROFEN (OTC)  
 INDOMETHACIN, INDOMETHACIN  
 ITRACONAZOLE, ITRACONAZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 LIDOCAINE, LIDOCAINE  
 LINEZOLID, LINEZOLID  
 LORAZEPAM, LORAZEPAM  
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 METAXALONE, METAXALONE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 NIACIN, NIACIN  
 NITROFURANTOIN, NITROFURANTOIN  
 NIZATIDINE, NIZATIDINE  
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXCARBAZEPINE, OXCARBAZEPINE  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PARICALCITOL, PARICALCITOL  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE  
 QUININE SULFATE, QUININE SULFATE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

- \* AMNEAL PHARMACEUTICALS
  - RISPERIDONE, RISPERIDONE
  - SILDENAFIL CITRATE, SILDENAFIL CITRATE
  - SPIRONOLACTONE, SPIRONOLACTONE
  - TELMISARTAN, TELMISARTAN
  - TEMOZOLOMIDE, TEMOZOLOMIDE
  - TOBRAMYCIN, TOBRAMYCIN
  - TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
  - VALSARTAN, VALSARTAN
  - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  - WARFARIN SODIUM, WARFARIN SODIUM
- \* AMNEAL PHARMACEUTICALS LLC
  - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
- \* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
  - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
  - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL

**AMNEAL PHARMS CO**

- \* AMNEAL PHARMACEUTICALS CO GMBH
  - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM

**AMNEAL PHARMS LLC**

- \* AMNEAL PHARMACEUTICALS LLC
  - ACTIVELLA, ESTRADIOL
  - AZATHIOPRINE, AZATHIOPRINE
  - BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE

**AMNEAL PHARMS NY**

- \* AMNEAL PHARMACEUTICALS NY LLC
  - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
  - ALPRAZOLAM, ALPRAZOLAM
  - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  - CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  - CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  - EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
  - GABAPENTIN, GABAPENTIN
  - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  - HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
  - IBUPROFEN, IBUPROFEN
  - IBUPROFEN, IBUPROFEN (OTC)
  - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  - NAPROXEN SODIUM, NAPROXEN SODIUM
  - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
  - NAPROXEN, NAPROXEN
  - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
  - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  - REPREXAIN, HYDROCODONE BITARTRATE
  - SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

**AMPHASTAR PHARM**

- \* AMPHASTAR PHARMACEUTICAL INC
  - AMPHADASE, HYALURONIDASE
  - ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
  - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

**AMPHASTAR PHARMS INC**

- \* AMPHASTAR PHARMACEUTICALS INC
  - CORTROSYN, COSYNTROPIN

**AMPOLGEN**

- \* AMPOLGEN PHARMACEUTICALS LLC
  - SODIUM PHENYL BUTYRATE, SODIUM PHENYL BUTYRATE

**ANACOR PHARMS INC**

- \* ANACOR PHARMACEUTICALS INC
  - KERYDIN, TAVABOROLE

**ANBEX**

- \* ANBEX INC
  - IOSAT, POTASSIUM IODIDE (OTC)

**ANBISON LAB CO LTD**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ANBISON LABORATORY CO LTD  
MONTELUKAST SODIUM, MONTELUKAST SODIUM

**ANCHEN PHARMS**

\* ANCHEN PHARMACEUTICALS INC  
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE  
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE  
FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
LAMOTRIGINE, LAMOTRIGINE  
LEVETIRACETAM, LEVETIRACETAM  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
TRETINOIN, TRETINOIN  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

\* ANCHEN PHARMACEUTICALS TAIWAN INC  
DIVALPROEX SODIUM, DIVALPROEX SODIUM

\* ANCHEN PHARMACEUTICALS, INC  
ALPRAZOLAM, ALPRAZOLAM  
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**ANDRX LABS LLC**

\* ANDRX LABS LLC  
FORTAMET, METFORMIN HYDROCHLORIDE

**ANI PHARMS**

\* ANI PHARMACEUTICALS INC  
CORTENEMA, HYDROCORTISONE  
LACTULOSE, LACTULOSE  
LUVOX, FLUVOXAMINE MALEATE  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

**ANI PHARMS INC**

\* ANI PHARMACEUTICALS INC  
ALPRAZOLAM, ALPRAZOLAM  
CEFUROXIME AXETIL, CEFUROXIME AXETIL  
CHLORPROPAMIDE, CHLORPROPAMIDE  
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE  
ETODOLAC, ETODOLAC  
FLECAINIDE ACETATE, FLECAINIDE ACETATE  
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
GLIPIZIDE, GLIPIZIDE  
GUANABENZ ACETATE, GUANABENZ ACETATE  
INDAPAMIDE, INDAPAMIDE  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
LITHOBID, LITHIUM CARBONATE  
LORAZEPAM, LORAZEPAM  
METHAZOLAMIDE, METHAZOLAMIDE  
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
NIZATIDINE, NIZATIDINE  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
RISPERIDONE, RISPERIDONE  
TESTOSTERONE, TESTOSTERONE  
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
VALPROIC ACID, VALPROIC ACID  
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**ANTARES PHARMA INC**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ANTARES PHARMA INC  
OTREXUP, METHOTREXATE  
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**ANTIBIOTICE**

\* ANTIBIOTICE SA  
AMPICILLIN SODIUM, AMPICILLIN SODIUM  
NAFCILLIN SODIUM, NAFCILLIN SODIUM

**ANTIBIOTICOS BRASIL**

\* ANTIBIOTICOS DO BRASIL LTDA  
CEFOXITIN, CEFOXITIN SODIUM

**ANTIBIOTICS SA**

\* ANTIBIOTICS SA  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

**ANTRIM PHARMS LLC**

\* ANTRIM PHARMACEUTICALS LLC  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

**APGDI**

\* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC  
MYRBETRIQ, MIRABEGRON

**APOPHARMA INC**

\* APOPHARMA INC  
FERRIPROX, DEFERIPRONE

**APOTEX**

\* APOTEX CORP  
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

\* APOTEX INC  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
CAPTOPRIL, CAPTOPRIL  
CARBIDOPA AND LEVODOPA, CARBIDOPA  
CEFUROXIME AXETIL, CEFUROXIME AXETIL  
CIMETIDINE, CIMETIDINE  
CIMETIDINE, CIMETIDINE (OTC)  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
CYCLOSPORINE, CYCLOSPORINE  
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
ENALAPRIL MALEATE, ENALAPRIL MALEATE  
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
EPLERENONE, EPLERENONE  
ETODOLAC, ETODOLAC  
FAMCICLOVIR, FAMCICLOVIR  
FAMOTIDINE, FAMOTIDINE  
FLUCONAZOLE, FLUCONAZOLE  
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
GEMFIBROZIL, GEMFIBROZIL  
GLIPIZIDE, GLIPIZIDE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LAMIVUDINE, LAMIVUDINE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
OMEPRAZOLE, OMEPRAZOLE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
PENTOXIFYLLINE, PENTOXIFYLLINE  
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
RAMIPRIL, RAMIPRIL  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* APOTEX INC**

TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE  
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

**APOTEX CORP****\* APOTEX CORP**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AZITHROMYCIN, AZITHROMYCIN  
 CABERGOLINE, CABERGOLINE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 RILUZOLE, RILUZOLE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**APOTEX INC****\* APOTEX INC**

ABACAVIR SULFATE, ABACAVIR SULFATE  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 ALPRAZOLAM, ALPRAZOLAM  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 ANASTROZOLE, ANASTROZOLE  
 ARIPIPIRAZOLE, ARIPIPIRAZOLE  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BENZONATATE, BENZONATATE  
 BICALUTAMIDE, BICALUTAMIDE  
 BIMATOPROST, BIMATOPROST  
 BROMFENAC SODIUM, BROMFENAC SODIUM  
 CALCITONIN-SALMON, CALCITONIN SALMON  
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CEFPROZIL, CEFPROZIL  
 CELECOXIB, CELECOXIB  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CEVIMELINE, CEVIMELINE HYDROCHLORIDE  
 CICLOPIROX, CICLOPIROX  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 DUTASTERIDE, DUTASTERIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 FENOFIBRATE (MICRONIZED), FENOFIBRATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IMIQUIMOD, IMIQUIMOD  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LAMIVUDINE, LAMIVUDINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* A \*\*

\* APOTEX INC  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LOVASTATIN, LOVASTATIN  
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE  
 MODAFINIL, MODAFINIL  
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID  
 NABUMETONE, NABUMETONE  
 NEVIRAPINE, NEVIRAPINE  
 OFLOXACIN, OFLOXACIN  
 OLANZAPINE, OLANZAPINE  
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 OXCARBAZEPINE, OXCARBAZEPINE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RAMIPRIL, RAMIPRIL  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RASAGILINE MESYLATE, RASAGILINE MESYLATE  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 RISPERIDONE, RISPERIDONE  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 TRAVOPROST, TRAVOPROST  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID  
 ZOLMITRIPTAN, ZOLMITRIPTAN  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

\* APOTEX INC ETOBICOKE SITE  
 ACYCLOVIR, ACYCLOVIR  
 ALLOPURINOL, ALLOPURINOL  
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CARVEDILOL, CARVEDILOL  
 CILOSTAZOL, CILOSTAZOL  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DILTIZAC, DILTIAZEM HYDROCHLORIDE  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ETODOLAC, ETODOLAC  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 GABAPENTIN, GABAPENTIN  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 LORATADINE, LORATADINE (OTC)  
 MELOXICAM, MELOXICAM  
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 OXAPROZIN, OXAPROZIN  
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

- \* APOTEX INC ETOBICOKE SITE  
TOPIRAMATE, TOPIRAMATE  
TORSEMIDE, TORSEMIDE  
ZONISAMIDE, ZONISAMIDE
- \* APOTEX INC RICHMOND HILL  
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
BUDESONIDE, BUDESONIDE  
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
FLUNISOLIDE, FLUNISOLIDE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
RISPERIDONE, RISPERIDONE
- \* APOTEX INC.  
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

**APOTEX TECHNOLOGIES**

- \* APOTEX TECHNOLOGIES INC  
PAXIL CR, PAROXETINE HYDROCHLORIDE  
PAXIL, PAROXETINE HYDROCHLORIDE

**APOTHECON**

- \* APOTHECON INC DIV BRISTOL MYERS SQUIBB  
KENALOG-10, TRIAMCINOLONE ACETONIDE  
KENALOG-40, TRIAMCINOLONE ACETONIDE

**APP PHARMS**

- \* APP PHARMACEUTICALS LLC  
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

**APPCO PHARMA LLC**

- \* APPCO PHARMA LLC  
METRONIDAZOLE, METRONIDAZOLE

**APRECIA PHARMS CO**

- \* APRECIA PHARMACEUTICALS CO  
SPRITAM, LEVETIRACETAM

**APTALIS PHARMA US**

- \* APTALIS PHARMA US INC  
BENTYL, DICYCLOMINE HYDROCHLORIDE

**AQUA PHARMS**

- \* AQUA PHARMACEUTICALS  
CORDRAN SP, FLURANDRENOLIDE  
CORDRAN, FLURANDRENOLIDE  
MONODOX, DOXYCYCLINE  
VERDESO, DESONIDE

- \* AQUA PHARMACEUTICALS LLC  
FLUOROPLEX, FLUOROURACIL  
XOLEGEL, KETOCONAZOLE

**AQUA PHARMS LLC**

- \* AQUA PHARMACEUTICALS LLC  
ACTICLATE, DOXYCYCLINE HYCLATE

**ARBOR PHARMS IRELAND**

- \* ARBOR PHARMACEUTICALS IRELAND LTD  
EDARBI, AZILSARTAN KAMEDOXOMIL  
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL

**ARBOR PHARMS LLC**

- \* ARBOR PHARMACEUTICALS LLC  
BIDIL, HYDRALAZINE HYDROCHLORIDE  
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE  
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE  
ERY-TAB, ERYTHROMYCIN  
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE  
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE  
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE  
ERYTHROMYCIN, ERYTHROMYCIN  
EVEKEO, AMPHETAMINE SULFATE  
GLIADEL, CARMUSTINE  
NYMALIZE, NIMODIPINE  
PCE, ERYTHROMYCIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ARBOR PHARMACEUTICALS LLC  
SOTYLIZE, SOTALOL HYDROCHLORIDE

**ARCO PHARMS LLC**

\* ARCO PHARMACEUTICALS LLC  
THYROSHIELD, POTASSIUM IODIDE (OTC)

**ARDEA BIOSCIENCES**

\* ARDEA BIOSCIENCES INC  
ZURAMPIC, LESINURAD

**AREVA PHARMS**

\* AREVA PHARMACEUTICALS INC  
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**ARIAD**

\* ARIAD PHARMACEUTICALS INC  
ICLUSIG, PONATINIB HYDROCHLORIDE

**ASCEND THERAPS US**

\* ASCEND THERAPEUTICS US LLC  
ESTROGEL, ESTRADIOL

**ASCENT PHARMS INC**

\* ASCENT PHARMACEUTICALS INC  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

**ASPEN GLOBAL**

\* ASPEN GLOBAL INC  
MYLERAN, BUSULFAN

**ASPEN GLOBAL INC**

\* ASPEN GLOBAL INC  
CYCLESSA, DESOGESTREL  
LEUKERAN, CHLORAMBUCIL  
THIOGUANINE, THIOGUANINE

**ASTELLAS**

\* ASTELLAS PHARMA US INC  
ADENOCARD, ADENOSINE  
ADENOSCAN, ADENOSINE  
AMBISOME, AMPHOTERICIN B  
ASTAGRAF XL, TACROLIMUS  
CRESEMBA, ISAVUCONAZONIUM SULFATE  
LEXISCAN, REGADENOSON  
MYCAMINE, MICAFUNGIN SODIUM  
PROGRAF, TACROLIMUS  
PROTOPIC, TACROLIMUS  
VESICARE, SOLIFENACIN SUCCINATE  
XTANDI, ENZALUTAMIDE

**ASTRAZENECA**

\* ASTRAZENECA LP  
ENTOCORT EC, BUDESONIDE  
PULMICORT FLEXHALER, BUDESONIDE  
SYMBICORT, BUDESONIDE  
\* ASTRAZENECA PHARMACEUTICALS LP  
ATACAND HCT, CANDESARTAN CILEXETIL  
ATACAND, CANDESARTAN CILEXETIL  
FASLODEX, FULVESTRANT  
SEROQUEL XR, QUETIAPINE FUMARATE  
ZOMIG, ZOLMITRIPTAN  
ZOMIG-ZMT, ZOLMITRIPTAN  
\* ASTRAZENECA UK LTD  
ARIMIDEX, ANASTROZOLE  
CASODEX, BICALUTAMIDE  
MERREM, MEROPENEM  
ZOLADEX, GOSERELIN ACETATE

**ASTRAZENECA AB**

\* ASTRAZENECA AB  
BYDUREON, EXENATIDE SYNTHETIC  
BYETTA, EXENATIDE SYNTHETIC  
FARXIGA, DAPAGLIFLOZIN PROPANEDIOL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ASTRAZENECA AB  
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE  
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE  
 SYMLIN, PRAMLINTIDE ACETATE  
 XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL

**ASTRAZENECA LP**

\* ASTRAZENECA LP  
 BRILINTA, TICAGRELOR  
 NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

**ASTRAZENECA PHARMS**

\* ASTRAZENECA PHARMACEUTICALS LP  
 DALIRESP, ROFLUMILAST  
 EPANOVA, OMEGA-3-CARBOXYLIC ACIDS  
 IRESSA, GEFITINIB  
 LYNPARZA, OLAPARIB  
 MOVANTIK, NALOXEGOL OXALATE  
 NEXIUM IV, ESOMEPRAZOLE SODIUM  
 NEXIUM, ESOMEPRAZOLE MAGNESIUM  
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)  
 PRILOSEC, OMEPRAZOLE  
 PRILOSEC, OMEPRAZOLE MAGNESIUM  
 PULMICORT RESPULES, BUDESONIDE  
 RHINOCORT ALLERGY, BUDESONIDE (OTC)  
 SEROQUEL, QUETIAPINE FUMARATE  
 TAGRISSE, OSIMERTINIB MESYLATE  
 TOPROL-XL, METOPROLOL SUCCINATE  
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE

**ATLAS PHARMS LLC**

\* ATLAS PHARMACEUTICALS LLC  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**ATON**

\* ATON PHARMA INC  
 CUPRIMINE, PENICILLAMINE  
 EDECRIN, ETHACRYNATE SODIUM  
 EDECRIN, ETHACRYNIC ACID  
 LACRISERT, HYDROXYPROPYL CELLULOSE  
 LODOSYN, CARBIDOPA  
 SYPRINE, TRIENTINE HYDROCHLORIDE  
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE  
 TIMOPTIC, TIMOLOL MALEATE

**ATON PHARMA VPNA**

\* ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC  
 DEMSER, METYROSINE

**AUROBINDO**

\* AUROBINDO PHARMA LTD  
 AMOXICILLIN, AMOXICILLIN  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 DIDANOSINE, DIDANOSINE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 NEVIRAPINE, NEVIRAPINE  
 ZIDOVUDINE, ZIDOVUDINE

**AUROBINDO PHARM**

\* AUROBINDO PHARMA USA INC  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 GABAPENTIN, GABAPENTIN  
 LEVETIRACETAM, LEVETIRACETAM  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

**AUROBINDO PHARMA**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* AUROBINDO PHARMA  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

\* AUROBINDO PHARMA LTD  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 ATENOLOL, ATENOLOL  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
 CARISOPRODOL, CARISOPRODOL  
 CARVEDILOL, CARVEDILOL  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFDINIR, CEFDINIR  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CEFPROZIL, CEFPROZIL  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DIDANOSINE, DIDANOSINE  
 FINASTERIDE, FINASTERIDE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
 GLYBURIDE, GLYBURIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MELOXICAM, MELOXICAM  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 RIBAVARIN, RIBAVIRIN  
 RIBAVIRIN, RIBAVIRIN  
 RISPERIDONE, RISPERIDONE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SIMVASTATIN, SIMVASTATIN  
 STAVUDINE, STAVUDINE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TOPIRAMATE, TOPIRAMATE  
 TORSEMIDE, TORSEMIDE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZALEPLON, ZALEPLON  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**AUROBINDO PHARMA LTD**

\* AUROBINDO PHARMA LIMITED  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

\* AUROBINDO PHARMA LTD

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* AUROBINDO PHARMA LTD**

ABACAVIR SULFATE, ABACAVIR SULFATE  
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 ALPRAZOLAM, ALPRAZOLAM  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 ARIPIPIRAZOLE, ARIPIPIRAZOLE  
 ATIENTIA NEXT, LEVONORGESTREL (OTC)  
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE  
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE  
 AZITHROMYCIN, AZITHROMYCIN  
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CEFIXIME, CEFIXIME  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ENTACAPONE, ENTACAPONE  
 ENTECAVIR, ENTECAVIR  
 EPTIFIBATIDE, EPTIFIBATIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
 FAMCICLOVIR, FAMCICLOVIR  
 FAMOTIDINE, FAMOTIDINE  
 FELODIPINE, FELODIPINE  
 FINASTERIDE, FINASTERIDE  
 FLECAINIDE ACETATE, FLECAINIDE ACETATE  
 GABAPENTIN, GABAPENTIN  
 GEMFIBROZIL, GEMFIBROZIL  
 GLIMEPIRIDE, GLIMEPIRIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LAMIVUDINE, LAMIVUDINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE  
 METRONIDAZOLE, METRONIDAZOLE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MODAFINIL, MODAFINIL  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE  
 OLANZAPINE, OLANZAPINE  
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXACILLIN SODIUM, OXACILLIN SODIUM  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PARICALCITOL, PARICALCITOL  
 PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* AUROBINDO PHARMA LTD**

PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE  
 RAMIPRIL, RAMIPRIL  
 REPAGLINIDE, REPAGLINIDE  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TELMISARTAN, TELMISARTAN  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALSARTAN, VALSARTAN

**\* AUROBINDO PHARMA LTD INC**

CEFPROZIL, CEFPROZIL  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEPHALEXIN, CEPHALEXIN  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 ZIDOVUDINE, ZIDOVUDINE

**AUROBINDO PHARMA USA****\* AUROBINDO PHARMA USA INC**

ALPRAZOLAM, ALPRAZOLAM  
 NAPROXEN, NAPROXEN  
 OMEPRAZOLE, OMEPRAZOLE

**AUROLIFE PHARMA LLC****\* AUROLIFE PHARMA LLC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**AUSTARPHARMA LLC****\* AUSTARPHARMA LLC**

ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 METHOCARBAMOL, METHOCARBAMOL  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

**AUXILIUM PHARMS****\* AUXILIUM PHARMACEUTICALS INC**

TESTIM, TESTOSTERONE

**AUXILIUM PHARMS LLC****\* AUXILIUM PHARMACEUTICALS LLC**

DILATRATE-SR, ISOSORBIDE DINITRATE  
 EDEX, ALPROSTADIL  
 ROBAXIN, METHOCARBAMOL  
 ROBAXIN-750, METHOCARBAMOL  
 SEMPREX-D, ACRIVASTINE  
 STRIANT, TESTOSTERONE

**AVACOR PRODS****\* AVACOR PRODUCTS LLC**

MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

**AVANIR PHARMS****\* AVANIR PHARMACEUTICALS INC**

NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****AVANTHI INC**

\* AVANTHI INC

CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)  
 DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

**AVEMA PHARMA**

\* AVEMA PHARMA SOLUTIONS

IBUPROFEN, IBUPROFEN (OTC)

**AVENT**

\* AVENT INC

PYTEST KIT, UREA, C-14  
 PYTEST, UREA, C-14

**AVEVA**

\* AVEVA DRUG DELIVERY SYSTEMS INC

CLONIDINE, CLONIDINE  
 FENTANYL-100, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-75, FENTANYL  
 NICOTINE, NICOTINE (OTC)

**AVID RADIOPHARMS INC**

\* AVID RADIOPHARMACEUTICALS INC

AMYVID, FLORBETAPIR F-18

**\*\* B \*\*****B BRAUN**

\* B BRAUN MEDICAL INC

ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
 AMINO ACIDS, AMINO ACIDS  
 BALANCED SALT, CALCIUM CHLORIDE  
 BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE  
 CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM  
 CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE  
 CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM  
 CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM  
 CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME  
 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM  
 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM  
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

## \* B BRAUN MEDICAL INC

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE  
 FREAMINE HBC 6.9%, AMINO ACIDS  
 FREAMINE III 10%, AMINO ACIDS  
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS  
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 FREAMINE III 8.5%, AMINO ACIDS  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPATAMINE 8%, AMINO ACIDS  
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE  
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
 NEPHRAMINE 5.4%, AMINO ACIDS  
 NUTRILIPID 10%, SOYBEAN OIL  
 NUTRILIPID 20%, SOYBEAN OIL  
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\*****\* B BRAUN MEDICAL INC**

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PROCALAMINE, AMINO ACIDS  
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION  
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 TROPHAMINE 10%, AMINO ACIDS  
 TROPHAMINE, AMINO ACIDS

**B BRAUN MEDICAL INC****\* B BRAUN MEDICAL INC**

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

**BAJAJ MEDICAL LLC****\* BAJAJ MEDICAL LLC**

DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)

**BANNER LIFE SCIENCES****\* BANNER LIFE SCIENCES LLC**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 BENZONATATE, BENZONATATE  
 CALCITRIOL, CALCITRIOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ETHOSUXIMIDE, ETHOSUXIMIDE  
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
 IBUPROFEN, IBUPROFEN (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MIDOL LIQUID GELS, IBUPROFEN (OTC)  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 NIMODIPINE, NIMODIPINE  
 PARICALCITOL, PARICALCITOL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BANNER LIFE SCIENCES LLC  
 PROGESTERONE, PROGESTERONE  
 VALPROIC ACID, VALPROIC ACID  
 VITAMIN D, ERGOCALCIFEROL  
 ZONISAMIDE, ZONISAMIDE

**BANNER PHARMACAPS**

\* BANNER PHARMACAPS INC  
 DUTASTERIDE, DUTASTERIDE

**BARR**

\* BARR LABORATORIES INC  
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 ARANELLE, ETHINYL ESTRADIOL  
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN  
 BALZIVA-28, ETHINYL ESTRADIOL  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 CAMILA, NORETHINDRONE  
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE  
 CHLORZOAZONE, CHLORZOAZONE  
 CLONAZEPAM, CLONAZEPAM  
 CLONIDINE, CLONIDINE  
 DANAZOL, DANAZOL  
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 DIAZEPAM, DIAZEPAM  
 DIDANOSINE, DIDANOSINE  
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
 DUTASTERIDE, DUTASTERIDE  
 ERRIN, NORETHINDRONE  
 ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE  
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL  
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL  
 ESTROPIPATE, ESTROPIPATE  
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE  
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 HYDROXYUREA, HYDROXYUREA  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 ISONIAZID, ISONIAZID  
 JUNEL 1.5/30, ETHINYL ESTRADIOL  
 JUNEL 1/20, ETHINYL ESTRADIOL  
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL  
 JUNEL FE 1/20, ETHINYL ESTRADIOL  
 KARIVA, DESOGESTREL  
 KELNOR, ETHINYL ESTRADIOL  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LESSINA-28, ETHINYL ESTRADIOL  
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE  
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE  
 MEGESTROL ACETATE, MEGESTROL ACETATE  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
 NIACIN, NIACIN  
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE  
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\*****\* BARR LABORATORIES INC**

NORTREL 0.5/35-28, ETHINYL ESTRADIOL  
 NORTREL 1/35-21, ETHINYL ESTRADIOL  
 NORTREL 1/35-28, ETHINYL ESTRADIOL  
 NORTREL 7/7/7, ETHINYL ESTRADIOL  
 ONDANSETRON, ONDANSETRON  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PORTIA-28, ETHINYL ESTRADIOL  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 SPRINTec, ETHINYL ESTRADIOL  
 TEMOZOLOMIDE, TEMOZOLOMIDE  
 TREXALL, METHOTREXATE SODIUM  
 TRI-LEGEST 21, ETHINYL ESTRADIOL  
 TRI-LEGEST FE, ETHINYL ESTRADIOL  
 TRI-SPRINTEC, ETHINYL ESTRADIOL  
 WARFARIN SODIUM, WARFARIN SODIUM

**\* BARR PHARMACEUTICALS**

LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

**BARR LABS DIV TEVA****\* BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA**

ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM  
 BUDESONIDE, BUDESONIDE  
 OXYBUTYNIN, OXYBUTYNIN

**BARR LABS INC****\* BARR LABORATORIES INC**

ACITRETIN, ACITRETIN  
 CLOZAPINE, CLOZAPINE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 ESTRADIOL, ESTRADIOL  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 NIMODIPINE, NIMODIPINE  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 OLANZAPINE, OLANZAPINE  
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE  
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN  
 TRETINOIN, TRETINOIN  
 TRI LO SPRINTec, ETHINYL ESTRADIOL

**BAUSCH AND LOMB****\* BAUSCH AND LOMB INC**

ALWAY, KETOTIFEN FUMARATE (OTC)  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 ALREX, LOTEPRDNOL ETABONATE  
 BESIVANCE, BESIFLOXACIN HYDROCHLORIDE  
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
 ISTALOL, TIMOLOL MALEATE  
 LATANOPROST, LATANOPROST  
 LOTEMAX, LOTEPRDNOL ETABONATE  
 MIOCHOL-E, ACETYLCHOLINE CHLORIDE  
 OFLOXACIN, OFLOXACIN  
 OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 PROLENSA, BROMFENAC SODIUM  
 RETISERT, FLUOCINOLONE ACETONIDE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 VITRASE, HYALURONIDASE  
 ZIRGAN, GANCICLOVIR  
 ZYLET, LOTEPRDNOL ETABONATE

**\* BAUSCH AND LOMB PHARMACEUTICALS INC**

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BAUSCH AND LOMB PHARMACEUTICALS INC  
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 CROLOM, CROMOLYN SODIUM  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DEXASPORIN, DEXAMETHASONE  
 ERYTHROMYCIN, ERYTHROMYCIN  
 FLUNISOLIDE, FLUNISOLIDE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC  
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN  
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE  
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC  
 OFLOXACIN, OFLOXACIN  
 OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
 OTICAIR, HYDROCORTISONE  
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE  
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE  
 TOBRAMYCIN, TOBRAMYCIN  
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 TROPICAMIDE, TROPICAMIDE

**BAUSCH AND LOMB INC**

\* BAUSCH AND LOMB INC  
 BEPREVE, BEPOTASTINE BESILATE  
 LOTEMAX, LOTEPIREDNOL ETABONATE  
 PODOFILOX, PODOFILOX

**BAXTER HLTHCARE**

\* BAXTER HEALTHCARE CORP  
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE  
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM  
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM  
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
 BREVIBLOC, ESMOLOL HYDROCHLORIDE  
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM  
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE  
 CEFTRIAOXONE IN PLASTIC CONTAINER, CEFTRIAOXONE SODIUM  
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

## \* BAXTER HEALTHCARE CORP

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINOLIPID 20%, OLIVE OIL  
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE  
 CYTOXAN (LYOPHILIZED), CYCLOPHOSPHAMIDE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC  
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

\* BAXTER HEALTHCARE CORP  
 ETHRANE, ENFLURANE  
 EXTRANEAL, ICODextrin  
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE  
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FORANE, ISOFLURANE  
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE  
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 IFEX, IFOSFAMIDE  
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 MESNEX, MESNA  
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM  
 NEXTERONE, AMIODARONE HYDROCHLORIDE  
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN  
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 10% IN WATER, MANNITOL  
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 15% IN WATER, MANNITOL  
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 20% IN WATER, MANNITOL  
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 5% IN WATER, MANNITOL  
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM  
 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS  
 PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

- \* BAXTER HEALTHCARE CORP  
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 SEVOFLURANE, SEVOFLURANE  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION  
 STERILE WATER, STERILE WATER FOR IRRIGATION  
 SUPRANE, DESFLURANE  
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 TIS-U-SOL, MAGNESIUM SULFATE  
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS  
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
- \* BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV  
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

**BAXTER HLTHCARE CORP**

- \* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE  
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
- \* BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**BAYER**

- \* BAYER HEALTHCARE LLC  
 ALEVE, NAPROXEN SODIUM (OTC)  
 ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)  
 FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)

**BAYER HEALTHCARE LLC**

- \* BAYER HEALTHCARE LLC  
 CHILDREN'S CLARITIN, LORATADINE (OTC)  
 CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)  
 CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)  
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)  
 CLARITIN HIVES RELIEF, LORATADINE (OTC)  
 CLARITIN REDITABS, LORATADINE (OTC)  
 CLARITIN, LORATADINE (OTC)  
 CLARITIN-D 24 HOUR, LORATADINE (OTC)  
 CLARITIN-D, LORATADINE (OTC)  
 GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)  
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)  
 MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)  
 MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 MYCELEX-7, CLOTRIMAZOLE (OTC)  
 OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)  
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)  
 SHADE UVAGUARD, AVOBENZONE (OTC)  
 ZEGERID OTC, OMEPRAZOLE (OTC)

**BAYER HLTHCARE**

- \* BAYER HEALTHCARE CONSUMER CARE  
 ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
- \* BAYER HEALTHCARE PHARMACEUTICALS INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\*****\* BAYER HEALTHCARE PHARMACEUTICALS INC**

ADALAT CC, NIFEDIPINE  
 ADEMPAS, RIOCIQUAT  
 ANGELIQ, DROSPIRENONE  
 AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE  
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE  
 BEYAZ, DROSPIRENONE  
 BILTRICIDE, PRAZIQUANTEL  
 CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 CIPRO, CIPROFLOXACIN  
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE  
 CLIMARA PRO, ESTRADIOL  
 CLIMARA, ESTRADIOL  
 DESONATE, DESONIDE  
 DTIC-DOME, DACARBAZINE  
 EOVIIST, GADOXETATE DISODIUM  
 FINACEA , AZELAIC ACID  
 FINACEA, AZELAIC ACID  
 GADAVIST, GADOBUTROL  
 LEVITRA, VARDENAFIL HYDROCHLORIDE  
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE  
 MENOSTAR, ESTRADIOL  
 MIRENA, LEVONORGESTREL  
 NATAZIA, DIENOGEST  
 NEXAVAR, SORAFENIB TOSYLATE  
 PRECOSE, ACARBOSE  
 SAFYRAL, DROSPIRENONE  
 SKYLA, LEVONORGESTREL  
 STAXYN, VARDENAFIL HYDROCHLORIDE  
 STIVARGA, REGORAFENIB  
 ULTRAVIST (PHARMACY BULK), IOPROMIDE  
 ULTRAVIST 150, IOPROMIDE  
 ULTRAVIST 240, IOPROMIDE  
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE  
 ULTRAVIST 300, IOPROMIDE  
 ULTRAVIST 370, IOPROMIDE  
 XOFIGO, RADIUM RA-223 DICHLORIDE  
 YASMIN, DROSPIRENONE  
 YAZ, DROSPIRENONE

**BAYSHORE PHARMS LLC**

**\* BAYSHORE PHARMACEUTICALS LLC**  
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE  
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

**BD RX**

**\* BD RX INC**  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

**BECTON DICKINSON**

**\* BECTON DICKINSON AND CO**  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)  
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)  
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

**BEDFORD**

**\* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC**  
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM  
 ADENOSINE, ADENOSINE  
 BUMETANIDE, BUMETANIDE  
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 CEFTRIAZONE, CEFTRIAZONE SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE  
 ENALAPRILAT, ENALAPRILAT  
 ETOMIDATE, ETOMIDATE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 MITOMYCIN, MITOMYCIN  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 RIFAMPIN, RIFAMPIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 VALPROATE SODIUM, VALPROATE SODIUM  
 VECURONIUM BROMIDE, VECURONIUM BROMIDE  
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE

**BEDFORD LABS**

\* BEDFORD LABORATORIES  
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUMAZENIL, FLUMAZENIL  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LORAZEPAM PRESERVATIVE FREE, LORAZEPAM  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

**BELCHER PHARMS**

\* BELCHER PHARMACEUTICALS LLC  
 CEPHALEXIN, CEPHALEXIN  
 DESLORATADINE, DESLORATADINE

**BELCHER PHARMS LLC**

\* BELCHER PHARMACEUTICALS LLC  
 EPINEPHRINE, EPINEPHRINE HYDROCHLORIDE

**BEXIMCO USA**

\* BEXIMCO PHARMACEUTICALS USA INC  
 CARVEDILOL, CARVEDILOL

**BIO NUCLEONICS**

\* BIO NUCLEONICS INC  
 STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

**BIO PHARM INC**

\* BIO PHARM INC  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE

**BIO-PHARM INC**

\* BIO-PHARM INC  
 LACTULOSE, LACTULOSE  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

**BIOCODEX INC**

\* BIOCODEX INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

- \* BIOCODEX INC  
TOTECT, DEXRAZOXANE HYDROCHLORIDE
- BIOCON LIMITED**
- \* BIOCON LIMITED  
SIMVASTATIN, SIMVASTATIN
- BIOCRYST**
- \* BIOCRYST PHARMACEUTICALS INC  
RAPIVAB, PERAMIVIR
- BIODELIVERY SCI INTL**
- \* BIODELIVERY SCIENCES INTERNATIONAL INC  
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
- BIOGEN IDEC INC**
- \* BIOGEN IDEC INC  
TECFIDERA, DIMETHYL FUMARATE
- BIOKEY**
- \* BIOKEY INC  
CILOSTAZOL, CILOSTAZOL
- BIOMARIN PHARM**
- \* BIOMARIN PHARMACEUTICAL INC  
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
- BIOMEDCL RES FDN**
- \* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- BIONPHARMA INC**
- \* BIONPHARMA INC  
BEXAROTENE, BEXAROTENE
- BLAIREX**
- \* BLAIREX LABORATORIES INC  
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
- BLU CARIBE**
- \* BLU CARIBE INC  
GEMFIBROZIL, GEMFIBROZIL
- BLU CARIBE INC**
- \* BLU CARIBE INC  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
- BOEHRINGER INGELHEIM**
- \* BOEHRINGER INGELHEIM  
CATAPRES, CLONIDINE HYDROCHLORIDE  
CATAPRES-TTS-1, CLONIDINE  
CATAPRES-TTS-2, CLONIDINE  
CATAPRES-TTS-3, CLONIDINE  
GILOTRIF, AFATINIB DIMALEATE  
GLYXAMBI, EMPAGLIFLOZIN  
MICARDIS HCT, HYDROCHLOROTHIAZIDE  
MICARDIS, TELMISARTAN  
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE  
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)  
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
- \* BOEHRINGER INGELHEIM PHARMACEUTICALS INC  
AGGRENOX, ASPIRIN  
APTIVUS, TIPRANAVIR  
ATROVENT HFA, IPRATROPIUM BROMIDE  
ATROVENT, IPRATROPIUM BROMIDE  
COMBIVENT RESPIMAT, ALBUTEROL SULFATE  
FLOMAX, TAMSULOSIN HYDROCHLORIDE  
JARDIANCE, EMPAGLIFLOZIN  
JENTADUETO, LINAGLIPTIN  
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE  
MOBIC, MELOXICAM  
OFEV, NINTEDANIB ESYLATE  
PERSANTINE, DIPYRIDAMOLE  
PRADAXA, DABIGATRAN ETEXILATE MESYLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BOEHRINGER INGELHEIM PHARMACEUTICALS INC  
 SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE  
 SPIRIVA, TIOTROPIUM BROMIDE  
 STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE  
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE  
 SYNJARDY, EMPAGLIFLOZIN  
 TRADJENTA, LINAGLIPTIN  
 TWYNSTA, AMLODIPINE BESYLATE  
 VIRAMUNE XR, NEVIRAPINE  
 VIRAMUNE, NEVIRAPINE

**BRACCO**

\* BRACCO DIAGNOSTICS INC  
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82  
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT  
 CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE  
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE  
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE  
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE  
 ISOVUE-200, IOPAMIDOL  
 ISOVUE-250, IOPAMIDOL  
 ISOVUE-300, IOPAMIDOL  
 ISOVUE-370, IOPAMIDOL  
 ISOVUE-M 200, IOPAMIDOL  
 ISOVUE-M 300, IOPAMIDOL  
 KINEVAC, SINCALIDE  
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES  
 MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT  
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE  
 MULTIHANCE, GADOBENATE DIMEGLUMINE  
 PROHANCE MULTIPACK, GADOTERIDOL  
 PROHANCE, GADOTERIDOL  
 RENOGRAFIN-76, DIATRIZOATE MEGLUMINE  
 SINOGRAFIN, DIATRIZOATE MEGLUMINE

**BRAINTREE**

\* BRAINTREE LABORATORIES INC  
 AXID, NIZATIDINE  
 GOLYTELY, POLYETHYLENE GLYCOL 3350  
 NULYTELY, POLYETHYLENE GLYCOL 3350  
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

**BRAINTREE LABS**

\* BRAINTREE LABORATORIES INC  
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS

**BRECKENRIDGE PHARM**

\* BRECKENRIDGE PHARMACEUTICAL INC  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CILOSTAZOL, CILOSTAZOL  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 DUTASTERIDE, DUTASTERIDE  
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL  
 LEVETIRACETAM, LEVETIRACETAM  
 MEFENAMIC ACID, MEFENAMIC ACID  
 MELOXICAM, MELOXICAM  
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE  
 OXCARBAZEPINE, OXCARBAZEPINE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

**BRECKENRIDGE PHARMS**

\* BRECKENRIDGE PHARMACEUTICALS INC  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

**BRIGHAM WOMENS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BRIGHAM AND WOMENS HOSP  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**BRIGHAM WOMENS HOSP**

\* BRIGHAM AND WOMENS HOSP INC  
AMMONIA N 13, AMMONIA N-13

**BRISTOL MYERS SQUIBB**

\* BRISTOL MYERS SQUIBB  
AZACTAM, AZTREONAM  
BARACLUDE, ENTECAVIR  
EVOTAZ, ATAZANAVIR SULFATE  
GLUCOVANCE, GLYBURIDE  
LYSODREN, MITOTANE  
MEGACE, MEGESTROL ACETATE  
PRAVACHOL, PRAVASTATIN SODIUM

\* BRISTOL MYERS SQUIBB CO  
AZACTAM IN PLASTIC CONTAINER, AZTREONAM  
DROXIA, HYDROXYUREA  
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE  
HYDREA, HYDROXYUREA  
REYATAZ, ATAZANAVIR SULFATE  
SPRYCEL, DASATINIB  
SUSTIVA, EFAVIRENZ  
VIDEX EC, DIDANOSINE

\* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE  
ELIQUIS, APIXABAN  
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE  
GLUCOPHAGE, METFORMIN HYDROCHLORIDE  
VIDEX, DIDANOSINE  
ZERIT, STAVUDINE

\* BRISTOL MYERS SQUIBB PHARMA CO  
COUMADIN, WARFARIN SODIUM

**BRISTOL-MYERS SQUIBB**

\* BRISTOL-MYERS SQUIBB CO  
DAKLINZA, DACLATASVIR DIHYDROCHLORIDE

**BRYAN**

\* BRYAN CORP  
SCLEROSOL, TALC  
TALC, TALC

**\*\* C \*\*****CADILA PHARMS LTD**

\* CADILA PHARMACEUTICALS LTD  
ACYCLOVIR, ACYCLOVIR  
FOLIC ACID, FOLIC ACID  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
OFLOXACIN, OFLOXACIN

**CADISTA PHARMS**

\* CADISTA PHARMACEUTICALS INC  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
LAMOTRIGINE, LAMOTRIGINE  
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
OXCARBAZEPINE, OXCARBAZEPINE

**CALL INC**

\* CALL INC DBA ROCHESTER PHARMACEUTICALS  
ADAPALENE, ADAPALENE

**CARACO**

\* CARACO PHARMACEUTICAL LABORATORIES LTD  
BACLOFEN, BACLOFEN  
FLUMADINE, RIMANTADINE HYDROCHLORIDE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

**CARDINAL HEALTH 414**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\***

- \* CARDINAL HEALTH 414 LLC  
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
- \* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**CARDINAL HEALTH 418**

- \* CARDINAL HEALTH 418 INC  
SODIUM IODIDE I 123, SODIUM IODIDE I-123

**CAREFUSION**

- \* CAREFUSION 213 LLC  
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)  
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

**CARLSBAD**

- \* CARLSBAD TECHNOLOGY INC  
ACYCLOVIR, ACYCLOVIR  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
FAMOTIDINE, FAMOTIDINE  
GLIMEPIRIDE, GLIMEPIRIDE  
LOVASTATIN, LOVASTATIN  
MELOXICAM, MELOXICAM  
MODAFINIL, MODAFINIL  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**CAROLINA MEDCL**

- \* CAROLINA MEDICAL PRODUCTS CO  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE  
ISONIAZID, ISONIAZID  
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE  
SPS, SODIUM POLYSTYRENE SULFONATE  
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

**CATALENT**

- \* CATALENT PHARMA SOLUTIONS LLC  
VALPROIC ACID, VALPROIC ACID

**CEDAR PHARMS**

- \* CEDAR PHARMACEUTICALS LLC  
METHIMAZOLE, METHIMAZOLE  
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

**CELGENE**

- \* CELGENE CORP  
ISTODAX, ROMIDEPSIN  
POMALYST, POMALIDOMIDE  
REVLIMID, LENALIDOMIDE  
THALOMID, THALIDOMIDE  
VIDAZA, AZACITIDINE

**CELGENE CORP**

- \* CELGENE CORP  
OTEZLA, APREMILAST

**CEPHALON**

- \* CEPHALON INC  
ACTIQ, FENTANYL CITRATE  
FENTORA, FENTANYL CITRATE  
GABITRIL, TIAGABINE HYDROCHLORIDE  
NUVIGIL, ARMODAFINIL  
PROVIGIL, MODAFINIL  
TREANDA, BENDAMUSTINE HYDROCHLORIDE  
TRISENOX, ARSENIC TRIOXIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****CEREXA**

\* CEREXA INC  
TEFLARO, CEFTAROLINE FOSAMIL

**CEREXA INC**

\* CEREXA INC  
AVYCAZ, AVIBACTAM SODIUM

**CHARTWELL LIFE SCI**

\* CHARTWELL LIFE SCIENCE LLC  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
DOXYCYCLINE, DOXYCYCLINE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**CHATTEM**

\* CHATTEM INC  
SELSUN, SELENIUM SULFIDE  
UNISOM, DOXYLAMINE SUCCINATE (OTC)

**CHEM WERTH INC**

\* CHEM WERTH INC  
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

**CHEMISCH FBRK KRSSLR**

\* CHEMISCHE FABRIK KREUSSLER & CO. GMBH  
ASCLERA, POLIDOCANOL

**CHIESI USA INC**

\* CHIESI USA INC  
BETHKIS, TOBRAMYCIN  
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE, NICARDIPINE HYDROCHLORIDE  
CUROSURF, PORACTANT ALFA  
ZYFLO CR, ZILEUTON  
ZYFLO, ZILEUTON

**CHILDRENS HOSP MI**

\* CHILDRENS HOSP MICHIGAN  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**CHINA RESOURCES**

\* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

**CHIRHOCLIN**

\* CHIRHOCLIN INC  
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

**CIPHER PHARMS INC**

\* CIPHER PHARMACEUTICALS INC  
CONZIP, TRAMADOL HYDROCHLORIDE  
LIPOFEN, FENOFIBRATE

**CIPLA**

\* CIPLA LTD  
NEVIRAPINE, NEVIRAPINE  
RISPERIDONE, RISPERIDONE  
ZIDOVUDINE, ZIDOVUDINE

**CIPLA LTD**

\* CIPLA LTD  
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
ANASTROZOLE, ANASTROZOLE  
CARBOPLATIN, CARBOPLATIN  
CARVEDILOL, CARVEDILOL  
CELECOXIB, CELECOXIB  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CICLOPIROX, CICLOPIROX  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****\* CIPLA LTD**

FAMCICLOVIR, FAMCICLOVIR  
 FINASTERIDE, FINASTERIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IRBESARTAN, IRBESARTAN  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MELOXICAM, MELOXICAM  
 NEVIRAPINE, NEVIRAPINE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 STAVUDINE, STAVUDINE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TOPIRAMATE, TOPIRAMATE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 ZALEPLON, ZALEPLON  
 ZIDOVUDINE, ZIDOVUDINE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**CITIUS PHARMS**

\* CITIUS PHARMACEUTICALS LLC  
 SUPRENZA, PHENTERMINE HYDROCHLORIDE

**CITRON PHARMA LLC**

\* CITRON PHARMA LLC  
 CORTISPORIN, HYDROCORTISONE

**CLARIS LIFESCIENCES**

\* CLARIS LIFESCIENCES LTD  
 FUROSEMIDE, FUROSEMIDE  
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE

**CLARIS PHARMASERVICE**

\* CLARIS PHARMASERVICES  
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 CIPROFLOXACIN, CIPROFLOXACIN  
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVOFLOXACIN, LEVOFLOXACIN  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

**CLINIGEN HLTHCARE**

\* CLINIGEN HEALTHCARE LTD  
 ETHYOL, AMIFOSTINE  
 FOSCAVIR, FOSCARNET SODIUM

**CLOVER PHARMS**

\* CLOVER PHARMACEUTICALS CORP  
 AMICAR, AMINOCAPROIC ACID

**CNTY LINE PHARMS**

\* COUNTY LINE PHARMACEUTICALS LLC  
 DYNACIN, MINOCYCLINE HYDROCHLORIDE  
 LIDEX, FLUOCINONIDE  
 LOPROX, CICLOPIROX  
 TRANDATE, LABETALOL HYDROCHLORIDE  
 UREX, METHENAMINE HIPPURATE

**COASTAL PHARMS**

\* COASTAL PHARMACEUTICALS  
 BROMFENAC SODIUM, BROMFENAC SODIUM  
 BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN  
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****\* COASTAL PHARMACEUTICALS**

LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM  
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE AND ASPIRIN, ASPIRIN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**COLGATE**

\* COLGATE ORAL PHARMACEUTICALS INC  
 PERIOGARD, CHLORHEXIDINE GLUCONATE

**COLGATE PALMOLIVE**

\* COLGATE PALMOLIVE  
 COLGATE TOTAL, SODIUM FLUORIDE (OTC)

**CONCORDIA LABS INC**

\* CONCORDIA LABORATORIES INC  
 PHOTOFIN, PORFIMER SODIUM

**CONCORDIA PHARMS INC**

\* CONCORDIA PHARMACEUTICALS INC  
 DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE  
 DUTOPROL, HYDROCHLOROTHIAZIDE  
 DYRENIUM, TRIAMTERENE  
 KAPVAY, CLONIDINE HYDROCHLORIDE  
 KAYEXALATE, SODIUM POLYSTYRENE SULFONATE  
 LANOXIN, DIGOXIN  
 NILANDRON, NILUTAMIDE  
 ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE  
 ORAPRED, PREDNISOLONE SODIUM PHOSPHATE  
 PARNATE, TRANYLCPROMINE SULFATE  
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE  
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE  
 ZANTAC, RANITIDINE HYDROCHLORIDE  
 ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM  
 ZINACEF, CEFUROXIME SODIUM

**CONTRACT PHARMACAL**

\* CONTRACT PHARMACAL CORP  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CIMETIDINE, CIMETIDINE (OTC)  
 FOLIC ACID, FOLIC ACID  
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN, IBUPROFEN (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 PREDNISONE, PREDNISONE  
 PROFEN, IBUPROFEN (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**CORCEPT THERAP**

\* CORCEPT THERAPEUTICS INC  
 KORLYM, MIFEPRISTONE

**CORDEN PHARMA**

\* CORDEN PHARMA LATINA SPA  
 GLEOSTINE, LOMUSTINE

**COREPHARMA**

\* COREPHARMA LLC  
 ALPRAZOLAM, ALPRAZOLAM  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 FELBAMATE, FELBAMATE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****\* COREPHARMA LLC**

GLYBURIDE, GLYBURIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 LEVOCARNITINE, LEVOCARNITINE  
 METAXALONE, METAXALONE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PHENYTOIN, PHENYTOIN  
 POTASSIUM CITRATE, POTASSIUM CITRATE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 URSODIOL, URSODIOL

**COVIS INJECTABLES**

**\* COVIS INJECTABLES SARL**  
 LANOXIN PEDIATRIC, DIGOXIN  
 LANOXIN, DIGOXIN

**COVIS PHARMA SARL**

**\* COVIS PHARMA SARL**  
 ALTOPREV, LOVASTATIN  
 BETAPACE AF, SOTALOL HYDROCHLORIDE  
 BETAPACE, SOTALOL HYDROCHLORIDE  
 RILUTEK, RILUZOLE

**CPDC**

**\* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION**  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**CPPI CV**

**\* CP PHARMACEUTICALS INTERNATIONAL CV**  
 SUTENT, SUNITINIB MALATE

**CRANFORD PHARMS LLC**

**\* CRANFORD PHARMACEUTICALS LLC**  
 INDERAL LA, PROPRANOLOL HYDROCHLORIDE

**CREALTA PHARMS LLC**

**\* CREALTA PHARMACEUTICALS LLC**  
 MIGERGOT, CAFFEINE

**CROWN LABS**

**\* CROWN LABORATORIES INC**  
 ALA-CORT, HYDROCORTISONE  
 ALA-SCALP, HYDROCORTISONE  
 TRIDERM, TRIAMCINOLONE ACETONIDE

**CSL BEHRING**

**\* CSL BEHRING LLC**  
 STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

**CSPC NBP PHARM CO**

**\* CSPC NBP PHARMACEUTICAL CO LTD**  
 BENZONATATE, BENZONATATE

**CSPC OUYI PHARM CO**

**\* CSPC OUYI PHARMACEUTICAL CO LTD**  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**CUBIST**

**\* CUBIST PHARMACEUTICALS INC**  
 CUBICIN, DAPTOMYCIN

**CUBIST PHARMS**

**\* CUBIST PHARMACEUTICALS INC**  
 ENTEREG, ALVIMOPAN

**CUBIST PHARMS LLC**

**\* CUBIST PHARMACEUTICALS LLC**  
 DIFICID, FIDAXOMICIN  
 SIVEXTRO, TEDIZOLID PHOSPHATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\***

\* CUBIST PHARMACEUTICALS LLC  
ZERBAXA, CEFTOLOZANE SULFATE

**CUMBERLAND PHARMS**

\* CUMBERLAND PHARMACEUTICALS INC  
ACETADOTE, ACETYLCYSTEINE  
CALDOLOR, IBUPROFEN  
LACTULOSE, LACTULOSE  
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE

**CUSTOPHARM INC**

\* CUSTOPHARM INC  
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**CYPRESS BIOSCIENCE**

\* CYPRESS BIOSCIENCE INC  
SAVELLA, MILNACIPRAN HYDROCHLORIDE

**CYPRESS PHARM**

\* CYPRESS PHARMACEUTICAL INC  
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
ELIPHOS, CALCIUM ACETATE  
REZIRA, HYDROCODONE BITARTRATE  
VITUZ, CHLORPHENIRAMINE MALEATE  
ZUTRIPRO, CHLORPHENIRAMINE MALEATE

**\*\* D \*\*****DAEWOONG PHARM CO**

\* DAEWOONG PHARMACEUTICAL CO LTD  
MEROPENEM, MEROPENEM

**DAIICHI**

\* DAIICHI PHARMACEUTICAL CORP  
FLOXIN OTIC, OFLOXACIN

**DAIICHI SANKYO**

\* DAIICHI SANKYO INC  
AZOR, AMLODIPINE BESYLATE  
BENICAR HCT, HYDROCHLOROTHIAZIDE  
BENICAR, OLMESARTAN MEDOXOMIL  
EVOXAC, CEVIMELINE HYDROCHLORIDE  
SAVAYSA, EDOXABAN TOSYLATE  
TRIBENZOR, AMLODIPINE BESYLATE  
WELCHOL, COLESEVELAM HYDROCHLORIDE

**DANCO LABS LLC**

\* DANCO LABORATORIES LLC  
MIFEPREX, MIFEPRISTONE

**DARA BIOSCIENCES**

\* DARA BIOSCIENCES INC  
ORAVIG, MICONAZOLE  
SOLTAMOX, TAMOXIFEN CITRATE

**DAVA INTL INC**

\* DAVA INTERNATIONAL INC  
ALPRAZOLAM, ALPRAZOLAM

**DAVA PHARMS INC**

\* DAVA PHARMACEUTICALS INC  
ACYCLOVIR, ACYCLOVIR  
AMOXICILLIN, AMOXICILLIN  
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE  
ATENOLOL, ATENOLOL  
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
GEMFIBROZIL, GEMFIBROZIL  
GLYBURIDE (MICRONIZED), GLYBURIDE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
METHOTREXATE SODIUM, METHOTREXATE SODIUM  
MORPHINE SULFATE, MORPHINE SULFATE  
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\***

\* DAVA PHARMACEUTICALS INC  
 PROPYLTHIOURACIL, PROPYLTHIOURACIL  
 PYRAZINAMIDE, PYRAZINAMIDE  
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
 VOSPIRE ER, ALBUTEROL SULFATE

**DAVIS AND GECK**

\* DAVIS AND GECK DIV AMERICAN CYANAMID CO  
 PRE-OP II, HEXACHLOROPHENE  
 PRE-OP, HEXACHLOROPHENE

**DELCOR ASSET**

\* DELCOR ASSET CORP  
 EVOCLIN, CLINDAMYCIN PHOSPHATE  
 LUXIQ, BETAMETHASONE VALERATE  
 OLUX E, CLOBETASOL PROPIONATE  
 OLUX, CLOBETASOL PROPIONATE  
 VUSION, MICONAZOLE NITRATE  
 ZOVIRAX, ACYCLOVIR

**DELCOR ASSET CORP**

\* DELCOR ASSET CORP  
 ERYGEL, ERYTHROMYCIN  
 EXTINA, KETOCONAZOLE  
 KENALOG, TRIAMCINOLONE ACETONIDE  
 ZONALON, DOXEPIN HYDROCHLORIDE

**DENCO ASSET**

\* DENCO ASSET LLC  
 DENAVIR, PENCICLOVIR SODIUM

**DENTSPLY PHARM**

\* DENTSPLY PHARMACEUTICAL INC  
 CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE  
 ORAQIX, LIDOCAINE

**DEPOMED INC**

\* DEPOMED INC  
 CAMBIA, DICLOFENAC POTASSIUM  
 GRALISE, GABAPENTIN  
 LAZANDA, FENTANYL CITRATE  
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE  
 NUCYNTA, TAPENTADOL HYDROCHLORIDE  
 ZIPSOR, DICLOFENAC POTASSIUM

**DEPROCO**

\* DEPROCO INC  
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE  
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE  
 SCANDONEST L, LEVONORDEFIN  
 SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE  
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE

**DEXCEL LTD**

\* DEXCEL LTD  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

**DEXCEL PHARMA**

\* DEXCEL PHARMA TECHNOLOGIES LTD  
 LEVETIRACETAM, LEVETIRACETAM  
 OMEPRAZOLE, OMEPRAZOLE (OTC)  
 PERIOCHIP, CHLORHEXIDINE GLUCONATE

**DIALYSIS SUPS**

\* DIALYSIS SUPPLIES INC  
 NORMOCARB HF 25, MAGNESIUM CHLORIDE  
 NORMOCARB HF 35, MAGNESIUM CHLORIDE

**DIGESTIVE CARE INC**

\* DIGESTIVE CARE INC  
 PERTZYE, PANCRELIPASE (AMYLASE)

**DORADO PHARMA**

\* DORADO PHARMA LLC  
 KETOPROFEN, KETOPROFEN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\*****DORC**

- \* DORC INTERNATIONAL BV  
MEMBRANEBLUE, TRYPAN BLUE  
VISIONBLUE, TRYPAN BLUE

**DOUGLAS PHARMS**

- \* DOUGLAS PHARMACEUTICALS AMERICA LTD  
MYORISAN, ISOTRETINOIN

**DOW PHARM**

- \* DOW PHARMACEUTICAL SCIENCES  
ACANYA, BENZOYL PEROXIDE  
AKNE-MYCIN, ERYTHROMYCIN  
ATRALIN, TRETINOIN  
JUBLIA, EFINACONAZOLE  
NUTRACORT, HYDROCORTISONE  
ONEXTON, BENZOYL PEROXIDE  
OXSORALEN-ULTRA, METHOXSALEN

**DR REDDYS LA**

- \* DR REDDYS LABORATORIES LOUISIANA LLC  
IBUPROFEN, IBUPROFEN  
IBUPROFEN, IBUPROFEN (OTC)  
LOPURIN, ALLOPURINOL  
SSD AF, SILVER SULFADIAZINE  
SSD, SILVER SULFADIAZINE

**DR REDDYS LABS INC**

- \* DR REDDYS LABORATORIES INC  
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
AMOXIL, AMOXICILLIN  
AUGMENTIN '125', AMOXICILLIN  
AUGMENTIN '200', AMOXICILLIN  
AUGMENTIN '250', AMOXICILLIN  
AUGMENTIN '400', AMOXICILLIN  
AUGMENTIN '500', AMOXICILLIN  
AUGMENTIN '875', AMOXICILLIN  
AUGMENTIN ES-600, AMOXICILLIN  
AUGMENTIN XR, AMOXICILLIN  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
FINASTERIDE, FINASTERIDE  
FLUCONAZOLE, FLUCONAZOLE  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
HABITROL, NICOTINE (OTC)  
IBUPROFEN, IBUPROFEN  
IBUPROFEN, IBUPROFEN (OTC)  
LAROTID, AMOXICILLIN  
LEVOFLOXACIN, LEVOFLOXACIN  
MELOXICAM, MELOXICAM  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)  
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE  
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
SIMVASTATIN, SIMVASTATIN  
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**DR REDDYS LABS LTD**

- \* DR REDDYS LABORATORIES LIMITED  
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
- \* DR REDDYS LABORATORIES LTD  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
ANASTROZOLE, ANASTROZOLE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\***

\* DR REDDYS LABORATORIES LTD  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 AZACITIDINE, AZACITIDINE  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
 CARVEDILOL, CARVEDILOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DECITABINE, DECITABINE  
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE  
 DESLORATADINE, DESLORATADINE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DOCETAXEL, DOCETAXEL  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
 ESZOPICLONE, ESZOPICLONE  
 FAMOTIDINE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 FINASTERIDE, FINASTERIDE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)  
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
 LATANOPROST, LATANOPROST  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NATEGLINIDE, NATEGLINIDE  
 NIZATIDINE, NIZATIDINE  
 OFLOXACIN, OFLOXACIN  
 OLANZAPINE, OLANZAPINE  
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)  
 OMEPRAZOLE, OMEPRAZOLE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXAPROZIN, OXAPROZIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\***

\* DR REDDYS LABORATORIES LTD  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PARICALCITOL, PARICALCITOL  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 RAMIPRIL, RAMIPRIL  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RISPERIDONE, RISPERIDONE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 SIROLIMUS, SIROLIMUS  
 TACROLIMUS, TACROLIMUS  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VINOIRELBINE TARTRATE, VINOIRELBINE TARTRATE  
 ZAFIRLUKAST, ZAFIRLUKAST  
 ZENATANE, ISOTRETINOIN  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**DR REDDYS LABS SA**

\* DR REDDYS LABORATORIES SA  
 FENOFIBRATE (MICRONIZED), FENOFIBRATE

**DRAximAGE**

\* DRAximAGE INC  
 DTPA, TECHNETIUM TC-99M PENTETATE KIT  
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

**DUCHESNAY**

\* DUCHESNAY INC  
 DICLEGIS, DOXYLAMINE SUCCINATE

**DURAMED PHARMS BARR**

\* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC  
 AVIANE-28, ETHINYL ESTRADIOL  
 CRYSELLE, ETHINYL ESTRADIOL  
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
 ENPRESSE-28, ETHINYL ESTRADIOL  
 METHYLPREDNISOLONE, METHYLPREDNISOLONE  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VELIVET, DESOGESTREL

**DURAMED RES**

\* DURAMED RESEARCH INC  
 AYGESTIN, NORETHINDRONE ACETATE

**DURATA THERAPS INTL**

\* DURATA THERAPEUTICS INTERNATIONAL BV  
 DALVANCE, DALBAVANCIN HYDROCHLORIDE

**DUSA**

\* DUSA PHARMACEUTICALS INC  
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**REDDYS**

\* DOCTOR REDDYS LABORATORIES LTD  
 DESLORATADINE, DESLORATADINE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**\*\* E \*\*****EAGLE PHARMS**

\* EAGLE PHARMACEUTICALS INC  
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN  
 BENDEKA, BENDAMUSTINE HYDROCHLORIDE  
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM  
 RYANODEX, DANTROLENE SODIUM



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\*****EASTMAN KODAK**

- \* EASTMAN KODAK CO  
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

**EBEWE PHARMA**

- \* EBEWE PHARMA GES MBH NFG KG  
CARBOPLATIN, CARBOPLATIN  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
OXALIPLATIN, OXALIPLATIN  
PACLITAXEL, PACLITAXEL

**ECLAT PHARMS LLC**

- \* ECLAT PHARMACEUTICALS LLC  
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE  
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

**ECOLAB**

- \* ECOLAB INC  
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

**ECR**

- \* ECR PHARMACEUTICALS  
DEXAMETHASONE, DEXAMETHASONE

**ECR PHARMA**

- \* ECR PHARMA  
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

**EDENBRIDGE PHARMS**

- \* EDENBRIDGE PHARMACEUTICALS LLC  
IVERMECTIN, IVERMECTIN  
TINIDAZOLE, TINIDAZOLE

**EDGEMONT PHARMS LLC**

- \* EDGEMONT PHARMACEUTICALS LLC  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FORFIVO XL, BUPROPION HYDROCHLORIDE

**EDISON THERAPS LLC**

- \* EDISON THERAPEUTICS LLC  
METHERGINE, METHYLERGONOVINE MALEATE

**EGALET US INC**

- \* EGALET US INC  
OXAYDO, OXYCODONE HYDROCHLORIDE  
SPRIX, KETOROLAC TROMETHAMINE

**EI INC**

- \* EI INC  
THEROXIDIL, MINOXIDIL (OTC)

**EISAI INC**

- \* EISAI INC  
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM  
ACIPHEX, RABEPRAZOLE SODIUM  
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE  
ARICEPT, DONEPEZIL HYDROCHLORIDE  
BANZEL, RUFINAMIDE  
BELVIQ, LORCASERIN HYDROCHLORIDE  
FYCOMPA, PERAMPANEL  
HALAVEN, ERIBULIN MESYLATE  
HEXALEN, ALTRETAMINE  
LENVIMA, LENVATINIB MESYLATE  
PANRETIN, ALITRETINOIN  
SALAGEN, PILOCARPINE HYDROCHLORIDE  
ZONEGRAN, ZONISAMIDE

**ELAN PHARMA INTL LTD**

- \* ELAN PHARMA INTERNATIONAL LTD  
CLINDESSE, CLINDAMYCIN PHOSPHATE  
EVAMIST, ESTRADIOL  
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

**ELI LILLY AND CO**

- \* ELI LILLY AND CO

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* ELI LILLY AND CO  
 AXIRON, TESTOSTERONE  
 BASAGLAR, INSULIN GLARGINE  
 EFFIENT, PRASUGREL HYDROCHLORIDE  
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT  
 PROZAC, FLUOXETINE HYDROCHLORIDE

**ELI LILLY CO**

\* ELI LILLY CO  
 ADCIRCA, TADALAFIL  
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE

**ELITE LABS**

\* ELITE LABORATORIES INC  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**ELITE LABS INC**

\* ELITE LABORATORIES INC  
 DANTROLENE SODIUM, DANTROLENE SODIUM  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 ISRADIPINE, ISRADIPINE  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

**EMCURE PHARMS**

\* EMCURE PHARMACEUTICALS LTD  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

**EMCURE PHARMS INDIA**

\* EMCURE PHARMACEUTICALS LTD INDIA  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM

**EMCURE PHARMS LTD**

\* EMCURE PHARMACEUTICALS LTD  
 ACARBOSE, ACARBOSE  
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
 ADENOSINE, ADENOSINE  
 AMIKACIN SULFATE, AMIKACIN SULFATE  
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
 BICNU, CARMUSTINE  
 CIDOFOVIR, CIDOFOVIR  
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
 ETOMIDATE, ETOMIDATE  
 FUROSEMIDE, FUROSEMIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE  
 RIFAMPIN, RIFAMPIN  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**EMCURE PHARMS USA**

\* EMCURE PHARMACEUTICALS USA INC  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE

**EMD SERONO**

\* EMD SERONO INC  
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA  
 GONAL-F RFF, FOLLITROPIN ALFA/BETA  
 GONAL-F, FOLLITROPIN ALFA/BETA  
 OVIDREL, CHORIOGONADOTROPIN ALFA  
 SAIZEN, SOMATROPIN RECOMBINANT  
 SEROSTIM, SOMATROPIN RECOMBINANT  
 ZORBTIVE, SOMATROPIN RECOMBINANT

**EMD SERONO INC**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* EMD SERONO INC  
CETROTIDE, CETRORELIX

**EMMAUS MEDCL**

\* EMMAUS MEDICAL INC  
NUTRESTORE, GLUTAMINE

**ENDO PHARM**

\* ENDO PHARMACEUTICAL SOLUTIONS INC  
SUPPRELIN LA, HISTRELIN ACETATE  
VALSTAR PRESERVATIVE FREE, VALRUBICIN  
VANTAS, HISTRELIN ACETATE

**ENDO PHARMS**

\* ENDO PHARMACEUTICALS INC  
DELATESTRYL, TESTOSTERONE ENANTHATE  
FORTESTA, TESTOSTERONE  
FROVA, FROVATRIPTAN SUCCINATE  
OPANA ER, OXYMORPHONE HYDROCHLORIDE  
OPANA, OXYMORPHONE HYDROCHLORIDE  
PERCODAN, ASPIRIN

**ENDO PHARMS INC**

\* ENDO PHARMACEUTICALS INC  
AVEED, TESTOSTERONE UNDECANOATE  
BELBUCA, BUPRENORPHINE HYDROCHLORIDE  
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

**ENDO VENTURES LTD**

\* ENDO VENTURES LTD  
NATESTO, TESTOSTERONE

\* ENDO VENTURES LTD IRELAND  
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

**EPIC PHARMA**

\* EPIC PHARMA INC  
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

\* EPIC PHARMA LLC  
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE  
SULINDAC, SULINDAC  
TRANDOLAPRIL, TRANDOLAPRIL  
URSODIOL, URSODIOL

**EPIC PHARMA INC**

\* EPIC PHARMA INC  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**EPIC PHARMA LLC**

\* EPIC PHARMA LLC  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE  
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

**ERGOJECT**

\* ERGOJECT LLC  
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

**ESSENTIAL ISOTOPES**

\* ESSENTIAL ISOTOPES LLC  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**ETHYPHARM**

\* ETHYPHARM  
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

**ETHYPHARM USA CORP**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* ETHYPHARM USA CORP

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

**EUROHLTH INTL SARL**

\* EUROHEALTH INTERNATIONAL SARL

ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM

ADENOSINE, ADENOSINE

ALLOPURINOL SODIUM, ALLOPURINOL SODIUM

ALPROSTADIL, ALPROSTADIL

AMIKACIN SULFATE, AMIKACIN SULFATE

AMRINONE LACTATE, INAMRINONE LACTATE

ATIVAN, LORAZEPAM

ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE

ATRACURIUM BESYLATE, ATRACURIUM BESYLATE

AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM

AZTREONAM, AZTREONAM

BLEOMYCIN SULFATE, BLEOMYCIN SULFATE

BUMETANIDE, BUMETANIDE

BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

CAFCIT, CAFFEINE CITRATE

CARBOPLATIN, CARBOPLATIN

CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE

CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE

CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE

CISPLATIN, CISPLATIN

CLADRIBINE, CLADRIBINE

CYCLOSPORINE, CYCLOSPORINE

CYTARABINE, CYTARABINE

DACARBAZINE, DACARBAZINE

DACTINOMYCIN, DACTINOMYCIN

DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE

DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE

DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE

DIGOXIN, DIGOXIN

DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

DIPYRIDAMOLE, DIPYRIDAMOLE

DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE

DOPRAM, DOXAPRAM HYDROCHLORIDE

DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

DOXYCYCLINE, DOXYCYCLINE HYCLATE

DURAMORPH PF, MORPHINE SULFATE

EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE

ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE

ETOPOSIDE, ETOPOSIDE

FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE

FAMOTIDINE, FAMOTIDINE

FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE

FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE

FLOXURIDINE, FLOXURIDINE

FLUMAZENIL, FLUMAZENIL

FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE

GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE

HALOPERIDOL, HALOPERIDOL LACTATE

HEPARIN SODIUM, HEPARIN SODIUM

IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE

IFOSFAMIDE, IFOSFAMIDE

INDOMETHACIN SODIUM, INDOMETHACIN SODIUM

INFUMORPH, MORPHINE SULFATE

KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE

LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM

LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* EUROHEALTH INTERNATIONAL SARL  
 LEVOCARNITINE, LEVOCARNITINE  
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 MESNA, MESNA  
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NALOXONE, NALOXONE HYDROCHLORIDE  
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 OXYTOCIN, OXYTOCIN  
 PACLITAXEL, PACLITAXEL  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PENTOSTATIN, PENTOSTATIN  
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE  
 PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 ROBAXIN, METHOCARBAMOL  
 ROBINUL, GLYCOPYRROLATE  
 SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE  
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX  
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION  
 SUFENTANIL CITRATE, SUFENTANIL CITRATE  
 THIOTEPA, THIOTEPA  
 VINBLASTINE SULFATE, VINBLASTINE SULFATE  
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE

**EXALENZ BIOSCIENCE**

\* EXALENZ BIOSCIENCE LTD  
 IDKIT:HP, CITRIC ACID

**EXELA PHARMA SCIENCE**

\* EXELA PHARMA SCIENCES  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

**EXELA PHARMA SCS LLC**

\* EXELA PHARMA SCIENCES LLC  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 POTASSIUM ACETATE, POTASSIUM ACETATE

**EXELIXIS**

\* EXELIXIS INC  
 COMETRIQ, CABOZANTINIB S-MALATE

**FOUGERA**

\* E FOUGERA DIV ALTANA INC  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
 FLUOCINONIDE, FLUOCINONIDE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 HYDROCORTISONE, HYDROCORTISONE  
 LIDOCAINE, LIDOCAINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* E FOUGERA DIV ALTANA INC  
 NITROGLYCERIN, NITROGLYCERIN  
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN  
 NYSTATIN, NYSTATIN

**LILLY**

\* ELI LILLY AND CO  
 ALIMTA, PEMETREXED DISODIUM  
 CIALIS, TADALAFIL  
 CYMBALTA, DULOXETINE HYDROCHLORIDE  
 EVISTA, RALOXIFENE HYDROCHLORIDE  
 FORTEO, TERIPARATIDE RECOMBINANT HUMAN  
 GEMZAR, GEMCITABINE HYDROCHLORIDE  
 GLUCAGON, GLUCAGON RECOMBINANT  
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT  
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG, INSULIN LISPRO RECOMBINANT  
 HUMATROPE, SOMATROPIN RECOMBINANT  
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN R, INSULIN RECOMBINANT HUMAN  
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE  
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE  
 STRATTERA, ATOMOXETINE HYDROCHLORIDE  
 SYMBYAX, FLUOXETINE HYDROCHLORIDE  
 ZYPREXA ZYDIS, OLANZAPINE  
 ZYPREXA, OLANZAPINE

**\*\* F \*\*****FACTA FARMA**

\* FACTA FARMACEUTICI SPA  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 CEFUROXIME SODIUM, CEFUROXIME SODIUM

**FALCON PHARMS**

\* FALCON PHARMACEUTICALS LTD  
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE

**FDC LTD**

\* FDC LTD  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 OFLOXACIN, OFLOXACIN  
 TIMOLOL MALEATE, TIMOLOL MALEATE

**FEINSTEIN**

\* FEINSTEIN INSTITUTE MEDICAL RESEARCH  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**FERA PHARMS**

\* FERA PHARMACEUTICALS LLC  
 OFLOXACIN, OFLOXACIN  
 TOBRAMYCIN, TOBRAMYCIN

**FERA PHARMS LLC**

\* FERA PHARMACEUTICALS LLC  
 DAPSONE, DAPSONE

**FERNDALE LABS**

\* FERNDALE LABORATORIES INC  
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE

**FERNDALE LABS INC**

\* FERNDALE LABORATORIES INC  
 ULTRAVATE, HALOBETASOL PROPIONATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\*****FERRING**

\* FERRING PHARMACEUTICALS INC  
 ACTHREL, CORTICORELIN OVINE TRIFLUTATE  
 BRAVELLE, UROFOLLITROPIN  
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 ENDOMETRIN, PROGESTERONE  
 FIRMAGON, DEGARELIX ACETATE  
 MENOPUR, MENOTROPINS (FSH)  
 MINIRIN, DESMOPRESSIN ACETATE  
 ZOMACTON, SOMATROPIN RECOMBINANT

**FERRING CONTROLLED**

\* FERRING CONTROLLED THERAPEUTICS LTD  
 CERVIDIL, DINOPROSTONE

**FERRING PHARMS AS**

\* FERRING PHARMACEUTICALS AS  
 LYSTEDA, TRANEXAMIC ACID  
 PREPOPIK, CITRIC ACID

**FERRING PHARMS INC**

\* FERRING PHARMACEUTICALS INC  
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
 DDAVP, DESMOPRESSIN ACETATE

**FOREST LABS**

\* FOREST LABORATORIES INC  
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE  
 CAMPRAL, ACAMPROSATE CALCIUM  
 CELEXA, CITALOPRAM HYDROBROMIDE  
 LEXAPRO, ESCITALOPRAM OXALATE  
 THYROLAR-0.25, LIOTRIX (T4)  
 THYROLAR-0.5, LIOTRIX (T4)  
 THYROLAR-1, LIOTRIX (T4)  
 THYROLAR-2, LIOTRIX (T4)  
 THYROLAR-3, LIOTRIX (T4)

**FOREST LABS INC**

\* FOREST LABORATORIES INC  
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE  
 BENTYL, DICYCLOMINE HYDROCHLORIDE  
 CARAFATE, SUCRALFATE  
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE  
 RECTIV, NITROGLYCERIN  
 ULTRESA, PANCRELIPASE (AMYLASE)  
 URSO 250, URSODIOL  
 URSO FORTE, URSODIOL  
 VIOKACE, PANCRELIPASE (AMYLASE)  
 ZENPEP, PANCRELIPASE (AMYLASE)

**FOREST LABS LLC**

\* FOREST LABORATORIES LLC  
 CANASA, MESALAMINE  
 LINZESS, LINACLOTIDE  
 NAMENDA XR, MEMANTINE HYDROCHLORIDE  
 NAMENDA, MEMANTINE HYDROCHLORIDE  
 NAMZARIC, DONEPEZIL HYDROCHLORIDE  
 PYLERA, BISMUTH SUBCITRATE POTASSIUM  
 SAPHRIS, ASENAPINE MALEATE  
 VIIBRYD, VILAZODONE HYDROCHLORIDE

**FOREST RES INST INC**

\* FOREST RESEARCH INSTITUTE INC  
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE

**FOREST TOSARA LTD**

\* FOREST TOSARA LTD  
 VIBERZI, ELUXADOLINE

**FOUGERA PHARMS**

\* FOUGERA PHARMACEUTICALS INC  
 ADAPALENE, ADAPALENE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FOUGERA PHARMACEUTICALS INC  
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE  
 AMCINONIDE, AMCINONIDE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 C-SOLVE-2, ERYTHROMYCIN  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CICLOPIROX, CICLOPIROX  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE  
 CUTIVATE, FLUTICASONE PROPIONATE  
 DESONIDE, DESONIDE  
 DESOXIMETASONE, DESOXIMETASONE  
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 ERYTHROMYCIN, ERYTHROMYCIN  
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE  
 FLUOCINONIDE, FLUOCINONIDE  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 HYDROCORTISONE, HYDROCORTISONE  
 IMIQUIMOD, IMIQUIMOD  
 KETOCONAZOLE, KETOCONAZOLE  
 LIDOCAINE AND PRILOCAINE, LIDOCAINE  
 METRONIDAZOLE, METRONIDAZOLE  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 MUPIROCIN, MUPIROCIN  
 NYSTATIN, NYSTATIN  
 OXISTAT, OXICONAZOLE NITRATE  
 PANDEL, HYDROCORTISONE PROBUTATE  
 PREDNICARBATE, PREDNICARBATE  
 SOLARAZE, DICLOFENAC SODIUM  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
 TEMOVATE, CLOBETASOL PROPIONATE  
 TERCONAZOLE, TERCONAZOLE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**FOUGERA PHARMS INC**

\* FOUGERA PHARMACEUTICALS INC  
 FLUOCINONIDE, FLUOCINONIDE  
 TACROLIMUS, TACROLIMUS

**FRESENIUS**

\* FRESENIUS KABI DEUTSCHLAND GMBH  
 INTRALIPID 10%, SOYBEAN OIL  
 INTRALIPID 20%, SOYBEAN OIL  
 INTRALIPID 30%, SOYBEAN OIL

**FRESENIUS KABI**

\* FRESENIUS KABI AUSTRIA GMBH  
 LACTULOSE, LACTULOSE

**FRESENIUS KABI ONCOL**

\* FRESENIUS KABI ONCOLOGY PLC  
 ANASTROZOLE, ANASTROZOLE  
 BICALUTAMIDE, BICALUTAMIDE  
 CARBOPLATIN, CARBOPLATIN  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LETROZOLE, LETROZOLE  
 OXALIPLATIN, OXALIPLATIN  
 PACLITAXEL, PACLITAXEL

**FRESENIUS KABI USA**

\* FRESENIUS KABI USA LLC  
 ACETAMINOPHEN, ACETAMINOPHEN



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FRESENIUS KABI USA LLC  
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM  
 ADENOSINE, ADENOSINE  
 AMIKACIN SULFATE, AMIKACIN SULFATE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 ARGATROBAN, ARGATROBAN  
 ASTRAMORPH PF, MORPHINE SULFATE  
 AZITHROMYCIN, AZITHROMYCIN  
 AZTREONAM, AZTREONAM  
 BACITRACIN, BACITRACIN  
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CARBOPLATIN, CARBOPLATIN  
 CEFOTETAN, CEFOTETAN DISODIUM  
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE  
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM  
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE  
 CISPLATIN, CISPLATIN  
 CLADRIBINE, CLADRIBINE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
 CYTARABINE, CYTARABINE  
 DACARBAZINE, DACARBAZINE  
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE  
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
 DIMENHYDRINATE, DIMENHYDRINATE  
 DIPRIVAN, PROPOFOL  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 DOXY 100, DOXYCYCLINE HYCLATE  
 DOXY 200, DOXYCYCLINE HYCLATE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
 ETOPOSIDE, ETOPOSIDE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE  
 FLOXURIDINE, FLOXURIDINE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 FLUMAZENIL, FLUMAZENIL  
 FLUOROURACIL, FLUOROURACIL  
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE  
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
 FOLIC ACID, FOLIC ACID  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 GANCICLOVIR, GANCICLOVIR SODIUM  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 GLUCAGON, GLUCAGON HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FRESENIUS KABI USA LLC  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE  
 IFOSFAMIDE, IFOSFAMIDE  
 INDOMETHACIN, INDOMETHACIN  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS  
 KANAMYCIN SULFATE, KANAMYCIN SULFATE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM  
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MANNITOL 25%, MANNITOL  
 MESNA, MESNA  
 METARAMINOL BITARTRATE, METARAMINOL BITARTRATE  
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 NAROPIN, ROPIVACAINE HYDROCHLORIDE  
 NEBUPENT, PENTAMIDINE ISETHIONATE  
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE  
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE  
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXALIPLATIN, OXALIPLATIN  
 OXYTOCIN, OXYTOCIN  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PENTAM, PENTAMIDINE ISETHIONATE  
 PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS  
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE  
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE  
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PROGESTERONE, PROGESTERONE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 PROTAMINE SULFATE, PROTAMINE SULFATE  
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE  
 RIFAMPIN, RIFAMPIN  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE  
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE  
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 VALPROATE SODIUM, VALPROATE SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FRESENIUS KABI USA LLC  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VIBISONE, CYANOCOBALAMIN  
 VINBLASTINE SULFATE, VINBLASTINE SULFATE  
 VINOELBINE TARTRATE, VINOELBINE TARTRATE  
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE  
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**FRESENIUS MEDCL**

\* FRESENIUS MEDICAL CARE NORTH AMERICA  
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM  
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM  
 DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM  
 DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PHOSLO GELCAPS, CALCIUM ACETATE  
 PHOSLYRA, CALCIUM ACETATE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**FSC**

\* FSC LABORATORIES INC  
 PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

**\*\* G \*\*****G AND W LABS**

\* G AND W LABORATORIES INC  
 ACEPHEN, ACETAMINOPHEN (OTC)  
 CICLOPIROX, CICLOPIROX  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 INDOMETHACIN, INDOMETHACIN  
 METRONIDAZOLE, METRONIDAZOLE  
 MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 PROCHLORPERAZINE, PROCHLORPERAZINE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**G AND W LABS INC**

\* G AND W LABORATORIES INC  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 BETA-VAL, BETAMETHASONE VALERATE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL  
 CICLOPIROX, CICLOPIROX  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 FLUOCINONIDE, FLUOCINONIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

\* G AND W LABORATORIES INC  
 IMIQUIMOD, IMIQUIMOD  
 MESALAMINE, MESALAMINE  
 METRONIDAZOLE, METRONIDAZOLE  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
 MYKACET, NYSTATIN  
 NYSTATIN, NYSTATIN  
 PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE  
 PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE  
 QUINIDINE SULFATE, QUINIDINE SULFATE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**GALDERMA LABS**

\* GALDERMA LABORATORIES INC  
 CLOBEX, CLOBETASOL PROPIONATE  
 EPIDUO FORTE, ADAPALENE

**GALDERMA LABS LP**

\* GALDERMA LABORATORIES L P  
 CLOBEX, CLOBETASOL PROPIONATE

\* GALDERMA LABORATORIES LP  
 CAPEX, FLUOCINOLONE ACETONIDE  
 CLOBEX, CLOBETASOL PROPIONATE  
 DESOWEN, DESONIDE  
 DIFFERIN, ADAPALENE  
 EPIDUO, ADAPALENE  
 METROCREAM, METRONIDAZOLE  
 METROGEL, METRONIDAZOLE  
 METROLOTION, METRONIDAZOLE  
 MIRVASO, BRIMONIDINE TARTRATE  
 ORACEA, DOXYCYCLINE  
 PLIAGLIS, LIDOCAINE  
 SOOLANTRA, IVERMECTIN  
 TRI-LUMA, FLUOCINOLONE ACETONIDE  
 VECTICAL, CALCITRIOL

**GALEN (UK)**

\* GALLEN LTD  
 DAUNOXOME, DAUNORUBICIN CITRATE

**GALEN SPECIALTY**

\* GALLEN SPECIALTY PHARMA US LLC  
 SYNERA, LIDOCAINE

**GALENA BIOPHARMA INC**

\* GALENA BIOPHARMA INC  
 ZUPLENZ, ONDANSETRON

**GASTROENTERO**

\* GASTROENTERO LOGIC LLC  
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

**GATE PHARMS**

\* GATE PHARMACEUTICALS  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

**GAVIS PHARMS**

\* GAVIS PHARMACEUTICALS LLC  
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 QUINARETIC, HYDROCHLOROTHIAZIDE  
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

**GAVIS PHARMS LLC**

\* GAVIS PHARMACEUTICALS LLC  
 CYANOCOBALAMIN, CYANOCOBALAMIN  
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

**GD SEARLE**

\* GD SEARLE LLC  
 CELEBREX, CELECOXIB

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

\* GD SEARLE LLC  
DAYPRO, OXAPROZIN

**GD SEARLE LLC**

\* GD SEARLE LLC  
ALDACTAZIDE, HYDROCHLOROTHIAZIDE  
ALDACTONE, SPIRONOLACTONE  
ARTHROTEC, DICLOFENAC SODIUM  
CALAN, VERAPAMIL HYDROCHLORIDE  
COVERA-HS, VERAPAMIL HYDROCHLORIDE  
CYTOTEC, MISOPROSTOL  
FLAGYL ER, METRONIDAZOLE  
FLAGYL, METRONIDAZOLE  
INSPIRA, EPLERENONE  
LOMOTIL, ATROPINE SULFATE  
NORPACE CR, DISOPYRAMIDE PHOSPHATE  
NORPACE, DISOPYRAMIDE PHOSPHATE  
SYNAREL, NAFARELIN ACETATE

**GE HEALTHCARE**

\* GE HEALTHCARE  
ADREVIEW, IOBENGUANE SULFATE I-123  
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT  
INDICLOR, INDIUM IN-111 CHLORIDE  
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE  
METASTRON, STRONTIUM CHLORIDE SR-89  
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT  
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM  
MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT  
MYOVUE, TECHNETIUM TC-99M TETROFOSMIN KIT  
OMNIPAQUE 140, IOHEXOL  
OMNIPAQUE 180, IOHEXOL  
OMNIPAQUE 240, IOHEXOL  
OMNIPAQUE 300, IOHEXOL  
OMNIPAQUE 350, IOHEXOL  
OMNISCAN, GADODIAMIDE  
OPTISON, ALBUMIN HUMAN  
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201  
VISIPAQUE 270, IODIXANOL  
VISIPAQUE 320, IODIXANOL  
VIZAMYL, FLUTEMETAMOL F-18

**GE HLTHCARE INC**

\* GE HEALTHCARE INC  
DATSCAN, IOFLUPANE I-123

**GEDEON RICHTER USA**

\* GEDEON RICHTER USA INC  
FINASTERIDE, FINASTERIDE

**GEMINI LABS LLC**

\* GEMINI LABORATORIES LLC  
OXANDRIN, OXANDROLONE

**GENENTECH**

\* GENENTECH INC  
ERIVEDGE, VISMODEGIB  
NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT  
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT

**GENENTECH INC**

\* GENENTECH INC  
COTELLIC, COBIMETINIB FUMARATE  
ESBRIET, PIRFENIDONE

**GENZYME**

\* GENZYME CORP  
CEREZYME, IMIGLUCERASE  
CLOLAR, CLOFARABINE  
MOZOBIL, PLERIXAFOR  
RENAGEL, SEVELAMER HYDROCHLORIDE  
RENVELA, SEVELAMER CARBONATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\*****\* GENZYME CORP**

THYROGEN, THYROTROPIN ALFA

**GENZYME CORP****\* GENZYME CORP**

CERDELGA, ELIGLUSTAT TARTRATE

HECTOROL, DOXERCALCIFEROL

KYNAMRO, MIPOMERSEN SODIUM

**GILEAD****\* GILEAD SCIENCES INC**

ATRIPLA, EFAVIRENZ

CAYSTON, AZTREONAM

EMTRIVA, EMTRICITABINE

HEPSERA, ADEFOVIR DIPIVOXIL

LETAIRIS, AMBRISENTAN

RANEXA, RANOLAZINE

TRUVADA, EMTRICITABINE

**GILEAD SCIENCES INC****\* GILEAD SCIENCES INC**

COMPLERA, EMTRICITABINE

GENVOYA, COBICISTAT

HARVONI, LEDIPASVIR

SOVALDI, SOFOSBUVIR

STRIBILD, COBICISTAT

TYBOST, COBICISTAT

VIREAD, TENOFOVIR DISOPROXIL FUMARATE

VITEKTA, ELVITEGRAVIR

ZYDELIG, IDELALISIB

**GLAND PHARMA LTD****\* GLAND PHARMA LTD**

ADENOSINE, ADENOSINE

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

AZITHROMYCIN, AZITHROMYCIN

GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

HALOPERIDOL, HALOPERIDOL LACTATE

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE

METOPROLOL TARTRATE, METOPROLOL TARTRATE

MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE

MILRINONE LACTATE, MILRINONE LACTATE

ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

ZOLEDRONIC ACID, ZOLEDRONIC ACID

**GLAXO GRP ENGLAND****\* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE**

INCRUSE ELLIPTA , UMECLIDINIUM BROMIDE

**GLAXO GRP LTD****\* GLAXO GROUP LTD DBA GLAXOSMITHKLINE**

ALTABAX, RETAPAMULIN

FLOVENT HFA, FLUTICASONE PROPIONATE

**\* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE**

ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE

ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE

ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE

ADVAIR HFA, FLUTICASONE PROPIONATE

BREQ ELLIPTA, FLUTICASONE FUROATE

FLOVENT DISKUS 100, FLUTICASONE PROPIONATE

FLOVENT DISKUS 250, FLUTICASONE PROPIONATE

FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

ZANTAC 150, RANITIDINE HYDROCHLORIDE

ZANTAC 300, RANITIDINE HYDROCHLORIDE

ZANTAC, RANITIDINE HYDROCHLORIDE

**GLAXOSMITHKLINE****\* GLAXOSMITHKLINE**

ABREVA, DOCOSANOL (OTC)

ALKERAN, MELPHALAN

ALKERAN, MELPHALAN HYDROCHLORIDE

AVODART, DUTASTERIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

- \* GLAXOSMITHKLINE
    - BACTROBAN, MUPIROCIN
    - BACTROBAN, MUPIROCIN CALCIUM
    - BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
    - CEFTIN, CEFUROXIME AXETIL
    - EPIVIR-HBV, LAMIVUDINE
    - FLONASE, FLUTICASONE PROPIONATE
    - IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
    - IMITREX, SUMATRIPTAN
    - IMITREX, SUMATRIPTAN SUCCINATE
    - JALYN, DUTASTERIDE
    - MALARONE PEDIATRIC, ATOVAQUONE
    - MALARONE, ATOVAQUONE
    - NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
    - NICORETTE, NICOTINE POLACRILEX (OTC)
    - POTIGA, EZOGABINE
    - RELENZA, ZANAMIVIR
    - VALTREX, VALACYCLOVIR HYDROCHLORIDE
    - VERAMYST, FLUTICASONE FUROATE
    - WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
    - WELLBUTRIN, BUPROPION HYDROCHLORIDE
    - ZYBAN, BUPROPION HYDROCHLORIDE
  - \* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
    - ANORO ELLIPTA, UMECLIDINIUM BROMIDE
    - ARNUITY ELLIPTA, FLUTICASONE FUROATE
  - \* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
    - SEREVENT, SALMETEROL XINAFOATE
    - VENTOLIN HFA, ALBUTEROL SULFATE
- GLAXOSMITHKLINE CONS**
- \* GLAXOSMITHKLINE CONSUMER HEALTHCARE
    - ALLI, ORLISTAT (OTC)
    - COMMIT, NICOTINE POLACRILEX (OTC)
    - FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
    - NICORETTE, NICOTINE POLACRILEX (OTC)
    - VOLTAREN, DICLOFENAC SODIUM
- GLAXOSMITHKLINE LLC**
- \* GLAXOSMITHKLINE LLC
    - AMERGE, NARATRIPTAN HYDROCHLORIDE
    - DYAZIDE, HYDROCHLOROTHIAZIDE
    - FLOLAN, EPOPROSTENOL SODIUM
    - INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
    - LAMICTAL CD, LAMOTRIGINE
    - LAMICTAL ODT, LAMOTRIGINE
    - LAMICTAL XR, LAMOTRIGINE
    - LAMICTAL, LAMOTRIGINE
    - MEPRON, ATOVAQUONE
    - REQUIP XL, ROPINIROLE HYDROCHLORIDE
    - REQUIP, ROPINIROLE HYDROCHLORIDE
    - RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
    - RYTHMOL, PROPAFENONE HYDROCHLORIDE
- GLENMARK GENERICS**
- \* GLENMARK GENERICS INC USA
    - ADAPALENE, ADAPALENE
    - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
    - CALCIPOTRIENE, CALCIPOTRIENE
    - IMIQUIMOD, IMIQUIMOD
    - MOMETASONE FUROATE, MOMETASONE FUROATE
    - MUPIROCIN, MUPIROCIN CALCIUM
    - NIZATIDINE, NIZATIDINE
    - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
    - ZONISAMIDE, ZONISAMIDE
  - \* GLENMARK GENERICS LIMITED
    - BRIELLYN, ETHINYL ESTRADIOL
    - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
    - LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

- \* GLENMARK GENERICS LTD  
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM  
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE  
 ALYACEN 1/35, ETHINYL ESTRADIOL  
 ALYACEN 7/7/7, ETHINYL ESTRADIOL  
 ASHLYNA, ETHINYL ESTRADIOL  
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE  
 CARVEDILOL, CARVEDILOL  
 CICLOPIROX, CICLOPIROX  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 DESOXIMETASONE, DESOXIMETASONE  
 ESZOPICLONE, ESZOPICLONE  
 FELODIPINE, FELODIPINE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOCINONIDE, FLUOCINONIDE  
 GABAPENTIN, GABAPENTIN  
 HEATHER, NORETHINDRONE  
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 MARLISSA, ETHINYL ESTRADIOL  
 MELOXICAM, MELOXICAM  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NAPROXEN, NAPROXEN  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE, NORETHINDRONE  
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 OMEPRAZOLE, OMEPRAZOLE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 OXCARBAZEPINE, OXCARBAZEPINE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 RILUZOLE, RILUZOLE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 TELMISARTAN, TELMISARTAN  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE  
 TOPIRAMATE, TOPIRAMATE  
 TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL  
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE  
 URSODIOL, URSODIOL  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 VIORELE, DESOGESTREL  
 ZOLMITRIPTAN, ZOLMITRIPTAN
- \* GLENMARK GENERICS LTD INDIA  
 INDOMETHACIN, INDOMETHACIN  
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**GLENMARK PHARMS**

- \* GLENMARK PHARMACEUTICALS INC USA  
 CICLOPIROX, CICLOPIROX  
 CLOTRIMAZOLE, CLOTRIMAZOLE  
 MUPIROCIN, MUPIROCIN
- \* GLENMARK PHARMACEUTICALS LTD  
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**GLENMARK PHARMS INC**

- \* GLENMARK PHARMACEUTICALS INC USA



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

\* GLENMARK PHARMACEUTICALS INC USA  
LITHIUM CARBONATE, LITHIUM CARBONATE

**GLENMARK PHARMS LTD**

\* GLENMARK PHARMACEUTICALS LTD  
CALCIPOTRIENE, CALCIPOTRIENE  
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
LINEZOLID, LINEZOLID  
VORICONAZOLE, VORICONAZOLE

**GLOBAL ISOTOPES LLC**

\* GLOBAL ISOTOPES LLC DBA ZEVACOR MOLECULAR  
AMMONIA N 13, AMMONIA N-13  
CHOLINE C-11, CHOLINE C-11  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**GRANULES INDIA**

\* GRANULES INDIA LTD  
IBUPROFEN, IBUPROFEN (OTC)  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

**GRANULES INDIA LTD**

\* GRANULES INDIA LTD  
IBUPROFEN, IBUPROFEN

**GUARDIAN DRUG**

\* GUARDIAN DRUG CO INC  
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

**GUERBET**

\* GUERBET LLC  
DOTAREM, GADOTERATE MEGLUMINE  
LIPIODOL, ETHIODIZED OIL  
OXILAN-300, IOXILAN  
OXILAN-350, IOXILAN

**HANFORD GC**

\* GC HANFORD MANUFACTURING CO  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
AMPICILLIN SODIUM, AMPICILLIN SODIUM  
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

**\*\* H \*\*****HAEMONETICS**

\* HAEMONETICS CORP  
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**HALOCARBON PRODS**

\* HALOCARBON PRODUCTS CORP  
ISOFLURANE, ISOFLURANE  
SEVOFLURANE, SEVOFLURANE

**HALOZYME THERAP**

\* HALOZYME THERAPEUTICS INC  
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

**HAMELN RDS GMBH**

\* HAMELN RDS GMBH  
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

**HANMI PHARM CO LTD**

\* HANMI PHARMACEUTICAL CO LTD  
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

**HARRIS PHARM**

\* HARRIS PHARMACEUTICAL INC  
FLUCONAZOLE, FLUCONAZOLE  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

**HAUPT PHARMA**

\* HAUPT PHARMA INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

\* HAUPT PHARMA INC  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE, NORETHINDRONE  
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

**HEC PHARM USA INC**

\* HEC PHARM USA INC  
 CLARITHROMYCIN, CLARITHROMYCIN

**HELSINN HLTHCARE**

\* HELSINN HEALTHCARE SA  
 AKYNZEO, NETUPITANT  
 ALOXI, PALONOSETRON HYDROCHLORIDE

**HERCON PHARM**

\* HERCON PHARMACEUTICAL LLC  
 NITROGLYCERIN, NITROGLYCERIN

**HERITAGE LIFE**

\* HERITAGE LIFE SCIENCES BARBADOS INC  
 CLOZARIL, CLOZAPINE

**HERITAGE PHARMA**

\* HERITAGE PHARMA LABS INC  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 DIFLUNISAL, DIFLUNISAL  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 METHIMAZOLE, METHIMAZOLE  
 NIFEDIPINE, NIFEDIPINE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**HERITAGE PHARMS INC**

\* HERITAGE PHARMACEUTICALS INC  
 ACETAZOLAMIDE, ACETAZOLAMIDE  
 ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE  
 ALPRAZOLAM, ALPRAZOLAM  
 CALCIUM ACETATE, CALCIUM ACETATE  
 CARISOPRODOL AND ASPIRIN, ASPIRIN  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 ETHOSUXIMIDE, ETHOSUXIMIDE  
 FELODIPINE, FELODIPINE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
 GLYBURIDE, GLYBURIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 LEFLUNOMIDE, LEFLUNOMIDE  
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE  
 SULINDAC, SULINDAC  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**HETERO LABS LTD III**

\* HETERO LABS LTD UNIT III  
 ABACAVIR SULFATE, ABACAVIR SULFATE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
 FINASTERIDE, FINASTERIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LEVETIRACETAM, LEVETIRACETAM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

\* HETERO LABS LTD UNIT III  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 METHOCARBAMOL, METHOCARBAMOL  
 NEVIRAPINE, NEVIRAPINE  
 SIMVASTATIN, SIMVASTATIN  
 STAVUDINE, STAVUDINE  
 TORSEMIDE, TORSEMIDE  
 ZIDOVUDINE, ZIDOVUDINE

**HETERO LABS LTD V**

\* HETERO LABS LTD UNIT V  
 ACYCLOVIR, ACYCLOVIR  
 ARIPIPIRAZOLE, ARIPIPIRAZOLE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 ENTECAVIR, ENTECAVIR  
 FAMCICLOVIR, FAMCICLOVIR  
 IRBESARTAN, IRBESARTAN  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LAMIVUDINE, LAMIVUDINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LINEZOLID, LINEZOLID  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALSARTAN, VALSARTAN

**HEYL CHEMISCH**

\* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK  
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

**HI TECH PHARMA**

\* HI TECH PHARMACAL CO INC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 ACYCLOVIR, ACYCLOVIR  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
 CICLOPIROX, CICLOPIROX  
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
 CORMAX, CLOBETASOL PROPIONATE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 EMBELINE E, CLOBETASOL PROPIONATE  
 EMBELINE, CLOBETASOL PROPIONATE  
 ERYTHRO-STATIN, ERYTHROMYCIN  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 GABAPENTIN, GABAPENTIN  
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 LACTULOSE, LACTULOSE  
 LEVOCARNITINE, LEVOCARNITINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LIDOCAINE AND PRILOCAINE, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)  
 NYSTATIN, NYSTATIN  
 OFLOXACIN, OFLOXACIN  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

\* HI TECH PHARMACAL CO INC

RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 VOSOL HC, ACETIC ACID, GLACIAL  
 VOSOL, ACETIC ACID, GLACIAL

**HI TECH PHARMA CO**

\* HI TECH PHARMACAL CO INC

FLUNISOLIDE, FLUNISOLIDE  
 PREDNISOLONE, PREDNISOLONE

**HI-TECH PHARMA CO**

\* HI-TECH PHARMACAL CO INC

FAMOTIDINE, FAMOTIDINE  
 GATIFLOXACIN, GATIFLOXACIN  
 LORAZEPAM, LORAZEPAM  
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

**HI-TECH PHARMACAL**

\* HI-TECH PHARMACAL CO INC

BROMFENAC SODIUM, BROMFENAC SODIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE

**HIGH TECH PHARMA**

\* HIGH TECHNOLOGY PHARMACAL CO INC

VALPROIC ACID, VALPROIC ACID

**HIKMA**

\* HIKMA FARMACEUTICA LDA

CEFOTAXIME, CEFOTAXIME SODIUM

\* HIKMA PHARMACEUTICALS

AMOXICILLIN, AMOXICILLIN  
 CEFACLOR, CEFACLOR  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEPHALEXIN, CEPHALEXIN  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 GABAPENTIN, GABAPENTIN  
 GLYBURIDE (MICRONIZED), GLYBURIDE  
 NAPROXEN SODIUM, NAPROXEN SODIUM

**HIKMA FARMACEUTICA**

\* HIKMA FARMACEUTICA (PORTUGAL) SA

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 CEFOXITIN, CEFOXITIN SODIUM  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 CIPROFLOXACIN, CIPROFLOXACIN  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 ENALAPRILAT, ENALAPRILAT  
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUMAZENIL, FLUMAZENIL  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 GRANISTERON HYDROCHLORIDE, GRANISERTRON HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PROGESTERONE, PROGESTERONE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

- \* HIKMA FARMACEUTICA (PORTUGAL) SA  
VALPROATE SODIUM, VALPROATE SODIUM
- \* HIKMA FARMACEUTICA PORTUGAL LDA  
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
CEFUROXIME SODIUM, CEFUROXIME SODIUM  
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
- \* HIKMA FARMACEUTICA PORTUGAL SA  
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
OXYTOCIN, OXYTOCIN  
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
- \* HIKMA FARMACEUTICA SA  
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**HIKMA INTL PHARMS**

- \* HIKMA INTERNATIONAL PHARMACEUTICALS LLC  
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN  
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN  
CORTISONE ACETATE, CORTISONE ACETATE  
DIGOXIN, DIGOXIN  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE  
HYDROCORTISONE, HYDROCORTISONE  
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LISINOPRIL, LISINOPRIL  
LITHIUM CARBONATE, LITHIUM CARBONATE  
METHOCARBAMOL, METHOCARBAMOL  
MITIGARE, COLCHICINE  
NAPROXEN, NAPROXEN

**HIKMA MAPLE**

- \* HIKMA MAPLE LTD  
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
CEFOXITIN, CEFOXITIN SODIUM  
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE  
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
MITOMYCIN, MITOMYCIN  
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

**HIKMA PHARM CO LTD**

- \* HIKMA PHARM CO LTD  
ARGATROBAN, ARGATROBAN

**HIKMA PHARMS**

- \* HIKMA PHARMACEUTICALS  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
AMOXICILLIN, AMOXICILLIN  
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE  
GEMFIBROZIL, GEMFIBROZIL  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
MODAFINIL, MODAFINIL  
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
- \* HIKMA PHARMACEUTICALS CO LTD  
PARICALCITOL, PARICALCITOL
- \* HIKMA PHARMACEUTICALS LLC  
PREDNISONE, PREDNISONE

**HIKMA PHARMS LLC**

- \* HIKMA PHARMACEUTICALS LLC  
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

\* HIKMA PHARMACEUTICALS LLC  
 CAPTOPRIL, CAPTOPRIL  
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
 DOXERCALCIFEROL, DOXERCALCIFEROL  
 FOLIC ACID, FOLIC ACID  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 PRIMIDONE, PRIMIDONE  
 ZALEPLON, ZALEPLON

**HILL DERMAC**

\* HILL DERMACEUTICALS INC  
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE  
 DERMOTIC, FLUOCINOLONE ACETONIDE

**HILL DERMACEUTICALS**

\* HILL DERMACEUTICALS INC  
 TOLAK, FLUOROURACIL

**HISAMITSU PHARM CO**

\* HISAMITSU PHARMACEUTICAL CO INC  
 SALONPAS, MENTHOL (OTC)

**HISUN PHARM HANGZHOU**

\* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

**HOFFMANN LA ROCHE**

\* HOFFMANN LA ROCHE INC  
 ANAPROX DS, NAPROXEN SODIUM  
 ANAPROX, NAPROXEN SODIUM  
 BONIVA, IBANDRONATE SODIUM  
 INVIRASE, SAQUINAVIR MESYLATE  
 ROCEPHIN, CEFTRIAZONE SODIUM  
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE  
 XELODA, CAPECITABINE  
 XENICAL, ORLISTAT  
 ZELBORAF, VEMURAFENIB

**HOFFMANN-LA ROCHE**

\* HOFFMANN-LA ROCHE INC  
 ALECENSA, ALECTINIB HYDROCHLORIDE  
 INVIRASE, SAQUINAVIR MESYLATE

**HOPE PHARMS**

\* HOPE PHARMACEUTICALS  
 NITHIODOTE, SODIUM NITRITE  
 SODIUM NITRITE, SODIUM NITRITE  
 SODIUM THIOSULFATE, SODIUM THIOSULFATE

**HORIZON PHARMA**

\* HORIZON PHARMA INC  
 DUEXIS, FAMOTIDINE  
 RAYOS, PREDNISONE  
 VIMOVO, ESOMEPRAZOLE MAGNESIUM  
 \* HORIZON PHARMA IRELAND LTD  
 PENNSAID, DICLOFENAC SODIUM

**HORIZON THERAPS INC**

\* HORIZON THERAPEUTICS INC  
 RAVICTI, GLYCEROL PHENYLBUTYRATE

**HOSPIRA**

\* HOSPIRA INC  
 A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE  
 A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE  
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
 ACETYLCYSTEINE, ACETYLCYSTEINE  
 ALFENTANIL, ALFENTANIL HYDROCHLORIDE  
 AMIDATE, ETOMIDATE  
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID  
 AMINOPHYLLINE, AMINOPHYLLINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\*****\* HOSPIRA INC**

AMINOSYN 10% (PH6), AMINO ACIDS  
 AMINOSYN 10%, AMINO ACIDS  
 AMINOSYN 3.5% M, AMINO ACIDS  
 AMINOSYN 3.5%, AMINO ACIDS  
 AMINOSYN 5%, AMINO ACIDS  
 AMINOSYN 7% (PH6), AMINO ACIDS  
 AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN 7%, AMINO ACIDS  
 AMINOSYN 8.5% (PH6), AMINO ACIDS  
 AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN 8.5%, AMINO ACIDS  
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN II 10%, AMINO ACIDS  
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS  
 AMINOSYN II 7%, AMINO ACIDS  
 AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN II 8.5%, AMINO ACIDS  
 AMINOSYN-HBC 7%, AMINO ACIDS  
 AMINOSYN-HF 8%, AMINO ACIDS  
 AMINOSYN-PF 10%, AMINO ACIDS  
 AMINOSYN-PF 7%, AMINO ACIDS  
 AMINOSYN-RF 5.2%, AMINO ACIDS  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE  
 AQUASOL A, VITAMIN A PALMITATE  
 ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE  
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE  
 AZITHROMYCIN, AZITHROMYCIN  
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
 BUMETANIDE, BUMETANIDE  
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE  
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE  
 CARBOPLATIN, CARBOPLATIN  
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE  
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE  
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 CIPROFLOXACIN, CIPROFLOXACIN  
 CORLOPAM, FENOLDOPAM MESYLATE  
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE  
 CYTARABINE, CYTARABINE  
 DACARBAZINE, DACARBAZINE  
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE  
 DEMEROL, MEPERIDINE HYDROCHLORIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 25%, DEXTROSE  
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* H \*\*

## \* HOSPIRA INC

DEXTROSE 50% , DEXTROSE  
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
 DIAZEPAM, DIAZEPAM  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE  
 DROPERIDOL, DROPERIDOL  
 ENALAPRILAT, ENALAPRILAT  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE  
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE  
 FENTANYL CITRATE, FENTANYL CITRATE  
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FOSCARNET SODIUM, FOSCARNET SODIUM  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 ISOFLURANE, ISOFLURANE  
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE  
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LEVOPHED, NOREPINEPHRINE BITARTRATE  
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE  
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 LORAZEPAM, LORAZEPAM  
 LTA II KIT, LIDOCAINE HYDROCHLORIDE  
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID  
 M.V.I. ADULT, ASCORBIC ACID  
 M.V.I. PEDIATRIC, ASCORBIC ACID  
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID  
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* H \*\*

## \* HOSPIRA INC

MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 25%, MANNITOL  
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE, BUPIVACAINE HYDROCHLORIDE  
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE  
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE  
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE  
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN  
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PACLITAXEL, PACLITAXEL  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE  
 PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 POTASSIUM ACETATE, POTASSIUM ACETATE  
 POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* H \*\*

## \* HOSPIRA INC

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE  
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE  
 PROPOFOL, PROPOFOL  
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE  
 QUELICIN, SUCCINYLCHOLINE CHLORIDE  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE  
 SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS  
 SODIUM BICARBONATE, SODIUM BICARBONATE  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE  
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE  
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION  
 SUFENTANIL CITRATE, SUFENTANIL CITRATE  
 TALWIN, PENTAZOCINE LACTATE  
 TAZICEF, CEFTAZIDIME  
 THAM, TROMETHAMINE  
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VECURONIUM BROMIDE, VECURONIUM BROMIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE  
 VITAMIN K1, PHYTONADIONE  
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

## \* HOSPIRA WORLDWIDE, INC

DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 NITROPRESS, SODIUM NITROPRUSSIDE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

**HOSPIRA INC**

## \* HOSPIRA INC

A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE  
 ADENOSINE, ADENOSINE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE  
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE  
 BIVALIRUDIN, BIVALIRUDIN  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE  
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM  
 CEFOXITIN, CEFOXITIN SODIUM  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 CEFUROXIME SODIUM, CEFUROXIME SODIUM  
 DAPTOMYCIN, DAPTOMYCIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\*****\* HOSPIRA INC**

DOCETAXEL, DOCETAXEL  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID  
 LINEZOLID, LINEZOLID  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MAXIPIME, CEFEPIME HYDROCHLORIDE  
 MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE  
 MEROPENEM, MEROPENEM  
 MILRINONE LACTATE, MILRINONE LACTATE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NIPENT, PENTOSTATIN  
 OXACILLIN SODIUM, OXACILLIN SODIUM  
 OXALIPLATIN, OXALIPLATIN  
 PARICALCITOL, PARICALCITOL  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**HOSPIRA WORLDWIDE**

\* HOSPIRA WORLDWIDE PTY  
 OXALIPLATIN, OXALIPLATIN

**HOT SHOTS NM LLC**

\* HOT SHOTS NUCLEAR MEDICINE LLC  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**HOUSTON CYCLOTRON**

\* HOUSTON CYCLOTRON PARTNERS LP  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**HQ SPCLT PHARMA**

\* HQ SPECIALTY PHARMA CORP  
 CISPLATIN, CISPLATIN  
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
 TAXOL, PACLITAXEL

**HQ SPECIALITY PHARMA**

\* HQ SPECIALITY PHARMA LLC  
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

**HQ SPECLT PHARMA**

\* HQ SPECIALTY PHARMA  
 VUMON, TENIPOSIDE

**HRA PHARMA**

\* HRA PHARMA LLC  
 METOPIRONE, METYRAPONE

**HYPERION THERAPS INC**

\* HYPERION THERAPEUTICS INC  
 BUPHENYL, SODIUM PHENYLBUTYRATE

**ROCHE**

\* HOFFMANN LA ROCHE INC  
 BONIVA, IBANDRONATE SODIUM  
 COPEGUS, RIBAVIRIN  
 FUZEON, ENFUVIRTIDE  
 KLONOPIN, CLONAZEPAM  
 TAMIFLU, OSELTAMIVIR PHOSPHATE  
 VALIUM, DIAZEPAM

**\*\* I \*\***

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\*****IBA MOLECULAR N AM**

\* IBA MOLECULAR NORTH AMERICA INC  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**IDENTI PHARMS INC**

\* IDENTI PHARMACEUTICALS INC  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

**IDT**

\* INSPIRION DELIVERY TECHNOLOGIES LLC  
 MORPHABOND, MORPHINE SULFATE

**IGI LABS INC**

\* IGI LABORATORIES INC  
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM  
 FORTAZ, CEFTAZIDIME  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

**IMPAX LABS**

\* IMPAX LABORATORIES INC  
 ACARBOSE, ACARBOSE  
 ALPRAZOLAM, ALPRAZOLAM  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 BACLOFEN, BACLOFEN  
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE  
 DANTROLENE SODIUM, DANTROLENE SODIUM  
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
 DIGOXIN, DIGOXIN  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 FENOFIBRATE (MICRONIZED), FENOFIBRATE  
 FENOFIBRATE, FENOFIBRATE  
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)  
 LORATADINE, LORATADINE (OTC)  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHYLTESTOSTERONE, METHYLTESTOSTERONE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE  
 OMEPRAZOLE, OMEPRAZOLE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PENTOXIFYLLINE, PENTOXIFYLLINE  
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
 PRIMIDONE, PRIMIDONE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE  
 RILUZOLE, RILUZOLE  
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

**IMPAX LABS INC**

\* IMPAX LABORATORIES INC  
 CABERGOLINE, CABERGOLINE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\*****\* IMPAX LABORATORIES INC**

GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 METHYLTESTOSTERONE, METHYLTESTOSTERONE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE  
 RYTARY, CARBIDOPA  
 URSODIOL, URSODIOL

**IMPAX PHARMS****\* IMPAX PHARMACEUTICALS**

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE  
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE  
 GEMFIBROZIL, GEMFIBROZIL  
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**INCYTE CORP****\* INCYTE CORP**

JAKAFI, RUXOLITINIB PHOSPHATE

**INDICUS PHARMA****\* INDICUS PHARMA LLC**

CARISOPRODOL, CARISOPRODOL  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 LETROZOLE, LETROZOLE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PERPHENAZINE, PERPHENAZINE

**INDIVIOR INC****\* INDIVIOR INC**

BUPRENEX, BUPRENORPHINE HYDROCHLORIDE  
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

**INDOCO REMEDIES****\* INDOCO REMEDIES LTD**

BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 GLIMEPIRIDE, GLIMEPIRIDE

**INJECTALIA****\* INJECTALIA SRL**

SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**INNOCUTIS HOLDINGS****\* INNOCUTIS HOLDINGS LLC**

SITAVIG, ACYCLOVIR

**INNOPHARMA LICENSING****\* INNOPHARMA LICENSING LLC**

ACETYLCYSTEINE, ACETYLCYSTEINE

**INO****\* INO THERAPEUTICS INC**

INOMAX, NITRIC OXIDE

**INST BIOCHEM****\* INSTITUT BIOCHEMIQUE SA**

FLECTOR, DICLOFENAC EPOLAMINE

**INST BIOCHIMIQUE****\* INSTITUTE BIOCHIMIQUE SA (IBSA)**

TIROSINT, LEVOTHYROXINE SODIUM

**INSTITUT BIOCHIMIQUE****\* INSTITUT BIOCHIMIQUE SA IBSA**

TIROSINT, LEVOTHYROXINE SODIUM

**INSYS THERAP****\* INSYS THERAPEUTICS INC**

SUBSYS, FENTANYL

**INTELLIPHARMACEUTICS****\* INTELLIPHARMACEUTICS CORP**

DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

**INTERGEL PHARM****\* INTERGEL PHARMACEUTICAL INC**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\***

\* INTERGEL PHARMACEUTICAL INC  
NIFEDIPINE, NIFEDIPINE

**INTERPHARMA PRAHA AS**

\* INTERPHARMA PRAHA AS  
ORALTAG, IOHEXOL

**INTL MEDICATED**

\* INTERNATIONAL MEDICATED SYSTEMS LTD  
MILRINONE LACTATE, MILRINONE LACTATE

**INTL MEDICATION**

\* INTERNATIONAL MEDICATION SYSTEM  
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
MANNITOL 25%, MANNITOL  
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
PHYTONADIONE, PHYTONADIONE

\* INTERNATIONAL MEDICATION SYSTEMS LTD  
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

**INTL MEDICATION SYS**

\* INTERNATIONAL MEDICATION SYSTEMS LTD  
LORAZEPAM, LORAZEPAM

**INVAGEN PHARMS**

\* INVAGEN PHARMACEUTICALS INC  
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
CALCIUM ACETATE, CALCIUM ACETATE  
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
FOLIC ACID, FOLIC ACID  
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
GABAPENTIN, GABAPENTIN  
GEMFIBROZIL, GEMFIBROZIL  
GLIMEPIRIDE, GLIMEPIRIDE  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
LEVETIRACETAM, LEVETIRACETAM  
LISINOPRIL, LISINOPRIL  
MEPROBAMATE, MEPROBAMATE  
NABUMETONE, NABUMETONE  
NADOLOL, NADOLOL  
NAPROXEN, NAPROXEN  
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE  
RAMIPRIL, RAMIPRIL  
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
TOPIRAMATE, TOPIRAMATE  
TRANDOLAPRIL, TRANDOLAPRIL  
WARFARIN SODIUM, WARFARIN SODIUM  
ZOLMITRIPTAN, ZOLMITRIPTAN  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE  
ZONISAMIDE, ZONISAMIDE

**INVENTIA HLTHCARE**

\* INVENTIA HEALTHCARE PRIVATE LTD  
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
TELMISARTAN, TELMISARTAN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\*****IPCA LABS LTD**

\* IPCA LABORATORIES LTD  
 ALLOPURINOL, ALLOPURINOL  
 ATENOLOL, ATENOLOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
 FUROSEMIDE, FUROSEMIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 WARFARIN SODIUM, WARFARIN SODIUM

**IPR**

\* IPR PHARMACEUTICALS INC  
 CRESTOR, ROSUVASTATIN CALCIUM  
 ZOMIG, ZOLMITRIPTAN

**IPR PHARMS INC**

\* IPR PHARMACEUTICALS INC  
 CAPRELSA, VANDETANIB

**IPSEN INC**

\* IPSEN BIOPHARMACEUTICALS INC  
 INCRELEX, MECASERMIN RECOMBINANT

**IPSEN PHARMA**

\* IPSEN PHARMA BIOTECH SAS  
 SOMATULINE DEPOT, LANREOTIDE ACETATE

**IROKO PHARMS**

\* IROKO PHARMACEUTICALS LLC  
 INDOCIN, INDOMETHACIN

**IROKO PHARMS LLC**

\* IROKO PHARMACEUTICALS LLC  
 TIVORBEX, INDOMETHACIN  
 VIVLODEX, MELOXICAM  
 ZORVOLEX, DICLOFENAC

**ISO TEX**

\* ISO TEX DIAGNOSTICS INC  
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM  
 MEGATOPE, ALBUMIN IODINATED I-131 SERUM

**ISOTEX**

\* ISOTEX DIAGNOSTICS  
 GLOFIL-125, IOTHALAMATE SODIUM I-125

**ISTITUTO BIO ITA SPA**

\* ISTITUTO BIOCHIMICO ITALIANO SPA  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 PIPERACILLIN, PIPERACILLIN SODIUM

**IVAX INTL**

\* IVAX INTERNATIONAL GMBH  
 AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE  
 SYNRIPO, OMACETAXINE MEPESUCCINATE

**IVAX PHARMS**

\* IVAX PHARMACEUTICALS INC  
 VALSARTAN, VALSARTAN

**IVAX PHARMS INC**

\* IVAX PHARMACEUTICALS INC  
 OLANZAPINE, OLANZAPINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\*****IVAX SUB TEVA PHARMS**

\* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 BACLOFEN, BACLOFEN  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BUMETANIDE, BUMETANIDE  
 CABERGOLINE, CABERGOLINE  
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CIMETIDINE, CIMETIDINE (OTC)  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CLOZAPINE, CLOZAPINE  
 CYCLOSPORINE, CYCLOSPORINE  
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
 DIAZEPAM, DIAZEPAM  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
 FAMOTIDINE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUTAMIDE, FLUTAMIDE  
 FUROSEMIDE, FUROSEMIDE  
 GABAPENTIN, GABAPENTIN  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 INDOMETHACIN, INDOMETHACIN  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINAPRIL, LISINAPRIL  
 METHYLDOPA, METHYLDOPA  
 MISOPROSTOL, MISOPROSTOL  
 NADOLOL, NADOLOL  
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE  
 OXAPROZIN, OXAPROZIN  
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 SIMVASTATIN, SIMVASTATIN  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE  
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**\*\* J \*\*****J AND J CONSUMER INC**

\* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION  
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)  
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)  
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)  
 IMODIUM, LOPERAMIDE HYDROCHLORIDE  
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)  
 MOTRIN IB, IBUPROFEN (OTC)  
 PEPCID AC, FAMOTIDINE (OTC)  
 PEPCID AC, FAMOTIDINE (OTC)  
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)  
 SINE-AID IB, IBUPROFEN (OTC)  
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 TYLENOL, ACETAMINOPHEN (OTC)  
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* J \*\***

\* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION  
 ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC, CETIRIZINE HYDROCHLORIDE  
 ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

**JACOBUS**

\* JACOBUS PHARMACEUTICAL CO  
 DAPSONE, DAPSONE  
 PASER, AMINOSALICYLIC ACID

**JAI PHARMA LTD**

\* JAI PHARMA LTD  
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE, NORETHINDRONE  
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

**JANSSEN BIOTECH**

\* JANSSEN BIOTECH INC  
 ZYTIGA, ABIRATERONE ACETATE

**JANSSEN PHARMS**

\* JANSSEN PHARMACEUTICALS INC  
 AXERT, ALMOTRIPTAN MALATE  
 CONCERTA, METHYLPHENIDATE HYDROCHLORIDE  
 DITROPAN XL, OXYBUTYNIN CHLORIDE  
 DURAGESIC-100, FENTANYL  
 DURAGESIC-12, FENTANYL  
 DURAGESIC-25, FENTANYL  
 DURAGESIC-50, FENTANYL  
 DURAGESIC-75, FENTANYL  
 ELMIRON, PENTOSAN POLYSULFATE SODIUM  
 HALDOL, HALOPERIDOL DECANOATE  
 HALDOL, HALOPERIDOL LACTATE  
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE  
 INVEGA TRINZA, PALIPERIDONE PALMITATE  
 INVEGA, PALIPERIDONE  
 INVOKAMET, CANAGLIFLOZIN  
 INVOKANA, CANAGLIFLOZIN  
 LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVAQUIN, LEVOFLOXACIN  
 MICRONOR, NORETHINDRONE  
 MODICON 28, ETHINYL ESTRADIOL  
 NIZORAL, KETOCONAZOLE  
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL  
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL  
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL  
 ORTHO-CEPT, DESOGESTREL  
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL  
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL  
 PANCREAZE, PANCRELIPASE (AMYLASE  
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE  
 RAZADYNE, GALANTAMINE HYDROBROMIDE  
 RISPERDAL CONSTA, RISPERIDONE  
 RISPERDAL, RISPERIDONE  
 SPORANOX, ITRACONAZOLE  
 TERAZOL 3, TERCONAZOLE  
 TERAZOL 7, TERCONAZOLE  
 TOPAMAX, TOPIRAMATE  
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN  
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN  
 ULTRACET, ACETAMINOPHEN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* J \*\***

\* JANSSEN PHARMACEUTICALS INC  
 ULTRAM, TRAMADOL HYDROCHLORIDE  
 XARELTO, RIVAROXABAN

**JANSSEN PRODS**

\* JANSSEN PRODUCTS LP  
 EDURANT, RILPIVIRINE HYDROCHLORIDE  
 OLYSIO, SIMEPREVIR SODIUM  
 PREZCOBIX, COBICISTAT  
 PREZISTA, DARUNAVIR ETHANOLATE  
 YONDELIS, TRABECTEDIN

**JANSSEN R AND D**

\* JANSSEN RESEARCH AND DEVELOPMENT LLC  
 INTELENCE, ETRAVIRINE

**JANSSEN RES AND DEV**

\* JANSSEN RESEARCH AND DEVELOPMENT LLC  
 DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

**JANSSEN THERAP**

\* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP  
 SIRTURO, BEDAQUILINE FUMARATE

**JAVELIN PHARMS INC**

\* JAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF HOSPIRA INC  
 DYLOJECT, DICLOFENAC SODIUM

**JAZZ PHARMS**

\* JAZZ PHARMACEUTICALS INC  
 LUVOX CR, FLUVOXAMINE MALEATE  
 XYREM, SODIUM OXYBATE

**JAZZ PHARMS III**

\* JAZZ PHARMACEUTICALS III INTERNATIONAL LTD  
 FAZACLO ODT, CLOZAPINE  
 \* JAZZ PHARMACEUTICALS INTERNATIONAL III  
 VERSACLOZ, CLOZAPINE

**JAZZ PHARMS INTL**

\* JAZZ PHARMACEUTICALS INTERNATIONAL LTD  
 PRIALT, ZICONOTIDE ACETATE

**JIANGSU HANSOH PHARM**

\* JIANGSU HANSOH PHARMACEUTICAL CO LTD  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

**JIANGSU HENGRUI MED**

\* JIANGSU HENGRUI MEDICINE CO LTD  
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LETROZOLE, LETROZOLE  
 OXALIPLATIN, OXALIPLATIN

**JOHNS HOPKINS UNIV**

\* JOHNS HOPKINS UNIV  
 AMMONIA N 13, AMMONIA N-13

**JOHNSON AND JOHNSON**

\* JOHNSON AND JOHNSON CONSUMER INC  
 VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)  
 VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 \* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES  
 MEN'S ROGAINE, MINOXIDIL (OTC)  
 ROGAINE (FOR MEN), MINOXIDIL (OTC)  
 ROGAINE (FOR WOMEN), MINOXIDIL (OTC)  
 ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 WOMEN'S ROGAINE, MINOXIDIL (OTC)  
 \* JOHNSON AND JOHNSON HEALTHCARE PRODUCTS DIV MCNEIL-PPC INC  
 NIZORAL A-D, KETOCONAZOLE (OTC)

**JUBILANT CADISTA**

\* JUBILANT CADISTA PHARMACEUTICALS INC  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* J \*\***

\* JUBILANT CADISTA PHARMACEUTICALS INC  
 METHYLPREDNISOLONE, METHYLPREDNISOLONE  
 PREDNISONE, PREDNISONE  
 PROCOMP, PROCHLORPERAZINE MALEATE  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

**JUBILANT DRAXIMAGE**

\* JUBILANT DRAXIMAGE INC  
 AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT  
 DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE  
 HICON, SODIUM IODIDE I-131  
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
 SODIUM IODIDE I-131, SODIUM IODIDE I-131

**JUBILANT GENERICS**

\* JUBILANT GENERICS LTD  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 INDOMETHACIN, INDOMETHACIN  
 IRBESARTAN, IRBESARTAN  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 OLANZAPINE, OLANZAPINE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RISPERIDONE, RISPERIDONE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALSARTAN, VALSARTAN  
 ZOLMITRIPTAN, ZOLMITRIPTAN

**STEVENS J**

\* JEROME STEVENS PHARMACEUTICALS INC  
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN  
 DIGOXIN, DIGOXIN  
 METHOCARBAMOL AND ASPIRIN, ASPIRIN  
 UNITHROID, LEVOTHYROXINE SODIUM \*\*

**\*\* K \*\*****GRIFFEN**

\* KW GRIFFEN CO  
 BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

**KALEO INC**

\* KALEO INC  
 EVZIO, NALOXONE HYDROCHLORIDE

**KEN LIFESCIENCE**

\* KEN LIFESCIENCE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**KERYX BIOPHARMS**

\* KERYX BIOPHARMACEUTICALS INC  
 AURYXIA, FERRIC CITRATE

**KETTERING MEDCTR**

\* KETTERING MEDCTR  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**KING PHARMS**

\* KING PHARMACEUTICALS INC  
 ALTACE, RAMIPRIL  
 BICILLIN C-R 900/300, PENICILLIN G BENZATHINE  
 BICILLIN C-R, PENICILLIN G BENZATHINE  
 BICILLIN L-A, PENICILLIN G BENZATHINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* K \*\***

- \* KING PHARMACEUTICALS INC  
CORZIDE, BENDROFLUMETHIAZIDE  
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE  
SILVADENE, SILVER SULFADIAZINE  
SKELAXIN, METAXALONE  
SYNERCID, DALFOPRISTIN  
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
- \* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC  
TAPAZOLE, METHIMAZOLE  
TUSSIGON, HOMATROPINE METHYLBROMIDE

**KING PHARMS R AND D**

- \* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC  
CYTOMEL, LIOTHYRONINE SODIUM  
LEVOXYL, LEVOTHYROXINE SODIUM \*\*

**KNIGHT THERAPS**

- \* KNIGHT THERAPEUTICS USA INC  
IMPAVIDO, MILTEFOSINE

**KOWA CO**

- \* KOWA CO LTD  
LIVALO, PITAVASTATIN CALCIUM

**KREITCHMAN PET CTR**

- \* KREITCHMAN PET CENTER  
AMMONIA N 13, AMMONIA N-13

**KREMERS URBAN DEV**

- \* KREMERS URBAN DEVELOPMENT CO  
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM

**KREMERS URBAN PHARMS**

- \* KREMERS URBAN PHARMACEUTICALS INC  
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
GLYCOLAX, POLYETHYLENE GLYCOL 3350  
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
MONOKET, ISOSORBIDE MONONITRATE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
OMEPRAZOLE, OMEPRAZOLE  
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

**KRKA TOVARNA ZDRAVIL**

- \* KRKA TOVARNA ZDRAVIL DD NOVO MESTO  
LANSOPRAZOLE , LANSOPRAZOLE

**KUDCO IRELAND**

- \* KUDCO IRELAND LTD  
LETROZOLE, LETROZOLE

**KVK TECH**

- \* KVK TECH INC  
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
KALEXATE, SODIUM POLYSTYRENE SULFONATE  
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**KYTHERA BIOPHARMS**

- \* KYTHERA BIOPHARMACEUTICALS INC  
KYBELLA, DEOXYCHOLIC ACID

**\*\* L \*\*****L PERRIGO CO**

- \* L PERRIGO CO  
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

**LAB HRA PHARMA**

- \* LABORATOIRE HRA PHARMA  
ELLA, ULIPRISTAL ACETATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\*****LANDELA PHARM**

\* LANDELA PHARMACEUTICAL  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

**LANNETT**

\* LANNETT CO INC  
 ACETAZOLAMIDE, ACETAZOLAMIDE  
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
 LANIAZID, ISONIAZID  
 LANORINAL, ASPIRIN  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PRIMIDONE, PRIMIDONE  
 PROBALAN, PROBENECID

\* LANNETT HOLDINGS INC  
 BACLOFEN, BACLOFEN  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 DANAZOL, DANAZOL  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
 RIFAMPIN, RIFAMPIN  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 URSODIOL, URSODIOL

**LANNETT HOLDINGS INC**

\* LANNETT HOLDINGS INC  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 CODEINE SULFATE, CODEINE SULFATE  
 DIAZEPAM, DIAZEPAM  
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LETROZOLE, LETROZOLE  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 METHOCARBAMOL, METHOCARBAMOL  
 MORPHINE SULFATE, MORPHINE SULFATE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**LANTHEUS MEDCL**

\* LANTHEUS MEDICAL IMAGING INC  
 ABLAVAR, GADOFOSVESET TRISODIUM  
 CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT  
 DEFINITY, PERFLUTREN  
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67  
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT  
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201  
 XENON XE 133, XENON XE-133

**LANTHEUS MEDICAL**

\* LANTHEUS MEDICAL IMAGING INC  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

**LARKEN LABS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\***

\* LARKEN LABORATORIES INC

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
OFLOXACIN, OFLOXACIN**LARKEN LABS INC**

\* LARKEN LABORATORIES INC

ALLZITAL, ACETAMINOPHEN  
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN**LAVIPHARM LABS**

\* LAVIPHARM LABORATORIES INC

FENTANYL-100, FENTANYL  
FENTANYL-25, FENTANYL  
FENTANYL-50, FENTANYL  
FENTANYL-75, FENTANYL**LEADING PHARMA LLC**

\* LEADING PHARMA LLC

BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
FOLIC ACID, FOLIC ACID  
FUROSEMIDE, FUROSEMIDE  
GLYCOPYRROLATE, GLYCOPYRROLATE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
LORAZEPAM, LORAZEPAM**LEHIGH VALLEY**

\* LEHIGH VALLEY TECHNOLOGIES INC

OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**LEK PHARMS**

\* LEK PHARMACEUTICALS D D

BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

**LEK PHARMS DD**

\* LEK PHARMACEUTICALS DD

ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**LEO PHARMA AS**

\* LEO PHARMA AS

DOVONEX, CALCIPOTRIENE  
ENSTILAR, BETAMETHASONE DIPROPIONATE  
PICATO, INGENOL MEBUTATE  
TACLONEX, BETAMETHASONE DIPROPIONATE**LG LIFE**

\* LG LIFE SCIENCES LTD

VALTROPIN, SOMATROPIN RECOMBINANT

**LG LIFE SCIENCES**

\* LG LIFE SCIENCES LTD

FACTIVE, GEMIFLOXACIN MESYLATE

**LIEBEL-FLARSHEIM**

\* LIEBEL-FLARSHEIM CO LLC

CONRAY 30, IOTHALAMATE MEGLUMINE  
CONRAY 43, IOTHALAMATE MEGLUMINE  
CONRAY, IOTHALAMATE MEGLUMINE  
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE  
MD-76R, DIATRIZOATE MEGLUMINE  
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE  
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE  
OPTIMARK, GADOVERSETAMIDE  
OPTIRAY 240, IOVERSOL  
OPTIRAY 300, IOVERSOL  
OPTIRAY 320, IOVERSOL  
OPTIRAY 350, IOVERSOL  
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE**LLOYD**

\* LLOYD INC

LEVOTHROID, LEVOTHYROXINE SODIUM \*\*

**LNK**

\* LNK INTERNATIONAL INC

DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\***

\* LNK INTERNATIONAL INC  
 IBUPROFEN, IBUPROFEN (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

**LOREAL USA**

\* LOREAL USA PRODUCTS INC  
 ANTHELIOS 20, AVOBENZONE (OTC)  
 ANTHELIOS 40, AVOBENZONE (OTC)  
 ANTHELIOS SX, AVOBENZONE (OTC)  
 CAPITAL SOLEIL 15, AVOBENZONE (OTC)

**LOTUS PHARM CO LTD**

\* LOTUS PHARMACEUTICAL CO LTD  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVONORGESTREL, LEVONORGESTREL (OTC)

**LUITPOLD**

\* LUITPOLD PHARMACEUTICALS INC  
 ACETYLCYSTEINE, ACETYLCYSTEINE  
 ADENOSINE, ADENOSINE  
 AMINOCAPROIC ACID, AMINOCAPROIC ACID  
 AMINOPHYLLINE, AMINOPHYLLINE  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE  
 BROMFENAC SODIUM, BROMFENAC SODIUM  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 CYANOCOBALAMIN, CYANOCOBALAMIN  
 CYCLOSPORINE, CYCLOSPORINE  
 DACTINOMYCIN, DACTINOMYCIN  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DEXFERRUM, IRON DEXTRAN  
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 DROPERIDOL, DROPERIDOL  
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
 ESTRADIOL VALERATE, ESTRADIOL VALERATE  
 ETOMIDATE, ETOMIDATE  
 FOMEPIZOLE, FOMEPIZOLE  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 GANCICLOVIR, GANCICLOVIR SODIUM  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE  
 INJECTAFER, FERRIC CARBOXYMALTOSIDE  
 LATANOPROST, LATANOPROST  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOCARNITINE, LEVOCARNITINE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 MANNITOL 25%, MANNITOL  
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE  
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN  
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NITROGLYCERIN, NITROGLYCERIN  
 OLANZAPINE, OLANZAPINE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PHENYTOIN SODIUM, PHENYTOIN SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\***

\* LUITPOLD PHARMACEUTICALS INC  
 PROGESTERONE, PROGESTERONE  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 VENOFER, IRON SUCROSE  
 ZIDOVUDINE, ZIDOVUDINE

**LUKARE MEDICAL LLC**

\* LUKARE MEDICAL LLC  
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

**LUMARA HEALTH INC**

\* LUMARA HEALTH INC  
 MAKENA, HYDROXYPROGESTERONE CAPROATE

**LUNDBECK LLC**

\* LUNDBECK LLC  
 ONFI, CLOBAZAM  
 SABRIL, VIGABATRIN

**LUNDBECK NA LTD**

\* LUNDBECK NA LTD  
 NORTHERA, DROXIDOPA

**LUPIN**

\* LUPIN LTD  
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 CARVEDILOL, CARVEDILOL  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFDINIR, CEFDINIR  
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM  
 CEFPROZIL, CEFPROZIL  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEPHALEXIN, CEPHALEXIN  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINAPRIL, LISINAPRIL  
 LOVASTATIN, LOVASTATIN  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RAMIPRIL, RAMIPRIL  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SIMVASTATIN, SIMVASTATIN  
 TOPIRAMATE, TOPIRAMATE  
 TRANDOLAPRIL, TRANDOLAPRIL

**LUPIN ATLANTIS**

\* LUPIN ATLANTIS HOLDINGS SA  
 ANTARA (MICRONIZED), FENOFIBRATE

**LUPIN LTD**

\* LUPIN LIMITED  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

\* LUPIN LTD  
 ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE  
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE  
 AZITHROMYCIN, AZITHROMYCIN  
 BEKYREE, DESOGESTREL  
 BIMATOPROST, BIMATOPROST  
 BLISOVI 24 FE, ETHINYL ESTRADIOL  
 BLISOVI FE 1.5/30, ETHINYL ESTRADIOL  
 BLISOVI FE 1/20, ETHINYL ESTRADIOL  
 CALCIUM ACETATE, CALCIUM ACETATE  
 CELECOXIB, CELECOXIB  
 CIPROFLOXACIN, CIPROFLOXACIN  
 CLARITHROMYCIN, CLARITHROMYCIN



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\*****\* LUPIN LTD**

DAYSEE, ETHINYL ESTRADIOL  
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXYCYCLINE, DOXYCYCLINE  
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ENSKYCE, DESOGESTREL  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 ESZOPICLONE, ESZOPICLONE  
 FALLBACK SOLO, LEVONORGESTREL (OTC)  
 FAMOTIDINE, FAMOTIDINE  
 FENOFIBRATE, FENOFIBRATE  
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
 FYAVOLV, ETHINYL ESTRADIOL  
 GATIFLOXACIN, GATIFLOXACIN  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 JENCYCLA, NORETHINDRONE  
 KAITLIB FE, ETHINYL ESTRADIOL  
 KURVELO, ETHINYL ESTRADIOL  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LAMIVUDINE, LAMIVUDINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LORAZEPAM, LORAZEPAM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MEFENAMIC ACID, MEFENAMIC ACID  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 NABUMETONE, NABUMETONE  
 NIACIN, NIACIN  
 NIKKI, DROSPIRENONE  
 NORETHINDRONE, NORETHINDRONE  
 OMEPRAZOLE, OMEPRAZOLE  
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PIRMELLA 1/35, ETHINYL ESTRADIOL  
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUININE SULFATE, QUININE SULFATE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 RANOLAZINE, RANOLAZINE  
 REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 RIFABUTIN, RIFABUTIN  
 SUPRAX, CEFIXIME  
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALSARTAN, VALSARTAN  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VYFEMLA, ETHINYL ESTRADIOL  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**LUPIN PHARMS****\* LUPIN PHARMACEUTICALS INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\***

\* LUPIN PHARMACEUTICALS INC  
 DESLORATADINE, DESLORATADINE  
 MELOXICAM, MELOXICAM  
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 RIFAMPIN, RIFAMPIN  
 SUPRAX, CEFIXIME  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**LYNE**

\* LYNE LABORATORIES INC  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
 DEXAMETHASONE, DEXAMETHASONE  
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
 LEVOCARNITINE, LEVOCARNITINE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**PERRIGO**

\* L PERRIGO CO  
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)  
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)  
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)  
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IBUPROFEN, IBUPROFEN (OTC)  
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 LORATADINE, LORATADINE (OTC)  
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 TAB-PROFEN, IBUPROFEN (OTC)  
 TIOCONAZOLE, TIOCONAZOLE (OTC)

**\*\* M \*\*****MA GENERAL HOSP**

\* MASSACHUSETTS GENERAL HOSP  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**MACLEODS PHARMS LTD**

\* MACLEODS PHARMACEUTICALS LTD  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 ESZOPICLONE, ESZOPICLONE  
 FAMCICLOVIR, FAMCICLOVIR  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 OLANZAPINE, OLANZAPINE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MACLEODS PHARMACEUTICALS LTD  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 ZOLMITRIPTAN, ZOLMITRIPTAN

**MALLINCKRODT**

\* MALLINCKRODT CHEMICAL INC  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHADOSE, METHADONE HYDROCHLORIDE

\* MALLINCKRODT INC  
 ANEXSIA 5/325, ACETAMINOPHEN  
 ANEXSIA 7.5/325, ACETAMINOPHEN  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 FENTANYL CITRATE, FENTANYL CITRATE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
 OXYCET, ACETAMINOPHEN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

\* MALLINCKRODT MEDICAL INC  
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE  
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT  
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

**MALLINCKRODT ARD**

\* MALLINCKRODT ARD INC  
 H.P. ACTHAR GEL, CORTICOTROPIN

**MALLINCKRODT INC**

\* MALLINCKRODT INC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 EXALGO, HYDROMORPHONE HYDROCHLORIDE  
 FENTANYL-100, FENTANYL  
 FENTANYL-12, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-75, FENTANYL  
 GABLOFEN, BACLOFEN  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 RESTORIL, TEMAZEPAM  
 ROXICODONE, OXYCODONE HYDROCHLORIDE  
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE  
 TOFRANIL-PM, IMIPRAMINE PAMOATE  
 XARTEMIS XR, ACETAMINOPHEN

**MALLINCKRODT IP**

\* MALLINCKRODT IP

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MALLINCKRODT IP

OFIRMEV, ACETAMINOPHEN

**MALLINCKRODT LLC**

\* MALLINCKRODT LLC

ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE

PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

**MALLINCKRODT NUCLEAR**

\* MALLINCKRODT NUCLEAR MEDICINE LLC

GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67

SODIUM IODIDE I 123, SODIUM IODIDE I-123

SODIUM IODIDE I 131, SODIUM IODIDE I-131

TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT

TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT

TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT

TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201

ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT

**MARATHON PHARMS**

\* MARATHON PHARMACEUTICALS LLC

SECONAL SODIUM, SECOBARBITAL SODIUM

**MARKSANS PHARMA**

\* MARKSANS PHARMA LTD

GABAPENTIN, GABAPENTIN

IBUPROFEN, IBUPROFEN

IBUPROFEN, IBUPROFEN (OTC)

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

NAPROXEN, NAPROXEN

**MATAWAN PHARMS**

\* MATAWAN PHARMACEUTICALS LLC

TRETINOIN, TRETINOIN

**MATRIX LABS LTD**

\* MATRIX LABORATORIES LTD

NIFEDIPINE, NIFEDIPINE

STAVUDINE, STAVUDINE

**MAYER LABS INC**

\* MAYER LABORATORIES INC

TODAY, NONOXYNOL-9 (OTC)

**MAYNE PHARMA**

\* MAYNE PHARMA INTERNATIONAL PTY LTD

DORYX, DOXYCYCLINE HYCLATE

DOXTERIC, DOXYCYCLINE HYCLATE

ERYC, ERYTHROMYCIN

**MCGUFF**

\* MCGUFF PHARMACEUTICALS INC

HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

**MCNEIL**

\* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC

IBUPROFEN, IBUPROFEN (OTC)

**MCNEIL CONS**

\* MCNEIL CONSUMER HEALTHCARE

SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

**MCPRF**

\* MAYO CLINIC PET RADIOCHEMISTRY FACILITY

AMMONIA N 13, AMMONIA N-13

CHOLINE C-11, CHOLINE C-11

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**MEDA PHARMS**

\* MEDA PHARMACEUTICALS

DYMISTA, AZELASTINE HYDROCHLORIDE

EDLUAR, ZOLPIDEM TARTRATE

\* MEDA PHARMACEUTICALS INC

ANADROL-50, OXYMETHOLONE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

- \* MEDA PHARMACEUTICALS INC  
 ASTELIN, AZELASTINE HYDROCHLORIDE  
 AVC, SULFANILAMIDE  
 BUTISOL SODIUM, BUTABARBITAL SODIUM  
 CESAMET, NABILONE  
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
 COLYTE, POLYETHYLENE GLYCOL 3350  
 CORTIFOAM, HYDROCORTISONE ACETATE  
 DEMADEX, TORSEMIDE  
 DEPEN, PENICILLAMINE  
 DIPENTUM, OLSALAZINE SODIUM  
 ELESTRIN, ESTRADIOL  
 EPIFOAM, HYDROCORTISONE ACETATE  
 FELBATOL, FELBAMATE  
 GASTROCROM, CROMOLYN SODIUM  
 LUFYLLIN, DYPHYLLINE  
 MUSE, ALPROSTADIL  
 OPTIVAR, AZELASTINE HYDROCHLORIDE  
 PROCTOFOAM HC, HYDROCORTISONE ACETATE  
 ROWASA, MESALAMINE  
 SFROWASA, MESALAMINE  
 TRILYTE, POLYETHYLENE GLYCOL 3350
- \* MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC  
 ASTEPRO, AZELASTINE HYDROCHLORIDE  
 SOMA COMPOUND W/ CODEINE, ASPIRIN  
 SOMA COMPOUND, ASPIRIN  
 SOMA, CARISOPRODOL

**MEDA PHARMS INC**

- \* MEDA PHARMACEUTICALS INC  
 AEROSPAN HFA, FLUNISOLIDE

**MEDAC PHARMA INC**

- \* MEDAC PHARMA INC  
 RASUVO, METHOTREXATE

**MEDEFIL INC**

- \* MEDEFIL INC  
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

**MEDICINES360**

- \* MEDICINES360  
 LILETTA, LEVONORGESTREL

**MEDICIS**

- \* MEDICIS PHARMACEUTICAL CORP  
 ALDARA, IMIQUIMOD  
 AMMONUL, SODIUM BENZOATE  
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 ESTRASORB, ESTRADIOL HEMIHYDRATE  
 LOPROX, CICLOPIROX  
 LUZU, LULICONAZOLE  
 METROGEL-VAGINAL, METRONIDAZOLE  
 MINITRAN, NITROGLYCERIN  
 SOLODYN, MINOCYCLINE HYDROCHLORIDE  
 SYNACORT, HYDROCORTISONE  
 VANOS, FLUOCINONIDE  
 ZIANA, CLINDAMYCIN PHOSPHATE  
 ZYCLARA, IMIQUIMOD

**MEDICURE**

- \* MEDICURE INTERNATIONAL INC  
 AGGRASTAT, TIROFIBAN HYDROCHLORIDE

**MEDIGENE AG**

- \* MEDIGENE AG  
 VEREGEN, SINECATECHINS

**MEDIMETRIKS PHARMS**

- \* MEDIMETRIKS PHARMACEUTICALS INC  
 LOPROX, CICLOPIROX  
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MEDIMETRIKS PHARMACEUTICALS INC  
SYNALAR, FLUOCINOLONE ACETONIDE

**MEDTECH PRODUCTS**

\* MEDTECH PRODUCTS INC  
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)  
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 3, MICONAZOLE NITRATE  
MONISTAT 3, MICONAZOLE NITRATE (OTC)  
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 7, MICONAZOLE NITRATE (OTC)  
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
NIX, PERMETHRIN (OTC)  
TAGAMET HB, CIMETIDINE (OTC)

**MEDTRONIC NEURO**

\* MEDTRONIC NEUROMODULATION  
LIORESAL, BACLOFEN

**MERCK**

\* MERCK AND CO INC  
CANCIDAS, CASPOFUNGIN ACETATE  
EMEND, APREPITANT  
FOSAMAX PLUS D, ALENDRONATE SODIUM  
FOSAMAX, ALENDRONATE SODIUM  
MAXALT, RIZATRIPTAN BENZOATE  
MAXALT-MLT, RIZATRIPTAN BENZOATE  
PRIMAXIN, CILASTATIN SODIUM  
PROSCAR, FINASTERIDE  
SINGULAIR, MONTELUKAST SODIUM  
ZOLINZA, VORINOSTAT

\* MERCK RESEARCH LABORATORIES DIV MERCK CO INC  
PRINIVIL, LISINAPRIL  
PROPECIA, FINASTERIDE  
SINGULAIR, MONTELUKAST SODIUM  
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE  
ZOCOR, SIMVASTATIN

**MERCK AND CO INC**

\* MERCK AND CO INC  
EMEND, FOSAPREPITANT DIMEGLUMINE  
FOSAMAX, ALENDRONATE SODIUM

**MERCK SHARP DOHME**

\* MERCK SHARP AND DOHME CORP  
ASMANEX HFA, MOMETASONE FUROATE  
ASMANEX TWISTHALER, MOMETASONE FUROATE  
BELSOMRA, SUVOREXANT  
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE  
CLARINEX D 24 HOUR, DESLORATADINE  
CLARINEX, DESLORATADINE  
CLARINEX-D 12 HOUR, DESLORATADINE  
COZAAR, LOSARTAN POTASSIUM  
CRIXIVAN, INDINAVIR SULFATE  
DIPROLENE AF, BETAMETHASONE DIPROPIONATE  
DIPROLENE, BETAMETHASONE DIPROPIONATE  
DULERA, FORMOTEROL FUMARATE  
ELOCON, MOMETASONE FUROATE  
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE  
HYZAAR, HYDROCHLOROTHIAZIDE  
INVANZ, ERTAPENEM SODIUM  
ISENTRESS, RALTEGRAVIR POTASSIUM  
JANUMET XR, METFORMIN HYDROCHLORIDE  
JANUMET, METFORMIN HYDROCHLORIDE  
JANUVIA, SITAGLIPTIN PHOSPHATE  
LOTRISONE, BETAMETHASONE DIPROPIONATE  
NASONEX, MOMETASONE FUROATE MONOHYDRATE  
NITRO-DUR, NITROGLYCERIN  
NOXAFIL, POSACONAZOLE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MERCK SHARP AND DOHME CORP  
 REBETOL, RIBAVIRIN  
 SINEMET CR, CARBIDOPA  
 SINEMET, CARBIDOPA  
 STROMECTOL, IVERMECTIN  
 TEMODAR, TEMOZOLOMIDE  
 VICTRELIS, BOCEPREVIR  
 ZONTIVITY, VORAPAXAR SULFATE

**MERIDIAN MEDCL**

\* MERIDIAN MEDICAL TECHNOLOGIES INC  
 DUODOTE, ATROPINE  
 \* MERIDIAN MEDICAL TECHNOLOGIES INC SUB KING PHARMACEUTICALS INC  
 ALSUMA, SUMATRIPTAN SUCCINATE

**MERIDIAN MEDCL TECHN**

\* MERIDIAN MEDICAL TECHNOLOGIES INC  
 ATROPEN, ATROPINE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

**MERRIMACK PHARMS**

\* MERRIMACK PHARMACEUTICALS INC  
 ONIVYDE, IRINOTECAN HYDROCHLORIDE

**MERRO PHARM**

\* MERRO PHARMACEUTICAL CO LTD  
 IBUPROFEN, IBUPROFEN (OTC)

**MERZ PHARMS**

\* MERZ PHARMACEUTICALS LLC  
 CUVPOSA, GLYCOPYRROLATE  
 NAFTIN, NAFTIFINE HYDROCHLORIDE  
 ONMEL, ITRACONAZOLE

**METHAPHARM**

\* METHAPHARM INC  
 LEVETIRACETAM, LEVETIRACETAM  
 PROVOCHOLINE, METHACHOLINE CHLORIDE

**MICRO LABS LTD**

\* MICRO LABS LTD  
 MEFENAMIC ACID, MEFENAMIC ACID  
 NEVIRAPINE, NEVIRAPINE  
 SIMVASTATIN, SIMVASTATIN

**MICRO LABS LTD INDIA**

\* MICRO LABS LTD INDIA  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 GLIMEPIRIDE, GLIMEPIRIDE  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

**MIDWEST MEDCL**

\* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**MIKAH PHARMA**

\* MIKAH PHARMA LLC  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

**MIKAH PHARMA LLC**

\* MIKAH PHARMA LLC  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**MIKART**

\* MIKART INC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 BENZONATATE, BENZONATATE  
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 BUTAPAP, ACETAMINOPHEN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MIKART INC  
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
 CHLORZOAZONE, CHLORZOAZONE  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
 ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE  
 ETHOSUXIMIDE, ETHOSUXIMIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METHAZOLAMIDE, METHAZOLAMIDE  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
 PYRAZINAMIDE, PYRAZINAMIDE  
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

**MIKART INC**

\* MIKART INC  
 HYCOFENIX, GUAIFENESIN

**MILLENNIUM PHARMS**

\* MILLENNIUM PHARMACEUTICALS INC  
 NINLARO, IXAZOMIB CITRATE  
 VELCADE, BORTEZOMIB

**MIPS CRF**

\* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**MIRROR PHARMS**

\* MIRROR PHARMACEUTICALS LLC  
 CARISOPRODOL AND ASPIRIN, ASPIRIN  
 CARISOPRODOL, CARISOPRODOL  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PROBENECID AND COLCHICINE, COLCHICINE

**MIRROR PHARMS LLC**

\* MIRROR PHARMACEUTICALS LLC  
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

**MISSION PHARMA**

\* MISSION PHARMACAL CO  
 BINOSTO, ALENDRONATE SODIUM  
 LITHOSTAT, ACETOHYDROXAMIC ACID  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 TEXACORT, HYDROCORTISONE  
 THIOLA, TIOPRONIN  
 TINDAMAX, TINIDAZOLE  
 UROCIT-K, POTASSIUM CITRATE

**MISSION PHARMACAL CO**

\* MISSION PHARMACAL CO  
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
 FLOWTUSS, GUAIFENESIN

**MIST PHARMS LLC**

\* MIST PHARMACEUTICALS LLC  
 NITROMIST, NITROGLYCERIN

**MOBERG PHARMA NORTH**

\* MOBERG PHARMA NORTH AMERICA LLC  
 CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

**MOBIUS THERAP**

\* MOBIUS THERAPEUTICS LLC  
 MITOSOL, MITOMYCIN

**MOLNLYCKE HLTH**

\* MOLNLYCKE HEALTH CARE  
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)  
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

**MONARCH PHARMS**

\* MONARCH PHARMACEUTICALS INC  
 CORTISPORIN, BACITRACIN ZINC



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

- \* MONARCH PHARMACEUTICALS INC  
CORTISPORIN, HYDROCORTISONE ACETATE  
CORTISPORIN, HYDROCORTISONE  
MENEST, ESTROGENS, ESTERIFIED  
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE  
NEOSPORIN, GRAMICIDIN  
PEDIOTIC, HYDROCORTISONE  
SEPTRA DS, SULFAMETHOXAZOLE  
SEPTRA, SULFAMETHOXAZOLE  
VIROPTIC, TRIFLURIDINE
- MORTON GROVE**
- \* MORTON GROVE PHARMACEUTICALS INC  
LACTULOSE, LACTULOSE
- MORTON GROVE PHARMS**
- \* MORTON GROVE PHARMACEUTICALS INC  
GENERLAC, LACTULOSE
- MSD INTL**
- \* MSD INTERNATIONAL GMBH  
VYTORIN, EZETIMIBE
- MSD INTL GMBH**
- \* MSD INTERNATIONAL GMBH  
ZETIA, EZETIMIBE
- MSD MERCK CO**
- \* MERCK SHARP AND DOHME CORP A SUBSIDIARY OF MERCK AND CO INC  
EMEND, APREPITANT
- MURTY PHARMS**
- \* MURTY PHARMACEUTICALS INC  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
DIPYRIDAMOLE, DIPYRIDAMOLE
- MUSTAFA NEVSAT**
- \* MUSTAFA NEVSAT ILAC SANAYII AS  
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
- MUSTAFA NEVZAT**
- \* MUSTAFA NEVZAT ILAC SANAYII AS  
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
VECURONIUM BROMIDE, VECURONIUM BROMIDE
- MUSTAFA NEVZAT ILAC**
- \* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
- MUTUAL PHARM**
- \* MUTUAL PHARMACEUTICAL CO INC  
ACETAZOLAMIDE, ACETAZOLAMIDE  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
ALLOPURINOL, ALLOPURINOL  
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
BACTRIM DS, SULFAMETHOXAZOLE  
BACTRIM, SULFAMETHOXAZOLE  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
DOXYCYCLINE HCLATE, DOXYCYCLINE HCLATE  
ERGOLOID MESYLATES, ERGOLOID MESYLATES  
FELODIPINE, FELODIPINE  
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
LOVASTATIN, LOVASTATIN  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
METOPROLOL TARTRATE, METOPROLOL TARTRATE  
METRONIDAZOLE, METRONIDAZOLE  
MINOXIDIL, MINOXIDIL  
NYSTATIN, NYSTATIN  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\*****\* MUTUAL PHARMACEUTICAL CO INC**

PINDOLOL, PINDOLOL  
 PIROXICAM, PIROXICAM  
 PREDNISON, PREDNISON  
 PRIMIDONE, PRIMIDONE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE  
 QUINIDINE SULFATE, QUINIDINE SULFATE  
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 SULINDAC, SULINDAC  
 TEMAZEPAM, TEMAZEPAM  
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE  
 TOLMETIN SODIUM, TOLMETIN SODIUM  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**MUTUAL PHARM CO INC**

**\* MUTUAL PHARMACEUTICAL CO INC**  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 QUALAQUIN, QUININE SULFATE

**MUTUAL PHARMA**

**\* MUTUAL PHARMACAL CO**  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

**MYLAN**

**\* MYLAN LABORATORIES INC**  
 ACYCLOVIR, ACYCLOVIR  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 CAPTOPRIL, CAPTOPRIL  
 ETODOLAC, ETODOLAC  
 OLANZAPINE, OLANZAPINE  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

**\* MYLAN PHARMACEUTICALS**  
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRANEXAMIC ACID, TRANEXAMIC ACID

**\* MYLAN PHARMACEUTICALS INC**  
 ACARBOSE, ACARBOSE  
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE  
 ACYCLOVIR, ACYCLOVIR  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 ALLOPURINOL, ALLOPURINOL  
 ALPRAZOLAM, ALPRAZOLAM  
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 ANASTROZOLE, ANASTROZOLE  
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
 ATENOLOL, ATENOLOL  
 AVITA, TRETINOIN  
 AZATHIOPRINE, AZATHIOPRINE  
 AZITHROMYCIN, AZITHROMYCIN  
 BACLOFEN, BACLOFEN  
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BICALUTAMIDE, BICALUTAMIDE  
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE  
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\*****\* MYLAN PHARMACEUTICALS INC**

BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE  
 BUDESONIDE, BUDESONIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CARVEDILOL, CARVEDILOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHLOROTHIAZIDE, CHLOROTHIAZIDE  
 CHLORPROPAMIDE, CHLORPROPAMIDE  
 CHLORTHALIDONE, CHLORTHALIDONE  
 CILOSTAZOL, CILOSTAZOL  
 CIMETIDINE, CIMETIDINE  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
 CLONAZEPAM, CLONAZEPAM  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM  
 CLORPRES, CHLORTHALIDONE  
 CLOZAPINE, CLOZAPINE  
 CYSTAGON, CYSTEAMINE BITARTRATE  
 DIAZEPAM, DIAZEPAM  
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ENALAPRIL MALEATE, ENALAPRIL MALEATE  
 ESTRADIOL, ESTRADIOL  
 ESTROPIPATE, ESTROPIPATE  
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM  
 ETOPOSIDE, ETOPOSIDE  
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 FAMCICLOVIR, FAMCICLOVIR  
 FAMOTIDINE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FELODIPINE, FELODIPINE  
 FENOFIBRATE, FENOFIBRATE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 FINASTERIDE, FINASTERIDE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
 FLURBIPROFEN, FLURBIPROFEN  
 FLUTAMIDE, FLUTAMIDE  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 FUROSEMIDE, FUROSEMIDE  
 GABAPENTIN, GABAPENTIN  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MYLAN PHARMACEUTICALS INC  
 GLIPIZIDE, GLIPIZIDE  
 GLYBURIDE (MICRONIZED), GLYBURIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 HALOPERIDOL, HALOPERIDOL  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 INDAPAMIDE, INDAPAMIDE  
 INDOMETHACIN, INDOMETHACIN  
 KETOCONAZOLE, KETOCONAZOLE  
 KETOPROFEN, KETOPROFEN  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LATANOPROST, LATANOPROST  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM \*\*  
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINAPRIL, LISINAPRIL  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE  
 LORATADINE, LORATADINE (OTC)  
 LORAZEPAM, LORAZEPAM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOVASTATIN, LOVASTATIN  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 MAPROTIline HYDROCHLORIDE, MAPROTIline HYDROCHLORIDE  
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM  
 MELOXICAM, MELOXICAM  
 MENTAX, BUTENAFINE HYDROCHLORIDE  
 MERCAPTOPYRINE, MERCAPTOPYRINE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHIMAZOLE, METHIMAZOLE  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 METHYLDOPA, METHYLDOPA  
 METOLAZONE, METOLAZONE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIRTAZAPINE, MIRTAZAPINE  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE  
 NADOLOL, NADOLOL  
 NAPROXEN, NAPROXEN  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NIFEDIPINE, NIFEDIPINE  
 NISOLDIPINE, NISOLDIPINE  
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN  
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 OMEPRAZOLE, OMEPRAZOLE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 OXYBUTYNYNIN CHLORIDE, OXYBUTYNYNIN CHLORIDE  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350  
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL  
 PENTOXIFYLLINE, PENTOXIFYLLINE  
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 PHENYTEK, PHENYTOIN SODIUM  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MYLAN PHARMACEUTICALS INC  
 PIROXICAM, PIROXICAM  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE  
 PROBENECID, PROBENECID  
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RISPERIDONE, RISPERIDONE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 STAVUDINE, STAVUDINE  
 SULINDAC, SULINDAC  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TACROLIMUS, TACROLIMUS  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TEMAZEPAM, TEMAZEPAM  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE  
 THIOTHIXENE, THIOTHIXENE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TOLMETIN SODIUM, TOLMETIN SODIUM  
 TOPIRAMATE, TOPIRAMATE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE  
 URSODIOL, URSODIOL  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 WARFARIN SODIUM, WARFARIN SODIUM  
 ZALEPLON, ZALEPLON  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE  
 ZONISAMIDE, ZONISAMIDE

**MYLAN INSTITUTIONAL**

\* MYLAN INSTITUTIONAL INC  
 SULFAMYLOL, MAFENIDE ACETATE

\* MYLAN INSTITUTIONAL LLC  
 ACETYLCYSTEINE, ACETYLCYSTEINE  
 ALOPRIM, ALLOPURINOL SODIUM  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 ARGATROBAN, ARGATROBAN  
 CARBOPLATIN, CARBOPLATIN  
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM  
 CIDOFOVIR, CIDOFOVIR  
 COSYNTROPIN, COSYNTROPIN  
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE  
 DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE  
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MYLAN INSTITUTIONAL LLC  
 DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 DURACLON, CLONIDINE HYDROCHLORIDE  
 ENLON, EDROPHONIUM CHLORIDE  
 ENLON-PLUS, ATROPINE SULFATE  
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
 FOMEPIZOLE, FOMEPIZOLE  
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE  
 ISOSULFAN BLUE, ISOSULFAN BLUE  
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE  
 MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM  
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE  
 MESNA, MESNA  
 METHOCARBAMOL, METHOCARBAMOL  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
 PENTOSTATIN, PENTOSTATIN  
 RIMSO-50, DIMETHYL SULFOXIDE  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 SCANLUX-300, IOPAMIDOL  
 SCANLUX-370, IOPAMIDOL  
 SOTRADECOL, SODIUM TETRADECYL SULFATE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE  
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 ULTIVA, REMIFENTANIL HYDROCHLORIDE

**MYLAN IRELAND LTD**

\* MYLAN IRELAND LTD  
 ARIXTRA, FONDAPARINUX SODIUM  
 MIACALCIN, CALCITONIN SALMON

**MYLAN LABS**

\* MYLAN LABORATORIES LTD  
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
 NEVIRAPINE, NEVIRAPINE

**MYLAN LABS LTD**

\* MYLAN LABORATORIES LTD  
 ADENOSINE, ADENOSINE  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 CARBOPLATIN, CARBOPLATIN  
 CISPLATIN, CISPLATIN  
 CLADRIBINE, CLADRIBINE  
 CYTARABINE, CYTARABINE  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 DOXYCYCLINE, DOXYCYCLINE HYCLATE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 ETOMIDATE, ETOMIDATE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 FLUMAZENIL, FLUMAZENIL  
 FLUOROURACIL, FLUOROURACIL  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE  
 IFOSFAMIDE, IFOSFAMIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\*****\* MYLAN LABORATORIES LTD**

LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 MESNA, MESNA  
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXACILLIN SODIUM, OXACILLIN SODIUM  
 OXALIPLATIN, OXALIPLATIN  
 PACLITAXEL, PACLITAXEL  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 RIFAMPIN, RIFAMPIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VALSARTAN, VALSARTAN  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VECURONIUM BROMIDE, VECURONIUM BROMIDE  
 VINORELBINE TARTRATE, VINORELBINE TARTRATE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**MYLAN PHARMS INC****\* MYLAN PHARMACEUTICALS INC**

ABACAVIR SULFATE, ABACAVIR SULFATE  
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM  
 ACITRETIN, ACITRETIN  
 ACYCLOVIR, ACYCLOVIR  
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE  
 ALPRAZOLAM, ALPRAZOLAM  
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMNESTEEM, ISOTRETINOIN  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE  
 AVITA, TRETINOIN  
 BACLOFEN, BACLOFEN  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 CABERGOLINE, CABERGOLINE  
 CAPECITABINE, CAPECITABINE  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CELECOXIB, CELECOXIB  
 CHLORDIAZEPoxide AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 CILOSTAZOL, CILOSTAZOL  
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
 CLONAZEPAM, CLONAZEPAM  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 CLOZAPINE, CLOZAPINE  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DESLORATADINE, DESLORATADINE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE  
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DIDANOSINE, DIDANOSINE  
 DIGOXIN, DIGOXIN  
 DISULFIRAM, DISULFIRAM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MYLAN PHARMACEUTICALS INC  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
DOXYCYCLINE, DOXYCYCLINE  
ENTACAPONE, ENTACAPONE  
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
ESZOPICLONE, ESZOPICLONE  
FELBAMATE, FELBAMATE  
FENOFIBRATE (MICRONIZED), FENOFIBRATE  
FENOFIBRATE, FENOFIBRATE  
FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM  
FINASTERIDE, FINASTERIDE  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE  
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM  
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE  
GABAPENTIN, GABAPENTIN  
GLIPIZIDE, GLIPIZIDE  
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IBANDRONATE SODIUM, IBANDRONATE SODIUM  
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE  
INDAPAMIDE, INDAPAMIDE  
INDOMETHACIN, INDOMETHACIN  
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IRBESARTAN, IRBESARTAN  
ISRADIPINE, ISRADIPINE  
ITRACONAZOLE, ITRACONAZOLE  
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
LAMIVUDINE, LAMIVUDINE  
LANSOPRAZOLE, LANSOPRAZOLE  
LEVETIRACETAM, LEVETIRACETAM  
LINEZOLID, LINEZOLID  
LITHIUM CARBONATE, LITHIUM CARBONATE  
MAXZIDE, HYDROCHLOROTHIAZIDE  
MAXZIDE-25, HYDROCHLOROTHIAZIDE  
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
MESALAMINE, MESALAMINE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE  
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
MIRTAZAPINE, MIRTAZAPINE  
MODAFINIL, MODAFINIL  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
MORPHINE SULFATE, MORPHINE SULFATE  
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID  
NABUMETONE, NABUMETONE  
NAPROXEN, NAPROXEN  
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
NEVIRAPINE, NEVIRAPINE  
OLANZAPINE, OLANZAPINE  
PALIPERIDONE, PALIPERIDONE  
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
PHENYTOIN, PHENYTOIN  
PINDOLOL, PINDOLOL  
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
PIROXICAM, PIROXICAM  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

- \* MYLAN PHARMACEUTICALS INC  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUININE SULFATE, QUININE SULFATE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 REPAGLINIDE, REPAGLINIDE  
 RILUZOLE, RILUZOLE  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 RISPERIDONE, RISPERIDONE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 SIMVASTATIN, SIMVASTATIN  
 SUCRALFATE, SUCRALFATE  
 SUNITINIB MALATE, SUNITINIB MALATE  
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TELMISARTAN, TELMISARTAN  
 THEOPHYLLINE, THEOPHYLLINE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TOLAZAMIDE, TOLAZAMIDE  
 TOLBUTAMIDE, TOLBUTAMIDE  
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TRIAZOLAM, TRIAZOLAM  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VORICONAZOLE, VORICONAZOLE  
 ZIDOVUDINE, ZIDOVUDINE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE  
 ZOLMITRIPTAN, ZOLMITRIPTAN  
 ZONISAMIDE, ZONISAMIDE
- \* MYLAN PHARMACEUTICALS INC.  
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM  
 NIZATIDINE, NIZATIDINE  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

**MYLAN SPECLT**

- \* MYLAN SPECIALTY LP  
 ACCUNEB, ALBUTEROL SULFATE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 DUONEB, ALBUTEROL SULFATE  
 EPIPEN JR., EPINEPHRINE  
 EPIPEN, EPINEPHRINE  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 PERFORMIST, FORMOTEROL FUMARATE

**MYLAN TECHNOLOGIES**

- \* MYLAN TECHNOLOGIES  
 XULANE, ETHINYL ESTRADIOL
- \* MYLAN TECHNOLOGIES INC  
 CLONIDINE, CLONIDINE  
 ESTRADIOL, ESTRADIOL  
 FENTANYL-100, FENTANYL  
 FENTANYL-12, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-37, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-62, FENTANYL  
 FENTANYL-75, FENTANYL  
 FENTANYL-87, FENTANYL  
 LIDOCAINE, LIDOCAINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MYLAN TECHNOLOGIES INC  
NITROGLYCERIN, NITROGLYCERIN

**MYLAN TEORANTA**

\* MYLAN TEORANTA  
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM

**\*\* N \*\*****NATCO PHARMA**

\* NATCO PHARMA LTD  
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

**NATCO PHARMA LTD**

\* NATCO PHARMA LIMITED  
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE

\* NATCO PHARMA LTD  
ALPRAZOLAM, ALPRAZOLAM  
ANASTROZOLE, ANASTROZOLE  
CARISOPRODOL, CARISOPRODOL  
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
LANSOPRAZOLE, LANSOPRAZOLE  
LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
LETROZOLE, LETROZOLE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE

**NAVIDEA BIOPHARMS**

\* NAVIDEA BIOPHARMACEUTICALS INC  
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT

**NAVINTA LLC**

\* NAVINTA LLC  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
FAMOTIDINE, FAMOTIDINE  
FOMEPIZOLE, FOMEPIZOLE  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

**NCM USA BRONX LLC**

\* NCM USA BRONX LLC  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**NEOS THERAP INC**

\* NEOS THERAPEUTICS INC  
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

**NEPHRON**

\* NEPHRON CORP  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

\* NEPHRON PHARMACEUTICALS CORP  
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
ALBUTEROL SULFATE, ALBUTEROL SULFATE

**NESHER PHARMS**

\* NESHER PHARMACEUTICALS USA LLC  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
MICRO-K 10, POTASSIUM CHLORIDE  
MICRO-K, POTASSIUM CHLORIDE  
MORPHINE SULFATE, MORPHINE SULFATE  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**NEW HAVEN PHARMS**

\* NEW HAVEN PHARMACEUTICALS INC  
DURLAZA, ASPIRIN

**NEW RIVER**

\* NEW RIVER PHARMACEUTICALS INC  
PROFERDEX, IRON DEXTRAN

**NEXGEN PHARMA**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\*****\* NEXGEN PHARMA INC**

BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 CHENODIOL, CHENODIOL  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

**NEXGEN PHARMA INC****\* NEXGEN PHARMA INC**

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

**NEXTWAVE PHARMS****\* NEXTWAVE PHARMACEUTICALS INC**

QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

**NEXUS PHARMS****\* NEXUS PHARMACEUTICALS INC**

DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 LEVOFLOXACIN, LEVOFLOXACIN

**NIAGARA PHARMS****\* NIAGARA PHARMACEUTICALS INC**

PUR-WASH, PURIFIED WATER (OTC)

**NORTEC DEV ASSOC****\* NORTEC DEVELOPMENT ASSOC INC**

PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**NORTHSTAR HLTHCARE****\* NORTHSTAR HEALTHCARE HOLDINGS LTD**

ALLOPURINOL, ALLOPURINOL  
 ATENOLOL, ATENOLOL  
 BACLOFEN, BACLOFEN  
 GEMFIBROZIL, GEMFIBROZIL  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**NOSTRUM LABS INC****\* NOSTRUM LABORATORIES INC**

CALCIUM ACETATE, CALCIUM ACETATE  
 PINDOLOL, PINDOLOL

**NOSTRUM PHARMS LLC****\* NOSTRUM PHARMACEUTICALS LLC**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**NOVA LABS LTD****\* NOVA LABORATORIES LTD**

PURIXAN, MERCAPTOPYRIMIDINE

**NOVARTIS****\* NOVARTIS CONSUMER HEALTH INC**

EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)  
 LAMISIL AT, TERBINAFINE (OTC)  
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)  
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)  
 PREVACID 24 HR, LANSOPRAZOLE (OTC)  
 THRIVE, NICOTINE POLACRILEX (OTC)  
 TRANSDERM SCOP, SCOPOLAMINE  
 VAGISTAT-1, TIOCONAZOLE (OTC)

**\* NOVARTIS PHARMACEUTICALS CORP**

AFINITOR, EVEROLIMUS  
 ARCAPTA NEOHALER, INDACATEROL MALEATE  
 CATAFLAM, DICLOFENAC POTASSIUM  
 COARTEM, ARTEMETHER  
 DESFERAL, DEFEROXAMINE MESYLATE  
 DIOVAN HCT, HYDROCHLOROTHIAZIDE  
 DIOVAN, VALSARTAN  
 ESTRADERM, ESTRADIOL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\***

\* NOVARTIS PHARMACEUTICALS CORP  
 EXELON, RIVASTIGMINE  
 EXELON, RIVASTIGMINE TARTRATE  
 EXFORGE HCT, AMLODIPINE BESYLATE  
 EXFORGE, AMLODIPINE BESYLATE  
 EXJADE, DEFERASIROX  
 FAMVIR, FAMCICLOVIR  
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 FORADIL, FORMOTEROL FUMARATE  
 GILENYA, FINGOLIMOD  
 GLEEVEC, IMATINIB MESYLATE  
 HYDERGINE, ERGOLOID MESYLATES  
 LAMISIL, TERBINAFINE HYDROCHLORIDE  
 LAMPRENE, CLOFAZIMINE  
 LESCOL XL, FLUVASTATIN SODIUM  
 LESCOL, FLUVASTATIN SODIUM  
 LOPRESSOR, METOPROLOL TARTRATE  
 LOTREL, AMLODIPINE BESYLATE  
 MYFORTIC, MYCOPHENOLIC ACID  
 NEORAL, CYCLOSPORINE  
 OCUPRESS, CARTEOLOL HYDROCHLORIDE  
 RECLAST, ZOLEDRONIC ACID  
 REGITINE, PHENTOLAMINE MESYLATE  
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE  
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE  
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE  
 SANDIMMUNE, CYCLOSPORINE  
 SANDOSTATIN LAR, OCTREOTIDE ACETATE  
 SANDOSTATIN, OCTREOTIDE ACETATE  
 SIGNIFOR, PASIREOTIDE DIASPARTATE  
 STARLIX, NATEGLINIDE  
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE  
 TAVIST-1, CLEMASTINE FUMARATE (OTC)  
 TEGRETOL, CARBAMAZEPINE  
 TEGRETOL-XR, CARBAMAZEPINE  
 TEKTRUNA HCT, ALISKIREN HEMIFUMARATE  
 TEKTRUNA, ALISKIREN HEMIFUMARATE  
 TOBI PODHALER, TOBRAMYCIN  
 TRILEPTAL, OXCARBAZEPINE  
 TYZEKA, TELBIVUDINE  
 VIVELLE, ESTRADIOL  
 VIVELLE-DOT, ESTRADIOL  
 VOLTAREN, DICLOFENAC SODIUM  
 VOLTAREN-XR, DICLOFENAC SODIUM  
 ZOMETA, ZOLEDRONIC ACID  
 ZORTRESS, EVEROLIMUS

**NOVARTIS PHARM**

\* NOVARTIS PHARMACEUTICAL CORP  
 AFINITOR DISPERZ, EVEROLIMUS

**NOVARTIS PHARMS**

\* NOVARTIS PHARMACEUTICALS CORP  
 FEMARA, LETROZOLE  
 TOBI, TOBRAMYCIN

**NOVARTIS PHARMS CORP**

\* NOVARTIS PHARMACEUTICALS CORP  
 ARRANON, NELARABINE  
 ENTRESTO, SACUBITRIL  
 FARYDAK, PANOBINOSTAT LACTATE  
 HYCANTIN, TOPOTECAN HYDROCHLORIDE  
 JADENU, DEFERASIROX  
 MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE  
 ODOMZO, SONIDEGIB PHOSPHATE  
 PROMACTA, ELTROMBOPAG OLAMINE  
 SEEBRI, GLYCOPYRROLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\***

\* NOVARTIS PHARMACEUTICALS CORP  
 SIGNIFOR LAR, PASIREOTIDE PAMOATE  
 TAFINLAR, DABRAFENIB MESYLATE  
 TYKERB, LAPATINIB DITOSYLATE  
 UTIBRON, GLYCOPYRROLATE  
 VOTRIENT, PAZOPANIB HYDROCHLORIDE  
 ZOFTRAN ODT, ONDANSETRON  
 ZOFTRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ZOFTRAN, ONDANSETRON HYDROCHLORIDE  
 ZYKADIA, CERITINIB

**NOVAST LABS**

\* NOVAST LABORATORIES CHINA LTD  
 NORETHINDRONE, NORETHINDRONE

**NOVAST LABS LTD**

\* NOVAST LABORATORIES LTD  
 DASETTA 1/35, ETHINYL ESTRADIOL  
 DASETTA 7/7/7, ETHINYL ESTRADIOL  
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
 ELINEST, ETHINYL ESTRADIOL  
 FALMINA, ETHINYL ESTRADIOL  
 LARIN 1.5/30, ETHINYL ESTRADIOL  
 LARIN 1/20, ETHINYL ESTRADIOL  
 LARIN 24 FE, ETHINYL ESTRADIOL  
 LARIN FE 1.5/30, ETHINYL ESTRADIOL  
 LARIN FE 1/20, ETHINYL ESTRADIOL  
 LEVONEST, ETHINYL ESTRADIOL  
 MONO-LINYAH, ETHINYL ESTRADIOL  
 NORETHINDRONE, NORETHINDRONE  
 PHILITH, ETHINYL ESTRADIOL  
 PIMTREA, DESOGESTREL  
 SETLAKIN, ETHINYL ESTRADIOL  
 TRI-LINYAH, ETHINYL ESTRADIOL  
 WERA, ETHINYL ESTRADIOL  
 YAELA, DROSPIRENONE

**NOVEL LABS INC**

\* NOVEL LABORATORIES INC  
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DOXYCYCLINE, DOXYCYCLINE  
 FAMOTIDINE, FAMOTIDINE  
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE  
 LEVONORGESTREL, LEVONORGESTREL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MISOPROSTOL, MISOPROSTOL  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NITROFURANTOIN, NITROFURANTOIN  
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350  
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL  
 PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL,  
 PHENELZINE SULFATE, PHENELZINE SULFATE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 TEMAZEPAM, TEMAZEPAM  
 TINIDAZOLE, TINIDAZOLE  
 TRIMETHOPRIM, TRIMETHOPRIM  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**NOVEN**

\* NOVEN PHARMACEUTICALS INC  
 MINIVELLE, ESTRADIOL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\*****NOVEN PHARMS INC**

\* NOVEN PHARMACEUTICALS INC  
 COMBIPATCH, ESTRADIOL  
 DAYTRANA, METHYLPHENIDATE

**NOVEN THERAP**

\* NOVEN THERAPEUTICS LLC  
 BRISDELLE, PAROXETINE MESYLATE  
 PEXEVA, PAROXETINE MESYLATE

**NOVEX**

\* NOVEX PHARMA  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

**NOVO NORDISK**

\* NOVO NORDISK PHARMACEUTICALS INC  
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

**NOVO NORDISK INC**

\* NOVO NORDISK INC  
 LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT  
 LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT  
 LEVEMIR, INSULIN DETEMIR RECOMBINANT  
 NORDITROPIN FLEXPEN, SOMATROPIN RECOMBINANT  
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT  
 NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT  
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT  
 NOVOLOG, INSULIN ASPART RECOMBINANT  
 PRANDIMET, METFORMIN HYDROCHLORIDE  
 PRANDIN, REPAGLINIDE  
 RYZODEG 70/30, INSULIN ASPART  
 SAXENDA, LIRAGLUTIDE RECOMBINANT  
 TRESIBA, INSULIN DEGLUDEC  
 VAGIFEM, ESTRADIOL  
 VICTOZA, LIRAGLUTIDE RECOMBINANT

**NOVOCOL**

\* NOVOCOL PHARMACEUTICAL INC  
 ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE

**NOVOCOL INC**

\* NOVOCOL INC  
 LIDOCAINE, LIDOCAINE

**NPS PHARMS INC**

\* NPS PHARMACEUTICALS INC  
 GATTEX KIT, TEDUGLUTIDE RECOMBINANT

**NU PHARM**

\* NU PHARM INC  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM

**NUVO PHARM INC**

\* NUVO PHARMACEUTICAL INC  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 FOLIC ACID, FOLIC ACID  
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

**NUVO RES INC**

\* NUVO RESEARCH INC  
 PENNSAID, DICLOFENAC SODIUM

**NYCOMED US**

\* NYCOMED US INC  
 TERCONAZOLE, TERCONAZOLE

**\*\* O \*\*****OAK PHARMS**

\* OAK PHARMACEUTICALS INC  
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**

\*\* O \*\*

\* OAK PHARMACEUTICALS INC  
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

**OAK PHARMS AKORN**

\* OAK PHARMACEUTICALS INC SUB AKORN INC  
COGENTIN, BENZTROPINE MESYLATE  
DIURIL, CHLOROTHIAZIDE SODIUM

**OAK PHARMS INC**

\* OAK PHARMACEUTICALS INC  
ZIOPTAN, TAFLUPROST

\* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC  
AZASITE, AZITHROMYCIN  
BETIMOL, TIMOLOL  
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE  
COSOPT, DORZOLAMIDE HYDROCHLORIDE  
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

**OC PHARMA**

\* OC PHARMA LLC  
LEVONORGESTREL, LEVONORGESTREL (OTC)  
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

**ODYSSEY PHARMS**

\* ODYSSEY PHARMACEUTICALS INC  
ANTABUSE, DISULFIRAM  
NYSTATIN, NYSTATIN  
SURMONTIL, TRIMIPRAMINE MALEATE  
URECHOLINE, BETHANECHOL CHLORIDE  
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

**OHM**

\* OHM CORP  
IBUPROFEN, IBUPROFEN (OTC)

**OHM LABS**

\* OHM LABORATORIES INC  
ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)  
IBUPROHM, IBUPROFEN (OTC)  
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

**OHM LABS INC**

\* OHM LABORATORIES INC  
VALSARTAN, VALSARTAN

**OLTA PHARMS**

\* OLTA PHARMACEUTICALS CORP  
LINDANE, LINDANE

**OMAN PHARM PRODUCTS**

\* OMAN PHARMACEUTICAL PRODUCTS CO LLC  
NEOMYCIN SULFATE, NEOMYCIN SULFATE

**OMEROS**

\* OMEROS CORP  
OMIDRIA, KETOROLAC TROMETHAMINE

**ONY**

\* ONY INC  
INFASURF PRESERVATIVE FREE, CALFACTANT

**ONYX PHARMS**

\* ONYX PHARMACEUTICALS INC  
KYPROLIS, CARFILZOMIB

**ORAPHARMA**

\* ORAPHARMA INC  
ARESTIN, MINOCYCLINE HYDROCHLORIDE

**ORCHID HLTHCARE**

\* ORCHID HEALTHCARE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
CEFDINIR, CEFDINIR  
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
CEFPROZIL, CEFPROZIL  
CEFUROXIME AXETIL, CEFUROXIME AXETIL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**

\*\* O \*\*

**\* ORCHID HEALTHCARE**

CEPHALEXIN, CEPHALEXIN  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 DESLORATADINE, DESLORATADINE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 ESZOPICLONE, ESZOPICLONE  
 FELODIPINE, FELODIPINE  
 GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MODAFINIL, MODAFINIL  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 OLANZAPINE, OLANZAPINE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZALEPLON, ZALEPLON

**OREXO AB**

\* OREXO AB  
 ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

**ORGANON SUB MERCK**

\* ORGANON USA INC A SUBSIDIARY OF MERCK AND CO INC  
 BRIDION, SUGAMMADEX SODIUM

**ORGANON USA INC**

\* ORGANON USA INC  
 DESOGEN, DESOGESTREL  
 FOLLISTIM AQ, FOLLITROPIN ALFA/BETA  
 GANIRELIX ACETATE, GANIRELIX ACETATE  
 NEXPLANON, ETNOGESTREL  
 NUVARING, ETHINYL ESTRADIOL  
 PREGNYL, GONADOTROPIN, CHORIONIC  
 REMERON SOLTAB, MIRTAZAPINE  
 REMERON, MIRTAZAPINE

**ORIENT PHARMA CO LTD**

\* ORIENT PHARMA CO LTD  
 CARISOPRODOL, CARISOPRODOL  
 MIGLITOL, MIGLITOL

**ORION CORP ORION**

\* ORION CORP ORION PHARMA  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 NADOLOL, NADOLOL  
 SPIRONOLACTONE, SPIRONOLACTONE

**ORION PHARMA**

\* ORION PHARMA  
 COMTAN, ENTACAPONE  
 STALEVO 100, CARBIDOPA  
 STALEVO 125, CARBIDOPA  
 STALEVO 150, CARBIDOPA  
 STALEVO 200, CARBIDOPA  
 STALEVO 50, CARBIDOPA  
 STALEVO 75, CARBIDOPA

**ORIT LABS LLC**

\* ORIT LABORATORIES LLC  
 BENZONATATE, BENZONATATE  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 ERGOCALCIFEROL, ERGOCALCIFEROL  
 LEVETIRACETAM, LEVETIRACETAM

**ORPHAN EUROPE**



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* O \*\***

\* ORPHAN EUROPE

CARBAGLU, CARGLUMIC ACID

**OSI PHARMS**

\* OSI PHARMACEUTICALS INC

TARCEVA, ERLOTINIB HYDROCHLORIDE

**OSMOTICA PHARM**

\* OSMOTICA PHARMACEUTICAL CORP

NIFEDIPINE, NIFEDIPINE

OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**OSMOTICA PHARM CORP**

\* OSMOTICA PHARMACEUTICAL CORP

KHEDEZLA, DESVENLAFAXINE

**OTONOMY INC**

\* OTONOMY INC

OTIPRIO, CIPROFLOXACIN

**OTSUKA**

\* OTSUKA PHARMACEUTICAL CO LTD

ABILIFY, ARIPIPRAZOLE

PLETAL, CILOSTAZOL

**OTSUKA AMERICA PHARM**

\* OTSUKA AMERICA PHARMACEUTICAL INC

SAMSCA, TOLVAPTAN

**OTSUKA PHARM**

\* OTSUKA PHARMACEUTICAL CO LTD

BUSULFEX, BUSULFAN

**OTSUKA PHARM CO LTD**

\* OTSUKA PHARMACEUTICAL CO LTD

ABILIFY MAINTENA KIT, ARIPIPRAZOLE

DACOGEN, DECTABINE

REXULTI, BREXPIPRAZOLE

**OUTLOOK PHARMS**

\* OUTLOOK PHARMACEUTICALS INC

DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

**\*\* P \*\*****P AND L DEV LLC**

\* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC

IBUPROFEN, IBUPROFEN (OTC)

**PACIFIC PHARMA**

\* PACIFIC PHARMA

TIMOLOL MALEATE, TIMOLOL MALEATE

\* PACIFIC PHARMA INC

TIMOLOL MALEATE, TIMOLOL MALEATE

**PACIRA PHARMS INC**

\* PACIRA PHARMACEUTICALS INC

DEPOCYT, CYTARABINE

EXPAREL, BUPIVACAINE

**PACK PHARMS LLC**

\* PACK PHARMACEUTICALS LLC

CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE

CROMOLYN SODIUM, CROMOLYN SODIUM

**PADDOCK**

\* PADDOCK LABORATORIES INC

BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

**PADDOCK LABS**

\* PADDOCK LABORATORIES INC

CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

**PADDOCK LLC**

\* PADDOCK LABORATORIES LLC

BROMFENAC SODIUM, BROMFENAC SODIUM

BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN

CALCIUM ACETATE, CALCIUM ACETATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PADDOCK LABORATORIES LLC  
 CICLOPIROX, CICLOPIROX  
 CLINDA-DERM, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE  
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
 COLOCORT, HYDROCORTISONE  
 COMPRO, PROCHLORPERAZINE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE  
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE  
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE ,  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 KIONEX, SODIUM POLYSTYRENE SULFONATE  
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
 LORAZEPAM, LORAZEPAM  
 MIDAMOR, AMILORIDE HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NYSTOP, NYSTATIN  
 PODOFILOX, PODOFILOX  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 REPAGLINIDE, REPAGLINIDE  
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE  
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

**PALADIN LABS**

\* PALADIN LABS USA INC  
 ANTIZOL, FOMEPIZOLE

**PANACEA BIOTEC LTD**

\* PANACEA BIOTEC LTD  
 TACROLIMUS, TACROLIMUS

**PAR FORM**

\* PAR FORMULATIONS PRIVATE LTD  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 MAFENIDE ACETATE, MAFENIDE ACETATE

**PAR PHARM**

\* PAR PHARMACEUTICAL  
 NABUMETONE, NABUMETONE  
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
 TESTOSTERONE, TESTOSTERONE

\* PAR PHARMACEUTICAL INC  
 ALPRAZOLAM, ALPRAZOLAM  
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE  
 CABERGOLINE, CABERGOLINE  
 CALCITONIN-SALMON, CALCITONIN SALMON  
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE  
 CHOLESTYRAMINE, CHOLESTYRAMINE  
 CLOMIPHENE CITRATE, CLOMIPHENE CITRATE  
 CLONAZEPAM, CLONAZEPAM  
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
 DEXAMETHASONE, DEXAMETHASONE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PAR PHARMACEUTICAL INC  
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
 DOXYCYCLINE, DOXYCYCLINE  
 ESTAZOLAM, ESTAZOLAM  
 FENTANYL CITRATE, FENTANYL CITRATE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUTAMIDE, FLUTAMIDE  
 GLIPIZIDE, GLIPIZIDE  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROXYUREA, HYDROXYUREA  
 IBUPROFEN, IBUPROFEN (OTC)  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
 MEGACE ES, MEGESTROL ACETATE  
 MEGESTROL ACETATE, MEGESTROL ACETATE  
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE  
 METRONIDAZOLE, METRONIDAZOLE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MINOXIDIL, MINOXIDIL  
 NASCOBAL, CYANOCOBALAMIN  
 NATEGLINIDE, NATEGLINIDE  
 NIFEDIPINE, NIFEDIPINE  
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 OLANZAPINE, OLANZAPINE  
 OXANDROLONE, OXANDROLONE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PIMOZIDE, PIMOZIDE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TORSEMIDE, TORSEMIDE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE  
 TRAVOPROST, TRAVOPROST  
 URSODIOL, URSODIOL  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**PAR PHARM INC**

\* PAR PHARMACEUTICAL INC  
 ACCOLATE, ZAFIRLUKAST  
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 FENTANYL-100, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-75, FENTANYL  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 TOLCAPONE, TOLCAPONE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**PAR STERILE PRODUCTS**

\* PAR STERILE PRODUCTS LLC  
 ADRENALIN, EPINEPHRINE  
 ARGATROBAN, ARGATROBAN  
 BREVITAL SODIUM, METHOHEXITAL SODIUM  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 COLY-MYCIN M, COLISTIMETHATE SODIUM  
 COLY-MYCIN S, COLISTIN SULFATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PAR STERILE PRODUCTS LLC  
 DANTRIUM, DANTROLENE SODIUM  
 DELESTROGEN, ESTRADIOL VALERATE  
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM  
 ETOMIDATE, ETOMIDATE  
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE  
 KETALAR, KETAMINE HYDROCHLORIDE  
 LEVOTHYroxINE SODIUM, LEVOTHYroxINE SODIUM  
 PITOCIN, OXYTOCIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 TRIOSTAT, LIOthyRONINE SODIUM  
 VASOSTRICT, VASOPRESSIN

**PARAGON BIOTECK**

\* PARAGON BIOTECK INC  
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

**PARAPRO LLC**

\* PARAPRO LLC  
 NATROBA, SPINOSAD

**PARKE DAVIS**

\* PARKE DAVIS DIV WARNER LAMBERT CO  
 CELONTIN, METHSUXIMIDE  
 CEREBYX, FOSPHENYTOIN SODIUM  
 DILANTIN, PHENYTOIN SODIUM  
 DILANTIN-125, PHENYTOIN  
 NARDIL, PHENELZINE SULFATE  
 NEURONTIN, GABAPENTIN  
 ZARONTIN, ETHOSUXIMIDE  
 \* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO  
 ZARONTIN, ETHOSUXIMIDE

**PEDIAPHARM INC**

\* PEDIAPHARM INC  
 NAPROSYN, NAPROXEN

**PERNIX IRELAND LTD**

\* PERNIX IRELAND LTD  
 TREXIMET, NAPROXEN SODIUM

**PERNIX IRELAND PAIN**

\* PERNIX IRELAND PAIN LIMITED  
 ZOHyDRO ER, HYDROCODONE BITARTRATE

**PERNIX THERAP**

\* PERNIX THERAPEUTICS LLC  
 CEDAX, CEFTIBUTEN DIHYDRATE

**PERNIX THERAPS LLC**

\* PERNIX THERAPEUTICS LLC  
 SILENOR, DOXEPIN HYDROCHLORIDE

**PERRIGO**

\* PERRIGO CO  
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
 CICLOPIROX, CICLOPIROX  
 CIMETIDINE, CIMETIDINE (OTC)  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)  
 CLINDETS, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 ERYTHROMYCIN, ERYTHROMYCIN  
 FAMOTIDINE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 IBUPROFEN, IBUPROFEN (OTC)  
 JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)  
 MOMETASONE FUROATE, MOMETASONE FUROATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PERRIGO CO  
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 STIE-CORT, HYDROCORTISONE

**PERRIGO CO TENNESSEE**

\* PERRIGO CO TENNESSEE INC  
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC  
 BACITRACIN, BACITRACIN  
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN  
 ERYTHROMYCIN, ERYTHROMYCIN  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC  
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

**PERRIGO ISRAEL**

\* PERRIGO ISRAEL PHARMACEUTICALS  
 FLUOCINONIDE, FLUOCINONIDE

\* PERRIGO ISRAEL PHARMACEUTICALS LTD  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 GYNAZOLE-1, BUTOCONAZOLE NITRATE  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 IMIQUIMOD, IMIQUIMOD  
 KETOCONAZOLE, KETOCONAZOLE  
 MESALAMINE, MESALAMINE  
 MINOXIDIL, MINOXIDIL (OTC)  
 NITROGLYCERIN, NITROGLYCERIN  
 TESTOSTERONE, TESTOSTERONE

**PERRIGO NEW YORK**

\* PERRIGO NEW YORK INC  
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
 AMMONIUM LACTATE, AMMONIUM LACTATE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CENTANY, MUPIROCIN  
 CICLOPIROX, CICLOPIROX  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 DESONIDE, DESONIDE  
 DESOXIMETASONE, DESOXIMETASONE  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 ERYTHROMYCIN, ERYTHROMYCIN  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE  
 HYDROCORTISONE, HYDROCORTISONE  
 KETOCONAZOLE, KETOCONAZOLE  
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 MUPIROCIN, MUPIROCIN  
 NYSTATIN, NYSTATIN  
 PERMETHRIN, PERMETHRIN  
 PERMETHRIN, PERMETHRIN (OTC)  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 SELENIUM SULFIDE, SELENIUM SULFIDE  
 TERCONAZOLE, TERCONAZOLE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**PERRIGO PHARMS CO**

\* PERRIGO PHARMACEUTICALS CO  
 SCOPOLAMINE, SCOPOLAMINE

**PERRIGO R AND D**

\* PERRIGO R AND D CO

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\*****\* PERRIGO R AND D CO**

CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 DESLORATADINE, DESLORATADINE  
 GUAIFENESIN, GUAIFENESIN (OTC)  
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)  
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN, IBUPROFEN (OTC)  
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
 LEVONORGESTREL, LEVONORGESTREL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
 NAPROXEN, NAPROXEN  
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**PERRIGO UK FINCO****\* PERRIGO UK FINCO LTD PARTNERSHIP**

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**PETNET****\* PETNET SOLUTIONS INC**

AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**PF PRISM CV****\* PF PRISM CV**

LYRICA, PREGABALIN  
 RAPAMUNE, SIROLIMUS  
 TORISEL, TEMSIROLIMUS  
 TYGACIL, TIGECYCLINE  
 VFEND, VORICONAZOLE  
 XALKORI, CRIZOTINIB  
 XELJANZ, TOFACITINIB CITRATE  
 ZMAX, AZITHROMYCIN

**PFIZER****\* PFIZER CENTRAL RESEARCH**

DIFLUCAN, FLUCONAZOLE  
 ZITHROMAX, AZITHROMYCIN

**\* PFIZER CHEMICALS DIV PFIZER INC**

DIFLUCAN, FLUCONAZOLE  
 ZITHROMAX, AZITHROMYCIN

**\* PFIZER INC**

ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)  
 ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
 ADVIL COLD AND SINUS, IBUPROFEN (OTC)  
 ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)  
 ADVIL LIQUI-GELS, IBUPROFEN (OTC)  
 ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)  
 ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)  
 ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
 ADVIL, IBUPROFEN (OTC)  
 ALAVERT, LORATADINE (OTC)  
 ARGATROBAN, ARGATROBAN  
 AXID AR, NIZATIDINE (OTC)  
 CADUET, AMLODIPINE BESYLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

- \* PFIZER INC  
 CALAN SR, VERAPAMIL HYDROCHLORIDE  
 CARDURA XL, DOXAZOSIN MESYLATE  
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)  
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 ELELYSO, TALIGLUCERASE ALFA  
 GEODON, ZIPRASIDONE HYDROCHLORIDE  
 GEODON, ZIPRASIDONE MESYLATE  
 GLUCOTROL XL, GLIPIZIDE  
 GLUCOTROL, GLIPIZIDE  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM  
 INLYTA, AXITINIB  
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)  
 LIPITOR, ATORVASTATIN CALCIUM  
 LORATADINE, LORATADINE (OTC)  
 NAVANE, THIOTHIXENE  
 NORVASC, AMLODIPINE BESYLATE  
 PEDIATRIC ADVIL, IBUPROFEN (OTC)  
 PROCARDIA, NIFEDIPINE  
 REVATIO, SILDENAFIL CITRATE  
 SONATA, ZALEPLON  
 TESSALON, BENZONATATE  
 TOVIAZ, FESOTERODINE FUMARATE  
 UNASYN, AMPICILLIN SODIUM  
 ZITHROMAX, AZITHROMYCIN
- \* PFIZER LABORATORIES DIV PFIZER INC  
 CARDURA, DOXAZOSIN MESYLATE  
 DIABINESE, CHLORPROPAMIDE  
 FELDENE, PIROXICAM  
 MINIPRESS, PRAZOSIN HYDROCHLORIDE  
 PERMAPEN, PENICILLIN G BENZATHINE  
 PFIZERPEN, PENICILLIN G POTASSIUM  
 PROCARDIA XL, NIFEDIPINE  
 TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE  
 UNASYN, AMPICILLIN SODIUM  
 VIBRAMYCIN, DOXYCYCLINE  
 VIBRAMYCIN, DOXYCYCLINE CALCIUM  
 VIBRAMYCIN, DOXYCYCLINE HYCLATE  
 VISTARIL, HYDROXYZINE PAMOATE
- \* PFIZER PHARMACEUTICALS INC  
 ZOLOFT, SERTRALINE HYDROCHLORIDE
- \* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD  
 TIKOSYN, DOFETILIDE
- PFIZER CONS HLTHCARE**
- \* PFIZER CONSUMER HEALTHCARE  
 ADVIL, IBUPROFEN SODIUM (OTC)
- PFIZER INC**
- \* PFIZER INC  
 CAMPTOSAR, IRINOTECAN HYDROCHLORIDE  
 CHANTIX, VARENICLINE TARTRATE  
 ELLENCE, EPIRUBICIN HYDROCHLORIDE  
 FRAGMIN, DALTEPARIN SODIUM  
 IBRANCE, PALBOCICLIB  
 NICOTROL, NICOTINE  
 QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
- PFIZER IRELAND**
- \* PFIZER IRELAND PHARMACEUTICALS  
 RELPAX, ELETRIPTAN HYDROBROMIDE  
 VIAGRA, SILDENAFIL CITRATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\*****PFIZER LABS**

\* PFIZER LABS  
DOCETAXEL, DOCETAXEL

**PFIZER PHARMS**

\* PFIZER PHARMACEUTICALS LTD  
ACCUPRIL, QUINAPRIL HYDROCHLORIDE  
ACCURETIC, HYDROCHLOROTHIAZIDE  
DILANTIN, PHENYTOIN  
LOPID, GEMFIBROZIL  
NEURONTIN, GABAPENTIN  
NITROSTAT, NITROGLYCERIN

**PHARM ASSOC**

\* PHARMACEUTICAL ASSOC INC  
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
LORAZEPAM, LORAZEPAM  
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

\* PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
ETHOSUXIMIDE, ETHOSUXIMIDE  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
HALOPERIDOL, HALOPERIDOL LACTATE  
LACTULOSE, LACTULOSE  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
NYSTATIN, NYSTATIN  
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
PREDNISOLONE, PREDNISOLONE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE  
VALPROIC ACID, VALPROIC ACID

\* PHARMACEUTICAL ASSOCIATES INC  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
LEVETIRACETAM, LEVETIRACETAM

**PHARMA RES SOFTWARE**

\* PHARMA RESEARCH SOFTWARE SOLUTION LLC  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**PHARMA-MED INC**

\* PHARMA-MED INC  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**PHARMACEUTICS**

\* PHARMACEUTICS INTERNATIONAL INC  
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**PHARMACEUTICS INTL**

\* PHARMACEUTICS INTERNATIONAL INC  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**PHARMACHEMIE BV**

\* PHARMACHEMIE BV  
CARBOPLATIN, CARBOPLATIN  
CISPLATIN, CISPLATIN  
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM  
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

**PHARMACIA AND UPJOHN**

\* PHARMACIA AND UPJOHN  
XANAX XR, ALPRAZOLAM

\* PHARMACIA AND UPJOHN CO  
AROMASIN, EXEMESTANE  
AZULFIDINE EN-TABS, SULFASALAZINE  
AZULFIDINE, SULFASALAZINE  
BACITRACIN, BACITRACIN



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

- \* PHARMACIA AND UPJOHN CO  
 CAVERJECT IMPULSE, ALPROSTADIL  
 CAVERJECT, ALPROSTADIL  
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLEOCIN T, CLINDAMYCIN PHOSPHATE  
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLEOCIN, CLINDAMYCIN PHOSPHATE  
 COLESTID, COLESTIPOL HYDROCHLORIDE  
 CORTEF, HYDROCORTISONE  
 CORVERT, IBUTILIDE FUMARATE  
 CYKLOKAPRON, TRANEXAMIC ACID  
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE  
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE  
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE  
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE  
 DETROL LA, TOLTERODINE TARTRATE  
 DETROL, TOLTERODINE TARTRATE  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM  
 ESTRING, ESTRADIOL  
 FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE  
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT  
 GENOTROPIN, SOMATROPIN RECOMBINANT  
 GLYNASE, GLYBURIDE  
 GLYSET, MIGLITOL  
 HALCION, TRIAZOLAM  
 HEMABATE, CARBOPROST TROMETHAMINE  
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE  
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE  
 MEDROL, METHYLPREDNISOLONE  
 MYCOBUTIN, RIFABUTIN  
 NICOTROL, NICOTINE  
 OGEN .625, ESTROPIPATE  
 OGEN 1.25, ESTROPIPATE  
 OGEN 2.5, ESTROPIPATE  
 OGEN 5, ESTROPIPATE  
 PREPIDIL, DINOPROSTONE  
 PROSTIN E2, DINOPROSTONE  
 PROSTIN VR PEDIATRIC, ALPROSTADIL  
 PROVERA, MEDROXYPROGESTERONE ACETATE  
 R-GENE 10, ARGININE HYDROCHLORIDE  
 SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE  
 SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE  
 SOMAVERT, PEGVISOMANT  
 XALATAN, LATANOPROST  
 XANAX, ALPRAZOLAM  
 ZINECARD, DEXRAZOXANE HYDROCHLORIDE  
 ZYVOX, LINEZOLID
- \* PHARMACIA AND UPJOHN SUB PFIZER INC  
 DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

**PHARMACYCLICS INC**

- \* PHARMACYCLICS INC  
 IMBRUVICA, IBRUTINIB

**PHARMADAX INC**

- \* PHARMADAX INC  
 LEVETIRACETAM, LEVETIRACETAM

**PHARMAFORCE**

- \* PHARMAFORCE INC  
 BUSULFAN, BUSULFAN  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 NANDROLONE DECANOATE, NANDROLONE DECANOATE

**PHARMALUCENCE**

- \* PHARMALUCENCE INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PHARMALUCENCE INC  
 AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT  
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT  
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT  
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT  
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT

**PHARMAX**

\* PHARMAX GROUP INC  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

**PHARMS**

\* PHARMACEUTICALS INTERNATIONAL  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**PHOTOCURE ASA**

\* PHOTOCURE ASA  
 CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

**PIERRE FABRE**

\* PIERRE FABRE MEDICAMENT  
 NAVELBINE, VINORELBINE TARTRATE

**PIERRE FABRE DERMA**

\* PIERRE FABRE DERMATOLOGIE  
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

**PIERREL**

\* PIERREL S.P.A.  
 ORABLOC, ARTICAINA HYDROCHLORIDE

**PIRAMAL CRITICAL**

\* PIRAMAL CRITICAL CARE INC  
 ENFLURANE, ENFLURANE  
 ISOFLURANE, ISOFLURANE  
 SOJOURN, SEVOFLURANE

**PIRAMAL ENT**

\* PIRAMAL ENTERPRISES LTD  
 ISOFLURANE, ISOFLURANE

**PIRAMAL IMAGING**

\* PIRAMAL IMAGING SA  
 NEURACEQ, FLORBETABEN F-18

**PLIVA**

\* PLIVA INC  
 AZITHROMYCIN, AZITHROMYCIN  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 CIMETIDINE, CIMETIDINE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 METRONIDAZOLE, METRONIDAZOLE  
 NAPROXEN, NAPROXEN  
 PENTOXIFYLLINE, PENTOXIFYLLINE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 WARFARIN SODIUM, WARFARIN SODIUM

**PLIVA HRVATSKA DOO**

\* PLIVA HRVATSKA DOO  
 ADAPALENE, ADAPALENE  
 CARVEDILOL, CARVEDILOL  
 CILOSTAZOL, CILOSTAZOL  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**

\*\* P \*\*

**PLIVA LACHEMA**

- \* PLIVA LACHEMA AS  
CARBOPLATIN, CARBOPLATIN  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**PLIVA PHARM IND**

- \* PLIVA PHARMACEUTICAL INDUSTRY INC  
TORSEMIDE, TORSEMIDE

**PLX PHARMA**

- \* PLX PHARMA INC  
ASPIRIN, ASPIRIN (OTC)

**POHL BOSKAMP**

- \* POHL BOSKAMP  
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

**POLYMEDICA**

- \* POLYMEDICA INDUSTRIES INC  
NEOPAP, ACETAMINOPHEN (OTC)

**POWDER PHARMS**

- \* POWDER PHARMACEUTICALS INC  
ZINGO, LIDOCAINE HYDROCHLORIDE

**PRAGMA PHARMS LLC**

- \* PRAGMA PHARMACEUTICALS LLC  
MOXATAG, AMOXICILLIN

**PRECISION DERMAT**

- \* PRECISION DERMATOLOGY INC  
CLINDAGEL, CLINDAMYCIN PHOSPHATE  
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE  
LOCOID, HYDROCORTISONE BUTYRATE  
MINOCIN, MINOCYCLINE HYDROCHLORIDE

**PRECISION DOSE**

- \* PRECISION DOSE INC  
RISPERIDONE, RISPERIDONE

**PRECISION NUCLEAR**

- \* PRECISION NUCLEAR LLC  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**PRINSTON INC**

- \* PRINSTON PHARMACEUTICAL INC  
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IRBESARTAN, IRBESARTAN  
LEVETIRACETAM, LEVETIRACETAM  
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LISINOPRIL, LISINOPRIL  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
METHOCARBAMOL, METHOCARBAMOL  
NEVIRAPINE, NEVIRAPINE  
PAROXETINE, PAROXETINE HYDROCHLORIDE  
RISPERIDONE, RISPERIDONE  
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
VALSARTAN, VALSARTAN

**PROCTER AND GAMBLE**

- \* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO  
DIDRONEL, ETIDRONATE DISODIUM

**PROF DSPLS**

- \* PROFESSIONAL DISPOSABLES INC  
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)  
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

**PROMETHEUS LABS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\*****\* PROMETHEUS LABORATORIES INC**

IMURAN, AZATHIOPRINE  
 LOTRONEX, ALOSETRON HYDROCHLORIDE  
 MERCAPTOPYRINE, MERCAPTOPYRINE  
 RIDAURA, AURANOFIN  
 ZYLOPRIM, ALLOPURINOL

**PROMIUS PHARMA****\* PROMIUS PHARMA LLC**

SECTRAL, ACEBUTOLOL HYDROCHLORIDE  
 TENEX, GUANFACINE HYDROCHLORIDE

**PROMIUS PHARMA LLC****\* PROMIUS PHARMA LLC**

CLODERM, CLOCORTOLONE PIVALATE

**PROSAM LABS****\* PROSAM LABS LLC**

BACLOFEN, BACLOFEN  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 CARISOPRODOL AND ASPIRIN, ASPIRIN  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 RIMACTANE, RIFAMPIN  
 RISPERIDONE, RISPERIDONE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SIMVASTATIN, SIMVASTATIN  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

**PROSTRAKAN INC****\* PROSTRAKAN INC**

FARESTON, TOREMIFENE CITRATE  
 SANCUSO, GRANISETRON

**PROVENSIS****\* PROVENSIS LTD**

VARITHENA, POLIDOCANOL

**PROVIDENT PHARM****\* PROVIDENT PHARMACEUTICAL INC**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**PULMOFLOW INC****\* PULMOFLOW INC**

KITABIS PAK, TOBRAMYCIN

**PULSION MEDCL****\* PULSION MEDICAL SYSTEMS AG**

INDOCYANINE GREEN, INDOCYANINE GREEN

**PURACAP PHARM****\* PURACAP PHARMACEUTICAL LLC**

MELOXICAM, MELOXICAM

**PURACAP PHARM LLC****\* PURACAP PHARMACEUTICAL LLC**

MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

**PURDUE GMP****\* PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY**

SEROMYCIN, CYCLOSERINE

**PURDUE PHARM PRODS****\* PURDUE PHARMACEUTICAL PRODUCTS LP**

DILAUDID, HYDROMORPHONE HYDROCHLORIDE  
 DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

**PURDUE PHARMA****\* PURDUE PHARMA PRODUCTS LP**

INTERMEZZO, ZOLPIDEM TARTRATE

**PURDUE PHARMA LP****\* PURDUE PHARMA LP**

BUTRANS, BUPRENORPHINE  
 HYSINGLA, HYDROCODONE BITARTRATE  
 MS CONTIN, MORPHINE SULFATE  
 OXYCONTIN, OXYCODONE HYDROCHLORIDE

**PUREPAC PHARM**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PUREPAC PHARMACEUTICAL CO  
DIPYRIDAMOLE, DIPYRIDAMOLE

**\*\* Q \*\*****QILU PHARM CO LTD**

\* QILU PHARMACEUTICAL CO LTD  
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

**QOL MEDCL**

\* QOL MEDICAL LLC  
ETHAMOLIN, ETHANOLAMINE OLEATE  
SUCRAID, SACROSIDASE

**QUEEN HAMAMATSU PET**

\* QUEEN HAMAMATSU PET IMAGING CENTER  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**\*\* R \*\*****R-PHARM US LLC**

\* R-PHARM US LLC  
IXEMPRA KIT, IXABEPILONE

**R-TECH UENO LTD**

\* R-TECH UENO LTD  
RESCULA, UNOPROSTONE ISOPROPYL

**RANBAXY**

\* RANBAXY INC  
ABSORICA, ISOTRETINOIN  
\* RANBAXY LABORATORIES INC  
EURAX, CROTAMITON  
EXELDERM, SULCONAZOLE NITRATE  
HALOG, HALCINONIDE  
LAC-HYDRIN, AMMONIUM LACTATE  
ULTRAVATE, HALOBETASOL PROPIONATE  
\* RANBAXY LABORATORIES LTD  
ACYCLOVIR, ACYCLOVIR

**RAPTOR INC**

\* RAPTOR PHARMACEUTICALS INC  
PROCYSBI, CYSTEAMINE BITARTRATE

**RARE DIS THERAP**

\* RARE DISEASE THERAPEUTICS INC  
CYSTADANE, BETAINE HYDROCHLORIDE

**RARITAN PHARMS INC**

\* RARITAN PHARMACEUTICALS INC  
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

**RECIP**

\* RECIP AB  
THYROSAFE, POTASSIUM IODIDE (OTC)

**RECKITT BENCKISER**

\* RECKITT BENCKISER LLC  
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)  
MUCINEX D, GUAIFENESIN (OTC)  
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)  
MUCINEX, GUAIFENESIN (OTC)

**RECORDATI RARE**

\* RECORDATI RARE DISEASES INC  
CHEMET, SUCCIMER  
COSMEGEN, DACTINOMYCIN  
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE  
INDOCIN, INDOMETHACIN SODIUM  
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE  
NEOPROFEN, IBUPROFEN LYSINE  
PEGANONE, ETHOTOIN  
TRANXENE, CLORAZEPATE DIPOTASSIUM

**RECRO GAINESVILLE**

\* RECRO GAINESVILLE LLC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\***

- \* RECRO GAINESVILLE LLC  
VERELAN PM, VERAPAMIL HYDROCHLORIDE  
VERELAN, VERAPAMIL HYDROCHLORIDE
- RELYPSA INC**
- \* RELYPSA INC  
VELTASSA, PATIROMER SORBITE X CALCIUM
- REMPEX PHARMS INC**
- \* REMPEX PHARMACEUTICALS INC  
MINOCIN, MINOCYCLINE HYDROCHLORIDE
- RENAISSANCE PHARMA**
- \* RENAISSANCE PHARMA US HOLDINGS INC  
ELIMITE, PERMETHRIN
- RHODES PHARMS**
- \* RHODES PHARMACEUTICALS LP  
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE  
MORPHINE SULFATE, MORPHINE SULFATE  
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
THEOPHYLLINE, THEOPHYLLINE  
UNIPHYL, THEOPHYLLINE
- RICONPHARMA LLC**
- \* RICONPHARMA LLC  
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE  
QUININE SULFATE, QUININE SULFATE
- RISING PHARMS INC**
- \* RISING PHARMACEUTICALS INC  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
DUTASTERIDE, DUTASTERIDE  
HYDROCORTISONE, HYDROCORTISONE  
PARICALCITOL, PARICALCITOL
- ROCHE PALO**
- \* ROCHE PALO ALTO LLC  
CELLCEPT, MYCOPHENOLATE MOFETIL  
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE  
CYTOVENE, GANCICLOVIR SODIUM  
EC-NAPROSYN, NAPROXEN  
NAPROSYN, NAPROXEN
- ROCKWELL MEDCL**
- \* ROCKWELL MEDICAL TECHNOLOGIES INC  
CALCITRIOL, CALCITRIOL
- ROCKWELL MEDICAL INC**
- \* ROCKWELL MEDICAL INC  
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
- ROMARK**
- \* ROMARK LABORATORIES  
ALINIA, NITAZOXANIDE
- ROSEDALE THERAPEUTIC**
- \* ROSEDALE THERAPEUTICS  
ERGOMAR, ERGOTAMINE TARTRATE
- ROUSES POINT PHARMS**
- \* ROUSES POINT PHARMACEUTICALS LLC  
LEVETIRACETAM, LEVETIRACETAM
- ROXANE**
- \* ROXANE LABORATORIES INC  
ACARBOSE, ACARBOSE  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE  
ALPRAZOLAM, ALPRAZOLAM  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
ANASTROZOLE, ANASTROZOLE  
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\***

\* ROXANE LABORATORIES INC  
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
CALCITRIOL, CALCITRIOL  
CALCIUM ACETATE, CALCIUM ACETATE  
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE  
CILOSTAZOL, CILOSTAZOL  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
CLARITHROMYCIN, CLARITHROMYCIN  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
CLOTRIMAZOLE, CLOTRIMAZOLE  
CODEINE SULFATE, CODEINE SULFATE  
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE  
DEXAMETHASONE INTENSOL, DEXAMETHASONE  
DEXAMETHASONE, DEXAMETHASONE  
DIAZEPAM INTENSOL, DIAZEPAM  
DIAZEPAM, DIAZEPAM  
DIGOXIN, DIGOXIN  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
DISULFIRAM, DISULFIRAM  
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DOXERCALCIFEROL, DOXERCALCIFEROL  
DUTASTERIDE, DUTASTERIDE  
ESZOPICLONE, ESZOPICLONE  
EXEMESTANE, EXEMESTANE  
FAMCICLOVIR, FAMCICLOVIR  
FLECAINIDE ACETATE, FLECAINIDE ACETATE  
FLUCONAZOLE, FLUCONAZOLE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
FUROSEMIDE, FUROSEMIDE  
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE  
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IRBESARTAN, IRBESARTAN  
LACTULOSE, LACTULOSE  
LETROZOLE, LETROZOLE  
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
LEVETIRACETAM, LEVETIRACETAM  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
LINEZOLID, LINEZOLID  
LITHIUM CARBONATE, LITHIUM CARBONATE  
LITHIUM CITRATE, LITHIUM CITRATE  
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
LORAZEPAM INTENSOL, LORAZEPAM  
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE  
MEGESTROL ACETATE, MEGESTROL ACETATE  
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
MERCAPTOPYRINE, MERCAPTOPYRINE  
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE  
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE  
METHOTREXATE SODIUM, METHOTREXATE SODIUM  
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
MORPHINE SULFATE, MORPHINE SULFATE  
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
NAPROXEN, NAPROXEN  
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\***

\* ROXANE LABORATORIES INC  
 OXCARBAZEPINE, OXCARBAZEPINE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE  
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
 PREDNISONE INTENSOL, PREDNISONE  
 PREDNISONE, PREDNISONE  
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RAMIPRIL, RAMIPRIL  
 RISPERIDONE, RISPERIDONE  
 RITONAVIR, RITONAVIR  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 ROXICET, ACETAMINOPHEN  
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE  
 TINIDAZOLE, TINIDAZOLE  
 TORSEMIDE, TORSEMIDE  
 TRIAZOLAM, TRIAZOLAM  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 ZALEPLON, ZALEPLON  
 ZIDOVUDINE, ZIDOVUDINE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**RP SCHERER**

\* RP SCHERER TECHNOLOGIES LLC  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**RTRX**

\* RETROPHIN INC  
 CHOLBAM, CHOLIC ACID

**RUBICON RES PVT LTD**

\* RUBICON RESEARCH PVT LTD  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE

**\*\* S \*\*****SAGE PRODS**

\* SAGE PRODUCTS INC  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

**SAGENT AGILA**

\* SAGENT AGILA LLC  
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**SAGENT PHARMS**

\* SAGENT PHARMACEUTICALS INC  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE  
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CARBOPLATIN, CARBOPLATIN  
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 FLUMAZENIL, FLUMAZENIL  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GLYDO, LIDOCAINE HYDROCHLORIDE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SAGENT PHARMACEUTICALS INC  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MESNA, MESNA  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 OXACILLIN SODIUM, OXACILLIN SODIUM  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**SAGENT STRIDES**

\* SAGENT STRIDES LLC  
 ADENOSINE, ADENOSINE  
 AZITHROMYCIN, AZITHROMYCIN  
 BACITRACIN, BACITRACIN  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE  
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**SALIX PHARMS**

\* SALIX PHARMACEUTICALS INC  
 ANUSOL HC, HYDROCORTISONE  
 DIURIL, CHLOROTHIAZIDE  
 FULYZAQ, CROFELEMER  
 METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE  
 MOVIPREP, ASCORBIC ACID  
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS  
 PEPCID, FAMOTIDINE  
 RELISTOR, METHYLNALTREXONE BROMIDE  
 XIFAXAN, RIFAXIMIN

**SAMSON MEDCL**

\* SAMSON MEDICAL TECHNOLOGIES LLC  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

**SANDOZ**

\* SANDOZ  
 DOCETAXEL, DOCETAXEL

\* SANDOZ CANADA INC  
 ANECTINE, SUCCINYLCHOLINE CHLORIDE  
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 DIGOXIN, DIGOXIN  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE  
 FLUMAZENIL, FLUMAZENIL  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE  
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID  
 INFUVITE PEDIATRIC, ASCORBIC ACID  
 ISONIAZID, ISONIAZID  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SANDOZ CANADA INC  
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 REGONOL, PYRIDOSTIGMINE BROMIDE  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

\* SANDOZ INC  
 ALPRAZOLAM, ALPRAZOLAM  
 ALTAVERA, ETHINYL ESTRADIOL  
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE  
 ANASTROZOLE, ANASTROZOLE  
 APREPITANT, APREPITANT  
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN  
 ATENOLOL, ATENOLOL  
 AZITHROMYCIN, AZITHROMYCIN  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BICALUTAMIDE, BICALUTAMIDE  
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE  
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
 BUMETANIDE, BUMETANIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CAFERGOT, CAFFEINE  
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL  
 CAPTOPRIL, CAPTOPRIL  
 CARISOPRODOL AND ASPIRIN, ASPIRIN  
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN  
 CARVEDILOL, CARVEDILOL  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFDINIR, CEFDINIR  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CEFPROZIL, CEFPROZIL  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE  
 CHOLESTYRAMINE, CHOLESTYRAMINE  
 CILOSTAZOL, CILOSTAZOL  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)  
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
 CLONAZEPAM, CLONAZEPAM  
 COSYNTROPIN, COSYNTROPIN  
 CYCLOSPORINE, CYCLOSPORINE  
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE  
 DESLORATADINE, DESLORATADINE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* S \*\*

\* SANDOZ INC  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 EPLERENONE, EPLERENONE  
 ESTARYLLA, ETHINYL ESTRADIOL  
 ETODOLAC, ETODOLAC  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 FLUOROURACIL, FLUOROURACIL  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GLIPIZIDE, GLIPIZIDE  
 HALOPERIDOL, HALOPERIDOL  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 INTROVALE, ETHINYL ESTRADIOL  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 ISONIAZID, ISONIAZID  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 ITRACONAZOLE, ITRACONAZOLE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 LONOX, ATROPINE SULFATE  
 LORATADINE, LORATADINE (OTC)  
 LORAZEPAM, LORAZEPAM  
 LORYNA, DROSPIRENONE  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOVASTATIN, LOVASTATIN  
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE  
 MEROPENEM, MEROPENEM  
 METAXALONE, METAXALONE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHAZOLAMIDE, METHAZOLAMIDE  
 METHIMAZOLE, METHIMAZOLE  
 METHOCARBAMOL, METHOCARBAMOL  
 METHYLPREDNISOLONE, METHYLPREDNISOLONE  
 METOLAZONE, METOLAZONE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NABUMETONE, NABUMETONE  
 NADOLOL, NADOLOL  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 NAPROXEN, NAPROXEN  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SANDOZ INC  
 NIZATIDINE, NIZATIDINE  
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 OMEPRAZOLE, OMEPRAZOLE  
 OMNITROPE, SOMATROPIN RECOMBINANT  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 OXACILLIN SODIUM, OXACILLIN SODIUM  
 OXALIPLATIN, OXALIPLATIN  
 OXAPROZIN, OXAPROZIN  
 OXAZEPAM, OXAZEPAM  
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM  
 PENICILLIN G SODIUM, PENICILLIN G SODIUM  
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
 PERPHENAZINE, PERPHENAZINE  
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUINIDINE SULFATE, QUINIDINE SULFATE  
 RAMIPRIL, RAMIPRIL  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RESERPINE, RESERPINE  
 RIBAVIRIN, RIBAVIRIN  
 RIFAMPIN, RIFAMPIN  
 RISPERIDONE, RISPERIDONE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 SULFADIAZINE, SULFADIAZINE  
 SYEDA, DROSPIRENONE  
 TACROLIMUS, TACROLIMUS  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TEMAZEPAM, TEMAZEPAM  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE  
 THIOTHIXENE, THIOTHIXENE  
 TRI-ESTARYLLA, ETHINYL ESTRADIOL  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**SANDOZ CANADA INC**

\* SANDOZ CANADA INC  
 PARICALCITOL, PARICALCITOL

**SANDOZ INC**

\* SANDOZ INC  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 BUDESONIDE, BUDESONIDE  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE  
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SANDOZ INC  
 DECITABINE, DECITABINE  
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE  
 DOXERCALCIFEROL, DOXERCALCIFEROL  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 DUTASTERIDE, DUTASTERIDE  
 ELIFEMME, ETHINYL ESTRADIOL  
 ENALAPRIL MALEATE, ENALAPRIL MALEATE  
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM  
 GLATOPA, GLATIRAMER ACETATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 ISIBLOOM, DESOGESTREL  
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN  
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM  
 LINEZOLID, LINEZOLID  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 NEVIRAPINE, NEVIRAPINE  
 OLANZAPINE, OLANZAPINE  
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 REPAGLINIDE, REPAGLINIDE  
 RIBAVIRIN, RIBAVIRIN  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 TELMISARTAN, TELMISARTAN  
 TIGECYCLINE, TIGECYCLINE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL  
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VIENVA, ETHINYL ESTRADIOL  
 VORICONAZOLE, VORICONAZOLE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**SANOFI AVENTIS**

\* SANOFI AVENTIS  
 AFREZZA, INSULIN RECOMBINANT HUMAN

**SANOFI AVENTIS US**

\* SANOFI AVENTIS US INC  
 JEVTANA KIT, CABAZITAXEL

\* SANOFI AVENTIS US LLC  
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA, FEXOFENADINE HYDROCHLORIDE  
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)  
 AMARYL, GLIMEPIRIDE  
 AMBIEN CR, ZOLPIDEM TARTRATE  
 AMBIEN, ZOLPIDEM TARTRATE  
 ANZEMET, DOLASETRON MESYLATE  
 APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT  
 APIDRA, INSULIN GLULISINE RECOMBINANT  
 ARALEN, CHLOROQUINE PHOSPHATE  
 ARAVA, LEFLUNOMIDE  
 AUBAGIO, TERIFLUNOMIDE  
 AUVI-Q, EPINEPHRINE  
 AVALIDE, HYDROCHLOROTHIAZIDE  
 AVAPRO, IRBESARTAN  
 CANTIL, MEPENZOLATE BROMIDE  
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM  
 CLAFORAN, CEFOTAXIME SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SANOFI AVENTIS US LLC  
 CLOMID, CLOMIPHENE CITRATE  
 DEMEROL, MEPERIDINE HYDROCHLORIDE  
 DIABETA, GLYBURIDE  
 DRISDOL, ERGOCALCIFEROL  
 ELOXATIN, OXALIPLATIN  
 FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX  
 GAVISCON, ALUMINUM HYDROXIDE (OTC)  
 HIPREX, METHENAMINE HIPPURATE  
 KETEK, TELITHROMYCIN  
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT  
 LANTUS, INSULIN GLARGINE RECOMBINANT  
 LASIX, FUROSEMIDE  
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 LOVENOX, ENOXAPARIN SODIUM  
 MULTAQ, DRONEDARONE HYDROCHLORIDE  
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)  
 NICODERM CQ, NICOTINE (OTC)  
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE  
 PHISOHEX, HEXACHLOROPHENE  
 PLAVIX, CLOPIDOGREL BISULFATE  
 PRIFTIN, RIFAPENTINE  
 PRIMAQUINE, PRIMAQUINE PHOSPHATE  
 RIFADIN, RIFAMPIN  
 RIFAMATE, ISONIAZID  
 RIFATER, ISONIAZID  
 TAXOTERE, DOCETAXEL

**SANOFI PASTEUR INC**

\* SANOFI PASTEUR INC  
 SKLICE, IVERMECTIN

**SANOFI US SERVICES**

\* SANOFI US SERVICES INC  
 TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT

**SANTARUS INC**

\* SANTARUS INC  
 FENOGLIDE, FENOFIBRATE  
 GLUMETZA, METFORMIN HYDROCHLORIDE  
 ZEGERID, OMEPRAZOLE

**SANTOS BIOTECH**

\* SANTOS BIOTECH INDUSTRIES INC  
 ANASTROZOLE, ANASTROZOLE

**SB PHARMCO**

\* SB PHARMCO PUERTO RICO INC  
 AVANDIA, ROSIGLITAZONE MALEATE  
 COREG CR, CARVEDILOL PHOSPHATE

**SCHERING**

\* SCHERING CORP  
 INTEGRILIN, EPTIFIBATIDE  
 NOXAFIL, POSACONAZOLE  
 REBETOL, RIBAVIRIN

**SCHERING PLOUGH**

\* SCHERING PLOUGH HEALTHCARE PRODUCTS INC  
 AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)

**SCIEGEN PHARMS INC**

\* SCIEGEN PHARMACEUTICALS INC  
 CARISOPRODOL, CARISOPRODOL  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SCIEGEN PHARMACEUTICALS INC  
NEVIRAPINE, NEVIRAPINE  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**SCIOS LLC**

\* SCIOS LLC  
NATRECOR, NESIRITIDE RECOMBINANT

**SEBELA IRELAND LTD**

\* SEBELA IRELAND LTD  
MICORT-HC, HYDROCORTISONE ACETATE  
MOTOFEN, ATROPINE SULFATE  
PRAMOSONE, HYDROCORTISONE ACETATE

**SECAN PHARMS**

\* SECAN PHARMACEUTICALS INC  
LEVETIRACETAM, LEVETIRACETAM

**SENTYNL THERAPS INC**

\* SENTYNL THERAPEUTICS INC  
ABSTRAL, FENTANYL CITRATE  
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

**SEPTODONT**

\* SEPTODONT INC  
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
OCTOCAINE, EPINEPHRINE

**SEPTODONT HOLDING**

\* SEPTODONT HOLDING SAS  
ORAVERSE, PHENTOLAMINE MESYLATE

**SEPTODONT INC**

\* SEPTODONT INC  
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE  
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

**SERB SAS**

\* SERB SAS  
CYANOKIT, HYDROXOCOBALAMIN

**SETON PHARM**

\* SETON PHARMACEUTICAL LLC  
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

**SHANGHAI HENGRUI**

\* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD  
SEVOFLURANE, SEVOFLURANE

**SHASUN CHEMS**

\* SHASUN CHEMICALS AND DRUGS LTD  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**SHASUN PHARMS LTD**

\* SHASUN PHARMACEUTICALS LTD  
CARISOPRODOL, CARISOPRODOL

**SHASUN USA**

\* SHASUN USA INC  
IBUPROFEN, IBUPROFEN

**SHENZHEN TECHDOW**

\* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD  
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
HEPARIN SODIUM, HEPARIN SODIUM

**SHERTECH LABS LLC**

\* SHERTECH LABORATORIES LLC  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**SHIONOGI INC**

\* SHIONOGI INC  
DORIBAX, DORIPENEM  
FURADANTIN, NITROFURANTOIN  
KEFLEX, CEPHALEXIN  
OSPHENA, OSPEMIFENE  
PONSTEL, MEFENAMIC ACID  
ROBINUL FORTE, GLYCOPYRROLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\*****\* SHIONOGI INC**

ROBINUL, GLYCOPYRROLATE  
 SULAR, NISOLDIPINE  
 ULESFIA, BENZYL ALCOHOL

**SHIRE****\* SHIRE DEVELOPMENT INC**

ADDERALL XR 10, AMPHETAMINE ASPARTATE  
 ADDERALL XR 15, AMPHETAMINE ASPARTATE  
 ADDERALL XR 20, AMPHETAMINE ASPARTATE  
 ADDERALL XR 25, AMPHETAMINE ASPARTATE  
 ADDERALL XR 30, AMPHETAMINE ASPARTATE  
 ADDERALL XR 5, AMPHETAMINE ASPARTATE  
 CARBATROL, CARBAMAZEPINE  
 INTUNIV, GUANFACINE HYDROCHLORIDE  
 LIALDA, MESALAMINE  
 PENTASA, MESALAMINE

**SHIRE DEV LLC****\* SHIRE DEVELOPMENT LLC**

FOSRENOL, LANTHANUM CARBONATE

**SHIRE DEVELOPMENT****\* SHIRE DEVELOPMENT INC**

VYVANSE, LISDEXAMFETAMINE DIMESYLATE

**SHIRE HUMAN GENETIC****\* SHIRE HUMAN GENETIC THERAPIES INC**

VPRIV, VELAGLUCERASE ALFA

**SHIRE LLC****\* SHIRE DEVELOPMENT LLC**

AGRYLIN, ANAGRELIDE HYDROCHLORIDE  
 FOSRENOL, LANTHANUM CARBONATE  
 SALURON, HYDROFLUMETHIAZIDE

**SHIRE ORPHAN THERAP****\* SHIRE ORPHAN THERAPIES INC**

FIRAZYR, ICATIBANT ACETATE

**SIDMAK LABS INDIA****\* SIDMAK LABORATORIES INDIA PVT LTD**

MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

**SIGMA TAU****\* SIGMA TAU PHARMACEUTICALS INC**

ABELCET, AMPHOTERICIN B  
 ADAGEN, PEGADEMASE BOVINE  
 CARNITOR SF, LEVOCARNITINE  
 CARNITOR, LEVOCARNITINE  
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE  
 MATULANE, PROCARBAZINE HYDROCHLORIDE

**SIGMAPHARM LABS LLC****\* SIGMAPHARM LABORATORIES LLC**

ACITRETIN, ACITRETIN  
 ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL  
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE  
 DISULFIRAM, DISULFIRAM  
 ERGOCALCIFEROL, ERGOCALCIFEROL  
 FLUCYTOSINE, FLUCYTOSINE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE  
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE  
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

**SILARX****\* SILARX PHARMACEUTICALS INC**

CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SILARX PHARMACEUTICALS INC  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 LEVETIRACETAM, LEVETIRACETAM  
 LORATADINE, LORATADINE (OTC)  
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE

**SILARX PHARMS INC**

\* SILARX PHARMACEUTICALS INC  
 ARIPIPIRAZOLE, ARIPIPIRAZOLE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 LAMIVUDINE, LAMIVUDINE  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE

**SILVERGATE PHARMS**

\* SILVERGATE PHARMACEUTICALS INC  
 EPANED KIT, ENALAPRIL MALEATE

**SKINMEDICA**

\* SKINMEDICA INC  
 VANIQA, EFLORNITHINE HYDROCHLORIDE

**SKYEPHARMA AG**

\* SKYEPHARMA AG  
 TRIGLIDE, FENOFIBRATE

**SMITHKLINE BEECHAM**

\* SMITHKLINE BEECHAM  
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS  
 \* SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE  
 COREG, CARVEDILOL

**SOAPCO**

\* SOAPCO INC  
 BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

**SOFGEN PHARMS**

\* SOFGEN PHARMACEUTICALS  
 NIMODIPINE, NIMODIPINE  
 \* SOFGEN PHARMACEUTICALS LLC  
 PROGESTERONE, PROGESTERONE

**SOMERSET**

\* SOMERSET PHARMACEUTICALS INC  
 ELDEPRYL, SELEGILINE HYDROCHLORIDE  
 EMSAM, SELEGILINE

**SOVEREIGN PHARMS**

\* SOVEREIGN PHARMACEUTICALS LLC  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 OBREDON, GUAIFENESIN

**SPEAR PHARMS**

\* SPEAR PHARMACEUTICALS INC  
 FLUOROURACIL, FLUOROURACIL

**SPEAR PHARMS INC**

\* SPEAR PHARMACEUTICALS INC  
 FLUOROURACIL, FLUOROURACIL  
 TRETINOIN, TRETINOIN

**SPECTRON MRC LLC**

\* SPECTRON MRC LLC  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**SPECTRUM PHARMS**

\* SPECTRUM PHARMACEUTICALS INC  
 BELEODAQ, BELINOSTAT

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SPECTRUM PHARMACEUTICALS INC  
FUSILEV, LEVOLEUCOVORIN CALCIUM

**SPRIASO LLC**

\* SPRIASO LLC  
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE

**SPROUT PHARMS**

\* SPROUT PHARMACEUTICALS INC  
ADDYI, FLIBANSERIN

**STAND HOMEOPATH**

\* STANDARD HOMEOPATHIC CO  
IVY BLOCK, BENTOQUATAM (OTC)

**STANDARD CHEM PHARM**

\* STANDARD CHEM AND PHARM CO LTD  
REPAGLINIDE, REPAGLINIDE

**STASON**

\* STASON INDUSTRIAL CORP  
ACYCLOVIR, ACYCLOVIR  
CAPTOPRIL, CAPTOPRIL  
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

**STASON PHARMS**

\* STASON PHARMACEUTICALS INC  
BICALUTAMIDE, BICALUTAMIDE  
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
GLYCOPYRROLATE, GLYCOPYRROLATE

**STI PHARMA LLC**

\* STI PHARMA LLC  
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
DEXAMETHASONE, DEXAMETHASONE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE  
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE  
TRIAICIN-C, CODEINE PHOSPHATE

**STIEFEL**

\* STIEFEL LABORATORIES INC  
DUAC, BENZOYL PEROXIDE

**STIEFEL GSK**

\* STIEFEL A GSK CO  
VELTIN, CLINDAMYCIN PHOSPHATE

**STIEFEL LABS INC**

\* STIEFEL LABORATORIES INC  
FABIOR, TAZAROTENE  
SORIATANE, ACITRETIN  
SORILUX, CALCIPOTRIENE

**STRIDES ARCOLAB LTD**

\* STRIDES ARCOLAB LTD  
AMPICILLIN SODIUM, AMPICILLIN SODIUM  
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
DUTASTERIDE, DUTASTERIDE  
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL

**STRIDES PHARMA**

\* STRIDES PHARMA GLOBAL PTE LTD  
ACARBOSE, ACARBOSE  
BENZONATATE, BENZONATATE  
CALCITRIOL, CALCITRIOL  
ERGOCALCIFEROL, ERGOCALCIFEROL  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
IMIQUIMOD, IMIQUIMOD  
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
MELOXICAM, MELOXICAM  
METHOXSALEN, METHOXSALEN  
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
NEVIRAPINE, NEVIRAPINE  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* STRIDES PHARMA GLOBAL PTE LTD  
TACROLIMUS, TACROLIMUS  
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**SUCAMPO PHARMA LLC**

\* SUCAMPO PHARMA AMERICAS LLC  
AMITIZA, LUBIPROSTONE

**SUMMERS**

\* SUMMERS LABORATORIES INC  
CROTAN, CROTAMITON

**SUN PHARM INDS**

\* SUN PHARMACEUTICAL INDUSTRIES INC  
ATENOLOL, ATENOLOL  
CARISOPRODOL, CARISOPRODOL  
CHLORTHALIDONE, CHLORTHALIDONE  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
SYNALGOS-DC, ASPIRIN

\* SUN PHARMACEUTICAL INDUSTRIES LTD  
CARBIDOPA AND LEVODOPA, CARBIDOPA  
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
DESLORATADINE, DESLORATADINE  
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
OLANZAPINE, OLANZAPINE  
ONDANSETRON, ONDANSETRON  
OXCARBAZEPINE, OXCARBAZEPINE  
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE  
TORSEMIDE, TORSEMIDE

**SUN PHARM INDS (IN)**

\* SUN PHARMACEUTICAL INDUSTRIES LTD  
CEPHALEXIN, CEPHALEXIN  
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
ZONISAMIDE, ZONISAMIDE

**SUN PHARM INDS INC**

\* SUN PHARMACEUTICAL INDUSTRIES INC  
ALLOPURINOL, ALLOPURINOL  
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
ATENOLOL, ATENOLOL  
BACLOFEN, BACLOFEN  
BENZONATATE, BENZONATATE  
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
CARVEDILOL, CARVEDILOL  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
CLONAZEPAM, CLONAZEPAM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SUN PHARMACEUTICAL INDUSTRIES INC  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 CLOZAPINE, CLOZAPINE  
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
 DIGOXIN, DIGOXIN  
 ELIXOPHYLLIN, THEOPHYLLINE  
 ERGOCALCIFEROL, ERGOCALCIFEROL  
 FLURBIPROFEN, FLURBIPROFEN  
 FUROSEMIDE, FUROSEMIDE  
 GEMFIBROZIL, GEMFIBROZIL  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GLIPIZIDE, GLIPIZIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 MELOXICAM, MELOXICAM  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHIMAZOLE, METHIMAZOLE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NIMODIPINE, NIMODIPINE  
 NITROFURANTOIN, NITROFURANTOIN  
 OXAPROZIN, OXAPROZIN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 REPAGLINIDE, REPAGLINIDE  
 RISPERIDONE, RISPERIDONE  
 THEOCHRON, THEOPHYLLINE  
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 VALPROIC ACID, VALPROIC ACID  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**SUN PHARM INDS LTD**

\* SUN PHARMACEUTICAL INDUSTRIES LTD  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
 ACYCLOVIR, ACYCLOVIR  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 AZITHROMYCIN, AZITHROMYCIN  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 CARISOPRODOL, CARISOPRODOL  
 CARVEDILOL, CARVEDILOL  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**

\*\* S \*\*

\* SUN PHARMACEUTICAL INDUSTRIES LTD  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEPHALEXIN, CEPHALEXIN  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXYCYCLINE, DOXYCYCLINE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FELODIPINE, FELODIPINE  
 FENOFIBRATE, FENOFIBRATE  
 FLECAINIDE ACETATE, FLECAINIDE ACETATE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 GABAPENTIN, GABAPENTIN  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 KENALOG, TRIAMCINOLONE ACETONIDE  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)  
 LORATADINE REDIDOSE, LORATADINE (OTC)  
 LORATADINE, LORATADINE (OTC)  
 LORAZEPAM, LORAZEPAM  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 OPCICON ONE-STEP, LEVONORGESTREL (OTC)  
 OXCARBAZEPINE, OXCARBAZEPINE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RILUZOLE, RILUZOLE  
 RIOMET, METFORMIN HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SIMVASTATIN, SIMVASTATIN  
 SOTRET, ISOTRETINOIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 TOPIRAMATE, TOPIRAMATE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

- \* SUN PHARMACEUTICAL INDUSTRIES LTD
  - VALPROIC ACID, VALPROIC ACID
  - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- \* SUN PHARMACEUTICAL INDUSTRIES LTD.
  - ANASTROZOLE, ANASTROZOLE
- SUN PHARMA GLOBAL**
- \* SUN PHARMA GLOBAL FZE
  - ALENDRONATE SODIUM, ALENDRONATE SODIUM
  - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
  - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  - CAFFEINE CITRATE, CAFFEINE CITRATE
  - CARBIDOPA AND LEVODOPA, CARBIDOPA
  - CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
  - CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  - CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  - CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
  - CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  - DECITABINE, DECITABINE
  - DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
  - DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
  - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
  - DOCEFREZ, DOCETAXEL
  - DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
  - DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  - ENTACAPONE, ENTACAPONE
  - ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
  - ESZOPICLONE, ESZOPICLONE
  - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
  - FINASTERIDE, FINASTERIDE
  - GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  - IMATINIB MESYLATE, IMATINIB MESYLATE
  - LANSOPRAZOLE, LANSOPRAZOLE
  - LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
  - LEVETIRACETAM, LEVETIRACETAM
  - LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
  - MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  - NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
  - NIACIN, NIACIN
  - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
  - OXALIPLATIN, OXALIPLATIN
  - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  - RISEDRONATE SODIUM, RISEDRONATE SODIUM
  - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  - TEMOZOLOMIDE, TEMOZOLOMIDE
  - TETRABENAZINE, TETRABENAZINE
  - TOPIRAMATE, TOPIRAMATE
  - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  - VECURONIUM BROMIDE, VECURONIUM BROMIDE
  - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  - ZOLEDRONIC ACID, ZOLEDRONIC ACID
  - ZOLMITRIPTAN, ZOLMITRIPTAN
- \* SUN PHARMA GLOBAL INC
  - ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
  - ALPRAZOLAM, ALPRAZOLAM
  - AMIFOSTINE, AMIFOSTINE
  - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
  - BICALUTAMIDE, BICALUTAMIDE
  - CARBOPLATIN, CARBOPLATIN
  - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
  - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
  - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
  - PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\*****SUNEVA MEDCL**

\* SUNEVA MEDICAL INC  
TRETINOIN, TRETINOIN

**SUNOVION**

\* SUNOVION PHARMACEUTICALS INC  
BROVANA, ARFORMOTEROL TARTRATE  
XOPENEX HFA, LEVALBUTEROL TARTRATE

**SUNOVION PHARMS INC**

\* SUNOVION PHARMACEUTICALS INC  
APTIOM, ESLICARBAZEPINE ACETATE  
LATUDA, LURASIDONE HYDROCHLORIDE  
LUNESTA, ESZOPICLONE

**SUNSHINE LAKE**

\* SUNSHINE LAKE PHARMA CO LTD  
ZIDOVUDINE, ZIDOVUDINE

**SUNSTAR AMERICAS**

\* SUNSTAR AMERICAS INC  
PAROEX, CHLORHEXIDINE GLUCONATE

**SUPERNUS PHARMS**

\* SUPERNUS PHARMACEUTICALS INC  
OXTELLAR XR, OXCARBAZEPINE  
TROKENDI XR, TOPIRAMATE

**SUVEN LIFE**

\* SUVEN LIFE SCIENCES LTD  
MALATHION, MALATHION

**SVADS HOLDINGS SA**

\* SVADS HOLDINGS SA  
IBUPROFEN, IBUPROFEN (OTC)  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**SVC PHARMA**

\* SVC PHARMA LP  
DRONABINOL, DRONABINOL

**SWAN PHARMS LLC**

\* SWAN PHARMACEUTICALS LLC  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

**SWEDISH ORPHAN**

\* SWEDISH ORPHAN BIOVITRUM AB PUBL  
ORFADIN, NITISINONE

**SYMLMED PHARMS LLC**

\* SYMLMED PHARMACEUTICALS LLC  
ACEON, PERINDOPRIL ERBUMINE  
PRESTALIA, AMLODIPINE BESYLATE

**SYNTHON PHARMS**

\* SYNTHON PHARMACEUTICALS INC  
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**\*\* T \*\*****METHODIST HOSP RES**

\* THE METHODIST HOSP RESEARCH INSTITUTE  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**REDITOSE CORP**

\* THE RITEDOSE CORP  
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

**TAIHO ONCOLOGY**

\* TAIHO ONCOLOGY INC  
LONSURF, TIPIRACIL HYDROCHLORIDE

**TAKEDA GMBH**

\* TAKEDA GMBH  
ALVESCO, CICLESONIDE  
OMNARIS, CICLESONIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TAKEDA GMBH  
ZETONNA, CICLESONIDE

**TAKEDA PHARMS USA**

\* TAKEDA PHARMACEUTICALS USA INC  
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE  
ACTOPLUS MET, METFORMIN HYDROCHLORIDE  
ACTOS, PIOGLITAZONE HYDROCHLORIDE  
BRINTELLIX, VORTIOXETINE HYDROBROMIDE  
COLCRYS, COLCHICINE  
CONTRAVE, BUPROPION HYDROCHLORIDE  
DEXILANT, DEXLANSOPRAZOLE  
DUETACT, GLIMEPIRIDE  
KAZANO, ALOGLIPTIN BENZOATE  
NESINA, ALOGLIPTIN BENZOATE  
OSEN, ALOGLIPTIN BENZOATE  
PREVACID, LANSOPRAZOLE  
PREVPAC, AMOXICILLIN  
ROZEREM, RAMELTEON  
ULORIC, FEBUXOSTAT

**TALON THERAP**

\* TALON THERAPEUTICS INC  
MARQIBO KIT, VINCRISTINE SULFATE

**TAMARANG**

\* TAMARANG SA  
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

**TARO**

\* TARO PHARMACEUTICAL INDUSTRIES LTD  
ACETAZOLAMIDE, ACETAZOLAMIDE  
CARBAMAZEPINE, CARBAMAZEPINE  
CARVEDILOL, CARVEDILOL  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
DESONIDE, DESONIDE  
ENALAPRIL MALEATE, ENALAPRIL MALEATE  
ETODOLAC, ETODOLAC  
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
FLUCONAZOLE, FLUCONAZOLE  
FLUOROURACIL, FLUOROURACIL  
GABAPENTIN, GABAPENTIN  
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE  
IMIQUIMOD, IMIQUIMOD  
KETOCONAZOLE, KETOCONAZOLE  
LAMOTRIGINE, LAMOTRIGINE  
LEVETIRACETAM, LEVETIRACETAM  
LORATADINE, LORATADINE (OTC)  
MELOXICAM, MELOXICAM  
METRONIDAZOLE, METRONIDAZOLE  
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
OXCARBAZEPINE, OXCARBAZEPINE  
PHENYTOIN, PHENYTOIN

\* TARO PHARMACEUTICALS INC  
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
CLOTRIMAZOLE, CLOTRIMAZOLE  
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)  
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE  
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
FLUOCINONIDE, FLUOCINONIDE  
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE  
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* T \*\*

- \* TARO PHARMACEUTICALS INC  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 TOPICORT, DESOXIMETASONE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
 WARFARIN SODIUM, WARFARIN SODIUM
- \* TARO PHARMACEUTICALS USA INC  
 ACETIC ACID, ACETIC ACID, GLACIAL  
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMMONIUM LACTATE, AMMONIUM LACTATE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CICLOPIROX, CICLOPIROX  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM  
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE  
 DERMABET, BETAMETHASONE VALERATE  
 DESONIDE, DESONIDE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE  
 FLUOCINONIDE, FLUOCINONIDE  
 FLUOROURACIL, FLUOROURACIL  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL  
 HYDROCORTISONE, HYDROCORTISONE  
 KETOZOLE, KETOCONAZOLE  
 KEVEYIS, DICHLORPHENAMIDE  
 LIDOCAINE, LIDOCAINE  
 LORATADINE, LORATADINE (OTC)  
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 MUPIROCIN, MUPIROCIN  
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE  
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN  
 NYSTATIN, NYSTATIN  
 PHENYTOIN, PHENYTOIN  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)  
 TERCONAZOLE, TERCONAZOLE  
 TERIL, CARBAMAZEPINE  
 TOPICORT, DESOXIMETASONE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)  
 U-CORT, HYDROCORTISONE ACETATE
- \* TARO PHARMACEUTICALS, INC.  
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE  
 TOPICORT, DESOXIMETASONE

**TARO PHARM INDS**

- \* TARO PHARMACEUTICAL INDUSTRIES LTD  
 AMCINONIDE, AMCINONIDE  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CICLOPIROX, CICLOPIROX  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 DESLORATADINE, DESLORATADINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TARO PHARMACEUTICAL INDUSTRIES LTD  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ETODOLAC, ETODOLAC  
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

**TARO PHARMS IRELAND**

\* TARO PHARMACEUTICALS IRELAND LTD  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

**TARO PHARMS NORTH**

\* TARO PHARMACEUTICALS NORTH AMERICA INC  
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)  
 OVIDE, MALATHION  
 TOPICORT, DESOXIMETASONE

**TEDOR PHARM**

\* TEDOR PHARMA INC  
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

**TEDOR PHARMA INC**

\* TEDOR PHARMA INC  
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

**TEIKOKU PHARMA**

\* TEIKOKU PHARMA USA INC  
 DOCETAXEL, DOCETAXEL

**TEIKOKU PHARMA USA**

\* TEIKOKU PHARMA USA INC  
 LIDODERM, LIDOCAINE

**TESARO INC**

\* TESARO INC  
 VARUBI, ROLAPITANT HYDROCHLORIDE

**TEVA**

\* TEVA NEUROSCIENCE INC  
 AZILECT, RASAGILINE MESYLATE

\* TEVA PHARMACEUTICALS USA INC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 ACYCLOVIR, ACYCLOVIR  
 ADIPEX-P, PHENTERMINE HYDROCHLORIDE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN PEDIATRIC, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF, AMPHETAMINE  
 ATENOLOL, ATENOLOL  
 AZITHROMYCIN, AZITHROMYCIN  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BICALUTAMIDE, BICALUTAMIDE  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 CALCITRIOL, CALCITRIOL  
 CAPTOPRIL, CAPTOPRIL  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CARVEDILOL, CARVEDILOL  
 CEFACLOR, CEFACLOR  
 CEFPROZIL, CEFPROZIL  
 CELECOXIB, CELECOXIB  
 CEPHALEXIN, CEPHALEXIN  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
 CILOSTAZOL, CILOSTAZOL  
 CIMETIDINE, CIMETIDINE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TEVA PHARMACEUTICALS USA INC  
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
 CLONAZEPAM, CLONAZEPAM  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE  
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM  
 DIFLUNISAL, DIFLUNISAL  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
 ENALAPRIL MALEATE, ENALAPRIL MALEATE  
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 EPITOL, CARBAMAZEPINE  
 ESTAZOLAM, ESTAZOLAM  
 ESZOPICLONE, ESZOPICLONE  
 ETODOLAC, ETODOLAC  
 FAMOTIDINE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FENOFIBRATE (MICRONIZED), FENOFIBRATE  
 FENOFIBRATE, FENOFIBRATE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 FINASTERIDE, FINASTERIDE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE  
 FLUOCINONIDE, FLUOCINONIDE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLURBIPROFEN, FLURBIPROFEN  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 GALZIN, ZINC ACETATE  
 GEMFIBROZIL, GEMFIBROZIL  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GLYBURIDE (MICRONIZED), GLYBURIDE  
 GLYBURIDE, GLYBURIDE  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 KETOCONAZOLE, KETOCONAZOLE  
 KETOPROFEN, KETOPROFEN  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE  
 LORATADINE, LORATADINE (OTC)  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOVASTATIN, LOVASTATIN  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
 MUPIROCIN, MUPIROCIN  
 NABUMETONE, NABUMETONE  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NAPROXEN, NAPROXEN  
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE  
 NEOMYCIN SULFATE, NEOMYCIN SULFATE  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\*****\* TEVA PHARMACEUTICALS USA INC**

NYSTATIN, NYSTATIN  
 OFLOXACIN, OFLOXACIN  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 ORAP, PIMOZIDE  
 OXAPROZIN, OXAPROZIN  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PENICILLIN-VK, PENICILLIN V POTASSIUM  
 PIROXICAM, PIROXICAM  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PRELONE, PREDNISOLONE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RIBAVIRIN, RIBAVIRIN  
 RISPERIDONE, RISPERIDONE  
 ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SUCRALFATE, SUCRALFATE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TOLMETIN SODIUM, TOLMETIN SODIUM  
 TOPIRAMATE, TOPIRAMATE  
 TORSEMIDE, TORSEMIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRIMETHOPRIM, TRIMETHOPRIM  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**TEVA BRANDED PHARM****\* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC**

CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A  
 DIAMOX, ACETAZOLAMIDE  
 LOSEASONIQUE, ETHINYL ESTRADIOL  
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)  
 PLAN B, LEVONORGESTREL  
 PLAN B, LEVONORGESTREL (OTC)  
 PROAIR HFA, ALBUTEROL SULFATE  
 PROAIR RESPICLICK, ALBUTEROL SULFATE  
 PROGLYCEM, DIAZOXIDE  
 QNASL, BECLOMETHASONE DIPROPIONATE  
 QUARTETTE, ETHINYL ESTRADIOL  
 QVAR 40, BECLOMETHASONE DIPROPIONATE  
 QVAR 80, BECLOMETHASONE DIPROPIONATE  
 SEASONALE, ETHINYL ESTRADIOL  
 SEASONIQUE, ETHINYL ESTRADIOL  
 ZECUITY, SUMATRIPTAN SUCCINATE

**TEVA PARENTERAL****\* TEVA PARENTERAL MEDICINES INC**

LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

**TEVA PHARMS****\* TEVA PHARMACEUTICALS USA**

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TEVA PHARMACEUTICALS USA  
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE  
 ANASTROZOLE, ANASTROZOLE  
 AZITHROMYCIN, AZITHROMYCIN  
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
 BUDESONIDE, BUDESONIDE  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFDINIR, CEFDINIR  
 CEFPROZIL, CEFPROZIL  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DESONIDE, DESONIDE  
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
 ETHOSUXIMIDE, ETHOSUXIMIDE  
 FAMCICLOVIR, FAMCICLOVIR  
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM  
 GABAPENTIN, GABAPENTIN  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 HYDROCORTISONE, HYDROCORTISONE  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 IRBESARTAN, IRBESARTAN  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LINEZOLID, LINEZOLID  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 MEGESTROL ACETATE, MEGESTROL ACETATE  
 MELOXICAM, MELOXICAM  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 OLANZAPINE, OLANZAPINE  
 OXALIPLATIN, OXALIPLATIN  
 PACLITAXEL, PACLITAXEL  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE  
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE  
 PROGESTERONE, PROGESTERONE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUININE SULFATE, QUININE SULFATE  
 RAMIPRIL, RAMIPRIL  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\*****\* TEVA PHARMACEUTICALS USA**

TRANDOLAPRIL, TRANDOLAPRIL  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
 URSODIOL, URSODIOL  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VANDAZOLE, METRONIDAZOLE  
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE  
 VORICONAZOLE, VORICONAZOLE  
 ZALEPLON, ZALEPLON

**TEVA PHARMS USA****\* TEVA PHARMACEUTICALS USA**

ACITRETIN, ACITRETIN  
 ADENOSINE, ADENOSINE  
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE  
 ALPROSTADIL, ALPROSTADIL  
 AMIKACIN SULFATE, AMIKACIN SULFATE  
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
 ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN  
 ARIPIPIRAZOLE, ARIPIPIRAZOLE  
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE  
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 CARBOPLATIN, CARBOPLATIN  
 CLARAVIS, ISOTRETINOIN  
 CLOZAPINE, CLOZAPINE  
 COPAXONE, GLATIRAMER ACETATE  
 CYTOSAR-U, CYTARABINE  
 DACARBAZINE, DACARBAZINE  
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DOCETAXEL, DOCETAXEL  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ENALAPRILAT, ENALAPRILAT  
 ENTECAVIR, ENTECAVIR  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM  
 EPTIFIBATIDE, EPTIFIBATIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 ETOPOSIDE, ETOPOSIDE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 FLUOROURACIL, FLUOROURACIL  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE  
 IFOSFAMIDE, IFOSFAMIDE  
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN  
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 LINEZOLID, LINEZOLID  
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE  
 MESNA, MESNA  
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

- \* TEVA PHARMACEUTICALS USA  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID  
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE  
 PARICALCITOL, PARICALCITOL  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PROPOFOL, PROPOFOL  
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE  
 RAMELTEON, RAMELTEON  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TOBRAMYCIN, TOBRAMYCIN  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VECURONIUM BROMIDE, VECURONIUM BROMIDE  
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE  
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE  
 ZANOSAR, STREPTOZOCIN  
 ZOLMITRIPTAN, ZOLMITRIPTAN
- \* TEVA PHARMACEUTICALS USA INC  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 CAPECITABINE, CAPECITABINE  
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL  
 METRONIDAZOLE, METRONIDAZOLE  
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 SELFEMRA, FLUOXETINE HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
- TEVA PHARMS USA INC**
- \* TEVA PHARMACEUTICALS USA INC  
 ADASUVE, LOXAPINE
- TEVA WOMENS**
- \* TEVA WOMENS HEALTH INC  
 ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B  
 PARAGARD T 380A, COPPER  
 REVIA, NALTREXONE HYDROCHLORIDE  
 ZEBETA, BISOPROLOL FUMARATE  
 ZIAC, BISOPROLOL FUMARATE
- THE FEINSTEIN INST**
- \* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- THE MEDICINES CO**
- \* THE MEDICINES CO  
 ANGIOMAX, BIVALIRUDIN  
 CLEVIPREX, CLEVIDIPINE  
 IONSYS, FENTANYL HYDROCHLORIDE  
 KENGREAL, CANGRELOR  
 ORBACTIV, ORITAVANCIN DIPHOSPHATE
- THE PHARMA NETWORK**
- \* THE PHARMA NETWORK LLC  
 BENZONATATE, BENZONATATE
- THE PHARMANETWORK**
- \* THE PHARMANETWORK LLC  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
- THEPHARMANETWORK LLC**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* THEPHARMANETWORK LLC  
 BENZONATATE, BENZONATATE  
 ISONIAZID, ISONIAZID  
 NIMODIPINE, NIMODIPINE  
 THERMAZENE, SILVER SULFADIAZINE

**THERAKOS**

\* THERAKOS INC  
 UVADEX, METHOXSALEN

**THERATECHNOLOGIES**

\* THERATECHNOLOGIES INC  
 EGRIFTA, TESAMORELIN ACETATE

**THERAVANCE BIOPHARMA**

\* THERAVANCE BIOPHARMA ANTIBIOTICS INC  
 VIBATIV, TELAVANCIN HYDROCHLORIDE

**THREE RIVERS PHARMS**

\* THREE RIVERS PHARMACEUTICALS LLC  
 RIBASPHERE, RIBAVIRIN  
 RIBAVIRIN, RIBAVIRIN

**TOLMAR**

\* TOLMAR INC  
 ADAPALENE, ADAPALENE  
 ATRIDOX, DOXYCYCLINE HYCLATE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CICLOPIROX, CICLOPIROX  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 IMIQUIMOD, IMIQUIMOD  
 KETOCONAZOLE, KETOCONAZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 LIDOCAINE AND PRILOCAINE, LIDOCAINE  
 METRONIDAZOLE, METRONIDAZOLE  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

**TOLMAR THERAP**

\* TOLMAR THERAPEUTICS INC  
 ELIGARD, LEUPROLIDE ACETATE

**TORPHARM**

\* TORPHARM INC  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**TORRENT PHARM**

\* TORRENT PHARMA INC  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**TORRENT PHARMA INC**

\* TORRENT PHARMA INC  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

**TORRENT PHARMS**

\* TORRENT PHARMACEUTICALS LIMITED  
 LEVOFLOXACIN, LEVOFLOXACIN

\* TORRENT PHARMACEUTICALS LTD  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

- \* TORRENT PHARMACEUTICALS LTD  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
RISPERIDONE, RISPERIDONE  
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
TOPIRAMATE, TOPIRAMATE  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- \* TORRENT PHARMACEUTICALS LTD.  
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

**TORRENT PHARMS LLC**

- \* TORRENT PHARMACEUTICALS LLC  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
OLANZAPINE, OLANZAPINE  
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**TORRENT PHARMS LTD**

- \* TORRENT PHARMACEUTICALS LTD  
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE  
ARIPIPIRAZOLE, ARIPIPIRAZOLE  
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
CELECOXIB, CELECOXIB  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
FELODIPINE, FELODIPINE  
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
LAMOTRIGINE, LAMOTRIGINE  
LEVETIRACETAM, LEVETIRACETAM  
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
OLANZAPINE, OLANZAPINE  
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
SILDENAFIL CITRATE, SILDENAFIL CITRATE  
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE  
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
TELMISARTAN, TELMISARTAN  
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
VALSARTAN, VALSARTAN

**TRIAD ISOTOPES INC**

- \* TRIAD ISOTOPES INC  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**TRIBUTE PHARMS INTL**

- \* TRIBUTE PHARMACEUTICALS INTERNATIONAL INC  
FIBRICOR, FENOFIBRIC ACID

**TRIS PHARMA INC**

- \* TRIS PHARMA INC  
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)  
DYANAVEL XR, AMPHETAMINE  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE  
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE  
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,  
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX  
IBUPROFEN, IBUPROFEN (OTC)  
KARBINAL ER, CARBINOXAMINE MALEATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TRIS PHARMA INC  
 LEVETIRACETAM, LEVETIRACETAM  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 THEOPHYLLINE, THEOPHYLLINE

**TRUSTEES UNIV PA**

\* TRUSTEES OF THE UNIV OF PENNSYLVANIA  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**TRYGG**

\* TRYGG PHARMA INC  
 OMTRYG, OMEGA-3-ACID ETHYL ESTERS

**TURING PHARMS AG**

\* TURING PHARMACEUTICALS AG  
 DARAPRIM, PYRIMETHAMINE

**TWI PHARMS INC**

\* TWI PHARMACEUTICALS INC  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 MEGESTROL ACETATE, MEGESTROL ACETATE  
 NIFEDIPINE, NIFEDIPINE

**\*\* U \*\*****UCB INC**

\* UCB INC  
 KEPPRA XR, LEVETIRACETAM  
 KEPPRA, LEVETIRACETAM  
 METADATE CD, METHYLPHENIDATE HYDROCHLORIDE  
 METADATE ER, METHYLPHENIDATE HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 NEUPRO, ROTIGOTINE  
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLYSTIREX  
 UNIRETIC, HYDROCHLOROTHIAZIDE  
 UNIVASC, MOEXIPRIL HYDROCHLORIDE  
 VIMPAT, LACOSAMIDE  
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE  
 ZAROXOLYN, METOLAZONE

**UCLA BIOMEDICAL**

\* UCLA BIOMEDICAL CYCLOTRON  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UCSF RODIOPHARM**

\* UCSF RADIOPHARMACEUTICAL FACILITY  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UIHC PET IMAGING**

\* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UNICHEM**

\* UNICHEM LABORATORIES LTD  
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 MELOXICAM, MELOXICAM  
 ZALEPLON, ZALEPLON

**UNICHEM LABS LTD**

\* UNICHEM LABORATORIES LIMITED

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* U \*\***

- \* UNICHEM LABORATORIES LIMITED  
DIVALPROEX SODIUM, DIVALPROEX SODIUM
- \* UNICHEM LABORATORIES LTD  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
IRBESARTAN, IRBESARTAN  
LAMOTRIGINE, LAMOTRIGINE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
METRONIDAZOLE, METRONIDAZOLE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
TOPIRAMATE, TOPIRAMATE

**UNICHEM PHARMS (USA)**

- \* UNICHEM PHARMACEUTICALS (USA) INC  
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

**UNIMARK REMEDIES LTD**

- \* UNIMARK REMEDIES LTD  
MONTELUKAST SODIUM, MONTELUKAST SODIUM

**UNIQUE PHARM LABS**

- \* UNIQUE PHARMACEUTICAL LABORATORIES  
ATENOLOL, ATENOLOL  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
FLUCONAZOLE, FLUCONAZOLE  
LITHIUM CARBONATE, LITHIUM CARBONATE  
TINIDAZOLE, TINIDAZOLE

**UNITED BIOMEDCL**

- \* UNITED BIOMEDICAL INC  
TERBUTALINE SULFATE, TERBUTALINE SULFATE

**UNITED GUARDIAN**

- \* UNITED GUARDIAN INC  
RENACIDIN, CITRIC ACID

**UNITED THERAP**

- \* UNITED THERAPEUTICS CORP  
ORENITRAM, TREPROSTINIL DIOLAMINE  
REMODULIN, TREPROSTINIL  
TYVASO, TREPROSTINIL

**UNIV MICHIGAN**

- \* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UNIV NORTH DAKOTA**

- \* UNIV NORTH DAKOTA  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UNIV TX MD ANDERSON**

- \* UNIV TEXAS MD ANDERSON CANCER CENTER  
AMMONIA N 13, AMMONIA N-13  
CHOLINE C-11, CHOLINE C-11  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UNIV UTAH CYCLOTRON**

- \* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UPSHER SMITH**

- \* UPSHER SMITH LABORATORIES INC  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
FORTICAL, CALCITONIN SALMON RECOMBINANT  
KLOR-CON, POTASSIUM CHLORIDE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* U \*\***

\* UPSHER SMITH LABORATORIES INC  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NIACOR, NIACIN  
 NYSTATIN, NYSTATIN  
 ORVATEN, MIDODRINE HYDROCHLORIDE  
 OXANDROLONE, OXANDROLONE  
 PACERONE, AMIODARONE HYDROCHLORIDE  
 PENTOXIL, PENTOXIFYLLINE  
 PREVALITE, CHOLESTYRAMINE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 QUDEXY XR, TOPIRAMATE  
 SORINE, SOTALOL HYDROCHLORIDE  
 TOPIRAMATE, TOPIRAMATE  
 VOGELXO, TESTOSTERONE  
 ZALEPLON, ZALEPLON

**UPSHER SMITH LABS**

\* UPSHER SMITH LABORATORIES INC  
 Klor-CON M10, POTASSIUM CHLORIDE  
 Klor-CON M15, POTASSIUM CHLORIDE  
 Klor-CON M20, POTASSIUM CHLORIDE

**UPSHER-SMITH LABS**

\* UPSHER-SMITH LABORATORIES INC  
 Klor-CON, POTASSIUM CHLORIDE

**US PHARMS HOLDINGS I**

\* US PHARMACEUTICALS HOLDINGS I LLC  
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE  
 LOPRESSOR, METOPROLOL TARTRATE  
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE  
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE  
 PARLODEL, BROMOCRIPTINE MESYLATE

**US WORLD MEDS LLC**

\* US WORLD MEDS LLC  
 CORGARD, NADOLOL

**US WORLDMEDS**

\* US WORLDMEDS LLC  
 APOKYN, APOMORPHINE HYDROCHLORIDE  
 REVONTO, DANTROLENE SODIUM

**USL PHARMA**

\* USL PHARMA INC  
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 BACLOFEN, BACLOFEN  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE  
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE  
 ESTRADIOL, ESTRADIOL  
 FLUOXYMESTERONE, FLUOXYMESTERONE  
 JANTOVEN, WARFARIN SODIUM  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

**USV NORTH AMERICA**

\* USV NORTH AMERICA INC  
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**\*\* V \*\*****VALEANT**

\* VALEANT PHARMACEUTICALS INTERNATIONAL  
 ANCOBON, FLUCYTOSINE  
 BONTRIL PDM, PHENDIMETRAZINE TARTRATE  
 D.H.E. 45, DIHYDROERGOTAMINE MESYLATE  
 MIGRANAL, DIHYDROERGOTAMINE MESYLATE  
 MYSOLINE, PRIMIDONE

**VALEANT BERMUDA**

\* VALEANT INTERNATIONAL BERMUDA  
 BENZACLIN, BENZOYL PEROXIDE  
 DERMATOP E EMOLLIENT, PREDNICARBATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\***

\* VALEANT INTERNATIONAL BERMUDA  
 ELIDEL, PIMECROLIMUS  
 PENLAC, CICLOPIROX  
 RETIN-A, TRETINOIN  
 XERESE, ACYCLOVIR  
 ZOVIRAX, ACYCLOVIR

**VALEANT INTL**

\* VALEANT INTERNATIONAL BARBADOS SRL  
 ATIVAN, LORAZEPAM  
 CARDIZEM CD, DILTIAZEM HYDROCHLORIDE  
 CARDIZEM LA, DILTIAZEM HYDROCHLORIDE  
 CARDIZEM, DILTIAZEM HYDROCHLORIDE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 NIFEDIPINE, NIFEDIPINE  
 RETIN-A MICRO, TRETINOIN  
 RETIN-A, TRETINOIN  
 RETIN-A-MICRO, TRETINOIN  
 ULTRAM ER, TRAMADOL HYDROCHLORIDE  
 VASERETIC, ENALAPRIL MALEATE  
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE

\* VALEANT INTERNATIONAL SRL  
 BENZAMYCIN, BENZOYL PEROXIDE

**VALEANT LUXEMBOURG**

\* VALEANT PHARMACEUTICALS LUXEMBOURG SARL  
 BENZAMYCIN PAK, BENZOYL PEROXIDE  
 ERTACZO, SERTACONAZOLE NITRATE  
 TARGRETIN, BEXAROTENE  
 VISUDYNE, VERTEPORFIN

**VALEANT PHARM INTL**

\* VALEANT PHARMACEUTICALS INTERNATIONAL  
 8-MOP, METHOXSALEN  
 ANDROID 10, METHYLTESTOSTERONE  
 ANDROID 25, METHYLTESTOSTERONE  
 EFUDEX, FLUOROURACIL  
 LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE  
 MESTINON, PYRIDOSTIGMINE BROMIDE  
 OXSORALEN, METHOXSALEN  
 TESTRED, METHYLTESTOSTERONE  
 VIRAZOLE, RIBAVIRIN  
 ZELAPAR, SELEGILINE HYDROCHLORIDE

**VALEANT PHARMS**

\* VALEANT PHARMACEUTICALS NORTH AMERICA  
 MEPHYTON, PHYTONADIONE

\* VALEANT PHARMACEUTICALS NORTH AMERICA LLC  
 MESTINON, PYRIDOSTIGMINE BROMIDE  
 MINITRAN, NITROGLYCERIN  
 PENTOXIFYLLINE, PENTOXIFYLLINE

**VALEANT PHARMS INC**

\* VALEANT PHARMACEUTICALS INTERNATIONAL INC  
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

**VALEANT PHARMS INTL**

\* VALEANT PHARMACEUTICALS INTERNATIONAL  
 APRISO, MESALAMINE  
 COLAZAL, BALSALAZIDE DISODIUM  
 GIAZO, BALSALAZIDE DISODIUM  
 UCERIS, BUDESONIDE

**VALEANT PHARMS LLC**

\* VALEANT PHARMACEUTICALS NORTH AMERICA LLC  
 CAPITAL AND CODEINE, ACETAMINOPHEN  
 MACUGEN, PEGAPTANIB SODIUM  
 MESTINON, PYRIDOSTIGMINE BROMIDE  
 TASMAR, TOLCAPONE  
 TIMOPTIC-XE, TIMOLOL MALEATE

**VALEANT PHARMS NORTH**

\* VALEANT PHARMACEUTICALS NORTH AMERICA LLC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\***

\* VALEANT PHARMACEUTICALS NORTH AMERICA LLC  
 APLENZIN, BUPROPION HYDROBROMIDE  
 CARAC, FLUOROURACIL  
 DERMATOP, PREDNICARBATE  
 DIASTAT ACUDIAL, DIAZEPAM  
 DIASTAT, DIAZEPAM  
 FENOFIBRATE, FENOFIBRATE  
 IPRIVASK, DESIRUDIN RECOMBINANT  
 ISORDIL, ISOSORBIDE DINITRATE  
 KLARON, SULFACETAMIDE SODIUM  
 NIFEDIPINE, NIFEDIPINE  
 NORITATE, METRONIDAZOLE  
 PEPCID, FAMOTIDINE  
 RENOVA, TRETINOIN  
 RETIN-A, TRETINOIN  
 TIAZAC, DILTIAZEM HYDROCHLORIDE  
 VASOTEC, ENALAPRIL MALEATE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 XENAZINE, TETRABENAZINE

**VALIDUS PHARMS**

\* VALIDUS PHARMACEUTICALS LLC  
 ROCALTROL, CALCITRIOL

**VALIDUS PHARMS INC**

\* VALIDUS PHARMACEUTICALS INC  
 BUMEX, BUMETANIDE  
 EQUETRO, CARBAMAZEPINE  
 MARPLAN, ISOCARBOXAZID

**VANDA PHARMS INC**

\* VANDA PHARMACEUTICALS INC  
 FANAPT, ILOPERIDONE  
 HETLIOZ, TASIMELTEON

**VANSEN PHARMA**

\* VANSEN PHARMA  
 SPECTRACEF, CEFDITOREN PIVOXIL

**VELDANA MEDICAL SA**

\* VELDANA MEDICAL SA  
 ECOZA, ECONAZOLE NITRATE

**VELOXIS PHARMS INC**

\* VELOXIS PHARMACEUTICALS INC  
 ENVARBUS XR, TACROLIMUS

**VERNALIS R AND D LTD**

\* VERNALIS R AND D LTD  
 TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX

**VEROSCIENCE**

\* VEROSCIENCE LLC  
 CYCLOSET, BROMOCRIPTINE MESYLATE

**VERSAPHARM**

\* VERSAPHARM INC  
 CICLOPIROX, CICLOPIROX  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
 DESOXIMETASONE, DESOXIMETASONE  
 ERYTHROMYCIN, ERYTHROMYCIN  
 ETHOSUXIMIDE, ETHOSUXIMIDE  
 RIFAMPIN, RIFAMPIN

**VERSAPHARM INC**

\* VERSAPHARM INC  
 AMINOCAPROIC ACID, AMINOCAPROIC ACID  
 AMINOCAPROIC, AMINOCAPROIC ACID  
 DESOXIMETASONE, DESOXIMETASONE  
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE  
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
 RIFAMPIN, RIFAMPIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\***

- \* VERSAPHARM INC  
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
- \* VERSAPHARM INCORPORATED  
TRANEXAMIC ACID, TRANEXAMIC ACID

**VERTEX PHARMS**

- \* VERTEX PHARMACEUTICALS INC  
KALYDECO, IVACAFTOR

**VERTEX PHARMS INC**

- \* VERTEX PHARMACEUTICALS INC  
KALYDECO, IVACAFTOR  
ORKAMBI, IVACAFTOR

**VERTICAL PHARMS LLC**

- \* VERTICAL PHARMACEUTICALS LLC  
DIVIGEL, ESTRADIOL

**VIB**

- \* VALEANT INTERNATIONAL BERMUDA  
ZOVIRAX, ACYCLOVIR

**VICURON**

- \* VICURON PHARMACEUTICALS INC  
ERAXIS, ANIDULAFUNGIN

**VIFOR FRESENIUS**

- \* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE  
VELPHORO, SUCROFERRIC OXYHYDROXIDE

**VIIV HLTHCARE**

- \* VIIV HEALTHCARE CO  
COMBIVIR, LAMIVUDINE  
EPIVIR, LAMIVUDINE  
EPZICOM, ABACAVIR SULFATE  
LEXIVA, FOSAMPRENAVIR CALCIUM  
RESCRIPTOR, DELAVIRDINE MESYLATE  
RETROVIR, ZIDOVUDINE  
SELZENTRY, MARAVIROC  
TIVICAY, DOLUTEGRAVIR SODIUM  
TRIUMEQ, ABACAVIR SULFATE  
TRIZIVIR, ABACAVIR SULFATE  
ZIAGEN, ABACAVIR SULFATE

**VINTAGE**

- \* VINTAGE PHARMACEUTICALS LLC  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
ACETIC ACID, ACETIC ACID, GLACIAL  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
ALPRAZOLAM, ALPRAZOLAM  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
FOLIC ACID, FOLIC ACID  
GLIMEPIRIDE, GLIMEPIRIDE  
GLYCOPYRROLATE, GLYCOPYRROLATE  
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL  
HYDROCORTISONE, HYDROCORTISONE  
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
LISINAPRIL, LISINAPRIL  
NYSTATIN, NYSTATIN  
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE  
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
PREDNISOLONE, PREDNISOLONE  
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE  
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE  
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE  
RISPERIDONE, RISPERIDONE  
SPIRONOLACTONE, SPIRONOLACTONE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\*****\* VINTAGE PHARMACEUTICALS LLC**

SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
 VALPROIC ACID, VALPROIC ACID  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**VINTAGE PHARMS****\* VINTAGE PHARMACEUTICALS**

ALPRAZOLAM, ALPRAZOLAM  
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN  
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CYCLAFEM 0.5/35, ETHINYL ESTRADIOL  
 DISULFIRAM, DISULFIRAM  
 GILDAGIA, ETHINYL ESTRADIOL  
 GILDESS 24 FE, ETHINYL ESTRADIOL  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 KIMIDESS, DESOGESTREL  
 LEVETIRACETAM, LEVETIRACETAM  
 METHIMAZOLE, METHIMAZOLE  
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**\* VINTAGE PHARMACEUTICALS INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 ALLOPURINOL, ALLOPURINOL  
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 BACLOFEN, BACLOFEN  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 CARISOPRODOL, CARISOPRODOL  
 CLONAZEPAM, CLONAZEPAM  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DEXAMETHASONE, DEXAMETHASONE  
 DIAZEPAM, DIAZEPAM  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 FUROSEMIDE, FUROSEMIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 HYDROCORTISONE, HYDROCORTISONE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN, IBUPROFEN (OTC)  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 LACTULOSE, LACTULOSE  
 LEVETIRACETAM, LEVETIRACETAM  
 LORAZEPAM, LORAZEPAM  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METHOCARBAMOL, METHOCARBAMOL  
 METHYLPREDNISOLONE, METHYLPREDNISOLONE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PERPHENAZINE, PERPHENAZINE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PREDNISONE, PREDNISONE  
 PRIMIDONE, PRIMIDONE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\***

\* VINTAGE PHARMACEUTICALS INC  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SULFASALAZINE, SULFASALAZINE  
 TEMAZEPAM, TEMAZEPAM  
 TORSEMIDE, TORSEMIDE  
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

**VINTAGE PHARMS LLC**

\* VINTAGE PHARMACEUTICALS LLC  
 CYCLAFEM 1/35, ETHINYL ESTRADIOL  
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL  
 DUTASTERIDE, DUTASTERIDE  
 EMOQUETTE, DESOGESTREL  
 FELODIPINE, FELODIPINE  
 GILDESS 1.5/30, ETHINYL ESTRADIOL  
 GILDESS 1/20, ETHINYL ESTRADIOL  
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL  
 GILDESS FE 1/20, ETHINYL ESTRADIOL  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 MEFENAMIC ACID, MEFENAMIC ACID  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MORPHINE SULFATE, MORPHINE SULFATE  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 MYZILRA, ETHINYL ESTRADIOL  
 ORSYTHIA, ETHINYL ESTRADIOL  
 PERCOCET, ACETAMINOPHEN  
 PREVIFEM, ETHINYL ESTRADIOL  
 TRI-PREVIFEM, ETHINYL ESTRADIOL

**VIRTUS PHARM**

\* VIRTUS PHARMACEUTICAL INC  
 ACARBOSE, ACARBOSE

**VISTA PHARMS**

\* VISTA PHARMACEUTICALS INC  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

**VISTAPHARM**

\* VISTAPHARM INC  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 LACTULOSE, LACTULOSE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NYSTATIN, NYSTATIN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PHENYTOIN, PHENYTOIN

**VIVIMED LABS**

\* VIVIMED LABS ALATHUR PRIVATE LTD  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

**VIVUS**

\* VIVUS INC  
 QSYMIA, PHENTERMINE HYDROCHLORIDE  
 STENDRA, AVANAFIL

**VPNA**

\* VALEANT PHARMACEUTICALS NORTH AMERICA  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM

**\*\* W \*\*****WA UNIV SCH MED**

\* WASHINGTON UNIV SCHOOL MEDICINE  
 AMMONIA N 13, AMMONIA N-13

**WARNER CHILCOTT**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\***

\* WARNER CHILCOTT CO LLC  
 LO MINASTRIN FE, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL

\* WARNER CHILCOTT INC  
 LOESTRIN 24 FE, ETHINYL ESTRADIOL  
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL

**WARNER CHILCOTT LLC**

\* WARNER CHILCOTT CO LLC  
 ACTONEL, RISEDRONATE SODIUM  
 ASACOL HD, MESALAMINE  
 ATELVIA, RISEDRONATE SODIUM  
 CHOLEDYL SA, OXTRIPHYLLINE  
 DELZICOL, MESALAMINE  
 ENABLEX, DARIFENACIN HYDROBROMIDE  
 ESTROSTEP FE, ETHINYL ESTRADIOL  
 FEMCON FE, ETHINYL ESTRADIOL  
 FEMHRT, ETHINYL ESTRADIOL  
 FEMTRACE, ESTRADIOL ACETATE  
 LO LOESTRIN FE, ETHINYL ESTRADIOL  
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL  
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL  
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL  
 MINASTRIN 24 FE, ETHINYL ESTRADIOL  
 SARAFEM, FLUOXETINE HYDROCHLORIDE

**WARNER CHILCOTT US**

\* WARNER CHILCOTT US LLC  
 ESTRACE, ESTRADIOL

**WARNER IRELAND**

\* WARNER CHILCOTT IRELAND LTD  
 FEMRING, ESTRADIOL ACETATE

**WATSON LABS**

\* WATSON LABORATORIES  
 FOLIC ACID, FOLIC ACID  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL  
 MICROGESTIN 1/20, ETHINYL ESTRADIOL  
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL  
 MICROGESTIN FE 1/20, ETHINYL ESTRADIOL  
 NORCO, ACETAMINOPHEN  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

\* WATSON LABORATORIES INC  
 ACARBOSE, ACARBOSE  
 AFEDITAB CR, NIFEDIPINE  
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 ALLOPURINOL, ALLOPURINOL  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMOXAPINE, AMOXAPINE  
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
 BACLOFEN, BACLOFEN  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 CAPTOPRIL, CAPTOPRIL  
 CARISOPRODOL, CARISOPRODOL  
 CHLORZOXAZONE, CHLORZOXAZONE  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLONAZEPAM, CLONAZEPAM  
 COL-PROBENECID, COLCHICINE  
 CYCLOSPORINE, CYCLOSPORINE  
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
 DIAZEPAM, DIAZEPAM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\***

\* WATSON LABORATORIES INC  
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE  
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
 ESTAZOLAM, ESTAZOLAM  
 ESTRADIOL, ESTRADIOL  
 ESTROPIPATE, ESTROPIPATE  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GLIPIZIDE, GLIPIZIDE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
 ISRADIPINE, ISRADIPINE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL, LEVONORGESTREL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL  
 LISINOPRIL, LISINOPRIL  
 LORAZEPAM, LORAZEPAM  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOW-OGESTREL-28, ETHINYL ESTRADIOL  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 MEPROBAMATE, MEPROBAMATE  
 METHOCARBAMOL, METHOCARBAMOL  
 METHYLDOPA, METHYLDOPA  
 METHYLPREDNISOLONE, METHYLPREDNISOLONE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 METRONIDAZOLE, METRONIDAZOLE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MINOXIDIL, MINOXIDIL  
 MIRTAZAPINE, MIRTAZAPINE  
 NABUMETONE, NABUMETONE  
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NATEGLINIDE, NATEGLINIDE  
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE  
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
 NIZATIDINE, NIZATIDINE  
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PREDNISOLONE, PREDNISOLONE  
 PREDNISON, PREDNISON  
 PRIMIDONE, PRIMIDONE  
 PROBENECID, PROBENECID  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 QUASENSE, ETHINYL ESTRADIOL  
 QUINIDINE SULFATE, QUINIDINE SULFATE  
 RAMIPRIL, RAMIPRIL  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 SIMVASTATIN, SIMVASTATIN  
 SULFASALAZINE, SULFASALAZINE  
 SULINDAC, SULINDAC  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TELMISARTAN, TELMISARTAN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\***

\* WATSON LABORATORIES INC  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE  
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE  
 TOPIRAMATE, TOPIRAMATE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE  
 TRIMETHOPRIM, TRIMETHOPRIM  
 TRIVORA-28, ETHINYL ESTRADIOL  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 ZOVIA 1/35E-28, ETHINYL ESTRADIOL  
 ZOVIA 1/50E-28, ETHINYL ESTRADIOL

\* WATSON LABS INC  
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**WATSON LABS FLORIDA**

\* WATSON LABORATORIES INC FLORIDA  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**WATSON LABS INC**

\* WATSON LABORATORIES INC  
 ACITRETIN, ACITRETIN  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 AMMONIUM LACTATE, AMMONIUM LACTATE  
 BUDESONIDE, BUDESONIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CELECOXIB, CELECOXIB  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CYCLOSPORINE, CYCLOSPORINE  
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 INDOMETHACIN, INDOMETHACIN  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LEVONORGESTREL, LEVONORGESTREL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 METRONIDAZOLE, METRONIDAZOLE  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
 PROPOFOL, PROPOFOL  
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 TRETINOIN, TRETINOIN  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALSARTAN, VALSARTAN  
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

**WELLSPRING PHARM**

\* WELLSPRING PHARMACEUTICAL CORP  
 DUVOID, BETHANECHOL CHLORIDE

**WELLSTAT THERAP**

\* WELLSTAT THERAPEUTICS CORP  
 VISTOGARD, URIDINE TRIACETATE  
 XURIDEN, URIDINE TRIACETATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\*****WEST WARD PHARM CORP**

\* WEST WARD PHARMACEUTICAL CORP  
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

**WEST-WARD PHARM CORP**

\* WEST-WARD PHARMACEUTICAL CORP  
CEFOTETAN, CEFOTETAN DISODIUM

**WI MEDCL CYCLOTRON**

\* WISCONSIN MEDICAL CYCLOTRON LLC  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**WILSHIRE PHARMS INC**

\* WILSHIRE PHARMACEUTICALS INC  
LAMOTRIGINE, LAMOTRIGINE

**WOCKHARDT**

\* WOCKHARDT AMERICAS INC  
CAPTOPRIL, CAPTOPRIL  
FAMOTIDINE, FAMOTIDINE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

\* WOCKHARDT EU OPERATIONS (SWISS) AG  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
ACETIC ACID, ACETIC ACID, GLACIAL  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
AMOXICILLIN, AMOXICILLIN  
BROMFED-DM, BROMPHENIRAMINE MALEATE  
CARBAMAZEPINE, CARBAMAZEPINE  
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE  
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
CROMOLYN SODIUM, CROMOLYN SODIUM  
CYCLOSPORINE, CYCLOSPORINE  
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE  
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
ERYTHROMYCIN, ERYTHROMYCIN  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
FUROSEMIDE, FUROSEMIDE  
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE  
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
LEVETIRACETAM, LEVETIRACETAM  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
LINDANE, LINDANE  
LITHIUM CITRATE, LITHIUM CITRATE  
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
LORATADINE, LORATADINE (OTC)  
MEGESTROL ACETATE, MEGESTROL ACETATE  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
NYSTATIN, NYSTATIN  
OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE  
PHENYTOIN, PHENYTOIN  
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
PREDNISOLONE, PREDNISOLONE  
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE  
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE  
SELENIUM SULFIDE, SELENIUM SULFIDE  
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
VALPROIC ACID, VALPROIC ACID

\* WOCKHARDT LTD  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\*****\* WOCKHARDT LTD**

AZITHROMYCIN, AZITHROMYCIN  
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM  
 CEFOTAXIME, CEFOTAXIME SODIUM  
 CEFPROZIL, CEFPROZIL  
 CEFTAZIDIME, CEFTAZIDIME  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LISINAPRIL, LISINAPRIL  
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
 NIACIN, NIACIN  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RISPERIDONE, RISPERIDONE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE  
 ZONISAMIDE, ZONISAMIDE

**WOCKHARDT BIO AG**

\* WOCKHARDT BIO AG  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**WOCKHARDT EU OPERATN**

\* WOCKHARDT EU OPERATIONS SWISS AG  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 DEXAMETHASONE, DEXAMETHASONE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**WOCKHARDT LTD**

\* WOCKHARDT LTD  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 ENTACAPONE, ENTACAPONE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 LAMOTRIGINE, LAMOTRIGINE  
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**WOCKHARDT USA**

\* WOCKHARDT USA INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\***

- \* WOCKHARDT USA INC  
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
- \* WOCKHARDT USA LLC  
ENALAPRIL MALEATE, ENALAPRIL MALEATE  
LANSOPRAZOLE, LANSOPRAZOLE

**WRASER PHARMS**

- \* WRASER PHARMACEUTICALS LLC  
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

**WRASER PHARMS LLC**

- \* WRASER PHARMACEUTICALS LLC  
TREZIX, ACETAMINOPHEN

**WUSM CYCLOTRON**

- \* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**WYETH PHARMS**

- \* WYETH PHARMACEUTICALS INC SUB PFIZER INC  
LO/OVRAL-28, ETHINYL ESTRADIOL

**WYETH PHARMS INC**

- \* WYETH PHARMACEUTICALS INC  
BOSULIF, BOSUTINIB MONOHYDRATE  
CORDARONE, AMIODARONE HYDROCHLORIDE  
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE  
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE  
PREMARIN, ESTROGENS, CONJUGATED  
PREMPHASE 14/14, ESTROGENS, CONJUGATED  
PREMPRO, ESTROGENS, CONJUGATED  
PRISTIQ, DESVENLAFAXINE SUCCINATE  
PROTONIX IV, PANTOPRAZOLE SODIUM  
PROTONIX, PANTOPRAZOLE SODIUM  
TRECATOR, ETHIONAMIDE  
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM  
ZOSYN, PIPERACILLIN SODIUM

**WYETH PHARMS PFIZER**

- \* WYETH PHARMACEUTICALS INC WHOLLY OWNED SUB PFIZER INC  
DUAVEE, BAZEDOXIFENE ACETATE

**\*\* X \*\*****X GEN PHARMS**

- \* X GEN PHARMACEUTICALS INC  
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
AMPHOTERICIN B, AMPHOTERICIN B  
BACIIM, BACITRACIN  
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
LEVETIRACETAM, LEVETIRACETAM  
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
NEO-FRADIN, NEOMYCIN SULFATE  
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE  
NEOMYCIN SULFATE, NEOMYCIN SULFATE  
NYSTATIN, NYSTATIN  
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE  
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

**X-GEN PHARMS**

- \* X-GEN PHARMACEUTICALS INC  
PHENYTOIN SODIUM, PHENYTOIN SODIUM  
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**X-GEN PHARMS INC**

- \* X-GEN PHARMACEUTICALS INC  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE  
TRANEXAMIC ACID, TRANEXAMIC ACID

**XELLIA PHARMS APS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* X \*\***

- \* XELLIA PHARMACEUTICALS APS
  - BACITRACIN, BACITRACIN
  - COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
  - POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
  - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
  - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**XENOPORT INC**

- \* XENOPORT INC
  - HORIZANT, GABAPENTIN ENACARBIL

**XSPIRE**

- \* XSPIRE LLC
  - NALFON, FENOPROFEN CALCIUM

**XTTRIUM**

- \* XTTRIUM LABORATORIES INC
  - CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
  - EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

**\*\* Y \*\*****YAOPHARMA CO LTD**

- \* YAOPHARMA CO LTD
  - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**YUNG SHIN PHARM**

- \* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
  - CEFACTOR, CEFACTOR
  - CEPHALEXIN, CEPHALEXIN

**\*\* Z \*\*****ZACH SYSTEM SPA**

- \* ZACH SYSTEM SPA
  - OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE

**ZACH SYSTEMS**

- \* ZACH SYSTEMS SPA
  - DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  - DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE

**ZAMBON SPA**

- \* ZAMBON SPA ITALY
  - MONUROL, FOSFOMYCIN TROMETHAMINE

**ZYDUS HLTHCARE**

- \* ZYDUS HEALTHCARE USA LLC
  - LANSOPRAZOLE, LANSOPRAZOLE
  - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**ZYDUS PHARMS USA**

- \* ZYDUS PHARMACEUTICALS USA INC
  - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  - ATENOLOL, ATENOLOL
  - AZATHIOPRINE, AZATHIOPRINE
  - BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
  - BENZONATATE, BENZONATATE
  - CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  - HALOPERIDOL, HALOPERIDOL
  - LAMOTRIGINE, LAMOTRIGINE
  - MELOXICAM, MELOXICAM
  - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  - NAPROXEN, NAPROXEN
  - PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
  - PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  - RAMIPRIL, RAMIPRIL
  - RIBAVIRIN, RIBAVIRIN
  - RISPERIDONE, RISPERIDONE
  - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
  - SIMVASTATIN, SIMVASTATIN
  - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  - WARFARIN SODIUM, WARFARIN SODIUM



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* Z \*\***

\* ZYDUS PHARMACEUTICALS USA INC  
ZONISAMIDE, ZONISAMIDE

**ZYDUS PHARMS USA INC**

\* ZYDUS PHARMACEUTICALS USA INC  
ACETAZOLAMIDE, ACETAZOLAMIDE  
ACYCLOVIR, ACYCLOVIR  
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
ANASTROZOLE, ANASTROZOLE  
BICALUTAMIDE, BICALUTAMIDE  
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE  
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
CARVEDILOL, CARVEDILOL  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
DIPYRIDAMOLE, DIPYRIDAMOLE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
ETODOLAC, ETODOLAC  
ETOMIDATE, ETOMIDATE  
FINASTERIDE, FINASTERIDE  
GABAPENTIN, GABAPENTIN  
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
INDOMETHACIN, INDOMETHACIN  
IRBESARTAN, IRBESARTAN  
LAMOTRIGINE, LAMOTRIGINE  
LEVETIRACETAM, LEVETIRACETAM  
LEVOFLOXACIN, LEVOFLOXACIN  
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
OMEPRAZOLE, OMEPRAZOLE  
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
POTASSIUM CITRATE, POTASSIUM CITRATE  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
RISPERIDONE, RISPERIDONE  
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
SIROLIMUS, SIROLIMUS  
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
TELMISARTAN, TELMISARTAN  
TOPIRAMATE, TOPIRAMATE  
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
ZOLMITRIPTAN, ZOLMITRIPTAN

**APPENDIX C****UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL, FOAM	OIL/DROPS
AEROSOL, METERED	OINTMENT
CAPSULE	OINTMENT, AUGMENTED
CAPSULE, DELAYED REL PELLETS	PASTE
CAPSULE, DELAYED RELEASE	PATCH
CAPSULE, EXTENDED RELEASE	PELLET
CLOTH	POWDER
CONCENTRATE	POWDER, EXTENDED RELEASE
CREAM	POWDER, METERED
CREAM, AUGMENTED	RING
ELIXIR	SHAMPOO
EMULSION	SOLUTION
ENEMA	SOLUTION FOR SLUSH
FILM	SOLUTION, GEL FORMING/DROPS
FILM, EXTENDED RELEASE	SOLUTION, METERED
FOR SOLUTION	SOLUTION/DROPS
FOR SUSPENSION	SPONGE
FOR SUSPENSION, DELAYED RELEASE	SPRAY
FOR SUSPENSION, EXTENDED RELEASE	SPRAY, METERED
GAS	SUPPOSITORY
GEL	SUSPENSION
GEL, AUGMENTED	SUSPENSION, EXTENDED RELEASE
GEL, METERED	SUSPENSION/DROPS
GRANULE	SWAB
GRANULE, DELAYED RELEASE	SYRUP
GUM, CHEWING	SYSTEM
IMPLANT	SYSTEM, EXTENDED RELEASE
INHALANT	TABLET
INJECTABLE	TABLET, CHEWABLE
INJECTABLE, LIPID COMPLEX	TABLET, COATED PARTICLES
INJECTABLE, LIPOSOMAL	TABLET, DELAYED RELEASE
INSERT	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING
INSERT, EXTENDED RELEASE	TABLET, EFFERVESCENT
INTRAUTERINE DEVICE	TABLET, EXTENDED RELEASE
JELLY	TABLET, FOR SUSPENSION
LIQUID	TABLET, ORALLY DISINTEGRATING
LOTION	TAPE
LOTION, AUGMENTED	TROCHE/LOZENGE
LOTION/SHAMPOO/OIL	
OIL	

Note: Terms comprise currently marketed products

**APPENDIX C****UNIFORM TERMS*****ROUTES OF ADMINISTRATION***

BUCCAL	IONTOPHORESIS
DENTAL	IRRIGATION
ENDOCERVICAL	IV (INFUSION)
ENTERAL	N/A
FOR RX COMPOUNDING	NASAL
IMPLANTATION	OPHTHALMIC
INHALATION	ORAL
INJECTION	ORAL-21
INTRA-ANAL	ORAL-28
INTRACRANIAL	OTIC
INTRADERMAL	PERFUSION, CARDIAC
INTRAMUSCULAR	PERIODONTAL
INTRAOCULAR	RECTAL
INTRAPERITONEAL	SPINAL
INTRAPLEURAL	SUBCUTANEOUS
INTRATHECAL	SUBLINGUAL
INTRATRACHEAL	TOPICAL
INTRAUTERINE	TRANSDERMAL
INTRAVENOUS	TRANSMUCOSAL
INTRAVESICAL	URETHRAL
INTRAVIDEAL	VAGINAL

Note: Terms comprise currently marketed products

**APPENDIX C**

**UNIFORM TERMS**

**ABBREVIATIONS**

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SC	SUBCUTANEOUS
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

## PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act, those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act, and those drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed by the trade name. Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the FD&C Act. It does not prevent the submission or approval of a second 505(b)(1) application except in the case of Orphan Drug exclusivity. Applications qualifying for periods of exclusivity include:

- (1) A new drug application approved after September 24, 1984, for a drug product (including an ester or salt of the active ingredient) of which has never been approved in any other new drug application under Section 505 (b) of the FD&C Act. No subsequent ANDA or application described in Section 505(b)(2) of the FD&C Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.
- (2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the FD&C Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications or use, this does not preclude the approval of an ANDA or 505(b)(2) application not covered by the exclusivity.
- (3) A supplement to a new drug application for a drug containing a previously approved active ingredient including (any ester or salt of the active ingredient) approved after September 24, 1984, that contains

reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent ANDA or 505(b)(2) application for a change approved in the supplement may not be *made effective* for *three years* from the date of approval of the original supplement.

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using FDA Form 3524a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the Agency within 30 days of approval on FDA Form 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement". Patent information on unapproved applications or on patents beyond the scope of the FD&C Act (i.e., process or manufacturing patents) will not be published. FDA Form 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents which include formulation/composition patents; use patents for a particular approved indication or method of using the product; and certain other patents as detailed on FDA Form 3542. This information, as provided by the sponsor on FDA Form 3542, will be published as described above.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the QI Program Supplemental Funding Act (Public Law 110-379) (QI Act). A guidance for industry on this subject is available at <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm080566.pdf>.

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published daily in the [Electronic Orange Book Query](#). The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977	001 6294540	May 14, 2018	DS DP U-65		D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978	001 6294540 6641843	May 14, 2018 Feb 04, 2019	DS DP U-65 DP		D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551	001 5905082 5905082*PED 6294540 6294540*PED 6417191 6417191*PED 8129385	May 18, 2016 Nov 18, 2016 May 14, 2018 Nov 14, 2018 Mar 28, 2016 Sep 28, 2016 Oct 05, 2027	DS DP  DS DP U-1572  DP U-1572  DS DP		NCE	Aug 12, 2018
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652	001 5905082 6294540 6417191 6417191*PED	May 18, 2016 May 14, 2018 Mar 28, 2016 Sep 28, 2016	DS DP DS DP U-257 DP U-257			
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N 021205	001 5905082 6294540 6417191	May 18, 2016 May 14, 2018 Mar 28, 2016	DS DP U-248 DS DP U-65 DP U-248			
<u>ABARELIX - PLENAXIS</u>						
N 021320	001 5843901 5968895 6180608 6699833	Dec 01, 2015 Dec 11, 2016 Dec 11, 2016 Dec 11, 2016	DS DP DP DP U-549 DP			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	001 5604213 5604213 8822438 8822438	Dec 13, 2016 Dec 13, 2016 Aug 24, 2027 Aug 24, 2027	DS DP U-1126 DS DP U-1314 U-1579 U-1580		I-663 NCE	Dec 10, 2015 Apr 28, 2016
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450	001 6028222 6992218	Aug 05, 2017 Jun 06, 2021	DP DP			
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N 020802	001 5972916	Jul 14, 2017	U-296			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031	001 6488962 7976870 8372432 8377453 8394408 8597681 8658631 8668929 8741885 8980319 8992975 9050335	Jun 20, 2020 Jun 01, 2027 Mar 11, 2029 Nov 19, 2029 Mar 11, 2029 Dec 21, 2030 May 16, 2032 Mar 11, 2029 May 16, 2032 Dec 21, 2030 May 16, 2032 May 16, 2032	DP U-1498 DP U-1499 DP U-1499 DP DP DP U-1499 DP U-1499 DP DP DP		NP	Mar 11, 2017
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539	001 8148356 8399445 8653061 8722738	May 21, 2026 Aug 24, 2025 Aug 24, 2025 Apr 06, 2032	DP U-1373 U-1373 U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001 5840279 6071498 6681768	Jun 21, 2016 Jun 21, 2016 Aug 07, 2022	DP DP DP		NCE	Jul 23, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	6750226	Sep 05, 2020	DS DP U-1264		
		7078412	Jul 16, 2020	DS DP U-1263		
		8051851	Apr 22, 2027	DP		
		9056100	Jul 07, 2020	DP U-1263		
<u>ACYCLOVIR - SITAVIG</u>						
N 203791	001	8592434	Jun 16, 2030	DP U-1460	NP	Apr 12, 2016
		8747896	Jun 03, 2027	DP U-1460		
		8791127	Mar 23, 2027	DP U-1460		
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436	001	6514980	Jan 24, 2019	DP U-1006	NPP	Jan 22, 2017
		6514980	Jan 24, 2019	DP U-1484		
		7223387	Jul 24, 2021	DP U-1006		
		7223387	Jul 24, 2021	DP U-1484		
		RE39264	Aug 02, 2016	DP U-1006		
		RE39264	Aug 02, 2016	DP U-1484		
<u>ADAPALENE - DIFFERIN</u>						
N 021753	001	7579377	Feb 23, 2025	U-818		
		7737181	Aug 29, 2024	DP		
		7834060	Mar 12, 2023	U-1078		
		7838558	Mar 12, 2023	DP		
		7868044	Mar 12, 2023	U-1078		
		8703820	Mar 12, 2023	U-1078		
<u>ADAPALENE - DIFFERIN</u>						
N 022502	001	7998467	May 31, 2028	DP U-1078		
		8435502	Sep 15, 2026	DP U-1078		
		8709392	Sep 15, 2026	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320	001	7820186	Nov 23, 2025	DP	NPP	Feb 01, 2016
		7964202	Sep 01, 2024	DP U-1078		
		8071644	Jul 18, 2027	DP U-1078		
		8080537	Jul 18, 2027	U-1078		
		8105618	Dec 23, 2022	U-1078		
		8129362	Jul 18, 2027	U-1078		
		8241649	Dec 23, 2022	DP		
		8445543	Jul 12, 2027	U-1078		
		8809305	Dec 23, 2022	U-1078		
		8936800	Dec 23, 2022	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917	001	8445543	Jul 12, 2027	U-1078	NP	Jul 15, 2018
		8703820	Mar 12, 2023	U-1078		
		8729127	Mar 12, 2023	U-1078		
		8785420	Dec 23, 2022	U-1078		
		8909305	Dec 23, 2022	U-1078		
		8936800	Dec 23, 2022	DP U-1078		
<u>ADEFОВIR DIPIVOXIL - HEPSERA</u>						
N 021449	001	6451340	Jul 23, 2018	DS DP U-470		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	001	6251912	Jul 29, 2018	DS DP U-1067	NCE	Jul 12, 2018
		8426586	Oct 10, 2029	DS DP	ODE	Jul 12, 2020
		8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	002	6251912	Jul 29, 2018	DS DP U-1067	NCE	Jul 12, 2018
		8426586	Oct 10, 2029	DS DP	ODE	Jul 12, 2020
		8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003	6251912	Jul 29, 2018	DS DP U-1067	NCE	Jul 12, 2018
		8426586	Oct 10, 2029	DS DP	ODE	Jul 12, 2020



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003	8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N 020760	001	6080756	Jul 05, 2016			
		6194429	Jul 23, 2018			
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N 020760	002	6080756	Jul 05, 2016			
		6194429	Jul 23, 2018			
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899	001	6723303	Apr 20, 2021	DP	M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N 020503	001	5775321	Jul 07, 2015	DP		
		6006745	Dec 28, 2016	DP		
<u>ALBUTEROL SULFATE - ACCUNEE</u>						
N 020949	001	6702997	Dec 28, 2021		U-558	
<u>ALBUTEROL SULFATE - ACCUNEE</u>						
N 020949	002	6702997	Dec 28, 2021		U-558	
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983	001	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6558651	Dec 19, 2016	DP	U-716	
		6743413	Jun 01, 2021		U-716	
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457	001	6446627	Dec 18, 2017	DP		
		7105152	Sep 12, 2023	DP		
		7566445	Jun 04, 2017	DP		
		8132712	Sep 07, 2028	DP		
		8834849	Jun 04, 2017	DP		
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	6446627	Dec 18, 2017	DP	NP	Mar 12, 2018
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEE</u>						
N 020950	001	6632842	Dec 28, 2021		U-532	
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747	001	5964416	Oct 04, 2016	DP		
		6149054	Dec 19, 2016	DP		
		6176442	Oct 04, 2016	DP		
		6453795	Dec 05, 2016	DP		
		6726124	Oct 04, 2016	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747	001	6846413	Aug 28, 2018	DP		
		6977042	Aug 28, 2018	DP		
		6988496	Feb 23, 2020	DP		
		7104470	Oct 04, 2016	DP		
		7246615	May 31, 2016	DP		
		7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP		
		7802568	Feb 26, 2019	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8733341	Dec 16, 2029	DP		
		9027967	Mar 31, 2027	DP		
<u>ALCAFTADINE - LASTACAPT</u>						
N 022134	001	5468743	Apr 20, 2016	DS DP	NCE	Jul 28, 2015
		8664215	Dec 23, 2027	U-1493		
<u>ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD</u>						
N 021074	001	5897031	Jun 21, 2016			
		7081246	Aug 03, 2016	DP		
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434	001	9126931	May 29, 2031	DS	NCE	Dec 11, 2020
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N 021575	001	5994329	Jul 17, 2018		Y	
		6015801	Jul 17, 2018		Y	
		6225294	Jul 17, 2018		Y	
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344	001	7488496	Aug 11, 2023	DS DP		
		7964212	Mar 06, 2023	DS DP		
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N 021762	001	5994329	Jul 17, 2018	U-647	Y	
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N 021287	001	6149940	Aug 22, 2017			
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985	001	5559111	Jul 21, 2018	DS DP U-3		
		8617595	Feb 19, 2026	DP		
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985	002	5559111	Jul 21, 2018	DS DP U-3		
		8617595	Feb 19, 2026	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	001	5559111	Jul 21, 2018	DS DP U-3		
		8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	002	5559111	Jul 21, 2018	DS DP U-3		
		8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	003	5559111	Jul 21, 2018	DS DP U-3		
		8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	004	5559111	Jul 21, 2018	DS DP U-3		
		8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	001	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	002	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	003	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	004	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	005	5559111	Jul 21, 2018	DS DP U-3		
		8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107	001	5559111	Jul 21, 2018	DS DP U-3		
		8618172	Jul 13, 2028	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107	002	5559111	Jul 21, 2018	DS DP U-3		
		8618172	Jul 13, 2028	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107	003	5559111	Jul 21, 2018	DS DP U-3		
		8618172	Jul 13, 2028	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107	004	5559111	Jul 21, 2018	DS DP U-3		
		8618172	Jul 13, 2028	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	001	5559111	Jul 21, 2018	DS DP U-3		
		8168616	Jul 03, 2026	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	002	5559111	Jul 21, 2018	DS DP U-3		
		8168616	Jul 03, 2026	DP		
<u>ALITRETINOIN - PANRETIN</u>						
N 020886	001	5932622	Aug 03, 2016	U-562		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	001	6150383	Jun 19, 2016	U-1330	NCE	Jan 25, 2018
		6211205	Jun 19, 2016	U-1331		
		6303640	Aug 09, 2016	U-1332		
		6303661	Apr 24, 2017	U-1333		
		6329404	Jun 19, 2016	DP U-1334		
		6890898	Feb 02, 2019	U-1335		
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		
		7807689	Jun 27, 2028	DS DP U-1337		
		8173663	Mar 15, 2025	U-1338		
		8288539	Mar 15, 2025	DS		
		8697125	Jan 22, 2029	DP		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	002	6150383	Jun 19, 2016	U-1330	NCE	Jan 25, 2018
		6211205	Jun 19, 2016	U-1331		
		6303640	Aug 09, 2016	U-1332		
		6303661	Apr 24, 2017	U-1333		
		6329404	Jun 19, 2016	DP U-1334		
		6890898	Feb 02, 2019	U-1335		
		7078381	Feb 02, 2019	U-1335		
		7459428	Feb 02, 2019	U-1336		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEK</u>						
N 021107 001	6284770	Oct 05, 2018	U-405			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEK</u>						
N 021107 002	6284770	Oct 05, 2018	U-405			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 003	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 004	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPROSTADIL - MUSE</u>						
N 020700 001	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 002	5886039	Mar 23, 2016	DP U-155			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPROSTADIL - MUSE</u>						
N 020700	003	5886039	Mar 23, 2016	DP U-155		
<u>ALPROSTADIL - MUSE</u>						
N 020700	004	5886039	Mar 23, 2016	DP U-155		
<u>ALVIMOPAN - ENTEREG</u>						
N 021775	001	5250542	Mar 29, 2016	DS DP U-878	M-128	Oct 18, 2016
		6469030	Nov 29, 2020	U-879		
		8112290	Jul 31, 2030	U-1443		
		8645160	Jun 18, 2029	U-1485		
		8946262	Feb 12, 2030	U-1655		
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081	001	5840722	Nov 24, 2015	U-821	I-716	Oct 02, 2018
		5840722	Nov 24, 2015	U-1297		
		7109205	Oct 07, 2015	DS DP		
		7601730	Oct 07, 2015	U-1080		
		8349843	Oct 07, 2015	DS DP		
		8377933	Dec 11, 2027	U-1754		
		RE42462	Jul 29, 2018	DS		
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081	002	5840722	Nov 24, 2015	U-821	I-716	Oct 02, 2018
		5840722	Nov 24, 2015	U-1297		
		7109205	Oct 07, 2015	DS DP		
		7601730	Oct 07, 2015	U-1080		
		8349843	Oct 07, 2015	DS DP		
		8377933	Dec 11, 2027	U-1754		
		RE42462	Jul 29, 2018	DS		
<u>AMIFOSTINE - ETHYOL</u>						
N 020221	001	5994409	Dec 08, 2017	U-305		
<u>AMIFOSTINE - ETHYOL</u>						
N 020221	002	5994409	Dec 08, 2017	U-305		
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965	001	5954703	Oct 31, 2017	U-289		
		6709446	May 01, 2018	U-289		
		7723910	Jun 17, 2019	U-289		
		8216289	May 01, 2018	U-289		
		8758418	May 01, 2018	U-289		
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	001	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	002	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	003	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	001	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	002	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	003	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	001	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	002	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	003	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	004	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	005	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	006	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	007	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	008	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	009	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	010	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	011	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	002	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	003	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	004	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	005	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	006	6162802	Dec 19, 2017	DS DP U-185		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	007	6162802	Dec 19, 2017	DS DP U-185		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	001	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	002	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	003	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	004	5616599	Apr 25, 2016	DS DP U-3		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	005 5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	001 6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	002 6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	003 6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	004 6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	005 6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100	001 5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100	002 5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100	003 5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100	004 5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	001 6696481	Apr 15, 2023	DS DP U-3			
	7846961	Oct 05, 2029	DS DP U-3			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	002 6696481	Apr 15, 2023	DS DP U-3			
	7846961	Oct 05, 2029	DS DP U-3			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	003 6696481	Apr 15, 2023	DS DP U-3			
	7846961	Oct 05, 2029	DS DP U-3			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	002 6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	003 6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	004 6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	005	6294197	Jun 18, 2017	DP U-3		
		6395728	Jul 08, 2019	DP		
<u>AMOXICILLIN - MOXATAG</u>						
N 050813	001	6544555	Oct 13, 2020	DS DP U-897		
		6669948	Oct 13, 2020	DS DP U-897		
		6723341	Oct 13, 2020	DS DP U-897		
		8299052	May 07, 2027	U-1304		
		8357394	Dec 08, 2026	DP		
		8778924	Dec 08, 2026	DS DP U-897		
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785	001	6746692	Apr 04, 2020	DP		
		6783773	Apr 04, 2020	DP		
		6878386	Apr 04, 2020	U-926		
		7217430	Apr 04, 2020	DP U-926		
		7250176	Apr 04, 2020	U-926		
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147	001	8062667	Mar 29, 2029	DP	NP	Oct 19, 2018
		8597684	Mar 15, 2027	DP		
		8747902	Mar 15, 2027	DP		
		8883217	Mar 15, 2027	DP		
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N 011522	007	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N 011522	008	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N 011522	009	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N 011522	010	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N 011522	011	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N 011522	012	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N 011522	013	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N 021303	001	6322819	Oct 21, 2018			
		6605300	Oct 21, 2018			
		RE41148	Oct 21, 2018	DP		
		RE42096	Oct 21, 2018	DP		
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N 021303	002	6322819	Oct 21, 2018			
		6605300	Oct 21, 2018			
		RE41148	Oct 21, 2018	DP		
		RE42096	Oct 21, 2018	DP		
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N 021303	003	6322819	Oct 21, 2018			
		6605300	Oct 21, 2018			
		RE41148	Oct 21, 2018	DP		
		RE42096	Oct 21, 2018	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N 021303 003	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N 021303 004	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N 021303 005	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N 021303 006	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHOTERICIN B - ABELCET</u>						
N 050724 001	6406713	Jun 18, 2019	DS			
<u>AMPHOTERICIN B - AMBISOME</u>						
N 050740 001	5874104	Feb 23, 2016	DP U-922			
	5965156	Oct 12, 2016	DP U-922			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 001	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 002	6730679	Nov 11, 2017	DP			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 001	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 002	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1501		I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1167		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
	6967208	Feb 03, 2023	DS DP U-1729			
	6967208	Feb 03, 2023	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1200		NCE	Dec 28, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155	002	6967208	Feb 03, 2023	DS DP U-1301		
		6967208	Feb 03, 2023	DS DP U-1302		
		6967208	Feb 03, 2023	DS DP U-1323		
<u>APREMILAST - OTEZLA</u>						
N 205437	001	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
		9018243	Mar 19, 2023	U-1505		
		9018243	Mar 19, 2023	U-1595		
<u>APREMILAST - OTEZLA</u>						
N 205437	002	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
		9018243	Mar 19, 2023	U-1505		
		9018243	Mar 19, 2023	U-1595		
<u>APREMILAST - OTEZLA</u>						
N 205437	003	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
		9018243	Mar 19, 2023	U-1505		
		9018243	Mar 19, 2023	U-1595		
<u>APREPITANT - EMEND</u>						
N 021549	001	6096742	Jul 01, 2018	DS DP U-745	NPP	Aug 28, 2018
		6096742	Jul 01, 2018	DS DP U-1743		
		6096742	Jul 01, 2018	DS DP U-1744		
		8258132	Sep 26, 2027	DP U-901		
		8258132	Sep 26, 2027	DP U-1743		
<u>APREPITANT - EMEND</u>						
N 021549	002	6096742	Jul 01, 2018	DS DP U-745	NPP	Aug 28, 2018
		6096742	Jul 01, 2018	DS DP U-1743		
		6096742	Jul 01, 2018	DS DP U-1744		
		8258132	Sep 26, 2027	DP U-901		
		8258132	Sep 26, 2027	DP U-1743		
<u>APREPITANT - EMEND</u>						
N 021549	003	6096742	Jul 01, 2018	DS DP U-745	NPP	Aug 28, 2018
		6096742	Jul 01, 2018	DS DP U-1743		
		6096742	Jul 01, 2018	DS DP U-1744		
		8258132	Sep 26, 2027	DP U-901		
		8258132	Sep 26, 2027	DP U-1743		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N 207865	001				NPP	Aug 28, 2018
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912	001	6040344	Nov 12, 2016	DS		
		6472563	Nov 09, 2021	DS		
		6667344	Jun 22, 2021	DP		
		6720453	Nov 09, 2021	DS		
		6814953	Jun 22, 2021		U-793	
		7145036	Nov 09, 2021	DS		
		7348362	Jun 22, 2021	DP	U-793	
		7462645	Jun 22, 2021		U-793	
		7465756	Jun 22, 2021	DP		
		7473710	Jun 22, 2021		U-793	
		7541385	Jun 22, 2021		U-793	
		8110706	Nov 09, 2021	DP		
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434	001	7589106	Sep 26, 2027	DP	U-1163	
		7687516	Sep 26, 2027	DP	U-1164	
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	001	7053092	Jan 28, 2022		U-839	I-700 Dec 12, 2017
		8017615	Jun 16, 2024	DP		M-137 Jun 09, 2017
		8017615*PED	Dec 16, 2024			ODE Dec 12, 2021
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022		U-1492	
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027		U-1529	
		9089567	Jan 28, 2022		U-543	
		9125939	Jul 28, 2026		U-1749	
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	002	7053092	Jan 28, 2022		U-839	I-700 Dec 12, 2017
		8017615	Jun 16, 2024	DP		M-137 Jun 09, 2017
		8017615*PED	Dec 16, 2024			ODE Dec 12, 2021
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022		U-1492	
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027		U-1529	
		9089567	Jan 28, 2022		U-543	
		9125939	Jul 28, 2026		U-1749	
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	003	7053092	Jan 28, 2022		U-839	I-700 Dec 12, 2017
		8017615	Jun 16, 2024	DP		M-137 Jun 09, 2017
		8017615*PED	Dec 16, 2024			ODE Dec 12, 2021
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022		U-1492	
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027		U-1529	
		9089567	Jan 28, 2022		U-543	
		9125939	Jul 28, 2026		U-1749	
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	004	7053092	Jan 28, 2022		U-839	I-700 Dec 12, 2017
		8017615	Jun 16, 2024	DP		M-137 Jun 09, 2017
		8017615*PED	Dec 16, 2024			ODE Dec 12, 2021
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022		U-1492	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	6977257	Apr 24, 2022	DP		I-700	Dec 12, 2017
	6977257*PED	Oct 24, 2022			M-137	Jun 09, 2017
	7053092	Jan 28, 2022		U-839	ODE	Dec 12, 2021
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 003	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021866 001	7115587	Jul 21, 2024	DP	U-764	I-700	Dec 12, 2017
	7115587*PED	Jan 21, 2025			M-137	Jun 09, 2017
	7550445	Jul 21, 2024	DP		ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024		U-543	NDF	Feb 28, 2016
	8030313	Oct 19, 2024		U-1632		
	8338427	Mar 15, 2025	DP	U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP	U-1530		
	8759351	Aug 06, 2023	DP	U-1633		
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022		U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024		U-543	NDF	Feb 28, 2016
	8030313	Oct 19, 2024		U-1632		
	8338427	Mar 15, 2025	DP	U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP	U-1530		
	8759351	Aug 06, 2023	DP	U-1633		
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022		U-543		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024	U-543		NDF	Feb 28, 2016
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024	U-543		NDF	Feb 28, 2016
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
N 022268 001					ODE	Apr 07, 2016
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	8865187	Mar 23, 2022	DP			
	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
<u>ASPIRIN; DIPYRIDAMOLE - AGGRENOL</u>						
N 020884 001	6015577	Jan 18, 2017	U-302			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			NPP	Sep 24, 2018
	6087383	Dec 21, 2018	DS DP		PED	Dec 02, 2017
	6087383*PED	Jun 21, 2019			PED	Mar 24, 2019

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353	001	5849911	Jun 20, 2017	DS DP U-167		
		5849911*PED	Dec 20, 2017			
		6087383	Dec 21, 2018	DS DP		
		6087383*PED	Jun 21, 2019			
		8148374	Sep 03, 2029	DS DP U-1279		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	001	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	002	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	003	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	004	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	005	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	006	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	007	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	008	5658590	Nov 26, 2016	U-494		
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	001	5969156	Jul 08, 2016	DS		
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	002	5969156	Jul 08, 2016	DS		
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	003	5969156	Jul 08, 2016	DS		
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	004	5969156	Jul 08, 2016	DS		
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	001	5969156	Jul 08, 2016	DS	NC	May 03, 2016
		5969156*PED	Jan 08, 2017			
		RE42461	Oct 25, 2016	DS DP U-1400		
		RE42461*PED	Apr 25, 2017			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	002	5969156	Jul 08, 2016	DS	NC	May 03, 2016
		5969156*PED	Jan 08, 2017			
		RE42461	Oct 25, 2016	DS DP U-1400		
		RE42461*PED	Apr 25, 2017			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	003	5969156	Jul 08, 2016	DS	NC	May 03, 2016
		5969156*PED	Jan 08, 2017			
		RE42461	Oct 25, 2016	DS DP U-1400		
		RE42461*PED	Apr 25, 2017			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	004	5969156	Jul 08, 2016	DS	NC	May 03, 2016
		5969156*PED	Jan 08, 2017			
		RE42461	Oct 25, 2016	DS DP U-1400		
		RE42461*PED	Apr 25, 2017			
<u>ATOVAQUONE - MEPRON</u>						
N 020500	001	6649659	Jul 10, 2016	DS DP U-69		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Sep 13, 2020	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Sep 13, 2020	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Sep 13, 2020	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
	8791140	Aug 05, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
	8791140	Aug 05, 2030	DS			
<u>AZELAIC ACID - FINACEA</u>						
N 021470 001	6534070	Nov 18, 2018				
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
	7700076	Sep 18, 2027	DP			
	8435498	Mar 01, 2024	U-1727			
	8722021	Oct 24, 2023	DP			
	8900554	Oct 24, 2023	DP			
	9211259	Jan 26, 2029	U-1796			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8071073	Jun 04, 2028	DP		M-129	Aug 30, 2016
	8518919	Nov 22, 2025	U-1430		NPP	Aug 30, 2016
					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	8071073	Jun 04, 2028	DP		M-129	Aug 30, 2016
	8518919	Nov 22, 2025	U-1430		NPP	Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	7157584	May 22, 2025	DS		NCE	Feb 25, 2016
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	7157584	May 22, 2025	DS		NCE	Feb 25, 2016
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	7157584	May 22, 2025	DS		NCE	Feb 25, 2016
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
	9169238	Feb 25, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	7157584	May 22, 2025	DS		NCE	Feb 25, 2016
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
	9169238	Feb 25, 2030	DP			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050693 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 002	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050711 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050730 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050733 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050784 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZMAX</u>						
N 050797 001	6068859	May 30, 2017	DP			
	6268489	Jul 31, 2018	DS			
	6984403	Feb 14, 2024	DP U-282			
	7887844	Feb 14, 2024	DP			
<u>AZITHROMYCIN - AZASITE</u>						
N 050810 001	6159458	Nov 04, 2017	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	7208141	Dec 20, 2021	DP U-1031		ODE	Feb 22, 2017
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
	8399496	Dec 20, 2021	DP U-1377			
<u>BACLOFEN - KEMSTRO</u>						
N 021589 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BACLOFEN - KEMSTRO</u>						
N 021589 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610 001	7452872	Aug 24, 2026	U-141			
	7625884	Aug 24, 2026	U-141			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	6197341	Mar 13, 2018	DP U-1229			
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
	8497256	Jun 23, 2031	U-1229			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001	5998402	Apr 04, 2017	DS DP U-594	NP	Oct 03, 2016
		6479535	May 06, 2019	DP U-594		
		6479535	May 06, 2019	DP U-904		
		7138392	Apr 04, 2017	DS DP U-594		
		7683051	Mar 10, 2027	DS DP U-594		
		7683051	Mar 10, 2027	DS DP U-904		
		8815934	May 06, 2019	DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911	001	5776432	Jul 07, 2015	DP U-645		
		6446627	Dec 18, 2017	DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911	002	5776432	Jul 07, 2015	DP U-645		
		6446627	Dec 18, 2017	DP		
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	001	5776432	Jul 07, 2015	DP		
		7780038	Jan 24, 2027	DP		
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	002	5776432	Jul 07, 2015	DP	NS	Dec 17, 2017
		7780038	Jan 24, 2027	DP		
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384	001	7498343	Oct 02, 2024	DS DP U-1321	NCE	Dec 28, 2017
		8546428	Mar 19, 2029	DS DP U-1321	ODE	Dec 28, 2019
<u>BELINOSTAT - BELEODAQ</u>						
N 206256	001	6888027	Sep 27, 2021	DS DP U-1544	NCE	Jul 03, 2019
		8835501	Oct 27, 2027	DP	ODE	Jul 03, 2021
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	001	8436190	Oct 26, 2030	DP	ODE	Oct 31, 2015
		8436190*PED	Apr 26, 2031		PED	Sep 20, 2015
		8445524	Mar 26, 2029	DS DP U-1402	PED	May 01, 2016
		8445524*PED	Sep 26, 2029			
		8609863	Jan 12, 2026	DP		
		8609863*PED	Jul 12, 2026			
		8669279	Mar 26, 2029	DP U-1402		
		8669279*PED	Sep 26, 2029			
		8791270	Jan 12, 2026	DP U-1542		
		8791270*PED	Jul 12, 2026			
		8883836	Mar 26, 2029	DP U-1402		
		8883836*PED	Sep 26, 2029			
		8895756	Jan 12, 2026	DP		
		8895756*PED	Jul 12, 2026			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	002	8436190	Oct 26, 2030	DP	ODE	Oct 31, 2015
		8436190*PED	Apr 26, 2031		PED	Sep 20, 2015
		8445524	Mar 26, 2029	DS DP U-1402	PED	May 01, 2016
		8445524*PED	Sep 26, 2029			
		8609863	Jan 12, 2026	DP		
		8609863*PED	Jul 12, 2026			
		8669279	Mar 26, 2029	DP U-1402		
		8669279*PED	Sep 26, 2029			
		8791270	Jan 12, 2026	DP U-1542		
		8791270*PED	Jul 12, 2026			
		8883836	Mar 26, 2029	DP U-1402		
		8883836*PED	Sep 26, 2029			
		8895756	Jan 12, 2026	DP		
		8895756*PED	Jul 12, 2026			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	003	8344006	Sep 23, 2029	DP U-1402	ODE	Oct 31, 2015
		8344006*PED	Mar 23, 2030		PED	May 01, 2016
		8445524	Mar 26, 2029	DS		
		8445524*PED	Sep 26, 2029			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402		ODE	Oct 31, 2015
	8344006*PED	Mar 23, 2030			PED	May 01, 2016
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	8609707	Aug 11, 2031	DP U-1542			
	8791270	Jan 12, 2026	DP U-1790			
	8791270*PED	Jul 12, 2026				
	9000021	Mar 15, 2033	U-1542			
	9034908	Mar 15, 2033	U-1542			
	9144568	Mar 15, 2033	U-1542			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8288434	Aug 05, 2029	DP U-124			
	8663699	Jun 03, 2029	U-124			
	8895070	Jun 03, 2029	U-124			
	9078870	Jun 03, 2029	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	8288434	Aug 05, 2029	DP U-124			
	8288434	Aug 05, 2029	DP U-134			
	8288434	Aug 05, 2029	DP U-818			
	8288434	Aug 05, 2029	DP U-916			
	8288434	Aug 05, 2029	DP U-921			
	8288434	Aug 05, 2029	DP U-1033			
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129 001	5858383	Aug 11, 2017	U-970			
	6139859	Aug 11, 2017	U-970			
	6793931	Jul 11, 2022	DP U-970			
	7294342	May 19, 2024	U-970			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP			
	8784789	Sep 05, 2024	DP			
	8877168	Jul 30, 2023	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	5447926	Apr 13, 2016	DS DP U-80			
	6685958	Jun 29, 2021	DP U-80			
	6699492	Mar 31, 2019	DP U-80			
	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
	8937062	Nov 13, 2029	U-80			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	6753013	Jan 27, 2020	DP U-1761		NP	Oct 16, 2018
	9119781	Jun 10, 2031	DP U-1761			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 021852 001	6753013	Jan 27, 2020	DP U-88		NPP	Dec 23, 2017
	6753013	Jan 27, 2020	DP U-193			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-88		I-659	Oct 17, 2015
	6753013	Jan 27, 2020	DP U-193		NPP	Aug 29, 2017
	6753013	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-1761			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185	002	6753013	Jan 27, 2020	DP	U-1761	
		6787529	Jan 27, 2020	DP	U-1761	
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
N 020934	001	6126920	Mar 01, 2016		U-484	
		7078058	May 24, 2017	DP		
<u>BEXAROTENE - TARGRETIN</u>						
N 021055	001	5780676	Jul 14, 2015		U-509	
		5962731	Oct 05, 2016		U-475	M-164 Jul 29, 2018
<u>BEXAROTENE - TARGRETIN</u>						
N 021056	001	5780676	Jul 14, 2015		U-510	
		5962731	Oct 05, 2016			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184	001	7851504	Jun 13, 2027	DS DP		
		8278353	Mar 16, 2025		DP	
		8299118	Mar 16, 2025		U-1295	
		8309605	Mar 16, 2025		U-1293	
		8309605	Mar 16, 2025		U-1294	
		8338479	Mar 16, 2025	DP	U-1295	
		8524777	Mar 16, 2025		U-1235	
		8586630	Mar 16, 2025		U-1458	
		8772338	Mar 16, 2025	DP	U-1528	
		8933120	Mar 16, 2025		DP	
		8933127	Mar 16, 2025		DP	
		9155716	Mar 16, 2025	DP	U-1528	
<u>BIMATOPROST - LATISSE</u>						
N 022369	001	7351404	May 25, 2024		U-939	
		7388029	Jan 21, 2022		U-938	
		8038988	Aug 25, 2023	DS DP	U-1208	
		8101161	May 25, 2024		U-1217	
		8101161	May 25, 2024		U-1218	
		8263054	Jan 15, 2023		U-1277	
		8541466	Jan 31, 2021		U-1217	
		8632760	Jan 15, 2023		U-1487	
		8758733	Jan 15, 2023		U-1487	
		8906962	Jan 31, 2021		U-1217	
		8926953	Jan 15, 2023		U-1217	
		8986715	Jan 15, 2023		U-1217	
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N 021551	003	7291324	Oct 22, 2022		U-837	
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
N 050786	001	6350468	Dec 14, 2018		U-932	
		6350468	Dec 14, 2018		U-956	
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873	001	7582727	Jul 27, 2028		DP	
		7598343	Jul 27, 2028		DP	
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258	001	7772178	Nov 11, 2027		DP U-1128	
		8119602	Mar 17, 2027		U-1233	
		RE43298	Feb 22, 2022	DS DP	U-1128	M-126 NCE NPP Feb 27, 2016 May 13, 2016 Feb 13, 2016
<u>BORTEZOMIB - VELCADE</u>						
N 021602	001	5780454	May 03, 2017	DS DP		D-141 Oct 08, 2017
		5780454*PED	Nov 03, 2017			D-142 Oct 08, 2017
		6713446	Jan 25, 2022	DS DP		I-695 Oct 08, 2017
		6713446*PED	Jul 25, 2022			M-139 Aug 08, 2017
		6958319	Jan 25, 2022	DS DP		M-165 Sep 14, 2018
		6958319*PED	Jul 25, 2022			ODE Oct 08, 2021
						PED Feb 08, 2018
						PED Apr 08, 2018
						PED Apr 08, 2018

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BORTEZOMIB - VELCADE</u>						
N 021602	001				PED	Apr 08, 2018
					PED	Mar 14, 2019
					PED	Apr 08, 2022
<u>BOSENTAN - TRACLEER</u>						
N 021290	001	5292740	Nov 20, 2015			
<u>BOSENTAN - TRACLEER</u>						
N 021290	002	5292740	Nov 20, 2015			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	001	6002008	Mar 27, 2018	DS DP U-1284	NCE	Sep 04, 2017
		7417148	Jan 23, 2026	U-1283	ODE	Sep 04, 2019
		7767678	Nov 23, 2026	DS DP		
		7919625	Dec 11, 2025	DP		
		RE42376	Sep 24, 2019	DS		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	002	6002008	Mar 27, 2018	DS DP U-1284	NCE	Sep 04, 2017
		7417148	Jan 23, 2026	U-1283	ODE	Sep 04, 2019
		7767678	Nov 23, 2026	DS DP		
		7919625	Dec 11, 2025	DP		
		RE42376	Sep 24, 2019	DS		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	001	7888362	Feb 23, 2027	DS	NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529		
		8618109	Apr 12, 2026	U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	002	7888362	Feb 23, 2027	DS	NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529		
		8618109	Apr 12, 2026	U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	003	7888362	Feb 23, 2027	DS	NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529		
		8618109	Apr 12, 2026	U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	004	7888362	Feb 23, 2027	DS	NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529		
		8618109	Apr 12, 2026	U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	005	7888362	Feb 23, 2027	DS	NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529		
		8618109	Apr 12, 2026	U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	006	7888362	Feb 23, 2027	DS	NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529		
		8618109	Apr 12, 2026	U-543		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262	001	6562873	Jul 10, 2021			
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
<u>BRIMONIDINE TARTRATE - OOLIANA</u>						
N 021764	001	7265117	Aug 19, 2025	DP		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770	001	6562873	Jul 10, 2021	DP		
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
		8858961	Sep 02, 2023	DP		
		8858961*PED	Mar 02, 2024			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770	001	6562873	Jul 10, 2021	DP		
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
		8858961	Sep 02, 2023	DP		
		8858961*PED	Mar 02, 2024			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708	001	7439241	Aug 25, 2025	U-1428	NDF	Aug 23, 2016
		8053427	Jun 13, 2031	DP U-1428		
		8163725	Jun 13, 2031	DP		
		8231885	May 24, 2025	DP		
		8410102	May 24, 2025	U-1428		
		8426410	May 24, 2025	U-1428		
		8513247	Mar 25, 2031	DP U-1428		
		8513249	Mar 25, 2031	DP U-1428		
		8859551	May 25, 2024	U-1428		
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251	001	6316441	Dec 07, 2019	U-778	NC	Apr 19, 2016
		9044484	Oct 30, 2030	DP		
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398	001	7030149	Apr 19, 2022	U-849		
		7320976	Apr 19, 2022	U-849		
		7323463	Jan 19, 2023	DP	Y	
		7642258	Apr 19, 2022	DS DP U-1024		
		8133890	Apr 19, 2022	U-1235		
		8354409	Apr 19, 2022	DP U-1371		
		8748425	Apr 19, 2022	DP U-1524		
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168	001	8129431	Sep 11, 2025	DS DP	NP	Apr 05, 2016
		8669290	Jan 16, 2024	DP		
		8754131	Jan 16, 2024	DP		
		8871813	Jan 16, 2024	DP		
		8927606	Jan 16, 2024	U-100		
		8927606	Jan 16, 2024	U-810		
		8927606	Jan 16, 2024	U-1095		
		9144609	Jan 16, 2024	DP		
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866	001	7888310	Jul 25, 2023	U-1433		
		8137992	Jul 25, 2023	U-1433		
		8137993	Jul 25, 2023	U-1433		
		8137994	Jul 25, 2023	U-1433		
		8431155	Apr 30, 2032	DP U-976		
		8613947	Apr 30, 2032	DP U-976		
		8877708	Jun 07, 2030	DP U-1706		
<u>BUDESONIDE - BUDESONIDE</u>						
A 201966	001				PC	Jan 23, 2016
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929	001	6598603	Dec 23, 2018	U-529		
		6899099	Dec 23, 2018	U-529		
		7524834	Nov 11, 2018	DP U-966		
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929	002	6598603	Dec 23, 2018	U-529		
		6899099	Dec 23, 2018	U-529		
		7524834	Nov 11, 2018	DP U-966		
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929	003	6598603	Dec 23, 2018	U-529		
		6899099	Dec 23, 2018	U-529		
		7524834	Nov 11, 2018	DP U-966		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949	001	6027714	Jan 09, 2018	DP U-787		
		6142145	May 08, 2018	DP		
		6287540	Jan 09, 2018	DP		
		7143764	Mar 13, 2018	DP		
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949	002	6027714	Jan 09, 2018	DP U-787		
		6142145	May 08, 2018	DP		
		6287540	Jan 09, 2018	DP		
		7143764	Mar 13, 2018	DP		
<u>BUDESONIDE - UCERIS</u>						
N 203634	001	7410651	Jun 09, 2020	DP U-1325	NDF	Jan 14, 2016
		7431943	Jun 09, 2020	DP		
		8293273	Jun 09, 2020	DP		
		8784888	Jun 09, 2020	DP		
		8895064	Sep 07, 2031	DP		
		9132093	Sep 07, 2031	DP		
		9192581	Sep 07, 2031	DP U-1325		
		RE43799	Jun 09, 2020	DP U-1325		
<u>BUDESONIDE - UCERIS</u>						
N 205613	001	5914122	Dec 19, 2015	DP	NP	Oct 07, 2017
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	001	6123924	Sep 26, 2017	DP		
		7367333	Nov 11, 2018	DP		
		7587988	Apr 10, 2026	DP		
		7759328	Jan 29, 2023	DP U-1073		
		7967011	Aug 11, 2021	DP		
		8143239	Jan 29, 2023	DP U-1073		
		8387615	Nov 10, 2024	DP		
		8528545	Oct 16, 2028	DP		
		8575137	Jan 29, 2023	DP U-1073		
		8616196	Apr 07, 2029	DP		
		8875699	Nov 10, 2024	DP		
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	002	6123924	Sep 26, 2017	DP		
		7367333	Nov 11, 2018	DP		
		7587988	Apr 10, 2026	DP		
		7759328	Jan 29, 2023	DP U-1073		
		7897646	Sep 09, 2018	U-1118		
		7967011	Aug 11, 2021	DP		
		8143239	Jan 29, 2023	DP U-1073		
		8387615	Nov 10, 2024	DP		
		8461211	Sep 09, 2018	U-1118		
		8528545	Oct 16, 2028	DP		
		8575137	Jan 29, 2023	DP U-1073		
		8616196	Apr 07, 2029	DP		
		8875699	Nov 10, 2024	DP		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	001	8182835	Sep 18, 2018	DP U-1246		
		8834921	Sep 18, 2018	DP U-1587		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	002	8182835	Sep 18, 2018	DP U-1246		
		8834921	Sep 18, 2018	DP U-1587		
		9205052	Sep 18, 2018	U-1246		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	001	6264980	Dec 18, 2015	DP		
		6344211	Dec 18, 2015	U-1072		
		6344211	Dec 18, 2015	U-1556		
		RE41408	Sep 29, 2017	U-1072		
		RE41408	Sep 29, 2017	U-1556		
		RE41489	Sep 29, 2017	U-1072		
		RE41489	Sep 29, 2017	U-1556		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	002	6159498	Oct 18, 2016	DP	NP	Jun 06, 2017
		7579019	Jan 22, 2020	U-1521		
		8147866	Jul 23, 2027	DP U-1521		
		8703177	Aug 20, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	003	6159498	Oct 18, 2016	DP	NP	Jun 06, 2017
		7579019	Jan 22, 2020	U-1521		
		8147866	Jul 23, 2027	DP U-1521		
		8703177	Aug 20, 2032	DP		
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	001	7241805	Jun 27, 2026	DP		
		7569610	Jun 27, 2026	U-997		
		7572935	Jun 27, 2026	DP		
		7585897	Jun 27, 2026	DP		
		7645802	Jun 27, 2026	DP		
		7649019	Jun 27, 2026	DP		
		7662407	Jun 27, 2026	DP		
		7671094	Jun 27, 2026	DP		
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	002	7241805	Jun 27, 2026	DP		
		7569610	Jun 27, 2026	U-997		
		7572935	Jun 27, 2026	DP		
		7585897	Jun 27, 2026	DP		
		7645802	Jun 27, 2026	DP		
		7649019	Jun 27, 2026	DP		
		7662407	Jun 27, 2026	DP		
		7671094	Jun 27, 2026	DP		
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	003	7241805	Jun 27, 2026	DP		
		7569610	Jun 27, 2026	U-997		
		7572935	Jun 27, 2026	DP		
		7585897	Jun 27, 2026	DP		
		7645802	Jun 27, 2026	DP		
		7649019	Jun 27, 2026	DP		
		7662407	Jun 27, 2026	DP		
		7671094	Jun 27, 2026	DP		
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515	001	6096341	Oct 30, 2018			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515	002	6096341	Oct 30, 2018			
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497	001	7674479	Jun 25, 2027	DP		
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063	001	7375111	Mar 26, 2025	DP	NC	Sep 10, 2017
		7462626	Jul 20, 2024	U-1583		
		8088786	Feb 03, 2029	DP		
		8318788	Nov 08, 2027	U-1584		
		8722085	Nov 08, 2027	U-1585		
		8815889	Jul 20, 2024	U-1586		
		8916195	Feb 02, 2030	U-1639		
		9107837	Jun 04, 2027	U-1639		
		9125868	Nov 08, 2027	U-1585		
<u>BUTOCONAZOLE NITRATE - BUTOCONAZOLE NITRATE</u>						
N 019881	001	5993856	Nov 17, 2017	DP U-457		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023	001	5847170	Mar 26, 2021	DS DP		
		6331635	Mar 26, 2016	DS DP		
		6372780	Mar 26, 2016	U-1067		
		6387946	Mar 26, 2016	U-1067		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023	001 7241907	Dec 10, 2025	DS			
	8927592	Oct 27, 2030	U-1630			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756	001 7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8877776	Oct 08, 2030	DS DP U-1617		ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756	002 7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8877776	Oct 08, 2030	DS DP U-1617		ODE	Nov 29, 2019
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563	001 8263580	Sep 27, 2028	DP U-1280		I-657	Sep 27, 2015
	8629128	May 26, 2026	DP U-1280			
	8629128	May 26, 2026	DP U-1767			
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406	001 6440392	Feb 02, 2021	DP U-227			
	RE40812	Feb 02, 2021	DP			
	RE43580	Feb 02, 2021	DP U-227			
<u>CALCITRIOL - CALCIJEX</u>						
N 018874	001 6051567	Aug 02, 2019				
	6265392	Aug 02, 2019				
	6274169	Aug 02, 2019				
<u>CALCITRIOL - CALCIJEX</u>						
N 018874	002 6051567	Aug 02, 2019				
	6265392	Aug 02, 2019				
	6274169	Aug 02, 2019				
<u>CALCIUM ACETATE - PHOSLO</u>						
N 021160	002 6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160	003 6576665	Apr 03, 2021				
	6875445	Jul 30, 2021	DP			
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581	001 8591938	Feb 23, 2030	DP U-1469			
	8592480	Jul 20, 2027	U-1469			
	9089528	Jul 20, 2027	U-1469			
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N 020958	001 5989588	Sep 30, 2017	DP U-349			
	5989588*PED	Mar 30, 2018				
	6814978	Aug 26, 2021	DP			
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N 021823	001 5994329	Jul 17, 2018		U-353		
	6015801	Jul 17, 2018		U-353		
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018		U-595		
	6465443	Aug 14, 2018	DP			
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N 022193	001 7084130	Nov 29, 2021	DP U-891			
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026	001				ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B2K 4/0 IN PLASTIC CONTAINER</u>						
N 207026	002				ODE	Jan 13, 2022
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001 7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	8222219	Jul 30, 2024		U-493		
	8513202	Dec 03, 2027	DS DP	U-493		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP	U-493	NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024		U-493		
	8513202	Dec 03, 2027	DS DP	U-493		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP	U-493	NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024		U-493		
	8513202	Dec 03, 2027	DS DP	U-493		
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP	U-493	NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024		U-493		
	8513202	Dec 03, 2027	DS DP	U-493		
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP	U-493	NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024		U-493		
	8513202	Dec 03, 2027	DS DP	U-493		
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP	U-493	NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024		U-493		
	8513202	Dec 03, 2027	DS DP	U-493		
	8785403	Jul 30, 2024	DP			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP	U-1715	NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP	U-1715		
	8680052	Mar 09, 2033		U-1715		
	8759316	May 13, 2029		U-1715		
<u>CAPECITABINE - XELODA</u>						
N 020896 001					M-131	Dec 10, 2016
					PED	Jun 10, 2017
<u>CAPECITABINE - XELODA</u>						
N 020896 002					M-131	Dec 10, 2016
					PED	Jun 10, 2017
<u>CAPSAICIN - OUTENZA</u>						
N 022395 001	6239180	Nov 06, 2016	DP		ODE	Nov 16, 2016
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 001	5912013	Jun 15, 2016		U-277		
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 002	5912013	Jun 15, 2016		U-277		
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 003	5912013	Jun 15, 2016		U-277		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 001	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024		U-693		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	002	5912013				
	6977253	Jun 15, 2016	DP			
		May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	003	5912013				
	6977253	Jun 15, 2016	DP			
		May 19, 2024	U-693			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N 021485	001	6500867				
	6797732	Jun 29, 2020	DP U-219			
		Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N 021485	002	6500867				
	6797732	Jun 29, 2020	DP U-219			
		Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N 021485	003	6500867				
	6797732	Jun 29, 2020	DP U-219			
		Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N 021485	004	6500867				
	6797732	Jun 29, 2020	DP U-219			
		Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N 021485	005	6500867				
	6797732	Jun 29, 2020	DP U-219			
		Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N 021485	006	6500867				
	6797732	Jun 29, 2020	DP U-219			
		Jun 29, 2020	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	7094427				
	8377474	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	7094427				
	8377474	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	7094427				
	8377474	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	8454998	Dec 26, 2028	DP U-1649		
		8557283	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	7094427	May 29, 2022	DP U-1645	NDF	Jan 07, 2018
		8377474	Dec 26, 2028	DP U-219		
		8377474	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8557283	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952	001				NP	Jan 09, 2018
					ODE	Jan 09, 2022
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556	001	8062667	Mar 29, 2029	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	7232818	Apr 14, 2025	DS DP	I-712	Jul 24, 2018
		7417042	Jun 07, 2026	DS DP	NCE	Jul 20, 2017
		7491704	Apr 14, 2025	U-1260	ODE	Jul 20, 2019
		7737112	Dec 07, 2027	DP		
		8129346	Dec 25, 2026	U-1260		
		8207125	Apr 14, 2025	DS DP		
		8207126	Apr 14, 2025	DP		
		8207127	Apr 14, 2025	U-1260		
		8207297	Apr 14, 2025	DS DP		
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562	001				ODE	Mar 18, 2017
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	001	7737142	Mar 27, 2027	DS DP U-1750	NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	002	7737142	Mar 27, 2027	DS DP U-1750	NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	003	7737142	Mar 27, 2027	DS DP U-1750	NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	004	7737142	Mar 27, 2027	DS DP U-1750	NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	001	6022562	Oct 17, 2015	DP	Y	
		7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	002	6022562	Oct 17, 2015	DP	Y	
		7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	002 8101209	Sep 11, 2025	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	003 6022562	Oct 17, 2015	DP	Y		
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	004 6022562	Oct 17, 2015	DP	Y		
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227	001 5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227	002 5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CEFditoren PIVOXIL - SPECTRACEF</u>						
N 021222	001 5958915	Oct 14, 2016				
<u>CEFditoren PIVOXIL - SPECTRACEF</u>						
N 021222	002 5958915	Oct 14, 2016	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	001 6417175	Apr 11, 2022	DS DP U-1676		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	002 6417175	Apr 11, 2022	DS DP U-1676		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001 7129232	Oct 21, 2024	DS DP U-36		NCE	Dec 19, 2019
	8476425	Sep 27, 2032	DS		GAIN	Dec 19, 2024
	8685957	Sep 27, 2032	DS U-36			
	8906898	May 28, 2034	DS DP			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CERITINIB - ZYKADIA</u>						
N 205755	001 7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8703787	Feb 02, 2032	U-1179			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621	003 6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621	004 6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621	005 6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621	006 6455533	Jul 02, 2018	DP U-295			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N 021150	002	6469009	Jul 13, 2019	DP U-295		
		6489329	Apr 08, 2016	DP		
		7014867	Jun 10, 2022	DP		
		7226614	Jun 10, 2022	U-295		
<u>CETRORELIX - CETROTIDE</u>						
N 021197	001	6319192	Apr 23, 2019	U-426		
<u>CETRORELIX - CETROTIDE</u>						
N 021197	002	6319192	Apr 23, 2019	U-426		
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N 021669	001	7066916	Feb 17, 2024	U-737		
		7427574	Apr 25, 2026	DP		
		7595021	May 12, 2023	DP U-1022		
		7717889	Feb 27, 2025	DP U-1022		
		7935093	Oct 02, 2027	DP U-1022		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	001	5690958	Sep 30, 2016	DP		
		6536975	Nov 10, 2020	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	002	5690958	Sep 30, 2016	DP		
		6729786	Mar 14, 2023	DP		
		6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>						
N 020832	003	5538353	Aug 25, 2015	DP		
		5690958	Sep 30, 2016	DP		
		5772346	Apr 22, 2017	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	004	5690958	Sep 30, 2016	DP		
		6536975	Nov 10, 2020	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	005	5690958	Sep 30, 2016	DP		
		6536975	Nov 10, 2020	DP		
		6729786	Mar 14, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	006	5690958	Sep 30, 2016	DP		
		6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	007	5690958	Sep 30, 2016	DP		
		6536975	Nov 10, 2020	DP		
		6729786	Mar 14, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524	003	D468424	Jan 07, 2017			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP</u>						
N 021555	001	5690958	Sep 30, 2016	DP		
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323	001	6248363	Nov 23, 2019	DP U-1716		
		6383471	Apr 06, 2019	DP U-1716		
		9066942	Jan 03, 2032	U-1716		
		9107921	Jan 03, 2032	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441	001	7863287	Feb 28, 2027	DP		
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768	001	8062667	Mar 29, 2029	DP		
		8790700	Mar 15, 2027	DP		
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				ODE	Mar 17, 2022
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N 203155	001				NCE W	Sep 12, 2017 Sep 12, 2017
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224	001	7259186	Jan 07, 2025	DS		
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224	002	7259186	Jan 07, 2025	DS		
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149	002	6706681	Mar 16, 2021	DP		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	002	5482934	Oct 24, 2017	DS DP U-1002	M-125	Dec 17, 2015
		5775321	Jul 07, 2015	DP		
		6006745	Dec 28, 2016	DP		
		6120752	May 13, 2018	DP		
		6264923	May 13, 2018	DP		
		8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	003	5482934	Oct 24, 2017	DS DP U-1002	M-125	Dec 17, 2015
		5775321	Jul 07, 2015	DP		
		6006745	Dec 28, 2016	DP		
		6120752	May 13, 2018	DP		
		6264923	May 13, 2018	DP		
		8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001	5482934	Oct 24, 2017	DS DP U-557		
		6767901	Oct 21, 2020	DP		
		6939559	Apr 21, 2019	DP		
		7235247	Apr 21, 2019	DP		
		8371292	Feb 01, 2028	U-1356		
		8383611	Oct 20, 2020	DP		
<u>CICLESONIDE - ZETONNA</u>						
N 202129	001	5482934	Oct 24, 2017	DS DP U-1002		
		5775321	Jul 07, 2015	DP		
		6006745	Dec 28, 2016	DP		
		6120752	May 13, 2018	DP		
		6264923	May 13, 2018	DP		
		8371292	Feb 01, 2028	U-1357		
<u>CICLOPIROX - LOPROX</u>						
N 020519	001	7018656	Sep 05, 2018	DP		
		7026337	Nov 21, 2016	U-714		
<u>CICLOPIROX - LOPROX</u>						
N 021159	001	7981909	Sep 16, 2017	U-1162		
		8227490	Sep 16, 2017	U-1256		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	001	6011068	Mar 08, 2018	DS DP	ODE	Feb 25, 2018
		6031003	Dec 14, 2016	U-559	ODE	Nov 21, 2021
		6211244	Oct 23, 2015	DS DP U-560		
		6313146	Dec 14, 2016	DS DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	001	7829595	Sep 22, 2026	DP U-1098		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	002	6011068	Mar 08, 2018	DS DP	ODE	Feb 25, 2018
		6031003	Dec 14, 2016		ODE	Nov 21, 2021
		6211244	Oct 23, 2015	DS DP U-560		
		6313146	Dec 14, 2016	DS DP		
		7829595	Sep 22, 2026	DP U-1098		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	003	6011068	Mar 08, 2018	DS DP	ODE	Feb 25, 2018
		6031003	Dec 14, 2016		ODE	Nov 21, 2021
		6211244	Oct 23, 2015	DS DP U-560		
		6313146	Dec 14, 2016	DS DP		
		7829595	Sep 22, 2026	DP U-1098		
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986	001	8318817	Apr 27, 2030	U-1792		
		9205048	Apr 21, 2029	U-1793		
		9220796	Jul 01, 2035	DP		
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N 021744	001	5972389	Sep 19, 2016	DP U-663		
		6340475	Sep 19, 2016	DP U-663		
		6488962	Jun 20, 2020	DP		
		6635280	Sep 19, 2016	DP U-663		
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473	001	7709022	Jun 23, 2021	DP		
		8187632	Jun 23, 2021	DP		
		8187632*PED	Dec 23, 2021			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473	002	7709022	Jun 23, 2021	DP		
		8187632	Jun 23, 2021	DP		
		8187632*PED	Dec 23, 2021			
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537	001	6284804	Aug 10, 2020			
		6359016	Aug 10, 2020			
		8846650	Jun 04, 2025	DP U-1578		
		9149486	Sep 13, 2022	DP U-1578		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535	001	8450338	Oct 10, 2028	DP	NP	Jul 16, 2015
		8481083	Oct 10, 2028	DP		
<u>CLARITHROMYCIN - BIAXIN XL</u>						
N 050775	001	6010718	Apr 11, 2017	DP U-924		
		6551616	Jun 15, 2017	U-924		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	001	5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	002	5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	003	5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N 050767	001	6495157	Jul 20, 2020	DP		
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N 050782	001	6387383	Aug 03, 2020	DP U-818		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793 001	5993856	Nov 17, 2017	DP U-137			
	6899890	Apr 27, 2023	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801 001	7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N 050802 001	6387383	Aug 03, 2020	DP U-916			
<u>CLOBAZAM - ONFI</u>						
N 202067 001					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067 002					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067 003					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 203993 001					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX</u>						
N 021142 001	6126920	Mar 01, 2016	U-484			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021535 001	6106848	Sep 22, 2017				
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021644 001	7316810	Jun 17, 2019	DP			
	7700081	Jan 03, 2022	U-1044			
	8066975	Jun 17, 2019	DP			
	8066976	Jun 17, 2019	DP			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021835 001	5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1410			
	8962000	Aug 31, 2025	DP U-1410			
<u>CLOFARABINE - CLOLAR</u>						
N 021673 001	5661136	Jan 14, 2018	U-626			
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331 003					M-149	Nov 20, 2017
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331 004					M-149	Nov 20, 2017
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839 001	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839 002	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 001	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 002	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 003	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 004	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 005	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590 006	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 001	8148374	Sep 03, 2029	DS DP U-1279		NP	Sep 24, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019			U-1660	
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019			U-1660	
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016			U-1660	
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2017				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020			U-257	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	7176220	Nov 20, 2023	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7635704	Oct 26, 2026	DS DP U-257			
	7800788	Feb 02, 2022			U-257	
	8148374	Sep 03, 2029	DS DP U-1279			
	8633219	Apr 24, 2030	DP U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	5814639	Sep 29, 2015	DS DP		I-704	Dec 17, 2017
	5914331	Jul 02, 2017	DS		NP	Aug 27, 2015
	5922695	Jul 25, 2017	DS	U-257		
	5935946	Jul 25, 2017	DS DP	U-257		
	5977089	Jul 25, 2017	DS DP	U-257		
	6043230	Jul 25, 2017		U-257		
	6642245	Nov 04, 2020		U-257		
	6703396	Mar 09, 2021	DS DP			
	7176220	Nov 20, 2023	DS DP	U-257		
	7635704	Oct 26, 2026	DS DP	U-257		
	8148374	Sep 03, 2029	DS DP	U-1279		
	8592397	Jan 13, 2024		DP U-257		
	8633219	Apr 24, 2030		DP U-257		
	8716264	Jan 13, 2024		DP U-257		
	8981103	Oct 26, 2026	DS DP			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	7803839	Feb 01, 2027	DS DP		NCE	Nov 10, 2020
	8362002	Oct 05, 2026		U-1776		
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	7601758	Feb 10, 2029		U-1007	ODE	Jul 29, 2016
	7619004	Dec 03, 2028		U-1020		
	7820681	Feb 17, 2029		U-1020		
	7906519	Feb 17, 2029		U-1116		
	7915269	Feb 17, 2029		U-1007		
	7935731	Dec 03, 2028		U-1116		
	7964647	Oct 06, 2028		U-1007		
	7964648	Oct 06, 2028		U-1161		
	7981938	Oct 06, 2028		U-1166		
	8093296	Oct 06, 2028		U-1007		
	8093297	Oct 06, 2028		U-1161		
	8093298	Oct 06, 2028		U-1116		
	8097655	Oct 06, 2028		U-1020		
	8415395	Oct 06, 2028		U-1007		
	8415396	Oct 06, 2028		U-1007		
	8440721	Feb 17, 2029		U-1007		
	8440722	Feb 17, 2029		U-1020		
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033		U-1020		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021176 001	7229613	Apr 17, 2022		U-851		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 001	7229613	Apr 17, 2022		U-493		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 002	7229613	Apr 17, 2022		U-493		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N 021697 001	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N 021697 002	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CORTICOTROPIN - H.P. ACTHAR GEL</u>						
N 008372 008					ODE	Oct 15, 2017
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
	7825137	May 12, 2027		U-1179	NCE	Aug 26, 2016
	7858643	Oct 08, 2029	DS DP		ODE	Aug 26, 2018
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
	7825137	May 12, 2027		U-1179	NCE	Aug 26, 2016
	7858643	Oct 08, 2029	DS DP		ODE	Aug 26, 2018
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	7323195	Jun 07, 2018	DP		NCE	Dec 31, 2017
	7341744	Jun 16, 2018		U-1319		
	8574634	Jan 11, 2018		U-1319		
	8962680	Oct 31, 2031		U-1319		
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP	U-817		
	7404489	Mar 12, 2024	DP			
	7879349	Aug 01, 2024	DP	U-1152		
	8003353	Aug 01, 2024		U-817		
	8940714	Feb 26, 2024		U-1152		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024		U-1479		
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024		U-1483		
	8685930	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027		U-1399	NDF	Apr 30, 2016
	9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
	9192590	Jan 26, 2027		U-1399	ODE	Apr 30, 2020
	9198882	Jan 26, 2027		U-1399	ODE	Aug 14, 2022
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027		U-1399	NDF	Apr 30, 2016
	9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
	9192590	Jan 26, 2027		U-1399	ODE	Apr 30, 2020
	9198882	Jan 26, 2027		U-1399	ODE	Aug 14, 2022
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N 200740 001					NP	Oct 02, 2015
					ODE	Oct 02, 2019
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Feb 18, 2018	DS DP	U-1089	I-682	Apr 04, 2017
	7866474	Aug 31, 2027		DP	I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		M-168	Nov 20, 2018
	9034822	Jan 20, 2031		U-1759	NCE	Oct 19, 2015
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Feb 18, 2018	DS DP	U-1089	I-682	Apr 04, 2017
	7866474	Aug 31, 2027		DP	I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		M-168	Nov 20, 2018
	9034822	Jan 20, 2031		U-1759	NCE	Oct 19, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Feb 18, 2018	DS DP U-1089		NS	Nov 20, 2018
	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
	9034822	Jan 20, 2031	U-1759			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8703781	Oct 15, 2030	DS DP U-1713		ODE	May 29, 2020
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8703781	Oct 15, 2030	DS DP U-1713		ODE	May 29, 2020
					ODE	Jan 09, 2021
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
	7115564	Nov 14, 2023	DP		GAIN	May 23, 2024
	7119061	Nov 14, 2023	DP			
	8143212	Nov 14, 2023	U-1517			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030		ODE	Jan 22, 2017
	8007826	May 26, 2027	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
	8663685	Jan 18, 2025	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	7758890	Jul 01, 2025	DP		ODE	Jul 22, 2021
	8110225	Dec 24, 2022	DP			
	8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		M-157	Mar 11, 2018
	6515117	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		M-157	Mar 11, 2018
	6515117	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6936590	Oct 04, 2020	U-493			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028		U-493		
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020		U-493		
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6414126	Oct 04, 2020	DS DP	U-493	NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	9198925	Oct 04, 2020		U-493		
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6414126	Oct 04, 2020	DS DP	U-493	NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	9198925	Oct 04, 2020		U-493		
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6414126	Oct 04, 2020	DS DP	U-493	NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	9198925	Oct 04, 2020		U-493		
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6414126	Oct 04, 2020	DS DP	U-493	NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	9198925	Oct 04, 2020		U-493		
<u>DAPSONE - ACZONE</u>						
N 021794 001	5863560	Sep 11, 2016	DP			
	6060085	Sep 11, 2016		U-124		
	6620435	Sep 11, 2016	DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 001	6468967	Sep 24, 2019		U-282		
	6852689	Sep 24, 2019		U-282		
	8058238	Nov 28, 2020	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002	6468967	Sep 24, 2019		U-282		
	6852689	Sep 24, 2019		U-282		
	8003673	Sep 04, 2028		U-1180		
	8058238	Nov 28, 2020	DS DP			
	8129342	Nov 28, 2020	DS DP			
	RE39071	Jun 15, 2016	DS DP	U-728		
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 001	6106864	Aug 21, 2016	DP	U-630		
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 002	6106864	Aug 21, 2016	DP	U-630		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-935			
	5843946	Dec 01, 2015	DP U-1209			
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-935			
	5843946	Dec 01, 2015	DP U-1209			
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-935			
	5843946	Dec 01, 2015	DP U-1209			
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-935			
	5843946	Dec 01, 2015	DP U-1209			
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-935			
	5843946	Dec 01, 2015	DP U-1209			
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-935			
	5843946	Dec 01, 2015	DP U-1209			
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	5843946	Dec 01, 2015	DP U-1209		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-1305		PED	Aug 01, 2016
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020			U-779	
	7125875	Apr 13, 2020			U-780	
	7153856	Apr 28, 2020			U-780	
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020			U-779	
	7125875	Apr 13, 2020			U-780	
	7153856	Apr 28, 2020			U-780	
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020			U-779	
	7125875	Apr 13, 2020			U-780	
	7153856	Apr 28, 2020			U-780	
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001	6465504	Apr 05, 2019	DS DP		I-665	Jan 23, 2016
	6596750	Jun 24, 2017	DS U-735		ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002	6465504	Apr 05, 2019	DS DP		I-665	Jan 23, 2016
	6596750	Jun 24, 2017	DS U-735		ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003	6465504	Apr 05, 2019	DS DP		I-665	Jan 23, 2016
	6596750	Jun 24, 2017	DS U-735		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021		U-735	NCE	Oct 14, 2016
					ODE	Oct 14, 2018
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021		U-735	NCE	Oct 14, 2016
	8703156	Oct 29, 2029	DP U-735		ODE	Oct 14, 2016
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	5925730	May 18, 2021	DS DP U-943			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAVIRDINE MESYLATE - RESCRIPTOR</u>						
N 020705	002 6177101	Jun 07, 2019				
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333	001 7622130	Dec 10, 2027		U-1690		
	7754230	Dec 10, 2027		U-1690		
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025		U-1690		
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP	U-1690		
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025		U-1690		
	8883770	Feb 21, 2028	DP			
<u>DES Loratadine - CLARINEX</u>						
N 021165	001 6100274	Jul 07, 2019				
	7405223	Jul 07, 2019		U-886		
<u>DES Loratadine - CLARINEX</u>						
N 021300	001 6514520	Jun 01, 2018	DP			
<u>DES Loratadine - CLARINEX</u>						
N 021312	001 6100274	Jul 07, 2019	DP			
	7618649	Dec 19, 2020	DP	U-1017		
<u>DES Loratadine - CLARINEX</u>						
N 021312	002 6100274	Jul 07, 2019	DP			
	7618649	Dec 19, 2020	DP	U-1017		
<u>DES Loratadine; Pseudoephedrine Sulfate - CLARINEX-D 12 HOUR</u>						
N 021313	001 6100274	Jul 07, 2019	DP			
	6709676	Feb 18, 2021	DP	U-707		
	7618649	Dec 19, 2020	DP	U-1017		
	8187630	Dec 19, 2020	DP	U-1017		
<u>DES Loratadine; Pseudoephedrine Sulfate - CLARINEX D 24 HOUR</u>						
N 021605	001 6100274	Jul 07, 2019	DP			
	6979463	Mar 28, 2022	DP			
	7618649	Dec 19, 2020	DP	U-1017		
	7820199	Mar 28, 2022	DP			
<u>DESONIDE - DESONATE</u>						
N 021844	001 6387383	Aug 03, 2020	DS DP	U-783		
<u>DESONIDE - VERDESO</u>						
N 021978	001 6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP	U-1412		
	8962000	Aug 31, 2025	DP	U-1412		
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141	001 5990100	Mar 24, 2018	DP	U-1408	NDF	Apr 11, 2016
	8277780	Sep 01, 2028	DP	U-1408		
	8715624	May 26, 2026	DP	U-1408		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	001 6673838	Mar 01, 2022	DS	U-860	I-675	Feb 14, 2016
	6673838	Mar 01, 2022	DS	U-1364		
	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	002 6673838	Mar 01, 2022	DS	U-860	I-675	Feb 14, 2016
	6673838	Mar 01, 2022	DS	U-1364		
	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	003 6673838	Mar 01, 2022	DS	U-860		
	6673838	Mar 01, 2022	DS	U-1364		
	8269040	Jul 05, 2027	DS			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	6726918	Oct 20, 2020	DP U-1204		I-686	Jun 29, 2017
	6726918	Oct 20, 2020	DP U-1205		ODE	Sep 24, 2017
	6899717	Nov 01, 2023	U-1206			
	7033605	Oct 20, 2020	DP			
	7767223	Nov 28, 2021	DP			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8043628	Oct 20, 2020	U-1205			
	8063031	Oct 20, 2020	DP			
	8088407	Oct 20, 2020	U-1205			
	8506987	Jan 09, 2023	U-1204			
	8506987	Jan 09, 2023	U-1205			
	9012437	Oct 20, 2020	U-1205			
	9192511	Jan 09, 2023	DP			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	6716867	Mar 31, 2019	U-1472		M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	6716867	Mar 31, 2019	U-1472		M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	6716867	Mar 31, 2019	U-1472		M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					PC	Dec 19, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 001	5908850	Dec 04, 2015	U-422			
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278	002	5908850				
		Dec 04, 2015			U-422	
		6355656				
		Dec 04, 2015				
		6528530				
		Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278	003	5908850				
		Dec 04, 2015			U-422	
		6355656				
		Dec 04, 2015				
		6528530				
		Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802	001	5837284				
		Dec 04, 2015				
		5908850				
		Dec 04, 2015	DP		U-678	
		6228398				
		Nov 01, 2019	DP		U-676	
		6355656				
		Dec 04, 2015	DP			
		6528530				
		Dec 04, 2015	DP			
		6635284				
		Dec 04, 2015	DP		U-677	
		6730325				
		Nov 01, 2019	DP		U-676	
		7431944				
		Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802	002	5837284				
		Dec 04, 2015				
		5908850				
		Dec 04, 2015	DP		U-678	
		6228398				
		Nov 01, 2019	DP		U-676	
		6355656				
		Dec 04, 2015	DP			
		6528530				
		Dec 04, 2015	DP			
		6635284				
		Dec 04, 2015	DP		U-677	
		6730325				
		Nov 01, 2019	DP		U-676	
		7431944				
		Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802	003	5837284				
		Dec 04, 2015				
		5908850				
		Dec 04, 2015	DP		U-678	
		6228398				
		Nov 01, 2019	DP		U-676	
		6355656				
		Dec 04, 2015	DP			
		6528530				
		Dec 04, 2015	DP			
		6635284				
		Dec 04, 2015	DP		U-677	
		6730325				
		Nov 01, 2019	DP		U-676	
		7431944				
		Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802	004	5837284				
		Dec 04, 2015				
		5908850				
		Dec 04, 2015	DP		U-678	
		6228398				
		Nov 01, 2019	DP		U-676	
		6355656				
		Dec 04, 2015	DP			
		6528530				
		Dec 04, 2015	DP			
		6635284				
		Dec 04, 2015	DP		U-677	
		6730325				
		Nov 01, 2019	DP		U-676	
		7431944				
		Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802	005	5837284				
		Dec 04, 2015				
		5908850				
		Dec 04, 2015	DP		U-678	
		6228398				
		Nov 01, 2019	DP		U-676	
		6355656				
		Dec 04, 2015	DP			
		6528530				
		Dec 04, 2015	DP			
		6635284				
		Dec 04, 2015	DP		U-677	
		6730325				
		Nov 01, 2019	DP		U-676	
		7431944				
		Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802	006	5837284				
		Dec 04, 2015				
		5908850				
		Dec 04, 2015	DP		U-678	
		6228398				
		Nov 01, 2019	DP		U-676	
		6355656				
		Dec 04, 2015	DP			
		6528530				
		Dec 04, 2015	DP			
		6635284				
		Dec 04, 2015	DP		U-677	
		6730325				
		Nov 01, 2019	DP		U-676	
		7431944				
		Dec 04, 2015	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 007	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP U-678			
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 008	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP U-678			
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N 022025 001	6727253	Mar 13, 2020		U-829		
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	7659282	Aug 13, 2026		U-1093		
	8227484	Jul 17, 2023		U-1093		
	RE38115	Jan 26, 2016	DP		Y	
<u>DEXTROMETHORPHAN POLYSTIREX - DELSYM</u>						
N 018658 001	5980882	Apr 16, 2017	DP			
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366 002					ODE	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
	8999387	Apr 23, 2030	U-55		NP	Oct 18, 2016
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
	8999387	Apr 23, 2030	U-55		NP	Oct 18, 2016
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	6974595	May 15, 2017		U-436		
	7482377	May 15, 2017	DS DP	U-436		
	7759394	Jun 16, 2026	DS DP	U-436		
	8097651	Jun 16, 2026	DS DP	U-436		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165	001 8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001 6287594	Jan 15, 2019	DP			
	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
	8110606	Feb 24, 2029	U-980			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947	001 8217078	Jul 10, 2029	U-1248			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N 021005	001 5792753	Aug 11, 2015				
	5914322	Aug 11, 2015				
	5985850	Aug 11, 2015	DP			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396	001 6407079	Jun 18, 2019	DP		NP	Dec 23, 2017
	8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001 8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
	8871809	Oct 17, 2027	U-1614			
	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
<u>DIENOEST; DIENOEST; DIENOEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 022252	001 6133251	Oct 25, 2016	DP U-1	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-828	Y		
	6884793	Oct 25, 2016	DP	Y		
	8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212	001 6114319	May 18, 2019	DP		M-127	Mar 22, 2016
	6114319*PED	Nov 18, 2019			ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Sep 22, 2016
					PED	Dec 13, 2019
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	001 6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	002 6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	003 6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 004	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 005	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 006	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
	8759393	Oct 29, 2019	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
	8759393	Oct 29, 2019	DP			
<u>DIMYRISTOYL LECITHIN; PERFLEXANE - IMAGENT</u>						
N 021191 001	5798091	Aug 25, 2015	U-458			
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N 021394 001	8263647	May 30, 2022	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	8883849	Jan 17, 2022	U-1618			
	9155718	Jan 17, 2022	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168 001	6419953	Dec 18, 2018				
	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6528091	Dec 18, 2018	U-106			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168 002	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	8940786	Sep 30, 2033	DP U-1789			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	8940786	Sep 30, 2033	DP U-1789			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	8940786	Sep 30, 2033	DP U-1789			
<u>DOFETILIDE - TIKOSYN</u>						
N 020931 001	6124363	Oct 09, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	002	6124363				
		Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	003	6124363				
		Oct 09, 2018				
<u>DOLUPEGRAVIR SODIUM - TIVICAY</u>						
N 204790	001	8129385		DS DP	M-166 NCE	Jul 30, 2018 Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N 021720	001	7727548		DP		
		Jun 23, 2022		U-1062		
		7727552		DP		
		Mar 26, 2018				
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N 021720	002	7727548		DP		
		Jun 23, 2022		U-1062		
		7727552		DP		
		Mar 26, 2018				
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568	001	8481565		DP		
		Oct 04, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	001	5061703*PED				
		Oct 11, 2015				
		8058291			U-1641	
		Dec 05, 2029				
		8168209		DP		
		Nov 22, 2025				
		8168209*PED				
		May 22, 2026				
		8173708			U-1641	
		Nov 22, 2025				
		8173708*PED				
		May 22, 2026				
		8283379			U-1641	
		Nov 22, 2025				
		8283379*PED				
		May 22, 2026				
		8293794		DP		
		Nov 22, 2025				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	002	5061703*PED				
		Oct 11, 2015				
		8039009			U-1641	
		Mar 24, 2029				
		8039009*PED				
		Sep 24, 2029				
		8058291			U-1641	
		Dec 05, 2029				
		8168209		DP		
		Nov 22, 2025				
		8168209*PED				
		May 22, 2026				
		8173708			U-1641	
		Nov 22, 2025				
		8173708*PED				
		May 22, 2026				
		8283379			U-1641	
		Nov 22, 2025				
		8283379*PED				
		May 22, 2026				
		8293794		DP		
		Nov 22, 2025				
		8329752		DP		
		Nov 22, 2025				
		8329752*PED				
		May 22, 2026				
		8338485		DP		
		Nov 22, 2025				
		8338486			U-1641	
		Nov 22, 2025				
		8362085			U-1641	
		Nov 22, 2025				
		8362085*PED				
		May 22, 2026				
		8580858			U-1641	
		Nov 22, 2025				
		8598233		DP		
		Nov 22, 2025				
		8598233*PED				
		May 22, 2026				
<u>DORIPENEM - DORIBAX</u>						
N 022106	001	8247402		DS DP		
		Mar 30, 2021				
<u>DORIPENEM - DORIBAX</u>						
N 022106	002	8247402		DS DP		
		Mar 30, 2021				
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001	6211229				
		Feb 17, 2020		U-620		
		7915307			U-620	
		Aug 24, 2027				
		8513299			U-620	
		Apr 14, 2030				
		9107898		DP	U-620	
		May 01, 2028				
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002	6211229				
		Feb 17, 2020		U-620		
		7915307			U-620	
		Aug 24, 2027				
		8513299			U-620	
		Apr 14, 2030				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002 9107898	May 01, 2028	DP U-620			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862	001 6903083	Jul 18, 2021	DS DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862	002 6903083	Jul 18, 2021	DS DP	Y		
<u>DOXYCYCLINE - ORACEA</u>						
N 050805	001 5789395	Aug 30, 2016	U-925	Y		
	5919775	Aug 30, 2016	U-925	Y		
	7211267	Apr 05, 2022	U-925			
	7232572	Apr 05, 2022	U-925			
	7749532	Dec 19, 2027	DP U-1063			
	8206740	Dec 24, 2025	DP U-925			
	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
	8603506	Apr 05, 2022	U-1063			
	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	001 6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	002 6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	003 6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	004 6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	005 6958161	Dec 15, 2022	DP U-918		D-136	Apr 11, 2016
	8715724	Feb 03, 2028	DP		NS	Apr 11, 2016
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795	006 6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876	001 6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425	001 5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	7323493	Jun 19, 2018	DP			
	8318800	Jun 19, 2018	DP			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
	8602215	Jun 30, 2031	U-1473			
	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355	001 8906890	Oct 22, 2031	DP			
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355	002 6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N 021098	001 6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DS			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676	001	5798338	Jul 10, 2015	DP		
		6787531	Aug 31, 2020	DP		
		6933395	Aug 11, 2017	DP		
		6958326	Dec 20, 2021	DP		
		6987101	Dec 22, 2017		U-758	
		7163931	Dec 20, 2021		U-1	
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532	001	5798338	Jul 10, 2015	DP		
		6441168	Jul 30, 2022	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022		U-1	
		8617597	Feb 08, 2030	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574	001	5798338	Jul 10, 2015	DP		
		6441168	Apr 17, 2020	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022		U-1	
		8617597	Feb 08, 2030	DP		
<u>DROXIDOPA - NORTHERA</u>						
N 203202	001				NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	002				NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	003				NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090694	003				PC	Jan 11, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	001	6596756	Sep 10, 2019	U-882	M-61	Oct 18, 2015
					NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	002	6596756	Sep 10, 2019	U-882	M-61	Oct 18, 2015
					NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	004	6596756	Sep 10, 2019	U-882	M-61	Oct 18, 2015
					NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DUTASTERIDE - AVODART</u>						
N 021319	001	5565467	Nov 20, 2015	DS DP		
<u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE - JALYN</u>						
N 022460	001	5565467	Nov 20, 2015	DS DP		
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175	001	5993830	Jan 16, 2018	DP	U-1449	NDF
						Oct 24, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	001	7365205	Jun 12, 2023	DS		NCE
		9149532	Mar 28, 2028	DP		Jan 08, 2020

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	002	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP		
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	003	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP		
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972	001	6238695	Apr 06, 2019	DP	NPP	May 02, 2016
		6238695*PED	Oct 06, 2019		PED	Nov 02, 2016
		6555133	Apr 06, 2019	U-248		
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972	002	6238695	Apr 06, 2019	DP		
		6238695*PED	Oct 06, 2019			
		6555133	Apr 06, 2019	U-248		
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972	003	6238695	Apr 06, 2019	DP	NPP	May 02, 2016
		6238695*PED	Oct 06, 2019		PED	Nov 02, 2016
		6555133	Apr 06, 2019	U-248		
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360	001	6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360	002	6639071	Feb 14, 2018	DS	NPP	May 02, 2016
		6639071*PED	Aug 14, 2018		PED	Nov 02, 2016
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	5814639	Sep 29, 2015	DS DP		
		5914331	Jul 02, 2017	DS		
		5922695	Jul 25, 2017	DS	U-750	
		5922695	Jul 25, 2017	DS	U-1170	
		5935946	Jul 25, 2017	DS DP	U-750	
		5935946	Jul 25, 2017	DS DP	U-1170	
		5977089	Jul 25, 2017	DS DP	U-750	
		5977089	Jul 25, 2017	DS DP	U-1170	
		6043230	Jul 25, 2017		U-750	
		6043230	Jul 25, 2017		U-1170	
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6642245	Nov 04, 2020		U-750	
		6642245	Nov 04, 2020		U-1170	
		6703396	Mar 09, 2021	DS DP		
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
		8592397	Jan 13, 2024	DP	U-750	
		8592397	Jan 13, 2024	DP	U-1170	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001 8598185	May 01, 2028	DP			
	8716264	Jan 13, 2024	DP U-257			
	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001 7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016	001 5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016	002 5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494	001 6916802	Apr 29, 2022	U-1571		NCE	Aug 19, 2019
	7196205	Apr 29, 2022	DS		ODE	Aug 19, 2021
	7615573	Apr 29, 2022	U-1571			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	001 6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Nov 20, 2015
	6280959*PED	Apr 30, 2019			ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Nov 20, 2015
	6280959*PED	Apr 30, 2019			ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Nov 20, 2015
	6280959*PED	Apr 30, 2019			ODE	Aug 26, 2021

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1575		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
	7332481	May 24, 2021	U-1736		ODE	Nov 20, 2015
	7452874	May 24, 2021	DS DP		PED	Dec 11, 2018
	7473686	May 24, 2021	DS DP U-1736		PED	Dec 11, 2018
	7547719	Jul 13, 2025	DS DP U-1736			
	7790704	May 24, 2021	U-1736			
	7795293	May 24, 2023	U-1736			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Nov 05, 2025	DS		M-160	Jun 26, 2018
	7713938	Apr 15, 2027	DS DP		M-161	Jun 26, 2018
					NCE	Aug 01, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Nov 05, 2025	DS		M-160	Jun 26, 2018
	7713938	Apr 15, 2027	DS DP		M-161	Jun 26, 2018
					NCE	Aug 01, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017		U-1651	NC	Jan 30, 2018
	6890898	Feb 02, 2019		U-1652	NCE	May 02, 2016
	7078381	Feb 02, 2019		U-1651	NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019		U-1651		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017		U-1651	NC	Jan 30, 2018
	6890898	Feb 02, 2019		U-1652	NCE	May 02, 2016
	7078381	Feb 02, 2019		U-1651	NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019		U-1651		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP	U-1653		
	8178541	Aug 12, 2023	DP	U-1654		
	8551957	Oct 19, 2029	DP	U-1651		
	8673927	May 04, 2027	DP	U-1652		
	8846695	Jun 04, 2030		U-1652		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP	U-1772		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017		U-1651	NC	Jan 30, 2018
	6890898	Feb 02, 2019		U-1652	NCE	May 02, 2016
	7078381	Feb 02, 2019		U-1651	NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019		U-1651		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP	U-1653		
	8178541	Aug 12, 2023	DP	U-1654		
	8551957	Oct 19, 2029	DP	U-1651		
	8673927	May 04, 2024	DP	U-1652		
	8846695	Jun 04, 2030		U-1652		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP	U-1772		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMTRICITABINE - EMTRIVA</u>						
N 021500 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020		U-257		
	6642245	Nov 04, 2020		U-541		
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE - EMTRIVA</u>						
N 021896 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020		U-257		
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	5814639	Sep 29, 2015	DS DP		NCE	May 20, 2016
	5914331	Jul 02, 2017	DS		NPP	Dec 13, 2016
	5922695	Jul 25, 2017	DS	U-257		
	5935946	Jul 25, 2017	DS DP	U-257		
	5977089	Jul 25, 2017	DS DP	U-257		
	6043230	Jul 25, 2017		U-257		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	6642245	Nov 04, 2020		U-257		
	6703396	Mar 09, 2021	DS DP			
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Aug 09, 2022	DS DP	U-257		
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8592397	Jan 13, 2024	DP	U-257		
	8716264	Jan 13, 2024	DP	U-257		
	8841310	Dec 09, 2025	DP	U-257		
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS DP	U-248		
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-541		
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-1259		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-541		
	5935946	Jul 25, 2017	DS DP	U-1170		
	5935946	Jul 25, 2017	DS DP	U-1259		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-541		
	5977089	Jul 25, 2017	DS DP	U-1170		
	5977089	Jul 25, 2017	DS DP	U-1259		
	6043230	Jul 25, 2017	DP	U-248		
	6043230	Jul 25, 2017	DP	U-541		
	6043230	Jul 25, 2017	DP	U-1170		
	6043230	Jul 25, 2017	DP	U-1259		
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6703396	Mar 09, 2021	DS DP			
	8592397	Jan 13, 2024	DP	U-248		
	8592397	Jan 13, 2024	DP	U-541		
	8592397	Jan 13, 2024	DP	U-1170		
	8716264	Jan 13, 2024	DP	U-257		
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032		U-3		
	8778366	Nov 06, 2032		U-185		
<u>ENTACAPONE - COMTAN</u>						
N 020796 001	6599530	Sep 14, 2018	DP	U-219		
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001	5206244*PED	Aug 21, 2015			NPP	Oct 12, 2015
					NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	7709517	Aug 13, 2027	DS DP		I-693	Sep 10, 2017
	8183274	May 15, 2026		U-1281	NCE	Aug 31, 2017
	8183274	May 15, 2026		U-1588		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415	001 9126941	May 15, 2026				U-1588
<u>EPINEPHRINE - EPIPEN</u>						
N 019430	001 7449012	Sep 11, 2025				DP
	7794432	Sep 11, 2025				DP
	8048035	Sep 11, 2025				DP
	8870827	Sep 11, 2025				DP
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430	002 7449012	Sep 11, 2025				DP
	7794432	Sep 11, 2025				DP
	8048035	Sep 11, 2025				DP
	8870827	Sep 11, 2025				DP
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800	001 7297136	Jan 18, 2025				DP
	7621891	Feb 04, 2025				DP
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800	002 7297136	Jan 18, 2025				DP
	7621891	Feb 04, 2025				DP
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	001 7731686	Jun 01, 2026				DP
	7731690	Jan 15, 2025				DP
	7749194	Oct 30, 2028				DP
	7918823	Nov 23, 2024				DP
	7947017	Mar 12, 2028				DP
	8016788	Mar 21, 2025				DP
	8021344	Nov 02, 2029				DP
	8206360	Feb 27, 2027				DP
	8226610	Apr 10, 2029				DP
	8231573	Nov 25, 2028				DP
	8313466	Nov 23, 2024				DP
	8361029	Nov 23, 2024				DP
	8425462	Nov 23, 2024				DP
	8608698	Nov 23, 2024				DP
	8920377	Nov 23, 2024				DP
	8926594	Mar 31, 2026				DP
	9056170	Nov 23, 2024				DP
	9149579	Jul 19, 2025				U-1758
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002 7731686	Jun 01, 2026				DP
	7731690	Jan 15, 2025				DP
	7749194	Oct 30, 2028				DP
	7918823	Nov 23, 2024				DP
	7947017	Mar 12, 2028				DP
	8016788	Mar 21, 2025				DP
	8021344	Nov 02, 2029				DP
	8206360	Feb 27, 2027				DP
	8226610	Apr 10, 2029				DP
	8231573	Nov 25, 2028				DP
	8313466	Nov 23, 2024				DP
	8361029	Nov 23, 2024				DP
	8425462	Nov 23, 2024				DP
	8608698	Nov 23, 2024				DP
	8920377	Nov 23, 2024				DP
	8926594	Mar 31, 2026				DP
	9056170	Nov 23, 2024				DP
	9149579	Jul 19, 2025				U-1758
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640	001 9119876	Mar 13, 2035				DP
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N 021504	001 6629968	Jun 30, 2020	DS			DP
	6635045	Jun 29, 2021	DS			DP

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLERENONE - INSPRA</u>						
N 021437 001	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPRA</u>						
N 021437 002	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPRA</u>						
N 021437 003	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N 020718 001	5807825	Sep 15, 2015	U-244			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N 020718 002	5807825	Sep 15, 2015	U-244			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS		NCE	Nov 15, 2015
	6469182	Jun 16, 2019	U-1096			
	7470720	Jun 16, 2019	DP			
	8097648	Jan 22, 2021	U-1096			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERTAPENEM SODIUM - INVANZ</u>						
N 021337 001	5478820	Nov 21, 2015	DS DP U-160			
	5952323	May 15, 2017	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
	8372431	Apr 17, 2030	DP		NCE	Nov 08, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
	8372431	Apr 17, 2030	DP		NCE	Nov 08, 2018

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
	8372431	Apr 17, 2030	DP		NCE	Nov 08, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
	8372431	Apr 17, 2030	DP		NCE	Nov 08, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
	8372431	Apr 17, 2030	DP		NCE	Nov 08, 2018
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	5900424	May 04, 2016	DS	U-373		
	5900424	May 04, 2016	DS	U-729		
	5900424	May 04, 2016	DS	U-770		
	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP	U-729		
	6369085	May 25, 2018	DS DP	U-770		
	6428810	Nov 03, 2019		DP U-469		
	6428810	Nov 03, 2019		DP U-729		
	6428810	Nov 03, 2019		DP U-770		
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018		U-1417		
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	5900424	May 04, 2016	DS	U-373		
	5900424	May 04, 2016	DS	U-729		
	5900424	May 04, 2016	DS	U-770		
	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP	U-729		
	6369085	May 25, 2018	DS DP	U-770		
	6428810	Nov 03, 2019		DP U-469		
	6428810	Nov 03, 2019		DP U-729		
	6428810	Nov 03, 2019		DP U-770		
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018		U-1417		
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	5900424	May 04, 2016	DS	U-729		
	5900424	May 04, 2016	DS	U-773		
	5900424	May 04, 2016	DS	U-1207		
	6369085	May 25, 2018	DS DP	U-729		
	6369085	May 25, 2018	DS DP	U-773		
	6369085	May 25, 2018	DS DP	U-1207		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-773			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 003	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 004	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 022101 001	5900424	May 04, 2016	DS U-858			
	6369085	May 25, 2018	DS DP U-858			
	6428810	Nov 03, 2019	DP U-858			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5714504*PED	Aug 03, 2015			RTO	Mar 28, 2017
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 01	5900424	May 04, 2016	DS U-1783			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1784			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1785			
	6428810*PED	May 03, 2020				
	7411070	May 18, 2018	DS			
	7411070*PED	Nov 18, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031				
	9161920	May 31, 2022		U-1661		
	9198888	May 31, 2022		U-1760		
				U-1781		
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	5900424	May 04, 2016	DS		U-1053	
	6369085	May 25, 2018	DS DP		U-1053	
	6926907	Feb 28, 2023			U-1052	
	7411070	May 25, 2018	DS		U-1053	
	7745466	Oct 13, 2018			U-1053	
	8557285	May 31, 2022			DP	
	8852636	May 31, 2022			U-1052	
	8858996	May 31, 2022			U-1052	
	8945621	Oct 17, 2031			U-1661	
	9161920	May 31, 2022			U-1760	
	9198888	May 31, 2022			U-1781	
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001					D-138	Mar 04, 2017
					I-679	Mar 04, 2017
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002					D-138	Mar 04, 2017
					I-679	Mar 04, 2017
<u>ESTRADIOL - VAGIFEM</u>						
N 020908 002	5860946	Jul 01, 2017		DP		
	7018992	Sep 17, 2022			U-1023	
<u>ESTRADIOL - MENOSTAR</u>						
N 021674 001	5891868	Nov 21, 2017		DP	U-594	
	6692763	Nov 21, 2017		DP	U-594	
<u>ESTRADIOL - ELESTRIN</u>						
N 021813 001	7198801	Jun 25, 2022		DP		
	7470433	Aug 03, 2021		DP		
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6299900	Feb 19, 2017		DP	U-888	
	6299900	Feb 19, 2017		DP	U-889	
	6818226	Feb 19, 2017		DP	U-888	
	6818226	Feb 19, 2017		DP	U-889	
	6923983	Feb 19, 2017		DP	U-888	
	6923983	Feb 19, 2017		DP	U-889	
	6978945	Jul 31, 2022		DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	6841716	Apr 27, 2020		DP		
	8231906	Jul 04, 2030		DS DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	6841716	Apr 27, 2020		DP		
	8231906	Jul 04, 2030		DS DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	6841716	Apr 27, 2020		DP		
	8231906	Jul 04, 2030		DS DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	6841716	Apr 27, 2020		DP		
	8231906	Jul 04, 2030		DS DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020		DP		
	8231906	Jul 04, 2030		DS DP		
<u>ESTRADIOL ACETATE - FEMRING</u>						
N 021367 001	5855906	Dec 19, 2015			U-508	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL ACETATE - FEMRING</u>						
N 021367	002 5855906	Dec 19, 2015	U-508			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	001 6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	002 6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	003 6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N 021040	001 6747019	Mar 20, 2020	U-311			
	7320970	Mar 30, 2020	DP U-844			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992	001 5908638	Jul 26, 2015	DP			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992	002 5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992	003 5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992	004 5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992	005 5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443	001 6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443	002 6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443	003 6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443	004 6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443	005 6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESZOPICLONE - LUNESTA</u>						
N 021476	001				M-61	Oct 10, 2015
					PED	Apr 10, 2016



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N 021476	002				M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476	003				M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO</u>						
N 021241	001	6214815	Jun 09, 2019	U-112		
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840	001	7320969	Jan 30, 2024	U-828		
		7615545	Jun 15, 2023	U-1		
		7855190	Dec 05, 2028	U-1		
		7858605	Jun 23, 2023	DP		
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262	001	7615545	Jun 15, 2023	U-1		
		7855190	Dec 05, 2028	U-1		
		7858605	Jun 23, 2023	DP		
<u>ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING</u>						
N 021187	001	5989581	Apr 08, 2018			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N 020946	001	6156742	Dec 05, 2020	U-374		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE</u>						
N 021544	001	5898032	Jun 23, 2017	U-1		
		RE39861	Jun 23, 2017	U-828		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL</u>						
N 021864	001	6500814	Sep 03, 2018	U-1		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061	001	8415332	Mar 11, 2029	DP	NP	Mar 28, 2016
		8450299	Oct 07, 2025	U-1		
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>						
N 021180	001	5876746	Nov 20, 2015	DP U-514		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE</u>						
N 021490	001	6667050	Apr 06, 2019	DP U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 022573	001	6667050	Apr 06, 2019	DP U-828		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501	001	7704984	Feb 02, 2029	U-1090		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667	001	6667050	Apr 06, 2019	DP U-1	NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426	001	6652880	Mar 29, 2020	DP		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654	001	6667050	Apr 06, 2019	DP U-1		
		7704984	Feb 02, 2029	U-1		
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190	001				ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002	8722037	Sep 28, 2027	DP		
		8888745	Aug 28, 2026	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	001	6878717				
		Nov 05, 2019	U-256			
		6878717				
		Nov 05, 2019	U-1016			
		6878717				
		Nov 05, 2019	U-1237			
		7037917				
		Dec 13, 2020	DS DP U-256			
		7037917				
		Dec 13, 2020	DS DP U-1016			
		7037917				
		Dec 13, 2020	DS DP U-1237			
		7887845				
		Mar 25, 2019	DP			
		8003789				
		Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	002	6878717				
		Nov 05, 2019	U-256			
		6878717				
		Nov 05, 2019	U-1016			
		6878717				
		Nov 05, 2019	U-1237			
		7037917				
		Dec 13, 2020	DS DP U-256			
		7037917				
		Dec 13, 2020	DS DP U-1016			
		7037917				
		Dec 13, 2020	DS DP U-1237			
		7887845				
		Mar 25, 2019	DP			
		8003789				
		Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	003	6878717				
		Nov 05, 2019	U-256			
		6878717				
		Nov 05, 2019	U-1016			
		6878717				
		Nov 05, 2019	U-1237			
		7037917				
		Dec 13, 2020	DS DP U-1237			
		7887845				
		Mar 25, 2019	DP			
		8003789				
		Nov 01, 2019	DS DP			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	001	5665772				
		Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
		5665772				
		Sep 09, 2019	DS DP U-1365			
		5665772*PED				
		Mar 09, 2020				
		6004973				
		Jul 12, 2016	DP U-1049			
		6004973				
		Jul 12, 2016	DP U-1365			
		6004973*PED				
		Jan 12, 2017				
		6239124				
		Aug 11, 2017	U-1049			
		6455518				
		Jul 29, 2017	U-1049			
		6455518				
		Jul 29, 2017	U-1365			
		6455518*PED				
		Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	002	5665772				
		Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
		5665772				
		Sep 09, 2019	DS DP U-1365			
		5665772*PED				
		Mar 09, 2020				
		6004973				
		Jul 12, 2016	DP U-1049			
		6004973				
		Jul 12, 2016	DP U-1365			
		6004973*PED				
		Jan 12, 2017				
		6239124				
		Aug 11, 2017	U-1049			
		6455518				
		Jul 29, 2017	U-1049			
		6455518				
		Jul 29, 2017	U-1365			
		6455518*PED				
		Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	003	5665772				
		Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
		5665772				
		Sep 09, 2019	DS DP U-1365			
		5665772*PED				
		Mar 09, 2020				
		6004973				
		Jul 12, 2016	DP U-1049			
		6004973				
		Jul 12, 2016	DP U-1365			
		6004973*PED				
		Jan 12, 2017				
		6239124				
		Aug 11, 2017	U-1049			
		6455518				
		Jul 29, 2017	U-1049			
		6455518				
		Jul 29, 2017	U-1365			
		6455518*PED				
		Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	001	5665772				
		Sep 09, 2019	DS DP		I-655	Jul 20, 2015
		6004973				
		Jul 12, 2016	DP		ODE	Oct 29, 2017
		7297703				
		Dec 06, 2019	DP		ODE	May 05, 2018
		7741338				
		Dec 06, 2019	DP		ODE	Apr 26, 2019
		8410131				
		Nov 01, 2025	DS DP U-1368		PED	Oct 26, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131*PED	May 01, 2026			PED	Apr 29, 2018
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2018
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2019
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028		U-1681		
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	6004973	Jul 12, 2016		DP	ODE	Oct 29, 2017
	7297703	Dec 06, 2019		DP	ODE	May 05, 2018
	7741338	Dec 06, 2019		DP	ODE	Apr 26, 2019
	8410131	Nov 01, 2025	DS DP U-1368		PED	Oct 26, 2015
	8410131*PED	May 01, 2026			PED	Apr 29, 2018
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2018
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2019
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028		U-1681		
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	6004973	Jul 12, 2016		DP	ODE	Oct 29, 2017
	7297703	Dec 06, 2019		DP	ODE	May 05, 2018
	7741338	Dec 06, 2019		DP	ODE	Apr 26, 2019
	8410131	Nov 01, 2025	DS DP U-1368		PED	Oct 26, 2015
	8410131*PED	May 01, 2026			PED	Apr 29, 2018
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2018
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2019
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028		U-1681		
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	6004973	Jul 12, 2016		DP	ODE	Oct 29, 2017
	7297703	Dec 06, 2019		DP	ODE	May 05, 2018
	7741338	Dec 06, 2019		DP	ODE	Apr 26, 2019
	8410131	Nov 01, 2025	DS DP U-1368		PED	Oct 26, 2015
	8410131*PED	May 01, 2026			PED	Apr 29, 2018
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2018
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2019
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028		U-1681		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016		DP	PED	Apr 29, 2018
	7297703	Dec 06, 2019		DP		
	8617598	Sep 27, 2022		DP		
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016		DP	PED	Apr 29, 2018
	7297703	Dec 06, 2019		DP		
	8617598	Sep 27, 2022		DP		
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016		DP	PED	Apr 29, 2018
	7297703	Dec 06, 2019		DP		
	8617598	Sep 27, 2022		DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	003	8617598*PED	Mar 27, 2023			
		8778962	Feb 18, 2022	U-1541		
		8778962*PED	Aug 18, 2022			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773	001	5424286	Dec 01, 2016	U-653	M-148	Nov 24, 2017
		5424286	Dec 01, 2016	U-1108		
		6858576	Jan 06, 2017	U-656		
		6858576	Jan 06, 2017	U-1108		
		6872700	Jan 14, 2020	U-654		
		6902744	Jan 14, 2020	DP		
		6956026	Jan 07, 2018	U-687		
		6956026	Jan 07, 2018	U-1074		
		6956026	Jan 07, 2018	U-1623		
		7297761	Oct 15, 2017	DP		
		7521423	Oct 15, 2017	DP		
		7741269	Jan 07, 2018	U-653		
		7741269	Jan 07, 2018	U-1074		
		7741269	Jan 07, 2018	U-1108		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773	002	5424286	Dec 01, 2016	U-653	M-148	Nov 24, 2017
		5424286	Dec 01, 2016	U-1108		
		6858576	Jan 06, 2017	U-656		
		6858576	Jan 06, 2017	U-1108		
		6872700	Jan 14, 2020	U-654		
		6902744	Jan 14, 2020	DP		
		6956026	Jan 07, 2018	U-687		
		6956026	Jan 07, 2018	U-1074		
		6956026	Jan 07, 2018	U-1623		
		7297761	Oct 15, 2017	DP		
		7521423	Oct 15, 2017	DP		
		7741269	Jan 07, 2018	U-653		
		7741269	Jan 07, 2018	U-1074		
		7741269	Jan 07, 2018	U-1108		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200	001	5424286	Dec 01, 2016	U-1108	M-162	Sep 24, 2018
		6479065	Aug 10, 2020	DP		
		6495164	May 25, 2020	DP		
		6667061	May 25, 2020	DP		
		6824822	Oct 09, 2022	DP		
		6858576	Jan 06, 2017	U-656		
		6872700	Jan 14, 2020	U-654		
		6956026	Jan 07, 2018	U-687		
		7223440	Aug 31, 2021	DP		
		7456254	Jun 30, 2025	DP	U-1223	
		7563871	Apr 15, 2024	DP		
		7612176	Apr 13, 2025	DP	U-1223	
		7741269	Jan 07, 2018	U-1224		
		8216180	Jan 12, 2028	DP		
		8329648	Aug 18, 2026	U-1313		
		8431685	Apr 13, 2025	DP	U-412	
		8439864	Mar 25, 2028	DP		
		8461105	Apr 13, 2025	DP	U-412	
		8906851	Aug 18, 2026	U-1313		
<u>EZETIMIBE - ZETIA</u>						
N 021445	001	7030106	Jan 25, 2022	DP		
		7612058	Oct 30, 2025	U-1027		
		7612058	Oct 30, 2025	U-1173		
		7612058*PED	Apr 30, 2026			
		RE37721	Oct 25, 2016	DS DP	U-473	
		RE42461	Oct 25, 2016	DS DP	U-473	
		RE42461	Oct 25, 2016	DS DP	U-1173	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687	001	RE37721	Oct 25, 2016	DS DP U-473		
		RE42461	Oct 25, 2016	DS DP U-473		
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687	002	RE37721	Oct 25, 2016	DS DP U-473		
		RE42461	Oct 25, 2016	DS DP U-473		
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687	003	RE37721	Oct 25, 2016	DS DP U-473		
		RE42461	Oct 25, 2016	DS DP U-473		
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687	004	RE37721	Oct 25, 2016	DS DP U-473		
		RE42461	Oct 25, 2016	DS DP U-473		
<u>EZOGABINE - POTIGA</u>						
N 022345	001				NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N 022345	002				NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N 022345	003				NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N 022345	004				NCE	Jun 10, 2016
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363	001	5840763	Sep 01, 2015	U-96		
		5916893	Sep 01, 2015	U-96		
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363	002	5840763	Sep 01, 2015	U-96		
		5916893	Sep 01, 2015	U-96		
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363	003	5840763	Sep 01, 2015	U-96		
		5916893	Sep 01, 2015	U-96		
<u>FAMOTIDINE - PEPCID AC</u>						
N 020325	001	5854267	Dec 29, 2015	U-267		
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801	001	5854267	Dec 29, 2015	U-267		
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801	002	6814978	Aug 26, 2021	DP		
<u>FAMOTIDINE - PEPCID AC</u>						
N 020902	001	5854267	Dec 29, 2015	U-368		
<u>FAMOTIDINE - FLUXID</u>						
N 021712	001	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>FAMOTIDINE - FLUXID</u>						
N 021712	002	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519	001	8067033	Jul 18, 2026	DP		
		8067451	Jul 18, 2026	DP U-1196		
		8309127	Jul 18, 2026	DP		
		8318202	Jul 18, 2026	DP		
		8449910	Jul 18, 2026	DP		
		8501228	Jul 18, 2026	U-1196		
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	001	5614520	Mar 25, 2019	DS DP U-954		
		6225474	Jun 18, 2019	DS		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	001	7361676	Mar 08, 2024	DP		
		8372872	Sep 08, 2031	U-1346		
		9107912	Sep 08, 2031	U-1346		
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	002	5614520	Mar 25, 2019	DS DP	U-954	
		6225474	Jun 18, 2019	DS		
		7361676	Mar 08, 2024	DP		
		8372872	Sep 08, 2031	U-1346		
		9107912	Sep 08, 2031	U-1346		
<u>FENOFIBRATE - TRICOR</u>						
N 021203	001	6074670	Jan 09, 2018			
		6277405	Jan 09, 2018			
		6589552	Jan 09, 2018			
		6652881	Jan 09, 2018	DP		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		
<u>FENOFIBRATE - TRICOR</u>						
N 021203	003	6074670	Jan 09, 2018			
		6277405	Jan 09, 2018			
		6589552	Jan 09, 2018			
		6652881	Jan 09, 2018	DP		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	001	6696084	Sep 11, 2021	DS DP	U-680	
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	002	6696084	Sep 11, 2021	DS DP	U-680	
<u>FENOFIBRATE - TRICOR</u>						
N 021656	001	6277405	Jan 09, 2018	DS		
		6375986	Sep 21, 2020	DP	U-615	
		6652881	Jan 09, 2018	DS		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		
		7276249	Feb 21, 2023	DP		
		7320802	Feb 21, 2023	U-847		
<u>FENOFIBRATE - TRICOR</u>						
N 021656	002	6277405	Jan 09, 2018	DS		
		6375986	Sep 21, 2020	DP	U-615	
		6652881	Jan 09, 2018	DS		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		
		7276249	Feb 21, 2023	DP		
		7320802	Feb 21, 2023	U-847		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	001	7101574	Aug 20, 2020	DS DP		
		7863331	Aug 08, 2020	U-1106		
		7863331	Aug 08, 2020	U-1107		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	003	7101574	Aug 20, 2020	DS DP		
		7863331	Aug 08, 2020	U-1106		
		7863331	Aug 08, 2020	U-1107		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	004	8026281	Apr 22, 2025	U-1447		
		8026281	Apr 22, 2025	U-1448		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	005	8026281	Apr 22, 2025	U-1447		
		8026281	Apr 22, 2025	U-1448		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	001	7658944				
		8124125				
		8481078				
		9173847				
			Dec 09, 2024	DP		
			Oct 01, 2024	DP	U-1234	
			Oct 01, 2024	DP	U-1416	
			Oct 01, 2024	DP		
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	002	7658944				
		8124125				
		8481078				
		9173847				
			Dec 09, 2024	DP		
			Oct 01, 2024	DP	U-1234	
			Oct 01, 2024	DP	U-1416	
			Oct 01, 2024	DP		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	001	7569612				
		7741373				
		7741374				
		7741374				
		7915247				
		7915247				
		7915247				
			Aug 20, 2027		U-1000	
			Aug 20, 2027		U-1059	
			Aug 20, 2027		U-1060	
			Aug 20, 2027		U-1061	
			Aug 20, 2027		U-1000	
			Aug 20, 2027		U-1059	
			Aug 20, 2027		U-1061	
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	002	7569612				
		7741373				
		7741374				
		7741374				
		7915247				
		7915247				
		7915247				
			Aug 20, 2027		U-1000	
			Aug 20, 2027		U-1059	
			Aug 20, 2027		U-1060	
			Aug 20, 2027		U-1061	
			Aug 20, 2027		U-1000	
			Aug 20, 2027		U-1059	
			Aug 20, 2027		U-1061	
<u>FENTANYL - SUBSYS</u>						
N 202788	001	8486972				
		8486973				
		8835459				
		8835460				
			Apr 27, 2030	DP		
			Apr 27, 2030		U-55	
			Jan 25, 2027	DP		
			Jan 25, 2027	DP	U-55	
<u>FENTANYL - SUBSYS</u>						
N 202788	002	8486972				
		8486973				
		8835460				
			Apr 27, 2030	DP		
			Apr 27, 2030		U-55	
			Jan 25, 2027	DP	U-55	
<u>FENTANYL - SUBSYS</u>						
N 202788	003	8486972				
		8486973				
		8835459				
		8835460				
			Apr 27, 2030	DP		
			Apr 27, 2030		U-55	
			Jan 25, 2027	DP		
			Jan 25, 2027	DP	U-55	
<u>FENTANYL - SUBSYS</u>						
N 202788	004	8486972				
		8486973				
		8835459				
		8835460				
			Apr 27, 2030	DP		
			Apr 27, 2030		U-55	
			Jan 25, 2027	DP		
			Jan 25, 2027	DP	U-55	
<u>FENTANYL - SUBSYS</u>						
N 202788	005	8486972				
		8486973				
		8835460				
			Apr 27, 2030	DP		
			Apr 27, 2030		U-55	
			Jan 25, 2027	DP	U-55	
<u>FENTANYL - SUBSYS</u>						
N 202788	006	8486972				
		8486973				
		8835459				
		8835460				
			Apr 27, 2030	DP		
			Apr 27, 2030		U-55	
			Jan 25, 2027	DP		
			Jan 25, 2027	DP	U-55	
<u>FENTANYL - SUBSYS</u>						
N 202788	007	8486972				
		8486973				
		8835459				
		8835460				
			Apr 27, 2030	DP		
			Apr 27, 2030		U-55	
			Jan 25, 2027	DP		
			Jan 25, 2027	DP	U-55	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 006	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020		U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020		U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020		U-767		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	5697896	Dec 16, 2016	DP			
	5843014	Dec 01, 2015	DP			
	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP U-736			
	6881208	Apr 19, 2022	U-736			
	6975902	Apr 01, 2024	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP U-1432			
	8895612	Jan 08, 2027	DP U-1620			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874	001	5753706				
		7767851				
		8093423				
		8299298				
		8338642				
		8609896				
		8754257				
		8754258				
		8846976				
		8901349				
		9050316				
			Feb 03, 2017	DP	U-1577	
			Feb 18, 2024	DS DP		
			Apr 21, 2026		U-1577	
			Feb 18, 2024	DP		
			Feb 18, 2024	DS DP	U-1577	
			Feb 18, 2024	DP		
			Feb 18, 2024	DP		
			Feb 18, 2024		U-1577	
			Feb 18, 2024		U-1577	
			Feb 18, 2024		U-1577	
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317	001	6689275				
		6779468				
		7816404				
			Dec 31, 2016		U-1656	
			Dec 31, 2016		U-1656	
			Apr 17, 2029	DP	U-1656	
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180	001	6599498				
		7553479				
		7871597				
		8501158				
		8591864				
		8926947				
			Jun 30, 2023	DS DP		
			Mar 08, 2020	DS DP		
			Mar 08, 2020	DS DP		
			Mar 08, 2020		U-1422	
			Mar 08, 2020	DP		
			Mar 08, 2020	DS DP		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	001	6858650				
		7384980				
		7807715				
		7855230				
		7985772				
		8088398				
		8338478				
		8501723				
			Jul 03, 2022	DS	U-913	
			May 11, 2019	DS DP	U-913	
			Jun 07, 2027	DP	U-913	
			May 11, 2019		U-913	
			May 11, 2019	DS DP	U-913	
			Jun 07, 2027	DP	U-913	
			May 11, 2019	DS DP	U-913	
			Jun 07, 2027	DP	U-913	
			Jun 07, 2027	DP		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	002	6858650				
		7384980				
		7807715				
		7855230				
		7985772				
		8088398				
		8338478				
		8501723				
			Jul 03, 2022	DS	U-913	
			May 11, 2019	DS DP	U-913	
			Jun 07, 2027	DP	U-913	
			May 11, 2019		U-913	
			May 11, 2019	DS DP	U-913	
			Jun 07, 2027	DP	U-913	
			May 11, 2019	DS DP	U-913	
			Jun 07, 2027	DP		
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 020625	001	6037353				
			Mar 14, 2017		U-138	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 020872	005	6037353				
			Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 020872	006	6037353				
			Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872	007	6037353				
			Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872	008	6037353				
			Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872	009	6037353				
			Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872	010	6037353				
			Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909	002	6037353				
		6037353				
			Mar 14, 2017		U-1158	
			Mar 14, 2017		U-1466	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909 002	6723348	Nov 26, 2021	DP U-1466			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909 003	6037353	Mar 14, 2017				
	6723348	Nov 26, 2021	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 021963 001	6037353	Mar 14, 2017	U-772			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	6037353	Mar 14, 2017	U-1157			
	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	6037353	Mar 14, 2017	U-1157			
	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N 020786 002	6037353	Mar 14, 2017	U-1159			
	6039974	Jul 31, 2018	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N 021704 002	6037353	Mar 14, 2017	U-1159			
	6613357	Dec 25, 2020	DP U-1159			
	RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027	U-319			
	8586551	Apr 12, 2024	DS DP			
	8859510	Jul 31, 2027	U-319			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP		NCE	Dec 17, 2019
	6432948	Apr 12, 2017	DS DP		PED	Jun 17, 2020
	8536167	Aug 08, 2031	U-1679			
	9119859	Jul 02, 2030	U-1679			
<u>FINASTERIDE - PROSCAR</u>						
N 020180 001	5942519	Oct 23, 2018	U-280			
<u>FINGOLIMOD - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2019	DS U-1086		NCE	Sep 21, 2015
	6004565	Sep 23, 2017	U-1086			
	8324283	Mar 29, 2026				
	9187405	Jun 25, 2027	U-1086			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	7807135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N 022273	001 7148207	Dec 20, 2022	DP U-944		ODE	Dec 18, 2015
	7547776	Dec 10, 2018	DS			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247	001 5776433	Jul 07, 2015	DP		M-128	Aug 28, 2016
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N 021737	001 6217895	Mar 22, 2019	DP U-708			
	6548078	Mar 22, 2019	DP U-708			
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923	001 6217895	Mar 22, 2019	DP U-1597		NP	Sep 26, 2017
	6375972	Apr 26, 2020	DP U-1597			
	6548078	Mar 22, 2019	DP U-1597			
	8252307	Jun 27, 2019	DP			
	8871241	Aug 12, 2027	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001 7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
	8247395	Oct 22, 2022	DP			
	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N 021758	001 6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023	U-861			
	7794738	Sep 11, 2022	U-1084			
	8232264	Mar 09, 2023	DP			
<u>FLUOROURACIL - CARAC</u>						
N 020985	001 6670335	Jun 02, 2021	DP U-68			
<u>FLUOROURACIL - TOLAK</u>						
N 022259	001 7169401	Jul 18, 2023	DP		NP	Sep 18, 2018
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	001 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	003 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	004				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	006 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>						
N 021235	001 5910319	May 29, 2017	U-396			
	5985322	May 29, 2017	U-397			
	RE39030	May 29, 2017	DP U-396			
	RE39030	May 29, 2017	DP U-397			
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	001 6960577	Nov 01, 2017	U-962		M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	002 5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	003 5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	004 5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005	5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Apr 14, 2027	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023	U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Apr 14, 2027	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023	U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	6858596	Aug 03, 2021	DP U-808			
	7101866	Aug 03, 2021	DS DP U-808			
	7541350	Aug 03, 2021	DP U-988			
	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	5873360	Feb 23, 2016	DP		NP	Aug 20, 2017
	7101866	Aug 03, 2021	DS DP U-1559			
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	5873360	Feb 23, 2016	DP		NP	Aug 20, 2017
	7101866	Aug 03, 2021	DS DP U-1559			
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1401		NP	May 10, 2016
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	002	5873360	Feb 23, 2016	DP	NP	Apr 30, 2018
		6537983	Aug 03, 2021	DP U-1691		
		6759398	Aug 03, 2021	DP U-1691		
		7101866	Aug 03, 2021	DS DP U-1691		
		7439393	Sep 11, 2022	DS DP U-1691		
		7629335	Aug 03, 2021	DP		
		7776895	Sep 11, 2022	DP		
		8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8511304	Jun 14, 2027	DP U-1691		
		8534281	Aug 10, 2029	DP		
		8746242	Oct 11, 2030	DP		
		RE44874	Mar 23, 2023	DS DP U-1691		
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
N 020833	001	5873360	Feb 23, 2016	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
N 020833	002	5873360	Feb 23, 2016	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
N 020833	003	5873360	Feb 23, 2016	DP		
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152	001	7300669	Oct 20, 2019	DP U-835	NPP	Jan 16, 2018
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	001	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6743413	Jun 01, 2021	U-581		
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	002	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6743413	Jun 01, 2021	U-581		
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	003	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6743413	Jun 01, 2021		U-581		
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF</u>						
N 205434 001					M-147	Jul 23, 2017
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077 001	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077 002	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077 003	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017				
	6743413	Jun 01, 2021		U-1591		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6743413	Jun 01, 2021		U-1591		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPRIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6743413	Jun 01, 2021		U-1591		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N 021192 001	6242003	Apr 13, 2020				
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 001	7465462	May 10, 2020	DP	U-929		
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 002	7465462	May 10, 2020	DP	U-929		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 004	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 005	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5929028	Jan 14, 2018	DP	U-567		
	5929028	Jan 14, 2018	DP	U-1366		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5929028	Jan 14, 2018	DP	U-567		
	5929028	Jan 14, 2018	DP	U-1366		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5929028	Jan 14, 2018	DP	U-567		
	5929028	Jan 14, 2018	DP	U-1366		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5929028	Jan 14, 2018	DP	U-567		
	5929028	Jan 14, 2018	DP	U-1366		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5929028	Jan 14, 2018	DP	U-1366		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5929028	Jan 14, 2018	DP	U-1366		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684	001	7446090	Aug 23, 2019	DP		
		7741268	Apr 02, 2024	DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684	002	7446090	Aug 23, 2019	DP		
		7741268	Apr 02, 2024	DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684	003	7446090	Aug 23, 2019	DP		
		7741268	Apr 02, 2024	DP		
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696	001	7553863	Jun 30, 2027	DS DP		
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N 020831	001	6488027	Mar 08, 2019			
		6887459	Nov 28, 2020	U-762		
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007	001	6667344	Jun 22, 2021	DP		
		6814953	Jun 22, 2021	DP	U-813	
		7348362	Jun 22, 2021	DP		
		7462645	Jun 22, 2021	DP	U-813	
		8623922	Jun 22, 2021	DP		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	001	6068832	Aug 27, 2017	DP	U-1068	
		7067502	May 21, 2020	DP	U-1068	
		7566705	May 21, 2020	DP	U-1068	
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	002	6068832	Aug 27, 2017	DP	U-1068	
		7067502	May 21, 2020	DP	U-1068	
		7566705	May 21, 2020	DP	U-1068	
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 021548	001	6436989	Dec 24, 2017	DS DP	U-257	PED Oct 27, 2015
		6514953	Jul 15, 2019	DS DP	U-257	
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 022116	001	6436989	Dec 24, 2017	DS DP	U-257	PED Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	001	5691336	Mar 04, 2019	DS DP		
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	002	5691336	Mar 04, 2019	DS DP		
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N 022244	001	6204257	Jul 01, 2022	DS DP	U-945	
		6872838	Aug 07, 2018	DS		
<u>FROVATRIPTAN SUCCINATE - FROVA</u>						
N 021006	001	5464864	Nov 07, 2015		U-436	
		5827871	Oct 27, 2015		U-436	
<u>FULVESTRANT - FASLODEX</u>						
N 021344	001	6774122	Jan 09, 2021		U-596	M-123 Nov 09, 2015
		7456160	Jan 09, 2021		U-596	
		8329680	Jan 09, 2021		U-596	
		8466139	Jan 09, 2021		U-596	
		8466139*PED	Jul 09, 2021			
<u>GABAPENTIN - NEURONTIN</u>						
N 020235	001	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 020235	002	6054482	Apr 25, 2017			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - NEURONTIN</u>						
N 020235	003	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 020882	001	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 020882	002	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 021129	001	6054482	Apr 25, 2017			
		7256216	May 28, 2022	DP		
<u>GABAPENTIN - GRALISE</u>						
N 022544	001	6340475	Sep 19, 2016	DP	ODE	Jan 28, 2018
		6488962	Jun 20, 2020	DP		
		6635280	Sep 19, 2016	DP		
		6723340	Oct 25, 2021	DP		
		7438927	Feb 26, 2024	U-1114		
		7731989	Oct 25, 2022	DP		
		8192756	Oct 25, 2022	DP U-1114		
		8252332	Oct 25, 2022	DP U-1114		
		8333992	Oct 25, 2022	DP U-1114		
<u>GABAPENTIN - GRALISE</u>						
N 022544	002	6340475	Sep 19, 2016	DP	ODE	Jan 28, 2018
		6488962	Jun 20, 2020	DP		
		6635280	Sep 19, 2016	DP		
		6723340	Oct 25, 2021	DP		
		7438927	Feb 26, 2024	U-1114		
		7731989	Oct 25, 2022	DP		
		8192756	Oct 25, 2022	DP U-1114		
		8252332	Oct 25, 2022	DP U-1114		
		8333992	Oct 25, 2022	DP U-1114		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	001	6818787	Nov 06, 2022	DS DP	NCE	Apr 06, 2016
		8026279	Nov 10, 2026	DS DP	ODE	Jun 06, 2019
		8048917	Nov 06, 2022	DS DP U-1247		
		8114909	Apr 11, 2026	U-1231		
		8686034	Jan 24, 2025	U-1231		
		8686034	Jan 24, 2025	U-1247		
		8795725	Jun 10, 2029	DP U-1231		
		8795725	Jun 10, 2029	DP U-1247		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	002	6818787	Nov 06, 2022	DS DP	NCE	Apr 06, 2016
		8026279	Nov 10, 2026	DS DP	ODE	Jun 06, 2019
		8048917	Nov 06, 2022	DS DP U-1247		
		8114909	Apr 11, 2026	U-1231		
		8686034	Jan 24, 2025	U-1231		
		8686034	Jan 24, 2025	U-1247		
		8795725	Jun 10, 2029	DP U-1231		
		8795725	Jun 10, 2029	DP U-1247		
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N 021357	001				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N 021357	002				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N 021357	003				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N 021357	004				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N 021358	001				I-654	Jul 06, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N 021358	002				I-654	Jul 06, 2015
<u>GADOBUTROL - GADAVIST</u>						
N 201277	001	5980864	Nov 09, 2016	DS DP U-1119	I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277	002	5980864	Nov 09, 2016	DS DP U-1119	I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277	003	5980864	Nov 09, 2016	DS DP U-1119	I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277	004	5980864	Nov 09, 2016	DS DP U-1119	I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277	005	5980864	Nov 09, 2016	DS DP U-1119	I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277	006				I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711	001	6676929	May 04, 2020	DP		
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711	002	6676929	May 04, 2020	DP		
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	001				NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	002				NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	003				NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	004				NCE	Mar 20, 2018
<u>GADOTERIDOL - PROHANCE</u>						
N 020131	001	5846519	Dec 08, 2015			
<u>GADOTERIDOL - PROHANCE MULTIPACK</u>						
N 021489	001	5846519	Dec 08, 2015			
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090	001	5798092 6039931	Aug 25, 2015 Nov 13, 2021	DS DP U-1239	M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090	002				M-155	Mar 27, 2018
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169	001	6099863 6358527	Jun 06, 2017 Jun 06, 2017	DP U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169	002	6099863 6358527	Jun 06, 2017 Jun 06, 2017	DP U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169	003	6099863 6358527	Jun 06, 2017 Jun 06, 2017	DP U-322		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615	001	7160559	Dec 20, 2019	DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615	002	7160559	Dec 20, 2019	DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615	003	7160559	Dec 20, 2019	DP		
<u>GANCICLOVIR - ZIRGAN</u>						
N 022211	001				ODE	Sep 15, 2016
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057	001	6653286	Jun 16, 2018	U-1354		
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493	001	5880283	Dec 05, 2015			
		6333045	Aug 20, 2019	DP	Y	
		6333045*PED	Feb 20, 2020			
<u>GATIFLOXACIN - ZYMAXID</u>						
N 022548	001	5880283	Dec 05, 2015	DS		
<u>GEFITINIB - IRESSA</u>						
N 021399	001	5770599	May 05, 2017	DS DP U-881		
<u>GEFITINIB - IRESSA</u>						
N 206995	001	5770599	May 05, 2017	DS DP U-1755	NP ODE	Jul 13, 2018 Jul 13, 2022
<u>GEMIFLOXACIN MESYLATE - FACTIVE</u>						
N 021158	001	5776944	Apr 04, 2017	DS DP		
		6262071	Sep 21, 2019		U-513	
		6331550	Sep 21, 2019		U-511	
		6340689	Sep 14, 2019		U-512	
		6455540	Sep 21, 2019		U-511	
		6723734	Mar 20, 2018	DS DP		
		6803376	Sep 21, 2019	DS DP U-608		
		6803376	Sep 21, 2019	DS DP U-609		
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622	003	8232250	Aug 19, 2030	U-441	NP	Jan 28, 2017
		8399413	Aug 19, 2030	U-441		
		8969302	Aug 19, 2030	U-441		
		9155776	Aug 19, 2030	U-441		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925	001	6150383	Jun 19, 2016	U-753		
		6211205	Jun 19, 2016	U-753		
		6303640	Aug 09, 2016	U-753		
		6329404	Jun 19, 2016	DP U-753		
		7538125	Jun 19, 2016	DP		
		7700128	Jan 30, 2027	DP		
		8071130	Jun 08, 2028	DP		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925	002	6150383	Jun 19, 2016	U-753		
		6211205	Jun 19, 2016	U-753		
		6303640	Aug 09, 2016	U-753		
		6329404	Jun 19, 2016	DP U-753		
		7538125	Jun 19, 2016	DP		
		7700128	Jan 30, 2027	DP		
		8071130	Jun 08, 2028	DP		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	001	7358366	Apr 19, 2020	DS		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	002	7358366	Apr 19, 2020	DS		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 001	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 002	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 003	RE44459	Mar 26, 2019	U-1431			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 001	6303146	Jul 14, 2019	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 002	6303146	Jul 14, 2019	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 003	6303146	Jul 14, 2019	U-412			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383		NE	Feb 01, 2016
	8642012	Sep 22, 2030	U-1383		ODE	Feb 01, 2020
	9095559	Mar 09, 2032	U-1383			
<u>GLYCOPYRROLATE - GLYCOPYRROLATE</u>						
A 091182 002					PC	Jun 18, 2016
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571 001	7638552	Aug 20, 2023	U-1076		ODE	Jul 28, 2017
	7816396	Aug 20, 2023	U-1076			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6521260	Jan 31, 2016	DP		NP	Oct 29, 2018
	6528678	Apr 24, 2018	DP			
	7229607	Apr 09, 2021	U-1773			
	7736670	Jun 27, 2021	DP			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8182838	Oct 20, 2028	DP			
	8303991	Jun 27, 2021	DP			
	8435567	Jun 27, 2021	DP			
	8479730	Oct 11, 2028	DP			
	8580306	Jun 27, 2021	DP			
	8956661	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6521260	Jan 31, 2016	DP		NP	Oct 29, 2018
	6582678	Apr 24, 2018	DP			
	6878721	Oct 10, 2020	DS DP U-1773			
	7229607	Apr 09, 2021	U-1773			
	7736670	Jun 27, 2021	DP			
	7820694	Jun 02, 2020	DP U-1773			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8067437	Jun 02, 2020	U-1773			
	8182838	Oct 20, 2028	DP			
	8283362	Jun 02, 2020	DP U-1773			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930	001	8303991	Jun 27, 2021	DP		
		8435567	Jun 27, 2021	DP		
		8479730	Oct 11, 2028	DP		
		8580306	Jun 27, 2021	DP		
		8658673	Jun 02, 2020	DP	U-1773	
		8796307	Jun 02, 2020	DP		
		8956661	Jun 27, 2021	DP		
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 019726	001	7118552	Apr 13, 2022	DP		
		7220247	Apr 09, 2022	DP		
		7500964	Feb 26, 2021	DP		
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 020578	001	7118552	Apr 13, 2022	DP		
		7220247	Apr 09, 2022	DP		
		7500964	Feb 26, 2021	DP		
<u>GRANISETRON - SANCUSO</u>						
N 022198	001	7608282	Oct 22, 2024	DP	U-1011	
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239	001	5952340	Sep 14, 2016		U-519	
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239	002	5952340	Sep 14, 2016		U-519	
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239	004	5952340	Sep 14, 2016		U-519	
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	001	6372252	Apr 28, 2020		U-489	
		6955821	Apr 28, 2020	DP	U-489	
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	002	6372252	Apr 28, 2020		U-489	
		6955821	Apr 28, 2020	DP	U-489	
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	001	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-686	
		7838032	Apr 28, 2020	DP		
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	002	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-686	
		7838032	Apr 28, 2020	DP		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	001	5854290	Sep 21, 2015		U-494	
		5854290*PED	Mar 21, 2016			D-145
		6287599	Dec 20, 2020	DP		M-154
		6287599*PED	Jun 20, 2021			PED
		6811794	Jul 04, 2022	DP	U-494	
		6811794*PED	Jan 04, 2023			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	002	5854290	Sep 21, 2015		U-494	
		5854290*PED	Mar 21, 2016			D-145
		6287599	Dec 20, 2020	DP		M-154
		6287599*PED	Jun 20, 2021			PED
		6811794	Jul 04, 2022	DP	U-494	
		6811794*PED	Jan 04, 2023			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003	5854290	Sep 21, 2015		U-494	
		5854290*PED	Mar 21, 2016			D-145
		6287599	Dec 20, 2020	DP		M-154
						PED

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			M-154	Mar 18, 2018
	6287599	Dec 20, 2020	DP		PED	May 19, 2018
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001	8962028	Jun 19, 2033	DP U-1775			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	6034267	Mar 08, 2016	U-1087			
	7247655	Mar 08, 2016	DP U-1087			
	7348361	Nov 06, 2020	DP U-1087			
	7530461	Jan 11, 2017	DP U-1087			
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058 001	8062652	Jun 16, 2026	U-1197			
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N 021859 001	7767429	Sep 23, 2027	DS DP			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N 020727 001	6465463	Sep 08, 2020	U-71			
	6784177	Sep 08, 2020	U-71			
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 002	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 003	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 005	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 001	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 002	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 001	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 002	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 003	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 004	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 005	6294197	Jun 18, 2017	U-3			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	007	8808740	Dec 21, 2031	DP U-1556		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021	U-1556		
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027	U-1556		
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2021	DP		
		9205056	Oct 30, 2021	DP		
<u>HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN</u>						
N 020716	001	6348216	Jun 10, 2017			
		6599531	Jun 10, 2017			
<u>HYDROCORTISONE BUTYRATE - LOCROID</u>						
N 022076	001	7378405	Dec 19, 2026	DP		
		7981877	Jan 23, 2025	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034	001	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034	002	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	003	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	004	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	005	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019891	001	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	001	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	002	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	003	6589960	Nov 09, 2020	DS DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	001	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	002	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	003	6589960	Nov 09, 2020	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	004	6589960	Nov 09, 2020	DP		
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041	001	5834448	Nov 14, 2016	DP		
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041	002	5834448	Nov 14, 2016	DP U-789		
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N 021945	001				ODE	Feb 03, 2018
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455	001	6143326	Apr 21, 2017	U-642		
		6294196	Oct 07, 2019	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455	002	6294196	Oct 07, 2019	DP		
		7192938	May 06, 2023	U-798		
		7410957	May 06, 2023	U-887		
		7718634	May 06, 2023	U-642		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	7514444	Dec 28, 2026	DS DP	I-680	Feb 12, 2017
		8008309	Dec 28, 2026	DS DP	I-689	Jul 28, 2017
		8476284	Dec 28, 2026	U-1456	I-702	Jan 29, 2018
		8476284	Dec 28, 2026	U-1491	NCE	Nov 13, 2018
		8497277	Dec 28, 2026	U-1456	ODE	Nov 13, 2020
		8497277	Dec 28, 2026	U-1491	ODE	Feb 12, 2021
		8497277	Dec 28, 2026	U-1650	ODE	Jul 28, 2021
		8697711	Dec 28, 2026	DS DP	ODE	Jan 29, 2022
		8703780	Dec 28, 2026	U-1491		
		8735403	Dec 28, 2026	DS DP		
		8754090	Jun 03, 2031	U-1456		
		8754091	Dec 28, 2026	DP		
		8957079	Dec 28, 2026	DS DP		
		8999999	Jun 03, 2031	U-1683		
		8999999	Jun 03, 2031	U-1684		
		9125889	Jun 03, 2031	U-1745		
		9181257	Dec 28, 2026	DS DP		
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N 021472	001	6251426	Jun 25, 2018			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	001	6727286	Nov 27, 2021	DP U-981		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	002	6727286	Nov 27, 2021	DP U-981	D-152	Nov 20, 2018
		8735452	Sep 30, 2029	U-981	NPP	Nov 20, 2018
		8871810	Sep 30, 2029	U-1599		
		9012508	Sep 14, 2030	U-981		
		9114068	Sep 30, 2029	U-1735		
		9138404	Sep 30, 2029	U-1756		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903	001	6342530	Nov 14, 2020	DP U-794		
		6342530	Nov 14, 2020	DP U-1127		
		6344479	Mar 20, 2021	DS DP U-794	Y	
		8415337	Mar 02, 2032	DS DP		
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N 021128	001	6211246	Jun 10, 2019			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150	001	5648333	Jul 15, 2019	DS DP U-1187	NCE ODE	Aug 25, 2016 Aug 25, 2018
<u>ICODEXTRIN - EXTRANEAL</u>						
N 021321	001	6077836	Jun 20, 2017	U-495		
		6248726	Jun 19, 2018	U-495		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	001	8188146	Jan 27, 2020	DS DP		
		8293727	Feb 09, 2030	U-1287		
		8293728	Feb 09, 2030	U-1287		
		8298554	Apr 29, 2030	DP		
		8314086	Feb 09, 2030	U-1287		
		8318715	Feb 09, 2030	U-1287		
		8357677	Feb 09, 2030	U-1287		
		8367652	Feb 09, 2030	U-1287		
		8377920	Feb 09, 2030	U-1287		
		8399446	Feb 09, 2030	U-1287		
		8415335	Feb 09, 2030	U-1287		
		8426399	Feb 09, 2030	U-1287		
		8431560	Feb 09, 2030	U-1287		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	001	8440650	Feb 09, 2030	U-1287		
		8445003	Apr 29, 2030	U-1287		
		8445013	Apr 29, 2030	U-1287		
		8501225	Apr 29, 2030	U-1287		
		8518929	Apr 29, 2030	U-1287		
		8524698	Apr 29, 2030	U-1287		
		8546372	Apr 29, 2030	U-1287		
		8551521	Apr 29, 2030	U-1287		
		8563608	Apr 29, 2030	U-1287		
		8617593	Apr 29, 2030	U-1478		
		8617594	Apr 29, 2030	U-1287		
		8623406	Apr 29, 2030	U-1478		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	001	6800620	Apr 24, 2021	DS U-1560	NCE	Jul 23, 2019
		6949535	Apr 24, 2021	DS U-1560		
		8138195	Apr 24, 2021	DS DP U-1549		
		8492389	Apr 24, 2021	DS DP		
		8637533	Apr 24, 2021	DS DP		
		8865730	Mar 05, 2033	DS DP U-1615		
		8980901	May 12, 2025	U-1678		
		9149477	May 12, 2025	U-1757		
		RE44599	Jul 21, 2025	U-1558		
		RE44599	Jul 21, 2025	U-1615		
		RE44638	Aug 05, 2025	DS DP		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	002	6800620	Apr 24, 2021	DS U-1560	NCE	Jul 23, 2019
		6949535	Apr 24, 2021	DS U-1560		
		8138195	Apr 24, 2021	DS DP U-1549		
		8492389	Apr 24, 2021	DS DP		
		8637533	Apr 24, 2021	DS DP		
		8865730	Mar 05, 2033	DS DP U-1615		
		8980901	May 12, 2025	U-1678		
		9149477	May 12, 2025	U-1757		
		RE44599	Jul 21, 2025	U-1558		
		RE44599	Jul 21, 2025	U-1615		
		RE44638	Aug 05, 2025	DS DP		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	001	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
		RE39198	Nov 15, 2016	DS DP U-971		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	002	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
		RE39198	Nov 15, 2016	DS DP U-971		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	003	8586610	Nov 02, 2027	U-1625		
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	9074255	Dec 17, 2030				
	9074256	Feb 10, 2031				
	9138432	Sep 30, 2025				
	9157121	Apr 05, 2030				
	RE39198	Nov 15, 2016	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8586610	Nov 02, 2027				
	8652776	Aug 31, 2030				
	8999638	Oct 28, 2030				
	9072742	Jan 16, 2031				
	9074254	Dec 28, 2031				
	9074255	Dec 17, 2030				
	9074256	Feb 10, 2031				
	9138432	Sep 30, 2025				
	9157121	Apr 05, 2030				
	RE39198	Nov 15, 2016	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8586610	Nov 02, 2027				
	8652776	Aug 31, 2030				
	8999638	Oct 28, 2030				
	9072742	Jan 16, 2031				
	9074254	Dec 28, 2031				
	9074255	Dec 17, 2030				
	9074256	Feb 10, 2031				
	9138432	Sep 30, 2025				
	9157121	Apr 05, 2030				
	RE39198	Nov 15, 2016	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8586610	Nov 02, 2027				
	8652776	Aug 31, 2030				
	8999638	Oct 28, 2030				
	9072742	Jan 16, 2031				
	9074254	Dec 28, 2031				
	9074255	Dec 17, 2030				
	9074256	Feb 10, 2031				
	9138432	Sep 30, 2025				
	9157121	Apr 05, 2030				
	RE39198	Nov 15, 2016	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8586610	Nov 02, 2027				
	8652776	Aug 31, 2030				
	8999638	Oct 28, 2030				
	9072742	Jan 16, 2031				
	9074254	Dec 28, 2031				
	9074255	Dec 17, 2030				
	9074256	Feb 10, 2031				
	9138432	Sep 30, 2025				
	9157121	Apr 05, 2030				
	RE39198	Nov 15, 2016	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	6894051	May 23, 2019	DS DP			
	6958335	Dec 19, 2021				
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	6894051	May 23, 2019	DS DP			
	6958335	Dec 19, 2021				
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	6894051	May 23, 2019	DS DP		I-666	Jan 25, 2016
	6958335	Dec 19, 2021			ODE	Dec 19, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jan 16, 2019	DS DP	Y	ODE	Jan 25, 2020
	7544799*PED	Jul 16, 2019				
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	6894051	May 23, 2019	DS DP U-649		I-666	Jan 25, 2016
	6958335	Dec 19, 2021	U-791		ODE	Dec 19, 2015
	7544799	Jan 16, 2019	DS DP	Y	ODE	Jan 25, 2020
	7544799*PED	Jul 16, 2019				
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMIQUIMOD - ALDARA</u>						
N 020723 001	7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-172			
	8598196	Aug 18, 2029	U-1455			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002	8222270	Dec 11, 2029	U-68			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
	8658673	Jun 02, 2020	DS DP U-1168			
	8796307	Jun 02, 2020	DS DP			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 001	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 003	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 005	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 006	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001	5776894	Jul 07, 2015	DS DP			
	6123916	Sep 26, 2017	U-1125			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6432452	Aug 19, 2018	U-68		M-169	Nov 19, 2018
	6787161	Aug 19, 2018	U-68		NCE	Jan 23, 2017
	6844013	Dec 13, 2018	U-1221			
	7410656	Aug 19, 2018	U-1222			
	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6432452	Aug 19, 2018	U-68		M-169	Nov 19, 2018
	6787161	Aug 19, 2018	U-68		NCE	Jan 23, 2017
	6844013	Dec 13, 2018	U-1221			
	7410656	Aug 19, 2018	U-1222			
	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N 021172 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172 002	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172 003	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50</u>						
N 021810 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG</u>						
N 020986 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N 020986 004	5866538	Jun 20, 2017	DP			
	RE41956	Jan 21, 2021	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	5866538	Jun 20, 2017	DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP			
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DS DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DS DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DS DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DS DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN GLARGINE - BASAGLAR</u>						
N 205692 001					NP	Dec 16, 2018
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N 021081 001	7476652	Jul 23, 2023	DP			
	7713930	Jun 13, 2023	DP			
	7918833	Sep 23, 2027	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081	002	8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024	DP		
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538	001	7918833	Sep 23, 2027	DP	NP	Feb 25, 2018
		7918833*PED	Mar 23, 2028			
		8512297	Sep 15, 2024	DP		
		8556864	Mar 03, 2024	DP		
		8603044	Mar 02, 2024	DP		
		8679069	Apr 12, 2025	DP		
		8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024	DP		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629	001	6221633	Jun 18, 2018	DS DP U-471		
		6960561	Jan 25, 2023	DP U-471		
		7452860	Mar 22, 2022	DP		
		7696162	Mar 22, 2022	DP U-471		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629	002	6221633	Jun 18, 2018	DS DP U-471		
		6960561	Jan 25, 2023	DP U-471		
		7452860	Mar 22, 2022	DP		
		7696162	Mar 22, 2022	DP U-471		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629	003	6221633	Jun 18, 2018	DS DP U-471		
		6960561	Jan 25, 2023	DP U-471		
		7452860	Mar 22, 2022	DP		
		7696162	Mar 22, 2022	DP U-471		
		7918833	Sep 23, 2027	DP		
		8512297	Sep 15, 2024	DP		
		8556864	Mar 03, 2024	DP		
		8603044	Mar 02, 2024	DP		
		8679069	Apr 12, 2025	DP		
		8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024	DP		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017	002	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018	002	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N 020563	001				NR	Oct 12, 2015
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N 020563	002				NR	Oct 12, 2015
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563	003	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747	001	6034054	Jun 11, 2018	DP U-1707		
		6034054	Jun 11, 2018	DP U-1708		
		6551992	Jun 11, 2018	DP U-1707		
		6551992	Jun 11, 2018	DP U-1708		
		7291132	Aug 09, 2024	DP		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868	001	6257233	May 14, 2019	U-704		
		6546929	May 14, 2019	U-704		
		6582728	Jun 24, 2020	DP		
		6685967	Sep 11, 2018	DP		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868	002	6257233	May 14, 2019	U-704		
		6546929	May 14, 2019	U-704		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 002	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029		U-1537		
	8389470	Jun 29, 2020	DP	U-1697		
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029		U-1537		
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP	U-1538		
	8889099	Jun 29, 2020	DP	U-1621		
	8912193	Jun 12, 2029	DP	U-1538		
	9192675	Jun 12, 2029	DP	U-1788		
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717 002	7291132	Aug 09, 2024	DP			
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781 001	7291132	Aug 09, 2024	DP			
<u>ILOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290 001					I-669 ODE	Mar 20, 2016 Sep 19, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001					NCE	Jan 14, 2016
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	6739333	May 26, 2020	DP			
	6983743	May 26, 2020	DP			
	8474447	Jan 17, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571 001	6403569	Apr 28, 2020		U-449		
	6794370	May 01, 2020		U-606		
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571 002	6403569	Apr 28, 2020		U-449		
	6794370	May 01, 2020		U-606		
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	8147867	Aug 29, 2028	DS DP		NP	Oct 22, 2018
	8329213	May 02, 2025	DS DP			
	8703181	May 02, 2025		U-1434		
	8992970	May 02, 2025	DS DP			
<u>IRON DEXTRAN - DEXFERRUM</u>						
N 040024 001	5624668	Sep 29, 2015				
<u>IRON SUCROSE - VENOFER</u>						
N 021135 001					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N 021135 002					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N 021135 005					NPP	Sep 21, 2015
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ITRACONAZOLE - SPORANOX</u>						
N 020657 001	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - SPORANOX</u>						
N 020966 001	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001	6509038	May 12, 2017	DP	U-1054		
	7081255	May 12, 2017	DP	U-1054		
	8486456	Oct 03, 2028	DP	U-1054		
	8591948	May 12, 2017	DP	U-1054		
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP	U-1694	NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP	U-1694		
	7867996	Feb 22, 2026	DS DP	U-1694		
	7879842	Feb 22, 2026	DS DP	U-1694		
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP	U-1694	NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP	U-1694		
	7867996	Feb 22, 2026	DS DP	U-1694		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	002 7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001 7495103	May 20, 2027	DS DP		I-705	Dec 30, 2017
	8324242	Apr 18, 2027		U-1311	NCE	Jan 31, 2017
	8354427	Jul 06, 2026		U-1311	ODE	Jan 31, 2019
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001 7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027		U-1311		
	8354427	Jul 06, 2026		U-1311		
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	002 7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027		U-1311		
	8354427	Jul 06, 2026		U-1311		
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	001 7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027		U-1311	ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP	U-1718		
	8741933	Nov 08, 2026		U-1717		
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028		U-1717		
	8993600	Dec 11, 2030	DP			
<u>IVERMECTIN - SKLICE</u>						
N 202736	001 6103248	May 22, 2018	DP			
	8791153	Oct 12, 2027	DP			
	8927595	Oct 12, 2027		U-1782		
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255	001 5952372	Sep 18, 2018		U-1631	NP	Dec 19, 2017
	6133310	Apr 26, 2019		U-1631		
	7550440	Apr 22, 2024	DP	U-1631		
	8080530	Apr 22, 2024	DP	U-1631		
	8093219	Apr 22, 2024	DP	U-1631		
	8415311	Apr 22, 2024	DP	U-1631		
	8470788	Apr 22, 2024	DP	U-1631		
	8815816	Apr 22, 2024	DP	U-1631		
	9089587	Mar 13, 2034		U-1631		
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	001 6670384	Jan 23, 2022	DP	U-959		
	6670384	Jan 23, 2022	DP	U-960		
	7022330	Jan 23, 2022	DP	U-958		
	7125899	May 26, 2018	DS DP	U-957		
	7312237	Aug 21, 2024		U-965		
	RE41393	Feb 08, 2022		U-961		
	RE41911	Sep 28, 2020	DS DP	U-961		
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	002 6670384	Jan 23, 2022	DP	U-959		
	6670384	Jan 23, 2022	DP	U-960		
	7022330	Jan 23, 2022	DP	U-958		
	7125899	May 26, 2018	DS DP	U-957		
	7312237	Aug 21, 2024		U-965		
	RE41393	Feb 08, 2022		U-961		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	002 RE41911	Sep 28, 2020	DS DP U-961			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	001 7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-1780			
	8530694	Aug 06, 2027	DS DP U-1780			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027		U-1779		
	9175017	Jun 16, 2029		U-1778		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	002 7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-1780			
	8530694	Aug 06, 2027	DS DP U-1780			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027		U-1779		
	9175017	Jun 16, 2029		U-1778		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	003 7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-1780			
	8530694	Aug 06, 2027	DS DP U-1780			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027		U-1779		
	9175017	Jun 16, 2029		U-1778		
<u>KETOCONAZOLE - EXTINA</u>						
N 021738	001 7553835	Oct 19, 2018	DP U-245			
	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946	001 7179475	Dec 04, 2018	DP U-792			
	8232276	Nov 24, 2020	DP			
	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528	001 8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024	U-1251			
	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
	8648107	May 28, 2024	DP			
	8906950	May 28, 2024	U-1626			
	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N 022382	001 6333044	Dec 25, 2018	DP U-1057			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427	001 7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
	8992952	Aug 05, 2024	DP			
	9192571	Mar 07, 2028	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388	001 8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			
	9066856	Oct 23, 2033	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	001 RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	001				I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	002	RE38551	Mar 17, 2022	DS DP U-1566	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS DP U-1567	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	003	RE38551	Mar 17, 2022	DS DP U-1566	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS DP U-1567	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	004	RE38551	Mar 17, 2022	DS DP U-1566	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS DP U-1567	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022254	001	RE38551	Mar 17, 2022	DS DP U-1565	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS DP U-1568	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022255	001	RE38551	Mar 17, 2022	DS DP U-1566	D-143	Aug 29, 2017
		RE38551	Mar 17, 2022	DS DP U-1567	D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564	001				PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564	001	5905082	May 18, 2016	DS DP	D-147	Mar 23, 2018
		5905082*PED	Nov 18, 2016			
<u>LAMIVUDINE - EPIVIR</u>						
N 020564	003	5905082	May 18, 2016	DS DP	D-147	Mar 23, 2018
		5905082*PED	Nov 18, 2016			
<u>LAMIVUDINE - EPIVIR</u>						
N 020596	001	5905082	May 18, 2016	DS DP	D-147	Mar 23, 2018
		5905082*PED	Nov 18, 2016			
		6004968	Mar 20, 2018	DP U-248		
		6004968*PED	Sep 20, 2018			
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021003	001	5905082	May 18, 2016			
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021004	001	6004968	Mar 20, 2018			
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510	001	7169780	Oct 03, 2023	DS DP		
		7217713	Oct 21, 2022		U-1663	
		7435734	Oct 21, 2022		U-1663	
		7754731	Mar 11, 2029	DS DP	U-1663	
		7820660	Apr 25, 2023	DS		
<u>LAMIVUDINE; ZIDOVUDINE - COMBIVIR</u>						
N 020857	001	5905082	May 18, 2016	DS DP	U-248	
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828	001				PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828	002				PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828	003				PC	Sep 28, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828	004				PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	001				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	002				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	003				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	004				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	005				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	006				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	001				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	002				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	003				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	004				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	001	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	002	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	003	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	004	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	005	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	006	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	001	7919115	Jan 04, 2029	DS DP	M-159	May 18, 2018
		8840925	Jul 02, 2028	DP U-1596		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	002	7919115	Jan 04, 2029	DS DP	M-159	May 18, 2018
		8840925	Jul 02, 2028	DP U-1596		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	003	7919115	Jan 04, 2029	DS DP	M-159	May 18, 2018
		8840925	Jul 02, 2028	DP U-1596		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	7919115	Jan 04, 2029	DS DP		M-159	May 18, 2018
	8840925	Jul 02, 2028	DP U-1596			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001	5595760	Mar 08, 2020	DP U-831		I-701 ODE	Dec 19, 2017 Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002	5595760	Mar 08, 2020	DP U-831		I-701 ODE	Dec 19, 2017 Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003	5595760	Mar 08, 2020	DP U-831		I-701 ODE	Dec 19, 2017 Dec 16, 2021
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID IV</u>						
N 021566 001	7396841	Aug 17, 2021	DP U-947			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 001	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 002	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 003	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 004	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6828320	Jul 11, 2017	U-800			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059	001 6828320	Jul 11, 2017		U-1429		
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
	8821927	Sep 18, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834	001 7964580	Mar 26, 2029	DS DP	U-1470	D-153	Nov 12, 2018
	8088368	May 12, 2030	DS DP		I-718	Nov 12, 2018
	8273341	May 12, 2030		U-1470	I-719	Nov 12, 2018
	8334270	Mar 21, 2028	DS DP	U-1470	I-720	Nov 12, 2018
	8580765	Mar 21, 2028	DS DP	U-1470	NCE	Oct 10, 2019
	8618076	Dec 11, 2030	DS DP	U-1470	NPP	Nov 12, 2018
	8633309	Mar 26, 2029	DS DP	U-1470		
	8735372	Mar 21, 2028		U-1470		
	8822430	May 12, 2030	DS DP	U-1470		
	8841278	May 12, 2030		DP U-1470		
	8889159	Mar 26, 2029		DP U-1470		
	9085573	Mar 21, 2028	DS DP	U-1470		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	001 5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	I-706	Feb 17, 2018
	6281230	Jul 24, 2016		U-1212	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1414	ODE	Feb 17, 2022
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
	9056120	Apr 11, 2023		U-1215		
	9101621	May 15, 2023		U-1216		
	9101622	May 15, 2023		U-1216		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	002 5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	I-706	Feb 17, 2018
	6281230	Jul 24, 2016		U-1212	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1414	ODE	Feb 17, 2022
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		I-706	Feb 17, 2018
	6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1414		ODE	Feb 17, 2022
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		I-706	Feb 17, 2018
	6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1414		ODE	Feb 17, 2022
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		I-706	Feb 17, 2018
	6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1414		ODE	Feb 17, 2022
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		I-706	Feb 17, 2018
	6281230	Jul 24, 2016	U-1212		NS	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	6315720	Oct 23, 2020	U-1210		ODE	Feb 17, 2022
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947	002	7253286	Oct 19, 2021	DS DP	NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP	ODE	Feb 13, 2022
		9006256	Jul 27, 2027	U-1695		
<u>LESINURAD - ZURAMPIC</u>						
N 207988	001				NCE	Dec 22, 2020
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 019732	001	6036976	Dec 13, 2016			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263	002	6036976	Dec 13, 2016			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263	005	6036976	Dec 13, 2016			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263	006	6036976	Dec 13, 2016			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263	007	6036976	Dec 13, 2016	DP		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263	008	6036976	Dec 13, 2016	DP		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	001	6036976	Dec 13, 2016			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	002	6036976	Dec 13, 2016			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	003	6036976	Dec 13, 2016	DP		
		7429559	Jan 13, 2019	DP		
		8815801	Jun 28, 2022	DP		
		8921326	Feb 05, 2031	DP	U-1666	
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020708	001	6036976	Dec 13, 2016			
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N 021088	001	5728396	Jan 30, 2017		U-316	
		5932547	Jun 13, 2017			
		5985305	Jan 30, 2017			
		6113938	Jul 24, 2018			
		6124261	Jun 13, 2017			
		6132420	Jan 30, 2017			
		6156331	Jan 30, 2017			
		6235712	Jun 13, 2017			
		6375978	Dec 17, 2018			
		6395292	Jan 30, 2017			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343	001	6565874	Oct 28, 2018	DP	U-801	
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP	U-801	
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379	001	6565874	Oct 28, 2018	DP	U-801	
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP	U-801	
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488	001	6565874	Oct 28, 2018	DP	U-801	
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP	U-801	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731	001 6565874	Oct 28, 2018	DP U-621			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	U-621			
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696	001 6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696	002 6036976	Dec 13, 2016	DP			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	001 6451289	Mar 21, 2021			M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	002 6451289	Mar 21, 2021			M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	003 6451289	Mar 21, 2021			M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	004 6451289	Mar 21, 2021	DP		M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730	001 5836299	Nov 17, 2015	DP		M-156	Mar 12, 2018
	7256310	Oct 08, 2024	DS DP U-636			
	8765153	Dec 08, 2023	DP			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	001 8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	002 8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	003 8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	004 8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285	001 7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285	002 7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	001 6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	002 6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	003 6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	004 6471992	Feb 20, 2018	DP			
<u>LEVOCARNITINE - CARNITOR</u>						
N 020182	001 6335369	Jan 18, 2021	U-433			
	6429230	Jan 18, 2021	U-433			
	6696493	Jan 18, 2021	U-433			
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N 021721	001 6806256	Feb 26, 2022	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563	001				PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563	002				PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	001	6500829	Mar 07, 2022	DS DP	ODE	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	002	6500829	Mar 07, 2022	DS DP	ODE	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	003	6500829	Mar 07, 2022	DS DP	ODE	Apr 29, 2018
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	001	8481598	Mar 02, 2031	U-839	NCE*	Jul 25, 2018
		8865937	May 23, 2032	DS DP		
		RE43879	Jun 03, 2023	U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	002	8481598	Mar 02, 2031	U-839	NCE*	Jul 25, 2018
		8865937	May 23, 2032	DS DP		
		RE43879	Jun 03, 2023	U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	003	8481598	Mar 02, 2031	U-839	NCE*	Jul 25, 2018
		8865937	May 23, 2032	DS DP		
		RE43879	Jun 03, 2023	U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	004	8481598	Mar 02, 2031	U-839	NCE*	Jul 25, 2018
		8865937	May 23, 2032	DS DP		
		RE43879	Jun 03, 2023	U-839		
<u>LEVONORGESTREL - MIRENA</u>						
N 021225	001	5785053	Dec 05, 2015	DP		
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998	001				RTO*	Apr 30, 2016
					RTO**	Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159	001	5785053	Dec 05, 2015	DP	NP	Jan 09, 2016
		7252839	Nov 13, 2023	DP		
<u>LEVONORGESTREL - LILETTA</u>						
N 206229	001				NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	001	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023	U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	002	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023	U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	003	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023	U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	004	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023	U-759		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 007	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 008	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 009	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 010	6399101	Mar 30, 2020				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	011 6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	002 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	003 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	004 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	005 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	006 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	007 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	008 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	009 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	010 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 022121	001 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	001 9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	002 9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	003 9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LIDOCAINE - LIDODERM</u>						
N 020612	001 5827529	Oct 27, 2015		U-486		
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114	001 5899880	May 04, 2016	DP			
	6004286	Mar 17, 2017	DP			
	6881200	Jun 11, 2016	DP			
	8540665	Oct 22, 2029		U-1438		
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221	001 8759401	Jul 24, 2026	DP	U-1523		
<u>LIDOCAINE; PRILCAINE - ORAOIX</u>						
N 021451	001 6031007	Apr 01, 2017	DP	U-553		
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623	001 5658583	Jul 28, 2015	DP			
	5919479	Jul 28, 2015	DP			
	6306431	Jul 28, 2015	DP			
	6465006	Jul 28, 2015	DP			
	6465709	Jul 07, 2020	DP			
	6546281	Jul 28, 2015	DP			
	6780426	Jul 28, 2015	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623	001	5658583	Jul 28, 2015	DP		
		5919479	Jul 28, 2015	DP		
		6306431	Jul 28, 2015	DP		
		6465006	Jul 28, 2015	DP		
		6465709	Jul 07, 2020	DP		
		6546281	Jul 28, 2015	DP		
		6780426	Jul 28, 2015	DP		
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717	001	5919479	Jul 28, 2015	DP		
		6528086	Sep 28, 2019	DP		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	001	7304036	Aug 30, 2026	DS DP U-1278	NCE	Aug 30, 2017
		7304036	Aug 30, 2026	DS DP U-1516		
		7371727	Jan 28, 2024	DS		
		7704947	Jan 28, 2024	DS DP		
		7745409	Jan 28, 2024	DS DP		
		8080526	Jan 28, 2024	DS DP		
		8110553	Jan 28, 2024		U-1278	
		8748573	Jun 20, 2031		U-1515	
		8748573	Jun 20, 2031		U-1516	
		8802628	Jul 24, 2031	DP		
		8933030	Feb 17, 2031	DP		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	002	7304036	Aug 30, 2026	DS DP U-1278	NCE	Aug 30, 2017
		7304036	Aug 30, 2026	DS DP U-1516		
		7371727	Jan 28, 2024	DS		
		7704947	Jan 28, 2024	DS DP		
		7745409	Jan 28, 2024	DS DP		
		8080526	Jan 28, 2024	DS DP		
		8110553	Jan 28, 2024		U-1278	
		8748573	Jun 20, 2031		U-1515	
		8748573	Jun 20, 2031		U-1516	
		8802628	Jul 24, 2031	DP		
		8933030	Feb 17, 2031	DP		
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280	001	6303661	Apr 24, 2017	U-774	M-118	Aug 13, 2015
		6303661	Apr 24, 2017	U-1270	M-121	Aug 13, 2015
		6890898	Feb 02, 2019	U-493	NCE	May 02, 2016
		6890898	Feb 02, 2019	U-1270		
		7078381	Feb 02, 2019	U-493		
		7078381	Feb 02, 2019	U-1270		
		7407955	Aug 12, 2023	DS DP		
		7459428	Feb 02, 2019	U-493		
		7459428	Feb 02, 2019	U-1270		
		8119648	Aug 12, 2023	U-774		
		8119648	Aug 12, 2023	U-1270		
		8178541	Aug 12, 2023	U-775		
		8178541	Aug 12, 2023	U-1244		
		8178541	Aug 12, 2023	U-1245		
		8178541	Aug 12, 2023	U-1270		
		8673927	May 04, 2027	U-1503		
		8846695	Jun 04, 2030	U-1503		
		8853156	Mar 05, 2031	U-1642		
		8883805	Nov 26, 2025	DP		
		9173859	May 04, 2027	DP U-1503		
		9173859	May 04, 2027	DP U-1768		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281	001	6303661	Apr 24, 2017	U-802	M-146	Jul 30, 2017
		6890898	Feb 02, 2019	U-1039	NCE	May 02, 2016
		7078381	Feb 02, 2019	U-1039		
		7407955	Aug 12, 2023	DS DP		
		7459428	Feb 02, 2019	U-1039		
		8119648	Aug 12, 2023	U-802		
		8178541	Aug 12, 2023	DP U-775		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	6303661	Apr 24, 2017	U-802		M-146	Jul 30, 2017
	6890898	Feb 02, 2019	U-1039		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	6303661	Apr 24, 2017	U-802		M-146	Jul 30, 2017
	6890898	Feb 02, 2019	U-1039		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					PC	Dec 19, 2015
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021130 001	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021130 002	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 001	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021132 001	6559305	Jan 29, 2021	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6004297	Jan 28, 2019	DP			
	6268343	Aug 22, 2022	DS DP U-968			
	6458924	Aug 22, 2017	DS DP U-968			
	7235627	Aug 22, 2017	DS DP			
	8114833	Aug 13, 2025	DP			
	8846618	Jun 27, 2022	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255		NP	Jan 25, 2017
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 26, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	006	5712279	Feb 21, 2016	DS	U-1317	NCE
		6492365	Dec 10, 2019		U-1318	ODE
		7932268	Aug 19, 2027		U-1316	
		8618135	Mar 07, 2025		U-1316	
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N 020448	001	6814978	Aug 26, 2021	DP		
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N 021140	001	6103260	Jul 17, 2017	DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021226	001	5914332	Dec 13, 2015		U-351	
		6037157	Jun 26, 2016		U-346	
		6232333	Nov 07, 2017			
		6284767	Feb 15, 2016	DP	U-401	
		6284767	Feb 15, 2016	DP	U-688	
		6458818	Nov 07, 2017			
		6521651	Nov 07, 2017	DP		
		6703403	Jun 26, 2016		U-257	
		7141593	May 22, 2020	DP		
		7432294	May 22, 2020	DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251	001	5914332	Dec 13, 2015	DS DP	U-351	
		5914332	Dec 13, 2015	DS DP	U-895	
		6037157	Jun 26, 2016		U-346	
		6037157	Jun 26, 2016		U-895	
		6284767	Feb 15, 2016	DP	U-401	
		6284767	Feb 15, 2016	DP	U-895	
		6703403	Jun 26, 2016		U-257	
		6703403	Jun 26, 2016		U-895	
		6911214	Nov 28, 2021	DP	U-895	
		8501219	Nov 28, 2021	DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906	001	5914332	Dec 13, 2015	DS DP	U-688	
		6037157	Jun 26, 2016		U-688	
		6284767	Feb 15, 2016	DP	U-688	
		6703403	Jun 26, 2016		U-688	
		7148359	Jul 19, 2019	DP		
		7364752	Nov 10, 2020	DP	U-688	
		8025899	Dec 14, 2027	DP		
		8025899*PED	Jun 14, 2028			
		8268349	Aug 25, 2024	DP		
		8309613	Dec 24, 2024		U-688	
		8377952	Oct 22, 2027		U-1372	
		8377952*PED	Apr 22, 2028			
		8399015	Aug 25, 2024	DP		
		8399015*PED	Feb 25, 2025			
		8470347	Sep 17, 2026	DP		
		8470347*PED	Mar 17, 2027			
		8691878	Aug 25, 2024		U-1513	
		8691878*PED	Feb 25, 2025			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906	002	5914332	Dec 13, 2015	DS DP	U-688	
		6037157	Jun 26, 2016		U-688	
		6284767	Feb 15, 2016	DP	U-688	
		6703403	Jun 26, 2016		U-688	
		7148359	Jul 19, 2019	DP		
		7364752	Nov 10, 2020	DP	U-688	
		8025899	Dec 14, 2027	DP		
		8025899*PED	Jun 14, 2028			
		8268349	Aug 25, 2024	DP		
		8309613	Dec 24, 2024		U-688	
		8377952	Oct 22, 2027		U-1372	
		8377952*PED	Apr 22, 2028			
		8399015	Aug 25, 2024	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024		U-1513		
	8691878*PED	Feb 25, 2025				
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023		U-1252		
	7514422	Apr 10, 2023		U-1253		
	7514422	Apr 10, 2023		U-1254		
	7514422	Apr 10, 2023		U-1255		
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023		U-1252		
	8207158	Apr 10, 2023		U-1253		
	8207158	Apr 10, 2023		U-1254		
	8207158	Apr 10, 2023		U-1255		
	8273734	Apr 10, 2023		U-1254		
	8273734	Apr 10, 2023		U-1255		
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023		U-1452		
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025		U-1252		
	8980881	Dec 20, 2025		U-1253		
	8980881	Dec 20, 2025		U-1254		
	8980881	Dec 20, 2025		U-1255		
	8999970	Feb 07, 2033		U-1688		
	8999970	Feb 07, 2033		U-1689		
	8999970	Feb 07, 2033		U-1692		
	9169213	Dec 06, 2032		U-1762		
	9169213	Dec 06, 2032		U-1763		
	9169213	Dec 06, 2032		U-1764		
	9169213	Dec 06, 2032		U-1765		
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP		NDF	Sep 28, 2015
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018		U-456		
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018		U-456		
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018		U-456		
	6485748	Dec 12, 2017	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN - ALTOPREV</u>						
N 021316	003	5916595				
		6080778		U-456		
		6485748		DP		
<u>LOVASTATIN - ALTOPREV</u>						
N 021316	004	5916595				
		6080778		U-456		
		6485748		DP		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249	001	6080428		U-447		
		6080428		U-1132		
		6080428		U-1133		
		6080428		U-1134		
		6469035		U-768		
		6469035		U-1129		
		6469035		U-1130		
		6469035		U-1131		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249	002	6080428		U-447		
		6080428		U-1132		
		6080428		U-1133		
		6080428		U-1134		
		6469035		U-768		
		6469035		U-1129		
		6469035		U-1130		
		6469035		U-1131		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249	003	6080428		U-447		
		6080428		U-1132		
		6080428		U-1133		
		6080428		U-1134		
		6469035		U-768		
		6469035		U-1129		
		6469035		U-1130		
		6469035		U-1131		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249	004	6080428		U-447		
		6080428		U-1132		
		6080428		U-1133		
		6080428		U-1134		
		6469035		U-768		
		6469035		U-1129		
		6469035		U-1130		
		6469035		U-1131		
<u>LOXAPINE - ADASUVE</u>						
N 022549	001	6716416		DP	NDF	Dec 21, 2015
		7052679		DP		
		7078020		DP	U-1375	
		7090830		DP		
		7458374		DP		
		7537009		DP		
		7585493		DP		
		7601337		DP		
		8074644		DP		
		8173107		DP		
		8235037		DP		
		8387612		DP		
		8955512		DP		
		8991387		DP		
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908	001	6414016		U-717	I-670	Apr 19, 2016
		6414016		U-1392		
		6583174		DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	7417067	Oct 16, 2020	DP			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1203			
	8071613	Sep 05, 2020	U-1393			
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
	8748481	Sep 01, 2025	U-1520			
	8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	6414016	Sep 05, 2020	U-874			
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-873			
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024	U-1085			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1202			
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2016	DS DP U-540		NCE	Nov 14, 2018
	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
	8729085	May 26, 2026	DP		NCE	Oct 28, 2015
	8883794	May 26, 2026	DP			
	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
	8729085	May 26, 2026	DP		NCE	Oct 28, 2015
	8883794	May 26, 2026	DP			
	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
	8729085	May 26, 2026	DP		NCE	Oct 28, 2015
	8883794	May 26, 2026	DP			
	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
	8729085	May 26, 2026	DP		NCE	Oct 28, 2015
	8883794	May 26, 2026	DP			
	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	005	5532372	Jul 02, 2018	DS	I-674	Jun 28, 2016
		8729085	May 26, 2026	DP	NCE	Oct 28, 2015
		8883794	May 26, 2026	DP		
		9174975	Jun 25, 2026	U-1770		
		RE45573	Jun 23, 2025	DS		
<u>MACITENTAN - OPSUMIT</u>						
N 204410	001	7094781	Oct 12, 2022	DS DP	NCE	Oct 18, 2018
		8268847	Apr 18, 2029	U-1446	ODE	Oct 18, 2020
		8367685	Oct 04, 2028	DP U-1445		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910	001	5945449	Oct 31, 2017	DP U-785		
		7300674	Mar 04, 2023	DP U-785		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N 021910	002	5945449	Oct 31, 2017	DP U-785		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850	001	6489346	Jul 16, 2016	DS DP U-588		
		6645988	Jul 16, 2016	DS DP U-588		
		6699885	Jul 16, 2016	U-588		
		7399772	Jul 16, 2016	U-588		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850	002	6489346	Jul 16, 2016	DS DP U-623		
		6645988	Jul 16, 2016	DS DP U-623		
		6699885	Jul 16, 2016	U-623		
		7399772	Jul 16, 2016	U-623		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456	001	6489346	Jul 16, 2016	DP U-588		
		6489346	Jul 16, 2016	DP U-1021		
		6645988	Jul 16, 2016	DP		
		6699885	Jul 16, 2016	DP U-588		
		6699885	Jul 16, 2016	DP U-1021		
		7399772	Jul 16, 2016	DP U-588		
		7399772	Jul 16, 2016	DP U-1021		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456	002	6489346	Jul 16, 2016	DP U-588		
		6489346	Jul 16, 2016	DP U-1021		
		6645988	Jul 16, 2016	DP		
		6699885	Jul 16, 2016	DP U-588		
		6699885	Jul 16, 2016	DP U-1021		
		7399772	Jul 16, 2016	DP U-588		
		7399772	Jul 16, 2016	DP U-1021		
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372	001	6946149	Mar 07, 2023	DP U-837		
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595	001				NC	Jan 18, 2016
<u>MALATHION - OVIDE</u>						
N 018613	001	7560445	Feb 01, 2027	DS DP U-986		
		7977324	Aug 14, 2026	DP		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	001	6586430	Dec 01, 2019	DS DP U-824		
		6667314	Aug 06, 2021	DS DP U-824		
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	002	6586430	Dec 01, 2019	DS DP U-824		
		6667314	Aug 06, 2021	DS DP U-824		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N 022128	002 7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N 021839	001 5681814	Sep 18, 2017	DP			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317	001 7838564	Mar 07, 2026	DP		NDF	Aug 23, 2016
	7872050	Jul 08, 2029		U-1427	ODE	Aug 23, 2020
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026		U-1427		
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBO PROVERA 104</u>						
N 021583	001 6495534	May 15, 2020	DP			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778	001 6592903	Sep 21, 2020	DP			
	7101576	Apr 22, 2024		U-755		
	9040088	Apr 22, 2024		U-755		
	9101540	Apr 22, 2024	DP	U-755		
	9101549	Apr 22, 2024		U-755		
	9107827	Apr 22, 2024		U-755		
<u>MELOXICAM - MOBIC</u>						
N 021530	001 6184220	Mar 25, 2019	DP			
<u>MELOXICAM - VIVLODEX</u>						
N 207233	001				NP	Oct 22, 2018
<u>MELOXICAM - VIVLODEX</u>						
N 207233	002				NP	Oct 22, 2018
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487	001 5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487	002 5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627	001 5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	001 5061703*PED	Oct 11, 2015			M-138	Jul 03, 2017
	8039009	Mar 24, 2029		U-539	PED	Jan 03, 2018
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025		U-539		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025		U-539		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025		U-539		
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	002 5061703*PED	Oct 11, 2015			M-138	Jul 03, 2017
	8039009	Mar 24, 2029		U-539	PED	Jan 03, 2018
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025		U-539		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025		U-539		
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	002	8362085				
		Nov 22, 2025	U-539			
		8362085*PED				
		May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	003	5061703*PED			M-138	Jul 03, 2017
		Oct 11, 2015				
		8039009			PED	Jan 03, 2018
		Mar 24, 2029	U-539			
		8039009*PED				
		Sep 24, 2029				
		8168209		DP		
		Nov 22, 2025				
		8168209*PED				
		May 22, 2026				
		8173708			U-539	
		Nov 22, 2025				
		8173708*PED				
		May 22, 2026				
		8283379			U-539	
		Nov 22, 2025				
		8283379*PED				
		May 22, 2026				
		8329752		DP		
		Nov 22, 2025				
		8329752*PED				
		May 22, 2026				
		8362085			U-539	
		Nov 22, 2025				
		8362085*PED				
		May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	004	5061703*PED			M-138	Jul 03, 2017
		Oct 11, 2015				
		8039009			PED	Jan 03, 2018
		Mar 24, 2029	U-539			
		8039009*PED				
		Sep 24, 2029				
		8168209		DP		
		Nov 22, 2025				
		8168209*PED				
		May 22, 2026				
		8173708			U-539	
		Nov 22, 2025				
		8173708*PED				
		May 22, 2026				
		8283379			U-539	
		Nov 22, 2025				
		8283379*PED				
		May 22, 2026				
		8329752		DP		
		Nov 22, 2025				
		8329752*PED				
		May 22, 2026				
		8362085			U-539	
		Nov 22, 2025				
		8362085*PED				
		May 22, 2026				
		8598233		DP		
		Nov 22, 2025				
		8598233*PED				
		May 22, 2026				
<u>MENOTROPINS (FSH;LH); MENOTROPINS (FSH;LH) - MENOPUR</u>						
N 021663	001				D-139	Feb 19, 2017
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	001	8809615				
		Jan 03, 2030	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	002	8809615				
		Jan 03, 2030	DP			
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N 020922	001	6353029				
		Aug 24, 2020				
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919	001				ODE	Apr 28, 2021
<u>MESALAMINE - SFROWASA</u>						
N 019618	002	7645801				
		Jul 24, 2027	DS DP			
<u>MESALAMINE - CANASA</u>						
N 021252	002	8217083				
		Jun 06, 2028	DP			
		8436051				
		Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830	001	6893662				
		Nov 15, 2021	DP	U-141		
		8580302				
		Nov 15, 2021	DP			
		9089492				
		Nov 15, 2021	DP			
<u>MESALAMINE - LIALDA</u>						
N 022000	001	6773720				
		Jun 08, 2020	DP			
<u>MESALAMINE - APRISO</u>						
N 022301	001	6551620				
		Apr 20, 2018	DS DP	U-907		
		8337886				
		Apr 20, 2018	DP	U-1310		
		8496965				
		Apr 20, 2018	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MESALAMINE - APRISO</u>						
N 022301	001	8865688	May 01, 2030	U-1310		
		8911778	Apr 20, 2018	DP U-1310		
		8940328	Apr 20, 2018	DP		
		8956647	Apr 20, 2018	DP		
<u>MESALAMINE - DELZICOL</u>						
N 204412	001	6649180	Apr 13, 2020	DP		
<u>METAXALONE - SKELAXIN</u>						
N 013217	003	7122566	Feb 06, 2026	U-915		
		7714006	Dec 03, 2021	U-1050		
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202	001	6475521	Mar 19, 2018			
		6660300	Mar 19, 2018	U-542		
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202	004	6475521	Mar 19, 2018			
		6660300	Mar 19, 2018	U-542		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	001	6099859	Mar 20, 2018	DP		
		6495162	Mar 20, 2018	DP		
		6790459	Mar 17, 2021	U-604		
		6866866	Mar 17, 2021	DP		
		7919116	Mar 20, 2018	DP		
		8475841	Mar 20, 2018	U-604		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	002	6099859	Mar 20, 2018	DP		
		6495162	Mar 20, 2018	DP		
		6790459	Mar 17, 2021	U-604		
		6866866	Mar 17, 2021	DP		
		7919116	Mar 20, 2018	DP		
		8475841	Mar 20, 2018	U-604		
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591	001	6890957	Sep 14, 2023	DP		
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	001	6340475	Sep 19, 2016	DS DP U-669		
		6488962	Jun 20, 2020	DS DP		
		6635280	Sep 19, 2016	DS DP		
		6723340	Oct 25, 2021	DS DP		
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	002	6488962	Jun 20, 2020	DS DP		
		7780987	Mar 23, 2025	DS DP		
		8323692	Mar 23, 2025	DP		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	001	5965584	Jun 19, 2016	DP U-1055		
		6166042	Jun 19, 2016	U-679		
		6166043	Jun 19, 2016	U-679		
		6172090	Jun 19, 2016	U-679		
		9101660	Jan 22, 2027	DP		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	002	5965584	Jun 19, 2016	DP U-1055		
		6166042	Jun 19, 2016	U-679		
		6166043	Jun 19, 2016	U-679		
		6172090	Jun 19, 2016	U-679		
		9101660	Jan 22, 2027	DP		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	001	5965584	Jun 19, 2016	DP U-973		
		6099859	Mar 20, 2018	DP		
		6166042	Jun 19, 2016	U-973		
		6166043	Jun 19, 2016	U-973		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			
	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			
	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 001	5965584	Jun 19, 2016	U-493		Y	
	6166042	Jun 19, 2016	U-493		Y	
	6288095	Feb 11, 2017	U-493		Y	
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 002	5965584	Jun 19, 2016	U-493		Y	
	6166042	Jun 19, 2016	U-493		Y	
	6288095	Feb 11, 2017	U-493		Y	
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 003	5965584	Jun 19, 2016	U-493		Y	
	6166042	Jun 19, 2016	U-493		Y	
	6288095	Feb 11, 2017	U-493		Y	
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 004	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 005	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-134	May 24, 2016

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	003 RE44186	Jul 31, 2023	DS DP U-1097		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	001 6699871	Jul 26, 2022	DS DP U-802			
	7125873	Jul 26, 2022	DP U-803			
	7125873	Jul 26, 2022	DP U-1036			
	7125873	Jul 26, 2022	DP U-1038			
	7326708	Apr 11, 2026	DS DP U-802			
	8414921	Jul 21, 2028	DP U-1036			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	002 6699871	Jul 26, 2022	DS DP U-802			
	7125873	Jul 26, 2022	DP U-803			
	7125873	Jul 26, 2022	DP U-1036			
	7125873	Jul 26, 2022	DP U-1038			
	7326708	Apr 11, 2026	DS DP U-802			
	8414921	Jul 21, 2028	DP U-1036			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	001 6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	002 6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	003 6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824	001 6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824	002 6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824	003 6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 005	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 006	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 007	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 008	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 009	8664231	Jun 01, 2029			U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776 010	8664231	Jun 01, 2029			U-1442	
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE - METVIXIA</u>						
N 021415 001	6034267	Mar 08, 2016			U-804	
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	6559158	Nov 03, 2017			U-1185	
	8247425	Dec 31, 2030			U-1185	
	8420663	Sep 30, 2029			U-1185	
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	6559158	Nov 03, 2017				
	8247425	Dec 31, 2030				
	8420663	Sep 30, 2029				
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029				
	9180125	Sep 30, 2029				
			U-1185			
			U-1185			
			U-1185			
			DP			
			DP			
			DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8247425	Dec 31, 2030				
	8420663	Sep 30, 2029				
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029				
	9180125	Sep 30, 2029				
			U-1185			
			U-1185			
			DP			
			DP			
			DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	6210705	Sep 30, 2018				
	6348211	Sep 30, 2018				
	8632802	Oct 07, 2025				
	9034370	Oct 07, 2025				
			DP			
			DP			
			DP			
			DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	6210705	Sep 30, 2018				
	6348211	Sep 30, 2018				
	8632802	Oct 07, 2025				
	9034370	Oct 07, 2025				
			DP			
			DP			
			DP			
			DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	6210705	Sep 30, 2018				
	6348211	Sep 30, 2018				
	8632802	Oct 07, 2025				
	9034370	Oct 07, 2025				
			DP			
			DP			
			DP			
			DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	6210705	Sep 30, 2018				
	6348211	Sep 30, 2018				
	8632802	Oct 07, 2025				
	9034370	Oct 07, 2025				
			DP			
			DP			
			DP			
			DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	6919373	Jul 31, 2017				
	6930129	Jul 31, 2017				
	8163798	Jul 31, 2017				
	8629179	Jul 31, 2017				
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017				
	9000038	Jul 31, 2017				
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017				
	9144549	Jul 31, 2017				
	9144549	Jul 31, 2017				
			U-666			
			U-666			
			DP			
			DP			
			U-666			
			U-1693			
			DP			
			DP			
			U-666			
			U-1747			
			U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	6919373	Jul 31, 2017				
	6930129	Jul 31, 2017				
	8163798	Jul 31, 2017				
	8629179	Jul 31, 2017				
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017				
	9000038	Jul 31, 2017				
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017				
	9144549	Jul 31, 2017				
	9144549	Jul 31, 2017				
			U-666			
			U-666			
			DP			
			DP			
			U-666			
			U-1747			
			U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	6919373	Jul 31, 2017				
	6930129	Jul 31, 2017				
	8163798	Jul 31, 2017				
	8629179	Jul 31, 2017				
			U-666			
			U-666			
			DP			
			DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121	003	8629179*PED	Jan 31, 2018			
		9000038	Jul 31, 2017	U-666		
		9000038	Jul 31, 2017	U-1693		
		9000038*PED	Jan 31, 2018			
		9029416	Jul 31, 2017	DP U-666		
		9144549	Jul 31, 2017	U-1747		
		9144549	Jul 31, 2017	U-1748		
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121	004	6919373	Jul 31, 2017	U-666		
		6930129	Jul 31, 2017	U-666		
		8163798	Jul 31, 2017	DP		
		8629179	Jul 31, 2017	DP		
		8629179*PED	Jan 31, 2018			
		9000038	Jul 31, 2017	U-666		
		9000038	Jul 31, 2017	U-1693		
		9000038*PED	Jan 31, 2018			
		9029416	Jul 31, 2017	DP U-666		
		9144549	Jul 31, 2017	U-1747		
		9144549	Jul 31, 2017	U-1748		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	001	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	002	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	003	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259	004	6344215	Oct 27, 2020	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284	001	5837284	Dec 04, 2015	DP		
		6228398	Nov 01, 2019	DP U-472		
		6635284	Dec 04, 2015	DP U-591		
		7431944	Dec 04, 2015	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284	002	5837284	Dec 04, 2015	DP		
		6228398	Nov 01, 2019	DP U-472		
		6635284	Dec 04, 2015	DP U-591		
		7431944	Dec 04, 2015	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284	003	5837284	Dec 04, 2015	DP		
		6228398	Nov 01, 2019	DP U-472		
		6635284	Dec 04, 2015	DP U-591		
		7431944	Dec 04, 2015	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284	004	5837284	Dec 04, 2015	DP		
		6228398	Nov 01, 2019	DP U-472		
		6635284	Dec 04, 2015	DP U-591		
		7431944	Dec 04, 2015	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419	001	7691880	Oct 07, 2024	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419	002	7691880	Oct 07, 2024	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100	001	8062667	Mar 29, 2029	DP	NDF	Sep 27, 2015
		8287903	Feb 15, 2031	DP		
		8465765	Feb 15, 2031	DP U-1415		
		8563033	Feb 15, 2031	DP U-1415		
		8778390	Feb 15, 2031	DP U-1543		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100	001	8956649	Feb 15, 2031	DP U-1665		
		9040083	Feb 15, 2031	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	001	6419960	Dec 16, 2019	DP	NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP		
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	002	6419960	Dec 16, 2019	DP	NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP		
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	003	6419960	Dec 16, 2019	DP	NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP		
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	004	6419960	Dec 16, 2019	DP	NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP		
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	005	6419960	Dec 16, 2019	DP	NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP		
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	006	6419960	Dec 16, 2019	DP	NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP		
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	007	6419960	Dec 16, 2019	DP	NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP		
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960	001	8202537	Mar 15, 2027	DP		
		8287903	Feb 15, 2031	DP		
		8999386	Apr 14, 2033	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960	002	8202537	Mar 15, 2027	DP		
		8287903	Feb 15, 2031	DP		
		8999386	Apr 14, 2033	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960	003	8202537	Mar 15, 2027	DP		
		8287903	Feb 15, 2031	DP		
		8999386	Apr 14, 2033	DP		
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793	001	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793	002	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246	001	6413549	Jul 11, 2017	DP		
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246	002	6413549	Jul 11, 2017	DP		
<u>METRONIDAZOLE - METROGEL</u>						
N 021789	001	6881726	Feb 21, 2022	DP U-743		
		7348317	Feb 21, 2022	DP U-743		
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806	001	7456207	Sep 22, 2024	DP		
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223	001	7893097	Feb 19, 2028	DP	NP	Mar 24, 2017
		8658678	Jun 27, 2028	U-1682		
		8877792	Feb 02, 2028	DP		
		8946276	Jun 28, 2032	U-1664		
		9198858	Jun 28, 2032	U-1664		
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	002	6107458	Mar 16, 2019	DS DP U-650		
		6107458	Mar 16, 2019	DS DP U-845		
		6265536	Sep 29, 2015	DS DP U-650		
		6265536	Sep 29, 2015	DS DP U-845		
		6774104	Jan 08, 2021	DP U-650		
		6774104	Jan 08, 2021	DP U-845		
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	003	6107458	Mar 16, 2019	DS DP U-650		
		6107458	Mar 16, 2019	DS DP U-845		
		6265536	Sep 29, 2015	DS DP U-650		
		6265536	Sep 29, 2015	DS DP U-845		
		6774104	Jan 08, 2021	DP U-650		
		6774104	Jan 08, 2021	DP U-845		
<u>MICONAZOLE - ORAVIG</u>						
N 022404	001	6916485	Sep 11, 2022	DP U-1051		
		7651698	Sep 11, 2022	U-1051		
		8518442	Sep 11, 2022	DP		
<u>MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N 021308	001	6153635	Nov 28, 2020		Y	
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026	001	8147852	Mar 30, 2028	U-1426		
<u>MIFEPRISTONE - KORLYM</u>						
N 202107	001	8921348	Aug 27, 2028	U-1643	ODE	Feb 17, 2019
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	001	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	002	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	003	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	004	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684	001				NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444	001	9084802	May 12, 2031	U-282		
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781	001	6682348	Mar 29, 2022	DP		
		7699609	Mar 29, 2022	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	001	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	002	5908838	Feb 19, 2018	U-917		
		7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	003	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	004	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		9192615	Nov 17, 2031	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	005	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		9192615	Nov 17, 2031	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOXIDIL - MEN'S ROGAINE</u>						
N 021812 001	6946120	Apr 20, 2019	DP U-702			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP U-702		NP	Feb 28, 2017
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	6166197	Dec 26, 2017	DS		NCE	Jan 29, 2018
	6451991	Feb 11, 2017	DS		ODE	Jan 29, 2020
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
	9205075	Jul 19, 2026	DP			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 001	7297346	Nov 29, 2023	DP			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 002	7297346	Nov 29, 2023	DP			
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625 002					NP	Apr 19, 2016
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 001	5829434	Nov 03, 2015	DP			
	6240918	Feb 20, 2017	DP			
	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 002	5829434	Nov 03, 2015	DP			
	6240918	Feb 20, 2017	DP			
	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	6068832	Aug 27, 2017	DP U-645			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	6068832	Aug 27, 2017	DP U-645			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N 020762 001	6127353	Oct 03, 2017	DS DP			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 021409 001	8007830	Oct 24, 2022	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 001	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP	U-584		
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 002	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP	U-584		
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 003	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP	U-584		
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001	5849752	Dec 05, 2016	U-298			
	6610327	Oct 29, 2019	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001	5849752	Dec 05, 2016	U-298			
	6548079	Jul 25, 2020	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N 021598 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	U-709			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	DP U-709			
	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MUPIROCIIN - CENTANY</u>						
N 050788	001 6013657	Jul 08, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791	001 6025391	Apr 10, 2017	DP	U-908		
	6172107	Apr 10, 2017	DP	U-908		
	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791	002 6025391	Apr 10, 2017	DP	U-908		
	6172107	Apr 10, 2017	DP	U-908		
	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286	001 8778365	Jan 31, 2033	DP		NP	Jun 27, 2016
	9161914	Jan 31, 2033	U-540			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760	001 7056500	Jun 29, 2024	DP	U-1185	NCE	Sep 16, 2019
	7662365	Oct 18, 2022	DS	DP		
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024		U-1185		
	8617530	Oct 18, 2022		U-1185		
	9012469	Apr 02, 2032	DS	DP		
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760	002 7056500	Jun 29, 2024	DP	U-1185	NCE	Sep 16, 2019
	7662365	Oct 18, 2022	DS	DP		
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024		U-1185		
	8617530	Oct 18, 2022		U-1185		
	9012469	Apr 02, 2032	DS	DP		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787	001 7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411	001 9211253	Mar 16, 2035	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777	001 6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	8969369	May 10, 2022	DP	U-1556		
	9056051	May 10, 2022	DP	U-1556		
	9073933	Mar 30, 2025	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	001	9084729	May 10, 2022		DP U-1556	
		9161937	May 10, 2022		DP U-1556	
		9168252	May 10, 2022		DP U-1556	
		9205082	May 10, 2022		DP U-1556	
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	002	6277384	Dec 22, 2018		DP	
		6696066	Dec 22, 2018		DP	
		7674799	Mar 30, 2025		DP	
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		8673355	Dec 22, 2018		DP	
		8822487	Dec 22, 2018		DP	
		8846090	Apr 04, 2023		DP	
		8846091	Apr 04, 2023		DP	
		8969369	May 10, 2022		DP U-1556	
		9056051	May 10, 2022		DP U-1556	
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022		DP U-1556	
		9161937	May 10, 2022		DP U-1556	
		9168252	May 10, 2022		DP U-1556	
		9205082	May 10, 2022		DP U-1556	
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777	003	6277384	Dec 22, 2018		DP	
		6696066	Dec 22, 2018		DP	
		7674799	Mar 30, 2025		DP	
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		8673355	Dec 22, 2018		DP	
		8822487	Dec 22, 2018		DP	
		8846090	Apr 04, 2023		DP	
		8846091	Apr 04, 2023		DP	
		8969369	May 10, 2022		DP U-1556	
		9056051	May 10, 2022		DP U-1556	
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022		DP U-1556	
		9161937	May 10, 2022		DP U-1556	
		9168252	May 10, 2022		DP U-1556	
		9205082	May 10, 2022		DP U-1556	
<u>NALTREXONE - VIVITROL</u>						
N 021897	001	5792477	May 02, 2017		DP	
		5916598	May 02, 2017		DP	
		6194006	Dec 30, 2018		DP	
		6264987	May 19, 2020		DP	
		6331317	Nov 12, 2019		DP	
		6379703	Dec 30, 2018		DP	
		6379704	May 19, 2020		DP	
		6395304	Nov 12, 2019		DP	
		6403114	May 02, 2017		DP	
		6495164	May 25, 2020		DP	
		6495166	Nov 12, 2019		DP	
		6534092	May 19, 2020		DP	
		6537586	Nov 12, 2019		DP	
		6596316	Dec 30, 2018		DP	
		6667061	May 25, 2020		DP	
		6713090	Nov 12, 2019		DP	
		6939033	Nov 12, 2019		DP	
		7799345	May 25, 2020		DP	
		7919499	Oct 15, 2029		U-1123	
		7919499	Oct 15, 2029		U-1124	
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	001	6060499	Aug 14, 2017		DP U-867	
		6060499*PED	Feb 14, 2018			
		6586458	Aug 14, 2017		DP U-867	
		6586458*PED	Feb 14, 2018			
		7332183	Oct 02, 2025		DP U-867	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	6060499	Aug 14, 2017	DP U-1719			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-1719			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
<u>NATEGLINIDE - STARLIX</u>						
N 021204 001	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NATEGLINIDE - STARLIX</u>						
N 021204 002	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 002	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 003	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 004	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 005	6545040	Dec 17, 2021	DP U-3			
<u>NELARABINE - ARRANON</u>						
N 021877 001	5424295	Jun 13, 2017	DS DP			
<u>NEPAFENAC - NEVANAC</u>						
N 021862 001	7834059	Jan 31, 2027		U-1095		
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	6403609	Jul 17, 2018	DP		NP	Oct 16, 2015
	7947295	Jun 08, 2024	DP			
	8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	6297375	Feb 22, 2020	DS		NCE	Oct 10, 2019
	8623826	Nov 18, 2030		U-528		
	8951969	Nov 18, 2030	DP			
	9186357	Nov 18, 2030		U-528		
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029		U-1409	NPP	Nov 08, 2015
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 002					NPP	Nov 08, 2015
<u>NIACIN - NIASPAN</u>						
N 020381 001	6080428	May 27, 2017		U-331		
<u>NIACIN - NIASPAN</u>						
N 020381 002	6080428	May 27, 2017		U-331		
	6080428	May 27, 2017		U-1138		
	6080428	May 27, 2017		U-1139		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N 020381 002	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN</u>						
N 020381 003	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN</u>						
N 020381 004	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>						
N 020381 005	6080428	May 27, 2017	U-331			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 001	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 002	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 003	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078	005	6080428	May 27, 2017	U-862		
		6080428	May 27, 2017	U-1132		
		6080428	May 27, 2017	U-1134		
		6469035	Mar 15, 2018	U-863		
		6469035	Mar 15, 2018	U-1129		
		6469035	Mar 15, 2018	U-1149		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	002	7612102	Dec 26, 2027	DP		
		7659291	Apr 18, 2027	U-1029		
		8455524	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	003	7612102	Dec 26, 2027	DP		
		7659291	Apr 18, 2027	U-1029		
		8455524	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	004	7612102	Dec 26, 2027	DP		
		7659291	Apr 18, 2027	U-1029		
		8455524	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	005	7612102	Dec 26, 2027	DP		
		7659291	Apr 18, 2027	U-1029		
		8455524	Apr 18, 2027	U-1029		
<u>NICOTINE - NICODERM CO</u>						
N 020165	004	8075911	May 22, 2021	DP		
		8663680	Feb 13, 2020	DP		
		8999379	Feb 13, 2020	U-1686		
		9205059	Dec 15, 2019	DP		
<u>NICOTINE - NICODERM CO</u>						
N 020165	005	8075911	May 22, 2021	DP		
		8663680	Feb 13, 2020	DP		
		8999379	Feb 13, 2020	U-1686		
		9205059	Dec 15, 2019	DP		
<u>NICOTINE - NICODERM CO</u>						
N 020165	006	8075911	May 22, 2021	DP		
		8663680	Feb 13, 2020	DP		
		8999379	Feb 13, 2020	U-1686		
		9205059	Dec 15, 2019	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612	002	8323683	Apr 30, 2028			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066	002	8323683	Apr 30, 2028	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	001	8501164	Jun 14, 2029	DP		
		8940772	Apr 30, 2029	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	002	8501164	Jun 14, 2029	DP		
		8940772	Apr 30, 2029	DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	001	7169791	Jul 04, 2023	DS DP	U-836	
		8163904	Aug 23, 2028	DS DP		
		8293756	Sep 25, 2027	DP		
		8389537	Jul 18, 2026	DS DP	U-1374	
		8415363	Jul 18, 2026	DS DP	U-1407	
		8501760	Jul 18, 2026	DS DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	002	7169791	Jul 04, 2023	DS DP U-836		
		8163904	Aug 23, 2028	DS DP		
		8293756	Sep 25, 2027	DP		
		8389537	Jul 18, 2026	DS DP U-1374		
		8415363	Jul 18, 2026	DS DP U-1407		
		8501760	Jul 18, 2026	DS DP		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	001				ODE	May 10, 2020
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001	6762180	Dec 10, 2020	DS DP	NCE	Oct 15, 2019
		7119093	Feb 21, 2024	DS DP	ODE	Oct 15, 2021
		7989474	Apr 06, 2024	U-1677		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	002	6762180	Dec 10, 2020	DS DP	NCE	Oct 15, 2019
		7119093	Feb 21, 2024	DS DP	ODE	Oct 15, 2021
		7989474	Apr 06, 2024	U-1677		
<u>NITAZOXANIDE - ALINIA</u>						
N 021497	001	5968961	May 07, 2017	DP		
<u>NITAZOXANIDE - ALINIA</u>						
N 021498	001	5965590	Jul 03, 2017	U-523		
		5968961	May 07, 2017			
		6117894	May 07, 2017			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	002	5732693	Dec 13, 2016	DP U-1230		
		5752504	Dec 13, 2016	DP U-1230		
		6125846	May 16, 2017	DP U-1457		
		6125846*PED	Nov 16, 2017			
		8282966	Jun 30, 2029	U-1286		
		8291904	Jan 06, 2031	DP U-1226		
		8293284	Jun 30, 2029	U-1286		
		8431163	Jun 30, 2029	U-1286		
		8431163*PED	Dec 30, 2029			
		8573209	Jan 06, 2031	DP		
		8573209*PED	Jul 06, 2031			
		8573210	Jan 06, 2031	DP U-1453		
		8573210*PED	Jul 06, 2031			
		8776794	Jan 06, 2031	DP U-1226		
		8776794*PED	Jul 06, 2031			
		8776795	Jan 06, 2031	DP U-1226		
		8776795*PED	Jul 06, 2031			
		8795741	Jun 30, 2029	U-1286		
		8795741*PED	Dec 30, 2029			
		8846112	Jun 30, 2029	U-1286		
		8846112*PED	Dec 30, 2029			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	003	5732693	Dec 13, 2016	DP U-1230	M-167	Oct 09, 2018
		5752504	Dec 13, 2016	DP U-1230		
		6125846	May 16, 2017	DP U-1457		
		6125846*PED	Nov 16, 2017			
		8282966	Jun 30, 2029	U-1286		
		8291904	Jan 06, 2031	DP U-1226		
		8293284	Jun 30, 2029	U-1286		
		8431163	Jun 30, 2029	U-1286		
		8431163*PED	Dec 30, 2029			
		8573209	Jan 06, 2031	DP		
		8573209*PED	Jul 06, 2031			
		8573210	Jan 06, 2031	DP U-1453		
		8573210*PED	Jul 06, 2031			
		8776794	Jan 06, 2031	DP U-1226		
		8776794*PED	Jul 06, 2031			
		8776795	Jan 06, 2031	DP U-1226		
		8776795*PED	Jul 06, 2031			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	003 8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705	002 7872049	Mar 14, 2028	DP U-39			
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134	001 6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134	002 6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134	003 6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROMIST</u>						
N 021780	001 5869082	Apr 16, 2016	DP			
<u>NIZATIDINE - AXID</u>						
N 021494	001 6930119	Jul 17, 2022	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008	001 5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008	002 5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008	003 5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	001 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	002 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	003 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	004 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	005 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	006 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	001 6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	002 6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	003 6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	004 6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	001 6169084	Sep 30, 2018	DS DP U-1026			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	002	6169084	Sep 30, 2018	DS DP U-1026		
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	003	6169084	Sep 30, 2018	DS DP U-1026		
<u>OLAPARIB - LYNPARZA</u>						
N 206162	001	7151102	Apr 29, 2022	DS DP	NCE	Dec 19, 2019
		7449464	Oct 11, 2024	DS DP	ODE	Dec 19, 2021
		7981889	Oct 11, 2024	DS DP		
		8143241	Aug 12, 2027	U-1634		
		8247416	Sep 24, 2028	DS		
		8859562	Aug 04, 2031	U-1634		
		8912187	Mar 12, 2024	U-1634		
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508	001	5840757	Nov 24, 2015	DP	NP	Oct 03, 2016
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286	001	5616599	Apr 25, 2016	DS DP U-500		
		6878703	Nov 19, 2021	U-3	Y	
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286	003	5616599	Apr 25, 2016	DS DP U-500		
		6878703	Nov 19, 2021	U-3	Y	
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286	004	5616599	Apr 25, 2016	DS DP U-500		
		6878703	Nov 19, 2021	U-3	Y	
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108	001	5964416	Oct 04, 2016	DP	NCE	Jul 31, 2019
		6149054	Dec 19, 2016	DP		
		6176442	Oct 04, 2016	DP		
		6453795	Dec 05, 2016	DP		
		6726124	Oct 04, 2016	DP		
		6846413	Aug 28, 2018	DP		
		6977042	Aug 28, 2018	DP		
		6988496	Feb 23, 2020	DP U-1547		
		7056916	Dec 07, 2023	DS DP		
		7104470	Oct 04, 2016	DP		
		7220742	May 12, 2025	DS DP U-1547		
		7246615	May 31, 2016	DP		
		7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP U-1547		
		7491719	Nov 10, 2023	DS DP		
		7727984	Nov 10, 2023	DS		
		7786111	Nov 10, 2023	DP		
		7802568	Feb 26, 2019	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8034809	May 12, 2025	U-1547		
		8044046	Nov 10, 2023	U-1547		
		8733341	Dec 16, 2029	DP		
		9027967	Mar 31, 2027	DP		
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001	5964416	Oct 04, 2016	DP	NC	May 21, 2018
		6149054	Dec 19, 2016	DP	NCE	Jul 31, 2019
		6176442	Oct 04, 2016	DP		
		6453795	Dec 05, 2016	DP		
		6726124	Oct 04, 2016	DP		
		6846413	Aug 28, 2018	DP		
		6977042	Aug 28, 2018	DP		
		6988496	Feb 23, 2020	DP		
		7056916	Dec 07, 2023	DS DP		
		7104470	Oct 04, 2016	DP		
		7220742	May 12, 2025	DS DP U-1703		
		7246615	May 31, 2016	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001	7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP		
		7491719	Nov 10, 2023	DS DP		
		7727984	Nov 10, 2023	DS		
		7786111	Nov 10, 2023	DP		
		7802568	Feb 26, 2019	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8034809	May 12, 2025		U-1702	
		8044046	Nov 10, 2023		U-1702	
		8733341	Dec 16, 2029	DP		
		9027967	Mar 31, 2027	DP		
		RE39820	Jan 30, 2018	DS DP	U-1702	
<u>LOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545	001	6995186	Nov 12, 2023	DP	U-765	
		7402609	Jun 19, 2022	DP		
<u>LOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861	001	7977376	Feb 02, 2023	DP		
		8399508	Sep 17, 2022		U-726	
		8399508*PED	Mar 17, 2023			
<u>LOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276	001	8791154	May 19, 2032	DP	U-1680	NP Jan 30, 2018 PED Jul 30, 2018
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585	001	6987103	Jun 28, 2023		U-1300	NCE Oct 26, 2017
		RE45128	Mar 16, 2019	DS DP	U-1576	ODE Oct 26, 2019
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931	001	6037157	Jun 26, 2016		U-1635	NCE Dec 19, 2019
		6037157*PED	Dec 26, 2016			NP Jul 24, 2018
		6703403	Jun 26, 2016		U-1635	
		6703403*PED	Dec 26, 2016			
		7148359	Jul 19, 2019	DP		
		7148359*PED	Jan 19, 2020			
		7364752	Nov 10, 2020	DP		
		7364752*PED	May 10, 2021			
		8268349	Aug 25, 2024	DP		
		8268349*PED	Feb 25, 2025			
		8399015	Aug 25, 2024	DP		
		8399015*PED	Feb 25, 2025			
		8420596	Apr 10, 2031	DS DP		
		8420596*PED	Oct 10, 2031			
		8642538	Sep 10, 2029	DS DP	U-1638	
		8686026	Jun 09, 2031	DP		
		8691938	Apr 13, 2032	DS DP		
		9006387	Jun 10, 2030		U-1687	
		9044480	Apr 10, 2031		U-1638	
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060	001	5792795	May 13, 2016	DP		
		5948818	May 13, 2016	DP		
		7960370	Feb 07, 2025	DP		
		8383678	Feb 07, 2025	DP	U-1511	
		9012501	Feb 07, 2025	DP	U-1511	
		9050308	Jan 04, 2033		U-1511	
		9050309	Jan 04, 2033	DS		
		9132112	Feb 07, 2025	DP	U-1511	
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	001	6147103	Oct 09, 2018			
		6150380	Nov 10, 2018			
		6166213	Oct 09, 2018			
		6191148	Oct 09, 2018			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	002	6147103				
		6150380				
		6166213				
		6191148				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	003	6147103				
		6150380				
		6166213				
		6191148				
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032	001	9023391		DP		
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC OTC</u>						
N 021229	001	5817338				
		5900424				
		6403616				
		6428810				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056	001	5900424	DS		U-864	
		6428810		DP	U-864	
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056	002	5900424	DS		U-864	
		6428810		DP	U-864	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636	001	5840737			U-588	
		6489346	DS DP		U-588	Y
		6645988	DS DP			Y
		6699885			U-588	Y
		6780882	DS DP			
		7399772			U-588	
		RE45198			U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636	002	5840737			U-623	
		5840737			U-624	
		6489346	DS DP		U-623	Y
		6489346	DS DP		U-624	Y
		6645988	DS DP			Y
		6699885			U-623	Y
		6699885			U-624	Y
		6780882	DS DP			
		7399772			U-623	
		7399772			U-624	
		RE45198			U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849	001	7399772			U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849	002	7399772			U-623	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281	001	6489346	DP	U-1025		Y
		6645988	DP			Y
		6699885	DP			Y
		7399772		U-1025		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283	001	5840737			U-1025	
		6780882	DP			
		7399772			U-1025	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ONDANSETRON - ZOFRAN ODT</u>						
N 020781 001	5955488	Nov 14, 2015				
	6063802	Nov 14, 2015				
<u>ONDANSETRON - ZOFRAN ODT</u>						
N 020781 002	5955488	Nov 14, 2015				
	6063802	Nov 14, 2015				
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON HYDROCHLORIDE - ZOFRAN</u>						
N 020605 001	5854270	Nov 20, 2015	DP U-44			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2016	DS DP U-1569		NCE	Aug 06, 2019
	5998581	Nov 12, 2017	DS		GAIN	Aug 06, 2024
	8420592	Aug 29, 2029		U-1570		
<u>ORLISTAT - XENICAL</u>						
N 020766 001	6004996	Jan 06, 2018				
<u>ORLISTAT - ALLI</u>						
N 021887 001	6004996	Jan 06, 2018	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001	5763483	Aug 23, 2016	DS DP U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002	5763483	Aug 23, 2016	DS DP U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003	5763483	Aug 23, 2016	DS DP U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001	5763483	Dec 27, 2016	DS U-376		NPP	Dec 21, 2015
	5763483	Dec 27, 2016	DS U-1113			
	5866601	Feb 02, 2016	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002	5763483	Aug 23, 2016	DS DP U-1113		NPP	Dec 21, 2015
	5763483*PED	Feb 23, 2017				
	5866601	Feb 02, 2016	DS DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	8946235	Aug 08, 2032	DS DP U-1777		NCE	Nov 13, 2020
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	8946235	Aug 08, 2032	DS DP U-1777		NCE	Nov 13, 2020
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020		U-1369	NCE	Feb 26, 2018
	8236861	Aug 11, 2026		U-1369		
	8236861	Aug 11, 2026		U-1370		
	8470890	Feb 13, 2024		U-1369		
	8470890	Feb 13, 2024		U-1370		
	8642079	Jul 09, 2028	DP			
	8772353	Feb 13, 2024		U-1369		
	8772353	Feb 13, 2024		U-1370		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492	001	5420319	Aug 09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492	002	5420319	Aug 09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759	001	5420319 5716988	Aug 09, 2016 Aug 07, 2015	DS DP		
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759	002	5420319 5716988	Aug 09, 2016 Aug 07, 2015	DS DP		
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759	003	5420319 5716988	Aug 09, 2016 Aug 07, 2015	DS DP		
<u>OXANDROLONE - OXANDRIN</u>						
N 013718	001	5872147 6090799 6576659 6828313	Dec 05, 2017 Jul 18, 2017 Dec 05, 2017 Dec 05, 2017	U-585 U-585 U-585 U-585		
<u>OXANDROLONE - OXANDRIN</u>						
N 013718	002	5872147 6090799 6576659 6828313	Dec 05, 2017 Jul 18, 2017 Dec 05, 2017 Dec 05, 2017	U-585 U-585 U-585 U-585		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	001	7037525	Feb 12, 2018	U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	002	7037525	Feb 12, 2018	U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	003	7037525	Feb 12, 2018	U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021285	001	7037525 8119148	Feb 12, 2018 Dec 19, 2020	U-724 DP U-724		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	001	7722898 7910131 8617600 8821930 9119791	Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027	DP U-1298 DP DP U-1298	NDF	Oct 19, 2015
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	002	7722898 7910131 8617600 8821930 9119791	Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027	DP U-1298 DP DP U-1298	NDF	Oct 19, 2015
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	003	7722898 7910131 8617600 8821930 9119791	Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027	DP U-1298 DP DP U-1298	NDF	Oct 19, 2015
<u>OXYBUTYNIN - OXYTROL</u>						
N 021351	002	6743441 7081249 7081250 7081251 7081252 7179483	Apr 26, 2020 Apr 26, 2020 Apr 26, 2020 Apr 26, 2020 Apr 26, 2020 Apr 26, 2020	DP U-318 DP U-318 DP U-318 DP U-318 DP U-318 DS DP U-318		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNYNIN - OXYTROL</u>						
N 021351	002	6743441	Apr 26, 2020	DP U-318		
		7081249	Apr 26, 2020	DP U-318		
		7081250	Apr 26, 2020	DP U-318		
		7081251	Apr 26, 2020	DP U-318		
		7081252	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	DS DP U-318		
<u>OXYBUTYNYNIN - OXYTROL FOR WOMEN</u>						
N 202211	001	6743441	Apr 26, 2020	DP U-1329	NP	Jan 25, 2016
		7081249	Apr 26, 2020	DP U-1329		
		7081250	Apr 26, 2020	DP U-1329		
		7081251	Apr 26, 2020	DP U-1329		
		7081252	Apr 26, 2020	DP U-1329		
		7179483	Apr 26, 2020	U-1329		
<u>OXYBUTYNYNIN - GELNIQUE 3%</u>						
N 202513	001	7029694	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	U-318		
		7198801	Jun 25, 2022	DP		
		8241662	Apr 26, 2020	U-318		
<u>OXYBUTYNYNIN CHLORIDE - GELNIQUE</u>						
N 022204	001	7029694	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	U-318		
		8241662	Apr 26, 2020	U-318		
		8920392	Mar 26, 2031	U-1644		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	001	6488963	Jun 24, 2017	DP	M-153	Apr 16, 2016
		7674799	Mar 30, 2025	DP	NPP	Aug 13, 2018
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		7776314	Apr 19, 2025	DP	Y	
		8114383	Oct 10, 2024	DP		
		8309060	Nov 20, 2023	DP U-1556		
		8337888	Aug 06, 2022	DP		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9060976	Aug 06, 2022	DP		
		9073933	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	002	6488963	Jun 24, 2017	DP	M-153	Apr 16, 2016
		7674799	Mar 30, 2025	DP	NPP	Aug 13, 2018
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		7776314	Apr 19, 2025	DP	Y	
		8114383	Oct 10, 2024	DP		
		8309060	Nov 20, 2023	DP U-1556		
		8337888	Aug 06, 2022	DP		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9060976	Aug 06, 2022	DP		
		9073933	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	003	6488963	Jun 24, 2017	DP	M-153	Apr 16, 2016
		7674799	Mar 30, 2025	DP	NPP	Aug 13, 2018
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		7776314	Apr 19, 2025	DP	Y	
		8114383	Oct 10, 2024	DP		
		8309060	Nov 20, 2023	DP U-1556		
		8337888	Aug 06, 2022	DP		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	6488963	Jun 24, 2017	DP		M-153	Apr 16, 2016
	7674799	Mar 30, 2025	DP		NPP	Aug 13, 2018
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	6488963	Jun 24, 2017	DP		M-153	Apr 16, 2016
	7674799	Mar 30, 2025	DP		NPP	Aug 13, 2018
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	6488963	Jun 24, 2017	DP		M-153	Apr 16, 2016
	7674799	Mar 30, 2025	DP		NPP	Aug 13, 2018
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	6488963	Jun 24, 2017	DP		M-153	Apr 16, 2016
	7674799	Mar 30, 2025	DP		NPP	Aug 13, 2018
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080	002	7201920	Mar 16, 2025	DP		
		7510726	Nov 26, 2023	DP		
		7981439	Nov 26, 2023	DP		
		8409616	Nov 26, 2023	DP		
		8637540	Nov 26, 2023	DP		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	001	7276250	Feb 04, 2023	DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	002	7276250	Feb 04, 2023	DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	003	7276250	Feb 04, 2023	DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	004	7276250	Feb 04, 2023	DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	005	7276250	Feb 04, 2023	DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	006	7276250	Feb 04, 2023	DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	007	7276250	Feb 04, 2023	DP	U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	001	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	002	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	003	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	004	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	004	8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	005	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	006	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	007	7851482	Jul 10, 2029	DS		
		8075872	Nov 20, 2023	DP		
		8114383	Aug 08, 2024	DP		
		8192722	Sep 15, 2025	DP		
		8309060	Nov 20, 2023	DP		
		8309122	Feb 04, 2023	DP		
		8329216	Feb 04, 2023	DP		
		8808737	Jun 21, 2027		U-1598	
		8871779	Nov 22, 2029	DS		
<u>PACLITAXEL - ABRAXANE</u>						
N 021660	001	7758891	Feb 21, 2026		U-1434	
		7820788	Oct 27, 2024	DP	U-1092	I-658 Oct 11, 2015
		7820788	Oct 27, 2024	DP	U-1290	I-676 Sep 06, 2016
		7820788	Oct 27, 2024	DP	U-1434	ODE Sep 06, 2020
		7923536	Dec 09, 2023		U-1117	
		7923536	Dec 09, 2023		U-1290	
		7923536	Dec 09, 2023		U-1434	
		8034375	Aug 13, 2026		U-1290	
		8138229	Dec 09, 2023	DP	U-1092	
		8138229	Dec 09, 2023	DP	U-1290	
		8138229	Dec 09, 2023	DP	U-1434	
		8268348	Feb 21, 2026		U-1290	
		8314156	Dec 09, 2023		U-1290	
		8314156	Dec 09, 2023		U-1434	
		8853260	Oct 10, 2020	DP	U-1092	
		8853260	Oct 10, 2020	DP	U-1290	
		8853260	Oct 10, 2020	DP	U-1434	
		9101543	Feb 21, 2026		U-1434	
		RE41884	Aug 14, 2016		U-1117	
		RE41884	Aug 14, 2016		U-1290	
		RE41884	Aug 14, 2016		U-1434	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	001	6936612	Jan 22, 2023	DS DP		NCE Feb 03, 2020
		7208489	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023		U-1658	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	002	6936612	Jan 22, 2023	DS DP		NCE Feb 03, 2020
		7208489	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023		U-1658	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	003	6936612	Jan 22, 2023	DS DP	NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023	U-1658		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	001	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543	M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	002	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543	M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	003	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543	M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	004	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543	M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	005	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543	M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	001	6077843	May 12, 2017	DP U-543	NP	May 18, 2018
		6077843*PED	Nov 12, 2017			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	002	6077843	May 12, 2017	DP U-543	NP	May 18, 2018
		6077843*PED	Nov 12, 2017			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	003	6077843	May 12, 2017	DP U-543	NP	May 18, 2018
		6077843*PED	Nov 12, 2017			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	004	6077843	May 12, 2017	DP U-543	NP	May 18, 2018
		6077843*PED	Nov 12, 2017			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	001	5202333*PED	Oct 13, 2015		I-684	May 27, 2017
		7947724	Jan 30, 2024	DP	M-136	May 27, 2017
		7947724*PED	Jul 30, 2024		PED	Nov 27, 2017
		7947725	Jan 30, 2024	DP	PED	Nov 27, 2017
		7947725*PED	Jul 30, 2024			
		7960424	Jan 30, 2024	DP		
		7960424*PED	Jul 30, 2024			
		8518981	Jan 30, 2024	DP		
		8518981*PED	Jul 30, 2024			
		8598218	Jan 30, 2024	DP		
		8598218*PED	Jul 30, 2024			
		8598219	Jan 30, 2024	DP		
		8598219*PED	Jul 30, 2024			
		8729094	Jan 30, 2024	DP U-528		
		8729094*PED	Jul 30, 2024			
		9066980	Jan 30, 2024	DP U-528		
		9125905	Jan 30, 2024	DP		
		9173942	Jan 30, 2024	DP		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	002	5202333*PED	Oct 13, 2015		I-684	May 27, 2017
		7947724	Jan 30, 2024	DP	M-136	May 27, 2017
		7947724*PED	Jul 30, 2024		PED	Nov 27, 2017
		7947725	Jan 30, 2024	DP	PED	Nov 27, 2017
		7947725*PED	Jul 30, 2024			
		7960424	Jan 30, 2024	DP		
		7960424*PED	Jul 30, 2024			
		8518981	Jan 30, 2024	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	002	8518981*PED	Jul 30, 2024			
		8598218	Jan 30, 2024	DP		
		8598218*PED	Jul 30, 2024			
		8598219	Jan 30, 2024	DP		
		8598219*PED	Jul 30, 2024			
		9125905	Jan 30, 2024	DP		
		9173942	Jan 30, 2024	DP		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175	001				NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175	002				NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	007	8221747	Feb 20, 2028	DP		
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP	U-1274	
		8562980	Feb 20, 2028	DP	U-1274	
		8562981	Feb 20, 2028		U-1274	
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	001	9198871	Feb 07, 2030	DP	U-1787	
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	002	9198871	Feb 07, 2030	DP	U-1787	
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	003	9198871	Feb 07, 2030	DP	U-1787	
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	004	9198871	Feb 07, 2030	DP	U-1787	M-93 Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	005	9198871	Feb 07, 2030	DP	U-1787	M-93 Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	001	7658918	Feb 20, 2028	DP		
		8221747	Feb 20, 2028	DP		
		8246950	Feb 20, 2028		U-1274	
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP	U-1274	
		8562980	Feb 20, 2028	DP	U-1274	
		8562981	Feb 20, 2028		U-1274	
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	002	7658918	Feb 20, 2028	DP		
		8221747	Feb 20, 2028	DP		
		8246950	Feb 20, 2028		U-1274	
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP	U-1274	
		8562980	Feb 20, 2028	DP	U-1274	
		8562981	Feb 20, 2028		U-1274	
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	003	7658918	Feb 20, 2028	DP		
		8221747	Feb 20, 2028	DP		
		8246950	Feb 20, 2028		U-1274	
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP	U-1274	
		8562980	Feb 20, 2028	DP	U-1274	
		8562981	Feb 20, 2028		U-1274	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542 002					NCE	Mar 01, 2017
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987 001	5997903	Dec 07, 2016				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987	002	5997903				Dec 07, 2016
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988	001	6780881				Nov 17, 2021
		7351723			DP	Nov 17, 2021
		8754108			DP	Nov 17, 2021
		8754108*PED				May 17, 2022
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020	001	7544370				Jun 07, 2026
		7550153			DP	Sep 30, 2024
		7553498			U-859	Sep 30, 2024
		7838027			DP U-859	Sep 30, 2024
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	001	5597815				Jul 13, 2015
		6136799				Apr 08, 2018
		6361758			DP	Apr 08, 2018
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	002	5597815				Jul 13, 2015
		6136799				Apr 08, 2018
		6361758			DP	Apr 08, 2018
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	003	5597815				Jul 13, 2015
		5597815*PED				Jan 13, 2016
		6136799				Apr 08, 2018
		6136799*PED				Oct 08, 2018
		6361758			DP	Apr 08, 2018
		6361758*PED				Oct 08, 2018
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	001	5597815				Jul 13, 2015
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	002	5597815				Jul 13, 2015
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	003	5597815				Jul 13, 2015
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	001	6121291				Mar 17, 2017
		6121291				Mar 17, 2017
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	002	6121291				Mar 17, 2017
		6121291				Mar 17, 2017
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	003	6121291				Mar 17, 2017
		6121291				Mar 17, 2017
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	004	6121291				Mar 17, 2017
		6121291				Mar 17, 2017
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	005	6121291				Mar 17, 2017
		6121291				Mar 17, 2017
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020710	001	5811436				Sep 22, 2015
		6121291				Mar 17, 2017
		6121291				Mar 17, 2017
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	001	6063927				Apr 23, 2019
		6121291				Mar 17, 2017
		6121291				Mar 17, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	001	6172233				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	002	6063927				
		6121291		U-286		
		6121291		U-431		
		6172233				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	003	6063927				
		6121291		U-286		
		6121291		U-431		
		6172233				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	004	6063927				
		6121291		U-286		
		6121291		U-431		
		6172233				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936	001	6121291		U-286		
		6548084				
		7229640		DP	U-816	
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936	002	6121291		U-286		
		6548084				
		7229640		DP	U-816	
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936	003	6121291		U-286		
		6548084				
		7229640		DP	U-816	
<u>PAROXETINE MESYLATE - PEVEVA</u>						
N 021299	001	5874447		U-46		
		5874447		U-286		
		5874447		U-518		
		7598271		DS	DP	
<u>PAROXETINE MESYLATE - PEVEVA</u>						
N 021299	002	5874447		U-46		
		5874447		U-286		
		5874447		U-518		
		7598271		DS	DP	
<u>PAROXETINE MESYLATE - PEVEVA</u>						
N 021299	003	5874447		U-46		
		5874447		U-286		
		5874447		U-518		
		7598271		DS	DP	
<u>PAROXETINE MESYLATE - PEVEVA</u>						
N 021299	004	5874447		U-46		
		5874447		U-286		
		5874447		U-518		
		7598271		DS	DP	
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001	5874447		DS		
		7598271		DS		
		8658663		DS	DP	U-904
		8946251		DS	DP	U-904
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	001	6225284		DS	DP	
		7473761		DS	DP	
		8299209		DS	DP	
					NCE	Dec 14, 2017
					ODE	Dec 14, 2019

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	002	6225284	Jun 28, 2016	DS DP	NCE	Dec 14, 2017
		7473761	Jul 29, 2025	DS DP	ODE	Dec 14, 2019
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	003	6225284	Jun 28, 2016	DS DP	NCE	Dec 14, 2017
		7473761	Jul 29, 2025	DS DP	ODE	Dec 14, 2019
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	001	6225284	Jun 28, 2016	DS DP U-1628	NCE	Dec 14, 2017
		7473761	Jul 29, 2025	DS DP	NP	Dec 15, 2017
		7759308	Oct 25, 2026	DP	ODE	Dec 15, 2021
		8822637	Aug 06, 2023	U-1629		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	002	6225284	Jun 28, 2016	DS DP U-1628	NCE	Dec 14, 2017
		7473761	Jul 29, 2025	DS DP	NP	Dec 15, 2017
		7759308	Oct 25, 2026	DP	ODE	Dec 15, 2021
		8822637	Aug 06, 2023	U-1629		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	003	6225284	Jun 28, 2016	DS DP U-1628	NCE	Dec 14, 2017
		7473761	Jul 29, 2025	DS DP	NP	Dec 15, 2017
		7759308	Oct 25, 2026	DP	ODE	Dec 15, 2021
		8822637	Aug 06, 2023	U-1629		
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739	001	7556799	Feb 27, 2025	U-1766	NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	Mar 11, 2026	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS U-1766		
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739	002	7556799	Feb 27, 2025	U-1766	NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	Mar 11, 2026	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS U-1766		
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739	003	7556799	Feb 27, 2025	U-1766	NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	Mar 11, 2026	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS U-1766		
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	001	7105530	Oct 19, 2023	DS DP	ODE	Apr 26, 2019
		7262203	Dec 19, 2021	DS DP		
		8114885	Dec 19, 2021	DS DP		
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	002	7105530	Oct 19, 2023	DS DP	ODE	Apr 26, 2019
		7262203	Dec 19, 2021	DS DP		
		8114885	Dec 19, 2021	DS DP		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	002	7105530	Oct 19, 2023	DS DP	ODE	Apr 26, 2019
		7262203	Dec 19, 2021	DS DP		
		8114885	Dec 19, 2021	DS DP		
<u>PEGAPTANIB SODIUM - MACUGEN</u>						
N 021756	001	5932462	Aug 03, 2016	DS		
		6011020	Jan 04, 2017	DS		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	001	7084245	May 12, 2024	DS DP U-1238	NCE	Mar 27, 2017
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	002	7084245	May 12, 2024	DS DP U-1238	NCE	Mar 27, 2017
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	003	7084245	May 12, 2024	DS DP U-1238	NCE	Mar 27, 2017
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	004	7084245	May 12, 2024	DS DP U-1238	NCE	Mar 27, 2017
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	005	7084245	May 12, 2024	DS DP U-1238	NCE	Mar 27, 2017
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	006	7084245	May 12, 2024	DS DP U-1238	NCE	Mar 27, 2017
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799	007	7084245	May 12, 2024	DS DP U-1238		
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026	U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799	008	7084245	May 12, 2024	DS DP U-1238		
		7414105	May 12, 2024	DS DP U-1238		
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026	U-1238		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 001	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015		U-507		
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 002	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015		U-507		
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 003	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015		U-507		
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 004	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015		U-507		
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 005	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015		U-507		
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 001	5344932	Jul 24, 2016	DS DP		M-122	Oct 17, 2015
	7772209	Nov 24, 2021		U-1077		
	7772209	Nov 24, 2021		U-1296		
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 002	5344932	Jul 24, 2016	DS DP		M-122	Oct 17, 2015
	7772209	Nov 24, 2021		U-1296		
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N 020629 001	5840763	Sep 01, 2015		U-501		
	5916893	Sep 01, 2015		U-501		
	6469015	Oct 22, 2019		U-501		
	6579981	Jun 17, 2020		U-501		
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	6503745	Nov 05, 2019	DS		NCE	Dec 19, 2019
	6562861	Dec 17, 2018	DS			
	8778997	May 07, 2027		U-1627		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PERFLUTREN - DEFINITY</u>						
N 021064	001	6033645				
		Jun 19, 2016		U-665		
		8658205		DP		
		Apr 20, 2019				
		8685441		U-665		
		Jan 13, 2019				
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	001	6149938				
		Jul 23, 2018		DP		
		8440170		DP		
		Mar 14, 2029				
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	002	6149938				
		Jul 23, 2018		DP		
		8440170		DP		
		Mar 14, 2029				
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	003	6149938				
		Jul 23, 2018		DP U-1243		
		8440170		DP		
		Mar 14, 2029				
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYミア</u>						
N 022580	001	6071537				
		Jun 23, 2017		U-1262	NC	Jul 17, 2015
		7056890		DP U-1262		
		Jun 14, 2020				
		7553818		U-1262		
		Jun 14, 2020				
		7659256		DP U-1262		
		Jun 14, 2020				
		7674776		DP U-1262		
		Jun 14, 2020				
		8580298		DP		
		May 15, 2029				
		8580299		U-1262		
		Jun 14, 2029				
		8895057		U-1262		
		Jun 09, 2028				
		8895058		DP		
		Jun 09, 2028				
		9011905		DP		
		Jun 09, 2028				
		9011906		U-1262		
		Jun 09, 2028				
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYミア</u>						
N 022580	002	6071537				
		Jun 23, 2017		U-1262	NC	Jul 17, 2015
		7056890		DP U-1262		
		Jun 14, 2020				
		7553818		U-1262		
		Jun 14, 2020				
		7659256		DP U-1262		
		Jun 14, 2020				
		7674776		DP U-1262		
		Jun 14, 2020				
		8580298		DP		
		May 15, 2029				
		8580299		U-1262		
		Jun 14, 2029				
		8895057		U-1262		
		Jun 09, 2028				
		8895058		DP		
		Jun 09, 2028				
		9011905		DP		
		Jun 09, 2028				
		9011906		U-1262		
		Jun 09, 2028				
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYミア</u>						
N 022580	003	6071537				
		Jun 23, 2017		U-1262	NC	Jul 17, 2015
		7056890		DP U-1262		
		Jun 14, 2020				
		7553818		U-1262		
		Jun 14, 2020				
		7659256		DP U-1262		
		Jun 14, 2020				
		7674776		DP U-1262		
		Jun 14, 2020				
		8580298		DP		
		May 15, 2029				
		8580299		U-1262		
		Jun 14, 2029				
		8895057		U-1262		
		Jun 09, 2028				
		8895058		DP		
		Jun 09, 2028				
		9011905		DP		
		Jun 09, 2028				
		9011906		U-1262		
		Jun 09, 2028				
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYミア</u>						
N 022580	004	6071537				
		Jun 23, 2017		U-1262	NC	Jul 17, 2015
		7056890		DP U-1262		
		Jun 14, 2020				
		7553818		U-1262		
		Jun 14, 2020				
		7659256		DP U-1262		
		Jun 14, 2020				
		7674776		DP U-1262		
		Jun 14, 2020				
		8580298		DP		
		May 15, 2029				
		8580299		U-1262		
		Jun 14, 2029				
		8895057		U-1262		
		Jun 09, 2028				
		8895058		DP		
		Jun 09, 2028				
		9011905		DP		
		Jun 09, 2028				
		9011906		U-1262		
		Jun 09, 2028				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159	001	6764678	May 11, 2021			U-967
		6872390	May 11, 2021	DP		
		7229630	Jun 20, 2023	DP		
		7569230	Oct 17, 2023			U-967
		7575757	Apr 21, 2025	DP		
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510	001	8859623	Nov 14, 2033			U-1594
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510	002	8859623	Nov 14, 2033			U-1594
<u>PIMECROLIMUS - ELIDEL</u>						
N 021302	001	5912238	Jun 15, 2016			
		6352998	Oct 26, 2015			
		6423722	Jun 26, 2018			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073	001	5965584	Jun 19, 2016			U-753
		6150383	Jun 19, 2016			U-418
		6150384	Jun 19, 2016			U-419
		6166042	Jun 19, 2016			U-414
		6166043	Jun 19, 2016			U-415
		6172090	Jun 19, 2016			U-416
		6211205	Jun 19, 2016			U-410
		6271243	Jun 19, 2016			U-411
		6303640	Aug 09, 2016			U-425
		6329404	Jun 19, 2016			U-753
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073	002	5965584	Jun 19, 2016			U-753
		6150383	Jun 19, 2016			U-418
		6150384	Jun 19, 2016			U-419
		6166042	Jun 19, 2016			U-414
		6166043	Jun 19, 2016			U-415
		6172090	Jun 19, 2016			U-416
		6211205	Jun 19, 2016			U-410
		6271243	Jun 19, 2016			U-411
		6303640	Aug 09, 2016			U-425
		6329404	Jun 19, 2016			U-753
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073	003	5965584	Jun 19, 2016			U-753
		6150383	Jun 19, 2016			U-418
		6150384	Jun 19, 2016			U-419
		6166042	Jun 19, 2016			U-414
		6166043	Jun 19, 2016			U-415
		6172090	Jun 19, 2016			U-416
		6211205	Jun 19, 2016			U-410
		6271243	Jun 19, 2016			U-411
		6303640	Aug 09, 2016			U-425
		6329404	Jun 19, 2016			U-753
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	001	6900184	Apr 14, 2023	DP		U-282
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP		U-282
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	002	6900184	Apr 14, 2023	DP		U-282
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP		U-282
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	003	6900184	Apr 14, 2023	DP		U-282
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP		U-282

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	004	6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	001	6207661	Feb 22, 2019	DP		
		6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	002	6207661	Feb 22, 2019	DP		
		6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	003	6207661	Feb 22, 2019	DP		
		6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP U-282		
<u>PIRFENIDONE - ESBRIET</u>						
N 022535	001	7566729	Apr 22, 2029	U-1600	NCE	Oct 16, 2019
		7635707	Apr 22, 2029	U-1609	ODE	Oct 15, 2021
		7696236	Dec 18, 2027	U-1601		
		7767225	Sep 22, 2026	DP U-1602		
		7767700	Dec 18, 2027	U-1601		
		7816383	Jan 08, 2030	U-1603		
		7910610	Jan 08, 2030	U-1604		
		7988994	Sep 22, 2026	DP U-1602		
		8013002	Jan 08, 2030	U-1603		
		8084475	Jan 08, 2030	U-1605		
		8318780	Jan 08, 2030	U-1606		
		8383150	Sep 22, 2026	DP U-1607		
		8420674	Dec 18, 2027	DP U-1608		
		8592462	Apr 22, 2029	U-1609		
		8609701	Apr 22, 2029	U-1610		
		8648098	Jan 08, 2030	U-1611		
		8753679	Sep 22, 2026	DP U-1602		
		8754109	Jan 08, 2030	U-1612		
		8778947	Aug 30, 2033	U-1613		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	001	5854259	Dec 29, 2015	DP		
		5856336	Dec 25, 2020	DS U-998		
		6465477	Dec 20, 2016	DP		
		7022713	Feb 19, 2024	U-998		
		8557993	Feb 02, 2024	DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	002	5854259	Dec 29, 2015	DP		
		5856336	Dec 25, 2020	DS U-998		
		6465477	Dec 20, 2016	DP		
		7022713	Feb 19, 2024	U-998		
		8557993	Feb 02, 2024	DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	003	5854259	Dec 29, 2015	DP		
		5856336	Dec 25, 2020	DS U-998		
		6465477	Dec 20, 2016	DP		
		7022713	Feb 19, 2024	U-998		
		8557993	Feb 02, 2024	DS DP		
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311	001	6987102	Jul 22, 2023	U-936	ODE	Dec 15, 2015
		7897590	Jul 22, 2023	U-936		
		RE42152	Dec 10, 2018	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POLIDOCANOL - VARITHENA</u>						
N 205098	001	6572873				
		6846412				
		6942165				
		7025290				
		7357336				
		7604185				
		7731986				
		7814943				
		7842282				
		7842283				
		8122917				
		8323677				
		8734833				
		RE40640				
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	001	5635517				
		6045501				
		6315720				
		6316471				
		6476052				
		6561976				
		6561977				
		6755784				
		6908432				
		8158653				
		8198262				
		8204763				
		8315886				
		8589188				
		8626531				
		8673939				
		8735428				
		8828427				
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	002	5635517				
		6045501				
		6315720				
		6316471				
		6476052				
		6561976				
		6561977				
		6755784				
		6908432				
		8158653				
		8198262				
		8204763				
		8315886				
		8589188				
		8626531				
		8673939				
		8735428				
		8828427				
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	003	5635517				
		6045501				
		6315720				
		6316471				
		6476052				
		6561976				
		6561977				
		6755784				
		6908432				
		8158653				
		8198262				
		8204763				
		8315886				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-836		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-836		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 022003 001	5661151	Jul 19, 2019	DS DP U-760			
	6958337	Oct 05, 2018	DS DP U-760			
	8263600	Apr 01, 2022	DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001	5661151	Jul 19, 2019	DS DP U-1454			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
	9023790	Jul 04, 2031	DP U-1698			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004		ODE	Sep 24, 2016
	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	002	6028071	Jul 16, 2022	DS DP U-1004	ODE	Sep 24, 2016
		7622470	May 31, 2025	U-1015		
		8299078	May 31, 2025	U-1004		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	001	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	002	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	003	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	005	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	006	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	007	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	001	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	002	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	003	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	004	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	005	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	006	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	007	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332	001	5686411	Mar 16, 2019	DS DP U-638		
		5814600	Sep 29, 2015	U-639		
		6114304	Sep 05, 2017	U-640		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332	002	5686411	Mar 16, 2019	DS DP U-638		
		5814600	Sep 29, 2015	U-637		
		5814600	Sep 29, 2015	U-638		
		5814600	Sep 29, 2015	U-639		
		6114304	Sep 05, 2017	U-637		
		6114304	Sep 05, 2017	U-640		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332	003	5686411	Mar 16, 2019	DS DP U-638		
		5814600	Sep 29, 2015	U-637		
		5814600	Sep 29, 2015	U-638		
		5814600	Sep 29, 2015	U-639		
		6114304	Sep 05, 2017	U-637		
		6114304	Sep 05, 2017	U-640		
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	001	5288726	Apr 14, 2017	DS DP U-991		
		8404703	Jan 02, 2023	U-1381		
		8569325	Jan 02, 2023	U-1381		
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	002	5288726	Apr 14, 2017	DS DP U-991		
		8404703	Jan 02, 2023	U-1381		
		8569325	Jan 02, 2023	U-1381		
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	001	5881926	Mar 16, 2016	DP		
		6071523	Jun 03, 2018	DP		
		6399079	Jun 03, 2018	DP		
		6656482	Jun 03, 2018	DP		
		7799331	Oct 11, 2028	DP U-139		
		7799331	Oct 11, 2028	DP U-1068		
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	002	5881926	Mar 16, 2016	DP		
		6071523	Jun 03, 2018	DP		
		6399079	Jun 03, 2018	DP		
		6656482	Jun 03, 2018	DP		
		7799331	Oct 11, 2028	DP U-139		
		7799331	Oct 11, 2028	DP U-1068		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959	001	6024981	Apr 09, 2018	DP	Y	
		6221392	Apr 09, 2018	DP	Y	
		6740341	Nov 24, 2019	DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959	002	6024981	Apr 09, 2018	DP	Y	
		6221392	Apr 09, 2018	DP	Y	
		6740341	Nov 24, 2019	DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959	003	6024981	Apr 09, 2018	DP	Y	
		6221392	Apr 09, 2018	DP	Y	
		6740341	Nov 24, 2019	DP		
<u>PREDNISONE - RAYOS</u>						
N 202020	001	6488960	Mar 14, 2020	DP U-1267	M-128	Jul 26, 2015
		6677326	Mar 14, 2020	DP U-1268		
		8309124	Apr 23, 2024	U-1292		
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
<u>PREDNISONE - RAYOS</u>						
N 202020	002	6488960	Mar 14, 2020	DP U-1267	M-128	Jul 26, 2015
		6677326	Mar 14, 2020	DP U-1268		
		8309124	Apr 23, 2024	U-1292		
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
<u>PREDNISONE - RAYOS</u>						
N 202020	003	8168218	Jan 07, 2028	DP U-1269	M-128	Jul 26, 2015
		8309124	Apr 23, 2024	U-1292		
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONONE - RAYOS</u>						
N 202020	003 9186332	Apr 23, 2024	U-1362			
<u>PREGABALIN - LYRICA</u>						
N 021446	001 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	002 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	003 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	004 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	005 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	006 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	007 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446	008 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 022488	001 6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PROGESTERONE - ENDOMETRIN</u>						
N 022057	001 7300664	Nov 17, 2019	U-856			
	7320800	Nov 17, 2019	U-856			
	7393543	Nov 17, 2019	DP U-880			
<u>PROPOFOL - DIPRIVAN</u>						
N 019627	002 8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	001 6500454	Oct 04, 2021	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	002	6500454	Oct 04, 2021	DP		
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410	001	8338489	Oct 16, 2028	U-1496	NP ODE	Mar 14, 2017 Mar 14, 2021
<u>QUAZEPAM - DORAL</u>						
N 018708	001	7608616	Jun 03, 2028	U-1012		
<u>QUAZEPAM - DORAL</u>						
N 018708	003	7608616	Jun 03, 2028	U-1012		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	001	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	002	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	003	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	004	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	005	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736	001				NDF PED	Mar 26, 2016 Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736	002				NDF PED	Mar 26, 2016 Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971	001	6635234	Jan 03, 2020	U-1405	NCE	May 15, 2018
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N 020815	001	6458811	Mar 10, 2017	DS DP U-825		
		6797719	Mar 10, 2017	DP		
		6894064	Mar 10, 2017	DP U-657		
		8030330	Mar 10, 2017	DP		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145	001	7169780	Oct 03, 2023	DS DP		
		7217713	Oct 21, 2022	U-257		
		7435734	Oct 21, 2022	U-257		
		7435734	Oct 21, 2022	U-900		
		7754731	Mar 11, 2029	DS DP U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	001	7169780	Oct 03, 2023	DS DP		
		7217713	Oct 21, 2022	U-257		
		7435734	Oct 21, 2022	U-257		
		7754731	Mar 11, 2029	DS DP U-257		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	002	7169780	Oct 03, 2023	DS DP		
		7217713	Oct 21, 2022	U-257		
		7435734	Oct 21, 2022	U-257		
		7754731	Mar 11, 2029	DS DP U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786	001	7169780	Oct 03, 2023	DS DP	NDF	Dec 20, 2016
		7217713	Oct 21, 2022	U-257		
		7435734	Oct 21, 2022	U-257		
		7754731	Mar 11, 2029	DS DP U-257		
<u>RAMELTEON - ROZEREM</u>						
N 021782	001	6034239	Jul 22, 2019	DS DP U-674		
<u>RAMIPRIL - ALTACE</u>						
N 019901	001	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901	002	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901	003	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901	004	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	001	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	002	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	003	7368469	Aug 30, 2020	U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021	004	7368469	Aug 30, 2020	U-871		
<u>RANOLAZINE - RANEXA</u>						
N 021526	001	6303607	May 27, 2019	U-705		
		6369062	May 27, 2019	DP	Y	
		6479496	May 27, 2019	U-705		
		6503911	May 27, 2019	DP		
		6525057	May 27, 2019	U-705		
		6562826	May 27, 2019	U-705		
		6617328	May 27, 2019	DP		
		6620814	May 27, 2019	U-705		
		6852724	May 27, 2019	U-705		
		6864258	May 27, 2019	U-705		
<u>RANOLAZINE - RANEXA</u>						
N 021526	002	6303607	May 27, 2019	U-705		
		6369062	May 27, 2019	DP		
		6479496	May 27, 2019	U-705		
		6503911	May 27, 2019	DP		
		6525057	May 27, 2019	U-705		
		6562826	May 27, 2019	U-705		
		6617328	May 27, 2019	DP		
		6620814	May 27, 2019	U-705		
		6852724	May 27, 2019	U-705		
		6864258	May 27, 2019	U-705		
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	001	5453446	Feb 07, 2017	U-219	I-685	May 29, 2017
		6126968	Sep 18, 2016	DP		
		7572834	Dec 05, 2026	DP		
		7815942	Aug 27, 2027	DS DP U-219		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	6403567	Apr 10, 2022	DS DP U-869			
	6642210	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-116			
	7144872	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-870			
	7183264	Jun 22, 2019	DP U-116			
	7183264	Jun 22, 2019	DP U-869			
	7183264	Jun 22, 2019	DP U-870			
	7582617	Jun 22, 2019	U-1003			
	7655636	Jun 22, 2019	U-869			
	7655637	Jun 22, 2019	DS DP U-869			
	7683037	Jun 22, 2019	U-1042			
	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
	8470801	Jun 22, 2019	U-116			
	8536150	Jun 22, 2019	U-116			
	9045519	Jun 22, 2019	DP			
	9085601	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jan 12, 2020	DS		I-667	Feb 25, 2016
	8637553	Feb 16, 2031	DS DP		NCE	Sep 27, 2017
	8680124	Jun 02, 2030	U-1506		ODE	Feb 25, 2020
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 001	5866591	Sep 10, 2017	DP			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 002	5866591	Sep 10, 2017	DP			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 003	5866591	Sep 10, 2017	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIBAVIRIN - VIRAZOLE</u>						
N 018859 001	6150337	Nov 21, 2017	U-400			
<u>RIBAVIRIN - REBETOL</u>						
N 020903 001	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
<u>RIBAVIRIN - REBETOL</u>						
N 020903 002	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-479			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBAVIRIN - REBETOL</u>						
N 020903	002	6472373	Sep 21, 2017	U-1014		
		6524570	Nov 01, 2016	U-499		
		6524570	Nov 01, 2016	U-1013		
<u>RIBAVIRIN - REBETOL</u>						
N 021546	001	6172046	Sep 21, 2017	U-521		
		6172046	Sep 21, 2017	U-1014		
		6177074	Nov 01, 2016	U-1013		
		6461605	Nov 01, 2016	U-521		
		6461605	Nov 01, 2016	U-1013		
		6472373	Sep 21, 2017	U-521		
		6524570	Nov 01, 2016	U-1013		
		6790837	Apr 05, 2023	DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001	7045620	Jun 19, 2024	DS DP		
		7612199	Jun 19, 2024	DS DP		
		7902206	Jun 19, 2024	DS DP		
		7906542	Jun 01, 2025	DS DP		
		7928115	Jul 24, 2029		U-1121	
		8158644	Jun 19, 2024	DP		
		8158781	Jun 19, 2024	DS		
		8193196	Sep 02, 2027	DS DP		
		8518949	Feb 27, 2026	DP		
		8741904	Feb 27, 2026	DS	U-1526	
		8835452	Jun 19, 2024	DS DP		
		8853231	Jun 19, 2024	DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	6861053	Aug 11, 2019	U-1707	I-709	May 27, 2018
		6861053	Aug 11, 2019	U-1708	ODE	Mar 24, 2017
		7045620	Jun 19, 2024	DS		
		7452857	Aug 11, 2019	U-1707		
		7452857	Aug 11, 2019	U-1708		
		7605240	Aug 11, 2019	U-1707		
		7605240	Aug 11, 2019	U-1708		
		7612199	Jun 19, 2024	DS DP		
		7718608	Aug 11, 2019	U-1707		
		7718608	Aug 11, 2019	U-1708		
		7902206	Jun 19, 2024	DS DP		
		7906542	Jun 01, 2025	DS DP		
		7915275	Feb 23, 2025	U-1707		
		7915275	Feb 23, 2025	U-1708		
		7935799	Aug 11, 2019	U-1707		
		7935799	Aug 11, 2019	U-1708		
		8158644	Jun 19, 2024	DP		
		8158781	Jun 19, 2024	DS		
		8193196	Sep 02, 2027	DS DP	U-1707	
		8193196	Sep 02, 2027	DS DP	U-1708	
		8309569	Jul 18, 2029	U-1707		
		8309569	Jul 18, 2029	U-1708		
		8518949	Feb 27, 2026	DP		
		8642573	Oct 02, 2029	U-1481		
		8741904	Feb 27, 2026	DS	U-1526	
		8741904	Feb 27, 2026	DS	U-1707	
		8741904	Feb 27, 2026	DS	U-1708	
		8829017	Jul 24, 2029	U-1562		
		8835452	Jun 19, 2024	DS DP		
		8853231	Jun 19, 2024	DP		
		8946252	Jul 24, 2029	U-1481		
		8969398	Oct 02, 2029	U-1481		
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022	001	6838464	Feb 26, 2021	DS DP	NCE	May 20, 2016
		7067522	Dec 20, 2019	DS DP	NPP	Aug 26, 2018
		7125879	Aug 09, 2022	DS DP	U-1153	
		7125879	Aug 09, 2022	DS DP	U-1307	
		7125879	Aug 09, 2022	DS DP	U-1740	
		7638522	Apr 14, 2023	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022	001	8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	001	6743798	Jul 16, 2019	DS DP	NCE	Oct 08, 2018
		7173037	Apr 25, 2023	DS DP	ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	002	6743798	Jul 16, 2019	DS DP	NCE	Oct 08, 2018
		7173037	Apr 25, 2023	DS DP	ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	003	6743798	Jul 16, 2019	DS DP	NCE	Oct 08, 2018
		7173037	Apr 25, 2023	DS DP	ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	004	6743798	Jul 16, 2019	DS DP	NCE	Oct 08, 2018
		7173037	Apr 25, 2023	DS DP	ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	005	6743798	Jul 16, 2019	DS DP	NCE	Oct 08, 2018
		7173037	Apr 25, 2023	DS DP	ODE	Oct 08, 2020
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132	001				PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132	002				PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132	003				PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835	001	6165513	Jun 10, 2018			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835	002	6165513	Jun 10, 2018			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835	003	5994329	Jul 17, 2018		U-353	
		6015801	Jul 17, 2018		U-353	
		6165513	Jun 10, 2018	DP		
		6432932	Jul 17, 2018		U-595	
		6465443	Aug 14, 2018	DP		
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835	004	6165513	Jun 10, 2018	DP		
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835	005	6165513	Jun 10, 2018	DP		
		7192938	May 06, 2023		U-353	
		7718634	May 06, 2023		U-662	
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560	001	7645459	Jan 09, 2028	DP	U-662	
		7645460	Jan 09, 2028	DP	U-662	
		8246989	Jan 16, 2026	DP		
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346	001	5792477	May 02, 2017	DP		
		5916598	May 02, 2017	DP		
		6194006	Dec 30, 2018	DP		
		6379703	Dec 30, 2018	DP		
		6403114	May 02, 2017	DP		
		6596316	Dec 30, 2018	DP		
		6667061	May 25, 2020	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 002	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 003	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 004	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 001	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 002	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 003	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 004	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 005	6224905	Jun 10, 2017	DP			
<u>RITONAVIR - NORVIR</u>						
N 020659 001	6037157	Jun 26, 2016				
	6703403	Jun 26, 2016		U-564		
<u>RITONAVIR - NORVIR</u>						
N 020945 001	6037157	Jun 26, 2016		U-895		
	6232333	Nov 07, 2017				
	6703403	Jun 26, 2016		U-564		
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	6037157	Jun 26, 2016		U-688		
	6703403	Jun 26, 2016		U-688		
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP	U-688		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024		U-688		
	8691878*PED	Feb 25, 2025				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Feb 08, 2021	DS DP	U-1301	I-660	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP	U-1302	I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS	U-1303	I-662	Nov 02, 2015
	7592339	Dec 11, 2020		U-1167	NCE	Jul 01, 2016



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Feb 08, 2021	DS DP U-1301		I-660	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP U-1302		I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-662	Nov 02, 2015
	7592339	Dec 11, 2020	U-1167		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Feb 08, 2021	DS DP U-1301		I-660	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP U-1302		I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-662	Nov 02, 2015
	7592339	Dec 11, 2020	U-1167		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVASTIGMINE - RIVASTIGMINE</u>						
A 204403 003					PC	Feb 29, 2016
<u>RIVASTIGMINE - EXELON</u>						
N 022083 001	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N 022083 002	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005	6316023	Jan 08, 2019	DP		NPP	Jun 27, 2016
	6335031	Jan 08, 2019	DP		NS	Aug 31, 2015
<u>ROFECOXIB - VIOXX</u>						
N 021042 001	6063811	May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021042 002	6063811	May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021042 003	6063811	May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021052 001	6063811	May 06, 2017	U-266			
<u>ROFECOXIB - VIOXX</u>						
N 021052 002	6063811	May 06, 2017	U-266			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2020	DS DP U-1115		NCE	Feb 28, 2016
	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
	7563801	Apr 04, 2027	DP			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Oct 09, 2029	U-1741			
	8470842	Jan 18, 2029	U-1741			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROLAPITANT HYDROCHLORIDE - VARUEI</u>						
N 206500	001 8796299	Dec 17, 2022	U-1741			
<u>ROMIDEPSIN - ISTODAX</u>						
N 022393	001 7608280	Aug 22, 2021	DS		ODE	Nov 05, 2016
	7611724	Aug 22, 2021	DS		ODE	Jun 16, 2018
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	001 7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	002 7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	003 7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	004 7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	005 7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	006 7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	001 7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	002 6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	003 6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	004 6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	002 6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-618			
	6858618	Dec 17, 2021	U-1032			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	003 6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-618			
	6858618	Dec 17, 2021	U-1032			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	004 6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-618			
	6858618	Dec 17, 2021	U-1032			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>RUFINAMIDE - BANZEL</u>						
N 021911 001	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUFINAMIDE - BANZEL</u>						
N 021911 001	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 002	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 003	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 201367 001	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	004	9079912				
		Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	005	7598257	DS DP	U-1201	I-699	Dec 04, 2017
		7598257	DS DP	U-1622	NCE	Nov 16, 2016
		8415362	DS DP		ODE	Nov 16, 2018
		8722693	DS DP		ODE	Dec 04, 2021
		8822481		U-1573		
		8829013		U-1201		
		8829013		U-1622		
		9079912		U-1573		
		9079912		U-1721		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	001	7468390		DP	NCE	Jul 07, 2020
		8101659		DP		
		8404744		DP		
		8796331		U-1723		
		8877938	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	002	7468390		DP	NCE	Jul 07, 2020
		8101659		DP		
		8404744		DP		
		8796331		U-1723		
		8877938	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	003	7468390		DP	NCE	Jul 07, 2020
		8101659		DP		
		8404744		DP		
		8796331		U-1723		
		8877938	DS DP			
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
N 020692	001	5873360		DP		
		Feb 23, 2016				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181	001	7566462		DP	NPP	Apr 23, 2017
		7566462*PED			PED	Oct 23, 2017
		7566714		U-989		
		7566714*PED				
		7612073		U-1010		
		7612073*PED				
		7727987		DP		
		7727987*PED				
		7947681		U-1156	Y	
		7947681*PED				
		8003126				
		8003126*PED				
		8067416		U-989		
		8067416*PED				
		8318745		DP		
		8318745*PED				
		RE43797		U-1156		
		RE43797*PED				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	001	7566714		U-1589		
		7566714*PED				
		7612073		U-1010		
		7612073*PED				
		8067416		U-1589		
		8067416*PED				
		RE43797		U-1590		
		RE43797*PED				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	002	7566714	Nov 17, 2024	U-1589		
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024	U-1010		
		8067416	Nov 17, 2024	U-1589		
		8067416*PED	May 17, 2025			
		RE43797	Nov 17, 2024	U-1590		
<u>SAQUINAVIR - FORTOVASE</u>						
N 020828	001	6352717	Nov 16, 2019			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628	001				M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785	001				M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	001	7951400	Nov 30, 2028	DP	M-134	May 24, 2016
		RE44186	Jul 31, 2023	DS DP U-995		
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	002	7951400	Nov 30, 2028	DP	M-134	May 24, 2016
		RE44186	Jul 31, 2023	DS DP U-995		
<u>SELEGILINE - EMSAM</u>						
N 021336	001	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		
<u>SELEGILINE - EMSAM</u>						
N 021336	002	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		
<u>SELEGILINE - EMSAM</u>						
N 021336	003	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		
<u>SELEGILINE HYDROCHLORIDE - ZELAPAR</u>						
N 021479	001	6423342	Mar 01, 2016	DP		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	001				NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	002				NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	003				NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	004				NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	005				NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	006				NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	007				NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	008				NCE	Dec 21, 2020

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990	001	6727283	Oct 11, 2019	DP U-580		
		7067555	Oct 11, 2019	DP		
		7067555*PED	Apr 11, 2020			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127	001	7985418	Oct 27, 2025	DP		
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179	001	6733780	Oct 18, 2020	DP		
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179	002	6733780	Oct 18, 2020	DP		
<u>SEVOFLURANE - ULTANE</u>						
N 020478	001	5990176	Jan 27, 2017			
		6074668	Jan 09, 2018			
		6288127	Jan 27, 2017			
		6444859	Jan 27, 2017			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895	001	6469012	Oct 22, 2019	U-155		
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895	002	6469012	Oct 22, 2019	U-155		
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895	003	6469012	Oct 22, 2019	U-155		
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845	001				D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					M-61	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473	001				D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					M-61	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109	001				D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					NDF	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILODOSIN - RAPAFLO</u>						
N 022206	001	5387603	Dec 01, 2018	DS DP		
<u>SILODOSIN - RAPAFLO</u>						
N 022206	002	5387603	Dec 01, 2018	DS DP		
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123	001	7671032	May 19, 2025	DS DP	D-151	Oct 05, 2018
		8148399	Sep 05, 2029	DS DP U-1467	I-697	Nov 05, 2017
		8349869	Jul 28, 2026	DS DP U-1467	I-717	Oct 05, 2018
		8741926	Jul 28, 2026	DS U-1467	NCE	Nov 22, 2018
		8754106	Jul 28, 2026	DS U-1467		
		9040562	Jul 28, 2026	DS DP U-1467		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	001	6303661	Apr 24, 2017		U-1188	
		6699871	Jul 26, 2022	DS DP U-1188		
		6890898	Feb 02, 2019		U-1189	
		6890898	Feb 02, 2019		U-1190	
		6890898	Feb 02, 2019		U-1191	
		7078381	Feb 02, 2019		U-1188	
		7125873	Jul 26, 2022	DP U-1189		
		7125873	Jul 26, 2022	DP U-1190		
		7125873	Jul 26, 2022	DP U-1192		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 001	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 002	6303661	Apr 24, 2017		U-1188		
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 003	6303661	Apr 24, 2017		U-1188		
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 004	6303661	Apr 24, 2017		U-1188		
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 005	6303661	Apr 24, 2017		U-1188		
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6303661	Apr 24, 2017		U-1188		
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SINCALIDE - KINEVAC</u>						
N 017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	5795911	Oct 31, 2020	U-172			
	5968973	Apr 10, 2017	U-172			
	7858662	Oct 02, 2026	DP U-172			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7326708	Apr 11, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7326708	Apr 11, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7326708	Apr 11, 2026	DS DP U-802			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP		ODE	Jan 14, 2018
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419		ODE	Jan 14, 2018
	8568793	Dec 24, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	6780889	Jul 04, 2020	DP			
	7262219	Jul 04, 2020	DP			
	7668730	Jun 16, 2024	U-1110			
	7765106	Jun 16, 2024	U-1069			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196	001	7765107	Jun 16, 2024	U-1070		
		7851506	Dec 22, 2019	U-1101		
		7851506	Dec 22, 2019	U-1102		
		7895059	Dec 17, 2022	U-1110		
		8263650	Dec 22, 2019	DP U-1101		
		8263650	Dec 22, 2019	DP U-1102		
		8324275	Dec 22, 2019	U-1101		
		8324275	Dec 22, 2019	U-1102		
		8457988	Dec 17, 2022	U-1110		
		8589182	Dec 17, 2022	U-1110		
		8731963	Dec 17, 2022	U-1110		
		8772306	Mar 15, 2033	U-1532		
		8859619	Dec 22, 2019	DP		
		8952062	Dec 22, 2019	U-1101		
		8952062	Dec 22, 2019	U-1102		
		9050302	Mar 15, 2033	U-1532		
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892	001	7687075	Jun 22, 2028	DS DP		
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923	001	8496973	Mar 29, 2031	DS DP U-1419	ODE	Jan 14, 2018
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	001	7964580	Mar 26, 2029	DS DP U-1470	NCE	Dec 06, 2018
		8334270	Mar 21, 2028	DS DP U-1470		
		8580765	Mar 21, 2028	DS DP U-1470		
		8618076	Dec 11, 2030	DS DP U-1470		
		8633309	Mar 26, 2029	DS DP U-1470		
		8889159	Mar 26, 2029	DP U-1470		
		9085573	Mar 21, 2028	DS DP U-1470		
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518	001	6017927	Nov 19, 2018	DS DP		
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518	002	6017927	Nov 19, 2018	DS DP		
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N 019764	002	5898030	Apr 27, 2016	DP		
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N 019764	003	5898030	Apr 27, 2016	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	001	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	002	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	003	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	005	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	008	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	009	6152897	Nov 20, 2018	DP		
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604	001	5898030	Apr 27, 2016	DP		
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604	002	5898030	Apr 27, 2016	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604	003	5898030	Apr 27, 2016	DP		
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604	004	5898030	Apr 27, 2016	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148	001	5849700	Dec 15, 2015		U-340	
		5849704	Dec 15, 2015			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148	002	5849700	Dec 15, 2015		U-340	
		5849704	Dec 15, 2015			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148	003	5849700	Dec 15, 2015		U-340	
		5849704	Dec 15, 2015			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	004	5849700	Dec 15, 2015		U-340	
		5849704	Dec 15, 2015	DP	U-340	
		6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	005	5849700	Dec 15, 2015		U-340	
		5849704	Dec 15, 2015	DP	U-340	
		6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	006	5849700	Dec 15, 2015		U-340	
		5849704	Dec 15, 2015	DP	U-340	
		6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	007	5849700	Dec 15, 2015		U-340	
		5849704	Dec 15, 2015	DP	U-340	
		6004297	Jan 28, 2019	DP		
		8841252	Dec 26, 2017	DP		
		RE41956	Jan 21, 2021	DP		
		RE43834	Jan 28, 2019	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	008	5849700	Dec 15, 2015		U-1041	
		5849704	Dec 15, 2015	DP	U-1041	
		6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8841252	Dec 26, 2017	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	009	5849700	Dec 15, 2015		U-1041	
		5849704	Dec 15, 2015	DP	U-1041	
		6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8841252	Dec 26, 2017	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	009	5849700				
		Dec 15, 2015		U-1041		
		5849704		DP U-1041		
		Dec 15, 2015				
		6899699		DP		
		Jan 02, 2022				
		7686786		DP		
		Aug 03, 2026				
		8672898		DP		
		Jan 02, 2022				
		8684969		DP		
		Oct 20, 2025				
		8841252		DP		
		Dec 26, 2017				
		8920383		DP		
		Jul 17, 2026				
		9108002		DP		
		Jan 20, 2026				
		9132239		DP		
		Feb 01, 2032				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	010	5849700				
		Dec 15, 2015		U-1041		
		5849704		DP U-1041		
		Dec 15, 2015				
		6899699		DP		
		Jan 02, 2022				
		7686786		DP		
		Aug 03, 2026				
		8672898		DP		
		Jan 02, 2022				
		8684969		DP		
		Oct 20, 2025				
		8841252		DP		
		Dec 26, 2017				
		8920383		DP		
		Jul 17, 2026				
		9108002		DP		
		Jan 20, 2026				
		9132239		DP		
		Feb 01, 2032				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	011	5849700				
		Dec 15, 2015		U-1041		
		5849704		DS DP U-1041		
		Dec 15, 2015				
		6899699		DP		
		Jan 02, 2022				
		7686786		DP		
		Aug 03, 2026				
		8672898		DP		
		Jan 02, 2022				
		8684969		DP		
		Oct 20, 2025				
		8841252		DP		
		Dec 26, 2017				
		8920383		DP		
		Jul 17, 2026				
		9108002		DP		
		Jan 20, 2026				
		9132239		DP		
		Feb 01, 2032				
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N 021597	004	5898030				
		Apr 27, 2016		DP		
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266	001	8063043				
		Sep 15, 2029	DS DP		NCE	Jul 24, 2020
		8178563		DS U-1722		
		Feb 06, 2029				
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923	001	7235576				
		Jan 12, 2020	DS DP		I-677	Nov 22, 2016
		7351834		DS	ODE	Nov 22, 2020
		Jan 12, 2020				
		7897623		DP		
		Jan 12, 2020				
		8124630			U-1459	
		Jan 12, 2020				
		8618141			U-1480	
		Feb 11, 2023				
		8841330			U-1696	
		Jan 12, 2020				
		8877933		DS DP U-1624		
		Dec 24, 2027				
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306	001					
					ODE	Jul 02, 2016
<u>SPINOSAD - NATROBA</u>						
N 022408	001	6063771				
		Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
		6342482		DP U-1105	NCE	Jan 18, 2016
		Jun 22, 2019				
		7030095		DP U-1105		
		Jul 02, 2021				
<u>STAVUDINE - ZERIT XR</u>						
N 021453	001	7135465				
		Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	002	7135465				
		Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	003	7135465				
		Feb 18, 2023	DP U-167			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>STAVUDINE - ZERIT XR</u>						
N 021453	004 7135465	Feb 18, 2023	DP U-167			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109	001 6174442	Dec 19, 2016	DS U-1468		NP	Nov 27, 2016
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	001 6949527	Jan 27, 2021	U-1795			
	7265009	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	002 6949527	Jan 27, 2021	U-1795			
	7265009	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684	001				NCE	Oct 10, 2019
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001 5957886	Mar 08, 2016	DP			
	6135979	Mar 21, 2017	DP			
	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
	8343130	Oct 18, 2022	DP			
	8491524	Nov 21, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377	001 7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - ZECURITY</u>						
N 202278	001 6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
	8983594	Nov 19, 2030	DP U-1328			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	001 6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	002 6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	003 6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	004 6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	001 7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	002 7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	003 7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	004 7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	001 6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	002 6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	003 6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	001 7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	002 7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	003 7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	003 9161907	Aug 30, 2024	DP U-1752			
<u>TADALAFIL - CIALIS</u>						
N 021368	001 5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6140329	Jul 11, 2016	DP U-1184			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-1184			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-1184			
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
<u>TADALAFIL - CIALIS</u>						
N 021368	002 5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N 021368	003 5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N 021368	004 5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - ADCIRCA</u>						
N 022332	001 5859006	Nov 21, 2017	DS DP U-975		ODE	May 22, 2016
	6821975	Nov 19, 2020	DS DP			
	7182958	Apr 26, 2020	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514	001 5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458	001 8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
	8741620	Feb 24, 2024	DS DP		NPP	Aug 27, 2017
	8790641	Oct 18, 2025	U-1564			
	8790641	Oct 18, 2025	U-1574			
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N 021807	001 6127425	Jun 26, 2018	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	001 6071970	Jun 06, 2017	U-931			
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	002 6071970	Jun 06, 2017	U-931			
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 003	6071970	Jun 06, 2017		U-931		
	7994364	Jun 27, 2025	DS DP	U-931		
	RE39593	Aug 05, 2022	DS DP	U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	6071970	Jun 06, 2017		U-1178	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP	Y	
	8309060	Nov 20, 2023		DP U-1178		
	8309060	Nov 20, 2023		DP U-1276		
	8420056	Nov 20, 2023		DP		
	8536130	Sep 22, 2028		U-1739		
	RE39593	Aug 05, 2022	DS DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	6071970	Jun 06, 2017		U-1178	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP	Y	
	8309060	Nov 20, 2023		DP U-1178		
	8309060	Nov 20, 2023		DP U-1276		
	8420056	Nov 20, 2023		DP		
	8536130	Sep 22, 2028		U-1739		
	RE39593	Aug 05, 2022	DS DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	6071970	Jun 06, 2017		U-1178	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP	Y	
	8309060	Nov 20, 2023		DP U-1178		
	8309060	Nov 20, 2023		DP U-1276		
	8420056	Nov 20, 2023		DP		
	8536130	Sep 22, 2028		U-1739		
	RE39593	Aug 05, 2022	DS DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	6071970	Jun 06, 2017		U-1178	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP	Y	
	8309060	Nov 20, 2023		DP U-1178		
	8309060	Nov 20, 2023		DP U-1276		
	8420056	Nov 20, 2023		DP		
	8536130	Sep 22, 2028		U-1739		
	RE39593	Aug 05, 2022	DS DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	6071970	Jun 06, 2017		U-1178	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP	Y	
	8309060	Nov 20, 2023		DP U-1178		
	8309060	Nov 20, 2023		DP U-1276		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	005 8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1739			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794	001 6071970	Jun 06, 2017	U-1289			
	7994364	Jun 27, 2025	DS DP U-1289			
	RE39593	Aug 05, 2022	DS DP U-1289			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001 5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
	8785492	Jan 25, 2033	U-1486		ODE	Jan 31, 2021
	9060995	Jan 25, 2033	U-1710			
<u>TAVABOROLE - KERYDIN</u>						
N 204427	001 7582621	May 26, 2027	U-718		NCE	Jul 07, 2019
	7767657	May 22, 2027	DP			
<u>TAZAROTENE - FABIOR</u>						
N 202428	001 8808716	Feb 24, 2030	DP			
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N 017858	001				ODE	Aug 13, 2019
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N 019928	001 6056941	Jul 28, 2019	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207	001 6409990	May 12, 2020	DS		I-687	Jun 13, 2017
					NCE	Mar 13, 2018
					ODE	Jun 13, 2021
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435	001 7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436	001 7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441	001 5789379	Apr 14, 2016	DS DP U-1320		NCE	Dec 21, 2017
	7056886	Sep 18, 2022	DP U-1320		ODE	Dec 21, 2019
	7847061	Nov 01, 2025	U-1320			
	9060992	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917	001 7820671	Feb 25, 2025	DS DP		NCE	May 23, 2016
	8431615	May 30, 2028	U-1398			
	8529882	Aug 31, 2021	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	001 6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021	U-1005			
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021	U-282			
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	002	6635618	Sep 11, 2023	DS DP U-728	I-673	Jun 21, 2016
		6858584	Aug 24, 2022	DP		
		6872701	Jun 05, 2021	DP		
		7008923	May 06, 2021	U-1005		
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP U-728		
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021	U-282		
		8101575	May 01, 2021	DP		
		8158580	May 01, 2021	DP		
<u>TELBIVUDINE - TYZEKA</u>						
N 022011	001	6395716	Aug 10, 2019	U-782	M-124	Jan 28, 2016
		6444652	Aug 10, 2019	U-782		
		6566344	Aug 10, 2019	U-782		
		6569837	Oct 25, 2020	U-782		
		6569837	Oct 25, 2020	U-999		
		7589079	Sep 11, 2023	DS DP U-999		
		7795238	Aug 10, 2019	U-999		
		7858594	Sep 11, 2023	DS DP U-999		
<u>TELBIVUDINE - TYZEKA</u>						
N 022154	001	6395716	Aug 10, 2019	U-999	M-124	Jan 28, 2016
		6444652	Aug 10, 2019	U-999		
		6566344	Aug 10, 2019	U-999		
		6569837	Oct 25, 2020	U-999		
		7795238	Aug 10, 2019	U-999		
		7858594	Sep 11, 2023	DS DP U-999		
<u>TELITHROMYCIN - KETEK</u>						
N 021144	001	5635485	Apr 01, 2018	DS DP U-578		
		D459798	Sep 24, 2015	DP		
<u>TELITHROMYCIN - KETEK</u>						
N 021144	002	5635485	Apr 01, 2018	DS DP U-578		
		D459798	Sep 24, 2015	DP		
<u>TELMISARTAN - MICARDIS</u>						
N 020850	001	6358986	Jan 10, 2020			
<u>TELMISARTAN - MICARDIS</u>						
N 020850	002	6358986	Jan 10, 2020			
		7998953	Jun 06, 2020	U-1177		
		8003679	Oct 06, 2022	U-1176		
<u>TELMISARTAN - MICARDIS</u>						
N 020850	003	6358986	Jan 10, 2020			
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001	6987108	Sep 08, 2023	DP		
		7786118	Feb 21, 2023	DP		
		8623868	Feb 21, 2023	DP		
<u>TEMSTIROLIMUS - TORISEL</u>						
N 022088	001	5362718	Feb 15, 2019	DS DP	Y	Nov 30, 2015
		5362718*PED	Aug 15, 2019			
		8026276	Jan 20, 2026	DP		
		8299116	Jul 25, 2023	DP		
		8455539	Jul 25, 2023	DP		
		8455539*PED	Jan 25, 2024			
		8722700	Jul 25, 2023	DP		
		8722700*PED	Jan 25, 2024			
		8791097	May 10, 2032	U-1550		
		8791097	May 10, 2032	U-1551		
		8791097*PED	Nov 10, 2032			
		RE44768	Feb 15, 2019	DS DP		
		RE44768*PED	Aug 15, 2019			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-999		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-999		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-999		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		ODE	Mar 24, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004	5922695	Jul 25, 2017	DS U-999		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-999		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Apr 15, 2022	U-1285		NCE	Sep 12, 2017
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034	U-1786			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Apr 15, 2022	U-1285		NCE	Sep 12, 2017
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034	U-1786			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	6770623	Dec 08, 2018	DP U-597			
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 002	6770623	Dec 08, 2018	DP U-982			
	6977077	Aug 19, 2019	U-982			
	6977077	Aug 19, 2019	U-994			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7351414	Aug 19, 2019	U-994			
	7517334	Mar 25, 2025	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318	002 7550434	Dec 08, 2018	DP U-982			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505	001 5861379	May 26, 2020	DS DP U-1100		NCE	Nov 10, 2015
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505	002 7144577	Jul 14, 2020	U-1100		NCE	Nov 10, 2015
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - TESTODERM</u>						
N 019762	001 5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM</u>						
N 019762	002 5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM TTS</u>						
N 020791	001 6348210	Nov 10, 2019	U-440			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	001 6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	002 6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015	003 6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - TESTIM</u>						
N 021454	001 7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
	7935690	Apr 21, 2023	U-1009			
	8063029	Apr 21, 2023	U-843			
	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - FORTESTA</u>						
N 021463	001 6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - STRIANT</u>						
N 021543	001 6248358	Aug 23, 2019	U-527			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309	001 6503894	Aug 30, 2020	U-1103			
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	6299900	Feb 19, 2017	DP U-1103			
	6818226	Feb 19, 2017	DP U-1103			
	6923983	Feb 19, 2017	DP U-1103			
	8071075	Feb 19, 2017	DP U-1103			
	8419307	Feb 26, 2027	U-1386			
	8435944	Sep 27, 2027	U-1390			
	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026	U-1500			
<u>TETRABENAZINE - XENAZINE</u>						
N 021894 001					ODE	Aug 15, 2015
<u>TETRABENAZINE - XENAZINE</u>						
N 021894 002					ODE	Aug 15, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-731			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THYROTROPIN ALFA - THYROGEN</u>						
N 020898 001	5840566	Nov 24, 2015				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 001	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 002	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 003	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646	004	5866590	Apr 29, 2016			
		5958951	Jun 10, 2017			
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646	005	5866590	Apr 29, 2016			
		5958951	Jun 10, 2017			
<u>TICAGRELOR - BRILINTA</u>						
N 022433	001	6251910	Jul 15, 2018	DS	I-714	Sep 03, 2018
		6525060	Dec 02, 2019	DS DP U-1171	NCE	Jul 20, 2016
		7250419	Dec 02, 2019	DS DP U-1171		
		7265124	Jul 09, 2021	DS DP U-1171		
		8425934	Apr 17, 2030	DP		
<u>TICAGRELOR - BRILINTA</u>						
N 022433	002	6251910	Jul 15, 2018	DS	NCE	Jul 20, 2016
		6525060	Dec 02, 2019	DS DP U-1171	NS	Sep 03, 2018
		7250419	Dec 02, 2019	DS DP U-1171		
		7265124	Jul 09, 2021	DS DP U-1171		
		8425934	Apr 17, 2030	DP		
<u>TIGECYCLINE - TYGACIL</u>						
N 021821	001	7879828	Feb 05, 2029	DP		
		8372995	Oct 08, 2030	DP		
		8975242	Oct 24, 2028	DP		
		RE40183	Apr 09, 2016	DS DP		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963	001	6174524	Mar 26, 2019	DP		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963	002	6174524	Mar 26, 2019	DP		
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516	001	6335335	Nov 02, 2018	DP		
		6645963	Nov 16, 2018	DP		
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395	001	6777423	Sep 24, 2021	DS DP		
		6908928	Sep 24, 2021	DS DP U-566		
		6908928	Sep 24, 2021	DS DP U-762		
		7070800	Jan 22, 2022	DP U-566		
		7309707	Sep 24, 2021	DS DP		
		7642268	Sep 24, 2021	DS DP		
		7694676	Mar 12, 2027	DP		
		8022082	Jan 19, 2026	DP U-1186		
		RE38912	Oct 11, 2021	DP		
		RE39820	Jan 30, 2018	DS DP U-566		
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936	001	5964416	Oct 04, 2016	DP	NP	Sep 24, 2017
		6149054	Dec 16, 2016	DP		
		6176442	May 31, 2016	DP		
		6453795	Dec 05, 2016	DP		
		6726124	Oct 04, 2016	DP		
		6846413	Aug 28, 2018	DP		
		6977042	Aug 28, 2018	DP		
		6988496	Feb 23, 2020	DP		
		7104470	Oct 04, 2016	DP		
		7246615	May 31, 2016	DP		
		7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP		
		7802568	Feb 26, 2019	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8733341	Dec 16, 2029	DP		
		9027967	Mar 31, 2027	DP		
		RE39820	Jan 30, 2018	DS DP U-1593		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NP	Sep 24, 2017
	6149054	Dec 16, 2016	DP			
	6176442	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP	U-1593		
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NP	Sep 15, 2018
	6149054	Dec 16, 2016	DP			
	6176442	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981 001	5744475	Mar 28, 2016	DS DP	U-1751	NCE	Sep 22, 2020
	6479500	Mar 16, 2020		U-1751		
	7799783	Dec 16, 2026		U-1751		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981 002	5744475	Mar 28, 2016	DS DP	U-1751	NCE	Sep 22, 2020
	6479500	Mar 16, 2020		U-1751		
	7799783	Dec 16, 2026		U-1751		
<u>TIPRANAVIR - APTIVUS</u>						
N 021814 001	5852195	Jun 22, 2019	DS			
	6147095	Oct 29, 2019		U-670		
	6231887	Jul 27, 2018	DP			
<u>TIPRANAVIR - APTIVUS</u>						
N 022292 001	5852195	Jun 22, 2019	DS			
	6147095	Oct 29, 2019		U-670		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	May 01, 2023				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
	8715623	Dec 19, 2022	DP U-909			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022		U-1324		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	6956041	Dec 08, 2020	DP		M-135	Feb 21, 2017
	6965027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	7091208	Dec 08, 2020		U-247		
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6630162	Nov 11, 2019	DP U-544			
	6770295	Aug 26, 2019	DP U-544			
	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6630162	Nov 11, 2019	DP U-544			
	6770295	Aug 26, 2019	DP U-544			
	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	003	5753677				
		8501730		U-978		
			DS			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	001	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7498311		U-723		
				U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	002	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7498311		U-723		
				U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	003	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7498311		U-723		
				U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	004	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7498311		U-723		
				U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	005	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7498311		U-723		
				U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	006	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7498311		U-723		
				U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844	001	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7125560		U-723		
		7498311		Mar 01, 2019	U-766	
				U-955		
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844	002	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7125560		U-723		
		7498311		Mar 01, 2019	U-766	
				U-955		
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844	003	5998380				
		6503884		U-598	NPP	Mar 28, 2017
		7018983		U-598		
		7125560		U-723		
		7498311		Mar 01, 2019	U-766	
				U-955		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001	8298576				
		8298580		DP U-106		
		8663683		DP U-106		
		8877248		DP U-106		
		8889191		DP U-106		
		8992989		U-106		
				DP U-1675		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002	8298576	Apr 04, 2028	DP U-106		
		8298580	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-106		
		8889191	Nov 16, 2027	U-106		
		8992989	Nov 16, 2027	DP U-1675		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	003	8298576	Apr 04, 2028	DP U-106		
		8298580	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-106		
		8889191	Nov 16, 2027	U-106		
		8992989	Nov 16, 2027	DP U-1675		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004	8298576	Apr 04, 2028	DP U-106		
		8298580	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-106		
		8889191	Nov 16, 2027	U-106		
		8992989	Nov 16, 2027	DP U-1675		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	001	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	002	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	003	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	004	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	005	8652527	Mar 19, 2033	DP		
		8889190	Mar 19, 2033	DP		
		9101545	Mar 19, 2033	DP		
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	001	8158645	Dec 10, 2024	DP		
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	002	8158645	Dec 10, 2024	DP		
<u>TRABECTEDIN - YONDELIS</u>						
N 207953	001	8895557	Jan 07, 2028	DP	NCE ODE	Oct 23, 2020 Oct 23, 2022
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281	001	6339105	Oct 12, 2019	U-435		
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281	002	6339105	Oct 12, 2019	U-435		
<u>TRAMADOL HYDROCHLORIDE - RYBIX ODT</u>						
N 021693	001	6106861	Dec 05, 2017	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 001	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 002	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 003	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 001	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 002	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 003	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8703781	Oct 15, 2030	DS DP U-1712		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1581		ODE	Jan 08, 2021
	8835443	Sep 13, 2025	U-1582			
	9155706	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8703781	Oct 15, 2030	DS DP U-1712		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1581		ODE	Jan 08, 2021
	8835443	Sep 13, 2025	U-1582			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8703781	Oct 15, 2030	DS DP U-1712		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1581		ODE	Jan 08, 2021
	8835443	Sep 13, 2025	U-1582			
	9155706	Jan 28, 2032	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
	8273795	Mar 04, 2025	U-1182			
	8487005	Mar 04, 2025	DP U-1182			
	8791160	Mar 04, 2025	DP U-1182			
	8809394	Mar 04, 2025	DP U-1182			
	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
	8388941	Sep 20, 2027	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8178582	Oct 10, 2029	DP		NP	May 15, 2017
	8722735	Oct 10, 2029	DP			
	8754123	May 19, 2029	DP			
	9144561	Mar 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	002	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	003	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	004	8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411	001	6607748	Jun 29, 2020	DP		
		7829120	Mar 27, 2027	DP U-796		
		8133893	Mar 13, 2029	DS DP		
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411	002	6607748	Jun 29, 2020	DP		
		7829120	Mar 27, 2027	DP U-796		
		8133893	Mar 13, 2029	DS DP		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	001	6765117	Oct 24, 2017	DS		
		7999007	Mar 29, 2029	DP U-1437		
		8497393	Dec 15, 2028	DS		
		8653137	Sep 05, 2028	U-1437		
		8658694	Sep 05, 2028	U-1437		
		9199908	May 24, 2024	U-1771		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	002	6765117	Oct 24, 2017	DS		
		7999007	Mar 29, 2029	DP U-1437		
		8497393	Dec 15, 2028	DS		
		8653137	Sep 05, 2028	U-1437		
		8658694	Sep 05, 2028	U-1437		
		9199908	May 24, 2024	U-1771		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	003	6765117	Oct 24, 2017	DS		
		7999007	Mar 29, 2029	DP U-1437		
		8497393	Dec 15, 2028	DS		
		8653137	Sep 05, 2028	U-1437		
		8658694	Sep 05, 2028	U-1437		
		9199908	May 24, 2024	U-1771		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	004	6765117	Oct 24, 2017	DS		
		7999007	Mar 29, 2029	DP U-1437		
		8497393	Dec 15, 2028	DS		
		8653137	Sep 05, 2028	U-1437		
		8658694	Sep 05, 2028	U-1437		
		9199908	May 24, 2024	U-1771		
<u>TREPROSTINIL - TYVASO</u>						
N 022387	001	6521212	Nov 13, 2018	U-1018	M-145	May 20, 2017
		6756033	Nov 13, 2018	U-1018	ODE	Jul 30, 2016
		6765117	Oct 24, 2017	DS		
		8497393	Dec 15, 2028	DS		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	001	6765117	Oct 24, 2017	DS	NDF	Dec 20, 2016
		7417070	Jul 30, 2026	DS		
		7544713	Jul 14, 2024	U-1475		
		8252839	May 24, 2024	DP		
		8349892	Jan 22, 2031	DP		
		8410169	Feb 13, 2030	DP		
		8497393	Dec 15, 2028	DS		
		8747897	Oct 08, 2029	DP		
		9050311	May 24, 2024	DS DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	6765117	Oct 24, 2017	DS		NDF	Dec 20, 2016
	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	6765117	Oct 24, 2017	DS		NDF	Dec 20, 2016
	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	6765117	Oct 24, 2017	DS		NDF	Dec 20, 2016
	7417070	Jul 30, 2026	DS			
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 001	5955109	Sep 21, 2016	DP	U-134		
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 002	5955109	Sep 21, 2016		U-134		
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP	U-134		
<u>TRETINOIN - RENOVA</u>						
N 021108 001	6531141	Mar 07, 2020				
<u>TRIAMCINOLONE ACETONIDE - NASACORT ALLERGY 24 HOUR</u>						
N 020468 002	5976573	Jul 03, 2016	DP			
	6143329	Jul 03, 2016	DP			
	7977045	Jul 03, 2016	DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENC</u>						
N 022048 001	6395294	Jan 13, 2020	DP	U-846		
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029		U-1257		
	8211880	Mar 10, 2029		U-1258		
<u>TRIMETHOPRIM HYDROCHLORIDE - PRIMSOL</u>						
N 074973 001	5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326 001	6017922	May 18, 2018				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326 002	6017922	May 18, 2018				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 020715 001	5776885	Jul 07, 2015				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 021288	001 5776885	Jul 07, 2015	DP			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437	001 5776885	Jul 07, 2015	DP			
<u>TROGLITAZONE - PRELAY</u>						
N 020719	001 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - PRELAY</u>						
N 020719	002 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - PRELAY</u>						
N 020719	003 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720	001 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720	002 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720	003 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROSPIUM CHLORIDE - SANCTURA XR</u>						
N 022103	001 7410978	Feb 01, 2025	DP			
	7759359	Nov 04, 2024	U-1071			
	7763635	Nov 04, 2024	U-1071			
	7781448	Nov 04, 2024	U-1071			
	7781449	Nov 04, 2024	U-1071			
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N 020759	001 6187341	Jan 20, 2019				
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N 020759	002 6187341	Jan 20, 2019				
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N 022278	001				ODE	Feb 20, 2016
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474	001 8426392	Jun 12, 2030	U-1389		NCE	Aug 13, 2015
	8512745	Jun 02, 2030	DP			
	8735380	Feb 20, 2029	DP			
	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382	001 5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975	001 5873360	Feb 23, 2016	DP		NP	Dec 18, 2016
	7439393	Sep 11, 2022	DS DP U-1476			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975	001 8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8309572	Apr 27, 2025	U-1476			
	8511304	Jun 14, 2027	DP U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214	001 6458836	Jul 09, 2021	U-333			
	6458836	Jul 09, 2021	U-1315			
	6770675	Nov 24, 2018	DP U-1322			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159	001 5968914	Oct 19, 2016	U-1791		NCE	Sep 04, 2020
	6258795	Jul 10, 2018	DP		NP	Dec 11, 2018
	7776838	Aug 17, 2027	U-1791			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169	001 6258795	Jul 10, 2018	DP		NCE	Sep 04, 2020
					ODE	Sep 04, 2022
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289	001				D-139	Feb 19, 2017
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N 020487	001 5879706	Jan 19, 2016	DP U-530			
	5879706	Jan 19, 2016	DP U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N 020487	002 5879706	Jan 19, 2016	DP U-530			
	5879706	Jan 19, 2016	DP U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304	001				D-148	Apr 23, 2018
					NPP	Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257	001 6083953*PED	Sep 29, 2015			D-148	Apr 23, 2018
					NPP	Apr 23, 2018
<u>VALSARTAN - DIOVAN</u>						
N 021283	001 5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283	002 5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283	003 5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283	004 5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VANDETANIB - CAPRELSA</u>						
N 022405	001 7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	8642608	Feb 06, 2022	U-1490			
	RE42353	Sep 23, 2017	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VANDETANIB - CAPRELSA</u>						
N 022405	002	7173038	Aug 14, 2021	DS DP	NCE	Apr 06, 2016
		8067427	Aug 08, 2028	DP	ODE	Apr 06, 2018
		8642608	Feb 06, 2022	U-1490		
		RE42353	Sep 23, 2017	DS DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	001	6362178	Oct 31, 2018	DS DP	U-533	
		7696206	Oct 31, 2018	DS DP	U-533	
		8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	002	6362178	Oct 31, 2018	DS DP	U-533	
		7696206	Oct 31, 2018	DS DP	U-533	
		8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	003	6362178	Oct 31, 2018	DS DP	U-533	
		7696206	Oct 31, 2018	DS DP	U-533	
		8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	004	6362178	Oct 31, 2018	DS DP	U-533	
		7696206	Oct 31, 2018	DS DP	U-533	
		8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179	001	6362178	Oct 31, 2018	U-155		
		7696206	Oct 31, 2018	U-155		
		8613950	Dec 23, 2028	DP		
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	001	6410550	May 10, 2020	DS DP	U-56	M-143
		6890927	May 06, 2022	DS DP	U-56	M-144
		7265119	Aug 03, 2022	DS DP	U-56	Oct 15, 2017
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	002	6410550	May 10, 2020	DS DP	U-56	M-143
		6890927	May 06, 2022	DS DP	U-56	M-144
		7265119	Aug 03, 2022	DS DP	U-56	Oct 15, 2017
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575	001				M-130	Nov 21, 2016
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575	002				M-130	Nov 21, 2016
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429	001	7504509	Oct 22, 2026	DS DP	NCE	Aug 17, 2016
		7863288	Jun 20, 2029	DS DP	ODE	Aug 17, 2018
		8143271	Jun 21, 2026	DS DP		
		8470818	Aug 02, 2026	U-1418		
		8741920	Jul 27, 2030	DS DP		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	001	6274171	Mar 20, 2017			
		6403120	Mar 20, 2017	U-451		
		6403120	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-459		
		6419958	Mar 20, 2017	U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	002	6274171	Mar 20, 2017			
		6403120	Mar 20, 2017	U-451		
		6403120	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-459		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	002	6419958	Mar 20, 2017	U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	003	6274171	Mar 20, 2017			
		6403120	Mar 20, 2017	U-451		
		6403120	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-459		
		6419958	Mar 20, 2017	U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	004	6274171	Mar 20, 2017			
		6403120	Mar 20, 2017	U-451		
		6403120	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-459		
		6419958	Mar 20, 2017	U-535		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104	001	6403120	Mar 20, 2017	U-535		
		6403120	Mar 20, 2017	U-839		
		6419958	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104	002	6403120	Mar 20, 2017	U-535		
		6403120	Mar 20, 2017	U-839		
		6419958	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104	003	6403120	Mar 20, 2017	U-535		
		6403120	Mar 20, 2017	U-839		
		6419958	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104	004	6403120	Mar 20, 2017	U-535		
		6403120	Mar 20, 2017	U-839		
		6419958	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-839		
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552	001	6096339	Apr 04, 2017	U-365		
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552	002	6096339	Apr 04, 2017	U-365		
<u>VERTEPORFIN - VISUDYNE</u>						
N 021119	001	5707608	Aug 02, 2015			
		5756541	Mar 11, 2016	U-357		
		5798349	Aug 25, 2015	U-357		
<u>VIGABATRIN - SABRIL</u>						
N 020427	001				NPP	Oct 26, 2016
					PED	Apr 26, 2017
<u>VIGABATRIN - SABRIL</u>						
N 022006	001				NPP	Oct 26, 2016
					ODE	Aug 21, 2016
					PED	Feb 21, 2017
					PED	Apr 26, 2017
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	001	5532241	Sep 29, 2019	DS DP	D-146	Mar 16, 2018
		7834020	Jun 05, 2022	DS DP	NCE	Jan 21, 2016
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	5532241	Sep 29, 2019	DS DP		D-146	Mar 16, 2018
	7834020	Jun 05, 2022	DS DP U-839		NCE	Jan 21, 2016
	8193195	Jun 05, 2022		U-839		
	8236804	Jun 05, 2022		U-839		
	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	5532241	Sep 29, 2019	DS DP		D-146	Mar 16, 2018
	7834020	Jun 05, 2022	DS DP U-839		NCE	Jan 21, 2016
	8193195	Jun 05, 2022		U-839		
	8236804	Jun 05, 2022		U-839		
	8673921	Jun 05, 2022	DS DP			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N 202497 001	6723338	Mar 31, 2020		U-1271	NP	Aug 09, 2015
	7247316	Sep 25, 2020		DP	ODE	Aug 09, 2019
	7887836	Mar 31, 2020		U-1271		
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
	7304078	Apr 06, 2024	DS DP U-1512			
<u>VORICONAZOLE - VFEND</u>						
N 021266 001	5567817	May 24, 2016	DS DP U-540			
<u>VORICONAZOLE - VFEND</u>						
N 021266 002	5567817	May 24, 2016	DS DP U-540			
<u>VORICONAZOLE - VFEND</u>						
N 021267 001	5567817	May 24, 2016	DS DP U-540			
	6632803	Jun 02, 2018		DP		
<u>VORICONAZOLE - VFEND</u>						
N 021630 001	5567817	May 24, 2016	DS DP U-540			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	7399787	Feb 09, 2025		U-892		
	7456219	Mar 11, 2027	DS			
	7652069	Mar 04, 2023		DP		
	7732490	Mar 04, 2023		U-892		
	7851509	Feb 21, 2024		DP U-892		
	8067472	Mar 04, 2023		U-892		
	8093295	May 16, 2026		DP		
	8101663	Mar 04, 2023		U-892		
	8450372	Mar 18, 2028		U-892		
	RE38506	Jul 07, 2015	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022		DP U-1439		
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022		DP U-1439		
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022		DP U-1439		
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 021483 001	6150366	May 27, 2019	DP U-719			
	6245766	Dec 18, 2018	U-601			
	7175855	May 18, 2020	DP			
<u>ZIPRASIDONE MESYLATE - GEODON</u>						
N 020919 001	6110918	Mar 26, 2017				
	6232304	Apr 01, 2017				
	6399777	Apr 01, 2017				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223 002	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	003 7932241	Feb 05, 2028	DP			
	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817	001 7932241	Feb 05, 2028	DP			
	8052987	Oct 27, 2023	U-1199			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	003 6750237	Nov 28, 2020	DP		NPP	Jun 12, 2018
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	004 6750237	Nov 28, 2020	DP		NPP	Jun 12, 2018
	7220767	Nov 28, 2020	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774	001 6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774	002 6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	001 6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019		U-674		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	002 6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019		U-674		
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196	001 7632517	Oct 01, 2017		U-70		
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	001 7658945	Apr 15, 2027	DP	U-1194		
	7682628	Feb 16, 2025		U-1194		
	8242131	Aug 20, 2029		U-1266		
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	002 7658945	Apr 15, 2027	DP	U-1194		
	7682628	Feb 16, 2025		U-1194		
	8242131	Aug 20, 2029		U-1266		
	8252809	Feb 16, 2025	DP			

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d) (5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

**PATENT AND EXCLUSIVITY TERMS****PATENT & EXCLUSIVITY ABBREVIATIONS**

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

**EXCLUSIVITY DOSING SCHEDULE**

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS



**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY DOSING SCHEDULE**

- D-34 EVERY FOUR MONTHS DOSAGE REGIMEN
- D-35 FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
- D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-48 ADMINISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL
- D-49 PEDIATRIC DOSING GUIDELINES
- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
- D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
- D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
- D-56 ADDITION OF POSTPRANDIAL DOSING
- D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
- D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
- D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH

**PATENT AND EXCLUSIVITY TERMS**

ADB 3 of 73

**EXCLUSIVITY DOSING SCHEDULE**

## NEW CYCLE

- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
- D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
- D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
- D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)
- D-95 BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
- D-96 ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
- D-97 PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
- D-98 DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
- D-99 ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
- D-100 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
- D-101 ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- D-102 NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
- D-103 NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
- D-104 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
- D-105 USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-106 FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
- D-107 PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-108 TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
- D-109 PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE

**PATENT AND EXCLUSIVITY TERMS**

ADB 4 of 73

**EXCLUSIVITY DOSING SCHEDULE**

D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULFATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.
D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY DOSING SCHEDULE**

D-148 EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT

D-149 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP

D-150 1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE

D-151 DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1

D-152 DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.

D-153 IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY

**EXCLUSIVITY INDICATION**

I-1 DYSMENORRHEA

I-2 CHOLANGIOPANCREATOGRAPHY

I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY

I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)

I-5 HYSTEROSALPINGOGRAPHY

I-6 TREATMENT OF JUVENILE ARTHRITIS

I-7 BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN

I-8 ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY

I-9 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

I-10 PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY

I-11 RELIEF OF MILD TO MODERATE PAIN

I-12 TREATMENT OF CUTANEOUS CANDIDIASIS

I-13 URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI

I-14 SEBORRHEIC DERMATITIS

I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT

I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM

I-17 MANAGEMENT OF CONGESTIVE HEART FAILURE

I-18 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY

I-19 HERNIOGRAPHY

I-20 KNEE ARTHROGRAPHY

I-21 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR

I-22 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA

I-23 SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

I-24 TREATMENT OF RHEUMATOID ARTHRITIS

I-25 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS

I-26 TREATMENT OF LIVER FLUKES

I-27 ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE

I-28 SELECTIVE ADULT VISCERAL ARTERIOGRAPHY

I-29 METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION

I-30 TREATMENT OF TINEA PEDIS

I-31 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES

I-32 PEDIATRIC MYELOGRAPHY

I-33 ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN

I-34 ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT

I-35 PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING

I-36 ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS

I-37 RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS

I-38 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)

I-39 TREATMENT OF ACUTE MYOCARDIAL INFARCTION

I-40 PRIMARY NOCTURNAL ENURESIS

I-41 MIGRAINE HEADACHE PROPHYLAXIS

I-42 HERPES ZOSTER

I-43 HERPES SIMPLEX ENCEPHALITIS

I-44 MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY

I-45 ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS

I-46 USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING

I-47 TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE

I-48 PEDIATRIC ANGIOCARDIOGRAPHY

I-49 TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI

I-50 FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER

I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS

I-52 PEDIATRIC EXCRETORY UROGRAPHY

I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA

I-54 RENAL CONCENTRATION CAPACITY TEST

I-55 HYPERTENSION

I-56 EROSIIVE GASTROESOPHAGEAL REFLUX DISEASE

I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER

I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS

I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE

I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE

I-61 FEMALE ANDROGENETIC ALOPECIA

I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION

I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS

I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

I-66 UNCOMPLICATED GONORRHEA

I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER

I-68 CENTRAL PRECOCIOUS PUBERTY

I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY

I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER

I-71 VARICELLA INFECTIONS (CHICKENPOX)

I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE

I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES

I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY

I-75 TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIIVE ESOPHAGITIS

I-76 PREVENTION OF OSTEOPOROSIS

I-77 DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM

I-78 CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY

I-79 MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM

I-80 DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE

I-81 PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS

I-82 TREATMENT OF TRAVELERS' DIARRHEA

I-83 ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN

I-84 INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION

I-85 TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS

I-86 TREATMENT OF SECONDARY CARNITINE DEFICIENCY

I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO <sub>2</sub> ) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH



**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
- I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
- I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
- I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
- I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
- I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
- I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
- I-229 PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
- I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
- I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
- I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

## FIRST-LINE CHEMOTHERAPY

- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
- I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
- I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
- I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
- I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
- I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
- I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
- I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
- I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
- I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
- I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
- I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
- I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER
- I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
- I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
- I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
- I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
- I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
- I-288 CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
- I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
- I-290 PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
- I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
- I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
- I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
- I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
- I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
- I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
- I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
- I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
- I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
- I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
- I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
- I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
- I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
- I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
- I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
- I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
- I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
- I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
- I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
- I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
- I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
- I-321 JUVENILE RHEUMATOID ARTHRITIS
- I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
- I-323 COLORECTAL CANCER
- I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
- I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
- I-326 GENERALIZED ANXIETY DISORDER
- I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
- I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
- I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTEMS IN PATIENTS WITH GERD
- I-331 TREATMENT OF MODERATE ACNE VULGARIS
- I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
- I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
- I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
- I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
- I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
- I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME
- I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
- I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
- I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
- I-341 BREAST CANCER COMBINATION THERAPY
- I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-343 USE OF COREG FOR SEVERE HEART FAILURE
- I-344 ACNE VULGARIS
- I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
- I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
- I-349 ACUTE CORONARY SYNDROME
- I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
- I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
- I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
- I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
- I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
- I-355 PREMENSTRUAL DYSPHORIC DISORDER
- I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-358 TREATMENT OF PANIC DISORDER
- I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
- I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN $\geq$ 2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI &
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION $\leq$ 40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPANILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERTHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
I-432	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
I-433	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
I-434	PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
I-435	CHRONIC IDIOPATHIC CONSTIPATION
I-436	FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
I-437	TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-438	EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
I-439	USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
I-440	FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
I-441	USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
I-442	USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
I-443	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN
- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
- I-491 INFLUENZA PROPHYLAXIS
- I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
- I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)



**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)

I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY

I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)

I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)

I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY

I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)

I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED

I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL

I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY

I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.

I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE

I-524 GENERALIZED ANXIETY DISORDER (GAD)

I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS

I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS

I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY

I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE

I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER

I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA

I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES

I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER

I-535 MANAGEMENT OF FIBROMYALGIA

I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME

I-537 LONG TERM TREATMENT OF PANIC DISORDER

I-538 SHORT TERM TREATMENT OF PANIC DISORDER

I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER

I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17

I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17

I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS

I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY

I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS

I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE

I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE

I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-552	ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
I-553	FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-554	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSSES
I-555	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
I-556	PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
I-557	USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
I-558	MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-559	ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
I-560	MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSpareunia, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOID FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-590 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
- I-591 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
- I-592 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
- I-593 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
- I-594 INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
- I-595 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-596 USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- I-597 MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- I-598 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
- I-599 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
- I-600 FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
- I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
- I-603 GOUT FLARES
- I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
- I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
- I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
- I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
- I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
- I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
- I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
- I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
- I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
- I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
- I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
- I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
- I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
- I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
- I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
- I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
- I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
- I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
- I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
- I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
- I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
- I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
- I-633 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-634 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
- I-635 ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- I-636 TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
- I-637 USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
- I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
- I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
- I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
- I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
- I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
- I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
- I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
- I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
- I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
- I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
- I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA
- I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
- I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
- I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- I-657 PLAQUE PSORIASIS OF THE SCALP
- I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
- I-659 PLAQUE PSORIASIS OF THE BODY
- I-660 TREATMENT OF DEEP VEIN THROMBOSIS
- I-661 TREATMENT OF PULMONARY EMBOLISM
- I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
- I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
- I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT) SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
- I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-667 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
- I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
- I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
- I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
- I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA- APPROVED TEST
- I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCL. METHICILLIN-SUSCEPTIBLE AND -RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
- I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
- I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
- I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
- I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
- I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
- I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
- I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
- I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
- I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
- I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
- I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
- I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
- I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
- I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
- I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
- I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
- I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
- I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
- I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
- I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
- I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

## ANTIDEPRESSANTS

- I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
- I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSIONFREE SURVIVAL.
- I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
- I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)
- I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN
- I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
- I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
- I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
- I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC - CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.
- I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
- I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
- I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE
- I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFRACTION
- I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.
- I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY
- I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4
- I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY
- I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.
- I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.

**EXCLUSIVITY MISCELLANEOUS**

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
- M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY MISCELLANEOUS**

	RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
M-30	CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
M-31	INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
M-32	ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
M-33	INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
M-34	EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-35	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
M-36	ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
M-37	INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
M-38	SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
M-39	FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
M-40	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
M-41	REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
M-42	ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
M-43	INCLUSION OF RESULTS OF STUDY-"PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
M-44	CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
M-45	INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING - EFFECTS OF HUMATROPE

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY MISCELLANEOUS**

- TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
- M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
- M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
- M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
- M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
- M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
- M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
- M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
- M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
- M-75 PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITS)
- M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
- M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS



**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY MISCELLANEOUS**

- M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
- M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
- M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
- M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
- M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
- M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
- M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
- M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
- M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
- M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
- M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
- M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
- M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION
- M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
- M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
- M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
- M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
- M-98 NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
- M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
- M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
- M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
- M-102 INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
- M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
- M-104 INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
- M-105 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
- M-106 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT

## PATENT AND EXCLUSIVITY TERMS

## EXCLUSIVITY MISCELLANEOUS

- M-107 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
- M-108 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
- M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-110 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-111 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
- M-112 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
- M-113 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
- M-114 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
- M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
- M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
- M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
- M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
- M-119 LABELING CHANGES REGARDING MISSED DOSES
- M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
- M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
- M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
- M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
- M-124 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
- M-125 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
- M-126 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
- M-127 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
- M-128 CLINICAL TRIAL STUDY RESULTS
- M-129 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
- M-130 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
- M-131 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
- M-132 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
- M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
- M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
- M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
- M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS
- M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
- M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
- M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
- M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY

**PATENT AND EXCLUSIVITY TERMS**

ADB 28 of 73

**EXCLUSIVITY MISCELLANEOUS**

- RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
- M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY
- M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER
- M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
- M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
- M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
- M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
- M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM
- M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
- M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
- M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
- M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
- M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
- M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
- M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
- M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
- M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
- M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
- M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
- M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
- M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
- M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
- M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
- M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)"
- M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS
- M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".
- M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY MISCELLANEOUS**

M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.

**PATENT USE**

U-1 PREVENTION OF PREGNANCY  
 U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA  
 U-3 TREATMENT OF HYPERTENSION  
 U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS  
 U-5 METHOD OF PRODUCING BRONCHODILATION  
 U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS  
 U-7 INCREASING CARDIAC CONTRACTILITY  
 U-8 ACUTE MYOCARDIAL INFARCTION  
 U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT  
 U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS  
 U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS  
 U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION  
 U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT  
 U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES  
 U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE  
 U-16 USE IN LUNG SCANNING PROCEDURES  
 U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS  
 U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS  
 U-19 TREATMENT OF INFLAMMATION  
 U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT  
 U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS  
 U-22 METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS  
 U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE  
 U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST  
 U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS  
 U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF  
 U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF  
 U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY  
 U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY  
 U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY  
 U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY  
 U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN  
 U-33 TREATING VIRAL INFECTIONS IN A MAMMAL  
 U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL  
 U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION  
 U-36 METHODS OF TREATING BACTERIAL ILLNESSES  
 U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE  
 U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA  
 U-39 ANGINA PECTORIS  
 U-40 METHOD OF TREATMENT OF BURNS  
 U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS  
 U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER  
 U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA  
 U-44 RELIEF OF NAUSEA AND VOMITING  
 U-45 TREATMENT OF INFLAMMATION AND ANALGESIA  
 U-46 TREATMENT OF PANIC DISORDER  
 U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE  
 U-48 ANALGESIA

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA  
U-50 USE IN TREATING INFLAMMATORY DERMATOSES  
U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING  
U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION  
U-53 HYPERCALCEMIA OF MALIGNANCY  
U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS  
U-55 TREATMENT OF PAIN  
U-56 AID TO SMOKING CESSATION  
U-57 OPHTHALMIC USE OF NORFLOXACIN  
U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES  
U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA  
U-60 NASAL ADMINISTRATION OF BUTORPHANOL  
U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD  
U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY  
U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE  
U-64 TREATMENT OF VIRAL INFECTIONS  
U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV  
U-66 TRIPHASIC REGIMEN  
U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL  
U-68 TREATMENT OF ACTINIC KERATOSIS  
U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS  
U-70 TREATMENT OF TRANSIENT INSOMNIA  
U-71 METHOD OF TREATMENT OF HEART FAILURE  
U-72 TREATMENT OF MIGRAINE  
U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES  
U-74 METHOD OF PROVIDING HYPNOTIC EFFECT  
U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS  
U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM  
U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS  
U-78 ULCERATIVE COLITIS  
U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD  
U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS  
U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS  
U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE  
U-83 TREATMENT OF SEIZURES  
U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS  
U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS  
U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY  
U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS  
U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS  
U-89 TREATMENT OR PROPHYLAXIS OF EMESIS  
U-90 TREATMENT OF PYSCHOTIC DISORDERS  
U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS  
U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY  
U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT  
U-94 TREATMENT-ADULTS W/ ADVANCED HIV, INTOLERANT OF APPROVED THERAPIES, INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED  
U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS  
U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS  
U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT  
U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL  
U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM  
U-100 METHOD OF TREATING OCULAR INFLAMMATION  
U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED  
U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN  
U-103 TREATMENT OF OCULAR HYPERTENSION

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE ESOPHAGITIS

U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE USE AS A RETRIEVABLE PERSSARY

U-110 USE AS A RETRIEVABLE PERSSARY

U-111 DIABETES

U-112 CONTRACEPTION

U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE

U-114 USE FOR INHIBITING BONE RESORPTION

U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS

U-116 METHOD OF MYOCARDIAL IMAGING

U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL

U-119 TREATMENT OF NASAL HYPERSECRETION

U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS

U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS

U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS

U-124 TREATMENT OF ACNE

U-125 TREATMENT NEUROGENERATIVE DISEASES

U-126 TREATMENT OF GASTRITIS

U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE

U-128 METHOD FOR TREATMENT OF TUMORS

U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS

U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS

U-131 PHOTODAMAGED SKIN

U-132 INHIBITING HIV PROTEASE

U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET

U-134 TREATMENT OF ACNE VULGARIS

U-135 ANTITUMOR AGENT

U-136 PROCESS FOR WASTE NITROGEN REMOVAL

U-137 METHOD OF TREATING BACTERIAL VAGINOSIS

U-138 TREATMENT OF ALLERGIC RHINITIS

U-139 TREATMENT OF ALLERGIC REACTIONS

U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION

U-141 TREATMENT OF ULCERATIVE COLITIS

U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE

U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING

U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS

U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS

U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS

U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2

U-148 DEVICE FOR COLLECTING A BREATH SAMPLE

U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES

U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE

U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD

U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES  
U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER  
U-155 TREATMENT OF ERECTILE DYSFUNCTION  
U-156 METHOD OF PROVIDING ANESTHESIA  
U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY  
U-158 ANGINA  
U-159 TREATMENT OF INTERSTITIAL CYSTITIS  
U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE  
U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT  
U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA  
U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS  
U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS  
U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA  
U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER  
U-167 METHOD FOR TREATING HIV-1 INFECTION  
U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA  
U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING  
U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT  
U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT  
U-172 TREATMENT OF GENITAL WARTS  
U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES  
U-174 USE AS AN ANTIHISTAMINE AGENT  
U-175 METHOD OF TREATING MALIGNANT TUMORS  
U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES  
U-177 FUNGICIDE  
U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN  
U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT  
U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION  
U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST  
U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION  
U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION  
U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS  
U-185 METHOD OF TREATING HYPERTENSION  
U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H.PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT  
U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS  
U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER  
U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE  
U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR  
U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN  
U-192 USE IN TREATING ALLERGIC REACTIONS  
U-193 PSORIASIS  
U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE  
U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON  
U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS  
U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER  
U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA  
U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS

U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY

U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-205 METHOD FOR TREATING HEARTBURN

U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION

U-207 USE AS NASAL SPRAY

U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION

U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION

U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE

U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE

U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA

U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT

U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS

U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE

U-217 METHOD OF PRODUCING ANESTHESIA

U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT

U-219 TREATMENT OF PARKINSON'S DISEASE

U-220 METHOD OF DIAGNOSIS

U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION

U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL

U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS

U-224 CONTROLLING INTRAOCULAR PRESSURE

U-225 METHOD FOR DELIVERY

U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE

U-227 NASAL ADMINISTRATION

U-228 ASTHMA

U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)

U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS

U-231 USE IN PARKINSON'S DISEASE

U-232 METHOD OF TREATING MIGRAINE

U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS

U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE

U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY

U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS

U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....

U-239 TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID

U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS

U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION

U-243 TOPICAL ADMINISTRATION



**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-244 PLATELET AGGREGATION INHIBITORS  
U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS  
U-246 PHOSPHATE BINDING  
U-247 TREATMENT OF RHEUMATOID ARTHRITIS  
U-248 TREATMENT OF HIV  
U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE  
U-250 TREATMENT OF HEPATITIS B INFECTION  
U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES  
U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE  
U-253 ORAL TRANSMUCOSAL USE  
U-254 USE OF AGGRSTAT IN COMBINATION WITH HEPARIN  
U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY  
U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS  
U-257 TREATMENT OF HIV INFECTION  
U-258 TREATMENT OF NEURODEGENERATIVE DISEASES  
U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE  
U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION  
U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE  
U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE  
U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN  
U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN  
U-265 USE AS LAXATIVE  
U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS  
U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE  
U-268 ACROMEGALY  
U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS  
U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT  
U-271 METHOD OF TREATING TUMORS  
U-272 METHOD OF TREATING CARCINOMA  
U-273 CUTANEOUS T-CELL LYMPHOMA  
U-274 ZANAMIVIR FOR INHALATION  
U-275 METHOD OF USE OF THE DRUG SUBSTANCE  
U-276 METHOD OF USE OF LEVOBUPIVACAINE  
U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)  
U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT  
U-279 METHOD OF USE OF THE APPROVED PRODUCT  
U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE  
U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS  
U-282 METHOD OF TREATING BACTERIAL INFECTIONS  
U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE  
U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS  
U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA  
U-286 DEPRESSION  
U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS  
U-288 THERAPY OF INFLUENZA  
U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP  
U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)  
U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

CYCLOSPORIN

U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE

U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID

U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS

U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY

U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS

U-298 METHOD OF COMBATING BACTERIA IN A PATIENT

U-299 TREATMENT OF ADENOMATOUS POLYPS

U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA

U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES

U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS

U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS

U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION

U-305 METHODS FOR USING THE DRUG PRODUCT

U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY

U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA

U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA

U-309 TREATING SJOEGREN SYNDROME

U-310 TREATMENT OF XEROSTOMIA

U-311 HORMONE REPLACEMENT

U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER

U-313 TREATMENT OF CONGESTIVE HEART FAILURE

U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY

U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT

U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER

U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE

U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE

U-319 TREATMENT OF MICROBIAL INFECTIONS

U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA

U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS

U-322 TREATMENT OF ALZHEIMER'S DEMENTIA

U-323 USE AS A BILE ACID SEQUESTRANT

U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE

U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE

U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER

U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE

U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH

U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-330 TREATMENT OF NAUSEA AND VOMITING

U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- U-333 METHOD OF TREATING OCULAR HYPERTENSION
- U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
- U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
- U-336 DIAGNOSTIC RADIOIMAGING
- U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
- U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
- U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
- U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
- U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
- U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
- U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
- U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
- U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
- U-348 METHOD OF USE FOR INHIBITING HIV INFECTION
- U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
- U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
- U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS
- U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA . . . PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
- U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
- U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
- U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
- U-359 METHOD OF USE OF VISICOL
- U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
- U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
- U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
- U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
- U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
- U-367 TREATMENT OF CARDIOVASCULAR DISORDERS
- U-368 HEARTBURN
- U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
- U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
- U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
- U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
- U-376 TREATMENT OF INFLUENZA
- U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
- U-378 METHOD FOR TREATING INCONTINENCE
- U-379 METHOD OF TREATING ONYCHROMYCOSIS
- U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
- U-381 TREATMENT OF HYPERPHOSPHATEMIA
- U-382 METHOD OF STABILIZING PROSTAGLANDIN
- U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
- U-384 TREATMENT OF CMV RETINITIS
- U-385 TREATMENT OF PEPTIC ULCERS
- U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
- U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
- U-388 SMOKING CESSATION AID APPLIED TO THE SKIN
- U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
- U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
- U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
- U-392 TREATMENT OF PATIENTS FOR INFLAMMATION
- U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
- U-394 METHOD OF USE OF ALPHAGAN
- U-395 METHOD OF USE OF ALPHAGAN P
- U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
- U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
- U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER
- U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
- U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
- U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
- U-402 TREATMENT OF ACTINIC KERATOSES
- U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
- U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS
- U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
- U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL
- U-407 METHOD OF TREATING OTOPATHY
- U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
- U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
- U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
- U-412 TREATMENT OF TYPE 2 DIABETES
- U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
- U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

- U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES
- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
- U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
- U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
- U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
- U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
- U-431 POSTTRAUMATIC STRESS DISORDER
- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 TREATMENT OF MIGRAINE
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
- U-463 VENOGRAPHY
- U-464 PERIPHERAL ARTERIOGRAPHY
- U-465 CT IMAGING OF THE HEAD
- U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
- U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
- U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
- U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
- U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
- U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
- U-480 CONTRAST AGENT FOR MRI
- U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

NEURALGIA

U-489 EXPECTORANT

U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-491 METHOD OF DELIVERING A DRUG TO THE LUNG

U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID

U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

U-495 PERITONEAL DIALYSIS SOLUTION

U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE

U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST

U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL (PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION

U-500 USE AS AN ANTIHYPERTENSIVE AGENT

U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

U-502 PITYRIASIS VERSICOLOR

U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR

U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS

U-505 ULTRASOUND CONTRAST AGENT

U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE.. ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

U-507 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS

U-508 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES

U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA

U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA

U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA

U-514 PREVENTION OF OVULATION IN A WOMAN

U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY

U-516 METHOD OF TREATING A PSYCHOTIC DISEASE

U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS

U-518 OBSESSIVE COMPULSIVE DISORDER

U-519 POST OPERATIVE NAUSEA AND VOMITING

U-520 PREMENOPAUSAL OSTEOPOROSIS

U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA

U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL

U-524 METHOD OF TREATING DIARRHEA

U-525 METHOD OF TREATING PARASITIC INFECTIONS

U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION

U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE

U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE

U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES

U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE  
BRONCHO DILATOR

U-533 ERECTILE DYSFUNCTION

U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH  
DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA

U-535 TREATMENT OF SOCIAL ANXIETY DISORDER

U-536 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND  
CARDIAC INSUFFICIENCY, WITH EPLERENONE

U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE  
ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK  
OF INITIATING COMBINATION THERAPY IN THESE PATIENTS

U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-540 TREATMENT OF FUNGAL INFECTIONS

U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1

U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION

U-543 TREATMENT OF SCHIZOPHRENIA

U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.

U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS  
MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS  
THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT

U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE

U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER

U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER  
AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER

U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER

U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC  
ACID

U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION

U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT  
PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO  
PERIODONTAL POCKETS

U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL  
AGENTS

U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED  
PYELONEPHRITIS

U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING

U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA  
(REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)

U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING  
PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF  
REDUCING SERUM IONIZED CALCIUM LEVEL

U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING  
HYPERPARATHYROIDISM

U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS  
WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE  
TO BETA BLOCKERS

U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S  
SARCOMA

U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN  
PATIENTS WITH AIDS

U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY

U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC  
URTICARIA

U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED  
WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS  
AND EMPHYSEMA

U-567 METHOD OF TREATING INFERTILITY

U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION

U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND  
WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED

U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND  
WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG

U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

U-572 INTENSIVE CARE UNIT SEDATION



**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- U-619 TREATMENT OF MALIGNANT NEOPLASM
- U-620 TREATMENT OF INSOMNIA
- U-621 METHOD OF TREATING CANCER
- U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
- U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
- U-625 ALLERGIC RHINITIS OR NASAL POLYPS
- U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
- U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
- U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
- U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
- U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
- U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
- U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
- U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
- U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
- U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
- U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
- U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
- U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
- U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA
- U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE

U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS

U-645 TREATMENT OF ASTHMA

U-646 METHOD OF TREATING OTITIS

U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN

U-649 A METHOD FOR TREATING A TUMOR DISEASE

U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS

U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)

U-652 TREATMENT OF CARDIAC ARRHYTHMIA

U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE

U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4

U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS

U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER

U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN

U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE

U-661 TREATMENT OF SEIZURE DISORDER

U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION

U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

U-666 METHOD OF TREATING ADHD

U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE

U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS

U-669 INDICATION OF TYPE II DIABETES

U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.

U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4

U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER

U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML

U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET

U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS

U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM

U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM

U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE

U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE

U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-685 EXPECTORANT AND COUGH SUPPRESSANT

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

U-686 EXPECTORANT AND NASAL DECONGESTANT

U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.

U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.

U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA

U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA

U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT

U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB

U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION

U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE

U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

U-707 ALLERGIC RHINITIS

U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE

U-709 METHOD OF COMBATING BACTERIA IN A PATIENT

U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549

U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER

U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA

U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE

U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM

U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER

U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-718 TREATMENT OF FUNGAL INFECTIONS

U-719 TREATMENT OF PSYCHOSIS

U-720 TREATMENT OF NEUROLEPTIC DISEASES

U-721 TREATMENT OF INFLUENZA

U-722 PROPHYLAXIS OF INFLUENZA

U-723 PROPHYLACTIC TREATMENT OF MIGRAINE

U-724 METHOD OF TREATING SEIZURES

U-725 ALLERGIC RHINITIS AND URTICARIA

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-726 ALLERGIC RHINITIS  
U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)  
U-728 METHOD FOR TREATING BACTERIAL INFECTION  
U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE  
U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS  
U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA  
U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)  
U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE  
U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS  
U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD  
U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE  
U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE  
U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER  
U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT  
U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS  
U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER  
U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.  
U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA  
U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS  
U-745 TREATMENT OR PREVENTION OF EMESIS  
U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT  
U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING  
U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER  
U-749 METHOD OF CONTRACEPTION  
U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS  
U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA  
U-752 SUNSCREEN  
U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES  
U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA  
U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)  
U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS  
U-757 USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL  
U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER  
U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE  
U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS  
U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA  
U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION  
U-764 TREATMENT OF SCHIZOPHRENIA  
U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS  
U-766 TREATMENT OF SEIZURES  
U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER  
U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID  
U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY  
U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS  
U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT  
U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS

U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA

U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.

U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA

U-780 A METHOD FOR THE TREATMENT OF CANCER

U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY

U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE

U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER

U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY

U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS

U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA

U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE

U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING

U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS

U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)

U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE

U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE

U-796 METHOD OF TREATING DEPRESSION

U-797 METHOD OF TREATING ANXIETY

U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID

U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE

U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB

U-801 METHOD OF TREATING CANCER

U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN

U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY

U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES

U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS

U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION

U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA

U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-814 TREATMENT OF SCHIZOPHRENIA

U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER

U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN

U-818 TOPICAL TREATMENT OF ACNE VULGARIS

U-819 MANAGEMENT OF FIBROMYALGIA

U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

U-821 METHOD OF INHIBITING ENTHOHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

U-822 USE IN LIPID MANAGEMENT

U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE

U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1

U-825 USE FOR PREVENTION OF BREAST CANCER

U-826 RELIEF OF MODERATE TO SEVERE PAIN

U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY

U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER

U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE

U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.

U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION

U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS

U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS

U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE

U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS

U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER

U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS

U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES

U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE

U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS  
U-853 TREATMENT OR PREVENTION OF EMESIS  
U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)  
U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION  
U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN  
U-857 INHIBITION OF TRANSPLANT REJECTION  
U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS  
U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD  
U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION  
U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER  
U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA  
U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY  
U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS  
U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE  
U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES  
U-867 TREATMENT OF MIGRAINE  
U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA  
U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART  
U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION  
U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH  
U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS  
U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)  
U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME  
U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE  
U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA  
U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER  
U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR  
U-879 A METHOD OF TREATING OR PREVENTING ILEUS  
U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN  
U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER  
U-882 MANAGEMENT OF FIBROMYALGIA (FM)  
U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB  
U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA  
U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY  
U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA  
U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS  
U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN  
U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)  
U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE  
U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE  
U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)  
U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION



**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE

U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER

U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER

U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT

U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME

U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION

U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS

U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER

U-907

U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS

U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY

U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE

U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER

U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET FOR THE TREATMENT OF DERMATITIS

U-919

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML) METHOD FOR INCREASING TEAR PRODUCTION

U-927

U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN

U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI

U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
- U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
- U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
- U-937 TREATMENT OF PROSTATE CANCER
- U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
- U-941 METHOD TO TREAT OVARIAN CANCER
- U-942 METHOD TO TREAT MULTIPLE MYELOMA
- U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
- U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
- U-946 TREATMENT OF BREAST CANCER
- U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS
- U-948 TREATMENT OF DIABETES MELLITUS
- U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
- U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
- U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
- U-952 USE AS AN ANALGESIC
- U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
- U-955 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
- U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
- U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS
- U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
- U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE

U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-975 TREATMENT OF PULMONARY HYPERTENSION

U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES

U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE

U-978 METHOD OF TREATING HYPONATREMIA

U-979 RELIEF OF MUSCLE SPASM

U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY

U-982 A METHOD OF TREATING OSTEOPOROSIS

U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE

U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE

U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)

U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS

U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350

U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

U-990 TREATMENT OF PROTOZOAL INFECTION

U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS

U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION

U-993 METHOD OF TREATING INFERTILITY

U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED

U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN

U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS

U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS

U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS

U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW

U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION

U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

U-1007 METHOD OF TREATING GOUT FLARES

U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION

U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION

U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION

U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B (PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS

U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

U-1019 TREATMENT OF PULMONARY HYPERTENSION

U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER

U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION

U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP

U-1025 TREATING FREQUENT HEARTBURN

U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL

U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY

U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS

U-1033 TOPICAL TREATMENT OF ACNE VULGARIS

U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN

U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST

U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST

U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN

U-1040 INHIBITION OF THROMBIN IN A PATIENT

U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE

U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN

U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS

U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY

U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY

U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)

U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES

U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS

U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA

U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA

U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE

U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA

U-1067 TREATMENT OF CANCER

U-1068 TREATMENT OF ASTHMA

U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE

U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIMUM SALT FORMULATION

U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME

U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD

U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

U-1075 USE FOR THE TREATMENT OF ASTHMA

U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING

U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION

U-1078 TREATMENT OF ACNE

U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT

U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS

U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES

U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME

U-1086 TREATMENT OF AUTOIMMUNE DISEASE

U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

U-1088 RELIEF OF MUSCLE SPASM

U-1089 INHIBITION OF THROMBIN

U-1090 LO OESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA

U-1092 TREATMENT OF BREAST CANCER

U-1093 TREATMENT OF PSEUDOBULBAR AFFECT

U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

U-1095 METHOD OF TREATING OCULAR INFLAMMATION

U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE

U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY

U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER

U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT

U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT

U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1112 METHOD OF MR IMAGING OF A MAMMAL

U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA

U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS

U-1117 TREATMENT OF BREAST CANCER

U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL

U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA

U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES

U-1123 TREATMENT OF ALCOHOL DEPENDENCE

U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION

U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL

U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS

U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS ( $\geq 18$  YEARS OF AGE) WITH COMPENSATED LIVER DISEASE

U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1131 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C

U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

## PATENT AND EXCLUSIVITY TERMS

ADB 56 of 73

## PATENT USE

U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1150 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C

U-1151 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C

U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION

U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION

U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB

U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)

U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)

U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER

U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER

U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER

U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP

U-1163 METHOD OF TREATING THROMBOSIS

U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION

U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS

U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)

U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA

U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN

U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME

U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

U-1173	HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
U-1174	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176	TREATMENT OR PREVENTION OF STROKE
U-1177	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178	RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179	TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
U-1180	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183	A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184	TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
U-1185	TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186	ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187	TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191	METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)
U-1192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194	METHOD FOR TREATING INSOMNIA
U-1195	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196	RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198	RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
U-1199	TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200	REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204	TREATMENT OF UVEITIS
U-1205	TREATMENT OF MACULAR EDEMA
U-1206	DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207	INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS
U-1208	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-1209	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3



## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

YEARS OF AGE AND OLDER

U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)

U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER

U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1217 METHOD OF INCREASING HAIR GROWTH

U-1218 METHOD OF STIMULATING HAIR GROWTH

U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS

U-1220 TREATMENT OF RENAL CELL CARCINOMA

U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION

U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS

U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE

U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE

U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS

U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT

U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE

U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN

U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS

U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT

U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI. INTENDED FOR USE W/ASPIRIN

U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD

U-1234 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA

U-1235 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1236 USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1237 COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS

U-1238 TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

U-1239 MAGNETIC RESONANCE IMAGING OF THE LIVER

U-1240 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

U-1241 MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1242 PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS

U-1243 WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER

U-1244 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYUREA

U-1245 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE

U-1246 SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA

U-1247 MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS

U-1248 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1249 TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG

U-1250 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1251 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT

U-1252 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE

U-1253 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY

U-1254 METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN

U-1255 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY

U-1256 TREATMENT OF SEBORRHEIC DERMATITIS

U-1257 TREATMENT OF OPHTHALMIC DISORDERS

U-1258 VISUALIZATION DURING VITRECTOMY PROCEDURES

U-1259 PROPHYLAXIS OF HIV-1 INFECTION

U-1260 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY

U-1261 REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION

U-1262 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT

U-1263 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS

U-1264 TREATMENT OF A RESPIRATORY DISEASE

U-1265 PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-1266 METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA

U-1267 TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE

U-1268 TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE

U-1269 TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET

U-1270 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)

U-1271 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES

U-1272 TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM

U-1273 TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM

U-1274 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS

U-1275 TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-1276 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

U-1277 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN

U-1278 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS

U-1279 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKNIETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE

U-1280 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS

U-1281 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL

U-1282 PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING

U-1283 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA

U-1284 A METHOD OF TREATING A NEOPLASM

U-1285 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS

U-1286 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE

U-1287 METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1288 TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET

U-1289 MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN

U-1290 TREATMENT OF LUNG CANCER

U-1291 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1292 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET

U-1293 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1294 METHOD OF TREATING GLAUCOMA IN A PATIENT

U-1295 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1296 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION

U-1297 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS

U-1298 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES

U-1299 TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1300 TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1301 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

U-1302 TREATMENT OF PULMONARY EMBOLISM (PE)

U-1303 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM

U-1304 USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES

U-1305 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS

U-1306 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

U-1307 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY

U-1308 MULTIPLE MYELOMA

U-1309 BONE METASTASES

U-1310 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

U-1311 METHOD OF TREATING CYSTIC FIBROSIS

U-1312 USE FOR THE TREATMENT OF HYPERGLYCEMIA

U-1313 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-1314 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1315 THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA

U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES

U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS

U-1322 METHOD OF REDUCING OCULAR HYPERTENSION

U-1323 REDUCING THE RISK OF STROKE

U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS

U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS

U-1326 METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE

U-1327 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION

U-1328 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF

U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER

U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

## PATENT AND EXCLUSIVITY TERMS

ADB 61 of 73

## PATENT USE

- U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
- U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
- U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
- U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
- U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
- U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
- U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
- U-1347 TREATMENT OF A SKIN DISORDER
- U-1348 TREATMENT OF OSTEOARTHRITIS
- U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
- U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS
- U-1351 TREATMENT OF ACUTE PAIN
- U-1352 TREATMENT OF PRIMARY DYSMENORRHEA
- U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
- U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
- U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
- U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
- U-1360 USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1361 USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
- U-1362 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

PREDNISONE TABLET

U-1363 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY

U-1364 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-1365 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

U-1366 TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN

U-1367 METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN

U-1368 TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB

U-1369 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE

U-1370 TREATMENT OF DYSpareunia ASSOCIATED WITH MENOPAUSE

U-1371 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA

U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION

U-1373 METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS

U-1374 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)

U-1375 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS

U-1376 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-1377 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1378 TREATMENT OF A NITROGEN METABOLISM DISORDER

U-1379 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

U-1380 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE

U-1381 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

U-1382 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT

U-1383 DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER

U-1384 METHOD OF TREATING MULTIPLE SCLEROSIS

U-1385 METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS

U-1386 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF

U-1387 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS

U-1388 TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1389 ELLA IS AN PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD

U-1390 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF

U-1391 METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION

U-1392 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION

U-1393 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION

U-1394 METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1395 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1396 TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE

U-1397 USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY

U-1398 METHOD OF TREATING CHRONIC HEPATITIS C

**PATENT AND EXCLUSIVITY TERMS**

ADB 63 of 73

**PATENT USE**

U-1399 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES

U-1400 FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1401 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS

U-1402 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)

U-1403 FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

U-1404 METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS

U-1405 THERAPEUTIC TREATMENT OF BONE METASTASES

U-1406 TREATMENT OF MELANOMA

U-1407 TREATMENT OF NEWLY DIAGNOSED PHILADELPIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)

U-1408 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

U-1409 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION

U-1410 TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES

U-1411 THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE

U-1412 TREATMENT OF ATOPIC DERMATITIS

U-1413 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION

U-1414 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)

U-1415 TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2

U-1416 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

U-1417 USE FOR TREATMENT OF HELICOBACTER INFECTIONS

U-1418 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST

U-1419 TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING

U-1420 METHOD OF ONCE A DAY ADMINISTRATION

U-1421 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE

U-1422 METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT

U-1423 AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

U-1424 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSOTO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-1425 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

U-1426 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS

U-1427 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY

U-1428 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

U-1429 TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR

U-1430 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-1431 METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE

U-1432 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX

U-1433 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

U-1434 TREATMENT OF PANCREATIC CANCER

U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AN DADMINISTRATION OF AN ORAL NSAID.

U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

- U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
- U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
- U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
- U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
- U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
- U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE
- U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
- U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
- U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
- U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA
- U-1449 METHOD OF ALLEVIATING A SKIN CONDITION
- U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
- U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY.  
PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
- U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT
- U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
- U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
- U-1455 TREATMENT OF PERIANAL WARTS
- U-1456 TREATMENT OF MANTLE CELL LYMPHOMA
- U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
- U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1459 TREATMENT OF CARCINOMA OF THE THYROID
- U-1460 TREATMENT OF HERPES LABIALIS
- U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
- U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
- U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
- U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
- U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
- U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1467 METHOD OF TREATING HEPATITIS C
- U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
- U-1469 USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
- U-1470 FOR THE TREATMENT OF HEPATITIS C
- U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
- U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
- U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
- U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
- U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
- U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
- U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE
- U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
- U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
- U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
- U-1481 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
- U-1482 DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-1483 INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
- U-1484 COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
- U-1485 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1486 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
- U-1487 METHOD OF INCREASING EYELASH GROWTH
- U-1488 USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
- U-1489 USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
- U-1490 FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
- U-1491 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
- U-1492 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- U-1493 METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
- U-1494 SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
- U-1495 RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
- U-1496 METHOD TO TREAT HEMANGIOMA.
- U-1497 NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
- U-1498 METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
- U-1499 MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
- U-1500 TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
- U-1501 PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
- U-1502 PROPHYLAXIS OF PULMONARY EMBOLISM
- U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1504 USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
- U-1505 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
- U-1506 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
- U-1507 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
- U-1508 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
- U-1509 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
- U-1510 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
- U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA
- U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
- U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
- U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
- U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
- U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.
- U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
- U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH



## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

IRRITABLE BOWEL SYNDROME

U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT

U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE

U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE

U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE

U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY

U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE

U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-1530 USE OF ARIPIPIRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION

U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE

U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.

U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.

U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.

U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.

U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.

U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.

U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.

U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.

U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.

U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA

U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23

U-1544 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).

U-1545 A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE

U-1546 FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.

U-1547 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA

U-1548 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-1549 FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA

U-1550 METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.

U-1551 METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.

U-1552 FOR HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE)

U-1553 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN

U-1554 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)

U-1555 MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1556 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1557 A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

U-1558 FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA

U-1559 INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER

U-1560 A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE

U-1561 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

U-1562 TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)

U-1563 A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.

U-1564 A METHOD OF TREATING GAUCHER'S DISEASE

U-1565 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1566 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-1567 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER

U-1568 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1569 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

U-1570 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE

U-1571 TREATMENT OF GAUCHER DISEASE TYPE 1

U-1572 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.

U-1573 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.

U-1574 A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.

U-1575 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY

U-1576 TREATMENT OF LEUKEMIA

U-1577 CONTROL OF SERUM PHOSPHOROUS LEVELS

U-1578 TREATMENT OF ACUTE OTITIS MEDIA

U-1579 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1580 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY

U-1581 IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.

U-1582 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA

U-1583 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

U-1584 USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS

U-1585 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE

U-1586 FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE

U-1587 SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.

U-1588 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).

U-1589 METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

U-1590 KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA

U-1591 TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER

U-1592 TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

U-1593 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.

U-1594 DILATION OF THE PUPIL

U-1595 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS

U-1596 LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

U-1597 TREATMENT OF DIABETIC MACULAR EDEMA

U-1598 METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE

U-1599 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1600 DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

U-1601 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

U-1602 METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION

U-1603 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE

U-1604 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2

U-1605 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER

U-1606 METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM

U-1607 METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION

U-1608 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION

U-1609 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

U-1610 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE

U-1611 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER

U-1612 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER

U-1613 DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN

U-1614 USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN

U-1615 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1616 NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1617 METHOD OF TREATING MEDULLARY THYROID CANCER

U-1618 A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FOMNULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT

U-1619 TREATMENT OF IMMUNE (IDIOPATIC) THROMBOCYTOPENIA (ITP)

U-1620 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.

U-1621 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.

U-1622 FOR THE TREATMENT OF POLYCYTHEMIA VERA

U-1623 USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.

U-1624 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.

U-1625 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6

U-1626 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING

U-1627 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

U-1628 METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION

U-1629 METHOD OF TREATING ACROMEGALY

U-1630 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED IWTH DOCETAXEL

U-1631 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

U-1632 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1633 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1634 TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR

U-1635 USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION

U-1636 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

U-1637 TREATMENT OF HCV INFECTION USING PARITAPREVR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

U-1638 TREATMENT OF HCV INFECTION USING PARITAPREVR

U-1639 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

U-1640 TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

COMPOSITION AS CLAIMED

U-1641 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-1642 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN

U-1643 TREATING CUSHING'S SYNDROME

U-1644 TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTININ CHLORIDE GEL TO SKIN

U-1645 TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1646 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1647 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1648 TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1649 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM

U-1650 TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA

U-1651 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN

U-1653 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)

U-1654 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)

U-1655 A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY

U-1656 METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

U-1657 METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99

U-1658 TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN

U-1659 MANAGEMENT OF PAIN

U-1660 TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

U-1661 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN

U-1662 A METHOD OF TREATING OCULAR PAIN

U-1663 TREATMENT OF HIV-1 INFECTION

U-1664 TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL

U-1665 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1

U-1666 PALLIATIVE TREATMENT OF PROSTATE CANCER

U-1667 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS

U-1668 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER

U-1669 TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE

U-1670 NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.

U-1671 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS

U-1672 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION

U-1673 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS

U-1674 DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1675 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

U-1676 METHODS FOR TREATING BACTERIAL INFECTIONS

U-1677 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

U-1678 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1679 TREATMENT OF ACUTE OTITIS EXTERNA

U-1680 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1681 TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC

**PATENT AND EXCLUSIVITY TERMS**

ADB 70 of 73

**PATENT USE**

U-1682 TREATMENT OF BACTERIAL VAGINOSIS

U-1683 TREATMENT FRO CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION

U-1684 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1685 DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1686 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION

U-1687 TREATMENT OF HCV INFECTION USING OMBITASVIR

U-1688 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1689 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1690 METHOD FOR REDUCTION OF SUBMENTAL FAT

U-1691 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER

U-1692 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1693 METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1694 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE

U-1695 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

U-1696 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

U-1697 PULMONARY ADMINISTRATION OF A COMPISITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.

U-1698 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1699 A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA

U-1700 A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

U-1701 A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN

U-1702 TREATMENT OF COPD

U-1703 TREATMENT OF RESPIRATORY COMPLAINTS

U-1704 USE FOR TREATMENT IN PATIENTS WITH DIABETES

U-1705 USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA

U-1706 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE

U-1707 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.

U-1708 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.

U-1709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).

U-1710 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE

U-1711 FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL

U-1712 MEKENIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

U-1713 TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

U-1714 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1715 P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR

U-1716 TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS

U-1717 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE

U-1718 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.

U-1719 ACUTE TREATMENT OF MIGRAINE

U-1720 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA

U-1721 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2

U-1722 TREATMENT OF BASAL CELL CARCINOMA

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1723 TREATMENT OF HEART FAILURE

U-1724 METHOD OF INHIBITING HEPATITIS C VIRUS

U-1725 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY

U-1726 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1727 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

U-1728 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1729 REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)

U-1730 REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM

U-1731 TEMPORARY RELIEF OF MINOR ACHES AND PAINS

U-1732 TEMPORARY REDUCTION OF FEVER

U-1733 TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE

U-1734 USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

U-1735 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL

U-1736 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1737 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE

U-1738 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)

U-1739 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

U-1740 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY

U-1741 PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1742 ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1743 FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY

U-1744 PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING

U-1745 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA

U-1746 MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY

U-1747 FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD

U-1748 FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1749 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

U-1750 TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE

U-1751 TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY

U-1752 PROPHYLAXIS OF ORGAN REJECTION

U-1753 TREATMENT OF HCV INFECTION USING DISABUVIR

U-1754 FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL

U-1755 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

U-1756 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF

U-1757 INHIBITION ON PI3K KINASE

U-1758 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION

U-1759 METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB

U-1760 RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT

U-1761 PLAQUE PSORIASIS

U-1762 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

U-1763 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1764 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1765 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1766 TREATMENT OF HYPERKALEMIA

U-1767 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER

U-1768 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN

U-1769 TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE

U-1770 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA

U-1771 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION

U-1772 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

U-1773 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-1774 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE

U-1775 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS

U-1776 METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA

U-1777 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTORE RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY

U-1778 METHOD FOR TREATING MULTIPLE MYELOMA

U-1779 METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS

U-1780 METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA

U-1781 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT

U-1782 FOR HEAD LICE INFESTATIONS

U-1783 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole MAGNESIUM AS CLAIMED

U-1784 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole MAGNESIUM TRIHYDRATE AS CLAIMED

U-1785 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole MAGNESIUM FORMULATION AS CLAIMED

U-1786 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE

U-1787 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY

U-1788 TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN

U-1789 METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION

U-1790 FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA

U-1791 EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS

U-1792 TREATMENT OF OTIC INFECTION OR INFLAMMATION

U-1793 TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT

U-1794 REVERSAL OF DRUG-INDUCED NEUROMUSCLUAR BLOCK

U-1795 REVERSAL OF NEUROMUSCLUAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE

U-1796 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

**PATENT AND EXCLUSIVITY TERMS**